- {entry_name: 5ht1a_human, from_res: D, pubmed: '1426261', seq: '82', to_res: N}
- {entry_name: 5ht1a_human, from_res: D, pubmed: '8474430', seq: '82', to_res: A}
- {entry_name: 5ht1a_human, from_res: D, pubmed: '1426261', seq: '116', to_res: N}
- {entry_name: 5ht1a_human, from_res: S, pubmed: '1426261', seq: '199', to_res: A}
- {entry_name: 5ht1a_human, from_res: T, pubmed: '1426261', seq: '200', to_res: A}
- {entry_name: 5ht1a_human, from_res: N, pubmed: '1349154', seq: '386', to_res: V}
- {entry_name: 5ht1a_human, from_res: S, pubmed: '8474430', seq: '391', to_res: A}
- {entry_name: 5ht1a_human, from_res: S, pubmed: '8474430', seq: '393', to_res: A}
- {entry_name: 5ht1a_human, from_res: N, pubmed: '8474430', seq: '396', to_res: V}
- {entry_name: 5ht1a_human, from_res: N, pubmed: '8474430', seq: '396', to_res: Q}
- {entry_name: 5ht1a_human, from_res: N, pubmed: '8474430', seq: '396', to_res: A}
- {entry_name: 5ht1a_human, from_res: N, pubmed: '8474430', seq: '396', to_res: F}
- {entry_name: 5ht1a_rat, from_res: N, pubmed: '8474430', seq: '396', to_res: Y}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '1436092', seq: '355', to_res: N}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '8417162', seq: '355', to_res: N}
- {entry_name: 5ht2a_human, from_res: S, pubmed: '1644189', seq: '242', to_res: A}
- {entry_name: 5ht2a_rat, from_res: D, pubmed: '8316224', seq: '120', to_res: N}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '8388989', seq: '125', to_res: L}
- {entry_name: 5ht2a_rat, from_res: D, pubmed: '8316224', seq: '172', to_res: N}
- {entry_name: 5ht2a_rat, from_res: A, pubmed: '8114677', seq: '242', to_res: S}
- {entry_name: 5ht2a_rat, from_res: A, pubmed: '8114677', seq: '242', to_res: T}
- {entry_name: 5ht2a_rat, from_res: A, pubmed: '8114677', seq: '242', to_res: V}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '8388989', seq: '339', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '8388989', seq: '340', to_res: L}
- {entry_name: ada2a_human, from_res: D, pubmed: '1678850', seq: '113', to_res: N}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '2158097', seq: '288', to_res: K}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '2158097', seq: '290', to_res: H}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '2158097', seq: '293', to_res: L}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: S}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: N}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: D}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: G}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: T}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: H}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: W}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: Y}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: P}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: V}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: L}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: M}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: Q}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: I}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: F}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: C}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: R}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: K}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '1346134', seq: '293', to_res: E}
- {entry_name: ada2a_human, from_res: D, pubmed: '1678850', seq: '79', to_res: N}
- {entry_name: ada2a_human, from_res: D, pubmed: '1678850', seq: '130', to_res: N}
- {entry_name: ada2a_human, from_res: S, pubmed: '1678850', seq: '200', to_res: A}
- {entry_name: ada2a_human, from_res: S, pubmed: '1678850', seq: '204', to_res: A}
- {entry_name: ada2a_human, from_res: F, pubmed: '1678390', seq: '412', to_res: N}
- {entry_name: ada2a_human, from_res: F, pubmed: '8101966', seq: '412', to_res: N}
- {entry_name: ada2a_pig, from_res: D, pubmed: '2174879', seq: '79', to_res: N}
- {entry_name: ada2a_pig, from_res: D, pubmed: '1354394', seq: '79', to_res: N}
- {entry_name: ada2a_pig, from_res: D, pubmed: '2174879', seq: '130', to_res: N}
- {entry_name: ada2a_pig, from_res: D, pubmed: '2174879', seq: '432', to_res: N}
- {entry_name: ada2a_pig, from_res: C, pubmed: '8385131', seq: '442', to_res: A}
- {entry_name: ada2a_pig, from_res: C, pubmed: '8385131', seq: '442', to_res: S}
- {entry_name: ada2a_mouse, from_res: S, pubmed: '1353249', seq: '201', to_res: C}
- {entry_name: adrb2_human, from_res: R, pubmed: '7915137', seq: '16', to_res: G}
- {entry_name: adrb2_human, from_res: Q, pubmed: '7915137', seq: '27', to_res: E}
- {entry_name: adrb2_human, from_res: L, pubmed: '2846532', seq: '64', to_res: G}
- {entry_name: adrb2_human, from_res: C, pubmed: '2542304', seq: '77', to_res: S}
- {entry_name: adrb2_human, from_res: D, pubmed: '2831218', seq: '79', to_res: N}
- {entry_name: adrb2_human, from_res: D, pubmed: '2840663', seq: '130', to_res: N}
- {entry_name: adrb2_human, from_res: P, pubmed: '2846532', seq: '138', to_res: S}
- {entry_name: adrb2_human, from_res: T, pubmed: '7901205', seq: '164', to_res: I}
- {entry_name: adrb2_human, from_res: E, pubmed: '2846532', seq: '268', to_res: G}
- {entry_name: adrb2_human, from_res: C, pubmed: '2542304', seq: '285', to_res: S}
- {entry_name: adrb2_human, from_res: N, pubmed: '8101966', seq: '312', to_res: F}
- {entry_name: adrb2_human, from_res: N, pubmed: '8101966', seq: '312', to_res: A}
- {entry_name: adrb2_human, from_res: N, pubmed: '8101966', seq: '312', to_res: T}
- {entry_name: adrb2_human, from_res: N, pubmed: '8101966', seq: '312', to_res: Q}
- {entry_name: adrb2_human, from_res: Y, pubmed: '7507928', seq: '326', to_res: A}
- {entry_name: adrb2_human, from_res: C, pubmed: '2542304', seq: '327', to_res: S}
- {entry_name: adrb2_human, from_res: C, pubmed: '2846532', seq: '327', to_res: R}
- {entry_name: adrb2_human, from_res: C, pubmed: '2846532', seq: '341', to_res: G}
- {entry_name: adrb2_human, from_res: C, pubmed: '2540197', seq: '341', to_res: G}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8388251', seq: '350', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8388251', seq: '354', to_res: A}
- {entry_name: adrb2_mesau, from_res: N, pubmed: '2162359', seq: '6', to_res: Q}
- {entry_name: adrb2_mesau, from_res: N, pubmed: '2162359', seq: '15', to_res: Q}
- {entry_name: adrb2_mesau, from_res: R, pubmed: '2855488', seq: '63', to_res: G}
- {entry_name: adrb2_mesau, from_res: Q, pubmed: '2855488', seq: '65', to_res: K}
- {entry_name: adrb2_mesau, from_res: T, pubmed: '2855488', seq: '66', to_res: E}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2855488', seq: '77', to_res: V}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2885836', seq: '79', to_res: A}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2899076', seq: '79', to_res: A}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '8120034', seq: '106', to_res: A}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '8120034', seq: '184', to_res: A}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '8120034', seq: '190', to_res: A}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '8120034', seq: '191', to_res: A}
- {entry_name: adrb2_mesau, from_res: E, pubmed: '2885836', seq: '107', to_res: A}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2885836', seq: '113', to_res: N}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '1670767', seq: '113', to_res: S}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2899076', seq: '113', to_res: N}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2899076', seq: '113', to_res: E}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2570781', seq: '113', to_res: E}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2570781', seq: '113', to_res: N}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2855488', seq: '116', to_res: V}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2547766', seq: '120', to_res: A}
- {entry_name: adrb2_mesau, from_res: D, pubmed: '2855488', seq: '130', to_res: G}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2855488', seq: '137', to_res: R}
- {entry_name: adrb2_mesau, from_res: Y, pubmed: '2855488', seq: '132', to_res: L}
- {entry_name: adrb2_mesau, from_res: F, pubmed: '2855488', seq: '139', to_res: L}
- {entry_name: adrb2_mesau, from_res: F, pubmed: '8226735', seq: '139', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2547766', seq: '161', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2547766', seq: '165', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2547766', seq: '203', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2547766', seq: '204', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2547766', seq: '207', to_res: A}
- {entry_name: adrb2_mesau, from_res: Y, pubmed: '2547766', seq: '219', to_res: L}
- {entry_name: adrb2_mesau, from_res: K, pubmed: '2855488', seq: '227', to_res: A}
- {entry_name: adrb2_mesau, from_res: Q, pubmed: '2855488', seq: '229', to_res: R}
- {entry_name: adrb2_mesau, from_res: E, pubmed: '2855488', seq: '268', to_res: G}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2855488', seq: '285', to_res: V}
- {entry_name: adrb2_mesau, from_res: F, pubmed: '2855488', seq: '289', to_res: A}
- {entry_name: adrb2_mesau, from_res: F, pubmed: '2855488', seq: '290', to_res: M}
- {entry_name: adrb2_mesau, from_res: Y, pubmed: '2547766', seq: '316', to_res: A}
- {entry_name: adrb2_mesau, from_res: N, pubmed: '2885836', seq: '318', to_res: K}
- {entry_name: adrb2_mesau, from_res: N, pubmed: '2855488', seq: '318', to_res: K}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2855488', seq: '319', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2547766', seq: '319', to_res: A}
- {entry_name: adrb2_mesau, from_res: P, pubmed: '2885836', seq: '323', to_res: S}
- {entry_name: adrb2_mesau, from_res: Y, pubmed: '2855488', seq: '326', to_res: L}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2855488', seq: '327', to_res: V}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2855488', seq: '341', to_res: L}
- {entry_name: drd1_human, from_res: D, pubmed: '8466481', seq: '70', to_res: V}
- {entry_name: drd1_human, from_res: K, pubmed: '8466481', seq: '81', to_res: E}
- {entry_name: drd1_human, from_res: S, pubmed: '1355478', seq: '198', to_res: A}
- {entry_name: drd1_human, from_res: S, pubmed: '1355478', seq: '199', to_res: A}
- {entry_name: drd2_mouse, from_res: H, pubmed: '8158118', seq: '394', to_res: L}
- {entry_name: drd1_human, from_res: S, pubmed: '1355478', seq: '202', to_res: A}
- {entry_name: drd1_human, from_res: C, pubmed: '8466481', seq: '283', to_res: V}
- {entry_name: drd1_human, from_res: F, pubmed: '8466481', seq: '319', to_res: L}
- {entry_name: drd1_human, from_res: W, pubmed: '8466481', seq: '321', to_res: Y}
- {entry_name: drd2_human, from_res: D, pubmed: '1358663', seq: '114', to_res: N}
- {entry_name: drd2_human, from_res: D, pubmed: '1358663', seq: '114', to_res: G}
- {entry_name: drd2_human, from_res: M, pubmed: '1358663', seq: '116', to_res: L}
- {entry_name: drd2_human, from_res: M, pubmed: '1358663', seq: '117', to_res: L}
- {entry_name: drd2_human, from_res: M, pubmed: '1358663', seq: '117', to_res: C}
- {entry_name: drd2_human, from_res: S, pubmed: '1358663', seq: '194', to_res: A}
- {entry_name: drd2_human, from_res: S, pubmed: '1358663', seq: '197', to_res: A}
- {entry_name: drd2_mouse, from_res: D, pubmed: '1828858', seq: '80', to_res: A}
- {entry_name: drd2_mouse, from_res: D, pubmed: '1828858', seq: '80', to_res: E}
- {entry_name: drd2_mouse, from_res: S, pubmed: '1321233', seq: '193', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '1321233', seq: '194', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '1321233', seq: '197', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '1321233', seq: '391', to_res: A}
- {entry_name: acm1_human, from_res: F, pubmed: '8226735', seq: '125', to_res: A}
- {entry_name: acm1_human, from_res: V, pubmed: '8226735', seq: '127', to_res: A}
- {entry_name: acm1_human, from_res: P, pubmed: '8226735', seq: '130', to_res: A}
- {entry_name: acm1_human, from_res: L, pubmed: '8226735', seq: '131', to_res: A}
- {entry_name: acm1_human, from_res: L, pubmed: '8226735', seq: '131', to_res: N}
- {entry_name: acm1_human, from_res: L, pubmed: '8226735', seq: '131', to_res: D}
- {entry_name: acm1_human, from_res: L, pubmed: '8226735', seq: '131', to_res: F}
- {entry_name: acm1_human, from_res: L, pubmed: '8226735', seq: '131', to_res: M}
- {entry_name: acm1_human, from_res: Y, pubmed: '8226735', seq: '133', to_res: A}
- {entry_name: acm1_human, from_res: K, pubmed: '8226735', seq: '136', to_res: A}
- {entry_name: acm1_rat, from_res: D, pubmed: '2557534', seq: '71', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '1625205', seq: '71', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '2557534', seq: '99', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '1625205', seq: '99', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '2557534', seq: '105', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '2557534', seq: '122', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '1625205', seq: '122', to_res: N}
- {entry_name: acm1_rat, from_res: R, pubmed: '8145736', seq: '123', to_res: N}
- {entry_name: acm1_rat, from_res: Y, pubmed: '8145736', seq: '124', to_res: F}
- {entry_name: acm2_human, from_res: E, pubmed: '8190113', seq: '22', to_res: Q}
- {entry_name: acm2_human, from_res: D, pubmed: '8190113', seq: '69', to_res: N}
- {entry_name: acm2_human, from_res: D, pubmed: '8190113', seq: '97', to_res: N}
- {entry_name: acm2_human, from_res: D, pubmed: '8190113', seq: '120', to_res: N}
- {entry_name: acm2_human, from_res: S, pubmed: '8157684', seq: '210', to_res: Y}
- {entry_name: acm2_human, from_res: E, pubmed: '8190113', seq: '382', to_res: Q}
- {entry_name: acm2_pig, from_res: C, pubmed: '1658226', seq: '457', to_res: G}
- {entry_name: acm2_rat, from_res: R, pubmed: '8145736', seq: '121', to_res: N}
- {entry_name: acm3_human, from_res: L, pubmed: '8226735', seq: '174', to_res: A}
- {entry_name: acm3_human, from_res: T, pubmed: '8157684', seq: '550', to_res: A}
- {entry_name: acm3_human, from_res: T, pubmed: '8157684', seq: '553', to_res: A}
- {entry_name: acm3_rat, from_res: S, pubmed: '1657592', seq: '120', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1657592', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1527051', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: W, pubmed: '7679072', seq: '192', to_res: F}
- {entry_name: acm3_rat, from_res: P, pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '1657592', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '1527051', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '1657592', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '7679072', seq: '242', to_res: A}
- {entry_name: acm3_rat, from_res: R, pubmed: '8276826', seq: '252', to_res: H}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1527051', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: I, pubmed: '8276826', seq: '253', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8276826', seq: '254', to_res: S}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8157684', seq: '254', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8157684', seq: '254', to_res: W}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8157684', seq: '254', to_res: A}
- {entry_name: acm3_rat, from_res: R, pubmed: '8276826', seq: '260', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '1657592', seq: '502', to_res: A}
- {entry_name: acm3_rat, from_res: W, pubmed: '7679072', seq: '503', to_res: F}
- {entry_name: acm3_rat, from_res: P, pubmed: '7679072', seq: '505', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1657592', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1527051', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: N, pubmed: '8034642', seq: '507', to_res: A}
- {entry_name: acm3_rat, from_res: N, pubmed: '8034642', seq: '507', to_res: S}
- {entry_name: acm3_rat, from_res: N, pubmed: '8034642', seq: '507', to_res: D}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1657592', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1527051', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: W, pubmed: '7679072', seq: '530', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '1657592', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: T, pubmed: '1657592', seq: '537', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '7679072', seq: '540', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8202499', seq: '296', to_res: E}
- {entry_name: hrh2_canfa, from_res: D, pubmed: '1356984', seq: '186', to_res: N}
- {entry_name: hrh1_human, from_res: D, pubmed: '8093027', seq: '107', to_res: A}
- {entry_name: hrh1_human, from_res: D, pubmed: '8093027', seq: '107', to_res: N}
- {entry_name: hrh1_human, from_res: D, pubmed: '8093027', seq: '107', to_res: E}
- {entry_name: hrh1_human, from_res: T, pubmed: '8093027', seq: '194', to_res: A}
- {entry_name: hrh1_human, from_res: N, pubmed: '8093027', seq: '198', to_res: A}
- {entry_name: hrh1_cavpo, from_res: T, pubmed: '8198587', seq: '203', to_res: A}
- {entry_name: hrh1_cavpo, from_res: N, pubmed: '8198587', seq: '207', to_res: A}
- {entry_name: hrh2_canfa, from_res: D, pubmed: '1356984', seq: '98', to_res: N}
- {entry_name: hrh2_canfa, from_res: D, pubmed: '1356984', seq: '186', to_res: A}
- {entry_name: hrh2_canfa, from_res: T, pubmed: '1356984', seq: '190', to_res: A}
- {entry_name: hrh2_canfa, from_res: T, pubmed: '1356984', seq: '190', to_res: C}
- {entry_name: opsd_human, from_res: P, pubmed: '8253795', seq: '23', to_res: L}
- {entry_name: opsd_human, from_res: G, pubmed: '8253795', seq: '51', to_res: V}
- {entry_name: opsd_human, from_res: P, pubmed: '8253795', seq: '53', to_res: R}
- {entry_name: opsd_human, from_res: G, pubmed: '8253795', seq: '106', to_res: R}
- {entry_name: opsd_human, from_res: L, pubmed: '8253795', seq: '125', to_res: R}
- {entry_name: opsd_human, from_res: R, pubmed: '8253795', seq: '135', to_res: G}
- {entry_name: opsd_human, from_res: C, pubmed: '8253795', seq: '167', to_res: R}
- {entry_name: opsd_human, from_res: P, pubmed: '8253795', seq: '171', to_res: L}
- {entry_name: opsd_human, from_res: E, pubmed: '8253795', seq: '181', to_res: K}
- {entry_name: opsd_human, from_res: G, pubmed: '8253795', seq: '182', to_res: S}
- {entry_name: opsd_human, from_res: S, pubmed: '8253795', seq: '186', to_res: P}
- {entry_name: opsd_human, from_res: G, pubmed: '8253795', seq: '188', to_res: E}
- {entry_name: opsd_human, from_res: G, pubmed: '8253795', seq: '188', to_res: R}
- {entry_name: opsd_human, from_res: D, pubmed: '8253795', seq: '190', to_res: N}
- {entry_name: opsd_human, from_res: H, pubmed: '8253795', seq: '211', to_res: P}
- {entry_name: opsd_human, from_res: H, pubmed: '8253795', seq: '211', to_res: R}
- {entry_name: opsd_human, from_res: P, pubmed: '8253795', seq: '267', to_res: L}
- {entry_name: opsd_human, from_res: V, pubmed: '8253795', seq: '345', to_res: M}
- {entry_name: opsd_human, from_res: P, pubmed: '8253795', seq: '347', to_res: S}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8193125', seq: '4', to_res: K}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8193125', seq: '17', to_res: M}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8193125', seq: '23', to_res: H}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8193125', seq: '23', to_res: L}
- {entry_name: opsd_bovin, from_res: Q, pubmed: '8193125', seq: '28', to_res: H}
- {entry_name: opsd_bovin, from_res: F, pubmed: '8193125', seq: '45', to_res: L}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8193125', seq: '51', to_res: R}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8193125', seq: '51', to_res: V}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8193125', seq: '53', to_res: R}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8193125', seq: '58', to_res: R}
- {entry_name: opsd_bovin, from_res: V, pubmed: '8193125', seq: '87', to_res: D}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8193125', seq: '89', to_res: D}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8193125', seq: '90', to_res: D}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8193125', seq: '106', to_res: R}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8193125', seq: '106', to_res: W}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8193125', seq: '110', to_res: Y}
- {entry_name: opsd_bovin, from_res: L, pubmed: '8193125', seq: '125', to_res: R}
- {entry_name: opsd_bovin, from_res: R, pubmed: '8193125', seq: '135', to_res: G}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8193125', seq: '167', to_res: R}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8193125', seq: '170', to_res: L}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8193125', seq: '171', to_res: L}
- {entry_name: opsd_bovin, from_res: Y, pubmed: '8193125', seq: '178', to_res: C}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8193125', seq: '181', to_res: K}
- {entry_name: opsd_bovin, from_res: S, pubmed: '8193125', seq: '186', to_res: P}
- {entry_name: opsd_bovin, from_res: D, pubmed: '8193125', seq: '190', to_res: G}
- {entry_name: opsd_bovin, from_res: D, pubmed: '8193125', seq: '190', to_res: N}
- {entry_name: opsd_bovin, from_res: D, pubmed: '8193125', seq: '190', to_res: Y}
- {entry_name: opsd_bovin, from_res: H, pubmed: '8193125', seq: '211', to_res: P}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8193125', seq: '222', to_res: R}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8193125', seq: '296', to_res: E}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8193125', seq: '296', to_res: R}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8193125', seq: '347', to_res: L}
- {entry_name: opsd_bovin, from_res: N, pubmed: '8171029', seq: '2', to_res: Q}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8193125', seq: '347', to_res: S}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8171029', seq: '3', to_res: C}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8171029', seq: '3', to_res: P}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8171029', seq: '4', to_res: K}
- {entry_name: opsd_bovin, from_res: N, pubmed: '8171029', seq: '15', to_res: A}
- {entry_name: opsd_bovin, from_res: N, pubmed: '8171029', seq: '15', to_res: R}
- {entry_name: opsd_bovin, from_res: N, pubmed: '8171029', seq: '15', to_res: C}
- {entry_name: opsd_bovin, from_res: N, pubmed: '8171029', seq: '15', to_res: E}
- {entry_name: opsd_bovin, from_res: N, pubmed: '8171029', seq: '15', to_res: K}
- {entry_name: opsd_bovin, from_res: N, pubmed: '8171029', seq: '15', to_res: Q}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8171029', seq: '16', to_res: R}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8171029', seq: '16', to_res: C}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8171029', seq: '17', to_res: M}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8171029', seq: '17', to_res: V}
- {entry_name: pe2r3_bovin, from_res: R, pubmed: '7608175', seq: '332', to_res: Q}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8486634', seq: '58', to_res: R}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8486634', seq: '58', to_res: M}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8486634', seq: '58', to_res: V}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8486634', seq: '58', to_res: A}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8486634', seq: '58', to_res: S}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1532320', seq: '65', to_res: F}
- {entry_name: opsd_bovin, from_res: D, pubmed: '2573154', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: D, pubmed: '2573154', seq: '83', to_res: E}
- {entry_name: opsd_bovin, from_res: D, pubmed: '2573154', seq: '83', to_res: A}
- {entry_name: opsd_bovin, from_res: D, pubmed: '1999419', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: D, pubmed: '8260503', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: D, pubmed: '8099498', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8107847', seq: '90', to_res: D}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1532320', seq: '100', to_res: F}
- {entry_name: opsd_bovin, from_res: C, pubmed: '3186735', seq: '110', to_res: S}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '113', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '113', to_res: K}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1329948', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573154', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573154', seq: '113', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1356370', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: F, pubmed: '1999419', seq: '115', to_res: A}
- {entry_name: opsd_bovin, from_res: A, pubmed: '1999419', seq: '117', to_res: F}
- {entry_name: opsd_bovin, from_res: A, pubmed: '1329948', seq: '117', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1999419', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1999419', seq: '122', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1999419', seq: '122', to_res: A}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '122', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '122', to_res: K}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573154', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573154', seq: '122', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8260503', seq: '122', to_res: I}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8099498', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1999419', seq: '126', to_res: F}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1999419', seq: '126', to_res: L}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1999419', seq: '126', to_res: A}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '134', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573063', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573154', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1634520', seq: '134', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1634520', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8260503', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8260503', seq: '134', to_res: L}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8099498', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8099498', seq: '134', to_res: D}
- {entry_name: opsd_bovin, from_res: R, pubmed: '2573063', seq: '135', to_res: Q}
- {entry_name: opsd_bovin, from_res: R, pubmed: '1634520', seq: '135', to_res: Q}
- {entry_name: opsd_bovin, from_res: R, pubmed: '8099498', seq: '135', to_res: Q}
- {entry_name: opsd_bovin, from_res: R, pubmed: '8486634', seq: '135', to_res: L}
- {entry_name: opsd_bovin, from_res: R, pubmed: '8486634', seq: '135', to_res: W}
- {entry_name: opsd_bovin, from_res: R, pubmed: '8486634', seq: '135', to_res: G}
- {entry_name: opsd_bovin, from_res: R, pubmed: '8486634', seq: '135', to_res: K}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '140', to_res: S}
- {entry_name: opsd_bovin, from_res: R, pubmed: '1634520', seq: '147', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8260503', seq: '150', to_res: Q}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1532320', seq: '152', to_res: F}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1999419', seq: '161', to_res: L}
- {entry_name: opsd_bovin, from_res: A, pubmed: '1577792', seq: '164', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '3186735', seq: '185', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '3186735', seq: '187', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8051054', seq: '187', to_res: Y}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8051054', seq: '187', to_res: N}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8051054', seq: '187', to_res: T}
- {entry_name: opsd_bovin, from_res: D, pubmed: '2367520', seq: '190', to_res: A}
- {entry_name: opsd_bovin, from_res: Y, pubmed: '2367520', seq: '191', to_res: L}
- {entry_name: opsd_bovin, from_res: Y, pubmed: '2367520', seq: '192', to_res: L}
- {entry_name: opsd_bovin, from_res: T, pubmed: '2367520', seq: '193', to_res: V}
- {entry_name: opsd_bovin, from_res: P, pubmed: '2367520', seq: '194', to_res: A}
- {entry_name: opsd_bovin, from_res: P, pubmed: '2367520', seq: '194', to_res: G}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1532320', seq: '195', to_res: F}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2573154', seq: '201', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8260503', seq: '201', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8099498', seq: '201', to_res: Q}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1532320', seq: '211', to_res: F}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1532320', seq: '211', to_res: C}
- {entry_name: opsd_bovin, from_res: H, pubmed: '8260503', seq: '211', to_res: E}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1999419', seq: '211', to_res: R}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8260503', seq: '232', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1634520', seq: '239', to_res: Q}
- {entry_name: opsd_bovin, from_res: S, pubmed: '1634520', seq: '240', to_res: A}
- {entry_name: opsd_bovin, from_res: T, pubmed: '1634520', seq: '243', to_res: V}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1634520', seq: '245', to_res: L}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1634520', seq: '248', to_res: L}
- {entry_name: opsd_bovin, from_res: F, pubmed: '1577792', seq: '261', to_res: Y}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1999419', seq: '265', to_res: Y}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1999419', seq: '265', to_res: F}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1999419', seq: '265', to_res: A}
- {entry_name: opsd_bovin, from_res: P, pubmed: '1999419', seq: '267', to_res: G}
- {entry_name: opsd_bovin, from_res: P, pubmed: '1999419', seq: '267', to_res: A}
- {entry_name: opsd_bovin, from_res: P, pubmed: '1999419', seq: '267', to_res: S}
- {entry_name: opsd_bovin, from_res: P, pubmed: '1999419', seq: '267', to_res: N}
- {entry_name: opsd_bovin, from_res: Y, pubmed: '1999419', seq: '268', to_res: F}
- {entry_name: opsd_bovin, from_res: A, pubmed: '1577792', seq: '269', to_res: T}
- {entry_name: opsd_bovin, from_res: Y, pubmed: '1999419', seq: '274', to_res: F}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1532320', seq: '278', to_res: F}
- {entry_name: opsd_bovin, from_res: A, pubmed: '1999419', seq: '292', to_res: D}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8260503', seq: '292', to_res: E}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8358437', seq: '292', to_res: E}
- {entry_name: opsd_bovin, from_res: F, pubmed: '8260503', seq: '293', to_res: E}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1990431', seq: '296', to_res: G}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1990431', seq: '296', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1356370', seq: '296', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1356370', seq: '296', to_res: E}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: E}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1356370', seq: '296', to_res: R}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: G}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: T}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: C}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: Q}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: V}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: H}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: L}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: F}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8099498', seq: '296', to_res: R}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8260503', seq: '299', to_res: E}
- {entry_name: opsd_bovin, from_res: V, pubmed: '8260503', seq: '300', to_res: E}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '316', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '322', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '323', to_res: S}
- {entry_name: nk1r_human, from_res: N, pubmed: '1281469', seq: '23', to_res: T}
- {entry_name: nk1r_human, from_res: N, pubmed: '8210503', seq: '23', to_res: T}
- {entry_name: nk1r_human, from_res: Q, pubmed: '1281469', seq: '24', to_res: A}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8210503', seq: '24', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '1281469', seq: '25', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '8210503', seq: '25', to_res: A}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8210503', seq: '27', to_res: M}
- {entry_name: nk1r_human, from_res: P, pubmed: '1281469', seq: '28', to_res: A}
- {entry_name: nk1r_human, from_res: P, pubmed: '8210503', seq: '28', to_res: A}
- {entry_name: nk1r_human, from_res: W, pubmed: '1281469', seq: '30', to_res: A}
- {entry_name: nk1r_human, from_res: T, pubmed: '8384323', seq: '40', to_res: A}
- {entry_name: nk1r_human, from_res: E, pubmed: '7510519', seq: '78', to_res: A}
- {entry_name: nk1r_human, from_res: E, pubmed: '7510519', seq: '78', to_res: Q}
- {entry_name: nk1r_human, from_res: S, pubmed: '1281470', seq: '80', to_res: C}
- {entry_name: nk1r_human, from_res: S, pubmed: '8058046', seq: '80', to_res: C}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '85', to_res: Q}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '85', to_res: S}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '85', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '89', to_res: S}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '89', to_res: Q}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '89', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '92', to_res: F}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '92', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '8384323', seq: '95', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '96', to_res: Q}
- {entry_name: nk1r_human, from_res: N, pubmed: '1281469', seq: '96', to_res: S}
- {entry_name: nk1r_human, from_res: N, pubmed: '7510519', seq: '96', to_res: S}
- {entry_name: nk1r_human, from_res: E, pubmed: '8058046', seq: '97', to_res: V}
- {entry_name: nk1r_human, from_res: T, pubmed: '8183248', seq: '170', to_res: K}
- {entry_name: nk1r_human, from_res: H, pubmed: '1281469', seq: '108', to_res: Q}
- {entry_name: nk1r_human, from_res: V, pubmed: '1281470', seq: '116', to_res: L}
- {entry_name: nk1r_human, from_res: V, pubmed: '8058046', seq: '116', to_res: L}
- {entry_name: nk1r_human, from_res: C, pubmed: '1281470', seq: '152', to_res: F}
- {entry_name: nk1r_human, from_res: C, pubmed: '8058046', seq: '152', to_res: F}
- {entry_name: nk1r_human, from_res: E, pubmed: '8183248', seq: '172', to_res: K}
- {entry_name: nk1r_human, from_res: E, pubmed: '8183248', seq: '172', to_res: A}
- {entry_name: nk1r_human, from_res: S, pubmed: '8183248', seq: '176', to_res: G}
- {entry_name: nk1r_human, from_res: M, pubmed: '8183248', seq: '181', to_res: F}
- {entry_name: nk1r_human, from_res: E, pubmed: '8183248', seq: '183', to_res: Q}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8183248', seq: '192', to_res: Q}
- {entry_name: nk1r_human, from_res: E, pubmed: '8183248', seq: '193', to_res: H}
- {entry_name: nk1r_human, from_res: E, pubmed: '8183248', seq: '193', to_res: A}
- {entry_name: nk1r_human, from_res: K, pubmed: '8183248', seq: '194', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8183248', seq: '272', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '8183248', seq: '274', to_res: Y}
- {entry_name: nk1r_human, from_res: P, pubmed: '8183248', seq: '275', to_res: Q}
- {entry_name: nk1r_human, from_res: D, pubmed: '8183248', seq: '276', to_res: Q}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8183248', seq: '278', to_res: N}
- {entry_name: nk1r_human, from_res: H, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, pubmed: '7509807', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, pubmed: '7509807', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, pubmed: '7509807', seq: '197', to_res: S}
- {entry_name: nk1r_human, from_res: H, pubmed: '8384323', seq: '197', to_res: S}
- {entry_name: nk1r_human, from_res: H, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7509807', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '8384323', seq: '197', to_res: Y}
- {entry_name: nk1r_human, from_res: T, pubmed: '8384323', seq: '201', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '205', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7509807', seq: '265', to_res: Y}
- {entry_name: nk1r_human, from_res: H, pubmed: '7509807', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7506676', seq: '265', to_res: F}
- {entry_name: nk1r_human, from_res: H, pubmed: '7506676', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7509807', seq: '265', to_res: Q}
- {entry_name: nk1r_human, from_res: H, pubmed: '7506676', seq: '265', to_res: Q}
- {entry_name: nk1r_human, from_res: H, pubmed: '8300604', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '8300604', seq: '265', to_res: F}
- {entry_name: nk1r_human, from_res: H, pubmed: '8300604', seq: '265', to_res: S}
- {entry_name: nk1r_human, from_res: H, pubmed: '8300604', seq: '265', to_res: Y}
- {entry_name: nk1r_human, from_res: H, pubmed: '8300604', seq: '265', to_res: Q}
- {entry_name: nk1r_human, from_res: I, pubmed: '1281470', seq: '266', to_res: V}
- {entry_name: nk1r_rat, from_res: C, pubmed: '7679096', seq: '80', to_res: S}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8384323', seq: '284', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '287', to_res: Q}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '287', to_res: F}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '287', to_res: W}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '287', to_res: A}
- {entry_name: nk1r_rat, from_res: C, pubmed: '8058046', seq: '80', to_res: S}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '287', to_res: S}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7510519', seq: '287', to_res: H}
- {entry_name: nk1r_human, from_res: I, pubmed: '1281470', seq: '290', to_res: S}
- {entry_name: nk1r_human, from_res: I, pubmed: '7679096', seq: '290', to_res: S}
- {entry_name: nk1r_human, from_res: I, pubmed: '8058046', seq: '290', to_res: S}
- {entry_name: nk1r_human, from_res: M, pubmed: '1281469', seq: '291', to_res: F}
- {entry_name: nk1r_rat, from_res: V, pubmed: '1280161', seq: '97', to_res: E}
- {entry_name: nk1r_rat, from_res: V, pubmed: '8058046', seq: '97', to_res: E}
- {entry_name: nk1r_rat, from_res: L, pubmed: '7679096', seq: '116', to_res: V}
- {entry_name: nk1r_rat, from_res: L, pubmed: '7509441', seq: '116', to_res: V}
- {entry_name: nk1r_rat, from_res: L, pubmed: '8058046', seq: '116', to_res: V}
- {entry_name: nk1r_rat, from_res: L, pubmed: '8300604', seq: '116', to_res: V}
- {entry_name: nk1r_rat, from_res: F, pubmed: '7679096', seq: '152', to_res: C}
- {entry_name: nk1r_rat, from_res: F, pubmed: '8058046', seq: '152', to_res: C}
- {entry_name: nk1r_rat, from_res: R, pubmed: '7679096', seq: '190', to_res: K}
- {entry_name: nk1r_rat, from_res: T, pubmed: '7679096', seq: '191', to_res: I}
- {entry_name: nk1r_rat, from_res: A, pubmed: '7679096', seq: '195', to_res: V}
- {entry_name: nk1r_rat, from_res: H, pubmed: '8300604', seq: '197', to_res: A}
- {entry_name: nk1r_rat, from_res: H, pubmed: '8300604', seq: '265', to_res: A}
- {entry_name: nk1r_rat, from_res: V, pubmed: '7679096', seq: '266', to_res: I}
- {entry_name: nk1r_rat, from_res: V, pubmed: '7509441', seq: '266', to_res: I}
- {entry_name: nk1r_rat, from_res: S, pubmed: '8058046', seq: '290', to_res: I}
- {entry_name: nk1r_rat, from_res: S, pubmed: '7509441', seq: '290', to_res: I}
- {entry_name: nk1r_rat, from_res: S, pubmed: '7679096', seq: '290', to_res: I}
- {entry_name: nk1r_rat, from_res: S, pubmed: '8300604', seq: '290', to_res: I}
- {entry_name: nk2r_human, from_res: H, pubmed: '7510519', seq: '198', to_res: A}
- {entry_name: nk2r_human, from_res: H, pubmed: '7510519', seq: '267', to_res: Y}
- {entry_name: ednra_human, from_res: Y, pubmed: '8175640', seq: '129', to_res: A}
- {entry_name: ednra_human, from_res: Y, pubmed: '8175640', seq: '129', to_res: H}
- {entry_name: ednra_human, from_res: Y, pubmed: '8041764', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Y, pubmed: '8041764', seq: '129', to_res: K}
- {entry_name: ednra_human, from_res: Y, pubmed: '8041764', seq: '129', to_res: A}
- {entry_name: ednra_human, from_res: Y, pubmed: '8041764', seq: '129', to_res: N}
- {entry_name: ednra_human, from_res: Y, pubmed: '8041764', seq: '129', to_res: S}
- {entry_name: ednra_human, from_res: Y, pubmed: '8041764', seq: '129', to_res: Q}
- {entry_name: ednra_human, from_res: Y, pubmed: '8041764', seq: '129', to_res: H}
- {entry_name: ednra_human, from_res: S, pubmed: '8175640', seq: '167', to_res: A}
- {entry_name: ednra_human, from_res: V, pubmed: '8175640', seq: '225', to_res: A}
- {entry_name: ednra_human, from_res: G, pubmed: '8175640', seq: '261', to_res: A}
- {entry_name: ednra_human, from_res: F, pubmed: '8175640', seq: '320', to_res: A}
- {entry_name: ednrb_human, from_res: H, pubmed: '8041764', seq: '150', to_res: A}
- {entry_name: ednrb_human, from_res: H, pubmed: '8041764', seq: '150', to_res: Y}
- {entry_name: ednrb_human, from_res: C, pubmed: '8461018', seq: '174', to_res: A}
- {entry_name: ednrb_human, from_res: C, pubmed: '8461018', seq: '255', to_res: A}
- {entry_name: ednrb_human, from_res: C, pubmed: '8461018', seq: '358', to_res: A}
- {entry_name: ednrb_rat, from_res: K, pubmed: '1429881', seq: '182', to_res: D}
- {entry_name: bkrb2_rat, from_res: R, pubmed: '1334628', seq: '106', to_res: A}
- {entry_name: bkrb2_rat, from_res: R, pubmed: '1334628', seq: '106', to_res: Q}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '1334628', seq: '110', to_res: A}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '1334628', seq: '113', to_res: F}
- {entry_name: bkrb2_rat, from_res: R, pubmed: '1334628', seq: '171', to_res: Q}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8002982', seq: '175', to_res: A}
- {entry_name: bkrb2_rat, from_res: E, pubmed: '8002982', seq: '178', to_res: A}
- {entry_name: bkrb2_rat, from_res: E, pubmed: '8002982', seq: '179', to_res: A}
- {entry_name: bkrb2_rat, from_res: E, pubmed: '8002982', seq: '196', to_res: A}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '1334628', seq: '199', to_res: A}
- {entry_name: bkrb2_rat, from_res: N, pubmed: '1334628', seq: '200', to_res: A}
- {entry_name: bkrb2_rat, from_res: N, pubmed: '1334628', seq: '204', to_res: A}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '1334628', seq: '261', to_res: A}
- {entry_name: bkrb2_rat, from_res: Q, pubmed: '1334628', seq: '262', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '1334628', seq: '268', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '1334628', seq: '268', to_res: R}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8002982', seq: '268', to_res: A}
- {entry_name: bkrb2_rat, from_res: E, pubmed: '8002982', seq: '282', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8002982', seq: '286', to_res: A}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '8183923', seq: '259', to_res: A}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '8183923', seq: '261', to_res: V}
- {entry_name: bkrb2_rat, from_res: Q, pubmed: '8183923', seq: '262', to_res: A}
- {entry_name: bkrb2_rat, from_res: I, pubmed: '8183923', seq: '263', to_res: A}
- {entry_name: bkrb2_rat, from_res: S, pubmed: '8183923', seq: '264', to_res: A}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '8183923', seq: '265', to_res: A}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '8183923', seq: '266', to_res: A}
- {entry_name: bkrb2_rat, from_res: L, pubmed: '8183923', seq: '267', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8183923', seq: '268', to_res: A}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '8183923', seq: '269', to_res: A}
- {entry_name: nmbr_rat, from_res: I, pubmed: '8392057', seq: '216', to_res: S}
- {entry_name: nmbr_rat, from_res: I, pubmed: '8392057', seq: '230', to_res: V}
- {entry_name: nmbr_rat, from_res: H, pubmed: '8392057', seq: '234', to_res: F}
- {entry_name: agtr1_human, from_res: A, pubmed: '8041743', seq: '283', to_res: G}
- {entry_name: agtr1_human, from_res: N, pubmed: '8041743', seq: '295', to_res: S}
- {entry_name: agtra_rat, from_res: N, pubmed: '1417818', seq: '4', to_res: D}
- {entry_name: agtra_rat, from_res: C, pubmed: '1417818', seq: '18', to_res: G}
- {entry_name: agtra_rat, from_res: D, pubmed: '8506360', seq: '74', to_res: N}
- {entry_name: agtra_rat, from_res: D, pubmed: '8506360', seq: '74', to_res: E}
- {entry_name: agtra_rat, from_res: C, pubmed: '1417818', seq: '101', to_res: G}
- {entry_name: agtra_rat, from_res: N, pubmed: '1417818', seq: '176', to_res: D}
- {entry_name: agtra_rat, from_res: C, pubmed: '1417818', seq: '180', to_res: G}
- {entry_name: agtra_rat, from_res: N, pubmed: '1417818', seq: '188', to_res: D}
- {entry_name: agtra_rat, from_res: K, pubmed: '1417818', seq: '199', to_res: Q}
- {entry_name: agtra_rat, from_res: C, pubmed: '1417818', seq: '274', to_res: G}
- {entry_name: agtra_rat, from_res: Y, pubmed: '8063694', seq: '292', to_res: F}
- {entry_name: agtra_rat, from_res: C, pubmed: '1472039', seq: '355', to_res: G}
- {entry_name: ssr2_mouse, from_res: D, pubmed: '8102784', seq: '89', to_res: N}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '6', to_res: A}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '11', to_res: K}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '11', to_res: A}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '11', to_res: E}
- {entry_name: cxcr1_human, from_res: F, pubmed: '8034699', seq: '12', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '18', to_res: A}
- {entry_name: cxcr1_human, from_res: G, pubmed: '8034699', seq: '19', to_res: A}
- {entry_name: cxcr1_human, from_res: M, pubmed: '8034699', seq: '20', to_res: A}
- {entry_name: cxcr1_human, from_res: P, pubmed: '8034699', seq: '21', to_res: A}
- {entry_name: cxcr1_human, from_res: P, pubmed: '8034699', seq: '22', to_res: A}
- {entry_name: cxcr1_human, from_res: Y, pubmed: '8034699', seq: '27', to_res: A}
- {entry_name: cxcr1_human, from_res: C, pubmed: '8034699', seq: '30', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '34', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '36', to_res: A}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '85', to_res: A}
- {entry_name: cxcr1_human, from_res: G, pubmed: '8034699', seq: '102', to_res: A}
- {entry_name: cxcr1_human, from_res: W, pubmed: '8034699', seq: '103', to_res: A}
- {entry_name: cxcr1_human, from_res: I, pubmed: '8034699', seq: '104', to_res: A}
- {entry_name: cxcr1_human, from_res: F, pubmed: '8034699', seq: '105', to_res: A}
- {entry_name: cxcr1_human, from_res: G, pubmed: '8034699', seq: '106', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '107', to_res: A}
- {entry_name: cxcr1_human, from_res: C, pubmed: '8034699', seq: '110', to_res: A}
- {entry_name: cxcr1_human, from_res: K, pubmed: '8034699', seq: '111', to_res: A}
- {entry_name: cxcr1_human, from_res: K, pubmed: '8103045', seq: '117', to_res: A}
- {entry_name: cxcr1_human, from_res: E, pubmed: '8103045', seq: '118', to_res: A}
- {entry_name: cxcr1_human, from_res: Y, pubmed: '8034699', seq: '178', to_res: A}
- {entry_name: cxcr1_human, from_res: H, pubmed: '8034699', seq: '179', to_res: A}
- {entry_name: cxcr1_human, from_res: P, pubmed: '8034699', seq: '180', to_res: A}
- {entry_name: cxcr1_human, from_res: C, pubmed: '8034699', seq: '187', to_res: A}
- {entry_name: cxcr1_human, from_res: Y, pubmed: '8034699', seq: '188', to_res: A}
- {entry_name: cxcr1_human, from_res: E, pubmed: '8103045', seq: '189', to_res: A}
- {entry_name: cxcr1_human, from_res: V, pubmed: '8034699', seq: '190', to_res: A}
- {entry_name: cxcr1_human, from_res: L, pubmed: '8034699', seq: '191', to_res: A}
- {entry_name: cxcr1_human, from_res: G, pubmed: '8034699', seq: '192', to_res: A}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '194', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8034699', seq: '199', to_res: A}
- {entry_name: cxcr1_human, from_res: M, pubmed: '8034699', seq: '200', to_res: A}
- {entry_name: cxcr1_human, from_res: V, pubmed: '8034699', seq: '201', to_res: A}
- {entry_name: cxcr1_human, from_res: L, pubmed: '8034699', seq: '202', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8034699', seq: '203', to_res: A}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '265', to_res: A}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8034699', seq: '265', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '266', to_res: A}
- {entry_name: cxcr1_human, from_res: L, pubmed: '8034699', seq: '267', to_res: A}
- {entry_name: cxcr1_human, from_res: M, pubmed: '8034699', seq: '268', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8034699', seq: '269', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '270', to_res: A}
- {entry_name: cxcr1_human, from_res: Q, pubmed: '8034699', seq: '271', to_res: A}
- {entry_name: cxcr1_human, from_res: V, pubmed: '8034699', seq: '272', to_res: A}
- {entry_name: cxcr1_human, from_res: I, pubmed: '8034699', seq: '273', to_res: A}
- {entry_name: cxcr1_human, from_res: Q, pubmed: '8034699', seq: '274', to_res: A}
- {entry_name: cxcr1_human, from_res: E, pubmed: '8103045', seq: '275', to_res: A}
- {entry_name: cxcr1_human, from_res: E, pubmed: '8034699', seq: '275', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '276', to_res: A}
- {entry_name: cxcr1_human, from_res: C, pubmed: '8034699', seq: '277', to_res: A}
- {entry_name: cxcr1_human, from_res: E, pubmed: '8103045', seq: '278', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8103045', seq: '279', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8103045', seq: '280', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8034699', seq: '280', to_res: A}
- {entry_name: cxcr1_human, from_res: L, pubmed: '8034699', seq: '287', to_res: A}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8103045', seq: '288', to_res: A}
- {entry_name: cxcr1_human, from_res: T, pubmed: '8034699', seq: '290', to_res: A}
- {entry_name: cxcr1_human, from_res: E, pubmed: '8103045', seq: '291', to_res: A}
- {entry_name: npy1r_human, from_res: E, pubmed: '8300621', seq: '10', to_res: A}
- {entry_name: npy1r_human, from_res: E, pubmed: '8300621', seq: '20', to_res: A}
- {entry_name: npy1r_human, from_res: E, pubmed: '8300621', seq: '29', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '32', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '104', to_res: A}
- {entry_name: npy1r_human, from_res: E, pubmed: '8300621', seq: '110', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '181', to_res: A}
- {entry_name: npy1r_human, from_res: E, pubmed: '8300621', seq: '182', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '190', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '194', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '200', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '205', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8300621', seq: '287', to_res: A}
- {entry_name: trfr_mouse, from_res: D, pubmed: '1332958', seq: '71', to_res: A}
- {entry_name: trfr_mouse, from_res: D, pubmed: '8247012', seq: '71', to_res: A}
- {entry_name: trfr_mouse, from_res: D, pubmed: '1332958', seq: '85', to_res: A}
- {entry_name: trfr_mouse, from_res: D, pubmed: '1332958', seq: '165', to_res: A}
- {entry_name: trfr_mouse, from_res: D, pubmed: '1332958', seq: '195', to_res: A}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '8294406', seq: '106', to_res: F}
- {entry_name: gasr_human, from_res: V, pubmed: '8185216', seq: '349', to_res: L}
- {entry_name: drd2_mouse, from_res: Y, pubmed: '7958215', seq: '417', to_res: F}
- {entry_name: gasr_canfa, from_res: G, pubmed: '8455720', seq: '322', to_res: S}
- {entry_name: gasr_canfa, from_res: Y, pubmed: '8455720', seq: '327', to_res: T}
- {entry_name: gasr_canfa, from_res: L, pubmed: '8455720', seq: '355', to_res: V}
- {entry_name: gasr_human, from_res: A, pubmed: '7890609', seq: '370', to_res: I}
- {entry_name: gasr_canfa, from_res: L, pubmed: '8185216', seq: '355', to_res: V}
- {entry_name: opsd_bovin, from_res: V, pubmed: '8193125', seq: '345', to_res: M}
- {entry_name: mshr_mouse, from_res: S, pubmed: '8458079', seq: '69', to_res: L}
- {entry_name: mshr_mouse, from_res: E, pubmed: '8458079', seq: '92', to_res: K}
- {entry_name: mshr_human, from_res: D, pubmed: '8060302', seq: '117', to_res: A}
- {entry_name: mshr_human, from_res: F, pubmed: '8060302', seq: '179', to_res: A}
- {entry_name: mshr_human, from_res: H, pubmed: '8060302', seq: '209', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1356370', seq: '296', to_res: G}
- {entry_name: mshr_human, from_res: H, pubmed: '8060302', seq: '260', to_res: A}
- {entry_name: lshr_human, from_res: D, pubmed: '7692306', seq: '578', to_res: G}
- {entry_name: lshr_rat, from_res: N, pubmed: '8420926', seq: '103', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '8420926', seq: '178', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '8420926', seq: '199', to_res: Q}
- {entry_name: lshr_rat, from_res: T, pubmed: '8420926', seq: '201', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '8420926', seq: '317', to_res: Q}
- {entry_name: lshr_rat, from_res: S, pubmed: '8420926', seq: '180', to_res: A}
- {entry_name: lshr_rat, from_res: T, pubmed: '8420926', seq: '201', to_res: A}
- {entry_name: lshr_rat, from_res: D, pubmed: '1714448', seq: '409', to_res: N}
- {entry_name: lshr_rat, from_res: D, pubmed: '8395653', seq: '409', to_res: N}
- {entry_name: lshr_rat, from_res: D, pubmed: '8407915', seq: '423', to_res: E}
- {entry_name: lshr_rat, from_res: D, pubmed: '8407915', seq: '423', to_res: N}
- {entry_name: lshr_rat, from_res: D, pubmed: '8407915', seq: '423', to_res: A}
- {entry_name: lshr_rat, from_res: D, pubmed: '8407915', seq: '423', to_res: K}
- {entry_name: lshr_rat, from_res: D, pubmed: '8407915', seq: '423', to_res: R}
- {entry_name: lshr_rat, from_res: D, pubmed: '8226810', seq: '423', to_res: A}
- {entry_name: lshr_rat, from_res: D, pubmed: '8226810', seq: '423', to_res: K}
- {entry_name: lshr_rat, from_res: D, pubmed: '8226810', seq: '423', to_res: R}
- {entry_name: lshr_rat, from_res: D, pubmed: '1714448', seq: '436', to_res: Q}
- {entry_name: lshr_rat, from_res: D, pubmed: '8407915', seq: '436', to_res: N}
- {entry_name: lshr_rat, from_res: D, pubmed: '8226810', seq: '436', to_res: K}
- {entry_name: lshr_rat, from_res: E, pubmed: '1714448', seq: '455', to_res: Q}
- {entry_name: lshr_rat, from_res: E, pubmed: '8383288', seq: '467', to_res: D}
- {entry_name: lshr_rat, from_res: E, pubmed: '8383288', seq: '467', to_res: Q}
- {entry_name: lshr_rat, from_res: D, pubmed: '8407915', seq: '522', to_res: N}
- {entry_name: lshr_rat, from_res: D, pubmed: '8226810', seq: '522', to_res: K}
- {entry_name: lshr_rat, from_res: E, pubmed: '8407915', seq: '524', to_res: Q}
- {entry_name: lshr_rat, from_res: E, pubmed: '8226810', seq: '524', to_res: K}
- {entry_name: lshr_rat, from_res: D, pubmed: '1714448', seq: '582', to_res: N}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '8114667', seq: '87', to_res: D}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '8114667', seq: '318', to_res: N}
- {entry_name: tshr_human, from_res: R, pubmed: '1584215', seq: '38', to_res: S}
- {entry_name: tshr_human, from_res: V, pubmed: '1584215', seq: '39', to_res: A}
- {entry_name: tshr_human, from_res: T, pubmed: '1584215', seq: '40', to_res: S}
- {entry_name: tshr_human, from_res: C, pubmed: '1584215', seq: '41', to_res: S}
- {entry_name: tshr_human, from_res: N, pubmed: '2017190', seq: '77', to_res: Q}
- {entry_name: tshr_human, from_res: N, pubmed: '2017190', seq: '99', to_res: Q}
- {entry_name: tshr_human, from_res: N, pubmed: '2017190', seq: '113', to_res: Q}
- {entry_name: tshr_human, from_res: N, pubmed: '2017190', seq: '177', to_res: Q}
- {entry_name: tshr_human, from_res: N, pubmed: '2017190', seq: '198', to_res: Q}
- {entry_name: tshr_human, from_res: N, pubmed: '2017190', seq: '302', to_res: Q}
- {entry_name: tshr_human, from_res: C, pubmed: '8135801', seq: '494', to_res: S}
- {entry_name: tshr_human, from_res: C, pubmed: '8135801', seq: '569', to_res: S}
- {entry_name: tshr_human, from_res: D, pubmed: '8413627', seq: '619', to_res: G}
- {entry_name: tshr_human, from_res: A, pubmed: '8413627', seq: '623', to_res: I}
- {entry_name: tshr_human, from_res: D, pubmed: '1663578', seq: '617', to_res: N}
- {entry_name: tshr_human, from_res: K, pubmed: '1663578', seq: '618', to_res: Q}
- {entry_name: tshr_human, from_res: D, pubmed: '1663578', seq: '619', to_res: N}
- {entry_name: tshr_human, from_res: T, pubmed: '1663578', seq: '620', to_res: A}
- {entry_name: tshr_human, from_res: K, pubmed: '1663578', seq: '621', to_res: G}
- {entry_name: tshr_human, from_res: K, pubmed: '1663578', seq: '624', to_res: Q}
- {entry_name: tshr_human, from_res: R, pubmed: '1663578', seq: '625', to_res: G}
- {entry_name: tshr_rat, from_res: C, pubmed: '1349156', seq: '31', to_res: S}
- {entry_name: tshr_rat, from_res: R, pubmed: '1349156', seq: '38', to_res: Q}
- {entry_name: tshr_rat, from_res: T, pubmed: '1349156', seq: '40', to_res: N}
- {entry_name: tshr_rat, from_res: T, pubmed: '1349156', seq: '40', to_res: A}
- {entry_name: tshr_rat, from_res: C, pubmed: '1349156', seq: '41', to_res: S}
- {entry_name: tshr_rat, from_res: E, pubmed: '1349156', seq: '43', to_res: Q}
- {entry_name: tshr_rat, from_res: H, pubmed: '1349156', seq: '45', to_res: G}
- {entry_name: tshr_rat, from_res: K, pubmed: '1349156', seq: '58', to_res: Q}
- {entry_name: tshr_rat, from_res: E, pubmed: '1349156', seq: '61', to_res: Q}
- {entry_name: tshr_rat, from_res: T, pubmed: '1349156', seq: '62', to_res: N}
- {entry_name: tshr_rat, from_res: H, pubmed: '1349156', seq: '63', to_res: G}
- {entry_name: tshr_rat, from_res: K, pubmed: '1349156', seq: '65', to_res: Q}
- {entry_name: tshr_rat, from_res: T, pubmed: '1349156', seq: '66', to_res: N}
- {entry_name: tshr_rat, from_res: T, pubmed: '1349156', seq: '66', to_res: S}
- {entry_name: tshr_rat, from_res: S, pubmed: '1349156', seq: '69', to_res: A}
- {entry_name: tshr_rat, from_res: S, pubmed: '1349156', seq: '73', to_res: A}
- {entry_name: tshr_rat, from_res: S, pubmed: '1349156', seq: '74', to_res: A}
- {entry_name: tshr_rat, from_res: T, pubmed: '1349156', seq: '88', to_res: A}
- {entry_name: tshr_rat, from_res: N, pubmed: '1726785', seq: '77', to_res: Q}
- {entry_name: tshr_rat, from_res: N, pubmed: '1726785', seq: '99', to_res: Q}
- {entry_name: tshr_rat, from_res: N, pubmed: '1726785', seq: '177', to_res: Q}
- {entry_name: tshr_rat, from_res: N, pubmed: '1726785', seq: '198', to_res: Q}
- {entry_name: tshr_rat, from_res: C, pubmed: '1336379', seq: '176', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '1336379', seq: '283', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '1336379', seq: '284', to_res: S}
- {entry_name: tshr_rat, from_res: N, pubmed: '1726785', seq: '302', to_res: Q}
- {entry_name: tshr_rat, from_res: Y, pubmed: '1349156', seq: '385', to_res: F}
- {entry_name: tshr_rat, from_res: Y, pubmed: '1349156', seq: '385', to_res: A}
- {entry_name: tshr_rat, from_res: T, pubmed: '8095322', seq: '62', to_res: A}
- {entry_name: tshr_rat, from_res: K, pubmed: '1655787', seq: '287', to_res: G}
- {entry_name: tshr_rat, from_res: N, pubmed: '1655787', seq: '288', to_res: G}
- {entry_name: tshr_rat, from_res: R, pubmed: '1655787', seq: '293', to_res: G}
- {entry_name: tshr_rat, from_res: M, pubmed: '1655787', seq: '300', to_res: I}
- {entry_name: tshr_rat, from_res: C, pubmed: '1655787', seq: '301', to_res: S}
- {entry_name: tshr_rat, from_res: N, pubmed: '1655787', seq: '302', to_res: Q}
- {entry_name: tshr_rat, from_res: S, pubmed: '1655787', seq: '383', to_res: A}
- {entry_name: tshr_rat, from_res: H, pubmed: '1655787', seq: '384', to_res: G}
- {entry_name: tshr_rat, from_res: Y, pubmed: '1655787', seq: '385', to_res: A}
- {entry_name: tshr_rat, from_res: Y, pubmed: '1655787', seq: '385', to_res: F}
- {entry_name: tshr_rat, from_res: Y, pubmed: '1655787', seq: '385', to_res: Q}
- {entry_name: tshr_rat, from_res: Y, pubmed: '1655787', seq: '385', to_res: T}
- {entry_name: tshr_rat, from_res: D, pubmed: '1655787', seq: '386', to_res: T}
- {entry_name: tshr_rat, from_res: Y, pubmed: '1719963', seq: '387', to_res: F}
- {entry_name: tshr_rat, from_res: T, pubmed: '1719963', seq: '388', to_res: A}
- {entry_name: tshr_rat, from_res: T, pubmed: '1719963', seq: '388', to_res: N}
- {entry_name: tshr_rat, from_res: C, pubmed: '1719963', seq: '390', to_res: S}
- {entry_name: tshr_rat, from_res: E, pubmed: '1655787', seq: '394', to_res: G}
- {entry_name: tshr_rat, from_res: D, pubmed: '1655787', seq: '395', to_res: G}
- {entry_name: tshr_rat, from_res: M, pubmed: '1655787', seq: '396', to_res: I}
- {entry_name: tshr_rat, from_res: C, pubmed: '1655787', seq: '398', to_res: S}
- {entry_name: tshr_rat, from_res: T, pubmed: '1655787', seq: '399', to_res: A}
- {entry_name: tshr_rat, from_res: K, pubmed: '1655787', seq: '401', to_res: Q}
- {entry_name: tshr_rat, from_res: S, pubmed: '1655787', seq: '402', to_res: A}
- {entry_name: tshr_rat, from_res: D, pubmed: '1655787', seq: '403', to_res: G}
- {entry_name: tshr_rat, from_res: D, pubmed: '1719963', seq: '403', to_res: Y}
- {entry_name: tshr_rat, from_res: D, pubmed: '1719963', seq: '403', to_res: N}
- {entry_name: tshr_rat, from_res: D, pubmed: '1719963', seq: '403', to_res: E}
- {entry_name: tshr_rat, from_res: E, pubmed: '1655787', seq: '404', to_res: G}
- {entry_name: tshr_rat, from_res: C, pubmed: '1336379', seq: '408', to_res: S}
- {entry_name: tshr_rat, from_res: T, pubmed: '8137933', seq: '447', to_res: Q}
- {entry_name: tshr_rat, from_res: C, pubmed: '1336379', seq: '494', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '1336379', seq: '569', to_res: S}
- {entry_name: tshr_rat, from_res: A, pubmed: '1332945', seq: '623', to_res: E}
- {entry_name: tshr_rat, from_res: A, pubmed: '1332945', seq: '623', to_res: K}
- {entry_name: c5ar_human, from_res: N, pubmed: '8298500', seq: '5', to_res: A}
- {entry_name: c5ar_human, from_res: D, pubmed: '8282089', seq: '10', to_res: N}
- {entry_name: c5ar_human, from_res: D, pubmed: '8106386', seq: '10', to_res: N}
- {entry_name: c5ar_human, from_res: P, pubmed: '8282089', seq: '9', to_res: N}
- {entry_name: c5ar_human, from_res: D, pubmed: '8282089', seq: '21', to_res: N}
- {entry_name: c5ar_human, from_res: D, pubmed: '8282089', seq: '27', to_res: N}
- {entry_name: c5ar_human, from_res: D, pubmed: '8106386', seq: '27', to_res: N}
- {entry_name: c5ar_human, from_res: P, pubmed: '8282089', seq: '36', to_res: L}
- {entry_name: c5ar_human, from_res: N, pubmed: '8282089', seq: '5', to_res: Q}
- {entry_name: oprm_rat, from_res: D, pubmed: '8051154', seq: '114', to_res: A}
- {entry_name: oprd_mouse, from_res: D, pubmed: '8226821', seq: '95', to_res: N}
- {entry_name: oprm_rat, from_res: D, pubmed: '8051154', seq: '114', to_res: N}
- {entry_name: oprm_rat, from_res: D, pubmed: '8051154', seq: '114', to_res: E}
- {entry_name: oprm_rat, from_res: D, pubmed: '8051154', seq: '147', to_res: A}
- {entry_name: oprm_rat, from_res: D, pubmed: '8051154', seq: '147', to_res: N}
- {entry_name: oprm_rat, from_res: D, pubmed: '8051154', seq: '147', to_res: E}
- {entry_name: oprm_rat, from_res: H, pubmed: '8051154', seq: '297', to_res: A}
- {entry_name: ta2r_human, from_res: L, pubmed: '8246916', seq: '291', to_res: F}
- {entry_name: ta2r_human, from_res: R, pubmed: '8246916', seq: '295', to_res: Q}
- {entry_name: ta2r_human, from_res: W, pubmed: '8246916', seq: '299', to_res: L}
- {entry_name: ta2r_human, from_res: W, pubmed: '8246916', seq: '299', to_res: R}
- {entry_name: aa1r_bovin, from_res: H, pubmed: '1587851', seq: '251', to_res: L}
- {entry_name: aa1r_bovin, from_res: H, pubmed: '1587851', seq: '278', to_res: L}
- {entry_name: gnrhr_rat, from_res: N, pubmed: '8133203', seq: '87', to_res: D}
- {entry_name: acm1_human, from_res: E, pubmed: '7706286', seq: '360', to_res: A}
- {entry_name: gnrhr_rat, from_res: D, pubmed: '8133203', seq: '318', to_res: N}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '69', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '98', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '178', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '391', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '394', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '407', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '417', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '421', to_res: S}
- {entry_name: acm1_rat, from_res: C, pubmed: '1317867', seq: '435', to_res: S}
- {entry_name: tshr_rat, from_res: S, pubmed: '8185569', seq: '113', to_res: Q}
- {entry_name: par1_human, from_res: R, pubmed: '1672265', seq: '41', to_res: A}
- {entry_name: par1_human, from_res: S, pubmed: '1672265', seq: '42', to_res: P}
- {entry_name: par1_human, from_res: R, pubmed: '1672265', seq: '46', to_res: A}
- {entry_name: par1_human, from_res: R, pubmed: '1672265', seq: '70', to_res: A}
- {entry_name: tshr_rat, from_res: C, pubmed: '1639025', seq: '41', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '1639025', seq: '398', to_res: S}
- {entry_name: par1_human, from_res: S, pubmed: '1320011', seq: '42', to_res: G}
- {entry_name: par1_human, from_res: S, pubmed: '1320011', seq: '42', to_res: A}
- {entry_name: par1_human, from_res: F, pubmed: '1320011', seq: '43', to_res: A}
- {entry_name: par1_human, from_res: R, pubmed: '1320011', seq: '46', to_res: A}
- {entry_name: par1_human, from_res: P, pubmed: '1320011', seq: '48', to_res: A}
- {entry_name: drd2_human, from_res: C, pubmed: '7937955', seq: '56', to_res: S}
- {entry_name: drd2_human, from_res: C, pubmed: '7937955', seq: '118', to_res: S}
- {entry_name: drd2_human, from_res: C, pubmed: '7937955', seq: '126', to_res: S}
- {entry_name: drd2_human, from_res: C, pubmed: '7937955', seq: '168', to_res: S}
- {entry_name: drd2_human, from_res: C, pubmed: '7937955', seq: '385', to_res: S}
- {entry_name: fpr1_human, from_res: H, pubmed: '8077194', seq: '90', to_res: A}
- {entry_name: fpr1_human, from_res: W, pubmed: '8077194', seq: '91', to_res: A}
- {entry_name: fpr1_human, from_res: P, pubmed: '8077194', seq: '92', to_res: A}
- {entry_name: fpr1_human, from_res: F, pubmed: '8077194', seq: '93', to_res: A}
- {entry_name: fpr1_human, from_res: G, pubmed: '8077194', seq: '94', to_res: A}
- {entry_name: fpr1_human, from_res: W, pubmed: '8077194', seq: '95', to_res: A}
- {entry_name: fpr1_human, from_res: F, pubmed: '8077194', seq: '96', to_res: A}
- {entry_name: fpr1_human, from_res: L, pubmed: '8077194', seq: '97', to_res: A}
- {entry_name: fpr1_human, from_res: C, pubmed: '8077194', seq: '98', to_res: A}
- {entry_name: fpr1_human, from_res: K, pubmed: '8077194', seq: '99', to_res: A}
- {entry_name: fpr1_human, from_res: C, pubmed: '8077194', seq: '176', to_res: A}
- {entry_name: tshr_human, from_res: P, pubmed: '8170469', seq: '556', to_res: L}
- {entry_name: gnrhr_mouse, from_res: E, pubmed: '7915716', seq: '8', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: E, pubmed: '7915716', seq: '90', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '7915716', seq: '98', to_res: N}
- {entry_name: gnrhr_mouse, from_res: E, pubmed: '7915716', seq: '111', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '7915716', seq: '185', to_res: N}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '7915716', seq: '292', to_res: N}
- {entry_name: gnrhr_mouse, from_res: E, pubmed: '7915716', seq: '294', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: E, pubmed: '7915716', seq: '301', to_res: Q}
- {entry_name: ta2r_human, from_res: R, pubmed: '7929844', seq: '60', to_res: L}
- {entry_name: ednra_human, from_res: K, pubmed: '8119297', seq: '140', to_res: I}
- {entry_name: ednra_human, from_res: L, pubmed: '8119297', seq: '142', to_res: M}
- {entry_name: ednra_human, from_res: A, pubmed: '8119297', seq: '143', to_res: K}
- {entry_name: ednra_human, from_res: G, pubmed: '8119297', seq: '144', to_res: M}
- {entry_name: nk3r_rat, from_res: L, pubmed: '8117303', seq: '81', to_res: V}
- {entry_name: nk3r_rat, from_res: F, pubmed: '8117303', seq: '88', to_res: L}
- {entry_name: nk3r_rat, from_res: V, pubmed: '8117303', seq: '121', to_res: M}
- {entry_name: nk3r_rat, from_res: I, pubmed: '8117303', seq: '128', to_res: V}
- {entry_name: nk3r_rat, from_res: G, pubmed: '8117303', seq: '133', to_res: A}
- {entry_name: v2r_human, from_res: R, pubmed: '8514744', seq: '137', to_res: H}
- {entry_name: agtrb_rat, from_res: T, pubmed: '8206967', seq: '2', to_res: L}
- {entry_name: agtrb_rat, from_res: Q, pubmed: '8206967', seq: '15', to_res: A}
- {entry_name: agtrb_rat, from_res: D, pubmed: '8206967', seq: '16', to_res: V}
- {entry_name: agtrb_rat, from_res: A, pubmed: '8206967', seq: '21', to_res: S}
- {entry_name: agtrb_rat, from_res: I, pubmed: '8206967', seq: '177', to_res: Q}
- {entry_name: agtrb_rat, from_res: H, pubmed: '8206967', seq: '183', to_res: V}
- {entry_name: agtrb_rat, from_res: Q, pubmed: '8206967', seq: '187', to_res: G}
- {entry_name: agtrb_rat, from_res: S, pubmed: '8206967', seq: '189', to_res: I}
- {entry_name: agtrb_rat, from_res: G, pubmed: '8206967', seq: '269', to_res: D}
- {entry_name: agtrb_rat, from_res: R, pubmed: '8206967', seq: '272', to_res: Q}
- {entry_name: agtrb_rat, from_res: L, pubmed: '8206967', seq: '128', to_res: S}
- {entry_name: agtrb_rat, from_res: W, pubmed: '8206967', seq: '219', to_res: G}
- {entry_name: agtrb_rat, from_res: K, pubmed: '8206967', seq: '224', to_res: E}
- {entry_name: agtrb_rat, from_res: K, pubmed: '8206967', seq: '227', to_res: E}
- {entry_name: agtrb_rat, from_res: L, pubmed: '8206967', seq: '305', to_res: F}
- {entry_name: agtrb_rat, from_res: S, pubmed: '8206967', seq: '331', to_res: N}
- {entry_name: agtrb_rat, from_res: N, pubmed: '8206967', seq: '344', to_res: T}
- {entry_name: agtrb_rat, from_res: S, pubmed: '8206967', seq: '352', to_res: A}
- {entry_name: agtrb_rat, from_res: L, pubmed: '8206967', seq: '34', to_res: I}
- {entry_name: agtrb_rat, from_res: L, pubmed: '8206967', seq: '79', to_res: I}
- {entry_name: agtrb_rat, from_res: S, pubmed: '8206967', seq: '107', to_res: A}
- {entry_name: agtrb_rat, from_res: V, pubmed: '8206967', seq: '108', to_res: I}
- {entry_name: agtrb_rat, from_res: K, pubmed: '8206967', seq: '146', to_res: R}
- {entry_name: agtrb_rat, from_res: I, pubmed: '8206967', seq: '151', to_res: G}
- {entry_name: agtrb_rat, from_res: G, pubmed: '8206967', seq: '157', to_res: L}
- {entry_name: agtrb_rat, from_res: A, pubmed: '8206967', seq: '163', to_res: S}
- {entry_name: agtrb_rat, from_res: L, pubmed: '8206967', seq: '191', to_res: F}
- {entry_name: agtrb_rat, from_res: P, pubmed: '8206967', seq: '192', to_res: M}
- {entry_name: agtrb_rat, from_res: T, pubmed: '8206967', seq: '198', to_res: A}
- {entry_name: agtrb_rat, from_res: L, pubmed: '8206967', seq: '202', to_res: V}
- {entry_name: agtrb_rat, from_res: F, pubmed: '8206967', seq: '206', to_res: I}
- {entry_name: agtrb_rat, from_res: I, pubmed: '8206967', seq: '241', to_res: M}
- {entry_name: agtrb_rat, from_res: M, pubmed: '8206967', seq: '243', to_res: V}
- {entry_name: agtrb_rat, from_res: F, pubmed: '8206967', seq: '248', to_res: L}
- {entry_name: agtrb_rat, from_res: S, pubmed: '8206967', seq: '252', to_res: C}
- {entry_name: agtrb_rat, from_res: I, pubmed: '8206967', seq: '258', to_res: V}
- {entry_name: agtrb_rat, from_res: A, pubmed: '8206967', seq: '277', to_res: Y}
- {entry_name: agtrb_rat, from_res: L, pubmed: '8206967', seq: '300', to_res: F}
- {entry_name: agtrb_rat, from_res: F, pubmed: '8206967', seq: '301', to_res: L}
- {entry_name: gasr_rat, from_res: V, pubmed: '7669996', seq: '354', to_res: L}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8202499', seq: '296', to_res: G}
- {entry_name: v2r_human, from_res: R, pubmed: '7984150', seq: '113', to_res: W}
- {entry_name: tshr_human, from_res: T, pubmed: '8045989', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: F, pubmed: '8045989', seq: '631', to_res: C}
- {entry_name: agtr1_human, from_res: N, pubmed: '7834178', seq: '295', to_res: S}
- {entry_name: c5ar_human, from_res: D, pubmed: '8035835', seq: '82', to_res: N}
- {entry_name: c5ar_human, from_res: E, pubmed: '8035835', seq: '179', to_res: Q}
- {entry_name: c5ar_human, from_res: E, pubmed: '8035835', seq: '180', to_res: Q}
- {entry_name: tshr_human, from_res: V, pubmed: '7920658', seq: '509', to_res: A}
- {entry_name: tshr_human, from_res: C, pubmed: '7920658', seq: '672', to_res: Y}
- {entry_name: par1_human, from_res: F, pubmed: '8206902', seq: '43', to_res: A}
- {entry_name: trfr_mouse, from_res: T, pubmed: '8089099', seq: '102', to_res: V}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '8089099', seq: '103', to_res: F}
- {entry_name: trfr_mouse, from_res: Q, pubmed: '8089099', seq: '105', to_res: A}
- {entry_name: trfr_mouse, from_res: N, pubmed: '8089099', seq: '110', to_res: A}
- {entry_name: trfr_mouse, from_res: N, pubmed: '8089099', seq: '110', to_res: S}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7929034', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7929034', seq: '134', to_res: D}
- {entry_name: nk1r_rat, from_res: R, pubmed: '7929043', seq: '190', to_res: Q}
- {entry_name: nk1r_rat, from_res: T, pubmed: '7929043', seq: '191', to_res: H}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '7929043', seq: '192', to_res: F}
- {entry_name: nk1r_rat, from_res: A, pubmed: '7929043', seq: '195', to_res: T}
- {entry_name: nk1r_rat, from_res: P, pubmed: '7929043', seq: '271', to_res: G}
- {entry_name: nk1r_rat, from_res: I, pubmed: '7929043', seq: '273', to_res: F}
- {entry_name: nk1r_rat, from_res: D, pubmed: '7929043', seq: '276', to_res: Q}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '7929043', seq: '272', to_res: T}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '7929043', seq: '272', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '8145734', seq: '261', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '8083204', seq: '261', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '8083204', seq: '262', to_res: A}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '8083204', seq: '262', to_res: D}
- {entry_name: acm1_human, from_res: S, pubmed: '8463213', seq: '284', to_res: A}
- {entry_name: nk1r_human, from_res: E, pubmed: '7525569', seq: '78', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '7525569', seq: '85', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '7525569', seq: '89', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7525569', seq: '92', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '7525569', seq: '96', to_res: A}
- {entry_name: aa1r_canfa, from_res: T, pubmed: '7961722', seq: '277', to_res: S}
- {entry_name: aa1r_canfa, from_res: M, pubmed: '7961722', seq: '270', to_res: I}
- {entry_name: aa1r_bovin, from_res: I, pubmed: '7961722', seq: '270', to_res: M}
- {entry_name: aa1r_bovin, from_res: S, pubmed: '7961722', seq: '277', to_res: T}
- {entry_name: nk2r_human, from_res: Q, pubmed: '7961636', seq: '109', to_res: H}
- {entry_name: nk2r_human, from_res: M, pubmed: '7961636', seq: '117', to_res: L}
- {entry_name: nk2r_human, from_res: L, pubmed: '7961636', seq: '160', to_res: F}
- {entry_name: nk2r_human, from_res: C, pubmed: '7961636', seq: '167', to_res: G}
- {entry_name: nk2r_human, from_res: G, pubmed: '7961636', seq: '190', to_res: N}
- {entry_name: nk2r_human, from_res: G, pubmed: '7961636', seq: '190', to_res: K}
- {entry_name: nk2r_human, from_res: G, pubmed: '7961636', seq: '191', to_res: K}
- {entry_name: nk2r_human, from_res: L, pubmed: '7961636', seq: '194', to_res: E}
- {entry_name: nk2r_human, from_res: L, pubmed: '7961636', seq: '194', to_res: T}
- {entry_name: nk2r_human, from_res: H, pubmed: '7961636', seq: '198', to_res: A}
- {entry_name: nk2r_human, from_res: H, pubmed: '7961636', seq: '198', to_res: L}
- {entry_name: nk2r_human, from_res: I, pubmed: '7961636', seq: '202', to_res: V}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7961636', seq: '266', to_res: F}
- {entry_name: nk2r_human, from_res: G, pubmed: '7961636', seq: '273', to_res: P}
- {entry_name: nk2r_human, from_res: G, pubmed: '7961636', seq: '273', to_res: T}
- {entry_name: nk2r_human, from_res: S, pubmed: '7961636', seq: '274', to_res: T}
- {entry_name: nk2r_human, from_res: S, pubmed: '7961636', seq: '274', to_res: Y}
- {entry_name: nk2r_human, from_res: L, pubmed: '7961636', seq: '292', to_res: I}
- {entry_name: nk2r_human, from_res: L, pubmed: '7961636', seq: '292', to_res: S}
- {entry_name: nk1r_human, from_res: M, pubmed: '8195129', seq: '81', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '8195129', seq: '109', to_res: A}
- {entry_name: nk1r_human, from_res: P, pubmed: '8195129', seq: '112', to_res: A}
- {entry_name: nk1r_human, from_res: P, pubmed: '8195129', seq: '164', to_res: A}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8195129', seq: '165', to_res: A}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8195129', seq: '165', to_res: S}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8195129', seq: '165', to_res: N}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8195129', seq: '168', to_res: A}
- {entry_name: nk1r_human, from_res: S, pubmed: '8195129', seq: '169', to_res: A}
- {entry_name: acm1_human, from_res: Y, pubmed: '1488411', seq: '82', to_res: F}
- {entry_name: adrb2_human, from_res: C, pubmed: '2556136', seq: '184', to_res: V}
- {entry_name: agtra_rat, from_res: D, pubmed: '8050598', seq: '74', to_res: N}
- {entry_name: opsg_human, from_res: I, pubmed: '8185948', seq: '65', to_res: T}
- {entry_name: opsg_human, from_res: A, pubmed: '8185948', seq: '180', to_res: S}
- {entry_name: opsg_human, from_res: T, pubmed: '8185948', seq: '230', to_res: I}
- {entry_name: opsg_human, from_res: S, pubmed: '8185948', seq: '233', to_res: A}
- {entry_name: opsg_human, from_res: F, pubmed: '8185948', seq: '277', to_res: Y}
- {entry_name: opsg_human, from_res: A, pubmed: '8185948', seq: '285', to_res: T}
- {entry_name: opsg_human, from_res: F, pubmed: '8185948', seq: '309', to_res: Y}
- {entry_name: opsr_human, from_res: T, pubmed: '8185948', seq: '65', to_res: I}
- {entry_name: opsr_human, from_res: S, pubmed: '8185948', seq: '180', to_res: A}
- {entry_name: opsr_human, from_res: I, pubmed: '8185948', seq: '230', to_res: T}
- {entry_name: opsr_human, from_res: A, pubmed: '8185948', seq: '233', to_res: S}
- {entry_name: opsr_human, from_res: Y, pubmed: '8185948', seq: '277', to_res: F}
- {entry_name: opsr_human, from_res: T, pubmed: '8185948', seq: '285', to_res: A}
- {entry_name: opsr_human, from_res: Y, pubmed: '8185948', seq: '309', to_res: F}
- {entry_name: acm2_pig, from_res: Y, pubmed: '8195213', seq: '459', to_res: F}
- {entry_name: acm2_pig, from_res: Y, pubmed: '8195213', seq: '459', to_res: W}
- {entry_name: acm2_pig, from_res: Y, pubmed: '8195213', seq: '459', to_res: A}
- {entry_name: acm2_pig, from_res: Y, pubmed: '8195213', seq: '459', to_res: I}
- {entry_name: par1_human, from_res: K, pubmed: '1717851', seq: '51', to_res: A}
- {entry_name: par1_human, from_res: Y, pubmed: '1717851', seq: '52', to_res: A}
- {entry_name: par1_human, from_res: E, pubmed: '1717851', seq: '53', to_res: A}
- {entry_name: par1_human, from_res: P, pubmed: '1717851', seq: '54', to_res: A}
- {entry_name: par1_human, from_res: F, pubmed: '1717851', seq: '55', to_res: A}
- {entry_name: par1_human, from_res: W, pubmed: '1717851', seq: '56', to_res: A}
- {entry_name: adrb2_human, from_res: C, pubmed: '8381352', seq: '341', to_res: G}
- {entry_name: acm1_human, from_res: D, pubmed: '1618842', seq: '71', to_res: N}
- {entry_name: acm1_human, from_res: T, pubmed: '1618842', seq: '215', to_res: A}
- {entry_name: acm1_human, from_res: S, pubmed: '1618842', seq: '228', to_res: A}
- {entry_name: acm1_human, from_res: S, pubmed: '1618842', seq: '322', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '1618842', seq: '330', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '1618842', seq: '354', to_res: A}
- {entry_name: acm1_human, from_res: S, pubmed: '1618842', seq: '356', to_res: A}
- {entry_name: acm1_human, from_res: S, pubmed: '1618842', seq: '368', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '1618842', seq: '428', to_res: A}
- {entry_name: acm3_human, from_res: E, pubmed: '7684986', seq: '257', to_res: P}
- {entry_name: acm3_human, from_res: E, pubmed: '7684986', seq: '257', to_res: A}
- {entry_name: acm3_human, from_res: T, pubmed: '7684986', seq: '258', to_res: P}
- {entry_name: adrb2_mesau, from_res: S, pubmed: '2828022', seq: '137', to_res: R}
- {entry_name: adrb2_mesau, from_res: F, pubmed: '2828022', seq: '139', to_res: L}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2828022', seq: '77', to_res: V}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2828022', seq: '106', to_res: V}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2828022', seq: '116', to_res: V}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2828022', seq: '184', to_res: V}
- {entry_name: adrb2_mesau, from_res: C, pubmed: '2828022', seq: '341', to_res: L}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '77', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '106', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '116', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '125', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '184', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '190', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '191', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '2159799', seq: '285', to_res: V}
- {entry_name: adrb2_human, from_res: C, pubmed: '1847493', seq: '341', to_res: G}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2014228', seq: '113', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2014228', seq: '113', to_res: N}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2014228', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2014228', seq: '113', to_res: A}
- {entry_name: ada2a_pig, from_res: D, pubmed: '8206950', seq: '79', to_res: N}
- {entry_name: ada2a_pig, from_res: Y, pubmed: '8206950', seq: '426', to_res: A}
- {entry_name: fshr_rat, from_res: N, pubmed: '7776966', seq: '191', to_res: Q}
- {entry_name: 5ht1a_human, from_res: I, pubmed: '8532077', seq: '28', to_res: V}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '125', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '125', to_res: S}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '339', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '340', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '339', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '340', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '339', to_res: Y}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '7700242', seq: '340', to_res: Y}
- {entry_name: ada1a_rat, from_res: V, pubmed: '7559466', seq: '185', to_res: A}
- {entry_name: ada1a_rat, from_res: M, pubmed: '7559466', seq: '292', to_res: L}
- {entry_name: ada1b_mesau, from_res: L, pubmed: '7559466', seq: '182', to_res: F}
- {entry_name: ada1b_mesau, from_res: T, pubmed: '7559466', seq: '174', to_res: L}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '7559466', seq: '204', to_res: V}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '7559466', seq: '208', to_res: A}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '7559466', seq: '313', to_res: V}
- {entry_name: ada1b_mesau, from_res: L, pubmed: '7559466', seq: '314', to_res: M}
- {entry_name: v2r_bovin, from_res: D, pubmed: '7698346', seq: '103', to_res: Y}
- {entry_name: adrb2_human, from_res: N, pubmed: '7492540', seq: '322', to_res: A}
- {entry_name: adrb2_human, from_res: N, pubmed: '7492540', seq: '322', to_res: D}
- {entry_name: adrb2_human, from_res: P, pubmed: '7492540', seq: '323', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '7492540', seq: '326', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '7492540', seq: '326', to_res: F}
- {entry_name: adrb2_mesau, from_res: Y, pubmed: '7592686', seq: '364', to_res: F}
- {entry_name: drd1_human, from_res: C, pubmed: '7643110', seq: '347', to_res: G}
- {entry_name: drd1_human, from_res: C, pubmed: '7643110', seq: '351', to_res: G}
- {entry_name: hrh1_cavpo, from_res: K, pubmed: '7669031', seq: '200', to_res: A}
- {entry_name: hrh2_canfa, from_res: N, pubmed: '7544576', seq: '168', to_res: Q}
- {entry_name: acm1_human, from_res: I, pubmed: '7706286', seq: '211', to_res: A}
- {entry_name: acm1_human, from_res: W, pubmed: '7706286', seq: '209', to_res: A}
- {entry_name: acm1_human, from_res: Y, pubmed: '7706286', seq: '212', to_res: A}
- {entry_name: acm1_human, from_res: K, pubmed: '7706286', seq: '362', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '7706286', seq: '366', to_res: A}
- {entry_name: acm2_human, from_res: C, pubmed: '7629074', seq: '124', to_res: S}
- {entry_name: acm2_human, from_res: K, pubmed: '7629074', seq: '127', to_res: R}
- {entry_name: acm2_human, from_res: M, pubmed: '7629074', seq: '139', to_res: R}
- {entry_name: acm2_human, from_res: P, pubmed: '7629074', seq: '132', to_res: R}
- {entry_name: acm2_human, from_res: S, pubmed: '7629074', seq: '210', to_res: Y}
- {entry_name: acm3_human, from_res: T, pubmed: '7565628', seq: '550', to_res: A}
- {entry_name: acm3_human, from_res: T, pubmed: '7565628', seq: '553', to_res: A}
- {entry_name: drd2_mouse, from_res: K, pubmed: '7706278', seq: '251', to_res: V}
- {entry_name: pe2r3_mouse, from_res: R, pubmed: '7733888', seq: '309', to_res: E}
- {entry_name: pe2r3_mouse, from_res: R, pubmed: '7733888', seq: '309', to_res: K}
- {entry_name: pe2r3_mouse, from_res: R, pubmed: '7733888', seq: '309', to_res: V}
- {entry_name: fshr_human, from_res: A, pubmed: '7553856', seq: '189', to_res: V}
- {entry_name: lshr_human, from_res: A, pubmed: '7629248', seq: '568', to_res: V}
- {entry_name: lshr_rat, from_res: N, pubmed: '7665591', seq: '178', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '7665591', seq: '199', to_res: Q}
- {entry_name: lshr_rat, from_res: S, pubmed: '7665591', seq: '180', to_res: A}
- {entry_name: lshr_rat, from_res: T, pubmed: '7665591', seq: '201', to_res: A}
- {entry_name: tshr_human, from_res: D, pubmed: '7556878', seq: '36', to_res: H}
- {entry_name: agtra_rat, from_res: L, pubmed: '7673193', seq: '316', to_res: F}
- {entry_name: agtra_rat, from_res: K, pubmed: '7673193', seq: '325', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7673193', seq: '312', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7673193', seq: '319', to_res: A}
- {entry_name: agtra_rat, from_res: K, pubmed: '7530721', seq: '102', to_res: A}
- {entry_name: agtra_rat, from_res: K, pubmed: '7530721', seq: '102', to_res: Q}
- {entry_name: agtra_rat, from_res: K, pubmed: '7530721', seq: '102', to_res: E}
- {entry_name: agtra_rat, from_res: R, pubmed: '7530721', seq: '167', to_res: Q}
- {entry_name: agtra_rat, from_res: K, pubmed: '7530721', seq: '199', to_res: A}
- {entry_name: agtra_rat, from_res: K, pubmed: '7530721', seq: '199', to_res: R}
- {entry_name: agtra_rat, from_res: K, pubmed: '7530721', seq: '199', to_res: Q}
- {entry_name: agtra_rat, from_res: K, pubmed: '7530721', seq: '199', to_res: E}
- {entry_name: agtra_rat, from_res: H, pubmed: '7530721', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7530721', seq: '256', to_res: R}
- {entry_name: agtra_rat, from_res: H, pubmed: '7530721', seq: '256', to_res: Q}
- {entry_name: agtra_rat, from_res: H, pubmed: '7530721', seq: '256', to_res: E}
- {entry_name: agtra_rat, from_res: N, pubmed: '7622467', seq: '298', to_res: A}
- {entry_name: agtra_rat, from_res: L, pubmed: '7622467', seq: '300', to_res: A}
- {entry_name: agtra_rat, from_res: F, pubmed: '7622467', seq: '301', to_res: A}
- {entry_name: agtra_rat, from_res: P, pubmed: '7622467', seq: '299', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7673193', seq: '302', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7622467', seq: '302', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7530721', seq: '183', to_res: Q}
- {entry_name: agtra_rat, from_res: H, pubmed: '7530721', seq: '272', to_res: Q}
- {entry_name: c5ar_human, from_res: G, pubmed: '7629117', seq: '306', to_res: A}
- {entry_name: c5ar_human, from_res: R, pubmed: '7629117', seq: '68', to_res: E}
- {entry_name: c5ar_human, from_res: T, pubmed: '7629117', seq: '235', to_res: A}
- {entry_name: c5ar_human, from_res: T, pubmed: '7629117', seq: '238', to_res: R}
- {entry_name: c5ar_human, from_res: W, pubmed: '7629117', seq: '230', to_res: F}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '36', to_res: N}
- {entry_name: c5ar_human, from_res: D, pubmed: '7957584', seq: '82', to_res: N}
- {entry_name: c5ar_human, from_res: D, pubmed: '7629117', seq: '82', to_res: N}
- {entry_name: c5ar_human, from_res: C, pubmed: '7629117', seq: '86', to_res: S}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '90', to_res: A}
- {entry_name: c5ar_human, from_res: N, pubmed: '7629117', seq: '119', to_res: Q}
- {entry_name: c5ar_human, from_res: D, pubmed: '7629117', seq: '133', to_res: N}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '113', to_res: A}
- {entry_name: c5ar_human, from_res: C, pubmed: '7629117', seq: '157', to_res: S}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '170', to_res: A}
- {entry_name: c5ar_human, from_res: C, pubmed: '7629117', seq: '221', to_res: S}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '214', to_res: A}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '257', to_res: A}
- {entry_name: c5ar_human, from_res: C, pubmed: '7629117', seq: '285', to_res: S}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '297', to_res: A}
- {entry_name: c5ar_human, from_res: C, pubmed: '7629117', seq: '109', to_res: S}
- {entry_name: c5ar_human, from_res: C, pubmed: '7629117', seq: '188', to_res: S}
- {entry_name: c5ar_human, from_res: E, pubmed: '7622471', seq: '199', to_res: Q}
- {entry_name: c5ar_human, from_res: L, pubmed: '7629117', seq: '277', to_res: P}
- {entry_name: c5ar_human, from_res: P, pubmed: '7629117', seq: '270', to_res: L}
- {entry_name: gasr_rat, from_res: N, pubmed: '7476907', seq: '391', to_res: D}
- {entry_name: fshr_rat, from_res: N, pubmed: '7776966', seq: '199', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: L, pubmed: '7559413', seq: '147', to_res: A}
- {entry_name: gnrhr_mouse, from_res: L, pubmed: '7559413', seq: '147', to_res: D}
- {entry_name: gnrhr_mouse, from_res: S, pubmed: '7559413', seq: '140', to_res: Y}
- {entry_name: fshr_rat, from_res: N, pubmed: '7776966', seq: '293', to_res: Q}
- {entry_name: fpr1_human, from_res: D, pubmed: '7738006', seq: '106', to_res: A}
- {entry_name: fpr1_human, from_res: R, pubmed: '7738006', seq: '163', to_res: F}
- {entry_name: agtra_rat, from_res: K, pubmed: '7726829', seq: '102', to_res: M}
- {entry_name: ntr1_rat, from_res: T, pubmed: '7852303', seq: '422', to_res: G}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '7852303', seq: '424', to_res: G}
- {entry_name: npy1r_human, from_res: F, pubmed: '7489825', seq: '96', to_res: A}
- {entry_name: npy1r_human, from_res: L, pubmed: '7489825', seq: '43', to_res: A}
- {entry_name: npy1r_human, from_res: F, pubmed: '7489825', seq: '41', to_res: A}
- {entry_name: npy1r_human, from_res: Y, pubmed: '7489825', seq: '100', to_res: A}
- {entry_name: npy1r_human, from_res: Y, pubmed: '7489825', seq: '100', to_res: R}
- {entry_name: npy1r_human, from_res: Y, pubmed: '7489825', seq: '100', to_res: Q}
- {entry_name: npy1r_human, from_res: Y, pubmed: '7489825', seq: '100', to_res: H}
- {entry_name: npy1r_human, from_res: Y, pubmed: '7489825', seq: '100', to_res: F}
- {entry_name: npy1r_human, from_res: Y, pubmed: '7489825', seq: '100', to_res: P}
- {entry_name: npy1r_human, from_res: Y, pubmed: '7489825', seq: '100', to_res: S}
- {entry_name: npy1r_human, from_res: F, pubmed: '7489825', seq: '286', to_res: A}
- {entry_name: npy1r_human, from_res: H, pubmed: '7489825', seq: '298', to_res: A}
- {entry_name: npy1r_human, from_res: H, pubmed: '7489825', seq: '298', to_res: R}
- {entry_name: npy1r_human, from_res: H, pubmed: '7489825', seq: '298', to_res: N}
- {entry_name: npy1r_human, from_res: H, pubmed: '7489825', seq: '298', to_res: Q}
- {entry_name: npy1r_human, from_res: H, pubmed: '7489825', seq: '298', to_res: S}
- {entry_name: npy1r_human, from_res: H, pubmed: '7489825', seq: '298', to_res: Y}
- {entry_name: oprd_rat, from_res: A, pubmed: '7589460', seq: '123', to_res: I}
- {entry_name: oprd_rat, from_res: L, pubmed: '7589460', seq: '125', to_res: I}
- {entry_name: oprd_rat, from_res: A, pubmed: '7589460', seq: '107', to_res: V}
- {entry_name: oprd_rat, from_res: E, pubmed: '7589460', seq: '112', to_res: G}
- {entry_name: oprd_rat, from_res: E, pubmed: '7589460', seq: '118', to_res: T}
- {entry_name: oprd_rat, from_res: L, pubmed: '7589460', seq: '119', to_res: I}
- {entry_name: oprd_rat, from_res: K, pubmed: '7589460', seq: '108', to_res: A}
- {entry_name: oprd_rat, from_res: K, pubmed: '7589460', seq: '108', to_res: R}
- {entry_name: oprd_rat, from_res: K, pubmed: '7589460', seq: '108', to_res: N}
- {entry_name: oprd_rat, from_res: K, pubmed: '7589460', seq: '108', to_res: D}
- {entry_name: oprm_rat, from_res: G, pubmed: '7589460', seq: '131', to_res: E}
- {entry_name: oprm_rat, from_res: I, pubmed: '7589460', seq: '138', to_res: L}
- {entry_name: oprm_rat, from_res: T, pubmed: '7589460', seq: '137', to_res: E}
- {entry_name: oprm_rat, from_res: V, pubmed: '7589460', seq: '126', to_res: A}
- {entry_name: ssr1_human, from_res: Q, pubmed: '7882976', seq: '291', to_res: N}
- {entry_name: ssr1_human, from_res: L, pubmed: '7882976', seq: '307', to_res: F}
- {entry_name: ssr1_human, from_res: S, pubmed: '7882976', seq: '305', to_res: F}
- {entry_name: ssr1_human, from_res: S, pubmed: '7882976', seq: '308', to_res: V}
- {entry_name: ssr2_rat, from_res: D, pubmed: '7488212', seq: '89', to_res: A}
- {entry_name: ssr2_rat, from_res: D, pubmed: '7488212', seq: '89', to_res: E}
- {entry_name: ssr2_rat, from_res: D, pubmed: '7488212', seq: '122', to_res: A}
- {entry_name: ssr2_rat, from_res: D, pubmed: '7488212', seq: '122', to_res: E}
- {entry_name: ssr2_rat, from_res: D, pubmed: '7488212', seq: '122', to_res: K}
- {entry_name: ssr3_rat, from_res: D, pubmed: '7576180', seq: '124', to_res: N}
- {entry_name: ssr3_rat, from_res: D, pubmed: '7576180', seq: '124', to_res: E}
- {entry_name: ssr5_rat, from_res: G, pubmed: '7838136', seq: '259', to_res: F}
- {entry_name: ssr5_rat, from_res: F, pubmed: '7838136', seq: '265', to_res: Y}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '283', to_res: A}
- {entry_name: trfr_mouse, from_res: C, pubmed: '7559582', seq: '98', to_res: S}
- {entry_name: trfr_mouse, from_res: C, pubmed: '7559582', seq: '179', to_res: A}
- {entry_name: trfr_mouse, from_res: C, pubmed: '7559582', seq: '179', to_res: S}
- {entry_name: nk1r_human, from_res: Q, pubmed: '7536886', seq: '165', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '197', to_res: A}
- {entry_name: nk2r_human, from_res: F, pubmed: '7499223', seq: '248', to_res: A}
- {entry_name: nk2r_human, from_res: F, pubmed: '7499223', seq: '248', to_res: E}
- {entry_name: nk2r_human, from_res: F, pubmed: '7499223', seq: '248', to_res: S}
- {entry_name: nk2r_human, from_res: S, pubmed: '7543277', seq: '27', to_res: A}
- {entry_name: nk2r_human, from_res: T, pubmed: '7543277', seq: '24', to_res: A}
- {entry_name: nk2r_human, from_res: W, pubmed: '7543277', seq: '31', to_res: A}
- {entry_name: v2r_bovin, from_res: R, pubmed: '7698346', seq: '106', to_res: L}
- {entry_name: nk2r_human, from_res: F, pubmed: '7543277', seq: '89', to_res: A}
- {entry_name: nk2r_human, from_res: N, pubmed: '7543277', seq: '86', to_res: A}
- {entry_name: nk2r_human, from_res: N, pubmed: '7543277', seq: '90', to_res: A}
- {entry_name: nk2r_human, from_res: D, pubmed: '7543277', seq: '79', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7543277', seq: '93', to_res: A}
- {entry_name: nk2r_human, from_res: Q, pubmed: '7543277', seq: '109', to_res: A}
- {entry_name: nk2r_human, from_res: F, pubmed: '7543277', seq: '112', to_res: A}
- {entry_name: nk2r_human, from_res: T, pubmed: '7543277', seq: '115', to_res: A}
- {entry_name: nk2r_human, from_res: Q, pubmed: '7543277', seq: '166', to_res: V}
- {entry_name: nk2r_human, from_res: H, pubmed: '7543277', seq: '198', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7543277', seq: '206', to_res: A}
- {entry_name: nk2r_human, from_res: H, pubmed: '7543277', seq: '267', to_res: F}
- {entry_name: nk2r_human, from_res: F, pubmed: '7543277', seq: '270', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7543277', seq: '266', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7543277', seq: '266', to_res: F}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7543277', seq: '266', to_res: S}
- {entry_name: nk2r_human, from_res: Q, pubmed: '7543277', seq: '286', to_res: A}
- {entry_name: nk2r_human, from_res: H, pubmed: '7543277', seq: '267', to_res: L}
- {entry_name: nk2r_human, from_res: F, pubmed: '7543277', seq: '293', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7543277', seq: '289', to_res: F}
- {entry_name: nk2r_human, from_res: N, pubmed: '7543277', seq: '97', to_res: A}
- {entry_name: nk2r_human, from_res: W, pubmed: '7543277', seq: '99', to_res: A}
- {entry_name: nk2r_human, from_res: S, pubmed: '7543277', seq: '170', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '7543277', seq: '169', to_res: A}
- {entry_name: nk2r_human, from_res: H, pubmed: '7543277', seq: '282', to_res: A}
- {entry_name: nk2r_human, from_res: S, pubmed: '7543277', seq: '274', to_res: A}
- {entry_name: v1ar_rat, from_res: D, pubmed: '7592759', seq: '97', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '7592759', seq: '104', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '7592759', seq: '108', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '7592759', seq: '131', to_res: A}
- {entry_name: v1ar_rat, from_res: K, pubmed: '7592759', seq: '128', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '7592759', seq: '185', to_res: A}
- {entry_name: v1ar_rat, from_res: T, pubmed: '7592759', seq: '223', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '7592759', seq: '317', to_res: A}
- {entry_name: v1ar_rat, from_res: Y, pubmed: '7774575', seq: '115', to_res: D}
- {entry_name: v1ar_rat, from_res: Y, pubmed: '7774575', seq: '115', to_res: L}
- {entry_name: v2r_human, from_res: R, pubmed: '7920187', seq: '137', to_res: H}
- {entry_name: v2r_pig, from_res: Y, pubmed: '7698346', seq: '102', to_res: N}
- {entry_name: ptafr_human, from_res: N, pubmed: '7559653', seq: '169', to_res: A}
- {entry_name: fpr1_human, from_res: R, pubmed: '7738006', seq: '123', to_res: G}
- {entry_name: fpr1_human, from_res: D, pubmed: '7738006', seq: '122', to_res: A}
- {entry_name: aa2ar_human, from_res: N, pubmed: '7775460', seq: '253', to_res: Q}
- {entry_name: aa2ar_human, from_res: N, pubmed: '7775460', seq: '253', to_res: S}
- {entry_name: aa2ar_human, from_res: H, pubmed: '7775460', seq: '278', to_res: Q}
- {entry_name: aa2ar_human, from_res: H, pubmed: '7775460', seq: '278', to_res: F}
- {entry_name: aa2ar_human, from_res: H, pubmed: '7775460', seq: '278', to_res: Y}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '7984276', seq: '355', to_res: N}
- {entry_name: 5ht1d_human, from_res: T, pubmed: '7984276', seq: '342', to_res: N}
- {entry_name: 5ht1e_human, from_res: T, pubmed: '7984276', seq: '330', to_res: N}
- {entry_name: 5ht1f_human, from_res: A, pubmed: '7984276', seq: '333', to_res: N}
- {entry_name: 5ht2a_human, from_res: D, pubmed: '7622478', seq: '120', to_res: A}
- {entry_name: 5ht2a_human, from_res: D, pubmed: '7622478', seq: '120', to_res: N}
- {entry_name: 5ht2a_human, from_res: N, pubmed: '7622478', seq: '376', to_res: A}
- {entry_name: 5ht2a_human, from_res: N, pubmed: '7622478', seq: '376', to_res: D}
- {entry_name: 5ht2c_human, from_res: C, pubmed: '7557992', seq: '23', to_res: S}
- {entry_name: ada2a_pig, from_res: D, pubmed: '7961941', seq: '79', to_res: N}
- {entry_name: ada2a_pig, from_res: D, pubmed: '7907086', seq: '79', to_res: N}
- {entry_name: ada2a_pig, from_res: D, pubmed: '7961941', seq: '79', to_res: Q}
- {entry_name: ada2a_pig, from_res: D, pubmed: '7961941', seq: '79', to_res: E}
- {entry_name: drd2_mouse, from_res: D, pubmed: '7706278', seq: '271', to_res: V}
- {entry_name: drd2_human, from_res: D, pubmed: '7706278', seq: '249', to_res: V}
- {entry_name: trfr_mouse, from_res: C, pubmed: '7559582', seq: '100', to_res: A}
- {entry_name: drd2_human, from_res: P, pubmed: '7706278', seq: '264', to_res: G}
- {entry_name: fshr_rat, from_res: S, pubmed: '7776966', seq: '201', to_res: A}
- {entry_name: hrh1_human, from_res: S, pubmed: '8903934', seq: '155', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '1527051', seq: '234', to_res: A}
- {entry_name: fshr_human, from_res: D, pubmed: '7608154', seq: '43', to_res: A}
- {entry_name: fshr_human, from_res: D, pubmed: '7608154', seq: '422', to_res: R}
- {entry_name: fshr_human, from_res: D, pubmed: '7608154', seq: '422', to_res: E}
- {entry_name: fshr_human, from_res: D, pubmed: '7608154', seq: '422', to_res: K}
- {entry_name: fshr_rat, from_res: S, pubmed: '7776966', seq: '295', to_res: A}
- {entry_name: fshr_human, from_res: D, pubmed: '7608154', seq: '422', to_res: S}
- {entry_name: fshr_human, from_res: D, pubmed: '7608154', seq: '422', to_res: Y}
- {entry_name: fshr_human, from_res: D, pubmed: '7608154', seq: '422', to_res: V}
- {entry_name: fshr_human, from_res: H, pubmed: '7608154', seq: '424', to_res: A}
- {entry_name: fshr_human, from_res: I, pubmed: '7608154', seq: '423', to_res: A}
- {entry_name: fshr_human, from_res: K, pubmed: '7608154', seq: '426', to_res: A}
- {entry_name: fshr_human, from_res: T, pubmed: '7608154', seq: '425', to_res: A}
- {entry_name: fshr_rat, from_res: T, pubmed: '7776966', seq: '193', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '1755859', seq: '103', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '1755859', seq: '178', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '1755859', seq: '199', to_res: Q}
- {entry_name: lshr_human, from_res: I, pubmed: '7892197', seq: '542', to_res: L}
- {entry_name: lshr_human, from_res: A, pubmed: '7719343', seq: '593', to_res: P}
- {entry_name: lshr_human, from_res: A, pubmed: '7714085', seq: '572', to_res: V}
- {entry_name: lshr_human, from_res: D, pubmed: '7714085', seq: '578', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '7757065', seq: '578', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '7892197', seq: '578', to_res: Y}
- {entry_name: lshr_human, from_res: C, pubmed: '7892197', seq: '581', to_res: R}
- {entry_name: lshr_human, from_res: M, pubmed: '7757065', seq: '571', to_res: I}
- {entry_name: lshr_human, from_res: T, pubmed: '7757065', seq: '577', to_res: I}
- {entry_name: lshr_rat, from_res: N, pubmed: '1755859', seq: '295', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '1755859', seq: '303', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '1755859', seq: '317', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '7665591', seq: '103', to_res: Q}
- {entry_name: tshr_human, from_res: A, pubmed: '7714109', seq: '623', to_res: S}
- {entry_name: tshr_human, from_res: I, pubmed: '7528344', seq: '167', to_res: N}
- {entry_name: tshr_human, from_res: K, pubmed: '7798220', seq: '262', to_res: Q}
- {entry_name: tshr_human, from_res: K, pubmed: '7798220', seq: '290', to_res: Q}
- {entry_name: tshr_human, from_res: K, pubmed: '7798220', seq: '291', to_res: Q}
- {entry_name: tshr_human, from_res: P, pubmed: '7528344', seq: '162', to_res: A}
- {entry_name: tshr_human, from_res: D, pubmed: '7805857', seq: '633', to_res: E}
- {entry_name: tshr_human, from_res: D, pubmed: '7805857', seq: '633', to_res: Y}
- {entry_name: tshr_human, from_res: F, pubmed: '7805857', seq: '631', to_res: C}
- {entry_name: tshr_human, from_res: F, pubmed: '8592518', seq: '631', to_res: L}
- {entry_name: tshr_human, from_res: F, pubmed: '7800007', seq: '631', to_res: L}
- {entry_name: tshr_human, from_res: T, pubmed: '7805857', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: I, pubmed: '8592518', seq: '486', to_res: M}
- {entry_name: tshr_human, from_res: I, pubmed: '8592518', seq: '486', to_res: F}
- {entry_name: tshr_human, from_res: I, pubmed: '8592518', seq: '568', to_res: T}
- {entry_name: tshr_rat, from_res: D, pubmed: '8054860', seq: '276', to_res: T}
- {entry_name: tshr_rat, from_res: C, pubmed: '8054860', seq: '301', to_res: E}
- {entry_name: tshr_rat, from_res: S, pubmed: '8054860', seq: '268', to_res: R}
- {entry_name: tshr_rat, from_res: P, pubmed: '7789342', seq: '556', to_res: L}
- {entry_name: agtr1_human, from_res: N, pubmed: '7829475', seq: '111', to_res: A}
- {entry_name: agtr1_human, from_res: N, pubmed: '7829475', seq: '294', to_res: A}
- {entry_name: agtr1_human, from_res: N, pubmed: '7700239', seq: '295', to_res: S}
- {entry_name: agtr1_human, from_res: V, pubmed: '7983030', seq: '280', to_res: A}
- {entry_name: agtr1_human, from_res: D, pubmed: '7983030', seq: '263', to_res: A}
- {entry_name: agtr1_human, from_res: D, pubmed: '7983030', seq: '278', to_res: A}
- {entry_name: agtr1_human, from_res: D, pubmed: '7829475', seq: '278', to_res: A}
- {entry_name: agtr1_human, from_res: D, pubmed: '7983030', seq: '281', to_res: A}
- {entry_name: agtr1_human, from_res: D, pubmed: '7829475', seq: '281', to_res: A}
- {entry_name: agtr1_human, from_res: Q, pubmed: '7983030', seq: '267', to_res: A}
- {entry_name: agtr1_human, from_res: I, pubmed: '7983030', seq: '266', to_res: A}
- {entry_name: agtr1_human, from_res: I, pubmed: '7983030', seq: '271', to_res: A}
- {entry_name: agtr1_human, from_res: L, pubmed: '7983030', seq: '265', to_res: A}
- {entry_name: agtr1_human, from_res: V, pubmed: '7983030', seq: '264', to_res: A}
- {entry_name: agtra_rat, from_res: C, pubmed: '7659790', seq: '18', to_res: G}
- {entry_name: agtra_rat, from_res: H, pubmed: '7983030', seq: '24', to_res: A}
- {entry_name: agtra_rat, from_res: I, pubmed: '7983030', seq: '14', to_res: A}
- {entry_name: agtra_rat, from_res: I, pubmed: '7829475', seq: '14', to_res: A}
- {entry_name: agtra_rat, from_res: I, pubmed: '7983030', seq: '27', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7983030', seq: '26', to_res: A}
- {entry_name: agtra_rat, from_res: D, pubmed: '7929158', seq: '74', to_res: N}
- {entry_name: agtra_rat, from_res: D, pubmed: '7929158', seq: '74', to_res: H}
- {entry_name: agtra_rat, from_res: D, pubmed: '7929158', seq: '74', to_res: Y}
- {entry_name: agtra_rat, from_res: N, pubmed: '7726829', seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '7726829', seq: '105', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '7726829', seq: '107', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '7726829', seq: '109', to_res: A}
- {entry_name: agtra_rat, from_res: R, pubmed: '7775462', seq: '167', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7775462', seq: '166', to_res: A}
- {entry_name: agtra_rat, from_res: K, pubmed: '7775462', seq: '199', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7730346', seq: '215', to_res: F}
- {entry_name: agtra_rat, from_res: D, pubmed: '7775462', seq: '263', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7700239', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7775462', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7700239', seq: '256', to_res: Q}
- {entry_name: agtra_rat, from_res: H, pubmed: '7700239', seq: '256', to_res: I}
- {entry_name: agtra_rat, from_res: H, pubmed: '7700239', seq: '256', to_res: F}
- {entry_name: agtra_rat, from_res: F, pubmed: '7775462', seq: '259', to_res: A}
- {entry_name: agtra_rat, from_res: T, pubmed: '7775462', seq: '260', to_res: A}
- {entry_name: agtra_rat, from_res: W, pubmed: '7775462', seq: '253', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '7829475', seq: '295', to_res: D}
- {entry_name: agtra_rat, from_res: N, pubmed: '7700239', seq: '295', to_res: S}
- {entry_name: agtra_rat, from_res: C, pubmed: '7659790', seq: '101', to_res: G}
- {entry_name: agtra_rat, from_res: K, pubmed: '7983030', seq: '102', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7983030', seq: '92', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7829475', seq: '92', to_res: A}
- {entry_name: agtra_rat, from_res: R, pubmed: '7983030', seq: '167', to_res: A}
- {entry_name: agtra_rat, from_res: C, pubmed: '7659790', seq: '180', to_res: G}
- {entry_name: agtra_rat, from_res: E, pubmed: '7775462', seq: '173', to_res: A}
- {entry_name: agtra_rat, from_res: E, pubmed: '7775462', seq: '185', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7775462', seq: '183', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '7983030', seq: '184', to_res: A}
- {entry_name: agtra_rat, from_res: V, pubmed: '7983030', seq: '179', to_res: A}
- {entry_name: agtra_rat, from_res: C, pubmed: '7659790', seq: '274', to_res: G}
- {entry_name: gasr_human, from_res: G, pubmed: '7890609', seq: '80', to_res: I}
- {entry_name: gasr_human, from_res: I, pubmed: '7890609', seq: '56', to_res: V}
- {entry_name: gasr_human, from_res: M, pubmed: '7890609', seq: '73', to_res: T}
- {entry_name: gasr_human, from_res: T, pubmed: '7890609', seq: '59', to_res: L}
- {entry_name: gasr_human, from_res: V, pubmed: '7890609', seq: '63', to_res: L}
- {entry_name: gasr_human, from_res: A, pubmed: '7890609', seq: '91', to_res: I}
- {entry_name: gasr_human, from_res: T, pubmed: '7890609', seq: '111', to_res: N}
- {entry_name: gasr_human, from_res: A, pubmed: '7890609', seq: '149', to_res: S}
- {entry_name: gasr_human, from_res: A, pubmed: '7890609', seq: '129', to_res: T}
- {entry_name: gasr_human, from_res: L, pubmed: '7890609', seq: '133', to_res: F}
- {entry_name: gasr_human, from_res: S, pubmed: '7890609', seq: '131', to_res: T}
- {entry_name: gasr_human, from_res: V, pubmed: '7890609', seq: '130', to_res: T}
- {entry_name: gasr_human, from_res: V, pubmed: '7890609', seq: '136', to_res: T}
- {entry_name: gasr_human, from_res: L, pubmed: '7890609', seq: '180', to_res: C}
- {entry_name: gasr_human, from_res: V, pubmed: '7890609', seq: '176', to_res: A}
- {entry_name: gasr_human, from_res: A, pubmed: '7890609', seq: '235', to_res: M}
- {entry_name: gasr_human, from_res: I, pubmed: '7890609', seq: '229', to_res: T}
- {entry_name: gasr_human, from_res: L, pubmed: '7890609', seq: '225', to_res: I}
- {entry_name: gasr_human, from_res: S, pubmed: '7890609', seq: '219', to_res: Q}
- {entry_name: gasr_human, from_res: S, pubmed: '7890609', seq: '219', to_res: H}
- {entry_name: gasr_human, from_res: L, pubmed: '7890609', seq: '347', to_res: M}
- {entry_name: gasr_human, from_res: T, pubmed: '7890609', seq: '354', to_res: A}
- {entry_name: gasr_human, from_res: Y, pubmed: '7890609', seq: '350', to_res: F}
- {entry_name: gasr_human, from_res: V, pubmed: '8455720', seq: '349', to_res: I}
- {entry_name: gasr_human, from_res: V, pubmed: '7890609', seq: '349', to_res: I}
- {entry_name: gasr_human, from_res: V, pubmed: '8455720', seq: '349', to_res: L}
- {entry_name: gasr_human, from_res: A, pubmed: '7890609', seq: '383', to_res: S}
- {entry_name: gasr_human, from_res: A, pubmed: '7890609', seq: '381', to_res: T}
- {entry_name: gasr_human, from_res: H, pubmed: '7890609', seq: '376', to_res: L}
- {entry_name: gasr_rat, from_res: D, pubmed: '7476907', seq: '100', to_res: N}
- {entry_name: ednra_human, from_res: G, pubmed: '7628480', seq: '97', to_res: A}
- {entry_name: ednra_human, from_res: D, pubmed: '7698331', seq: '126', to_res: A}
- {entry_name: acthr_human, from_res: S, pubmed: '8250922', seq: '74', to_res: I}
- {entry_name: ednra_human, from_res: D, pubmed: '7698331', seq: '133', to_res: A}
- {entry_name: ednra_human, from_res: D, pubmed: '7628480', seq: '133', to_res: N}
- {entry_name: ednra_human, from_res: K, pubmed: '7628480', seq: '140', to_res: I}
- {entry_name: ednra_human, from_res: Y, pubmed: '7628480', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Q, pubmed: '7628480', seq: '165', to_res: D}
- {entry_name: ednra_human, from_res: K, pubmed: '7628480', seq: '159', to_res: Q}
- {entry_name: ednra_human, from_res: T, pubmed: '7628480', seq: '172', to_res: V}
- {entry_name: ednra_human, from_res: E, pubmed: '7628480', seq: '220', to_res: N}
- {entry_name: ednra_human, from_res: F, pubmed: '7628480', seq: '264', to_res: L}
- {entry_name: ednra_human, from_res: F, pubmed: '7628480', seq: '260', to_res: Y}
- {entry_name: ednra_human, from_res: Y, pubmed: '7628480', seq: '263', to_res: F}
- {entry_name: ednra_human, from_res: R, pubmed: '7628480', seq: '326', to_res: Q}
- {entry_name: ednra_human, from_res: H, pubmed: '7628480', seq: '323', to_res: F}
- {entry_name: ednra_human, from_res: F, pubmed: '7628480', seq: '315', to_res: L}
- {entry_name: ednra_human, from_res: N, pubmed: '7628480', seq: '361', to_res: A}
- {entry_name: ednra_human, from_res: D, pubmed: '7628480', seq: '351', to_res: N}
- {entry_name: ednra_human, from_res: F, pubmed: '7628480', seq: '156', to_res: I}
- {entry_name: ednrb_human, from_res: D, pubmed: '7698331', seq: '154', to_res: A}
- {entry_name: ednrb_human, from_res: D, pubmed: '7698331', seq: '147', to_res: A}
- {entry_name: ednrb_human, from_res: H, pubmed: '7698331', seq: '150', to_res: A}
- {entry_name: ednrb_human, from_res: H, pubmed: '7698331', seq: '150', to_res: Y}
- {entry_name: oprk_rat, from_res: E, pubmed: '7541509', seq: '297', to_res: K}
- {entry_name: ednrb_human, from_res: W, pubmed: '8001158', seq: '276', to_res: C}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '7768336', seq: '18', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '7768336', seq: '4', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '7768336', seq: '102', to_res: Q}
- {entry_name: fpr1_human, from_res: D, pubmed: '7738006', seq: '71', to_res: A}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '283', to_res: E}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '283', to_res: H}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '283', to_res: L}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '283', to_res: K}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '283', to_res: S}
- {entry_name: trfr_mouse, from_res: W, pubmed: '7700246', seq: '279', to_res: A}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '306', to_res: A}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '306', to_res: E}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '306', to_res: L}
- {entry_name: trfr_mouse, from_res: R, pubmed: '7700246', seq: '306', to_res: K}
- {entry_name: trfr_mouse, from_res: C, pubmed: '7559582', seq: '98', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '197', to_res: S}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '265', to_res: Q}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '265', to_res: F}
- {entry_name: nk1r_human, from_res: H, pubmed: '7536886', seq: '265', to_res: Y}
- {entry_name: nk1r_human, from_res: I, pubmed: '7532784', seq: '290', to_res: S}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7536886', seq: '287', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7536886', seq: '287', to_res: Q}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7536886', seq: '287', to_res: H}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7536886', seq: '287', to_res: F}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7536886', seq: '287', to_res: S}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7536886', seq: '287', to_res: W}
- {entry_name: nk1r_human, from_res: E, pubmed: '7532784', seq: '97', to_res: V}
- {entry_name: nk1r_rat, from_res: C, pubmed: '7532784', seq: '80', to_res: S}
- {entry_name: nk1r_rat, from_res: E, pubmed: '7538194', seq: '78', to_res: D}
- {entry_name: nk1r_rat, from_res: E, pubmed: '7538194', seq: '78', to_res: Q}
- {entry_name: nk1r_rat, from_res: E, pubmed: '7538194', seq: '78', to_res: K}
- {entry_name: nk1r_rat, from_res: L, pubmed: '7532784', seq: '116', to_res: V}
- {entry_name: nk1r_rat, from_res: S, pubmed: '7532784', seq: '290', to_res: I}
- {entry_name: nk1r_rat, from_res: V, pubmed: '7532784', seq: '97', to_res: E}
- {entry_name: nk2r_human, from_res: F, pubmed: '7543277', seq: '26', to_res: A}
- {entry_name: v1ar_rat, from_res: Y, pubmed: '7774575', seq: '115', to_res: F}
- {entry_name: v2r_human, from_res: R, pubmed: '7598729', seq: '143', to_res: P}
- {entry_name: v2r_human, from_res: A, pubmed: '7527400', seq: '61', to_res: V}
- {entry_name: v2r_human, from_res: Y, pubmed: '7527400', seq: '128', to_res: S}
- {entry_name: v2r_human, from_res: P, pubmed: '7527400', seq: '286', to_res: R}
- {entry_name: v2r_human, from_res: R, pubmed: '7527400', seq: '181', to_res: C}
- {entry_name: v2r_human, from_res: R, pubmed: '7564126', seq: '202', to_res: C}
- {entry_name: v2r_pig, from_res: Y, pubmed: '7698346', seq: '102', to_res: D}
- {entry_name: p2ry2_mouse, from_res: R, pubmed: '7876172', seq: '110', to_res: L}
- {entry_name: p2ry2_mouse, from_res: K, pubmed: '7876172', seq: '107', to_res: I}
- {entry_name: p2ry2_mouse, from_res: R, pubmed: '7876172', seq: '265', to_res: L}
- {entry_name: p2ry2_mouse, from_res: H, pubmed: '7876172', seq: '262', to_res: L}
- {entry_name: p2ry2_mouse, from_res: R, pubmed: '7876172', seq: '292', to_res: L}
- {entry_name: p2ry2_mouse, from_res: K, pubmed: '7876172', seq: '289', to_res: R}
- {entry_name: p2ry2_mouse, from_res: K, pubmed: '7876172', seq: '289', to_res: I}
- {entry_name: opsd_bovin, from_res: E, pubmed: '3123487', seq: '239', to_res: Q}
- {entry_name: opsd_bovin, from_res: K, pubmed: '3123487', seq: '248', to_res: L}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8193125', seq: '296', to_res: D}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '175', to_res: R}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '175', to_res: A}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '182', to_res: M}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '182', to_res: R}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '182', to_res: A}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '182', to_res: D}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '182', to_res: E}
- {entry_name: tshr_human, from_res: A, pubmed: '7989485', seq: '623', to_res: V}
- {entry_name: tshr_human, from_res: T, pubmed: '7989485', seq: '632', to_res: I}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8569696', seq: '128', to_res: F}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '8569696', seq: '293', to_res: E}
- {entry_name: acm2_pig, from_res: A, pubmed: '8569698', seq: '212', to_res: E}
- {entry_name: drd2_human, from_res: C, pubmed: '7718244', seq: '118', to_res: S}
- {entry_name: agtr1_human, from_res: Y, pubmed: '8569717', seq: '302', to_res: F}
- {entry_name: agtr1_human, from_res: Y, pubmed: '8569717', seq: '302', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '7547930', seq: '296', to_res: G}
- {entry_name: opsd_bovin, from_res: K, pubmed: '7547930', seq: '296', to_res: E}
- {entry_name: opsd_bovin, from_res: K, pubmed: '7547930', seq: '296', to_res: M}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7547930', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: G, pubmed: '7547930', seq: '90', to_res: D}
- {entry_name: opsd_bovin, from_res: A, pubmed: '7547930', seq: '292', to_res: E}
- {entry_name: opsd_human, from_res: K, pubmed: '7724596', seq: '296', to_res: E}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8444840', seq: '113', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8444840', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8444840', seq: '113', to_res: A}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1351402', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1351402', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1351402', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1351402', seq: '113', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1472495', seq: '296', to_res: E}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1472495', seq: '296', to_res: G}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1472495', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: K, pubmed: '1472495', seq: '296', to_res: H}
- {entry_name: opsd_bovin, from_res: H, pubmed: '1472495', seq: '211', to_res: F}
- {entry_name: opsd_bovin, from_res: A, pubmed: '1532391', seq: '117', to_res: F}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1532391', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1532391', seq: '122', to_res: A}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1532391', seq: '122', to_res: D}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1532391', seq: '126', to_res: F}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1532391', seq: '126', to_res: L}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1532391', seq: '126', to_res: A}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1532391', seq: '265', to_res: A}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1532391', seq: '265', to_res: Y}
- {entry_name: opsd_bovin, from_res: W, pubmed: '1532391', seq: '265', to_res: F}
- {entry_name: opsd_bovin, from_res: Y, pubmed: '1532391', seq: '268', to_res: F}
- {entry_name: opsd_bovin, from_res: A, pubmed: '1532391', seq: '292', to_res: D}
- {entry_name: opsd_astfa, from_res: Y, pubmed: '7706043', seq: '261', to_res: F}
- {entry_name: nk1r_human, from_res: N, pubmed: '8846422', seq: '23', to_res: A}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8846422', seq: '24', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '8846422', seq: '25', to_res: A}
- {entry_name: nk1r_human, from_res: E, pubmed: '8846422', seq: '78', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '8846422', seq: '85', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '8846422', seq: '89', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8846422', seq: '92', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '8846422', seq: '96', to_res: S}
- {entry_name: nk1r_human, from_res: H, pubmed: '8846422', seq: '108', to_res: Q}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8846422', seq: '165', to_res: A}
- {entry_name: nk1r_human, from_res: S, pubmed: '8846422', seq: '169', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '8846422', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8846422', seq: '205', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '8846422', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8846422', seq: '272', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8846422', seq: '287', to_res: A}
- {entry_name: v2r_human, from_res: R, pubmed: '8104196', seq: '113', to_res: W}
- {entry_name: v2r_human, from_res: R, pubmed: '8104196', seq: '137', to_res: H}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '8593815', seq: '318', to_res: N}
- {entry_name: v2r_human, from_res: C, pubmed: '8573100', seq: '341', to_res: S}
- {entry_name: v2r_human, from_res: C, pubmed: '8573100', seq: '342', to_res: S}
- {entry_name: trfr_rat, from_res: N, pubmed: '7577928', seq: '289', to_res: D}
- {entry_name: trfr_rat, from_res: N, pubmed: '7577928', seq: '289', to_res: E}
- {entry_name: trfr_rat, from_res: N, pubmed: '7577928', seq: '289', to_res: A}
- {entry_name: trfr_rat, from_res: S, pubmed: '7577928', seq: '290', to_res: D}
- {entry_name: trfr_rat, from_res: N, pubmed: '7577928', seq: '110', to_res: D}
- {entry_name: gnrhr_human, from_res: K, pubmed: '8643087', seq: '121', to_res: R}
- {entry_name: gnrhr_human, from_res: K, pubmed: '8643087', seq: '121', to_res: Q}
- {entry_name: gnrhr_human, from_res: K, pubmed: '8643087', seq: '121', to_res: L}
- {entry_name: gnrhr_human, from_res: K, pubmed: '8643087', seq: '121', to_res: D}
- {entry_name: agtra_rat, from_res: K, pubmed: '7499361', seq: '199', to_res: A}
- {entry_name: agtra_rat, from_res: K, pubmed: '7499361', seq: '199', to_res: Q}
- {entry_name: agtra_rat, from_res: K, pubmed: '7499361', seq: '199', to_res: R}
- {entry_name: agtra_rat, from_res: H, pubmed: '7499361', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '7499361', seq: '256', to_res: Q}
- {entry_name: agtra_rat, from_res: H, pubmed: '7499361', seq: '256', to_res: R}
- {entry_name: lshr_rat, from_res: R, pubmed: '8530405', seq: '47', to_res: D}
- {entry_name: lshr_rat, from_res: R, pubmed: '8530405', seq: '57', to_res: K}
- {entry_name: lshr_rat, from_res: R, pubmed: '8530405', seq: '57', to_res: D}
- {entry_name: lshr_rat, from_res: K, pubmed: '8530405', seq: '81', to_res: R}
- {entry_name: lshr_rat, from_res: K, pubmed: '8530405', seq: '81', to_res: D}
- {entry_name: lshr_rat, from_res: E, pubmed: '8530405', seq: '91', to_res: K}
- {entry_name: lshr_rat, from_res: E, pubmed: '8530405', seq: '94', to_res: K}
- {entry_name: lshr_rat, from_res: R, pubmed: '8530405', seq: '140', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '8530405', seq: '147', to_res: D}
- {entry_name: lshr_rat, from_res: E, pubmed: '8530405', seq: '247', to_res: K}
- {entry_name: lshr_rat, from_res: K, pubmed: '8530405', seq: '261', to_res: D}
- {entry_name: lshr_rat, from_res: E, pubmed: '8530405', seq: '358', to_res: K}
- {entry_name: lshr_rat, from_res: D, pubmed: '8530405', seq: '359', to_res: K}
- {entry_name: lshr_rat, from_res: R, pubmed: '8557706', seq: '367', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '8557706', seq: '427', to_res: D}
- {entry_name: lshr_rat, from_res: K, pubmed: '8557706', seq: '514', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '8557706', seq: '609', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '8557706', seq: '609', to_res: Q}
- {entry_name: lshr_rat, from_res: K, pubmed: '8557706', seq: '609', to_res: R}
- {entry_name: lshr_rat, from_res: K, pubmed: '8557706', seq: '609', to_res: P}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '8531139', seq: '340', to_res: L}
- {entry_name: galr1_human, from_res: H, pubmed: '8617199', seq: '112', to_res: Q}
- {entry_name: galr1_human, from_res: H, pubmed: '8617199', seq: '264', to_res: A}
- {entry_name: galr1_human, from_res: H, pubmed: '8617199', seq: '267', to_res: A}
- {entry_name: galr1_human, from_res: E, pubmed: '8617199', seq: '271', to_res: S}
- {entry_name: galr1_human, from_res: F, pubmed: '8617199', seq: '282', to_res: G}
- {entry_name: galr1_human, from_res: H, pubmed: '8617199', seq: '289', to_res: S}
- {entry_name: agtrb_rat, from_res: M, pubmed: '7568109', seq: '30', to_res: A}
- {entry_name: agtrb_rat, from_res: T, pubmed: '7568109', seq: '33', to_res: I}
- {entry_name: agtrb_rat, from_res: I, pubmed: '7568109', seq: '37', to_res: T}
- {entry_name: agtrb_rat, from_res: I, pubmed: '7568109', seq: '43', to_res: V}
- {entry_name: agtrb_rat, from_res: L, pubmed: '7568109', seq: '68', to_res: M}
- {entry_name: agtrb_rat, from_res: A, pubmed: '7568109', seq: '73', to_res: S}
- {entry_name: agtrb_rat, from_res: L, pubmed: '7568109', seq: '78', to_res: V}
- {entry_name: agtrb_rat, from_res: V, pubmed: '7568109', seq: '108', to_res: I}
- {entry_name: agtrb_rat, from_res: V, pubmed: '7568109', seq: '108', to_res: A}
- {entry_name: agtrb_rat, from_res: S, pubmed: '7568109', seq: '109', to_res: T}
- {entry_name: agtrb_rat, from_res: S, pubmed: '7568109', seq: '109', to_res: A}
- {entry_name: agtrb_rat, from_res: F, pubmed: '7568109', seq: '110', to_res: L}
- {entry_name: agtrb_rat, from_res: A, pubmed: '7568109', seq: '114', to_res: T}
- {entry_name: agtrb_rat, from_res: S, pubmed: '7568109', seq: '115', to_res: T}
- {entry_name: agtrb_rat, from_res: V, pubmed: '7568109', seq: '147', to_res: L}
- {entry_name: agtrb_rat, from_res: I, pubmed: '7568109', seq: '150', to_res: V}
- {entry_name: agtrb_rat, from_res: M, pubmed: '7568109', seq: '155', to_res: V}
- {entry_name: agtrb_rat, from_res: A, pubmed: '7568109', seq: '163', to_res: S}
- {entry_name: agtrb_rat, from_res: T, pubmed: '7568109', seq: '190', to_res: Y}
- {entry_name: agtrb_rat, from_res: P, pubmed: '7568109', seq: '192', to_res: M}
- {entry_name: agtrb_rat, from_res: T, pubmed: '7568109', seq: '198', to_res: A}
- {entry_name: agtrb_rat, from_res: K, pubmed: '7568109', seq: '199', to_res: A}
- {entry_name: agtrb_rat, from_res: I, pubmed: '7568109', seq: '245', to_res: V}
- {entry_name: agtrb_rat, from_res: F, pubmed: '7568109', seq: '248', to_res: L}
- {entry_name: agtrb_rat, from_res: V, pubmed: '7568109', seq: '254', to_res: I}
- {entry_name: agtrb_rat, from_res: S, pubmed: '7568109', seq: '252', to_res: C}
- {entry_name: agtrb_rat, from_res: S, pubmed: '7568109', seq: '252', to_res: A}
- {entry_name: agtrb_rat, from_res: A, pubmed: '7568109', seq: '283', to_res: G}
- {entry_name: agtrb_rat, from_res: N, pubmed: '7568109', seq: '295', to_res: S}
- {entry_name: agtrb_rat, from_res: N, pubmed: '7568109', seq: '295', to_res: A}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '8569707', seq: '355', to_res: N}
- {entry_name: drd2_mouse, from_res: S, pubmed: '8522980', seq: '193', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '8522980', seq: '194', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '8522980', seq: '197', to_res: A}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '8626475', seq: '204', to_res: V}
- {entry_name: ada1b_mesau, from_res: L, pubmed: '8626475', seq: '314', to_res: M}
- {entry_name: ada1a_rat, from_res: V, pubmed: '8626475', seq: '185', to_res: A}
- {entry_name: ada1a_rat, from_res: M, pubmed: '8626475', seq: '292', to_res: L}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8672451', seq: '326', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '8576196', seq: '310', to_res: F}
- {entry_name: adrb2_human, from_res: L, pubmed: '8576196', seq: '311', to_res: F}
- {entry_name: adrb2_human, from_res: N, pubmed: '8576196', seq: '312', to_res: F}
- {entry_name: adrb2_human, from_res: Y, pubmed: '7559596', seq: '326', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8553074', seq: '326', to_res: A}
- {entry_name: ada2a_human, from_res: F, pubmed: '1688262', seq: '412', to_res: N}
- {entry_name: adrb2_human, from_res: N, pubmed: '1688262', seq: '312', to_res: F}
- {entry_name: adrb3_human, from_res: W, pubmed: '8641219', seq: '64', to_res: R}
- {entry_name: ada2a_human, from_res: C, pubmed: '7972030', seq: '442', to_res: F}
- {entry_name: ada2a_human, from_res: C, pubmed: '7972030', seq: '442', to_res: A}
- {entry_name: ada2c_human, from_res: F, pubmed: '7972030', seq: '452', to_res: C}
- {entry_name: ada1a_rat, from_res: S, pubmed: '8626427', seq: '188', to_res: A}
- {entry_name: ada1a_rat, from_res: S, pubmed: '8626427', seq: '192', to_res: A}
- {entry_name: ada1a_rat, from_res: M, pubmed: '8626427', seq: '292', to_res: L}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8521811', seq: '141', to_res: F}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8521811', seq: '350', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8521811', seq: '354', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8521811', seq: '366', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '8670860', seq: '142', to_res: E}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '8670860', seq: '142', to_res: R}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '8670860', seq: '142', to_res: N}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '8670860', seq: '142', to_res: A}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '8670860', seq: '143', to_res: A}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '8670860', seq: '143', to_res: N}
- {entry_name: ada1b_mesau, from_res: N, pubmed: '8670860', seq: '63', to_res: A}
- {entry_name: ada1b_mesau, from_res: N, pubmed: '8670860', seq: '63', to_res: D}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '8670860', seq: '293', to_res: E}
- {entry_name: adrb2_human, from_res: N, pubmed: '1331041', seq: '312', to_res: F}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8609897', seq: '151', to_res: A}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8609897', seq: '151', to_res: Q}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8609897', seq: '151', to_res: D}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8609897', seq: '161', to_res: A}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8609897', seq: '169', to_res: A}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8609897', seq: '169', to_res: Q}
- {entry_name: aa2ar_human, from_res: D, pubmed: '8609897', seq: '170', to_res: K}
- {entry_name: aa2ar_human, from_res: P, pubmed: '8609897', seq: '173', to_res: R}
- {entry_name: aa2ar_human, from_res: C, pubmed: '8609897', seq: '262', to_res: G}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8884226', seq: '13', to_res: Q}
- {entry_name: drd2_human, from_res: C, pubmed: '8609898', seq: '118', to_res: K}
- {entry_name: drd2_human, from_res: C, pubmed: '8609898', seq: '118', to_res: M}
- {entry_name: drd2_human, from_res: C, pubmed: '8609898', seq: '118', to_res: S}
- {entry_name: drd2_human, from_res: C, pubmed: '8609898', seq: '118', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '7758672', seq: '193', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '7758672', seq: '194', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '7758672', seq: '197', to_res: A}
- {entry_name: drd4_human, from_res: V, pubmed: '8741875', seq: '194', to_res: G}
- {entry_name: drd2_human, from_res: F, pubmed: '7595496', seq: '198', to_res: A}
- {entry_name: drd2_human, from_res: F, pubmed: '7595496', seq: '389', to_res: A}
- {entry_name: drd2_human, from_res: F, pubmed: '7595496', seq: '390', to_res: A}
- {entry_name: drd2_human, from_res: F, pubmed: '7595496', seq: '411', to_res: A}
- {entry_name: drd2_human, from_res: L, pubmed: '7595496', seq: '387', to_res: A}
- {entry_name: hrh2_rat, from_res: L, pubmed: '8631790', seq: '124', to_res: A}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: L}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: V}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: C}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: A}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: Y}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: T}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: F}
- {entry_name: acm5_human, from_res: I, pubmed: '8621674', seq: '216', to_res: G}
- {entry_name: acm2_human, from_res: D, pubmed: '10188794', seq: '103', to_res: E}
- {entry_name: acm2_human, from_res: D, pubmed: '10188794', seq: '103', to_res: N}
- {entry_name: acm2_human, from_res: D, pubmed: '10188794', seq: '103', to_res: A}
- {entry_name: acm1_rat, from_res: D, pubmed: '10188790', seq: '105', to_res: E}
- {entry_name: acm1_rat, from_res: D, pubmed: '10188790', seq: '105', to_res: N}
- {entry_name: acm1_rat, from_res: R, pubmed: '10188790', seq: '123', to_res: K}
- {entry_name: acm1_rat, from_res: R, pubmed: '10188790', seq: '123', to_res: A}
- {entry_name: acm1_rat, from_res: R, pubmed: '10188790', seq: '123', to_res: L}
- {entry_name: acm1_rat, from_res: R, pubmed: '10188790', seq: '123', to_res: Q}
- {entry_name: acm1_rat, from_res: R, pubmed: '10188790', seq: '123', to_res: E}
- {entry_name: acm2_human, from_res: D, pubmed: '10188790', seq: '103', to_res: E}
- {entry_name: acm1_rat, from_res: D, pubmed: '7556411', seq: '105', to_res: E}
- {entry_name: acm1_rat, from_res: D, pubmed: '7556411', seq: '105', to_res: N}
- {entry_name: acm2_rat, from_res: D, pubmed: '7556411', seq: '103', to_res: E}
- {entry_name: acm1_human, from_res: D, pubmed: '8120019', seq: '122', to_res: N}
- {entry_name: acm1_human, from_res: F, pubmed: '8120019', seq: '125', to_res: A}
- {entry_name: acm1_human, from_res: V, pubmed: '8120019', seq: '127', to_res: A}
- {entry_name: acm1_human, from_res: P, pubmed: '8120019', seq: '130', to_res: A}
- {entry_name: acm1_human, from_res: L, pubmed: '8120019', seq: '131', to_res: A}
- {entry_name: acm1_human, from_res: L, pubmed: '8120019', seq: '131', to_res: N}
- {entry_name: acm1_human, from_res: L, pubmed: '8120019', seq: '131', to_res: D}
- {entry_name: acm1_human, from_res: L, pubmed: '8120019', seq: '131', to_res: F}
- {entry_name: acm1_human, from_res: L, pubmed: '8120019', seq: '131', to_res: M}
- {entry_name: acm1_human, from_res: Y, pubmed: '8120019', seq: '133', to_res: A}
- {entry_name: acm1_human, from_res: K, pubmed: '8120019', seq: '136', to_res: A}
- {entry_name: acm3_human, from_res: T, pubmed: '8264552', seq: '550', to_res: A}
- {entry_name: acm3_human, from_res: T, pubmed: '8264552', seq: '553', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '8385357', seq: '540', to_res: A}
- {entry_name: acm4_mouse, from_res: T, pubmed: '8536700', seq: '145', to_res: A}
- {entry_name: acm4_mouse, from_res: T, pubmed: '8536700', seq: '399', to_res: A}
- {entry_name: acm4_mouse, from_res: T, pubmed: '8536700', seq: '399', to_res: S}
- {entry_name: acm4_mouse, from_res: T, pubmed: '8536700', seq: '399', to_res: D}
- {entry_name: acm5_human, from_res: R, pubmed: '8621701', seq: '218', to_res: G}
- {entry_name: acm5_human, from_res: Q, pubmed: '8621701', seq: '231', to_res: L}
- {entry_name: acm5_human, from_res: E, pubmed: '8621701', seq: '219', to_res: D}
- {entry_name: acm5_human, from_res: R, pubmed: '8621701', seq: '218', to_res: W}
- {entry_name: acm5_human, from_res: T, pubmed: '8621701', seq: '224', to_res: N}
- {entry_name: acm5_human, from_res: E, pubmed: '8621701', seq: '219', to_res: A}
- {entry_name: acm5_human, from_res: E, pubmed: '8621701', seq: '221', to_res: V}
- {entry_name: acm5_human, from_res: I, pubmed: '8621701', seq: '216', to_res: S}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8851517', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: T, pubmed: '8851517', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '8851517', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8851517', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8851517', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '8851517', seq: '533', to_res: F}
- {entry_name: acm1_rat, from_res: K, pubmed: '8700106', seq: '136', to_res: A}
- {entry_name: acm1_rat, from_res: R, pubmed: '8700106', seq: '137', to_res: A}
- {entry_name: acm1_rat, from_res: R, pubmed: '8700106', seq: '140', to_res: A}
- {entry_name: acm1_rat, from_res: K, pubmed: '8700106', seq: '361', to_res: A}
- {entry_name: acm1_rat, from_res: K, pubmed: '8700106', seq: '362', to_res: A}
- {entry_name: acm1_rat, from_res: R, pubmed: '8700106', seq: '365', to_res: A}
- {entry_name: acm4_mouse, from_res: T, pubmed: '8700152', seq: '399', to_res: A}
- {entry_name: 5ht1a_human, from_res: R, pubmed: '8645269', seq: '220', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '8531139', seq: '240', to_res: L}
- {entry_name: 5ht1a_rat, from_res: T, pubmed: '8848001', seq: '229', to_res: A}
- {entry_name: 5ht1a_rat, from_res: S, pubmed: '8848001', seq: '253', to_res: G}
- {entry_name: 5ht1a_rat, from_res: T, pubmed: '8848001', seq: '343', to_res: A}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '8569707', seq: '355', to_res: N}
- {entry_name: 5ht2a_human, from_res: S, pubmed: '8700116', seq: '242', to_res: A}
- {entry_name: 5ht2c_human, from_res: A, pubmed: '8700116', seq: '222', to_res: S}
- {entry_name: 5ht2a_human, from_res: S, pubmed: '8663249', seq: '159', to_res: A}
- {entry_name: 5ht2a_human, from_res: S, pubmed: '8663249', seq: '159', to_res: C}
- {entry_name: pe2r3_mouse, from_res: T, pubmed: '8615686', seq: '221', to_res: A}
- {entry_name: pe2r3_mouse, from_res: S, pubmed: '8615686', seq: '268', to_res: A}
- {entry_name: pe2r3_mouse, from_res: S, pubmed: '8615686', seq: '272', to_res: A}
- {entry_name: pe2r3_mouse, from_res: S, pubmed: '8615686', seq: '268', to_res: T}
- {entry_name: pe2r3_mouse, from_res: T, pubmed: '8615686', seq: '221', to_res: S}
- {entry_name: pe2r3_mouse, from_res: S, pubmed: '8615686', seq: '272', to_res: T}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '11', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '68', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '102', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '105', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '183', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '223', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '257', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8626415', seq: '223', to_res: A}
- {entry_name: ta2r_human, from_res: T, pubmed: '8626415', seq: '221', to_res: M}
- {entry_name: ta2r_human, from_res: H, pubmed: '8626415', seq: '224', to_res: R}
- {entry_name: ta2r_human, from_res: H, pubmed: '8626415', seq: '227', to_res: R}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '34', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '38', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '40', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '48', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '135', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '160', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '283', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '284', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '308', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '340', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '347', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '357', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '443', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '2890637', seq: '518', to_res: S}
- {entry_name: lshr_rat, from_res: T, pubmed: '8672431', seq: '450', to_res: A}
- {entry_name: lshr_rat, from_res: P, pubmed: '8672431', seq: '505', to_res: L}
- {entry_name: lshr_rat, from_res: M, pubmed: '8672431', seq: '586', to_res: L}
- {entry_name: lshr_rat, from_res: S, pubmed: '8672431', seq: '590', to_res: A}
- {entry_name: lshr_rat, from_res: P, pubmed: '8672431', seq: '588', to_res: L}
- {entry_name: lshr_rat, from_res: Y, pubmed: '8672431', seq: '616', to_res: A}
- {entry_name: lshr_rat, from_res: P, pubmed: '8672431', seq: '617', to_res: L}
- {entry_name: lshr_rat, from_res: P, pubmed: '8672431', seq: '624', to_res: L}
- {entry_name: lshr_rat, from_res: Y, pubmed: '8672431', seq: '627', to_res: A}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '599', to_res: A}
- {entry_name: lshr_rat, from_res: V, pubmed: '8631747', seq: '600', to_res: A}
- {entry_name: lshr_rat, from_res: P, pubmed: '8631747', seq: '601', to_res: A}
- {entry_name: lshr_rat, from_res: L, pubmed: '8631747', seq: '602', to_res: A}
- {entry_name: lshr_rat, from_res: I, pubmed: '8631747', seq: '603', to_res: A}
- {entry_name: lshr_rat, from_res: T, pubmed: '8631747', seq: '604', to_res: A}
- {entry_name: lshr_rat, from_res: V, pubmed: '8631747', seq: '605', to_res: A}
- {entry_name: lshr_rat, from_res: T, pubmed: '8631747', seq: '606', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '8631747', seq: '607', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '8631747', seq: '608', to_res: A}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '609', to_res: A}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '609', to_res: R}
- {entry_name: lshr_rat, from_res: C, pubmed: '7982985', seq: '647', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '7982985', seq: '648', to_res: S}
- {entry_name: lshr_human, from_res: M, pubmed: '7593421', seq: '398', to_res: T}
- {entry_name: lshr_human, from_res: M, pubmed: '7593421', seq: '571', to_res: I}
- {entry_name: lshr_human, from_res: D, pubmed: '7593421', seq: '578', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '7527413', seq: '578', to_res: G}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '609', to_res: D}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '609', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '609', to_res: Q}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '609', to_res: Y}
- {entry_name: lshr_rat, from_res: K, pubmed: '8631747', seq: '609', to_res: L}
- {entry_name: lshr_rat, from_res: D, pubmed: '8732685', seq: '409', to_res: N}
- {entry_name: lshr_rat, from_res: R, pubmed: '8732685', seq: '468', to_res: H}
- {entry_name: lshr_rat, from_res: K, pubmed: '8702611', seq: '609', to_res: A}
- {entry_name: lshr_rat, from_res: K, pubmed: '8702611', seq: '609', to_res: R}
- {entry_name: lshr_rat, from_res: K, pubmed: '8702611', seq: '609', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '8702611', seq: '609', to_res: L}
- {entry_name: tshr_rat, from_res: C, pubmed: '8100829', seq: '301', to_res: S}
- {entry_name: tshr_rat, from_res: Y, pubmed: '8100829', seq: '385', to_res: F}
- {entry_name: tshr_rat, from_res: Y, pubmed: '8100829', seq: '385', to_res: A}
- {entry_name: tshr_rat, from_res: C, pubmed: '8100829', seq: '390', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8630013', seq: '699', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8630013', seq: '712', to_res: S}
- {entry_name: tshr_human, from_res: P, pubmed: '8681963', seq: '52', to_res: T}
- {entry_name: agtra_rat, from_res: D, pubmed: '7699988', seq: '74', to_res: N}
- {entry_name: agtra_rat, from_res: L, pubmed: '7989302', seq: '330', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '7989302', seq: '331', to_res: A}
- {entry_name: agtra_rat, from_res: T, pubmed: '7989302', seq: '332', to_res: A}
- {entry_name: agtra_rat, from_res: K, pubmed: '7989302', seq: '333', to_res: A}
- {entry_name: agtra_rat, from_res: M, pubmed: '7989302', seq: '334', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '7989302', seq: '335', to_res: A}
- {entry_name: agtra_rat, from_res: T, pubmed: '7989302', seq: '336', to_res: A}
- {entry_name: agtra_rat, from_res: L, pubmed: '7989302', seq: '337', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '7989302', seq: '338', to_res: A}
- {entry_name: grpr_mouse, from_res: R, pubmed: '7852420', seq: '139', to_res: G}
- {entry_name: grpr_mouse, from_res: A, pubmed: '7852420', seq: '264', to_res: E}
- {entry_name: grpr_rat, from_res: Y, pubmed: '8063819', seq: '324', to_res: A}
- {entry_name: grpr_mouse, from_res: R, pubmed: '7935330', seq: '139', to_res: G}
- {entry_name: grpr_mouse, from_res: A, pubmed: '7935330', seq: '264', to_res: E}
- {entry_name: c5ar_human, from_res: M, pubmed: '7642584', seq: '120', to_res: L}
- {entry_name: c5ar_human, from_res: S, pubmed: '7642584', seq: '314', to_res: T}
- {entry_name: c5ar_human, from_res: S, pubmed: '7642584', seq: '317', to_res: T}
- {entry_name: c5ar_human, from_res: S, pubmed: '7642584', seq: '327', to_res: T}
- {entry_name: c5ar_human, from_res: S, pubmed: '7642584', seq: '332', to_res: T}
- {entry_name: c5ar_human, from_res: S, pubmed: '7642584', seq: '334', to_res: T}
- {entry_name: c5ar_human, from_res: S, pubmed: '7642584', seq: '338', to_res: T}
- {entry_name: c5ar_human, from_res: D, pubmed: '8631370', seq: '37', to_res: A}
- {entry_name: c5ar_human, from_res: D, pubmed: '8631370', seq: '82', to_res: A}
- {entry_name: c5ar_human, from_res: D, pubmed: '8631370', seq: '82', to_res: N}
- {entry_name: c5ar_human, from_res: R, pubmed: '8631370', seq: '175', to_res: A}
- {entry_name: c5ar_human, from_res: R, pubmed: '8631370', seq: '206', to_res: A}
- {entry_name: c5ar_human, from_res: R, pubmed: '8631370', seq: '206', to_res: K}
- {entry_name: c5ar_human, from_res: R, pubmed: '8631370', seq: '206', to_res: Q}
- {entry_name: c5ar_human, from_res: N, pubmed: '8631370', seq: '119', to_res: A}
- {entry_name: c5ar_human, from_res: T, pubmed: '8631370', seq: '168', to_res: A}
- {entry_name: c5ar_human, from_res: D, pubmed: '8631370', seq: '282', to_res: A}
- {entry_name: c5ar_human, from_res: D, pubmed: '8631370', seq: '282', to_res: N}
- {entry_name: c5ar_human, from_res: Q, pubmed: '8631370', seq: '259', to_res: A}
- {entry_name: cckar_rat, from_res: S, pubmed: '8631990', seq: '260', to_res: A}
- {entry_name: cckar_rat, from_res: S, pubmed: '8631990', seq: '264', to_res: A}
- {entry_name: cckar_rat, from_res: S, pubmed: '8631990', seq: '275', to_res: A}
- {entry_name: cckar_rat, from_res: T, pubmed: '8631990', seq: '424', to_res: A}
- {entry_name: gasr_canfa, from_res: L, pubmed: '7929324', seq: '355', to_res: V}
- {entry_name: gasr_rat, from_res: H, pubmed: '8720482', seq: '381', to_res: L}
- {entry_name: gasr_rat, from_res: H, pubmed: '8720482', seq: '381', to_res: F}
- {entry_name: gasr_rat, from_res: H, pubmed: '8720482', seq: '381', to_res: R}
- {entry_name: ednrb_human, from_res: K, pubmed: '7981216', seq: '182', to_res: glx}
- {entry_name: ednrb_human, from_res: C, pubmed: '7509994', seq: '174', to_res: A}
- {entry_name: ednrb_human, from_res: C, pubmed: '7509994', seq: '255', to_res: A}
- {entry_name: ednrb_rat, from_res: K, pubmed: '1283771', seq: '182', to_res: D}
- {entry_name: ednrb_rat, from_res: G, pubmed: '8125970', seq: '75', to_res: D}
- {entry_name: ednrb_rat, from_res: N, pubmed: '8125970', seq: '97', to_res: Q}
- {entry_name: ednra_human, from_res: V, pubmed: '8473300', seq: '225', to_res: D}
- {entry_name: ednra_human, from_res: K, pubmed: '8473300', seq: '330', to_res: I}
- {entry_name: ednrb_human, from_res: D, pubmed: '8473300', seq: '241', to_res: V}
- {entry_name: ednrb_human, from_res: L, pubmed: '8473300', seq: '347', to_res: K}
- {entry_name: ednrb_human, from_res: K, pubmed: '8086489', seq: '161', to_res: I}
- {entry_name: ednra_human, from_res: Y, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Y, pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: ednra_human, from_res: Y, pubmed: '8611558', seq: '129', to_res: K}
- {entry_name: ednra_human, from_res: Y, pubmed: '8611558', seq: '129', to_res: I}
- {entry_name: ednra_human, from_res: Y, pubmed: '8611558', seq: '129', to_res: T}
- {entry_name: ednra_human, from_res: Y, pubmed: '8611558', seq: '129', to_res: S}
- {entry_name: ednra_human, from_res: Y, pubmed: '8611558', seq: '129', to_res: A}
- {entry_name: ednra_human, from_res: D, pubmed: '8611558', seq: '126', to_res: A}
- {entry_name: ednra_human, from_res: D, pubmed: '8611558', seq: '133', to_res: A}
- {entry_name: gnrhr_human, from_res: N, pubmed: '8663086', seq: '102', to_res: A}
- {entry_name: npy1r_human, from_res: Y, pubmed: '8834002', seq: '100', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8834002', seq: '194', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8834002', seq: '200', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8834002', seq: '287', to_res: A}
- {entry_name: npy1r_human, from_res: N, pubmed: '8834002', seq: '289', to_res: A}
- {entry_name: npy1r_human, from_res: H, pubmed: '8834002', seq: '298', to_res: A}
- {entry_name: npy1r_human, from_res: Y, pubmed: '8700135', seq: '100', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8700135', seq: '104', to_res: A}
- {entry_name: npy1r_human, from_res: H, pubmed: '8700135', seq: '105', to_res: A}
- {entry_name: npy1r_human, from_res: W, pubmed: '8700135', seq: '163', to_res: A}
- {entry_name: npy1r_human, from_res: S, pubmed: '8700135', seq: '170', to_res: A}
- {entry_name: npy1r_human, from_res: F, pubmed: '8700135', seq: '173', to_res: A}
- {entry_name: npy1r_human, from_res: L, pubmed: '8700135', seq: '174', to_res: A}
- {entry_name: npy1r_human, from_res: V, pubmed: '8700135', seq: '178', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8700135', seq: '200', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8700135', seq: '205', to_res: A}
- {entry_name: npy1r_human, from_res: S, pubmed: '8700135', seq: '206', to_res: A}
- {entry_name: npy1r_human, from_res: H, pubmed: '8700135', seq: '207', to_res: A}
- {entry_name: npy1r_human, from_res: S, pubmed: '8700135', seq: '210', to_res: A}
- {entry_name: npy1r_human, from_res: Y, pubmed: '8700135', seq: '211', to_res: A}
- {entry_name: npy1r_human, from_res: T, pubmed: '8700135', seq: '212', to_res: A}
- {entry_name: npy1r_human, from_res: Q, pubmed: '8700135', seq: '219', to_res: A}
- {entry_name: npy1r_human, from_res: T, pubmed: '8700135', seq: '280', to_res: A}
- {entry_name: npy1r_human, from_res: N, pubmed: '8700135', seq: '283', to_res: A}
- {entry_name: npy1r_human, from_res: T, pubmed: '8700135', seq: '284', to_res: A}
- {entry_name: npy1r_human, from_res: F, pubmed: '8700135', seq: '286', to_res: A}
- {entry_name: npy1r_human, from_res: D, pubmed: '8700135', seq: '287', to_res: A}
- {entry_name: npy1r_human, from_res: W, pubmed: '8700135', seq: '288', to_res: A}
- {entry_name: npy1r_human, from_res: N, pubmed: '8700135', seq: '289', to_res: A}
- {entry_name: npy1r_human, from_res: H, pubmed: '8700135', seq: '290', to_res: A}
- {entry_name: npy1r_human, from_res: Q, pubmed: '8700135', seq: '291', to_res: A}
- {entry_name: npy1r_human, from_res: H, pubmed: '8700135', seq: '298', to_res: A}
- {entry_name: ntr1_human, from_res: D, pubmed: '8663052', seq: '340', to_res: H}
- {entry_name: ntr1_human, from_res: Y, pubmed: '8663052', seq: '341', to_res: F}
- {entry_name: oprm_rat, from_res: C, pubmed: '8621408', seq: '159', to_res: S}
- {entry_name: oprm_rat, from_res: C, pubmed: '8621408', seq: '190', to_res: S}
- {entry_name: oprm_rat, from_res: C, pubmed: '8621408', seq: '235', to_res: S}
- {entry_name: oprm_rat, from_res: C, pubmed: '8621408', seq: '292', to_res: S}
- {entry_name: oprm_rat, from_res: C, pubmed: '8621408', seq: '321', to_res: S}
- {entry_name: oprm_rat, from_res: H, pubmed: '8621408', seq: '223', to_res: S}
- {entry_name: oprd_mouse, from_res: S, pubmed: '8650158', seq: '177', to_res: L}
- {entry_name: oprm_rat, from_res: S, pubmed: '8650158', seq: '196', to_res: L}
- {entry_name: oprd_mouse, from_res: S, pubmed: '8626742', seq: '344', to_res: G}
- {entry_name: oprd_mouse, from_res: T, pubmed: '8626742', seq: '352', to_res: A}
- {entry_name: oprd_mouse, from_res: T, pubmed: '8626742', seq: '353', to_res: A}
- {entry_name: oprd_mouse, from_res: D, pubmed: '8632752', seq: '128', to_res: A}
- {entry_name: oprd_mouse, from_res: D, pubmed: '8632752', seq: '128', to_res: N}
- {entry_name: oprm_mouse, from_res: D, pubmed: '8632752', seq: '147', to_res: A}
- {entry_name: oprk_rat, from_res: A, pubmed: '8626461', seq: '298', to_res: H}
- {entry_name: oprd_human, from_res: A, pubmed: '8702536', seq: '275', to_res: G}
- {entry_name: oprd_human, from_res: F, pubmed: '8702536', seq: '280', to_res: A}
- {entry_name: oprd_human, from_res: V, pubmed: '8702536', seq: '283', to_res: A}
- {entry_name: oprd_human, from_res: W, pubmed: '8702536', seq: '284', to_res: A}
- {entry_name: oprd_human, from_res: T, pubmed: '8702536', seq: '285', to_res: A}
- {entry_name: oprd_human, from_res: D, pubmed: '8702536', seq: '288', to_res: A}
- {entry_name: oprd_human, from_res: I, pubmed: '8702536', seq: '289', to_res: A}
- {entry_name: oprd_human, from_res: D, pubmed: '8702536', seq: '290', to_res: A}
- {entry_name: oprd_human, from_res: R, pubmed: '8702536', seq: '291', to_res: A}
- {entry_name: oprd_human, from_res: R, pubmed: '8702536', seq: '292', to_res: A}
- {entry_name: oprd_human, from_res: D, pubmed: '8702536', seq: '293', to_res: R}
- {entry_name: oprd_human, from_res: P, pubmed: '8702536', seq: '294', to_res: A}
- {entry_name: oprd_human, from_res: L, pubmed: '8702536', seq: '295', to_res: A}
- {entry_name: oprd_human, from_res: V, pubmed: '8702536', seq: '296', to_res: A}
- {entry_name: oprd_human, from_res: V, pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: oprd_human, from_res: A, pubmed: '8702536', seq: '298', to_res: G}
- {entry_name: oprd_human, from_res: A, pubmed: '8702536', seq: '299', to_res: G}
- {entry_name: oprd_human, from_res: L, pubmed: '8702536', seq: '302', to_res: A}
- {entry_name: oprd_human, from_res: A, pubmed: '8702536', seq: '309', to_res: G}
- {entry_name: oprd_human, from_res: S, pubmed: '8702536', seq: '312', to_res: A}
- {entry_name: oprd_human, from_res: W, pubmed: '8702536', seq: '284', to_res: K}
- {entry_name: oprd_mouse, from_res: Y, pubmed: '8626577', seq: '129', to_res: F}
- {entry_name: oprd_mouse, from_res: Y, pubmed: '8626577', seq: '129', to_res: A}
- {entry_name: oprd_mouse, from_res: W, pubmed: '8626577', seq: '173', to_res: A}
- {entry_name: oprd_mouse, from_res: F, pubmed: '8626577', seq: '218', to_res: A}
- {entry_name: oprd_mouse, from_res: F, pubmed: '8626577', seq: '222', to_res: A}
- {entry_name: oprd_mouse, from_res: W, pubmed: '8626577', seq: '274', to_res: A}
- {entry_name: oprd_mouse, from_res: Y, pubmed: '8626577', seq: '308', to_res: F}
- {entry_name: nk1r_rat, from_res: C, pubmed: '8567643', seq: '199', to_res: S}
- {entry_name: nk1r_rat, from_res: V, pubmed: '1376175', seq: '97', to_res: E}
- {entry_name: nk1r_human, from_res: E, pubmed: '7532789', seq: '193', to_res: H}
- {entry_name: nk1r_human, from_res: T, pubmed: '7532789', seq: '201', to_res: H}
- {entry_name: nk1r_human, from_res: F, pubmed: '7532789', seq: '268', to_res: H}
- {entry_name: nk1r_human, from_res: L, pubmed: '7532789', seq: '269', to_res: H}
- {entry_name: nk1r_human, from_res: Y, pubmed: '7532789', seq: '272', to_res: H}
- {entry_name: nk1r_human, from_res: H, pubmed: '7532789', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '7532789', seq: '265', to_res: A}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '8036739', seq: '106', to_res: F}
- {entry_name: trfr_mouse, from_res: T, pubmed: '8036739', seq: '102', to_res: Y}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '8036739', seq: '103', to_res: F}
- {entry_name: trfr_mouse, from_res: Q, pubmed: '8036739', seq: '105', to_res: A}
- {entry_name: trfr_mouse, from_res: Q, pubmed: '8036739', seq: '105', to_res: E}
- {entry_name: trfr_mouse, from_res: Q, pubmed: '8036739', seq: '105', to_res: V}
- {entry_name: trfr_mouse, from_res: Q, pubmed: '8036739', seq: '105', to_res: L}
- {entry_name: trfr_rat, from_res: C, pubmed: '8770906', seq: '98', to_res: S}
- {entry_name: trfr_rat, from_res: C, pubmed: '8770906', seq: '98', to_res: A}
- {entry_name: trfr_rat, from_res: C, pubmed: '8770906', seq: '179', to_res: S}
- {entry_name: trfr_rat, from_res: C, pubmed: '8770906', seq: '179', to_res: A}
- {entry_name: trfr_rat, from_res: C, pubmed: '8770906', seq: '100', to_res: S}
- {entry_name: trfr_rat, from_res: C, pubmed: '8770906', seq: '100', to_res: A}
- {entry_name: trfr_mouse, from_res: Q, pubmed: '8672465', seq: '105', to_res: V}
- {entry_name: trfr_mouse, from_res: F, pubmed: '8672465', seq: '199', to_res: A}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '8672465', seq: '282', to_res: A}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '8672465', seq: '282', to_res: F}
- {entry_name: trfr_mouse, from_res: R, pubmed: '8672465', seq: '283', to_res: K}
- {entry_name: trfr_mouse, from_res: R, pubmed: '8672465', seq: '306', to_res: A}
- {entry_name: trfr_mouse, from_res: S, pubmed: '8672465', seq: '113', to_res: A}
- {entry_name: v2r_human, from_res: R, pubmed: '7560098', seq: '143', to_res: P}
- {entry_name: v2r_human, from_res: R, pubmed: '7560098', seq: '202', to_res: C}
- {entry_name: oxyr_human, from_res: G, pubmed: '8713985', seq: '107', to_res: A}
- {entry_name: oxyr_human, from_res: F, pubmed: '8713985', seq: '293', to_res: I}
- {entry_name: oxyr_human, from_res: D, pubmed: '8713985', seq: '85', to_res: N}
- {entry_name: v2r_human, from_res: Y, pubmed: '8635461', seq: '128', to_res: S}
- {entry_name: v2r_human, from_res: Y, pubmed: '8635461', seq: '280', to_res: C}
- {entry_name: v2r_human, from_res: L, pubmed: '8635461', seq: '292', to_res: F}
- {entry_name: opsd_bovin, from_res: P, pubmed: '7488190', seq: '347', to_res: S}
- {entry_name: opsd_bovin, from_res: D, pubmed: '7662872', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7662872', seq: '122', to_res: L}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7662872', seq: '134', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7662872', seq: '134', to_res: R}
- {entry_name: opsd_bovin, from_res: N, pubmed: '7808422', seq: '310', to_res: A}
- {entry_name: opsd_bovin, from_res: K, pubmed: '7808422', seq: '311', to_res: A}
- {entry_name: opsd_bovin, from_res: Q, pubmed: '7808422', seq: '312', to_res: A}
- {entry_name: opsd_bovin, from_res: Q, pubmed: '7808422', seq: '312', to_res: L}
- {entry_name: opsd_bovin, from_res: F, pubmed: '7808422', seq: '313', to_res: A}
- {entry_name: opsd_bovin, from_res: R, pubmed: '7808422', seq: '314', to_res: A}
- {entry_name: opsd_bovin, from_res: N, pubmed: '7808422', seq: '315', to_res: A}
- {entry_name: opsd_bovin, from_res: N, pubmed: '7808422', seq: '315', to_res: I}
- {entry_name: opsd_bovin, from_res: H, pubmed: '7836439', seq: '65', to_res: Y}
- {entry_name: opsd_bovin, from_res: P, pubmed: '7836439', seq: '71', to_res: A}
- {entry_name: opsd_bovin, from_res: A, pubmed: '7514180', seq: '26', to_res: G}
- {entry_name: opsd_bovin, from_res: T, pubmed: '7514180', seq: '97', to_res: G}
- {entry_name: opsd_bovin, from_res: P, pubmed: '7514180', seq: '107', to_res: S}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7514180', seq: '239', to_res: G}
- {entry_name: opsd_bovin, from_res: A, pubmed: '7514180', seq: '333', to_res: G}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7916209', seq: '113', to_res: A}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7916209', seq: '113', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8343512', seq: '134', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8343512', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8396426', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: D, pubmed: '1673866', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1673866', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1673866', seq: '113', to_res: D}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1673866', seq: '113', to_res: Y}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1673866', seq: '134', to_res: R}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1673866', seq: '134', to_res: D}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8120004', seq: '296', to_res: G}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8120004', seq: '296', to_res: E}
- {entry_name: opsd_bovin, from_res: K, pubmed: '8120004', seq: '296', to_res: M}
- {entry_name: opsd_human, from_res: F, pubmed: '1924344', seq: '45', to_res: L}
- {entry_name: opsd_human, from_res: P, pubmed: '1924344', seq: '347', to_res: L}
- {entry_name: opsd_human, from_res: T, pubmed: '1924344', seq: '17', to_res: M}
- {entry_name: opsd_human, from_res: P, pubmed: '1924344', seq: '23', to_res: H}
- {entry_name: opsd_human, from_res: Y, pubmed: '1924344', seq: '178', to_res: C}
- {entry_name: opsd_human, from_res: D, pubmed: '1924344', seq: '190', to_res: G}
- {entry_name: opsd_human, from_res: T, pubmed: '1924344', seq: '58', to_res: R}
- {entry_name: opsd_human, from_res: V, pubmed: '1924344', seq: '87', to_res: D}
- {entry_name: opsd_human, from_res: G, pubmed: '1924344', seq: '89', to_res: D}
- {entry_name: opsd_human, from_res: G, pubmed: '1924344', seq: '106', to_res: W}
- {entry_name: opsd_human, from_res: R, pubmed: '1924344', seq: '135', to_res: L}
- {entry_name: opsd_human, from_res: R, pubmed: '1924344', seq: '135', to_res: W}
- {entry_name: opsd_bovin, from_res: D, pubmed: '7901852', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: E, pubmed: '7901852', seq: '122', to_res: Q}
- {entry_name: opsr_human, from_res: T, pubmed: '8284327', seq: '65', to_res: I}
- {entry_name: opsr_human, from_res: I, pubmed: '8284327', seq: '230', to_res: T}
- {entry_name: opsr_human, from_res: A, pubmed: '8284327', seq: '233', to_res: S}
- {entry_name: opsr_human, from_res: Y, pubmed: '8284327', seq: '277', to_res: F}
- {entry_name: opsr_human, from_res: T, pubmed: '8284327', seq: '285', to_res: A}
- {entry_name: opsd_bovin, from_res: C, pubmed: '3076084', seq: '110', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '3076084', seq: '185', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '3076084', seq: '187', to_res: S}
- {entry_name: ptafr_human, from_res: D, pubmed: '8645288', seq: '63', to_res: N}
- {entry_name: ptafr_human, from_res: A, pubmed: '8626474', seq: '230', to_res: E}
- {entry_name: ptafr_human, from_res: A, pubmed: '8626474', seq: '230', to_res: Q}
- {entry_name: ptafr_human, from_res: L, pubmed: '8626474', seq: '231', to_res: R}
- {entry_name: par1_human, from_res: F, pubmed: '7665575', seq: '87', to_res: A}
- {entry_name: opsd_bovin, from_res: V, pubmed: '8848049', seq: '138', to_res: H}
- {entry_name: opsd_bovin, from_res: T, pubmed: '8848049', seq: '251', to_res: H}
- {entry_name: ssr2_mouse, from_res: F, pubmed: '8702767', seq: '294', to_res: S}
- {entry_name: ssr1_mouse, from_res: S, pubmed: '8702767', seq: '305', to_res: F}
- {entry_name: ssr1_mouse, from_res: Q, pubmed: '8702767', seq: '291', to_res: N}
- {entry_name: fshr_human, from_res: D, pubmed: '8798412', seq: '581', to_res: G}
- {entry_name: fshr_human, from_res: D, pubmed: '8798412', seq: '581', to_res: Y}
- {entry_name: fshr_human, from_res: C, pubmed: '8798412', seq: '584', to_res: R}
- {entry_name: adrb2_human, from_res: C, pubmed: '8702933', seq: '341', to_res: G}
- {entry_name: cnr1_human, from_res: K, pubmed: '8622639', seq: '192', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '7838137', seq: '83', to_res: A}
- {entry_name: acm1_human, from_res: Y, pubmed: '7838137', seq: '85', to_res: A}
- {entry_name: acm1_human, from_res: W, pubmed: '7838137', seq: '91', to_res: A}
- {entry_name: acm1_human, from_res: W, pubmed: '7838137', seq: '91', to_res: F}
- {entry_name: acm1_human, from_res: G, pubmed: '7838137', seq: '94', to_res: A}
- {entry_name: acm1_human, from_res: W, pubmed: '7838137', seq: '101', to_res: A}
- {entry_name: acm1_human, from_res: W, pubmed: '7838137', seq: '101', to_res: F}
- {entry_name: acm1_human, from_res: W, pubmed: '7838137', seq: '164', to_res: A}
- {entry_name: acm1_human, from_res: Q, pubmed: '7838137', seq: '165', to_res: A}
- {entry_name: acm1_human, from_res: G, pubmed: '7838137', seq: '169', to_res: A}
- {entry_name: acm1_human, from_res: R, pubmed: '7838137', seq: '171', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '7838137', seq: '172', to_res: A}
- {entry_name: acm1_human, from_res: Q, pubmed: '7838137', seq: '181', to_res: A}
- {entry_name: acm1_human, from_res: F, pubmed: '7838137', seq: '182', to_res: A}
- {entry_name: acm1_human, from_res: S, pubmed: '7838137', seq: '184', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '7838137', seq: '389', to_res: A}
- {entry_name: acm1_human, from_res: F, pubmed: '7838137', seq: '390', to_res: A}
- {entry_name: acm1_human, from_res: C, pubmed: '7838137', seq: '391', to_res: A}
- {entry_name: acm1_human, from_res: C, pubmed: '7838137', seq: '394', to_res: A}
- {entry_name: acm1_human, from_res: P, pubmed: '7838137', seq: '396', to_res: A}
- {entry_name: acm1_human, from_res: T, pubmed: '7838137', seq: '398', to_res: A}
- {entry_name: acm1_human, from_res: W, pubmed: '7838137', seq: '400', to_res: A}
- {entry_name: acm1_human, from_res: W, pubmed: '7838137', seq: '400', to_res: F}
- {entry_name: acm1_human, from_res: Y, pubmed: '7838137', seq: '404', to_res: A}
- {entry_name: acm1_human, from_res: Y, pubmed: '7838137', seq: '404', to_res: F}
- {entry_name: tshr_human, from_res: S, pubmed: '8636266', seq: '505', to_res: R}
- {entry_name: tshr_human, from_res: N, pubmed: '8636266', seq: '650', to_res: Y}
- {entry_name: tshr_human, from_res: N, pubmed: '8636266', seq: '670', to_res: S}
- {entry_name: tshr_human, from_res: P, pubmed: '7556171', seq: '52', to_res: T}
- {entry_name: tshr_rat, from_res: C, pubmed: '8651910', seq: '454', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8651910', seq: '462', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8651910', seq: '549', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8651910', seq: '598', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8651910', seq: '600', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8651910', seq: '636', to_res: S}
- {entry_name: tshr_rat, from_res: C, pubmed: '8651910', seq: '672', to_res: S}
- {entry_name: fshr_human, from_res: D, pubmed: '8636335', seq: '567', to_res: G}
- {entry_name: lshr_human, from_res: M, pubmed: '8607787', seq: '398', to_res: T}
- {entry_name: ta2r_human, from_res: R, pubmed: '8613548', seq: '60', to_res: L}
- {entry_name: v2r_human, from_res: Y, pubmed: '8704106', seq: '205', to_res: C}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8643443', seq: '122', to_res: R}
- {entry_name: opsd_bovin, from_res: I, pubmed: '8643443', seq: '123', to_res: R}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8643443', seq: '124', to_res: R}
- {entry_name: opsd_bovin, from_res: L, pubmed: '8643443', seq: '125', to_res: R}
- {entry_name: opsd_bovin, from_res: L, pubmed: '8643443', seq: '125', to_res: F}
- {entry_name: opsd_bovin, from_res: L, pubmed: '8643443', seq: '125', to_res: A}
- {entry_name: opsd_bovin, from_res: S, pubmed: '8643443', seq: '127', to_res: R}
- {entry_name: opsd_bovin, from_res: P, pubmed: '8643442', seq: '23', to_res: H}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8643442', seq: '188', to_res: R}
- {entry_name: opsd_bovin, from_res: D, pubmed: '8643442', seq: '190', to_res: A}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8652533', seq: '90', to_res: D}
- {entry_name: acthr_human, from_res: C, pubmed: '8636348', seq: '251', to_res: F}
- {entry_name: acthr_human, from_res: D, pubmed: '8636348', seq: '107', to_res: N}
- {entry_name: acthr_human, from_res: V, pubmed: '8636348', seq: '45', to_res: I}
- {entry_name: acthr_human, from_res: C, pubmed: '8881288', seq: '251', to_res: F}
- {entry_name: acthr_human, from_res: D, pubmed: '8881288', seq: '107', to_res: N}
- {entry_name: opsd_bovin, from_res: R, pubmed: '8260503', seq: '135', to_res: L}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '110', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '140', to_res: A}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '140', to_res: H}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '140', to_res: Y}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '185', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '8419942', seq: '187', to_res: S}
- {entry_name: gasr_human, from_res: V, pubmed: '8185216', seq: '349', to_res: I}
- {entry_name: ada2a_pig, from_res: C, pubmed: '8385131', seq: '442', to_res: S}
- {entry_name: ada2a_pig, from_res: F, pubmed: '8206950', seq: '429', to_res: A}
- {entry_name: ada2a_pig, from_res: C, pubmed: '8206950', seq: '442', to_res: A}
- {entry_name: adrb2_human, from_res: C, pubmed: '2542304', seq: '190', to_res: S}
- {entry_name: adrb2_human, from_res: C, pubmed: '2542304', seq: '191', to_res: S}
- {entry_name: par1_human, from_res: E, pubmed: '7994033', seq: '90', to_res: A}
- {entry_name: par1_human, from_res: D, pubmed: '7994033', seq: '91', to_res: A}
- {entry_name: trfr_rat, from_res: Y, pubmed: '8614407', seq: '93', to_res: A}
- {entry_name: trfr_rat, from_res: Y, pubmed: '8614407', seq: '181', to_res: F}
- {entry_name: trfr_rat, from_res: Y, pubmed: '8614407', seq: '188', to_res: A}
- {entry_name: trfr_rat, from_res: F, pubmed: '8614407', seq: '199', to_res: A}
- {entry_name: trfr_rat, from_res: N, pubmed: '8614407', seq: '289', to_res: A}
- {entry_name: trfr_rat, from_res: S, pubmed: '8614407', seq: '290', to_res: A}
- {entry_name: fshr_rat, from_res: D, pubmed: '8614409', seq: '421', to_res: E}
- {entry_name: fshr_rat, from_res: D, pubmed: '8614409', seq: '421', to_res: A}
- {entry_name: fshr_rat, from_res: D, pubmed: '8614409', seq: '421', to_res: K}
- {entry_name: lshr_rat, from_res: D, pubmed: '8614409', seq: '423', to_res: K}
- {entry_name: tshr_human, from_res: F, pubmed: '7566968', seq: '631', to_res: C}
- {entry_name: tshr_human, from_res: T, pubmed: '7566968', seq: '632', to_res: I}
- {entry_name: agtra_rat, from_res: K, pubmed: '8576145', seq: '102', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '8576145', seq: '105', to_res: R}
- {entry_name: agtra_rat, from_res: S, pubmed: '8576145', seq: '107', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '8576145', seq: '109', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '8576145', seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '8576145', seq: '115', to_res: A}
- {entry_name: agtra_rat, from_res: K, pubmed: '8576145', seq: '199', to_res: A}
- {entry_name: nk1r_human, from_res: P, pubmed: '8947044', seq: '112', to_res: H}
- {entry_name: nk1r_human, from_res: N, pubmed: '8947044', seq: '109', to_res: H}
- {entry_name: nk1r_human, from_res: H, pubmed: '8947044', seq: '95', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8947044', seq: '92', to_res: H}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '121', to_res: A}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '121', to_res: S}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '121', to_res: T}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '121', to_res: V}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '121', to_res: I}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '121', to_res: L}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '121', to_res: W}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '114', to_res: A}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '114', to_res: V}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '114', to_res: I}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '114', to_res: M}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943295', seq: '114', to_res: W}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8943295', seq: '117', to_res: G}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8943295', seq: '117', to_res: V}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8943295', seq: '117', to_res: I}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8943295', seq: '117', to_res: M}
- {entry_name: opsd_bovin, from_res: A, pubmed: '8943295', seq: '117', to_res: W}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943296', seq: '121', to_res: L}
- {entry_name: opsd_bovin, from_res: F, pubmed: '8943296', seq: '261', to_res: A}
- {entry_name: opsd_bovin, from_res: F, pubmed: '8943296', seq: '261', to_res: T}
- {entry_name: opsd_bovin, from_res: F, pubmed: '8943296', seq: '261', to_res: V}
- {entry_name: opsd_bovin, from_res: F, pubmed: '8943296', seq: '261', to_res: W}
- {entry_name: opsd_bovin, from_res: G, pubmed: '8943296', seq: '121', to_res: W}
- {entry_name: opsd_bovin, from_res: M, pubmed: '8943296', seq: '257', to_res: A}
- {entry_name: opsd_bovin, from_res: V, pubmed: '8943296', seq: '258', to_res: A}
- {entry_name: opsd_bovin, from_res: W, pubmed: '8943296', seq: '265', to_res: Y}
- {entry_name: opsd_bovin, from_res: E, pubmed: '8943296', seq: '113', to_res: A}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: G}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: A}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: F}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: L}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: M}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: W}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: V}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: P}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: I}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: S}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: Y}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: T}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: N}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: Q}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: E}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: D}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: H}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: K}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8910453', seq: '128', to_res: R}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '8910453', seq: '331', to_res: A}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '8910453', seq: '331', to_res: E}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '8910453', seq: '125', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '8910453', seq: '125', to_res: K}
- {entry_name: drd1_human, from_res: F, pubmed: '8910419', seq: '264', to_res: I}
- {entry_name: drd1_human, from_res: R, pubmed: '8910419', seq: '266', to_res: K}
- {entry_name: drd5_human, from_res: I, pubmed: '8910419', seq: '288', to_res: F}
- {entry_name: drd5_human, from_res: K, pubmed: '8910419', seq: '290', to_res: R}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '74', to_res: E}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '74', to_res: K}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '263', to_res: A}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '263', to_res: K}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '263', to_res: E}
- {entry_name: agtra_rat, from_res: E, pubmed: '7759541', seq: '185', to_res: D}
- {entry_name: agtra_rat, from_res: E, pubmed: '7759541', seq: '185', to_res: K}
- {entry_name: agtra_rat, from_res: E, pubmed: '7759541', seq: '185', to_res: Q}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '278', to_res: A}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '278', to_res: K}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '281', to_res: A}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '281', to_res: E}
- {entry_name: agtra_rat, from_res: D, pubmed: '7759541', seq: '281', to_res: K}
- {entry_name: ptafr_human, from_res: N, pubmed: '8798529', seq: '285', to_res: I}
- {entry_name: ptafr_human, from_res: N, pubmed: '8798529', seq: '285', to_res: A}
- {entry_name: ptafr_human, from_res: D, pubmed: '8798529', seq: '289', to_res: N}
- {entry_name: ptafr_human, from_res: D, pubmed: '8798529', seq: '289', to_res: A}
- {entry_name: bkrb2_rat, from_res: R, pubmed: '8910447', seq: '106', to_res: A}
- {entry_name: bkrb2_rat, from_res: R, pubmed: '8910447', seq: '106', to_res: Q}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '8910447', seq: '110', to_res: A}
- {entry_name: bkrb2_rat, from_res: N, pubmed: '8910447', seq: '109', to_res: A}
- {entry_name: bkrb2_rat, from_res: M, pubmed: '8910447', seq: '111', to_res: W}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '8910447', seq: '113', to_res: F}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '8910447', seq: '113', to_res: T}
- {entry_name: bkrb2_rat, from_res: N, pubmed: '8910447', seq: '115', to_res: A}
- {entry_name: bkrb2_rat, from_res: L, pubmed: '8910447', seq: '116', to_res: W}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '8910447', seq: '117', to_res: A}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '8910447', seq: '117', to_res: F}
- {entry_name: bkrb2_rat, from_res: S, pubmed: '8910447', seq: '118', to_res: A}
- {entry_name: bkrb2_rat, from_res: S, pubmed: '8910447', seq: '119', to_res: A}
- {entry_name: bkrb2_rat, from_res: C, pubmed: '8910447', seq: '121', to_res: A}
- {entry_name: bkrb2_rat, from_res: W, pubmed: '8910447', seq: '157', to_res: A}
- {entry_name: bkrb2_rat, from_res: W, pubmed: '8910447', seq: '157', to_res: F}
- {entry_name: bkrb2_rat, from_res: S, pubmed: '8910447', seq: '164', to_res: A}
- {entry_name: bkrb2_rat, from_res: S, pubmed: '8910447', seq: '165', to_res: A}
- {entry_name: bkrb2_rat, from_res: S, pubmed: '8910447', seq: '165', to_res: T}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '8910447', seq: '170', to_res: A}
- {entry_name: bkrb2_rat, from_res: K, pubmed: '8910447', seq: '174', to_res: A}
- {entry_name: bkrb2_rat, from_res: E, pubmed: '8910447', seq: '196', to_res: D}
- {entry_name: bkrb2_rat, from_res: E, pubmed: '8910447', seq: '196', to_res: R}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '8910447', seq: '199', to_res: A}
- {entry_name: bkrb2_rat, from_res: N, pubmed: '8910447', seq: '200', to_res: A}
- {entry_name: bkrb2_rat, from_res: N, pubmed: '8910447', seq: '204', to_res: A}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '8910447', seq: '254', to_res: M}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '8910447', seq: '254', to_res: A}
- {entry_name: bkrb2_rat, from_res: W, pubmed: '8910447', seq: '258', to_res: A}
- {entry_name: bkrb2_rat, from_res: W, pubmed: '8910447', seq: '258', to_res: F}
- {entry_name: bkrb2_rat, from_res: W, pubmed: '8910447', seq: '258', to_res: H}
- {entry_name: bkrb2_rat, from_res: W, pubmed: '8910447', seq: '258', to_res: M}
- {entry_name: bkrb2_rat, from_res: F, pubmed: '8910447', seq: '261', to_res: A}
- {entry_name: bkrb2_rat, from_res: Q, pubmed: '8910447', seq: '262', to_res: A}
- {entry_name: bkrb2_rat, from_res: S, pubmed: '8910447', seq: '264', to_res: R}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '8910447', seq: '265', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8910447', seq: '268', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8910447', seq: '268', to_res: N}
- {entry_name: bkrb2_rat, from_res: R, pubmed: '8910447', seq: '272', to_res: A}
- {entry_name: bkrb2_rat, from_res: R, pubmed: '8910447', seq: '283', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8910447', seq: '286', to_res: A}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8910447', seq: '286', to_res: R}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8910447', seq: '286', to_res: K}
- {entry_name: bkrb2_rat, from_res: Q, pubmed: '8910447', seq: '290', to_res: A}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '8910447', seq: '297', to_res: A}
- {entry_name: lshr_human, from_res: S, pubmed: '8559204', seq: '616', to_res: Y}
- {entry_name: bkrb2_human, from_res: C, pubmed: '8939910', seq: '20', to_res: S}
- {entry_name: bkrb2_human, from_res: C, pubmed: '8939910', seq: '277', to_res: S}
- {entry_name: bkrb2_human, from_res: C, pubmed: '8939910', seq: '103', to_res: S}
- {entry_name: bkrb2_human, from_res: C, pubmed: '8939910', seq: '184', to_res: S}
- {entry_name: oprd_rat, from_res: A, pubmed: '8913373', seq: '107', to_res: V}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: N}
- {entry_name: oprd_rat, from_res: E, pubmed: '8913373', seq: '112', to_res: G}
- {entry_name: oprd_rat, from_res: E, pubmed: '8913373', seq: '118', to_res: T}
- {entry_name: oprd_rat, from_res: L, pubmed: '8913373', seq: '119', to_res: I}
- {entry_name: oprd_rat, from_res: A, pubmed: '8913373', seq: '123', to_res: I}
- {entry_name: oprd_rat, from_res: L, pubmed: '8913373', seq: '125', to_res: I}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: R}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: D}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: E}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: Q}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: S}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: T}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: C}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: M}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: A}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: V}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: L}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: I}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: P}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: G}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: F}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: Y}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: H}
- {entry_name: oprd_rat, from_res: K, pubmed: '8913373', seq: '108', to_res: W}
- {entry_name: oprm_rat, from_res: N, pubmed: '8913373', seq: '127', to_res: K}
- {entry_name: drd1_human, from_res: I, pubmed: '8913366', seq: '205', to_res: A}
- {entry_name: drd1_human, from_res: I, pubmed: '8913366', seq: '205', to_res: Y}
- {entry_name: drd1_human, from_res: L, pubmed: '8913366', seq: '286', to_res: A}
- {entry_name: drd1_human, from_res: L, pubmed: '8913366', seq: '286', to_res: Y}
- {entry_name: ada1b_mesau, from_res: G, pubmed: '8913343', seq: '196', to_res: Q}
- {entry_name: ada1b_mesau, from_res: V, pubmed: '8913343', seq: '197', to_res: I}
- {entry_name: ada1b_mesau, from_res: T, pubmed: '8913343', seq: '198', to_res: N}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '8913343', seq: '202', to_res: G}
- {entry_name: ada1b_mesau, from_res: I, pubmed: '8913343', seq: '214', to_res: V}
- {entry_name: ada1b_mesau, from_res: V, pubmed: '8913343', seq: '218', to_res: I}
- {entry_name: aa1r_human, from_res: S, pubmed: '8967987', seq: '94', to_res: T}
- {entry_name: oprd_human, from_res: W, pubmed: '8967985', seq: '284', to_res: L}
- {entry_name: oprd_human, from_res: R, pubmed: '8967985', seq: '291', to_res: S}
- {entry_name: oprd_human, from_res: R, pubmed: '8967985', seq: '292', to_res: E}
- {entry_name: oprd_human, from_res: H, pubmed: '8967985', seq: '301', to_res: N}
- {entry_name: nk1r_human, from_res: H, pubmed: '8967983', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '8967983', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: Q, pubmed: '8967983', seq: '284', to_res: A}
- {entry_name: aa2ar_human, from_res: T, pubmed: '8794889', seq: '88', to_res: A}
- {entry_name: aa2ar_human, from_res: T, pubmed: '8794889', seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, pubmed: '8794889', seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: Q, pubmed: '8794889', seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: S, pubmed: '8794889', seq: '90', to_res: A}
- {entry_name: aa2ar_human, from_res: S, pubmed: '8794889', seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, pubmed: '8794889', seq: '277', to_res: C}
- {entry_name: aa2ar_human, from_res: S, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: Q, pubmed: '8794889', seq: '89', to_res: N}
- {entry_name: aa2ar_human, from_res: Q, pubmed: '8794889', seq: '89', to_res: S}
- {entry_name: aa2ar_human, from_res: Q, pubmed: '8794889', seq: '89', to_res: L}
- {entry_name: aa2ar_human, from_res: Q, pubmed: '8794889', seq: '89', to_res: H}
- {entry_name: aa2ar_human, from_res: Q, pubmed: '8794889', seq: '89', to_res: R}
- {entry_name: aa2ar_human, from_res: E, pubmed: '8884226', seq: '13', to_res: Q}
- {entry_name: agtra_rat, from_res: A, pubmed: '8816747', seq: '221', to_res: S}
- {entry_name: agtra_rat, from_res: A, pubmed: '8816747', seq: '221', to_res: R}
- {entry_name: agtra_rat, from_res: A, pubmed: '8816747', seq: '221', to_res: K}
- {entry_name: agtra_rat, from_res: L, pubmed: '8816747', seq: '222', to_res: A}
- {entry_name: agtra_rat, from_res: L, pubmed: '8816747', seq: '222', to_res: S}
- {entry_name: agtra_rat, from_res: L, pubmed: '8816747', seq: '222', to_res: N}
- {entry_name: agtra_rat, from_res: L, pubmed: '8816747', seq: '222', to_res: R}
- {entry_name: agtra_rat, from_res: L, pubmed: '8816747', seq: '222', to_res: K}
- {entry_name: agtra_rat, from_res: L, pubmed: '8816747', seq: '222', to_res: V}
- {entry_name: agtra_rat, from_res: L, pubmed: '8816747', seq: '222', to_res: I}
- {entry_name: agtra_rat, from_res: S, pubmed: '8987975', seq: '107', to_res: G}
- {entry_name: agtra_rat, from_res: S, pubmed: '8987975', seq: '115', to_res: G}
- {entry_name: agtra_rat, from_res: N, pubmed: '8987975', seq: '111', to_res: G}
- {entry_name: agtra_rat, from_res: N, pubmed: '8987975', seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '8987975', seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, pubmed: '8987975', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: H, pubmed: '8987975', seq: '256', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '8799191', seq: '165', to_res: A}
- {entry_name: adrb2_human, from_res: N, pubmed: '8799191', seq: '293', to_res: L}
- {entry_name: v2r_human, from_res: L, pubmed: '8863826', seq: '44', to_res: P}
- {entry_name: v2r_human, from_res: L, pubmed: '8863826', seq: '44', to_res: F}
- {entry_name: v2r_human, from_res: W, pubmed: '8863826', seq: '164', to_res: S}
- {entry_name: v2r_human, from_res: S, pubmed: '8863826', seq: '167', to_res: L}
- {entry_name: v2r_human, from_res: S, pubmed: '8863826', seq: '167', to_res: T}
- {entry_name: v2r_human, from_res: S, pubmed: '8863826', seq: '167', to_res: A}
- {entry_name: oprk_rat, from_res: S, pubmed: '8863844', seq: '123', to_res: A}
- {entry_name: oprk_rat, from_res: Y, pubmed: '8863844', seq: '119', to_res: A}
- {entry_name: oprk_rat, from_res: T, pubmed: '8863844', seq: '109', to_res: A}
- {entry_name: oprk_rat, from_res: D, pubmed: '8863844', seq: '105', to_res: N}
- {entry_name: bkrb2_rat, from_res: D, pubmed: '8873604', seq: '78', to_res: N}
- {entry_name: oprd_mouse, from_res: S, pubmed: '8910588', seq: '344', to_res: G}
- {entry_name: oprd_mouse, from_res: T, pubmed: '8910588', seq: '352', to_res: A}
- {entry_name: oprd_mouse, from_res: T, pubmed: '8910588', seq: '353', to_res: A}
- {entry_name: oprd_mouse, from_res: T, pubmed: '8910588', seq: '358', to_res: A}
- {entry_name: oprd_mouse, from_res: T, pubmed: '8910588', seq: '361', to_res: A}
- {entry_name: oprd_mouse, from_res: S, pubmed: '8910588', seq: '363', to_res: A}
- {entry_name: oprx_human, from_res: Q, pubmed: '8849681', seq: '280', to_res: H}
- {entry_name: ada1a_human, from_res: I, pubmed: '8916917', seq: '85', to_res: T}
- {entry_name: ada1a_human, from_res: F, pubmed: '8916917', seq: '86', to_res: M}
- {entry_name: ada1d_human, from_res: M, pubmed: '8916917', seq: '156', to_res: F}
- {entry_name: ops1_drome, from_res: N, pubmed: '1534022', seq: '20', to_res: I}
- {entry_name: agtra_rat, from_res: N, pubmed: '8999867', seq: '111', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: N}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: E}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: F}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: R}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: W}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: P}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: Y}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: G}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: H}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: K}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: S}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: C}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: L}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: M}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: Q}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: V}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: I}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9023338', seq: '142', to_res: T}
- {entry_name: lshr_rat, from_res: P, pubmed: '9020129', seq: '489', to_res: F}
- {entry_name: lshr_rat, from_res: P, pubmed: '9020129', seq: '505', to_res: G}
- {entry_name: lshr_rat, from_res: P, pubmed: '9020129', seq: '505', to_res: A}
- {entry_name: lshr_rat, from_res: P, pubmed: '9020129', seq: '505', to_res: F}
- {entry_name: lshr_rat, from_res: P, pubmed: '9020129', seq: '588', to_res: F}
- {entry_name: lshr_rat, from_res: P, pubmed: '9020129', seq: '617', to_res: F}
- {entry_name: lshr_rat, from_res: P, pubmed: '9020129', seq: '624', to_res: F}
- {entry_name: cckar_human, from_res: E, pubmed: '9006937', seq: '38', to_res: D}
- {entry_name: cckar_human, from_res: W, pubmed: '9006937', seq: '39', to_res: F}
- {entry_name: cckar_human, from_res: Q, pubmed: '9006937', seq: '40', to_res: N}
- {entry_name: cckar_human, from_res: A, pubmed: '9006937', seq: '42', to_res: V}
- {entry_name: cckar_human, from_res: W, pubmed: '9006937', seq: '39', to_res: I}
- {entry_name: cckar_human, from_res: Q, pubmed: '9006937', seq: '40', to_res: E}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '9023266', seq: '340', to_res: L}
- {entry_name: par1_xenla, from_res: D, pubmed: '7665575', seq: '258', to_res: A}
- {entry_name: drd3_human, from_res: T, pubmed: '8099332', seq: '328', to_res: S}
- {entry_name: cxcr4_human, from_res: T, pubmed: '9353342', seq: '318', to_res: A}
- {entry_name: tshr_human, from_res: T, pubmed: '9024242', seq: '620', to_res: S}
- {entry_name: cnr1_human, from_res: C, pubmed: '8636122', seq: '257', to_res: S}
- {entry_name: cnr1_human, from_res: C, pubmed: '8636122', seq: '264', to_res: S}
- {entry_name: cnr1_human, from_res: C, pubmed: '8636122', seq: '257', to_res: A}
- {entry_name: cnr1_human, from_res: C, pubmed: '8636122', seq: '264', to_res: A}
- {entry_name: cnr2_human, from_res: C, pubmed: '8636122', seq: '174', to_res: S}
- {entry_name: cnr2_human, from_res: C, pubmed: '8636122', seq: '179', to_res: S}
- {entry_name: acm2_pig, from_res: K, pubmed: '8569698', seq: '214', to_res: A}
- {entry_name: par1_human, from_res: Y, pubmed: '7665575', seq: '266', to_res: A}
- {entry_name: par1_human, from_res: Y, pubmed: '7665575', seq: '267', to_res: A}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '260', to_res: A}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '260', to_res: R}
- {entry_name: par1_human, from_res: F, pubmed: '7665575', seq: '87', to_res: R}
- {entry_name: par1_human, from_res: I, pubmed: '7665575', seq: '88', to_res: R}
- {entry_name: par1_human, from_res: S, pubmed: '7665575', seq: '89', to_res: R}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '90', to_res: R}
- {entry_name: par1_human, from_res: F, pubmed: '7665575', seq: '163', to_res: R}
- {entry_name: par1_human, from_res: D, pubmed: '7665575', seq: '167', to_res: R}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '173', to_res: R}
- {entry_name: par1_human, from_res: Q, pubmed: '7665575', seq: '245', to_res: R}
- {entry_name: par1_human, from_res: N, pubmed: '7665575', seq: '250', to_res: R}
- {entry_name: par1_human, from_res: H, pubmed: '7665575', seq: '255', to_res: R}
- {entry_name: par1_human, from_res: D, pubmed: '7665575', seq: '256', to_res: R}
- {entry_name: par1_human, from_res: V, pubmed: '7665575', seq: '257', to_res: R}
- {entry_name: par1_human, from_res: L, pubmed: '7665575', seq: '258', to_res: R}
- {entry_name: par1_human, from_res: N, pubmed: '7665575', seq: '259', to_res: R}
- {entry_name: par1_human, from_res: T, pubmed: '7665575', seq: '261', to_res: R}
- {entry_name: par1_human, from_res: L, pubmed: '7665575', seq: '262', to_res: R}
- {entry_name: par1_human, from_res: L, pubmed: '7665575', seq: '263', to_res: R}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '264', to_res: R}
- {entry_name: par1_human, from_res: G, pubmed: '7665575', seq: '265', to_res: R}
- {entry_name: par1_human, from_res: Y, pubmed: '7665575', seq: '266', to_res: R}
- {entry_name: par1_human, from_res: Y, pubmed: '7665575', seq: '267', to_res: R}
- {entry_name: par1_human, from_res: A, pubmed: '7665575', seq: '268', to_res: R}
- {entry_name: par1_human, from_res: Y, pubmed: '7665575', seq: '269', to_res: R}
- {entry_name: par1_human, from_res: Y, pubmed: '7665575', seq: '270', to_res: R}
- {entry_name: par1_human, from_res: F, pubmed: '7665575', seq: '339', to_res: R}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '347', to_res: R}
- {entry_name: par1_human, from_res: A, pubmed: '7665575', seq: '348', to_res: R}
- {entry_name: par1_xenla, from_res: N, pubmed: '7665575', seq: '86', to_res: A}
- {entry_name: par1_human, from_res: I, pubmed: '7665575', seq: '88', to_res: A}
- {entry_name: par1_human, from_res: S, pubmed: '7665575', seq: '89', to_res: A}
- {entry_name: par1_human, from_res: N, pubmed: '7665575', seq: '259', to_res: A}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '260', to_res: A}
- {entry_name: par1_human, from_res: T, pubmed: '7665575', seq: '261', to_res: A}
- {entry_name: par1_human, from_res: L, pubmed: '7665575', seq: '262', to_res: A}
- {entry_name: par1_human, from_res: L, pubmed: '7665575', seq: '263', to_res: A}
- {entry_name: par1_human, from_res: E, pubmed: '7665575', seq: '264', to_res: A}
- {entry_name: par1_human, from_res: G, pubmed: '7665575', seq: '265', to_res: A}
- {entry_name: pthr1_rat, from_res: R, pubmed: '8662729', seq: '233', to_res: H}
- {entry_name: pthr1_rat, from_res: R, pubmed: '8662729', seq: '233', to_res: Q}
- {entry_name: pthr1_rat, from_res: R, pubmed: '8662729', seq: '233', to_res: N}
- {entry_name: pthr1_rat, from_res: R, pubmed: '8662729', seq: '233', to_res: K}
- {entry_name: pthr1_rat, from_res: Q, pubmed: '8662729', seq: '451', to_res: K}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '8843414', seq: '318', to_res: N}
- {entry_name: gnrhr_mouse, from_res: Y, pubmed: '8843414', seq: '322', to_res: A}
- {entry_name: gnrhr_mouse, from_res: Y, pubmed: '8843414', seq: '322', to_res: F}
- {entry_name: 5ht1a_human, from_res: I, pubmed: '8546152', seq: '28', to_res: V}
- {entry_name: glp1r_rat, from_res: S, pubmed: '8702711', seq: '416', to_res: A}
- {entry_name: lshr_rat, from_res: E, pubmed: '8977389', seq: '467', to_res: Q}
- {entry_name: lshr_rat, from_res: T, pubmed: '8977389', seq: '201', to_res: A}
- {entry_name: acm2_human, from_res: V, pubmed: '9063897', seq: '385', to_res: A}
- {entry_name: acm2_human, from_res: T, pubmed: '9063897', seq: '386', to_res: A}
- {entry_name: acm2_human, from_res: I, pubmed: '9063897', seq: '389', to_res: L}
- {entry_name: acm2_human, from_res: L, pubmed: '9063897', seq: '390', to_res: S}
- {entry_name: cxcr1_human, from_res: D, pubmed: '8903513', seq: '134', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8903513', seq: '135', to_res: A}
- {entry_name: cxcr1_human, from_res: Y, pubmed: '8903513', seq: '136', to_res: A}
- {entry_name: cxcr1_human, from_res: L, pubmed: '8903513', seq: '137', to_res: A}
- {entry_name: cxcr1_human, from_res: I, pubmed: '8903513', seq: '139', to_res: A}
- {entry_name: cxcr1_human, from_res: V, pubmed: '8903513', seq: '140', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8903513', seq: '239', to_res: A}
- {entry_name: cxcr1_human, from_res: M, pubmed: '8903513', seq: '241', to_res: A}
- {entry_name: cxcr1_human, from_res: R, pubmed: '8903513', seq: '242', to_res: A}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '90', to_res: S}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '90', to_res: A}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '95', to_res: S}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '95', to_res: A}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '173', to_res: S}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '173', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '23', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '33', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '58', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '60', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, pubmed: '9065450', seq: '63', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '69', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '100', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '101', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '104', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '112', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '138', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '150', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9065450', seq: '188', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '236', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9065450', seq: '248', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9065450', seq: '249', to_res: A}
- {entry_name: ptafr_cavpo, from_res: Q, pubmed: '9065450', seq: '252', to_res: A}
- {entry_name: ptafr_cavpo, from_res: Q, pubmed: '9065450', seq: '276', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '278', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '283', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '284', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '285', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, pubmed: '9065450', seq: '289', to_res: A}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '8999947', seq: '331', to_res: A}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '8999947', seq: '341', to_res: A}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '8999947', seq: '349', to_res: A}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '8999947', seq: '305', to_res: A}
- {entry_name: nk1r_rat, from_res: Y, pubmed: '8999947', seq: '305', to_res: F}
- {entry_name: nk1r_rat, from_res: K, pubmed: '8999947', seq: '337', to_res: A}
- {entry_name: car1_dicdi, from_res: V, pubmed: '8999904', seq: '188', to_res: D}
- {entry_name: car1_dicdi, from_res: K, pubmed: '8999904', seq: '207', to_res: N}
- {entry_name: car1_dicdi, from_res: V, pubmed: '8999904', seq: '189', to_res: D}
- {entry_name: car1_dicdi, from_res: E, pubmed: '8999904', seq: '199', to_res: D}
- {entry_name: car1_dicdi, from_res: H, pubmed: '8999904', seq: '201', to_res: N}
- {entry_name: car1_dicdi, from_res: K, pubmed: '8999904', seq: '207', to_res: I}
- {entry_name: car1_dicdi, from_res: Y, pubmed: '8999904', seq: '204', to_res: I}
- {entry_name: car1_dicdi, from_res: R, pubmed: '8999904', seq: '184', to_res: G}
- {entry_name: car1_dicdi, from_res: N, pubmed: '8999904', seq: '197', to_res: I}
- {entry_name: car1_dicdi, from_res: Y, pubmed: '8999904', seq: '185', to_res: N}
- {entry_name: car1_dicdi, from_res: I, pubmed: '8999903', seq: '108', to_res: N}
- {entry_name: car1_dicdi, from_res: H, pubmed: '8999903', seq: '191', to_res: P}
- {entry_name: car1_dicdi, from_res: R, pubmed: '8999903', seq: '160', to_res: S}
- {entry_name: car1_dicdi, from_res: N, pubmed: '8999903', seq: '210', to_res: S}
- {entry_name: car1_dicdi, from_res: N, pubmed: '8999903', seq: '229', to_res: D}
- {entry_name: lshr_rat, from_res: K, pubmed: '8885249', seq: '66', to_res: R}
- {entry_name: lshr_rat, from_res: K, pubmed: '8885249', seq: '66', to_res: D}
- {entry_name: lshr_rat, from_res: K, pubmed: '8885249', seq: '130', to_res: D}
- {entry_name: lshr_rat, from_res: D, pubmed: '8885249', seq: '144', to_res: K}
- {entry_name: lshr_rat, from_res: E, pubmed: '8885249', seq: '158', to_res: K}
- {entry_name: lshr_rat, from_res: D, pubmed: '8885249', seq: '161', to_res: K}
- {entry_name: ste2_yeast, from_res: I, pubmed: '9067610', seq: '142', to_res: N}
- {entry_name: ste2_yeast, from_res: E, pubmed: '9067610', seq: '143', to_res: K}
- {entry_name: ste2_yeast, from_res: T, pubmed: '9067610', seq: '144', to_res: A}
- {entry_name: ste2_yeast, from_res: A, pubmed: '9067610', seq: '140', to_res: P}
- {entry_name: ste2_yeast, from_res: R, pubmed: '9067610', seq: '58', to_res: G}
- {entry_name: ste2_yeast, from_res: M, pubmed: '9067610', seq: '218', to_res: T}
- {entry_name: ste2_yeast, from_res: Y, pubmed: '9067610', seq: '266', to_res: C}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8832227', seq: '326', to_res: F}
- {entry_name: adrb2_human, from_res: Y, pubmed: '8832227', seq: '326', to_res: A}
- {entry_name: aa1r_human, from_res: E, pubmed: '8967987', seq: '16', to_res: A}
- {entry_name: aa1r_human, from_res: E, pubmed: '8967987', seq: '16', to_res: Q}
- {entry_name: aa1r_human, from_res: S, pubmed: '8967987', seq: '50', to_res: A}
- {entry_name: aa1r_human, from_res: D, pubmed: '8967987', seq: '55', to_res: A}
- {entry_name: aa1r_human, from_res: S, pubmed: '8967987', seq: '93', to_res: A}
- {entry_name: aa1r_human, from_res: S, pubmed: '8967987', seq: '94', to_res: A}
- {entry_name: aa1r_human, from_res: S, pubmed: '8967987', seq: '135', to_res: A}
- {entry_name: aa1r_human, from_res: T, pubmed: '8967987', seq: '141', to_res: A}
- {entry_name: drd1_human, from_res: C, pubmed: '9141061', seq: '347', to_res: A}
- {entry_name: drd1_human, from_res: C, pubmed: '9141061', seq: '351', to_res: A}
- {entry_name: acm2_human, from_res: V, pubmed: '9063897', seq: '385', to_res: A}
- {entry_name: acm2_human, from_res: T, pubmed: '9063897', seq: '386', to_res: A}
- {entry_name: acm2_human, from_res: I, pubmed: '9063897', seq: '389', to_res: L}
- {entry_name: acm2_human, from_res: L, pubmed: '9063897', seq: '390', to_res: S}
- {entry_name: tshr_human, from_res: S, pubmed: '9360556', seq: '281', to_res: N}
- {entry_name: tshr_human, from_res: S, pubmed: '9360556', seq: '281', to_res: T}
- {entry_name: tshr_human, from_res: M, pubmed: '9360556', seq: '453', to_res: T}
- {entry_name: tshr_human, from_res: I, pubmed: '9360556', seq: '486', to_res: F}
- {entry_name: tshr_human, from_res: I, pubmed: '9360556', seq: '486', to_res: M}
- {entry_name: tshr_human, from_res: S, pubmed: '9360556', seq: '505', to_res: R}
- {entry_name: tshr_human, from_res: S, pubmed: '9360556', seq: '505', to_res: N}
- {entry_name: tshr_human, from_res: V, pubmed: '9360556', seq: '509', to_res: A}
- {entry_name: tshr_human, from_res: R, pubmed: '9360556', seq: '528', to_res: H}
- {entry_name: tshr_human, from_res: I, pubmed: '9360556', seq: '568', to_res: T}
- {entry_name: tshr_human, from_res: V, pubmed: '9360556', seq: '597', to_res: L}
- {entry_name: tshr_human, from_res: D, pubmed: '9360556', seq: '619', to_res: G}
- {entry_name: tshr_human, from_res: A, pubmed: '9360556', seq: '623', to_res: I}
- {entry_name: tshr_human, from_res: A, pubmed: '9360556', seq: '623', to_res: V}
- {entry_name: tshr_human, from_res: A, pubmed: '9360556', seq: '623', to_res: S}
- {entry_name: tshr_human, from_res: L, pubmed: '9360556', seq: '629', to_res: F}
- {entry_name: tshr_human, from_res: F, pubmed: '9360556', seq: '631', to_res: L}
- {entry_name: tshr_human, from_res: F, pubmed: '9360556', seq: '631', to_res: C}
- {entry_name: tshr_human, from_res: T, pubmed: '9360556', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: D, pubmed: '9360556', seq: '633', to_res: E}
- {entry_name: tshr_human, from_res: D, pubmed: '9360556', seq: '633', to_res: Y}
- {entry_name: tshr_human, from_res: D, pubmed: '9360556', seq: '633', to_res: H}
- {entry_name: tshr_human, from_res: N, pubmed: '9360556', seq: '650', to_res: Y}
- {entry_name: tshr_human, from_res: V, pubmed: '9360556', seq: '656', to_res: F}
- {entry_name: tshr_human, from_res: N, pubmed: '9360556', seq: '670', to_res: S}
- {entry_name: tshr_human, from_res: C, pubmed: '9360556', seq: '672', to_res: Y}
- {entry_name: tshr_human, from_res: S, pubmed: '9253356', seq: '281', to_res: N}
- {entry_name: tshr_human, from_res: S, pubmed: '9253356', seq: '281', to_res: T}
- {entry_name: tshr_human, from_res: I, pubmed: '9253356', seq: '486', to_res: M}
- {entry_name: tshr_human, from_res: I, pubmed: '9253356', seq: '486', to_res: F}
- {entry_name: tshr_human, from_res: I, pubmed: '9253356', seq: '568', to_res: T}
- {entry_name: tshr_human, from_res: D, pubmed: '9253356', seq: '619', to_res: G}
- {entry_name: tshr_human, from_res: A, pubmed: '9253356', seq: '623', to_res: I}
- {entry_name: tshr_human, from_res: L, pubmed: '9253356', seq: '629', to_res: F}
- {entry_name: tshr_human, from_res: I, pubmed: '9253356', seq: '630', to_res: L}
- {entry_name: tshr_human, from_res: F, pubmed: '9253356', seq: '631', to_res: L}
- {entry_name: tshr_human, from_res: T, pubmed: '9253356', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: D, pubmed: '9253356', seq: '633', to_res: A}
- {entry_name: tshr_human, from_res: D, pubmed: '9253356', seq: '633', to_res: E}
- {entry_name: tshr_human, from_res: D, pubmed: '9253356', seq: '633', to_res: H}
- {entry_name: tshr_human, from_res: D, pubmed: '9253356', seq: '633', to_res: Y}
- {entry_name: tshr_human, from_res: A, pubmed: '9024242', seq: '623', to_res: V}
- {entry_name: tshr_human, from_res: T, pubmed: '9024242', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: F, pubmed: '9024242', seq: '631', to_res: C}
- {entry_name: tshr_human, from_res: T, pubmed: '9024242', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: D, pubmed: '9024242', seq: '633', to_res: E}
- {entry_name: tshr_human, from_res: D, pubmed: '9024242', seq: '633', to_res: Y}
- {entry_name: tshr_human, from_res: V, pubmed: '9024242', seq: '509', to_res: A}
- {entry_name: tshr_human, from_res: C, pubmed: '9024242', seq: '672', to_res: Y}
- {entry_name: tshr_human, from_res: S, pubmed: '9024242', seq: '505', to_res: R}
- {entry_name: tshr_human, from_res: N, pubmed: '9024242', seq: '650', to_res: Y}
- {entry_name: tshr_human, from_res: N, pubmed: '9024242', seq: '650', to_res: S}
- {entry_name: tshr_human, from_res: F, pubmed: '9024242', seq: '631', to_res: L}
- {entry_name: tshr_human, from_res: M, pubmed: '9024242', seq: '453', to_res: T}
- {entry_name: tshr_human, from_res: I, pubmed: '9024242', seq: '486', to_res: F}
- {entry_name: tshr_human, from_res: I, pubmed: '9024242', seq: '486', to_res: M}
- {entry_name: tshr_human, from_res: I, pubmed: '9024242', seq: '568', to_res: T}
- {entry_name: tshr_human, from_res: F, pubmed: '9024242', seq: '631', to_res: L}
- {entry_name: tshr_human, from_res: A, pubmed: '9024242', seq: '623', to_res: S}
- {entry_name: 5ht7r_mouse, from_res: E, pubmed: '9256244', seq: '325', to_res: G}
- {entry_name: 5ht7r_mouse, from_res: K, pubmed: '9256244', seq: '327', to_res: S}
- {entry_name: 5ht7r_mouse, from_res: K, pubmed: '9256244', seq: '267', to_res: A}
- {entry_name: 5ht7r_mouse, from_res: R, pubmed: '9256244', seq: '183', to_res: A}
- {entry_name: ada2c_human, from_res: T, pubmed: '9207236', seq: '380', to_res: K}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '452', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '465', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '369', to_res: A}
- {entry_name: ada1b_mesau, from_res: T, pubmed: '9353340', seq: '385', to_res: A}
- {entry_name: ada1b_mesau, from_res: T, pubmed: '9353340', seq: '390', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '394', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '400', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '404', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '398', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '421', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '423', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '425', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '9353340', seq: '447', to_res: A}
- {entry_name: grpr_mouse, from_res: R, pubmed: '9211882', seq: '288', to_res: H}
- {entry_name: grpr_mouse, from_res: Q, pubmed: '9211882', seq: '121', to_res: R}
- {entry_name: grpr_mouse, from_res: S, pubmed: '9211882', seq: '100', to_res: T}
- {entry_name: grpr_mouse, from_res: D, pubmed: '9211882', seq: '105', to_res: E}
- {entry_name: grpr_mouse, from_res: I, pubmed: '9211882', seq: '117', to_res: L}
- {entry_name: grpr_mouse, from_res: L, pubmed: '9211882', seq: '172', to_res: F}
- {entry_name: grpr_mouse, from_res: Y, pubmed: '9211882', seq: '292', to_res: S}
- {entry_name: grpr_mouse, from_res: P, pubmed: '9211882', seq: '199', to_res: S}
- {entry_name: grpr_mouse, from_res: A, pubmed: '9211882', seq: '308', to_res: S}
- {entry_name: cxcr2_human, from_res: K, pubmed: '9325518', seq: '246', to_res: A}
- {entry_name: cxcr2_human, from_res: H, pubmed: '9325518', seq: '247', to_res: A}
- {entry_name: cxcr2_human, from_res: R, pubmed: '9325518', seq: '248', to_res: A}
- {entry_name: cxcr2_human, from_res: K, pubmed: '9325518', seq: '158', to_res: A}
- {entry_name: cxcr2_human, from_res: R, pubmed: '9325518', seq: '159', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '9295303', seq: '312', to_res: A}
- {entry_name: agtra_rat, from_res: F, pubmed: '9295303', seq: '313', to_res: A}
- {entry_name: agtra_rat, from_res: L, pubmed: '9295303', seq: '314', to_res: A}
- {entry_name: ptafr_human, from_res: Y, pubmed: '9261140', seq: '293', to_res: F}
- {entry_name: ptafr_human, from_res: Y, pubmed: '9261140', seq: '293', to_res: A}
- {entry_name: car1_dicdi, from_res: S, pubmed: '8120068', seq: '299', to_res: A}
- {entry_name: car1_dicdi, from_res: S, pubmed: '8120068', seq: '308', to_res: A}
- {entry_name: car1_dicdi, from_res: S, pubmed: '8120068', seq: '331', to_res: A}
- {entry_name: gasr_rat, from_res: K, pubmed: '9084447', seq: '333', to_res: M}
- {entry_name: gasr_rat, from_res: K, pubmed: '9084447', seq: '334', to_res: T}
- {entry_name: gasr_rat, from_res: R, pubmed: '9084447', seq: '335', to_res: L}
- {entry_name: pthr1_human, from_res: H, pubmed: '7701349', seq: '223', to_res: R}
- {entry_name: cxcr4_human, from_res: N, pubmed: '9151832', seq: '11', to_res: I}
- {entry_name: cxcr4_human, from_res: N, pubmed: '9151832', seq: '176', to_res: Q}
- {entry_name: ghrhr_mouse, from_res: D, pubmed: '8391647', seq: '60', to_res: G}
- {entry_name: ghrhr_mouse, from_res: D, pubmed: '8395283', seq: '60', to_res: G}
- {entry_name: fpr1_human, from_res: T, pubmed: '8373373', seq: '226', to_res: A}
- {entry_name: fpr1_human, from_res: K, pubmed: '8373373', seq: '227', to_res: E}
- {entry_name: fpr1_human, from_res: H, pubmed: '8373373', seq: '229', to_res: A}
- {entry_name: fpr1_human, from_res: K, pubmed: '8373373', seq: '230', to_res: Q}
- {entry_name: fpr1_human, from_res: K, pubmed: '8373373', seq: '235', to_res: Q}
- {entry_name: fpr1_human, from_res: S, pubmed: '8373373', seq: '236', to_res: A}
- {entry_name: fpr1_human, from_res: R, pubmed: '8373373', seq: '238', to_res: G}
- {entry_name: fpr1_human, from_res: R, pubmed: '8373373', seq: '241', to_res: E}
- {entry_name: fpr1_human, from_res: S, pubmed: '8373373', seq: '244', to_res: A}
- {entry_name: pthr1_human, from_res: E, pubmed: '7745008', seq: '546', to_res: K}
- {entry_name: ptafr_rat, from_res: A, pubmed: '9015866', seq: '230', to_res: E}
- {entry_name: agtra_rat, from_res: N, pubmed: '9020140', seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, pubmed: '9020140', seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9020140', seq: '295', to_res: S}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '23', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '33', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '58', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '60', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, pubmed: '9065450', seq: '63', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '69', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '100', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '101', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '104', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '112', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '138', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '150', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9065450', seq: '188', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '236', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9065450', seq: '248', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9065450', seq: '249', to_res: A}
- {entry_name: ptafr_cavpo, from_res: Q, pubmed: '9065450', seq: '252', to_res: A}
- {entry_name: ptafr_cavpo, from_res: Q, pubmed: '9065450', seq: '276', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '278', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9065450', seq: '283', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9065450', seq: '284', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9065450', seq: '285', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, pubmed: '9065450', seq: '289', to_res: A}
- {entry_name: aa2ar_human, from_res: V, pubmed: '9258366', seq: '84', to_res: A}
- {entry_name: aa2ar_human, from_res: V, pubmed: '9258366', seq: '84', to_res: D}
- {entry_name: aa2ar_human, from_res: V, pubmed: '9258366', seq: '84', to_res: L}
- {entry_name: aa2ar_human, from_res: H, pubmed: '9258366', seq: '250', to_res: N}
- {entry_name: aa2ar_human, from_res: H, pubmed: '9258366', seq: '278', to_res: K}
- {entry_name: aa2ar_human, from_res: H, pubmed: '9258366', seq: '278', to_res: N}
- {entry_name: galr1_human, from_res: H, pubmed: '9370372', seq: '112', to_res: V}
- {entry_name: galr1_human, from_res: F, pubmed: '9370372', seq: '115', to_res: A}
- {entry_name: galr1_human, from_res: E, pubmed: '9370372', seq: '189', to_res: A}
- {entry_name: galr1_human, from_res: W, pubmed: '9370372', seq: '191', to_res: A}
- {entry_name: galr1_human, from_res: D, pubmed: '9370372', seq: '193', to_res: A}
- {entry_name: galr1_human, from_res: K, pubmed: '9370372', seq: '197', to_res: A}
- {entry_name: galr1_human, from_res: V, pubmed: '9370372', seq: '201', to_res: A}
- {entry_name: galr1_human, from_res: T, pubmed: '9370372', seq: '204', to_res: A}
- {entry_name: galr1_human, from_res: F, pubmed: '9370372', seq: '205', to_res: V}
- {entry_name: galr1_human, from_res: H, pubmed: '9370372', seq: '263', to_res: A}
- {entry_name: galr1_human, from_res: E, pubmed: '9370372', seq: '271', to_res: S}
- {entry_name: galr1_human, from_res: E, pubmed: '9370372', seq: '271', to_res: K}
- {entry_name: galr1_human, from_res: F, pubmed: '9370372', seq: '282', to_res: A}
- {entry_name: galr1_human, from_res: F, pubmed: '9370372', seq: '282', to_res: Y}
- {entry_name: galr1_human, from_res: R, pubmed: '9370372', seq: '285', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '9261122', seq: '108', to_res: A}
- {entry_name: nk1r_human, from_res: N, pubmed: '9261122', seq: '109', to_res: A}
- {entry_name: nk1r_human, from_res: P, pubmed: '9261122', seq: '112', to_res: A}
- {entry_name: nk1r_human, from_res: P, pubmed: '9261122', seq: '112', to_res: D}
- {entry_name: nk1r_human, from_res: Q, pubmed: '9261122', seq: '165', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '9261122', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: I, pubmed: '9261122', seq: '198', to_res: A}
- {entry_name: nk1r_human, from_res: V, pubmed: '9261122', seq: '200', to_res: A}
- {entry_name: nk1r_human, from_res: T, pubmed: '9261122', seq: '201', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '9261122', seq: '264', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '9261122', seq: '264', to_res: Y}
- {entry_name: nk1r_human, from_res: H, pubmed: '9261122', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '9261122', seq: '265', to_res: F}
- {entry_name: nk1r_human, from_res: F, pubmed: '9261122', seq: '267', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '9261122', seq: '267', to_res: Y}
- {entry_name: nk1r_human, from_res: F, pubmed: '9261122', seq: '268', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '9261122', seq: '272', to_res: A}
- {entry_name: nk1r_human, from_res: I, pubmed: '9261122', seq: '290', to_res: A}
- {entry_name: ops1_drops, from_res: L, pubmed: '9130705', seq: '81', to_res: Q}
- {entry_name: ops1_drops, from_res: N, pubmed: '9130705', seq: '86', to_res: I}
- {entry_name: gnrhr_mouse, from_res: Y, pubmed: '8843414', seq: '322', to_res: F}
- {entry_name: gnrhr_mouse, from_res: Y, pubmed: '8843414', seq: '322', to_res: A}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '8843414', seq: '318', to_res: N}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '34', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '38', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '40', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '48', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '135', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '160', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '283', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '284', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '308', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '340', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '347', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '357', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '443', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '8621442', seq: '518', to_res: S}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '90', to_res: S}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '90', to_res: A}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '95', to_res: S}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '95', to_res: A}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '173', to_res: S}
- {entry_name: ptafr_human, from_res: C, pubmed: '9037196', seq: '173', to_res: A}
- {entry_name: tshr_rat, from_res: D, pubmed: '9109404', seq: '474', to_res: E}
- {entry_name: tshr_rat, from_res: D, pubmed: '9109404', seq: '474', to_res: K}
- {entry_name: tshr_rat, from_res: D, pubmed: '9109404', seq: '474', to_res: L}
- {entry_name: tshr_rat, from_res: D, pubmed: '9109404', seq: '474', to_res: N}
- {entry_name: oprd_mouse, from_res: D, pubmed: '9271350', seq: '128', to_res: N}
- {entry_name: ada2a_human, from_res: T, pubmed: '8393865', seq: '373', to_res: F}
- {entry_name: ada2a_human, from_res: T, pubmed: '8393865', seq: '373', to_res: A}
- {entry_name: ada2a_human, from_res: T, pubmed: '8393865', seq: '373', to_res: C}
- {entry_name: ada2a_human, from_res: T, pubmed: '8393865', seq: '373', to_res: E}
- {entry_name: ada2a_human, from_res: T, pubmed: '8393865', seq: '373', to_res: K}
- {entry_name: aa1r_human, from_res: T, pubmed: '8300561', seq: '277', to_res: S}
- {entry_name: aa1r_human, from_res: T, pubmed: '8300561', seq: '277', to_res: A}
- {entry_name: aa2ar_human, from_res: F, pubmed: '7775460', seq: '180', to_res: A}
- {entry_name: aa2ar_human, from_res: N, pubmed: '7775460', seq: '181', to_res: S}
- {entry_name: aa2ar_human, from_res: F, pubmed: '7775460', seq: '182', to_res: W}
- {entry_name: aa2ar_human, from_res: F, pubmed: '7775460', seq: '182', to_res: A}
- {entry_name: aa2ar_human, from_res: H, pubmed: '7775460', seq: '250', to_res: F}
- {entry_name: aa2ar_human, from_res: F, pubmed: '7775460', seq: '182', to_res: Y}
- {entry_name: aa2ar_human, from_res: H, pubmed: '7775460', seq: '250', to_res: A}
- {entry_name: aa2ar_human, from_res: H, pubmed: '7775460', seq: '250', to_res: Y}
- {entry_name: aa2ar_human, from_res: N, pubmed: '7775460', seq: '253', to_res: A}
- {entry_name: aa2ar_human, from_res: C, pubmed: '7775460', seq: '254', to_res: A}
- {entry_name: aa2ar_human, from_res: F, pubmed: '7775460', seq: '257', to_res: A}
- {entry_name: aa2ar_human, from_res: Y, pubmed: '7775460', seq: '271', to_res: A}
- {entry_name: aa2ar_human, from_res: I, pubmed: '7775460', seq: '274', to_res: A}
- {entry_name: aa2ar_human, from_res: S, pubmed: '7775460', seq: '277', to_res: A}
- {entry_name: aa2ar_human, from_res: S, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: aa2ar_human, from_res: S, pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: H, pubmed: '7775460', seq: '278', to_res: A}
- {entry_name: aa2ar_human, from_res: S, pubmed: '7775460', seq: '281', to_res: T}
- {entry_name: aa2ar_human, from_res: S, pubmed: '7775460', seq: '281', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8845375', seq: '216', to_res: F}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8845375', seq: '216', to_res: W}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8845375', seq: '216', to_res: L}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8845375', seq: '216', to_res: E}
- {entry_name: nk1r_human, from_res: Y, pubmed: '8845375', seq: '216', to_res: A}
- {entry_name: acm1_rat, from_res: R, pubmed: '7774669', seq: '123', to_res: K}
- {entry_name: acm1_rat, from_res: R, pubmed: '7774669', seq: '123', to_res: A}
- {entry_name: acm1_rat, from_res: R, pubmed: '7774669', seq: '123', to_res: L}
- {entry_name: acm1_rat, from_res: R, pubmed: '7774669', seq: '123', to_res: E}
- {entry_name: acm1_rat, from_res: R, pubmed: '7774669', seq: '123', to_res: Q}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: N}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: E}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: L}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: S}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: Y}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: F}
- {entry_name: lshr_human, from_res: D, pubmed: '8943222', seq: '578', to_res: P}
- {entry_name: drd3_human, from_res: T, pubmed: '8099332', seq: '328', to_res: S}
- {entry_name: bkrb2_human, from_res: S, pubmed: '9575169', seq: '111', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '9575169', seq: '111', to_res: M}
- {entry_name: bkrb2_human, from_res: S, pubmed: '9575169', seq: '111', to_res: H}
- {entry_name: bkrb2_human, from_res: S, pubmed: '9575169', seq: '111', to_res: R}
- {entry_name: ghrhr_human, from_res: V, pubmed: '9605937', seq: '129', to_res: L}
- {entry_name: vipr1_rat, from_res: V, pubmed: '9605937', seq: '143', to_res: L}
- {entry_name: ghrhr_human, from_res: V, pubmed: '9605937', seq: '129', to_res: L}
- {entry_name: oprk_human, from_res: E, pubmed: '9419379', seq: '297', to_res: Q}
- {entry_name: ccr5_human, from_res: S, pubmed: '9499044', seq: '7', to_res: V}
- {entry_name: acm1_mouse, from_res: E, pubmed: '2557912', seq: '221', to_res: R}
- {entry_name: tshr_human, from_res: I, pubmed: '1547731', seq: '419', to_res: L}
- {entry_name: tshr_human, from_res: I, pubmed: '1547731', seq: '419', to_res: L}
- {entry_name: 5ht2a_rat, from_res: E, pubmed: '1872857', seq: '2', to_res: D}
- {entry_name: 5ht2a_rat, from_res: E, pubmed: '1872857', seq: '2', to_res: D}
- {entry_name: 5ht2a_rat, from_res: E, pubmed: '1872857', seq: '2', to_res: D}
- {entry_name: 5ht2a_rat, from_res: C, pubmed: '1872857', seq: '397', to_res: S}
- {entry_name: tshr_human, from_res: I, pubmed: '1992482', seq: '419', to_res: L}
- {entry_name: tshr_human, from_res: I, pubmed: '1992482', seq: '419', to_res: L}
- {entry_name: tshr_human, from_res: I, pubmed: '1992482', seq: '419', to_res: L}
- {entry_name: c5ar_human, from_res: L, pubmed: '8428903', seq: '256', to_res: S}
- {entry_name: c5ar_human, from_res: L, pubmed: '8428903', seq: '256', to_res: S}
- {entry_name: c5ar_human, from_res: L, pubmed: '8428903', seq: '256', to_res: S}
- {entry_name: tshr_human, from_res: I, pubmed: '1711544', seq: '419', to_res: L}
- {entry_name: tshr_human, from_res: I, pubmed: '1711544', seq: '419', to_res: L}
- {entry_name: tshr_human, from_res: I, pubmed: '1711544', seq: '419', to_res: L}
- {entry_name: grm2_rat, from_res: D, pubmed: '9497291', seq: '146', to_res: S}
- {entry_name: grm3_rat, from_res: S, pubmed: '9497291', seq: '152', to_res: D}
- {entry_name: vipr1_human, from_res: Q, pubmed: '8662697', seq: '207', to_res: H}
- {entry_name: vipr1_human, from_res: G, pubmed: '8662697', seq: '211', to_res: A}
- {entry_name: vipr1_human, from_res: M, pubmed: '8662697', seq: '219', to_res: V}
- {entry_name: lshr_rat, from_res: L, pubmed: '9169417', seq: '578', to_res: P}
- {entry_name: cnr1_rat, from_res: S, pubmed: '9526000', seq: '304', to_res: A}
- {entry_name: cnr1_rat, from_res: S, pubmed: '9526000', seq: '317', to_res: A}
- {entry_name: cnr1_rat, from_res: S, pubmed: '9526000', seq: '323', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9560162', seq: '413', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9560162', seq: '412', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '9560162', seq: '411', to_res: A}
- {entry_name: adrb2_human, from_res: D, pubmed: '9560162', seq: '410', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '9575169', seq: '111', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '9575169', seq: '111', to_res: K}
- {entry_name: bkrb2_human, from_res: S, pubmed: '9575169', seq: '111', to_res: E}
- {entry_name: bkrb1_human, from_res: K, pubmed: '9575169', seq: '118', to_res: S}
- {entry_name: bkrb2_human, from_res: C, pubmed: '9446564', seq: '324', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '7876256', seq: '212', to_res: A}
- {entry_name: ssr5_human, from_res: A, pubmed: '9351971', seq: '36', to_res: M}
- {entry_name: ccr5_macfa, from_res: Q, pubmed: '9343222', seq: '93', to_res: R}
- {entry_name: ccr5_macfa, from_res: Y, pubmed: '9343222', seq: '14', to_res: N}
- {entry_name: ccr5_macfa, from_res: T, pubmed: '9343222', seq: '9', to_res: I}
- {entry_name: ccr5_macfa, from_res: D, pubmed: '9343222', seq: '13', to_res: N}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9343222', seq: '14', to_res: N}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9305971', seq: '121', to_res: A}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9305971', seq: '121', to_res: V}
- {entry_name: agtr1_human, from_res: A, pubmed: '9203636', seq: '104', to_res: V}
- {entry_name: agtr1_human, from_res: S, pubmed: '9203636', seq: '109', to_res: A}
- {entry_name: agtr1_human, from_res: N, pubmed: '9203636', seq: '111', to_res: A}
- {entry_name: agtr1_human, from_res: S, pubmed: '9203636', seq: '115', to_res: A}
- {entry_name: agtr1_human, from_res: W, pubmed: '9203636', seq: '153', to_res: A}
- {entry_name: agtr1_human, from_res: W, pubmed: '9203636', seq: '253', to_res: A}
- {entry_name: agtr1_human, from_res: T, pubmed: '9203636', seq: '260', to_res: A}
- {entry_name: agtr1_human, from_res: M, pubmed: '9203636', seq: '284', to_res: A}
- {entry_name: agtr1_human, from_res: T, pubmed: '9203636', seq: '287', to_res: A}
- {entry_name: agtr1_human, from_res: A, pubmed: '9203636', seq: '291', to_res: G}
- {entry_name: agtr1_human, from_res: A, pubmed: '9203636', seq: '291', to_res: S}
- {entry_name: agtr1_human, from_res: N, pubmed: '9203636', seq: '294', to_res: A}
- {entry_name: agtra_rat, from_res: V, pubmed: '9203636', seq: '108', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '9203636', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9203636', seq: '295', to_res: D}
- {entry_name: agtra_rat, from_res: N, pubmed: '9203636', seq: '298', to_res: D}
- {entry_name: trfr_mouse, from_res: N, pubmed: '9115256', seq: '43', to_res: A}
- {entry_name: trfr_mouse, from_res: N, pubmed: '9115256', seq: '316', to_res: A}
- {entry_name: trfr_mouse, from_res: D, pubmed: '9115256', seq: '71', to_res: A}
- {entry_name: trfr_mouse, from_res: N, pubmed: '9115256', seq: '43', to_res: D}
- {entry_name: trfr_mouse, from_res: D, pubmed: '9115256', seq: '71', to_res: N}
- {entry_name: trfr_mouse, from_res: N, pubmed: '9115256', seq: '316', to_res: D}
- {entry_name: nk2r_human, from_res: A, pubmed: '9606724', seq: '52', to_res: nbd}
- {entry_name: nk2r_human, from_res: V, pubmed: '9606724', seq: '249', to_res: nbd}
- {entry_name: nk2r_human, from_res: Q, pubmed: '9606724', seq: '286', to_res: nbd}
- {entry_name: nk2r_human, from_res: W, pubmed: '9606724', seq: '56', to_res: nbd}
- {entry_name: nk2r_human, from_res: R, pubmed: '9606724', seq: '103', to_res: nbd}
- {entry_name: nk2r_human, from_res: I, pubmed: '9606724', seq: '152', to_res: nbd}
- {entry_name: nk2r_human, from_res: Q, pubmed: '9606724', seq: '233', to_res: nbd}
- {entry_name: nk2r_human, from_res: K, pubmed: '9606724', seq: '245', to_res: nbd}
- {entry_name: nk2r_human, from_res: F, pubmed: '9606724', seq: '248', to_res: nbd}
- {entry_name: nk2r_human, from_res: M, pubmed: '9606724', seq: '252', to_res: nbd}
- {entry_name: nk2r_human, from_res: D, pubmed: '9606724', seq: '278', to_res: nbd}
- {entry_name: nk2r_human, from_res: Y, pubmed: '9606724', seq: '280', to_res: nbd}
- {entry_name: nk2r_human, from_res: F, pubmed: '9606724', seq: '139', to_res: nbd}
- {entry_name: nk2r_human, from_res: I, pubmed: '9606724', seq: '58', to_res: nbd}
- {entry_name: nk2r_human, from_res: R, pubmed: '9606724', seq: '63', to_res: nbd}
- {entry_name: nk2r_human, from_res: T, pubmed: '9606724', seq: '66', to_res: nbd}
- {entry_name: nk2r_human, from_res: V, pubmed: '9606724', seq: '67', to_res: nbd}
- {entry_name: nk2r_human, from_res: T, pubmed: '9606724', seq: '125', to_res: nbd}
- {entry_name: nk2r_human, from_res: A, pubmed: '9606724', seq: '128', to_res: nbd}
- {entry_name: nk2r_human, from_res: M, pubmed: '9606724', seq: '133', to_res: nbd}
- {entry_name: nk2r_human, from_res: P, pubmed: '9606724', seq: '138', to_res: nbd}
- {entry_name: nk2r_human, from_res: R, pubmed: '9606724', seq: '142', to_res: nbd}
- {entry_name: nk2r_human, from_res: S, pubmed: '9606724', seq: '144', to_res: nbd}
- {entry_name: nk2r_human, from_res: K, pubmed: '9606724', seq: '149', to_res: nbd}
- {entry_name: nk2r_human, from_res: Y, pubmed: '9606724', seq: '217', to_res: nbd}
- {entry_name: nk2r_human, from_res: I, pubmed: '9606724', seq: '220', to_res: nbd}
- {entry_name: nk2r_human, from_res: T, pubmed: '9606724', seq: '223', to_res: nbd}
- {entry_name: nk2r_human, from_res: P, pubmed: '9606724', seq: '230', to_res: nbd}
- {entry_name: opsd_bovin, from_res: H, pubmed: '9585578', seq: '100', to_res: N}
- {entry_name: opsd_bovin, from_res: H, pubmed: '9585578', seq: '152', to_res: N}
- {entry_name: opsd_bovin, from_res: H, pubmed: '9585578', seq: '211', to_res: N}
- {entry_name: opsd_bovin, from_res: H, pubmed: '9585578', seq: '211', to_res: F}
- {entry_name: opsd_bovin, from_res: E, pubmed: '9585578', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '9585578', seq: '122', to_res: A}
- {entry_name: oprd_mouse, from_res: D, pubmed: '9435189', seq: '95', to_res: N}
- {entry_name: oprd_mouse, from_res: D, pubmed: '9435189', seq: '128', to_res: N}
- {entry_name: mshr_human, from_res: E, pubmed: '9287296', seq: '94', to_res: A}
- {entry_name: mshr_human, from_res: D, pubmed: '9287296', seq: '117', to_res: A}
- {entry_name: mshr_human, from_res: D, pubmed: '9287296', seq: '121', to_res: A}
- {entry_name: mshr_human, from_res: F, pubmed: '9287296', seq: '175', to_res: A}
- {entry_name: mshr_human, from_res: F, pubmed: '9287296', seq: '179', to_res: A}
- {entry_name: mshr_human, from_res: Y, pubmed: '9287296', seq: '183', to_res: A}
- {entry_name: mshr_human, from_res: Y, pubmed: '9287296', seq: '182', to_res: A}
- {entry_name: mshr_human, from_res: F, pubmed: '9287296', seq: '195', to_res: A}
- {entry_name: mshr_human, from_res: F, pubmed: '9287296', seq: '196', to_res: A}
- {entry_name: mshr_human, from_res: F, pubmed: '9287296', seq: '257', to_res: A}
- {entry_name: mshr_human, from_res: H, pubmed: '9287296', seq: '260', to_res: A}
- {entry_name: mshr_human, from_res: N, pubmed: '9287296', seq: '281', to_res: A}
- {entry_name: mshr_human, from_res: D, pubmed: '9287296', seq: '121', to_res: N}
- {entry_name: mshr_human, from_res: D, pubmed: '9287296', seq: '121', to_res: K}
- {entry_name: mshr_human, from_res: F, pubmed: '9287296', seq: '280', to_res: A}
- {entry_name: npy1r_rat, from_res: D, pubmed: '9705087', seq: '85', to_res: N}
- {entry_name: npy1r_rat, from_res: D, pubmed: '9705087', seq: '85', to_res: A}
- {entry_name: npy1r_rat, from_res: D, pubmed: '9705087', seq: '85', to_res: E}
- {entry_name: npy1r_rat, from_res: D, pubmed: '9705087', seq: '103', to_res: A}
- {entry_name: npy1r_rat, from_res: D, pubmed: '9705087', seq: '286', to_res: A}
- {entry_name: npy1r_rat, from_res: L, pubmed: '9705087', seq: '34', to_res: R}
- {entry_name: npy1r_rat, from_res: D, pubmed: '9705087', seq: '199', to_res: A}
- {entry_name: npy1r_rat, from_res: L, pubmed: '9705087', seq: '34', to_res: E}
- {entry_name: npy1r_rat, from_res: P, pubmed: '9705087', seq: '35', to_res: H}
- {entry_name: npy1r_rat, from_res: D, pubmed: '9705087', seq: '193', to_res: A}
- {entry_name: cxcr2_human, from_res: S, pubmed: '9514913', seq: '351', to_res: A}
- {entry_name: cxcr2_human, from_res: S, pubmed: '9514913', seq: '352', to_res: A}
- {entry_name: cxcr2_human, from_res: S, pubmed: '9514913', seq: '353', to_res: A}
- {entry_name: cxcr2_human, from_res: D, pubmed: '9398246', seq: '94', to_res: E}
- {entry_name: cxcr2_human, from_res: D, pubmed: '9398246', seq: '94', to_res: N}
- {entry_name: cxcr2_human, from_res: A, pubmed: '9398246', seq: '249', to_res: A}
- {entry_name: ghsr_human, from_res: D, pubmed: '9440817', seq: '99', to_res: N}
- {entry_name: ghsr_human, from_res: C, pubmed: '9440817', seq: '116', to_res: A}
- {entry_name: ghsr_human, from_res: E, pubmed: '9440817', seq: '124', to_res: D}
- {entry_name: ghsr_human, from_res: E, pubmed: '9440817', seq: '124', to_res: Q}
- {entry_name: ghsr_human, from_res: S, pubmed: '9440817', seq: '123', to_res: A}
- {entry_name: ghsr_human, from_res: Q, pubmed: '9440817', seq: '120', to_res: H}
- {entry_name: ghsr_human, from_res: Y, pubmed: '9440817', seq: '142', to_res: A}
- {entry_name: ghsr_human, from_res: M, pubmed: '9440817', seq: '213', to_res: K}
- {entry_name: ghsr_human, from_res: S, pubmed: '9440817', seq: '217', to_res: A}
- {entry_name: ghsr_human, from_res: S, pubmed: '9440817', seq: '218', to_res: A}
- {entry_name: ghsr_human, from_res: F, pubmed: '9440817', seq: '279', to_res: H}
- {entry_name: ghsr_human, from_res: F, pubmed: '9440817', seq: '279', to_res: L}
- {entry_name: ghsr_human, from_res: H, pubmed: '9440817', seq: '280', to_res: Q}
- {entry_name: ghsr_human, from_res: Y, pubmed: '9440817', seq: '284', to_res: F}
- {entry_name: tshr_human, from_res: I, pubmed: '9398745', seq: '630', to_res: L}
- {entry_name: v2r_human, from_res: S, pubmed: '9482866', seq: '362', to_res: A}
- {entry_name: v2r_human, from_res: S, pubmed: '9482866', seq: '363', to_res: A}
- {entry_name: v2r_human, from_res: S, pubmed: '9482866', seq: '364', to_res: A}
- {entry_name: tshr_human, from_res: L, pubmed: '9353284', seq: '330', to_res: A}
- {entry_name: tshr_human, from_res: G, pubmed: '9353284', seq: '367', to_res: A}
- {entry_name: tshr_human, from_res: Q, pubmed: '9353284', seq: '368', to_res: A}
- {entry_name: tshr_human, from_res: E, pubmed: '9353284', seq: '369', to_res: A}
- {entry_name: tshr_human, from_res: K, pubmed: '9353284', seq: '371', to_res: A}
- {entry_name: tshr_human, from_res: G, pubmed: '9353284', seq: '331', to_res: A}
- {entry_name: tshr_human, from_res: D, pubmed: '9353284', seq: '332', to_res: A}
- {entry_name: tshr_human, from_res: S, pubmed: '9353284', seq: '333', to_res: A}
- {entry_name: tshr_human, from_res: I, pubmed: '9353284', seq: '334', to_res: A}
- {entry_name: tshr_human, from_res: V, pubmed: '9353284', seq: '335', to_res: A}
- {entry_name: tshr_human, from_res: G, pubmed: '9353284', seq: '336', to_res: A}
- {entry_name: tshr_human, from_res: Y, pubmed: '9353284', seq: '337', to_res: A}
- {entry_name: tshr_human, from_res: K, pubmed: '9353284', seq: '338', to_res: A}
- {entry_name: cnr1_rat, from_res: S, pubmed: '9526000', seq: '317', to_res: A}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: A}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: R}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: N}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: D}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: E}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: L}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: K}
- {entry_name: oprm_rat, from_res: H, pubmed: '9415708', seq: '297', to_res: F}
- {entry_name: agtra_rat, from_res: N, pubmed: '9388598', seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, pubmed: '9388598', seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9388598', seq: '295', to_res: S}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9445013', seq: '4', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9445013', seq: '10', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9445013', seq: '11', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9445013', seq: '14', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9445013', seq: '15', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9445013', seq: '18', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9445013', seq: '21', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9445013', seq: '22', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9445013', seq: '26', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '9445013', seq: '31', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9445013', seq: '88', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9445013', seq: '89', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9445013', seq: '93', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9445013', seq: '95', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9445013', seq: '181', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9445013', seq: '184', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9445013', seq: '188', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9445013', seq: '191', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9445013', seq: '261', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9445013', seq: '262', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '9445013', seq: '264', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '9445013', seq: '274', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9445013', seq: '277', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9445013', seq: '280', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9420225', seq: '2', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9420225', seq: '11', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9420225', seq: '18', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9420225', seq: '95', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9420225', seq: '171', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9420225', seq: '262', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9420225', seq: '22', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9420225', seq: '26', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '9420225', seq: '31', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9420225', seq: '88', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '9420225', seq: '168', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9420225', seq: '175', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9420225', seq: '181', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '9420225', seq: '13', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9420225', seq: '93', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9420225', seq: '102', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9420225', seq: '184', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9420225', seq: '188', to_res: A}
- {entry_name: ednrb_human, from_res: C, pubmed: '9595445', seq: '402', to_res: S}
- {entry_name: ednrb_human, from_res: C, pubmed: '9595445', seq: '403', to_res: S}
- {entry_name: ednrb_human, from_res: C, pubmed: '9595445', seq: '405', to_res: S}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9561146', seq: '23', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9561146', seq: '33', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9561146', seq: '58', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9561146', seq: '60', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, pubmed: '9561146', seq: '63', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9561146', seq: '69', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9561146', seq: '100', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9561146', seq: '101', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9561146', seq: '104', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9561146', seq: '112', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9561146', seq: '138', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9561146', seq: '150', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9561146', seq: '188', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9561146', seq: '236', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9561146', seq: '248', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, pubmed: '9561146', seq: '249', to_res: A}
- {entry_name: ptafr_cavpo, from_res: Q, pubmed: '9561146', seq: '252', to_res: A}
- {entry_name: ptafr_cavpo, from_res: Q, pubmed: '9561146', seq: '276', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9561146', seq: '278', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, pubmed: '9561146', seq: '283', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, pubmed: '9561146', seq: '284', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, pubmed: '9561146', seq: '285', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, pubmed: '9561146', seq: '289', to_res: A}
- {entry_name: mshr_human, from_res: S, pubmed: '8605020', seq: '6', to_res: A}
- {entry_name: mshr_human, from_res: E, pubmed: '8605020', seq: '102', to_res: A}
- {entry_name: mshr_human, from_res: R, pubmed: '8605020', seq: '109', to_res: A}
- {entry_name: mshr_human, from_res: D, pubmed: '8605020', seq: '184', to_res: A}
- {entry_name: mshr_human, from_res: E, pubmed: '8605020', seq: '269', to_res: A}
- {entry_name: mshr_human, from_res: T, pubmed: '8605020', seq: '272', to_res: A}
- {entry_name: mshr_human, from_res: R, pubmed: '9571181', seq: '151', to_res: C}
- {entry_name: mshr_human, from_res: V, pubmed: '8944016', seq: '92', to_res: M}
- {entry_name: mc5r_human, from_res: Q, pubmed: '9240466', seq: '235', to_res: K}
- {entry_name: mc5r_human, from_res: R, pubmed: '9240466', seq: '272', to_res: C}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '171', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '9614108', seq: '179', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '181', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '182', to_res: A}
- {entry_name: cxcr4_human, from_res: R, pubmed: '9614108', seq: '183', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '187', to_res: A}
- {entry_name: cxcr4_human, from_res: R, pubmed: '9614108', seq: '188', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '193', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '171', to_res: K}
- {entry_name: cxcr4_human, from_res: E, pubmed: '9614108', seq: '179', to_res: K}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '181', to_res: K}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '182', to_res: K}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '187', to_res: K}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '193', to_res: K}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '187', to_res: V}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '187', to_res: F}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '187', to_res: S}
- {entry_name: cxcr4_human, from_res: D, pubmed: '9614108', seq: '187', to_res: N}
- {entry_name: cxcr4_human, from_res: E, pubmed: '9614108', seq: '179', to_res: Q}
- {entry_name: cxcr4_human, from_res: F, pubmed: '9614108', seq: '189', to_res: A}
- {entry_name: cxcr4_human, from_res: Y, pubmed: '9614108', seq: '190', to_res: A}
- {entry_name: lshr_rat, from_res: C, pubmed: '9099916', seq: '647', to_res: S}
- {entry_name: lshr_rat, from_res: C, pubmed: '9099916', seq: '648', to_res: S}
- {entry_name: lshr_human, from_res: M, pubmed: '8929952', seq: '398', to_res: T}
- {entry_name: gnrhr_human, from_res: R, pubmed: '9678526', seq: '262', to_res: Q}
- {entry_name: gnrhr_human, from_res: Y, pubmed: '9678526', seq: '284', to_res: C}
- {entry_name: gnrhr_human, from_res: Q, pubmed: '9678526', seq: '106', to_res: R}
- {entry_name: acm5_human, from_res: A, pubmed: '9733718', seq: '140', to_res: V}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '133', to_res: A}
- {entry_name: acm5_human, from_res: I, pubmed: '9733718', seq: '132', to_res: V}
- {entry_name: acm5_human, from_res: L, pubmed: '9733718', seq: '136', to_res: M}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '139', to_res: W}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '143', to_res: A}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '129', to_res: C}
- {entry_name: acm5_human, from_res: D, pubmed: '9733718', seq: '127', to_res: N}
- {entry_name: acm5_human, from_res: P, pubmed: '9733718', seq: '135', to_res: Q}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: L}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: Q}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: C}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: M}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: S}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: E}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: H}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: K}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: R}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: G}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: T}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: D}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: N}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: E}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: T}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: Q}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: A}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: C}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: V}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: G}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: A}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: C}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: T}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: S}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: M}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: V}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: G}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: L}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: N}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: H}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: T}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: G}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: Q}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: F}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: S}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: D}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: A}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: C}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: W}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: Q}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: I}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: C}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '137', to_res: I}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '137', to_res: K}
- {entry_name: oprk_human, from_res: T, pubmed: '9733719', seq: '363', to_res: A}
- {entry_name: sctr_rat, from_res: H, pubmed: '9694908', seq: '178', to_res: R}
- {entry_name: sctr_rat, from_res: T, pubmed: '9694908', seq: '344', to_res: P}
- {entry_name: cckar_rat, from_res: Y, pubmed: '9655684', seq: '386', to_res: A}
- {entry_name: agtra_rat, from_res: S, pubmed: '9626656', seq: '252', to_res: A}
- {entry_name: agtra_rat, from_res: W, pubmed: '9626656', seq: '253', to_res: A}
- {entry_name: agtra_rat, from_res: V, pubmed: '9626656', seq: '254', to_res: A}
- {entry_name: agtra_rat, from_res: P, pubmed: '9626656', seq: '255', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '9626656', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: F, pubmed: '9626656', seq: '259', to_res: A}
- {entry_name: agtra_rat, from_res: F, pubmed: '9626656', seq: '261', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9721244', seq: '18', to_res: Q}
- {entry_name: ccr5_human, from_res: H, pubmed: '9721244', seq: '88', to_res: D}
- {entry_name: agtra_rat, from_res: F, pubmed: '9687585', seq: '293', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '294', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: S}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: T}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: D}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: K}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: L}
- {entry_name: agtra_rat, from_res: N, pubmed: '9687585', seq: '295', to_res: V}
- {entry_name: ntr1_rat, from_res: V, pubmed: '9632698', seq: '65', to_res: A}
- {entry_name: ntr1_rat, from_res: T, pubmed: '9632698', seq: '156', to_res: A}
- {entry_name: ntr1_rat, from_res: M, pubmed: '9632698', seq: '204', to_res: A}
- {entry_name: ntr1_rat, from_res: M, pubmed: '9632698', seq: '208', to_res: A}
- {entry_name: ntr1_rat, from_res: K, pubmed: '9632698', seq: '235', to_res: A}
- {entry_name: ntr1_rat, from_res: L, pubmed: '9632698', seq: '66', to_res: A}
- {entry_name: ntr1_rat, from_res: K, pubmed: '9632698', seq: '235', to_res: Q}
- {entry_name: ntr1_rat, from_res: K, pubmed: '9632698', seq: '235', to_res: R}
- {entry_name: ntr1_rat, from_res: Q, pubmed: '9632698', seq: '239', to_res: A}
- {entry_name: ntr1_rat, from_res: T, pubmed: '9632698', seq: '242', to_res: A}
- {entry_name: ntr1_rat, from_res: H, pubmed: '9632698', seq: '325', to_res: A}
- {entry_name: ntr1_rat, from_res: R, pubmed: '9632698', seq: '327', to_res: M}
- {entry_name: ntr1_rat, from_res: R, pubmed: '9632698', seq: '327', to_res: E}
- {entry_name: ntr1_rat, from_res: R, pubmed: '9632698', seq: '328', to_res: M}
- {entry_name: ntr1_rat, from_res: H, pubmed: '9632698', seq: '348', to_res: A}
- {entry_name: ntr1_rat, from_res: T, pubmed: '9632698', seq: '354', to_res: A}
- {entry_name: ntr1_rat, from_res: V, pubmed: '9632698', seq: '67', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '145', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '146', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '9632698', seq: '147', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '154', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '9632698', seq: '206', to_res: A}
- {entry_name: ntr1_rat, from_res: V, pubmed: '9632698', seq: '236', to_res: A}
- {entry_name: ntr1_rat, from_res: V, pubmed: '9632698', seq: '237', to_res: A}
- {entry_name: ntr1_rat, from_res: I, pubmed: '9632698', seq: '238', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '9632698', seq: '243', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '324', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '9632698', seq: '331', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '333', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '9632698', seq: '346', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '347', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '349', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '9632698', seq: '350', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '351', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '9632698', seq: '358', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '9632698', seq: '359', to_res: A}
- {entry_name: ntr1_rat, from_res: T, pubmed: '9632698', seq: '68', to_res: A}
- {entry_name: ntr1_rat, from_res: R, pubmed: '9632698', seq: '143', to_res: K}
- {entry_name: ntr1_rat, from_res: R, pubmed: '9632698', seq: '143', to_res: Q}
- {entry_name: ntr1_rat, from_res: R, pubmed: '9632698', seq: '143', to_res: M}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: V}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: L}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: T}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: C}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: A}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: Q}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: N}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: G}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: W}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: P}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: S}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: H}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: Y}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: K}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: T}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: Q}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: C}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: D}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: A}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: G}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: V}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: F}
- {entry_name: acm5_human, from_res: I, pubmed: '9705286', seq: '447', to_res: S}
- {entry_name: acm5_human, from_res: A, pubmed: '9705286', seq: '450', to_res: V}
- {entry_name: acm5_human, from_res: I, pubmed: '9705286', seq: '452', to_res: M}
- {entry_name: acm5_human, from_res: M, pubmed: '9705286', seq: '461', to_res: V}
- {entry_name: acm5_human, from_res: I, pubmed: '9705286', seq: '453', to_res: V}
- {entry_name: ste2_yeast, from_res: K, pubmed: '9659916', seq: '337', to_res: R}
- {entry_name: duffy_human, from_res: R, pubmed: '9731074', seq: '87', to_res: C}
- {entry_name: ta2r_human, from_res: N, pubmed: '9694965', seq: '4', to_res: Q}
- {entry_name: ta2r_human, from_res: N, pubmed: '9694965', seq: '16', to_res: Q}
- {entry_name: opsd_bovin, from_res: C, pubmed: '9405602', seq: '316', to_res: S}
- {entry_name: opsd_bovin, from_res: C, pubmed: '9405602', seq: '140', to_res: S}
- {entry_name: gasr_rat, from_res: F, pubmed: '9584214', seq: '227', to_res: A}
- {entry_name: gasr_rat, from_res: F, pubmed: '9584214', seq: '347', to_res: A}
- {entry_name: gasr_rat, from_res: W, pubmed: '9584214', seq: '351', to_res: A}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: A}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: C}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: D}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: E}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: F}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: G}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: H}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: I}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: K}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: L}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: N}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: P}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: Q}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: S}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: T}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: V}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: W}
- {entry_name: opsd_bovin, from_res: M, pubmed: '9609722', seq: '257', to_res: Y}
- {entry_name: opsd_bovin, from_res: E, pubmed: '9609722', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '9609722', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: F, pubmed: '9609722', seq: '261', to_res: V}
- {entry_name: v2r_human, from_res: E, pubmed: '9730911', seq: '335', to_res: Q}
- {entry_name: v2r_human, from_res: L, pubmed: '9730911', seq: '339', to_res: I}
- {entry_name: v2r_human, from_res: L, pubmed: '9730911', seq: '340', to_res: I}
- {entry_name: v2r_human, from_res: L, pubmed: '9730911', seq: '339', to_res: T}
- {entry_name: v2r_human, from_res: L, pubmed: '9730911', seq: '340', to_res: T}
- {entry_name: oprk_human, from_res: E, pubmed: '9419379', seq: '297', to_res: Q}
- {entry_name: ada2a_pig, from_res: D, pubmed: '9727043', seq: '113', to_res: N}
- {entry_name: ccr5_human, from_res: D, pubmed: '9420225', seq: '2', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9420225', seq: '11', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '9420225', seq: '13', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9420225', seq: '18', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9420225', seq: '22', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9420225', seq: '26', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '9420225', seq: '31', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9420225', seq: '88', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9420225', seq: '93', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9420225', seq: '95', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9420225', seq: '102', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '9420225', seq: '168', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9420225', seq: '171', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9420225', seq: '172', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9420225', seq: '175', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '9420225', seq: '181', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9420225', seq: '184', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9420225', seq: '188', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '9420225', seq: '191', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '9420225', seq: '192', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '9420225', seq: '262', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '9420225', seq: '274', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '9420225', seq: '276', to_res: A}
- {entry_name: ada1a_human, from_res: I, pubmed: '9548959', seq: '85', to_res: T}
- {entry_name: ada1a_human, from_res: F, pubmed: '9548959', seq: '86', to_res: M}
- {entry_name: ada1a_human, from_res: V, pubmed: '9548959', seq: '185', to_res: A}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9391044', seq: '121', to_res: A}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9391044', seq: '121', to_res: S}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9391044', seq: '121', to_res: T}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9391044', seq: '121', to_res: V}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9391044', seq: '121', to_res: L}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9391044', seq: '121', to_res: I}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9391044', seq: '121', to_res: W}
- {entry_name: v2r_human, from_res: R, pubmed: '9537515', seq: '337', to_res: Q}
- {entry_name: v2r_human, from_res: K, pubmed: '9537515', seq: '367', to_res: Q}
- {entry_name: adrb2_human, from_res: E, pubmed: '9443940', seq: '306', to_res: A}
- {entry_name: adrb2_human, from_res: V, pubmed: '9443940', seq: '307', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '9443940', seq: '308', to_res: A}
- {entry_name: adrb2_human, from_res: I, pubmed: '9443940', seq: '309', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9443940', seq: '310', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9443940', seq: '311', to_res: A}
- {entry_name: adrb2_human, from_res: I, pubmed: '9443940', seq: '314', to_res: A}
- {entry_name: adrb2_human, from_res: V, pubmed: '9443940', seq: '317', to_res: A}
- {entry_name: adrb2_human, from_res: G, pubmed: '9443940', seq: '320', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9443940', seq: '324', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '9585128', seq: '308', to_res: A}
- {entry_name: adrb2_human, from_res: I, pubmed: '9585128', seq: '309', to_res: A}
- {entry_name: aa1r_human, from_res: T, pubmed: '9827575', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: F, pubmed: '9554879', seq: '131', to_res: A}
- {entry_name: p2ry1_human, from_res: H, pubmed: '9554879', seq: '132', to_res: A}
- {entry_name: p2ry1_human, from_res: Y, pubmed: '9554879', seq: '136', to_res: A}
- {entry_name: p2ry1_human, from_res: T, pubmed: '9554879', seq: '221', to_res: A}
- {entry_name: p2ry1_human, from_res: T, pubmed: '9554879', seq: '222', to_res: A}
- {entry_name: p2ry1_human, from_res: F, pubmed: '9554879', seq: '226', to_res: A}
- {entry_name: p2ry1_human, from_res: H, pubmed: '9554879', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: K, pubmed: '9554879', seq: '280', to_res: A}
- {entry_name: p2ry1_human, from_res: Q, pubmed: '9554879', seq: '307', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '9554879', seq: '310', to_res: K}
- {entry_name: p2ry1_human, from_res: S, pubmed: '9554879', seq: '314', to_res: T}
- {entry_name: p2ry1_human, from_res: S, pubmed: '9554879', seq: '317', to_res: A}
- {entry_name: gnrhr_human, from_res: R, pubmed: '9425890', seq: '262', to_res: Q}
- {entry_name: gnrhr_human, from_res: Y, pubmed: '9425890', seq: '284', to_res: C}
- {entry_name: gnrhr_human, from_res: Q, pubmed: '9371856', seq: '106', to_res: R}
- {entry_name: gnrhr_human, from_res: R, pubmed: '9371856', seq: '262', to_res: Q}
- {entry_name: cxcr4_human, from_res: N, pubmed: '9151868', seq: '11', to_res: Q}
- {entry_name: gasr_rat, from_res: V, pubmed: '8663021', seq: '187', to_res: T}
- {entry_name: cckar_rat, from_res: Q, pubmed: '8663021', seq: '253', to_res: L}
- {entry_name: nk2r_human, from_res: F, pubmed: '8702716', seq: '248', to_res: nbd}
- {entry_name: nk2r_human, from_res: R, pubmed: '8702716', seq: '103', to_res: nbd}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: C}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: K}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: L}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: I}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: V}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: R}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: E}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: Y}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: G}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: S}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: P}
- {entry_name: acm5_human, from_res: A, pubmed: '7852396', seq: '441', to_res: T}
- {entry_name: fshr_human, from_res: N, pubmed: '9027356', seq: '191', to_res: I}
- {entry_name: fshr_human, from_res: A, pubmed: '9027356', seq: '189', to_res: V}
- {entry_name: fshr_human, from_res: D, pubmed: '9027356', seq: '567', to_res: G}
- {entry_name: glp1r_rat, from_res: F, pubmed: '9092794', seq: '169', to_res: A}
- {entry_name: glp1r_rat, from_res: F, pubmed: '9092794', seq: '321', to_res: A}
- {entry_name: glp1r_rat, from_res: L, pubmed: '9092794', seq: '322', to_res: A}
- {entry_name: glp1r_rat, from_res: I, pubmed: '9092794', seq: '323', to_res: A}
- {entry_name: glp1r_rat, from_res: F, pubmed: '9092794', seq: '324', to_res: A}
- {entry_name: glp1r_rat, from_res: V, pubmed: '9092794', seq: '327', to_res: A}
- {entry_name: glp1r_rat, from_res: I, pubmed: '9092794', seq: '328', to_res: A}
- {entry_name: glp1r_rat, from_res: C, pubmed: '9092794', seq: '329', to_res: A}
- {entry_name: glp1r_rat, from_res: I, pubmed: '9092794', seq: '330', to_res: A}
- {entry_name: glp1r_rat, from_res: V, pubmed: '9092794', seq: '331', to_res: A}
- {entry_name: glp1r_rat, from_res: I, pubmed: '9092794', seq: '332', to_res: A}
- {entry_name: glp1r_rat, from_res: A, pubmed: '9092794', seq: '333', to_res: L}
- {entry_name: glp1r_rat, from_res: K, pubmed: '9092794', seq: '334', to_res: A}
- {entry_name: glp1r_rat, from_res: L, pubmed: '9092794', seq: '335', to_res: A}
- {entry_name: glp1r_rat, from_res: K, pubmed: '9092794', seq: '336', to_res: L}
- {entry_name: glp1r_rat, from_res: R, pubmed: '9092794', seq: '170', to_res: A}
- {entry_name: glp1r_rat, from_res: H, pubmed: '9092794', seq: '171', to_res: A}
- {entry_name: glp1r_rat, from_res: L, pubmed: '9092794', seq: '172', to_res: A}
- {entry_name: glp1r_rat, from_res: H, pubmed: '9092794', seq: '173', to_res: A}
- {entry_name: glp1r_rat, from_res: C, pubmed: '9092794', seq: '174', to_res: A}
- {entry_name: glp1r_rat, from_res: T, pubmed: '9092794', seq: '175', to_res: A}
- {entry_name: glp1r_rat, from_res: R, pubmed: '9092794', seq: '176', to_res: A}
- {entry_name: glp1r_rat, from_res: N, pubmed: '9092794', seq: '177', to_res: A}
- {entry_name: glp1r_rat, from_res: E, pubmed: '9092794', seq: '262', to_res: A}
- {entry_name: glp1r_rat, from_res: Q, pubmed: '9092794', seq: '263', to_res: A}
- {entry_name: glp1r_rat, from_res: R, pubmed: '9092794', seq: '264', to_res: A}
- {entry_name: glp1r_rat, from_res: I, pubmed: '9092794', seq: '265', to_res: A}
- {entry_name: glp1r_rat, from_res: F, pubmed: '9092794', seq: '266', to_res: A}
- {entry_name: glp1r_rat, from_res: K, pubmed: '9092794', seq: '267', to_res: A}
- {entry_name: glp1r_rat, from_res: L, pubmed: '9092794', seq: '268', to_res: A}
- {entry_name: avt_catco, from_res: K, pubmed: '8692917', seq: '101', to_res: M}
- {entry_name: avt_catco, from_res: K, pubmed: '8692917', seq: '101', to_res: A}
- {entry_name: avt_catco, from_res: Q, pubmed: '8692917', seq: '104', to_res: L}
- {entry_name: avt_catco, from_res: T, pubmed: '8692917', seq: '156', to_res: S}
- {entry_name: avt_catco, from_res: Y, pubmed: '8692917', seq: '159', to_res: V}
- {entry_name: avt_catco, from_res: F, pubmed: '8692917', seq: '162', to_res: A}
- {entry_name: 5ht2a_rat, from_res: E, pubmed: '1872857', seq: '2', to_res: D}
- {entry_name: 5ht2a_rat, from_res: Q, pubmed: '1872857', seq: '20', to_res: D}
- {entry_name: grm1_rat, from_res: S, pubmed: '8338667', seq: '165', to_res: A}
- {entry_name: grm1_rat, from_res: T, pubmed: '8338667', seq: '188', to_res: A}
- {entry_name: grm1_rat, from_res: S, pubmed: '8338667', seq: '164', to_res: A}
- {entry_name: grm1_rat, from_res: S, pubmed: '8338667', seq: '186', to_res: A}
- {entry_name: acm1_rat, from_res: R, pubmed: '9566019', seq: '123', to_res: N}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9566019', seq: '85', to_res: A}
- {entry_name: adrb3_human, from_res: W, pubmed: '9288945', seq: '64', to_res: R}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '30', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '44', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '54', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '68', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '87', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '102', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '188', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '258', to_res: A}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '128', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '149', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '211', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '233', to_res: S}
- {entry_name: crfr1_mouse, from_res: C, pubmed: '9376348', seq: '364', to_res: S}
- {entry_name: grm1_rat, from_res: K, pubmed: '9488690', seq: '690', to_res: A}
- {entry_name: grm1_rat, from_res: K, pubmed: '9488690', seq: '692', to_res: G}
- {entry_name: grm1_rat, from_res: T, pubmed: '9488690', seq: '695', to_res: A}
- {entry_name: grm1_rat, from_res: T, pubmed: '9488690', seq: '695', to_res: E}
- {entry_name: grm1_rat, from_res: R, pubmed: '9488690', seq: '696', to_res: G}
- {entry_name: grm1_rat, from_res: K, pubmed: '9488690', seq: '697', to_res: M}
- {entry_name: grm1_rat, from_res: P, pubmed: '9488690', seq: '698', to_res: R}
- {entry_name: grm1_rat, from_res: S, pubmed: '9488690', seq: '702', to_res: R}
- {entry_name: grm1_rat, from_res: S, pubmed: '9488690', seq: '702', to_res: S}
- {entry_name: grm1_rat, from_res: A, pubmed: '9488690', seq: '705', to_res: S}
- {entry_name: grm1_rat, from_res: R, pubmed: '9488690', seq: '775', to_res: W}
- {entry_name: grm1_rat, from_res: R, pubmed: '9488690', seq: '775', to_res: K}
- {entry_name: grm1_rat, from_res: P, pubmed: '9488690', seq: '778', to_res: Q}
- {entry_name: grm1_rat, from_res: A, pubmed: '9488690', seq: '779', to_res: E}
- {entry_name: grm1_rat, from_res: F, pubmed: '9488690', seq: '781', to_res: S}
- {entry_name: grm1_rat, from_res: F, pubmed: '9488690', seq: '781', to_res: P}
- {entry_name: grm1_rat, from_res: N, pubmed: '9488690', seq: '782', to_res: I}
- {entry_name: grm1_rat, from_res: E, pubmed: '9488690', seq: '783', to_res: Q}
- {entry_name: vipr1_human, from_res: H, pubmed: '9478946', seq: '178', to_res: R}
- {entry_name: vipr1_human, from_res: H, pubmed: '9478946', seq: '178', to_res: A}
- {entry_name: vipr1_human, from_res: H, pubmed: '9478946', seq: '178', to_res: D}
- {entry_name: vipr1_human, from_res: H, pubmed: '9478946', seq: '178', to_res: K}
- {entry_name: vipr1_human, from_res: E, pubmed: '9478946', seq: '36', to_res: A}
- {entry_name: vipr1_human, from_res: D, pubmed: '9478946', seq: '68', to_res: A}
- {entry_name: vipr1_human, from_res: D, pubmed: '9478946', seq: '132', to_res: A}
- {entry_name: ada2a_human, from_res: T, pubmed: '9207236', seq: '373', to_res: K}
- {entry_name: drd2_human, from_res: C, pubmed: '9454590', seq: '118', to_res: S}
- {entry_name: glr_rat, from_res: H, pubmed: '9440812', seq: '178', to_res: R}
- {entry_name: glr_rat, from_res: H, pubmed: '9440812', seq: '178', to_res: A}
- {entry_name: glr_rat, from_res: H, pubmed: '9440812', seq: '178', to_res: K}
- {entry_name: glr_rat, from_res: H, pubmed: '9440812', seq: '178', to_res: E}
- {entry_name: glr_rat, from_res: T, pubmed: '9440812', seq: '352', to_res: S}
- {entry_name: glr_rat, from_res: T, pubmed: '9440812', seq: '352', to_res: P}
- {entry_name: glr_rat, from_res: T, pubmed: '9440812', seq: '352', to_res: A}
- {entry_name: glr_rat, from_res: H, pubmed: '9440812', seq: '178', to_res: R}
- {entry_name: adrb3_human, from_res: G, pubmed: '9490030', seq: '53', to_res: F}
- {entry_name: adrb3_human, from_res: D, pubmed: '9490030', seq: '117', to_res: L}
- {entry_name: adrb3_human, from_res: N, pubmed: '9490030', seq: '312', to_res: A}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: R}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: L}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: I}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: V}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: R}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: L}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: E}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: Y}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: G}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: S}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: P}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: T}
- {entry_name: acm5_human, from_res: R, pubmed: '9521726', seq: '223', to_res: E}
- {entry_name: acm5_human, from_res: Y, pubmed: '9521726', seq: '217', to_res: S}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: V}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: Q}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: M}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: T}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: I}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: C}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: S}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: E}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: A}
- {entry_name: acm5_human, from_res: K, pubmed: '9521726', seq: '439', to_res: G}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: T}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: K}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: I}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: P}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: G}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: R}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: N}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: L}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: H}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: Q}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '440', to_res: E}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: C}
- {entry_name: acm5_human, from_res: A, pubmed: '9521726', seq: '441', to_res: K}
- {entry_name: acm2_human, from_res: S, pubmed: '9295309', seq: '210', to_res: Y}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: E}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: W}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: H}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: M}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: C}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: H}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: A}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: S}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: C}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: L}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: K}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: F}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: W}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: H}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: M}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: C}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: I}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: R}
- {entry_name: acm1_rat, from_res: Y, pubmed: '9203628', seq: '124', to_res: E}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: A}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: S}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: L}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: E}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: N}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: H}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: A}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: S}
- {entry_name: acm1_rat, from_res: D, pubmed: '9203628', seq: '122', to_res: L}
- {entry_name: grm1_rat, from_res: S, pubmed: '9497291', seq: '166', to_res: D}
- {entry_name: drd1_human, from_res: S, pubmed: '9561802', seq: '56', to_res: L}
- {entry_name: ada1a_human, from_res: I, pubmed: '9548959', seq: '85', to_res: T}
- {entry_name: ada1a_human, from_res: F, pubmed: '9548959', seq: '86', to_res: M}
- {entry_name: ada1a_human, from_res: I, pubmed: '9548959', seq: '85', to_res: A}
- {entry_name: sctr_rat, from_res: R, pubmed: '9539152', seq: '188', to_res: L}
- {entry_name: sctr_rat, from_res: R, pubmed: '9539152', seq: '188', to_res: D}
- {entry_name: sctr_rat, from_res: R, pubmed: '9539152', seq: '188', to_res: Q}
- {entry_name: sctr_rat, from_res: N, pubmed: '9539152', seq: '192', to_res: A}
- {entry_name: sctr_rat, from_res: D, pubmed: '9539152', seq: '196', to_res: V}
- {entry_name: sctr_rat, from_res: D, pubmed: '9539152', seq: '196', to_res: N}
- {entry_name: sctr_rat, from_res: K, pubmed: '9539152', seq: '195', to_res: I}
- {entry_name: sctr_rat, from_res: K, pubmed: '9539152', seq: '195', to_res: Q}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: D}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: G}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: E}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: P}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: W}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: A}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: L}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: C}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: V}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: F}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: R}
- {entry_name: acm5_human, from_res: S, pubmed: '9254607', seq: '465', to_res: K}
- {entry_name: ada1a_human, from_res: S, pubmed: '9014240', seq: '188', to_res: A}
- {entry_name: ada1a_human, from_res: A, pubmed: '9014240', seq: '189', to_res: S}
- {entry_name: ada1a_human, from_res: A, pubmed: '9014240', seq: '189', to_res: T}
- {entry_name: ada1a_human, from_res: S, pubmed: '9014240', seq: '192', to_res: A}
- {entry_name: ada1a_human, from_res: F, pubmed: '9014240', seq: '193', to_res: L}
- {entry_name: ada1a_human, from_res: Y, pubmed: '9014240', seq: '194', to_res: F}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '9012678', seq: '128', to_res: F}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '9012678', seq: '204', to_res: V}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '9012678', seq: '293', to_res: E}
- {entry_name: 5ht2a_rat, from_res: W, pubmed: '9271348', seq: '76', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '9271348', seq: '125', to_res: L}
- {entry_name: 5ht2a_rat, from_res: W, pubmed: '9271348', seq: '200', to_res: A}
- {entry_name: 5ht2a_rat, from_res: W, pubmed: '9271348', seq: '336', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '9271348', seq: '339', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '9271348', seq: '340', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '9271348', seq: '365', to_res: L}
- {entry_name: 5ht2a_rat, from_res: W, pubmed: '9271348', seq: '367', to_res: A}
- {entry_name: 5ht2a_rat, from_res: Y, pubmed: '9271348', seq: '370', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '9271348', seq: '383', to_res: A}
- {entry_name: 5ht2c_rat, from_res: S, pubmed: '9282936', seq: '312', to_res: K}
- {entry_name: 5ht2c_rat, from_res: S, pubmed: '9282936', seq: '312', to_res: F}
- {entry_name: 5ht1a_human, from_res: N, pubmed: '9145928', seq: '386', to_res: V}
- {entry_name: 5ht1a_rat, from_res: T, pubmed: '9224826', seq: '149', to_res: A}
- {entry_name: 5ht6r_rat, from_res: T, pubmed: '9284367', seq: '196', to_res: A}
- {entry_name: 5ht6r_rat, from_res: A, pubmed: '9284367', seq: '154', to_res: S}
- {entry_name: adrb2_human, from_res: C, pubmed: '9461522', seq: '341', to_res: G}
- {entry_name: ada1b_mesau, from_res: Y, pubmed: '9271354', seq: '348', to_res: A}
- {entry_name: ada2a_human, from_res: S, pubmed: '9309797', seq: '165', to_res: A}
- {entry_name: casr_human, from_res: F, pubmed: '9253358', seq: '612', to_res: S}
- {entry_name: hrh1_human, from_res: D, pubmed: '9593602', seq: '107', to_res: A}
- {entry_name: hrh1_human, from_res: T, pubmed: '9593602', seq: '194', to_res: A}
- {entry_name: hrh1_human, from_res: N, pubmed: '9593602', seq: '198', to_res: A}
- {entry_name: drd1_human, from_res: C, pubmed: '9137920', seq: '347', to_res: A}
- {entry_name: drd1_human, from_res: C, pubmed: '9137920', seq: '351', to_res: A}
- {entry_name: drd3_human, from_res: Y, pubmed: '9651882', seq: '36', to_res: L}
- {entry_name: drd3_human, from_res: C, pubmed: '9651882', seq: '102', to_res: H}
- {entry_name: drd3_human, from_res: H, pubmed: '9651882', seq: '349', to_res: L}
- {entry_name: drd3_human, from_res: S, pubmed: '9651882', seq: '361', to_res: A}
- {entry_name: drd3_human, from_res: S, pubmed: '9651882', seq: '361', to_res: P}
- {entry_name: drd3_human, from_res: T, pubmed: '9651882', seq: '368', to_res: F}
- {entry_name: drd3_human, from_res: T, pubmed: '9651882', seq: '368', to_res: V}
- {entry_name: drd3_human, from_res: T, pubmed: '9651882', seq: '369', to_res: V}
- {entry_name: drd3_human, from_res: F, pubmed: '9651882', seq: '172', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '9687586', seq: '193', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '9687586', seq: '194', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '9687586', seq: '197', to_res: A}
- {entry_name: ada2a_human, from_res: C, pubmed: '9495800', seq: '201', to_res: S}
- {entry_name: ada2a_mouse, from_res: S, pubmed: '9495800', seq: '201', to_res: C}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '207', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '208', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '211', to_res: A}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8980109', seq: '129', to_res: A}
- {entry_name: ada1b_mesau, from_res: T, pubmed: '8980109', seq: '130', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '132', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '135', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '140', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '173', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '177', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, pubmed: '8980109', seq: '203', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, pubmed: '8980109', seq: '213', to_res: A}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '8980109', seq: '306', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '8980109', seq: '318', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, pubmed: '8980109', seq: '338', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '8980109', seq: '125', to_res: A}
- {entry_name: casr_human, from_res: L, pubmed: '9253358', seq: '773', to_res: R}
- {entry_name: casr_human, from_res: N, pubmed: '9253358', seq: '118', to_res: K}
- {entry_name: casr_human, from_res: F, pubmed: '9253358', seq: '806', to_res: S}
- {entry_name: crfr1_human, from_res: D, pubmed: '9178757', seq: '254', to_res: E}
- {entry_name: crfr1_human, from_res: K, pubmed: '9178757', seq: '257', to_res: Q}
- {entry_name: crfr1_human, from_res: R, pubmed: '9178757', seq: '263', to_res: E}
- {entry_name: crfr1_human, from_res: V, pubmed: '9178757', seq: '266', to_res: D}
- {entry_name: crfr1_human, from_res: R, pubmed: '9178757', seq: '189', to_res: H}
- {entry_name: crfr1_human, from_res: L, pubmed: '9178757', seq: '190', to_res: C}
- {entry_name: crfr1_human, from_res: V, pubmed: '9178757', seq: '191', to_res: I}
- {entry_name: glp1r_rat, from_res: W, pubmed: '9149304', seq: '39', to_res: A}
- {entry_name: glp1r_rat, from_res: W, pubmed: '9149304', seq: '72', to_res: A}
- {entry_name: glp1r_rat, from_res: W, pubmed: '9149304', seq: '87', to_res: A}
- {entry_name: glp1r_rat, from_res: W, pubmed: '9149304', seq: '91', to_res: A}
- {entry_name: glp1r_rat, from_res: W, pubmed: '9149304', seq: '110', to_res: A}
- {entry_name: glp1r_rat, from_res: W, pubmed: '9149304', seq: '120', to_res: A}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: V}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: L}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: T}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: C}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: A}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: Q}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: N}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: G}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: W}
- {entry_name: acm5_human, from_res: F, pubmed: '9705286', seq: '451', to_res: P}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: S}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: H}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: Y}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: K}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: T}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: Q}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: C}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: D}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: A}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: G}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: V}
- {entry_name: acm5_human, from_res: N, pubmed: '9705286', seq: '459', to_res: F}
- {entry_name: acm5_human, from_res: I, pubmed: '9705286', seq: '447', to_res: S}
- {entry_name: acm5_human, from_res: A, pubmed: '9705286', seq: '450', to_res: V}
- {entry_name: acm5_human, from_res: I, pubmed: '9705286', seq: '452', to_res: M}
- {entry_name: acm5_human, from_res: M, pubmed: '9705286', seq: '461', to_res: V}
- {entry_name: acm5_human, from_res: I, pubmed: '9705286', seq: '453', to_res: V}
- {entry_name: pthr2_human, from_res: H, pubmed: '9461563', seq: '180', to_res: R}
- {entry_name: pthr2_human, from_res: R, pubmed: '9461563', seq: '190', to_res: E}
- {entry_name: pthr2_human, from_res: V, pubmed: '9461563', seq: '241', to_res: T}
- {entry_name: pthr2_human, from_res: M, pubmed: '9461563', seq: '242', to_res: V}
- {entry_name: pthr2_human, from_res: I, pubmed: '9461563', seq: '244', to_res: L}
- {entry_name: pthr2_human, from_res: C, pubmed: '9461563', seq: '397', to_res: Y}
- {entry_name: pthr2_human, from_res: L, pubmed: '9461563', seq: '399', to_res: M}
- {entry_name: pthr2_human, from_res: F, pubmed: '9461563', seq: '400', to_res: L}
- {entry_name: adrb2_human, from_res: Y, pubmed: '9341139', seq: '326', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '9249239', seq: '204', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '9249239', seq: '207', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '9145918', seq: '326', to_res: A}
- {entry_name: acm2_pig, from_res: Y, pubmed: '9415719', seq: '403', to_res: F}
- {entry_name: 5ht1b_human, from_res: S, pubmed: '9671119', seq: '181', to_res: A}
- {entry_name: 5ht1b_human, from_res: F, pubmed: '9671119', seq: '185', to_res: A}
- {entry_name: 5ht1b_human, from_res: F, pubmed: '9671119', seq: '185', to_res: M}
- {entry_name: 5ht1b_human, from_res: S, pubmed: '9671119', seq: '334', to_res: A}
- {entry_name: 5ht1b_human, from_res: F, pubmed: '9671119', seq: '354', to_res: A}
- {entry_name: 5ht1b_human, from_res: F, pubmed: '9671119', seq: '354', to_res: Y}
- {entry_name: acm1_human, from_res: V, pubmed: '9003046', seq: '127', to_res: A}
- {entry_name: acm1_human, from_res: L, pubmed: '9003046', seq: '131', to_res: A}
- {entry_name: acm1_human, from_res: I, pubmed: '9003046', seq: '211', to_res: A}
- {entry_name: acm1_human, from_res: E, pubmed: '9003046', seq: '360', to_res: A}
- {entry_name: acm1_human, from_res: K, pubmed: '9003046', seq: '362', to_res: A}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: W}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: E}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: R}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: L}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: A}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: Q}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: V}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: M}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: K}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: P}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: G}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: I}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: C}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: P}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: D}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: T}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: G}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: Q}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: E}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: Y}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: S}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: A}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: V}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: C}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: M}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: I}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: F}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: L}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: N}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: K}
- {entry_name: pthr1_human, from_res: H, pubmed: '9178745', seq: '223', to_res: R}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: Y}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: F}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: W}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: S}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: D}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: H}
- {entry_name: pthr1_human, from_res: T, pubmed: '9178745', seq: '410', to_res: N}
- {entry_name: adrb2_human, from_res: L, pubmed: '9560162', seq: '413', to_res: A}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: A}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: I}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: L}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: M}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: V}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: D}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: E}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: H}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: K}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: R}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: C}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: G}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: N}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: Q}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: S}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: T}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: Y}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: F}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: W}
- {entry_name: ste2_yeast, from_res: P, pubmed: '9529386', seq: '258', to_res: L}
- {entry_name: ste3_yeast, from_res: P, pubmed: '9529386', seq: '222', to_res: L}
- {entry_name: ste3_yeast, from_res: P, pubmed: '9529386', seq: '222', to_res: F}
- {entry_name: adrb2_human, from_res: C, pubmed: '9452461', seq: '116', to_res: F}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '133', to_res: A}
- {entry_name: acm5_human, from_res: I, pubmed: '9733718', seq: '132', to_res: V}
- {entry_name: acm5_human, from_res: L, pubmed: '9733718', seq: '136', to_res: M}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '139', to_res: W}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '143', to_res: A}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '129', to_res: C}
- {entry_name: acm5_human, from_res: D, pubmed: '9733718', seq: '127', to_res: N}
- {entry_name: acm5_human, from_res: P, pubmed: '9733718', seq: '135', to_res: Q}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: Q}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: C}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: M}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: S}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: E}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: H}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: K}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: R}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: G}
- {entry_name: acm5_human, from_res: F, pubmed: '9733718', seq: '130', to_res: T}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: D}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: N}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: E}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: T}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: Q}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: L}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: A}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: C}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: V}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: G}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: A}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: C}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: T}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: S}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: M}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: V}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: G}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: L}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: N}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: H}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: T}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: G}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: Q}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: F}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: S}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: D}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: A}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: C}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '142', to_res: W}
- {entry_name: acm5_human, from_res: R, pubmed: '9733718', seq: '134', to_res: Q}
- {entry_name: acm5_human, from_res: Y, pubmed: '9733718', seq: '138', to_res: C}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '137', to_res: I}
- {entry_name: acm5_human, from_res: T, pubmed: '9733718', seq: '137', to_res: K}
- {entry_name: acm5_human, from_res: A, pubmed: '9733718', seq: '140', to_res: V}
- {entry_name: adrb2_human, from_res: E, pubmed: '9443940', seq: '306', to_res: A}
- {entry_name: adrb2_human, from_res: V, pubmed: '9443940', seq: '307', to_res: A}
- {entry_name: adrb2_human, from_res: Y, pubmed: '9443940', seq: '308', to_res: A}
- {entry_name: adrb2_human, from_res: I, pubmed: '9443940', seq: '309', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9443940', seq: '310', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9443940', seq: '311', to_res: A}
- {entry_name: adrb2_human, from_res: I, pubmed: '9443940', seq: '314', to_res: A}
- {entry_name: adrb2_human, from_res: V, pubmed: '9443940', seq: '317', to_res: A}
- {entry_name: adrb2_human, from_res: G, pubmed: '9443940', seq: '320', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9443940', seq: '324', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '9443940', seq: '204', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '9443940', seq: '207', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9356441', seq: '339', to_res: A}
- {entry_name: adrb2_human, from_res: L, pubmed: '9356441', seq: '340', to_res: A}
- {entry_name: ste2_yeast, from_res: F, pubmed: '9824658', seq: '55', to_res: V}
- {entry_name: ste2_yeast, from_res: S, pubmed: '9824658', seq: '219', to_res: P}
- {entry_name: ste2_yeast, from_res: S, pubmed: '9824658', seq: '259', to_res: P}
- {entry_name: pthr1_rat, from_res: L, pubmed: '9572838', seq: '385', to_res: M}
- {entry_name: pthr1_rat, from_res: A, pubmed: '9572838', seq: '480', to_res: M}
- {entry_name: pthr1_rat, from_res: A, pubmed: '9572838', seq: '537', to_res: M}
- {entry_name: pthr1_rat, from_res: A, pubmed: '9572838', seq: '577', to_res: M}
- {entry_name: vipr1_human, from_res: D, pubmed: '9016768', seq: '196', to_res: A}
- {entry_name: vipr1_human, from_res: L, pubmed: '9016768', seq: '199', to_res: A}
- {entry_name: vipr1_human, from_res: W, pubmed: '9016768', seq: '286', to_res: A}
- {entry_name: vipr1_human, from_res: W, pubmed: '9016768', seq: '294', to_res: A}
- {entry_name: ada2a_human, from_res: C, pubmed: '9843377', seq: '442', to_res: A}
- {entry_name: casr_human, from_res: R, pubmed: '9011580', seq: '185', to_res: Q}
- {entry_name: pthr1_didma, from_res: R, pubmed: '8969199', seq: '377', to_res: A}
- {entry_name: pthr1_didma, from_res: V, pubmed: '8969199', seq: '378', to_res: A}
- {entry_name: pthr1_didma, from_res: L, pubmed: '8969199', seq: '379', to_res: A}
- {entry_name: pthr1_didma, from_res: T, pubmed: '8969199', seq: '381', to_res: A}
- {entry_name: pthr1_didma, from_res: K, pubmed: '8969199', seq: '382', to_res: A}
- {entry_name: pthr1_didma, from_res: L, pubmed: '8969199', seq: '383', to_res: A}
- {entry_name: pthr1_didma, from_res: R, pubmed: '8969199', seq: '384', to_res: A}
- {entry_name: drd3_human, from_res: S, pubmed: '8780735', seq: '9', to_res: G}
- {entry_name: acm2_pig, from_res: D, pubmed: '9882458', seq: '69', to_res: N}
- {entry_name: acm2_pig, from_res: D, pubmed: '9882458', seq: '97', to_res: N}
- {entry_name: acm3_rat, from_res: P, pubmed: '9880506', seq: '505', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '9880506', seq: '540', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '9880506', seq: '242', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '502', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '537', to_res: A}
- {entry_name: v2r_human, from_res: N, pubmed: '9843382', seq: '22', to_res: Q}
- {entry_name: casr_rat, from_res: R, pubmed: '9422777', seq: '795', to_res: W}
- {entry_name: casr_human, from_res: P, pubmed: '8878438', seq: '55', to_res: L}
- {entry_name: casr_human, from_res: N, pubmed: '8878438', seq: '178', to_res: D}
- {entry_name: casr_human, from_res: P, pubmed: '8878438', seq: '221', to_res: S}
- {entry_name: casr_human, from_res: R, pubmed: '8878438', seq: '227', to_res: V}
- {entry_name: casr_human, from_res: V, pubmed: '8878438', seq: '817', to_res: I}
- {entry_name: casr_human, from_res: R, pubmed: '8878438', seq: '680', to_res: C}
- {entry_name: casr_human, from_res: Y, pubmed: '8878438', seq: '218', to_res: S}
- {entry_name: casr_human, from_res: F, pubmed: '8878438', seq: '128', to_res: L}
- {entry_name: casr_human, from_res: T, pubmed: '8878438', seq: '151', to_res: M}
- {entry_name: casr_human, from_res: E, pubmed: '8878438', seq: '191', to_res: K}
- {entry_name: gipr_rat, from_res: H, pubmed: '9125160', seq: '170', to_res: R}
- {entry_name: gipr_rat, from_res: T, pubmed: '9125160', seq: '340', to_res: P}
- {entry_name: 5ht2a_rat, from_res: S, pubmed: '9387857', seq: '239', to_res: A}
- {entry_name: 5ht2a_rat, from_res: S, pubmed: '9387857', seq: '207', to_res: A}
- {entry_name: pthr1_human, from_res: M, pubmed: '9712875', seq: '414', to_res: L}
- {entry_name: pthr1_human, from_res: M, pubmed: '9712875', seq: '425', to_res: L}
- {entry_name: pthr1_rat, from_res: M, pubmed: '9642250', seq: '63', to_res: I}
- {entry_name: pthr1_rat, from_res: V, pubmed: '9642250', seq: '31', to_res: A}
- {entry_name: pthr1_rat, from_res: F, pubmed: '9642250', seq: '32', to_res: A}
- {entry_name: pthr1_rat, from_res: T, pubmed: '9642250', seq: '33', to_res: A}
- {entry_name: pthr1_rat, from_res: K, pubmed: '9642250', seq: '34', to_res: A}
- {entry_name: pthr1_rat, from_res: E, pubmed: '9642250', seq: '35', to_res: A}
- {entry_name: pthr1_rat, from_res: E, pubmed: '9642250', seq: '36', to_res: A}
- {entry_name: pthr1_rat, from_res: Q, pubmed: '9642250', seq: '37', to_res: A}
- {entry_name: pthr1_rat, from_res: I, pubmed: '9642250', seq: '38', to_res: A}
- {entry_name: pthr1_rat, from_res: F, pubmed: '9642250', seq: '39', to_res: A}
- {entry_name: pthr1_rat, from_res: E, pubmed: '9054374', seq: '317', to_res: A}
- {entry_name: pthr1_rat, from_res: E, pubmed: '9054374', seq: '317', to_res: D}
- {entry_name: pthr1_rat, from_res: E, pubmed: '9054374', seq: '317', to_res: K}
- {entry_name: pthr1_rat, from_res: K, pubmed: '9054374', seq: '318', to_res: A}
- {entry_name: pthr1_rat, from_res: K, pubmed: '9054374', seq: '318', to_res: E}
- {entry_name: pthr1_rat, from_res: K, pubmed: '9054374', seq: '318', to_res: S}
- {entry_name: pthr1_rat, from_res: K, pubmed: '9054374', seq: '319', to_res: A}
- {entry_name: pthr1_rat, from_res: K, pubmed: '9054374', seq: '319', to_res: E}
- {entry_name: pthr1_rat, from_res: Y, pubmed: '9054374', seq: '320', to_res: F}
- {entry_name: pthr1_rat, from_res: Y, pubmed: '9054374', seq: '320', to_res: A}
- {entry_name: pthr1_rat, from_res: Y, pubmed: '9054374', seq: '320', to_res: L}
- {entry_name: hrh2_canfa, from_res: T, pubmed: '9235948', seq: '315', to_res: A}
- {entry_name: hrh2_canfa, from_res: S, pubmed: '9235948', seq: '316', to_res: A}
- {entry_name: adrb2_mesau, from_res: Y, pubmed: '9830057', seq: '350', to_res: F}
- {entry_name: ada2a_pig, from_res: D, pubmed: '9727043', seq: '113', to_res: N}
- {entry_name: ada2a_pig, from_res: V, pubmed: '9305937', seq: '450', to_res: A}
- {entry_name: ada2a_mouse, from_res: S, pubmed: '9092501', seq: '134', to_res: A}
- {entry_name: ada2a_mouse, from_res: Q, pubmed: '9092501', seq: '137', to_res: R}
- {entry_name: ada2a_mouse, from_res: L, pubmed: '9092501', seq: '143', to_res: S}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '90', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '130', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '261', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '287', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '446', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '468', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '488', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '541', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '594', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '386', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '400', to_res: Q}
- {entry_name: casr_human, from_res: T, pubmed: '9792684', seq: '876', to_res: D}
- {entry_name: casr_human, from_res: T, pubmed: '9694886', seq: '646', to_res: V}
- {entry_name: casr_human, from_res: S, pubmed: '9694886', seq: '794', to_res: A}
- {entry_name: casr_human, from_res: T, pubmed: '9694886', seq: '888', to_res: V}
- {entry_name: casr_human, from_res: S, pubmed: '9694886', seq: '895', to_res: A}
- {entry_name: casr_human, from_res: S, pubmed: '9694886', seq: '915', to_res: A}
- {entry_name: agtr2_rat, from_res: S, pubmed: '10069367', seq: '243', to_res: V}
- {entry_name: mc4r_human, from_res: I, pubmed: '10078568', seq: '103', to_res: V}
- {entry_name: ntr1_rat, from_res: D, pubmed: '9927610', seq: '113', to_res: A}
- {entry_name: ntr2_mouse, from_res: A, pubmed: '9927610', seq: '79', to_res: D}
- {entry_name: ccr5_cerae, from_res: R, pubmed: '9890944', seq: '163', to_res: G}
- {entry_name: ccr5_human, from_res: G, pubmed: '9890944', seq: '163', to_res: R}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9890944', seq: '14', to_res: N}
- {entry_name: agtra_rat, from_res: N, pubmed: '10066768', seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, pubmed: '10066768', seq: '111', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '10066768', seq: '111', to_res: H}
- {entry_name: agtra_rat, from_res: N, pubmed: '10066768', seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, pubmed: '10066768', seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: H, pubmed: '10066768', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: H, pubmed: '10066768', seq: '256', to_res: Q}
- {entry_name: agtra_rat, from_res: H, pubmed: '10066768', seq: '256', to_res: Y}
- {entry_name: bkrb2_human, from_res: N, pubmed: '9882702', seq: '113', to_res: A}
- {entry_name: bkrb2_human, from_res: W, pubmed: '9882702', seq: '256', to_res: F}
- {entry_name: bkrb2_human, from_res: D, pubmed: '9882702', seq: '76', to_res: N}
- {entry_name: bkrb2_human, from_res: Y, pubmed: '9882702', seq: '295', to_res: F}
- {entry_name: bkrb2_human, from_res: W, pubmed: '9882702', seq: '256', to_res: Q}
- {entry_name: bkrb2_human, from_res: D, pubmed: '9882702', seq: '76', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9882373', seq: '89', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '9882373', seq: '267', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '9882373', seq: '268', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '9882373', seq: '269', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '9882373', seq: '270', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '9882373', seq: '271', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '9882373', seq: '272', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '9882373', seq: '273', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9882373', seq: '277', to_res: A}
- {entry_name: ccr5_human, from_res: W, pubmed: '9882373', seq: '94', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '9882373', seq: '96', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '9882373', seq: '98', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '9882373', seq: '99', to_res: A}
- {entry_name: ccr5_human, from_res: M, pubmed: '9882373', seq: '100', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '9882373', seq: '101', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '9882373', seq: '169', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9882373', seq: '170', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9882373', seq: '176', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '9882373', seq: '177', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '9882373', seq: '178', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '9882373', seq: '179', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '9882373', seq: '180', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '9882373', seq: '182', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '9882373', seq: '183', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '9882373', seq: '185', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9882373', seq: '186', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '9882373', seq: '187', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '9882373', seq: '189', to_res: A}
- {entry_name: ccr5_human, from_res: W, pubmed: '9882373', seq: '190', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '9882373', seq: '193', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9882373', seq: '194', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '9882373', seq: '261', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '9882373', seq: '263', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '9882373', seq: '264', to_res: A}
- {entry_name: mshr_mouse, from_res: M, pubmed: '9892731', seq: '71', to_res: K}
- {entry_name: mshr_mouse, from_res: D, pubmed: '9892731', seq: '119', to_res: N}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '9837936', seq: '137', to_res: P}
- {entry_name: bkrb2_rat, from_res: T, pubmed: '9837936', seq: '137', to_res: D}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '9837936', seq: '322', to_res: F}
- {entry_name: mshr_human, from_res: R, pubmed: '9861445', seq: '213', to_res: A}
- {entry_name: mshr_human, from_res: H, pubmed: '9861445', seq: '217', to_res: A}
- {entry_name: mshr_human, from_res: R, pubmed: '9861445', seq: '223', to_res: A}
- {entry_name: mshr_human, from_res: K, pubmed: '9861445', seq: '226', to_res: A}
- {entry_name: mshr_human, from_res: R, pubmed: '9861445', seq: '227', to_res: A}
- {entry_name: mshr_human, from_res: Q, pubmed: '9861445', seq: '228', to_res: A}
- {entry_name: mshr_human, from_res: R, pubmed: '9861445', seq: '229', to_res: A}
- {entry_name: mshr_human, from_res: H, pubmed: '9861445', seq: '232', to_res: A}
- {entry_name: mshr_human, from_res: Q, pubmed: '9861445', seq: '233', to_res: A}
- {entry_name: mshr_human, from_res: K, pubmed: '9861445', seq: '238', to_res: A}
- {entry_name: fpr1_human, from_res: D, pubmed: '10029516', seq: '71', to_res: A}
- {entry_name: fpr1_human, from_res: R, pubmed: '10029516', seq: '123', to_res: G}
- {entry_name: fshr_human, from_res: D, pubmed: '9973249', seq: '567', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '9973249', seq: '564', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '9973249', seq: '564', to_res: E}
- {entry_name: lshr_human, from_res: D, pubmed: '9973249', seq: '564', to_res: N}
- {entry_name: lshr_human, from_res: D, pubmed: '9973249', seq: '564', to_res: K}
- {entry_name: lshr_human, from_res: R, pubmed: '9973249', seq: '464', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '9973249', seq: '477', to_res: A}
- {entry_name: lshr_human, from_res: R, pubmed: '9973249', seq: '479', to_res: A}
- {entry_name: lshr_human, from_res: R, pubmed: '9973249', seq: '481', to_res: A}
- {entry_name: lshr_human, from_res: H, pubmed: '9973249', seq: '482', to_res: A}
- {entry_name: tshr_human, from_res: M, pubmed: '9917102', seq: '453', to_res: T}
- {entry_name: tshr_human, from_res: S, pubmed: '9917102', seq: '505', to_res: N}
- {entry_name: tshr_human, from_res: V, pubmed: '9917102', seq: '509', to_res: A}
- {entry_name: tshr_human, from_res: F, pubmed: '9917102', seq: '631', to_res: L}
- {entry_name: tshr_human, from_res: N, pubmed: '9917102', seq: '650', to_res: Y}
- {entry_name: tshr_human, from_res: N, pubmed: '9917102', seq: '670', to_res: S}
- {entry_name: tshr_human, from_res: C, pubmed: '9917102', seq: '672', to_res: Y}
- {entry_name: tshr_human, from_res: A, pubmed: '9917102', seq: '623', to_res: V}
- {entry_name: tshr_human, from_res: T, pubmed: '9917102', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: S, pubmed: '9917102', seq: '281', to_res: I}
- {entry_name: tshr_human, from_res: S, pubmed: '9917102', seq: '281', to_res: N}
- {entry_name: trfr_mouse, from_res: W, pubmed: '9855624', seq: '279', to_res: A}
- {entry_name: trfr_mouse, from_res: F, pubmed: '9855624', seq: '199', to_res: A}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '9855624', seq: '282', to_res: A}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '9855624', seq: '282', to_res: F}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '9855624', seq: '200', to_res: A}
- {entry_name: trfr_mouse, from_res: Y, pubmed: '9855624', seq: '200', to_res: F}
- {entry_name: tshr_human, from_res: K, pubmed: '9854118', seq: '183', to_res: R}
- {entry_name: casr_human, from_res: P, pubmed: '10230755', seq: '39', to_res: A}
- {entry_name: casr_human, from_res: F, pubmed: '10230755', seq: '128', to_res: L}
- {entry_name: casr_human, from_res: T, pubmed: '10230755', seq: '151', to_res: M}
- {entry_name: casr_human, from_res: E, pubmed: '10230755', seq: '191', to_res: K}
- {entry_name: casr_human, from_res: Q, pubmed: '10230755', seq: '245', to_res: R}
- {entry_name: casr_human, from_res: F, pubmed: '10230755', seq: '612', to_res: S}
- {entry_name: casr_human, from_res: Q, pubmed: '10230755', seq: '681', to_res: H}
- {entry_name: casr_human, from_res: F, pubmed: '10230755', seq: '806', to_res: S}
- {entry_name: casr_human, from_res: S, pubmed: '10230755', seq: '53', to_res: P}
- {entry_name: casr_human, from_res: P, pubmed: '10230755', seq: '55', to_res: L}
- {entry_name: casr_human, from_res: R, pubmed: '10230755', seq: '62', to_res: M}
- {entry_name: casr_human, from_res: R, pubmed: '10230755', seq: '66', to_res: C}
- {entry_name: casr_human, from_res: T, pubmed: '10230755', seq: '138', to_res: M}
- {entry_name: casr_human, from_res: G, pubmed: '10230755', seq: '143', to_res: E}
- {entry_name: casr_human, from_res: N, pubmed: '10230755', seq: '178', to_res: D}
- {entry_name: casr_human, from_res: R, pubmed: '10230755', seq: '185', to_res: Q}
- {entry_name: casr_human, from_res: D, pubmed: '10230755', seq: '215', to_res: G}
- {entry_name: casr_human, from_res: Y, pubmed: '10230755', seq: '218', to_res: S}
- {entry_name: casr_human, from_res: P, pubmed: '10230755', seq: '221', to_res: S}
- {entry_name: casr_human, from_res: R, pubmed: '10230755', seq: '227', to_res: L}
- {entry_name: casr_human, from_res: R, pubmed: '10230755', seq: '227', to_res: Q}
- {entry_name: casr_human, from_res: E, pubmed: '10230755', seq: '297', to_res: K}
- {entry_name: casr_human, from_res: C, pubmed: '10230755', seq: '582', to_res: Y}
- {entry_name: casr_human, from_res: S, pubmed: '10230755', seq: '657', to_res: Y}
- {entry_name: casr_human, from_res: G, pubmed: '10230755', seq: '670', to_res: R}
- {entry_name: casr_human, from_res: R, pubmed: '10230755', seq: '680', to_res: C}
- {entry_name: casr_human, from_res: P, pubmed: '10230755', seq: '748', to_res: R}
- {entry_name: casr_human, from_res: R, pubmed: '10230755', seq: '795', to_res: W}
- {entry_name: casr_human, from_res: V, pubmed: '10230755', seq: '817', to_res: I}
- {entry_name: casr_human, from_res: A, pubmed: '10230755', seq: '116', to_res: T}
- {entry_name: casr_human, from_res: N, pubmed: '10230755', seq: '118', to_res: K}
- {entry_name: casr_human, from_res: E, pubmed: '10230755', seq: '127', to_res: A}
- {entry_name: calcr_human, from_res: N, pubmed: '10026267', seq: '26', to_res: A}
- {entry_name: calcr_human, from_res: N, pubmed: '10026267', seq: '78', to_res: A}
- {entry_name: calcr_human, from_res: N, pubmed: '10026267', seq: '83', to_res: A}
- {entry_name: c5ar_human, from_res: F, pubmed: '10336477', seq: '288', to_res: L}
- {entry_name: c5ar_human, from_res: L, pubmed: '10336477', seq: '112', to_res: A}
- {entry_name: c5ar_human, from_res: S, pubmed: '10336477', seq: '123', to_res: A}
- {entry_name: c5ar_human, from_res: L, pubmed: '10336477', seq: '126', to_res: A}
- {entry_name: c5ar_human, from_res: T, pubmed: '10336477', seq: '129', to_res: A}
- {entry_name: c5ar_human, from_res: I, pubmed: '10336477', seq: '130', to_res: A}
- {entry_name: c5ar_human, from_res: I, pubmed: '10336477', seq: '124', to_res: N}
- {entry_name: c5ar_human, from_res: L, pubmed: '10336477', seq: '127', to_res: Q}
- {entry_name: c5ar_human, from_res: A, pubmed: '10336477', seq: '203', to_res: V}
- {entry_name: c5ar_human, from_res: R, pubmed: '10336477', seq: '206', to_res: H}
- {entry_name: c5ar_human, from_res: L, pubmed: '10336477', seq: '207', to_res: A}
- {entry_name: c5ar_human, from_res: L, pubmed: '10336477', seq: '207', to_res: I}
- {entry_name: c5ar_human, from_res: Y, pubmed: '10336477', seq: '222', to_res: A}
- {entry_name: c5ar_human, from_res: S, pubmed: '10336477', seq: '266', to_res: A}
- {entry_name: c5ar_human, from_res: V, pubmed: '10336477', seq: '260', to_res: A}
- {entry_name: c5ar_human, from_res: F, pubmed: '10336477', seq: '251', to_res: A}
- {entry_name: c5ar_human, from_res: K, pubmed: '10336477', seq: '242', to_res: A}
- {entry_name: c5ar_human, from_res: D, pubmed: '10336477', seq: '282', to_res: A}
- {entry_name: c5ar_human, from_res: V, pubmed: '10336477', seq: '286', to_res: A}
- {entry_name: c5ar_human, from_res: V, pubmed: '10336477', seq: '286', to_res: L}
- {entry_name: c5ar_human, from_res: S, pubmed: '10336477', seq: '287', to_res: A}
- {entry_name: c5ar_human, from_res: N, pubmed: '10336477', seq: '296', to_res: A}
- {entry_name: casr_human, from_res: C, pubmed: '10206973', seq: '60', to_res: S}
- {entry_name: casr_human, from_res: C, pubmed: '10206973', seq: '131', to_res: S}
- {entry_name: casr_human, from_res: C, pubmed: '10206973', seq: '101', to_res: S}
- {entry_name: casr_human, from_res: C, pubmed: '10206973', seq: '236', to_res: S}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '843', to_res: E}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '116', to_res: T}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '840', to_res: E}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '843', to_res: K}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '843', to_res: V}
- {entry_name: mc4r_human, from_res: F, pubmed: '10358030', seq: '267', to_res: L}
- {entry_name: mc4r_human, from_res: Y, pubmed: '10358030', seq: '268', to_res: I}
- {entry_name: mc4r_human, from_res: S, pubmed: '10358030', seq: '270', to_res: T}
- {entry_name: mc4r_human, from_res: Q, pubmed: '10358030', seq: '273', to_res: T}
- {entry_name: mc4r_human, from_res: M, pubmed: '10358030', seq: '281', to_res: T}
- {entry_name: gasr_human, from_res: S, pubmed: '10220557', seq: '82', to_res: D}
- {entry_name: gasr_human, from_res: S, pubmed: '10220557', seq: '82', to_res: T}
- {entry_name: gasr_human, from_res: S, pubmed: '10220557', seq: '82', to_res: A}
- {entry_name: ptafr_human, from_res: D, pubmed: '10212233', seq: '63', to_res: N}
- {entry_name: ptafr_human, from_res: N, pubmed: '10212233', seq: '285', to_res: I}
- {entry_name: ptafr_human, from_res: D, pubmed: '10212233', seq: '289', to_res: A}
- {entry_name: ptafr_human, from_res: Y, pubmed: '10212233', seq: '293', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10212257', seq: '339', to_res: A}
- {entry_name: bkrb2_human, from_res: T, pubmed: '10212257', seq: '342', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10212257', seq: '346', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '10191272', seq: '176', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '10191272', seq: '188', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '10191272', seq: '176', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '10191272', seq: '188', to_res: Q}
- {entry_name: agtr2_rat, from_res: H, pubmed: '10208847', seq: '273', to_res: R}
- {entry_name: agtr2_rat, from_res: H, pubmed: '10208847', seq: '273', to_res: E}
- {entry_name: agtra_rat, from_res: N, pubmed: '10218949', seq: '4', to_res: K}
- {entry_name: agtra_rat, from_res: N, pubmed: '10218949', seq: '176', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '10218949', seq: '188', to_res: Q}
- {entry_name: ccr5_human, from_res: D, pubmed: '10196311', seq: '2', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '10196311', seq: '95', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10196311', seq: '96', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10196311', seq: '98', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10196311', seq: '99', to_res: A}
- {entry_name: ccr5_human, from_res: M, pubmed: '10196311', seq: '100', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10196311', seq: '101', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '102', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '10196311', seq: '168', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '169', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '170', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '10196311', seq: '171', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '10196311', seq: '172', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '10196311', seq: '175', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '176', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10196311', seq: '177', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10196311', seq: '178', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '179', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '180', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '10196311', seq: '181', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10196311', seq: '182', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '10196311', seq: '183', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '184', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '185', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '186', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '187', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '188', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '3', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10196311', seq: '189', to_res: A}
- {entry_name: ccr5_human, from_res: W, pubmed: '10196311', seq: '190', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '10196311', seq: '191', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10196311', seq: '192', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10196311', seq: '193', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '194', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '10196311', seq: '262', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10196311', seq: '263', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10196311', seq: '264', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10196311', seq: '267', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10196311', seq: '268', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10196311', seq: '269', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '270', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '271', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '272', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10196311', seq: '273', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '10196311', seq: '274', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '277', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '4', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '6', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '7', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '10196311', seq: '8', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '10', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '10196311', seq: '11', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10196311', seq: '13', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '14', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '15', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10196311', seq: '16', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10196311', seq: '17', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '10196311', seq: '18', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '10196311', seq: '19', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10196311', seq: '20', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '21', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '10196311', seq: '22', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10196311', seq: '24', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '10196311', seq: '26', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '27', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '10196311', seq: '31', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '10196311', seq: '88', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10196311', seq: '89', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10196311', seq: '93', to_res: A}
- {entry_name: ccr5_human, from_res: W, pubmed: '10196311', seq: '94', to_res: A}
- {entry_name: ccr3_mouse, from_res: R, pubmed: '10187784', seq: '135', to_res: N}
- {entry_name: ednrb_rat, from_res: F, pubmed: '10187821', seq: '332', to_res: A}
- {entry_name: ednrb_rat, from_res: C, pubmed: '10187821', seq: '335', to_res: A}
- {entry_name: ednrb_rat, from_res: W, pubmed: '10187821', seq: '336', to_res: A}
- {entry_name: ednrb_rat, from_res: P, pubmed: '10187821', seq: '338', to_res: A}
- {entry_name: ednrb_rat, from_res: S, pubmed: '10187821', seq: '342', to_res: A}
- {entry_name: ednrb_rat, from_res: K, pubmed: '10187821', seq: '346', to_res: A}
- {entry_name: ednrb_rat, from_res: M, pubmed: '10187821', seq: '300', to_res: A}
- {entry_name: ednrb_rat, from_res: Q, pubmed: '10187821', seq: '317', to_res: A}
- {entry_name: ednrb_rat, from_res: K, pubmed: '10187821', seq: '323', to_res: A}
- {entry_name: ednrb_rat, from_res: T, pubmed: '10187821', seq: '324', to_res: A}
- {entry_name: ednrb_rat, from_res: M, pubmed: '10187821', seq: '307', to_res: A}
- {entry_name: ednrb_rat, from_res: D, pubmed: '10187821', seq: '313', to_res: A}
- {entry_name: ednrb_rat, from_res: D, pubmed: '10187821', seq: '368', to_res: A}
- {entry_name: ednrb_rat, from_res: N, pubmed: '10187821', seq: '373', to_res: A}
- {entry_name: ednrb_rat, from_res: N, pubmed: '10187821', seq: '378', to_res: P}
- {entry_name: ednrb_rat, from_res: S, pubmed: '10187821', seq: '379', to_res: K}
- {entry_name: ednrb_rat, from_res: P, pubmed: '10187821', seq: '383', to_res: K}
- {entry_name: ednrb_rat, from_res: A, pubmed: '10187821', seq: '385', to_res: K}
- {entry_name: ednrb_rat, from_res: L, pubmed: '10187821', seq: '386', to_res: A}
- {entry_name: ednrb_rat, from_res: F, pubmed: '10187821', seq: '393', to_res: A}
- {entry_name: ednrb_rat, from_res: V, pubmed: '10187821', seq: '389', to_res: K}
- {entry_name: ednrb_rat, from_res: K, pubmed: '10187821', seq: '391', to_res: A}
- {entry_name: ccr2_human, from_res: Y, pubmed: '10097088', seq: '139', to_res: F}
- {entry_name: agtra_rat, from_res: N, pubmed: '10100078', seq: '111', to_res: G}
- {entry_name: c5ar_human, from_res: E, pubmed: '10195437', seq: '199', to_res: Q}
- {entry_name: c5ar_human, from_res: E, pubmed: '10195437', seq: '199', to_res: K}
- {entry_name: cnr1_rat, from_res: T, pubmed: '10234009', seq: '419', to_res: A}
- {entry_name: cnr1_rat, from_res: S, pubmed: '10234009', seq: '426', to_res: A}
- {entry_name: cnr1_rat, from_res: S, pubmed: '10234009', seq: '430', to_res: A}
- {entry_name: nk2r_human, from_res: N, pubmed: '10085227', seq: '51', to_res: D}
- {entry_name: nk2r_human, from_res: N, pubmed: '10085227', seq: '51', to_res: H}
- {entry_name: nk2r_human, from_res: N, pubmed: '10085227', seq: '51', to_res: S}
- {entry_name: nk2r_human, from_res: D, pubmed: '10085227', seq: '79', to_res: A}
- {entry_name: nk2r_human, from_res: D, pubmed: '10085227', seq: '79', to_res: E}
- {entry_name: nk2r_human, from_res: D, pubmed: '10085227', seq: '79', to_res: N}
- {entry_name: nk2r_human, from_res: N, pubmed: '10085227', seq: '303', to_res: A}
- {entry_name: nk2r_human, from_res: N, pubmed: '10085227', seq: '303', to_res: D}
- {entry_name: nk2r_human, from_res: N, pubmed: '10085227', seq: '303', to_res: S}
- {entry_name: oprm_rat, from_res: D, pubmed: '10214970', seq: '114', to_res: N}
- {entry_name: oprm_rat, from_res: N, pubmed: '10214970', seq: '332', to_res: D}
- {entry_name: hrh1_human, from_res: S, pubmed: '10101032', seq: '396', to_res: A}
- {entry_name: hrh1_human, from_res: S, pubmed: '10101032', seq: '398', to_res: A}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10090736', seq: '209', to_res: A}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10090736', seq: '209', to_res: D}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10090736', seq: '209', to_res: Q}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10090736', seq: '209', to_res: R}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10090736', seq: '287', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10090736', seq: '287', to_res: K}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10090736', seq: '287', to_res: E}
- {entry_name: casr_human, from_res: G, pubmed: '10077597', seq: '143', to_res: E}
- {entry_name: casr_human, from_res: E, pubmed: '10077597', seq: '297', to_res: K}
- {entry_name: casr_human, from_res: G, pubmed: '10077597', seq: '143', to_res: E}
- {entry_name: casr_human, from_res: E, pubmed: '10077597', seq: '297', to_res: K}
- {entry_name: casr_human, from_res: R, pubmed: '10077597', seq: '795', to_res: W}
- {entry_name: casr_human, from_res: R, pubmed: '10077597', seq: '795', to_res: W}
- {entry_name: casr_human, from_res: R, pubmed: '10077597', seq: '185', to_res: Q}
- {entry_name: casr_human, from_res: R, pubmed: '10077597', seq: '185', to_res: Q}
- {entry_name: acm1_rat, from_res: L, pubmed: '10066794', seq: '100', to_res: A}
- {entry_name: acm1_rat, from_res: W, pubmed: '10066794', seq: '101', to_res: A}
- {entry_name: acm1_rat, from_res: L, pubmed: '10066794', seq: '102', to_res: A}
- {entry_name: acm1_rat, from_res: A, pubmed: '10066794', seq: '103', to_res: G}
- {entry_name: acm1_rat, from_res: L, pubmed: '10066794', seq: '104', to_res: A}
- {entry_name: acm1_rat, from_res: D, pubmed: '10066794', seq: '105', to_res: A}
- {entry_name: acm1_rat, from_res: Y, pubmed: '10066794', seq: '106', to_res: A}
- {entry_name: acm1_rat, from_res: V, pubmed: '10066794', seq: '107', to_res: A}
- {entry_name: acm1_rat, from_res: A, pubmed: '10066794', seq: '108', to_res: G}
- {entry_name: acm1_rat, from_res: S, pubmed: '10066794', seq: '109', to_res: A}
- {entry_name: acm1_rat, from_res: N, pubmed: '10066794', seq: '110', to_res: A}
- {entry_name: acm1_rat, from_res: A, pubmed: '10066794', seq: '111', to_res: G}
- {entry_name: acm1_rat, from_res: S, pubmed: '10066794', seq: '112', to_res: A}
- {entry_name: acm1_rat, from_res: V, pubmed: '10066794', seq: '113', to_res: A}
- {entry_name: acm1_rat, from_res: M, pubmed: '10066794', seq: '114', to_res: A}
- {entry_name: acm1_rat, from_res: N, pubmed: '10066794', seq: '115', to_res: A}
- {entry_name: acm1_rat, from_res: L, pubmed: '10066794', seq: '116', to_res: A}
- {entry_name: acm1_rat, from_res: L, pubmed: '10066794', seq: '117', to_res: A}
- {entry_name: acm1_rat, from_res: L, pubmed: '10066794', seq: '118', to_res: A}
- {entry_name: acm1_rat, from_res: I, pubmed: '10066794', seq: '119', to_res: A}
- {entry_name: acm1_rat, from_res: S, pubmed: '10066794', seq: '120', to_res: A}
- {entry_name: acm1_rat, from_res: F, pubmed: '10066794', seq: '121', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10086323', seq: '289', to_res: F}
- {entry_name: oprm_rat, from_res: Y, pubmed: '10188634', seq: '148', to_res: F}
- {entry_name: oprm_rat, from_res: W, pubmed: '10188634', seq: '318', to_res: A}
- {entry_name: oprm_rat, from_res: H, pubmed: '10188634', seq: '319', to_res: A}
- {entry_name: pthr1_didma, from_res: L, pubmed: '10067856', seq: '379', to_res: A}
- {entry_name: pthr1_didma, from_res: T, pubmed: '10067856', seq: '381', to_res: A}
- {entry_name: pthr1_didma, from_res: K, pubmed: '10067856', seq: '382', to_res: A}
- {entry_name: ada2a_human, from_res: T, pubmed: '10193774', seq: '373', to_res: K}
- {entry_name: oprm_rat, from_res: T, pubmed: '10037504', seq: '279', to_res: C}
- {entry_name: oprm_rat, from_res: R, pubmed: '10037504', seq: '280', to_res: L}
- {entry_name: acm1_human, from_res: T, pubmed: '10188986', seq: '192', to_res: A}
- {entry_name: acm1_human, from_res: N, pubmed: '10188986', seq: '382', to_res: A}
- {entry_name: oprm_rat, from_res: T, pubmed: '9927617', seq: '394', to_res: A}
- {entry_name: vipr1_human, from_res: T, pubmed: '9920725', seq: '343', to_res: K}
- {entry_name: vipr1_human, from_res: T, pubmed: '9920725', seq: '343', to_res: C}
- {entry_name: vipr1_human, from_res: T, pubmed: '9920725', seq: '343', to_res: P}
- {entry_name: vipr1_human, from_res: T, pubmed: '9920725', seq: '343', to_res: E}
- {entry_name: vipr1_human, from_res: T, pubmed: '9920725', seq: '343', to_res: A}
- {entry_name: vipr1_human, from_res: T, pubmed: '9920725', seq: '343', to_res: F}
- {entry_name: vipr1_human, from_res: E, pubmed: '9920725', seq: '36', to_res: A}
- {entry_name: vipr1_human, from_res: D, pubmed: '9920725', seq: '68', to_res: A}
- {entry_name: vipr1_human, from_res: D, pubmed: '9920725', seq: '132', to_res: A}
- {entry_name: acm2_pig, from_res: D, pubmed: '9882458', seq: '69', to_res: N}
- {entry_name: acm2_pig, from_res: D, pubmed: '9882458', seq: '97', to_res: N}
- {entry_name: v2r_human, from_res: D, pubmed: '9891993', seq: '136', to_res: A}
- {entry_name: lshr_rat, from_res: L, pubmed: '9857020', seq: '461', to_res: R}
- {entry_name: lshr_rat, from_res: D, pubmed: '9857020', seq: '582', to_res: Y}
- {entry_name: lshr_rat, from_res: Y, pubmed: '9857020', seq: '550', to_res: F}
- {entry_name: 5ht1b_human, from_res: S, pubmed: '9879059', seq: '212', to_res: A}
- {entry_name: 5ht1b_human, from_res: F, pubmed: '9879059', seq: '331', to_res: A}
- {entry_name: oprm_rat, from_res: C, pubmed: '9877183', seq: '351', to_res: A}
- {entry_name: gnrhr_rat, from_res: T, pubmed: '9828194', seq: '238', to_res: A}
- {entry_name: gnrhr_rat, from_res: S, pubmed: '9828194', seq: '253', to_res: A}
- {entry_name: gnrhr_rat, from_res: T, pubmed: '9828194', seq: '264', to_res: A}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '90', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '130', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '261', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '287', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '446', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '488', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '541', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '594', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '386', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '400', to_res: Q}
- {entry_name: casr_human, from_res: N, pubmed: '9852126', seq: '468', to_res: Q}
- {entry_name: cnr2_human, from_res: K, pubmed: '10051546', seq: '109', to_res: A}
- {entry_name: cnr2_human, from_res: K, pubmed: '10051546', seq: '109', to_res: R}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '10071787', seq: '104', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '10071787', seq: '108', to_res: A}
- {entry_name: v1ar_rat, from_res: K, pubmed: '10071787', seq: '128', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '10071787', seq: '131', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '10071787', seq: '185', to_res: A}
- {entry_name: v1ar_rat, from_res: T, pubmed: '10071787', seq: '223', to_res: A}
- {entry_name: v1ar_rat, from_res: Q, pubmed: '10071787', seq: '317', to_res: A}
- {entry_name: pe2r3_mouse, from_res: D, pubmed: '10082673', seq: '318', to_res: N}
- {entry_name: pe2r3_mouse, from_res: D, pubmed: '10082673', seq: '318', to_res: L}
- {entry_name: pf2r_rat, from_res: H, pubmed: '10025963', seq: '81', to_res: Q}
- {entry_name: pf2r_rat, from_res: H, pubmed: '10025963', seq: '81', to_res: D}
- {entry_name: pf2r_rat, from_res: H, pubmed: '10025963', seq: '81', to_res: R}
- {entry_name: pf2r_rat, from_res: H, pubmed: '10025963', seq: '81', to_res: G}
- {entry_name: pf2r_rat, from_res: H, pubmed: '10025963', seq: '81', to_res: A}
- {entry_name: aa1r_human, from_res: N, pubmed: '9920910', seq: '70', to_res: A}
- {entry_name: aa1r_human, from_res: Q, pubmed: '9920910', seq: '92', to_res: A}
- {entry_name: aa1r_human, from_res: V, pubmed: '9920910', seq: '87', to_res: A}
- {entry_name: aa1r_human, from_res: L, pubmed: '9920910', seq: '88', to_res: A}
- {entry_name: aa1r_human, from_res: T, pubmed: '9920910', seq: '91', to_res: A}
- {entry_name: drd1_human, from_res: P, pubmed: '10807903', seq: '412', to_res: I}
- {entry_name: drd1_human, from_res: P, pubmed: '10807903', seq: '412', to_res: A}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '843', to_res: E}
- {entry_name: fpr1_human, from_res: D, pubmed: '10823817', seq: '71', to_res: A}
- {entry_name: fpr1_human, from_res: R, pubmed: '10823817', seq: '123', to_res: G}
- {entry_name: oprx_rat, from_res: L, pubmed: '8943250', seq: '56', to_res: S}
- {entry_name: oprx_rat, from_res: A, pubmed: '8943250', seq: '213', to_res: K}
- {entry_name: oprx_rat, from_res: T, pubmed: '8943250', seq: '302', to_res: I}
- {entry_name: aa2ar_canfa, from_res: T, pubmed: '9020781', seq: '298', to_res: A}
- {entry_name: aa2ar_canfa, from_res: S, pubmed: '9020781', seq: '305', to_res: A}
- {entry_name: drd5_human, from_res: Q, pubmed: '10807903', seq: '439', to_res: A}
- {entry_name: drd5_human, from_res: Q, pubmed: '10807903', seq: '439', to_res: I}
- {entry_name: acm1_human, from_res: S, pubmed: '8463213', seq: '284', to_res: A}
- {entry_name: v2r_human, from_res: N, pubmed: '8999963', seq: '22', to_res: Q}
- {entry_name: v2r_human, from_res: R, pubmed: '8999963', seq: '137', to_res: H}
- {entry_name: ada2a_pig, from_res: D, pubmed: '8206950', seq: '79', to_res: N}
- {entry_name: ada2a_pig, from_res: Y, pubmed: '8206950', seq: '426', to_res: A}
- {entry_name: ada2a_pig, from_res: F, pubmed: '8206950', seq: '429', to_res: A}
- {entry_name: ada2a_pig, from_res: C, pubmed: '8206950', seq: '442', to_res: A}
- {entry_name: adrb1_human, from_res: L, pubmed: '10471797', seq: '323', to_res: I}
- {entry_name: adrb1_human, from_res: L, pubmed: '10471797', seq: '323', to_res: T}
- {entry_name: adrb1_human, from_res: L, pubmed: '10471797', seq: '323', to_res: E}
- {entry_name: adrb1_human, from_res: L, pubmed: '10471797', seq: '323', to_res: F}
- {entry_name: adrb1_human, from_res: L, pubmed: '10471797', seq: '323', to_res: C}
- {entry_name: adrb1_human, from_res: L, pubmed: '10471797', seq: '323', to_res: A}
- {entry_name: adrb1_human, from_res: L, pubmed: '10471797', seq: '323', to_res: K}
- {entry_name: glr_rat, from_res: H, pubmed: '10383462', seq: '178', to_res: R}
- {entry_name: ednrb_rat, from_res: F, pubmed: '10187821', seq: '331', to_res: A}
- {entry_name: ednrb_rat, from_res: C, pubmed: '10187821', seq: '334', to_res: A}
- {entry_name: ednrb_rat, from_res: W, pubmed: '10187821', seq: '335', to_res: A}
- {entry_name: ednrb_rat, from_res: P, pubmed: '10187821', seq: '337', to_res: A}
- {entry_name: ednrb_rat, from_res: S, pubmed: '10187821', seq: '341', to_res: K}
- {entry_name: ednrb_rat, from_res: K, pubmed: '10187821', seq: '345', to_res: A}
- {entry_name: ednrb_rat, from_res: M, pubmed: '10187821', seq: '299', to_res: A}
- {entry_name: ednrb_rat, from_res: Q, pubmed: '10187821', seq: '316', to_res: A}
- {entry_name: ednrb_rat, from_res: K, pubmed: '10187821', seq: '322', to_res: A}
- {entry_name: ednrb_rat, from_res: T, pubmed: '10187821', seq: '323', to_res: K}
- {entry_name: ednrb_rat, from_res: M, pubmed: '10187821', seq: '306', to_res: A}
- {entry_name: ednrb_rat, from_res: D, pubmed: '10187821', seq: '312', to_res: A}
- {entry_name: ednrb_rat, from_res: D, pubmed: '10187821', seq: '367', to_res: A}
- {entry_name: ednrb_rat, from_res: N, pubmed: '10187821', seq: '372', to_res: A}
- {entry_name: ednrb_rat, from_res: N, pubmed: '10187821', seq: '377', to_res: P}
- {entry_name: ednrb_rat, from_res: S, pubmed: '10187821', seq: '378', to_res: K}
- {entry_name: ednrb_rat, from_res: P, pubmed: '10187821', seq: '382', to_res: K}
- {entry_name: ednrb_rat, from_res: A, pubmed: '10187821', seq: '384', to_res: K}
- {entry_name: ednrb_rat, from_res: L, pubmed: '10187821', seq: '385', to_res: A}
- {entry_name: ednrb_rat, from_res: F, pubmed: '10187821', seq: '392', to_res: A}
- {entry_name: ednrb_rat, from_res: V, pubmed: '10187821', seq: '388', to_res: K}
- {entry_name: ednrb_rat, from_res: K, pubmed: '10187821', seq: '390', to_res: A}
- {entry_name: ednrb_rat, from_res: I, pubmed: '10187821', seq: '380', to_res: A}
- {entry_name: v2r_human, from_res: K, pubmed: '9792651', seq: '100', to_res: D}
- {entry_name: v2r_human, from_res: R, pubmed: '9792651', seq: '106', to_res: N}
- {entry_name: v2r_human, from_res: N, pubmed: '9792651', seq: '182', to_res: D}
- {entry_name: v2r_human, from_res: E, pubmed: '9792651', seq: '184', to_res: G}
- {entry_name: v2r_human, from_res: G, pubmed: '9792651', seq: '185', to_res: N}
- {entry_name: v2r_human, from_res: T, pubmed: '9792651', seq: '190', to_res: F}
- {entry_name: v2r_human, from_res: C, pubmed: '9792651', seq: '195', to_res: R}
- {entry_name: v2r_human, from_res: R, pubmed: '9792651', seq: '202', to_res: L}
- {entry_name: v2r_human, from_res: T, pubmed: '9792651', seq: '204', to_res: L}
- {entry_name: v2r_human, from_res: A, pubmed: '9792651', seq: '305', to_res: P}
- {entry_name: v2r_human, from_res: G, pubmed: '9792651', seq: '304', to_res: R}
- {entry_name: fshr_rat, from_res: D, pubmed: '9733722', seq: '407', to_res: N}
- {entry_name: fshr_rat, from_res: Y, pubmed: '9733722', seq: '548', to_res: F}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9287308', seq: '121', to_res: L}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9287308', seq: '121', to_res: A}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9287308', seq: '121', to_res: S}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9287308', seq: '121', to_res: T}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9287308', seq: '121', to_res: V}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9287308', seq: '121', to_res: W}
- {entry_name: opsd_bovin, from_res: G, pubmed: '9287308', seq: '121', to_res: I}
- {entry_name: opsd_bovin, from_res: F, pubmed: '9287308', seq: '261', to_res: A}
- {entry_name: opsd_bovin, from_res: F, pubmed: '9287308', seq: '261', to_res: T}
- {entry_name: opsd_bovin, from_res: F, pubmed: '9287308', seq: '261', to_res: V}
- {entry_name: opsd_bovin, from_res: F, pubmed: '9287308', seq: '261', to_res: W}
- {entry_name: opsd_bovin, from_res: E, pubmed: '9287308', seq: '113', to_res: A}
- {entry_name: oprm_rat, from_res: T, pubmed: '9312100', seq: '394', to_res: A}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '116', to_res: T}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '840', to_res: E}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '843', to_res: E}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '843', to_res: K}
- {entry_name: casr_human, from_res: A, pubmed: '10217436', seq: '843', to_res: V}
- {entry_name: adrb2_human, from_res: D, pubmed: '10385699', seq: '130', to_res: N}
- {entry_name: adrb2_human, from_res: D, pubmed: '10385699', seq: '130', to_res: A}
- {entry_name: adrb2_human, from_res: C, pubmed: '10385699', seq: '285', to_res: S}
- {entry_name: oxyr_human, from_res: R, pubmed: '10385703', seq: '137', to_res: A}
- {entry_name: oxyr_human, from_res: D, pubmed: '10385703', seq: '85', to_res: A}
- {entry_name: gasr_rat, from_res: L, pubmed: '9687578', seq: '113', to_res: A}
- {entry_name: gasr_rat, from_res: N, pubmed: '9687578', seq: '115', to_res: A}
- {entry_name: gasr_rat, from_res: L, pubmed: '9687578', seq: '116', to_res: A}
- {entry_name: gasr_rat, from_res: M, pubmed: '9687578', seq: '117', to_res: A}
- {entry_name: gasr_rat, from_res: G, pubmed: '9687578', seq: '118', to_res: K}
- {entry_name: gasr_rat, from_res: T, pubmed: '9687578', seq: '119', to_res: A}
- {entry_name: gasr_rat, from_res: F, pubmed: '9687578', seq: '120', to_res: A}
- {entry_name: gasr_rat, from_res: I, pubmed: '9687578', seq: '121', to_res: A}
- {entry_name: gasr_rat, from_res: F, pubmed: '9687578', seq: '122', to_res: A}
- {entry_name: gasr_rat, from_res: T, pubmed: '9687578', seq: '124', to_res: A}
- {entry_name: gasr_rat, from_res: V, pubmed: '9687578', seq: '125', to_res: A}
- {entry_name: gasr_rat, from_res: I, pubmed: '9687578', seq: '126', to_res: A}
- {entry_name: gasr_rat, from_res: E, pubmed: '9687578', seq: '51', to_res: A}
- {entry_name: gasr_rat, from_res: L, pubmed: '9687578', seq: '52', to_res: A}
- {entry_name: gasr_rat, from_res: E, pubmed: '9687578', seq: '53', to_res: A}
- {entry_name: gasr_rat, from_res: M, pubmed: '9687578', seq: '54', to_res: A}
- {entry_name: gasr_rat, from_res: A, pubmed: '9687578', seq: '55', to_res: L}
- {entry_name: gasr_rat, from_res: I, pubmed: '9687578', seq: '56', to_res: A}
- {entry_name: gasr_rat, from_res: R, pubmed: '9687578', seq: '57', to_res: A}
- {entry_name: gasr_rat, from_res: I, pubmed: '9687578', seq: '58', to_res: A}
- {entry_name: cckar_rat, from_res: F, pubmed: '9687578', seq: '213', to_res: A}
- {entry_name: cckar_rat, from_res: N, pubmed: '9687578', seq: '117', to_res: A}
- {entry_name: cckar_rat, from_res: L, pubmed: '9687578', seq: '118', to_res: A}
- {entry_name: cckar_rat, from_res: F, pubmed: '9687578', seq: '122', to_res: A}
- {entry_name: cckar_rat, from_res: F, pubmed: '9687578', seq: '124', to_res: A}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: G}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: S}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: P}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: V}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: L}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: I}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: E}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: K}
- {entry_name: gnrhr_human, from_res: A, pubmed: '9560319', seq: '261', to_res: F}
- {entry_name: cnr1_human, from_res: D, pubmed: '9580609', seq: '163', to_res: E}
- {entry_name: cnr1_human, from_res: D, pubmed: '9580609', seq: '163', to_res: N}
- {entry_name: cnr2_human, from_res: D, pubmed: '9580609', seq: '80', to_res: E}
- {entry_name: cnr2_human, from_res: D, pubmed: '9580609', seq: '80', to_res: N}
- {entry_name: 5ht2a_rat, from_res: C, pubmed: '9655845', seq: '322', to_res: K}
- {entry_name: 5ht2a_rat, from_res: C, pubmed: '9655845', seq: '322', to_res: E}
- {entry_name: 5ht2a_rat, from_res: C, pubmed: '9655845', seq: '322', to_res: R}
- {entry_name: gnrhr_human, from_res: F, pubmed: '9820623', seq: '272', to_res: L}
- {entry_name: gnrhr_human, from_res: F, pubmed: '9820623', seq: '272', to_res: Y}
- {entry_name: gnrhr_human, from_res: F, pubmed: '9820623', seq: '272', to_res: A}
- {entry_name: gnrhr_human, from_res: F, pubmed: '9820623', seq: '272', to_res: E}
- {entry_name: gnrhr_human, from_res: F, pubmed: '9820623', seq: '272', to_res: K}
- {entry_name: gnrhr_human, from_res: F, pubmed: '9820623', seq: '276', to_res: L}
- {entry_name: gnrhr_human, from_res: F, pubmed: '9820623', seq: '276', to_res: Y}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: H}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: A}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: F}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: P}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: S}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: W}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: K}
- {entry_name: tshr_human, from_res: H, pubmed: '9806755', seq: '601', to_res: D}
- {entry_name: tshr_human, from_res: Y, pubmed: '9806755', seq: '605', to_res: A}
- {entry_name: tshr_human, from_res: Y, pubmed: '9806755', seq: '605', to_res: H}
- {entry_name: tshr_human, from_res: A, pubmed: '9806755', seq: '623', to_res: Y}
- {entry_name: ccr5_human, from_res: S, pubmed: '10085131', seq: '336', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10085131', seq: '337', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10085131', seq: '342', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10085131', seq: '349', to_res: A}
- {entry_name: cxcr4_human, from_res: Y, pubmed: '10074102', seq: '184', to_res: A}
- {entry_name: cxcr4_human, from_res: I, pubmed: '10074102', seq: '185', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '187', to_res: A}
- {entry_name: cxcr4_human, from_res: R, pubmed: '10074102', seq: '188', to_res: A}
- {entry_name: cxcr4_human, from_res: F, pubmed: '10074102', seq: '199', to_res: G}
- {entry_name: cxcr4_human, from_res: F, pubmed: '10074102', seq: '201', to_res: L}
- {entry_name: cxcr4_human, from_res: N, pubmed: '10074102', seq: '176', to_res: D}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '182', to_res: G}
- {entry_name: cxcr4_human, from_res: F, pubmed: '10074102', seq: '189', to_res: L}
- {entry_name: cxcr4_human, from_res: N, pubmed: '10074102', seq: '192', to_res: D}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '193', to_res: S}
- {entry_name: cxcr4_human, from_res: V, pubmed: '10074102', seq: '196', to_res: M}
- {entry_name: cxcr4_rat, from_res: D, pubmed: '10074102', seq: '173', to_res: N}
- {entry_name: cxcr4_rat, from_res: M, pubmed: '10074102', seq: '193', to_res: V}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '193', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '193', to_res: E}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '193', to_res: N}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '193', to_res: R}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10074102', seq: '181', to_res: A}
- {entry_name: cxcr4_human, from_res: R, pubmed: '10074102', seq: '183', to_res: A}
- {entry_name: acm3_rat, from_res: C, pubmed: '10347230', seq: '111', to_res: S}
- {entry_name: acm3_rat, from_res: I, pubmed: '10347230', seq: '169', to_res: C}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '310', to_res: A}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '310', to_res: L}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '311', to_res: A}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '311', to_res: L}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '303', to_res: A}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '303', to_res: L}
- {entry_name: ada1b_mesau, from_res: Y, pubmed: '10347189', seq: '348', to_res: L}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '310', to_res: C}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '311', to_res: C}
- {entry_name: ada1b_mesau, from_res: F, pubmed: '10347189', seq: '310', to_res: W}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '10347189', seq: '293', to_res: E}
- {entry_name: ssr1_mouse, from_res: D, pubmed: '10329447', seq: '137', to_res: N}
- {entry_name: ssr1_mouse, from_res: L, pubmed: '10329447', seq: '107', to_res: F}
- {entry_name: adrb2_human, from_res: C, pubmed: '10405763', seq: '341', to_res: G}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10212257', seq: '339', to_res: A}
- {entry_name: bkrb2_human, from_res: T, pubmed: '10212257', seq: '342', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10212257', seq: '346', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '9880506', seq: '505', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '9880506', seq: '540', to_res: A}
- {entry_name: acm3_rat, from_res: P, pubmed: '9880506', seq: '242', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, pubmed: '9880506', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '502', to_res: A}
- {entry_name: acm3_rat, from_res: T, pubmed: '9880506', seq: '537', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9927627', seq: '142', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '9927627', seq: '142', to_res: T}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '9927627', seq: '293', to_res: E}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '9927627', seq: '293', to_res: I}
- {entry_name: oprk_rat, from_res: E, pubmed: '9836606', seq: '297', to_res: K}
- {entry_name: oprm_rat, from_res: K, pubmed: '9836606', seq: '303', to_res: E}
- {entry_name: v2r_human, from_res: S, pubmed: '10071767', seq: '363', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10383387', seq: '20', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10383387', seq: '269', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10383387', seq: '101', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10383387', seq: '178', to_res: A}
- {entry_name: ccr2_human, from_res: Y, pubmed: '9670957', seq: '139', to_res: F}
- {entry_name: opsd_bovin, from_res: D, pubmed: '2111169', seq: '83', to_res: G}
- {entry_name: opsd_bovin, from_res: D, pubmed: '2111169', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: M, pubmed: '2111169', seq: '86', to_res: E}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2111169', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2111169', seq: '122', to_res: I}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2111169', seq: '134', to_res: I}
- {entry_name: opsd_bovin, from_res: E, pubmed: '2111169', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: R, pubmed: '2111169', seq: '135', to_res: L}
- {entry_name: opsd_bovin, from_res: H, pubmed: '2111169', seq: '211', to_res: C}
- {entry_name: opsd_bovin, from_res: H, pubmed: '2111169', seq: '211', to_res: F}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '5', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '25', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '33', to_res: Q}
- {entry_name: opsd_bovin, from_res: D, pubmed: '1980212', seq: '83', to_res: N}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '113', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '122', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '134', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '150', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '181', to_res: Q}
- {entry_name: opsd_bovin, from_res: D, pubmed: '1980212', seq: '190', to_res: N}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '196', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '197', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '201', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '232', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '239', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '247', to_res: Q}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '249', to_res: Q}
- {entry_name: opsd_bovin, from_res: D, pubmed: '1980212', seq: '282', to_res: N}
- {entry_name: opsd_bovin, from_res: E, pubmed: '1980212', seq: '341', to_res: Q}
- {entry_name: 5ht1b_human, from_res: I, pubmed: '8863519', seq: '333', to_res: K}
- {entry_name: 5ht1b_human, from_res: S, pubmed: '8863519', seq: '334', to_res: E}
- {entry_name: p2ry1_human, from_res: R, pubmed: '9281613', seq: '128', to_res: A}
- {entry_name: p2ry1_human, from_res: F, pubmed: '9281613', seq: '131', to_res: A}
- {entry_name: p2ry1_human, from_res: H, pubmed: '9281613', seq: '132', to_res: A}
- {entry_name: p2ry1_human, from_res: Y, pubmed: '9281613', seq: '136', to_res: A}
- {entry_name: p2ry1_human, from_res: T, pubmed: '9281613', seq: '221', to_res: A}
- {entry_name: p2ry1_human, from_res: T, pubmed: '9281613', seq: '222', to_res: A}
- {entry_name: p2ry1_human, from_res: F, pubmed: '9281613', seq: '226', to_res: A}
- {entry_name: p2ry1_human, from_res: H, pubmed: '9281613', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: K, pubmed: '9281613', seq: '280', to_res: A}
- {entry_name: p2ry1_human, from_res: Q, pubmed: '9281613', seq: '307', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '9281613', seq: '310', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '9281613', seq: '310', to_res: K}
- {entry_name: p2ry1_human, from_res: S, pubmed: '9281613', seq: '314', to_res: A}
- {entry_name: p2ry1_human, from_res: S, pubmed: '9281613', seq: '314', to_res: T}
- {entry_name: p2ry1_human, from_res: S, pubmed: '9281613', seq: '317', to_res: A}
- {entry_name: 5ht1d_human, from_res: S, pubmed: '9855638', seq: '196', to_res: L}
- {entry_name: 5ht1d_human, from_res: I, pubmed: '9855638', seq: '199', to_res: V}
- {entry_name: 5ht1d_human, from_res: C, pubmed: '9855638', seq: '203', to_res: V}
- {entry_name: 5ht1d_human, from_res: I, pubmed: '9855638', seq: '208', to_res: F}
- {entry_name: ada2a_human, from_res: C, pubmed: '10419505', seq: '201', to_res: S}
- {entry_name: adrb2_human, from_res: N, pubmed: '10535920', seq: '312', to_res: H}
- {entry_name: adrb2_human, from_res: N, pubmed: '10535920', seq: '312', to_res: C}
- {entry_name: adrb2_human, from_res: D, pubmed: '10535920', seq: '113', to_res: A}
- {entry_name: adrb2_human, from_res: D, pubmed: '10535920', seq: '113', to_res: C}
- {entry_name: adrb2_human, from_res: D, pubmed: '10535920', seq: '113', to_res: H}
- {entry_name: ada1a_rat, from_res: F, pubmed: '10766790', seq: '163', to_res: Q}
- {entry_name: ada1a_rat, from_res: F, pubmed: '10766790', seq: '187', to_res: A}
- {entry_name: adrb2_mesau, from_res: Q, pubmed: '10766790', seq: '170', to_res: F}
- {entry_name: adrb2_mesau, from_res: A, pubmed: '10766790', seq: '202', to_res: F}
- {entry_name: 5ht1b_human, from_res: C, pubmed: '10513577', seq: '326', to_res: A}
- {entry_name: 5ht1b_human, from_res: D, pubmed: '10513577', seq: '352', to_res: A}
- {entry_name: 5ht1b_human, from_res: W, pubmed: '10513577', seq: '327', to_res: A}
- {entry_name: 5ht2a_rat, from_res: C, pubmed: '9928250', seq: '322', to_res: K}
- {entry_name: 5ht2c_rat, from_res: S, pubmed: '9928251', seq: '312', to_res: K}
- {entry_name: 5ht2a_rat, from_res: D, pubmed: '10869371', seq: '155', to_res: A}
- {entry_name: 5ht2a_rat, from_res: D, pubmed: '10869371', seq: '155', to_res: E}
- {entry_name: 5ht2a_rat, from_res: D, pubmed: '10869371', seq: '155', to_res: N}
- {entry_name: 5ht2a_rat, from_res: D, pubmed: '10869371', seq: '155', to_res: Q}
- {entry_name: 5ht2a_rat, from_res: N, pubmed: '10869371', seq: '363', to_res: A}
- {entry_name: 5ht1d_cavpo, from_res: T, pubmed: '10385247', seq: '100', to_res: I}
- {entry_name: 5ht1d_cavpo, from_res: R, pubmed: '10385247', seq: '102', to_res: H}
- {entry_name: 5ht1d_cavpo, from_res: A, pubmed: '10385247', seq: '222', to_res: R}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: H}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: V}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: W}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: T}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: D}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: I}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: N}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: C}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: E}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: Y}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: P}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: M}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: S}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: G}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: L}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: F}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: A}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: K}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: Q}
- {entry_name: 5ht1b_human, from_res: T, pubmed: '10510311', seq: '313', to_res: R}
- {entry_name: 5ht2c_rat, from_res: S, pubmed: '10816555', seq: '458', to_res: A}
- {entry_name: 5ht2c_rat, from_res: S, pubmed: '10816555', seq: '459', to_res: A}
- {entry_name: 5ht4r_mouse, from_res: A, pubmed: '10220570', seq: '258', to_res: L}
- {entry_name: 5ht2c_rat, from_res: S, pubmed: '10991983', seq: '312', to_res: K}
- {entry_name: 5ht1a_human, from_res: V, pubmed: '10936212', seq: '344', to_res: E}
- {entry_name: 5ht1d_canfa, from_res: Q, pubmed: '10936201', seq: '189', to_res: L}
- {entry_name: 5ht1d_human, from_res: L, pubmed: '10936201', seq: '189', to_res: Q}
- {entry_name: drd2_human, from_res: W, pubmed: '10570038', seq: '90', to_res: L}
- {entry_name: drd2_human, from_res: V, pubmed: '10570038', seq: '91', to_res: F}
- {entry_name: drd2_human, from_res: L, pubmed: '10570038', seq: '94', to_res: S}
- {entry_name: drd2_human, from_res: F, pubmed: '10570038', seq: '110', to_res: L}
- {entry_name: drd2_human, from_res: V, pubmed: '10570038', seq: '111', to_res: M}
- {entry_name: drd2_human, from_res: F, pubmed: '10570038', seq: '189', to_res: Y}
- {entry_name: drd2_human, from_res: V, pubmed: '10570038', seq: '196', to_res: C}
- {entry_name: drd2_human, from_res: T, pubmed: '10570038', seq: '392', to_res: V}
- {entry_name: drd2_human, from_res: Y, pubmed: '10570038', seq: '408', to_res: V}
- {entry_name: drd2_human, from_res: F, pubmed: '10570038', seq: '411', to_res: V}
- {entry_name: drd4_human, from_res: V, pubmed: '10570038', seq: '350', to_res: Y}
- {entry_name: drd2_human, from_res: C, pubmed: '10387039', seq: '118', to_res: S}
- {entry_name: drd4_rat, from_res: M, pubmed: '10617689', seq: '107', to_res: V}
- {entry_name: drd4_rat, from_res: L, pubmed: '10617689', seq: '87', to_res: W}
- {entry_name: drd4_rat, from_res: F, pubmed: '10617689', seq: '88', to_res: V}
- {entry_name: drd4_rat, from_res: S, pubmed: '10617689', seq: '91', to_res: L}
- {entry_name: adrb2_human, from_res: D, pubmed: '10385699', seq: '130', to_res: N}
- {entry_name: adrb2_human, from_res: D, pubmed: '10385699', seq: '130', to_res: A}
- {entry_name: hrh1_cavpo, from_res: W, pubmed: '10514483', seq: '161', to_res: A}
- {entry_name: hrh1_cavpo, from_res: W, pubmed: '10514483', seq: '161', to_res: M}
- {entry_name: hrh1_cavpo, from_res: W, pubmed: '10514483', seq: '161', to_res: F}
- {entry_name: hrh1_cavpo, from_res: W, pubmed: '10514483', seq: '167', to_res: A}
- {entry_name: hrh1_cavpo, from_res: W, pubmed: '10514483', seq: '167', to_res: M}
- {entry_name: hrh1_cavpo, from_res: W, pubmed: '10514483', seq: '167', to_res: F}
- {entry_name: hrh1_cavpo, from_res: W, pubmed: '10514483', seq: '174', to_res: A}
- {entry_name: hrh1_cavpo, from_res: F, pubmed: '10514483', seq: '433', to_res: A}
- {entry_name: hrh1_cavpo, from_res: F, pubmed: '10514483', seq: '433', to_res: M}
- {entry_name: hrh1_cavpo, from_res: F, pubmed: '10514483', seq: '435', to_res: A}
- {entry_name: hrh1_cavpo, from_res: F, pubmed: '10514483', seq: '436', to_res: A}
- {entry_name: hrh1_cavpo, from_res: F, pubmed: '10514483', seq: '436', to_res: M}
- {entry_name: hrh1_cavpo, from_res: K, pubmed: '10514483', seq: '200', to_res: A}
- {entry_name: hrh1_cavpo, from_res: K, pubmed: '10514483', seq: '200', to_res: M}
- {entry_name: hrh1_cavpo, from_res: K, pubmed: '10514483', seq: '200', to_res: M}
- {entry_name: adrb2_human, from_res: D, pubmed: '10652295', seq: '130', to_res: A}
- {entry_name: adrb2_human, from_res: E, pubmed: '10652295', seq: '268', to_res: A}
- {entry_name: adrb2_human, from_res: E, pubmed: '10652295', seq: '122', to_res: A}
- {entry_name: ada2a_human, from_res: C, pubmed: '10438518', seq: '201', to_res: S}
- {entry_name: ada2a_human, from_res: C, pubmed: '10737629', seq: '201', to_res: S}
- {entry_name: ada2a_mouse, from_res: S, pubmed: '10737629', seq: '201', to_res: C}
- {entry_name: drd3_human, from_res: C, pubmed: '9831905', seq: '114', to_res: S}
- {entry_name: drd4_human, from_res: C, pubmed: '9831905', seq: '119', to_res: S}
- {entry_name: drd5_human, from_res: N, pubmed: '10531415', seq: '7', to_res: Q}
- {entry_name: drd5_human, from_res: N, pubmed: '10531415', seq: '7', to_res: T}
- {entry_name: drd5_human, from_res: N, pubmed: '10531415', seq: '199', to_res: T}
- {entry_name: drd5_human, from_res: N, pubmed: '10531415', seq: '222', to_res: Q}
- {entry_name: drd1_human, from_res: N, pubmed: '10531415', seq: '5', to_res: Q}
- {entry_name: drd5_human, from_res: T, pubmed: '10531415', seq: '9', to_res: V}
- {entry_name: drd2_human, from_res: D, pubmed: '10860933', seq: '114', to_res: N}
- {entry_name: drd1_rat, from_res: T, pubmed: '10496949', seq: '135', to_res: V}
- {entry_name: drd1_rat, from_res: S, pubmed: '10496949', seq: '229', to_res: A}
- {entry_name: drd1_rat, from_res: T, pubmed: '10496949', seq: '268', to_res: V}
- {entry_name: drd1_rat, from_res: S, pubmed: '10496949', seq: '380', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '10574914', seq: '125', to_res: K}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10574914', seq: '331', to_res: D}
- {entry_name: ada1b_mesau, from_res: S, pubmed: '10727513', seq: '369', to_res: A}
- {entry_name: ada1b_mesau, from_res: C, pubmed: '10727513', seq: '367', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '10908313', seq: '142', to_res: A}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '10908313', seq: '293', to_res: E}
- {entry_name: 5ht2a_rat, from_res: S, pubmed: '11040033', seq: '239', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '11040033', seq: '240', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '11040033', seq: '243', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, pubmed: '11040033', seq: '244', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: G}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: F}
- {entry_name: ccr5_human, from_res: D, pubmed: '10779565', seq: '2', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '96', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '98', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '99', to_res: A}
- {entry_name: ccr5_human, from_res: M, pubmed: '10779565', seq: '100', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10779565', seq: '101', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '102', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '10779565', seq: '168', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '169', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '170', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '10779565', seq: '175', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '176', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '177', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10779565', seq: '178', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '179', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '180', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '10779565', seq: '181', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '182', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '10779565', seq: '183', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '184', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '185', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '186', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '187', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '188', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '189', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '3', to_res: A}
- {entry_name: ccr5_human, from_res: W, pubmed: '10779565', seq: '190', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '193', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '194', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '10779565', seq: '262', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '263', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '264', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '267', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '268', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10779565', seq: '269', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '270', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '271', to_res: A}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '9169425', seq: '131', to_res: A}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '9169425', seq: '131', to_res: S}
- {entry_name: bkrb2_rat, from_res: Y, pubmed: '9169425', seq: '131', to_res: F}
- {entry_name: bkrb2_rat, from_res: V, pubmed: '9169425', seq: '321', to_res: A}
- {entry_name: agtr2_rat, from_res: K, pubmed: '9537673', seq: '215', to_res: E}
- {entry_name: agtr2_rat, from_res: K, pubmed: '9537673', seq: '215', to_res: Q}
- {entry_name: agtr2_rat, from_res: K, pubmed: '9537673', seq: '215', to_res: A}
- {entry_name: agtr2_rat, from_res: K, pubmed: '9537673', seq: '215', to_res: R}
- {entry_name: agtr2_mouse, from_res: Y, pubmed: '9652982', seq: '108', to_res: A}
- {entry_name: agtr2_mouse, from_res: R, pubmed: '9652982', seq: '182', to_res: A}
- {entry_name: agtr2_mouse, from_res: D, pubmed: '9652982', seq: '297', to_res: A}
- {entry_name: gnrr2_claga, from_res: D, pubmed: '9299543', seq: '321', to_res: N}
- {entry_name: gnrr2_claga, from_res: D, pubmed: '9299543', seq: '90', to_res: N}
- {entry_name: nk1r_human, from_res: E, pubmed: '9389383', seq: '97', to_res: V}
- {entry_name: nk1r_human, from_res: H, pubmed: '9389383', seq: '108', to_res: A}
- {entry_name: nk1r_human, from_res: A, pubmed: '9389383', seq: '162', to_res: L}
- {entry_name: nk1r_human, from_res: Q, pubmed: '9389383', seq: '165', to_res: A}
- {entry_name: nk1r_human, from_res: T, pubmed: '9389383', seq: '170', to_res: A}
- {entry_name: nk1r_human, from_res: E, pubmed: '9389383', seq: '172', to_res: Q}
- {entry_name: nk1r_human, from_res: E, pubmed: '9389383', seq: '193', to_res: Q}
- {entry_name: nk1r_human, from_res: H, pubmed: '9389383', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '9389383', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '9389383', seq: '268', to_res: A}
- {entry_name: nk1r_human, from_res: Q, pubmed: '9389383', seq: '284', to_res: A}
- {entry_name: agtr1_human, from_res: A, pubmed: '9606715', seq: '221', to_res: E}
- {entry_name: agtr1_human, from_res: A, pubmed: '9606715', seq: '221', to_res: Q}
- {entry_name: agtr1_human, from_res: L, pubmed: '9606715', seq: '222', to_res: R}
- {entry_name: agtr1_human, from_res: L, pubmed: '9606715', seq: '222', to_res: Q}
- {entry_name: nk1r_human, from_res: P, pubmed: '9443945', seq: '112', to_res: A}
- {entry_name: nk1r_human, from_res: P, pubmed: '9443945', seq: '112', to_res: D}
- {entry_name: nk1r_human, from_res: P, pubmed: '9443945', seq: '112', to_res: H}
- {entry_name: nk1r_human, from_res: A, pubmed: '9443945', seq: '115', to_res: V}
- {entry_name: nk1r_human, from_res: T, pubmed: '9443945', seq: '201', to_res: A}
- {entry_name: nk1r_human, from_res: T, pubmed: '9443945', seq: '201', to_res: I}
- {entry_name: nk1r_human, from_res: T, pubmed: '9443945', seq: '201', to_res: H}
- {entry_name: nk1r_human, from_res: F, pubmed: '9443945', seq: '268', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '9443945', seq: '268', to_res: W}
- {entry_name: nk1r_human, from_res: F, pubmed: '9443945', seq: '268', to_res: H}
- {entry_name: nk1r_human, from_res: A, pubmed: '9443945', seq: '294', to_res: V}
- {entry_name: agtr2_rat, from_res: K, pubmed: '9427526', seq: '215', to_res: Q}
- {entry_name: nk1r_human, from_res: G, pubmed: '9373180', seq: '166', to_res: C}
- {entry_name: nk1r_human, from_res: Y, pubmed: '9373180', seq: '167', to_res: F}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '9537328', seq: '318', to_res: N}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '9259312', seq: '138', to_res: N}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '9259312', seq: '138', to_res: E}
- {entry_name: gnrhr_mouse, from_res: R, pubmed: '9259312', seq: '139', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: R, pubmed: '9259312', seq: '139', to_res: S}
- {entry_name: gnrhr_mouse, from_res: R, pubmed: '9259312', seq: '139', to_res: A}
- {entry_name: gnrhr_mouse, from_res: S, pubmed: '9259312', seq: '140', to_res: A}
- {entry_name: nk1r_human, from_res: W, pubmed: '9547942', seq: '155', to_res: A}
- {entry_name: nk1r_human, from_res: W, pubmed: '9547942', seq: '155', to_res: F}
- {entry_name: nk1r_human, from_res: Q, pubmed: '9547942', seq: '165', to_res: A}
- {entry_name: nk1r_human, from_res: E, pubmed: '9547942', seq: '193', to_res: A}
- {entry_name: nk1r_human, from_res: E, pubmed: '9547942', seq: '193', to_res: K}
- {entry_name: nk1r_human, from_res: H, pubmed: '9547942', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '9547942', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, pubmed: '9547942', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: F, pubmed: '9547942', seq: '264', to_res: A}
- {entry_name: nk1r_human, from_res: H, pubmed: '9547942', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: F, pubmed: '9547942', seq: '267', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '9547942', seq: '272', to_res: A}
- {entry_name: nk1r_human, from_res: I, pubmed: '9547942', seq: '283', to_res: A}
- {entry_name: nk1r_human, from_res: Y, pubmed: '9547942', seq: '287', to_res: F}
- {entry_name: agtrb_rat, from_res: V, pubmed: '8982494', seq: '108', to_res: I}
- {entry_name: agtrb_rat, from_res: V, pubmed: '8982494', seq: '108', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '375', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '375', to_res: S}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '409', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '409', to_res: S}
- {entry_name: gabr1_rat, from_res: Q, pubmed: '10224098', seq: '188', to_res: A}
- {entry_name: gabr1_rat, from_res: E, pubmed: '10224098', seq: '192', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10224098', seq: '246', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10224098', seq: '247', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10224098', seq: '249', to_res: A}
- {entry_name: gabr1_rat, from_res: T, pubmed: '10224098', seq: '250', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10224098', seq: '268', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10224098', seq: '269', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10224098', seq: '270', to_res: A}
- {entry_name: gabr1_rat, from_res: T, pubmed: '10224098', seq: '310', to_res: A}
- {entry_name: gabr1_rat, from_res: Q, pubmed: '10224098', seq: '312', to_res: A}
- {entry_name: gabr1_rat, from_res: Q, pubmed: '10224098', seq: '313', to_res: A}
- {entry_name: gabr1_rat, from_res: T, pubmed: '10224098', seq: '314', to_res: A}
- {entry_name: gabr1_rat, from_res: T, pubmed: '10224098', seq: '315', to_res: A}
- {entry_name: gabr1_rat, from_res: E, pubmed: '10224098', seq: '316', to_res: A}
- {entry_name: gabr1_rat, from_res: E, pubmed: '10224098', seq: '458', to_res: A}
- {entry_name: gabr1_rat, from_res: E, pubmed: '10224098', seq: '459', to_res: A}
- {entry_name: gabr1_rat, from_res: T, pubmed: '10224098', seq: '460', to_res: A}
- {entry_name: gabr1_rat, from_res: Q, pubmed: '10224098', seq: '464', to_res: A}
- {entry_name: gabr1_rat, from_res: Y, pubmed: '10224098', seq: '470', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '187', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '187', to_res: S}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '219', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '219', to_res: S}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '245', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10224098', seq: '245', to_res: S}
- {entry_name: grm4_rat, from_res: R, pubmed: '10559233', seq: '78', to_res: A}
- {entry_name: grm4_rat, from_res: S, pubmed: '10559233', seq: '157', to_res: A}
- {entry_name: grm4_rat, from_res: S, pubmed: '10559233', seq: '159', to_res: A}
- {entry_name: grm4_rat, from_res: S, pubmed: '10559233', seq: '160', to_res: A}
- {entry_name: grm4_rat, from_res: S, pubmed: '10559233', seq: '181', to_res: A}
- {entry_name: grm4_rat, from_res: T, pubmed: '10559233', seq: '182', to_res: A}
- {entry_name: acm1_rat, from_res: I, pubmed: '10860940', seq: '188', to_res: C}
- {entry_name: acm1_rat, from_res: I, pubmed: '10860940', seq: '188', to_res: A}
- {entry_name: acm1_rat, from_res: T, pubmed: '10860940', seq: '189', to_res: C}
- {entry_name: acm1_rat, from_res: T, pubmed: '10860940', seq: '189', to_res: S}
- {entry_name: acm1_rat, from_res: F, pubmed: '10860940', seq: '190', to_res: C}
- {entry_name: acm1_rat, from_res: F, pubmed: '10860940', seq: '190', to_res: A}
- {entry_name: acm1_rat, from_res: G, pubmed: '10860940', seq: '191', to_res: C}
- {entry_name: acm1_rat, from_res: G, pubmed: '10860940', seq: '191', to_res: A}
- {entry_name: acm1_rat, from_res: T, pubmed: '10860940', seq: '192', to_res: C}
- {entry_name: acm1_rat, from_res: T, pubmed: '10860940', seq: '192', to_res: A}
- {entry_name: acm1_rat, from_res: A, pubmed: '10860940', seq: '193', to_res: C}
- {entry_name: acm1_rat, from_res: A, pubmed: '10860940', seq: '193', to_res: G}
- {entry_name: acm1_rat, from_res: M, pubmed: '10860940', seq: '194', to_res: C}
- {entry_name: acm1_rat, from_res: A, pubmed: '10860940', seq: '195', to_res: C}
- {entry_name: acm1_rat, from_res: A, pubmed: '10860940', seq: '195', to_res: G}
- {entry_name: acm1_rat, from_res: A, pubmed: '10860940', seq: '196', to_res: C}
- {entry_name: acm1_rat, from_res: A, pubmed: '10860940', seq: '196', to_res: G}
- {entry_name: grm1_rat, from_res: R, pubmed: '10844121', seq: '78', to_res: L}
- {entry_name: grm1_rat, from_res: R, pubmed: '10844121', seq: '78', to_res: E}
- {entry_name: 5ht4r_human, from_res: D, pubmed: '10821780', seq: '66', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, pubmed: '10821780', seq: '100', to_res: N}
- {entry_name: 5ht4r_human, from_res: P, pubmed: '10821780', seq: '149', to_res: A}
- {entry_name: 5ht4r_human, from_res: T, pubmed: '10821780', seq: '150', to_res: V}
- {entry_name: 5ht4r_human, from_res: S, pubmed: '10821780', seq: '153', to_res: A}
- {entry_name: 5ht4r_human, from_res: C, pubmed: '10821780', seq: '196', to_res: A}
- {entry_name: 5ht4r_human, from_res: S, pubmed: '10821780', seq: '197', to_res: A}
- {entry_name: 5ht4r_human, from_res: F, pubmed: '10821780', seq: '275', to_res: A}
- {entry_name: 5ht4r_human, from_res: F, pubmed: '10821780', seq: '276', to_res: V}
- {entry_name: 5ht4r_human, from_res: N, pubmed: '10821780', seq: '279', to_res: L}
- {entry_name: 5ht4r_human, from_res: Y, pubmed: '10821780', seq: '302', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '272', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '273', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '277', to_res: A}
- {entry_name: ccr5_human, from_res: R, pubmed: '10779565', seq: '31', to_res: A}
- {entry_name: ccr5_human, from_res: L, pubmed: '10779565', seq: '33', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '37', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '41', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '48', to_res: A}
- {entry_name: ccr5_human, from_res: I, pubmed: '10779565', seq: '52', to_res: A}
- {entry_name: ccr5_human, from_res: L, pubmed: '10779565', seq: '55', to_res: A}
- {entry_name: ccr5_human, from_res: I, pubmed: '10779565', seq: '56', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '68', to_res: A}
- {entry_name: ccr5_human, from_res: L, pubmed: '10779565', seq: '69', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '4', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '71', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '10779565', seq: '76', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '79', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '82', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '85', to_res: A}
- {entry_name: ccr5_human, from_res: W, pubmed: '10779565', seq: '86', to_res: A}
- {entry_name: ccr5_human, from_res: L, pubmed: '10779565', seq: '104', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '105', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '108', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '112', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '113', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '117', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '118', to_res: A}
- {entry_name: ccr5_human, from_res: L, pubmed: '10779565', seq: '121', to_res: A}
- {entry_name: ccr5_human, from_res: L, pubmed: '10779565', seq: '122', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '123', to_res: A}
- {entry_name: ccr5_human, from_res: F, pubmed: '10779565', seq: '144', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '195', to_res: A}
- {entry_name: ccr5_human, from_res: I, pubmed: '10779565', seq: '198', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '251', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '252', to_res: A}
- {entry_name: ccr5_human, from_res: L, pubmed: '10779565', seq: '255', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '258', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '259', to_res: A}
- {entry_name: ccr5_human, from_res: M, pubmed: '10779565', seq: '279', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '10779565', seq: '283', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '6', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '10779565', seq: '289', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '293', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '297', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '7', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '10779565', seq: '8', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '10', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '10779565', seq: '11', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '13', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '14', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '15', to_res: A}
- {entry_name: ccr5_human, from_res: T, pubmed: '10779565', seq: '16', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10779565', seq: '17', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '10779565', seq: '18', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '10779565', seq: '19', to_res: A}
- {entry_name: ccr5_human, from_res: C, pubmed: '10779565', seq: '20', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '21', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '10779565', seq: '22', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10779565', seq: '24', to_res: A}
- {entry_name: ccr5_human, from_res: K, pubmed: '10779565', seq: '26', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '27', to_res: A}
- {entry_name: ccr5_human, from_res: H, pubmed: '10779565', seq: '88', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10779565', seq: '89', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10779565', seq: '93', to_res: A}
- {entry_name: ccr5_human, from_res: W, pubmed: '10779565', seq: '94', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '10779565', seq: '95', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '10574939', seq: '2', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10574939', seq: '3', to_res: A}
- {entry_name: ccr5_human, from_res: Q, pubmed: '10574939', seq: '4', to_res: A}
- {entry_name: ccr5_human, from_res: V, pubmed: '10574939', seq: '5', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10574939', seq: '6', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10574939', seq: '7', to_res: A}
- {entry_name: ccr5_human, from_res: P, pubmed: '10574939', seq: '8', to_res: A}
- {entry_name: ccr5_human, from_res: I, pubmed: '10574939', seq: '9', to_res: A}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10574939', seq: '10', to_res: A}
- {entry_name: ccr5_human, from_res: D, pubmed: '10574939', seq: '11', to_res: A}
- {entry_name: ccr5_human, from_res: I, pubmed: '10574939', seq: '12', to_res: A}
- {entry_name: ccr5_human, from_res: N, pubmed: '10574939', seq: '13', to_res: A}
- {entry_name: ccr5_human, from_res: E, pubmed: '10574939', seq: '18', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10602038', seq: '6', to_res: P}
- {entry_name: ccr5_human, from_res: Y, pubmed: '10602038', seq: '10', to_res: G}
- {entry_name: ccr5_human, from_res: K, pubmed: '10602038', seq: '26', to_res: G}
- {entry_name: ccr5_human, from_res: R, pubmed: '10602038', seq: '31', to_res: G}
- {entry_name: ccr5_human, from_res: T, pubmed: '10602038', seq: '167', to_res: W}
- {entry_name: ccr5_human, from_res: S, pubmed: '10602038', seq: '180', to_res: V}
- {entry_name: ccr5_human, from_res: S, pubmed: '10602038', seq: '185', to_res: R}
- {entry_name: ccr5_human, from_res: I, pubmed: '10347178', seq: '12', to_res: T}
- {entry_name: ccr5_human, from_res: C, pubmed: '10347178', seq: '20', to_res: S}
- {entry_name: ccr5_human, from_res: A, pubmed: '10347178', seq: '29', to_res: S}
- {entry_name: ccr5_human, from_res: I, pubmed: '10347178', seq: '42', to_res: F}
- {entry_name: ccr5_human, from_res: L, pubmed: '10347178', seq: '55', to_res: Q}
- {entry_name: ccr5_human, from_res: A, pubmed: '10347178', seq: '73', to_res: V}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10827088', seq: '187', to_res: A}
- {entry_name: ccr5_human, from_res: S, pubmed: '10827088', seq: '179', to_res: D}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10692480', seq: '247', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10692480', seq: '268', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10692480', seq: '269', to_res: A}
- {entry_name: cxcr2_human, from_res: D, pubmed: '10438939', seq: '143', to_res: V}
- {entry_name: cxcr2_human, from_res: D, pubmed: '10438939', seq: '143', to_res: Q}
- {entry_name: cxcr1_human, from_res: D, pubmed: '10438939', seq: '134', to_res: V}
- {entry_name: vg74_hhv8, from_res: C, pubmed: '10531332', seq: '39', to_res: A}
- {entry_name: vg74_hhv8, from_res: C, pubmed: '10531332', seq: '286', to_res: A}
- {entry_name: p2ry1_human, from_res: C, pubmed: '10329657', seq: '42', to_res: A}
- {entry_name: p2ry1_human, from_res: C, pubmed: '10329657', seq: '124', to_res: A}
- {entry_name: p2ry1_human, from_res: K, pubmed: '10329657', seq: '125', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '195', to_res: A}
- {entry_name: p2ry1_human, from_res: K, pubmed: '10329657', seq: '196', to_res: A}
- {entry_name: p2ry1_human, from_res: K, pubmed: '10329657', seq: '198', to_res: A}
- {entry_name: p2ry1_human, from_res: C, pubmed: '10329657', seq: '202', to_res: A}
- {entry_name: p2ry1_human, from_res: D, pubmed: '10329657', seq: '204', to_res: A}
- {entry_name: p2ry1_human, from_res: D, pubmed: '10329657', seq: '204', to_res: N}
- {entry_name: p2ry1_human, from_res: D, pubmed: '10329657', seq: '204', to_res: E}
- {entry_name: p2ry1_human, from_res: D, pubmed: '10329657', seq: '208', to_res: A}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10329657', seq: '209', to_res: A}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10329657', seq: '209', to_res: D}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10329657', seq: '209', to_res: Q}
- {entry_name: p2ry1_human, from_res: E, pubmed: '10329657', seq: '209', to_res: R}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '212', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '285', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '287', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '287', to_res: K}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '287', to_res: Q}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '287', to_res: E}
- {entry_name: p2ry1_human, from_res: D, pubmed: '10329657', seq: '289', to_res: A}
- {entry_name: p2ry1_human, from_res: C, pubmed: '10329657', seq: '296', to_res: A}
- {entry_name: p2ry1_human, from_res: D, pubmed: '10329657', seq: '300', to_res: A}
- {entry_name: p2ry1_human, from_res: R, pubmed: '10329657', seq: '301', to_res: A}
- {entry_name: grpr_mouse, from_res: S, pubmed: '10945859', seq: '180', to_res: A}
- {entry_name: grpr_mouse, from_res: D, pubmed: '10945859', seq: '181', to_res: A}
- {entry_name: grpr_mouse, from_res: S, pubmed: '10945859', seq: '212', to_res: A}
- {entry_name: grpr_mouse, from_res: S, pubmed: '10945859', seq: '215', to_res: A}
- {entry_name: grpr_mouse, from_res: F, pubmed: '10945859', seq: '216', to_res: A}
- {entry_name: grpr_mouse, from_res: F, pubmed: '10945859', seq: '270', to_res: A}
- {entry_name: grpr_mouse, from_res: W, pubmed: '10945859', seq: '278', to_res: A}
- {entry_name: grpr_mouse, from_res: N, pubmed: '10945859', seq: '281', to_res: A}
- {entry_name: grpr_mouse, from_res: Y, pubmed: '10945859', seq: '285', to_res: A}
- {entry_name: grpr_mouse, from_res: F, pubmed: '10945859', seq: '313', to_res: A}
- {entry_name: casr_rat, from_res: S, pubmed: '10373443', seq: '147', to_res: A}
- {entry_name: casr_rat, from_res: S, pubmed: '10373443', seq: '169', to_res: A}
- {entry_name: casr_rat, from_res: S, pubmed: '10373443', seq: '170', to_res: A}
- {entry_name: casr_rat, from_res: S, pubmed: '10373443', seq: '171', to_res: A}
- {entry_name: nk1r_human, from_res: C, pubmed: '10651631', seq: '105', to_res: S}
- {entry_name: nk1r_human, from_res: C, pubmed: '10651631', seq: '180', to_res: S}
- {entry_name: nk1r_human, from_res: P, pubmed: '10651631', seq: '22', to_res: C}
- {entry_name: nk1r_human, from_res: L, pubmed: '10651631', seq: '279', to_res: C}
- {entry_name: nk1r_human, from_res: I, pubmed: '10651631', seq: '191', to_res: C}
- {entry_name: nk1r_human, from_res: P, pubmed: '10908293', seq: '112', to_res: H}
- {entry_name: nk1r_human, from_res: P, pubmed: '10908293', seq: '112', to_res: D}
- {entry_name: nk1r_human, from_res: M, pubmed: '10908293', seq: '291', to_res: C}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10648631', seq: '143', to_res: K}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10648631', seq: '143', to_res: H}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10648631', seq: '143', to_res: D}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10648631', seq: '143', to_res: A}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10648631', seq: '143', to_res: N}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10648631', seq: '143', to_res: I}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10648631', seq: '143', to_res: E}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '10648631', seq: '142', to_res: A}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '10648631', seq: '293', to_res: E}
- {entry_name: acm2_human, from_res: N, pubmed: '10570052', seq: '419', to_res: D}
- {entry_name: acm2_human, from_res: N, pubmed: '10570052', seq: '419', to_res: E}
- {entry_name: acm2_human, from_res: N, pubmed: '10570052', seq: '419', to_res: K}
- {entry_name: acm3_human, from_res: K, pubmed: '10570052', seq: '523', to_res: N}
- {entry_name: acm4_human, from_res: D, pubmed: '10570052', seq: '432', to_res: N}
- {entry_name: acm5_human, from_res: T, pubmed: '10570052', seq: '456', to_res: A}
- {entry_name: acm5_human, from_res: I, pubmed: '10570052', seq: '460', to_res: V}
- {entry_name: acm5_human, from_res: V, pubmed: '10570052', seq: '464', to_res: I}
- {entry_name: acm5_human, from_res: S, pubmed: '10570052', seq: '465', to_res: N}
- {entry_name: acm5_human, from_res: D, pubmed: '10570052', seq: '469', to_res: A}
- {entry_name: acm5_human, from_res: K, pubmed: '10570052', seq: '470', to_res: P}
- {entry_name: acm5_human, from_res: V, pubmed: '10570052', seq: '474', to_res: N}
- {entry_name: acm1_rat, from_res: Y, pubmed: '10531410', seq: '381', to_res: A}
- {entry_name: acm1_rat, from_res: N, pubmed: '10531410', seq: '382', to_res: A}
- {entry_name: acm1_rat, from_res: N, pubmed: '10531410', seq: '382', to_res: A}
- {entry_name: acm1_rat, from_res: I, pubmed: '10531410', seq: '383', to_res: A}
- {entry_name: acm1_rat, from_res: M, pubmed: '10531410', seq: '384', to_res: A}
- {entry_name: acm1_rat, from_res: V, pubmed: '10531410', seq: '385', to_res: A}
- {entry_name: acm1_rat, from_res: L, pubmed: '10531410', seq: '386', to_res: A}
- {entry_name: acm1_rat, from_res: V, pubmed: '10531410', seq: '387', to_res: A}
- {entry_name: acm1_human, from_res: S, pubmed: '10496961', seq: '388', to_res: Y}
- {entry_name: acm1_human, from_res: T, pubmed: '10496961', seq: '389', to_res: P}
- {entry_name: adrb2_human, from_res: S, pubmed: '10617695', seq: '204', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '10617695', seq: '207', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '10617695', seq: '204', to_res: C}
- {entry_name: adrb2_human, from_res: S, pubmed: '10617695', seq: '207', to_res: C}
- {entry_name: adrb2_human, from_res: S, pubmed: '10510435', seq: '203', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '10510435', seq: '204', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '10510435', seq: '207', to_res: A}
- {entry_name: ada1a_human, from_res: A, pubmed: '10531388', seq: '271', to_res: K}
- {entry_name: ada1a_human, from_res: A, pubmed: '10531388', seq: '271', to_res: E}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '10531388', seq: '293', to_res: K}
- {entry_name: ada1b_mesau, from_res: A, pubmed: '10531388', seq: '293', to_res: E}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: H}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: A}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: Q}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: M}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: L}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: D}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: W}
- {entry_name: ada1b_mesau, from_res: K, pubmed: '10604981', seq: '331', to_res: E}
- {entry_name: ada1b_mesau, from_res: D, pubmed: '10604981', seq: '125', to_res: A}
- {entry_name: hrh2_rat, from_res: D, pubmed: '10779371', seq: '115', to_res: N}
- {entry_name: hrh2_rat, from_res: D, pubmed: '10779371', seq: '115', to_res: A}
- {entry_name: hrh2_rat, from_res: R, pubmed: '10779371', seq: '116', to_res: N}
- {entry_name: hrh2_rat, from_res: R, pubmed: '10779371', seq: '116', to_res: A}
- {entry_name: ada1b_mesau, from_res: R, pubmed: '10779371', seq: '143', to_res: A}
- {entry_name: adrb2_human, from_res: H, pubmed: '10358054', seq: '269', to_res: A}
- {entry_name: adrb2_human, from_res: E, pubmed: '10358054', seq: '268', to_res: H}
- {entry_name: adrb2_human, from_res: K, pubmed: '10358054', seq: '270', to_res: H}
- {entry_name: adrb2_human, from_res: A, pubmed: '10358054', seq: '271', to_res: H}
- {entry_name: adrb2_human, from_res: L, pubmed: '10358054', seq: '272', to_res: H}
- {entry_name: adrb2_human, from_res: K, pubmed: '10358054', seq: '273', to_res: H}
- {entry_name: adrb2_human, from_res: A, pubmed: '10358054', seq: '134', to_res: H}
- {entry_name: pthr1_didma, from_res: Y, pubmed: '10358054', seq: '397', to_res: H}
- {entry_name: pthr1_didma, from_res: R, pubmed: '10358054', seq: '398', to_res: H}
- {entry_name: pthr1_didma, from_res: K, pubmed: '10358054', seq: '399', to_res: H}
- {entry_name: pthr1_didma, from_res: L, pubmed: '10358054', seq: '400', to_res: H}
- {entry_name: pthr1_didma, from_res: L, pubmed: '10358054', seq: '401', to_res: H}
- {entry_name: pthr1_didma, from_res: K, pubmed: '10358054', seq: '402', to_res: H}
- {entry_name: drd5_human, from_res: L, pubmed: '10376767', seq: '88', to_res: F}
- {entry_name: drd5_human, from_res: A, pubmed: '10376767', seq: '269', to_res: V}
- {entry_name: drd5_human, from_res: P, pubmed: '10376767', seq: '330', to_res: Q}
- {entry_name: drd5_human, from_res: N, pubmed: '10376767', seq: '351', to_res: D}
- {entry_name: drd5_human, from_res: S, pubmed: '10376767', seq: '453', to_res: C}
- {entry_name: drd2_mouse, from_res: S, pubmed: '10956209', seq: '193', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '10956209', seq: '194', to_res: A}
- {entry_name: drd2_mouse, from_res: S, pubmed: '10956209', seq: '197', to_res: A}
- {entry_name: 5ht6r_rat, from_res: D, pubmed: '9798944', seq: '106', to_res: N}
- {entry_name: 5ht6r_rat, from_res: W, pubmed: '9798944', seq: '102', to_res: F}
- {entry_name: gasr_human, from_res: Y, pubmed: '10908308', seq: '61', to_res: A}
- {entry_name: gasr_human, from_res: F, pubmed: '10908308', seq: '110', to_res: A}
- {entry_name: gasr_human, from_res: T, pubmed: '10908308', seq: '111', to_res: A}
- {entry_name: gasr_human, from_res: S, pubmed: '10908308', seq: '131', to_res: A}
- {entry_name: gasr_human, from_res: G, pubmed: '10908308', seq: '135', to_res: A}
- {entry_name: gasr_human, from_res: M, pubmed: '10908308', seq: '186', to_res: A}
- {entry_name: gasr_human, from_res: T, pubmed: '10908308', seq: '193', to_res: A}
- {entry_name: gasr_human, from_res: S, pubmed: '10908308', seq: '219', to_res: A}
- {entry_name: gasr_human, from_res: L, pubmed: '10908308', seq: '226', to_res: A}
- {entry_name: gasr_human, from_res: F, pubmed: '10908308', seq: '227', to_res: A}
- {entry_name: gasr_human, from_res: W, pubmed: '10908308', seq: '346', to_res: A}
- {entry_name: gasr_human, from_res: V, pubmed: '10908308', seq: '349', to_res: A}
- {entry_name: gasr_human, from_res: Y, pubmed: '10908308', seq: '350', to_res: A}
- {entry_name: gasr_human, from_res: N, pubmed: '10908308', seq: '353', to_res: L}
- {entry_name: gasr_human, from_res: T, pubmed: '10908308', seq: '354', to_res: A}
- {entry_name: gasr_human, from_res: S, pubmed: '10908308', seq: '379', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '9843384', seq: '292', to_res: G}
- {entry_name: agtra_rat, from_res: Y, pubmed: '9843384', seq: '292', to_res: A}
- {entry_name: agtra_rat, from_res: Y, pubmed: '9843384', seq: '292', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '295', to_res: G}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '295', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '295', to_res: C}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '295', to_res: S}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '295', to_res: I}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '295', to_res: F}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: G}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: C}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: Q}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: H}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, pubmed: '9843384', seq: '111', to_res: Y}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10514427', seq: '316', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10514427', seq: '339', to_res: A}
- {entry_name: bkrb2_human, from_res: T, pubmed: '10514427', seq: '342', to_res: A}
- {entry_name: bkrb2_human, from_res: T, pubmed: '10514427', seq: '345', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10514427', seq: '346', to_res: A}
- {entry_name: bkrb2_human, from_res: S, pubmed: '10514427', seq: '348', to_res: A}
- {entry_name: ntr1_rat, from_res: M, pubmed: '10617622', seq: '208', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '10617622', seq: '331', to_res: A}
- {entry_name: ntr1_rat, from_res: W, pubmed: '10617622', seq: '339', to_res: A}
- {entry_name: ntr1_rat, from_res: F, pubmed: '10617622', seq: '344', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '10617622', seq: '347', to_res: A}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '10617622', seq: '347', to_res: M}
- {entry_name: ntr1_rat, from_res: Y, pubmed: '10617622', seq: '347', to_res: F}
- {entry_name: ntr1_rat, from_res: R, pubmed: '10617622', seq: '327', to_res: M}
- {entry_name: ntr1_rat, from_res: D, pubmed: '10617622', seq: '139', to_res: A}
- {entry_name: brs3_human, from_res: H, pubmed: '9632639', seq: '294', to_res: R}
- {entry_name: brs3_human, from_res: R, pubmed: '9632639', seq: '127', to_res: Q}
- {entry_name: agtra_rat, from_res: K, pubmed: '10747880', seq: '232', to_res: A}
- {entry_name: agtra_rat, from_res: P, pubmed: '10747880', seq: '233', to_res: A}
- {entry_name: agtra_rat, from_res: R, pubmed: '10747880', seq: '234', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '10747880', seq: '235', to_res: A}
- {entry_name: agtra_rat, from_res: D, pubmed: '10747880', seq: '236', to_res: A}
- {entry_name: agtra_rat, from_res: D, pubmed: '10747880', seq: '237', to_res: A}
- {entry_name: agtra_rat, from_res: I, pubmed: '10747880', seq: '238', to_res: A}
- {entry_name: agtra_rat, from_res: I, pubmed: '10747880', seq: '238', to_res: S}
- {entry_name: agtra_rat, from_res: I, pubmed: '10747880', seq: '238', to_res: K}
- {entry_name: agtra_rat, from_res: I, pubmed: '10747880', seq: '238', to_res: D}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: A}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: L}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: N}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: S}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: Y}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: K}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: R}
- {entry_name: agtra_rat, from_res: F, pubmed: '10747880', seq: '239', to_res: D}
- {entry_name: drd3_human, from_res: S, pubmed: '10349875', seq: '192', to_res: A}
- {entry_name: drd3_human, from_res: S, pubmed: '10349875', seq: '193', to_res: A}
- {entry_name: drd3_human, from_res: S, pubmed: '10349875', seq: '196', to_res: A}
- {entry_name: acm5_human, from_res: T, pubmed: '10940778', seq: '456', to_res: A}
- {entry_name: acm5_human, from_res: I, pubmed: '10940778', seq: '460', to_res: V}
- {entry_name: acm5_human, from_res: V, pubmed: '10940778', seq: '464', to_res: I}
- {entry_name: acm5_human, from_res: S, pubmed: '10940778', seq: '465', to_res: N}
- {entry_name: acm5_human, from_res: D, pubmed: '10940778', seq: '469', to_res: A}
- {entry_name: acm5_human, from_res: K, pubmed: '10940778', seq: '470', to_res: P}
- {entry_name: acm5_human, from_res: V, pubmed: '10940778', seq: '474', to_res: N}
- {entry_name: acm5_human, from_res: L, pubmed: '10940778', seq: '476', to_res: V}
- {entry_name: acm2_human, from_res: A, pubmed: '10940778', seq: '401', to_res: T}
- {entry_name: drd2_human, from_res: C, pubmed: '11015197', seq: '118', to_res: S}
- {entry_name: adrb2_human, from_res: S, pubmed: '10964911', seq: '203', to_res: T}
- {entry_name: adrb2_human, from_res: S, pubmed: '10964911', seq: '203', to_res: C}
- {entry_name: adrb2_human, from_res: S, pubmed: '10964911', seq: '203', to_res: A}
- {entry_name: adrb2_human, from_res: S, pubmed: '10964911', seq: '203', to_res: V}
- {entry_name: adrb2_human, from_res: S, pubmed: '10964911', seq: '204', to_res: A}
- {entry_name: bkrb2_rat, from_res: K, pubmed: '8910316', seq: '174', to_res: A}
- {entry_name: nk2r_human, from_res: Q, pubmed: '10818258', seq: '166', to_res: A}
- {entry_name: nk2r_human, from_res: S, pubmed: '10818258', seq: '170', to_res: A}
- {entry_name: nk2r_human, from_res: T, pubmed: '10818258', seq: '171', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10818258', seq: '206', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10818258', seq: '206', to_res: F}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10818258', seq: '266', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10818258', seq: '266', to_res: T}
- {entry_name: nk2r_human, from_res: H, pubmed: '10818258', seq: '267', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10818258', seq: '289', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10818258', seq: '289', to_res: T}
- {entry_name: nk2r_human, from_res: H, pubmed: '10411554', seq: '198', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10411554', seq: '266', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10411554', seq: '266', to_res: F}
- {entry_name: nk2r_human, from_res: F, pubmed: '10411554', seq: '270', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10411554', seq: '289', to_res: A}
- {entry_name: nk2r_human, from_res: Y, pubmed: '10411554', seq: '289', to_res: F}
- {entry_name: nk1r_rat, from_res: M, pubmed: '11108840', seq: '174', to_res: A}
- {entry_name: nk1r_rat, from_res: M, pubmed: '11108840', seq: '181', to_res: A}
- {entry_name: nk1r_human, from_res: G, pubmed: '9786514', seq: '166', to_res: C}
- {entry_name: agtra_rat, from_res: D, pubmed: '10852946', seq: '273', to_res: N}
- {entry_name: agtra_rat, from_res: I, pubmed: '10852946', seq: '38', to_res: V}
- {entry_name: agtra_rat, from_res: W, pubmed: '10852946', seq: '253', to_res: R}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '316', to_res: P}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '77', to_res: Y}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '78', to_res: F}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '191', to_res: P}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '212', to_res: H}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '293', to_res: L}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '110', to_res: C}
- {entry_name: agtra_rat, from_res: I, pubmed: '10852946', seq: '201', to_res: T}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '304', to_res: I}
- {entry_name: agtra_rat, from_res: N, pubmed: '10852946', seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, pubmed: '10852946', seq: '231', to_res: S}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '112', to_res: H}
- {entry_name: agtra_rat, from_res: V, pubmed: '10852946', seq: '29', to_res: A}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '143', to_res: P}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '44', to_res: S}
- {entry_name: agtra_rat, from_res: T, pubmed: '10852946', seq: '175', to_res: A}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '77', to_res: S}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '182', to_res: Y}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '112', to_res: F}
- {entry_name: agtra_rat, from_res: V, pubmed: '10852946', seq: '164', to_res: A}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '118', to_res: H}
- {entry_name: agtra_rat, from_res: K, pubmed: '10852946', seq: '318', to_res: E}
- {entry_name: agtra_rat, from_res: P, pubmed: '10852946', seq: '162', to_res: Q}
- {entry_name: agtra_rat, from_res: A, pubmed: '10852946', seq: '181', to_res: V}
- {entry_name: agtra_rat, from_res: I, pubmed: '10852946', seq: '193', to_res: K}
- {entry_name: agtra_rat, from_res: M, pubmed: '10852946', seq: '142', to_res: R}
- {entry_name: agtra_rat, from_res: S, pubmed: '10852946', seq: '186', to_res: P}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '195', to_res: P}
- {entry_name: agtra_rat, from_res: G, pubmed: '10852946', seq: '306', to_res: R}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '195', to_res: R}
- {entry_name: agtra_rat, from_res: T, pubmed: '10852946', seq: '178', to_res: S}
- {entry_name: agtra_rat, from_res: S, pubmed: '10852946', seq: '329', to_res: G}
- {entry_name: agtra_rat, from_res: T, pubmed: '10852946', seq: '198', to_res: I}
- {entry_name: agtra_rat, from_res: K, pubmed: '10852946', seq: '310', to_res: N}
- {entry_name: agtra_rat, from_res: M, pubmed: '10852946', seq: '142', to_res: T}
- {entry_name: agtra_rat, from_res: H, pubmed: '10852946', seq: '256', to_res: F}
- {entry_name: agtra_rat, from_res: F, pubmed: '10852946', seq: '44', to_res: L}
- {entry_name: agtra_rat, from_res: S, pubmed: '10852946', seq: '107', to_res: F}
- {entry_name: agtra_rat, from_res: E, pubmed: '10852946', seq: '173', to_res: G}
- {entry_name: agtra_rat, from_res: I, pubmed: '10852946', seq: '245', to_res: T}
- {entry_name: agtra_rat, from_res: L, pubmed: '10852946', seq: '305', to_res: Q}
- {entry_name: agtra_rat, from_res: G, pubmed: '10852946', seq: '203', to_res: A}
- {entry_name: agtra_rat, from_res: T, pubmed: '10903964', seq: '88', to_res: H}
- {entry_name: agtra_rat, from_res: Y, pubmed: '10903964', seq: '92', to_res: H}
- {entry_name: agtra_rat, from_res: G, pubmed: '10903964', seq: '196', to_res: I}
- {entry_name: agtra_rat, from_res: G, pubmed: '10903964', seq: '196', to_res: W}
- {entry_name: agtra_rat, from_res: D, pubmed: '10903964', seq: '278', to_res: E}
- {entry_name: agtr1_human, from_res: I, pubmed: '10933782', seq: '177', to_res: M}
- {entry_name: agtr1_human, from_res: T, pubmed: '10933782', seq: '175', to_res: M}
- {entry_name: agtr1_human, from_res: I, pubmed: '10933782', seq: '172', to_res: M}
- {entry_name: agtr2_rat, from_res: C, pubmed: '11068047', seq: '35', to_res: A}
- {entry_name: agtr2_rat, from_res: C, pubmed: '11068047', seq: '117', to_res: A}
- {entry_name: agtr2_rat, from_res: C, pubmed: '11068047', seq: '195', to_res: A}
- {entry_name: agtr2_rat, from_res: C, pubmed: '11068047', seq: '290', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '10644757', seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, pubmed: '10644757', seq: '111', to_res: G}
- {entry_name: agtra_rat, from_res: Y, pubmed: '10745091', seq: '127', to_res: H}
- {entry_name: agtra_rat, from_res: L, pubmed: '10745091', seq: '128', to_res: H}
- {entry_name: agtra_rat, from_res: A, pubmed: '10745091', seq: '129', to_res: H}
- {entry_name: agtra_rat, from_res: I, pubmed: '10745091', seq: '130', to_res: H}
- {entry_name: agtra_rat, from_res: R, pubmed: '10745091', seq: '234', to_res: H}
- {entry_name: agtra_rat, from_res: N, pubmed: '10745091', seq: '235', to_res: H}
- {entry_name: agtra_rat, from_res: D, pubmed: '10745091', seq: '236', to_res: H}
- {entry_name: agtra_rat, from_res: D, pubmed: '10745091', seq: '237', to_res: H}
- {entry_name: agtra_rat, from_res: F, pubmed: '10745091', seq: '239', to_res: H}
- {entry_name: agtra_rat, from_res: R, pubmed: '10745091', seq: '240', to_res: H}
- {entry_name: agtr1_human, from_res: N, pubmed: '10393537', seq: '4', to_res: D}
- {entry_name: agtr1_human, from_res: N, pubmed: '10393537', seq: '176', to_res: D}
- {entry_name: agtr1_human, from_res: N, pubmed: '10393537', seq: '188', to_res: D}
- {entry_name: gnrhr_rat, from_res: S, pubmed: '10588818', seq: '140', to_res: F}
- {entry_name: gnrhr_rat, from_res: W, pubmed: '10692505', seq: '279', to_res: S}
- {entry_name: gnrhr_rat, from_res: W, pubmed: '10692505', seq: '279', to_res: R}
- {entry_name: gnrhr_rat, from_res: V, pubmed: '10692505', seq: '299', to_res: A}
- {entry_name: gnrhr_rat, from_res: W, pubmed: '10692505', seq: '279', to_res: L}
- {entry_name: gnrhr_human, from_res: D, pubmed: '10889019', seq: '98', to_res: E}
- {entry_name: gnrhr_human, from_res: D, pubmed: '10889019', seq: '98', to_res: N}
- {entry_name: gnrhr_human, from_res: D, pubmed: '10889019', seq: '98', to_res: A}
- {entry_name: gnrhr_human, from_res: D, pubmed: '10889019', seq: '98', to_res: V}
- {entry_name: gnrr2_claga, from_res: S, pubmed: '10570050', seq: '356', to_res: A}
- {entry_name: gnrr2_claga, from_res: S, pubmed: '10570050', seq: '363', to_res: A}
- {entry_name: gnrr2_claga, from_res: S, pubmed: '10570050', seq: '356', to_res: A}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '10506131', seq: '87', to_res: D}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '10506131', seq: '87', to_res: Q}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '10506131', seq: '87', to_res: A}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '10506131', seq: '318', to_res: N}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '10506131', seq: '318', to_res: E}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '10506131', seq: '318', to_res: A}
- {entry_name: gnrhr_mouse, from_res: D, pubmed: '10506131', seq: '318', to_res: L}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '10506131', seq: '53', to_res: D}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '10506131', seq: '53', to_res: A}
- {entry_name: gnrhr_mouse, from_res: N, pubmed: '10506131', seq: '53', to_res: L}
- {entry_name: ccr2_human, from_res: D, pubmed: '10770925', seq: '284', to_res: A}
- {entry_name: ccr2_human, from_res: D, pubmed: '10770925', seq: '284', to_res: N}
- {entry_name: ccr2_human, from_res: D, pubmed: '10770925', seq: '284', to_res: K}
- {entry_name: ccr2_human, from_res: E, pubmed: '10770925', seq: '291', to_res: A}
- {entry_name: ccr2_human, from_res: E, pubmed: '10770925', seq: '291', to_res: Q}
- {entry_name: vg74_hhv8, from_res: L, pubmed: '10842179', seq: '91', to_res: D}
- {entry_name: vg74_hhv8, from_res: N, pubmed: '10842179', seq: '92', to_res: D}
- {entry_name: vg74_hhv8, from_res: S, pubmed: '10842179', seq: '93', to_res: D}
- {entry_name: vg74_hhv8, from_res: L, pubmed: '10842179', seq: '94', to_res: D}
- {entry_name: vg74_hhv8, from_res: Y, pubmed: '10842179', seq: '128', to_res: S}
- {entry_name: vg74_hhv8, from_res: V, pubmed: '10842179', seq: '142', to_res: D}
- {entry_name: vg74_hhv8, from_res: V, pubmed: '10842179', seq: '310', to_res: N}
- {entry_name: ccr2_human, from_res: T, pubmed: '11046064', seq: '21', to_res: A}
- {entry_name: ccr2_human, from_res: T, pubmed: '11046064', seq: '22', to_res: A}
- {entry_name: ccr2_human, from_res: F, pubmed: '11046064', seq: '23', to_res: A}
- {entry_name: ccr2_human, from_res: F, pubmed: '11046064', seq: '24', to_res: A}
- {entry_name: ccr2_human, from_res: D, pubmed: '11046064', seq: '25', to_res: A}
- {entry_name: ccr2_human, from_res: Y, pubmed: '11046064', seq: '26', to_res: A}
- {entry_name: ccr2_human, from_res: Y, pubmed: '11046064', seq: '26', to_res: F}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10986293', seq: '246', to_res: A}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10986293', seq: '246', to_res: P}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10986293', seq: '246', to_res: T}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10986293', seq: '246', to_res: N}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10986293', seq: '265', to_res: A}
- {entry_name: gabr1_rat, from_res: Y, pubmed: '10986293', seq: '266', to_res: F}
- {entry_name: gabr1_rat, from_res: S, pubmed: '10986293', seq: '270', to_res: A}
- {entry_name: gabr1_rat, from_res: C, pubmed: '10986293', seq: '187', to_res: A}
- {entry_name: gabr1_rat, from_res: E, pubmed: '10986293', seq: '192', to_res: A}
- {entry_name: gabr1_rat, from_res: F, pubmed: '10986293', seq: '463', to_res: A}
- {entry_name: gabr1_rat, from_res: E, pubmed: '10986293', seq: '465', to_res: A}
- {entry_name: gabr1_rat, from_res: Y, pubmed: '10986293', seq: '470', to_res: A}
- {entry_name: gabr1_rat, from_res: Y, pubmed: '10986293', seq: '470', to_res: F}
- {entry_name: gabr1_rat, from_res: D, pubmed: '10986293', seq: '471', to_res: A}
- {entry_name: gabr1_rat, from_res: D, pubmed: '10986293', seq: '471', to_res: E}
- {entry_name: gabr1_rat, from_res: Q, pubmed: '10986293', seq: '312', to_res: A}
- {entry_name: gabr1_rat, from_res: F, pubmed: '10986293', seq: '365', to_res: A}
- {entry_name: gabr1_rat, from_res: Y, pubmed: '10986293', seq: '366', to_res: A}
- {entry_name: gabr1_rat, from_res: E, pubmed: '10986293', seq: '367', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '262', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10825158', seq: '268', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10825158', seq: '271', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10825158', seq: '275', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10825158', seq: '277', to_res: A}
- {entry_name: ccr2_human, from_res: D, pubmed: '10529171', seq: '36', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '277', to_res: A}
- {entry_name: cxcr4_human, from_res: H, pubmed: '10400757', seq: '281', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10400757', seq: '282', to_res: A}
- {entry_name: cxcr4_human, from_res: C, pubmed: '10400757', seq: '28', to_res: A}
- {entry_name: cxcr4_human, from_res: C, pubmed: '10400757', seq: '109', to_res: A}
- {entry_name: cxcr4_human, from_res: C, pubmed: '10400757', seq: '186', to_res: A}
- {entry_name: cxcr4_human, from_res: C, pubmed: '10400757', seq: '274', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '2', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '10', to_res: A}
- {entry_name: cxcr4_human, from_res: N, pubmed: '10400757', seq: '11', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '14', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '15', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '20', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '22', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10400757', seq: '25', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '26', to_res: A}
- {entry_name: cxcr4_human, from_res: R, pubmed: '10400757', seq: '30', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '31', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '32', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '97', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10400757', seq: '110', to_res: A}
- {entry_name: cxcr4_human, from_res: N, pubmed: '10400757', seq: '176', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '179', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '181', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '182', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '187', to_res: A}
- {entry_name: cxcr4_human, from_res: R, pubmed: '10400757', seq: '188', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '193', to_res: A}
- {entry_name: cxcr4_human, from_res: F, pubmed: '10400757', seq: '201', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10400757', seq: '262', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '268', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10400757', seq: '271', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10400757', seq: '275', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10825158', seq: '282', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '97', to_res: N}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '84', to_res: N}
- {entry_name: cxcr4_human, from_res: T, pubmed: '10756055', seq: '13', to_res: A}
- {entry_name: cxcr4_human, from_res: N, pubmed: '10756055', seq: '11', to_res: A}
- {entry_name: cxcr4_human, from_res: N, pubmed: '10756055', seq: '176', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '171', to_res: N}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10825158', seq: '288', to_res: Q}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10825158', seq: '2', to_res: A}
- {entry_name: cxcr4_human, from_res: Y, pubmed: '10825158', seq: '7', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '10', to_res: A}
- {entry_name: cxcr4_human, from_res: N, pubmed: '10825158', seq: '11', to_res: Q}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '20', to_res: A}
- {entry_name: cxcr4_human, from_res: Y, pubmed: '10825158', seq: '21', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '22', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10825158', seq: '25', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10825158', seq: '26', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10825158', seq: '38', to_res: A}
- {entry_name: cxcr4_human, from_res: K, pubmed: '10825158', seq: '110', to_res: A}
- {entry_name: cxcr4_human, from_res: E, pubmed: '10825158', seq: '179', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '181', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '182', to_res: G}
- {entry_name: cxcr4_human, from_res: R, pubmed: '10825158', seq: '183', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '187', to_res: A}
- {entry_name: cxcr4_human, from_res: R, pubmed: '10825158', seq: '188', to_res: A}
- {entry_name: cxcr4_human, from_res: D, pubmed: '10825158', seq: '193', to_res: A}
- {entry_name: tshr_human, from_res: A, pubmed: '10487707', seq: '623', to_res: V}
- {entry_name: tshr_human, from_res: D, pubmed: '10487707', seq: '727', to_res: E}
- {entry_name: tshr_human, from_res: N, pubmed: '11095460', seq: '113', to_res: Q}
- {entry_name: tshr_human, from_res: R, pubmed: '11095460', seq: '310', to_res: C}
- {entry_name: tshr_human, from_res: L, pubmed: '11095460', seq: '677', to_res: V}
- {entry_name: tshr_human, from_res: A, pubmed: '10490813', seq: '623', to_res: I}
- {entry_name: ta2r_human, from_res: R, pubmed: '9112632', seq: '60', to_res: L}
- {entry_name: ta2r_human, from_res: F, pubmed: '10527859', seq: '138', to_res: D}
- {entry_name: ta2r_human, from_res: F, pubmed: '10527859', seq: '138', to_res: Y}
- {entry_name: ta2r_human, from_res: N, pubmed: '9587408', seq: '4', to_res: L}
- {entry_name: ta2r_human, from_res: N, pubmed: '9587408', seq: '16', to_res: L}
- {entry_name: ta2r_human, from_res: C, pubmed: '8837733', seq: '102', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8837733', seq: '105', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8837733', seq: '183', to_res: S}
- {entry_name: ta2r_human, from_res: C, pubmed: '8837733', seq: '257', to_res: S}
- {entry_name: ta2r_human, from_res: S, pubmed: '8837733', seq: '201', to_res: A}
- {entry_name: ta2r_human, from_res: S, pubmed: '8837733', seq: '255', to_res: A}
- {entry_name: pe2r3_mouse, from_res: N, pubmed: '9849653', seq: '16', to_res: Q}
- {entry_name: pe2r3_mouse, from_res: N, pubmed: '9849653', seq: '193', to_res: Q}
- {entry_name: pe2r2_human, from_res: T, pubmed: '9788776', seq: '185', to_res: A}
- {entry_name: pe2r2_human, from_res: T, pubmed: '9788776', seq: '185', to_res: S}
- {entry_name: pe2r4_human, from_res: T, pubmed: '9788776', seq: '168', to_res: A}
- {entry_name: pe2r4_human, from_res: T, pubmed: '9788776', seq: '168', to_res: S}
- {entry_name: pe2r2_human, from_res: L, pubmed: '9730918', seq: '84', to_res: F}
- {entry_name: pe2r2_human, from_res: L, pubmed: '9730918', seq: '90', to_res: F}
- {entry_name: pe2r2_human, from_res: Q, pubmed: '9730918', seq: '97', to_res: S}
- {entry_name: pe2r2_human, from_res: P, pubmed: '9730918', seq: '104', to_res: R}
- {entry_name: pe2r2_human, from_res: Y, pubmed: '9730918', seq: '111', to_res: A}
- {entry_name: pe2r2_human, from_res: S, pubmed: '9730918', seq: '120', to_res: G}
- {entry_name: pe2r2_human, from_res: R, pubmed: '9730918', seq: '190', to_res: N}
- {entry_name: pe2r2_human, from_res: Q, pubmed: '9730918', seq: '299', to_res: L}
- {entry_name: pe2r2_human, from_res: L, pubmed: '9730918', seq: '301', to_res: F}
- {entry_name: pe2r2_human, from_res: R, pubmed: '9730918', seq: '302', to_res: E}
- {entry_name: pe2r2_human, from_res: R, pubmed: '9730918', seq: '302', to_res: Q}
- {entry_name: pe2r2_human, from_res: L, pubmed: '9730918', seq: '304', to_res: Y}
- {entry_name: pe2r2_human, from_res: S, pubmed: '9730918', seq: '305', to_res: A}
- {entry_name: pe2r2_human, from_res: F, pubmed: '9730918', seq: '315', to_res: Y}
- {entry_name: pe2r3_rabit, from_res: Q, pubmed: '9153190', seq: '198', to_res: A}
- {entry_name: pe2r3_rabit, from_res: W, pubmed: '9153190', seq: '199', to_res: A}
- {entry_name: pe2r3_rabit, from_res: P, pubmed: '9153190', seq: '200', to_res: S}
- {entry_name: pe2r3_rabit, from_res: T, pubmed: '9153190', seq: '202', to_res: A}
- {entry_name: pe2r3_rabit, from_res: W, pubmed: '9153190', seq: '203', to_res: A}
- {entry_name: pe2r3_rabit, from_res: C, pubmed: '9153190', seq: '204', to_res: A}
- {entry_name: pe2r3_rabit, from_res: F, pubmed: '9153190', seq: '205', to_res: A}
- {entry_name: pe2r3_rabit, from_res: K, pubmed: '9016347', seq: '300', to_res: A}
- {entry_name: pe2r3_rabit, from_res: R, pubmed: '9016347', seq: '329', to_res: A}
- {entry_name: pe2r3_rabit, from_res: D, pubmed: '9016347', seq: '338', to_res: A}
- {entry_name: pe2r3_mouse, from_res: R, pubmed: '9065782', seq: '309', to_res: Q}
- {entry_name: pe2r3_mouse, from_res: R, pubmed: '9065782', seq: '309', to_res: N}
- {entry_name: pe2r3_mouse, from_res: R, pubmed: '9065782', seq: '309', to_res: L}
- {entry_name: fshr_human, from_res: D, pubmed: '9973249', seq: '567', to_res: G}
- {entry_name: cnr1_human, from_res: K, pubmed: '9422383', seq: '192', to_res: R}
- {entry_name: cnr1_human, from_res: K, pubmed: '9422383', seq: '192', to_res: Q}
- {entry_name: cnr1_human, from_res: K, pubmed: '9422383', seq: '192', to_res: E}
- {entry_name: cnr1_human, from_res: G, pubmed: '10525107', seq: '195', to_res: S}
- {entry_name: cnr1_human, from_res: A, pubmed: '10525107', seq: '198', to_res: M}
- {entry_name: cnr2_human, from_res: D, pubmed: '10682848', seq: '130', to_res: A}
- {entry_name: cnr2_human, from_res: R, pubmed: '10682848', seq: '131', to_res: A}
- {entry_name: cnr2_human, from_res: Y, pubmed: '10682848', seq: '132', to_res: A}
- {entry_name: cnr2_human, from_res: W, pubmed: '11080201', seq: '158', to_res: A}
- {entry_name: cnr2_human, from_res: W, pubmed: '11080201', seq: '158', to_res: F}
- {entry_name: cnr2_human, from_res: W, pubmed: '11080201', seq: '158', to_res: Y}
- {entry_name: cnr2_human, from_res: W, pubmed: '11080201', seq: '172', to_res: A}
- {entry_name: cnr2_human, from_res: W, pubmed: '11080201', seq: '172', to_res: F}
- {entry_name: cnr1_human, from_res: K, pubmed: '9855635', seq: '192', to_res: A}
- {entry_name: cnr1_rat, from_res: D, pubmed: '10373467', seq: '164', to_res: N}
- {entry_name: fshr_human, from_res: L, pubmed: '10551778', seq: '601', to_res: V}
- {entry_name: fshr_human, from_res: D, pubmed: '10551778', seq: '224', to_res: V}
- {entry_name: fshr_human, from_res: I, pubmed: '10551778', seq: '160', to_res: T}
- {entry_name: fshr_human, from_res: R, pubmed: '10551778', seq: '573', to_res: D}
- {entry_name: cnr1_human, from_res: V, pubmed: '10496968', seq: '282', to_res: F}
- {entry_name: cnr2_human, from_res: F, pubmed: '10496968', seq: '197', to_res: V}
- {entry_name: cnr1_human, from_res: D, pubmed: '10525080', seq: '163', to_res: N}
- {entry_name: pi2r_human, from_res: S, pubmed: '9722557', seq: '328', to_res: A}
- {entry_name: pi2r_human, from_res: S, pubmed: '9722557', seq: '374', to_res: A}
- {entry_name: mtr1a_sheep, from_res: V, pubmed: '9344844', seq: '208', to_res: A}
- {entry_name: mtr1a_sheep, from_res: V, pubmed: '9344844', seq: '208', to_res: L}
- {entry_name: mtr1a_sheep, from_res: H, pubmed: '9344844', seq: '211', to_res: F}
- {entry_name: mtr1a_sheep, from_res: H, pubmed: '9344844', seq: '211', to_res: L}
- {entry_name: mtr1a_human, from_res: M, pubmed: '9712731', seq: '107', to_res: D}
- {entry_name: mtr1a_human, from_res: M, pubmed: '9712731', seq: '107', to_res: T}
- {entry_name: mtr1a_human, from_res: N, pubmed: '9712731', seq: '124', to_res: A}
- {entry_name: mtr1a_human, from_res: H, pubmed: '9712731', seq: '195', to_res: A}
- {entry_name: mtr1a_human, from_res: P, pubmed: '9712731', seq: '253', to_res: A}
- {entry_name: mtr1a_human, from_res: S, pubmed: '9712731', seq: '280', to_res: A}
- {entry_name: mtr1a_human, from_res: R, pubmed: '10471411', seq: '54', to_res: W}
- {entry_name: mtr1a_human, from_res: A, pubmed: '10471411', seq: '157', to_res: V}
- {entry_name: fprl1_human, from_res: Y, pubmed: '11063592', seq: '302', to_res: F}
- {entry_name: fshr_human, from_res: L, pubmed: '10935550', seq: '460', to_res: R}
- {entry_name: fshr_human, from_res: L, pubmed: '10935550', seq: '460', to_res: K}
- {entry_name: fshr_human, from_res: L, pubmed: '10935550', seq: '460', to_res: A}
- {entry_name: fshr_human, from_res: L, pubmed: '10935550', seq: '460', to_res: D}
- {entry_name: cnr2_human, from_res: W, pubmed: '11080201', seq: '172', to_res: L}
- {entry_name: cnr2_human, from_res: W, pubmed: '11080201', seq: '172', to_res: Y}
- {entry_name: fshr_human, from_res: F, pubmed: '9100567', seq: '591', to_res: S}
- {entry_name: fshr_human, from_res: R, pubmed: '9769327', seq: '573', to_res: C}
- {entry_name: fshr_human, from_res: I, pubmed: '9769327', seq: '160', to_res: T}
- {entry_name: fshr_human, from_res: T, pubmed: '10022448', seq: '307', to_res: A}
- {entry_name: fshr_human, from_res: N, pubmed: '10022448', seq: '680', to_res: S}
- {entry_name: pe2r2_human, from_res: H, pubmed: '9730918', seq: '226', to_res: Y}
- {entry_name: tshr_human, from_res: M, pubmed: '9519872', seq: '453', to_res: T}
- {entry_name: tshr_human, from_res: S, pubmed: '9589634', seq: '281', to_res: N}
- {entry_name: tshr_human, from_res: R, pubmed: '9589634', seq: '528', to_res: H}
- {entry_name: tshr_human, from_res: I, pubmed: '9467563', seq: '486', to_res: M}
- {entry_name: tshr_human, from_res: D, pubmed: '9467563', seq: '619', to_res: G}
- {entry_name: tshr_human, from_res: A, pubmed: '9467563', seq: '623', to_res: V}
- {entry_name: tshr_human, from_res: L, pubmed: '9467563', seq: '629', to_res: F}
- {entry_name: tshr_human, from_res: I, pubmed: '9467563', seq: '630', to_res: L}
- {entry_name: tshr_human, from_res: T, pubmed: '9467563', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: D, pubmed: '9467563', seq: '633', to_res: E}
- {entry_name: tshr_human, from_res: P, pubmed: '9467563', seq: '639', to_res: S}
- {entry_name: tshr_human, from_res: R, pubmed: '9100579', seq: '109', to_res: Q}
- {entry_name: tshr_human, from_res: A, pubmed: '9185526', seq: '553', to_res: T}
- {entry_name: tshr_human, from_res: S, pubmed: '9224711', seq: '281', to_res: T}
- {entry_name: tshr_human, from_res: S, pubmed: '9224711', seq: '281', to_res: N}
- {entry_name: tshr_human, from_res: S, pubmed: '9360555', seq: '505', to_res: N}
- {entry_name: fshr_human, from_res: S, pubmed: '9660834', seq: '682', to_res: T}
- {entry_name: fshr_human, from_res: G, pubmed: '9660834', seq: '681', to_res: A}
- {entry_name: fshr_human, from_res: S, pubmed: '9660834', seq: '682', to_res: A}
- {entry_name: fshr_human, from_res: V, pubmed: '9660834', seq: '678', to_res: A}
- {entry_name: fshr_human, from_res: T, pubmed: '9660834', seq: '679', to_res: A}
- {entry_name: fshr_human, from_res: N, pubmed: '9660834', seq: '680', to_res: A}
- {entry_name: fshr_human, from_res: G, pubmed: '9660834', seq: '681', to_res: A}
- {entry_name: fshr_human, from_res: S, pubmed: '9660834', seq: '682', to_res: A}
- {entry_name: fshr_human, from_res: T, pubmed: '9660834', seq: '683', to_res: A}
- {entry_name: fshr_human, from_res: Y, pubmed: '9660834', seq: '684', to_res: A}
- {entry_name: fshr_human, from_res: I, pubmed: '9660834', seq: '685', to_res: A}
- {entry_name: fshr_human, from_res: L, pubmed: '9660834', seq: '686', to_res: A}
- {entry_name: fshr_human, from_res: V, pubmed: '9660834', seq: '687', to_res: A}
- {entry_name: fshr_human, from_res: P, pubmed: '9660834', seq: '688', to_res: A}
- {entry_name: fshr_human, from_res: L, pubmed: '9660834', seq: '689', to_res: A}
- {entry_name: fshr_human, from_res: S, pubmed: '9660834', seq: '690', to_res: A}
- {entry_name: fshr_human, from_res: H, pubmed: '9660834', seq: '691', to_res: A}
- {entry_name: tshr_human, from_res: F, pubmed: '9266964', seq: '631', to_res: C}
- {entry_name: tshr_human, from_res: T, pubmed: '9266964', seq: '632', to_res: I}
- {entry_name: tshr_human, from_res: D, pubmed: '9266964', seq: '633', to_res: Y}
- {entry_name: tshr_human, from_res: D, pubmed: '9266964', seq: '633', to_res: E}
- {entry_name: pe2r3_rabit, from_res: R, pubmed: '9016347', seq: '329', to_res: E}
- {entry_name: tshr_human, from_res: C, pubmed: '9329388', seq: '390', to_res: W}
- {entry_name: tshr_human, from_res: C, pubmed: '8954020', seq: '390', to_res: W}
- {entry_name: tshr_human, from_res: D, pubmed: '8954020', seq: '410', to_res: N}
- {entry_name: tshr_human, from_res: F, pubmed: '8954020', seq: '525', to_res: L}
- {entry_name: pi2r_human, from_res: S, pubmed: '10889200', seq: '328', to_res: A}
- {entry_name: pi2r_human, from_res: S, pubmed: '10889200', seq: '374', to_res: A}
- {entry_name: lshr_human, from_res: E, pubmed: '9626144', seq: '354', to_res: K}
- {entry_name: pe2r3_rat, from_res: N, pubmed: '10970800', seq: '16', to_res: Q}
- {entry_name: pe2r3_rat, from_res: N, pubmed: '10970800', seq: '193', to_res: Q}
- {entry_name: lshr_human, from_res: F, pubmed: '9253338', seq: '576', to_res: I}
- {entry_name: lshr_human, from_res: F, pubmed: '9253338', seq: '576', to_res: G}
- {entry_name: lshr_human, from_res: F, pubmed: '9253338', seq: '576', to_res: Y}
- {entry_name: lshr_human, from_res: F, pubmed: '9253338', seq: '576', to_res: E}
- {entry_name: lshr_human, from_res: A, pubmed: '9467560', seq: '373', to_res: V}
- {entry_name: lshr_rat, from_res: N, pubmed: '9139799', seq: '103', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '9139799', seq: '178', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '9139799', seq: '199', to_res: Q}
- {entry_name: lshr_rat, from_res: T, pubmed: '9139799', seq: '201', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '9139799', seq: '295', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '9139799', seq: '303', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '9139799', seq: '317', to_res: Q}
- {entry_name: lshr_rat, from_res: K, pubmed: '9140087', seq: '394', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '9140087', seq: '394', to_res: Q}
- {entry_name: lshr_rat, from_res: K, pubmed: '9140087', seq: '481', to_res: E}
- {entry_name: lshr_rat, from_res: R, pubmed: '9140087', seq: '485', to_res: E}
- {entry_name: lshr_rat, from_res: H, pubmed: '9140087', seq: '486', to_res: E}
- {entry_name: lshr_rat, from_res: R, pubmed: '9140087', seq: '552', to_res: E}
- {entry_name: lshr_rat, from_res: Y, pubmed: '9140087', seq: '554', to_res: S}
- {entry_name: lshr_human, from_res: C, pubmed: '9215288', seq: '131', to_res: R}
- {entry_name: lshr_rat, from_res: L, pubmed: '9497355', seq: '519', to_res: A}
- {entry_name: lshr_human, from_res: R, pubmed: '10967122', seq: '388', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '390', to_res: A}
- {entry_name: lshr_human, from_res: R, pubmed: '10967122', seq: '395', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '548', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '566', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '569', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '570', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '628', to_res: A}
- {entry_name: lshr_human, from_res: R, pubmed: '10967122', seq: '632', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '640', to_res: A}
- {entry_name: lshr_human, from_res: K, pubmed: '10967122', seq: '645', to_res: A}
- {entry_name: lshr_human, from_res: R, pubmed: '10967122', seq: '646', to_res: A}
- {entry_name: lshr_rat, from_res: K, pubmed: '10727611', seq: '609', to_res: R}
- {entry_name: lshr_rat, from_res: D, pubmed: '10393545', seq: '582', to_res: G}
- {entry_name: lshr_rat, from_res: D, pubmed: '10393545', seq: '582', to_res: Y}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '564', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '564', to_res: A}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '564', to_res: V}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '564', to_res: E}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '564', to_res: N}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '564', to_res: L}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '564', to_res: F}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '578', to_res: C}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '578', to_res: S}
- {entry_name: lshr_human, from_res: D, pubmed: '9584216', seq: '578', to_res: Y}
- {entry_name: lshr_rat, from_res: S, pubmed: '9660797', seq: '661', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '9660797', seq: '665', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '9660797', seq: '675', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '9660797', seq: '678', to_res: A}
- {entry_name: lshr_rat, from_res: D, pubmed: '9857020', seq: '409', to_res: N}
- {entry_name: lshr_rat, from_res: L, pubmed: '9857020', seq: '461', to_res: R}
- {entry_name: lshr_rat, from_res: Y, pubmed: '9857020', seq: '550', to_res: F}
- {entry_name: lshr_rat, from_res: D, pubmed: '9857020', seq: '582', to_res: Y}
- {entry_name: lshr_rat, from_res: P, pubmed: '9497355', seq: '588', to_res: F}
- {entry_name: lshr_rat, from_res: P, pubmed: '9497355', seq: '489', to_res: F}
- {entry_name: lshr_rat, from_res: P, pubmed: '9497355', seq: '617', to_res: F}
- {entry_name: lshr_rat, from_res: S, pubmed: '9497355', seq: '510', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '9497355', seq: '511', to_res: A}
- {entry_name: lshr_rat, from_res: Y, pubmed: '9497355', seq: '512', to_res: A}
- {entry_name: lshr_rat, from_res: M, pubmed: '9497355', seq: '513', to_res: A}
- {entry_name: lshr_rat, from_res: K, pubmed: '9497355', seq: '514', to_res: A}
- {entry_name: lshr_rat, from_res: V, pubmed: '9497355', seq: '515', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '9497355', seq: '516', to_res: A}
- {entry_name: lshr_rat, from_res: I, pubmed: '9497355', seq: '517', to_res: A}
- {entry_name: lshr_rat, from_res: C, pubmed: '9497355', seq: '518', to_res: A}
- {entry_name: lshr_rat, from_res: P, pubmed: '9497355', seq: '520', to_res: A}
- {entry_name: lshr_rat, from_res: M, pubmed: '9497355', seq: '521', to_res: A}
- {entry_name: lshr_rat, from_res: D, pubmed: '9497355', seq: '522', to_res: A}
- {entry_name: lshr_rat, from_res: V, pubmed: '9497355', seq: '523', to_res: A}
- {entry_name: lshr_rat, from_res: E, pubmed: '9497355', seq: '524', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '9497355', seq: '525', to_res: A}
- {entry_name: lshr_rat, from_res: T, pubmed: '9497355', seq: '526', to_res: A}
- {entry_name: lshr_rat, from_res: L, pubmed: '9497355', seq: '527', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '9497355', seq: '528', to_res: A}
- {entry_name: lshr_rat, from_res: Q, pubmed: '9497355', seq: '529', to_res: A}
- {entry_name: fshr_human, from_res: S, pubmed: '10889210', seq: '273', to_res: I}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: A}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: H}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: Y}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: F}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: C}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: T}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: W}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: G}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: E}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: Q}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: N}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: P}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: I}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: M}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: V}
- {entry_name: lshr_human, from_res: S, pubmed: '10889210', seq: '277', to_res: L}
- {entry_name: lshr_human, from_res: P, pubmed: '10889210', seq: '276', to_res: G}
- {entry_name: lshr_human, from_res: P, pubmed: '10889210', seq: '276', to_res: A}
- {entry_name: lshr_human, from_res: D, pubmed: '10889210', seq: '564', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '10889210', seq: '578', to_res: Y}
- {entry_name: tshr_human, from_res: N, pubmed: '11014210', seq: '302', to_res: Q}
- {entry_name: tshr_human, from_res: N, pubmed: '11014210', seq: '302', to_res: Q}
- {entry_name: fshr_rat, from_res: D, pubmed: '9733722', seq: '407', to_res: N}
- {entry_name: fshr_rat, from_res: Y, pubmed: '9733722', seq: '548', to_res: F}
- {entry_name: lshr_human, from_res: D, pubmed: '9973550', seq: '578', to_res: G}
- {entry_name: lshr_human, from_res: D, pubmed: '9973550', seq: '578', to_res: Y}
- {entry_name: lshr_human, from_res: D, pubmed: '9973550', seq: '578', to_res: W}
- {entry_name: lshr_human, from_res: D, pubmed: '9973550', seq: '578', to_res: E}
- {entry_name: lshr_human, from_res: L, pubmed: '11134146', seq: '368', to_res: P}
- {entry_name: lshr_human, from_res: L, pubmed: '9661624', seq: '457', to_res: R}
- {entry_name: lshr_rat, from_res: L, pubmed: '10496955', seq: '639', to_res: A}
- {entry_name: lshr_rat, from_res: L, pubmed: '10496955', seq: '640', to_res: A}
- {entry_name: lshr_rat, from_res: L, pubmed: '10496955', seq: '639', to_res: F}
- {entry_name: lshr_rat, from_res: D, pubmed: '10496955', seq: '637', to_res: N}
- {entry_name: lshr_human, from_res: F, pubmed: '10496955', seq: '635', to_res: L}
- {entry_name: lshr_rat, from_res: E, pubmed: '10499511', seq: '83', to_res: K}
- {entry_name: lshr_rat, from_res: E, pubmed: '10499511', seq: '106', to_res: K}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '184', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '184', to_res: R}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '184', to_res: Q}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '184', to_res: G}
- {entry_name: lshr_rat, from_res: E, pubmed: '10499511', seq: '207', to_res: K}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '209', to_res: E}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '209', to_res: R}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '209', to_res: Q}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '209', to_res: G}
- {entry_name: lshr_rat, from_res: E, pubmed: '10499511', seq: '210', to_res: K}
- {entry_name: lshr_rat, from_res: E, pubmed: '10499511', seq: '210', to_res: N}
- {entry_name: lshr_rat, from_res: E, pubmed: '10499511', seq: '215', to_res: K}
- {entry_name: lshr_rat, from_res: K, pubmed: '10499511', seq: '216', to_res: E}
- {entry_name: lshr_rat, from_res: D, pubmed: '10499511', seq: '232', to_res: K}
- {entry_name: lshr_rat, from_res: D, pubmed: '10499511', seq: '232', to_res: E}
- {entry_name: lshr_rat, from_res: D, pubmed: '10499511', seq: '232', to_res: Q}
- {entry_name: lshr_rat, from_res: L, pubmed: '10770485', seq: '612', to_res: A}
- {entry_name: lshr_rat, from_res: E, pubmed: '10770485', seq: '455', to_res: D}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '539', to_res: G}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '539', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '539', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '539', to_res: L}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '539', to_res: D}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '539', to_res: H}
- {entry_name: lshr_rat, from_res: V, pubmed: '10770485', seq: '613', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: A}
- {entry_name: lshr_rat, from_res: S, pubmed: '10770485', seq: '620', to_res: A}
- {entry_name: lshr_rat, from_res: C, pubmed: '10770485', seq: '621', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '623', to_res: A}
- {entry_name: lshr_rat, from_res: F, pubmed: '10770485', seq: '630', to_res: A}
- {entry_name: lshr_rat, from_res: T, pubmed: '10770485', seq: '631', to_res: A}
- {entry_name: lshr_rat, from_res: C, pubmed: '10770485', seq: '621', to_res: M}
- {entry_name: lshr_rat, from_res: F, pubmed: '10770485', seq: '630', to_res: Y}
- {entry_name: lshr_rat, from_res: T, pubmed: '10770485', seq: '631', to_res: Y}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: S}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: K}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: D}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: E}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '619', to_res: R}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '623', to_res: A}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '623', to_res: Q}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '623', to_res: D}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '623', to_res: K}
- {entry_name: lshr_rat, from_res: N, pubmed: '10770485', seq: '623', to_res: R}
- {entry_name: lshr_rat, from_res: E, pubmed: '10770485', seq: '455', to_res: A}
- {entry_name: lshr_rat, from_res: E, pubmed: '10770485', seq: '455', to_res: S}
- {entry_name: lshr_rat, from_res: E, pubmed: '10770485', seq: '455', to_res: Q}
- {entry_name: lshr_human, from_res: L, pubmed: '11075813', seq: '457', to_res: R}
- {entry_name: lshr_human, from_res: D, pubmed: '11075813', seq: '578', to_res: Y}
- {entry_name: lshr_human, from_res: D, pubmed: '11075813', seq: '578', to_res: H}
- {entry_name: lshr_human, from_res: I, pubmed: '11075813', seq: '625', to_res: K}
- {entry_name: lshr_human, from_res: D, pubmed: '11075813', seq: '405', to_res: N}
- {entry_name: lshr_human, from_res: Y, pubmed: '11075813', seq: '546', to_res: F}
- {entry_name: lshr_rat, from_res: D, pubmed: '10446904', seq: '409', to_res: N}
- {entry_name: lshr_rat, from_res: Y, pubmed: '10446904', seq: '550', to_res: F}
- {entry_name: lshr_rat, from_res: D, pubmed: '10446904', seq: '582', to_res: Y}
- {entry_name: lshr_rat, from_res: K, pubmed: '9788760', seq: '609', to_res: E}
- {entry_name: tshr_human, from_res: S, pubmed: '10595453', seq: '281', to_res: I}
- {entry_name: tshr_human, from_res: D, pubmed: '10595453', seq: '619', to_res: G}
- {entry_name: tshr_human, from_res: A, pubmed: '10595453', seq: '623', to_res: V}
- {entry_name: tshr_human, from_res: D, pubmed: '10595453', seq: '633', to_res: Y}
- {entry_name: tshr_human, from_res: D, pubmed: '10595453', seq: '727', to_res: E}
- {entry_name: tshr_human, from_res: P, pubmed: '10560953', seq: '162', to_res: A}
- {entry_name: tshr_human, from_res: I, pubmed: '10560953', seq: '167', to_res: N}
- {entry_name: tshr_human, from_res: A, pubmed: '10560953', seq: '553', to_res: T}
- {entry_name: tshr_human, from_res: Y, pubmed: '10691307', seq: '601', to_res: N}
- {entry_name: tshr_human, from_res: Y, pubmed: '10691307', seq: '601', to_res: H}
- {entry_name: tshr_human, from_res: Y, pubmed: '10691307', seq: '601', to_res: F}
- {entry_name: tshr_human, from_res: C, pubmed: '9449658', seq: '699', to_res: A}
- {entry_name: fshr_human, from_res: K, pubmed: '9786899', seq: '598', to_res: A}
- {entry_name: fshr_human, from_res: V, pubmed: '9786899', seq: '599', to_res: A}
- {entry_name: fshr_human, from_res: P, pubmed: '9786899', seq: '600', to_res: A}
- {entry_name: fshr_human, from_res: L, pubmed: '9786899', seq: '601', to_res: A}
- {entry_name: fshr_human, from_res: I, pubmed: '9786899', seq: '602', to_res: A}
- {entry_name: fshr_human, from_res: T, pubmed: '9786899', seq: '603', to_res: A}
- {entry_name: fshr_human, from_res: V, pubmed: '9786899', seq: '604', to_res: A}
- {entry_name: fshr_human, from_res: S, pubmed: '9786899', seq: '605', to_res: A}
- {entry_name: fshr_human, from_res: K, pubmed: '9786899', seq: '606', to_res: A}
- {entry_name: fshr_human, from_res: K, pubmed: '9786899', seq: '608', to_res: A}
- {entry_name: fshr_human, from_res: A, pubmed: '9786899', seq: '607', to_res: G}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '46', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '46', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '80', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '80', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '85', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '85', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '131', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '131', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '169', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '169', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '255', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '255', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '260', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '260', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '263', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '263', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '309', to_res: A}
- {entry_name: aa1r_human, from_res: C, pubmed: '11077047', seq: '309', to_res: S}
- {entry_name: aa1r_human, from_res: C, pubmed: '10455026', seq: '309', to_res: A}
- {entry_name: aa2ar_human, from_res: E, pubmed: '10927024', seq: '13', to_res: Q}
- {entry_name: aa2ar_human, from_res: H, pubmed: '10927024', seq: '278', to_res: Y}
- {entry_name: aa2br_human, from_res: V, pubmed: '11093773', seq: '11', to_res: I}
- {entry_name: aa2br_human, from_res: A, pubmed: '11093773', seq: '12', to_res: T}
- {entry_name: aa2br_human, from_res: L, pubmed: '11093773', seq: '58', to_res: V}
- {entry_name: aa2br_human, from_res: F, pubmed: '11093773', seq: '59', to_res: L}
- {entry_name: aa2br_human, from_res: N, pubmed: '11093773', seq: '273', to_res: Y}
- {entry_name: aa2br_human, from_res: V, pubmed: '11093773', seq: '11', to_res: I}
- {entry_name: aa2br_human, from_res: A, pubmed: '11093773', seq: '12', to_res: T}
- {entry_name: aa2br_human, from_res: L, pubmed: '11093773', seq: '58', to_res: V}
- {entry_name: aa2br_human, from_res: F, pubmed: '11093773', seq: '59', to_res: L}
- {entry_name: aa2br_human, from_res: N, pubmed: '11093773', seq: '273', to_res: Y}
- {entry_name: 5HT1A_HUMAN, from_res: P, pubmed: '15037200', seq: '16', to_res: L}
- {entry_name: 5HT1A_HUMAN, from_res: A, pubmed: '15037200', seq: '17', to_res: P}
- {entry_name: 5HT1A_HUMAN, from_res: G, pubmed: '15037200', seq: '22', to_res: S}
- {entry_name: 5HT1A_HUMAN, from_res: I, pubmed: '15037200', seq: '28', to_res: V}
- {entry_name: 5HT1A_HUMAN, from_res: I, pubmed: '8546152', seq: '28', to_res: V}
- {entry_name: 5HT1A_HUMAN, from_res: A, pubmed: '15037200', seq: '50', to_res: V}
- {entry_name: 5HT1A_HUMAN, from_res: C, pubmed: '15037200', seq: '109', to_res: R}
- {entry_name: 5HT1A_HUMAN, from_res: A, pubmed: '15037200', seq: '155', to_res: G}
- {entry_name: 5HT1A_HUMAN, from_res: M, pubmed: '15037200', seq: '172', to_res: I}
- {entry_name: 5HT1A_HUMAN, from_res: P, pubmed: '15037200', seq: '184', to_res: L}
- {entry_name: 5HT1A_HUMAN, from_res: R, pubmed: '15037200', seq: '220', to_res: L}
- {entry_name: 5HT1A_HUMAN, from_res: K, pubmed: '15037200', seq: '228', to_res: R}
- {entry_name: 5HT1A_HUMAN, from_res: G, pubmed: '15037200', seq: '273', to_res: D}
- {entry_name: 5HT1A_HUMAN, from_res: L, pubmed: '15037200', seq: '381', to_res: F}
- {entry_name: 5HT1A_HUMAN, from_res: K, pubmed: '15037200', seq: '418', to_res: N}
- {entry_name: 5HT1A_MOUSE, from_res: C, pubmed: '14604995', seq: '417', to_res: S}
- {entry_name: 5HT1A_MOUSE, from_res: C, pubmed: '14604995', seq: '420', to_res: S}
- {entry_name: 5HT1A_RAT, from_res: V, pubmed: '16410407', seq: '145', to_res: L}
- {entry_name: 5HT1A_RAT, from_res: N, pubmed: '16410407', seq: '146', to_res: T}
- {entry_name: 5HT1A_RAT, from_res: K, pubmed: '16410407', seq: '147', to_res: R}
- {entry_name: 5HT1A_RAT, from_res: R, pubmed: '16410407', seq: '148', to_res: G}
- {entry_name: 5HT1A_RAT, from_res: R, pubmed: '16410407', seq: '148', to_res: K}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '15733090', seq: '149', to_res: A}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '16410407', seq: '149', to_res: A}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '16410407', seq: '149', to_res: G}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '16410407', seq: '149', to_res: R}
- {entry_name: 5HT1A_RAT, from_res: P, pubmed: '16410407', seq: '150', to_res: T}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '15733090', seq: '229', to_res: A}
- {entry_name: 5HT1A_RAT, from_res: S, pubmed: '15733090', seq: '253', to_res: G}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '9224826', seq: '343', to_res: A}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '15733090', seq: '343', to_res: A}
- {entry_name: 5HT1A_RAT, from_res: T, pubmed: '16410407', seq: '343', to_res: A}
- {entry_name: 5HT1A_RAT, from_res: V, pubmed: '16410407', seq: '344', to_res: E}
- {entry_name: 5HT1B_HUMAN, from_res: F, pubmed: '12437478', seq: '124', to_res: C}
- {entry_name: 5HT1B_HUMAN, from_res: S, pubmed: '9879059', seq: '212', to_res: A}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: A}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: F}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: G}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: H}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: I}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: K}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: N}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: Q}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: R}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '10510311', seq: '313', to_res: T}
- {entry_name: 5HT1B_HUMAN, from_res: F, pubmed: '9879059', seq: '331', to_res: A}
- {entry_name: 5HT1B_HUMAN, from_res: S, pubmed: '9671119', seq: '334', to_res: A}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '8417162', seq: '355', to_res: N}
- {entry_name: 5HT1B_HUMAN, from_res: T, pubmed: '8569707', seq: '355', to_res: N}
- {entry_name: 5HT1D_CAVPO, from_res: T, pubmed: '10385247', seq: '100', to_res: I}
- {entry_name: 5HT1D_CAVPO, from_res: R, pubmed: '10385247', seq: '102', to_res: H}
- {entry_name: 5HT1D_HUMAN, from_res: S, pubmed: '9855638', seq: '193', to_res: D}
- {entry_name: 5HT1D_HUMAN, from_res: S, pubmed: '9855638', seq: '196', to_res: L}
- {entry_name: 5HT1D_HUMAN, from_res: I, pubmed: '9855638', seq: '199', to_res: V}
- {entry_name: 5HT1D_HUMAN, from_res: C, pubmed: '9855638', seq: '203', to_res: V}
- {entry_name: 5HT1D_HUMAN, from_res: I, pubmed: '9855638', seq: '208', to_res: F}
- {entry_name: 5HT1D_HUMAN, from_res: S, pubmed: '9855638', seq: '210', to_res: E}
- {entry_name: 5HT1D_HUMAN, from_res: S, pubmed: '9855638', seq: '210', to_res: T}
- {entry_name: 5HT1D_HUMAN, from_res: V, pubmed: '9855638', seq: '211', to_res: L}
- {entry_name: 5HT1D_HUMAN, from_res: I, pubmed: '9855638', seq: '215', to_res: A}
- {entry_name: 5HT1D_MOUSE, from_res: T, pubmed: '14729271', seq: '354', to_res: N}
- {entry_name: 5HT2A_DROME, from_res: C, pubmed: '14525988', seq: '305', to_res: V}
- {entry_name: 5HT2A_HUMAN, from_res: T, pubmed: '12563180', seq: '25', to_res: N}
- {entry_name: 5HT2A_HUMAN, from_res: I, pubmed: '12563180', seq: '197', to_res: V}
- {entry_name: 5HT2A_HUMAN, from_res: S, pubmed: '9776378', seq: '242', to_res: A}
- {entry_name: 5HT2A_HUMAN, from_res: A, pubmed: '12563180', seq: '447', to_res: V}
- {entry_name: 5HT2A_HUMAN, from_res: H, pubmed: '12563180', seq: '452', to_res: Y}
- {entry_name: 5HT2A_RAT, from_res: W, pubmed: '9776378', seq: '76', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '9776378', seq: '81', to_res: I}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '9776378', seq: '82', to_res: I}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '100', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '109', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: D, pubmed: '9776378', seq: '120', to_res: N}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '9776378', seq: '125', to_res: L}
- {entry_name: 5HT2A_RAT, from_res: M, pubmed: '9776378', seq: '132', to_res: L}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '9776378', seq: '134', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: D, pubmed: '9776378', seq: '155', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: D, pubmed: '9776378', seq: '155', to_res: E}
- {entry_name: 5HT2A_RAT, from_res: D, pubmed: '9776378', seq: '155', to_res: N}
- {entry_name: 5HT2A_RAT, from_res: D, pubmed: '9776378', seq: '155', to_res: Q}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '9776378', seq: '159', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: R, pubmed: '11801601', seq: '173', to_res: E}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '184', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '188', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '188', to_res: D}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '190', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: W, pubmed: '9776378', seq: '200', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '9387857', seq: '207', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '11040033', seq: '239', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '9387857', seq: '239', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '11040033', seq: '240', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: A, pubmed: '8114677', seq: '242', to_res: S}
- {entry_name: 5HT2A_RAT, from_res: A, pubmed: '9776378', seq: '242', to_res: S}
- {entry_name: 5HT2A_RAT, from_res: A, pubmed: '8114677', seq: '242', to_res: T}
- {entry_name: 5HT2A_RAT, from_res: A, pubmed: '8114677', seq: '242', to_res: V}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '11040033', seq: '243', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '11040033', seq: '244', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '257', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '260', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '266', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '270', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '273', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '274', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '291', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '311', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '314', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '11801601', seq: '316', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '316', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: N, pubmed: '11801601', seq: '317', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: E, pubmed: '11801601', seq: '318', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: E, pubmed: '11801601', seq: '318', to_res: R}
- {entry_name: 5HT2A_RAT, from_res: Q, pubmed: '11801601', seq: '319', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: K, pubmed: '11801601', seq: '320', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: C, pubmed: '11801601', seq: '322', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: C, pubmed: '9655845', seq: '322', to_res: E}
- {entry_name: 5HT2A_RAT, from_res: C, pubmed: '9655845', seq: '322', to_res: K}
- {entry_name: 5HT2A_RAT, from_res: C, pubmed: '9928250', seq: '322', to_res: K}
- {entry_name: 5HT2A_RAT, from_res: C, pubmed: '9655845', seq: '322', to_res: R}
- {entry_name: 5HT2A_RAT, from_res: K, pubmed: '11801601', seq: '323', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: V, pubmed: '11801601', seq: '324', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: L, pubmed: '11801601', seq: '325', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: G, pubmed: '11801601', seq: '326', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: I, pubmed: '11801601', seq: '327', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: V, pubmed: '11801601', seq: '328', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: W, pubmed: '9776378', seq: '336', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '9776378', seq: '339', to_res: L}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '9776378', seq: '340', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '9776378', seq: '340', to_res: L}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '9776378', seq: '340', to_res: Y}
- {entry_name: 5HT2A_RAT, from_res: N, pubmed: '10869371', seq: '363', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: F, pubmed: '9776378', seq: '365', to_res: L}
- {entry_name: 5HT2A_RAT, from_res: W, pubmed: '9776378', seq: '367', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: Y, pubmed: '9776378', seq: '370', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: Y, pubmed: '9776378', seq: '370', to_res: F}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '386', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '389', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '392', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: T, pubmed: '12962510', seq: '413', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '421', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '421', to_res: D}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '421', to_res: F}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '422', to_res: A}
- {entry_name: 5HT2A_RAT, from_res: S, pubmed: '12962510', seq: '432', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: K, pubmed: '12695524', seq: '44', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: D, pubmed: '11859080', seq: '100', to_res: N}
- {entry_name: 5HT2B_HUMAN, from_res: D, pubmed: '11859080', seq: '135', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: S, pubmed: '11859080', seq: '139', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: R, pubmed: '12695524', seq: '169', to_res: E}
- {entry_name: 5HT2B_HUMAN, from_res: A, pubmed: '11859080', seq: '187', to_res: S}
- {entry_name: 5HT2B_HUMAN, from_res: S, pubmed: '11859080', seq: '222', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: T, pubmed: '11859080', seq: '228', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: P, pubmed: '11859080', seq: '229', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: A, pubmed: '11859080', seq: '231', to_res: T}
- {entry_name: 5HT2B_HUMAN, from_res: W, pubmed: '11859080', seq: '337', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: F, pubmed: '11859080', seq: '341', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: N, pubmed: '11859080', seq: '344', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: E, pubmed: '11859080', seq: '363', to_res: A}
- {entry_name: 5HT2B_HUMAN, from_res: N, pubmed: '11859080', seq: '376', to_res: D}
- {entry_name: 5HT2B_HUMAN, from_res: R, pubmed: '15625277', seq: '393', to_res: X}
- {entry_name: 5HT2B_MOUSE, from_res: A, pubmed: '11859080', seq: '79', to_res: S}
- {entry_name: 5HT2C_HUMAN, from_res: C, pubmed: '9200673', seq: '23', to_res: S}
- {entry_name: 5HT2C_HUMAN, from_res: C, pubmed: '15912142', seq: '23', to_res: S}
- {entry_name: 5HT2C_HUMAN, from_res: S, pubmed: '16195233', seq: '138', to_res: R}
- {entry_name: 5HT2C_HUMAN, from_res: I, pubmed: '15087490', seq: '156', to_res: V}
- {entry_name: 5HT2C_HUMAN, from_res: N, pubmed: '15087490', seq: '158', to_res: G}
- {entry_name: 5HT2C_HUMAN, from_res: I, pubmed: '15087490', seq: '160', to_res: V}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '9282936', seq: '312', to_res: F}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '9282936', seq: '312', to_res: K}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '9928251', seq: '312', to_res: K}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '10816555', seq: '458', to_res: A}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '12682077', seq: '458', to_res: A}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '12682077', seq: '458', to_res: D}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '10816555', seq: '459', to_res: A}
- {entry_name: 5HT2C_RAT, from_res: S, pubmed: '12682077', seq: '459', to_res: D}
- {entry_name: 5HT2C_RAT, from_res: V, pubmed: '12682077', seq: '460', to_res: A}
- {entry_name: 5HT4R_MOUSE, from_res: D, pubmed: '11976337', seq: '100', to_res: A}
- {entry_name: 5HT4R_MOUSE, from_res: R, pubmed: '11976337', seq: '118', to_res: A}
- {entry_name: 5HT4R_MOUSE, from_res: T, pubmed: '11976337', seq: '134', to_res: A}
- {entry_name: 5HT4R_MOUSE, from_res: S, pubmed: '11976337', seq: '197', to_res: A}
- {entry_name: 5HT4R_MOUSE, from_res: A, pubmed: '10220570', seq: '258', to_res: L}
- {entry_name: 5HT4R_MOUSE, from_res: A, pubmed: '11976337', seq: '258', to_res: L}
- {entry_name: 5HT4R_MOUSE, from_res: W, pubmed: '11976337', seq: '272', to_res: A}
- {entry_name: 5HT4R_MOUSE, from_res: F, pubmed: '11976337', seq: '275', to_res: A}
- {entry_name: 5HT4R_MOUSE, from_res: N, pubmed: '11976337', seq: '308', to_res: D}
- {entry_name: 5HT5B_MOUSE, from_res: Q, pubmed: '12466127', seq: '209', to_res: L}
- {entry_name: 5HT6R_MOUSE, from_res: K, pubmed: '11406289', seq: '264', to_res: I}
- {entry_name: 5HT6R_MOUSE, from_res: K, pubmed: '11406289', seq: '267', to_res: A}
- {entry_name: 5HT6R_MOUSE, from_res: A, pubmed: '11406289', seq: '268', to_res: R}
- {entry_name: 5HT6R_RAT, from_res: N, pubmed: '11406289', seq: '288', to_res: S}
- {entry_name: 5HT7R_HUMAN, from_res: G, pubmed: '14704167', seq: '42', to_res: V}
- {entry_name: 5HT7R_MOUSE, from_res: R, pubmed: '9256244', seq: '183', to_res: A}
- {entry_name: 5HT7R_MOUSE, from_res: G, pubmed: '14729271', seq: '186', to_res: C}
- {entry_name: 5HT7R_MOUSE, from_res: R, pubmed: '9256244', seq: '270', to_res: A}
- {entry_name: 5HT7R_MOUSE, from_res: K, pubmed: '9256244', seq: '271', to_res: A}
- {entry_name: 5HT7R_MOUSE, from_res: E, pubmed: '9256244', seq: '325', to_res: G}
- {entry_name: 5HT7R_MOUSE, from_res: K, pubmed: '9256244', seq: '327', to_res: S}
- {entry_name: AA1R_BOVIN, from_res: H, pubmed: '1587851', seq: '251', to_res: L}
- {entry_name: AA1R_BOVIN, from_res: I, pubmed: '10722120', seq: '270', to_res: M}
- {entry_name: AA1R_BOVIN, from_res: H, pubmed: '1587851', seq: '278', to_res: L}
- {entry_name: AA1R_HUMAN, from_res: G, pubmed: '9920910', seq: '14', to_res: T}
- {entry_name: AA1R_HUMAN, from_res: E, pubmed: '8967987', seq: '16', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: P, pubmed: '9920910', seq: '25', to_res: L}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '46', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '46', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: D, pubmed: '8967987', seq: '55', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '80', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '80', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '85', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '85', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11306703', seq: '85', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: P, pubmed: '9920910', seq: '86', to_res: F}
- {entry_name: AA1R_HUMAN, from_res: V, pubmed: '9920910', seq: '87', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: L, pubmed: '9920910', seq: '88', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: T, pubmed: '9920910', seq: '91', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: Q, pubmed: '11891221', seq: '92', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: Q, pubmed: '9920910', seq: '92', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: S, pubmed: '8967987', seq: '94', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: S, pubmed: '8967987', seq: '94', to_res: T}
- {entry_name: AA1R_HUMAN, from_res: L, pubmed: '9920910', seq: '96', to_res: F}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '131', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '131', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '169', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '169', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: H, pubmed: '11891221', seq: '251', to_res: L}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '255', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '255', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '260', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '260', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '263', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '263', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: H, pubmed: '11306703', seq: '264', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: K, pubmed: '11306703', seq: '265', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: P, pubmed: '11306703', seq: '266', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: S, pubmed: '11306703', seq: '267', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: I, pubmed: '11306703', seq: '268', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: L, pubmed: '11306703', seq: '269', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: T, pubmed: '11306703', seq: '270', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: Y, pubmed: '11306703', seq: '271', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: I, pubmed: '11306703', seq: '272', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: A, pubmed: '11306703', seq: '273', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: I, pubmed: '11306703', seq: '274', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: F, pubmed: '11306703', seq: '275', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: L, pubmed: '11306703', seq: '276', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: T, pubmed: '10722120', seq: '277', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: T, pubmed: '8300561', seq: '277', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: T, pubmed: '9827575', seq: '277', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: T, pubmed: '11306703', seq: '277', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: T, pubmed: '8300561', seq: '277', to_res: S}
- {entry_name: AA1R_HUMAN, from_res: H, pubmed: '11306703', seq: '278', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: H, pubmed: '11306703', seq: '278', to_res: L}
- {entry_name: AA1R_HUMAN, from_res: G, pubmed: '11306703', seq: '279', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: N, pubmed: '11306703', seq: '280', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: S, pubmed: '11306703', seq: '281', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: A, pubmed: '11306703', seq: '282', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: M, pubmed: '11306703', seq: '283', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: N, pubmed: '11306703', seq: '284', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: P, pubmed: '11306703', seq: '285', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: I, pubmed: '11306703', seq: '286', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: V, pubmed: '11306703', seq: '287', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: Y, pubmed: '11306703', seq: '288', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: A, pubmed: '11306703', seq: '289', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: F, pubmed: '11306703', seq: '290', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: R, pubmed: '11306703', seq: '291', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: I, pubmed: '11306703', seq: '292', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: Q, pubmed: '11306703', seq: '293', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: K, pubmed: '11306703', seq: '294', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: F, pubmed: '11306703', seq: '295', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: R, pubmed: '11306703', seq: '296', to_res: C}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '10455026', seq: '309', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '309', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '12475223', seq: '309', to_res: A}
- {entry_name: AA1R_HUMAN, from_res: C, pubmed: '11077047', seq: '309', to_res: S}
- {entry_name: AA1R_MOUSE, from_res: G, pubmed: '11734617', seq: '14', to_res: T}
- {entry_name: AA1R_MOUSE, from_res: E, pubmed: '11734617', seq: '16', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: P, pubmed: '11734617', seq: '25', to_res: L}
- {entry_name: AA1R_MOUSE, from_res: I, pubmed: '11734617', seq: '31', to_res: C}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '46', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '50', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: D, pubmed: '11734617', seq: '55', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: L, pubmed: '11734617', seq: '65', to_res: F}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '80', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: M, pubmed: '11734617', seq: '82', to_res: F}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '85', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '85', to_res: S}
- {entry_name: AA1R_MOUSE, from_res: P, pubmed: '11734617', seq: '86', to_res: F}
- {entry_name: AA1R_MOUSE, from_res: V, pubmed: '11734617', seq: '87', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: L, pubmed: '11734617', seq: '88', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: T, pubmed: '11734617', seq: '91', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: Q, pubmed: '11734617', seq: '92', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '93', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '94', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '94', to_res: T}
- {entry_name: AA1R_MOUSE, from_res: A, pubmed: '11734617', seq: '125', to_res: K}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '131', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '135', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: T, pubmed: '11734617', seq: '141', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: F, pubmed: '11734617', seq: '144', to_res: L}
- {entry_name: AA1R_MOUSE, from_res: E, pubmed: '11734617', seq: '151', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '169', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: H, pubmed: '11734617', seq: '251', to_res: L}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '255', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '260', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '263', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: I, pubmed: '11734617', seq: '270', to_res: M}
- {entry_name: AA1R_MOUSE, from_res: I, pubmed: '11734617', seq: '274', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: T, pubmed: '11734617', seq: '277', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: T, pubmed: '11734617', seq: '277', to_res: S}
- {entry_name: AA1R_MOUSE, from_res: H, pubmed: '11734617', seq: '278', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: H, pubmed: '11734617', seq: '278', to_res: L}
- {entry_name: AA1R_MOUSE, from_res: H, pubmed: '11734617', seq: '278', to_res: Y}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '281', to_res: A}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '281', to_res: N}
- {entry_name: AA1R_MOUSE, from_res: S, pubmed: '11734617', seq: '281', to_res: T}
- {entry_name: AA1R_MOUSE, from_res: C, pubmed: '11734617', seq: '309', to_res: A}
- {entry_name: AA1R_RAT, from_res: L, pubmed: '16414025', seq: '65', to_res: T}
- {entry_name: AA1R_RAT, from_res: I, pubmed: '16414025', seq: '69', to_res: S}
- {entry_name: AA1R_RAT, from_res: I, pubmed: '16414025', seq: '69', to_res: T}
- {entry_name: AA2AR_HUMAN, from_res: E, pubmed: '10927024', seq: '13', to_res: Q}
- {entry_name: AA2AR_HUMAN, from_res: T, pubmed: '14584936', seq: '88', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: T, pubmed: '8794889', seq: '88', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: T, pubmed: '14584936', seq: '88', to_res: D}
- {entry_name: AA2AR_HUMAN, from_res: T, pubmed: '15734651', seq: '88', to_res: D}
- {entry_name: AA2AR_HUMAN, from_res: T, pubmed: '14584936', seq: '88', to_res: E}
- {entry_name: AA2AR_HUMAN, from_res: T, pubmed: '8794889', seq: '88', to_res: S}
- {entry_name: AA2AR_HUMAN, from_res: Q, pubmed: '11891221', seq: '89', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: Q, pubmed: '8794889', seq: '89', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: Q, pubmed: '14584936', seq: '89', to_res: D}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '8794889', seq: '90', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '8794889', seq: '91', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: T, pubmed: '11891221', seq: '119', to_res: C}
- {entry_name: AA2AR_HUMAN, from_res: E, pubmed: '8609897', seq: '151', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: E, pubmed: '8609897', seq: '151', to_res: D}
- {entry_name: AA2AR_HUMAN, from_res: E, pubmed: '8609897', seq: '151', to_res: Q}
- {entry_name: AA2AR_HUMAN, from_res: E, pubmed: '8609897', seq: '161', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: E, pubmed: '8609897', seq: '169', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: E, pubmed: '8609897', seq: '169', to_res: Q}
- {entry_name: AA2AR_HUMAN, from_res: D, pubmed: '8609897', seq: '170', to_res: K}
- {entry_name: AA2AR_HUMAN, from_res: P, pubmed: '8609897', seq: '173', to_res: R}
- {entry_name: AA2AR_HUMAN, from_res: F, pubmed: '7775460', seq: '180', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: N, pubmed: '7775460', seq: '181', to_res: S}
- {entry_name: AA2AR_HUMAN, from_res: F, pubmed: '7775460', seq: '182', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: F, pubmed: '7775460', seq: '182', to_res: W}
- {entry_name: AA2AR_HUMAN, from_res: F, pubmed: '7775460', seq: '182', to_res: Y}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '11891221', seq: '250', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '14584936', seq: '250', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '7775460', seq: '250', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '7775460', seq: '250', to_res: F}
- {entry_name: AA2AR_HUMAN, from_res: N, pubmed: '11891221', seq: '253', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: N, pubmed: '14584936', seq: '253', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: N, pubmed: '7775460', seq: '253', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: N, pubmed: '7775460', seq: '253', to_res: S}
- {entry_name: AA2AR_HUMAN, from_res: C, pubmed: '7775460', seq: '254', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: F, pubmed: '7775460', seq: '257', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: F, pubmed: '7775460', seq: '257', to_res: R}
- {entry_name: AA2AR_HUMAN, from_res: C, pubmed: '11077047', seq: '262', to_res: G}
- {entry_name: AA2AR_HUMAN, from_res: C, pubmed: '8609897', seq: '262', to_res: G}
- {entry_name: AA2AR_HUMAN, from_res: Y, pubmed: '7775460', seq: '271', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: I, pubmed: '14584936', seq: '274', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: I, pubmed: '7775460', seq: '274', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '14584936', seq: '277', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '7775460', seq: '277', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '8794889', seq: '277', to_res: C}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '14584936', seq: '277', to_res: D}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '14584936', seq: '277', to_res: E}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '14584936', seq: '278', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '7775460', seq: '278', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '14584936', seq: '278', to_res: D}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '14584936', seq: '278', to_res: E}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '7775460', seq: '278', to_res: Q}
- {entry_name: AA2AR_HUMAN, from_res: H, pubmed: '10927024', seq: '278', to_res: Y}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '7775460', seq: '281', to_res: A}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: AA2AR_HUMAN, from_res: S, pubmed: '7775460', seq: '281', to_res: T}
- {entry_name: AA2AR_MOUSE, from_res: N, pubmed: '11891221', seq: '110', to_res: A}
- {entry_name: AA2AR_MOUSE, from_res: K, pubmed: '14584936', seq: '152', to_res: A}
- {entry_name: AA2AR_MOUSE, from_res: Q, pubmed: '9287315', seq: '209', to_res: L}
- {entry_name: AA2AR_RAT, from_res: Q, pubmed: '9287315', seq: '205', to_res: L}
- {entry_name: AA2BR_RAT, from_res: S, pubmed: '11333255', seq: '326', to_res: A}
- {entry_name: AA2BR_RAT, from_res: S, pubmed: '11333255', seq: '329', to_res: G}
- {entry_name: AA3R_HUMAN, from_res: E, pubmed: '11708915', seq: '19', to_res: X}
- {entry_name: AA3R_HUMAN, from_res: N, pubmed: '11396942', seq: '30', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: S, pubmed: '11708915', seq: '73', to_res: X}
- {entry_name: AA3R_HUMAN, from_res: C, pubmed: '11396942', seq: '88', to_res: F}
- {entry_name: AA3R_HUMAN, from_res: H, pubmed: '11891221', seq: '95', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: D, pubmed: '11396942', seq: '107', to_res: K}
- {entry_name: AA3R_HUMAN, from_res: D, pubmed: '11396942', seq: '107', to_res: N}
- {entry_name: AA3R_HUMAN, from_res: D, pubmed: '11396942', seq: '107', to_res: R}
- {entry_name: AA3R_HUMAN, from_res: R, pubmed: '11396942', seq: '108', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: R, pubmed: '11396942', seq: '108', to_res: E}
- {entry_name: AA3R_HUMAN, from_res: R, pubmed: '11396942', seq: '108', to_res: H}
- {entry_name: AA3R_HUMAN, from_res: R, pubmed: '11396942', seq: '108', to_res: K}
- {entry_name: AA3R_HUMAN, from_res: R, pubmed: '11396942', seq: '108', to_res: N}
- {entry_name: AA3R_HUMAN, from_res: Y, pubmed: '11396942', seq: '109', to_res: F}
- {entry_name: AA3R_HUMAN, from_res: K, pubmed: '11891221', seq: '152', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: A, pubmed: '11396942', seq: '229', to_res: E}
- {entry_name: AA3R_HUMAN, from_res: W, pubmed: '11891221', seq: '243', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: W, pubmed: '11891221', seq: '243', to_res: F}
- {entry_name: AA3R_HUMAN, from_res: L, pubmed: '11891221', seq: '244', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: S, pubmed: '11891221', seq: '247', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: S, pubmed: '11891221', seq: '247', to_res: H}
- {entry_name: AA3R_HUMAN, from_res: N, pubmed: '11891221', seq: '250', to_res: A}
- {entry_name: AA3R_HUMAN, from_res: H, pubmed: '11708915', seq: '272', to_res: E}
- {entry_name: AA3R_HUMAN, from_res: H, pubmed: '11891221', seq: '272', to_res: E}
- {entry_name: AA3R_HUMAN, from_res: Y, pubmed: '11396942', seq: '282', to_res: F}
- {entry_name: AA3R_RABIT, from_res: D, pubmed: '9507174', seq: '3', to_res: I}
- {entry_name: AA3R_RAT, from_res: C, pubmed: '10692494', seq: '305', to_res: A}
- {entry_name: AA3R_RAT, from_res: T, pubmed: '10692494', seq: '307', to_res: A}
- {entry_name: AA3R_RAT, from_res: T, pubmed: '10692494', seq: '318', to_res: A}
- {entry_name: AA3R_RAT, from_res: T, pubmed: '10692494', seq: '318', to_res: E}
- {entry_name: AA3R_RAT, from_res: T, pubmed: '10692494', seq: '319', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: D, pubmed: '1618842', seq: '71', to_res: N}
- {entry_name: ACM1_HUMAN, from_res: Y, pubmed: '1488411', seq: '82', to_res: F}
- {entry_name: ACM1_HUMAN, from_res: V, pubmed: '8120019', seq: '127', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: V, pubmed: '9003046', seq: '127', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: L, pubmed: '8120019', seq: '131', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: L, pubmed: '8226735', seq: '131', to_res: D}
- {entry_name: ACM1_HUMAN, from_res: V, pubmed: '12049494', seq: '173', to_res: M}
- {entry_name: ACM1_HUMAN, from_res: T, pubmed: '10188986', seq: '192', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: W, pubmed: '7706286', seq: '209', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: I, pubmed: '7706286', seq: '211', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: I, pubmed: '9003046', seq: '211', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: Y, pubmed: '7706286', seq: '212', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: E, pubmed: '7706286', seq: '214', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: E, pubmed: '7706286', seq: '216', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: E, pubmed: '7706286', seq: '221', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: K, pubmed: '7706286', seq: '359', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: E, pubmed: '7706286', seq: '360', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: E, pubmed: '9003046', seq: '360', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: K, pubmed: '7706286', seq: '361', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: K, pubmed: '7706286', seq: '362', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: K, pubmed: '9003046', seq: '362', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: T, pubmed: '7706286', seq: '366', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: N, pubmed: '10188986', seq: '382', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: S, pubmed: '10496961', seq: '388', to_res: Y}
- {entry_name: ACM1_HUMAN, from_res: S, pubmed: '9732369', seq: '388', to_res: Y}
- {entry_name: ACM1_HUMAN, from_res: T, pubmed: '10496961', seq: '389', to_res: P}
- {entry_name: ACM1_HUMAN, from_res: T, pubmed: '9732369', seq: '389', to_res: P}
- {entry_name: ACM1_HUMAN, from_res: T, pubmed: '9732369', seq: '389', to_res: Y}
- {entry_name: ACM1_HUMAN, from_res: M, pubmed: '10930431', seq: '416', to_res: A}
- {entry_name: ACM1_HUMAN, from_res: C, pubmed: '12049494', seq: '417', to_res: R}
- {entry_name: ACM1_HUMAN, from_res: C, pubmed: '12049494', seq: '417', to_res: S}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '2557534', seq: '71', to_res: N}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '2557534', seq: '99', to_res: N}
- {entry_name: ACM1_RAT, from_res: W, pubmed: '10066794', seq: '101', to_res: A}
- {entry_name: ACM1_RAT, from_res: W, pubmed: '11441014', seq: '101', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '10066794', seq: '102', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '11441014', seq: '102', to_res: A}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '10066794', seq: '105', to_res: A}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '10066794', seq: '105', to_res: E}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '11441014', seq: '105', to_res: N}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '2557534', seq: '105', to_res: N}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '10066794', seq: '106', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '106', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '106', to_res: N}
- {entry_name: ACM1_RAT, from_res: S, pubmed: '10066794', seq: '109', to_res: A}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '10066794', seq: '110', to_res: A}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '11441014', seq: '110', to_res: A}
- {entry_name: ACM1_RAT, from_res: S, pubmed: '10066794', seq: '112', to_res: A}
- {entry_name: ACM1_RAT, from_res: V, pubmed: '10066794', seq: '113', to_res: A}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '10066794', seq: '115', to_res: A}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '11441014', seq: '115', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '10066794', seq: '116', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '11441014', seq: '116', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '9203628', seq: '116', to_res: A}
- {entry_name: ACM1_RAT, from_res: I, pubmed: '10066794', seq: '119', to_res: A}
- {entry_name: ACM1_RAT, from_res: S, pubmed: '10066794', seq: '120', to_res: A}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: A}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: C}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: E}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: H}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: K}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: L}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '2557534', seq: '122', to_res: N}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: N}
- {entry_name: ACM1_RAT, from_res: D, pubmed: '9203628', seq: '122', to_res: S}
- {entry_name: ACM1_RAT, from_res: R, pubmed: '10066794', seq: '123', to_res: A}
- {entry_name: ACM1_RAT, from_res: R, pubmed: '10066794', seq: '123', to_res: K}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '10066794', seq: '124', to_res: C}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: C}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: E}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: F}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: H}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: I}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: M}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: R}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '9203628', seq: '124', to_res: W}
- {entry_name: ACM1_RAT, from_res: M, pubmed: '11441014', seq: '145', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '11441014', seq: '148', to_res: A}
- {entry_name: ACM1_RAT, from_res: W, pubmed: '11441014', seq: '150', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '11441014', seq: '151', to_res: A}
- {entry_name: ACM1_RAT, from_res: S, pubmed: '11441014', seq: '153', to_res: A}
- {entry_name: ACM1_RAT, from_res: W, pubmed: '11441014', seq: '157', to_res: A}
- {entry_name: ACM1_RAT, from_res: P, pubmed: '11441014', seq: '159', to_res: A}
- {entry_name: ACM1_RAT, from_res: A, pubmed: '11441014', seq: '160', to_res: G}
- {entry_name: ACM1_RAT, from_res: I, pubmed: '11441014', seq: '161', to_res: A}
- {entry_name: ACM1_RAT, from_res: F, pubmed: '11441014', seq: '163', to_res: A}
- {entry_name: ACM1_RAT, from_res: F, pubmed: '10860940', seq: '190', to_res: C}
- {entry_name: ACM1_RAT, from_res: T, pubmed: '10860940', seq: '192', to_res: C}
- {entry_name: ACM1_RAT, from_res: A, pubmed: '10860940', seq: '193', to_res: C}
- {entry_name: ACM1_RAT, from_res: A, pubmed: '10860940', seq: '193', to_res: G}
- {entry_name: ACM1_RAT, from_res: E, pubmed: '8626406', seq: '360', to_res: A}
- {entry_name: ACM1_RAT, from_res: W, pubmed: '11441014', seq: '378', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '10531410', seq: '381', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '381', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '10531410', seq: '381', to_res: F}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '381', to_res: N}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '10531410', seq: '382', to_res: A}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '11441014', seq: '382', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '10531410', seq: '386', to_res: A}
- {entry_name: ACM1_RAT, from_res: V, pubmed: '10531410', seq: '387', to_res: A}
- {entry_name: ACM1_RAT, from_res: L, pubmed: '11441014', seq: '402', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '404', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '404', to_res: F}
- {entry_name: ACM1_RAT, from_res: W, pubmed: '11441014', seq: '405', to_res: A}
- {entry_name: ACM1_RAT, from_res: C, pubmed: '11441014', seq: '407', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '408', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '408', to_res: F}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '11441014', seq: '410', to_res: A}
- {entry_name: ACM1_RAT, from_res: S, pubmed: '11441014', seq: '411', to_res: A}
- {entry_name: ACM1_RAT, from_res: T, pubmed: '11441014', seq: '412', to_res: A}
- {entry_name: ACM1_RAT, from_res: V, pubmed: '11441014', seq: '413', to_res: A}
- {entry_name: ACM1_RAT, from_res: N, pubmed: '11441014', seq: '414', to_res: A}
- {entry_name: ACM1_RAT, from_res: P, pubmed: '11441014', seq: '415', to_res: A}
- {entry_name: ACM1_RAT, from_res: M, pubmed: '11441014', seq: '416', to_res: A}
- {entry_name: ACM1_RAT, from_res: C, pubmed: '11441014', seq: '417', to_res: A}
- {entry_name: ACM1_RAT, from_res: Y, pubmed: '11441014', seq: '418', to_res: A}
- {entry_name: ACM1_RAT, from_res: A, pubmed: '11441014', seq: '419', to_res: G}
- {entry_name: ACM1_RAT, from_res: C, pubmed: '11441014', seq: '421', to_res: A}
- {entry_name: ACM2_HUMAN, from_res: D, pubmed: '10513578', seq: '103', to_res: A}
- {entry_name: ACM2_HUMAN, from_res: W, pubmed: '10513578', seq: '155', to_res: A}
- {entry_name: ACM2_HUMAN, from_res: Y, pubmed: '11602604', seq: '177', to_res: F}
- {entry_name: ACM2_HUMAN, from_res: T, pubmed: '10513578', seq: '187', to_res: A}
- {entry_name: ACM2_HUMAN, from_res: T, pubmed: '10513578', seq: '190', to_res: A}
- {entry_name: ACM2_HUMAN, from_res: W, pubmed: '10513578', seq: '400', to_res: A}
- {entry_name: ACM2_HUMAN, from_res: Y, pubmed: '10513578', seq: '403', to_res: A}
- {entry_name: ACM2_HUMAN, from_res: N, pubmed: '10513578', seq: '404', to_res: A}
- {entry_name: ACM2_MOUSE, from_res: G, pubmed: '9609688', seq: '251', to_res: C}
- {entry_name: ACM2_PIG, from_res: A, pubmed: '8569698', seq: '212', to_res: E}
- {entry_name: ACM2_PIG, from_res: K, pubmed: '8569698', seq: '214', to_res: A}
- {entry_name: ACM2_PIG, from_res: Y, pubmed: '9415719', seq: '403', to_res: F}
- {entry_name: ACM2_RAT, from_res: D, pubmed: '11689554', seq: '69', to_res: N}
- {entry_name: ACM2_RAT, from_res: D, pubmed: '11689554', seq: '103', to_res: N}
- {entry_name: ACM2_RAT, from_res: T, pubmed: '11689554', seq: '187', to_res: A}
- {entry_name: ACM2_RAT, from_res: Y, pubmed: '11689554', seq: '403', to_res: F}
- {entry_name: ACM3_HUMAN, from_res: S, pubmed: '11877431', seq: '17', to_res: N}
- {entry_name: ACM3_HUMAN, from_res: R, pubmed: '11562438', seq: '133', to_res: G}
- {entry_name: ACM3_HUMAN, from_res: Y, pubmed: '11562438', seq: '209', to_res: F}
- {entry_name: ACM3_HUMAN, from_res: F, pubmed: '11562438', seq: '210', to_res: I}
- {entry_name: ACM3_HUMAN, from_res: K, pubmed: '11562438', seq: '213', to_res: T}
- {entry_name: ACM3_HUMAN, from_res: K, pubmed: '11562438', seq: '213', to_res: V}
- {entry_name: ACM3_HUMAN, from_res: P, pubmed: '11562438', seq: '217', to_res: D}
- {entry_name: ACM3_HUMAN, from_res: P, pubmed: '11562438', seq: '217', to_res: E}
- {entry_name: ACM3_HUMAN, from_res: P, pubmed: '11562438', seq: '218', to_res: D}
- {entry_name: ACM3_HUMAN, from_res: P, pubmed: '11562438', seq: '218', to_res: E}
- {entry_name: ACM3_HUMAN, from_res: F, pubmed: '11562438', seq: '222', to_res: Y}
- {entry_name: ACM3_HUMAN, from_res: L, pubmed: '11562438', seq: '226', to_res: F}
- {entry_name: ACM3_HUMAN, from_res: E, pubmed: '11562438', seq: '228', to_res: N}
- {entry_name: ACM3_HUMAN, from_res: P, pubmed: '11562438', seq: '229', to_res: A}
- {entry_name: ACM3_HUMAN, from_res: T, pubmed: '11562438', seq: '230', to_res: A}
- {entry_name: ACM3_HUMAN, from_res: I, pubmed: '11562438', seq: '231', to_res: V}
- {entry_name: ACM3_HUMAN, from_res: L, pubmed: '14625299', seq: '250', to_res: S}
- {entry_name: ACM3_HUMAN, from_res: E, pubmed: '7684986', seq: '257', to_res: A}
- {entry_name: ACM3_HUMAN, from_res: E, pubmed: '7684986', seq: '257', to_res: P}
- {entry_name: ACM3_HUMAN, from_res: T, pubmed: '7684986', seq: '258', to_res: P}
- {entry_name: ACM3_HUMAN, from_res: F, pubmed: '10999941', seq: '500', to_res: A}
- {entry_name: ACM3_HUMAN, from_res: D, pubmed: '11562438', seq: '518', to_res: A}
- {entry_name: ACM3_HUMAN, from_res: S, pubmed: '11562438', seq: '519', to_res: P}
- {entry_name: ACM3_HUMAN, from_res: K, pubmed: '11562438', seq: '523', to_res: N}
- {entry_name: ACM3_HUMAN, from_res: F, pubmed: '11562438', seq: '525', to_res: V}
- {entry_name: ACM3_HUMAN, from_res: N, pubmed: '11562438', seq: '527', to_res: T}
- {entry_name: ACM3_HUMAN, from_res: T, pubmed: '8264552', seq: '550', to_res: A}
- {entry_name: ACM3_HUMAN, from_res: T, pubmed: '8264552', seq: '553', to_res: A}
- {entry_name: ACM3_MOUSE, from_res: R, pubmed: '10999941', seq: '183', to_res: C}
- {entry_name: ACM3_MOUSE, from_res: F, pubmed: '9609688', seq: '224', to_res: C}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10383466', seq: '6', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '12056896', seq: '6', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10347230', seq: '15', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10383466', seq: '15', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '12056896', seq: '15', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10383466', seq: '41', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '12056896', seq: '41', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10347230', seq: '48', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10383466', seq: '48', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '11698401', seq: '48', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '12056896', seq: '48', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10347230', seq: '52', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10383466', seq: '52', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '11698401', seq: '52', to_res: Q}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '12056896', seq: '52', to_res: Q}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '12056896', seq: '71', to_res: C}
- {entry_name: ACM3_RAT, from_res: F, pubmed: '12056896', seq: '72', to_res: C}
- {entry_name: ACM3_RAT, from_res: L, pubmed: '12056896', seq: '73', to_res: C}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '12056896', seq: '74', to_res: C}
- {entry_name: ACM3_RAT, from_res: G, pubmed: '12056896', seq: '75', to_res: C}
- {entry_name: ACM3_RAT, from_res: F, pubmed: '12056896', seq: '76', to_res: C}
- {entry_name: ACM3_RAT, from_res: L, pubmed: '12056896', seq: '77', to_res: C}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '12056896', seq: '78', to_res: C}
- {entry_name: ACM3_RAT, from_res: L, pubmed: '12056896', seq: '79', to_res: C}
- {entry_name: ACM3_RAT, from_res: V, pubmed: '12056896', seq: '80', to_res: C}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '111', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '111', to_res: S}
- {entry_name: ACM3_RAT, from_res: D, pubmed: '15572356', seq: '113', to_res: N}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '140', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '140', to_res: A}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '9880506', seq: '148', to_res: F}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '15572356', seq: '165', to_res: A}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '12750375', seq: '165', to_res: E}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '15572356', seq: '165', to_res: E}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '15572356', seq: '165', to_res: L}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '15572356', seq: '165', to_res: M}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '15572356', seq: '165', to_res: Q}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '15572356', seq: '165', to_res: W}
- {entry_name: ACM3_RAT, from_res: I, pubmed: '10347230', seq: '169', to_res: C}
- {entry_name: ACM3_RAT, from_res: W, pubmed: '7679072', seq: '192', to_res: F}
- {entry_name: ACM3_RAT, from_res: P, pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '220', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '220', to_res: A}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '12750375', seq: '229', to_res: R}
- {entry_name: ACM3_RAT, from_res: I, pubmed: '12750375', seq: '230', to_res: S}
- {entry_name: ACM3_RAT, from_res: I, pubmed: '12750375', seq: '230', to_res: T}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '12750375', seq: '231', to_res: A}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '9880506', seq: '231', to_res: A}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '10188986', seq: '234', to_res: A}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '9880506', seq: '234', to_res: A}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '12750375', seq: '238', to_res: T}
- {entry_name: ACM3_RAT, from_res: P, pubmed: '7679072', seq: '242', to_res: A}
- {entry_name: ACM3_RAT, from_res: P, pubmed: '9880506', seq: '242', to_res: A}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '15572356', seq: '250', to_res: A}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '15572356', seq: '250', to_res: D}
- {entry_name: ACM3_RAT, from_res: I, pubmed: '12750375', seq: '253', to_res: T}
- {entry_name: ACM3_RAT, from_res: I, pubmed: '9880506', seq: '253', to_res: Y}
- {entry_name: ACM3_RAT, from_res: I, pubmed: '15572356', seq: '253', to_res: Y}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '8157684', seq: '254', to_res: A}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '11698401', seq: '254', to_res: C}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '9880506', seq: '254', to_res: I}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '15572356', seq: '254', to_res: I}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '10722752', seq: '292', to_res: A}
- {entry_name: ACM3_RAT, from_res: E, pubmed: '10722752', seq: '293', to_res: A}
- {entry_name: ACM3_RAT, from_res: L, pubmed: '10722752', seq: '294', to_res: A}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '10722752', seq: '307', to_res: A}
- {entry_name: ACM3_RAT, from_res: R, pubmed: '10722752', seq: '309', to_res: A}
- {entry_name: ACM3_RAT, from_res: H, pubmed: '10722752', seq: '311', to_res: A}
- {entry_name: ACM3_RAT, from_res: F, pubmed: '10722752', seq: '312', to_res: A}
- {entry_name: ACM3_RAT, from_res: F, pubmed: '10722752', seq: '314', to_res: A}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '10722752', seq: '317', to_res: A}
- {entry_name: ACM3_RAT, from_res: W, pubmed: '10722752', seq: '319', to_res: A}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '10722752', seq: '320', to_res: A}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '10347230', seq: '484', to_res: C}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '11698401', seq: '484', to_res: C}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '12750375', seq: '484', to_res: E}
- {entry_name: ACM3_RAT, from_res: E, pubmed: '10347230', seq: '485', to_res: C}
- {entry_name: ACM3_RAT, from_res: E, pubmed: '11698401', seq: '485', to_res: C}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '10347230', seq: '486', to_res: C}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '11698401', seq: '486', to_res: C}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '10347230', seq: '487', to_res: C}
- {entry_name: ACM3_RAT, from_res: K, pubmed: '11698401', seq: '487', to_res: C}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '10347230', seq: '488', to_res: C}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '11698401', seq: '488', to_res: C}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '10347230', seq: '489', to_res: C}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '7629074', seq: '489', to_res: K}
- {entry_name: ACM3_RAT, from_res: A, pubmed: '12750375', seq: '489', to_res: T}
- {entry_name: ACM3_RAT, from_res: Q, pubmed: '10347230', seq: '490', to_res: C}
- {entry_name: ACM3_RAT, from_res: Q, pubmed: '11698401', seq: '490', to_res: C}
- {entry_name: ACM3_RAT, from_res: Q, pubmed: '12750375', seq: '490', to_res: L}
- {entry_name: ACM3_RAT, from_res: Q, pubmed: '15572356', seq: '490', to_res: L}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '10347230', seq: '491', to_res: C}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '11698401', seq: '491', to_res: C}
- {entry_name: ACM3_RAT, from_res: L, pubmed: '10347230', seq: '492', to_res: C}
- {entry_name: ACM3_RAT, from_res: L, pubmed: '11698401', seq: '492', to_res: C}
- {entry_name: ACM3_RAT, from_res: S, pubmed: '10347230', seq: '493', to_res: C}
- {entry_name: ACM3_RAT, from_res: S, pubmed: '11698401', seq: '493', to_res: C}
- {entry_name: ACM3_RAT, from_res: S, pubmed: '12750375', seq: '493', to_res: G}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '9880506', seq: '502', to_res: A}
- {entry_name: ACM3_RAT, from_res: W, pubmed: '7679072', seq: '503', to_res: F}
- {entry_name: ACM3_RAT, from_res: P, pubmed: '7679072', seq: '505', to_res: A}
- {entry_name: ACM3_RAT, from_res: P, pubmed: '9880506', seq: '505', to_res: A}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '10531410', seq: '506', to_res: F}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '9880506', seq: '506', to_res: F}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10531410', seq: '507', to_res: A}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '8034642', seq: '507', to_res: A}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '10531410', seq: '507', to_res: S}
- {entry_name: ACM3_RAT, from_res: V, pubmed: '12750375', seq: '510', to_res: I}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '516', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '516', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '519', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '519', to_res: A}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '9880506', seq: '529', to_res: F}
- {entry_name: ACM3_RAT, from_res: W, pubmed: '7679072', seq: '530', to_res: F}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '532', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '532', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '12056896', seq: '532', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '532', to_res: S}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '9880506', seq: '533', to_res: F}
- {entry_name: ACM3_RAT, from_res: T, pubmed: '9880506', seq: '537', to_res: A}
- {entry_name: ACM3_RAT, from_res: P, pubmed: '7679072', seq: '540', to_res: A}
- {entry_name: ACM3_RAT, from_res: P, pubmed: '9880506', seq: '540', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '542', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '542', to_res: A}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '542', to_res: S}
- {entry_name: ACM3_RAT, from_res: Y, pubmed: '12750375', seq: '543', to_res: H}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '546', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '546', to_res: S}
- {entry_name: ACM3_RAT, from_res: N, pubmed: '12750375', seq: '547', to_res: D}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '560', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '560', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '11698401', seq: '560', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '12056896', seq: '560', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10347230', seq: '562', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '10383466', seq: '562', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '11698401', seq: '562', to_res: S}
- {entry_name: ACM3_RAT, from_res: C, pubmed: '12056896', seq: '562', to_res: S}
- {entry_name: ACM4_HUMAN, from_res: R, pubmed: '10999941', seq: '178', to_res: C}
- {entry_name: ACM4_HUMAN, from_res: P, pubmed: '9609688', seq: '248', to_res: C}
- {entry_name: ACM4_HUMAN, from_res: L, pubmed: '9609688', seq: '272', to_res: C}
- {entry_name: ACM4_MOUSE, from_res: Q, pubmed: '9794239', seq: '61', to_res: L}
- {entry_name: ACM4_MOUSE, from_res: L, pubmed: '9658200', seq: '411', to_res: A}
- {entry_name: ACM4_RAT, from_res: Y, pubmed: '12151401', seq: '415', to_res: F}
- {entry_name: ACM4_XENLA, from_res: V, pubmed: '9609688', seq: '266', to_res: C}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '129', to_res: F}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: C}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: E}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: G}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: H}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: K}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: M}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: Q}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: R}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: S}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: T}
- {entry_name: ACM5_HUMAN, from_res: F, pubmed: '9733718', seq: '130', to_res: X}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: A}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: C}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: D}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: E}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: G}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: N}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: Q}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: T}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: V}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '134', to_res: X}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: A}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: C}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: G}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: M}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: S}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: T}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: V}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9733718', seq: '138', to_res: X}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '139', to_res: W}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: A}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: C}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: D}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: F}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: G}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: H}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: L}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: N}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: Q}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: S}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: T}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: W}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9733718', seq: '142', to_res: X}
- {entry_name: ACM5_HUMAN, from_res: Y, pubmed: '9521726', seq: '217', to_res: S}
- {entry_name: ACM5_HUMAN, from_res: R, pubmed: '9521726', seq: '223', to_res: E}
- {entry_name: ACM5_HUMAN, from_res: K, pubmed: '9521726', seq: '439', to_res: E}
- {entry_name: ACM5_HUMAN, from_res: K, pubmed: '9521726', seq: '439', to_res: G}
- {entry_name: ACM5_HUMAN, from_res: A, pubmed: '9521726', seq: '440', to_res: E}
- {entry_name: ACM5_HUMAN, from_res: A, pubmed: '9521726', seq: '440', to_res: Q}
- {entry_name: ACM5_HUMAN, from_res: A, pubmed: '9521726', seq: '440', to_res: T}
- {entry_name: ACM5_HUMAN, from_res: A, pubmed: '9521726', seq: '441', to_res: K}
- {entry_name: ACM5_HUMAN, from_res: A, pubmed: '9521726', seq: '441', to_res: S}
- {entry_name: ACM5_HUMAN, from_res: A, pubmed: '9521726', seq: '441', to_res: T}
- {entry_name: ACM5_HUMAN, from_res: S, pubmed: '10496961', seq: '465', to_res: Y}
- {entry_name: ACM5_HUMAN, from_res: S, pubmed: '9732369', seq: '465', to_res: Y}
- {entry_name: ACM5_HUMAN, from_res: T, pubmed: '10496961', seq: '466', to_res: P}
- {entry_name: ACM5_HUMAN, from_res: T, pubmed: '9732369', seq: '466', to_res: P}
- {entry_name: ACM5_MOUSE, from_res: Y, pubmed: '8621674', seq: '217', to_res: S}
- {entry_name: ACM5_MOUSE, from_res: Y, pubmed: '8621674', seq: '217', to_res: T}
- {entry_name: ACM5_MOUSE, from_res: T, pubmed: '8621674', seq: '220', to_res: A}
- {entry_name: ACM5_MOUSE, from_res: T, pubmed: '8621674', seq: '220', to_res: C}
- {entry_name: ACM5_MOUSE, from_res: T, pubmed: '8621674', seq: '220', to_res: F}
- {entry_name: ACM5_MOUSE, from_res: T, pubmed: '8621674', seq: '220', to_res: L}
- {entry_name: ACM5_MOUSE, from_res: T, pubmed: '8621674', seq: '220', to_res: S}
- {entry_name: ACM5_MOUSE, from_res: T, pubmed: '8621674', seq: '220', to_res: V}
- {entry_name: ACM5_MOUSE, from_res: R, pubmed: '8621674', seq: '223', to_res: E}
- {entry_name: ACM5_MOUSE, from_res: R, pubmed: '8621674', seq: '223', to_res: L}
- {entry_name: ACM5_MOUSE, from_res: R, pubmed: '8621674', seq: '223', to_res: M}
- {entry_name: ACTHR_HUMAN, from_res: C, pubmed: '10443676', seq: '21', to_res: R}
- {entry_name: ACTHR_HUMAN, from_res: C, pubmed: '15062562', seq: '21', to_res: R}
- {entry_name: ACTHR_HUMAN, from_res: I, pubmed: '10443676', seq: '44', to_res: M}
- {entry_name: ACTHR_HUMAN, from_res: S, pubmed: '10443676', seq: '74', to_res: I}
- {entry_name: ACTHR_HUMAN, from_res: S, pubmed: '8250922', seq: '74', to_res: I}
- {entry_name: ACTHR_HUMAN, from_res: D, pubmed: '10443676', seq: '103', to_res: N}
- {entry_name: ACTHR_HUMAN, from_res: D, pubmed: '8881288', seq: '107', to_res: N}
- {entry_name: ACTHR_HUMAN, from_res: R, pubmed: '10443676', seq: '128', to_res: C}
- {entry_name: ACTHR_HUMAN, from_res: R, pubmed: '10443676', seq: '146', to_res: H}
- {entry_name: ACTHR_HUMAN, from_res: T, pubmed: '10443676', seq: '159', to_res: K}
- {entry_name: ACTHR_HUMAN, from_res: S, pubmed: '10443676', seq: '247', to_res: G}
- {entry_name: ACTHR_HUMAN, from_res: S, pubmed: '15062562', seq: '247', to_res: G}
- {entry_name: ACTHR_HUMAN, from_res: C, pubmed: '8636348', seq: '251', to_res: F}
- {entry_name: ACTHR_HUMAN, from_res: C, pubmed: '8881288', seq: '251', to_res: F}
- {entry_name: ACTHR_MOUSE, from_res: S, pubmed: '11579104', seq: '208', to_res: A}
- {entry_name: ADA1A_HUMAN, from_res: R, pubmed: '15900517', seq: '166', to_res: K}
- {entry_name: ADA1A_HUMAN, from_res: I, pubmed: '15900517', seq: '200', to_res: S}
- {entry_name: ADA1A_HUMAN, from_res: G, pubmed: '15900517', seq: '247', to_res: R}
- {entry_name: ADA1A_HUMAN, from_res: A, pubmed: '11015306', seq: '271', to_res: T}
- {entry_name: ADA1A_HUMAN, from_res: V, pubmed: '15900517', seq: '311', to_res: I}
- {entry_name: ADA1A_RAT, from_res: F, pubmed: '10766790', seq: '163', to_res: Q}
- {entry_name: ADA1A_RAT, from_res: F, pubmed: '10766790', seq: '187', to_res: A}
- {entry_name: ADA1A_RAT, from_res: F, pubmed: '11331292', seq: '312', to_res: A}
- {entry_name: ADA1A_RAT, from_res: F, pubmed: '11331292', seq: '312', to_res: N}
- {entry_name: ADA1B_HUMAN, from_res: D, pubmed: '9547369', seq: '125', to_res: A}
- {entry_name: ADA1B_HUMAN, from_res: D, pubmed: '9547369', seq: '125', to_res: K}
- {entry_name: ADA1B_HUMAN, from_res: A, pubmed: '12490615', seq: '293', to_res: E}
- {entry_name: ADA1B_HUMAN, from_res: K, pubmed: '9547369', seq: '331', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: N, pubmed: '8670860', seq: '63', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '74', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: H, pubmed: '11585821', seq: '75', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '77', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '10574914', seq: '125', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '10604981', seq: '125', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '8910453', seq: '125', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '10574914', seq: '125', to_res: K}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '8910453', seq: '125', to_res: K}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '10908313', seq: '128', to_res: F}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '8910453', seq: '128', to_res: F}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '9012678', seq: '128', to_res: F}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '10347189', seq: '128', to_res: S}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '10347189', seq: '129', to_res: S}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '11993999', seq: '129', to_res: S}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '10347189', seq: '137', to_res: S}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '10648631', seq: '142', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '10908313', seq: '142', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '11585821', seq: '142', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '12183666', seq: '142', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '8670860', seq: '142', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: D, pubmed: '11585821', seq: '142', to_res: R}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '10648631', seq: '143', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '10648631', seq: '143', to_res: D}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '10648631', seq: '143', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '143', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '10648631', seq: '143', to_res: H}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '10648631', seq: '143', to_res: I}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '10648631', seq: '143', to_res: K}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '10648631', seq: '143', to_res: N}
- {entry_name: ADA1B_MESAU, from_res: Y, pubmed: '11585821', seq: '144', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: V, pubmed: '11585821', seq: '147', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: V, pubmed: '11585821', seq: '147', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '148', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '148', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: L, pubmed: '11585821', seq: '151', to_res: D}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '159', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '159', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '160', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '160', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '11585821', seq: '161', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '9012678', seq: '204', to_res: V}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '254', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '254', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '11585821', seq: '258', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '11585821', seq: '258', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '288', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '11585821', seq: '288', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: R, pubmed: '12183666', seq: '288', to_res: K}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '12183666', seq: '290', to_res: H}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '11585821', seq: '291', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '11585821', seq: '291', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '10347189', seq: '293', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '10531388', seq: '293', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '10648631', seq: '293', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '10908313', seq: '293', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '10993115', seq: '293', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '12183666', seq: '293', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '9012678', seq: '293', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '10531388', seq: '293', to_res: K}
- {entry_name: ADA1B_MESAU, from_res: A, pubmed: '12183666', seq: '293', to_res: L}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '303', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '11993999', seq: '303', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '11752108', seq: '303', to_res: G}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '11993999', seq: '303', to_res: G}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '303', to_res: L}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '11752108', seq: '303', to_res: N}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '11993999', seq: '303', to_res: N}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '310', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '310', to_res: C}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '310', to_res: L}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '310', to_res: W}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '311', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '311', to_res: C}
- {entry_name: ADA1B_MESAU, from_res: F, pubmed: '10347189', seq: '311', to_res: L}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '8910453', seq: '331', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10574914', seq: '331', to_res: D}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: D}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10574914', seq: '331', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '8910453', seq: '331', to_res: E}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: H}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: L}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: M}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: Q}
- {entry_name: ADA1B_MESAU, from_res: K, pubmed: '10604981', seq: '331', to_res: W}
- {entry_name: ADA1B_MESAU, from_res: Y, pubmed: '10727513', seq: '348', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: Y, pubmed: '11752108', seq: '348', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: Y, pubmed: '9271354', seq: '348', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: Y, pubmed: '10347189', seq: '348', to_res: L}
- {entry_name: ADA1B_MESAU, from_res: C, pubmed: '10727513', seq: '367', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: S, pubmed: '10727513', seq: '369', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: Y, pubmed: '12644451', seq: '386', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: L, pubmed: '12644451', seq: '450', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: L, pubmed: '12644451', seq: '451', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: L, pubmed: '12644451', seq: '473', to_res: A}
- {entry_name: ADA1B_MESAU, from_res: L, pubmed: '12644451', seq: '474', to_res: A}
- {entry_name: ADA1B_RAT, from_res: R, pubmed: '9571086', seq: '143', to_res: A}
- {entry_name: ADA1D_MOUSE, from_res: A, pubmed: '11278430', seq: '293', to_res: E}
- {entry_name: ADA2A_BOVIN, from_res: D, pubmed: '11888275', seq: '130', to_res: I}
- {entry_name: ADA2A_HUMAN, from_res: D, pubmed: '10928951', seq: '79', to_res: N}
- {entry_name: ADA2A_HUMAN, from_res: D, pubmed: '12970108', seq: '113', to_res: S}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '9309797', seq: '165', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: V, pubmed: '10419505', seq: '197', to_res: C}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '10433494', seq: '200', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '10928951', seq: '200', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '10419505', seq: '200', to_res: C}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '12970108', seq: '200', to_res: C}
- {entry_name: ADA2A_HUMAN, from_res: C, pubmed: '10419505', seq: '201', to_res: S}
- {entry_name: ADA2A_HUMAN, from_res: C, pubmed: '12970108', seq: '201', to_res: S}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '10433494', seq: '204', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '10928951', seq: '204', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '10419505', seq: '204', to_res: C}
- {entry_name: ADA2A_HUMAN, from_res: T, pubmed: '11864637', seq: '227', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '11864637', seq: '232', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '11864637', seq: '258', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '11864637', seq: '324', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: S, pubmed: '11864637', seq: '360', to_res: A}
- {entry_name: ADA2A_HUMAN, from_res: T, pubmed: '10193774', seq: '373', to_res: K}
- {entry_name: ADA2A_HUMAN, from_res: T, pubmed: '10928951', seq: '373', to_res: K}
- {entry_name: ADA2A_HUMAN, from_res: T, pubmed: '11383713', seq: '373', to_res: K}
- {entry_name: ADA2A_HUMAN, from_res: F, pubmed: '8576196', seq: '412', to_res: N}
- {entry_name: ADA2A_MOUSE, from_res: D, pubmed: '11125002', seq: '79', to_res: N}
- {entry_name: ADA2A_MOUSE, from_res: D, pubmed: '12205290', seq: '79', to_res: N}
- {entry_name: ADA2A_MOUSE, from_res: D, pubmed: '9278550', seq: '79', to_res: N}
- {entry_name: ADA2A_MOUSE, from_res: D, pubmed: '9421280', seq: '79', to_res: N}
- {entry_name: ADA2A_MOUSE, from_res: D, pubmed: '9482787', seq: '79', to_res: N}
- {entry_name: ADA2A_MOUSE, from_res: D, pubmed: '9952154', seq: '79', to_res: N}
- {entry_name: ADA2A_PIG, from_res: D, pubmed: '11781138', seq: '79', to_res: N}
- {entry_name: ADA2A_PIG, from_res: D, pubmed: '9727043', seq: '113', to_res: N}
- {entry_name: ADA2A_PIG, from_res: T, pubmed: '11179449', seq: '373', to_res: K}
- {entry_name: ADA2A_PIG, from_res: C, pubmed: '9305937', seq: '442', to_res: A}
- {entry_name: ADA2A_RAT, from_res: S, pubmed: '12095982', seq: '165', to_res: A}
- {entry_name: ADA2A_RAT, from_res: T, pubmed: '12015212', seq: '373', to_res: K}
- {entry_name: ADA2B_HUMAN, from_res: T, pubmed: '10617142', seq: '370', to_res: K}
- {entry_name: ADA2B_HUMAN, from_res: T, pubmed: '11383713', seq: '370', to_res: K}
- {entry_name: ADA2C_HUMAN, from_res: S, pubmed: '15469414', seq: '189', to_res: C}
- {entry_name: ADA2C_HUMAN, from_res: S, pubmed: '15469414', seq: '189', to_res: L}
- {entry_name: ADA2C_HUMAN, from_res: S, pubmed: '15469414', seq: '189', to_res: M}
- {entry_name: ADA2C_HUMAN, from_res: T, pubmed: '11383713', seq: '381', to_res: K}
- {entry_name: ADMR_HUMAN, from_res: M, pubmed: '11591721', seq: '88', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: S, pubmed: '16412278', seq: '49', to_res: G}
- {entry_name: ADRB1_HUMAN, from_res: M, pubmed: '11907156', seq: '98', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: S, pubmed: '11907156', seq: '102', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: L, pubmed: '11907156', seq: '110', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: T, pubmed: '11907156', seq: '117', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: I, pubmed: '11907156', seq: '118', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: V, pubmed: '11907156', seq: '119', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: V, pubmed: '11907156', seq: '120', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: W, pubmed: '11907156', seq: '121', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: L, pubmed: '11907156', seq: '323', to_res: K}
- {entry_name: ADRB1_HUMAN, from_res: P, pubmed: '11907156', seq: '355', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: D, pubmed: '11907156', seq: '356', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: R, pubmed: '11907156', seq: '357', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: L, pubmed: '11907156', seq: '358', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: F, pubmed: '11907156', seq: '359', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: V, pubmed: '11907156', seq: '360', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: F, pubmed: '11907156', seq: '361', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: F, pubmed: '11907156', seq: '362', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: L, pubmed: '11907156', seq: '365', to_res: A}
- {entry_name: ADRB1_HUMAN, from_res: I, pubmed: '11907156', seq: '375', to_res: A}
- {entry_name: ADRB2_BOVIN, from_res: D, pubmed: '11375997', seq: '130', to_res: N}
- {entry_name: ADRB2_BOVIN, from_res: L, pubmed: '11375997', seq: '266', to_res: S}
- {entry_name: ADRB2_BOVIN, from_res: K, pubmed: '11375997', seq: '267', to_res: R}
- {entry_name: ADRB2_BOVIN, from_res: E, pubmed: '11375997', seq: '268', to_res: A}
- {entry_name: ADRB2_BOVIN, from_res: E, pubmed: '11375997', seq: '268', to_res: Q}
- {entry_name: ADRB2_BOVIN, from_res: H, pubmed: '11375997', seq: '269', to_res: K}
- {entry_name: ADRB2_BOVIN, from_res: L, pubmed: '11375997', seq: '272', to_res: A}
- {entry_name: ADRB2_BOVIN, from_res: C, pubmed: '12167654', seq: '285', to_res: S}
- {entry_name: ADRB2_BOVIN, from_res: C, pubmed: '9341194', seq: '341', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: R, pubmed: '11713122', seq: '16', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: R, pubmed: '7915137', seq: '16', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: R, pubmed: '9607174', seq: '16', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: R, pubmed: '15703163', seq: '16', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: R, pubmed: '15922102', seq: '16', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '10205587', seq: '27', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '10395196', seq: '27', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '11713122', seq: '27', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '7915137', seq: '27', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '9607174', seq: '27', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '15703163', seq: '27', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '16573811', seq: '27', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11118431', seq: '77', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9228019', seq: '77', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '77', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '15102946', seq: '79', to_res: N}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '10535920', seq: '93', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '12409304', seq: '93', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '10535920', seq: '113', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '10535920', seq: '113', to_res: H}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9452461', seq: '116', to_res: F}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9228019', seq: '116', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '116', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: E, pubmed: '10652295', seq: '122', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '10935550', seq: '124', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '10935550', seq: '124', to_res: K}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '10935550', seq: '124', to_res: R}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9228019', seq: '125', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '125', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '10385699', seq: '130', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '10652295', seq: '130', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '10385699', seq: '130', to_res: N}
- {entry_name: ADRB2_HUMAN, from_res: A, pubmed: '10358054', seq: '134', to_res: H}
- {entry_name: ADRB2_HUMAN, from_res: F, pubmed: '8120019', seq: '139', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: T, pubmed: '8799191', seq: '164', to_res: I}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '8799191', seq: '165', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '12409304', seq: '172', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: R, pubmed: '9360951', seq: '175', to_res: E}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '12409304', seq: '178', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '10964911', seq: '203', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '10964911', seq: '203', to_res: C}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '10964911', seq: '203', to_res: T}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '10964911', seq: '203', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '10964911', seq: '203', to_res: X}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '10964911', seq: '204', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '11934812', seq: '204', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '10964911', seq: '207', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '11934812', seq: '207', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: Q, pubmed: '11353823', seq: '224', to_res: K}
- {entry_name: ADRB2_HUMAN, from_res: E, pubmed: '12409304', seq: '225', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '12409304', seq: '241', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '12409304', seq: '256', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '261', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '261', to_res: D}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '262', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '262', to_res: D}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11118431', seq: '265', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '12409304', seq: '265', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '265', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '10385699', seq: '266', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '15102946', seq: '266', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '9228019', seq: '266', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: K, pubmed: '10385699', seq: '267', to_res: R}
- {entry_name: ADRB2_HUMAN, from_res: K, pubmed: '15102946', seq: '267', to_res: R}
- {entry_name: ADRB2_HUMAN, from_res: K, pubmed: '9228019', seq: '267', to_res: R}
- {entry_name: ADRB2_HUMAN, from_res: E, pubmed: '10652295', seq: '268', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '10358054', seq: '269', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '12409304', seq: '269', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '11118431', seq: '269', to_res: C}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '10385699', seq: '269', to_res: K}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '15102946', seq: '269', to_res: K}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '9228019', seq: '269', to_res: K}
- {entry_name: ADRB2_HUMAN, from_res: K, pubmed: '11118431', seq: '270', to_res: C}
- {entry_name: ADRB2_HUMAN, from_res: A, pubmed: '11118431', seq: '271', to_res: C}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '10385699', seq: '272', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '15102946', seq: '272', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '9228019', seq: '272', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '11118431', seq: '272', to_res: C}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '10358054', seq: '272', to_res: H}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '10385699', seq: '285', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9228019', seq: '285', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '285', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: N, pubmed: '8799191', seq: '293', to_res: L}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '10535920', seq: '296', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: H, pubmed: '12409304', seq: '296', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: K, pubmed: '9398350', seq: '305', to_res: R}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '8576196', seq: '310', to_res: F}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '8576196', seq: '311', to_res: F}
- {entry_name: ADRB2_HUMAN, from_res: N, pubmed: '10535920', seq: '312', to_res: C}
- {entry_name: ADRB2_HUMAN, from_res: N, pubmed: '8576196', seq: '312', to_res: F}
- {entry_name: ADRB2_HUMAN, from_res: Y, pubmed: '14691047', seq: '326', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: Y, pubmed: '7559596', seq: '326', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: Y, pubmed: '8672451', seq: '326', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11118431', seq: '327', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9228019', seq: '327', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '327', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: E, pubmed: '11418112', seq: '338', to_res: Q}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '9356441', seq: '339', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '9356441', seq: '340', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '2540197', seq: '341', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9137920', seq: '341', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11418112', seq: '341', to_res: S}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '11418112', seq: '342', to_res: Y}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '345', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '345', to_res: D}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '346', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '7559596', seq: '346', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '12063255', seq: '346', to_res: D}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '8621600', seq: '356', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '11279203', seq: '364', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '8621600', seq: '364', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11118431', seq: '378', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11353823', seq: '378', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '378', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11118431', seq: '378', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11118431', seq: '406', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11353823', seq: '406', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '9362488', seq: '406', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: C, pubmed: '11118431', seq: '406', to_res: V}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '7559596', seq: '407', to_res: G}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '11577089', seq: '410', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: D, pubmed: '12954981', seq: '410', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '11577089', seq: '411', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: S, pubmed: '7559596', seq: '411', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '11577089', seq: '412', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '12954981', seq: '412', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '11046132', seq: '413', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '11577089', seq: '413', to_res: A}
- {entry_name: ADRB2_HUMAN, from_res: L, pubmed: '12502786', seq: '413', to_res: A}
- {entry_name: ADRB2_MESAU, from_res: Y, pubmed: '7592686', seq: '350', to_res: A}
- {entry_name: ADRB2_MESAU, from_res: Y, pubmed: '7592686', seq: '350', to_res: F}
- {entry_name: ADRB2_MESAU, from_res: Y, pubmed: '9830057', seq: '350', to_res: F}
- {entry_name: ADRB2_MESAU, from_res: Y, pubmed: '7592686', seq: '354', to_res: A}
- {entry_name: ADRB2_MESAU, from_res: Y, pubmed: '7592686', seq: '354', to_res: F}
- {entry_name: ADRB2_MESAU, from_res: Y, pubmed: '7592686', seq: '364', to_res: F}
- {entry_name: ADRB2_MOUSE, from_res: T, pubmed: '16280323', seq: '68', to_res: F}
- {entry_name: ADRB2_MOUSE, from_res: D, pubmed: '9415717', seq: '79', to_res: N}
- {entry_name: ADRB2_MOUSE, from_res: Y, pubmed: '16280323', seq: '132', to_res: G}
- {entry_name: ADRB2_MOUSE, from_res: Y, pubmed: '16280323', seq: '219', to_res: A}
- {entry_name: ADRB2_MOUSE, from_res: Y, pubmed: '11602178', seq: '326', to_res: A}
- {entry_name: ADRB2_MOUSE, from_res: S, pubmed: '11602178', seq: '412', to_res: D}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '8621600', seq: '64', to_res: K}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '10395196', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '10443326', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '10757633', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '11872697', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '12375271', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '14742851', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '8641219', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '8903328', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '8968848', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '8968850', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '9416435', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '9449691', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '9892231', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: W, pubmed: '16286518', seq: '64', to_res: R}
- {entry_name: ADRB3_HUMAN, from_res: T, pubmed: '8621600', seq: '65', to_res: K}
- {entry_name: ADRB3_HUMAN, from_res: P, pubmed: '8621600', seq: '66', to_res: K}
- {entry_name: ADRB3_HUMAN, from_res: M, pubmed: '8621600', seq: '71', to_res: K}
- {entry_name: ADRB3_HUMAN, from_res: R, pubmed: '8621600', seq: '152', to_res: N}
- {entry_name: ADRB3_HUMAN, from_res: C, pubmed: '8621600', seq: '153', to_res: N}
- {entry_name: ADRB3_MOUSE, from_res: S, pubmed: '16144970', seq: '388', to_res: A}
- {entry_name: ADRB3_MOUSE, from_res: S, pubmed: '16144970', seq: '389', to_res: A}
- {entry_name: ADRB3_MOUSE, from_res: Y, pubmed: '16144970', seq: '392', to_res: A}
- {entry_name: AGTR1_HUMAN, from_res: D, pubmed: '12826267', seq: '74', to_res: N}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12842881', seq: '111', to_res: A}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12960024', seq: '111', to_res: A}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12006574', seq: '111', to_res: G}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12842881', seq: '111', to_res: G}
- {entry_name: AGTR1_HUMAN, from_res: R, pubmed: '12356298', seq: '126', to_res: H}
- {entry_name: AGTR1_HUMAN, from_res: I, pubmed: '11301053', seq: '164', to_res: T}
- {entry_name: AGTR1_HUMAN, from_res: K, pubmed: '11881039', seq: '199', to_res: Q}
- {entry_name: AGTR1_HUMAN, from_res: A, pubmed: '9606715', seq: '221', to_res: E}
- {entry_name: AGTR1_HUMAN, from_res: L, pubmed: '9606715', seq: '222', to_res: R}
- {entry_name: AGTR1_HUMAN, from_res: H, pubmed: '11881039', seq: '256', to_res: A}
- {entry_name: AGTR1_HUMAN, from_res: I, pubmed: '12842881', seq: '276', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: A, pubmed: '12842881', seq: '277', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: D, pubmed: '12842881', seq: '278', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: I, pubmed: '12842881', seq: '279', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: V, pubmed: '12842881', seq: '280', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: D, pubmed: '12006574', seq: '281', to_res: A}
- {entry_name: AGTR1_HUMAN, from_res: D, pubmed: '12842881', seq: '281', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: T, pubmed: '12842881', seq: '282', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: A, pubmed: '12842881', seq: '283', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: M, pubmed: '12842881', seq: '284', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: M, pubmed: '12450401', seq: '284', to_res: L}
- {entry_name: AGTR1_HUMAN, from_res: P, pubmed: '12842881', seq: '285', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: I, pubmed: '12842881', seq: '286', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: T, pubmed: '12842881', seq: '287', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: I, pubmed: '12842881', seq: '288', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: I, pubmed: '12842881', seq: '290', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: I, pubmed: '12450401', seq: '290', to_res: M}
- {entry_name: AGTR1_HUMAN, from_res: A, pubmed: '12842881', seq: '291', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: A, pubmed: '12450401', seq: '291', to_res: M}
- {entry_name: AGTR1_HUMAN, from_res: Y, pubmed: '12842881', seq: '292', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: Y, pubmed: '12826267', seq: '292', to_res: F}
- {entry_name: AGTR1_HUMAN, from_res: F, pubmed: '12842881', seq: '293', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: F, pubmed: '12450401', seq: '293', to_res: M}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12450401', seq: '294', to_res: A}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12842881', seq: '294', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12450401', seq: '294', to_res: M}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12842881', seq: '295', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12826267', seq: '295', to_res: S}
- {entry_name: AGTR1_HUMAN, from_res: L, pubmed: '12842881', seq: '297', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: N, pubmed: '12842881', seq: '298', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: P, pubmed: '12842881', seq: '299', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: L, pubmed: '12842881', seq: '300', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: L, pubmed: '12450401', seq: '300', to_res: M}
- {entry_name: AGTR1_HUMAN, from_res: F, pubmed: '12842881', seq: '301', to_res: C}
- {entry_name: AGTR1_HUMAN, from_res: Y, pubmed: '12842881', seq: '302', to_res: C}
- {entry_name: AGTR1_RABIT, from_res: T, pubmed: '11179453', seq: '336', to_res: A}
- {entry_name: AGTR2_HUMAN, from_res: G, pubmed: '14598163', seq: '21', to_res: V}
- {entry_name: AGTR2_HUMAN, from_res: G, pubmed: '14615403', seq: '21', to_res: V}
- {entry_name: AGTR2_HUMAN, from_res: I, pubmed: '14598163', seq: '53', to_res: F}
- {entry_name: AGTR2_HUMAN, from_res: R, pubmed: '14615403', seq: '182', to_res: A}
- {entry_name: AGTR2_HUMAN, from_res: K, pubmed: '14615403', seq: '215', to_res: E}
- {entry_name: AGTR2_HUMAN, from_res: I, pubmed: '14615403', seq: '217', to_res: V}
- {entry_name: AGTR2_HUMAN, from_res: D, pubmed: '14615403', seq: '297', to_res: K}
- {entry_name: AGTR2_HUMAN, from_res: R, pubmed: '14615403', seq: '324', to_res: Q}
- {entry_name: AGTR2_HUMAN, from_res: I, pubmed: '14615403', seq: '337', to_res: V}
- {entry_name: AGTR2_RAT, from_res: C, pubmed: '11068047', seq: '35', to_res: A}
- {entry_name: AGTR2_RAT, from_res: C, pubmed: '11068047', seq: '117', to_res: A}
- {entry_name: AGTR2_RAT, from_res: N, pubmed: '10921883', seq: '127', to_res: G}
- {entry_name: AGTR2_RAT, from_res: S, pubmed: '11040065', seq: '152', to_res: A}
- {entry_name: AGTR2_RAT, from_res: C, pubmed: '11068047', seq: '195', to_res: A}
- {entry_name: AGTR2_RAT, from_res: K, pubmed: '9537673', seq: '215', to_res: A}
- {entry_name: AGTR2_RAT, from_res: K, pubmed: '9537673', seq: '215', to_res: E}
- {entry_name: AGTR2_RAT, from_res: K, pubmed: '9537673', seq: '215', to_res: Q}
- {entry_name: AGTR2_RAT, from_res: K, pubmed: '9537673', seq: '215', to_res: R}
- {entry_name: AGTR2_RAT, from_res: H, pubmed: '10208847', seq: '273', to_res: E}
- {entry_name: AGTR2_RAT, from_res: H, pubmed: '10208847', seq: '273', to_res: R}
- {entry_name: AGTR2_RAT, from_res: C, pubmed: '11068047', seq: '290', to_res: A}
- {entry_name: AGTR2_RAT, from_res: S, pubmed: '11040065', seq: '348', to_res: A}
- {entry_name: AGTR2_RAT, from_res: S, pubmed: '11040065', seq: '354', to_res: A}
- {entry_name: AGTRA_MOUSE, from_res: Y, pubmed: '12692121', seq: '302', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '12047908', seq: '3', to_res: D}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10066768', seq: '4', to_res: I}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '10218949', seq: '6', to_res: A}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '10644757', seq: '74', to_res: E}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '12047908', seq: '74', to_res: E}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '12623864', seq: '74', to_res: E}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '7929158', seq: '74', to_res: H}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '10967200', seq: '74', to_res: N}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '7929158', seq: '74', to_res: N}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '8576145', seq: '74', to_res: N}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '11875120', seq: '74', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '7929158', seq: '74', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '76', to_res: A}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '12446719', seq: '77', to_res: A}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '12446719', seq: '77', to_res: C}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '12446719', seq: '77', to_res: G}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '12446719', seq: '77', to_res: I}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '12446719', seq: '77', to_res: S}
- {entry_name: AGTRA_RAT, from_res: T, pubmed: '10903964', seq: '88', to_res: A}
- {entry_name: AGTRA_RAT, from_res: T, pubmed: '10903964', seq: '88', to_res: H}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '10903964', seq: '92', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '10903964', seq: '92', to_res: H}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '8576145', seq: '102', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7530721', seq: '102', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: A, pubmed: '9843384', seq: '104', to_res: F}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '8576145', seq: '105', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '9843384', seq: '105', to_res: G}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '8576145', seq: '107', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '9843384', seq: '107', to_res: F}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '8987975', seq: '107', to_res: G}
- {entry_name: AGTRA_RAT, from_res: V, pubmed: '9203636', seq: '108', to_res: A}
- {entry_name: AGTRA_RAT, from_res: V, pubmed: '9506833', seq: '108', to_res: I}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '8576145', seq: '109', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '9506833', seq: '109', to_res: T}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10644757', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10967200', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '11495923', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '12047908', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '12694873', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '8576145', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '8987975', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '8999867', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9020140', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9325274', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: C}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '8987975', seq: '111', to_res: F}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: F}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10100078', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10644757', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10967200', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '11495923', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '12446719', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '12694873', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '8987975', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '15901848', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '16218991', seq: '111', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10066768', seq: '111', to_res: H}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: H}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10066768', seq: '111', to_res: I}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '8987975', seq: '111', to_res: I}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: I}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10066768', seq: '111', to_res: K}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: K}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10066768', seq: '111', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: S}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10066768', seq: '111', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '111', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '16218991', seq: '112', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '16218991', seq: '112', to_res: C}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '16218991', seq: '112', to_res: F}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '16218991', seq: '113', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '12047908', seq: '115', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '8576145', seq: '115', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '8987975', seq: '115', to_res: G}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '16218991', seq: '117', to_res: A}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '121', to_res: A}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '12746278', seq: '125', to_res: A}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '15998700', seq: '125', to_res: A}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '12746278', seq: '126', to_res: A}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '15998700', seq: '126', to_res: L}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '12746278', seq: '127', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '10745091', seq: '127', to_res: H}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '12746278', seq: '128', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '10745091', seq: '128', to_res: H}
- {entry_name: AGTRA_RAT, from_res: A, pubmed: '10745091', seq: '129', to_res: H}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '12746278', seq: '130', to_res: A}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '10745091', seq: '130', to_res: H}
- {entry_name: AGTRA_RAT, from_res: V, pubmed: '12746278', seq: '131', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '12746278', seq: '132', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '10745091', seq: '132', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: P, pubmed: '12746278', seq: '133', to_res: A}
- {entry_name: AGTRA_RAT, from_res: M, pubmed: '12746278', seq: '134', to_res: A}
- {entry_name: AGTRA_RAT, from_res: M, pubmed: '12746278', seq: '134', to_res: D}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '10585429', seq: '146', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '149', to_res: A}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '10585429', seq: '150', to_res: P}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '16218991', seq: '152', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '10585429', seq: '154', to_res: C}
- {entry_name: AGTRA_RAT, from_res: G, pubmed: '10585429', seq: '157', to_res: C}
- {entry_name: AGTRA_RAT, from_res: A, pubmed: '10585429', seq: '159', to_res: S}
- {entry_name: AGTRA_RAT, from_res: A, pubmed: '10585429', seq: '163', to_res: T}
- {entry_name: AGTRA_RAT, from_res: V, pubmed: '10585429', seq: '164', to_res: F}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '10585429', seq: '165', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '14754891', seq: '166', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '14754891', seq: '166', to_res: E}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '14754891', seq: '166', to_res: G}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '14754891', seq: '167', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10191272', seq: '176', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '14754891', seq: '183', to_res: E}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7530721', seq: '183', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '14754891', seq: '187', to_res: E}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10191272', seq: '188', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: G, pubmed: '10903964', seq: '196', to_res: I}
- {entry_name: AGTRA_RAT, from_res: G, pubmed: '10903964', seq: '196', to_res: W}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7499361', seq: '199', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7530721', seq: '199', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '8576145', seq: '199', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '9626656', seq: '199', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7530721', seq: '199', to_res: E}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '1417818', seq: '199', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '14754891', seq: '199', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7499361', seq: '199', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7530721', seq: '199', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7499361', seq: '199', to_res: R}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7530721', seq: '199', to_res: R}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '8816747', seq: '217', to_res: A}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '8816747', seq: '218', to_res: A}
- {entry_name: AGTRA_RAT, from_res: W, pubmed: '8816747', seq: '219', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '8816747', seq: '220', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '11495923', seq: '220', to_res: M}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '11495923', seq: '220', to_res: R}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '15998700', seq: '220', to_res: R}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '11495923', seq: '220', to_res: W}
- {entry_name: AGTRA_RAT, from_res: A, pubmed: '8816747', seq: '221', to_res: K}
- {entry_name: AGTRA_RAT, from_res: A, pubmed: '8816747', seq: '221', to_res: R}
- {entry_name: AGTRA_RAT, from_res: A, pubmed: '8816747', seq: '221', to_res: S}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '8816747', seq: '222', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '8816747', seq: '222', to_res: K}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '8816747', seq: '222', to_res: N}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '8816747', seq: '222', to_res: S}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '8816747', seq: '223', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '8816747', seq: '224', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '10747880', seq: '232', to_res: A}
- {entry_name: AGTRA_RAT, from_res: P, pubmed: '10747880', seq: '233', to_res: A}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '10747880', seq: '234', to_res: A}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '10745091', seq: '234', to_res: H}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10747880', seq: '235', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '10745091', seq: '235', to_res: H}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '10747880', seq: '236', to_res: A}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '11495923', seq: '236', to_res: A}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '10745091', seq: '236', to_res: H}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '11495923', seq: '236', to_res: N}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '10747880', seq: '237', to_res: A}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '11495923', seq: '237', to_res: A}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '10745091', seq: '237', to_res: H}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '11495923', seq: '237', to_res: N}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '10747880', seq: '238', to_res: A}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '10747880', seq: '238', to_res: D}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '10747880', seq: '238', to_res: K}
- {entry_name: AGTRA_RAT, from_res: I, pubmed: '10747880', seq: '238', to_res: S}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: A}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: D}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10745091', seq: '239', to_res: H}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: K}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: L}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: N}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: R}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: S}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '10747880', seq: '239', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '10747880', seq: '240', to_res: A}
- {entry_name: AGTRA_RAT, from_res: R, pubmed: '10745091', seq: '240', to_res: H}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '9626656', seq: '252', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '9506833', seq: '252', to_res: C}
- {entry_name: AGTRA_RAT, from_res: W, pubmed: '9626656', seq: '253', to_res: A}
- {entry_name: AGTRA_RAT, from_res: V, pubmed: '12047908', seq: '254', to_res: A}
- {entry_name: AGTRA_RAT, from_res: V, pubmed: '9626656', seq: '254', to_res: A}
- {entry_name: AGTRA_RAT, from_res: P, pubmed: '9626656', seq: '255', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '10066768', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '12047908', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '14754891', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7499361', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7530721', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7700239', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '8987975', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '9203636', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '9626656', seq: '256', to_res: A}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7499361', seq: '256', to_res: F}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7700239', seq: '256', to_res: I}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '10066768', seq: '256', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7499361', seq: '256', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7530721', seq: '256', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7499361', seq: '256', to_res: R}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7530721', seq: '256', to_res: R}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '10066768', seq: '256', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: Q, pubmed: '14754891', seq: '257', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Q, pubmed: '14754891', seq: '257', to_res: E}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '9626656', seq: '259', to_res: A}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '9626656', seq: '259', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '9626656', seq: '261', to_res: Y}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '12047908', seq: '262', to_res: D}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '12047908', seq: '265', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '12047908', seq: '265', to_res: D}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '12047908', seq: '268', to_res: D}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '12047908', seq: '268', to_res: R}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '14754891', seq: '272', to_res: G}
- {entry_name: AGTRA_RAT, from_res: H, pubmed: '7530721', seq: '272', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: D, pubmed: '10903964', seq: '278', to_res: E}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '289', to_res: A}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '289', to_res: G}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '9843384', seq: '292', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '12047908', seq: '292', to_res: F}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '8063694', seq: '292', to_res: F}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '8576145', seq: '292', to_res: F}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '9843384', seq: '292', to_res: G}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '9843384', seq: '292', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '9687585', seq: '293', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '14754891', seq: '295', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '295', to_res: A}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '295', to_res: C}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9203636', seq: '295', to_res: D}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9687585', seq: '295', to_res: D}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '295', to_res: F}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '295', to_res: G}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '295', to_res: I}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9020140', seq: '295', to_res: S}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9506833', seq: '295', to_res: S}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9687585', seq: '295', to_res: S}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9843384', seq: '295', to_res: S}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '15901848', seq: '295', to_res: S}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '296', to_res: A}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '296', to_res: F}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '296', to_res: G}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '296', to_res: I}
- {entry_name: AGTRA_RAT, from_res: N, pubmed: '9203636', seq: '298', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '10644757', seq: '302', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '7673193', seq: '302', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '15901848', seq: '305', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '9654124', seq: '309', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '9295303', seq: '310', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '9654124', seq: '311', to_res: A}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '9295303', seq: '311', to_res: Q}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '7673193', seq: '312', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '9295303', seq: '312', to_res: A}
- {entry_name: AGTRA_RAT, from_res: F, pubmed: '9295303', seq: '313', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '9295303', seq: '314', to_res: A}
- {entry_name: AGTRA_RAT, from_res: L, pubmed: '7673193', seq: '316', to_res: F}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '7673193', seq: '319', to_res: A}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '12522132', seq: '319', to_res: E}
- {entry_name: AGTRA_RAT, from_res: Y, pubmed: '12522132', seq: '319', to_res: F}
- {entry_name: AGTRA_RAT, from_res: K, pubmed: '7673193', seq: '325', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '10644757', seq: '331', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '11495923', seq: '335', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '7989302', seq: '335', to_res: A}
- {entry_name: AGTRA_RAT, from_res: T, pubmed: '10644757', seq: '336', to_res: A}
- {entry_name: AGTRA_RAT, from_res: T, pubmed: '11495923', seq: '336', to_res: A}
- {entry_name: AGTRA_RAT, from_res: T, pubmed: '7989302', seq: '336', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '10644757', seq: '338', to_res: A}
- {entry_name: AGTRA_RAT, from_res: S, pubmed: '10644757', seq: '348', to_res: A}
- {entry_name: AGTRA_RAT, from_res: C, pubmed: '12446719', seq: '355', to_res: A}
- {entry_name: BACS1_HALSA, from_res: G, pubmed: '11714274', seq: '66', to_res: C}
- {entry_name: BACS1_HALSA, from_res: A, pubmed: '9555883', seq: '116', to_res: T}
- {entry_name: BACS1_HALSA, from_res: N, pubmed: '9555883', seq: '161', to_res: D}
- {entry_name: BACS1_HALSA, from_res: H, pubmed: '9555883', seq: '166', to_res: A}
- {entry_name: BACS1_HALSA, from_res: H, pubmed: '9677402', seq: '166', to_res: A}
- {entry_name: BACS1_HALSA, from_res: H, pubmed: '9677402', seq: '166', to_res: R}
- {entry_name: BACS1_HALSA, from_res: H, pubmed: '9555883', seq: '166', to_res: S}
- {entry_name: BACS1_HALSA, from_res: H, pubmed: '9677402', seq: '166', to_res: Y}
- {entry_name: BACS1_HALSA, from_res: D, pubmed: '8692855', seq: '201', to_res: N}
- {entry_name: BACS1_HALSA, from_res: D, pubmed: '9555883', seq: '201', to_res: N}
- {entry_name: BACS1_HALSA, from_res: D, pubmed: '9677402', seq: '201', to_res: N}
- {entry_name: BACS1_HALSA, from_res: R, pubmed: '9555883', seq: '215', to_res: A}
- {entry_name: BACS1_HALSA, from_res: R, pubmed: '9555883', seq: '215', to_res: W}
- {entry_name: BACS1_HALSA, from_res: R, pubmed: '9555883', seq: '216', to_res: A}
- {entry_name: BACS1_HALSA, from_res: R, pubmed: '9555883', seq: '217', to_res: A}
- {entry_name: BACS1_HALSS, from_res: A, pubmed: '9677402', seq: '4', to_res: C}
- {entry_name: BACS1_HALSS, from_res: L, pubmed: '11714274', seq: '70', to_res: C}
- {entry_name: BACS1_HALSS, from_res: V, pubmed: '9555883', seq: '71', to_res: F}
- {entry_name: BACS1_HALSS, from_res: V, pubmed: '9555883', seq: '71', to_res: I}
- {entry_name: BACS1_HALSS, from_res: T, pubmed: '11714274', seq: '81', to_res: C}
- {entry_name: BACS2_HALSA, from_res: R, pubmed: '8692855', seq: '70', to_res: A}
- {entry_name: BACS2_HALSA, from_res: R, pubmed: '9555883', seq: '70', to_res: H}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '10984603', seq: '73', to_res: A}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '9144172', seq: '73', to_res: E}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '9421965', seq: '73', to_res: E}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '10984603', seq: '73', to_res: N}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '9144172', seq: '73', to_res: N}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '9421965', seq: '73', to_res: N}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '10984603', seq: '73', to_res: Q}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '10984603', seq: '73', to_res: S}
- {entry_name: BACS2_HALSA, from_res: L, pubmed: '11714274', seq: '75', to_res: C}
- {entry_name: BACS2_HALSA, from_res: D, pubmed: '9421965', seq: '103', to_res: N}
- {entry_name: BACS2_HALSA, from_res: V, pubmed: '8710852', seq: '106', to_res: M}
- {entry_name: BACS2_HALSA, from_res: V, pubmed: '9421965', seq: '106', to_res: M}
- {entry_name: BACS2_NATPH, from_res: D, pubmed: '15951432', seq: '75', to_res: N}
- {entry_name: BACS2_NATPH, from_res: F, pubmed: '10443011', seq: '86', to_res: L}
- {entry_name: BKRB1_RAT, from_res: L, pubmed: '15807523', seq: '63', to_res: N}
- {entry_name: BKRB1_RAT, from_res: V, pubmed: '15634338', seq: '323', to_res: S}
- {entry_name: BKRB2_HUMAN, from_res: C, pubmed: '8939910', seq: '47', to_res: S}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '75', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: D, pubmed: '11495910', seq: '103', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: D, pubmed: '9882702', seq: '103', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: D, pubmed: '11495910', seq: '103', to_res: N}
- {entry_name: BKRB2_HUMAN, from_res: D, pubmed: '9882702', seq: '103', to_res: N}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '119', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: C, pubmed: '8939910', seq: '130', to_res: S}
- {entry_name: BKRB2_HUMAN, from_res: I, pubmed: '14757160', seq: '137', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '138', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '138', to_res: K}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '9575169', seq: '138', to_res: K}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '140', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '9882702', seq: '140', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '140', to_res: H}
- {entry_name: BKRB2_HUMAN, from_res: L, pubmed: '14757160', seq: '141', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '11495910', seq: '142', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '11495910', seq: '142', to_res: F}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '143', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '144', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '147', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: M, pubmed: '11495910', seq: '192', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: M, pubmed: '11495910', seq: '192', to_res: T}
- {entry_name: BKRB2_HUMAN, from_res: C, pubmed: '8939910', seq: '211', to_res: S}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '225', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '229', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '233', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '279', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: C, pubmed: '11495910', seq: '282', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: C, pubmed: '11495910', seq: '282', to_res: S}
- {entry_name: BKRB2_HUMAN, from_res: W, pubmed: '11495910', seq: '283', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: W, pubmed: '14757160', seq: '283', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: W, pubmed: '11495910', seq: '283', to_res: F}
- {entry_name: BKRB2_HUMAN, from_res: W, pubmed: '9882702', seq: '283', to_res: F}
- {entry_name: BKRB2_HUMAN, from_res: W, pubmed: '11495910', seq: '283', to_res: H}
- {entry_name: BKRB2_HUMAN, from_res: W, pubmed: '11495910', seq: '283', to_res: Q}
- {entry_name: BKRB2_HUMAN, from_res: W, pubmed: '9882702', seq: '283', to_res: Q}
- {entry_name: BKRB2_HUMAN, from_res: P, pubmed: '11495910', seq: '285', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '286', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '286', to_res: H}
- {entry_name: BKRB2_HUMAN, from_res: Q, pubmed: '11495910', seq: '287', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: Q, pubmed: '11495910', seq: '287', to_res: H}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '289', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '289', to_res: F}
- {entry_name: BKRB2_HUMAN, from_res: T, pubmed: '11495910', seq: '290', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '291', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: D, pubmed: '8939910', seq: '293', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: T, pubmed: '8939910', seq: '294', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: C, pubmed: '8939910', seq: '304', to_res: S}
- {entry_name: BKRB2_HUMAN, from_res: D, pubmed: '11495910', seq: '311', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: D, pubmed: '8939910', seq: '311', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: T, pubmed: '11495910', seq: '314', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: T, pubmed: '11495910', seq: '314', to_res: L}
- {entry_name: BKRB2_HUMAN, from_res: Q, pubmed: '11495910', seq: '315', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '318', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '319', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '14757160', seq: '319', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: F, pubmed: '11495910', seq: '319', to_res: Y}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '11495910', seq: '322', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '14757160', seq: '322', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '11495910', seq: '322', to_res: F}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '14757160', seq: '322', to_res: F}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '9882702', seq: '322', to_res: F}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '323', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '324', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '11495910', seq: '325', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '328', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: N, pubmed: '11495910', seq: '328', to_res: D}
- {entry_name: BKRB2_HUMAN, from_res: Y, pubmed: '15161928', seq: '332', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '10212257', seq: '343', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: C, pubmed: '9446564', seq: '351', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '10212257', seq: '358', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '10212257', seq: '366', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: T, pubmed: '10212257', seq: '369', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: T, pubmed: '10212257', seq: '372', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '10212257', seq: '373', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '10514427', seq: '373', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '10212257', seq: '375', to_res: A}
- {entry_name: BKRB2_HUMAN, from_res: S, pubmed: '10514427', seq: '375', to_res: A}
- {entry_name: BKRB2_MOUSE, from_res: N, pubmed: '11134011', seq: '121', to_res: A}
- {entry_name: BKRB2_RAT, from_res: N, pubmed: '15807523', seq: '93', to_res: D}
- {entry_name: BKRB2_RAT, from_res: N, pubmed: '15807523', seq: '93', to_res: L}
- {entry_name: BKRB2_RAT, from_res: N, pubmed: '15807523', seq: '93', to_res: Q}
- {entry_name: BKRB2_RAT, from_res: C, pubmed: '15807523', seq: '94', to_res: K}
- {entry_name: BKRB2_RAT, from_res: E, pubmed: '15807523', seq: '98', to_res: S}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '9882702', seq: '108', to_res: N}
- {entry_name: BKRB2_RAT, from_res: R, pubmed: '8910447', seq: '136', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '8910447', seq: '147', to_res: F}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9169425', seq: '161', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9837936', seq: '161', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9169425', seq: '161', to_res: F}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9837936', seq: '161', to_res: F}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9169425', seq: '161', to_res: S}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9837936', seq: '161', to_res: S}
- {entry_name: BKRB2_RAT, from_res: T, pubmed: '9837936', seq: '167', to_res: D}
- {entry_name: BKRB2_RAT, from_res: T, pubmed: '9837936', seq: '167', to_res: P}
- {entry_name: BKRB2_RAT, from_res: W, pubmed: '8910447', seq: '187', to_res: F}
- {entry_name: BKRB2_RAT, from_res: K, pubmed: '8910316', seq: '204', to_res: A}
- {entry_name: BKRB2_RAT, from_res: E, pubmed: '8576178', seq: '209', to_res: A}
- {entry_name: BKRB2_RAT, from_res: N, pubmed: '8910447', seq: '230', to_res: A}
- {entry_name: BKRB2_RAT, from_res: N, pubmed: '8910447', seq: '234', to_res: A}
- {entry_name: BKRB2_RAT, from_res: F, pubmed: '8910447', seq: '284', to_res: A}
- {entry_name: BKRB2_RAT, from_res: W, pubmed: '8910447', seq: '288', to_res: F}
- {entry_name: BKRB2_RAT, from_res: F, pubmed: '8910447', seq: '291', to_res: A}
- {entry_name: BKRB2_RAT, from_res: F, pubmed: '8939910', seq: '291', to_res: A}
- {entry_name: BKRB2_RAT, from_res: F, pubmed: '8183923', seq: '291', to_res: V}
- {entry_name: BKRB2_RAT, from_res: Q, pubmed: '8183923', seq: '292', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Q, pubmed: '8910447', seq: '292', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Q, pubmed: '8939910', seq: '292', to_res: A}
- {entry_name: BKRB2_RAT, from_res: T, pubmed: '8183923', seq: '295', to_res: A}
- {entry_name: BKRB2_RAT, from_res: T, pubmed: '8910447', seq: '295', to_res: A}
- {entry_name: BKRB2_RAT, from_res: T, pubmed: '8939910', seq: '295', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8002982', seq: '298', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8183923', seq: '298', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8576178', seq: '298', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8910316', seq: '298', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8910447', seq: '298', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8910447', seq: '298', to_res: N}
- {entry_name: BKRB2_RAT, from_res: T, pubmed: '8183923', seq: '299', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8002982', seq: '316', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8576178', seq: '316', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8910316', seq: '316', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8910447', seq: '316', to_res: A}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8910447', seq: '316', to_res: K}
- {entry_name: BKRB2_RAT, from_res: D, pubmed: '8910447', seq: '316', to_res: R}
- {entry_name: BKRB2_RAT, from_res: Q, pubmed: '8910447', seq: '320', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '8910447', seq: '327', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9837936', seq: '352', to_res: A}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9837936', seq: '352', to_res: F}
- {entry_name: BKRB2_RAT, from_res: Y, pubmed: '9837936', seq: '352', to_res: S}
- {entry_name: BOSS_DROVI, from_res: K, pubmed: '12427870', seq: '39', to_res: A}
- {entry_name: BRS3_HUMAN, from_res: L, pubmed: '9765358', seq: '13', to_res: C}
- {entry_name: BRS3_HUMAN, from_res: R, pubmed: '10206964', seq: '127', to_res: Q}
- {entry_name: BRS3_HUMAN, from_res: R, pubmed: '9211882', seq: '127', to_res: Q}
- {entry_name: BRS3_HUMAN, from_res: R, pubmed: '9632639', seq: '127', to_res: Q}
- {entry_name: BRS3_HUMAN, from_res: S, pubmed: '10206964', seq: '205', to_res: P}
- {entry_name: BRS3_HUMAN, from_res: S, pubmed: '9211882', seq: '205', to_res: P}
- {entry_name: BRS3_HUMAN, from_res: S, pubmed: '9632639', seq: '205', to_res: P}
- {entry_name: BRS3_HUMAN, from_res: H, pubmed: '10206964', seq: '294', to_res: R}
- {entry_name: BRS3_HUMAN, from_res: H, pubmed: '9211882', seq: '294', to_res: R}
- {entry_name: BRS3_HUMAN, from_res: H, pubmed: '9632639', seq: '294', to_res: R}
- {entry_name: BRS3_HUMAN, from_res: S, pubmed: '10206964', seq: '315', to_res: A}
- {entry_name: BRS3_HUMAN, from_res: S, pubmed: '9211882', seq: '315', to_res: A}
- {entry_name: BRS3_HUMAN, from_res: S, pubmed: '9632639', seq: '315', to_res: A}
- {entry_name: C3AR_HUMAN, from_res: D, pubmed: '10092660', seq: '183', to_res: K}
- {entry_name: C3AR_HUMAN, from_res: D, pubmed: '10092660', seq: '186', to_res: K}
- {entry_name: C3AR_HUMAN, from_res: D, pubmed: '10092660', seq: '325', to_res: K}
- {entry_name: C3AR_HUMAN, from_res: D, pubmed: '10092660', seq: '326', to_res: K}
- {entry_name: C3AR_HUMAN, from_res: D, pubmed: '10092660', seq: '327', to_res: K}
- {entry_name: C5AR_CAVPO, from_res: L, pubmed: '14570896', seq: '71', to_res: C}
- {entry_name: C5AR_HUMAN, from_res: N, pubmed: '9410877', seq: '5', to_res: Q}
- {entry_name: C5AR_HUMAN, from_res: P, pubmed: '8282089', seq: '9', to_res: I}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '15542591', seq: '10', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '8282089', seq: '10', to_res: N}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '9553099', seq: '18', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '9553099', seq: '21', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '9553099', seq: '21', to_res: N}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '9553099', seq: '27', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '9553099', seq: '27', to_res: N}
- {entry_name: C5AR_HUMAN, from_res: P, pubmed: '8282089', seq: '36', to_res: L}
- {entry_name: C5AR_HUMAN, from_res: L, pubmed: '10952985', seq: '41', to_res: C}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '7957584', seq: '82', to_res: N}
- {entry_name: C5AR_HUMAN, from_res: P, pubmed: '10952985', seq: '90', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: P, pubmed: '10952985', seq: '90', to_res: I}
- {entry_name: C5AR_HUMAN, from_res: P, pubmed: '11377387', seq: '103', to_res: Y}
- {entry_name: C5AR_HUMAN, from_res: G, pubmed: '11377387', seq: '105', to_res: D}
- {entry_name: C5AR_HUMAN, from_res: L, pubmed: '11062244', seq: '112', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: I, pubmed: '11062244', seq: '116', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: I, pubmed: '15661745', seq: '116', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10336477', seq: '123', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: I, pubmed: '10336477', seq: '124', to_res: N}
- {entry_name: C5AR_HUMAN, from_res: I, pubmed: '11062244', seq: '124', to_res: N}
- {entry_name: C5AR_HUMAN, from_res: L, pubmed: '10336477', seq: '127', to_res: Q}
- {entry_name: C5AR_HUMAN, from_res: L, pubmed: '11062244', seq: '127', to_res: Q}
- {entry_name: C5AR_HUMAN, from_res: T, pubmed: '10336477', seq: '129', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: I, pubmed: '10336477', seq: '130', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: C, pubmed: '10952985', seq: '157', to_res: S}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '14563493', seq: '175', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '8631370', seq: '175', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '14563493', seq: '175', to_res: D}
- {entry_name: C5AR_HUMAN, from_res: E, pubmed: '11705397', seq: '199', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: E, pubmed: '10423250', seq: '199', to_res: K}
- {entry_name: C5AR_HUMAN, from_res: E, pubmed: '11705397', seq: '199', to_res: K}
- {entry_name: C5AR_HUMAN, from_res: E, pubmed: '14563493', seq: '199', to_res: K}
- {entry_name: C5AR_HUMAN, from_res: E, pubmed: '10423250', seq: '199', to_res: Q}
- {entry_name: C5AR_HUMAN, from_res: A, pubmed: '10336477', seq: '203', to_res: V}
- {entry_name: C5AR_HUMAN, from_res: A, pubmed: '11062244', seq: '203', to_res: V}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '10423250', seq: '206', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '11062244', seq: '206', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '11705397', seq: '206', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '7608153', seq: '206', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '10336477', seq: '206', to_res: H}
- {entry_name: C5AR_HUMAN, from_res: R, pubmed: '11062244', seq: '206', to_res: H}
- {entry_name: C5AR_HUMAN, from_res: L, pubmed: '10336477', seq: '207', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: L, pubmed: '11062244', seq: '207', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: L, pubmed: '10336477', seq: '207', to_res: I}
- {entry_name: C5AR_HUMAN, from_res: C, pubmed: '10336477', seq: '221', to_res: S}
- {entry_name: C5AR_HUMAN, from_res: Y, pubmed: '10336477', seq: '222', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: Y, pubmed: '10336477', seq: '222', to_res: H}
- {entry_name: C5AR_HUMAN, from_res: T, pubmed: '10336477', seq: '223', to_res: N}
- {entry_name: C5AR_HUMAN, from_res: K, pubmed: '10336477', seq: '242', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: F, pubmed: '10336477', seq: '251', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: V, pubmed: '10336477', seq: '260', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10336477', seq: '266', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '10336477', seq: '282', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '11705397', seq: '282', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '14563493', seq: '282', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '8631370', seq: '282', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '11705397', seq: '282', to_res: R}
- {entry_name: C5AR_HUMAN, from_res: D, pubmed: '14563493', seq: '282', to_res: R}
- {entry_name: C5AR_HUMAN, from_res: V, pubmed: '10336477', seq: '286', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: V, pubmed: '11062244', seq: '286', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: V, pubmed: '10336477', seq: '286', to_res: L}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10336477', seq: '287', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '11062244', seq: '287', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: N, pubmed: '10336477', seq: '296', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '314', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '9410877', seq: '314', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '317', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '327', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '332', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '9410877', seq: '332', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '332', to_res: D}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '334', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '334', to_res: D}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '338', to_res: A}
- {entry_name: C5AR_HUMAN, from_res: S, pubmed: '10636859', seq: '338', to_res: D}
- {entry_name: C5AR_RAT, from_res: R, pubmed: '14570896', seq: '69', to_res: A}
- {entry_name: C5AR_RAT, from_res: R, pubmed: '14570896', seq: '69', to_res: D}
- {entry_name: CALCR_HUMAN, from_res: S, pubmed: '14583624', seq: '27', to_res: M}
- {entry_name: CALCR_HUMAN, from_res: T, pubmed: '14583624', seq: '30', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: M, pubmed: '14583624', seq: '48', to_res: I}
- {entry_name: CALCR_HUMAN, from_res: M, pubmed: '14583624', seq: '49', to_res: I}
- {entry_name: CALCR_HUMAN, from_res: Y, pubmed: '12684503', seq: '71', to_res: N}
- {entry_name: CALCR_HUMAN, from_res: L, pubmed: '14623894', seq: '90', to_res: M}
- {entry_name: CALCR_HUMAN, from_res: F, pubmed: '12684503', seq: '102', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: V, pubmed: '14623894', seq: '108', to_res: M}
- {entry_name: CALCR_HUMAN, from_res: V, pubmed: '14623894', seq: '117', to_res: M}
- {entry_name: CALCR_HUMAN, from_res: M, pubmed: '14623894', seq: '133', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: M, pubmed: '14623894', seq: '133', to_res: L}
- {entry_name: CALCR_HUMAN, from_res: C, pubmed: '14623894', seq: '134', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: N, pubmed: '14623894', seq: '135', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: A, pubmed: '14623894', seq: '136', to_res: V}
- {entry_name: CALCR_HUMAN, from_res: F, pubmed: '14583624', seq: '137', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: F, pubmed: '14623894', seq: '137', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: T, pubmed: '14623894', seq: '138', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: P, pubmed: '14623894', seq: '139', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: E, pubmed: '14623894', seq: '140', to_res: A}
- {entry_name: CALCR_HUMAN, from_res: K, pubmed: '14623894', seq: '141', to_res: A}
- {entry_name: CALCR_MOUSE, from_res: N, pubmed: '11854283', seq: '28', to_res: S}
- {entry_name: CALCR_MOUSE, from_res: Y, pubmed: '11854283', seq: '71', to_res: N}
- {entry_name: CALCR_MOUSE, from_res: N, pubmed: '11854283', seq: '144', to_res: S}
- {entry_name: CALCR_MOUSE, from_res: H, pubmed: '9075694', seq: '184', to_res: R}
- {entry_name: CALCR_RAT, from_res: I, pubmed: '11927592', seq: '285', to_res: T}
- {entry_name: CALRL_HUMAN, from_res: C, pubmed: '12630808', seq: '212', to_res: A}
- {entry_name: CALRL_HUMAN, from_res: C, pubmed: '12630808', seq: '225', to_res: A}
- {entry_name: CALRL_HUMAN, from_res: C, pubmed: '12630808', seq: '282', to_res: A}
- {entry_name: CALRL_MOUSE, from_res: D, pubmed: '15823033', seq: '69', to_res: N}
- {entry_name: CALRL_MOUSE, from_res: C, pubmed: '12684503', seq: '104', to_res: A}
- {entry_name: CALRL_MOUSE, from_res: N, pubmed: '11331002', seq: '117', to_res: A}
- {entry_name: CALRL_MOUSE, from_res: N, pubmed: '15823033', seq: '117', to_res: A}
- {entry_name: CALRL_MOUSE, from_res: N, pubmed: '11331002', seq: '117', to_res: D}
- {entry_name: CALRL_MOUSE, from_res: N, pubmed: '11331002', seq: '117', to_res: P}
- {entry_name: CALRL_MOUSE, from_res: N, pubmed: '11331002', seq: '117', to_res: Q}
- {entry_name: CALRL_MOUSE, from_res: N, pubmed: '11331002', seq: '117', to_res: T}
- {entry_name: CALRL_RAT, from_res: G, pubmed: '12684503', seq: '60', to_res: S}
- {entry_name: CAR1_DICDI, from_res: S, pubmed: '8999903', seq: '90', to_res: R}
- {entry_name: CAR1_DICDI, from_res: T, pubmed: '8999903', seq: '97', to_res: A}
- {entry_name: CAR1_DICDI, from_res: L, pubmed: '8999903', seq: '107', to_res: S}
- {entry_name: CAR1_DICDI, from_res: I, pubmed: '8999903', seq: '108', to_res: N}
- {entry_name: CAR1_DICDI, from_res: V, pubmed: '8999903', seq: '136', to_res: T}
- {entry_name: CAR1_DICDI, from_res: R, pubmed: '8999903', seq: '160', to_res: S}
- {entry_name: CAR1_DICDI, from_res: F, pubmed: '8999903', seq: '164', to_res: Y}
- {entry_name: CAR1_DICDI, from_res: I, pubmed: '8999903', seq: '171', to_res: V}
- {entry_name: CAR1_DICDI, from_res: S, pubmed: '8999904', seq: '183', to_res: P}
- {entry_name: CAR1_DICDI, from_res: R, pubmed: '8999904', seq: '184', to_res: C}
- {entry_name: CAR1_DICDI, from_res: R, pubmed: '8999904', seq: '184', to_res: G}
- {entry_name: CAR1_DICDI, from_res: T, pubmed: '8999904', seq: '186', to_res: S}
- {entry_name: CAR1_DICDI, from_res: V, pubmed: '8999903', seq: '189', to_res: A}
- {entry_name: CAR1_DICDI, from_res: H, pubmed: '8999903', seq: '191', to_res: P}
- {entry_name: CAR1_DICDI, from_res: N, pubmed: '8999903', seq: '197', to_res: I}
- {entry_name: CAR1_DICDI, from_res: Y, pubmed: '8999904', seq: '204', to_res: D}
- {entry_name: CAR1_DICDI, from_res: K, pubmed: '8999904', seq: '207', to_res: I}
- {entry_name: CAR1_DICDI, from_res: K, pubmed: '8999904', seq: '207', to_res: N}
- {entry_name: CAR1_DICDI, from_res: N, pubmed: '8999903', seq: '210', to_res: S}
- {entry_name: CAR1_DICDI, from_res: N, pubmed: '8999903', seq: '229', to_res: D}
- {entry_name: CAR1_DICDI, from_res: Y, pubmed: '8999903', seq: '259', to_res: H}
- {entry_name: CASR_BOVIN, from_res: T, pubmed: '11095989', seq: '112', to_res: A}
- {entry_name: CASR_BOVIN, from_res: E, pubmed: '9050237', seq: '128', to_res: A}
- {entry_name: CASR_BOVIN, from_res: R, pubmed: '9050237', seq: '186', to_res: Q}
- {entry_name: CASR_BOVIN, from_res: Y, pubmed: '9050237', seq: '219', to_res: S}
- {entry_name: CASR_BOVIN, from_res: E, pubmed: '9050237', seq: '298', to_res: K}
- {entry_name: CASR_BOVIN, from_res: S, pubmed: '9050237', seq: '658', to_res: Y}
- {entry_name: CASR_BOVIN, from_res: F, pubmed: '11897705', seq: '707', to_res: W}
- {entry_name: CASR_BOVIN, from_res: P, pubmed: '9050237', seq: '749', to_res: R}
- {entry_name: CASR_BOVIN, from_res: R, pubmed: '11231970', seq: '796', to_res: W}
- {entry_name: CASR_BOVIN, from_res: R, pubmed: '9050237', seq: '796', to_res: W}
- {entry_name: CASR_BOVIN, from_res: V, pubmed: '9050237', seq: '818', to_res: I}
- {entry_name: CASR_BOVIN, from_res: H, pubmed: '11535593', seq: '880', to_res: A}
- {entry_name: CASR_BOVIN, from_res: F, pubmed: '11535593', seq: '882', to_res: A}
- {entry_name: CASR_BOVIN, from_res: F, pubmed: '11535593', seq: '882', to_res: L}
- {entry_name: CASR_BOVIN, from_res: K, pubmed: '11535593', seq: '883', to_res: A}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '15879434', seq: '11', to_res: S}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '15879434', seq: '13', to_res: P}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '10468915', seq: '27', to_res: R}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '11763315', seq: '27', to_res: R}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '10468915', seq: '39', to_res: A}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '11399760', seq: '39', to_res: A}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '9920108', seq: '39', to_res: A}
- {entry_name: CASR_HUMAN, from_res: I, pubmed: '12191970', seq: '40', to_res: F}
- {entry_name: CASR_HUMAN, from_res: K, pubmed: '11136551', seq: '47', to_res: N}
- {entry_name: CASR_HUMAN, from_res: K, pubmed: '12241879', seq: '47', to_res: N}
- {entry_name: CASR_HUMAN, from_res: K, pubmed: '9920108', seq: '47', to_res: N}
- {entry_name: CASR_HUMAN, from_res: D, pubmed: '11399760', seq: '48', to_res: A}
- {entry_name: CASR_HUMAN, from_res: D, pubmed: '11399760', seq: '50', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '11399760', seq: '53', to_res: P}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '9920108', seq: '53', to_res: P}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '11399760', seq: '55', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '11763315', seq: '55', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '12580936', seq: '55', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '9920108', seq: '55', to_res: L}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11399760', seq: '59', to_res: A}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '10206973', seq: '60', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '60', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '60', to_res: S}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '8702647', seq: '62', to_res: M}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '9920108', seq: '62', to_res: M}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11069904', seq: '66', to_res: C}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '8702647', seq: '66', to_res: C}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '9011580', seq: '66', to_res: C}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '9920108', seq: '66', to_res: C}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9852126', seq: '90', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '14985373', seq: '100', to_res: I}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '10206973', seq: '101', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '101', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '101', to_res: S}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '14729680', seq: '112', to_res: S}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '11136551', seq: '116', to_res: T}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '12191970', seq: '116', to_res: T}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '9661634', seq: '116', to_res: T}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '9920108', seq: '116', to_res: T}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '11399760', seq: '117', to_res: N}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '11136551', seq: '118', to_res: K}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '8813042', seq: '118', to_res: K}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9253358', seq: '118', to_res: K}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9661634', seq: '118', to_res: K}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9920108', seq: '118', to_res: K}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '11701698', seq: '125', to_res: P}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '12107202', seq: '125', to_res: P}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '12191970', seq: '125', to_res: P}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11069904', seq: '127', to_res: A}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11136551', seq: '127', to_res: A}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '8702647', seq: '127', to_res: A}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '9661634', seq: '127', to_res: A}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '9920108', seq: '127', to_res: A}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11701698', seq: '127', to_res: K}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '11069904', seq: '128', to_res: L}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '11136551', seq: '128', to_res: L}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '12191970', seq: '128', to_res: L}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '8813042', seq: '128', to_res: L}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9661634', seq: '128', to_res: L}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9920108', seq: '128', to_res: L}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11701698', seq: '129', to_res: F}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '10835431', seq: '129', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '129', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11289719', seq: '129', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '14729680', seq: '129', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '129', to_res: S}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9852126', seq: '130', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '15960151', seq: '131', to_res: F}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '10206973', seq: '131', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '10835431', seq: '131', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '131', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '14729680', seq: '131', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '131', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '12241879', seq: '131', to_res: W}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '11889203', seq: '138', to_res: M}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '8702647', seq: '138', to_res: M}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '10077597', seq: '143', to_res: E}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '12095982', seq: '143', to_res: E}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '12114500', seq: '143', to_res: E}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '14729680', seq: '143', to_res: E}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '8702647', seq: '143', to_res: E}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '9011580', seq: '143', to_res: E}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12095982', seq: '147', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12114500', seq: '147', to_res: A}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '11136551', seq: '151', to_res: M}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12067826', seq: '151', to_res: M}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '8698326', seq: '151', to_res: M}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '8813042', seq: '151', to_res: M}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '9661634', seq: '151', to_res: M}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '9920108', seq: '151', to_res: M}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '14729680', seq: '156', to_res: S}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12095982', seq: '169', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12114500', seq: '169', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12095982', seq: '170', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12114500', seq: '170', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12095982', seq: '171', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12114500', seq: '171', to_res: A}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '16497624', seq: '173', to_res: P}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9039332', seq: '178', to_res: D}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '10077597', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '10206973', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '10230755', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '10770217', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11038250', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '12095982', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '12114500', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '14729680', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '8702647', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '9011580', seq: '185', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: D, pubmed: '12095982', seq: '190', to_res: A}
- {entry_name: CASR_HUMAN, from_res: D, pubmed: '12114500', seq: '190', to_res: A}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '10230755', seq: '191', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11136551', seq: '191', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '8813042', seq: '191', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '9661634', seq: '191', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '9920108', seq: '191', to_res: K}
- {entry_name: CASR_HUMAN, from_res: I, pubmed: '14602739', seq: '212', to_res: T}
- {entry_name: CASR_HUMAN, from_res: D, pubmed: '10230755', seq: '215', to_res: E}
- {entry_name: CASR_HUMAN, from_res: D, pubmed: '10230755', seq: '215', to_res: G}
- {entry_name: CASR_HUMAN, from_res: Y, pubmed: '12095982', seq: '218', to_res: A}
- {entry_name: CASR_HUMAN, from_res: Y, pubmed: '12114500', seq: '218', to_res: A}
- {entry_name: CASR_HUMAN, from_res: Y, pubmed: '12580936', seq: '218', to_res: C}
- {entry_name: CASR_HUMAN, from_res: Y, pubmed: '12095982', seq: '218', to_res: S}
- {entry_name: CASR_HUMAN, from_res: Y, pubmed: '12114500', seq: '218', to_res: S}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11889203', seq: '220', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '9039332', seq: '220', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11763315', seq: '220', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11889203', seq: '220', to_res: W}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '11136551', seq: '221', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '11701698', seq: '221', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '12067826', seq: '221', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '12241879', seq: '221', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '12733714', seq: '221', to_res: L}
- {entry_name: CASR_HUMAN, from_res: P, pubmed: '9039332', seq: '221', to_res: S}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '15572418', seq: '227', to_res: L}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '15572418', seq: '227', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11136551', seq: '228', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '10206973', seq: '236', to_res: S}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '11136551', seq: '245', to_res: R}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '9661634', seq: '245', to_res: R}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9852126', seq: '287', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '10077597', seq: '297', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11069904', seq: '297', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '12095982', seq: '297', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '12114500', seq: '297', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '8702647', seq: '297', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '9011580', seq: '297', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '12095982', seq: '297', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '10971459', seq: '395', to_res: R}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9852126', seq: '400', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '437', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '437', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '449', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '449', to_res: S}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9852126', seq: '468', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '482', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '482', to_res: S}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9852126', seq: '488', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '11889203', seq: '549', to_res: R}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '12095982', seq: '549', to_res: R}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '12114500', seq: '549', to_res: R}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '11762699', seq: '557', to_res: E}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11889154', seq: '562', to_res: Y}
- {entry_name: CASR_HUMAN, from_res: N, pubmed: '9852126', seq: '594', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11069904', seq: '598', to_res: S}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9801147', seq: '598', to_res: S}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '12574188', seq: '604', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '14519094', seq: '604', to_res: K}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '8813042', seq: '604', to_res: K}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '11136551', seq: '612', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '12191970', seq: '612', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '8813042', seq: '612', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9661634', seq: '612', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9719629', seq: '612', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9920108', seq: '612', to_res: S}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '9694886', seq: '646', to_res: V}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11231970', seq: '648', to_res: X}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '14985373', seq: '650', to_res: P}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14660633', seq: '667', to_res: A}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14660633', seq: '668', to_res: A}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14660633', seq: '668', to_res: L}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14660633', seq: '668', to_res: V}
- {entry_name: CASR_HUMAN, from_res: G, pubmed: '9050237', seq: '670', to_res: R}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '14660633', seq: '680', to_res: A}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11069904', seq: '680', to_res: C}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '14660633', seq: '680', to_res: L}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '14660633', seq: '680', to_res: V}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '10217436', seq: '681', to_res: H}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '11136551', seq: '681', to_res: H}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '9920108', seq: '681', to_res: H}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14660633', seq: '684', to_res: A}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14660633', seq: '684', to_res: L}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14660633', seq: '684', to_res: V}
- {entry_name: CASR_HUMAN, from_res: V, pubmed: '14985373', seq: '689', to_res: M}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '15551332', seq: '767', to_res: K}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '10217436', seq: '773', to_res: R}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '11136551', seq: '773', to_res: R}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '9253358', seq: '773', to_res: R}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '9661634', seq: '773', to_res: R}
- {entry_name: CASR_HUMAN, from_res: L, pubmed: '9920108', seq: '773', to_res: R}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '10217436', seq: '788', to_res: C}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '11136551', seq: '788', to_res: C}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '11701698', seq: '788', to_res: C}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9661634', seq: '788', to_res: C}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9920108', seq: '788', to_res: C}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '9694886', seq: '794', to_res: A}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '10077597', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '10230755', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '10843194', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '11889203', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '12095982', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '12114500', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '8702647', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '9011580', seq: '795', to_res: W}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '11701698', seq: '799', to_res: K}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '11136551', seq: '806', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9253358', seq: '806', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9661634', seq: '806', to_res: S}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '9920108', seq: '806', to_res: S}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '11134112', seq: '820', to_res: F}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12050233', seq: '820', to_res: F}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '8813042', seq: '820', to_res: F}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '14677060', seq: '821', to_res: L}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '10352095', seq: '826', to_res: T}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '14660633', seq: '837', to_res: I}
- {entry_name: CASR_HUMAN, from_res: E, pubmed: '14660633', seq: '837', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '10217436', seq: '840', to_res: E}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '10217436', seq: '843', to_res: E}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '10835431', seq: '843', to_res: E}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '11701698', seq: '843', to_res: E}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '12107202', seq: '843', to_res: E}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '12241879', seq: '843', to_res: E}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '10217436', seq: '843', to_res: K}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '10217436', seq: '843', to_res: V}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '11136551', seq: '851', to_res: S}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '12399473', seq: '873', to_res: A}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '9792684', seq: '873', to_res: A}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '12399473', seq: '874', to_res: A}
- {entry_name: CASR_HUMAN, from_res: C, pubmed: '9792684', seq: '874', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '12399473', seq: '875', to_res: A}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '9792684', seq: '875', to_res: A}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12399473', seq: '876', to_res: A}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12399473', seq: '876', to_res: D}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '9792684', seq: '876', to_res: D}
- {entry_name: CASR_HUMAN, from_res: H, pubmed: '12399473', seq: '879', to_res: A}
- {entry_name: CASR_HUMAN, from_res: F, pubmed: '10843194', seq: '881', to_res: L}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12356761', seq: '888', to_res: A}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: A}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: D}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: E}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: G}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: K}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: N}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: Q}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: V}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '9694886', seq: '888', to_res: V}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: W}
- {entry_name: CASR_HUMAN, from_res: T, pubmed: '12409307', seq: '888', to_res: Y}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '9694886', seq: '895', to_res: A}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '16497624', seq: '896', to_res: H}
- {entry_name: CASR_HUMAN, from_res: S, pubmed: '9694886', seq: '915', to_res: A}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '11733622', seq: '986', to_res: S}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '12040821', seq: '986', to_res: S}
- {entry_name: CASR_HUMAN, from_res: A, pubmed: '14985373', seq: '986', to_res: S}
- {entry_name: CASR_HUMAN, from_res: R, pubmed: '14985373', seq: '990', to_res: G}
- {entry_name: CASR_HUMAN, from_res: Q, pubmed: '14985373', seq: '1011', to_res: E}
- {entry_name: CASR_MOUSE, from_res: R, pubmed: '15547142', seq: '185', to_res: Q}
- {entry_name: CASR_RAT, from_res: R, pubmed: '12644311', seq: '795', to_res: W}
- {entry_name: CCKAR_HUMAN, from_res: D, pubmed: '15634012', seq: '2', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: E, pubmed: '9006937', seq: '38', to_res: D}
- {entry_name: CCKAR_HUMAN, from_res: W, pubmed: '9006937', seq: '39', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: W, pubmed: '15634012', seq: '39', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: W, pubmed: '9006937', seq: '39', to_res: I}
- {entry_name: CCKAR_HUMAN, from_res: Q, pubmed: '9006937', seq: '40', to_res: E}
- {entry_name: CCKAR_HUMAN, from_res: Q, pubmed: '9006937', seq: '40', to_res: N}
- {entry_name: CCKAR_HUMAN, from_res: Q, pubmed: '15634012', seq: '40', to_res: N}
- {entry_name: CCKAR_HUMAN, from_res: A, pubmed: '9006937', seq: '42', to_res: V}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '11724786', seq: '50', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '15634012', seq: '50', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '11724786', seq: '51', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '15634012', seq: '51', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '11724786', seq: '53', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '15634012', seq: '53', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '10220557', seq: '68', to_res: L}
- {entry_name: CCKAR_HUMAN, from_res: N, pubmed: '10220557', seq: '69', to_res: S}
- {entry_name: CCKAR_HUMAN, from_res: M, pubmed: '10220557', seq: '72', to_res: L}
- {entry_name: CCKAR_HUMAN, from_res: D, pubmed: '15634012', seq: '87', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: D, pubmed: '15634012', seq: '87', to_res: E}
- {entry_name: CCKAR_HUMAN, from_res: C, pubmed: '11724786', seq: '94', to_res: L}
- {entry_name: CCKAR_HUMAN, from_res: C, pubmed: '15634012', seq: '94', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '15634012', seq: '105', to_res: L}
- {entry_name: CCKAR_HUMAN, from_res: D, pubmed: '15634012', seq: '106', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '16033264', seq: '107', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '15634012', seq: '107', to_res: W}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '15634012', seq: '109', to_res: W}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '10594328', seq: '115', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '15634012', seq: '115', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '15634012', seq: '115', to_res: L}
- {entry_name: CCKAR_HUMAN, from_res: T, pubmed: '15634012', seq: '117', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: T, pubmed: '16033264', seq: '117', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: T, pubmed: '15634012', seq: '118', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: M, pubmed: '11724786', seq: '121', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: M, pubmed: '11724786', seq: '121', to_res: V}
- {entry_name: CCKAR_HUMAN, from_res: M, pubmed: '15634012', seq: '121', to_res: V}
- {entry_name: CCKAR_HUMAN, from_res: S, pubmed: '15634012', seq: '124', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: V, pubmed: '11724786', seq: '125', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: V, pubmed: '15634012', seq: '125', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '15634012', seq: '139', to_res: E}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '15634012', seq: '170', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '10594328', seq: '187', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '15634012', seq: '187', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: M, pubmed: '16033264', seq: '195', to_res: L}
- {entry_name: CCKAR_HUMAN, from_res: M, pubmed: '15634012', seq: '195', to_res: Y}
- {entry_name: CCKAR_HUMAN, from_res: M, pubmed: '16033264', seq: '195', to_res: Y}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '10595537', seq: '197', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '11724786', seq: '197', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '16033264', seq: '197', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '11724786', seq: '197', to_res: Y}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '15634012', seq: '197', to_res: Y}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '16033264', seq: '197', to_res: Y}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '11724786', seq: '218', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '15634012', seq: '218', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '15634012', seq: '308', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: K, pubmed: '15634012', seq: '309', to_res: T}
- {entry_name: CCKAR_HUMAN, from_res: W, pubmed: '11724786', seq: '326', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: W, pubmed: '15634012', seq: '326', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '11724786', seq: '329', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '16033264', seq: '329', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '11724786', seq: '329', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '15634012', seq: '329', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '16033264', seq: '329', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '11724786', seq: '330', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: F, pubmed: '15634012', seq: '330', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: N, pubmed: '10400673', seq: '333', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: N, pubmed: '11724786', seq: '333', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: N, pubmed: '15634012', seq: '333', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: N, pubmed: '16033264', seq: '333', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: N, pubmed: '16033264', seq: '333', to_res: Y}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '10400673', seq: '336', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '10400673', seq: '336', to_res: D}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '10400673', seq: '336', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '11724786', seq: '336', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '15634012', seq: '336', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '16033264', seq: '336', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: R, pubmed: '16033264', seq: '336', to_res: Y}
- {entry_name: CCKAR_HUMAN, from_res: S, pubmed: '15634012', seq: '342', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: S, pubmed: '16033264', seq: '342', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: S, pubmed: '16033264', seq: '342', to_res: W}
- {entry_name: CCKAR_HUMAN, from_res: S, pubmed: '16033264', seq: '348', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: S, pubmed: '15634012', seq: '348', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '11724786', seq: '352', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '16033264', seq: '352', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: I, pubmed: '15634012', seq: '352', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '10594328', seq: '356', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '11724786', seq: '356', to_res: A}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '10594328', seq: '356', to_res: H}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '15634012', seq: '356', to_res: M}
- {entry_name: CCKAR_HUMAN, from_res: L, pubmed: '10594328', seq: '356', to_res: N}
- {entry_name: CCKAR_HUMAN, from_res: Y, pubmed: '11724786', seq: '360', to_res: F}
- {entry_name: CCKAR_HUMAN, from_res: Y, pubmed: '15634012', seq: '360', to_res: M}
- {entry_name: CCKAR_RAT, from_res: L, pubmed: '15774770', seq: '119', to_res: M}
- {entry_name: CCKAR_RAT, from_res: K, pubmed: '10594328', seq: '130', to_res: A}
- {entry_name: CCKAR_RAT, from_res: K, pubmed: '10594328', seq: '202', to_res: A}
- {entry_name: CCKAR_RAT, from_res: S, pubmed: '8631990', seq: '260', to_res: A}
- {entry_name: CCKAR_RAT, from_res: S, pubmed: '8631990', seq: '264', to_res: A}
- {entry_name: CCKAR_RAT, from_res: S, pubmed: '8631990', seq: '275', to_res: A}
- {entry_name: CCKAR_RAT, from_res: E, pubmed: '15634012', seq: '360', to_res: G}
- {entry_name: CCKAR_RAT, from_res: T, pubmed: '8631990', seq: '424', to_res: A}
- {entry_name: CCR1_HUMAN, from_res: Y, pubmed: '15548526', seq: '41', to_res: A}
- {entry_name: CCR1_HUMAN, from_res: D, pubmed: '15548526', seq: '80', to_res: N}
- {entry_name: CCR1_HUMAN, from_res: T, pubmed: '15548526', seq: '86', to_res: A}
- {entry_name: CCR1_HUMAN, from_res: L, pubmed: '15548526', seq: '87', to_res: A}
- {entry_name: CCR1_HUMAN, from_res: D, pubmed: '15548526', seq: '92', to_res: N}
- {entry_name: CCR1_HUMAN, from_res: Y, pubmed: '15548526', seq: '113', to_res: A}
- {entry_name: CCR1_HUMAN, from_res: Y, pubmed: '15548526', seq: '118', to_res: A}
- {entry_name: CCR1_HUMAN, from_res: E, pubmed: '15548526', seq: '120', to_res: Q}
- {entry_name: CCR1_HUMAN, from_res: F, pubmed: '12181451', seq: '149', to_res: N}
- {entry_name: CCR1_HUMAN, from_res: L, pubmed: '12181451', seq: '205', to_res: G}
- {entry_name: CCR1_HUMAN, from_res: E, pubmed: '15548526', seq: '287', to_res: A}
- {entry_name: CCR1_HUMAN, from_res: E, pubmed: '15548526', seq: '287', to_res: Q}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10529171', seq: '15', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10529171', seq: '18', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10529171', seq: '19', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: T, pubmed: '11046064', seq: '21', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: T, pubmed: '11046064', seq: '22', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: F, pubmed: '11046064', seq: '23', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: F, pubmed: '11046064', seq: '24', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '10529171', seq: '25', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '11046064', seq: '25', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '11046064', seq: '26', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '11046064', seq: '26', to_res: F}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '10529171', seq: '27', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: C, pubmed: '9287323', seq: '32', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '10529171', seq: '36', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: K, pubmed: '12954060', seq: '38', to_res: D}
- {entry_name: CCR2_HUMAN, from_res: P, pubmed: '9252328', seq: '47', to_res: L}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '12954060', seq: '49', to_res: F}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '12954060', seq: '49', to_res: L}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '12954060', seq: '49', to_res: Q}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '12954060', seq: '49', to_res: R}
- {entry_name: CCR2_HUMAN, from_res: V, pubmed: '12325020', seq: '64', to_res: I}
- {entry_name: CCR2_HUMAN, from_res: V, pubmed: '9500612', seq: '64', to_res: I}
- {entry_name: CCR2_HUMAN, from_res: S, pubmed: '9252328', seq: '87', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '12954060', seq: '120', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '12954060', seq: '120', to_res: H}
- {entry_name: CCR2_HUMAN, from_res: H, pubmed: '12954060', seq: '121', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: H, pubmed: '12954060', seq: '121', to_res: F}
- {entry_name: CCR2_HUMAN, from_res: H, pubmed: '12954060', seq: '121', to_res: R}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '10097088', seq: '139', to_res: F}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '9670957', seq: '139', to_res: F}
- {entry_name: CCR2_HUMAN, from_res: H, pubmed: '12954060', seq: '202', to_res: R}
- {entry_name: CCR2_HUMAN, from_res: Y, pubmed: '12954060', seq: '259', to_res: H}
- {entry_name: CCR2_HUMAN, from_res: N, pubmed: '12325020', seq: '260', to_res: N}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10770925', seq: '270', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: C, pubmed: '9287323', seq: '277', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10770925', seq: '278', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '10529171', seq: '284', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '10770925', seq: '284', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '12954060', seq: '284', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '10770925', seq: '284', to_res: K}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '12954060', seq: '284', to_res: K}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '10770925', seq: '284', to_res: N}
- {entry_name: CCR2_HUMAN, from_res: D, pubmed: '12954060', seq: '284', to_res: Q}
- {entry_name: CCR2_HUMAN, from_res: Q, pubmed: '12954060', seq: '288', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: Q, pubmed: '12954060', seq: '288', to_res: T}
- {entry_name: CCR2_HUMAN, from_res: T, pubmed: '12954060', seq: '290', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10529171', seq: '291', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10770925', seq: '291', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '12954060', seq: '291', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10770925', seq: '291', to_res: K}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '10770925', seq: '291', to_res: Q}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '12954060', seq: '291', to_res: Q}
- {entry_name: CCR2_HUMAN, from_res: E, pubmed: '12954060', seq: '291', to_res: T}
- {entry_name: CCR2_HUMAN, from_res: T, pubmed: '12954060', seq: '292', to_res: A}
- {entry_name: CCR2_HUMAN, from_res: T, pubmed: '12954060', seq: '292', to_res: Y}
- {entry_name: CCR3_HUMAN, from_res: D, pubmed: '11920572', seq: '130', to_res: A}
- {entry_name: CCR3_HUMAN, from_res: D, pubmed: '11920572', seq: '130', to_res: E}
- {entry_name: CCR3_HUMAN, from_res: D, pubmed: '11920572', seq: '130', to_res: N}
- {entry_name: CCR3_HUMAN, from_res: R, pubmed: '11920572', seq: '131', to_res: K}
- {entry_name: CCR3_HUMAN, from_res: R, pubmed: '11920572', seq: '131', to_res: L}
- {entry_name: CCR5_CERAE, from_res: R, pubmed: '9890944', seq: '163', to_res: G}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '10574939', seq: '2', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9420225', seq: '2', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9445013', seq: '2', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10574939', seq: '3', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9445013', seq: '3', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '3', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9499044', seq: '3', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '3', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '10574939', seq: '4', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: V, pubmed: '10574939', seq: '5', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: V, pubmed: '9499044', seq: '5', to_res: G}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10574939', seq: '6', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10574939', seq: '7', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '9499044', seq: '7', to_res: V}
- {entry_name: CCR5_HUMAN, from_res: P, pubmed: '10574939', seq: '8', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: P, pubmed: '9525683', seq: '8', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10574939', seq: '9', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '9343222', seq: '9', to_res: T}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10574939', seq: '10', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9445013', seq: '10', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '10', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '10', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '10574939', seq: '11', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9420225', seq: '11', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9445013', seq: '11', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9525683', seq: '11', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9882373', seq: '11', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10574939', seq: '12', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10961858', seq: '12', to_res: L}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10347178', seq: '12', to_res: T}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '10574939', seq: '13', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9420225', seq: '13', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9343222', seq: '13', to_res: D}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9499044', seq: '13', to_res: D}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9890944', seq: '13', to_res: D}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9445013', seq: '14', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '14', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '14', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '15546882', seq: '14', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9343222', seq: '14', to_res: N}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9445013', seq: '15', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '15', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10823934', seq: '15', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9525683', seq: '15', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9499044', seq: '15', to_res: G}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '9525683', seq: '16', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '9499044', seq: '16', to_res: M}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '9525683', seq: '17', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '10574939', seq: '18', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '9420225', seq: '18', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '9445013', seq: '18', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '9499044', seq: '18', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: P, pubmed: '9525683', seq: '19', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10347178', seq: '20', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10383387', seq: '20', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '9445013', seq: '20', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '9525683', seq: '20', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '9882373', seq: '20', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10347178', seq: '20', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10383387', seq: '20', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10961858', seq: '20', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9445013', seq: '21', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9420225', seq: '22', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9420225', seq: '26', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '15851912', seq: '26', to_res: R}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9445013', seq: '27', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: A, pubmed: '10347178', seq: '29', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: A, pubmed: '10961858', seq: '29', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '10779565', seq: '31', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '9420225', seq: '31', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10779565', seq: '33', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10779565', seq: '37', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '41', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10347178', seq: '42', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10961858', seq: '42', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '10779565', seq: '48', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10779565', seq: '52', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10779565', seq: '55', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10347178', seq: '55', to_res: Q}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10961858', seq: '55', to_res: Q}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10779565', seq: '56', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '10961858', seq: '60', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '11369664', seq: '60', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10779565', seq: '68', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10779565', seq: '69', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '10779565', seq: '71', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: A, pubmed: '10347178', seq: '73', to_res: V}
- {entry_name: CCR5_HUMAN, from_res: A, pubmed: '10961858', seq: '73', to_res: V}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '10779565', seq: '76', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '79', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '10779565', seq: '82', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '11278962', seq: '82', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '11278962', seq: '82', to_res: C}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '11278962', seq: '82', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '11278962', seq: '82', to_res: V}
- {entry_name: CCR5_HUMAN, from_res: P, pubmed: '11278962', seq: '84', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '85', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '12466283', seq: '85', to_res: L}
- {entry_name: CCR5_HUMAN, from_res: W, pubmed: '10779565', seq: '86', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: H, pubmed: '9420225', seq: '88', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9882373', seq: '89', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: A, pubmed: '9499044', seq: '92', to_res: N}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9420225', seq: '93', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9882373', seq: '93', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9499044', seq: '93', to_res: E}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9882373', seq: '93', to_res: R}
- {entry_name: CCR5_HUMAN, from_res: W, pubmed: '9882373', seq: '94', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9420225', seq: '95', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9445013', seq: '95', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9499044', seq: '95', to_res: V}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9882373', seq: '98', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10196311', seq: '101', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10383387', seq: '101', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '11600494', seq: '101', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '9882373', seq: '101', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10961858', seq: '101', to_res: X}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9420225', seq: '102', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9499044', seq: '102', to_res: K}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10779565', seq: '104', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '12466283', seq: '104', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '10779565', seq: '105', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: G, pubmed: '15793360', seq: '106', to_res: R}
- {entry_name: CCR5_HUMAN, from_res: G, pubmed: '15851912', seq: '106', to_res: R}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10779565', seq: '108', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '12466283', seq: '109', to_res: H}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '112', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '12466283', seq: '112', to_res: Y}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '113', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '117', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '118', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10779565', seq: '121', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10779565', seq: '122', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '10779565', seq: '123', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9144190', seq: '125', to_res: G}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9054370', seq: '125', to_res: N}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '9144190', seq: '126', to_res: G}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '9054370', seq: '126', to_res: N}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '15761117', seq: '126', to_res: N}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9144190', seq: '127', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '9144190', seq: '135', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '10779565', seq: '144', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '12466283', seq: '168', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '9420225', seq: '168', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '9445013', seq: '168', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '9882373', seq: '169', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '10196311', seq: '171', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9420225', seq: '171', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9445013', seq: '171', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '12466283', seq: '172', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '9420225', seq: '172', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '9499044', seq: '174', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: H, pubmed: '9420225', seq: '175', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9445013', seq: '176', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10383387', seq: '178', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '11600494', seq: '178', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '9445013', seq: '178', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '9882373', seq: '178', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10961858', seq: '178', to_res: R}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '15851912', seq: '178', to_res: R}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10827088', seq: '179', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10827088', seq: '179', to_res: D}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10827088', seq: '180', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '9499044', seq: '180', to_res: P}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '9882373', seq: '180', to_res: P}
- {entry_name: CCR5_HUMAN, from_res: H, pubmed: '9420225', seq: '181', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '9882373', seq: '182', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: P, pubmed: '9343222', seq: '183', to_res: L}
- {entry_name: CCR5_HUMAN, from_res: P, pubmed: '9882373', seq: '183', to_res: L}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9420225', seq: '184', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9499044', seq: '184', to_res: H}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '9499044', seq: '185', to_res: T}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9420225', seq: '188', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9499044', seq: '188', to_res: H}
- {entry_name: CCR5_HUMAN, from_res: W, pubmed: '9882373', seq: '190', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '12466283', seq: '191', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9420225', seq: '191', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9445013', seq: '191', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '10196311', seq: '192', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9420225', seq: '192', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9499044', seq: '192', to_res: S}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '10779565', seq: '195', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9420225', seq: '197', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '9882373', seq: '197', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: I, pubmed: '10779565', seq: '198', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10961858', seq: '215', to_res: L}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '10961858', seq: '223', to_res: Q}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '15793360', seq: '223', to_res: Q}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '15851912', seq: '223', to_res: Q}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10779565', seq: '251', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '10779565', seq: '252', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '10779565', seq: '255', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '10779565', seq: '258', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '10779565', seq: '259', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '9420225', seq: '262', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '9882373', seq: '263', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: F, pubmed: '9882373', seq: '264', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '9882373', seq: '267', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '10383387', seq: '269', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '9882373', seq: '269', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '9445013', seq: '270', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: R, pubmed: '9420225', seq: '274', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '12466283', seq: '276', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9420225', seq: '276', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9445013', seq: '276', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: D, pubmed: '9882373', seq: '276', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: M, pubmed: '10779565', seq: '279', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Q, pubmed: '9445013', seq: '280', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: E, pubmed: '10779565', seq: '283', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: M, pubmed: '11237703', seq: '287', to_res: Y}
- {entry_name: CCR5_HUMAN, from_res: H, pubmed: '10779565', seq: '289', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: N, pubmed: '10779565', seq: '293', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '9303305', seq: '297', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: G, pubmed: '10961858', seq: '301', to_res: V}
- {entry_name: CCR5_HUMAN, from_res: K, pubmed: '11356952', seq: '318', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '11323418', seq: '321', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '11323418', seq: '323', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: C, pubmed: '11323418', seq: '324', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: A, pubmed: '10961858', seq: '335', to_res: V}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10085131', seq: '336', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '12065593', seq: '336', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '15793360', seq: '336', to_res: I}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10085131', seq: '337', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '12065593', seq: '337', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: Y, pubmed: '10961858', seq: '339', to_res: F}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10085131', seq: '342', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '11782464', seq: '342', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '12065593', seq: '342', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: T, pubmed: '11782464', seq: '343', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '10085131', seq: '349', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '11782464', seq: '349', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: S, pubmed: '12065593', seq: '349', to_res: A}
- {entry_name: CCR5_HUMAN, from_res: L, pubmed: '9343222', seq: '352', to_res: F}
- {entry_name: CCR5_RAT, from_res: K, pubmed: '11356952', seq: '316', to_res: A}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '36', to_res: A}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '36', to_res: D}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '36', to_res: G}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '36', to_res: S}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '118', to_res: S}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '197', to_res: S}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '288', to_res: A}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '288', to_res: G}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '288', to_res: R}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '288', to_res: S}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '336', to_res: S}
- {entry_name: CCR6_HUMAN, from_res: C, pubmed: '12081481', seq: '348', to_res: S}
- {entry_name: CCR8_MOUSE, from_res: N, pubmed: '14736884', seq: '8', to_res: Q}
- {entry_name: CELR2_HUMAN, from_res: H, pubmed: '8621427', seq: '86', to_res: A}
- {entry_name: CELR2_HUMAN, from_res: P, pubmed: '12209972', seq: '125', to_res: A}
- {entry_name: CELR3_HUMAN, from_res: E, pubmed: '8621427', seq: '13', to_res: A}
- {entry_name: CELR3_HUMAN, from_res: E, pubmed: '8621427', seq: '72', to_res: A}
- {entry_name: CELR3_HUMAN, from_res: E, pubmed: '8621427', seq: '103', to_res: A}
- {entry_name: CLTR1_HUMAN, from_res: N, pubmed: '14718577', seq: '106', to_res: A}
- {entry_name: CLTR1_HUMAN, from_res: I, pubmed: '14718577', seq: '232', to_res: R}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '98', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '107', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: S, pubmed: '12754098', seq: '114', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: Q, pubmed: '12754098', seq: '115', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: D, pubmed: '9580609', seq: '163', to_res: E}
- {entry_name: CNR1_HUMAN, from_res: D, pubmed: '10462549', seq: '163', to_res: N}
- {entry_name: CNR1_HUMAN, from_res: D, pubmed: '10525080', seq: '163', to_res: N}
- {entry_name: CNR1_HUMAN, from_res: D, pubmed: '9580609', seq: '163', to_res: N}
- {entry_name: CNR1_HUMAN, from_res: H, pubmed: '12754098', seq: '181', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: R, pubmed: '12754098', seq: '182', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '12754098', seq: '183', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: D, pubmed: '12754098', seq: '184', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: V, pubmed: '12754098', seq: '188', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: F, pubmed: '12754098', seq: '189', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: F, pubmed: '10525107', seq: '191', to_res: L}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '10051546', seq: '192', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '12110371', seq: '192', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '12435794', seq: '192', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '9855635', seq: '192', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '10525107', seq: '192', to_res: E}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '9422383', seq: '192', to_res: E}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '9855635', seq: '192', to_res: E}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '10051546', seq: '192', to_res: Q}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '9422383', seq: '192', to_res: Q}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '10051546', seq: '192', to_res: R}
- {entry_name: CNR1_HUMAN, from_res: K, pubmed: '9422383', seq: '192', to_res: R}
- {entry_name: CNR1_HUMAN, from_res: L, pubmed: '10525107', seq: '193', to_res: I}
- {entry_name: CNR1_HUMAN, from_res: G, pubmed: '10525107', seq: '195', to_res: S}
- {entry_name: CNR1_HUMAN, from_res: A, pubmed: '10525107', seq: '198', to_res: M}
- {entry_name: CNR1_HUMAN, from_res: S, pubmed: '10525107', seq: '199', to_res: T}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '8636122', seq: '257', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '257', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '8636122', seq: '257', to_res: S}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '8636122', seq: '264', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '264', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '8636122', seq: '264', to_res: S}
- {entry_name: CNR1_HUMAN, from_res: Y, pubmed: '12110371', seq: '275', to_res: F}
- {entry_name: CNR1_HUMAN, from_res: Y, pubmed: '12110371', seq: '275', to_res: I}
- {entry_name: CNR1_HUMAN, from_res: V, pubmed: '12754098', seq: '282', to_res: F}
- {entry_name: CNR1_HUMAN, from_res: L, pubmed: '10217281', seq: '341', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: A, pubmed: '10217281', seq: '342', to_res: L}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '355', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '382', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '386', to_res: A}
- {entry_name: CNR1_HUMAN, from_res: C, pubmed: '15952782', seq: '386', to_res: M}
- {entry_name: CNR1_RAT, from_res: D, pubmed: '10462549', seq: '164', to_res: N}
- {entry_name: CNR1_RAT, from_res: S, pubmed: '9526000', seq: '304', to_res: A}
- {entry_name: CNR1_RAT, from_res: S, pubmed: '9526000', seq: '317', to_res: A}
- {entry_name: CNR1_RAT, from_res: S, pubmed: '9526000', seq: '323', to_res: A}
- {entry_name: CNR1_RAT, from_res: N, pubmed: '10462549', seq: '394', to_res: D}
- {entry_name: CNR1_RAT, from_res: T, pubmed: '10234009', seq: '419', to_res: A}
- {entry_name: CNR1_RAT, from_res: S, pubmed: '10234009', seq: '426', to_res: A}
- {entry_name: CNR1_RAT, from_res: S, pubmed: '10234009', seq: '430', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: D, pubmed: '9580609', seq: '80', to_res: E}
- {entry_name: CNR2_HUMAN, from_res: D, pubmed: '9580609', seq: '80', to_res: N}
- {entry_name: CNR2_HUMAN, from_res: K, pubmed: '10051546', seq: '109', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: K, pubmed: '12110371', seq: '109', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: K, pubmed: '10051546', seq: '109', to_res: R}
- {entry_name: CNR2_HUMAN, from_res: W, pubmed: '11080201', seq: '158', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: W, pubmed: '11080201', seq: '158', to_res: F}
- {entry_name: CNR2_HUMAN, from_res: W, pubmed: '11080201', seq: '158', to_res: Y}
- {entry_name: CNR2_HUMAN, from_res: S, pubmed: '10915832', seq: '161', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: V, pubmed: '10915832', seq: '164', to_res: I}
- {entry_name: CNR2_HUMAN, from_res: S, pubmed: '10915832', seq: '165', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '10915832', seq: '174', to_res: S}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '8636122', seq: '174', to_res: S}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '10915832', seq: '175', to_res: S}
- {entry_name: CNR2_HUMAN, from_res: R, pubmed: '10915832', seq: '177', to_res: S}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '10915832', seq: '179', to_res: S}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '8636122', seq: '179', to_res: S}
- {entry_name: CNR2_HUMAN, from_res: S, pubmed: '10915832', seq: '193', to_res: G}
- {entry_name: CNR2_HUMAN, from_res: Y, pubmed: '11470278', seq: '299', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '15550382', seq: '313', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '11470278', seq: '320', to_res: A}
- {entry_name: CNR2_HUMAN, from_res: C, pubmed: '15550382', seq: '320', to_res: A}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '30', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '44', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '54', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '68', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '87', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '102', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '128', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '188', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '211', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '233', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '258', to_res: A}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '258', to_res: S}
- {entry_name: CRFR1_MOUSE, from_res: C, pubmed: '9376348', seq: '364', to_res: S}
- {entry_name: CRFR1_RAT, from_res: D, pubmed: '9914475', seq: '337', to_res: Q}
- {entry_name: CRFR1_RAT, from_res: E, pubmed: '9914475', seq: '338', to_res: Q}
- {entry_name: CRFR1_RAT, from_res: N, pubmed: '9914475', seq: '348', to_res: A}
- {entry_name: CRFR2_HUMAN, from_res: V, pubmed: '9454589', seq: '126', to_res: G}
- {entry_name: CRFR2_RAT, from_res: Q, pubmed: '11448846', seq: '269', to_res: P}
- {entry_name: CX3C1_HUMAN, from_res: E, pubmed: '16317113', seq: '13', to_res: A}
- {entry_name: CX3C1_HUMAN, from_res: D, pubmed: '16317113', seq: '16', to_res: A}
- {entry_name: CX3C1_HUMAN, from_res: V, pubmed: '12551893', seq: '249', to_res: I}
- {entry_name: CX3C1_HUMAN, from_res: V, pubmed: '12697743', seq: '249', to_res: I}
- {entry_name: CX3C1_HUMAN, from_res: V, pubmed: '14990582', seq: '249', to_res: I}
- {entry_name: CX3C1_HUMAN, from_res: V, pubmed: '15787642', seq: '249', to_res: I}
- {entry_name: CX3C1_HUMAN, from_res: D, pubmed: '16317113', seq: '266', to_res: A}
- {entry_name: CX3C1_HUMAN, from_res: T, pubmed: '12551893', seq: '280', to_res: M}
- {entry_name: CX3C1_HUMAN, from_res: T, pubmed: '12697743', seq: '280', to_res: M}
- {entry_name: CX3C1_HUMAN, from_res: T, pubmed: '14990582', seq: '280', to_res: M}
- {entry_name: CX3C1_HUMAN, from_res: T, pubmed: '15787642', seq: '280', to_res: M}
- {entry_name: CX3C1_MOUSE, from_res: D, pubmed: '10187784', seq: '127', to_res: N}
- {entry_name: CX3C1_MOUSE, from_res: R, pubmed: '10187784', seq: '128', to_res: N}
- {entry_name: CXCR1_HUMAN, from_res: C, pubmed: '8034699', seq: '30', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: K, pubmed: '15974585', seq: '99', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: C, pubmed: '8034699', seq: '110', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: C, pubmed: '8034699', seq: '187', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: R, pubmed: '12077146', seq: '199', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: R, pubmed: '8034699', seq: '199', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: R, pubmed: '12077146', seq: '199', to_res: H}
- {entry_name: CXCR1_HUMAN, from_res: R, pubmed: '12077146', seq: '203', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: R, pubmed: '8034699', seq: '203', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: R, pubmed: '12077146', seq: '203', to_res: H}
- {entry_name: CXCR1_HUMAN, from_res: H, pubmed: '12077146', seq: '207', to_res: Q}
- {entry_name: CXCR1_HUMAN, from_res: D, pubmed: '12077146', seq: '265', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: D, pubmed: '8034699', seq: '265', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: D, pubmed: '12077146', seq: '265', to_res: H}
- {entry_name: CXCR1_HUMAN, from_res: C, pubmed: '8034699', seq: '277', to_res: A}
- {entry_name: CXCR1_HUMAN, from_res: E, pubmed: '15974585', seq: '291', to_res: A}
- {entry_name: CXCR1_RABIT, from_res: R, pubmed: '12077146', seq: '208', to_res: H}
- {entry_name: CXCR2_HUMAN, from_res: E, pubmed: '11023662', seq: '7', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: D, pubmed: '11023662', seq: '9', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: E, pubmed: '11023662', seq: '12', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: D, pubmed: '11023662', seq: '13', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: K, pubmed: '11023662', seq: '108', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: N, pubmed: '11023662', seq: '110', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: K, pubmed: '11023662', seq: '120', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: S, pubmed: '9079638', seq: '347', to_res: A}
- {entry_name: CXCR2_HUMAN, from_res: L, pubmed: '9651375', seq: '360', to_res: A}
- {entry_name: CXCR2_RABIT, from_res: L, pubmed: '11751889', seq: '324', to_res: A}
- {entry_name: CXCR2_RABIT, from_res: I, pubmed: '11751889', seq: '326', to_res: A}
- {entry_name: CXCR2_RABIT, from_res: I, pubmed: '11751889', seq: '333', to_res: A}
- {entry_name: CXCR2_RAT, from_res: R, pubmed: '9651375', seq: '183', to_res: C}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '2', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '2', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: S, pubmed: '11551942', seq: '5', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '10825158', seq: '7', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '11551942', seq: '7', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10620340', seq: '10', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '10', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '10', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10400757', seq: '11', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10756055', seq: '11', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10827088', seq: '11', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10486146', seq: '11', to_res: L}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10825158', seq: '11', to_res: Q}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '9151868', seq: '11', to_res: Q}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '10825158', seq: '12', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: T, pubmed: '10756055', seq: '13', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '14', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '14', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '15', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '15', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '20', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '20', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11551942', seq: '20', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '10825158', seq: '21', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '11551942', seq: '21', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '22', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '22', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10400757', seq: '25', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10825158', seq: '25', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '26', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '26', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '11551942', seq: '26', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10620340', seq: '28', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10400757', seq: '28', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10756055', seq: '28', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10400757', seq: '30', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10756055', seq: '30', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10827088', seq: '30', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '31', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '32', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10825158', seq: '38', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: I, pubmed: '15880586', seq: '53', to_res: L}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '84', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '97', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '97', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '15880586', seq: '97', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10620340', seq: '109', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10400757', seq: '109', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10400757', seq: '110', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10825158', seq: '110', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '11154697', seq: '113', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '12534283', seq: '113', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '171', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11154697', seq: '171', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11408611', seq: '171', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '12534283', seq: '171', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10400757', seq: '176', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10756055', seq: '176', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10827088', seq: '176', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10825158', seq: '176', to_res: D}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10486146', seq: '176', to_res: L}
- {entry_name: CXCR4_HUMAN, from_res: S, pubmed: '10756055', seq: '178', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '179', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '179', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '179', to_res: Q}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '9614108', seq: '179', to_res: Q}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '181', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '181', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '181', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '181', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '181', to_res: K}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '182', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '182', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '182', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '182', to_res: G}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '182', to_res: G}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '182', to_res: K}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '182', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11154697', seq: '182', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '12534283', seq: '182', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '182', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10074102', seq: '183', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10825158', seq: '183', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '11551942', seq: '183', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '10074102', seq: '184', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '11551942', seq: '184', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: I, pubmed: '10074102', seq: '185', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10620340', seq: '186', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10400757', seq: '186', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '187', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '187', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10756055', seq: '187', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '187', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10827088', seq: '187', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '187', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10827088', seq: '187', to_res: K}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10827088', seq: '187', to_res: S}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '187', to_res: V}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '187', to_res: V}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10074102', seq: '188', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10400757', seq: '188', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '10825158', seq: '188', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '9614108', seq: '188', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: F, pubmed: '9614108', seq: '189', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '11551942', seq: '190', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Y, pubmed: '9614108', seq: '190', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: N, pubmed: '10074102', seq: '192', to_res: D}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '193', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '193', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10756055', seq: '193', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '193', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10827088', seq: '193', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11356952', seq: '193', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '9614108', seq: '193', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '193', to_res: E}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '193', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11154697', seq: '193', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '12534283', seq: '193', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '193', to_res: R}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11356952', seq: '193', to_res: R}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10074102', seq: '193', to_res: S}
- {entry_name: CXCR4_HUMAN, from_res: W, pubmed: '11551942', seq: '195', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: V, pubmed: '10074102', seq: '196', to_res: M}
- {entry_name: CXCR4_HUMAN, from_res: V, pubmed: '9614108', seq: '197', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: F, pubmed: '10074102', seq: '199', to_res: G}
- {entry_name: CXCR4_HUMAN, from_res: Q, pubmed: '11551942', seq: '200', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: F, pubmed: '10400757', seq: '201', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: F, pubmed: '10074102', seq: '201', to_res: G}
- {entry_name: CXCR4_HUMAN, from_res: F, pubmed: '10074102', seq: '201', to_res: L}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '11154697', seq: '203', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '12534283', seq: '203', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10400757', seq: '262', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10620340', seq: '262', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '10825158', seq: '262', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11154697', seq: '262', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '11408611', seq: '262', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: D, pubmed: '12534283', seq: '262', to_res: N}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10620340', seq: '268', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '268', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '268', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '11551942', seq: '268', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10400757', seq: '271', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10825158', seq: '271', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: Q, pubmed: '11551942', seq: '272', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10620340', seq: '274', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10400757', seq: '274', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: C, pubmed: '10756055', seq: '274', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '275', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10620340', seq: '275', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '275', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10400757', seq: '277', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10620340', seq: '277', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '277', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '10400757', seq: '281', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '11154697', seq: '281', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '11408611', seq: '281', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '12534283', seq: '281', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10400757', seq: '282', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: K, pubmed: '10825158', seq: '282', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '10825158', seq: '288', to_res: Q}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '11154697', seq: '294', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: H, pubmed: '12534283', seq: '294', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: S, pubmed: '9177234', seq: '312', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: T, pubmed: '9177234', seq: '318', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: S, pubmed: '9718374', seq: '324', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: S, pubmed: '9718374', seq: '325', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: I, pubmed: '9718374', seq: '328', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: I, pubmed: '12393663', seq: '328', to_res: S}
- {entry_name: CXCR4_HUMAN, from_res: L, pubmed: '11751889', seq: '329', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: L, pubmed: '9718374', seq: '329', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: L, pubmed: '12393663', seq: '329', to_res: S}
- {entry_name: CXCR4_HUMAN, from_res: S, pubmed: '10521508', seq: '330', to_res: A}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '12692554', seq: '334', to_res: X}
- {entry_name: CXCR4_HUMAN, from_res: R, pubmed: '15781337', seq: '334', to_res: X}
- {entry_name: CXCR4_HUMAN, from_res: E, pubmed: '12692554', seq: '343', to_res: X}
- {entry_name: CXCR4_HUMAN, from_res: S, pubmed: '10521508', seq: '344', to_res: A}
- {entry_name: CXCR4_MOUSE, from_res: K, pubmed: '11352904', seq: '27', to_res: S}
- {entry_name: CXCR4_MOUSE, from_res: L, pubmed: '15618472', seq: '213', to_res: Q}
- {entry_name: DRD1_HUMAN, from_res: F, pubmed: '8910419', seq: '264', to_res: I}
- {entry_name: DRD1_HUMAN, from_res: R, pubmed: '8910419', seq: '266', to_res: K}
- {entry_name: DRD1_HUMAN, from_res: C, pubmed: '7643110', seq: '347', to_res: G}
- {entry_name: DRD1_HUMAN, from_res: C, pubmed: '7643110', seq: '351', to_res: G}
- {entry_name: DRD1_RAT, from_res: T, pubmed: '10496949', seq: '135', to_res: V}
- {entry_name: DRD1_RAT, from_res: S, pubmed: '10496949', seq: '229', to_res: A}
- {entry_name: DRD1_RAT, from_res: T, pubmed: '10496949', seq: '268', to_res: V}
- {entry_name: DRD1_RAT, from_res: S, pubmed: '10496949', seq: '380', to_res: A}
- {entry_name: DRD2_BOVIN, from_res: D, pubmed: '15689154', seq: '2', to_res: L}
- {entry_name: DRD2_BOVIN, from_res: I, pubmed: '15689154', seq: '184', to_res: C}
- {entry_name: DRD2_BOVIN, from_res: N, pubmed: '15689154', seq: '186', to_res: C}
- {entry_name: DRD2_BOVIN, from_res: I, pubmed: '9454590', seq: '378', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: D, pubmed: '11473130', seq: '2', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: N, pubmed: '12974638', seq: '5', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: N, pubmed: '12974638', seq: '17', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: N, pubmed: '12974638', seq: '23', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: A, pubmed: '10387039', seq: '77', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10387039', seq: '78', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: A, pubmed: '10387039', seq: '79', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: D, pubmed: '10387039', seq: '80', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '10387039', seq: '81', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '10387039', seq: '82', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10387039', seq: '83', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: A, pubmed: '10387039', seq: '84', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: T, pubmed: '10387039', seq: '85', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '10387039', seq: '86', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10387039', seq: '87', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: M, pubmed: '10387039', seq: '88', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: P, pubmed: '10387039', seq: '89', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: W, pubmed: '10387039', seq: '90', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: W, pubmed: '10570038', seq: '90', to_res: L}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10387039', seq: '91', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10570038', seq: '91', to_res: F}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10387039', seq: '92', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: Y, pubmed: '10387039', seq: '93', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '10387039', seq: '94', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '10570038', seq: '94', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: E, pubmed: '10387039', seq: '95', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '12796525', seq: '96', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10387039', seq: '96', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10387039', seq: '97', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: G, pubmed: '10387039', seq: '98', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: D, pubmed: '10387039', seq: '108', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '10570038', seq: '110', to_res: L}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10570038', seq: '111', to_res: M}
- {entry_name: DRD2_HUMAN, from_res: D, pubmed: '10387039', seq: '114', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: D, pubmed: '10860933', seq: '114', to_res: N}
- {entry_name: DRD2_HUMAN, from_res: D, pubmed: '14999101', seq: '114', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: C, pubmed: '8609898', seq: '118', to_res: K}
- {entry_name: DRD2_HUMAN, from_res: C, pubmed: '10387039', seq: '118', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: C, pubmed: '7937955', seq: '118', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: C, pubmed: '9454590', seq: '118', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10220438', seq: '154', to_res: I}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '10716258', seq: '154', to_res: I}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '11215567', seq: '154', to_res: I}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '11342690', seq: '154', to_res: I}
- {entry_name: DRD2_HUMAN, from_res: M, pubmed: '12974638', seq: '155', to_res: P}
- {entry_name: DRD2_HUMAN, from_res: S, pubmed: '10570038', seq: '167', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '10570038', seq: '172', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: C, pubmed: '12974638', seq: '182', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '10570038', seq: '189', to_res: Y}
- {entry_name: DRD2_HUMAN, from_res: S, pubmed: '10860933', seq: '194', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: S, pubmed: '10860933', seq: '197', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: P, pubmed: '7706278', seq: '264', to_res: G}
- {entry_name: DRD2_HUMAN, from_res: P, pubmed: '12796525', seq: '310', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: S, pubmed: '12796525', seq: '311', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: S, pubmed: '9259374', seq: '311', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: M, pubmed: '15755724', seq: '345', to_res: S}
- {entry_name: DRD2_HUMAN, from_res: A, pubmed: '11522600', seq: '371', to_res: K}
- {entry_name: DRD2_HUMAN, from_res: T, pubmed: '11522600', seq: '372', to_res: R}
- {entry_name: DRD2_HUMAN, from_res: T, pubmed: '12490615', seq: '372', to_res: R}
- {entry_name: DRD2_HUMAN, from_res: Q, pubmed: '11522600', seq: '373', to_res: K}
- {entry_name: DRD2_HUMAN, from_res: I, pubmed: '9454590', seq: '377', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '9454590', seq: '378', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '9454590', seq: '379', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: G, pubmed: '9454590', seq: '380', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: V, pubmed: '9454590', seq: '381', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '9454590', seq: '382', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: I, pubmed: '9454590', seq: '383', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: I, pubmed: '9454590', seq: '384', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: W, pubmed: '9454590', seq: '386', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '9454590', seq: '387', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: P, pubmed: '9454590', seq: '388', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '10387039', seq: '389', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '9454590', seq: '389', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '9454590', seq: '390', to_res: A}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '10387039', seq: '390', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: F, pubmed: '9454590', seq: '390', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: I, pubmed: '9454590', seq: '391', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: T, pubmed: '9454590', seq: '392', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: H, pubmed: '9454590', seq: '393', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: I, pubmed: '9454590', seq: '394', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: L, pubmed: '9454590', seq: '395', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: N, pubmed: '9454590', seq: '396', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: I, pubmed: '9454590', seq: '397', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: H, pubmed: '9454590', seq: '398', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: Y, pubmed: '10570038', seq: '408', to_res: V}
- {entry_name: DRD2_HUMAN, from_res: T, pubmed: '10387039', seq: '412', to_res: C}
- {entry_name: DRD2_HUMAN, from_res: T, pubmed: '9454590', seq: '412', to_res: C}
- {entry_name: DRD2_MOUSE, from_res: D, pubmed: '7706278', seq: '271', to_res: V}
- {entry_name: DRD2_RAT, from_res: N, pubmed: '11455025', seq: '52', to_res: A}
- {entry_name: DRD2_RAT, from_res: N, pubmed: '11455025', seq: '52', to_res: L}
- {entry_name: DRD2_RAT, from_res: N, pubmed: '11455025', seq: '52', to_res: Q}
- {entry_name: DRD2_RAT, from_res: D, pubmed: '11455025', seq: '80', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '11455025', seq: '121', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '11455025', seq: '121', to_res: L}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '11455025', seq: '121', to_res: N}
- {entry_name: DRD2_RAT, from_res: N, pubmed: '11455025', seq: '124', to_res: A}
- {entry_name: DRD2_RAT, from_res: N, pubmed: '11455025', seq: '124', to_res: L}
- {entry_name: DRD2_RAT, from_res: N, pubmed: '11455025', seq: '124', to_res: Q}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '10617140', seq: '193', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '10956209', seq: '193', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '9687586', seq: '193', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '10956209', seq: '194', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '9687586', seq: '194', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '10956209', seq: '197', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '9687586', seq: '197', to_res: A}
- {entry_name: DRD2_RAT, from_res: R, pubmed: '14581469', seq: '233', to_res: G}
- {entry_name: DRD2_RAT, from_res: A, pubmed: '14581469', seq: '234', to_res: T}
- {entry_name: DRD2_RAT, from_res: T, pubmed: '12490615', seq: '373', to_res: K}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '11455025', seq: '420', to_res: A}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '11455025', seq: '420', to_res: L}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '11455025', seq: '420', to_res: N}
- {entry_name: DRD2_RAT, from_res: S, pubmed: '11455025', seq: '420', to_res: V}
- {entry_name: DRD3_HUMAN, from_res: S, pubmed: '12796525', seq: '9', to_res: G}
- {entry_name: DRD3_HUMAN, from_res: S, pubmed: '8780735', seq: '9', to_res: G}
- {entry_name: DRD3_HUMAN, from_res: S, pubmed: '15917720', seq: '9', to_res: G}
- {entry_name: DRD3_HUMAN, from_res: C, pubmed: '9831905', seq: '114', to_res: S}
- {entry_name: DRD3_HUMAN, from_res: H, pubmed: '9651882', seq: '349', to_res: L}
- {entry_name: DRD3_HUMAN, from_res: T, pubmed: '9651882', seq: '369', to_res: V}
- {entry_name: DRD4_HUMAN, from_res: L, pubmed: '10570038', seq: '90', to_res: W}
- {entry_name: DRD4_HUMAN, from_res: F, pubmed: '10570038', seq: '91', to_res: V}
- {entry_name: DRD4_HUMAN, from_res: S, pubmed: '10570038', seq: '94', to_res: L}
- {entry_name: DRD4_HUMAN, from_res: L, pubmed: '10570038', seq: '111', to_res: F}
- {entry_name: DRD4_HUMAN, from_res: M, pubmed: '10570038', seq: '112', to_res: V}
- {entry_name: DRD4_HUMAN, from_res: T, pubmed: '11522600', seq: '373', to_res: K}
- {entry_name: DRD4_RAT, from_res: F, pubmed: '10617689', seq: '88', to_res: V}
- {entry_name: DRD5_HUMAN, from_res: N, pubmed: '10531415', seq: '7', to_res: Q}
- {entry_name: DRD5_HUMAN, from_res: N, pubmed: '10531415', seq: '7', to_res: T}
- {entry_name: DRD5_HUMAN, from_res: T, pubmed: '10531415', seq: '9', to_res: V}
- {entry_name: DRD5_HUMAN, from_res: L, pubmed: '10376767', seq: '88', to_res: F}
- {entry_name: DRD5_HUMAN, from_res: L, pubmed: '9613858', seq: '88', to_res: F}
- {entry_name: DRD5_HUMAN, from_res: N, pubmed: '10531415', seq: '222', to_res: Q}
- {entry_name: DRD5_HUMAN, from_res: A, pubmed: '10376767', seq: '269', to_res: V}
- {entry_name: DRD5_HUMAN, from_res: I, pubmed: '8910419', seq: '288', to_res: F}
- {entry_name: DRD5_HUMAN, from_res: K, pubmed: '8910419', seq: '290', to_res: R}
- {entry_name: DRD5_HUMAN, from_res: P, pubmed: '10376767', seq: '330', to_res: Q}
- {entry_name: DRD5_HUMAN, from_res: N, pubmed: '10376767', seq: '351', to_res: D}
- {entry_name: DRD5_HUMAN, from_res: Q, pubmed: '10807903', seq: '439', to_res: A}
- {entry_name: DRD5_HUMAN, from_res: S, pubmed: '10376767', seq: '453', to_res: C}
- {entry_name: DUFFY_HUMAN, from_res: F, pubmed: '9195930', seq: '22', to_res: V}
- {entry_name: DUFFY_HUMAN, from_res: E, pubmed: '9195930', seq: '23', to_res: A}
- {entry_name: DUFFY_HUMAN, from_res: C, pubmed: '9195930', seq: '51', to_res: S}
- {entry_name: DUFFY_HUMAN, from_res: C, pubmed: '9195930', seq: '54', to_res: S}
- {entry_name: DUFFY_HUMAN, from_res: R, pubmed: '10738032', seq: '89', to_res: C}
- {entry_name: DUFFY_HUMAN, from_res: R, pubmed: '9731074', seq: '89', to_res: C}
- {entry_name: DUFFY_HUMAN, from_res: A, pubmed: '10738032', seq: '100', to_res: T}
- {entry_name: DUFFY_HUMAN, from_res: A, pubmed: '9731074', seq: '100', to_res: T}
- {entry_name: DUFFY_HUMAN, from_res: A, pubmed: '16110438', seq: '100', to_res: T}
- {entry_name: DUFFY_HUMAN, from_res: C, pubmed: '9195930', seq: '276', to_res: S}
- {entry_name: EDG7_RAT, from_res: F, pubmed: '11179453', seq: '12', to_res: K}
- {entry_name: EDNRA_HUMAN, from_res: D, pubmed: '7698331', seq: '126', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: D, pubmed: '8611558', seq: '126', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8041764', seq: '129', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8175640', seq: '129', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8611558', seq: '129', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8041764', seq: '129', to_res: F}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8611558', seq: '129', to_res: I}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8611558', seq: '129', to_res: K}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8611558', seq: '129', to_res: S}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8611558', seq: '129', to_res: T}
- {entry_name: EDNRA_HUMAN, from_res: Y, pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: EDNRA_HUMAN, from_res: D, pubmed: '7698331', seq: '133', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: D, pubmed: '8611558', seq: '133', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: K, pubmed: '8119297', seq: '140', to_res: I}
- {entry_name: EDNRA_HUMAN, from_res: W, pubmed: '10651633', seq: '257', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: W, pubmed: '10651633', seq: '257', to_res: F}
- {entry_name: EDNRA_HUMAN, from_res: W, pubmed: '10651633', seq: '258', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: C, pubmed: '8702836', seq: '388', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: T, pubmed: '15713850', seq: '396', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: T, pubmed: '15713850', seq: '396', to_res: D}
- {entry_name: EDNRA_HUMAN, from_res: S, pubmed: '15713850', seq: '397', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: S, pubmed: '15713850', seq: '397', to_res: D}
- {entry_name: EDNRA_HUMAN, from_res: V, pubmed: '15713850', seq: '398', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: V, pubmed: '15713850', seq: '398', to_res: G}
- {entry_name: EDNRA_HUMAN, from_res: T, pubmed: '15713850', seq: '403', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: T, pubmed: '15713850', seq: '403', to_res: D}
- {entry_name: EDNRA_HUMAN, from_res: S, pubmed: '15713850', seq: '404', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: S, pubmed: '15713850', seq: '404', to_res: D}
- {entry_name: EDNRA_HUMAN, from_res: I, pubmed: '15713850', seq: '405', to_res: A}
- {entry_name: EDNRA_HUMAN, from_res: I, pubmed: '15713850', seq: '405', to_res: G}
- {entry_name: EDNRB_HORSE, from_res: I, pubmed: '10964697', seq: '118', to_res: K}
- {entry_name: EDNRB_HORSE, from_res: I, pubmed: '11197568', seq: '118', to_res: K}
- {entry_name: EDNRB_HORSE, from_res: I, pubmed: '9585428', seq: '118', to_res: K}
- {entry_name: EDNRB_HUMAN, from_res: V, pubmed: '11301053', seq: '16', to_res: A}
- {entry_name: EDNRB_HUMAN, from_res: G, pubmed: '10964697', seq: '57', to_res: S}
- {entry_name: EDNRB_HUMAN, from_res: G, pubmed: '11471546', seq: '57', to_res: S}
- {entry_name: EDNRB_HUMAN, from_res: G, pubmed: '8852660', seq: '57', to_res: S}
- {entry_name: EDNRB_HUMAN, from_res: G, pubmed: '9760196', seq: '57', to_res: S}
- {entry_name: EDNRB_HUMAN, from_res: G, pubmed: '16145050', seq: '57', to_res: S}
- {entry_name: EDNRB_HUMAN, from_res: N, pubmed: '10964697', seq: '104', to_res: I}
- {entry_name: EDNRB_HUMAN, from_res: N, pubmed: '12080062', seq: '104', to_res: I}
- {entry_name: EDNRB_HUMAN, from_res: N, pubmed: '9556633', seq: '104', to_res: I}
- {entry_name: EDNRB_HUMAN, from_res: C, pubmed: '10651633', seq: '109', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: C, pubmed: '10964697', seq: '109', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: C, pubmed: '12080062', seq: '109', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: C, pubmed: '9556633', seq: '109', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: V, pubmed: '14633923', seq: '185', to_res: M}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '16237557', seq: '196', to_res: N}
- {entry_name: EDNRB_HUMAN, from_res: R, pubmed: '11891690', seq: '201', to_res: X}
- {entry_name: EDNRB_HUMAN, from_res: D, pubmed: '16145050', seq: '246', to_res: F}
- {entry_name: EDNRB_HUMAN, from_res: V, pubmed: '16145050', seq: '260', to_res: F}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '10651633', seq: '275', to_res: A}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '10651633', seq: '275', to_res: F}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '10651633', seq: '276', to_res: A}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '10651633', seq: '276', to_res: C}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '10964697', seq: '276', to_res: C}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '12080062', seq: '276', to_res: C}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '8001158', seq: '276', to_res: C}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '8852659', seq: '276', to_res: C}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '8852660', seq: '276', to_res: C}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '16145050', seq: '276', to_res: C}
- {entry_name: EDNRB_HUMAN, from_res: W, pubmed: '10651633', seq: '276', to_res: F}
- {entry_name: EDNRB_HUMAN, from_res: P, pubmed: '10964697', seq: '285', to_res: L}
- {entry_name: EDNRB_HUMAN, from_res: Y, pubmed: '10651633', seq: '293', to_res: L}
- {entry_name: EDNRB_HUMAN, from_res: Y, pubmed: '10964697', seq: '293', to_res: L}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '10874640', seq: '305', to_res: N}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '10964697', seq: '305', to_res: N}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '8852659', seq: '305', to_res: N}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '16145050', seq: '305', to_res: N}
- {entry_name: EDNRB_HUMAN, from_res: R, pubmed: '10964697', seq: '319', to_res: W}
- {entry_name: EDNRB_HUMAN, from_res: R, pubmed: '11471546', seq: '319', to_res: W}
- {entry_name: EDNRB_HUMAN, from_res: R, pubmed: '8852660', seq: '319', to_res: W}
- {entry_name: EDNRB_HUMAN, from_res: M, pubmed: '10964697', seq: '374', to_res: I}
- {entry_name: EDNRB_HUMAN, from_res: N, pubmed: '10651633', seq: '378', to_res: I}
- {entry_name: EDNRB_HUMAN, from_res: N, pubmed: '8852659', seq: '378', to_res: I}
- {entry_name: EDNRB_HUMAN, from_res: P, pubmed: '10964697', seq: '383', to_res: L}
- {entry_name: EDNRB_HUMAN, from_res: P, pubmed: '11471546', seq: '383', to_res: L}
- {entry_name: EDNRB_HUMAN, from_res: P, pubmed: '14633923', seq: '383', to_res: L}
- {entry_name: EDNRB_HUMAN, from_res: P, pubmed: '8852660', seq: '383', to_res: L}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '10651633', seq: '390', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '10964697', seq: '390', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '12080062', seq: '390', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: S, pubmed: '9556633', seq: '390', to_res: R}
- {entry_name: EDNRB_HUMAN, from_res: R, pubmed: '16145050', seq: '434', to_res: C}
- {entry_name: EDNRB_MOUSE, from_res: W, pubmed: '9371807', seq: '276', to_res: C}
- {entry_name: EDNRB_MOUSE, from_res: P, pubmed: '9371807', seq: '285', to_res: L}
- {entry_name: EDNRB_RAT, from_res: A, pubmed: '9300652', seq: '144', to_res: T}
- {entry_name: EDNRB_RAT, from_res: K, pubmed: '1429881', seq: '182', to_res: D}
- {entry_name: EDNRB_RAT, from_res: C, pubmed: '12710522', seq: '283', to_res: Y}
- {entry_name: EDNRB_RAT, from_res: M, pubmed: '10187821', seq: '300', to_res: A}
- {entry_name: EDNRB_RAT, from_res: M, pubmed: '10187821', seq: '307', to_res: A}
- {entry_name: EDNRB_RAT, from_res: D, pubmed: '10187821', seq: '313', to_res: A}
- {entry_name: EDNRB_RAT, from_res: Q, pubmed: '10187821', seq: '317', to_res: A}
- {entry_name: EDNRB_RAT, from_res: K, pubmed: '10187821', seq: '323', to_res: A}
- {entry_name: EDNRB_RAT, from_res: T, pubmed: '10187821', seq: '324', to_res: A}
- {entry_name: EDNRB_RAT, from_res: F, pubmed: '10187821', seq: '332', to_res: A}
- {entry_name: EDNRB_RAT, from_res: C, pubmed: '10187821', seq: '335', to_res: A}
- {entry_name: EDNRB_RAT, from_res: W, pubmed: '10187821', seq: '336', to_res: A}
- {entry_name: EDNRB_RAT, from_res: P, pubmed: '10187821', seq: '338', to_res: A}
- {entry_name: EDNRB_RAT, from_res: S, pubmed: '10187821', seq: '342', to_res: K}
- {entry_name: EDNRB_RAT, from_res: K, pubmed: '10187821', seq: '346', to_res: A}
- {entry_name: EDNRB_RAT, from_res: D, pubmed: '10187821', seq: '368', to_res: A}
- {entry_name: EDNRB_RAT, from_res: N, pubmed: '10187821', seq: '373', to_res: A}
- {entry_name: EDNRB_RAT, from_res: M, pubmed: '10187821', seq: '374', to_res: K}
- {entry_name: EDNRB_RAT, from_res: N, pubmed: '10187821', seq: '378', to_res: P}
- {entry_name: EDNRB_RAT, from_res: S, pubmed: '10187821', seq: '379', to_res: K}
- {entry_name: EDNRB_RAT, from_res: I, pubmed: '10187821', seq: '381', to_res: A}
- {entry_name: EDNRB_RAT, from_res: P, pubmed: '10187821', seq: '383', to_res: K}
- {entry_name: EDNRB_RAT, from_res: I, pubmed: '10187821', seq: '384', to_res: A}
- {entry_name: EDNRB_RAT, from_res: A, pubmed: '10187821', seq: '385', to_res: K}
- {entry_name: EDNRB_RAT, from_res: L, pubmed: '10187821', seq: '386', to_res: A}
- {entry_name: EDNRB_RAT, from_res: V, pubmed: '10187821', seq: '389', to_res: K}
- {entry_name: EDNRB_RAT, from_res: K, pubmed: '10187821', seq: '391', to_res: A}
- {entry_name: EDNRB_RAT, from_res: F, pubmed: '10187821', seq: '393', to_res: A}
- {entry_name: EMR2_HUMAN, from_res: S, pubmed: '12860403', seq: '518', to_res: A}
- {entry_name: EMR2_HUMAN, from_res: S, pubmed: '15150276', seq: '518', to_res: T}
- {entry_name: EMR2_HUMAN, from_res: S, pubmed: '12860403', seq: '519', to_res: A}
- {entry_name: ETBR2_HUMAN, from_res: A, pubmed: '11301053', seq: '16', to_res: V}
- {entry_name: ETBR2_HUMAN, from_res: D, pubmed: '9300652', seq: '92', to_res: K}
- {entry_name: FFAR1_HUMAN, from_res: R, pubmed: '9344866', seq: '104', to_res: Y}
- {entry_name: FPR1_HUMAN, from_res: D, pubmed: '10029516', seq: '71', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: D, pubmed: '10823817', seq: '71', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: D, pubmed: '7738006', seq: '71', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: D, pubmed: '7738006', seq: '106', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: D, pubmed: '10960471', seq: '106', to_res: N}
- {entry_name: FPR1_HUMAN, from_res: D, pubmed: '7738006', seq: '122', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '10029516', seq: '123', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '10823817', seq: '123', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '11297412', seq: '123', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '7738006', seq: '123', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '7738006', seq: '163', to_res: F}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '10960471', seq: '201', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '10960471', seq: '205', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: T, pubmed: '8373373', seq: '226', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: K, pubmed: '8373373', seq: '227', to_res: E}
- {entry_name: FPR1_HUMAN, from_res: H, pubmed: '8373373', seq: '229', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: K, pubmed: '8373373', seq: '230', to_res: Q}
- {entry_name: FPR1_HUMAN, from_res: K, pubmed: '8373373', seq: '235', to_res: Q}
- {entry_name: FPR1_HUMAN, from_res: S, pubmed: '8373373', seq: '236', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: S, pubmed: '8373373', seq: '237', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '8373373', seq: '238', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '8373373', seq: '241', to_res: E}
- {entry_name: FPR1_HUMAN, from_res: S, pubmed: '8373373', seq: '244', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '10029516', seq: '309', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '7738006', seq: '309', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: E, pubmed: '10029516', seq: '310', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: E, pubmed: '7738006', seq: '310', to_res: A}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '10029516', seq: '311', to_res: G}
- {entry_name: FPR1_HUMAN, from_res: R, pubmed: '7738006', seq: '311', to_res: G}
- {entry_name: FRIZ3_DROME, from_res: T, pubmed: '12399314', seq: '17', to_res: N}
- {entry_name: FSHR_CHICK, from_res: R, pubmed: '9988386', seq: '262', to_res: Q}
- {entry_name: FSHR_HUMAN, from_res: H, pubmed: '11750736', seq: '20', to_res: W}
- {entry_name: FSHR_HUMAN, from_res: C, pubmed: '11847099', seq: '23', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '51', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: F, pubmed: '10880516', seq: '53', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '8619629', seq: '108', to_res: S}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '10551778', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '10714362', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '10773385', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '11163840', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '11889179', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '11912278', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '12571157', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '9769327', seq: '160', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '10022448', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '10551778', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '10714362', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '10773385', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '11163840', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '11420132', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '11420133', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '11756374', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '11889179', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '11912278', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '12095499', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '12444891', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '12571157', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '9027356', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '9769327', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '9988386', seq: '189', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: N, pubmed: '10714362', seq: '191', to_res: I}
- {entry_name: FSHR_HUMAN, from_res: N, pubmed: '12444891', seq: '191', to_res: I}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '10551778', seq: '224', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '10714362', seq: '224', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '11163840', seq: '224', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '11889179', seq: '224', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '12571157', seq: '224', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '273', to_res: I}
- {entry_name: FSHR_HUMAN, from_res: S, pubmed: '15166252', seq: '273', to_res: I}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '11036902', seq: '307', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '11253976', seq: '307', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '11383926', seq: '307', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: V, pubmed: '10714362', seq: '341', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: V, pubmed: '15249125', seq: '341', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: P, pubmed: '12571157', seq: '348', to_res: R}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '11889179', seq: '419', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '12571157', seq: '419', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '15001619', seq: '449', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '15080154', seq: '449', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '15166252', seq: '449', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '15001619', seq: '449', to_res: I}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '15080154', seq: '449', to_res: I}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '15166252', seq: '449', to_res: I}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '460', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '460', to_res: D}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '460', to_res: K}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '460', to_res: R}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '12039074', seq: '467', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '12039074', seq: '467', to_res: H}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '12039074', seq: '467', to_res: K}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '12039074', seq: '470', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12039074', seq: '477', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12039074', seq: '477', to_res: D}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12039074', seq: '477', to_res: K}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12039074', seq: '477', to_res: P}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12039074', seq: '477', to_res: R}
- {entry_name: FSHR_HUMAN, from_res: S, pubmed: '10935550', seq: '509', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: P, pubmed: '12915623', seq: '519', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: Y, pubmed: '12850288', seq: '530', to_res: F}
- {entry_name: FSHR_HUMAN, from_res: S, pubmed: '12145341', seq: '533', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '12145341', seq: '550', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '10202864', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '10714362', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '10773385', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '10935550', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '12145341', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '12403847', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '14695976', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '8798412', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '9027356', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '9988386', seq: '567', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '15001619', seq: '567', to_res: N}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '15080154', seq: '567', to_res: N}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '15166252', seq: '567', to_res: N}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '10773385', seq: '567', to_res: R}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '10551778', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '10714362', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '10773385', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '11163840', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '11889179', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '11912278', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '12571157', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '9769327', seq: '573', to_res: C}
- {entry_name: FSHR_HUMAN, from_res: R, pubmed: '10551778', seq: '573', to_res: D}
- {entry_name: FSHR_HUMAN, from_res: M, pubmed: '12145341', seq: '576', to_res: T}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '12145341', seq: '581', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '8798412', seq: '581', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: D, pubmed: '8798412', seq: '581', to_res: Y}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12374801', seq: '583', to_res: Y}
- {entry_name: FSHR_HUMAN, from_res: C, pubmed: '8798412', seq: '584', to_res: R}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '9988386', seq: '586', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: F, pubmed: '10714362', seq: '591', to_res: S}
- {entry_name: FSHR_HUMAN, from_res: F, pubmed: '11056247', seq: '591', to_res: S}
- {entry_name: FSHR_HUMAN, from_res: F, pubmed: '9100567', seq: '591', to_res: S}
- {entry_name: FSHR_HUMAN, from_res: K, pubmed: '9786899', seq: '598', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: V, pubmed: '12374801', seq: '599', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: V, pubmed: '9786899', seq: '599', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: P, pubmed: '12374801', seq: '600', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: P, pubmed: '9786899', seq: '600', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12374801', seq: '601', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '9786899', seq: '601', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12374801', seq: '601', to_res: F}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12374801', seq: '601', to_res: Q}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '10551778', seq: '601', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '10714362', seq: '601', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '11163840', seq: '601', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '11889179', seq: '601', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '12571157', seq: '601', to_res: V}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '12374801', seq: '602', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '9786899', seq: '602', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '12374801', seq: '602', to_res: Y}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '9786899', seq: '603', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: V, pubmed: '9786899', seq: '604', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: S, pubmed: '9786899', seq: '605', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: K, pubmed: '9786899', seq: '606', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '12374801', seq: '607', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: A, pubmed: '9786899', seq: '607', to_res: G}
- {entry_name: FSHR_HUMAN, from_res: K, pubmed: '12374801', seq: '608', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: K, pubmed: '9786899', seq: '608', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: K, pubmed: '12374801', seq: '608', to_res: F}
- {entry_name: FSHR_HUMAN, from_res: K, pubmed: '12374801', seq: '608', to_res: L}
- {entry_name: FSHR_HUMAN, from_res: K, pubmed: '12374801', seq: '608', to_res: R}
- {entry_name: FSHR_HUMAN, from_res: H, pubmed: '12145341', seq: '615', to_res: Y}
- {entry_name: FSHR_HUMAN, from_res: V, pubmed: '9660834', seq: '678', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '9660834', seq: '679', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: N, pubmed: '10022448', seq: '680', to_res: S}
- {entry_name: FSHR_HUMAN, from_res: N, pubmed: '11036902', seq: '680', to_res: S}
- {entry_name: FSHR_HUMAN, from_res: N, pubmed: '11253976', seq: '680', to_res: S}
- {entry_name: FSHR_HUMAN, from_res: G, pubmed: '9660834', seq: '681', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: S, pubmed: '9660834', seq: '682', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: T, pubmed: '9660834', seq: '683', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: Y, pubmed: '9660834', seq: '684', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: I, pubmed: '9660834', seq: '685', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '9660834', seq: '686', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: V, pubmed: '9660834', seq: '687', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: P, pubmed: '9660834', seq: '688', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: L, pubmed: '9660834', seq: '689', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: S, pubmed: '9660834', seq: '690', to_res: A}
- {entry_name: FSHR_HUMAN, from_res: H, pubmed: '9660834', seq: '691', to_res: A}
- {entry_name: FSHR_MOUSE, from_res: I, pubmed: '11041448', seq: '160', to_res: T}
- {entry_name: FSHR_MOUSE, from_res: A, pubmed: '11041448', seq: '189', to_res: V}
- {entry_name: FSHR_MOUSE, from_res: A, pubmed: '9562960', seq: '189', to_res: V}
- {entry_name: FSHR_MOUSE, from_res: N, pubmed: '11041448', seq: '191', to_res: I}
- {entry_name: FSHR_MOUSE, from_res: N, pubmed: '9562960', seq: '191', to_res: I}
- {entry_name: FSHR_MOUSE, from_res: D, pubmed: '11041448', seq: '224', to_res: V}
- {entry_name: FSHR_MOUSE, from_res: S, pubmed: '11041448', seq: '680', to_res: N}
- {entry_name: FSHR_MOUSE, from_res: S, pubmed: '9988386', seq: '680', to_res: N}
- {entry_name: FSHR_PIG, from_res: L, pubmed: '11041448', seq: '460', to_res: R}
- {entry_name: FSHR_RAT, from_res: E, pubmed: '11041448', seq: '73', to_res: A}
- {entry_name: FSHR_RAT, from_res: D, pubmed: '8614409', seq: '421', to_res: A}
- {entry_name: FSHR_RAT, from_res: D, pubmed: '8614409', seq: '421', to_res: E}
- {entry_name: FSHR_RAT, from_res: D, pubmed: '8614409', seq: '421', to_res: K}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '549', to_res: A}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '549', to_res: D}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '549', to_res: I}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '549', to_res: S}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '559', to_res: A}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '559', to_res: D}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '559', to_res: I}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '559', to_res: N}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '14636063', seq: '559', to_res: S}
- {entry_name: FSHR_RAT, from_res: K, pubmed: '14636063', seq: '568', to_res: I}
- {entry_name: FSHR_RAT, from_res: K, pubmed: '14636063', seq: '568', to_res: R}
- {entry_name: FSHR_RAT, from_res: T, pubmed: '12145341', seq: '575', to_res: M}
- {entry_name: FSHR_RAT, from_res: D, pubmed: '12145341', seq: '580', to_res: G}
- {entry_name: FSHR_RAT, from_res: Y, pubmed: '12145341', seq: '614', to_res: H}
- {entry_name: FZD4_RAT, from_res: M, pubmed: '9147651', seq: '13', to_res: F}
- {entry_name: FZD9_HUMAN, from_res: S, pubmed: '9716412', seq: '65', to_res: T}
- {entry_name: GABR1_HUMAN, from_res: A, pubmed: '11295833', seq: '20', to_res: V}
- {entry_name: GABR1_HUMAN, from_res: A, pubmed: '12210273', seq: '20', to_res: V}
- {entry_name: GABR1_HUMAN, from_res: A, pubmed: '12645817', seq: '20', to_res: V}
- {entry_name: GABR1_HUMAN, from_res: T, pubmed: '14724235', seq: '316', to_res: C}
- {entry_name: GABR1_HUMAN, from_res: G, pubmed: '11295833', seq: '489', to_res: S}
- {entry_name: GABR1_HUMAN, from_res: G, pubmed: '12210273', seq: '489', to_res: S}
- {entry_name: GABR1_HUMAN, from_res: G, pubmed: '12645817', seq: '489', to_res: S}
- {entry_name: GABR1_HUMAN, from_res: L, pubmed: '15863499', seq: '743', to_res: V}
- {entry_name: GABR1_HUMAN, from_res: F, pubmed: '15863499', seq: '781', to_res: P}
- {entry_name: GABR1_MOUSE, from_res: S, pubmed: '12196556', seq: '246', to_res: A}
- {entry_name: GABR1_MOUSE, from_res: Y, pubmed: '12196556', seq: '395', to_res: A}
- {entry_name: GABR1_MOUSE, from_res: D, pubmed: '12196556', seq: '397', to_res: A}
- {entry_name: GABR1_MOUSE, from_res: N, pubmed: '12196556', seq: '398', to_res: A}
- {entry_name: GABR1_MOUSE, from_res: E, pubmed: '12196556', seq: '465', to_res: A}
- {entry_name: GABR1_MOUSE, from_res: E, pubmed: '12196556', seq: '465', to_res: D}
- {entry_name: GABR1_MOUSE, from_res: E, pubmed: '12196556', seq: '465', to_res: S}
- {entry_name: GABR1_MOUSE, from_res: D, pubmed: '12196556', seq: '471', to_res: R}
- {entry_name: GABR1_MOUSE, from_res: K, pubmed: '11711539', seq: '791', to_res: W}
- {entry_name: GABR1_RAT, from_res: C, pubmed: '10224098', seq: '187', to_res: A}
- {entry_name: GABR1_RAT, from_res: C, pubmed: '10986293', seq: '187', to_res: A}
- {entry_name: GABR1_RAT, from_res: C, pubmed: '10224098', seq: '187', to_res: S}
- {entry_name: GABR1_RAT, from_res: Q, pubmed: '10224098', seq: '188', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10224098', seq: '192', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10986293', seq: '192', to_res: A}
- {entry_name: GABR1_RAT, from_res: C, pubmed: '10224098', seq: '219', to_res: A}
- {entry_name: GABR1_RAT, from_res: C, pubmed: '10224098', seq: '245', to_res: A}
- {entry_name: GABR1_RAT, from_res: C, pubmed: '10224098', seq: '245', to_res: S}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10224098', seq: '246', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '246', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '14724235', seq: '246', to_res: C}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '246', to_res: N}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '246', to_res: P}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '246', to_res: T}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10224098', seq: '247', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10692480', seq: '247', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '247', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '14724235', seq: '247', to_res: C}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10224098', seq: '249', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '249', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10224098', seq: '250', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10986293', seq: '250', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '265', to_res: A}
- {entry_name: GABR1_RAT, from_res: Y, pubmed: '10986293', seq: '266', to_res: F}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10224098', seq: '268', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10692480', seq: '268', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '268', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10224098', seq: '269', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10692480', seq: '269', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '269', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10224098', seq: '270', to_res: A}
- {entry_name: GABR1_RAT, from_res: S, pubmed: '10986293', seq: '270', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10224098', seq: '310', to_res: A}
- {entry_name: GABR1_RAT, from_res: Q, pubmed: '10224098', seq: '312', to_res: A}
- {entry_name: GABR1_RAT, from_res: Q, pubmed: '10986293', seq: '312', to_res: A}
- {entry_name: GABR1_RAT, from_res: Q, pubmed: '10224098', seq: '313', to_res: A}
- {entry_name: GABR1_RAT, from_res: Q, pubmed: '10986293', seq: '313', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10224098', seq: '314', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10986293', seq: '314', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10224098', seq: '315', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10986293', seq: '315', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '14724235', seq: '315', to_res: C}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10224098', seq: '316', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10986293', seq: '316', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '14724235', seq: '316', to_res: C}
- {entry_name: GABR1_RAT, from_res: F, pubmed: '10986293', seq: '365', to_res: A}
- {entry_name: GABR1_RAT, from_res: Y, pubmed: '10986293', seq: '366', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10986293', seq: '367', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10224098', seq: '458', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10986293', seq: '458', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10224098', seq: '459', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10986293', seq: '459', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10224098', seq: '460', to_res: A}
- {entry_name: GABR1_RAT, from_res: T, pubmed: '10986293', seq: '460', to_res: A}
- {entry_name: GABR1_RAT, from_res: F, pubmed: '10986293', seq: '463', to_res: A}
- {entry_name: GABR1_RAT, from_res: Q, pubmed: '10224098', seq: '464', to_res: A}
- {entry_name: GABR1_RAT, from_res: Q, pubmed: '10986293', seq: '464', to_res: A}
- {entry_name: GABR1_RAT, from_res: E, pubmed: '10986293', seq: '465', to_res: A}
- {entry_name: GABR1_RAT, from_res: Y, pubmed: '10224098', seq: '470', to_res: A}
- {entry_name: GABR1_RAT, from_res: Y, pubmed: '10986293', seq: '470', to_res: A}
- {entry_name: GABR1_RAT, from_res: Y, pubmed: '10224098', seq: '470', to_res: F}
- {entry_name: GABR1_RAT, from_res: Y, pubmed: '10986293', seq: '470', to_res: F}
- {entry_name: GABR1_RAT, from_res: D, pubmed: '10986293', seq: '471', to_res: A}
- {entry_name: GABR1_RAT, from_res: D, pubmed: '10986293', seq: '471', to_res: E}
- {entry_name: GABR2_HUMAN, from_res: P, pubmed: '12196556', seq: '136', to_res: S}
- {entry_name: GABR2_HUMAN, from_res: T, pubmed: '12196556', seq: '160', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: T, pubmed: '12196556', seq: '160', to_res: S}
- {entry_name: GABR2_HUMAN, from_res: S, pubmed: '12196556', seq: '178', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: D, pubmed: '12196556', seq: '179', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: R, pubmed: '12196556', seq: '207', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: F, pubmed: '12196556', seq: '208', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: D, pubmed: '12196556', seq: '256', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: D, pubmed: '12196556', seq: '256', to_res: E}
- {entry_name: GABR2_HUMAN, from_res: D, pubmed: '12196556', seq: '256', to_res: W}
- {entry_name: GABR2_HUMAN, from_res: D, pubmed: '12196556', seq: '256', to_res: Y}
- {entry_name: GABR2_HUMAN, from_res: K, pubmed: '12196556', seq: '353', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: F, pubmed: '12196556', seq: '354', to_res: E}
- {entry_name: GABR2_HUMAN, from_res: D, pubmed: '12196556', seq: '360', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: K, pubmed: '11588177', seq: '586', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: K, pubmed: '11588177', seq: '586', to_res: E}
- {entry_name: GABR2_HUMAN, from_res: M, pubmed: '11588177', seq: '587', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: M, pubmed: '11588177', seq: '587', to_res: E}
- {entry_name: GABR2_HUMAN, from_res: K, pubmed: '11588177', seq: '590', to_res: A}
- {entry_name: GABR2_HUMAN, from_res: K, pubmed: '11588177', seq: '590', to_res: E}
- {entry_name: GABR2_HUMAN, from_res: R, pubmed: '11711539', seq: '679', to_res: D}
- {entry_name: GABR2_HUMAN, from_res: R, pubmed: '11711539', seq: '679', to_res: W}
- {entry_name: GABR2_HUMAN, from_res: L, pubmed: '11711539', seq: '686', to_res: P}
- {entry_name: GABR2_HUMAN, from_res: L, pubmed: '12130687', seq: '686', to_res: P}
- {entry_name: GABR2_HUMAN, from_res: L, pubmed: '11711539', seq: '686', to_res: S}
- {entry_name: GALR1_HUMAN, from_res: C, pubmed: '9168941', seq: '15', to_res: W}
- {entry_name: GALR1_HUMAN, from_res: F, pubmed: '11983932', seq: '115', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: F, pubmed: '9370372', seq: '115', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: S, pubmed: '10688965', seq: '235', to_res: L}
- {entry_name: GALR1_HUMAN, from_res: S, pubmed: '10688965', seq: '238', to_res: L}
- {entry_name: GALR1_HUMAN, from_res: S, pubmed: '10688965', seq: '241', to_res: L}
- {entry_name: GALR1_HUMAN, from_res: T, pubmed: '10688965', seq: '245', to_res: L}
- {entry_name: GALR1_HUMAN, from_res: H, pubmed: '9370372', seq: '264', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: H, pubmed: '9928161', seq: '264', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: H, pubmed: '8617199', seq: '267', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: H, pubmed: '9370372', seq: '267', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: H, pubmed: '11983932', seq: '267', to_res: I}
- {entry_name: GALR1_HUMAN, from_res: E, pubmed: '9370372', seq: '271', to_res: K}
- {entry_name: GALR1_HUMAN, from_res: E, pubmed: '8617199', seq: '271', to_res: S}
- {entry_name: GALR1_HUMAN, from_res: E, pubmed: '11983932', seq: '271', to_res: W}
- {entry_name: GALR1_HUMAN, from_res: F, pubmed: '9370372', seq: '282', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: F, pubmed: '9928161', seq: '282', to_res: A}
- {entry_name: GALR1_HUMAN, from_res: F, pubmed: '8617199', seq: '282', to_res: G}
- {entry_name: GALR1_HUMAN, from_res: F, pubmed: '9370372', seq: '282', to_res: Y}
- {entry_name: GALR2_MOUSE, from_res: S, pubmed: '15899880', seq: '6', to_res: A}
- {entry_name: GASR_CANFA, from_res: L, pubmed: '10368033', seq: '355', to_res: V}
- {entry_name: GASR_CANFA, from_res: L, pubmed: '11714907', seq: '355', to_res: V}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '15817487', seq: '57', to_res: A}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '7890609', seq: '57', to_res: Q}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '15817487', seq: '57', to_res: Q}
- {entry_name: GASR_HUMAN, from_res: Y, pubmed: '10908308', seq: '61', to_res: A}
- {entry_name: GASR_HUMAN, from_res: L, pubmed: '10220557', seq: '85', to_res: M}
- {entry_name: GASR_HUMAN, from_res: C, pubmed: '10908308', seq: '107', to_res: A}
- {entry_name: GASR_HUMAN, from_res: F, pubmed: '10908308', seq: '110', to_res: A}
- {entry_name: GASR_HUMAN, from_res: T, pubmed: '10908308', seq: '111', to_res: A}
- {entry_name: GASR_HUMAN, from_res: T, pubmed: '7890609', seq: '111', to_res: N}
- {entry_name: GASR_HUMAN, from_res: F, pubmed: '15817487', seq: '120', to_res: A}
- {entry_name: GASR_HUMAN, from_res: S, pubmed: '10908308', seq: '131', to_res: A}
- {entry_name: GASR_HUMAN, from_res: S, pubmed: '7890609', seq: '131', to_res: T}
- {entry_name: GASR_HUMAN, from_res: M, pubmed: '15850403', seq: '134', to_res: L}
- {entry_name: GASR_HUMAN, from_res: G, pubmed: '10908308', seq: '135', to_res: A}
- {entry_name: GASR_HUMAN, from_res: V, pubmed: '10908308', seq: '138', to_res: A}
- {entry_name: GASR_HUMAN, from_res: M, pubmed: '10908308', seq: '186', to_res: A}
- {entry_name: GASR_HUMAN, from_res: Y, pubmed: '15817487', seq: '189', to_res: A}
- {entry_name: GASR_HUMAN, from_res: Y, pubmed: '15817487', seq: '189', to_res: F}
- {entry_name: GASR_HUMAN, from_res: T, pubmed: '10908308', seq: '193', to_res: A}
- {entry_name: GASR_HUMAN, from_res: V, pubmed: '15817487', seq: '206', to_res: M}
- {entry_name: GASR_HUMAN, from_res: H, pubmed: '15817487', seq: '207', to_res: A}
- {entry_name: GASR_HUMAN, from_res: S, pubmed: '10908308', seq: '219', to_res: A}
- {entry_name: GASR_HUMAN, from_res: S, pubmed: '7890609', seq: '219', to_res: H}
- {entry_name: GASR_HUMAN, from_res: L, pubmed: '10908308', seq: '223', to_res: A}
- {entry_name: GASR_HUMAN, from_res: F, pubmed: '10908308', seq: '227', to_res: A}
- {entry_name: GASR_HUMAN, from_res: M, pubmed: '15817487', seq: '234', to_res: I}
- {entry_name: GASR_HUMAN, from_res: W, pubmed: '10908308', seq: '346', to_res: A}
- {entry_name: GASR_HUMAN, from_res: V, pubmed: '10908308', seq: '349', to_res: A}
- {entry_name: GASR_HUMAN, from_res: V, pubmed: '7890609', seq: '349', to_res: I}
- {entry_name: GASR_HUMAN, from_res: Y, pubmed: '10908308', seq: '350', to_res: A}
- {entry_name: GASR_HUMAN, from_res: Y, pubmed: '7890609', seq: '350', to_res: F}
- {entry_name: GASR_HUMAN, from_res: N, pubmed: '15817487', seq: '353', to_res: A}
- {entry_name: GASR_HUMAN, from_res: N, pubmed: '10908308', seq: '353', to_res: L}
- {entry_name: GASR_HUMAN, from_res: T, pubmed: '10908308', seq: '354', to_res: A}
- {entry_name: GASR_HUMAN, from_res: T, pubmed: '7890609', seq: '354', to_res: A}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '15817487', seq: '356', to_res: A}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '15817487', seq: '356', to_res: D}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '15817487', seq: '356', to_res: H}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '15817487', seq: '356', to_res: I}
- {entry_name: GASR_HUMAN, from_res: R, pubmed: '15817487', seq: '356', to_res: K}
- {entry_name: GASR_HUMAN, from_res: H, pubmed: '10594328', seq: '376', to_res: A}
- {entry_name: GASR_HUMAN, from_res: H, pubmed: '10594328', seq: '376', to_res: L}
- {entry_name: GASR_HUMAN, from_res: H, pubmed: '7890609', seq: '376', to_res: L}
- {entry_name: GASR_HUMAN, from_res: H, pubmed: '9687578', seq: '376', to_res: L}
- {entry_name: GASR_HUMAN, from_res: H, pubmed: '15817487', seq: '376', to_res: L}
- {entry_name: GASR_HUMAN, from_res: S, pubmed: '10908308', seq: '379', to_res: A}
- {entry_name: GASR_RAT, from_res: E, pubmed: '9687578', seq: '51', to_res: A}
- {entry_name: GASR_RAT, from_res: M, pubmed: '9687578', seq: '54', to_res: A}
- {entry_name: GASR_RAT, from_res: A, pubmed: '9687578', seq: '55', to_res: L}
- {entry_name: GASR_RAT, from_res: I, pubmed: '9687578', seq: '56', to_res: A}
- {entry_name: GASR_RAT, from_res: R, pubmed: '9687578', seq: '57', to_res: A}
- {entry_name: GASR_RAT, from_res: I, pubmed: '9687578', seq: '58', to_res: A}
- {entry_name: GASR_RAT, from_res: D, pubmed: '10748160', seq: '100', to_res: N}
- {entry_name: GASR_RAT, from_res: N, pubmed: '9687578', seq: '115', to_res: A}
- {entry_name: GASR_RAT, from_res: L, pubmed: '9687578', seq: '116', to_res: A}
- {entry_name: GASR_RAT, from_res: G, pubmed: '9687578', seq: '118', to_res: K}
- {entry_name: GASR_RAT, from_res: C, pubmed: '9687578', seq: '127', to_res: A}
- {entry_name: GASR_RAT, from_res: V, pubmed: '8663021', seq: '187', to_res: T}
- {entry_name: GASR_RAT, from_res: M, pubmed: '15817487', seq: '194', to_res: V}
- {entry_name: GASR_RAT, from_res: Q, pubmed: '8663021', seq: '204', to_res: M}
- {entry_name: GASR_RAT, from_res: C, pubmed: '9687578', seq: '205', to_res: A}
- {entry_name: GASR_RAT, from_res: M, pubmed: '8663021', seq: '206', to_res: R}
- {entry_name: GASR_RAT, from_res: H, pubmed: '10438490', seq: '207', to_res: A}
- {entry_name: GASR_RAT, from_res: H, pubmed: '9687578', seq: '207', to_res: A}
- {entry_name: GASR_RAT, from_res: H, pubmed: '10438490', seq: '207', to_res: D}
- {entry_name: GASR_RAT, from_res: H, pubmed: '10438490', seq: '207', to_res: F}
- {entry_name: GASR_RAT, from_res: H, pubmed: '8663021', seq: '207', to_res: F}
- {entry_name: GASR_RAT, from_res: H, pubmed: '9687578', seq: '207', to_res: F}
- {entry_name: GASR_RAT, from_res: R, pubmed: '8663021', seq: '208', to_res: L}
- {entry_name: GASR_RAT, from_res: W, pubmed: '8663021', seq: '209', to_res: L}
- {entry_name: GASR_RAT, from_res: A, pubmed: '8663021', seq: '212', to_res: D}
- {entry_name: GASR_RAT, from_res: R, pubmed: '8663021', seq: '213', to_res: A}
- {entry_name: GASR_RAT, from_res: V, pubmed: '8663021', seq: '214', to_res: M}
- {entry_name: GASR_RAT, from_res: F, pubmed: '10368033', seq: '227', to_res: A}
- {entry_name: GASR_RAT, from_res: F, pubmed: '9584214', seq: '227', to_res: A}
- {entry_name: GASR_RAT, from_res: A, pubmed: '9154342', seq: '332', to_res: E}
- {entry_name: GASR_RAT, from_res: K, pubmed: '9084447', seq: '333', to_res: M}
- {entry_name: GASR_RAT, from_res: R, pubmed: '9084447', seq: '335', to_res: L}
- {entry_name: GASR_RAT, from_res: F, pubmed: '10368033', seq: '347', to_res: A}
- {entry_name: GASR_RAT, from_res: F, pubmed: '9584214', seq: '347', to_res: A}
- {entry_name: GASR_RAT, from_res: W, pubmed: '9584214', seq: '351', to_res: A}
- {entry_name: GASR_RAT, from_res: N, pubmed: '15817487', seq: '358', to_res: A}
- {entry_name: GASR_RAT, from_res: H, pubmed: '10368033', seq: '381', to_res: F}
- {entry_name: GASR_RAT, from_res: H, pubmed: '10368033', seq: '381', to_res: L}
- {entry_name: GASR_RAT, from_res: H, pubmed: '8720482', seq: '381', to_res: R}
- {entry_name: GASR_RAT, from_res: N, pubmed: '10748160', seq: '391', to_res: A}
- {entry_name: GASR_RAT, from_res: N, pubmed: '10748160', seq: '391', to_res: D}
- {entry_name: GASR_RAT, from_res: N, pubmed: '7476907', seq: '391', to_res: D}
- {entry_name: GHRHR_HUMAN, from_res: D, pubmed: '9029497', seq: '60', to_res: G}
- {entry_name: GHRHR_HUMAN, from_res: D, pubmed: '16135671', seq: '60', to_res: G}
- {entry_name: GHRHR_HUMAN, from_res: E, pubmed: '10549302', seq: '72', to_res: X}
- {entry_name: GHRHR_HUMAN, from_res: E, pubmed: '12794696', seq: '72', to_res: X}
- {entry_name: GHRHR_HUMAN, from_res: E, pubmed: '15336233', seq: '72', to_res: X}
- {entry_name: GHRHR_HUMAN, from_res: E, pubmed: '16355809', seq: '72', to_res: X}
- {entry_name: GHRHR_HUMAN, from_res: P, pubmed: '11502843', seq: '113', to_res: L}
- {entry_name: GHRHR_HUMAN, from_res: E, pubmed: '11502843', seq: '121', to_res: D}
- {entry_name: GHRHR_HUMAN, from_res: H, pubmed: '16135671', seq: '137', to_res: L}
- {entry_name: GHRHR_HUMAN, from_res: H, pubmed: '11502843', seq: '137', to_res: Y}
- {entry_name: GHRHR_HUMAN, from_res: L, pubmed: '12100073', seq: '144', to_res: H}
- {entry_name: GHRHR_HUMAN, from_res: L, pubmed: '16135671', seq: '144', to_res: H}
- {entry_name: GHRHR_HUMAN, from_res: A, pubmed: '12534354', seq: '176', to_res: V}
- {entry_name: GHRHR_HUMAN, from_res: A, pubmed: '16135671', seq: '176', to_res: V}
- {entry_name: GHRHR_HUMAN, from_res: D, pubmed: '11502843', seq: '183', to_res: N}
- {entry_name: GHRHR_HUMAN, from_res: A, pubmed: '16135671', seq: '222', to_res: E}
- {entry_name: GHRHR_HUMAN, from_res: V, pubmed: '11502843', seq: '225', to_res: I}
- {entry_name: GHRHR_HUMAN, from_res: F, pubmed: '16135671', seq: '242', to_res: C}
- {entry_name: GHRHR_HUMAN, from_res: W, pubmed: '11502843', seq: '250', to_res: X}
- {entry_name: GHRHR_HUMAN, from_res: V, pubmed: '11502843', seq: '254', to_res: M}
- {entry_name: GHRHR_HUMAN, from_res: S, pubmed: '11502843', seq: '262', to_res: N}
- {entry_name: GHRHR_HUMAN, from_res: G, pubmed: '11502843', seq: '294', to_res: R}
- {entry_name: GHRHR_HUMAN, from_res: K, pubmed: '16135671', seq: '329', to_res: E}
- {entry_name: GHRHR_HUMAN, from_res: T, pubmed: '11502843', seq: '410', to_res: P}
- {entry_name: GHRHR_HUMAN, from_res: C, pubmed: '11502843', seq: '423', to_res: Y}
- {entry_name: GHSR_HUMAN, from_res: D, pubmed: '9440817', seq: '99', to_res: N}
- {entry_name: GHSR_HUMAN, from_res: C, pubmed: '9440817', seq: '116', to_res: A}
- {entry_name: GHSR_HUMAN, from_res: E, pubmed: '10628755', seq: '124', to_res: D}
- {entry_name: GHSR_HUMAN, from_res: E, pubmed: '9440817', seq: '124', to_res: D}
- {entry_name: GHSR_HUMAN, from_res: E, pubmed: '10628755', seq: '124', to_res: Q}
- {entry_name: GHSR_HUMAN, from_res: E, pubmed: '9440817', seq: '124', to_res: Q}
- {entry_name: GHSR_HUMAN, from_res: M, pubmed: '9440817', seq: '213', to_res: K}
- {entry_name: GHSR_HUMAN, from_res: S, pubmed: '9440817', seq: '217', to_res: A}
- {entry_name: GHSR_HUMAN, from_res: F, pubmed: '9440817', seq: '279', to_res: L}
- {entry_name: GHSR_HUMAN, from_res: H, pubmed: '9440817', seq: '280', to_res: F}
- {entry_name: GHSR_RAT, from_res: E, pubmed: '12118081', seq: '352', to_res: K}
- {entry_name: GIPR_HUMAN, from_res: G, pubmed: '10611300', seq: '198', to_res: C}
- {entry_name: GIPR_RAT, from_res: T, pubmed: '9125160', seq: '340', to_res: P}
- {entry_name: GIPR_RAT, from_res: S, pubmed: '9705086', seq: '406', to_res: A}
- {entry_name: GIPR_RAT, from_res: S, pubmed: '9705086', seq: '406', to_res: R}
- {entry_name: GIPR_RAT, from_res: C, pubmed: '9705086', seq: '411', to_res: A}
- {entry_name: GIPR_RAT, from_res: C, pubmed: '9705086', seq: '411', to_res: G}
- {entry_name: GLP1R_RAT, from_res: F, pubmed: '9092794', seq: '169', to_res: A}
- {entry_name: GLP1R_RAT, from_res: R, pubmed: '9092794', seq: '170', to_res: A}
- {entry_name: GLP1R_RAT, from_res: H, pubmed: '9092794', seq: '171', to_res: A}
- {entry_name: GLP1R_RAT, from_res: L, pubmed: '9092794', seq: '172', to_res: A}
- {entry_name: GLP1R_RAT, from_res: H, pubmed: '9092794', seq: '173', to_res: A}
- {entry_name: GLP1R_RAT, from_res: C, pubmed: '9092794', seq: '174', to_res: A}
- {entry_name: GLP1R_RAT, from_res: T, pubmed: '9092794', seq: '175', to_res: A}
- {entry_name: GLP1R_RAT, from_res: R, pubmed: '9092794', seq: '176', to_res: A}
- {entry_name: GLP1R_RAT, from_res: N, pubmed: '9092794', seq: '177', to_res: A}
- {entry_name: GLP1R_RAT, from_res: H, pubmed: '9092794', seq: '180', to_res: R}
- {entry_name: GLP1R_RAT, from_res: I, pubmed: '9092794', seq: '265', to_res: A}
- {entry_name: GLP1R_RAT, from_res: F, pubmed: '9092794', seq: '266', to_res: A}
- {entry_name: GLP1R_RAT, from_res: V, pubmed: '9092794', seq: '327', to_res: A}
- {entry_name: GLP1R_RAT, from_res: I, pubmed: '9092794', seq: '328', to_res: A}
- {entry_name: GLP1R_RAT, from_res: V, pubmed: '9092794', seq: '331', to_res: A}
- {entry_name: GLP1R_RAT, from_res: R, pubmed: '9092794', seq: '348', to_res: A}
- {entry_name: GLP1R_RAT, from_res: R, pubmed: '9092794', seq: '348', to_res: G}
- {entry_name: GLP1R_RAT, from_res: A, pubmed: '9092794', seq: '350', to_res: E}
- {entry_name: GLP1R_RAT, from_res: A, pubmed: '9092794', seq: '350', to_res: K}
- {entry_name: GLP1R_RAT, from_res: S, pubmed: '8702711', seq: '416', to_res: A}
- {entry_name: GLP1R_RAT, from_res: S, pubmed: '8702711', seq: '431', to_res: A}
- {entry_name: GLP1R_RAT, from_res: S, pubmed: '8702711', seq: '432', to_res: A}
- {entry_name: GLP1R_RAT, from_res: S, pubmed: '8702711', seq: '441', to_res: A}
- {entry_name: GLP1R_RAT, from_res: S, pubmed: '8702711', seq: '444', to_res: A}
- {entry_name: GLP1R_RAT, from_res: S, pubmed: '8702711', seq: '451', to_res: A}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '10090412', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '10406817', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '10510728', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '11692154', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '11961492', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '7589886', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '7773293', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '8635644', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '8690179', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '8712800', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '8732719', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '8858207', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '8879960', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '8931690', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '9028723', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '9285210', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: G, pubmed: '9673441', seq: '40', to_res: S}
- {entry_name: GLR_HUMAN, from_res: F, pubmed: '10085108', seq: '184', to_res: A}
- {entry_name: GLR_HUMAN, from_res: K, pubmed: '12724331', seq: '187', to_res: R}
- {entry_name: GLR_HUMAN, from_res: I, pubmed: '12724331', seq: '194', to_res: K}
- {entry_name: GLR_HUMAN, from_res: Y, pubmed: '10085108', seq: '239', to_res: A}
- {entry_name: GLR_HUMAN, from_res: A, pubmed: '9914475', seq: '348', to_res: N}
- {entry_name: GLR_HUMAN, from_res: V, pubmed: '12724331', seq: '360', to_res: T}
- {entry_name: GLR_HUMAN, from_res: V, pubmed: '12724331', seq: '364', to_res: I}
- {entry_name: GLR_HUMAN, from_res: T, pubmed: '12724331', seq: '369', to_res: M}
- {entry_name: GLR_HUMAN, from_res: Q, pubmed: '12724331', seq: '374', to_res: R}
- {entry_name: GLR_HUMAN, from_res: S, pubmed: '12724331', seq: '379', to_res: F}
- {entry_name: GLR_HUMAN, from_res: F, pubmed: '12724331', seq: '384', to_res: T}
- {entry_name: GLR_HUMAN, from_res: D, pubmed: '12724331', seq: '385', to_res: E}
- {entry_name: GLR_RAT, from_res: D, pubmed: '7499239', seq: '64', to_res: E}
- {entry_name: GLR_RAT, from_res: D, pubmed: '7499239', seq: '64', to_res: G}
- {entry_name: GLR_RAT, from_res: D, pubmed: '7499239', seq: '64', to_res: K}
- {entry_name: GLR_RAT, from_res: D, pubmed: '7499239', seq: '64', to_res: N}
- {entry_name: GLR_RAT, from_res: H, pubmed: '10383462', seq: '178', to_res: R}
- {entry_name: GLR_RAT, from_res: H, pubmed: '10791965', seq: '178', to_res: R}
- {entry_name: GLR_RAT, from_res: H, pubmed: '9440812', seq: '178', to_res: R}
- {entry_name: GLR_RAT, from_res: K, pubmed: '11853547', seq: '188', to_res: R}
- {entry_name: GLR_RAT, from_res: I, pubmed: '11853547', seq: '195', to_res: K}
- {entry_name: GLR_RAT, from_res: I, pubmed: '11853547', seq: '195', to_res: R}
- {entry_name: GLR_RAT, from_res: R, pubmed: '12269822', seq: '202', to_res: A}
- {entry_name: GLR_RAT, from_res: R, pubmed: '12269822', seq: '202', to_res: D}
- {entry_name: GLR_RAT, from_res: K, pubmed: '12269822', seq: '206', to_res: A}
- {entry_name: GLR_RAT, from_res: K, pubmed: '12269822', seq: '206', to_res: D}
- {entry_name: GLR_RAT, from_res: D, pubmed: '12269822', seq: '209', to_res: A}
- {entry_name: GLR_RAT, from_res: D, pubmed: '12269822', seq: '209', to_res: Q}
- {entry_name: GLR_RAT, from_res: D, pubmed: '12269822', seq: '210', to_res: A}
- {entry_name: GLR_RAT, from_res: D, pubmed: '12269822', seq: '210', to_res: H}
- {entry_name: GLR_RAT, from_res: D, pubmed: '12269822', seq: '219', to_res: A}
- {entry_name: GLR_RAT, from_res: D, pubmed: '12269822', seq: '219', to_res: Y}
- {entry_name: GLR_RAT, from_res: T, pubmed: '9440812', seq: '352', to_res: P}
- {entry_name: GNRHR_HUMAN, from_res: M, pubmed: '12568864', seq: '1', to_res: T}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '15105440', seq: '2', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '9335546', seq: '8', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '11397871', seq: '10', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '12606630', seq: '10', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '15105440', seq: '10', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '15886197', seq: '10', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '9335546', seq: '14', to_res: S}
- {entry_name: GNRHR_HUMAN, from_res: M, pubmed: '16420049', seq: '24', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: M, pubmed: '16420049', seq: '24', to_res: I}
- {entry_name: GNRHR_HUMAN, from_res: M, pubmed: '16420049', seq: '24', to_res: T}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '27', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '27', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: T, pubmed: '11297587', seq: '32', to_res: I}
- {entry_name: GNRHR_HUMAN, from_res: T, pubmed: '12606630', seq: '32', to_res: I}
- {entry_name: GNRHR_HUMAN, from_res: T, pubmed: '15105440', seq: '32', to_res: I}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '10894158', seq: '36', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '16420049', seq: '50', to_res: T}
- {entry_name: GNRHR_HUMAN, from_res: T, pubmed: '16420049', seq: '51', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '10894158', seq: '87', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '10894158', seq: '87', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '10894158', seq: '90', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '12606630', seq: '90', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '15105440', seq: '90', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '15886197', seq: '90', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '9335546', seq: '90', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '10894158', seq: '98', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '10894158', seq: '98', to_res: N}
- {entry_name: GNRHR_HUMAN, from_res: W, pubmed: '10894158', seq: '101', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '10894158', seq: '102', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '102', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '10894158', seq: '102', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '8663086', seq: '102', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '12679486', seq: '106', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '10022417', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '10527669', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '10894158', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '10999776', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '11297587', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '11397842', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '11397871', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '12057744', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '12568864', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '12606630', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '12679486', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '15105440', seq: '106', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '16420049', seq: '111', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '16420049', seq: '111', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '9335546', seq: '111', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '16420049', seq: '111', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '16420049', seq: '112', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '16420049', seq: '112', to_res: F}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '16420049', seq: '112', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '9335546', seq: '114', to_res: S}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '16420049', seq: '115', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '16420049', seq: '115', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '16420049', seq: '117', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '118', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '118', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '118', to_res: N}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '16420049', seq: '121', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '16420049', seq: '121', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '10894158', seq: '121', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '10894158', seq: '121', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '124', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '124', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '10523035', seq: '129', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '12477532', seq: '129', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '12606630', seq: '129', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '15105440', seq: '129', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '10894158', seq: '138', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '10894158', seq: '138', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '10894158', seq: '138', to_res: N}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '9335546', seq: '138', to_res: N}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '11397871', seq: '139', to_res: H}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '12568864', seq: '139', to_res: H}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '12606630', seq: '139', to_res: H}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '15105440', seq: '139', to_res: H}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '15886197', seq: '139', to_res: H}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '11397871', seq: '139', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '12568864', seq: '139', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: I, pubmed: '10894158', seq: '143', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '10585457', seq: '145', to_res: P}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '168', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '168', to_res: I}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '10523035', seq: '168', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '11397871', seq: '168', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '12606630', seq: '168', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '12679486', seq: '168', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '15105440', seq: '168', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '15886197', seq: '168', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '12679486', seq: '171', to_res: T}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '15105440', seq: '171', to_res: T}
- {entry_name: GNRHR_HUMAN, from_res: H, pubmed: '16420049', seq: '182', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: H, pubmed: '16420049', seq: '182', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: H, pubmed: '10379888', seq: '182', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '186', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '10379888', seq: '186', to_res: G}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '186', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '16420049', seq: '189', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '16420049', seq: '189', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '16420049', seq: '189', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '10379888', seq: '189', to_res: P}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '16420049', seq: '189', to_res: P}
- {entry_name: GNRHR_HUMAN, from_res: T, pubmed: '16420049', seq: '190', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '10379888', seq: '191', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '10379888', seq: '191', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '16420049', seq: '191', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '15886197', seq: '191', to_res: G}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '10379888', seq: '191', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: K, pubmed: '10379888', seq: '191', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '9335546', seq: '196', to_res: S}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '9335546', seq: '200', to_res: S}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '11297587', seq: '200', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '12606630', seq: '200', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '15105440', seq: '200', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '15886197', seq: '200', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '203', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '203', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '10379888', seq: '203', to_res: P}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '203', to_res: P}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '16420049', seq: '203', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '10894158', seq: '204', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: W, pubmed: '10894158', seq: '205', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: H, pubmed: '10894158', seq: '207', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '10894158', seq: '208', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '16420049', seq: '208', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: Q, pubmed: '16420049', seq: '208', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '10894158', seq: '210', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '10894158', seq: '212', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '10894158', seq: '212', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '10894158', seq: '213', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: T, pubmed: '10894158', seq: '215', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '10894158', seq: '216', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '10894158', seq: '216', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '10894158', seq: '217', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '15886197', seq: '217', to_res: G}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '10022417', seq: '217', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '10894158', seq: '217', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '12606630', seq: '217', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '15105440', seq: '217', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: S, pubmed: '15886197', seq: '217', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: F}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: G}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: I}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: P}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: S}
- {entry_name: GNRHR_HUMAN, from_res: A, pubmed: '9560319', seq: '261', to_res: V}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '10022417', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '10523035', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '10527669', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '10894158', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '10999776', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '11297587', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '11397842', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '11397871', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '11802711', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '12477532', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '12568864', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '12606630', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '15105440', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: R, pubmed: '16322390', seq: '262', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '11297587', seq: '266', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '12606630', seq: '266', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '15105440', seq: '266', to_res: R}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '9820623', seq: '272', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '16420049', seq: '272', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '11297587', seq: '279', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '12606630', seq: '279', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: C, pubmed: '15105440', seq: '279', to_res: Y}
- {entry_name: GNRHR_HUMAN, from_res: W, pubmed: '16420049', seq: '280', to_res: F}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '11802711', seq: '283', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '15886197', seq: '283', to_res: C}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '16420049', seq: '283', to_res: F}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '16420049', seq: '283', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '11802711', seq: '284', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '10022417', seq: '284', to_res: C}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '10527669', seq: '284', to_res: C}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '11802711', seq: '284', to_res: C}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '12606630', seq: '284', to_res: C}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '15105440', seq: '284', to_res: C}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '15886197', seq: '284', to_res: C}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '16420049', seq: '284', to_res: F}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '16420049', seq: '284', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: W, pubmed: '11802711', seq: '289', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '11802711', seq: '290', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '16420049', seq: '290', to_res: F}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '16420049', seq: '290', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: Y, pubmed: '16420049', seq: '290', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: W, pubmed: '11802711', seq: '291', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: W, pubmed: '16420049', seq: '291', to_res: F}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '11802711', seq: '292', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '16420049', seq: '293', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '16420049', seq: '293', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '16420049', seq: '293', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '16420049', seq: '293', to_res: N}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '16420049', seq: '295', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '16420049', seq: '295', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: E, pubmed: '16420049', seq: '295', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '16420049', seq: '300', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '16420049', seq: '300', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '16420049', seq: '300', to_res: V}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '16420049', seq: '302', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '9751490', seq: '302', to_res: N}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '16420049', seq: '302', to_res: N}
- {entry_name: GNRHR_HUMAN, from_res: D, pubmed: '16420049', seq: '302', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '305', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '305', to_res: D}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '305', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: H, pubmed: '16420049', seq: '306', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: H, pubmed: '16420049', seq: '306', to_res: E}
- {entry_name: GNRHR_HUMAN, from_res: H, pubmed: '16420049', seq: '306', to_res: K}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '16420049', seq: '309', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '16420049', seq: '309', to_res: Q}
- {entry_name: GNRHR_HUMAN, from_res: F, pubmed: '16420049', seq: '313', to_res: L}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '10999776', seq: '314', to_res: X}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '12679486', seq: '314', to_res: X}
- {entry_name: GNRHR_HUMAN, from_res: L, pubmed: '15105440', seq: '314', to_res: X}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '315', to_res: A}
- {entry_name: GNRHR_HUMAN, from_res: N, pubmed: '16420049', seq: '315', to_res: D}
- {entry_name: GNRHR_MOUSE, from_res: P, pubmed: '15886197', seq: '11', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: I, pubmed: '15886197', seq: '24', to_res: T}
- {entry_name: GNRHR_MOUSE, from_res: L, pubmed: '9748222', seq: '58', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: K, pubmed: '9748222', seq: '59', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: Q, pubmed: '9748222', seq: '61', to_res: E}
- {entry_name: GNRHR_MOUSE, from_res: K, pubmed: '9748222', seq: '62', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: L, pubmed: '9748222', seq: '73', to_res: R}
- {entry_name: GNRHR_MOUSE, from_res: S, pubmed: '9748222', seq: '74', to_res: E}
- {entry_name: GNRHR_MOUSE, from_res: L, pubmed: '9748222', seq: '80', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: K, pubmed: '11470271', seq: '121', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: D, pubmed: '9259312', seq: '138', to_res: E}
- {entry_name: GNRHR_MOUSE, from_res: D, pubmed: '9259312', seq: '138', to_res: N}
- {entry_name: GNRHR_MOUSE, from_res: R, pubmed: '9259312', seq: '139', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: R, pubmed: '9259312', seq: '139', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: R, pubmed: '9259312', seq: '139', to_res: S}
- {entry_name: GNRHR_MOUSE, from_res: S, pubmed: '7559413', seq: '140', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: S, pubmed: '9259312', seq: '140', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: S, pubmed: '7559413', seq: '140', to_res: Y}
- {entry_name: GNRHR_MOUSE, from_res: L, pubmed: '7559413', seq: '147', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: L, pubmed: '7559413', seq: '147', to_res: D}
- {entry_name: GNRHR_MOUSE, from_res: S, pubmed: '9259312', seq: '151', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: S, pubmed: '9259312', seq: '153', to_res: A}
- {entry_name: GNRHR_MOUSE, from_res: K, pubmed: '9259312', seq: '154', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: E, pubmed: '9259312', seq: '156', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: G, pubmed: '15886197', seq: '216', to_res: S}
- {entry_name: GNRHR_MOUSE, from_res: L, pubmed: '15886197', seq: '265', to_res: R}
- {entry_name: GNRHR_MOUSE, from_res: E, pubmed: '7915716', seq: '301', to_res: Q}
- {entry_name: GNRHR_MOUSE, from_res: E, pubmed: '9751490', seq: '301', to_res: Q}
- {entry_name: GNRHR_RAT, from_res: C, pubmed: '9202220', seq: '14', to_res: A}
- {entry_name: GNRHR_RAT, from_res: N, pubmed: '8133203', seq: '87', to_res: D}
- {entry_name: GNRHR_RAT, from_res: C, pubmed: '9202220', seq: '114', to_res: A}
- {entry_name: GNRHR_RAT, from_res: S, pubmed: '10588818', seq: '140', to_res: F}
- {entry_name: GNRHR_RAT, from_res: C, pubmed: '9202220', seq: '195', to_res: A}
- {entry_name: GNRHR_RAT, from_res: C, pubmed: '9202220', seq: '199', to_res: A}
- {entry_name: GNRHR_RAT, from_res: S, pubmed: '15886197', seq: '216', to_res: G}
- {entry_name: GNRHR_RAT, from_res: S, pubmed: '15886197', seq: '216', to_res: R}
- {entry_name: GNRHR_RAT, from_res: T, pubmed: '9828194', seq: '238', to_res: A}
- {entry_name: GNRHR_RAT, from_res: S, pubmed: '9828194', seq: '253', to_res: A}
- {entry_name: GNRHR_RAT, from_res: T, pubmed: '9828194', seq: '264', to_res: A}
- {entry_name: GNRHR_RAT, from_res: W, pubmed: '10692505', seq: '279', to_res: L}
- {entry_name: GNRHR_RAT, from_res: W, pubmed: '10692505', seq: '279', to_res: R}
- {entry_name: GNRHR_RAT, from_res: W, pubmed: '10692505', seq: '279', to_res: S}
- {entry_name: GNRHR_RAT, from_res: W, pubmed: '11434905', seq: '279', to_res: S}
- {entry_name: GNRHR_RAT, from_res: V, pubmed: '10692505', seq: '299', to_res: A}
- {entry_name: GNRHR_RAT, from_res: F, pubmed: '11434905', seq: '310', to_res: L}
- {entry_name: GNRHR_RAT, from_res: D, pubmed: '8133203', seq: '318', to_res: N}
- {entry_name: GNRHR_RAT, from_res: S, pubmed: '11997175', seq: '326', to_res: Y}
- {entry_name: GNRR2_CLAGA, from_res: L, pubmed: '11802781', seq: '7', to_res: W}
- {entry_name: GNRR2_CLAGA, from_res: D, pubmed: '11470271', seq: '90', to_res: N}
- {entry_name: GNRR2_CLAGA, from_res: M, pubmed: '11470271', seq: '93', to_res: E}
- {entry_name: GNRR2_CLAGA, from_res: K, pubmed: '11470271', seq: '124', to_res: M}
- {entry_name: GNRR2_CLAGA, from_res: D, pubmed: '11802781', seq: '304', to_res: A}
- {entry_name: GNRR2_CLAGA, from_res: D, pubmed: '11802781', seq: '304', to_res: E}
- {entry_name: GNRR2_CLAGA, from_res: D, pubmed: '11802781', seq: '304', to_res: N}
- {entry_name: GNRR2_CLAGA, from_res: H, pubmed: '11278484', seq: '354', to_res: D}
- {entry_name: GNRR2_CLAGA, from_res: A, pubmed: '11278484', seq: '366', to_res: E}
- {entry_name: GNRR2_CLAGA, from_res: G, pubmed: '11278484', seq: '371', to_res: D}
- {entry_name: GNRR2_HUMAN, from_res: T, pubmed: '11250931', seq: '7', to_res: R}
- {entry_name: GP128_HUMAN, from_res: K, pubmed: '12890682', seq: '758', to_res: R}
- {entry_name: GP143_HUMAN, from_res: R, pubmed: '11115845', seq: '5', to_res: C}
- {entry_name: GP143_HUMAN, from_res: G, pubmed: '11115845', seq: '35', to_res: D}
- {entry_name: GP143_HUMAN, from_res: D, pubmed: '11115845', seq: '78', to_res: N}
- {entry_name: GP143_HUMAN, from_res: G, pubmed: '11115845', seq: '84', to_res: D}
- {entry_name: GP143_HUMAN, from_res: C, pubmed: '11115845', seq: '116', to_res: S}
- {entry_name: GP143_HUMAN, from_res: G, pubmed: '11115845', seq: '118', to_res: E}
- {entry_name: GP143_HUMAN, from_res: Q, pubmed: '11115845', seq: '124', to_res: R}
- {entry_name: GP143_HUMAN, from_res: W, pubmed: '11115845', seq: '133', to_res: R}
- {entry_name: GP143_HUMAN, from_res: A, pubmed: '11115845', seq: '138', to_res: V}
- {entry_name: GP143_HUMAN, from_res: S, pubmed: '11115845', seq: '152', to_res: N}
- {entry_name: GP143_HUMAN, from_res: A, pubmed: '11115845', seq: '173', to_res: D}
- {entry_name: GP143_HUMAN, from_res: G, pubmed: '11115845', seq: '229', to_res: V}
- {entry_name: GP143_HUMAN, from_res: T, pubmed: '11115845', seq: '232', to_res: K}
- {entry_name: GP143_HUMAN, from_res: E, pubmed: '11115845', seq: '235', to_res: K}
- {entry_name: GP143_HUMAN, from_res: I, pubmed: '11115845', seq: '244', to_res: V}
- {entry_name: GP143_HUMAN, from_res: I, pubmed: '11115845', seq: '261', to_res: N}
- {entry_name: GP143_HUMAN, from_res: E, pubmed: '11115845', seq: '271', to_res: G}
- {entry_name: GP143_HUMAN, from_res: W, pubmed: '11115845', seq: '292', to_res: G}
- {entry_name: GP143_MOUSE, from_res: G, pubmed: '9887374', seq: '35', to_res: D}
- {entry_name: GP143_MOUSE, from_res: L, pubmed: '9887374', seq: '39', to_res: R}
- {entry_name: GP143_MOUSE, from_res: D, pubmed: '9887374', seq: '78', to_res: V}
- {entry_name: GP143_MOUSE, from_res: W, pubmed: '9887374', seq: '133', to_res: R}
- {entry_name: GP143_MOUSE, from_res: E, pubmed: '9887374', seq: '233', to_res: K}
- {entry_name: GP152_MOUSE, from_res: V, pubmed: '9419375', seq: '380', to_res: D}
- {entry_name: GP154_MOUSE, from_res: A, pubmed: '9405068', seq: '25', to_res: Y}
- {entry_name: GP154_MOUSE, from_res: T, pubmed: '14573774', seq: '27', to_res: N}
- {entry_name: GP154_MOUSE, from_res: T, pubmed: '14573774', seq: '31', to_res: N}
- {entry_name: GP154_MOUSE, from_res: S, pubmed: '12119292', seq: '188', to_res: A}
- {entry_name: GP174_HUMAN, from_res: P, pubmed: '11815371', seq: '2', to_res: T}
- {entry_name: GPR37_HUMAN, from_res: S, pubmed: '11382773', seq: '25', to_res: N}
- {entry_name: GPR42_HUMAN, from_res: N, pubmed: '9344866', seq: '32', to_res: D}
- {entry_name: GPR42_HUMAN, from_res: C, pubmed: '9344866', seq: '88', to_res: P}
- {entry_name: GPR42_HUMAN, from_res: C, pubmed: '9344866', seq: '169', to_res: P}
- {entry_name: GPR42_HUMAN, from_res: P, pubmed: '9344866', seq: '240', to_res: N}
- {entry_name: GPR42_HUMAN, from_res: P, pubmed: '9344866', seq: '273', to_res: N}
- {entry_name: GPR64_HUMAN, from_res: K, pubmed: '12890682', seq: '898', to_res: R}
- {entry_name: GR05A_DROME, from_res: A, pubmed: '11566105', seq: '218', to_res: T}
- {entry_name: GRPR_MOUSE, from_res: N, pubmed: '11093789', seq: '5', to_res: Q}
- {entry_name: GRPR_MOUSE, from_res: N, pubmed: '11093789', seq: '20', to_res: Q}
- {entry_name: GRPR_MOUSE, from_res: N, pubmed: '11093789', seq: '24', to_res: Q}
- {entry_name: GRPR_MOUSE, from_res: D, pubmed: '10413511', seq: '98', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: D, pubmed: '10413511', seq: '98', to_res: R}
- {entry_name: GRPR_MOUSE, from_res: S, pubmed: '9211882', seq: '100', to_res: T}
- {entry_name: GRPR_MOUSE, from_res: D, pubmed: '9211882', seq: '105', to_res: E}
- {entry_name: GRPR_MOUSE, from_res: I, pubmed: '9211882', seq: '117', to_res: L}
- {entry_name: GRPR_MOUSE, from_res: Q, pubmed: '9211882', seq: '121', to_res: R}
- {entry_name: GRPR_MOUSE, from_res: R, pubmed: '7852420', seq: '139', to_res: G}
- {entry_name: GRPR_MOUSE, from_res: L, pubmed: '9211882', seq: '172', to_res: F}
- {entry_name: GRPR_MOUSE, from_res: S, pubmed: '10945859', seq: '180', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: D, pubmed: '10945859', seq: '181', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: L, pubmed: '12021405', seq: '182', to_res: V}
- {entry_name: GRPR_MOUSE, from_res: H, pubmed: '12021405', seq: '183', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: P, pubmed: '12021405', seq: '184', to_res: R}
- {entry_name: GRPR_MOUSE, from_res: F, pubmed: '12021405', seq: '185', to_res: I}
- {entry_name: GRPR_MOUSE, from_res: N, pubmed: '11093789', seq: '191', to_res: E}
- {entry_name: GRPR_MOUSE, from_res: N, pubmed: '11093789', seq: '191', to_res: Q}
- {entry_name: GRPR_MOUSE, from_res: A, pubmed: '12021405', seq: '198', to_res: I}
- {entry_name: GRPR_MOUSE, from_res: P, pubmed: '9211882', seq: '199', to_res: S}
- {entry_name: GRPR_MOUSE, from_res: S, pubmed: '10945859', seq: '212', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: S, pubmed: '10945859', seq: '215', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: F, pubmed: '10945859', seq: '216', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: F, pubmed: '10945859', seq: '270', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: W, pubmed: '10945859', seq: '278', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: N, pubmed: '10945859', seq: '281', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: Y, pubmed: '10945859', seq: '285', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: R, pubmed: '9211882', seq: '288', to_res: H}
- {entry_name: GRPR_MOUSE, from_res: Y, pubmed: '9211882', seq: '292', to_res: S}
- {entry_name: GRPR_MOUSE, from_res: S, pubmed: '11463790', seq: '293', to_res: K}
- {entry_name: GRPR_MOUSE, from_res: V, pubmed: '11463790', seq: '295', to_res: I}
- {entry_name: GRPR_MOUSE, from_res: T, pubmed: '11463790', seq: '297', to_res: P}
- {entry_name: GRPR_MOUSE, from_res: F, pubmed: '11463790', seq: '302', to_res: M}
- {entry_name: GRPR_MOUSE, from_res: V, pubmed: '11463790', seq: '303', to_res: I}
- {entry_name: GRPR_MOUSE, from_res: T, pubmed: '11463790', seq: '304', to_res: V}
- {entry_name: GRPR_MOUSE, from_res: S, pubmed: '11463790', seq: '305', to_res: T}
- {entry_name: GRPR_MOUSE, from_res: A, pubmed: '9211882', seq: '308', to_res: S}
- {entry_name: GRPR_MOUSE, from_res: R, pubmed: '10413511', seq: '309', to_res: A}
- {entry_name: GRPR_MOUSE, from_res: R, pubmed: '10413511', seq: '309', to_res: D}
- {entry_name: GRPR_MOUSE, from_res: F, pubmed: '10945859', seq: '313', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: W, pubmed: '10514483', seq: '161', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: W, pubmed: '10514483', seq: '161', to_res: F}
- {entry_name: HRH1_CAVPO, from_res: W, pubmed: '10514483', seq: '161', to_res: M}
- {entry_name: HRH1_CAVPO, from_res: W, pubmed: '10514483', seq: '167', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: W, pubmed: '10514483', seq: '167', to_res: F}
- {entry_name: HRH1_CAVPO, from_res: W, pubmed: '10514483', seq: '167', to_res: M}
- {entry_name: HRH1_CAVPO, from_res: W, pubmed: '10514483', seq: '174', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: K, pubmed: '10514483', seq: '200', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: K, pubmed: '7669031', seq: '200', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: F, pubmed: '10514483', seq: '433', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: F, pubmed: '10514483', seq: '433', to_res: M}
- {entry_name: HRH1_CAVPO, from_res: F, pubmed: '10514483', seq: '435', to_res: A}
- {entry_name: HRH1_CAVPO, from_res: F, pubmed: '10514483', seq: '436', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: D, pubmed: '9593602', seq: '107', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: S, pubmed: '8903934', seq: '155', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: T, pubmed: '8903934', seq: '194', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: T, pubmed: '9593602', seq: '194', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: N, pubmed: '8903934', seq: '198', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: N, pubmed: '9593602', seq: '198', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: S, pubmed: '10101032', seq: '396', to_res: A}
- {entry_name: HRH1_HUMAN, from_res: S, pubmed: '10101032', seq: '398', to_res: A}
- {entry_name: HRH2_CANFA, from_res: D, pubmed: '1356984', seq: '186', to_res: A}
- {entry_name: HRH2_CANFA, from_res: T, pubmed: '1356984', seq: '190', to_res: A}
- {entry_name: HRH2_CANFA, from_res: S, pubmed: '9235948', seq: '316', to_res: A}
- {entry_name: HRH2_RAT, from_res: D, pubmed: '10779371', seq: '115', to_res: A}
- {entry_name: HRH2_RAT, from_res: D, pubmed: '10779371', seq: '115', to_res: N}
- {entry_name: HRH2_RAT, from_res: D, pubmed: '11557261', seq: '115', to_res: N}
- {entry_name: HRH2_RAT, from_res: R, pubmed: '10779371', seq: '116', to_res: A}
- {entry_name: HRH2_RAT, from_res: R, pubmed: '10779371', seq: '116', to_res: N}
- {entry_name: HRH4_HUMAN, from_res: D, pubmed: '12065753', seq: '94', to_res: A}
- {entry_name: HRH4_HUMAN, from_res: D, pubmed: '12065753', seq: '94', to_res: E}
- {entry_name: HRH4_HUMAN, from_res: D, pubmed: '12065753', seq: '94', to_res: N}
- {entry_name: HRH4_HUMAN, from_res: N, pubmed: '12065753', seq: '147', to_res: A}
- {entry_name: HRH4_HUMAN, from_res: N, pubmed: '12065753', seq: '147', to_res: F}
- {entry_name: HRH4_HUMAN, from_res: N, pubmed: '12065753', seq: '147', to_res: Y}
- {entry_name: HRH4_HUMAN, from_res: T, pubmed: '12065753', seq: '178', to_res: A}
- {entry_name: HRH4_HUMAN, from_res: S, pubmed: '12065753', seq: '179', to_res: A}
- {entry_name: HRH4_HUMAN, from_res: E, pubmed: '12065753', seq: '182', to_res: A}
- {entry_name: HRH4_HUMAN, from_res: E, pubmed: '12065753', seq: '182', to_res: D}
- {entry_name: HRH4_HUMAN, from_res: E, pubmed: '12065753', seq: '182', to_res: N}
- {entry_name: HRH4_HUMAN, from_res: E, pubmed: '12065753', seq: '182', to_res: Q}
- {entry_name: HRH4_HUMAN, from_res: S, pubmed: '12065753', seq: '320', to_res: A}
- {entry_name: HRH4_HUMAN, from_res: S, pubmed: '12065753', seq: '320', to_res: F}
- {entry_name: LPHN1_RAT, from_res: C, pubmed: '9799228', seq: '71', to_res: S}
- {entry_name: LSHR_BOVIN, from_res: L, pubmed: '8626439', seq: '61', to_res: R}
- {entry_name: LSHR_BOVIN, from_res: I, pubmed: '8626439', seq: '247', to_res: V}
- {entry_name: LSHR_BOVIN, from_res: T, pubmed: '15345720', seq: '274', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '9593728', seq: '26', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '12217647', seq: '29', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '56', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '64', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10880516', seq: '69', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10880516', seq: '70', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: G, pubmed: '10880516', seq: '71', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '72', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '10880516', seq: '73', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '10880516', seq: '74', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '10880516', seq: '75', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '76', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10880516', seq: '77', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '78', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '78', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '11041448', seq: '79', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '80', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '12217647', seq: '80', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '83', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10880516', seq: '84', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10880516', seq: '88', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '103', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '12217647', seq: '105', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: Q, pubmed: '11987903', seq: '106', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: Y, pubmed: '11889161', seq: '113', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10884391', seq: '124', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '11849253', seq: '124', to_res: Q}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10884391', seq: '125', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10880517', seq: '126', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10884391', seq: '126', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: Y, pubmed: '10884391', seq: '127', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '128', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880517', seq: '128', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10884391', seq: '128', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10884391', seq: '128', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10884391', seq: '128', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10884391', seq: '128', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10884391', seq: '128', to_res: W}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10884391', seq: '129', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '130', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880517', seq: '130', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10884391', seq: '130', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10884391', seq: '130', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10884391', seq: '130', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10884391', seq: '130', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10884391', seq: '130', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10884391', seq: '131', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10714363', seq: '131', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '9215288', seq: '131', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '9562960', seq: '131', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '9817592', seq: '131', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '10884391', seq: '132', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10884391', seq: '133', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: G, pubmed: '10884391', seq: '134', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '135', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10884391', seq: '135', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10884391', seq: '136', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10880517', seq: '137', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10884391', seq: '137', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '15472221', seq: '144', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '153', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '12217647', seq: '179', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '11987903', seq: '194', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '12444891', seq: '194', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '202', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '12217647', seq: '202', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '204', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10880516', seq: '227', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10880516', seq: '229', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '11987903', seq: '262', to_res: Q}
- {entry_name: LSHR_HUMAN, from_res: P, pubmed: '10889210', seq: '276', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: P, pubmed: '10889210', seq: '276', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: P, pubmed: '12770743', seq: '276', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12770743', seq: '277', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: C}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: D}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12770743', seq: '277', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12770743', seq: '277', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12770743', seq: '277', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: M}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12770743', seq: '277', to_res: M}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12356766', seq: '277', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: Q}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12770743', seq: '277', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '12770743', seq: '277', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: W}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10889210', seq: '277', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '11987903', seq: '279', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '10202864', seq: '291', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '8812739', seq: '291', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '8843415', seq: '291', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '11987903', seq: '307', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '8812739', seq: '312', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '9215288', seq: '312', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10714363', seq: '343', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '11987903', seq: '343', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '12050206', seq: '343', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '10619974', seq: '354', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '10714363', seq: '354', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '11987903', seq: '354', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '9562960', seq: '354', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '9626144', seq: '354', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '9817592', seq: '354', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11134146', seq: '368', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11987903', seq: '368', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10084607', seq: '373', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10698637', seq: '373', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '11134146', seq: '373', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '11987903', seq: '373', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '12242044', seq: '373', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9467560', seq: '373', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10967122', seq: '388', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '390', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10967122', seq: '395', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '10084607', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '10698637', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '11134146', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '11200941', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '11936470', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '11943741', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '11987903', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '8607787', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '9253338', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '9562960', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '9584216', seq: '398', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11075813', seq: '405', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11118455', seq: '405', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11696538', seq: '405', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '446', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '10698637', seq: '447', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '10698637', seq: '447', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10698637', seq: '449', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10698637', seq: '449', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10698637', seq: '450', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10698637', seq: '450', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10698637', seq: '450', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '10698637', seq: '451', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '10698637', seq: '454', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '10698637', seq: '454', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '10698637', seq: '454', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '457', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11376115', seq: '457', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '457', to_res: D}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11376115', seq: '457', to_res: D}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11376115', seq: '457', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '457', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11376115', seq: '457', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11943741', seq: '457', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '15908694', seq: '457', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10698637', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10935550', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11075813', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11106922', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11134146', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11376115', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11696538', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11861529', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11943741', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11987903', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '12242044', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '12629106', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '9661624', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '9857020', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '15908694', seq: '457', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '458', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '458', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10698637', seq: '460', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '461', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '461', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '461', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: E, pubmed: '11943741', seq: '463', to_res: Q}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '11943741', seq: '464', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '11041448', seq: '485', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '11118455', seq: '512', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '11696538', seq: '512', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '11118455', seq: '514', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '11118455', seq: '515', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '11696538', seq: '515', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '11118455', seq: '519', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: V, pubmed: '11696538', seq: '519', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '11118455', seq: '521', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '11696538', seq: '521', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10698637', seq: '528', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10698637', seq: '528', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10698637', seq: '531', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '10698637', seq: '535', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '10698637', seq: '535', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '539', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10084607', seq: '542', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10698637', seq: '542', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '11134146', seq: '542', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '7892197', seq: '542', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '8812739', seq: '542', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '9562960', seq: '542', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '9661624', seq: '542', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10698637', seq: '543', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10714363', seq: '543', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '11987903', seq: '543', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '12050206', seq: '543', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10698637', seq: '545', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: Y, pubmed: '11075813', seq: '546', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: Y, pubmed: '11118455', seq: '546', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: Y, pubmed: '11696538', seq: '546', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '548', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '14636063', seq: '548', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '14636063', seq: '554', to_res: Q}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '14636063', seq: '559', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '14636063', seq: '559', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '14636063', seq: '561', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '14636063', seq: '561', to_res: D}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10967122', seq: '561', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '14636063', seq: '561', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '14636063', seq: '561', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '14636063', seq: '561', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10967122', seq: '564', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '564', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10698637', seq: '564', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11943741', seq: '564', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '564', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973249', seq: '564', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '564', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10084607', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10698637', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10889210', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11943741', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11987903', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12770743', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8798412', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9562960', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973249', seq: '564', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973249', seq: '564', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '564', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10967122', seq: '564', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '564', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973249', seq: '564', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '564', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '566', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10084607', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10698637', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '11106922', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '11134146', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '11987903', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '8812739', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9562960', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9661624', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '15375328', seq: '568', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10698637', seq: '569', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '569', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10698637', seq: '569', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '570', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '10084607', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '10698637', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '7757065', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '7892197', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '8702611', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '9562960', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '9584216', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '9849960', seq: '571', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9562960', seq: '572', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10084607', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10698637', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10770485', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '11987903', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '7714085', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '8702611', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '8812739', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9253338', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9562960', seq: '572', to_res: V}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10698637', seq: '573', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10698637', seq: '574', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10698637', seq: '574', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10084607', seq: '575', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10698637', seq: '575', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '8812739', seq: '575', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '9562960', seq: '575', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '9849960', seq: '575', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '9253338', seq: '576', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '9253338', seq: '576', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '9253338', seq: '576', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '9253338', seq: '576', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10084607', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '11106922', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '11134146', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '7757065', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '7892197', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '8702611', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '9562960', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '9849960', seq: '577', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9849960', seq: '578', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973550', seq: '578', to_res: E}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '578', to_res: F}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10084607', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10698637', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10704433', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10714362', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11118455', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11134146', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11889161', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11943741', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12145341', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12356766', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12667061', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '7714085', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '7757065', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '7892197', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8702611', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8812739', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9253338', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9467560', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9562960', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9661624', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9703386', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9849960', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9892662', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973550', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '15711023', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '15908694', seq: '578', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10698637', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11056247', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11075813', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11118455', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11356670', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11696538', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11861529', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11889161', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11943741', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12356766', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '15539429', seq: '578', to_res: H}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '578', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9849960', seq: '578', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '15908694', seq: '578', to_res: N}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '578', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973550', seq: '578', to_res: W}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10084607', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10674399', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10889210', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '10935549', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11075813', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11118455', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11696538', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11861529', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11943741', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '11987903', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12242044', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12667061', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '12770743', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '7892197', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8702611', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '8943222', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9562960', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9584216', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9598734', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9849960', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9857020', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: D, pubmed: '9973550', seq: '578', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '579', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '579', to_res: I}
- {entry_name: LSHR_HUMAN, from_res: T, pubmed: '10698637', seq: '580', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10084607', seq: '581', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '10698637', seq: '581', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '11987903', seq: '581', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '7892197', seq: '581', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '8812739', seq: '581', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '9562960', seq: '581', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '9661624', seq: '581', to_res: R}
- {entry_name: LSHR_HUMAN, from_res: M, pubmed: '10698637', seq: '582', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: P, pubmed: '10698637', seq: '584', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10698637', seq: '586', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '588', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '588', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '9100567', seq: '588', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10698637', seq: '589', to_res: S}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10202864', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10619974', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10714363', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '11987903', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '7719343', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9215288', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9253338', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9514160', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9562960', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '9817592', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '15105436', seq: '593', to_res: P}
- {entry_name: LSHR_HUMAN, from_res: L, pubmed: '10698637', seq: '607', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '611', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '10698637', seq: '615', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '10698637', seq: '615', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10202864', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10698637', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10714363', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '10770485', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '11134146', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '11987903', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '8843415', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '9215288', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '9238276', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '9253338', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '9514160', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '9562960', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '9817592', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '15105436', seq: '616', to_res: Y}
- {entry_name: LSHR_HUMAN, from_res: A, pubmed: '10698637', seq: '618', to_res: T}
- {entry_name: LSHR_HUMAN, from_res: N, pubmed: '15908694', seq: '619', to_res: L}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '10714363', seq: '625', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '11075813', seq: '625', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '11118455', seq: '625', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '11849253', seq: '625', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '11943741', seq: '625', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: I, pubmed: '9817592', seq: '625', to_res: K}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '626', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '626', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: F, pubmed: '10698637', seq: '626', to_res: Q}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '628', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10967122', seq: '632', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '640', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '15539429', seq: '643', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: C, pubmed: '15539429', seq: '644', to_res: G}
- {entry_name: LSHR_HUMAN, from_res: K, pubmed: '10967122', seq: '645', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: R, pubmed: '10967122', seq: '646', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '11696538', seq: '674', to_res: A}
- {entry_name: LSHR_HUMAN, from_res: S, pubmed: '11696538', seq: '676', to_res: A}
- {entry_name: LSHR_MOUSE, from_res: A, pubmed: '10098495', seq: '564', to_res: I}
- {entry_name: LSHR_PIG, from_res: R, pubmed: '11943741', seq: '2', to_res: C}
- {entry_name: LSHR_PIG, from_res: C, pubmed: '11041448', seq: '131', to_res: R}
- {entry_name: LSHR_PIG, from_res: F, pubmed: '11041448', seq: '194', to_res: V}
- {entry_name: LSHR_PIG, from_res: N, pubmed: '11041448', seq: '291', to_res: S}
- {entry_name: LSHR_PIG, from_res: T, pubmed: '11041448', seq: '307', to_res: A}
- {entry_name: LSHR_PIG, from_res: N, pubmed: '11041448', seq: '312', to_res: S}
- {entry_name: LSHR_PIG, from_res: C, pubmed: '11041448', seq: '343', to_res: S}
- {entry_name: LSHR_PIG, from_res: E, pubmed: '11041448', seq: '354', to_res: K}
- {entry_name: LSHR_PIG, from_res: A, pubmed: '11041448', seq: '373', to_res: V}
- {entry_name: LSHR_PIG, from_res: M, pubmed: '11041448', seq: '398', to_res: T}
- {entry_name: LSHR_PIG, from_res: L, pubmed: '11041448', seq: '457', to_res: R}
- {entry_name: LSHR_PIG, from_res: I, pubmed: '11041448', seq: '542', to_res: L}
- {entry_name: LSHR_PIG, from_res: C, pubmed: '11041448', seq: '543', to_res: R}
- {entry_name: LSHR_PIG, from_res: D, pubmed: '11041448', seq: '564', to_res: G}
- {entry_name: LSHR_PIG, from_res: A, pubmed: '11041448', seq: '568', to_res: V}
- {entry_name: LSHR_PIG, from_res: M, pubmed: '11041448', seq: '571', to_res: I}
- {entry_name: LSHR_PIG, from_res: A, pubmed: '11041448', seq: '572', to_res: V}
- {entry_name: LSHR_PIG, from_res: I, pubmed: '11041448', seq: '575', to_res: L}
- {entry_name: LSHR_PIG, from_res: T, pubmed: '11041448', seq: '577', to_res: I}
- {entry_name: LSHR_PIG, from_res: D, pubmed: '11041448', seq: '578', to_res: E}
- {entry_name: LSHR_PIG, from_res: D, pubmed: '11041448', seq: '578', to_res: G}
- {entry_name: LSHR_PIG, from_res: D, pubmed: '11041448', seq: '578', to_res: H}
- {entry_name: LSHR_PIG, from_res: D, pubmed: '11041448', seq: '578', to_res: Y}
- {entry_name: LSHR_PIG, from_res: C, pubmed: '11041448', seq: '581', to_res: R}
- {entry_name: LSHR_PIG, from_res: A, pubmed: '11041448', seq: '593', to_res: P}
- {entry_name: LSHR_PIG, from_res: S, pubmed: '11041448', seq: '616', to_res: Y}
- {entry_name: LSHR_PIG, from_res: I, pubmed: '11041448', seq: '625', to_res: K}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '11591722', seq: '12', to_res: C}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8626807', seq: '28', to_res: C}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8626807', seq: '28', to_res: M}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8626807', seq: '28', to_res: N}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '34', to_res: S}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8702502', seq: '38', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '38', to_res: S}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '40', to_res: S}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '11859079', seq: '46', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '11859079', seq: '48', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '9593729', seq: '48', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '48', to_res: S}
- {entry_name: LSHR_RAT, from_res: G, pubmed: '9593729', seq: '50', to_res: A}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '11861891', seq: '51', to_res: R}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8885249', seq: '66', to_res: D}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8885249', seq: '66', to_res: R}
- {entry_name: LSHR_RAT, from_res: V, pubmed: '11041448', seq: '79', to_res: M}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8530405', seq: '81', to_res: D}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8530405', seq: '81', to_res: R}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10499511', seq: '83', to_res: K}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8530405', seq: '91', to_res: K}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8530405', seq: '94', to_res: K}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '1755859', seq: '103', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '7665591', seq: '103', to_res: Q}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '7665591', seq: '105', to_res: A}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10499511', seq: '106', to_res: K}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8885249', seq: '130', to_res: D}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8530405', seq: '147', to_res: D}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8885249', seq: '158', to_res: K}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '8885249', seq: '161', to_res: K}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '1755859', seq: '178', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '7665591', seq: '178', to_res: Q}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '7665591', seq: '180', to_res: A}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '184', to_res: E}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '184', to_res: G}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '184', to_res: Q}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '184', to_res: R}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '1755859', seq: '199', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '7665591', seq: '199', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '8420926', seq: '199', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '9139799', seq: '199', to_res: Q}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '7665591', seq: '201', to_res: A}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '8420926', seq: '201', to_res: A}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '9139799', seq: '201', to_res: A}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10499511', seq: '207', to_res: K}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '209', to_res: E}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '209', to_res: G}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '209', to_res: Q}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '209', to_res: R}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10499511', seq: '210', to_res: K}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10499511', seq: '210', to_res: N}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10499511', seq: '215', to_res: K}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '10499511', seq: '216', to_res: E}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10499511', seq: '232', to_res: E}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10499511', seq: '232', to_res: K}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10499511', seq: '232', to_res: Q}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8530405', seq: '261', to_res: D}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '10098515', seq: '276', to_res: K}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '283', to_res: S}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '284', to_res: S}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '308', to_res: S}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '10098515', seq: '337', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '340', to_res: S}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '347', to_res: S}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10098515', seq: '352', to_res: A}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10098515', seq: '352', to_res: K}
- {entry_name: LSHR_RAT, from_res: F, pubmed: '10098515', seq: '354', to_res: A}
- {entry_name: LSHR_RAT, from_res: F, pubmed: '10098515', seq: '354', to_res: Y}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10098515', seq: '355', to_res: A}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '10098515', seq: '356', to_res: A}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '10098515', seq: '356', to_res: D}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '10098515', seq: '357', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '10098515', seq: '357', to_res: R}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '357', to_res: S}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10098515', seq: '358', to_res: A}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10098515', seq: '358', to_res: D}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10098515', seq: '358', to_res: K}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10499511', seq: '358', to_res: K}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8530405', seq: '358', to_res: K}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8557706', seq: '358', to_res: K}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10098515', seq: '359', to_res: A}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10098515', seq: '359', to_res: E}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '8530405', seq: '359', to_res: K}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '8557706', seq: '359', to_res: K}
- {entry_name: LSHR_RAT, from_res: I, pubmed: '10098515', seq: '360', to_res: V}
- {entry_name: LSHR_RAT, from_res: M, pubmed: '10098515', seq: '361', to_res: A}
- {entry_name: LSHR_RAT, from_res: G, pubmed: '10098515', seq: '362', to_res: A}
- {entry_name: LSHR_RAT, from_res: G, pubmed: '10098515', seq: '362', to_res: F}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '10098515', seq: '363', to_res: D}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '10098515', seq: '363', to_res: F}
- {entry_name: LSHR_RAT, from_res: R, pubmed: '8557706', seq: '367', to_res: E}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '9140087', seq: '394', to_res: E}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10393545', seq: '409', to_res: N}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10446904', seq: '409', to_res: N}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '11943741', seq: '409', to_res: N}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '8626807', seq: '409', to_res: N}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12667061', seq: '409', to_res: S}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '8557706', seq: '423', to_res: K}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '8614409', seq: '423', to_res: K}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8557706', seq: '427', to_res: D}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '443', to_res: S}
- {entry_name: LSHR_RAT, from_res: A, pubmed: '11041448', seq: '445', to_res: T}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '8672431', seq: '450', to_res: A}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10770485', seq: '455', to_res: D}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10770485', seq: '455', to_res: Q}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '10770485', seq: '455', to_res: S}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '12667061', seq: '457', to_res: A}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '10446904', seq: '461', to_res: R}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '9857020', seq: '461', to_res: R}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8383288', seq: '467', to_res: D}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '11943741', seq: '467', to_res: Q}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8383288', seq: '467', to_res: Q}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '8621442', seq: '467', to_res: Q}
- {entry_name: LSHR_RAT, from_res: E, pubmed: '9584216', seq: '467', to_res: Q}
- {entry_name: LSHR_RAT, from_res: R, pubmed: '10393545', seq: '468', to_res: H}
- {entry_name: LSHR_RAT, from_res: R, pubmed: '11943741', seq: '468', to_res: H}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '9140087', seq: '481', to_res: E}
- {entry_name: LSHR_RAT, from_res: R, pubmed: '9140087', seq: '485', to_res: E}
- {entry_name: LSHR_RAT, from_res: H, pubmed: '9140087', seq: '486', to_res: E}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '11859079', seq: '505', to_res: A}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '11859079', seq: '505', to_res: G}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '8672431', seq: '505', to_res: L}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8626807', seq: '514', to_res: D}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8557706', seq: '514', to_res: E}
- {entry_name: LSHR_RAT, from_res: I, pubmed: '8626807', seq: '517', to_res: D}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '8621442', seq: '518', to_res: S}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '8626807', seq: '519', to_res: D}
- {entry_name: LSHR_RAT, from_res: V, pubmed: '10847593', seq: '523', to_res: A}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '539', to_res: G}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '10446904', seq: '550', to_res: F}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '9857020', seq: '550', to_res: F}
- {entry_name: LSHR_RAT, from_res: R, pubmed: '9140087', seq: '552', to_res: E}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '9140087', seq: '554', to_res: S}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8977389', seq: '567', to_res: K}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12070159', seq: '568', to_res: G}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12070159', seq: '568', to_res: N}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12070159', seq: '582', to_res: A}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12141913', seq: '582', to_res: A}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10393545', seq: '582', to_res: G}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12667061', seq: '582', to_res: G}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '8631747', seq: '582', to_res: G}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '9038211', seq: '582', to_res: G}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12070159', seq: '582', to_res: H}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12070159', seq: '582', to_res: N}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12070159', seq: '582', to_res: Q}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10393545', seq: '582', to_res: Y}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10446904', seq: '582', to_res: Y}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '12667061', seq: '582', to_res: Y}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '9857020', seq: '582', to_res: Y}
- {entry_name: LSHR_RAT, from_res: M, pubmed: '8672431', seq: '586', to_res: L}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '8672431', seq: '588', to_res: L}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '8672431', seq: '588', to_res: Y}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '8672431', seq: '590', to_res: A}
- {entry_name: LSHR_RAT, from_res: A, pubmed: '11750736', seq: '593', to_res: G}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8631747', seq: '609', to_res: A}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8702611', seq: '609', to_res: A}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8557706', seq: '609', to_res: D}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8557706', seq: '609', to_res: E}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8702611', seq: '609', to_res: E}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '9788760', seq: '609', to_res: E}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8702611', seq: '609', to_res: L}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8557706', seq: '609', to_res: P}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8557706', seq: '609', to_res: Q}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '11859079', seq: '609', to_res: R}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8557706', seq: '609', to_res: R}
- {entry_name: LSHR_RAT, from_res: K, pubmed: '8702611', seq: '609', to_res: R}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '10770485', seq: '612', to_res: A}
- {entry_name: LSHR_RAT, from_res: V, pubmed: '10770485', seq: '613', to_res: A}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '8672431', seq: '616', to_res: A}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '10770485', seq: '617', to_res: L}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '8672431', seq: '617', to_res: L}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '8672431', seq: '617', to_res: Y}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '619', to_res: A}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12070159', seq: '619', to_res: A}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12667061', seq: '619', to_res: A}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '619', to_res: D}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12070159', seq: '619', to_res: D}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '619', to_res: K}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '619', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '619', to_res: R}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12070159', seq: '619', to_res: R}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '10770485', seq: '620', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '10770485', seq: '621', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '10770485', seq: '621', to_res: M}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '623', to_res: A}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12070159', seq: '623', to_res: A}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12667061', seq: '623', to_res: A}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '623', to_res: D}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12070159', seq: '623', to_res: D}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '623', to_res: K}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '623', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '12070159', seq: '623', to_res: Q}
- {entry_name: LSHR_RAT, from_res: N, pubmed: '10770485', seq: '623', to_res: R}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '10770485', seq: '624', to_res: L}
- {entry_name: LSHR_RAT, from_res: P, pubmed: '8672431', seq: '624', to_res: L}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '10770485', seq: '627', to_res: A}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '11943741', seq: '627', to_res: A}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '8672431', seq: '627', to_res: A}
- {entry_name: LSHR_RAT, from_res: Y, pubmed: '8672431', seq: '627', to_res: P}
- {entry_name: LSHR_RAT, from_res: F, pubmed: '10770485', seq: '630', to_res: A}
- {entry_name: LSHR_RAT, from_res: F, pubmed: '10770485', seq: '630', to_res: Y}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '10770485', seq: '631', to_res: A}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '10770485', seq: '631', to_res: Y}
- {entry_name: LSHR_RAT, from_res: D, pubmed: '10496955', seq: '637', to_res: N}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '10496955', seq: '639', to_res: A}
- {entry_name: LSHR_RAT, from_res: L, pubmed: '10496955', seq: '642', to_res: A}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '9099916', seq: '647', to_res: G}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '9099916', seq: '648', to_res: G}
- {entry_name: LSHR_RAT, from_res: C, pubmed: '9099916', seq: '648', to_res: S}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '9660797', seq: '661', to_res: A}
- {entry_name: LSHR_RAT, from_res: T, pubmed: '9013765', seq: '664', to_res: A}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '9660797', seq: '665', to_res: A}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '9660797', seq: '675', to_res: A}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '9660797', seq: '678', to_res: A}
- {entry_name: LSHR_RAT, from_res: S, pubmed: '9013765', seq: '685', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '14688279', seq: '292', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '14688279', seq: '293', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: S, pubmed: '15561704', seq: '295', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: S, pubmed: '15561704', seq: '295', to_res: D}
- {entry_name: LT4R1_HUMAN, from_res: V, pubmed: '12902330', seq: '301', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '12902330', seq: '304', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '14688279', seq: '304', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '15561704', seq: '304', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '12902330', seq: '305', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '14688279', seq: '305', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: L, pubmed: '15561704', seq: '305', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: T, pubmed: '12077128', seq: '308', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: T, pubmed: '14688279', seq: '308', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: T, pubmed: '12077128', seq: '308', to_res: P}
- {entry_name: LT4R1_HUMAN, from_res: T, pubmed: '12077128', seq: '308', to_res: S}
- {entry_name: LT4R1_HUMAN, from_res: S, pubmed: '12077128', seq: '310', to_res: A}
- {entry_name: LT4R1_HUMAN, from_res: S, pubmed: '12077128', seq: '310', to_res: P}
- {entry_name: MAS1L_HUMAN, from_res: W, pubmed: '11823449', seq: '8', to_res: R}
- {entry_name: MAS_HUMAN, from_res: N, pubmed: '15096488', seq: '64', to_res: D}
- {entry_name: MAS_HUMAN, from_res: N, pubmed: '9614131', seq: '182', to_res: S}
- {entry_name: MAS_RAT, from_res: S, pubmed: '9020189', seq: '73', to_res: A}
- {entry_name: MAS_RAT, from_res: S, pubmed: '9020189', seq: '73', to_res: D}
- {entry_name: MC3R_HUMAN, from_res: T, pubmed: '16123355', seq: '6', to_res: K}
- {entry_name: MC3R_HUMAN, from_res: V, pubmed: '15636422', seq: '81', to_res: I}
- {entry_name: MC3R_HUMAN, from_res: V, pubmed: '16123355', seq: '81', to_res: I}
- {entry_name: MC3R_HUMAN, from_res: F, pubmed: '9893984', seq: '112', to_res: A}
- {entry_name: MC3R_HUMAN, from_res: F, pubmed: '9893984', seq: '113', to_res: A}
- {entry_name: MC3R_HUMAN, from_res: F, pubmed: '12604699', seq: '157', to_res: I}
- {entry_name: MC3R_HUMAN, from_res: I, pubmed: '16123355', seq: '183', to_res: N}
- {entry_name: MC4R_HUMAN, from_res: H, pubmed: '11101306', seq: '6', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: H, pubmed: '16114870', seq: '6', to_res: R}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '12646666', seq: '11', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '16030156', seq: '11', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '10903341', seq: '11', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '12690102', seq: '11', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '10903341', seq: '18', to_res: C}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '12690102', seq: '18', to_res: C}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '10508193', seq: '30', to_res: F}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12499395', seq: '30', to_res: F}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12690102', seq: '30', to_res: F}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12499395', seq: '30', to_res: P}
- {entry_name: MC4R_HUMAN, from_res: Y, pubmed: '15951321', seq: '35', to_res: X}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '10508193', seq: '37', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '12499395', seq: '37', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '12690102', seq: '37', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '12959994', seq: '37', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: P, pubmed: '12959994', seq: '48', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: E, pubmed: '11101306', seq: '49', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: V, pubmed: '12499395', seq: '50', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: V, pubmed: '12959994', seq: '50', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '12646666', seq: '51', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '16030156', seq: '51', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12499395', seq: '58', to_res: C}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12959994', seq: '58', to_res: C}
- {entry_name: MC4R_HUMAN, from_res: E, pubmed: '11101306', seq: '61', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: N, pubmed: '12499395', seq: '62', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: N, pubmed: '12594226', seq: '62', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: N, pubmed: '12690102', seq: '62', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: N, pubmed: '12959994', seq: '62', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: P, pubmed: '10508193', seq: '78', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: P, pubmed: '12499395', seq: '78', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: P, pubmed: '12690102', seq: '78', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: P, pubmed: '12959994', seq: '78', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '90', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: G, pubmed: '12959994', seq: '98', to_res: R}
- {entry_name: MC4R_HUMAN, from_res: E, pubmed: '11101306', seq: '100', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12499395', seq: '102', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '16030156', seq: '102', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '16030156', seq: '102', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12499395', seq: '103', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: V, pubmed: '16030156', seq: '103', to_res: I}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '10508193', seq: '112', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '10903341', seq: '112', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '12646666', seq: '112', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '12690102', seq: '112', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '16030156', seq: '112', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '122', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '12604699', seq: '122', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '122', to_res: N}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12604699', seq: '125', to_res: F}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '126', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '16114870', seq: '126', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '126', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '126', to_res: N}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '126', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12499395', seq: '127', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '16114870', seq: '129', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: C, pubmed: '11101306', seq: '130', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '10903341', seq: '137', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12604699', seq: '137', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12690102', seq: '137', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '10903341', seq: '150', to_res: I}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '12690102', seq: '150', to_res: I}
- {entry_name: MC4R_HUMAN, from_res: A, pubmed: '16030156', seq: '154', to_res: D}
- {entry_name: MC4R_HUMAN, from_res: Y, pubmed: '12959994', seq: '157', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: K, pubmed: '11101306', seq: '164', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '11101306', seq: '165', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '12499395', seq: '165', to_res: Q}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '12690102', seq: '165', to_res: Q}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '10508193', seq: '165', to_res: W}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '10903341', seq: '165', to_res: W}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '12499395', seq: '165', to_res: W}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '12690102', seq: '165', to_res: W}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '10903341', seq: '170', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12499395', seq: '170', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12690102', seq: '170', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12959994', seq: '170', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '12604699', seq: '184', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '12604699', seq: '184', to_res: M}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '12604699', seq: '184', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12604699', seq: '190', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12604699', seq: '191', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: C, pubmed: '11101306', seq: '196', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '11101306', seq: '199', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: M, pubmed: '11101306', seq: '200', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: M, pubmed: '12646666', seq: '200', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: M, pubmed: '16030156', seq: '200', to_res: V}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '16030156', seq: '202', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '11101306', seq: '203', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: M, pubmed: '11101306', seq: '204', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: H, pubmed: '11101306', seq: '214', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: N, pubmed: '16030156', seq: '240', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: A, pubmed: '12499395', seq: '244', to_res: E}
- {entry_name: MC4R_HUMAN, from_res: L, pubmed: '10903341', seq: '250', to_res: Q}
- {entry_name: MC4R_HUMAN, from_res: L, pubmed: '12499395', seq: '250', to_res: Q}
- {entry_name: MC4R_HUMAN, from_res: L, pubmed: '12690102', seq: '250', to_res: Q}
- {entry_name: MC4R_HUMAN, from_res: L, pubmed: '16030156', seq: '250', to_res: Q}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '10508193', seq: '251', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '10903341', seq: '251', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '16030156', seq: '251', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: G, pubmed: '10508193', seq: '252', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: G, pubmed: '12499395', seq: '252', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: G, pubmed: '12690102', seq: '252', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: V, pubmed: '12499395', seq: '253', to_res: I}
- {entry_name: MC4R_HUMAN, from_res: V, pubmed: '12690102', seq: '253', to_res: I}
- {entry_name: MC4R_HUMAN, from_res: W, pubmed: '11101306', seq: '258', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: W, pubmed: '16114870', seq: '258', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '11101306', seq: '261', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '12604699', seq: '261', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '16114870', seq: '262', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: H, pubmed: '11101306', seq: '264', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: H, pubmed: '16114870', seq: '264', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '11101306', seq: '267', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '12604699', seq: '267', to_res: L}
- {entry_name: MC4R_HUMAN, from_res: Y, pubmed: '11101306', seq: '268', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: Y, pubmed: '16114870', seq: '268', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: C, pubmed: '15115780', seq: '271', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: C, pubmed: '12690102', seq: '271', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: C, pubmed: '12499395', seq: '271', to_res: Y}
- {entry_name: MC4R_HUMAN, from_res: C, pubmed: '12959994', seq: '271', to_res: Y}
- {entry_name: MC4R_HUMAN, from_res: C, pubmed: '15115780', seq: '271', to_res: Y}
- {entry_name: MC4R_HUMAN, from_res: N, pubmed: '12959994', seq: '274', to_res: S}
- {entry_name: MC4R_HUMAN, from_res: H, pubmed: '11101306', seq: '283', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '12604699', seq: '284', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: N, pubmed: '11101306', seq: '285', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '16030156', seq: '295', to_res: P}
- {entry_name: MC4R_HUMAN, from_res: D, pubmed: '11101306', seq: '298', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: P, pubmed: '12499395', seq: '299', to_res: H}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '10903341', seq: '301', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12690102', seq: '301', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '11101306', seq: '305', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12639913', seq: '306', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: R, pubmed: '15865442', seq: '310', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: K, pubmed: '15865442', seq: '311', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '12639913', seq: '312', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: T, pubmed: '15865442', seq: '312', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: F, pubmed: '15865442', seq: '313', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: K, pubmed: '15865442', seq: '314', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: E, pubmed: '15865442', seq: '315', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '15865442', seq: '316', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12594226', seq: '316', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '15865442', seq: '317', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '10508193', seq: '317', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12499395', seq: '317', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12594226', seq: '317', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: I, pubmed: '12690102', seq: '317', to_res: T}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12639913', seq: '329', to_res: A}
- {entry_name: MC4R_HUMAN, from_res: S, pubmed: '12639913', seq: '330', to_res: A}
- {entry_name: MC4R_MOUSE, from_res: Q, pubmed: '15951321', seq: '43', to_res: X}
- {entry_name: MC4R_MOUSE, from_res: V, pubmed: '12690102', seq: '103', to_res: I}
- {entry_name: MC4R_MOUSE, from_res: T, pubmed: '15951321', seq: '112', to_res: M}
- {entry_name: MC4R_MOUSE, from_res: W, pubmed: '15951321', seq: '174', to_res: C}
- {entry_name: MC4R_MOUSE, from_res: A, pubmed: '15951321', seq: '175', to_res: T}
- {entry_name: MC4R_MOUSE, from_res: I, pubmed: '15951321', seq: '317', to_res: T}
- {entry_name: MC4R_MOUSE, from_res: I, pubmed: '15951321', seq: '317', to_res: V}
- {entry_name: MC4R_PIG, from_res: D, pubmed: '14732454', seq: '298', to_res: N}
- {entry_name: MC4R_RAT, from_res: F, pubmed: '10358030', seq: '267', to_res: L}
- {entry_name: MC4R_RAT, from_res: Y, pubmed: '10358030', seq: '268', to_res: I}
- {entry_name: MC4R_RAT, from_res: S, pubmed: '10358030', seq: '270', to_res: T}
- {entry_name: MC4R_RAT, from_res: Q, pubmed: '10358030', seq: '273', to_res: T}
- {entry_name: MC4R_RAT, from_res: M, pubmed: '10358030', seq: '281', to_res: T}
- {entry_name: MC5R_HUMAN, from_res: Q, pubmed: '9240466', seq: '235', to_res: K}
- {entry_name: MC5R_HUMAN, from_res: R, pubmed: '9240466', seq: '272', to_res: C}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '12804782', seq: '166', to_res: D}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '12804782', seq: '166', to_res: E}
- {entry_name: MGR1_HUMAN, from_res: D, pubmed: '12804782', seq: '191', to_res: N}
- {entry_name: MGR1_HUMAN, from_res: E, pubmed: '12804782', seq: '238', to_res: Q}
- {entry_name: MGR1_HUMAN, from_res: D, pubmed: '12804782', seq: '242', to_res: N}
- {entry_name: MGR1_HUMAN, from_res: K, pubmed: '12804782', seq: '260', to_res: Q}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '12223474', seq: '408', to_res: A}
- {entry_name: MGR1_HUMAN, from_res: T, pubmed: '11461909', seq: '620', to_res: A}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '11461909', seq: '627', to_res: G}
- {entry_name: MGR1_HUMAN, from_res: T, pubmed: '11461909', seq: '679', to_res: A}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '11461909', seq: '689', to_res: G}
- {entry_name: MGR1_HUMAN, from_res: T, pubmed: '11461909', seq: '695', to_res: A}
- {entry_name: MGR1_HUMAN, from_res: D, pubmed: '11461909', seq: '854', to_res: A}
- {entry_name: MGR1_HUMAN, from_res: D, pubmed: '11461909', seq: '854', to_res: G}
- {entry_name: MGR1_HUMAN, from_res: D, pubmed: '11461909', seq: '854', to_res: T}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '11461909', seq: '892', to_res: A}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '11461909', seq: '940', to_res: A}
- {entry_name: MGR1_HUMAN, from_res: S, pubmed: '11461909', seq: '950', to_res: G}
- {entry_name: MGR1_MOUSE, from_res: C, pubmed: '10874032', seq: '67', to_res: A}
- {entry_name: MGR1_MOUSE, from_res: C, pubmed: '10874032', seq: '109', to_res: A}
- {entry_name: MGR1_MOUSE, from_res: C, pubmed: '10874032', seq: '140', to_res: A}
- {entry_name: MGR1_MOUSE, from_res: D, pubmed: '15305863', seq: '854', to_res: T}
- {entry_name: MGR1_RAT, from_res: V, pubmed: '10945991', seq: '2', to_res: R}
- {entry_name: MGR1_RAT, from_res: C, pubmed: '10945991', seq: '67', to_res: S}
- {entry_name: MGR1_RAT, from_res: Y, pubmed: '15466247', seq: '74', to_res: A}
- {entry_name: MGR1_RAT, from_res: Y, pubmed: '15466247', seq: '74', to_res: E}
- {entry_name: MGR1_RAT, from_res: R, pubmed: '14764583', seq: '106', to_res: A}
- {entry_name: MGR1_RAT, from_res: R, pubmed: '15870073', seq: '106', to_res: A}
- {entry_name: MGR1_RAT, from_res: C, pubmed: '10945991', seq: '109', to_res: S}
- {entry_name: MGR1_RAT, from_res: S, pubmed: '10945991', seq: '119', to_res: C}
- {entry_name: MGR1_RAT, from_res: S, pubmed: '10945991', seq: '126', to_res: C}
- {entry_name: MGR1_RAT, from_res: S, pubmed: '10945991', seq: '129', to_res: C}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '10945991', seq: '134', to_res: C}
- {entry_name: MGR1_RAT, from_res: C, pubmed: '15466247', seq: '140', to_res: A}
- {entry_name: MGR1_RAT, from_res: C, pubmed: '15466247', seq: '140', to_res: E}
- {entry_name: MGR1_RAT, from_res: C, pubmed: '10945991', seq: '140', to_res: S}
- {entry_name: MGR1_RAT, from_res: D, pubmed: '10945991', seq: '143', to_res: C}
- {entry_name: MGR1_RAT, from_res: T, pubmed: '10945991', seq: '146', to_res: C}
- {entry_name: MGR1_RAT, from_res: T, pubmed: '10945991', seq: '152', to_res: C}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '14764583', seq: '220', to_res: R}
- {entry_name: MGR1_RAT, from_res: H, pubmed: '11133983', seq: '231', to_res: A}
- {entry_name: MGR1_RAT, from_res: H, pubmed: '11133983', seq: '231', to_res: E}
- {entry_name: MGR1_RAT, from_res: E, pubmed: '11133983', seq: '233', to_res: A}
- {entry_name: MGR1_RAT, from_res: E, pubmed: '11133983', seq: '233', to_res: H}
- {entry_name: MGR1_RAT, from_res: E, pubmed: '11133983', seq: '238', to_res: A}
- {entry_name: MGR1_RAT, from_res: E, pubmed: '11133983', seq: '238', to_res: H}
- {entry_name: MGR1_RAT, from_res: H, pubmed: '11133983', seq: '257', to_res: A}
- {entry_name: MGR1_RAT, from_res: D, pubmed: '11133983', seq: '259', to_res: A}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '11133983', seq: '260', to_res: A}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '11133983', seq: '260', to_res: H}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '12912984', seq: '283', to_res: A}
- {entry_name: MGR1_RAT, from_res: S, pubmed: '15184361', seq: '317', to_res: R}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '9488690', seq: '690', to_res: A}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '15870073', seq: '691', to_res: A}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '15870073', seq: '692', to_res: A}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '9488690', seq: '692', to_res: G}
- {entry_name: MGR1_RAT, from_res: T, pubmed: '9488690', seq: '695', to_res: A}
- {entry_name: MGR1_RAT, from_res: T, pubmed: '9488690', seq: '695', to_res: E}
- {entry_name: MGR1_RAT, from_res: R, pubmed: '9488690', seq: '696', to_res: G}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '9488690', seq: '697', to_res: M}
- {entry_name: MGR1_RAT, from_res: P, pubmed: '9488690', seq: '698', to_res: R}
- {entry_name: MGR1_RAT, from_res: S, pubmed: '9488690', seq: '702', to_res: R}
- {entry_name: MGR1_RAT, from_res: S, pubmed: '9488690', seq: '702', to_res: T}
- {entry_name: MGR1_RAT, from_res: A, pubmed: '9488690', seq: '705', to_res: S}
- {entry_name: MGR1_RAT, from_res: R, pubmed: '9488690', seq: '775', to_res: K}
- {entry_name: MGR1_RAT, from_res: R, pubmed: '9488690', seq: '775', to_res: W}
- {entry_name: MGR1_RAT, from_res: P, pubmed: '9488690', seq: '778', to_res: Q}
- {entry_name: MGR1_RAT, from_res: A, pubmed: '9488690', seq: '779', to_res: E}
- {entry_name: MGR1_RAT, from_res: F, pubmed: '9488690', seq: '781', to_res: P}
- {entry_name: MGR1_RAT, from_res: F, pubmed: '9488690', seq: '781', to_res: S}
- {entry_name: MGR1_RAT, from_res: N, pubmed: '9488690', seq: '782', to_res: I}
- {entry_name: MGR1_RAT, from_res: E, pubmed: '9488690', seq: '783', to_res: Q}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '11896159', seq: '879', to_res: A}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '9417099', seq: '879', to_res: M}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '11896159', seq: '880', to_res: A}
- {entry_name: MGR1_RAT, from_res: K, pubmed: '9417099', seq: '880', to_res: M}
- {entry_name: MGR2_RAT, from_res: S, pubmed: '10908604', seq: '601', to_res: A}
- {entry_name: MGR2_RAT, from_res: S, pubmed: '10908604', seq: '675', to_res: A}
- {entry_name: MGR2_RAT, from_res: S, pubmed: '10908604', seq: '837', to_res: A}
- {entry_name: MGR2_RAT, from_res: S, pubmed: '10908604', seq: '843', to_res: A}
- {entry_name: MGR2_RAT, from_res: S, pubmed: '10908604', seq: '843', to_res: G}
- {entry_name: MGR3_MOUSE, from_res: R, pubmed: '9407094', seq: '59', to_res: P}
- {entry_name: MGR3_RAT, from_res: R, pubmed: '12887692', seq: '64', to_res: A}
- {entry_name: MGR3_RAT, from_res: R, pubmed: '12887692', seq: '68', to_res: A}
- {entry_name: MGR3_RAT, from_res: Y, pubmed: '12887692', seq: '150', to_res: A}
- {entry_name: MGR3_RAT, from_res: S, pubmed: '12887692', seq: '151', to_res: A}
- {entry_name: MGR3_RAT, from_res: T, pubmed: '12887692', seq: '174', to_res: A}
- {entry_name: MGR3_RAT, from_res: D, pubmed: '12887692', seq: '194', to_res: A}
- {entry_name: MGR3_RAT, from_res: Y, pubmed: '12887692', seq: '222', to_res: A}
- {entry_name: MGR3_RAT, from_res: R, pubmed: '12887692', seq: '277', to_res: A}
- {entry_name: MGR3_RAT, from_res: D, pubmed: '12887692', seq: '301', to_res: A}
- {entry_name: MGR4_HUMAN, from_res: V, pubmed: '11525421', seq: '797', to_res: I}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '71', to_res: A}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '71', to_res: Y}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '74', to_res: A}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '15184361', seq: '74', to_res: A}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '74', to_res: N}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '74', to_res: Q}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '74', to_res: Y}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '15184361', seq: '74', to_res: Y}
- {entry_name: MGR4_RAT, from_res: H, pubmed: '11744707', seq: '77', to_res: Q}
- {entry_name: MGR4_RAT, from_res: G, pubmed: '11744707', seq: '158', to_res: A}
- {entry_name: MGR4_RAT, from_res: D, pubmed: '11744707', seq: '202', to_res: A}
- {entry_name: MGR4_RAT, from_res: Y, pubmed: '11744707', seq: '230', to_res: A}
- {entry_name: MGR4_RAT, from_res: R, pubmed: '11744707', seq: '258', to_res: A}
- {entry_name: MGR4_RAT, from_res: N, pubmed: '11744707', seq: '286', to_res: A}
- {entry_name: MGR4_RAT, from_res: E, pubmed: '11744707', seq: '287', to_res: A}
- {entry_name: MGR4_RAT, from_res: E, pubmed: '15184361', seq: '287', to_res: G}
- {entry_name: MGR4_RAT, from_res: D, pubmed: '11744707', seq: '312', to_res: A}
- {entry_name: MGR4_RAT, from_res: S, pubmed: '15184361', seq: '313', to_res: G}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '317', to_res: A}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '15184361', seq: '317', to_res: R}
- {entry_name: MGR4_RAT, from_res: K, pubmed: '11744707', seq: '405', to_res: A}
- {entry_name: MGR5_HUMAN, from_res: C, pubmed: '11125023', seq: '57', to_res: S}
- {entry_name: MGR5_HUMAN, from_res: C, pubmed: '11125023', seq: '93', to_res: S}
- {entry_name: MGR5_HUMAN, from_res: C, pubmed: '11125023', seq: '99', to_res: S}
- {entry_name: MGR5_HUMAN, from_res: C, pubmed: '11125023', seq: '129', to_res: S}
- {entry_name: MGR5_HUMAN, from_res: G, pubmed: '10934211', seq: '650', to_res: L}
- {entry_name: MGR5_HUMAN, from_res: I, pubmed: '10934211', seq: '651', to_res: V}
- {entry_name: MGR5_HUMAN, from_res: S, pubmed: '10934211', seq: '658', to_res: C}
- {entry_name: MGR5_HUMAN, from_res: M, pubmed: '10934211', seq: '802', to_res: T}
- {entry_name: MGR5_HUMAN, from_res: S, pubmed: '10934211', seq: '805', to_res: A}
- {entry_name: MGR5_HUMAN, from_res: A, pubmed: '10934211', seq: '810', to_res: G}
- {entry_name: MGR5_HUMAN, from_res: A, pubmed: '10934211', seq: '810', to_res: V}
- {entry_name: MGR5_HUMAN, from_res: S, pubmed: '12681368', seq: '840', to_res: A}
- {entry_name: MGR5_RAT, from_res: N, pubmed: '12764131', seq: '88', to_res: G}
- {entry_name: MGR5_RAT, from_res: N, pubmed: '12764131', seq: '209', to_res: A}
- {entry_name: MGR5_RAT, from_res: N, pubmed: '12764131', seq: '377', to_res: L}
- {entry_name: MGR5_RAT, from_res: N, pubmed: '12764131', seq: '381', to_res: A}
- {entry_name: MGR5_RAT, from_res: N, pubmed: '12764131', seq: '444', to_res: G}
- {entry_name: MGR5_RAT, from_res: S, pubmed: '9443943', seq: '613', to_res: G}
- {entry_name: MGR5_RAT, from_res: N, pubmed: '12764131', seq: '733', to_res: G}
- {entry_name: MGR5_RAT, from_res: F, pubmed: '16352303', seq: '787', to_res: A}
- {entry_name: MGR5_RAT, from_res: S, pubmed: '15894802', seq: '834', to_res: A}
- {entry_name: MGR5_RAT, from_res: T, pubmed: '15894802', seq: '837', to_res: A}
- {entry_name: MGR5_RAT, from_res: T, pubmed: '15894802', seq: '838', to_res: A}
- {entry_name: MGR5_RAT, from_res: S, pubmed: '15894802', seq: '839', to_res: A}
- {entry_name: MGR5_RAT, from_res: T, pubmed: '12681368', seq: '840', to_res: A}
- {entry_name: MGR5_RAT, from_res: T, pubmed: '15894802', seq: '840', to_res: A}
- {entry_name: MGR5_RAT, from_res: T, pubmed: '15894802', seq: '840', to_res: D}
- {entry_name: MGR5_RAT, from_res: T, pubmed: '15894802', seq: '840', to_res: S}
- {entry_name: MGR5_RAT, from_res: G, pubmed: '12681368', seq: '847', to_res: A}
- {entry_name: MGR5_RAT, from_res: D, pubmed: '12764131', seq: '848', to_res: E}
- {entry_name: MGR5_RAT, from_res: S, pubmed: '15894802', seq: '853', to_res: A}
- {entry_name: MGR5_RAT, from_res: S, pubmed: '15894802', seq: '853', to_res: T}
- {entry_name: MGR6_RABIT, from_res: E, pubmed: '14764583', seq: '532', to_res: A}
- {entry_name: MGR7_RAT, from_res: S, pubmed: '12021391', seq: '862', to_res: A}
- {entry_name: MGR7_RAT, from_res: S, pubmed: '12021391', seq: '862', to_res: E}
- {entry_name: MGR7_RAT, from_res: S, pubmed: '12021391', seq: '873', to_res: A}
- {entry_name: MGR7_RAT, from_res: S, pubmed: '12021391', seq: '877', to_res: A}
- {entry_name: MGR7_RAT, from_res: S, pubmed: '12021391', seq: '881', to_res: A}
- {entry_name: MGR8_RAT, from_res: R, pubmed: '11744707', seq: '75', to_res: A}
- {entry_name: MLO_HORVU, from_res: L, pubmed: '15703292', seq: '420', to_res: R}
- {entry_name: MLO_HORVU, from_res: W, pubmed: '15703292', seq: '423', to_res: R}
- {entry_name: MRGA6_MOUSE, from_res: V, pubmed: '15096488', seq: '126', to_res: L}
- {entry_name: MRGRF_HUMAN, from_res: I, pubmed: '11562434', seq: '38', to_res: F}
- {entry_name: MRGRF_HUMAN, from_res: R, pubmed: '9737977', seq: '312', to_res: K}
- {entry_name: MSHR_CHICK, from_res: D, pubmed: '9300652', seq: '37', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '35', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '35', to_res: S}
- {entry_name: MSHR_HUMAN, from_res: V, pubmed: '10403794', seq: '60', to_res: L}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '75', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '78', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '79', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: S, pubmed: '9640562', seq: '83', to_res: F}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '8894704', seq: '84', to_res: E}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '8990005', seq: '84', to_res: E}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9640562', seq: '84', to_res: E}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '15482480', seq: '84', to_res: E}
- {entry_name: MSHR_HUMAN, from_res: N, pubmed: '8894704', seq: '91', to_res: D}
- {entry_name: MSHR_HUMAN, from_res: V, pubmed: '8894704', seq: '92', to_res: M}
- {entry_name: MSHR_HUMAN, from_res: V, pubmed: '8990005', seq: '92', to_res: M}
- {entry_name: MSHR_HUMAN, from_res: V, pubmed: '9640562', seq: '92', to_res: M}
- {entry_name: MSHR_HUMAN, from_res: V, pubmed: '15482480', seq: '92', to_res: M}
- {entry_name: MSHR_HUMAN, from_res: E, pubmed: '9287296', seq: '94', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: E, pubmed: '9287296', seq: '94', to_res: K}
- {entry_name: MSHR_HUMAN, from_res: E, pubmed: '9640562', seq: '94', to_res: K}
- {entry_name: MSHR_HUMAN, from_res: E, pubmed: '9640562', seq: '94', to_res: R}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '10403794', seq: '117', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9089659', seq: '117', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9287296', seq: '117', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9640562', seq: '117', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9287296', seq: '121', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9287296', seq: '121', to_res: K}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9287296', seq: '121', to_res: L}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9287296', seq: '121', to_res: N}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '125', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '9640562', seq: '125', to_res: R}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '133', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: R, pubmed: '10403794', seq: '142', to_res: H}
- {entry_name: MSHR_HUMAN, from_res: R, pubmed: '10403794', seq: '151', to_res: C}
- {entry_name: MSHR_HUMAN, from_res: R, pubmed: '9571181', seq: '151', to_res: C}
- {entry_name: MSHR_HUMAN, from_res: R, pubmed: '10403794', seq: '160', to_res: W}
- {entry_name: MSHR_HUMAN, from_res: R, pubmed: '15482480', seq: '163', to_res: Q}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9287296', seq: '175', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9287296', seq: '179', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9640562', seq: '179', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: Y, pubmed: '9287296', seq: '182', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: Y, pubmed: '9287296', seq: '183', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '8605020', seq: '184', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '191', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9287296', seq: '195', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9287296', seq: '196', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: H, pubmed: '9640562', seq: '209', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '215', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '253', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9287296', seq: '257', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9287296', seq: '258', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: H, pubmed: '10403794', seq: '260', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: H, pubmed: '8060302', seq: '260', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: H, pubmed: '9089659', seq: '260', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: H, pubmed: '9287296', seq: '260', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: H, pubmed: '9640562', seq: '260', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '267', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '267', to_res: S}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '273', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '273', to_res: S}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '275', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '275', to_res: S}
- {entry_name: MSHR_HUMAN, from_res: F, pubmed: '9287296', seq: '280', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: N, pubmed: '9287296', seq: '281', to_res: A}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '289', to_res: G}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '10403794', seq: '294', to_res: H}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '8894704', seq: '294', to_res: H}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '9640562', seq: '294', to_res: H}
- {entry_name: MSHR_HUMAN, from_res: D, pubmed: '15482480', seq: '294', to_res: H}
- {entry_name: MSHR_HUMAN, from_res: C, pubmed: '11237737', seq: '315', to_res: G}
- {entry_name: MSHR_MOUSE, from_res: E, pubmed: '12653999', seq: '92', to_res: K}
- {entry_name: MSHR_MOUSE, from_res: E, pubmed: '9287296', seq: '92', to_res: K}
- {entry_name: MSHR_MOUSE, from_res: E, pubmed: '9892731', seq: '92', to_res: K}
- {entry_name: MSHR_SHEEP, from_res: M, pubmed: '9892731', seq: '73', to_res: K}
- {entry_name: MSHR_SHEEP, from_res: D, pubmed: '9892731', seq: '121', to_res: N}
- {entry_name: MTR1A_HUMAN, from_res: S, pubmed: '9892008', seq: '6', to_res: K}
- {entry_name: MTR1A_HUMAN, from_res: R, pubmed: '10471411', seq: '54', to_res: W}
- {entry_name: MTR1A_HUMAN, from_res: M, pubmed: '12732358', seq: '107', to_res: D}
- {entry_name: MTR1A_HUMAN, from_res: M, pubmed: '12732358', seq: '107', to_res: T}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '11463855', seq: '124', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '12732358', seq: '124', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '9712731', seq: '124', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '11463855', seq: '124', to_res: D}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '12732358', seq: '124', to_res: D}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '11463855', seq: '124', to_res: E}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '12732358', seq: '124', to_res: E}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '11463855', seq: '124', to_res: K}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '12732358', seq: '124', to_res: K}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '11463855', seq: '124', to_res: L}
- {entry_name: MTR1A_HUMAN, from_res: N, pubmed: '12732358', seq: '124', to_res: L}
- {entry_name: MTR1A_HUMAN, from_res: C, pubmed: '15978051', seq: '127', to_res: S}
- {entry_name: MTR1A_HUMAN, from_res: C, pubmed: '15978051', seq: '130', to_res: S}
- {entry_name: MTR1A_HUMAN, from_res: A, pubmed: '10471411', seq: '157', to_res: V}
- {entry_name: MTR1A_HUMAN, from_res: V, pubmed: '12732358', seq: '192', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: V, pubmed: '12732358', seq: '192', to_res: T}
- {entry_name: MTR1A_HUMAN, from_res: H, pubmed: '12732358', seq: '195', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: H, pubmed: '9712731', seq: '195', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: P, pubmed: '12732358', seq: '253', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: A, pubmed: '12732358', seq: '279', to_res: S}
- {entry_name: MTR1A_HUMAN, from_res: S, pubmed: '12732358', seq: '280', to_res: A}
- {entry_name: MTR1A_HUMAN, from_res: S, pubmed: '12732358', seq: '280', to_res: F}
- {entry_name: MTR1A_HUMAN, from_res: A, pubmed: '12732358', seq: '284', to_res: G}
- {entry_name: MTR1A_SHEEP, from_res: V, pubmed: '9344844', seq: '208', to_res: A}
- {entry_name: MTR1A_SHEEP, from_res: V, pubmed: '9344844', seq: '208', to_res: L}
- {entry_name: MTR1A_SHEEP, from_res: H, pubmed: '9344844', seq: '211', to_res: F}
- {entry_name: MTR1A_SHEEP, from_res: H, pubmed: '9344844', seq: '211', to_res: L}
- {entry_name: MTR1B_HUMAN, from_res: S, pubmed: '12826274', seq: '123', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: S, pubmed: '12826274', seq: '127', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: S, pubmed: '12826274', seq: '127', to_res: N}
- {entry_name: MTR1B_HUMAN, from_res: N, pubmed: '12826274', seq: '175', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: N, pubmed: '12826274', seq: '175', to_res: H}
- {entry_name: MTR1B_HUMAN, from_res: V, pubmed: '15525337', seq: '205', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: H, pubmed: '12826274', seq: '208', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: H, pubmed: '12826274', seq: '208', to_res: F}
- {entry_name: MTR1B_HUMAN, from_res: F, pubmed: '15525337', seq: '209', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: F, pubmed: '12826274', seq: '257', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: F, pubmed: '12826274', seq: '257', to_res: W}
- {entry_name: MTR1B_HUMAN, from_res: W, pubmed: '12826274', seq: '264', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: W, pubmed: '12826274', seq: '264', to_res: S}
- {entry_name: MTR1B_HUMAN, from_res: G, pubmed: '15525337', seq: '271', to_res: T}
- {entry_name: MTR1B_HUMAN, from_res: L, pubmed: '15525337', seq: '272', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: S, pubmed: '12826274', seq: '293', to_res: A}
- {entry_name: MTR1B_HUMAN, from_res: Y, pubmed: '15525337', seq: '298', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: E, pubmed: '9389383', seq: '97', to_res: V}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9261122', seq: '108', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9389383', seq: '108', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: N, pubmed: '9261122', seq: '109', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '11279104', seq: '111', to_res: S}
- {entry_name: NK1R_HUMAN, from_res: P, pubmed: '9261122', seq: '112', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: P, pubmed: '9443945', seq: '112', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: P, pubmed: '10908293', seq: '112', to_res: D}
- {entry_name: NK1R_HUMAN, from_res: P, pubmed: '9261122', seq: '112', to_res: D}
- {entry_name: NK1R_HUMAN, from_res: P, pubmed: '10908293', seq: '112', to_res: H}
- {entry_name: NK1R_HUMAN, from_res: P, pubmed: '9443945', seq: '112', to_res: H}
- {entry_name: NK1R_HUMAN, from_res: V, pubmed: '1281470', seq: '116', to_res: L}
- {entry_name: NK1R_HUMAN, from_res: W, pubmed: '10658591', seq: '155', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: W, pubmed: '10658591', seq: '155', to_res: F}
- {entry_name: NK1R_HUMAN, from_res: A, pubmed: '9389383', seq: '162', to_res: L}
- {entry_name: NK1R_HUMAN, from_res: Q, pubmed: '10658591', seq: '165', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Q, pubmed: '7536886', seq: '165', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Q, pubmed: '9261122', seq: '165', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Q, pubmed: '9389383', seq: '165', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: G, pubmed: '9786514', seq: '166', to_res: C}
- {entry_name: NK1R_HUMAN, from_res: T, pubmed: '9389383', seq: '170', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: E, pubmed: '8183248', seq: '172', to_res: K}
- {entry_name: NK1R_HUMAN, from_res: E, pubmed: '9389383', seq: '172', to_res: Q}
- {entry_name: NK1R_HUMAN, from_res: Y, pubmed: '15452552', seq: '192', to_res: H}
- {entry_name: NK1R_HUMAN, from_res: E, pubmed: '10658591', seq: '193', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: E, pubmed: '10658591', seq: '193', to_res: K}
- {entry_name: NK1R_HUMAN, from_res: E, pubmed: '10214937', seq: '193', to_res: L}
- {entry_name: NK1R_HUMAN, from_res: E, pubmed: '9389383', seq: '193', to_res: Q}
- {entry_name: NK1R_HUMAN, from_res: V, pubmed: '10214937', seq: '195', to_res: R}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '10658591', seq: '197', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '7536886', seq: '197', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9261122', seq: '197', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9389383', seq: '197', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '10658591', seq: '197', to_res: F}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '10658591', seq: '197', to_res: Q}
- {entry_name: NK1R_HUMAN, from_res: I, pubmed: '9261122', seq: '198', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: V, pubmed: '9261122', seq: '200', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: T, pubmed: '9261122', seq: '201', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: T, pubmed: '9443945', seq: '201', to_res: I}
- {entry_name: NK1R_HUMAN, from_res: L, pubmed: '10658591', seq: '203', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: I, pubmed: '10658591', seq: '204', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Y, pubmed: '8845375', seq: '216', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '10658591', seq: '264', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '9261122', seq: '264', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '10658591', seq: '264', to_res: Y}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '9261122', seq: '264', to_res: Y}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '10658591', seq: '265', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '7536886', seq: '265', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9261122', seq: '265', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9389383', seq: '265', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9443945', seq: '265', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: H, pubmed: '9261122', seq: '265', to_res: F}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '10658591', seq: '267', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '9261122', seq: '267', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '10658591', seq: '267', to_res: Y}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '9261122', seq: '267', to_res: Y}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '9261122', seq: '268', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: F, pubmed: '9389383', seq: '268', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Y, pubmed: '10658591', seq: '272', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Y, pubmed: '8183248', seq: '272', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Y, pubmed: '9261122', seq: '272', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: I, pubmed: '10658591', seq: '283', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Q, pubmed: '9389383', seq: '284', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: Y, pubmed: '10658591', seq: '287', to_res: F}
- {entry_name: NK1R_HUMAN, from_res: I, pubmed: '9261122', seq: '290', to_res: A}
- {entry_name: NK1R_HUMAN, from_res: I, pubmed: '1281470', seq: '290', to_res: S}
- {entry_name: NK1R_HUMAN, from_res: T, pubmed: '12464618', seq: '339', to_res: A}
- {entry_name: NK1R_RAT, from_res: L, pubmed: '7509441', seq: '116', to_res: V}
- {entry_name: NK1R_RAT, from_res: M, pubmed: '11108840', seq: '174', to_res: A}
- {entry_name: NK1R_RAT, from_res: M, pubmed: '11108840', seq: '181', to_res: A}
- {entry_name: NK1R_RAT, from_res: C, pubmed: '8567643', seq: '199', to_res: S}
- {entry_name: NK1R_RAT, from_res: S, pubmed: '7509441', seq: '290', to_res: I}
- {entry_name: NK1R_RAT, from_res: Y, pubmed: '8999947', seq: '305', to_res: A}
- {entry_name: NK1R_RAT, from_res: Y, pubmed: '8999947', seq: '305', to_res: F}
- {entry_name: NK1R_RAT, from_res: Y, pubmed: '8999947', seq: '331', to_res: A}
- {entry_name: NK1R_RAT, from_res: K, pubmed: '8999947', seq: '337', to_res: A}
- {entry_name: NK1R_RAT, from_res: S, pubmed: '8999947', seq: '338', to_res: G}
- {entry_name: NK1R_RAT, from_res: T, pubmed: '8999947', seq: '339', to_res: A}
- {entry_name: NK1R_RAT, from_res: Y, pubmed: '8999947', seq: '341', to_res: A}
- {entry_name: NK1R_RAT, from_res: S, pubmed: '8999947', seq: '347', to_res: A}
- {entry_name: NK1R_RAT, from_res: Y, pubmed: '8999947', seq: '349', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: T, pubmed: '11489908', seq: '24', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: F, pubmed: '11489908', seq: '26', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: N, pubmed: '10085227', seq: '51', to_res: H}
- {entry_name: NK2R_HUMAN, from_res: N, pubmed: '10085227', seq: '51', to_res: S}
- {entry_name: NK2R_HUMAN, from_res: D, pubmed: '10085227', seq: '79', to_res: E}
- {entry_name: NK2R_HUMAN, from_res: N, pubmed: '11489908', seq: '86', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: N, pubmed: '11489908', seq: '97', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: W, pubmed: '11489908', seq: '99', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: Q, pubmed: '11489908', seq: '109', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: Q, pubmed: '7961636', seq: '109', to_res: H}
- {entry_name: NK2R_HUMAN, from_res: N, pubmed: '11489908', seq: '110', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: W, pubmed: '10658591', seq: '156', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: W, pubmed: '10658591', seq: '156', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: Q, pubmed: '10658591', seq: '166', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Q, pubmed: '10818258', seq: '166', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: S, pubmed: '10818258', seq: '170', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: T, pubmed: '10818258', seq: '171', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '10411554', seq: '198', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '10658591', seq: '198', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '10818258', seq: '198', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '7961636', seq: '198', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '11489908', seq: '198', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '10658591', seq: '198', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '7961636', seq: '198', to_res: L}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '10658591', seq: '198', to_res: Q}
- {entry_name: NK2R_HUMAN, from_res: I, pubmed: '11489908', seq: '202', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: I, pubmed: '7961636', seq: '202', to_res: V}
- {entry_name: NK2R_HUMAN, from_res: L, pubmed: '10658591', seq: '204', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: I, pubmed: '10658591', seq: '205', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '206', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '206', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: F, pubmed: '7499223', seq: '248', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: F, pubmed: '7499223', seq: '248', to_res: E}
- {entry_name: NK2R_HUMAN, from_res: F, pubmed: '7499223', seq: '248', to_res: S}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10411554', seq: '266', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10658591', seq: '266', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '266', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '11489908', seq: '266', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10411554', seq: '266', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '266', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10411554', seq: '266', to_res: S}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '266', to_res: T}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '10658591', seq: '267', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '10818258', seq: '267', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: H, pubmed: '11489908', seq: '267', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10658591', seq: '269', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: F, pubmed: '10411554', seq: '270', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: F, pubmed: '10818258', seq: '270', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: F, pubmed: '11489908', seq: '270', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: G, pubmed: '7961636', seq: '273', to_res: P}
- {entry_name: NK2R_HUMAN, from_res: G, pubmed: '7961636', seq: '273', to_res: T}
- {entry_name: NK2R_HUMAN, from_res: S, pubmed: '10658591', seq: '274', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: I, pubmed: '10658591', seq: '285', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10411554', seq: '289', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10658591', seq: '289', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '289', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10086323', seq: '289', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10411554', seq: '289', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10658591', seq: '289', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '289', to_res: F}
- {entry_name: NK2R_HUMAN, from_res: Y, pubmed: '10818258', seq: '289', to_res: T}
- {entry_name: NK2R_HUMAN, from_res: L, pubmed: '7961636', seq: '292', to_res: S}
- {entry_name: NK2R_HUMAN, from_res: M, pubmed: '11489908', seq: '297', to_res: C}
- {entry_name: NK2R_HUMAN, from_res: M, pubmed: '11489908', seq: '297', to_res: L}
- {entry_name: NK2R_HUMAN, from_res: N, pubmed: '10085227', seq: '303', to_res: A}
- {entry_name: NK2R_HUMAN, from_res: N, pubmed: '10085227', seq: '303', to_res: S}
- {entry_name: NK3R_RAT, from_res: V, pubmed: '8117303', seq: '121', to_res: M}
- {entry_name: NK3R_RAT, from_res: G, pubmed: '8117303', seq: '133', to_res: A}
- {entry_name: NMBR_RAT, from_res: I, pubmed: '11013243', seq: '216', to_res: S}
- {entry_name: NPFF1_HUMAN, from_res: G, pubmed: '12118081', seq: '252', to_res: R}
- {entry_name: NPFF1_HUMAN, from_res: D, pubmed: '12118081', seq: '380', to_res: G}
- {entry_name: NPFF1_RAT, from_res: S, pubmed: '12118081', seq: '393', to_res: R}
- {entry_name: NPY1R_HUMAN, from_res: Y, pubmed: '7489825', seq: '100', to_res: F}
- {entry_name: NPY1R_HUMAN, from_res: H, pubmed: '11997008', seq: '139', to_res: Q}
- {entry_name: NPY1R_HUMAN, from_res: Y, pubmed: '8700135', seq: '211', to_res: A}
- {entry_name: NPY1R_HUMAN, from_res: Q, pubmed: '11997008', seq: '219', to_res: A}
- {entry_name: NPY1R_RAT, from_res: L, pubmed: '9705087', seq: '34', to_res: E}
- {entry_name: NPY1R_RAT, from_res: L, pubmed: '9705087', seq: '34', to_res: R}
- {entry_name: NPY1R_RAT, from_res: P, pubmed: '9705087', seq: '35', to_res: H}
- {entry_name: NPY1R_RAT, from_res: D, pubmed: '9705087', seq: '85', to_res: A}
- {entry_name: NPY1R_RAT, from_res: D, pubmed: '9705087', seq: '85', to_res: E}
- {entry_name: NPY1R_RAT, from_res: D, pubmed: '9705087', seq: '85', to_res: N}
- {entry_name: NPY1R_RAT, from_res: D, pubmed: '9705087', seq: '103', to_res: A}
- {entry_name: NPY1R_RAT, from_res: D, pubmed: '9705087', seq: '193', to_res: A}
- {entry_name: NPY1R_RAT, from_res: D, pubmed: '9705087', seq: '199', to_res: A}
- {entry_name: NPY1R_RAT, from_res: D, pubmed: '9705087', seq: '286', to_res: A}
- {entry_name: NPY2R_CHICK, from_res: Q, pubmed: '11997008', seq: '231', to_res: L}
- {entry_name: NPY2R_HUMAN, from_res: Q, pubmed: '11997008', seq: '135', to_res: H}
- {entry_name: NPY2R_HUMAN, from_res: L, pubmed: '11997008', seq: '227', to_res: Q}
- {entry_name: NPY2R_HUMAN, from_res: L, pubmed: '11997008', seq: '284', to_res: F}
- {entry_name: NPY2R_HUMAN, from_res: L, pubmed: '11997008', seq: '284', to_res: T}
- {entry_name: NTR1_RAT, from_res: V, pubmed: '9632698', seq: '65', to_res: A}
- {entry_name: NTR1_RAT, from_res: V, pubmed: '9632698', seq: '67', to_res: A}
- {entry_name: NTR1_RAT, from_res: T, pubmed: '9632698', seq: '68', to_res: A}
- {entry_name: NTR1_RAT, from_res: D, pubmed: '9927610', seq: '113', to_res: A}
- {entry_name: NTR1_RAT, from_res: D, pubmed: '10617622', seq: '139', to_res: A}
- {entry_name: NTR1_RAT, from_res: D, pubmed: '10617622', seq: '139', to_res: G}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '9632698', seq: '143', to_res: K}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '9632698', seq: '143', to_res: M}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '10617622', seq: '143', to_res: Q}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '9632698', seq: '143', to_res: Q}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '145', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '146', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '147', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '154', to_res: A}
- {entry_name: NTR1_RAT, from_res: T, pubmed: '9632698', seq: '156', to_res: A}
- {entry_name: NTR1_RAT, from_res: M, pubmed: '9632698', seq: '204', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '206', to_res: A}
- {entry_name: NTR1_RAT, from_res: M, pubmed: '10617622', seq: '208', to_res: A}
- {entry_name: NTR1_RAT, from_res: M, pubmed: '9632698', seq: '208', to_res: A}
- {entry_name: NTR1_RAT, from_res: K, pubmed: '9632698', seq: '235', to_res: A}
- {entry_name: NTR1_RAT, from_res: K, pubmed: '9632698', seq: '235', to_res: Q}
- {entry_name: NTR1_RAT, from_res: K, pubmed: '9632698', seq: '235', to_res: R}
- {entry_name: NTR1_RAT, from_res: V, pubmed: '9632698', seq: '236', to_res: A}
- {entry_name: NTR1_RAT, from_res: V, pubmed: '9632698', seq: '237', to_res: A}
- {entry_name: NTR1_RAT, from_res: I, pubmed: '9632698', seq: '238', to_res: A}
- {entry_name: NTR1_RAT, from_res: Q, pubmed: '9632698', seq: '239', to_res: A}
- {entry_name: NTR1_RAT, from_res: T, pubmed: '9632698', seq: '242', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '243', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '324', to_res: A}
- {entry_name: NTR1_RAT, from_res: H, pubmed: '9632698', seq: '325', to_res: A}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '9632698', seq: '327', to_res: E}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '10617622', seq: '327', to_res: M}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '9632698', seq: '327', to_res: M}
- {entry_name: NTR1_RAT, from_res: R, pubmed: '9632698', seq: '328', to_res: M}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '10617622', seq: '331', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '331', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '331', to_res: Y}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '333', to_res: A}
- {entry_name: NTR1_RAT, from_res: W, pubmed: '10617622', seq: '339', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '10617622', seq: '344', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '10617622', seq: '346', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '346', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '10617622', seq: '347', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '347', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '10617622', seq: '347', to_res: F}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '10617622', seq: '347', to_res: M}
- {entry_name: NTR1_RAT, from_res: H, pubmed: '9632698', seq: '348', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '10617622', seq: '349', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '349', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '350', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '351', to_res: A}
- {entry_name: NTR1_RAT, from_res: T, pubmed: '9632698', seq: '354', to_res: A}
- {entry_name: NTR1_RAT, from_res: F, pubmed: '9632698', seq: '358', to_res: A}
- {entry_name: NTR1_RAT, from_res: Y, pubmed: '9632698', seq: '359', to_res: A}
- {entry_name: NTR2_MOUSE, from_res: A, pubmed: '9927610', seq: '79', to_res: D}
- {entry_name: NTR2_RAT, from_res: Y, pubmed: '11801734', seq: '237', to_res: A}
- {entry_name: O10AD_HUMAN, from_res: N, pubmed: '14962981', seq: '156', to_res: Y}
- {entry_name: O10T2_HUMAN, from_res: C, pubmed: '14962981', seq: '165', to_res: R}
- {entry_name: O35190_MOUSE, from_res: T, pubmed: '11807089', seq: '662', to_res: A}
- {entry_name: O43192_HUMAN, from_res: R, pubmed: '15166253', seq: '137', to_res: H}
- {entry_name: O43192_HUMAN, from_res: R, pubmed: '15166253', seq: '143', to_res: E}
- {entry_name: O43192_HUMAN, from_res: W, pubmed: '15166253', seq: '164', to_res: S}
- {entry_name: O43898_HUMAN, from_res: Y, pubmed: '14688263', seq: '190', to_res: W}
- {entry_name: O51B4_HUMAN, from_res: G, pubmed: '11137294', seq: '70', to_res: A}
- {entry_name: O51B4_HUMAN, from_res: T, pubmed: '11137294', seq: '125', to_res: C}
- {entry_name: O51I1_HUMAN, from_res: G, pubmed: '11137294', seq: '74', to_res: A}
- {entry_name: O52A1_HUMAN, from_res: A, pubmed: '11137294', seq: '70', to_res: G}
- {entry_name: O52A1_HUMAN, from_res: A, pubmed: '11137294', seq: '74', to_res: G}
- {entry_name: O52A1_HUMAN, from_res: A, pubmed: '11137294', seq: '297', to_res: G}
- {entry_name: O52B2_HUMAN, from_res: T, pubmed: '11137294', seq: '79', to_res: C}
- {entry_name: O52B2_HUMAN, from_res: C, pubmed: '11137294', seq: '156', to_res: T}
- {entry_name: O5AR1_HUMAN, from_res: V, pubmed: '14962981', seq: '114', to_res: L}
- {entry_name: O70409_MOUSE, from_res: G, pubmed: '11807089', seq: '490', to_res: R}
- {entry_name: O70410_MOUSE, from_res: D, pubmed: '11807089', seq: '488', to_res: A}
- {entry_name: OL226_RAT, from_res: K, pubmed: '10781022', seq: '164', to_res: A}
- {entry_name: OL226_RAT, from_res: D, pubmed: '10781022', seq: '204', to_res: A}
- {entry_name: OL226_RAT, from_res: V, pubmed: '10781022', seq: '206', to_res: A}
- {entry_name: OL226_RAT, from_res: V, pubmed: '10781022', seq: '206', to_res: I}
- {entry_name: OP1S1_BRARE, from_res: Y, pubmed: '15647516', seq: '261', to_res: F}
- {entry_name: OP1S2_BRARE, from_res: A, pubmed: '15623516', seq: '87', to_res: S}
- {entry_name: OP1S2_BRARE, from_res: S, pubmed: '15623516', seq: '94', to_res: A}
- {entry_name: OP1S2_BRARE, from_res: I, pubmed: '15623516', seq: '119', to_res: L}
- {entry_name: OP1S2_BRARE, from_res: A, pubmed: '15623516', seq: '295', to_res: S}
- {entry_name: OPN3_MOUSE, from_res: D, pubmed: '15641808', seq: '108', to_res: H}
- {entry_name: OPN3_MOUSE, from_res: S, pubmed: '15641808', seq: '118', to_res: T}
- {entry_name: OPN3_MOUSE, from_res: S, pubmed: '15647516', seq: '118', to_res: T}
- {entry_name: OPN4_HUMAN, from_res: T, pubmed: '15647516', seq: '52', to_res: F}
- {entry_name: OPN4_MOUSE, from_res: T, pubmed: '15647516', seq: '93', to_res: P}
- {entry_name: OPRD_HUMAN, from_res: D, pubmed: '15590769', seq: '21', to_res: G}
- {entry_name: OPRD_HUMAN, from_res: D, pubmed: '11927547', seq: '95', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: D, pubmed: '9224819', seq: '95', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: D, pubmed: '9675164', seq: '95', to_res: N}
- {entry_name: OPRD_HUMAN, from_res: T, pubmed: '15590769', seq: '134', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: N, pubmed: '15590769', seq: '169', to_res: S}
- {entry_name: OPRD_HUMAN, from_res: W, pubmed: '9675164', seq: '173', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: S, pubmed: '9675164', seq: '177', to_res: L}
- {entry_name: OPRD_HUMAN, from_res: T, pubmed: '15590769', seq: '213', to_res: S}
- {entry_name: OPRD_HUMAN, from_res: M, pubmed: '15590769', seq: '262', to_res: T}
- {entry_name: OPRD_HUMAN, from_res: W, pubmed: '15590769', seq: '274', to_res: R}
- {entry_name: OPRD_HUMAN, from_res: A, pubmed: '8702536', seq: '275', to_res: G}
- {entry_name: OPRD_HUMAN, from_res: F, pubmed: '8702536', seq: '280', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: V, pubmed: '8702536', seq: '283', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: V, pubmed: '15590769', seq: '283', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: W, pubmed: '8702536', seq: '284', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: W, pubmed: '8702536', seq: '284', to_res: K}
- {entry_name: OPRD_HUMAN, from_res: W, pubmed: '11358332', seq: '284', to_res: L}
- {entry_name: OPRD_HUMAN, from_res: T, pubmed: '8702536', seq: '285', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: D, pubmed: '8702536', seq: '288', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: I, pubmed: '8702536', seq: '289', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: D, pubmed: '8702536', seq: '290', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: R, pubmed: '8702536', seq: '291', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: R, pubmed: '8702536', seq: '292', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: D, pubmed: '8702536', seq: '293', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: P, pubmed: '8702536', seq: '294', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: L, pubmed: '8702536', seq: '295', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: V, pubmed: '8702536', seq: '296', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: V, pubmed: '8702536', seq: '296', to_res: Q}
- {entry_name: OPRD_HUMAN, from_res: V, pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: V, pubmed: '8702536', seq: '297', to_res: T}
- {entry_name: OPRD_HUMAN, from_res: A, pubmed: '8702536', seq: '298', to_res: G}
- {entry_name: OPRD_HUMAN, from_res: A, pubmed: '8702536', seq: '299', to_res: G}
- {entry_name: OPRD_HUMAN, from_res: L, pubmed: '8702536', seq: '302', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: Y, pubmed: '15590769', seq: '308', to_res: H}
- {entry_name: OPRD_HUMAN, from_res: A, pubmed: '8702536', seq: '309', to_res: G}
- {entry_name: OPRD_HUMAN, from_res: S, pubmed: '8702536', seq: '312', to_res: A}
- {entry_name: OPRD_HUMAN, from_res: E, pubmed: '15590769', seq: '323', to_res: K}
- {entry_name: OPRD_HUMAN, from_res: C, pubmed: '15590769', seq: '328', to_res: R}
- {entry_name: OPRD_MOUSE, from_res: D, pubmed: '8226821', seq: '95', to_res: N}
- {entry_name: OPRD_MOUSE, from_res: D, pubmed: '10373467', seq: '128', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: D, pubmed: '10373467', seq: '128', to_res: N}
- {entry_name: OPRD_MOUSE, from_res: D, pubmed: '8626577', seq: '128', to_res: N}
- {entry_name: OPRD_MOUSE, from_res: Y, pubmed: '10373467', seq: '129', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: Y, pubmed: '8626577', seq: '129', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: Y, pubmed: '10373467', seq: '129', to_res: F}
- {entry_name: OPRD_MOUSE, from_res: Y, pubmed: '8626577', seq: '129', to_res: F}
- {entry_name: OPRD_MOUSE, from_res: W, pubmed: '8626577', seq: '173', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: F, pubmed: '8626577', seq: '218', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: F, pubmed: '8626577', seq: '222', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: W, pubmed: '8626577', seq: '274', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: W, pubmed: '11038249', seq: '284', to_res: K}
- {entry_name: OPRD_MOUSE, from_res: Y, pubmed: '8626577', seq: '308', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: Y, pubmed: '10373467', seq: '308', to_res: F}
- {entry_name: OPRD_MOUSE, from_res: Y, pubmed: '8626577', seq: '308', to_res: F}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11085981', seq: '344', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '8910588', seq: '344', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11085981', seq: '344', to_res: D}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11040053', seq: '344', to_res: G}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11085981', seq: '344', to_res: G}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '8626742', seq: '344', to_res: G}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '8910588', seq: '344', to_res: G}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '10701775', seq: '352', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11040053', seq: '352', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11085981', seq: '352', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '8626742', seq: '352', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '8910588', seq: '352', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '10701775', seq: '353', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11040053', seq: '353', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11085981', seq: '353', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '8626742', seq: '353', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '8910588', seq: '353', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '9346897', seq: '353', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '10701775', seq: '353', to_res: E}
- {entry_name: OPRD_MOUSE, from_res: E, pubmed: '12750365', seq: '355', to_res: Q}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '10701775', seq: '358', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11040053', seq: '358', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11085981', seq: '358', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '12750365', seq: '358', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '8910588', seq: '358', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11040053', seq: '358', to_res: D}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11085981', seq: '358', to_res: D}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '10701775', seq: '361', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11040053', seq: '361', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11085981', seq: '361', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '12750365', seq: '361', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '8910588', seq: '361', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11040053', seq: '361', to_res: D}
- {entry_name: OPRD_MOUSE, from_res: T, pubmed: '11085981', seq: '361', to_res: D}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '10701775', seq: '363', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11040053', seq: '363', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '8910588', seq: '363', to_res: A}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11040053', seq: '363', to_res: D}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11085981', seq: '363', to_res: D}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11040053', seq: '363', to_res: G}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '11085981', seq: '363', to_res: G}
- {entry_name: OPRD_MOUSE, from_res: S, pubmed: '12750365', seq: '363', to_res: G}
- {entry_name: OPRD_MOUSE, from_res: D, pubmed: '12750365', seq: '364', to_res: N}
- {entry_name: OPRD_RAT, from_res: K, pubmed: '8913373', seq: '108', to_res: N}
- {entry_name: OPRD_RAT, from_res: S, pubmed: '11278615', seq: '143', to_res: T}
- {entry_name: OPRD_RAT, from_res: K, pubmed: '10777506', seq: '214', to_res: A}
- {entry_name: OPRD_RAT, from_res: I, pubmed: '10777506', seq: '277', to_res: V}
- {entry_name: OPRD_RAT, from_res: H, pubmed: '10777506', seq: '278', to_res: Q}
- {entry_name: OPRD_RAT, from_res: I, pubmed: '10777506', seq: '279', to_res: V}
- {entry_name: OPRD_RAT, from_res: I, pubmed: '10777506', seq: '304', to_res: T}
- {entry_name: OPRD_RAT, from_res: A, pubmed: '10701775', seq: '353', to_res: T}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '119', to_res: A}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '119', to_res: C}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '119', to_res: F}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '139', to_res: A}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '139', to_res: F}
- {entry_name: OPRK_HUMAN, from_res: I, pubmed: '15952771', seq: '294', to_res: C}
- {entry_name: OPRK_HUMAN, from_res: E, pubmed: '9419379', seq: '297', to_res: A}
- {entry_name: OPRK_HUMAN, from_res: E, pubmed: '15952771', seq: '297', to_res: C}
- {entry_name: OPRK_HUMAN, from_res: E, pubmed: '9419379', seq: '297', to_res: Q}
- {entry_name: OPRK_HUMAN, from_res: L, pubmed: '15952771', seq: '309', to_res: C}
- {entry_name: OPRK_HUMAN, from_res: S, pubmed: '15952771', seq: '310', to_res: C}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '312', to_res: A}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '312', to_res: F}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '313', to_res: A}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '313', to_res: C}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '313', to_res: F}
- {entry_name: OPRK_HUMAN, from_res: C, pubmed: '15952771', seq: '315', to_res: S}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '320', to_res: A}
- {entry_name: OPRK_HUMAN, from_res: Y, pubmed: '15952771', seq: '320', to_res: F}
- {entry_name: OPRK_HUMAN, from_res: S, pubmed: '9733719', seq: '356', to_res: A}
- {entry_name: OPRK_HUMAN, from_res: T, pubmed: '9733719', seq: '357', to_res: G}
- {entry_name: OPRK_HUMAN, from_res: S, pubmed: '9733719', seq: '358', to_res: G}
- {entry_name: OPRK_MOUSE, from_res: R, pubmed: '11782458', seq: '170', to_res: E}
- {entry_name: OPRK_RAT, from_res: V, pubmed: '15967873', seq: '160', to_res: E}
- {entry_name: OPRK_RAT, from_res: D, pubmed: '8626461', seq: '223', to_res: H}
- {entry_name: OPRK_RAT, from_res: K, pubmed: '11861808', seq: '227', to_res: A}
- {entry_name: OPRK_RAT, from_res: K, pubmed: '8626461', seq: '227', to_res: H}
- {entry_name: OPRK_RAT, from_res: E, pubmed: '10969141', seq: '297', to_res: K}
- {entry_name: OPRK_RAT, from_res: E, pubmed: '7541509', seq: '297', to_res: K}
- {entry_name: OPRK_RAT, from_res: A, pubmed: '8626461', seq: '298', to_res: H}
- {entry_name: OPRK_RAT, from_res: T, pubmed: '11861808', seq: '302', to_res: I}
- {entry_name: OPRK_RAT, from_res: I, pubmed: '11861808', seq: '316', to_res: T}
- {entry_name: OPRK_RAT, from_res: N, pubmed: '12183679', seq: '358', to_res: S}
- {entry_name: OPRM_HUMAN, from_res: A, pubmed: '9399694', seq: '6', to_res: V}
- {entry_name: OPRM_HUMAN, from_res: A, pubmed: '9689128', seq: '6', to_res: V}
- {entry_name: OPRM_HUMAN, from_res: A, pubmed: '16046395', seq: '6', to_res: V}
- {entry_name: OPRM_HUMAN, from_res: N, pubmed: '11751037', seq: '40', to_res: D}
- {entry_name: OPRM_HUMAN, from_res: N, pubmed: '9399694', seq: '40', to_res: D}
- {entry_name: OPRM_HUMAN, from_res: N, pubmed: '9689128', seq: '40', to_res: D}
- {entry_name: OPRM_HUMAN, from_res: N, pubmed: '16046395', seq: '40', to_res: D}
- {entry_name: OPRM_HUMAN, from_res: N, pubmed: '16344716', seq: '40', to_res: D}
- {entry_name: OPRM_HUMAN, from_res: C, pubmed: '10529478', seq: '142', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: C, pubmed: '10529478', seq: '142', to_res: S}
- {entry_name: OPRM_HUMAN, from_res: S, pubmed: '9399694', seq: '147', to_res: C}
- {entry_name: OPRM_HUMAN, from_res: C, pubmed: '10529478', seq: '219', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: C, pubmed: '10529478', seq: '219', to_res: S}
- {entry_name: OPRM_HUMAN, from_res: R, pubmed: '11457836', seq: '260', to_res: H}
- {entry_name: OPRM_HUMAN, from_res: R, pubmed: '9689128', seq: '260', to_res: H}
- {entry_name: OPRM_HUMAN, from_res: R, pubmed: '11457836', seq: '265', to_res: H}
- {entry_name: OPRM_HUMAN, from_res: S, pubmed: '11457836', seq: '268', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: S, pubmed: '11457836', seq: '268', to_res: P}
- {entry_name: OPRM_HUMAN, from_res: K, pubmed: '10419536', seq: '273', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: K, pubmed: '10737597', seq: '273', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: K, pubmed: '10899953', seq: '273', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: K, pubmed: '11457825', seq: '273', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: K, pubmed: '11457836', seq: '273', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: K, pubmed: '15944153', seq: '273', to_res: A}
- {entry_name: OPRM_HUMAN, from_res: D, pubmed: '11457836', seq: '274', to_res: N}
- {entry_name: OPRM_HUMAN, from_res: R, pubmed: '10899953', seq: '275', to_res: A}
- {entry_name: OPRM_MOUSE, from_res: D, pubmed: '9224819', seq: '114', to_res: A}
- {entry_name: OPRM_MOUSE, from_res: D, pubmed: '12604666', seq: '114', to_res: N}
- {entry_name: OPRM_MOUSE, from_res: D, pubmed: '9618424', seq: '114', to_res: N}
- {entry_name: OPRM_MOUSE, from_res: S, pubmed: '15579496', seq: '196', to_res: A}
- {entry_name: OPRM_MOUSE, from_res: S, pubmed: '15579496', seq: '196', to_res: L}
- {entry_name: OPRM_MOUSE, from_res: W, pubmed: '11705461', seq: '318', to_res: Y}
- {entry_name: OPRM_MOUSE, from_res: H, pubmed: '11705461', seq: '319', to_res: Y}
- {entry_name: OPRM_MOUSE, from_res: Y, pubmed: '12604666', seq: '326', to_res: F}
- {entry_name: OPRM_MOUSE, from_res: T, pubmed: '15579496', seq: '327', to_res: A}
- {entry_name: OPRM_MOUSE, from_res: S, pubmed: '12604666', seq: '329', to_res: A}
- {entry_name: OPRM_MOUSE, from_res: C, pubmed: '15579496', seq: '330', to_res: A}
- {entry_name: OPRM_MOUSE, from_res: C, pubmed: '15579496', seq: '330', to_res: S}
- {entry_name: OPRM_MOUSE, from_res: N, pubmed: '12604666', seq: '332', to_res: D}
- {entry_name: OPRM_MOUSE, from_res: C, pubmed: '16525132', seq: '351', to_res: L}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '15595835', seq: '96', to_res: C}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '8051154', seq: '114', to_res: N}
- {entry_name: OPRM_RAT, from_res: Q, pubmed: '15595835', seq: '124', to_res: E}
- {entry_name: OPRM_RAT, from_res: C, pubmed: '8621408', seq: '140', to_res: S}
- {entry_name: OPRM_RAT, from_res: V, pubmed: '15595835', seq: '143', to_res: H}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '10416823', seq: '147', to_res: A}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '15595835', seq: '147', to_res: A}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '16353922', seq: '147', to_res: A}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '10416823', seq: '147', to_res: E}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '10416823', seq: '147', to_res: N}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '10188634', seq: '148', to_res: F}
- {entry_name: OPRM_RAT, from_res: N, pubmed: '8978745', seq: '150', to_res: A}
- {entry_name: OPRM_RAT, from_res: C, pubmed: '8621408', seq: '159', to_res: S}
- {entry_name: OPRM_RAT, from_res: C, pubmed: '8621408', seq: '190', to_res: S}
- {entry_name: OPRM_RAT, from_res: S, pubmed: '8650158', seq: '196', to_res: L}
- {entry_name: OPRM_RAT, from_res: V, pubmed: '8978745', seq: '202', to_res: I}
- {entry_name: OPRM_RAT, from_res: G, pubmed: '15595835', seq: '213', to_res: C}
- {entry_name: OPRM_RAT, from_res: S, pubmed: '15595835', seq: '214', to_res: A}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '15595835', seq: '216', to_res: V}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '8621408', seq: '223', to_res: S}
- {entry_name: OPRM_RAT, from_res: E, pubmed: '9675164', seq: '229', to_res: D}
- {entry_name: OPRM_RAT, from_res: E, pubmed: '15595835', seq: '229', to_res: D}
- {entry_name: OPRM_RAT, from_res: N, pubmed: '15595835', seq: '230', to_res: H}
- {entry_name: OPRM_RAT, from_res: N, pubmed: '9675164', seq: '230', to_res: T}
- {entry_name: OPRM_RAT, from_res: K, pubmed: '15595835', seq: '233', to_res: C}
- {entry_name: OPRM_RAT, from_res: C, pubmed: '8621408', seq: '235', to_res: S}
- {entry_name: OPRM_RAT, from_res: F, pubmed: '15595835', seq: '237', to_res: C}
- {entry_name: OPRM_RAT, from_res: F, pubmed: '15595835', seq: '237', to_res: H}
- {entry_name: OPRM_RAT, from_res: L, pubmed: '15595835', seq: '254', to_res: C}
- {entry_name: OPRM_RAT, from_res: I, pubmed: '15595835', seq: '256', to_res: C}
- {entry_name: OPRM_RAT, from_res: R, pubmed: '15595835', seq: '258', to_res: E}
- {entry_name: OPRM_RAT, from_res: D, pubmed: '15595835', seq: '272', to_res: C}
- {entry_name: OPRM_RAT, from_res: L, pubmed: '12356297', seq: '275', to_res: E}
- {entry_name: OPRM_RAT, from_res: R, pubmed: '12626655', seq: '276', to_res: A}
- {entry_name: OPRM_RAT, from_res: R, pubmed: '15595835', seq: '276', to_res: H}
- {entry_name: OPRM_RAT, from_res: I, pubmed: '12626655', seq: '278', to_res: A}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '12626655', seq: '279', to_res: A}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '15595835', seq: '279', to_res: C}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '12356297', seq: '279', to_res: D}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '15595835', seq: '279', to_res: D}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '15595835', seq: '279', to_res: K}
- {entry_name: OPRM_RAT, from_res: R, pubmed: '12626655', seq: '280', to_res: A}
- {entry_name: OPRM_RAT, from_res: R, pubmed: '15595835', seq: '280', to_res: C}
- {entry_name: OPRM_RAT, from_res: R, pubmed: '10037504', seq: '280', to_res: L}
- {entry_name: OPRM_RAT, from_res: M, pubmed: '15595835', seq: '281', to_res: C}
- {entry_name: OPRM_RAT, from_res: V, pubmed: '15595835', seq: '282', to_res: C}
- {entry_name: OPRM_RAT, from_res: V, pubmed: '15595835', seq: '285', to_res: N}
- {entry_name: OPRM_RAT, from_res: C, pubmed: '8621408', seq: '292', to_res: S}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '8978745', seq: '297', to_res: A}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '9415708', seq: '297', to_res: A}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '9415708', seq: '297', to_res: L}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '10719216', seq: '297', to_res: N}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '9415708', seq: '297', to_res: N}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '15595835', seq: '297', to_res: N}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '9415708', seq: '297', to_res: Q}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '16353922', seq: '297', to_res: Q}
- {entry_name: OPRM_RAT, from_res: H, pubmed: '9415708', seq: '297', to_res: R}
- {entry_name: OPRM_RAT, from_res: V, pubmed: '15595835', seq: '300', to_res: C}
- {entry_name: OPRM_RAT, from_res: V, pubmed: '15595835', seq: '300', to_res: H}
- {entry_name: OPRM_RAT, from_res: K, pubmed: '10969141', seq: '303', to_res: E}
- {entry_name: OPRM_RAT, from_res: K, pubmed: '15595835', seq: '303', to_res: E}
- {entry_name: OPRM_RAT, from_res: K, pubmed: '10969141', seq: '303', to_res: Q}
- {entry_name: OPRM_RAT, from_res: K, pubmed: '10969141', seq: '303', to_res: W}
- {entry_name: OPRM_RAT, from_res: A, pubmed: '15595835', seq: '304', to_res: C}
- {entry_name: OPRM_RAT, from_res: E, pubmed: '15595835', seq: '310', to_res: R}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '15595835', seq: '315', to_res: C}
- {entry_name: OPRM_RAT, from_res: W, pubmed: '10969141', seq: '318', to_res: A}
- {entry_name: OPRM_RAT, from_res: W, pubmed: '10969141', seq: '318', to_res: K}
- {entry_name: OPRM_RAT, from_res: W, pubmed: '10969141', seq: '318', to_res: L}
- {entry_name: OPRM_RAT, from_res: W, pubmed: '15595835', seq: '318', to_res: L}
- {entry_name: OPRM_RAT, from_res: C, pubmed: '8621408', seq: '321', to_res: S}
- {entry_name: OPRM_RAT, from_res: I, pubmed: '15595835', seq: '322', to_res: C}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '12183679', seq: '326', to_res: A}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '10719216', seq: '326', to_res: F}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '8978745', seq: '326', to_res: F}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '15595835', seq: '326', to_res: H}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '15857395', seq: '336', to_res: A}
- {entry_name: OPRM_RAT, from_res: Y, pubmed: '10488100', seq: '336', to_res: F}
- {entry_name: OPRM_RAT, from_res: C, pubmed: '15967873', seq: '351', to_res: I}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '10488100', seq: '394', to_res: A}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '10820022', seq: '394', to_res: A}
- {entry_name: OPRM_RAT, from_res: T, pubmed: '9927617', seq: '394', to_res: A}
- {entry_name: OPRX_HUMAN, from_res: L, pubmed: '14550303', seq: '113', to_res: M}
- {entry_name: OPRX_HUMAN, from_res: D, pubmed: '10692489', seq: '130', to_res: A}
- {entry_name: OPRX_HUMAN, from_res: D, pubmed: '10692489', seq: '130', to_res: E}
- {entry_name: OPRX_HUMAN, from_res: D, pubmed: '10692489', seq: '130', to_res: N}
- {entry_name: OPRX_HUMAN, from_res: Y, pubmed: '10692489', seq: '131', to_res: A}
- {entry_name: OPRX_HUMAN, from_res: Y, pubmed: '10692489', seq: '131', to_res: F}
- {entry_name: OPRX_HUMAN, from_res: N, pubmed: '12472900', seq: '133', to_res: W}
- {entry_name: OPRX_HUMAN, from_res: F, pubmed: '10692489', seq: '220', to_res: A}
- {entry_name: OPRX_HUMAN, from_res: F, pubmed: '10692489', seq: '224', to_res: A}
- {entry_name: OPRX_HUMAN, from_res: W, pubmed: '10692489', seq: '276', to_res: A}
- {entry_name: OPRX_HUMAN, from_res: Q, pubmed: '8849681', seq: '280', to_res: H}
- {entry_name: OPRX_HUMAN, from_res: Q, pubmed: '10692489', seq: '286', to_res: A}
- {entry_name: OPRX_HUMAN, from_res: Q, pubmed: '10692489', seq: '286', to_res: E}
- {entry_name: OPRX_HUMAN, from_res: E, pubmed: '10880520', seq: '295', to_res: D}
- {entry_name: OPRX_MOUSE, from_res: S, pubmed: '9547359', seq: '16', to_res: A}
- {entry_name: OPRX_MOUSE, from_res: C, pubmed: '16525132', seq: '352', to_res: L}
- {entry_name: OPRX_RAT, from_res: A, pubmed: '10777506', seq: '213', to_res: K}
- {entry_name: OPRX_RAT, from_res: A, pubmed: '11861808', seq: '213', to_res: K}
- {entry_name: OPRX_RAT, from_res: A, pubmed: '8943250', seq: '213', to_res: K}
- {entry_name: OPRX_RAT, from_res: A, pubmed: '9547370', seq: '213', to_res: K}
- {entry_name: OPRX_RAT, from_res: Q, pubmed: '10777506', seq: '277', to_res: H}
- {entry_name: OPRX_RAT, from_res: T, pubmed: '8943250', seq: '302', to_res: I}
- {entry_name: OPRX_RAT, from_res: T, pubmed: '9547370', seq: '302', to_res: I}
- {entry_name: OPS6_DROME, from_res: V, pubmed: '11602178', seq: '53', to_res: D}
- {entry_name: OPS6_DROME, from_res: E, pubmed: '15843174', seq: '121', to_res: Q}
- {entry_name: OPS6_DROME, from_res: V, pubmed: '9016359', seq: '170', to_res: A}
- {entry_name: OPSB_HUMAN, from_res: F, pubmed: '10443011', seq: '86', to_res: D}
- {entry_name: OPSB_HUMAN, from_res: F, pubmed: '15641808', seq: '86', to_res: L}
- {entry_name: OPSB_HUMAN, from_res: F, pubmed: '15647516', seq: '86', to_res: L}
- {entry_name: OPSB_HUMAN, from_res: C, pubmed: '16096063', seq: '330', to_res: Y}
- {entry_name: OPSB_MOUSE, from_res: R, pubmed: '11773633', seq: '309', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '16170112', seq: '20', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: P, pubmed: '8643443', seq: '23', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: P, pubmed: '16170112', seq: '23', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '7836439', seq: '62', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '7836439', seq: '63', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: Q, pubmed: '7836439', seq: '64', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: H, pubmed: '11408595', seq: '65', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '7836439', seq: '72', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: N, pubmed: '7836439', seq: '73', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '12427730', seq: '76', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '14660595', seq: '79', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '14660595', seq: '79', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: D, pubmed: '11106612', seq: '83', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: D, pubmed: '7662872', seq: '83', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: D, pubmed: '7901852', seq: '83', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '11408595', seq: '90', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '11683644', seq: '90', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '14660595', seq: '90', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '15641808', seq: '93', to_res: P}
- {entry_name: OPSD_BOVIN, from_res: H, pubmed: '9585578', seq: '100', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '16170112', seq: '110', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10642185', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11683644', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1351402', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '2014228', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '7916209', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8444840', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8943295', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8943296', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9238015', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9287308', seq: '113', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10642185', seq: '113', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '113', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '2014228', seq: '113', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '7916209', seq: '113', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9238015', seq: '113', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '15966721', seq: '113', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '2014228', seq: '113', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10642185', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11683644', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '12835420', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1329948', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1351402', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '14660595', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1472495', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '14732701', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '2014228', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8396426', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8943295', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9287308', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9538004', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '15641808', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '15966721', seq: '113', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '114', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '114', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '114', to_res: I}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '114', to_res: M}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '114', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '114', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8943296', seq: '117', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '10642185', seq: '117', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '11683644', seq: '117', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8444840', seq: '117', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8943296', seq: '117', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '9238015', seq: '117', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '1532391', seq: '117', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '1999419', seq: '117', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8943295', seq: '117', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8943295', seq: '117', to_res: I}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8943295', seq: '117', to_res: M}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8943295', seq: '117', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8943295', seq: '117', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '121', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9287308', seq: '121', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9305971', seq: '121', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '121', to_res: I}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9287308', seq: '121', to_res: I}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '11408595', seq: '121', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '121', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943296', seq: '121', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9287308', seq: '121', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9305971', seq: '121', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '121', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9287308', seq: '121', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '121', to_res: T}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9287308', seq: '121', to_res: T}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '121', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9287308', seq: '121', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9305971', seq: '121', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943295', seq: '121', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8943296', seq: '121', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '9287308', seq: '121', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9585578', seq: '122', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1532391', seq: '122', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9585578', seq: '122', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9585578', seq: '122', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '7662872', seq: '122', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11106612', seq: '122', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1351402', seq: '122', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1999419', seq: '122', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '7901852', seq: '122', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8444840', seq: '122', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9585578', seq: '122', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '16460011', seq: '122', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8643443', seq: '122', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: I, pubmed: '8643443', seq: '123', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '8643443', seq: '124', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '8643443', seq: '125', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '8643443', seq: '125', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '8643443', seq: '125', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '16170112', seq: '125', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1532391', seq: '126', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1999419', seq: '126', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '8643443', seq: '127', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '16170112', seq: '131', to_res: P}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10529192', seq: '134', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '7662872', seq: '134', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10636895', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10956053', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '12601165', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '1351402', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '8943296', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '9405602', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '15966721', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '16460011', seq: '134', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10529192', seq: '134', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '10636895', seq: '134', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '7662872', seq: '134', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '7737995', seq: '134', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '9538004', seq: '135', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '10636895', seq: '135', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '7737995', seq: '135', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '9538004', seq: '135', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '9538004', seq: '135', to_res: K}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '9538004', seq: '135', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '9405602', seq: '135', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '9538004', seq: '135', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '9538004', seq: '135', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: Y, pubmed: '11408595', seq: '136', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '12427730', seq: '137', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '11408595', seq: '138', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '11408595', seq: '139', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '9405602', seq: '140', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '7836439', seq: '144', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: N, pubmed: '7836439', seq: '145', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '7836439', seq: '146', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '7836439', seq: '147', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '7737995', seq: '147', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '7836439', seq: '148', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '7836439', seq: '149', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: H, pubmed: '9585578', seq: '152', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '16170112', seq: '164', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: L, pubmed: '9016359', seq: '172', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '14660595', seq: '175', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '14660595', seq: '175', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '14660595', seq: '175', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '16170112', seq: '176', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '12835420', seq: '181', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: I}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: K}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: M}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: P}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '12835420', seq: '181', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '16169009', seq: '181', to_res: Q}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: T}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11888278', seq: '181', to_res: Y}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '12835420', seq: '186', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '12835420', seq: '186', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '12835420', seq: '186', to_res: I}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '8643443', seq: '188', to_res: R}
- {entry_name: OPSD_BOVIN, from_res: G, pubmed: '12427730', seq: '188', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '11408595', seq: '198', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: N, pubmed: '11408595', seq: '200', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '11408595', seq: '204', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: H, pubmed: '1532320', seq: '211', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: H, pubmed: '9585578', seq: '211', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: H, pubmed: '9585578', seq: '211', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: H, pubmed: '15966721', seq: '211', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: P, pubmed: '16170112', seq: '215', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: P, pubmed: '15966721', seq: '215', to_res: Y}
- {entry_name: OPSD_BOVIN, from_res: I, pubmed: '9287308', seq: '219', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: Q, pubmed: '11408595', seq: '225', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '9405602', seq: '227', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '7836439', seq: '233', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '7836439', seq: '233', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '7836439', seq: '234', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '7836439', seq: '234', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '7836439', seq: '235', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '7836439', seq: '235', to_res: N}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '1634520', seq: '240', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '7836439', seq: '240', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '7836439', seq: '242', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '7836439', seq: '243', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '1634520', seq: '243', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11408595', seq: '247', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '11408595', seq: '248', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '1634520', seq: '248', to_res: L}
- {entry_name: OPSD_BOVIN, from_res: E, pubmed: '11408595', seq: '249', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '7836439', seq: '250', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '11408595', seq: '250', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '9405602', seq: '250', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '7836439', seq: '251', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '11408595', seq: '251', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '11408595', seq: '251', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '7836439', seq: '252', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: R, pubmed: '11408595', seq: '252', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: M, pubmed: '8943296', seq: '257', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: M, pubmed: '9287308', seq: '257', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '8943296', seq: '258', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: V, pubmed: '9287308', seq: '258', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '11408595', seq: '261', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '8943295', seq: '261', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '8943296', seq: '261', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '9287308', seq: '261', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '9305971', seq: '261', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '8943296', seq: '261', to_res: T}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '9287308', seq: '261', to_res: T}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '8943296', seq: '261', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '9287308', seq: '261', to_res: V}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '8943296', seq: '261', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '9287308', seq: '261', to_res: W}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1532391', seq: '265', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1999419', seq: '265', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1532391', seq: '265', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1999419', seq: '265', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1532391', seq: '265', to_res: Y}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '1999419', seq: '265', to_res: Y}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '8943296', seq: '265', to_res: Y}
- {entry_name: OPSD_BOVIN, from_res: W, pubmed: '9287308', seq: '265', to_res: Y}
- {entry_name: OPSD_BOVIN, from_res: P, pubmed: '1999419', seq: '267', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: Y, pubmed: '1532391', seq: '268', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: Y, pubmed: '1999419', seq: '268', to_res: F}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '11408595', seq: '276', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '12695530', seq: '277', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '16170112', seq: '289', to_res: P}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '1532391', seq: '292', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '1999419', seq: '292', to_res: D}
- {entry_name: OPSD_BOVIN, from_res: A, pubmed: '9538004', seq: '292', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '1472495', seq: '296', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '9538004', seq: '296', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '16170112', seq: '296', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '1472495', seq: '296', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '9538004', seq: '296', to_res: G}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '1472495', seq: '296', to_res: H}
- {entry_name: OPSD_BOVIN, from_res: K, pubmed: '9538004', seq: '296', to_res: M}
- {entry_name: OPSD_BOVIN, from_res: N, pubmed: '12601165', seq: '302', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: P, pubmed: '12601165', seq: '303', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: Y, pubmed: '12601165', seq: '306', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: Y, pubmed: '12860986', seq: '306', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: Y, pubmed: '12601165', seq: '306', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: Y, pubmed: '12860986', seq: '306', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '12601165', seq: '313', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '12860986', seq: '313', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '12601165', seq: '313', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: F, pubmed: '12860986', seq: '313', to_res: C}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '12601165', seq: '316', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '9405602', seq: '316', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '10636895', seq: '322', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '8419942', seq: '322', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '10636895', seq: '323', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: C, pubmed: '8419942', seq: '323', to_res: S}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '9169442', seq: '334', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '9169442', seq: '335', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '12033931', seq: '336', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '9169442', seq: '336', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '12033931', seq: '336', to_res: P}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '9169442', seq: '338', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '9169442', seq: '340', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '9169442', seq: '340', to_res: E}
- {entry_name: OPSD_BOVIN, from_res: T, pubmed: '9169442', seq: '342', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '9169442', seq: '343', to_res: A}
- {entry_name: OPSD_BOVIN, from_res: S, pubmed: '9169442', seq: '343', to_res: E}
- {entry_name: OPSD_CANFA, from_res: T, pubmed: '15459196', seq: '4', to_res: K}
- {entry_name: OPSD_CANFA, from_res: T, pubmed: '15459196', seq: '4', to_res: R}
- {entry_name: OPSD_HUMAN, from_res: T, pubmed: '11972042', seq: '4', to_res: K}
- {entry_name: OPSD_HUMAN, from_res: T, pubmed: '14769795', seq: '17', to_res: M}
- {entry_name: OPSD_HUMAN, from_res: T, pubmed: '1924344', seq: '17', to_res: M}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '16049034', seq: '23', to_res: A}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '14769795', seq: '23', to_res: H}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '1924344', seq: '23', to_res: H}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '15014127', seq: '23', to_res: H}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '15509574', seq: '23', to_res: H}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '15877050', seq: '23', to_res: H}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '16049034', seq: '23', to_res: H}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '16049034', seq: '23', to_res: L}
- {entry_name: OPSD_HUMAN, from_res: L, pubmed: '10443011', seq: '40', to_res: T}
- {entry_name: OPSD_HUMAN, from_res: L, pubmed: '11513812', seq: '40', to_res: T}
- {entry_name: OPSD_HUMAN, from_res: L, pubmed: '12627944', seq: '40', to_res: T}
- {entry_name: OPSD_HUMAN, from_res: F, pubmed: '1924344', seq: '45', to_res: L}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '8253795', seq: '51', to_res: V}
- {entry_name: OPSD_HUMAN, from_res: T, pubmed: '1924344', seq: '58', to_res: R}
- {entry_name: OPSD_HUMAN, from_res: D, pubmed: '10532961', seq: '83', to_res: N}
- {entry_name: OPSD_HUMAN, from_res: V, pubmed: '1924344', seq: '87', to_res: D}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '1924344', seq: '89', to_res: D}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '15014127', seq: '90', to_res: D}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '15306683', seq: '90', to_res: D}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '15914464', seq: '90', to_res: D}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '16565402', seq: '90', to_res: V}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '1924344', seq: '106', to_res: W}
- {entry_name: OPSD_HUMAN, from_res: N, pubmed: '11495910', seq: '111', to_res: A}
- {entry_name: OPSD_HUMAN, from_res: N, pubmed: '11495910', seq: '111', to_res: W}
- {entry_name: OPSD_HUMAN, from_res: E, pubmed: '8652533', seq: '113', to_res: A}
- {entry_name: OPSD_HUMAN, from_res: E, pubmed: '8652533', seq: '113', to_res: D}
- {entry_name: OPSD_HUMAN, from_res: E, pubmed: '8652533', seq: '113', to_res: Q}
- {entry_name: OPSD_HUMAN, from_res: E, pubmed: '9144172', seq: '113', to_res: Q}
- {entry_name: OPSD_HUMAN, from_res: E, pubmed: '15306683', seq: '113', to_res: Q}
- {entry_name: OPSD_HUMAN, from_res: A, pubmed: '8652533', seq: '117', to_res: E}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '9425074', seq: '121', to_res: A}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '9425074', seq: '121', to_res: I}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '9425074', seq: '121', to_res: L}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '15667221', seq: '121', to_res: L}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '9425074', seq: '121', to_res: V}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '9425074', seq: '121', to_res: W}
- {entry_name: OPSD_HUMAN, from_res: E, pubmed: '10532961', seq: '134', to_res: Q}
- {entry_name: OPSD_HUMAN, from_res: R, pubmed: '1924344', seq: '135', to_res: L}
- {entry_name: OPSD_HUMAN, from_res: R, pubmed: '1924344', seq: '135', to_res: W}
- {entry_name: OPSD_HUMAN, from_res: W, pubmed: '16492774', seq: '175', to_res: C}
- {entry_name: OPSD_HUMAN, from_res: Y, pubmed: '1924344', seq: '178', to_res: C}
- {entry_name: OPSD_HUMAN, from_res: C, pubmed: '9477956', seq: '185', to_res: S}
- {entry_name: OPSD_HUMAN, from_res: G, pubmed: '15509574', seq: '188', to_res: R}
- {entry_name: OPSD_HUMAN, from_res: Y, pubmed: '16492774', seq: '206', to_res: C}
- {entry_name: OPSD_HUMAN, from_res: M, pubmed: '15306683', seq: '257', to_res: Y}
- {entry_name: OPSD_HUMAN, from_res: F, pubmed: '9425074', seq: '261', to_res: A}
- {entry_name: OPSD_HUMAN, from_res: F, pubmed: '15667221', seq: '261', to_res: A}
- {entry_name: OPSD_HUMAN, from_res: A, pubmed: '15772376', seq: '292', to_res: S}
- {entry_name: OPSD_HUMAN, from_res: K, pubmed: '9391065', seq: '296', to_res: E}
- {entry_name: OPSD_HUMAN, from_res: K, pubmed: '15014127', seq: '296', to_res: E}
- {entry_name: OPSD_HUMAN, from_res: K, pubmed: '15914464', seq: '296', to_res: E}
- {entry_name: OPSD_HUMAN, from_res: K, pubmed: '9391065', seq: '296', to_res: G}
- {entry_name: OPSD_HUMAN, from_res: K, pubmed: '9391065', seq: '296', to_res: M}
- {entry_name: OPSD_HUMAN, from_res: K, pubmed: '16399688', seq: '296', to_res: R}
- {entry_name: OPSD_HUMAN, from_res: V, pubmed: '8253795', seq: '345', to_res: M}
- {entry_name: OPSD_HUMAN, from_res: V, pubmed: '15509574', seq: '345', to_res: M}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '15844309', seq: '347', to_res: L}
- {entry_name: OPSD_HUMAN, from_res: P, pubmed: '8253795', seq: '347', to_res: S}
- {entry_name: OPSD_MOUSE, from_res: V, pubmed: '12466267', seq: '87', to_res: D}
- {entry_name: OPSD_MOUSE, from_res: G, pubmed: '12466267', seq: '89', to_res: D}
- {entry_name: OPSD_MOUSE, from_res: G, pubmed: '12297272', seq: '90', to_res: D}
- {entry_name: OPSD_MOUSE, from_res: G, pubmed: '12466267', seq: '90', to_res: D}
- {entry_name: OPSD_MOUSE, from_res: G, pubmed: '15349976', seq: '90', to_res: D}
- {entry_name: OPSD_MOUSE, from_res: T, pubmed: '12466267', seq: '94', to_res: D}
- {entry_name: OPSD_MOUSE, from_res: T, pubmed: '12466267', seq: '94', to_res: I}
- {entry_name: OPSD_MOUSE, from_res: T, pubmed: '12466267', seq: '94', to_res: K}
- {entry_name: OPSD_MOUSE, from_res: T, pubmed: '12466267', seq: '94', to_res: S}
- {entry_name: OPSD_MOUSE, from_res: E, pubmed: '12466267', seq: '113', to_res: Q}
- {entry_name: OPSD_MOUSE, from_res: M, pubmed: '12466267', seq: '257', to_res: A}
- {entry_name: OPSD_MOUSE, from_res: A, pubmed: '15726226', seq: '269', to_res: G}
- {entry_name: OPSD_MOUSE, from_res: I, pubmed: '11782458', seq: '286', to_res: A}
- {entry_name: OPSD_MOUSE, from_res: A, pubmed: '12466267', seq: '292', to_res: E}
- {entry_name: OPSD_MOUSE, from_res: C, pubmed: '15851469', seq: '322', to_res: T}
- {entry_name: OPSD_MOUSE, from_res: C, pubmed: '15851469', seq: '323', to_res: S}
- {entry_name: OPSD_MOUSE, from_res: E, pubmed: '15726226', seq: '341', to_res: X}
- {entry_name: OPSD_MOUSE, from_res: Q, pubmed: '15726226', seq: '344', to_res: X}
- {entry_name: OPSD_MOUSE, from_res: V, pubmed: '15726226', seq: '345', to_res: M}
- {entry_name: OPSD_MOUSE, from_res: P, pubmed: '12297272', seq: '347', to_res: L}
- {entry_name: OPSD_MOUSE, from_res: P, pubmed: '15726226', seq: '347', to_res: L}
- {entry_name: OPSD_RAT, from_res: P, pubmed: '12634110', seq: '23', to_res: H}
- {entry_name: OPSD_RAT, from_res: S, pubmed: '11455025', seq: '281', to_res: A}
- {entry_name: OPSG4_BRARE, from_res: F, pubmed: '15647516', seq: '46', to_res: T}
- {entry_name: OPSG4_BRARE, from_res: E, pubmed: '15647516', seq: '122', to_res: Q}
- {entry_name: OPSG4_BRARE, from_res: M, pubmed: '15647516', seq: '207', to_res: L}
- {entry_name: OPSG4_BRARE, from_res: A, pubmed: '15647516', seq: '292', to_res: S}
- {entry_name: OPSG_MOUSE, from_res: S, pubmed: '16286727', seq: '308', to_res: A}
- {entry_name: OPSX_HUMAN, from_res: I, pubmed: '15623516', seq: '49', to_res: A}
- {entry_name: OPSX_HUMAN, from_res: S, pubmed: '15623516', seq: '82', to_res: A}
- {entry_name: OPSX_HUMAN, from_res: G, pubmed: '15623516', seq: '109', to_res: A}
- {entry_name: OPSX_HUMAN, from_res: L, pubmed: '15623516', seq: '116', to_res: T}
- {entry_name: OPSX_HUMAN, from_res: T, pubmed: '12200476', seq: '213', to_res: I}
- {entry_name: OR6F1_HUMAN, from_res: C, pubmed: '14962981', seq: '123', to_res: R}
- {entry_name: OR8D4_HUMAN, from_res: C, pubmed: '14962981', seq: '235', to_res: Y}
- {entry_name: OR8K1_HUMAN, from_res: W, pubmed: '14962981', seq: '102', to_res: R}
- {entry_name: OXYR_HUMAN, from_res: N, pubmed: '11274341', seq: '8', to_res: D}
- {entry_name: OXYR_HUMAN, from_res: N, pubmed: '9433921', seq: '8', to_res: D}
- {entry_name: OXYR_HUMAN, from_res: N, pubmed: '11274341', seq: '15', to_res: D}
- {entry_name: OXYR_HUMAN, from_res: N, pubmed: '9433921', seq: '26', to_res: D}
- {entry_name: OXYR_HUMAN, from_res: P, pubmed: '11955056', seq: '32', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: R, pubmed: '11955056', seq: '33', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: R, pubmed: '11955056', seq: '34', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: N, pubmed: '11955056', seq: '35', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: E, pubmed: '11955056', seq: '36', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: N, pubmed: '10385703', seq: '57', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: N, pubmed: '11274341', seq: '57', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: M, pubmed: '11337500', seq: '78', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '10385703', seq: '85', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '11274341', seq: '85', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '11274341', seq: '85', to_res: E}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '11274341', seq: '85', to_res: N}
- {entry_name: OXYR_HUMAN, from_res: G, pubmed: '11274341', seq: '107', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: M, pubmed: '11337500', seq: '123', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '10385703', seq: '136', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '11274341', seq: '136', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '16042376', seq: '136', to_res: N}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '10385703', seq: '136', to_res: Q}
- {entry_name: OXYR_HUMAN, from_res: D, pubmed: '11274341', seq: '136', to_res: Q}
- {entry_name: OXYR_HUMAN, from_res: R, pubmed: '10385703', seq: '137', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: R, pubmed: '11274341', seq: '137', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: R, pubmed: '10385703', seq: '137', to_res: K}
- {entry_name: OXYR_HUMAN, from_res: P, pubmed: '11440186', seq: '197', to_res: R}
- {entry_name: OXYR_HUMAN, from_res: Y, pubmed: '11440186', seq: '200', to_res: W}
- {entry_name: OXYR_HUMAN, from_res: W, pubmed: '11440186', seq: '203', to_res: L}
- {entry_name: OXYR_HUMAN, from_res: Y, pubmed: '11274341', seq: '209', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: Y, pubmed: '11274341', seq: '209', to_res: F}
- {entry_name: OXYR_HUMAN, from_res: K, pubmed: '11923477', seq: '268', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: K, pubmed: '11923477', seq: '270', to_res: V}
- {entry_name: OXYR_HUMAN, from_res: F, pubmed: '11274341', seq: '284', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: F, pubmed: '11274341', seq: '284', to_res: Y}
- {entry_name: OXYR_HUMAN, from_res: F, pubmed: '11274341', seq: '293', to_res: I}
- {entry_name: OXYR_HUMAN, from_res: M, pubmed: '11337500', seq: '296', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: M, pubmed: '11440186', seq: '296', to_res: T}
- {entry_name: OXYR_HUMAN, from_res: M, pubmed: '11337500', seq: '315', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: M, pubmed: '11337500', seq: '330', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: S, pubmed: '11279203', seq: '348', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: T, pubmed: '11279203', seq: '360', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: S, pubmed: '11279203', seq: '363', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: S, pubmed: '11279203', seq: '370', to_res: A}
- {entry_name: OXYR_HUMAN, from_res: S, pubmed: '11279203', seq: '379', to_res: A}
- {entry_name: OXYR_RAT, from_res: T, pubmed: '11279203', seq: '332', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: C, pubmed: '10329657', seq: '42', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: C, pubmed: '10329657', seq: '124', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: K, pubmed: '10090736', seq: '125', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: K, pubmed: '10329657', seq: '125', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '9281613', seq: '128', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: F, pubmed: '9281613', seq: '131', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: F, pubmed: '9554879', seq: '131', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: H, pubmed: '9281613', seq: '132', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: Y, pubmed: '9281613', seq: '136', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '195', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: K, pubmed: '10329657', seq: '196', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: K, pubmed: '10329657', seq: '198', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: C, pubmed: '10329657', seq: '202', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: D, pubmed: '10090736', seq: '204', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: D, pubmed: '10329657', seq: '204', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: D, pubmed: '10329657', seq: '204', to_res: E}
- {entry_name: P2RY1_HUMAN, from_res: D, pubmed: '10329657', seq: '204', to_res: N}
- {entry_name: P2RY1_HUMAN, from_res: D, pubmed: '10329657', seq: '208', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10090736', seq: '209', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10329657', seq: '209', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10090736', seq: '209', to_res: D}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10329657', seq: '209', to_res: D}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10090736', seq: '209', to_res: Q}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10329657', seq: '209', to_res: Q}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10090736', seq: '209', to_res: R}
- {entry_name: P2RY1_HUMAN, from_res: E, pubmed: '10329657', seq: '209', to_res: R}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '212', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: T, pubmed: '9281613', seq: '221', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: T, pubmed: '9554879', seq: '221', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: T, pubmed: '9281613', seq: '222', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: F, pubmed: '9281613', seq: '226', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: F, pubmed: '9554879', seq: '226', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: H, pubmed: '9281613', seq: '277', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: H, pubmed: '9554879', seq: '277', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: K, pubmed: '9281613', seq: '280', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: K, pubmed: '9554879', seq: '280', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '285', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10090736', seq: '287', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '287', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10090736', seq: '287', to_res: E}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '287', to_res: E}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10090736', seq: '287', to_res: K}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '287', to_res: K}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10090736', seq: '287', to_res: Q}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '287', to_res: Q}
- {entry_name: P2RY1_HUMAN, from_res: D, pubmed: '10329657', seq: '289', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: C, pubmed: '10329657', seq: '296', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: D, pubmed: '10329657', seq: '300', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '10329657', seq: '301', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: Q, pubmed: '9281613', seq: '307', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: Q, pubmed: '9554879', seq: '307', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '9281613', seq: '310', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '9281613', seq: '310', to_res: K}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '9554879', seq: '310', to_res: K}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '9281613', seq: '310', to_res: S}
- {entry_name: P2RY1_HUMAN, from_res: S, pubmed: '9281613', seq: '314', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: S, pubmed: '9281613', seq: '314', to_res: R}
- {entry_name: P2RY1_HUMAN, from_res: S, pubmed: '9281613', seq: '314', to_res: T}
- {entry_name: P2RY1_HUMAN, from_res: S, pubmed: '9281613', seq: '317', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: S, pubmed: '9554879', seq: '317', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '15509659', seq: '333', to_res: A}
- {entry_name: P2RY1_HUMAN, from_res: R, pubmed: '15509659', seq: '334', to_res: A}
- {entry_name: P2RY1_RAT, from_res: T, pubmed: '9514958', seq: '330', to_res: I}
- {entry_name: P2RY1_RAT, from_res: T, pubmed: '12805284', seq: '339', to_res: A}
- {entry_name: P2RY1_RAT, from_res: K, pubmed: '9514958', seq: '366', to_res: I}
- {entry_name: P2RY2_HUMAN, from_res: T, pubmed: '14978243', seq: '15', to_res: A}
- {entry_name: P2RY2_HUMAN, from_res: Y, pubmed: '14978243', seq: '40', to_res: A}
- {entry_name: P2RY2_HUMAN, from_res: C, pubmed: '14978243', seq: '164', to_res: A}
- {entry_name: P2RY2_HUMAN, from_res: R, pubmed: '15852220', seq: '265', to_res: W}
- {entry_name: P2RY2_HUMAN, from_res: R, pubmed: '15632318', seq: '318', to_res: A}
- {entry_name: P2RY2_HUMAN, from_res: R, pubmed: '15632318', seq: '318', to_res: K}
- {entry_name: P2RY2_RAT, from_res: D, pubmed: '9514958', seq: '349', to_res: V}
- {entry_name: P2RY4_HUMAN, from_res: S, pubmed: '14670966', seq: '177', to_res: N}
- {entry_name: P2RY4_HUMAN, from_res: N, pubmed: '14670966', seq: '178', to_res: A}
- {entry_name: P2RY4_HUMAN, from_res: K, pubmed: '14670966', seq: '179', to_res: N}
- {entry_name: P2RY4_HUMAN, from_res: V, pubmed: '14670966', seq: '183', to_res: I}
- {entry_name: P2RY4_HUMAN, from_res: R, pubmed: '14670966', seq: '190', to_res: L}
- {entry_name: P2RY4_HUMAN, from_res: S, pubmed: '11114308', seq: '333', to_res: A}
- {entry_name: P2RY4_HUMAN, from_res: S, pubmed: '11114308', seq: '334', to_res: A}
- {entry_name: P2RY4_HUMAN, from_res: S, pubmed: '11114308', seq: '339', to_res: A}
- {entry_name: P2RY6_HUMAN, from_res: A, pubmed: '11114308', seq: '237', to_res: S}
- {entry_name: P2RY9_HUMAN, from_res: S, pubmed: '11278310', seq: '17', to_res: N}
- {entry_name: P2RY9_HUMAN, from_res: K, pubmed: '11278310', seq: '95', to_res: R}
- {entry_name: PAR1_HUMAN, from_res: R, pubmed: '11157484', seq: '28', to_res: C}
- {entry_name: PAR1_HUMAN, from_res: D, pubmed: '7608215', seq: '39', to_res: G}
- {entry_name: PAR1_HUMAN, from_res: S, pubmed: '10978167', seq: '42', to_res: P}
- {entry_name: PAR1_HUMAN, from_res: S, pubmed: '8557676', seq: '42', to_res: P}
- {entry_name: PAR1_HUMAN, from_res: S, pubmed: '8955127', seq: '42', to_res: P}
- {entry_name: PAR1_HUMAN, from_res: K, pubmed: '10194379', seq: '76', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: K, pubmed: '10194379', seq: '82', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: F, pubmed: '11093752', seq: '87', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: I, pubmed: '11093752', seq: '88', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: S, pubmed: '11093752', seq: '89', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '90', to_res: Q}
- {entry_name: PAR1_HUMAN, from_res: D, pubmed: '11093752', seq: '91', to_res: N}
- {entry_name: PAR1_HUMAN, from_res: S, pubmed: '11093752', seq: '93', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: Y, pubmed: '11093752', seq: '95', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: L, pubmed: '11093752', seq: '96', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: T, pubmed: '11093752', seq: '97', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: L, pubmed: '10194379', seq: '103', to_res: M}
- {entry_name: PAR1_HUMAN, from_res: D, pubmed: '11093752', seq: '167', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '173', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: C, pubmed: '11093752', seq: '175', to_res: S}
- {entry_name: PAR1_HUMAN, from_res: R, pubmed: '11588040', seq: '214', to_res: Q}
- {entry_name: PAR1_HUMAN, from_res: R, pubmed: '11588040', seq: '214', to_res: W}
- {entry_name: PAR1_HUMAN, from_res: K, pubmed: '11683636', seq: '240', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '241', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: C, pubmed: '11093752', seq: '254', to_res: S}
- {entry_name: PAR1_HUMAN, from_res: D, pubmed: '11093752', seq: '256', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: D, pubmed: '11093752', seq: '256', to_res: N}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '260', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '10556949', seq: '260', to_res: R}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '264', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: S, pubmed: '14699102', seq: '299', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: S, pubmed: '11494060', seq: '306', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '347', to_res: A}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '347', to_res: N}
- {entry_name: PAR1_HUMAN, from_res: E, pubmed: '11093752', seq: '347', to_res: Q}
- {entry_name: PAR1_MOUSE, from_res: S, pubmed: '14699102', seq: '297', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: N, pubmed: '12171601', seq: '30', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: R, pubmed: '9354658', seq: '36', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: S, pubmed: '10978167', seq: '37', to_res: P}
- {entry_name: PAR2_HUMAN, from_res: S, pubmed: '11304490', seq: '195', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: S, pubmed: '7641816', seq: '195', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: S, pubmed: '8537445', seq: '195', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: L, pubmed: '12171601', seq: '221', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: N, pubmed: '12171601', seq: '222', to_res: A}
- {entry_name: PAR2_HUMAN, from_res: N, pubmed: '12171601', seq: '222', to_res: Q}
- {entry_name: PAR2_HUMAN, from_res: I, pubmed: '12171601', seq: '223', to_res: A}
- {entry_name: PAR2_MOUSE, from_res: R, pubmed: '9437201', seq: '32', to_res: C}
- {entry_name: PAR2_RAT, from_res: S, pubmed: '11701462', seq: '133', to_res: A}
- {entry_name: PAR2_RAT, from_res: S, pubmed: '11701463', seq: '133', to_res: A}
- {entry_name: PAR3_HUMAN, from_res: S, pubmed: '9712882', seq: '188', to_res: A}
- {entry_name: PAR3_HUMAN, from_res: V, pubmed: '8621593', seq: '238', to_res: L}
- {entry_name: PAR3_HUMAN, from_res: Q, pubmed: '11683636', seq: '239', to_res: A}
- {entry_name: PD2R_MOUSE, from_res: A, pubmed: '10827082', seq: '19', to_res: P}
- {entry_name: PD2R_MOUSE, from_res: G, pubmed: '10827082', seq: '22', to_res: S}
- {entry_name: PD2R_MOUSE, from_res: L, pubmed: '10827082', seq: '25', to_res: M}
- {entry_name: PD2R_MOUSE, from_res: L, pubmed: '10827082', seq: '30', to_res: V}
- {entry_name: PE2R2_HUMAN, from_res: Q, pubmed: '9730918', seq: '97', to_res: S}
- {entry_name: PE2R2_HUMAN, from_res: P, pubmed: '9730918', seq: '104', to_res: R}
- {entry_name: PE2R2_HUMAN, from_res: Y, pubmed: '9730918', seq: '111', to_res: A}
- {entry_name: PE2R2_HUMAN, from_res: S, pubmed: '9730918', seq: '120', to_res: G}
- {entry_name: PE2R2_HUMAN, from_res: R, pubmed: '9730918', seq: '190', to_res: N}
- {entry_name: PE2R2_HUMAN, from_res: H, pubmed: '9730918', seq: '226', to_res: Y}
- {entry_name: PE2R2_HUMAN, from_res: Q, pubmed: '9730918', seq: '299', to_res: L}
- {entry_name: PE2R2_HUMAN, from_res: R, pubmed: '9730918', seq: '302', to_res: E}
- {entry_name: PE2R2_HUMAN, from_res: R, pubmed: '9730918', seq: '302', to_res: Q}
- {entry_name: PE2R2_HUMAN, from_res: L, pubmed: '9730918', seq: '304', to_res: Y}
- {entry_name: PE2R2_HUMAN, from_res: S, pubmed: '9730918', seq: '305', to_res: A}
- {entry_name: PE2R2_HUMAN, from_res: F, pubmed: '9730918', seq: '315', to_res: Y}
- {entry_name: PE2R3_BOVIN, from_res: R, pubmed: '7608175', seq: '332', to_res: Q}
- {entry_name: PE2R3_MOUSE, from_res: T, pubmed: '8615686', seq: '221', to_res: A}
- {entry_name: PE2R3_MOUSE, from_res: S, pubmed: '8615686', seq: '268', to_res: A}
- {entry_name: PE2R3_MOUSE, from_res: S, pubmed: '8615686', seq: '272', to_res: A}
- {entry_name: PE2R3_MOUSE, from_res: R, pubmed: '9065782', seq: '309', to_res: L}
- {entry_name: PE2R3_MOUSE, from_res: R, pubmed: '9065782', seq: '309', to_res: N}
- {entry_name: PE2R3_MOUSE, from_res: R, pubmed: '9065782', seq: '309', to_res: Q}
- {entry_name: PE2R3_RABIT, from_res: W, pubmed: '9153190', seq: '199', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: W, pubmed: '9153190', seq: '199', to_res: Y}
- {entry_name: PE2R3_RABIT, from_res: P, pubmed: '9153190', seq: '200', to_res: S}
- {entry_name: PE2R3_RABIT, from_res: T, pubmed: '9153190', seq: '202', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: W, pubmed: '9153190', seq: '203', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: C, pubmed: '9153190', seq: '204', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: F, pubmed: '9153190', seq: '205', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: K, pubmed: '9016347', seq: '300', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: R, pubmed: '9016347', seq: '329', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: R, pubmed: '9153190', seq: '329', to_res: A}
- {entry_name: PE2R3_RABIT, from_res: R, pubmed: '9016347', seq: '329', to_res: E}
- {entry_name: PE2R3_RABIT, from_res: D, pubmed: '9016347', seq: '338', to_res: A}
- {entry_name: PE2R3_RAT, from_res: N, pubmed: '10970800', seq: '16', to_res: Q}
- {entry_name: PE2R4_HUMAN, from_res: S, pubmed: '10051157', seq: '370', to_res: A}
- {entry_name: PE2R4_HUMAN, from_res: S, pubmed: '10051157', seq: '371', to_res: A}
- {entry_name: PF2R_HUMAN, from_res: E, pubmed: '15651980', seq: '132', to_res: T}
- {entry_name: PI2R_BOVIN, from_res: S, pubmed: '16271145', seq: '168', to_res: T}
- {entry_name: PI2R_BOVIN, from_res: R, pubmed: '16271145', seq: '173', to_res: A}
- {entry_name: PI2R_BOVIN, from_res: R, pubmed: '16271145', seq: '173', to_res: T}
- {entry_name: PI2R_HUMAN, from_res: C, pubmed: '11961139', seq: '5', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: N, pubmed: '12446735', seq: '7', to_res: P}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '17', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '12446735', seq: '20', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '24', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: V, pubmed: '11854299', seq: '25', to_res: M}
- {entry_name: PI2R_HUMAN, from_res: V, pubmed: '12446735', seq: '25', to_res: M}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '16114876', seq: '42', to_res: G}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '16114876', seq: '43', to_res: G}
- {entry_name: PI2R_HUMAN, from_res: A, pubmed: '16114876', seq: '44', to_res: G}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '16114876', seq: '45', to_res: E}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '16114876', seq: '45', to_res: K}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '16114876', seq: '45', to_res: L}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '16114876', seq: '45', to_res: Q}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '16114876', seq: '45', to_res: T}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '16114876', seq: '46', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '16114876', seq: '46', to_res: G}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '16114876', seq: '47', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '16114876', seq: '47', to_res: G}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '16114876', seq: '47', to_res: L}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '16114876', seq: '47', to_res: T}
- {entry_name: PI2R_HUMAN, from_res: A, pubmed: '16114876', seq: '48', to_res: G}
- {entry_name: PI2R_HUMAN, from_res: A, pubmed: '16114876', seq: '48', to_res: L}
- {entry_name: PI2R_HUMAN, from_res: A, pubmed: '16114876', seq: '48', to_res: T}
- {entry_name: PI2R_HUMAN, from_res: A, pubmed: '16114876', seq: '48', to_res: V}
- {entry_name: PI2R_HUMAN, from_res: D, pubmed: '12446735', seq: '60', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '12446735', seq: '65', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '66', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: L, pubmed: '12446735', seq: '67', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: L, pubmed: '12446735', seq: '67', to_res: W}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '12446735', seq: '68', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '69', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: V, pubmed: '12446735', seq: '71', to_res: F}
- {entry_name: PI2R_HUMAN, from_res: V, pubmed: '12446735', seq: '71', to_res: L}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '72', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: Y, pubmed: '12446735', seq: '75', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: Y, pubmed: '12446735', seq: '75', to_res: F}
- {entry_name: PI2R_HUMAN, from_res: Y, pubmed: '12446735', seq: '75', to_res: S}
- {entry_name: PI2R_HUMAN, from_res: N, pubmed: '12446735', seq: '78', to_res: P}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '89', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: D, pubmed: '12446735', seq: '93', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '95', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '97', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: M, pubmed: '12446735', seq: '99', to_res: L}
- {entry_name: PI2R_HUMAN, from_res: T, pubmed: '12446735', seq: '100', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '101', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '102', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '12446735', seq: '106', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '141', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '150', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '154', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '179', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '184', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '12446735', seq: '185', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: Y, pubmed: '12446735', seq: '188', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '11854299', seq: '212', to_res: H}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '12446735', seq: '212', to_res: H}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '12446735', seq: '252', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '254', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '12446735', seq: '258', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '260', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: E, pubmed: '12446735', seq: '271', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: D, pubmed: '12446735', seq: '274', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '278', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: R, pubmed: '12446735', seq: '279', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '280', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: Y, pubmed: '12446735', seq: '281', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: F, pubmed: '12446735', seq: '283', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '285', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: P, pubmed: '11961139', seq: '289', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: C, pubmed: '12488443', seq: '308', to_res: S}
- {entry_name: PI2R_HUMAN, from_res: C, pubmed: '12488443', seq: '309', to_res: S}
- {entry_name: PI2R_HUMAN, from_res: C, pubmed: '12488443', seq: '311', to_res: S}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '10889200', seq: '328', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '12016224', seq: '328', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '9722557', seq: '328', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '10889200', seq: '374', to_res: A}
- {entry_name: PI2R_HUMAN, from_res: S, pubmed: '9722557', seq: '374', to_res: A}
- {entry_name: PTAFR_CAVPO, from_res: S, pubmed: '9545329', seq: '305', to_res: G}
- {entry_name: PTAFR_CAVPO, from_res: T, pubmed: '9545329', seq: '335', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: P, pubmed: '7559653', seq: '3', to_res: L}
- {entry_name: PTAFR_HUMAN, from_res: H, pubmed: '7559653', seq: '4', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '7559653', seq: '5', to_res: S}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '10212233', seq: '63', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '11309383', seq: '63', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '11561099', seq: '63', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '12834809', seq: '63', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '8645288', seq: '63', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '9065450', seq: '63', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '9261140', seq: '63', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: C, pubmed: '10212233', seq: '90', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: C, pubmed: '9037196', seq: '90', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: C, pubmed: '10212233', seq: '90', to_res: S}
- {entry_name: PTAFR_HUMAN, from_res: C, pubmed: '9037196', seq: '95', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: F, pubmed: '8798529', seq: '97', to_res: G}
- {entry_name: PTAFR_HUMAN, from_res: F, pubmed: '8798529', seq: '98', to_res: G}
- {entry_name: PTAFR_HUMAN, from_res: N, pubmed: '7559653', seq: '169', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: C, pubmed: '10212233', seq: '173', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: C, pubmed: '9037196', seq: '173', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: C, pubmed: '10212233', seq: '173', to_res: S}
- {entry_name: PTAFR_HUMAN, from_res: A, pubmed: '11560941', seq: '224', to_res: D}
- {entry_name: PTAFR_HUMAN, from_res: A, pubmed: '8626474', seq: '230', to_res: E}
- {entry_name: PTAFR_HUMAN, from_res: A, pubmed: '9261140', seq: '230', to_res: E}
- {entry_name: PTAFR_HUMAN, from_res: A, pubmed: '8626474', seq: '230', to_res: Q}
- {entry_name: PTAFR_HUMAN, from_res: L, pubmed: '11561099', seq: '231', to_res: R}
- {entry_name: PTAFR_HUMAN, from_res: L, pubmed: '8626474', seq: '231', to_res: R}
- {entry_name: PTAFR_HUMAN, from_res: N, pubmed: '8798529', seq: '285', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: N, pubmed: '10212233', seq: '285', to_res: I}
- {entry_name: PTAFR_HUMAN, from_res: N, pubmed: '8798529', seq: '285', to_res: I}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '10212233', seq: '289', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '11309383', seq: '289', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '11729201', seq: '289', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '12834809', seq: '289', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '14500680', seq: '289', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '8798529', seq: '289', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '9261140', seq: '289', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '11729201', seq: '289', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '8798529', seq: '289', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: D, pubmed: '9261140', seq: '289', to_res: N}
- {entry_name: PTAFR_HUMAN, from_res: Y, pubmed: '10212233', seq: '293', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: Y, pubmed: '11309383', seq: '293', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: Y, pubmed: '11729201', seq: '293', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: Y, pubmed: '12834809', seq: '293', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: Y, pubmed: '9261140', seq: '293', to_res: A}
- {entry_name: PTAFR_HUMAN, from_res: Y, pubmed: '11729201', seq: '293', to_res: F}
- {entry_name: PTAFR_HUMAN, from_res: Y, pubmed: '9261140', seq: '293', to_res: F}
- {entry_name: PTHR1_DIDMA, from_res: I, pubmed: '8621578', seq: '187', to_res: M}
- {entry_name: PTHR1_DIDMA, from_res: H, pubmed: '8969199', seq: '220', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: H, pubmed: '8969199', seq: '220', to_res: D}
- {entry_name: PTHR1_DIDMA, from_res: H, pubmed: '9178745', seq: '220', to_res: R}
- {entry_name: PTHR1_DIDMA, from_res: I, pubmed: '8621578', seq: '234', to_res: N}
- {entry_name: PTHR1_DIDMA, from_res: N, pubmed: '11726668', seq: '289', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: H, pubmed: '10358054', seq: '301', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: R, pubmed: '10674397', seq: '377', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: V, pubmed: '10674397', seq: '378', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: V, pubmed: '8969199', seq: '378', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: L, pubmed: '10067856', seq: '379', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: L, pubmed: '10674397', seq: '379', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: L, pubmed: '8969199', seq: '379', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: T, pubmed: '10067856', seq: '381', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: T, pubmed: '8969199', seq: '381', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: K, pubmed: '10067856', seq: '382', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: K, pubmed: '11726668', seq: '382', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: K, pubmed: '8969199', seq: '382', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: L, pubmed: '8969199', seq: '383', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: R, pubmed: '8969199', seq: '384', to_res: A}
- {entry_name: PTHR1_DIDMA, from_res: Y, pubmed: '10358054', seq: '397', to_res: H}
- {entry_name: PTHR1_DIDMA, from_res: R, pubmed: '10358054', seq: '398', to_res: H}
- {entry_name: PTHR1_DIDMA, from_res: K, pubmed: '10358054', seq: '399', to_res: H}
- {entry_name: PTHR1_DIDMA, from_res: L, pubmed: '10358054', seq: '400', to_res: H}
- {entry_name: PTHR1_DIDMA, from_res: L, pubmed: '10358054', seq: '401', to_res: H}
- {entry_name: PTHR1_DIDMA, from_res: K, pubmed: '10358054', seq: '402', to_res: H}
- {entry_name: PTHR1_DIDMA, from_res: S, pubmed: '9849959', seq: '467', to_res: T}
- {entry_name: PTHR1_DIDMA, from_res: S, pubmed: '9849959', seq: '469', to_res: T}
- {entry_name: PTHR1_DIDMA, from_res: S, pubmed: '9849959', seq: '485', to_res: T}
- {entry_name: PTHR1_DIDMA, from_res: S, pubmed: '9849959', seq: '486', to_res: T}
- {entry_name: PTHR1_DIDMA, from_res: S, pubmed: '9849959', seq: '489', to_res: T}
- {entry_name: PTHR1_HUMAN, from_res: P, pubmed: '10564229', seq: '132', to_res: L}
- {entry_name: PTHR1_HUMAN, from_res: H, pubmed: '10487664', seq: '223', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: H, pubmed: '10521488', seq: '223', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: H, pubmed: '10564229', seq: '223', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: H, pubmed: '11145746', seq: '223', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: H, pubmed: '11160151', seq: '223', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: H, pubmed: '11553625', seq: '223', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: H, pubmed: '9178745', seq: '223', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: T, pubmed: '10487664', seq: '410', to_res: P}
- {entry_name: PTHR1_HUMAN, from_res: T, pubmed: '10521488', seq: '410', to_res: P}
- {entry_name: PTHR1_HUMAN, from_res: T, pubmed: '10564229', seq: '410', to_res: P}
- {entry_name: PTHR1_HUMAN, from_res: T, pubmed: '11145746', seq: '410', to_res: P}
- {entry_name: PTHR1_HUMAN, from_res: T, pubmed: '11553625', seq: '410', to_res: P}
- {entry_name: PTHR1_HUMAN, from_res: T, pubmed: '9178745', seq: '410', to_res: P}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '10617579', seq: '414', to_res: L}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '9712875', seq: '414', to_res: L}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '11553625', seq: '414', to_res: V}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '10617579', seq: '425', to_res: L}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '11553625', seq: '425', to_res: L}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '9712875', seq: '425', to_res: L}
- {entry_name: PTHR1_HUMAN, from_res: Q, pubmed: '9482662', seq: '440', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '11553625', seq: '441', to_res: L}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '11553625', seq: '445', to_res: I}
- {entry_name: PTHR1_HUMAN, from_res: I, pubmed: '10487664', seq: '458', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: I, pubmed: '10564229', seq: '458', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: I, pubmed: '11553625', seq: '458', to_res: R}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '12920119', seq: '593', to_res: A}
- {entry_name: PTHR1_HUMAN, from_res: M, pubmed: '15611080', seq: '593', to_res: A}
- {entry_name: PTHR1_MOUSE, from_res: H, pubmed: '9391087', seq: '223', to_res: R}
- {entry_name: PTHR1_MOUSE, from_res: T, pubmed: '9391087', seq: '410', to_res: P}
- {entry_name: PTHR1_RAT, from_res: T, pubmed: '9642250', seq: '33', to_res: A}
- {entry_name: PTHR1_RAT, from_res: Q, pubmed: '9642250', seq: '37', to_res: A}
- {entry_name: PTHR1_RAT, from_res: L, pubmed: '9642250', seq: '40', to_res: M}
- {entry_name: PTHR1_RAT, from_res: L, pubmed: '9642250', seq: '41', to_res: M}
- {entry_name: PTHR1_RAT, from_res: M, pubmed: '9642250', seq: '63', to_res: I}
- {entry_name: PTHR1_RAT, from_res: R, pubmed: '8662729', seq: '233', to_res: H}
- {entry_name: PTHR1_RAT, from_res: R, pubmed: '8662729', seq: '233', to_res: K}
- {entry_name: PTHR1_RAT, from_res: R, pubmed: '8662729', seq: '233', to_res: N}
- {entry_name: PTHR1_RAT, from_res: R, pubmed: '8662729', seq: '233', to_res: Q}
- {entry_name: PTHR1_RAT, from_res: K, pubmed: '9054374', seq: '319', to_res: R}
- {entry_name: PTHR1_RAT, from_res: L, pubmed: '9572838', seq: '385', to_res: M}
- {entry_name: PTHR1_RAT, from_res: Q, pubmed: '8662729', seq: '451', to_res: K}
- {entry_name: PTHR1_RAT, from_res: A, pubmed: '9572838', seq: '480', to_res: M}
- {entry_name: PTHR1_RAT, from_res: A, pubmed: '9572838', seq: '537', to_res: M}
- {entry_name: PTHR1_RAT, from_res: A, pubmed: '9572838', seq: '577', to_res: M}
- {entry_name: PTHR2_HUMAN, from_res: H, pubmed: '11897155', seq: '9', to_res: A}
- {entry_name: PTHR2_HUMAN, from_res: F, pubmed: '9461563', seq: '156', to_res: L}
- {entry_name: PTHR2_HUMAN, from_res: A, pubmed: '9461563', seq: '160', to_res: T}
- {entry_name: PTHR2_HUMAN, from_res: H, pubmed: '9461563', seq: '180', to_res: R}
- {entry_name: PTHR2_HUMAN, from_res: R, pubmed: '9461563', seq: '190', to_res: E}
- {entry_name: PTHR2_HUMAN, from_res: T, pubmed: '9461563', seq: '192', to_res: V}
- {entry_name: PTHR2_HUMAN, from_res: V, pubmed: '9461563', seq: '196', to_res: I}
- {entry_name: PTHR2_HUMAN, from_res: V, pubmed: '9461563', seq: '241', to_res: T}
- {entry_name: PTHR2_HUMAN, from_res: M, pubmed: '9461563', seq: '242', to_res: V}
- {entry_name: PTHR2_HUMAN, from_res: I, pubmed: '9461563', seq: '244', to_res: L}
- {entry_name: PTHR2_HUMAN, from_res: A, pubmed: '9461563', seq: '293', to_res: V}
- {entry_name: PTHR2_HUMAN, from_res: A, pubmed: '9461563', seq: '295', to_res: V}
- {entry_name: PTHR2_HUMAN, from_res: V, pubmed: '9461563', seq: '296', to_res: T}
- {entry_name: PTHR2_HUMAN, from_res: A, pubmed: '9461563', seq: '297', to_res: V}
- {entry_name: PTHR2_HUMAN, from_res: Y, pubmed: '9461563', seq: '318', to_res: I}
- {entry_name: PTHR2_HUMAN, from_res: G, pubmed: '9461563', seq: '327', to_res: V}
- {entry_name: PTHR2_HUMAN, from_res: L, pubmed: '9461563', seq: '328', to_res: V}
- {entry_name: PTHR2_HUMAN, from_res: V, pubmed: '9461563', seq: '369', to_res: M}
- {entry_name: PTHR2_HUMAN, from_res: L, pubmed: '9461563', seq: '370', to_res: P}
- {entry_name: PTHR2_HUMAN, from_res: V, pubmed: '9461563', seq: '371', to_res: L}
- {entry_name: PTHR2_HUMAN, from_res: V, pubmed: '9461563', seq: '380', to_res: M}
- {entry_name: PTHR2_HUMAN, from_res: R, pubmed: '9482662', seq: '394', to_res: Q}
- {entry_name: PTHR2_HUMAN, from_res: C, pubmed: '9461563', seq: '397', to_res: Y}
- {entry_name: PTHR2_HUMAN, from_res: L, pubmed: '9461563', seq: '399', to_res: M}
- {entry_name: PTHR2_HUMAN, from_res: F, pubmed: '9461563', seq: '400', to_res: L}
- {entry_name: PTHR2_MOUSE, from_res: Y, pubmed: '12368206', seq: '373', to_res: C}
- {entry_name: Q3MIJ6_HUMAN, from_res: D, pubmed: '16262250', seq: '122', to_res: A}
- {entry_name: Q3MIJ6_HUMAN, from_res: D, pubmed: '16262250', seq: '126', to_res: A}
- {entry_name: Q3MIJ6_HUMAN, from_res: S, pubmed: '16262250', seq: '190', to_res: A}
- {entry_name: Q3MIJ6_HUMAN, from_res: S, pubmed: '16262250', seq: '191', to_res: A}
- {entry_name: Q3MIJ6_HUMAN, from_res: M, pubmed: '16262250', seq: '200', to_res: A}
- {entry_name: Q3MIJ6_HUMAN, from_res: F, pubmed: '16262250', seq: '261', to_res: A}
- {entry_name: Q3MIJ6_HUMAN, from_res: F, pubmed: '16262250', seq: '284', to_res: A}
- {entry_name: Q3TY71_MOUSE, from_res: A, pubmed: '15591052', seq: '2', to_res: E}
- {entry_name: Q3TY71_MOUSE, from_res: R, pubmed: '15689355', seq: '76', to_res: W}
- {entry_name: Q3V0X3_MOUSE, from_res: R, pubmed: '15689355', seq: '41', to_res: Q}
- {entry_name: Q3V0X3_MOUSE, from_res: R, pubmed: '15689355', seq: '41', to_res: W}
- {entry_name: Q3V3A3_MOUSE, from_res: S, pubmed: '15736952', seq: '190', to_res: H}
- {entry_name: Q3V3A3_MOUSE, from_res: L, pubmed: '15736952', seq: '265', to_res: A}
- {entry_name: Q4QRJ0_HUMAN, from_res: T, pubmed: '16338988', seq: '428', to_res: V}
- {entry_name: Q4QRJ0_HUMAN, from_res: S, pubmed: '16338988', seq: '431', to_res: A}
- {entry_name: Q698K7_CAVPO, from_res: V, pubmed: '15209496', seq: '86', to_res: F}
- {entry_name: Q698K7_CAVPO, from_res: V, pubmed: '15209496', seq: '86', to_res: L}
- {entry_name: Q698K7_CAVPO, from_res: V, pubmed: '15209496', seq: '86', to_res: M}
- {entry_name: Q698K7_CAVPO, from_res: V, pubmed: '15209496', seq: '86', to_res: Y}
- {entry_name: Q78PE2_MOUSE, from_res: S, pubmed: '15736952', seq: '188', to_res: Y}
- {entry_name: Q78PE2_MOUSE, from_res: C, pubmed: '15736952', seq: '271', to_res: A}
- {entry_name: Q78PE2_MOUSE, from_res: C, pubmed: '15736952', seq: '271', to_res: R}
- {entry_name: Q78PE2_MOUSE, from_res: C, pubmed: '15736952', seq: '271', to_res: Y}
- {entry_name: Q8BHH0_MOUSE, from_res: E, pubmed: '15689355', seq: '80', to_res: A}
- {entry_name: Q8BHH0_MOUSE, from_res: M, pubmed: '15736952', seq: '128', to_res: A}
- {entry_name: Q8BHH0_MOUSE, from_res: W, pubmed: '15689355', seq: '234', to_res: S}
- {entry_name: Q8BHH0_MOUSE, from_res: F, pubmed: '15736952', seq: '262', to_res: A}
- {entry_name: Q8BHH0_MOUSE, from_res: F, pubmed: '15736952', seq: '262', to_res: S}
- {entry_name: Q8BHH0_MOUSE, from_res: I, pubmed: '15736952', seq: '264', to_res: Y}
- {entry_name: Q8BLT7_MOUSE, from_res: D, pubmed: '15736952', seq: '189', to_res: H}
- {entry_name: Q8BLT7_MOUSE, from_res: D, pubmed: '15851576', seq: '226', to_res: N}
- {entry_name: Q8BLT7_MOUSE, from_res: R, pubmed: '15689355', seq: '234', to_res: S}
- {entry_name: Q8BLT7_MOUSE, from_res: K, pubmed: '15851576', seq: '238', to_res: E}
- {entry_name: Q8BLT7_MOUSE, from_res: C, pubmed: '15736952', seq: '279', to_res: A}
- {entry_name: Q8BLT7_MOUSE, from_res: L, pubmed: '15736952', seq: '288', to_res: F}
- {entry_name: Q8K0D8_MOUSE, from_res: E, pubmed: '15755727', seq: '5', to_res: R}
- {entry_name: Q8K0D8_MOUSE, from_res: P, pubmed: '15851576', seq: '23', to_res: H}
- {entry_name: Q8K0D8_MOUSE, from_res: C, pubmed: '15736952', seq: '110', to_res: F}
- {entry_name: Q8K0D8_MOUSE, from_res: C, pubmed: '15736952', seq: '110', to_res: Y}
- {entry_name: Q8K0D8_MOUSE, from_res: G, pubmed: '15851576', seq: '114', to_res: V}
- {entry_name: Q8K0D8_MOUSE, from_res: Q, pubmed: '15851576', seq: '184', to_res: P}
- {entry_name: Q8K0D8_MOUSE, from_res: C, pubmed: '15736952', seq: '187', to_res: A}
- {entry_name: Q8K0D8_MOUSE, from_res: C, pubmed: '15736952', seq: '187', to_res: Y}
- {entry_name: Q8K0D8_MOUSE, from_res: F, pubmed: '15736952', seq: '261', to_res: A}
- {entry_name: Q8K0D8_MOUSE, from_res: F, pubmed: '15736952', seq: '261', to_res: L}
- {entry_name: Q8K0D8_MOUSE, from_res: P, pubmed: '15851576', seq: '347', to_res: L}
- {entry_name: Q8MIP6_CANFA, from_res: R, pubmed: '16186414', seq: '248', to_res: Q}
- {entry_name: Q8MIR8_PIG, from_res: Y, pubmed: '15209496', seq: '86', to_res: F}
- {entry_name: Q8MIR8_PIG, from_res: S, pubmed: '15209496', seq: '90', to_res: C}
- {entry_name: Q8VF69_MOUSE, from_res: D, pubmed: '15736952', seq: '125', to_res: A}
- {entry_name: Q8VF69_MOUSE, from_res: R, pubmed: '16103122', seq: '238', to_res: A}
- {entry_name: Q8VF69_MOUSE, from_res: R, pubmed: '16103122', seq: '238', to_res: E}
- {entry_name: Q8VF69_MOUSE, from_res: R, pubmed: '16103122', seq: '238', to_res: K}
- {entry_name: Q920Y6_MOUSE, from_res: D, pubmed: '15736952', seq: '117', to_res: A}
- {entry_name: Q920Y6_MOUSE, from_res: R, pubmed: '15689355', seq: '311', to_res: Q}
- {entry_name: Q920Y7_MOUSE, from_res: C, pubmed: '11919159', seq: '3', to_res: T}
- {entry_name: Q920Y7_MOUSE, from_res: F, pubmed: '15736952', seq: '175', to_res: S}
- {entry_name: Q920Y7_MOUSE, from_res: R, pubmed: '15851576', seq: '224', to_res: P}
- {entry_name: Q920Y7_MOUSE, from_res: Q, pubmed: '11919159', seq: '229', to_res: L}
- {entry_name: Q920Y7_MOUSE, from_res: Q, pubmed: '12771155', seq: '229', to_res: L}
- {entry_name: Q920Y7_MOUSE, from_res: Q, pubmed: '9468525', seq: '229', to_res: L}
- {entry_name: Q920Y7_MOUSE, from_res: H, pubmed: '15736952', seq: '264', to_res: A}
- {entry_name: Q920Y8_MOUSE, from_res: T, pubmed: '11919159', seq: '31', to_res: K}
- {entry_name: Q920Z0_MOUSE, from_res: D, pubmed: '15736952', seq: '184', to_res: H}
- {entry_name: Q920Z0_MOUSE, from_res: L, pubmed: '15736952', seq: '284', to_res: A}
- {entry_name: Q96KP5_HUMAN, from_res: P, pubmed: '9837883', seq: '8', to_res: A}
- {entry_name: Q96KP5_HUMAN, from_res: P, pubmed: '9837883', seq: '8', to_res: Q}
- {entry_name: Q96RG8_HUMAN, from_res: V, pubmed: '12588888', seq: '134', to_res: L}
- {entry_name: Q96RG8_HUMAN, from_res: K, pubmed: '15452105', seq: '177', to_res: E}
- {entry_name: Q96RG8_HUMAN, from_res: P, pubmed: '15452105', seq: '181', to_res: L}
- {entry_name: Q96RG8_HUMAN, from_res: F, pubmed: '15452105', seq: '186', to_res: Y}
- {entry_name: Q9DDR1_XENLA, from_res: Q, pubmed: '9116009', seq: '105', to_res: E}
- {entry_name: Q9DDR1_XENLA, from_res: Q, pubmed: '9116009', seq: '105', to_res: K}
- {entry_name: Q9DDR1_XENLA, from_res: Q, pubmed: '9116009', seq: '105', to_res: S}
- {entry_name: Q9DDR1_XENLA, from_res: Q, pubmed: '9116009', seq: '105', to_res: Y}
- {entry_name: Q9DDR1_XENLA, from_res: Y, pubmed: '9116009', seq: '106', to_res: F}
- {entry_name: Q9H573_HUMAN, from_res: L, pubmed: '11290742', seq: '14', to_res: W}
- {entry_name: Q9H573_HUMAN, from_res: K, pubmed: '9341153', seq: '44', to_res: E}
- {entry_name: Q9H573_HUMAN, from_res: K, pubmed: '9737953', seq: '44', to_res: E}
- {entry_name: Q9R1M0_MOUSE, from_res: R, pubmed: '10779393', seq: '387', to_res: A}
- {entry_name: RL3R1_HUMAN, from_res: K, pubmed: '12118081', seq: '398', to_res: R}
- {entry_name: RL3R1_HUMAN, from_res: K, pubmed: '12118081', seq: '423', to_res: E}
- {entry_name: RXFP1_HUMAN, from_res: D, pubmed: '10935549', seq: '637', to_res: Y}
- {entry_name: SCTR_HUMAN, from_res: F, pubmed: '12475394', seq: '200', to_res: Y}
- {entry_name: SCTR_HUMAN, from_res: K, pubmed: '11517171', seq: '323', to_res: I}
- {entry_name: SCTR_HUMAN, from_res: R, pubmed: '11517171', seq: '330', to_res: I}
- {entry_name: SCTR_HUMAN, from_res: R, pubmed: '11517171', seq: '339', to_res: A}
- {entry_name: SCTR_HUMAN, from_res: R, pubmed: '11517171', seq: '339', to_res: E}
- {entry_name: SCTR_HUMAN, from_res: R, pubmed: '11517171', seq: '339', to_res: I}
- {entry_name: SCTR_HUMAN, from_res: R, pubmed: '11517171', seq: '342', to_res: A}
- {entry_name: SCTR_HUMAN, from_res: R, pubmed: '11517171', seq: '342', to_res: I}
- {entry_name: SCTR_RAT, from_res: P, pubmed: '14500709', seq: '30', to_res: M}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '33', to_res: A}
- {entry_name: SCTR_RAT, from_res: V, pubmed: '10859300', seq: '35', to_res: M}
- {entry_name: SCTR_RAT, from_res: V, pubmed: '14500709', seq: '35', to_res: M}
- {entry_name: SCTR_RAT, from_res: V, pubmed: '10859300', seq: '38', to_res: M}
- {entry_name: SCTR_RAT, from_res: V, pubmed: '14500709', seq: '38', to_res: M}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '46', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '15664984', seq: '46', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '15664984', seq: '46', to_res: S}
- {entry_name: SCTR_RAT, from_res: A, pubmed: '10859300', seq: '63', to_res: M}
- {entry_name: SCTR_RAT, from_res: A, pubmed: '14500709', seq: '63', to_res: M}
- {entry_name: SCTR_RAT, from_res: A, pubmed: '15664984', seq: '63', to_res: M}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '66', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '15664984', seq: '66', to_res: S}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '10573290', seq: '71', to_res: A}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '10573290', seq: '71', to_res: E}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '10573290', seq: '71', to_res: H}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '10573290', seq: '71', to_res: N}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '10573290', seq: '71', to_res: R}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '75', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '15664984', seq: '75', to_res: S}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '89', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '15664984', seq: '89', to_res: S}
- {entry_name: SCTR_RAT, from_res: M, pubmed: '15664984', seq: '95', to_res: I}
- {entry_name: SCTR_RAT, from_res: R, pubmed: '10573290', seq: '105', to_res: D}
- {entry_name: SCTR_RAT, from_res: R, pubmed: '10573290', seq: '105', to_res: L}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '107', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '15664984', seq: '107', to_res: S}
- {entry_name: SCTR_RAT, from_res: L, pubmed: '15664984', seq: '121', to_res: M}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '123', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '15664984', seq: '123', to_res: S}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '11040037', seq: '133', to_res: D}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '10573290', seq: '143', to_res: L}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '10573290', seq: '143', to_res: Q}
- {entry_name: SCTR_RAT, from_res: H, pubmed: '9694908', seq: '178', to_res: R}
- {entry_name: SCTR_RAT, from_res: I, pubmed: '8621578', seq: '186', to_res: M}
- {entry_name: SCTR_RAT, from_res: N, pubmed: '8621578', seq: '192', to_res: I}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '8579602', seq: '195', to_res: H}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '11853547', seq: '195', to_res: I}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '8579602', seq: '195', to_res: I}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '10573290', seq: '196', to_res: A}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '10573290', seq: '196', to_res: N}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '11040037', seq: '208', to_res: A}
- {entry_name: SCTR_RAT, from_res: C, pubmed: '8579602', seq: '208', to_res: S}
- {entry_name: SCTR_RAT, from_res: H, pubmed: '8579602', seq: '211', to_res: L}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '8579602', seq: '212', to_res: S}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '10573290', seq: '216', to_res: A}
- {entry_name: SCTR_RAT, from_res: K, pubmed: '10573290', seq: '216', to_res: Q}
- {entry_name: SCTR_RAT, from_res: R, pubmed: '10573290', seq: '277', to_res: D}
- {entry_name: SCTR_RAT, from_res: R, pubmed: '10573290', seq: '277', to_res: Q}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '10573290', seq: '281', to_res: N}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '10573290', seq: '281', to_res: Q}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '10573290', seq: '281', to_res: V}
- {entry_name: SCTR_RAT, from_res: R, pubmed: '10573290', seq: '299', to_res: E}
- {entry_name: SCTR_RAT, from_res: R, pubmed: '10573290', seq: '299', to_res: Q}
- {entry_name: SCTR_RAT, from_res: T, pubmed: '9694908', seq: '344', to_res: P}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '15731172', seq: '363', to_res: A}
- {entry_name: SCTR_RAT, from_res: D, pubmed: '15731172', seq: '364', to_res: A}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '15731172', seq: '367', to_res: A}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '15731172', seq: '373', to_res: A}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '10573290', seq: '373', to_res: Q}
- {entry_name: SCTR_RAT, from_res: E, pubmed: '10573290', seq: '373', to_res: V}
- {entry_name: SMO_DROME, from_res: C, pubmed: '9811578', seq: '155', to_res: Y}
- {entry_name: SMO_DROME, from_res: S, pubmed: '9811578', seq: '220', to_res: N}
- {entry_name: SMO_HUMAN, from_res: A, pubmed: '9746760', seq: '102', to_res: T}
- {entry_name: SMO_HUMAN, from_res: W, pubmed: '11133163', seq: '535', to_res: L}
- {entry_name: SSR1_HUMAN, from_res: F, pubmed: '11853883', seq: '2', to_res: K}
- {entry_name: SSR1_HUMAN, from_res: Q, pubmed: '7882976', seq: '291', to_res: N}
- {entry_name: SSR1_HUMAN, from_res: Q, pubmed: '9351971', seq: '291', to_res: N}
- {entry_name: SSR1_HUMAN, from_res: S, pubmed: '7882976', seq: '305', to_res: F}
- {entry_name: SSR1_HUMAN, from_res: S, pubmed: '9351971', seq: '305', to_res: F}
- {entry_name: SSR1_HUMAN, from_res: S, pubmed: '15893521', seq: '360', to_res: A}
- {entry_name: SSR1_MOUSE, from_res: Q, pubmed: '8702767', seq: '291', to_res: N}
- {entry_name: SSR1_MOUSE, from_res: S, pubmed: '8702767', seq: '305', to_res: F}
- {entry_name: SSR2_MOUSE, from_res: Y, pubmed: '12972574', seq: '228', to_res: F}
- {entry_name: SSR2_MOUSE, from_res: F, pubmed: '8702767', seq: '294', to_res: S}
- {entry_name: SSR2_RAT, from_res: L, pubmed: '14507916', seq: '3', to_res: Q}
- {entry_name: SSR2_RAT, from_res: D, pubmed: '7488212', seq: '122', to_res: K}
- {entry_name: SSR3_HUMAN, from_res: P, pubmed: '14507916', seq: '37', to_res: L}
- {entry_name: SSR3_MOUSE, from_res: T, pubmed: '11513875', seq: '3', to_res: R}
- {entry_name: SSR3_RAT, from_res: N, pubmed: '11087995', seq: '18', to_res: T}
- {entry_name: SSR3_RAT, from_res: N, pubmed: '11087995', seq: '31', to_res: T}
- {entry_name: SSR3_RAT, from_res: S, pubmed: '9295322', seq: '341', to_res: A}
- {entry_name: SSR3_RAT, from_res: S, pubmed: '9295322', seq: '346', to_res: A}
- {entry_name: SSR3_RAT, from_res: S, pubmed: '9295322', seq: '351', to_res: A}
- {entry_name: SSR3_RAT, from_res: T, pubmed: '9295322', seq: '357', to_res: A}
- {entry_name: SSR4_HUMAN, from_res: S, pubmed: '11250922', seq: '2', to_res: A}
- {entry_name: SSR4_HUMAN, from_res: S, pubmed: '11250922', seq: '2', to_res: C}
- {entry_name: SSR4_RAT, from_res: T, pubmed: '9809748', seq: '331', to_res: A}
- {entry_name: SSR5_HUMAN, from_res: A, pubmed: '9351971', seq: '36', to_res: M}
- {entry_name: SSR5_HUMAN, from_res: L, pubmed: '12192619', seq: '48', to_res: M}
- {entry_name: SSR5_HUMAN, from_res: A, pubmed: '12192619', seq: '52', to_res: V}
- {entry_name: SSR5_HUMAN, from_res: I, pubmed: '14507916', seq: '62', to_res: N}
- {entry_name: SSR5_HUMAN, from_res: P, pubmed: '11502816', seq: '109', to_res: S}
- {entry_name: SSR5_HUMAN, from_res: P, pubmed: '12192619', seq: '109', to_res: S}
- {entry_name: SSR5_HUMAN, from_res: R, pubmed: '11502816', seq: '240', to_res: W}
- {entry_name: SSR5_HUMAN, from_res: Y, pubmed: '9694905', seq: '304', to_res: A}
- {entry_name: SSR5_HUMAN, from_res: S, pubmed: '9694905', seq: '314', to_res: T}
- {entry_name: SSR5_HUMAN, from_res: C, pubmed: '9694905', seq: '320', to_res: A}
- {entry_name: SSR5_HUMAN, from_res: S, pubmed: '9694905', seq: '325', to_res: T}
- {entry_name: SSR5_HUMAN, from_res: P, pubmed: '12192619', seq: '335', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15667221', seq: '7', to_res: K}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15667221', seq: '8', to_res: P}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '9858568', seq: '21', to_res: R}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '11583169', seq: '25', to_res: Q}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '11583169', seq: '32', to_res: Q}
- {entry_name: STE2_YEAST, from_res: M, pubmed: '15667221', seq: '54', to_res: E}
- {entry_name: STE2_YEAST, from_res: M, pubmed: '15667221', seq: '54', to_res: I}
- {entry_name: STE2_YEAST, from_res: M, pubmed: '15667221', seq: '54', to_res: T}
- {entry_name: STE2_YEAST, from_res: M, pubmed: '15667221', seq: '54', to_res: V}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '15667221', seq: '55', to_res: L}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '9824658', seq: '55', to_res: V}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '15667221', seq: '55', to_res: V}
- {entry_name: STE2_YEAST, from_res: G, pubmed: '15966721', seq: '56', to_res: A}
- {entry_name: STE2_YEAST, from_res: R, pubmed: '9067610', seq: '58', to_res: G}
- {entry_name: STE2_YEAST, from_res: R, pubmed: '12525156', seq: '58', to_res: H}
- {entry_name: STE2_YEAST, from_res: C, pubmed: '10846179', seq: '59', to_res: I}
- {entry_name: STE2_YEAST, from_res: G, pubmed: '15966721', seq: '60', to_res: A}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15966721', seq: '62', to_res: L}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '11955023', seq: '65', to_res: P}
- {entry_name: STE2_YEAST, from_res: W, pubmed: '11955023', seq: '70', to_res: P}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11955023', seq: '73', to_res: P}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '15667221', seq: '84', to_res: S}
- {entry_name: STE2_YEAST, from_res: H, pubmed: '11955023', seq: '94', to_res: L}
- {entry_name: STE2_YEAST, from_res: H, pubmed: '12525156', seq: '94', to_res: R}
- {entry_name: STE2_YEAST, from_res: H, pubmed: '11955023', seq: '94', to_res: Y}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15966721', seq: '95', to_res: H}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '15966721', seq: '98', to_res: H}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '15667221', seq: '119', to_res: L}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '15667221', seq: '119', to_res: S}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '11955023', seq: '140', to_res: P}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15667221', seq: '141', to_res: P}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '11955023', seq: '142', to_res: N}
- {entry_name: STE2_YEAST, from_res: E, pubmed: '15667221', seq: '143', to_res: K}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '11955023', seq: '144', to_res: A}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '11955023', seq: '144', to_res: P}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15667221', seq: '145', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15667221', seq: '145', to_res: T}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '11955023', seq: '146', to_res: P}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15667221', seq: '146', to_res: Q}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '11955023', seq: '146', to_res: R}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '15966721', seq: '147', to_res: A}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '15966721', seq: '149', to_res: I}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '15667221', seq: '149', to_res: N}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '11955023', seq: '149', to_res: P}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '11955023', seq: '149', to_res: R}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '15667221', seq: '149', to_res: R}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '11955023', seq: '150', to_res: R}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '15667221', seq: '153', to_res: F}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '15667221', seq: '153', to_res: N}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '15667221', seq: '154', to_res: L}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '15667221', seq: '175', to_res: V}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '12525156', seq: '181', to_res: N}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '12525156', seq: '199', to_res: C}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '12525156', seq: '200', to_res: C}
- {entry_name: STE2_YEAST, from_res: D, pubmed: '12525156', seq: '201', to_res: C}
- {entry_name: STE2_YEAST, from_res: K, pubmed: '12525156', seq: '202', to_res: C}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '12525156', seq: '203', to_res: C}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '12525156', seq: '203', to_res: H}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '12525156', seq: '204', to_res: C}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '12525156', seq: '204', to_res: S}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '15667221', seq: '204', to_res: S}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '12525156', seq: '205', to_res: C}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '12525156', seq: '205', to_res: D}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '12525156', seq: '206', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '12525156', seq: '207', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '12525156', seq: '207', to_res: F}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '12525156', seq: '208', to_res: C}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '209', to_res: C}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '12525156', seq: '209', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '210', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '12525156', seq: '210', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '211', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '12525156', seq: '211', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '11955023', seq: '211', to_res: G}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '10846179', seq: '212', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '12525156', seq: '212', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '11955023', seq: '212', to_res: G}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '11955023', seq: '212', to_res: P}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15667221', seq: '212', to_res: V}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '10846179', seq: '213', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '12525156', seq: '213', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11955023', seq: '213', to_res: H}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '10846179', seq: '214', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '12525156', seq: '214', to_res: C}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '215', to_res: C}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '10846179', seq: '216', to_res: C}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '12525156', seq: '216', to_res: D}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '15667221', seq: '216', to_res: D}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '15966721', seq: '216', to_res: D}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '15966721', seq: '216', to_res: E}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '15667221', seq: '216', to_res: Y}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '10846179', seq: '217', to_res: C}
- {entry_name: STE2_YEAST, from_res: M, pubmed: '10846179', seq: '218', to_res: C}
- {entry_name: STE2_YEAST, from_res: M, pubmed: '9067610', seq: '218', to_res: T}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '10846179', seq: '219', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9824658', seq: '219', to_res: P}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '10846179', seq: '220', to_res: C}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '10846179', seq: '221', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '222', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15667221', seq: '222', to_res: P}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15667221', seq: '222', to_res: Q}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '10846179', seq: '223', to_res: C}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '15966721', seq: '223', to_res: C}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '10846179', seq: '223', to_res: S}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '10846179', seq: '224', to_res: C}
- {entry_name: STE2_YEAST, from_res: K, pubmed: '10846179', seq: '225', to_res: C}
- {entry_name: STE2_YEAST, from_res: K, pubmed: '9819407', seq: '225', to_res: C}
- {entry_name: STE2_YEAST, from_res: K, pubmed: '15667221', seq: '225', to_res: C}
- {entry_name: STE2_YEAST, from_res: K, pubmed: '15667221', seq: '225', to_res: R}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '226', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '12525156', seq: '226', to_res: D}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15966721', seq: '226', to_res: D}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '226', to_res: S}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '227', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '228', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '10846179', seq: '229', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15667221', seq: '229', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15667221', seq: '229', to_res: V}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '246', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '247', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '12525156', seq: '247', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15966721', seq: '247', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '248', to_res: C}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '249', to_res: C}
- {entry_name: STE2_YEAST, from_res: M, pubmed: '10846179', seq: '250', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '10846179', seq: '251', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11955023', seq: '251', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '251', to_res: L}
- {entry_name: STE2_YEAST, from_res: C, pubmed: '10846179', seq: '252', to_res: A}
- {entry_name: STE2_YEAST, from_res: C, pubmed: '9798427', seq: '252', to_res: A}
- {entry_name: STE2_YEAST, from_res: C, pubmed: '15667221', seq: '252', to_res: G}
- {entry_name: STE2_YEAST, from_res: C, pubmed: '11955023', seq: '252', to_res: L}
- {entry_name: STE2_YEAST, from_res: C, pubmed: '9819407', seq: '252', to_res: L}
- {entry_name: STE2_YEAST, from_res: C, pubmed: '15491163', seq: '252', to_res: S}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '10846179', seq: '253', to_res: C}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '11955023', seq: '253', to_res: L}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '9819407', seq: '253', to_res: L}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '12525156', seq: '253', to_res: S}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '9819407', seq: '253', to_res: S}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '15966721', seq: '253', to_res: S}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '254', to_res: A}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '10846179', seq: '254', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '10846179', seq: '254', to_res: F}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11955023', seq: '254', to_res: F}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '8692892', seq: '254', to_res: F}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '254', to_res: F}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '254', to_res: G}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11955023', seq: '254', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '254', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11955023', seq: '254', to_res: Y}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '255', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15667221', seq: '255', to_res: S}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '256', to_res: C}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '10846179', seq: '257', to_res: C}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '10846179', seq: '258', to_res: C}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '9529386', seq: '258', to_res: D}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '11394869', seq: '258', to_res: L}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '11955023', seq: '258', to_res: L}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '8692892', seq: '258', to_res: L}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '9529386', seq: '258', to_res: L}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '9798427', seq: '258', to_res: L}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '9819407', seq: '258', to_res: L}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '9529386', seq: '258', to_res: Y}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '10846179', seq: '259', to_res: C}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11394869', seq: '259', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '11955023', seq: '259', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '8692892', seq: '259', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '259', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15966721', seq: '259', to_res: L}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9824658', seq: '259', to_res: P}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15667221', seq: '259', to_res: P}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15966721', seq: '259', to_res: P}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '260', to_res: C}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '15667221', seq: '260', to_res: M}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '15667221', seq: '260', to_res: T}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '261', to_res: C}
- {entry_name: STE2_YEAST, from_res: F, pubmed: '10846179', seq: '262', to_res: C}
- {entry_name: STE2_YEAST, from_res: I, pubmed: '10846179', seq: '263', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '10846179', seq: '264', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '10846179', seq: '265', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '12525156', seq: '265', to_res: C}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '12525156', seq: '265', to_res: D}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15966721', seq: '265', to_res: N}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '10846179', seq: '266', to_res: C}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '12525156', seq: '266', to_res: C}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '9067610', seq: '266', to_res: C}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '15667221', seq: '266', to_res: C}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '12525156', seq: '266', to_res: D}
- {entry_name: STE2_YEAST, from_res: Y, pubmed: '12525156', seq: '266', to_res: W}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '12525156', seq: '267', to_res: C}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '12525156', seq: '268', to_res: C}
- {entry_name: STE2_YEAST, from_res: K, pubmed: '12525156', seq: '269', to_res: C}
- {entry_name: STE2_YEAST, from_res: P, pubmed: '12525156', seq: '270', to_res: C}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '12525156', seq: '271', to_res: C}
- {entry_name: STE2_YEAST, from_res: Q, pubmed: '12525156', seq: '272', to_res: C}
- {entry_name: STE2_YEAST, from_res: G, pubmed: '12525156', seq: '273', to_res: C}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '12525156', seq: '274', to_res: A}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '12525156', seq: '274', to_res: C}
- {entry_name: STE2_YEAST, from_res: D, pubmed: '12525156', seq: '275', to_res: C}
- {entry_name: STE2_YEAST, from_res: D, pubmed: '12525156', seq: '275', to_res: V}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '15667221', seq: '276', to_res: A}
- {entry_name: STE2_YEAST, from_res: V, pubmed: '15667221', seq: '280', to_res: D}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15667221', seq: '281', to_res: T}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '15667221', seq: '282', to_res: A}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15667221', seq: '284', to_res: H}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '288', to_res: A}
- {entry_name: STE2_YEAST, from_res: L, pubmed: '15667221', seq: '289', to_res: S}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '292', to_res: A}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '292', to_res: Q}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9819407', seq: '293', to_res: A}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '15966721', seq: '293', to_res: N}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15667221', seq: '296', to_res: T}
- {entry_name: STE2_YEAST, from_res: A, pubmed: '15966721', seq: '299', to_res: P}
- {entry_name: STE2_YEAST, from_res: G, pubmed: '11394869', seq: '322', to_res: E}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9548714', seq: '331', to_res: A}
- {entry_name: STE2_YEAST, from_res: K, pubmed: '9548714', seq: '337', to_res: R}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9548714', seq: '338', to_res: A}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9548714', seq: '338', to_res: D}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9548714', seq: '338', to_res: E}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9548714', seq: '339', to_res: A}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9548714', seq: '339', to_res: D}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '9548714', seq: '339', to_res: E}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '8524302', seq: '382', to_res: A}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '8524302', seq: '384', to_res: A}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '8524302', seq: '385', to_res: A}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '8524302', seq: '386', to_res: A}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '11394869', seq: '388', to_res: D}
- {entry_name: STE2_YEAST, from_res: S, pubmed: '8524302', seq: '398', to_res: A}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '8524302', seq: '411', to_res: A}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '8524302', seq: '414', to_res: A}
- {entry_name: STE2_YEAST, from_res: T, pubmed: '8524302', seq: '425', to_res: A}
- {entry_name: STE2_YEAST, from_res: N, pubmed: '15491163', seq: '430', to_res: A}
- {entry_name: STE3_YEAST, from_res: P, pubmed: '9529386', seq: '222', to_res: F}
- {entry_name: STE3_YEAST, from_res: P, pubmed: '9529386', seq: '222', to_res: L}
- {entry_name: STE3_YEAST, from_res: T, pubmed: '8524302', seq: '389', to_res: A}
- {entry_name: T2R05_RAT, from_res: S, pubmed: '12912984', seq: '284', to_res: A}
- {entry_name: T2R23_RAT, from_res: S, pubmed: '12912984', seq: '151', to_res: A}
- {entry_name: T2R60_HUMAN, from_res: S, pubmed: '12912984', seq: '111', to_res: A}
- {entry_name: TA2R_BOVIN, from_res: S, pubmed: '14530262', seq: '329', to_res: A}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '11', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: N, pubmed: '9587408', seq: '16', to_res: L}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '35', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: V, pubmed: '9139686', seq: '36', to_res: A}
- {entry_name: TA2R_HUMAN, from_res: V, pubmed: '9139686', seq: '37', to_res: L}
- {entry_name: TA2R_HUMAN, from_res: A, pubmed: '9139686', seq: '40', to_res: G}
- {entry_name: TA2R_HUMAN, from_res: R, pubmed: '10595649', seq: '60', to_res: L}
- {entry_name: TA2R_HUMAN, from_res: R, pubmed: '11154981', seq: '60', to_res: L}
- {entry_name: TA2R_HUMAN, from_res: R, pubmed: '7929844', seq: '60', to_res: L}
- {entry_name: TA2R_HUMAN, from_res: R, pubmed: '8613548', seq: '60', to_res: L}
- {entry_name: TA2R_HUMAN, from_res: R, pubmed: '8626415', seq: '60', to_res: L}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '68', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '102', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8837733', seq: '102', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '105', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8837733', seq: '105', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: F, pubmed: '10527859', seq: '138', to_res: D}
- {entry_name: TA2R_HUMAN, from_res: F, pubmed: '10527859', seq: '138', to_res: Y}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '183', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8837733', seq: '183', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: T, pubmed: '8626415', seq: '221', to_res: M}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '223', to_res: A}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '223', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: H, pubmed: '8626415', seq: '224', to_res: R}
- {entry_name: TA2R_HUMAN, from_res: H, pubmed: '8626415', seq: '227', to_res: R}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8626415', seq: '257', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: C, pubmed: '8837733', seq: '257', to_res: S}
- {entry_name: TA2R_HUMAN, from_res: S, pubmed: '14530262', seq: '331', to_res: A}
- {entry_name: TRFR_HUMAN, from_res: N, pubmed: '7528344', seq: '167', to_res: I}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9115256', seq: '43', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9115256', seq: '43', to_res: D}
- {entry_name: TRFR_MOUSE, from_res: D, pubmed: '8247012', seq: '71', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: D, pubmed: '9115256', seq: '71', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: D, pubmed: '9115256', seq: '71', to_res: N}
- {entry_name: TRFR_MOUSE, from_res: C, pubmed: '7559582', seq: '98', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: C, pubmed: '9398295', seq: '98', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: C, pubmed: '7559582', seq: '98', to_res: S}
- {entry_name: TRFR_MOUSE, from_res: C, pubmed: '7559582', seq: '100', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: Q, pubmed: '8672465', seq: '105', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: Q, pubmed: '8672465', seq: '105', to_res: V}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '8294406', seq: '106', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9398295', seq: '106', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '8672465', seq: '110', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9398295', seq: '110', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: S, pubmed: '8672465', seq: '113', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '9115256', seq: '123', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: C, pubmed: '7559582', seq: '179', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: C, pubmed: '9398295', seq: '179', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: C, pubmed: '7559582', seq: '179', to_res: S}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9398295', seq: '181', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9512011', seq: '181', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '9512011', seq: '185', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9512011', seq: '186', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: F, pubmed: '8672465', seq: '199', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: F, pubmed: '9855624', seq: '199', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9855624', seq: '200', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9855624', seq: '200', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '11014227', seq: '261', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '11014227', seq: '261', to_res: E}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '11014227', seq: '261', to_res: Q}
- {entry_name: TRFR_MOUSE, from_res: K, pubmed: '11014227', seq: '262', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: K, pubmed: '11014227', seq: '262', to_res: E}
- {entry_name: TRFR_MOUSE, from_res: K, pubmed: '11014227', seq: '262', to_res: Q}
- {entry_name: TRFR_MOUSE, from_res: Q, pubmed: '11014227', seq: '263', to_res: E}
- {entry_name: TRFR_MOUSE, from_res: Q, pubmed: '11014227', seq: '263', to_res: R}
- {entry_name: TRFR_MOUSE, from_res: W, pubmed: '9855624', seq: '279', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '8672465', seq: '282', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9855624', seq: '282', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '8672465', seq: '282', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9855624', seq: '282', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '9398295', seq: '282', to_res: H}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '8672465', seq: '282', to_res: N}
- {entry_name: TRFR_MOUSE, from_res: Y, pubmed: '8672465', seq: '282', to_res: S}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '7700246', seq: '283', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '7700246', seq: '283', to_res: H}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '7700246', seq: '283', to_res: K}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '8672465', seq: '283', to_res: K}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9398295', seq: '289', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9512011', seq: '289', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9512011', seq: '289', to_res: D}
- {entry_name: TRFR_MOUSE, from_res: S, pubmed: '9512011', seq: '290', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: F, pubmed: '9398295', seq: '296', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: E, pubmed: '9398295', seq: '298', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: E, pubmed: '9512011', seq: '298', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: E, pubmed: '9398295', seq: '298', to_res: F}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '7700246', seq: '306', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '8672465', seq: '306', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '7700246', seq: '306', to_res: E}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '7700246', seq: '306', to_res: K}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '8672465', seq: '306', to_res: K}
- {entry_name: TRFR_MOUSE, from_res: R, pubmed: '7700246', seq: '306', to_res: L}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9115256', seq: '316', to_res: A}
- {entry_name: TRFR_MOUSE, from_res: N, pubmed: '9115256', seq: '316', to_res: D}
- {entry_name: TRFR_RAT, from_res: D, pubmed: '8999941', seq: '71', to_res: A}
- {entry_name: TRFR_RAT, from_res: Y, pubmed: '8614407', seq: '93', to_res: A}
- {entry_name: TRFR_RAT, from_res: N, pubmed: '7577928', seq: '110', to_res: D}
- {entry_name: TRFR_RAT, from_res: Y, pubmed: '8614407', seq: '181', to_res: F}
- {entry_name: TRFR_RAT, from_res: Y, pubmed: '8614407', seq: '188', to_res: A}
- {entry_name: TRFR_RAT, from_res: F, pubmed: '8614407', seq: '196', to_res: A}
- {entry_name: TRFR_RAT, from_res: F, pubmed: '8614407', seq: '199', to_res: A}
- {entry_name: TRFR_RAT, from_res: N, pubmed: '7577928', seq: '289', to_res: A}
- {entry_name: TRFR_RAT, from_res: N, pubmed: '8614407', seq: '289', to_res: A}
- {entry_name: TRFR_RAT, from_res: N, pubmed: '7577928', seq: '289', to_res: D}
- {entry_name: TRFR_RAT, from_res: N, pubmed: '7577928', seq: '289', to_res: E}
- {entry_name: TRFR_RAT, from_res: S, pubmed: '8614407', seq: '290', to_res: A}
- {entry_name: TRFR_RAT, from_res: C, pubmed: '8999941', seq: '335', to_res: S}
- {entry_name: TRFR_RAT, from_res: C, pubmed: '8999941', seq: '337', to_res: S}
- {entry_name: TRFR_RAT, from_res: T, pubmed: '11278484', seq: '365', to_res: A}
- {entry_name: TRFR_RAT, from_res: T, pubmed: '11278484', seq: '371', to_res: A}
- {entry_name: TRFR_RAT, from_res: S, pubmed: '11278484', seq: '383', to_res: A}
- {entry_name: TS1R3_RAT, from_res: T, pubmed: '11326277', seq: '55', to_res: A}
- {entry_name: TS1R3_RAT, from_res: I, pubmed: '11326277', seq: '60', to_res: T}
- {entry_name: TSHR_BOVIN, from_res: S, pubmed: '15345720', seq: '281', to_res: G}
- {entry_name: TSHR_BOVIN, from_res: S, pubmed: '9224711', seq: '281', to_res: I}
- {entry_name: TSHR_BOVIN, from_res: S, pubmed: '9294132', seq: '281', to_res: I}
- {entry_name: TSHR_BOVIN, from_res: S, pubmed: '15345720', seq: '281', to_res: N}
- {entry_name: TSHR_BOVIN, from_res: C, pubmed: '15345720', seq: '283', to_res: S}
- {entry_name: TSHR_BOVIN, from_res: C, pubmed: '15345720', seq: '284', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '16060907', seq: '27', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: E, pubmed: '16060907', seq: '34', to_res: K}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10037069', seq: '36', to_res: H}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '7556878', seq: '36', to_res: H}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '8954020', seq: '41', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9398691', seq: '41', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9589691', seq: '41', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '16060907', seq: '41', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '16060907', seq: '46', to_res: P}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '10037069', seq: '52', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '7556171', seq: '52', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '9100579', seq: '109', to_res: Q}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '9398691', seq: '109', to_res: Q}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '9589691', seq: '109', to_res: Q}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '16060907', seq: '109', to_res: Q}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '10560953', seq: '162', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '8954020', seq: '162', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '9329388', seq: '162', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '9398691', seq: '162', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '9589691', seq: '162', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '16060907', seq: '162', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '7528344', seq: '162', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9589691', seq: '167', to_res: D}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '10560953', seq: '167', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9329388', seq: '167', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9398691', seq: '167', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: L, pubmed: '16060907', seq: '252', to_res: P}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '11923470', seq: '281', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '12062436', seq: '281', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '10852462', seq: '281', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '11127522', seq: '281', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '11549687', seq: '281', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9253356', seq: '281', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9360556', seq: '281', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9589634', seq: '281', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '16364538', seq: '281', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9253356', seq: '281', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '16364538', seq: '301', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '11014210', seq: '302', to_res: Q}
- {entry_name: TSHR_HUMAN, from_res: Q, pubmed: '9398691', seq: '324', to_res: X}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '16006563', seq: '333', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '16006563', seq: '333', to_res: D}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '11549661', seq: '377', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '16364538', seq: '390', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '11095460', seq: '390', to_res: W}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '8954020', seq: '390', to_res: W}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9329388', seq: '390', to_res: W}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9398691', seq: '390', to_res: W}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9589691', seq: '390', to_res: W}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '16060907', seq: '403', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '8954020', seq: '410', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9398691', seq: '410', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9589691', seq: '410', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '16260895', seq: '428', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: G, pubmed: '11549687', seq: '431', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: G, pubmed: '11549687', seq: '431', to_res: C}
- {entry_name: TSHR_HUMAN, from_res: G, pubmed: '11127522', seq: '431', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: G, pubmed: '11549687', seq: '431', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '11442002', seq: '450', to_res: H}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '11073720', seq: '451', to_res: X}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9849963', seq: '451', to_res: X}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '10095169', seq: '453', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '12213664', seq: '453', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '12919313', seq: '453', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '8964822', seq: '453', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '9253356', seq: '453', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '9398746', seq: '453', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '9589634', seq: '453', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '11874187', seq: '463', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '10852462', seq: '486', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '11923470', seq: '486', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '12062436', seq: '486', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9253356', seq: '486', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9360555', seq: '486', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '16364538', seq: '486', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '10852462', seq: '486', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '11923470', seq: '486', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '12213664', seq: '486', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9253356', seq: '486', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9467563', seq: '486', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9709907', seq: '486', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: W, pubmed: '16060907', seq: '488', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '8135801', seq: '494', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: G, pubmed: '11442002', seq: '498', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9589634', seq: '505', to_res: D}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '10482366', seq: '505', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '15163335', seq: '505', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9360555', seq: '505', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9398746', seq: '505', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '10935550', seq: '505', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '11022192', seq: '505', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '8636266', seq: '505', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9360555', seq: '505', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9398746', seq: '505', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: S, pubmed: '9589634', seq: '505', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '11022192', seq: '509', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '7920658', seq: '509', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '9398746', seq: '509', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '9589634', seq: '509', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: L, pubmed: '11022192', seq: '512', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: L, pubmed: '12213664', seq: '512', to_res: R}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '16339276', seq: '515', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '8954020', seq: '525', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9398691', seq: '525', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9589691', seq: '525', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '16060907', seq: '527', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '9398746', seq: '528', to_res: H}
- {entry_name: TSHR_HUMAN, from_res: R, pubmed: '9589634', seq: '528', to_res: H}
- {entry_name: TSHR_HUMAN, from_res: W, pubmed: '12629076', seq: '546', to_res: X}
- {entry_name: TSHR_HUMAN, from_res: W, pubmed: '9100579', seq: '546', to_res: X}
- {entry_name: TSHR_HUMAN, from_res: W, pubmed: '9398691', seq: '546', to_res: X}
- {entry_name: TSHR_HUMAN, from_res: W, pubmed: '7528344', seq: '546', to_res: X}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '9185526', seq: '553', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '9589691', seq: '553', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '11923470', seq: '568', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9253356', seq: '568', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9360556', seq: '568', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9435429', seq: '568', to_res: T}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '16187920', seq: '568', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '8135801', seq: '569', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '12589819', seq: '593', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '12589819', seq: '597', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '10560955', seq: '597', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '12589819', seq: '597', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '9398746', seq: '597', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '10487707', seq: '606', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10319940', seq: '619', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10595453', seq: '619', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9253356', seq: '619', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9360556', seq: '619', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9467563', seq: '619', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9525885', seq: '619', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9973249', seq: '619', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '7673402', seq: '620', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9360556', seq: '620', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9525885', seq: '620', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '11923470', seq: '623', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '7989485', seq: '623', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '9253356', seq: '623', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '10487707', seq: '623', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '10595453', seq: '623', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '7989485', seq: '623', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '9360556', seq: '623', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '9398746', seq: '623', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '9435429', seq: '623', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '9467563', seq: '623', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: M, pubmed: '16339276', seq: '626', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: L, pubmed: '10852462', seq: '629', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: L, pubmed: '9253356', seq: '629', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: L, pubmed: '9398746', seq: '629', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: L, pubmed: '9467563', seq: '629', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9253356', seq: '630', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9398745', seq: '630', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '9467563', seq: '630', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '10319940', seq: '631', to_res: C}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '7805857', seq: '631', to_res: C}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9253356', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9294132', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9360555', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9360556', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9398745', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9398746', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9435429', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '9589634', seq: '631', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '15876166', seq: '631', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '10852462', seq: '632', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '12213664', seq: '632', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9435429', seq: '632', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '10319940', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '10852462', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '7805857', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '7989485', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9253356', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9360556', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9398745', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9435429', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9467563', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: T, pubmed: '9709907', seq: '632', to_res: I}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '11312274', seq: '633', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '11923470', seq: '633', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9253356', seq: '633', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10319940', seq: '633', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10852462', seq: '633', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '7805857', seq: '633', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9253356', seq: '633', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9360556', seq: '633', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9435429', seq: '633', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9467563', seq: '633', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9253356', seq: '633', to_res: H}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '16364538', seq: '633', to_res: H}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '11312274', seq: '633', to_res: N}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10595453', seq: '633', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '7805857', seq: '633', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '9253356', seq: '633', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: I, pubmed: '11796491', seq: '635', to_res: M}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '11434721', seq: '639', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: P, pubmed: '9467563', seq: '639', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '10852462', seq: '647', to_res: V}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '8636266', seq: '650', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '9360556', seq: '650', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '9398746', seq: '650', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '9589634', seq: '650', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '9360556', seq: '656', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: V, pubmed: '9435429', seq: '656', to_res: F}
- {entry_name: TSHR_HUMAN, from_res: F, pubmed: '10319940', seq: '666', to_res: L}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '8636266', seq: '670', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '9398746', seq: '670', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '9589634', seq: '670', to_res: S}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '7920658', seq: '672', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9360555', seq: '672', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9398746', seq: '672', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9589634', seq: '672', to_res: Y}
- {entry_name: TSHR_HUMAN, from_res: N, pubmed: '11312274', seq: '674', to_res: D}
- {entry_name: TSHR_HUMAN, from_res: C, pubmed: '9449658', seq: '699', to_res: A}
- {entry_name: TSHR_HUMAN, from_res: A, pubmed: '10487707', seq: '703', to_res: G}
- {entry_name: TSHR_HUMAN, from_res: Q, pubmed: '10487707', seq: '720', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10487707', seq: '727', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10595453', seq: '727', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '10946859', seq: '727', to_res: E}
- {entry_name: TSHR_HUMAN, from_res: D, pubmed: '12589819', seq: '727', to_res: E}
- {entry_name: TSHR_MOUSE, from_res: R, pubmed: '8672465', seq: '2', to_res: H}
- {entry_name: TSHR_MOUSE, from_res: P, pubmed: '9185526', seq: '556', to_res: L}
- {entry_name: TSHR_RAT, from_res: I, pubmed: '16150909', seq: '486', to_res: F}
- {entry_name: TSHR_RAT, from_res: I, pubmed: '16150909', seq: '568', to_res: T}
- {entry_name: UR2R_RAT, from_res: M, pubmed: '9056720', seq: '1', to_res: R}
- {entry_name: UR2R_RAT, from_res: M, pubmed: '12495432', seq: '184', to_res: A}
- {entry_name: UR2R_RAT, from_res: M, pubmed: '12495432', seq: '184', to_res: L}
- {entry_name: UR2R_RAT, from_res: M, pubmed: '12495432', seq: '185', to_res: A}
- {entry_name: UR2R_RAT, from_res: M, pubmed: '12495432', seq: '185', to_res: L}
- {entry_name: US28_HCMVA, from_res: E, pubmed: '14761190', seq: '124', to_res: D}
- {entry_name: US28_HCMVA, from_res: E, pubmed: '14761190', seq: '124', to_res: Q}
- {entry_name: US28_HCMVA, from_res: R, pubmed: '12646575', seq: '129', to_res: A}
- {entry_name: US28_HCMVA, from_res: K, pubmed: '9658079', seq: '257', to_res: V}
- {entry_name: US28_HCMVA, from_res: E, pubmed: '9658079', seq: '266', to_res: V}
- {entry_name: US28_HCMVA, from_res: R, pubmed: '9658079', seq: '267', to_res: V}
- {entry_name: US28_HCMVA, from_res: E, pubmed: '12456673', seq: '277', to_res: Q}
- {entry_name: US28_HCMVA, from_res: S, pubmed: '12244063', seq: '338', to_res: T}
- {entry_name: US28_HCMVA, from_res: S, pubmed: '12244063', seq: '339', to_res: T}
- {entry_name: US28_HCMVA, from_res: S, pubmed: '12244063', seq: '343', to_res: T}
- {entry_name: US28_HCMVA, from_res: S, pubmed: '12244063', seq: '350', to_res: T}
- {entry_name: US28_HCMVT, from_res: T, pubmed: '11432858', seq: '7', to_res: A}
- {entry_name: V1AR_HUMAN, from_res: Y, pubmed: '9334232', seq: '115', to_res: D}
- {entry_name: V1AR_HUMAN, from_res: K, pubmed: '11337500', seq: '128', to_res: A}
- {entry_name: V1AR_HUMAN, from_res: K, pubmed: '12869559', seq: '128', to_res: C}
- {entry_name: V1AR_HUMAN, from_res: G, pubmed: '10871312', seq: '134', to_res: A}
- {entry_name: V1AR_HUMAN, from_res: F, pubmed: '12482593', seq: '187', to_res: A}
- {entry_name: V1AR_HUMAN, from_res: G, pubmed: '10871312', seq: '222', to_res: S}
- {entry_name: V1AR_HUMAN, from_res: I, pubmed: '10871312', seq: '224', to_res: V}
- {entry_name: V1AR_HUMAN, from_res: F, pubmed: '12869559', seq: '225', to_res: C}
- {entry_name: V1AR_HUMAN, from_res: S, pubmed: '14519593', seq: '256', to_res: A}
- {entry_name: V1AR_HUMAN, from_res: Y, pubmed: '12869559', seq: '300', to_res: C}
- {entry_name: V1AR_HUMAN, from_res: W, pubmed: '9334232', seq: '304', to_res: A}
- {entry_name: V1AR_HUMAN, from_res: F, pubmed: '9334232', seq: '307', to_res: V}
- {entry_name: V1AR_HUMAN, from_res: F, pubmed: '12869559', seq: '308', to_res: C}
- {entry_name: V1AR_HUMAN, from_res: F, pubmed: '9334232', seq: '308', to_res: L}
- {entry_name: V1AR_HUMAN, from_res: I, pubmed: '10871312', seq: '310', to_res: V}
- {entry_name: V1AR_HUMAN, from_res: P, pubmed: '10871312', seq: '318', to_res: G}
- {entry_name: V1AR_HUMAN, from_res: M, pubmed: '10871312', seq: '319', to_res: N}
- {entry_name: V1AR_HUMAN, from_res: E, pubmed: '10871312', seq: '324', to_res: D}
- {entry_name: V1AR_HUMAN, from_res: G, pubmed: '10871312', seq: '337', to_res: A}
- {entry_name: V1AR_RAT, from_res: N, pubmed: '11415438', seq: '14', to_res: Q}
- {entry_name: V1AR_RAT, from_res: N, pubmed: '11520055', seq: '14', to_res: Q}
- {entry_name: V1AR_RAT, from_res: N, pubmed: '11415438', seq: '27', to_res: Q}
- {entry_name: V1AR_RAT, from_res: N, pubmed: '11520055', seq: '27', to_res: Q}
- {entry_name: V1AR_RAT, from_res: L, pubmed: '11875119', seq: '42', to_res: A}
- {entry_name: V1AR_RAT, from_res: G, pubmed: '11875119', seq: '43', to_res: A}
- {entry_name: V1AR_RAT, from_res: D, pubmed: '11875119', seq: '44', to_res: A}
- {entry_name: V1AR_RAT, from_res: V, pubmed: '11875119', seq: '45', to_res: A}
- {entry_name: V1AR_RAT, from_res: R, pubmed: '11875119', seq: '46', to_res: A}
- {entry_name: V1AR_RAT, from_res: R, pubmed: '11955056', seq: '46', to_res: A}
- {entry_name: V1AR_RAT, from_res: R, pubmed: '11875119', seq: '46', to_res: E}
- {entry_name: V1AR_RAT, from_res: R, pubmed: '11875119', seq: '46', to_res: K}
- {entry_name: V1AR_RAT, from_res: R, pubmed: '11875119', seq: '46', to_res: L}
- {entry_name: V1AR_RAT, from_res: N, pubmed: '11875119', seq: '47', to_res: A}
- {entry_name: V1AR_RAT, from_res: N, pubmed: '11415438', seq: '198', to_res: Q}
- {entry_name: V2R_CANFA, from_res: C, pubmed: '11181969', seq: '282', to_res: Y}
- {entry_name: V2R_HUMAN, from_res: T, pubmed: '10820168', seq: '7', to_res: S}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '9027323', seq: '12', to_res: E}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '8910530', seq: '22', to_res: A}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '8999963', seq: '22', to_res: Q}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '9224808', seq: '22', to_res: Q}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '12509923', seq: '34', to_res: R}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '43', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '44', to_res: F}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '10432391', seq: '44', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '44', to_res: P}
- {entry_name: V2R_HUMAN, from_res: I, pubmed: '10770218', seq: '46', to_res: K}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '53', to_res: R}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '11181969', seq: '55', to_res: D}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '11181969', seq: '55', to_res: H}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '9773787', seq: '55', to_res: H}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '59', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9773787', seq: '59', to_res: P}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '12509923', seq: '61', to_res: G}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '7527400', seq: '61', to_res: V}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '10820168', seq: '62', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '62', to_res: P}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '10644689', seq: '71', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '10820168', seq: '71', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '71', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11389590', seq: '71', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '7920187', seq: '71', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '8104196', seq: '71', to_res: X}
- {entry_name: V2R_HUMAN, from_res: H, pubmed: '11181969', seq: '80', to_res: R}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '81', to_res: F}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '83', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '83', to_res: Q}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9773787', seq: '83', to_res: Q}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '11181969', seq: '84', to_res: D}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '10477431', seq: '85', to_res: N}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '10714359', seq: '85', to_res: N}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '10749568', seq: '85', to_res: N}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '10770218', seq: '85', to_res: N}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '11181969', seq: '85', to_res: N}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '9369448', seq: '85', to_res: N}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '10820168', seq: '88', to_res: L}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '11181969', seq: '88', to_res: L}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '10749568', seq: '88', to_res: M}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '10820168', seq: '88', to_res: M}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '11181969', seq: '88', to_res: M}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '9773787', seq: '88', to_res: M}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '11181969', seq: '88', to_res: N}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '11181969', seq: '92', to_res: R}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '10820168', seq: '94', to_res: Q}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '94', to_res: Q}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '11181969', seq: '95', to_res: L}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '99', to_res: R}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11389590', seq: '99', to_res: R}
- {entry_name: V2R_HUMAN, from_res: K, pubmed: '9792651', seq: '100', to_res: D}
- {entry_name: V2R_HUMAN, from_res: K, pubmed: '16234409', seq: '100', to_res: D}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '14709855', seq: '104', to_res: C}
- {entry_name: V2R_HUMAN, from_res: F, pubmed: '10770218', seq: '105', to_res: V}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10770218', seq: '106', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11116139', seq: '106', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11181969', seq: '106', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11916004', seq: '106', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11923476', seq: '106', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9792651', seq: '106', to_res: H}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '11181969', seq: '107', to_res: E}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '16234409', seq: '110', to_res: W}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '10644689', seq: '112', to_res: A}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '10648821', seq: '112', to_res: A}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '11181969', seq: '112', to_res: R}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '10648821', seq: '112', to_res: S}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10770218', seq: '113', to_res: W}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11181969', seq: '113', to_res: W}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '12801889', seq: '113', to_res: W}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7920187', seq: '113', to_res: W}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7984150', seq: '113', to_res: W}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9369448', seq: '113', to_res: W}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '11181969', seq: '119', to_res: X}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '16234409', seq: '120', to_res: V}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '11181969', seq: '122', to_res: R}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '10820168', seq: '123', to_res: K}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '11181969', seq: '123', to_res: K}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '11181969', seq: '124', to_res: X}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11181969', seq: '126', to_res: F}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10820168', seq: '127', to_res: F}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11181969', seq: '127', to_res: F}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '10820168', seq: '128', to_res: S}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '11181969', seq: '128', to_res: S}
- {entry_name: V2R_HUMAN, from_res: I, pubmed: '10770218', seq: '130', to_res: F}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '11181969', seq: '132', to_res: D}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '7920187', seq: '132', to_res: D}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '10820168', seq: '135', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '135', to_res: P}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '9891993', seq: '136', to_res: A}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10026823', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10644689', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10714359', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11134505', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11181969', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '12356298', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '14757828', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7920187', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '8514744', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '8999963', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9029506', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9369448', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9711877', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9826914', seq: '137', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '12356298', seq: '143', to_res: A}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '12356298', seq: '143', to_res: E}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '12356298', seq: '143', to_res: H}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '12356298', seq: '143', to_res: K}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '12356298', seq: '143', to_res: N}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11181969', seq: '143', to_res: P}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7560098', seq: '143', to_res: P}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7598729', seq: '143', to_res: P}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '11375990', seq: '145', to_res: A}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '11375990', seq: '145', to_res: G}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '11375990', seq: '145', to_res: L}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '11375990', seq: '145', to_res: W}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11375990', seq: '146', to_res: R}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11375990', seq: '146', to_res: W}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '11181969', seq: '147', to_res: T}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '11375990', seq: '147', to_res: T}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '10820168', seq: '147', to_res: V}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '11181969', seq: '147', to_res: V}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '11375990', seq: '148', to_res: F}
- {entry_name: V2R_HUMAN, from_res: H, pubmed: '11375990', seq: '150', to_res: R}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11375990', seq: '152', to_res: R}
- {entry_name: V2R_HUMAN, from_res: H, pubmed: '11375990', seq: '155', to_res: L}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '10477431', seq: '163', to_res: P}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '164', to_res: S}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '164', to_res: X}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10644689', seq: '167', to_res: L}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10820168', seq: '167', to_res: L}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11181969', seq: '167', to_res: L}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11181969', seq: '167', to_res: T}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10820168', seq: '167', to_res: X}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11181969', seq: '167', to_res: X}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '10820168', seq: '174', to_res: L}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '11181969', seq: '174', to_res: L}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '16234409', seq: '175', to_res: Y}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '10820168', seq: '180', to_res: X}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '11181969', seq: '180', to_res: X}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10644689', seq: '181', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10770218', seq: '181', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11116139', seq: '181', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11181969', seq: '181', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7527400', seq: '181', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9369448', seq: '181', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9711877', seq: '181', to_res: C}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '9792651', seq: '182', to_res: D}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '9792651', seq: '184', to_res: G}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '10648821', seq: '185', to_res: C}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '10770218', seq: '185', to_res: C}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '11116139', seq: '185', to_res: C}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '11181969', seq: '185', to_res: C}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '11389590', seq: '185', to_res: C}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '10648821', seq: '185', to_res: N}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '9792651', seq: '185', to_res: N}
- {entry_name: V2R_HUMAN, from_res: T, pubmed: '9792651', seq: '190', to_res: F}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '10820168', seq: '191', to_res: G}
- {entry_name: V2R_HUMAN, from_res: D, pubmed: '11181969', seq: '191', to_res: G}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '10644689', seq: '192', to_res: A}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '12509923', seq: '192', to_res: R}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '10648821', seq: '192', to_res: S}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '10820168', seq: '193', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '193', to_res: X}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '11116139', seq: '195', to_res: A}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '9792651', seq: '195', to_res: R}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '10648821', seq: '195', to_res: S}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '10714359', seq: '201', to_res: D}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '11181969', seq: '201', to_res: D}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '9369448', seq: '201', to_res: D}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10648821', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10770218', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11116139', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11181969', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11389590', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7560098', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '7564126', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9369448', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '16234409', seq: '202', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9792651', seq: '202', to_res: L}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '16234409', seq: '202', to_res: S}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10770218', seq: '203', to_res: C}
- {entry_name: V2R_HUMAN, from_res: T, pubmed: '9792651', seq: '204', to_res: A}
- {entry_name: V2R_HUMAN, from_res: T, pubmed: '11181969', seq: '204', to_res: N}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '10714359', seq: '205', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '10770218', seq: '205', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '11116139', seq: '205', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '11181969', seq: '205', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '9369448', seq: '205', to_res: C}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '11181969', seq: '206', to_res: D}
- {entry_name: V2R_HUMAN, from_res: T, pubmed: '11181969', seq: '207', to_res: N}
- {entry_name: V2R_HUMAN, from_res: I, pubmed: '11181969', seq: '209', to_res: F}
- {entry_name: V2R_HUMAN, from_res: I, pubmed: '9773787', seq: '209', to_res: F}
- {entry_name: V2R_HUMAN, from_res: F, pubmed: '10820168', seq: '214', to_res: S}
- {entry_name: V2R_HUMAN, from_res: F, pubmed: '11181969', seq: '214', to_res: S}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '10820168', seq: '215', to_res: M}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '10820168', seq: '217', to_res: T}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '11181969', seq: '217', to_res: T}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '219', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '219', to_res: R}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '10770218', seq: '225', to_res: X}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '11181969', seq: '225', to_res: X}
- {entry_name: V2R_HUMAN, from_res: Q, pubmed: '9756892', seq: '225', to_res: Y}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '9756892', seq: '226', to_res: G}
- {entry_name: V2R_HUMAN, from_res: F, pubmed: '9756892', seq: '229', to_res: C}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9756892', seq: '230', to_res: Y}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '9756892', seq: '231', to_res: H}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '11181969', seq: '231', to_res: X}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '10644689', seq: '242', to_res: X}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '11181969', seq: '242', to_res: X}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '11923476', seq: '242', to_res: X}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9756892', seq: '247', to_res: A}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9756892', seq: '248', to_res: A}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9756892', seq: '249', to_res: A}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9756892', seq: '251', to_res: A}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9756892', seq: '252', to_res: A}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10820168', seq: '252', to_res: W}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '11181969', seq: '258', to_res: K}
- {entry_name: V2R_HUMAN, from_res: K, pubmed: '12960162', seq: '268', to_res: R}
- {entry_name: V2R_HUMAN, from_res: M, pubmed: '11181969', seq: '272', to_res: K}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '11181969', seq: '277', to_res: A}
- {entry_name: V2R_HUMAN, from_res: V, pubmed: '9027323', seq: '277', to_res: A}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '10026824', seq: '280', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '10644689', seq: '280', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '11181969', seq: '280', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '9027323', seq: '280', to_res: C}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '9294123', seq: '280', to_res: C}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '10820168', seq: '284', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '284', to_res: X}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '11181969', seq: '285', to_res: P}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '11181969', seq: '286', to_res: L}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '11181969', seq: '286', to_res: R}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '10820168', seq: '286', to_res: S}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '11181969', seq: '286', to_res: S}
- {entry_name: V2R_HUMAN, from_res: F, pubmed: '11916004', seq: '287', to_res: L}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '10820168', seq: '289', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '289', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '292', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9027323', seq: '292', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9294123', seq: '292', to_res: P}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '293', to_res: X}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '10820168', seq: '294', to_res: P}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '11181969', seq: '294', to_res: P}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '9773787', seq: '294', to_res: P}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '296', to_res: X}
- {entry_name: V2R_HUMAN, from_res: G, pubmed: '9792651', seq: '304', to_res: R}
- {entry_name: V2R_HUMAN, from_res: A, pubmed: '9792651', seq: '305', to_res: P}
- {entry_name: V2R_HUMAN, from_res: F, pubmed: '16234409', seq: '307', to_res: I}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '309', to_res: P}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '312', to_res: X}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '7920187', seq: '312', to_res: X}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '11181969', seq: '312', to_res: Y}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10820168', seq: '315', to_res: R}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11181969', seq: '315', to_res: R}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11389590', seq: '315', to_res: R}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '11181969', seq: '317', to_res: K}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10820168', seq: '318', to_res: T}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '11181969', seq: '319', to_res: R}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '10820168', seq: '321', to_res: D}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '11181969', seq: '321', to_res: D}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '10820168', seq: '321', to_res: K}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '11181969', seq: '321', to_res: K}
- {entry_name: V2R_HUMAN, from_res: N, pubmed: '11181969', seq: '321', to_res: Y}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '11181969', seq: '322', to_res: H}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '8929875', seq: '322', to_res: H}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '9773787', seq: '322', to_res: H}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '10714359', seq: '322', to_res: S}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '11181969', seq: '322', to_res: S}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '8929875', seq: '322', to_res: S}
- {entry_name: V2R_HUMAN, from_res: P, pubmed: '9773787', seq: '322', to_res: S}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '323', to_res: R}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '323', to_res: S}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '10820168', seq: '323', to_res: X}
- {entry_name: V2R_HUMAN, from_res: W, pubmed: '11181969', seq: '323', to_res: X}
- {entry_name: V2R_HUMAN, from_res: Y, pubmed: '12801889', seq: '325', to_res: F}
- {entry_name: V2R_HUMAN, from_res: E, pubmed: '9730911', seq: '335', to_res: Q}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10644689', seq: '337', to_res: X}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '10749568', seq: '337', to_res: X}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11181969', seq: '337', to_res: X}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11389590', seq: '337', to_res: X}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '11916004', seq: '337', to_res: X}
- {entry_name: V2R_HUMAN, from_res: R, pubmed: '9537515', seq: '337', to_res: X}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9730911', seq: '339', to_res: I}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9730911', seq: '339', to_res: T}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9730911', seq: '340', to_res: I}
- {entry_name: V2R_HUMAN, from_res: L, pubmed: '9730911', seq: '340', to_res: T}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '12900404', seq: '341', to_res: A}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '12900404', seq: '341', to_res: G}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '12900404', seq: '341', to_res: S}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '8573100', seq: '341', to_res: S}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '9224808', seq: '341', to_res: S}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '12900404', seq: '342', to_res: A}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '12900404', seq: '342', to_res: G}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '12900404', seq: '342', to_res: S}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '8573100', seq: '342', to_res: S}
- {entry_name: V2R_HUMAN, from_res: C, pubmed: '9224808', seq: '342', to_res: S}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '12482593', seq: '357', to_res: A}
- {entry_name: V2R_HUMAN, from_res: T, pubmed: '12482593', seq: '359', to_res: A}
- {entry_name: V2R_HUMAN, from_res: T, pubmed: '12482593', seq: '360', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10542263', seq: '362', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '9482866', seq: '362', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10542263', seq: '363', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11150299', seq: '363', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '11353798', seq: '363', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '12482593', seq: '363', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '9482866', seq: '363', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10542263', seq: '364', to_res: A}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '9482866', seq: '364', to_res: A}
- {entry_name: V2R_HUMAN, from_res: K, pubmed: '12960162', seq: '367', to_res: R}
- {entry_name: V2R_HUMAN, from_res: S, pubmed: '10542263', seq: '371', to_res: A}
- {entry_name: VG74_HHV8, from_res: D, pubmed: '10531332', seq: '13', to_res: A}
- {entry_name: VG74_HHV8, from_res: D, pubmed: '10531332', seq: '14', to_res: A}
- {entry_name: VG74_HHV8, from_res: E, pubmed: '10531332', seq: '15', to_res: A}
- {entry_name: VG74_HHV8, from_res: C, pubmed: '10531332', seq: '39', to_res: A}
- {entry_name: VG74_HHV8, from_res: D, pubmed: '11031271', seq: '83', to_res: A}
- {entry_name: VG74_HHV8, from_res: D, pubmed: '11031271', seq: '83', to_res: N}
- {entry_name: VG74_HHV8, from_res: L, pubmed: '10842179', seq: '91', to_res: D}
- {entry_name: VG74_HHV8, from_res: L, pubmed: '11748262', seq: '91', to_res: D}
- {entry_name: VG74_HHV8, from_res: N, pubmed: '10842179', seq: '92', to_res: D}
- {entry_name: VG74_HHV8, from_res: S, pubmed: '10842179', seq: '93', to_res: D}
- {entry_name: VG74_HHV8, from_res: L, pubmed: '10842179', seq: '94', to_res: D}
- {entry_name: VG74_HHV8, from_res: Y, pubmed: '10842179', seq: '128', to_res: S}
- {entry_name: VG74_HHV8, from_res: D, pubmed: '11031271', seq: '132', to_res: A}
- {entry_name: VG74_HHV8, from_res: D, pubmed: '11031271', seq: '132', to_res: N}
- {entry_name: VG74_HHV8, from_res: V, pubmed: '10842179', seq: '142', to_res: D}
- {entry_name: VG74_HHV8, from_res: V, pubmed: '11031271', seq: '142', to_res: D}
- {entry_name: VG74_HHV8, from_res: V, pubmed: '11507211', seq: '142', to_res: D}
- {entry_name: VG74_HHV8, from_res: V, pubmed: '11031271', seq: '142', to_res: N}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '11031271', seq: '143', to_res: A}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '11031271', seq: '143', to_res: K}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '11031271', seq: '143', to_res: Q}
- {entry_name: VG74_HHV8, from_res: Y, pubmed: '11031271', seq: '144', to_res: A}
- {entry_name: VG74_HHV8, from_res: Y, pubmed: '11031271', seq: '144', to_res: F}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '10842179', seq: '208', to_res: H}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '11748262', seq: '208', to_res: H}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '10842179', seq: '212', to_res: H}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '10842179', seq: '278', to_res: A}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '10842179', seq: '279', to_res: A}
- {entry_name: VG74_HHV8, from_res: C, pubmed: '10531332', seq: '286', to_res: A}
- {entry_name: VG74_HHV8, from_res: V, pubmed: '10842179', seq: '310', to_res: N}
- {entry_name: VG74_HHV8, from_res: R, pubmed: '14963144', seq: '322', to_res: W}
- {entry_name: VG74_HHV8, from_res: M, pubmed: '14963144', seq: '325', to_res: S}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '37', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '50', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '63', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: D, pubmed: '7818527', seq: '68', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '72', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: W, pubmed: '7818527', seq: '73', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '86', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: P, pubmed: '7818527', seq: '87', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '105', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: W, pubmed: '7818527', seq: '110', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '122', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: D, pubmed: '9016768', seq: '196', to_res: A}
- {entry_name: VIPR1_HUMAN, from_res: L, pubmed: '9016768', seq: '199', to_res: A}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '208', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '9257707', seq: '215', to_res: A}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '7598720', seq: '215', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '9257707', seq: '215', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '9257707', seq: '215', to_res: S}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '9257707', seq: '285', to_res: A}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '9257707', seq: '285', to_res: G}
- {entry_name: VIPR1_HUMAN, from_res: C, pubmed: '9257707', seq: '285', to_res: S}
- {entry_name: VIPR1_HUMAN, from_res: W, pubmed: '9016768', seq: '286', to_res: A}
- {entry_name: VIPR1_HUMAN, from_res: W, pubmed: '9016768', seq: '294', to_res: A}
- {entry_name: VIPR1_MOUSE, from_res: A, pubmed: '12576099', seq: '212', to_res: Q}
- {entry_name: VIPR1_MOUSE, from_res: V, pubmed: '12576099', seq: '220', to_res: Q}
- {entry_name: VIPR1_PIG, from_res: F, pubmed: '11445245', seq: '12', to_res: K}
- {entry_name: VIPR2_HUMAN, from_res: G, pubmed: '7818527', seq: '87', to_res: P}
- {entry_name: nk1r_human, from_res: H, info: 'These mutant receptors have normal
        binding affinity for 125I-SPAn analog of L-732,138 in which the indole is
        substituted by a benzothiophene moiety (L-709,400) has 5-fold reduced affinity
        for the human NK-1 receptor. As with L-732,138, this compound has 45- and
        50-fold reduced affinity for the H197A and H265A mutant receptors, respectively.The
        affinity of L-708,568 for the H265A mutant is reduced 80-fold compared to
        its affinity for the wild type receptor', ligand_long: 125I-SP, ligand_short: 'L-709,400',
    pubmed: '7509807', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'These mutant receptors have normal
        binding affinity for 125I-SPAn analog of L-732,138 in which the indole is
        substituted by a benzothiophene moiety (L-709,400) has 5-fold reduced affinity
        for the human NK-1 receptor. As with L-732,138, this compound has 45- and
        50-fold reduced affinity for the H197A and H265A mutant receptors, respectively.The
        affinity of L-708,568 for the H265A mutant is reduced 80-fold compared to
        its affinity for the wild type receptor', ligand_long: 125I-SP, ligand_short: 'L-708,568',
    pubmed: '7509807', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'These mutant receptors have normal
        binding affinity for 125I-SPAn analog of L-732,138 in which the indole is
        substituted by a benzothiophene moiety (L-709,400) has 5-fold reduced affinity
        for the human NK-1 receptor. As with L-732,138, this compound has 45- and
        50-fold reduced affinity for the H197A and H265A mutant receptors, respectively.The
        affinity of L-708,568 for the H265A mutant is reduced 80-fold compared to
        its affinity for the wild type receptor', ligand_long: 125I-SP, ligand_short: 'L-732,138',
    pubmed: '7509807', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'In contrast to L -732,138, phenylalanine
        will not completely substitute for histidine 197 in its interaction with L-709,400',
    ligand_long: 125I-SP, ligand_short: 'L-709,400', pubmed: '7509807', seq: '197',
    to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'In contrast to L -732,138, phenylalanine
        will not completely substitute for histidine 197 in its interaction with L-709,400',
    ligand_long: 125I-SP, ligand_short: 'L-708,568', pubmed: '7509807', seq: '197',
    to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'In contrast to L -732,138, phenylalanine
        will not completely substitute for histidine 197 in its interaction with L-709,400',
    ligand_long: 125I-SP, ligand_short: 'L-732,138', pubmed: '7509807', seq: '197',
    to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'These mutant receptors have normal
        binding affinity for 125I-SPAn analog of L-732,138 in which the indole is
        substituted by a benzothiophene moiety (L-709,400) has 5-fold reduced affinity
        for the human NK-1 receptor. As with L-732,138, this compound has 45- and
        50-fold reduced affinity for the H197A and H265A mutant receptors, respectively.The
        affinity of L-708,568 for the H265A mutant is reduced 80-fold compared to
        its affinity for the wild type receptor, while its affinity for the H197A
        mutant is reduced by 20-fold.', ligand_long: 125I-SP, ligand_short: 'L-709,400',
    pubmed: '7509807', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'These mutant receptors have normal
        binding affinity for 125I-SPAn analog of L-732,138 in which the indole is
        substituted by a benzothiophene moiety (L-709,400) has 5-fold reduced affinity
        for the human NK-1 receptor. As with L-732,138, this compound has 45- and
        50-fold reduced affinity for the H197A and H265A mutant receptors, respectively.The
        affinity of L-708,568 for the H265A mutant is reduced 80-fold compared to
        its affinity for the wild type receptor, while its affinity for the H197A
        mutant is reduced by 20-fold.', ligand_long: 125I-SP, ligand_short: 'L-708,568',
    pubmed: '7509807', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'These mutant receptors have normal
        binding affinity for 125I-SPAn analog of L-732,138 in which the indole is
        substituted by a benzothiophene moiety (L-709,400) has 5-fold reduced affinity
        for the human NK-1 receptor. As with L-732,138, this compound has 45- and
        50-fold reduced affinity for the H197A and H265A mutant receptors, respectively.The
        affinity of L-708,568 for the H265A mutant is reduced 80-fold compared to
        its affinity for the wild type receptor, while its affinity for the H197A
        mutant is reduced by 20-fold.', ligand_long: 125I-SP, ligand_short: 'L-732,138',
    pubmed: '7509807', seq: '197', to_res: A}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3)., ligand_long: '', ligand_short: Carbachol, pubmed: '7679072',
    seq: '530', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3)., ligand_long: '', ligand_short: Acetylcholine, pubmed: '7679072',
    seq: '530', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3).Trp192 -> Phe and Trp503 -> Phe displayed clearly reduced
        carbachol potencies, ligand_long: '', ligand_short: Acetylcholine, pubmed: '7679072',
    seq: '503', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3).Trp192 -> Phe and Trp503 -> Phe displayed clearly reduced
        carbachol potencies, ligand_long: '', ligand_short: Carbachol, pubmed: '7679072',
    seq: '503', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3).Trp192 -> Phe and Trp503 -> Phe displayed clearly reduced
        carbachol potencies, ligand_long: '', ligand_short: Acetylcholine, pubmed: '7679072',
    seq: '503', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: Trp192 -> Phe induced a maximum accumulation
        of inositol phosphates similar to the wild type receptorTrp192 -> Phe and
        Trp503 -> Phe displayed clearly reduced carbachol potencies, ligand_long: '',
    ligand_short: Carbachol, pubmed: '7679072', seq: '192', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: Trp192 -> Phe induced a maximum accumulation
        of inositol phosphates similar to the wild type receptorTrp192 -> Phe and
        Trp503 -> Phe displayed clearly reduced carbachol potencies, ligand_long: '',
    ligand_short: Acetylcholine, pubmed: '7679072', seq: '192', to_res: F}
- {entry_name: acm3_rat, from_res: P, info: 'Pro540 -> Ala gained the ability to bind
        acetylcholine and carbachol with exceptionally high affinities, which exceeded
        the corresponding wild type affinities by 7- and 19-fold, respectivelyPro540
        -> Ala (a mutant receptor that displayed exceptionally high agonist binding
        affinities; Table I) proved to be severely impaired in its ability to stimulate
        inositol phosphate formation (Emax ~ 25% of that of wild type m3)', ligand_long: '',
    ligand_short: Carbachol, pubmed: '7679072', seq: '540', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: 'Pro540 -> Ala gained the ability to bind
        acetylcholine and carbachol with exceptionally high affinities, which exceeded
        the corresponding wild type affinities by 7- and 19-fold, respectivelyPro540
        -> Ala (a mutant receptor that displayed exceptionally high agonist binding
        affinities; Table I) proved to be severely impaired in its ability to stimulate
        inositol phosphate formation (Emax ~ 25% of that of wild type m3)', ligand_long: '',
    ligand_short: Acetylcholine, pubmed: '7679072', seq: '540', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: only a slight decrease in agonist binding
        affinities (~3-fold) was found with Pro505 -> Ala.Pro201-> Ala and Pro505
        -> Ala stimulated PI hydrolysis to a similar maximum extent as the wild type
        receptor, ligand_long: '', ligand_short: Carbachol, pubmed: '7679072', seq: '505',
    to_res: A}
- {entry_name: acm3_rat, from_res: P, info: only a slight decrease in agonist binding
        affinities (~3-fold) was found with Pro505 -> Ala.Pro201-> Ala and Pro505
        -> Ala stimulated PI hydrolysis to a similar maximum extent as the wild type
        receptor, ligand_long: '', ligand_short: Acetylcholine, pubmed: '7679072',
    seq: '505', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro242 -> Ala bound the agonists acetylcholine
        and carbachol with 16- to 34-fold reduced affinities (compared with wild type
        m3)the functional activity of Pro242 -> Ala was somewhat reduced (Emax ~ 70%
        of that of wild type m3), ligand_long: '', ligand_short: Carbachol, pubmed: '7679072',
    seq: '242', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro201 -> Ala and Pro505 -> Ala stimulated
        PI hydrolysis to a similar maximum extent as the wild type receptor, ligand_long: '',
    ligand_short: Acetylcholine, pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro242 -> Ala bound the agonists acetylcholine
        and carbachol with 16- to 34-fold reduced affinities (compared with wild type
        m3)the functional activity of Pro242 -> Ala was somewhat reduced (Emax ~ 70%
        of that of wild type m3), ligand_long: '', ligand_short: Acetylcholine, pubmed: '7679072',
    seq: '242', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro201 -> Ala and Pro505 -> Ala stimulated
        PI hydrolysis to a similar maximum extent as the wild type receptor, ligand_long: '',
    ligand_short: Carbachol, pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3)., ligand_long: '', ligand_short: 4-DAMP, pubmed: '7679072',
    seq: '530', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3)., ligand_long: '[3H]NMS', ligand_short: '', pubmed: '7679072',
    seq: '530', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3).Trp192 -> Phe and Trp503 -> Phe displayed clearly reduced
        carbachol potencies, ligand_long: '', ligand_short: 4-DAMP, pubmed: '7679072',
    seq: '503', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: The maximum functional responses found
        with Trp503 -> Phe and Trp530- Phe were somewhat decreased (Emax ~ 70% of
        that of wild type m3).Trp192 -> Phe and Trp503 -> Phe displayed clearly reduced
        carbachol potencies, ligand_long: '[3H]NMS', ligand_short: '', pubmed: '7679072',
    seq: '503', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: Trp192 -> Phe induced a maximum accumulation
        of inositol phosphates similar to the wild type receptorTrp192 -> Phe and
        Trp503 -> Phe displayed clearly reduced carbachol potencies, ligand_long: '',
    ligand_short: 4-DAMP, pubmed: '7679072', seq: '192', to_res: F}
- {entry_name: acm3_rat, from_res: W, info: Trp192 -> Phe induced a maximum accumulation
        of inositol phosphates similar to the wild type receptorTrp192 -> Phe and
        Trp503 -> Phe displayed clearly reduced carbachol potencies, ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '7679072', seq: '192', to_res: F}
- {entry_name: acm3_rat, from_res: P, info: 'Pro540 -> Ala gained the ability to bind
        acetylcholine and carbachol with exceptionally high affinities, which exceeded
        the corresponding wild type affinities by 7- and 19-fold, respectivelyPro540
        -> Ala (a mutant receptor that displayed exceptionally high agonist binding
        affinities; Table I) proved to be severely impaired in its ability to stimulate
        inositol phosphate formation (Emax ~ 25% of that of wild type m3)', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '7679072', seq: '540', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: only a slight decrease in agonist binding
        affinities (~3-fold) was found with Pro505 -> Ala.Pro201-> Ala and Pro505
        -> Ala stimulated PI hydrolysis to a similar maximum extent as the wild type
        receptor, ligand_long: '', ligand_short: 4-DAMP, pubmed: '7679072', seq: '505',
    to_res: A}
- {entry_name: acm3_rat, from_res: P, info: only a slight decrease in agonist binding
        affinities (~3-fold) was found with Pro505 -> Ala.Pro201-> Ala and Pro505
        -> Ala stimulated PI hydrolysis to a similar maximum extent as the wild type
        receptor, ligand_long: '[3H]NMS', ligand_short: '', pubmed: '7679072', seq: '505',
    to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro201 -> Ala and Pro505 -> Ala stimulated
        PI hydrolysis to a similar maximum extent as the wild type receptor, ligand_long: '',
    ligand_short: 4-DAMP, pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro201 -> Ala and Pro505 -> Ala stimulated
        PI hydrolysis to a similar maximum extent as the wild type receptor, ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro242 -> Ala bound the agonists acetylcholine
        and carbachol with 16- to 34-fold reduced affinities (compared with wild type
        m3)the functional activity of Pro242 -> Ala was somewhat reduced (Emax ~ 70%
        of that of wild type m3), ligand_long: '', ligand_short: 4-DAMP, pubmed: '7679072',
    seq: '242', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro242 -> Ala bound the agonists acetylcholine
        and carbachol with 16- to 34-fold reduced affinities (compared with wild type
        m3)the functional activity of Pro242 -> Ala was somewhat reduced (Emax ~ 70%
        of that of wild type m3), ligand_long: '[3H]NMS', ligand_short: '', pubmed: '7679072',
    seq: '242', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro201 -> Ala and Pro505 -> Ala stimulated
        PI hydrolysis to a similar maximum extent as the wild type receptor, ligand_long: '',
    ligand_short: 4-DAMP, pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: Pro201 -> Ala and Pro505 -> Ala stimulated
        PI hydrolysis to a similar maximum extent as the wild type receptor, ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '7679072', seq: '201', to_res: A}
- {entry_name: nk1r_rat, from_res: L, info: shown), ligand_long: '', ligand_short: '',
    pubmed: '7679096', seq: '116', to_res: V}
- {entry_name: nk1r_rat, from_res: C, info: shown), ligand_long: '', ligand_short: '',
    pubmed: '7679096', seq: '80', to_res: S}
- {entry_name: a8k7i1_human, from_res: Y, info: '[3H] SR 48968 shows the main interactions
        with the aromatic ring of Tyr266 and both the aromatic ring and the OH group
        of Tyr289', ligand_long: '[3H]MEN 11420', ligand_short: '', pubmed: '10818258',
    seq: '289', to_res: F}
- {entry_name: a8k7i1_human, from_res: Y, info: '[3H] SR 48968 shows the main interactions
        with the aromatic ring of Tyr266 and both the aromatic ring and the OH group
        of Tyr289', ligand_long: '[125I]NKA', ligand_short: '', pubmed: '10818258',
    seq: '289', to_res: F}
- {entry_name: a8k7i1_human, from_res: F, info: 'all the mutations we performed on
        TM VI abolished the binding of [3H] MEN 11420', ligand_long: '[3H]SR 48968',
    ligand_short: '', pubmed: '10818258', seq: '270', to_res: A}
- {entry_name: a8k7i1_human, from_res: Y, info: 'all the mutations we performed on
        TM VI abolished the binding of [3H] MEN 11420[3H] SR 48968 shows the main
        interactions with the aromatic ring of Tyr266', ligand_long: '', ligand_short: '',
    pubmed: '10818258', seq: '266', to_res: T}
- {entry_name: a8k7i1_human, from_res: Y, info: 'all the mutations we performed on
        TM VI abolished the binding of [3H] MEN 11420[3H] SR 48968 shows the main
        interactions with the aromatic ring of Tyr266', ligand_long: '[3H]SR 48968',
    ligand_short: '', pubmed: '10818258', seq: '266', to_res: F}
- {entry_name: a8k7i1_human, from_res: Y, info: 'all the mutations we performed on
        TM VI abolished the binding of [3H] MEN 11420[3H] SR 48968 shows the main
        interactions with the aromatic ring of Tyr266', ligand_long: '[125I]NKA',
    ligand_short: '', pubmed: '10818258', seq: '266', to_res: F}
- {entry_name: a8k7i1_human, from_res: Y, info: 'all the mutations we performed on
        TM VI abolished the binding of [3H] MEN 11420[3H] SR 48968 shows the main
        interactions with the aromatic ring of Tyr266', ligand_long: '', ligand_short: '',
    pubmed: '10818258', seq: '266', to_res: A}
- {entry_name: a8k7i1_human, from_res: H, info: 'all the mutations we performed on
        TM VI abolished the binding of [3H] MEN 11420', ligand_long: '', ligand_short: '',
    pubmed: '10818258', seq: '267', to_res: A}
- {entry_name: a8k7i1_human, from_res: Y, info: 'the mutant Tyr206Ala maintains intact
        binding for [3H] SR 48968, even if with smaller Bmax as compared to the wild
        type receptor', ligand_long: '[3H]SR 48968', ligand_short: '', pubmed: '10818258',
    seq: '206', to_res: A}
- {entry_name: lshr_rat, from_res: Y, info: "All mutant receptors bound hCG with an\
        \ affinity comparable with that detected in cells expressing rLHR-wtthe Y524F\
        \ mutation is a signaling-impairing mutationThe EC50 for the hCG-induced increase\
        \ in cAMP levels is 27-fold higher in 293L(Y524F-22) than in 293L(wt-12).\
        \ 293L(Y524F-22) cells also display a low to normal level of cAMP under basal\
        \ conditions, but their maximal response to hCG is only 14% lower (as judged\
        \ by the response ratio) than the response of 293L(wt-12) cells.the t1/2 \
        \ values of internalization of hCG in cells expressing signaling-impairing\
        \ mutations (i.e. 293L(Y524F-22) and 293L(D383N-9) cells) are still faster\
        \ (200\u2013300 min; see Table II) than the t1/2  of internalization of the\
        \ free rLHR-wt (\u223C450 min; see Table III)one mutation that impairs signal\
        \ transduction (Y524F) and one mutation that induces constitutive activation\
        \ (D556Y) had little or no effect on the t1/2  of internalization of the mature\
        \ free rLHRthe conditions used here to proteolyze the cell surface rLHR (see\
        \ \u201CMaterials and Methods\u201D for details) resulted in a quantitative\
        \ loss (i.e. 96\u201398%) of125I-hCG binding to cells expressing rLHR-wt,\
        \ rLHR-Y524F, rLHR-D556Y, and myc-rLHR-wtthe intracellular rLHR precursor\
        \ is degraded with a t1/2  of \u223C100 min. This t 1/2 is not affected by\
        \ a mutation that impairs signal transduction (Y524F)", ligand_long: 125I-hCG,
    ligand_short: '', pubmed: '9857020', seq: '550', to_res: F}
- {entry_name: lshr_rat, from_res: D, info: "All mutant receptors bound hCG with an\
        \ affinity comparable with that detected in cells expressing rLHR-wtthe D556Y\
        \ mutation induced constitutive activation of the rLHR as illustrated by a\
        \ 25-fold increase in the levels of cAMP detected in cells incubated without\
        \ hormone. This elevated basal level of cAMP corresponds to only 10\u2013\
        20% of the maximally attainable levels, however, and the cells expressing\
        \ rLHR-D556Y still responded to hCG with a robust increase in cAMP accumulation.\
        \ The maximal cAMP response to hCG detected in 293L(D556Y-6) cells corresponded\
        \ to about 75% of the maximal response of 293L(wt-12) cells (as judged by\
        \ the response ratio), and the EC50 for this response was comparable between\
        \ these two cell linesthe two constitutively active mutants, rLHR-D556Y and\
        \ myc-rLHR-L435R, enhance the rate of internalization of hCGone mutation that\
        \ impairs signal transduction (Y524F) and one mutation that induces constitutive\
        \ activation (D556Y) had little or no effect on the t1/2  of internalization\
        \ of the mature free rLHRboth activating mutations of the rLHR (i.e. D556Y\
        \ and L435R) increase the rate of internalization of the agonist-occupied\
        \ receptorthe rate of internalization of the agonist-occupied constitutively\
        \ active mutants is 3\u201320-times faster than the rate of internalization\
        \ of the agonist-occupied rLHR-wtthe conditions used here to proteolyze the\
        \ cell surface rLHR (see \u201CMaterials and Methods\u201D for details) resulted\
        \ in a quantitative loss (i.e. 96\u201398%) of125I-hCG binding to cells expressing\
        \ rLHR-wt, rLHR-Y524F, rLHR-D556Y, and myc-rLHR-wtthe rLHR conformations induced\
        \ by the D556Y or L435R mutations are not equivalent to the conformation induced\
        \ by agonist binding to rLHR-wt. Moreover, we can also conclude that the rLHR\
        \ conformations induced by the binding of agonist to the D556Y or L435R mutants\
        \ are also different from each other and different from that induced by the\
        \ binding of agonist to the rLHR-wt", ligand_long: 125I-hCG, ligand_short: '',
    pubmed: '9857020', seq: '582', to_res: Y}
- {entry_name: lshr_rat, from_res: L, info: "All mutant receptors bound hCG with an\
        \ affinity comparable with that detected in cells expressing rLHR-wtcompared\
        \ with 293Lmyc(wt-11) cells, 293Lmyc(L435R-2) cells displayed a 42-fold increase\
        \ in the levels of cAMP detected under basal conditions. This elevated basal\
        \ level of cAMP corresponds to 40\u201350% of the maximal response detected\
        \ in 293Lmyc(wt-11) cells. 293Lmyc(L435R-2) cells did not respond to further\
        \ stimulation by hCG, however, despite the fact that they bind hCG with normal\
        \ affinitythe two constitutively active mutants, rLHR-D556Y and myc-rLHR-L435R,\
        \ enhance the rate of internalization of hCGthe t1/2  of internalization of\
        \ the free mature myc-rLHR-L435R is about twice as fast as that of the mature\
        \ myc-rLHR-wtboth activating mutations of the rLHR (i.e. D556Y and L435R)\
        \ increase the rate of internalization of the agonist-occupied receptorthe\
        \ rate of internalization of the agonist-occupied constitutively active mutants\
        \ is 3\u201320-times faster than the rate of internalization of the agonist-occupied\
        \ rLHR-wtthe stronger activating mutation (i.e. the L435R mutation) increases\
        \ the internalization of the free receptorthe conditions used here to proteolyze\
        \ the cell surface rLHR (see \u201CMaterials and Methods\u201D for details)\
        \ resulted in a quantitative loss (i.e. 96\u201398%) of125I-hCG binding to\
        \ cells expressing rLHR-wt, rLHR-Y524F, rLHR-D556Y, and myc-rLHR-wt. The loss\
        \ of binding activity detected in cells expressing myc-rLHR-L435R was at best\
        \ 85%that the intracellular rLHR precursor is degraded with a t1/2  of \u223C\
        100 min. This t1/2 is not affected by a mutation that impairs signal transduction\
        \ (Y524F) or by a mutation that causes constitutive activation (L435R)the\
        \ rLHR conformations induced by the D556Y or L435R mutations are not equivalent\
        \ to the conformation induced by agonist binding to rLHR-wt. Moreover, we\
        \ can also conclude that the rLHR conformations induced by the binding of\
        \ agonist to the D556Y or L435R mutants are also different from each other\
        \ and different from that induced by the binding of agonist to the rLHR-wtIn\
        \ contrast to the data obtained with intact cells expressing rLHR-L435R, which\
        \ do not respond to hCG with further cAMP accumulation (cf. Fig. 1 and Table\
        \ I), we found that membranes prepared from these cells do respond to hCG\
        \ with an increase in adenylyl cyclase activity (Table IV). The magnitude\
        \ of this increase (\u223C2-fold) is comparable with the 1.7-fold increase\
        \ in adenylyl cyclase detected upon the addition of hCG to membranes prepared\
        \ from cells expressing rLHR-wt", ligand_long: 125I-hCG, ligand_short: '',
    pubmed: '9857020', seq: '461', to_res: R}
- {entry_name: lshr_rat, from_res: D, info: "All mutant receptors bound hCG with an\
        \ affinity comparable with that detected in cells expressing rLHR-wtthe D556Y\
        \ mutation induced constitutive activation of the rLHR as illustrated by a\
        \ 25-fold increase in the levels of cAMP detected in cells incubated without\
        \ hormone. This elevated basal level of cAMP corresponds to only 10\u2013\
        20% of the maximally attainable levels, however, and the cells expressing\
        \ rLHR-D556Y still responded to hCG with a robust increase in cAMP accumulation.\
        \ The maximal cAMP response to hCG detected in 293L(D556Y-6) cells corresponded\
        \ to about 75% of the maximal response of 293L(wt-12) cells (as judged by\
        \ the response ratio), and the EC50 for this response was comparable between\
        \ these two cell linesthe two constitutively active mutants, rLHR-D556Y and\
        \ myc-rLHR-L435R, enhance the rate of internalization of hCGone mutation that\
        \ impairs signal transduction (Y524F) and one mutation that induces constitutive\
        \ activation (D556Y) had little or no effect on the t1/2  of internalization\
        \ of the mature free rLHRboth activating mutations of the rLHR (i.e. D556Y\
        \ and L435R) increase the rate of internalization of the agonist-occupied\
        \ receptorthe rate of internalization of the agonist-occupied constitutively\
        \ active mutants is 3\u201320-times faster than the rate of internalization\
        \ of the agonist-occupied rLHR-wtthe conditions used here to proteolyze the\
        \ cell surface rLHR (see \u201CMaterials and Methods\u201D for details) resulted\
        \ in a quantitative loss (i.e. 96\u201398%) of125I-hCG binding to cells expressing\
        \ rLHR-wt, rLHR-Y524F, rLHR-D556Y, and myc-rLHR-wtthe rLHR conformations induced\
        \ by the D556Y or L435R mutations are not equivalent to the conformation induced\
        \ by agonist binding to rLHR-wt. Moreover, we can also conclude that the rLHR\
        \ conformations induced by the binding of agonist to the D556Y or L435R mutants\
        \ are also different from each other and different from that induced by the\
        \ binding of agonist to the rLHR-wt", ligand_long: 125I-hCG, ligand_short: '',
    pubmed: '9857020', seq: '582', to_res: Y}
- {entry_name: cnr2_human, from_res: W, info: 'the W172F and W172Y mutants retained
        almost normal specific binding, at 80 and 68% of wt values, respectively.W172Y
        and W172F showed binding values close to those obtained with HA-CB2 (wt).the
        binding affinities of W172Y and W172F did not appreciably differ from that
        of the wt receptor.Heterologous competitive binding studies showed that the
        W172F and W172Y mutants bound the tricyclic cannabinoid agonist HU-210 (a
        compound very similar in structure to HU-243) with affinities essentially
        equivalent to that observed with the wt receptorthe binding of the bicyclic
        cannabinoid CP55,940 was not affected by these mutationsbinding of the aminoalkylindole
        WIN55,212-2 was slightly reduced by the mutationsthe W172F and W172Y mutants
        showed similar AC inhibition patterns to that observed with the wt receptor',
    ligand_long: '', ligand_short: 'WIN55,212-2', pubmed: '11080201', seq: '172',
    to_res: Y}
- {entry_name: cnr2_human, from_res: W, info: 'the W172F and W172Y mutants retained
        almost normal specific binding, at 80 and 68% of wt values, respectively.W172Y
        and W172F showed binding values close to those obtained with HA-CB2 (wt).the
        binding affinities of W172Y and W172F did not appreciably differ from that
        of the wt receptor.Heterologous competitive binding studies showed that the
        W172F and W172Y mutants bound the tricyclic cannabinoid agonist HU-210 (a
        compound very similar in structure to HU-243) with affinities essentially
        equivalent to that observed with the wt receptorthe binding of the bicyclic
        cannabinoid CP55,940 was not affected by these mutationsbinding of the aminoalkylindole
        WIN55,212-2 was slightly reduced by the mutationsthe W172F and W172Y mutants
        showed similar AC inhibition patterns to that observed with the wt receptor',
    ligand_long: '', ligand_short: 'CP55,940', pubmed: '11080201', seq: '172', to_res: Y}
- {entry_name: cnr2_human, from_res: W, info: 'the W172F and W172Y mutants retained
        almost normal specific binding, at 80 and 68% of wt values, respectively.W172Y
        and W172F showed binding values close to those obtained with HA-CB2 (wt).the
        binding affinities of W172Y and W172F did not appreciably differ from that
        of the wt receptor.Heterologous competitive binding studies showed that the
        W172F and W172Y mutants bound the tricyclic cannabinoid agonist HU-210 (a
        compound very similar in structure to HU-243) with affinities essentially
        equivalent to that observed with the wt receptorthe binding of the bicyclic
        cannabinoid CP55,940 was not affected by these mutationsbinding of the aminoalkylindole
        WIN55,212-2 was slightly reduced by the mutationsthe W172F and W172Y mutants
        showed similar AC inhibition patterns to that observed with the wt receptor',
    ligand_long: '', ligand_short: HU-210, pubmed: '11080201', seq: '172', to_res: Y}
- {entry_name: cnr2_human, from_res: W, info: 'the W172F and W172Y mutants retained
        almost normal specific binding, at 80 and 68% of wt values, respectivelyW172Y
        and W172F showed binding values close to those obtained with HA-CB2 (wt)the
        binding affinities of W172Y and W172F did not appreciably differ from that
        of the wt receptorHeterologous competitive binding studies showed that the
        W172F and W172Y mutants bound the tricyclic cannabinoid agonist HU-210 (a
        compound very similar in structure to HU-243) with affinities essentially
        equivalent to that observed with the wt receptorthe binding of the bicyclic
        cannabinoid CP55,940 was not affected by these mutationsbinding of the aminoalkylindole
        WIN55,212-2 was slightly reduced by the mutationsthe W172F and W172Y mutants
        showed similar AC inhibition patterns to that observed with the wt receptor',
    ligand_long: '', ligand_short: 'WIN55,212-2', pubmed: '11080201', seq: '172',
    to_res: F}
- {entry_name: cnr2_human, from_res: W, info: 'the W172F and W172Y mutants retained
        almost normal specific binding, at 80 and 68% of wt values, respectivelyW172Y
        and W172F showed binding values close to those obtained with HA-CB2 (wt)the
        binding affinities of W172Y and W172F did not appreciably differ from that
        of the wt receptorHeterologous competitive binding studies showed that the
        W172F and W172Y mutants bound the tricyclic cannabinoid agonist HU-210 (a
        compound very similar in structure to HU-243) with affinities essentially
        equivalent to that observed with the wt receptorthe binding of the bicyclic
        cannabinoid CP55,940 was not affected by these mutationsbinding of the aminoalkylindole
        WIN55,212-2 was slightly reduced by the mutationsthe W172F and W172Y mutants
        showed similar AC inhibition patterns to that observed with the wt receptor',
    ligand_long: '', ligand_short: 'CP55,940', pubmed: '11080201', seq: '172', to_res: F}
- {entry_name: cnr2_human, from_res: W, info: 'the W172F and W172Y mutants retained
        almost normal specific binding, at 80 and 68% of wt values, respectivelyW172Y
        and W172F showed binding values close to those obtained with HA-CB2 (wt)the
        binding affinities of W172Y and W172F did not appreciably differ from that
        of the wt receptorHeterologous competitive binding studies showed that the
        W172F and W172Y mutants bound the tricyclic cannabinoid agonist HU-210 (a
        compound very similar in structure to HU-243) with affinities essentially
        equivalent to that observed with the wt receptorthe binding of the bicyclic
        cannabinoid CP55,940 was not affected by these mutationsbinding of the aminoalkylindole
        WIN55,212-2 was slightly reduced by the mutationsthe W172F and W172Y mutants
        showed similar AC inhibition patterns to that observed with the wt receptor',
    ligand_long: '', ligand_short: HU-210, pubmed: '11080201', seq: '172', to_res: F}
- {entry_name: cnr2_human, from_res: W, info: 'W172A binds [3H]HU-243 at <10% of the
        levels observed for HA-CB2 (wt)W172A did not show any significant bindingagonist
        activation of W172L did not inhibit and that of W172A only negligibly inhibited
        AC activityBoth the W172A and W172L mutants were well expressedW172A showed
        almost no apparent binding and relatively low inhibition of AC', ligand_long: '',
    ligand_short: '', pubmed: '11080201', seq: '172', to_res: A}
- {entry_name: cnr2_human, from_res: W, info: 'the W172L mutant does not bind [3H]HU243W172L
        and W172A did not show any significant bindingagonist activation of W172L
        did not inhibit and that of W172A only negligibly inhibited AC activityBoth
        the W172A and W172L mutants were well expressedW172L did not bind HU-243 and
        did not show any AC inhibition', ligand_long: '', ligand_short: '', pubmed: '11080201',
    seq: '172', to_res: L}
- {entry_name: cnr2_human, from_res: W, info: "W158A did not bind [3H]HU-243W158A\
        \ and W158L showed only a very slight inhibition of AC activity in response\
        \ to relatively high (1 \u03BCM) concentrations of HU-210 or WIN55,212-2",
    ligand_long: '', ligand_short: '', pubmed: '11080201', seq: '158', to_res: A}
- {entry_name: cnr2_human, from_res: W, info: "replacement of this W residue with\
        \ Y also led to a complete loss of binding activityW158A and W158L showed\
        \ only a very slight inhibition of AC activity in response to relatively high\
        \ (1 \u03BCM) concentrations of HU-210 or WIN55,212-2", ligand_long: '', ligand_short: '',
    pubmed: '11080201', seq: '158', to_res: Y}
- {entry_name: cnr2_human, from_res: W, info: the conservative substitution of W158F
        retained most of its binding capacity. A small reduction in the Bmax of the
        binding of HU-243 and a very small reduction in binding affinity were observedthe
        W158F mutant showed an identical AC inhibition pattern to that obtained with
        HA-CB2 (wt)the conservative W158F mutation has little or no effect on cannabinoid
        binding and signaling, ligand_long: '', ligand_short: '', pubmed: '11080201',
    seq: '158', to_res: F}
- {entry_name: cnr2_human, from_res: W, info: the conservative substitution of W158F
        retained most of its binding capacity. A small reduction in the Bmax of the
        binding of HU-243 and a very small reduction in binding affinity were observedthe
        W158F mutant showed an identical AC inhibition pattern to that obtained with
        HA-CB2 (wt)the conservative W158F mutation has little or no effect on cannabinoid
        binding and signaling, ligand_long: '', ligand_short: '', pubmed: '11080201',
    seq: '158', to_res: F}
- {entry_name: cnr2_human, from_res: W, info: the conservative substitution of W158F
        retained most of its binding capacity. A small reduction in the Bmax of the
        binding of HU-243 and a very small reduction in binding affinity were observedthe
        W158F mutant showed an identical AC inhibition pattern to that obtained with
        HA-CB2 (wt)the conservative W158F mutation has little or no effect on cannabinoid
        binding and signaling, ligand_long: '', ligand_short: '', pubmed: '11080201',
    seq: '158', to_res: F}
- {entry_name: c5ar_human, from_res: D, info: 'any residual ligand-binding capacity,
        while an Asn282 substitutionrestores wild-type affinity.', ligand_long: 125I-C5a,
    ligand_short: '', pubmed: '8631370', seq: '282', to_res: N}
- {entry_name: c5ar_human, from_res: D, info: 'any residual ligand-binding capacity,
        while an Asn282 substitutionrestores wild-type affinity.', ligand_long: 125I-C5a,
    ligand_short: '', pubmed: '8631370', seq: '282', to_res: A}
- {entry_name: c5ar_human, from_res: D, info: helices at the extracellular side.,
    ligand_long: 125I-C5a, ligand_short: '', pubmed: '8183923', seq: '37', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705081, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703774, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703766, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703605, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705084, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L706164, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705081, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703774, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703766, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703605, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705084, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L706164, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: tshr_human, from_res: Y, info: The mutant protein gets trapped intracellularly,
    ligand_long: '', ligand_short: '', pubmed: '9806755', seq: '601', to_res: X}
- {entry_name: acm1_rat, from_res: Y, info: 'Single histidine substitutions of Ser120,
        Tyr208, Phe 374, Asn414 and Tyr418 gave less than 6-fold increases in Zn2+
        affinity. However, the mutation of Leu116 increased the affinity by 14-fold.',
    ligand_long: '[3H]NMS', ligand_short: '', pubmed: '10681352', seq: '208', to_res: H}
- {entry_name: acm1_rat, from_res: S, info: 'Single histidine substitutions of Ser120,
        Tyr208, Phe 374, Asn414 and Tyr418 gave less than 6-fold increases in Zn2+
        affinity. However, the mutation of Leu116 increased the affinity by 14-fold.Ala-substitutions
        of Leu116 and Ser120 simultaneously increased Ach affinity, raised basal activity,
        and enhanced signaling efficacy, suggesting that the intramolecular contacts
        made by these highly conversed residues help to stabilize the inactive ground
        state of the M1 mAChR (3,4). A similar role has been proposed for Phe374 in
        TM 6 (7, 22). Mutation of Ser120 to histidine caused little change in agonist
        and antagonist binding.In contrast with mutation of S120A and S120C,2 S120H
        strongly reduced signaling efficacy and maximum PI response', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '10681352', seq: '120', to_res: H}
- {entry_name: acm1_rat, from_res: Y, info: 'Single histidine substitutions of Ser120,
        Tyr208, Phe 374, Asn414 and Tyr418 gave less than 6-fold increases in Zn2+
        affinity. However, the mutation of Leu116 increased the affinity by 14-fold.His
        substitutions of the TM 7 residues Asn414 and Tyr418 (Table I) increased ACh
        affinity but essentially abolished Gq-mediated phosphoinositide signaling.
        These findings were confirmed by Ala-substitution. In the case of N414H, as
        reported for L116A, there was also a large reduction in receptor expression.
        Asn414 and Tyr418 may resemble Leu116, Ser120 and Phe374 in making intramolecular
        contacts that stabilize the inactive ground state of the receptor.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '10681352', seq: '418', to_res: H}
- {entry_name: acm1_rat, from_res: N, info: 'Single histidine substitutions of Ser120,
        Tyr208, Phe 374, Asn414 and Tyr418 gave less than 6-fold increases in Zn2+
        affinity. However, the mutation of Leu116 increased the affinity by 14-fold.His
        substitutions of the TM 7 residues Asn414 and Tyr418 (Table I) increased ACh
        affinity but essentially abolished Gq-mediated phosphoinositide signaling.
        These findings were confirmed by Ala-substitution. In the case of N414H, as
        reported for L116A, there was also a large reduction in receptor expression.
        Asn414 and Tyr418 may resemble Leu116, Ser120 and Phe374 in making intramolecular
        contacts that stabilize the inactive ground state of the receptor.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '10681352', seq: '414', to_res: H}
- {entry_name: acm1_rat, from_res: F, info: 'The mutation of F374H reduced ACh affinity
        by 17-fold (Table I), whereas mutation of Asn414 and Tyr 418 to His (Table
        I) increased it by between 4 and 15-fold.Signaling efficacies for the L116H
        and F374H mutants, calculated as described (3,4), were close to wild-type.
        Decreases were found for Y208H (4-fold) S120H (25-fold), and Y418H (35-fold),
        whereas the N414H mutant had, essentially, zero efficacy. These reductions
        mirror the decreased maximum PI responses for these mutants.Single histidine
        substitutions of Ser120, Tyr208, Phe 374, Asn414 and Tyr418 gave less than
        6-fold increases in Zn2+ affinity. However, the mutation of Leu116 increased
        the affinity by 14-fold.Ala-substitutions of Leu116 and Ser120 simultaneously
        increased Ach affinity, raised basal activity, and enhanced signaling efficacy,
        suggesting that the intramolecular contacts made by these highly conversed
        residues help to stabilize the inactive ground state of the M1 mAChR (3,4).
        A similar role has been proposed for Phe374 in TM 6 (7, 22).', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '10681352', seq: '374', to_res: H}
- {entry_name: acm1_rat, from_res: L, info: 'Single histidine substitutions of Ser120,
        Tyr208, Phe 374, Asn414 and Tyr418 gave less than 6-fold increases in Zn2+
        affinity. However, the mutation of Leu116 increased the affinity by 14-fold.Ala-substitutions
        of Leu116 and Ser120 simultaneously increased Ach affinity, raised basal activity,
        and enhanced signaling efficacy, suggesting that the intramolecular contacts
        made by these highly conversed residues help to stabilize the inactive ground
        state of the M1 mAChR (3,4). A similar role has been proposed for Phe374 in
        TM 6 (7, 22).His substitutions of the TM 7 residues Asn414 and Tyr418 (Table
        I) increased ACh affinity but essentially abolished Gq-mediated phosphoinositide
        signaling. These findings were confirmed by Ala-substitution. In the case
        of N414H, as reported for L116A, there was also a large reduction in receptor
        expression. Asn414 and Tyr418 may resemble Leu116, Ser120 and Phe374 in making
        intramolecular contacts that stabilize the inactive ground state of the receptor.',
    ligand_long: '[3H]NMS', ligand_short: '', pubmed: '10681352', seq: '116', to_res: H}
- {entry_name: agtra_rat, from_res: H, info: "The binding affinity of H256A, H256Q\
        \ and H256Y mutants for [Sar1]Ang II was within 2-fold of the binding affinity\
        \ for the wild-type. The receptor activation was reduced \u224860% in the\
        \ H256Q and \u224870% in the H256A mutant receptors. In contrast, substitution\
        \ of His256 with a Tyr (H256Y) led to a \u22486% reduction of a maximal IP\
        \ response.The [Sar1,Cha8]Ang II evoked \u224840% response in the wild-type\
        \ receptor, \u224852% in the H256Y mutant, \u224835% in the H256Q mutant and\
        \ \u224828% in the H256A mutant receptor.", ligand_long: '[Sar1, Cha8]Ang
        II', ligand_short: '', pubmed: '10066768', seq: '256', to_res: Y}
- {entry_name: agtra_rat, from_res: H, info: "The binding affinity of H256A, H256Q\
        \ and H256Y mutants for [Sar1]Ang II was within 2-fold of the binding affinity\
        \ for the wild-type. The receptor activation was reduced \u224860% in the\
        \ H256Q and \u224870% in the H256A mutant receptors. In contrast, substitution\
        \ of His256 with a Tyr (H256Y) led to a \u22486% reduction of a maximal IP\
        \ response.The [Sar1,Cha8]Ang II evoked \u224840% response in the wild-type\
        \ receptor, \u224852% in the H256Y mutant, \u224835% in the H256Q mutant and\
        \ \u224828% in the H256A mutant receptor.", ligand_long: '[Sar1]Ang II', ligand_short: '',
    pubmed: '10066768', seq: '256', to_res: Y}
- {entry_name: agtra_rat, from_res: H, info: "The binding affinity of H256A, H256Q\
        \ and H256Y mutants for [Sar1]Ang II was within 2-fold of the binding affinity\
        \ for the wild-type. The receptor activation was reduced \u224860% in the\
        \ H256Q and \u224870% in the H256A mutant receptors. In contrast, substitution\
        \ of His256 with a Tyr (H256Y) led to a \u22486% reduction of a maximal IP\
        \ response.The [Sar1,Cha8]Ang II evoked \u224840% response in the wild-type\
        \ receptor, \u224852% in the H256Y mutant, \u224835% in the H256Q mutant and\
        \ \u224828% in the H256A mutant receptor.", ligand_long: '[Sar1, Cha8]Ang
        II', ligand_short: '', pubmed: '10066768', seq: '256', to_res: Q}
- {entry_name: agtra_rat, from_res: H, info: "The binding affinity of H256A, H256Q\
        \ and H256Y mutants for [Sar1]Ang II was within 2-fold of the binding affinity\
        \ for the wild-type. The receptor activation was reduced \u224860% in the\
        \ H256Q and \u224870% in the H256A mutant receptors. In contrast, substitution\
        \ of His256 with a Tyr (H256Y) led to a \u22486% reduction of a maximal IP\
        \ response.The [Sar1,Cha8]Ang II evoked \u224840% response in the wild-type\
        \ receptor, \u224852% in the H256Y mutant, \u224835% in the H256Q mutant and\
        \ \u224828% in the H256A mutant receptor.", ligand_long: '[Sar1]Ang II', ligand_short: '',
    pubmed: '10066768', seq: '256', to_res: Q}
- {entry_name: agtra_rat, from_res: H, info: "The binding affinity of H256A, H256Q\
        \ and H256Y mutants for [Sar1]Ang II was within 2-fold of the binding affinity\
        \ for the wild-type. The receptor activation was reduced \u224860% in the\
        \ H256Q and \u224870% in the H256A mutant receptors. In contrast, substitution\
        \ of His256 with a Tyr (H256Y) led to a \u22486% reduction of a maximal IP\
        \ response.The [Sar1,Cha8]Ang II evoked \u224840% response in the wild-type\
        \ receptor, \u224852% in the H256Y mutant, \u224835% in the H256Q mutant and\
        \ \u224828% in the H256A mutant receptor.", ligand_long: '[Sar1, Cha8]Ang
        II', ligand_short: '', pubmed: '10066768', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: H, info: "The binding affinity of H256A, H256Q\
        \ and H256Y mutants for [Sar1]Ang II was within 2-fold of the binding affinity\
        \ for the wild-type. The receptor activation was reduced \u224860% in the\
        \ H256Q and \u224870% in the H256A mutant receptors. In contrast, substitution\
        \ of His256 with a Tyr (H256Y) led to a \u22486% reduction of a maximal IP\
        \ response.The [Sar1,Cha8]Ang II evoked \u224840% response in the wild-type\
        \ receptor, \u224852% in the H256Y mutant, \u224835% in the H256Q mutant and\
        \ \u224828% in the H256A mutant receptor.", ligand_long: '[Sar1]Ang II', ligand_short: '',
    pubmed: '10066768', seq: '256', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '[Sar1,
        Cha4]Ang II', ligand_short: '', pubmed: '10066768', seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '[Sar1]Ang
        II', ligand_short: '', pubmed: '10066768', seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '[Sar1,
        Cha4] Ang II', ligand_short: '', pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '[Sar1]Ang
        II', ligand_short: '', pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: 'Most importantly, magnitude of increased
        affinity of the N111I mutant was consistent with an interaction dependent
        of the size and hydrophobicity.', ligand_long: '[Sar1, Cha4]Ang II', ligand_short: '',
    pubmed: '10066768', seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'Most importantly, magnitude of increased
        affinity of the N111I mutant was consistent with an interaction dependent
        of the size and hydrophobicity.', ligand_long: '[Sar1]Ang II', ligand_short: '',
    pubmed: '10066768', seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'The affinity of N111F, N111Y and N111K
        mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang
        II was 290, 198 and 2980 nM, respectively.', ligand_long: '', ligand_short: '',
    pubmed: '10066768', seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, info: 'The affinity of N111F, N111Y and N111K
        mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang
        II was 290, 198 and 2980 nM, respectively.', ligand_long: '[Sar1, Cha4]Ang
        II', ligand_short: '', pubmed: '10066768', seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, info: 'The affinity of N111F, N111Y and N111K
        mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang
        II was 290, 198 and 2980 nM, respectively.', ligand_long: '[Sar1]Ang II',
    ligand_short: '', pubmed: '10066768', seq: '111', to_res: K}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: CTOP, pubmed: '9413708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: Buprenorphine, pubmed: '9413708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: Sufentanyl, pubmed: '9413708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: Morphine, pubmed: '9413708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: PL017, pubmed: '9413708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: DAMGO, pubmed: '9413708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: Naloxone, ligand_short: '', pubmed: '9413708', seq: '297', to_res: Q}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: CTOP, pubmed: '9413708', seq: '297', to_res: N}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: Buprenorphine, pubmed: '9413708', seq: '297', to_res: N}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: Sufentanyl, pubmed: '9413708', seq: '297', to_res: N}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: Morphine, pubmed: '9413708', seq: '297', to_res: N}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: PL017, pubmed: '9413708', seq: '297', to_res: N}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: '', ligand_short: DAMGO, pubmed: '9413708', seq: '297', to_res: N}
- {entry_name: oprm_rat, from_res: H, info: DAMGO and PL017(agonists) and CTOP (an
        antagonist) exhibited 2-5-fold higher affinities for the glutamine mutant
        than that of asparagines. PL017 was also bound by the H297Q receptor with
        an affinity 5-fold above that of the wild-type receptor (Table 1).The wild-type
        histidine residue was preferred by the alkaloid antagonist naloxone; affinity
        for the drug decreased 2- and >5-fold with glutamine and asparagines substitution.,
    ligand_long: Naloxone, ligand_short: '', pubmed: '9413708', seq: '297', to_res: N}
- {entry_name: 5ht2a_rat, from_res: F, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).The other tested mutations (W76A, F125L, F339L,
        F365L and F383A) had few consistent effects (<10-fold change in Ki) on the
        binding of any of the agonist tested (Fig. 1).', ligand_long: '[3H]Ketanserin',
    ligand_short: '', pubmed: '9271348', seq: '383', to_res: A}
- {entry_name: 5ht2a_rat, from_res: Y, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).', ligand_long: '[3H]Ketanserin', ligand_short: '',
    pubmed: '9271348', seq: '370', to_res: A}
- {entry_name: 5ht2a_rat, from_res: W, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).', ligand_long: '[3H]Ketanserin', ligand_short: '',
    pubmed: '9271348', seq: '367', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).The other tested mutations (W76A, F125L, F339L,
        F365L and F383A) had few consistent effects (<10-fold change in Ki) on the
        binding of any of the agonist tested (Fig. 1).', ligand_long: '[3H]Ketanserin',
    ligand_short: '', pubmed: '9271348', seq: '365', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).In addition, the F340L mutation greatly diminished
        agonist efficacy for all tested agonists, which is in support of our previous
        findings (3). Interestingly, however, the Kact and percent Vmax values for
        DOM were greatly attenuated, while the Ki value for DOM was only minimally
        altered (compare Fig. 2 with Table 2).', ligand_long: '[3H]ketanserin', ligand_short: '',
    pubmed: '9271348', seq: '340', to_res: L}
- {entry_name: 5ht2a_rat, from_res: F, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).The other tested mutations (W76A, F125L, F339L,
        F365L and F383A) had few consistent effects (<10-fold change in Ki) on the
        binding of any of the agonist tested (Fig. 1).', ligand_long: '[3H]Ketanserin',
    ligand_short: '', pubmed: '9271348', seq: '339', to_res: L}
- {entry_name: 5ht2a_rat, from_res: W, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).', ligand_long: '[3H]Ketanserin', ligand_short: '',
    pubmed: '9271348', seq: '336', to_res: A}
- {entry_name: 5ht2a_rat, from_res: W, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).', ligand_long: '[3H]Ketanserin', ligand_short: '',
    pubmed: '9271348', seq: '200', to_res: A}
- {entry_name: 5ht2a_rat, from_res: F, info: 'With the exception of the W336A, W367A
        and Y370A mutants, all of the mutant 5-HT2A receptors were able to bind [3H]ketanserin
        with high affinity (Table 1).The other tested mutations (W76A, F125L, F339L,
        F365L and F383A) had few consistent effects (<10-fold change in Ki) on the
        binding of any of the agonist tested (Fig. 1).', ligand_long: '[3H]Ketanserin',
    ligand_short: '', pubmed: '9271348', seq: '125', to_res: L}
- {entry_name: 5ht2a_rat, from_res: W, info: 'The other tested mutations (W76A, F125L,
        F339L, F365L and F383A) had few consistent effects (<10-fold change in Ki)
        on the binding of any of the agonist tested (Fig. 1).Interestingly, the W76A
        mutation did not substantially alter agonist binding affinity or the Kact
        value, whereas the percent Vmax value for PI hydrolysis was diminished for
        several tested agonists, even though receptor expression was similar to the
        native receptor (see Table 1).', ligand_long: '[3H]Ketanserin', ligand_short: '',
    pubmed: '9271348', seq: '76', to_res: A}
- {entry_name: q5zgx3_human, from_res: D, info: 'Specific binding (fmol/mg of protein):wt
        : 277.5 +/- 35.0D82A: 2.4 +/- 0.3', ligand_long: '', ligand_short: '', pubmed: '8474430',
    seq: '82', to_res: A}
- {entry_name: q5zgx3_human, from_res: S, info: 'Specific binding (fmol/mg of protein):wt
        : 277.5 +/- 35.0S393A: 38.2 +/- 2.1', ligand_long: '', ligand_short: '', pubmed: '8474430',
    seq: '393', to_res: A}
- {entry_name: q5zgx3_human, from_res: S, info: 'Specific binding (fmol/mg of protein):wt
        : 277.5 +/- 35.0S391A: 274.4 +/- 34.4', ligand_long: '', ligand_short: '',
    pubmed: '8474430', seq: '391', to_res: A}
- {entry_name: q5zgx3_human, from_res: N, info: 'Specific binding (fmol/mg of protein):wt
        : 277.5 +/- 35.0N396Q: 274.1 +/- 34.8', ligand_long: '', ligand_short: '',
    pubmed: '8474430', seq: '396', to_res: Q}
- {entry_name: q5zgx3_human, from_res: N, info: 'Specific binding (fmol/mg of protein):wt
        : 277.5 +/- 35.0N396V: 1.0 +/- 0.1', ligand_long: '', ligand_short: '', pubmed: '8474430',
    seq: '396', to_res: V}
- {entry_name: q5zgx3_human, from_res: N, info: 'Specific binding (fmol/mg of protein):wt
        : 277.5 +/- 35.0N396F: 1.2 +/- 0.3', ligand_long: '', ligand_short: '', pubmed: '8474430',
    seq: '396', to_res: F}
- {entry_name: q5zgx3_human, from_res: N, info: 'Specific binding (fmol/mg of protein):wt
        : 277.5 +/- 35.0N396A: 1.2 +/- 0.3', ligand_long: '', ligand_short: '', pubmed: '8474430',
    seq: '396', to_res: A}
- {entry_name: ada1b_mesau, from_res: K, info: 'pKa of wt: 6.25 +/- 0.02pKa of mutant
        K331E: 6.97 +/- 0.12', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: E}
- {entry_name: ada1b_mesau, from_res: K, info: 'pKa of wt: 6.25 +/- 0.02pKa of mutant
        K331W: 6.95 +/- 0.06', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: W}
- {entry_name: ada1b_mesau, from_res: K, info: 'pKa of wt: 6.25 +/- 0.02pKa of mutant
        K331D: 6.94 +/- 0.06', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: D}
- {entry_name: ada1b_mesau, from_res: K, info: 'pKa of wt: 6.25 +/- 0.02pKa of mutant
        K331L: 7.95 +/- 0.17', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: L}
- {entry_name: ada1b_mesau, from_res: K, info: 'pKa of wt: 6.25 +/- 0.02pKa of mutant
        K331M: 7.20 +/- 0.09', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: M}
- {entry_name: ada1b_mesau, from_res: K, info: 'pKa of wt: 6.25 +/- 0.02pKa of mutant
        K331Q: 7.07 +/- 0.05', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: Q}
- {entry_name: ada1b_mesau, from_res: K, info: 'Wild type:pKa = 6.25 +/- 0.02Mutant
        (K331A)pKa = 6.78 +/- 0.13', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: A}
- {entry_name: ada1b_mesau, from_res: K, info: 'Wild type:pKa = 6.25 +/- 0.02Mutant
        (K331H)pKa = 6.45 +/- 0.03', ligand_long: '', ligand_short: '', pubmed: '10604981',
    seq: '331', to_res: H}
- {entry_name: ednra_human, from_res: D, info: 'In all cases, naphthalene sulfonamide
        binding was more severely affected by mutation of Asp133 than by mutation
        of Asp126.', ligand_long: '', ligand_short: BMS-185008, pubmed: '8611558',
    seq: '133', to_res: A}
- {entry_name: ednra_human, from_res: D, info: 'In all cases, naphthalene sulfonamide
        binding was more severely affected by mutation of Asp133 than by mutation
        of Asp126.', ligand_long: '', ligand_short: BMS-185511, pubmed: '8611558',
    seq: '133', to_res: A}
- {entry_name: ednra_human, from_res: D, info: 'In all cases, naphthalene sulfonamide
        binding was more severely affected by mutation of Asp133 than by mutation
        of Asp126.', ligand_long: '', ligand_short: BMS-182874, pubmed: '8611558',
    seq: '133', to_res: A}
- {entry_name: ednra_human, from_res: D, info: 'In all cases, naphthalene sulfonamide
        binding was more severely affected by mutation of Asp133 than by mutation
        of Asp126.', ligand_long: '', ligand_short: BMS-185008, pubmed: '8611558',
    seq: '126', to_res: A}
- {entry_name: ednra_human, from_res: D, info: 'In all cases, naphthalene sulfonamide
        binding was more severely affected by mutation of Asp133 than by mutation
        of Asp126.', ligand_long: '', ligand_short: BMS-185511, pubmed: '8611558',
    seq: '126', to_res: A}
- {entry_name: gasr_human, from_res: S, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.', ligand_long: '', ligand_short: CCK-8, pubmed: '10908308',
    seq: '379', to_res: A}
- {entry_name: gasr_human, from_res: T, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.The amino acids substitutions T111A, N353L, and T354A
        primarily reduced binding of the peptoid molecules, PD-135,158 and PD-136,450,
        with only slight effect on peptide affinity.', ligand_long: '', ligand_short: cck-8,
    pubmed: '10908308', seq: '354', to_res: A}
- {entry_name: gasr_human, from_res: N, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.The N353L mutation only slightly decreased CCK-4 affinity
        and did not significantly affect CCK-8 binding.The amino acids substitutions
        T111A, N353L, and T354A primarily reduced binding of the peptoid molecules,
        PD-135,158 and PD-136,450, with only slight effect on peptide affinity.At
        four of the mutant receptors (Y61A, T111A, Y350A, N353L) efficacy decreases
        were observed for both L740,093S and at least one of the peptoids.The mutation
        that decreased PD-136,450 affinity to different degrees (M186A, N353L) also
        resulted in concomitant decreases in potency.', ligand_long: '', ligand_short: CCK-8,
    pubmed: '10908308', seq: '353', to_res: L}
- {entry_name: gasr_human, from_res: Y, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Peptoid efficacy was decreased by six other amino
        acids substitutions, Y61A, T111A, F227A, V349A, Y350A, and N353L.At four of
        the mutant receptors (Y61A, T111A, Y350A, N353L) efficacy decreases were observed
        for both L740,093S and at least one of the peptoids.', ligand_long: '', ligand_short: CCK-8,
    pubmed: '10908308', seq: '350', to_res: A}
- {entry_name: gasr_human, from_res: V, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Three receptor point mutations, Y61A, T193A, and V349A,
        selectively decreased affinities for the two endogenous peptides, CCK-8 and
        CCK-4.Peptoid efficacy was decreased by six other amino acids substitutions,
        Y61A, T111A, F227A, V349A, Y350A, and N353L.Alanine substitution of Val-349
        decreased peptoid-induced signaling and at the same time increased L-740,093S
        efficacy.', ligand_long: '', ligand_short: cck-8, pubmed: '10908308', seq: '349',
    to_res: A}
- {entry_name: gasr_human, from_res: W, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Two mutations (M186A, W346A) significantly increased
        the efficacy of PD-135,158 and/or PD-136,450 while decreasing the functional
        activity of L-740,093S.', ligand_long: '', ligand_short: CCK-8, pubmed: '10908308',
    seq: '346', to_res: A}
- {entry_name: gasr_human, from_res: F, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Peptoid efficacy was decreased by six other amino
        acids substitutions, Y61A, T111A, F227A, V349A, Y350A, and N353L.The F227A
        mutant selectively decreased peptoid efficacy without significantly altering
        L-740,093S induced inositol phosphate production.', ligand_long: '', ligand_short: CCK-8,
    pubmed: '10908308', seq: '227', to_res: A}
- {entry_name: gasr_human, from_res: L, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.', ligand_long: '', ligand_short: CCK-8, pubmed: '10908308',
    seq: '226', to_res: A}
- {entry_name: gasr_human, from_res: L, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Three single amino acids substitutions (C107A, V138A,
        and L223A) resulted in constitutive receptor activation, indicated by a significant
        elevation in the basal levels of inositol phosphate production.', ligand_long: '',
    ligand_short: '', pubmed: '10908308', seq: '223', to_res: A}
- {entry_name: gasr_human, from_res: S, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.', ligand_long: '', ligand_short: CCK-8, pubmed: '10908308',
    seq: '219', to_res: A}
- {entry_name: gasr_human, from_res: T, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Three receptor point mutations, Y61A, T193A, and V349A,
        selectively decreased affinities for the two endogenous peptides, CCK-8 and
        CCK-4.', ligand_long: '', ligand_short: CCK-8, pubmed: '10908308', seq: '193',
    to_res: A}
- {entry_name: gasr_human, from_res: V, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Three single amino acids substitutions (C107A, V138A,
        and L223A) resulted in constitutive receptor activation, indicated by a significant
        elevation in the basal levels of inositol phosphate production.', ligand_long: '',
    ligand_short: '', pubmed: '10908308', seq: '138', to_res: A}
- {entry_name: gasr_human, from_res: M, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Three single amino acids substitutions (C107A, V138A,
        and L223A) resulted in constitutive receptor activation, indicated by a significant
        elevation in the basal levels of inositol phosphate production.', ligand_long: '',
    ligand_short: CCK-8, pubmed: '10908308', seq: '186', to_res: A}
- {entry_name: gasr_human, from_res: G, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.', ligand_long: '', ligand_short: CCK-8, pubmed: '10908308',
    seq: '135', to_res: A}
- {entry_name: gasr_human, from_res: S, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.', ligand_long: '', ligand_short: CCk-8, pubmed: '10908308',
    seq: '131', to_res: A}
- {entry_name: gasr_human, from_res: T, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.The amino acids substitutions T111A, N353L, and T354A
        primarily reduced binding of the peptoid molecules, PD-135,158 and PD-136,450,
        with only slight effect on peptide affinity.At four of the mutant receptors
        (Y61A, T111A, Y350A, N353L) efficacy decreases were observed for both L740,093S
        and at least one of the peptoids.', ligand_long: '', ligand_short: CCK-8,
    pubmed: '10908308', seq: '111', to_res: A}
- {entry_name: gasr_human, from_res: C, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Three single amino acids substitutions (C107A, V138A,
        and L223A) resulted in constitutive receptor activation, indicated by a significant
        elevation in the basal levels of inositol phosphate production.', ligand_long: '',
    ligand_short: '', pubmed: '10908308', seq: '107', to_res: A}
- {entry_name: gasr_human, from_res: F, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.', ligand_long: '', ligand_short: CCK-8, pubmed: '10908308',
    seq: '110', to_res: A}
- {entry_name: gasr_human, from_res: Y, info: 'When stimulated with saturated concentrations
        of CCK-8, all 19 mutant receptors triggered inositol phosphate formation comparable
        to the wild type CCK-BR.Three receptor point mutations, Y61A, T193A, and V349A,
        selectively decreased affinities for the two endogenous peptides, CCK-8 and
        CCK-4.Peptoid efficacy was decreased by six other amino acids substitutions,
        Y61A, T111A, F227A, V349A, Y350A, and N353L.At four of the mutant receptors
        (Y61A, T111A, Y350A, N353L) efficacy decreases were observed for both L740,093S
        and at least one of the peptoids.The receptor mutation that did not alter
        affinity (Y61A) had no significant effect on the potency of PD-136.450.',
    ligand_long: '', ligand_short: CCK-8, pubmed: '10908308', seq: '61', to_res: A}
- {entry_name: c5ar_human, from_res: V, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;The V286A receptor mutant C5aR, carrying a substitution
        for the other side chain that appears to interact with the residue at position
        5 ot the hexapeptide, did not recognize ChaW as an antagonist;', ligand_long: '[125]I-C5a',
    ligand_short: R6H, pubmed: '11062244', seq: '286', to_res: A}
- {entry_name: c5ar_human, from_res: R, info: 'Indeed, replacement of Arg-206 by alanine
        (instead of histidine, as in our experiment) similarly failed to alter affinity
        for C5a.In this study, DeMartino and coworkers used an R206A receptor mutant
        and a series of ChaW derivatives to show that the side chain of Arg-206 acts
        as a "gate-keeper," allowing hexapeptide ligands to bind to the transmembrane
        receptor core only when the ligands present a C-terminalcarboxylate, which
        appears to interact with the guanidinium group of Arg-206.', ligand_long: '[125]I-C5a',
    ligand_short: R6H, pubmed: '11062244', seq: '206', to_res: H}
- {entry_name: c5ar_human, from_res: I, info: '[...], replacement of Ile-116 by alanine
        in the receptor converted ChaW from an antagonist (or weak partial agonist)
        into a very strong agonist.In cells expressing the I116A receptor mutant,
        ChaW -at best a weak partial agonsit for the WT C5aR- induced IP accumulation
        comparable to responses observed with W5Cha acting on the WT or any mutant
        C5aR.', ligand_long: '[125]I-C5a', ligand_short: R6H, pubmed: '11062244',
    seq: '116', to_res: A}
- {entry_name: c5ar_human, from_res: V, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;The V286A receptor mutant C5aR, carrying a substitution
        for the other side chain that appears to interact with the residue at position
        5 ot the hexapeptide, did not recognize ChaW as an antagonist;', ligand_long: '[125]I-C5a',
    ligand_short: dCha4dL, pubmed: '11062244', seq: '286', to_res: A}
- {entry_name: c5ar_human, from_res: V, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;The V286A receptor mutant C5aR, carrying a substitution
        for the other side chain that appears to interact with the residue at position
        5 ot the hexapeptide, did not recognize ChaW as an antagonist;', ligand_long: '[125]I-C5a',
    ligand_short: F1L, pubmed: '11062244', seq: '286', to_res: A}
- {entry_name: c5ar_human, from_res: V, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;The V286A receptor mutant C5aR, carrying a substitution
        for the other side chain that appears to interact with the residue at position
        5 ot the hexapeptide, did not recognize ChaW as an antagonist;', ligand_long: '[125]I-C5a',
    ligand_short: ChaW, pubmed: '11062244', seq: '286', to_res: A}
- {entry_name: c5ar_human, from_res: V, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;The V286A receptor mutant C5aR, carrying a substitution
        for the other side chain that appears to interact with the residue at position
        5 ot the hexapeptide, did not recognize ChaW as an antagonist;', ligand_long: '[125]I-C5a',
    ligand_short: W5Cha, pubmed: '11062244', seq: '286', to_res: A}
- {entry_name: c5ar_human, from_res: V, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;The V286A receptor mutant C5aR, carrying a substitution
        for the other side chain that appears to interact with the residue at position
        5 ot the hexapeptide, did not recognize ChaW as an antagonist;', ligand_long: '[125]I-C5a',
    ligand_short: '', pubmed: '11062244', seq: '286', to_res: A}
- {entry_name: c5ar_human, from_res: R, info: 'Indeed, replacement of Arg-206 by alanine
        (instead of histidine, as in our experiment) similarly failed to alter affinity
        for C5a.In this study, DeMartino and coworkers used an R206A receptor mutant
        and a series of ChaW derivatives to show that the side chain of Arg-206 acts
        as a "gate-keeper," allowing hexapeptide ligands to bind to the transmembrane
        receptor core only when the ligands present a C-terminalcarboxylate, which
        appears to interact with the guanidinium group of Arg-206.', ligand_long: '[125]I-C5a',
    ligand_short: dCha4dL, pubmed: '11062244', seq: '206', to_res: H}
- {entry_name: c5ar_human, from_res: R, info: 'Indeed, replacement of Arg-206 by alanine
        (instead of histidine, as in our experiment) similarly failed to alter affinity
        for C5a.In this study, DeMartino and coworkers used an R206A receptor mutant
        and a series of ChaW derivatives to show that the side chain of Arg-206 acts
        as a "gate-keeper," allowing hexapeptide ligands to bind to the transmembrane
        receptor core only when the ligands present a C-terminalcarboxylate, which
        appears to interact with the guanidinium group of Arg-206.', ligand_long: '[125]I-C5a',
    ligand_short: F1L, pubmed: '11062244', seq: '206', to_res: H}
- {entry_name: c5ar_human, from_res: R, info: 'Indeed, replacement of Arg-206 by alanine
        (instead of histidine, as in our experiment) similarly failed to alter affinity
        for C5a.In this study, DeMartino and coworkers used an R206A receptor mutant
        and a series of ChaW derivatives to show that the side chain of Arg-206 acts
        as a "gate-keeper," allowing hexapeptide ligands to bind to the transmembrane
        receptor core only when the ligands present a C-terminalcarboxylate, which
        appears to interact with the guanidinium group of Arg-206.', ligand_long: '[125]I-C5a',
    ligand_short: ChaW, pubmed: '11062244', seq: '206', to_res: H}
- {entry_name: c5ar_human, from_res: R, info: 'Indeed, replacement of Arg-206 by alanine
        (instead of histidine, as in our experiment) similarly failed to alter affinity
        for C5a.In this study, DeMartino and coworkers used an R206A receptor mutant
        and a series of ChaW derivatives to show that the side chain of Arg-206 acts
        as a "gate-keeper," allowing hexapeptide ligands to bind to the transmembrane
        receptor core only when the ligands present a C-terminalcarboxylate, which
        appears to interact with the guanidinium group of Arg-206.', ligand_long: '[125]I-C5a',
    ligand_short: W5Cha, pubmed: '11062244', seq: '206', to_res: H}
- {entry_name: c5ar_human, from_res: R, info: 'Indeed, replacement of Arg-206 by alanine
        (instead of histidine, as in our experiment) similarly failed to alter affinity
        for C5a.In this study, DeMartino and coworkers used an R206A receptor mutant
        and a series of ChaW derivatives to show that the side chain of Arg-206 acts
        as a "gate-keeper," allowing hexapeptide ligands to bind to the transmembrane
        receptor core only when the ligands present a C-terminalcarboxylate, which
        appears to interact with the guanidinium group of Arg-206.', ligand_long: '[125]I-C5a',
    ligand_short: '', pubmed: '11062244', seq: '206', to_res: H}
- {entry_name: c5ar_human, from_res: A, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;[...], replacement of Ile-116 by alanine in the receptor
        converted ChaW from an antagonist (or weak partial agonist) into a very strong
        agonist.In cells expressing the I116A receptor mutant, ChaW -at best a weak
        partial agonsit for the WT C5aR- induced IP accumulation comparable to responses
        observed with W5Cha acting on the WT or any mutant C5aR.', ligand_long: '[125]I-C5a',
    ligand_short: dCha4dL, pubmed: '11062244', seq: '203', to_res: V}
- {entry_name: c5ar_human, from_res: I, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;[...], replacement of Ile-116 by alanine in the receptor
        converted ChaW from an antagonist (or weak partial agonist) into a very strong
        agonist.In cells expressing the I116A receptor mutant, ChaW -at best a weak
        partial agonsit for the WT C5aR- induced IP accumulation comparable to responses
        observed with W5Cha acting on the WT or any mutant C5aR.', ligand_long: '[125]I-C5a',
    ligand_short: dCha4dL, pubmed: '11062244', seq: '116', to_res: A}
- {entry_name: c5ar_human, from_res: I, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;[...], replacement of Ile-116 by alanine in the receptor
        converted ChaW from an antagonist (or weak partial agonist) into a very strong
        agonist.In cells expressing the I116A receptor mutant, ChaW -at best a weak
        partial agonsit for the WT C5aR- induced IP accumulation comparable to responses
        observed with W5Cha acting on the WT or any mutant C5aR.', ligand_long: '[125]I-C5a',
    ligand_short: F1L, pubmed: '11062244', seq: '116', to_res: A}
- {entry_name: c5ar_human, from_res: I, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;[...], replacement of Ile-116 by alanine in the receptor
        converted ChaW from an antagonist (or weak partial agonist) into a very strong
        agonist.In cells expressing the I116A receptor mutant, ChaW -at best a weak
        partial agonsit for the WT C5aR- induced IP accumulation comparable to responses
        observed with W5Cha acting on the WT or any mutant C5aR.', ligand_long: '[125]I-C5a',
    ligand_short: ChaW, pubmed: '11062244', seq: '116', to_res: A}
- {entry_name: c5ar_human, from_res: I, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;[...], replacement of Ile-116 by alanine in the receptor
        converted ChaW from an antagonist (or weak partial agonist) into a very strong
        agonist.In cells expressing the I116A receptor mutant, ChaW -at best a weak
        partial agonsit for the WT C5aR- induced IP accumulation comparable to responses
        observed with W5Cha acting on the WT or any mutant C5aR.', ligand_long: '[125]I-C5a',
    ligand_short: W5Cha, pubmed: '11062244', seq: '116', to_res: A}
- {entry_name: c5ar_human, from_res: I, info: 'The apparent specificities of the I116A
        and V286A mutations for cooperating with the side chains at position 5 of
        the ligand make it unlikely that these receptor mutations act indirectly to
        alter ligand affinity;[...], replacement of Ile-116 by alanine in the receptor
        converted ChaW from an antagonist (or weak partial agonist) into a very strong
        agonist.In cells expressing the I116A receptor mutant, ChaW -at best a weak
        partial agonsit for the WT C5aR- induced IP accumulation comparable to responses
        observed with W5Cha acting on the WT or any mutant C5aR.', ligand_long: '[125]I-C5a',
    ligand_short: '', pubmed: '11062244', seq: '116', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705081, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703774, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703774, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703605, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705084, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L706164, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705081, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703774, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703774, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L703605, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L705084, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]TyrB-SP',
    ligand_short: L706164, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: RP 67580, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: CP96345, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]SP',
    ligand_short: SP, pubmed: '8384323', seq: '197', to_res: K}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: RP67580, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: CP96345, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Therefore, only glutamine and, to a
        lesser extent, phenylalanine could substitute directly for His 197 in the
        interaction with CP 96345 (Table 1).Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]SP',
    ligand_short: SP, pubmed: '8384323', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: RP67850, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125I]SP',
    ligand_short: CP96345, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]sp',
    ligand_short: sp, pubmed: '8384323', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: RP67580, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: CP96345, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]SP',
    ligand_short: SP, pubmed: '8384323', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: T, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]substance
        P', ligand_short: RP 67580, pubmed: '8384323', seq: '40', to_res: A}
- {entry_name: nk1r_human, from_res: T, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]Substance
        P', ligand_short: CP 96345, pubmed: '8384323', seq: '40', to_res: A}
- {entry_name: nk1r_human, from_res: T, info: 'Most of the point mutations described
        here retained normal binding affinity for substance P (Table 1), indicating
        that the gross conformation of the NK-1R is not perturbed by the substitution
        of His 197. One mutant (H197K) showed a 5-fold reduction in affinity for substance
        P, but not in the affinities of other neurokinin peptides.', ligand_long: '[125i]Substance
        P', ligand_short: Substance P, pubmed: '8384323', seq: '40', to_res: A}
- {entry_name: nk2r_human, from_res: N, info: "The D79N and D79E mutants, as well\
        \ as the three Asn-303 mutants, also displayed wild-type-like binding affinities\
        \ for 125I-NKA (Figure 2). In contrast, the D79A mutant could not be easily\
        \ detected in 125I-NKA homologous binding assays, despite it wild-type-like\
        \ expression levels and antagonist-binding properties.In oocytes expressing\
        \ receptors from cells injected with 10 ng of cDNA, all of the Asp-79 and\
        \ Asn-303 mutant receptors displayed an agonist-induced current amplitude\
        \ similar to that of the wild-type receptor upon application of 100 nM NKA\
        \ (Table 1).The ability of all the mutant receptors to undergo agonist-induced\
        \ desensitization also resembled that of the wild-type receptor, with the\
        \ exception of the D79A mutant, which was almost completely resistant to 100\
        \ nM-NKA-induced desensitization (R2/R1 = 0.90\xB10.10 ; n=33 ; Table 1).\
        \ However, this mutant was fully desensitized upon the application of 1 \xB5\
        M NKA, despite a similar current amplitude.Whereas N303D displayed wild-type-like\
        \ activation and desensitization properties, the N303A and N303S mutants displayed\
        \ marked decreases in agonist-induced current amplitudes and the ability to\
        \ be desensitized by NKA.", ligand_long: '[3H]SR48968', ligand_short: '',
    pubmed: '10085227', seq: '303', to_res: S}
- {entry_name: nk2r_human, from_res: N, info: "The D79N and D79E mutants, as well\
        \ as the three Asn-303 mutants, also displayed wild-type-like binding affinities\
        \ for 125I-NKA (Figure 2). In contrast, the D79A mutant could not be easily\
        \ detected in 125I-NKA homologous binding assays, despite it wild-type-like\
        \ expression levels and antagonist-binding properties.In oocytes expressing\
        \ receptors from cells injected with 10 ng of cDNA, all of the Asp-79 and\
        \ Asn-303 mutant receptors displayed an agonist-induced current amplitude\
        \ similar to that of the wild-type receptor upon application of 100 nM NKA\
        \ (Table 1).The ability of all the mutant receptors to undergo agonist-induced\
        \ desensitization also resembled that of the wild-type receptor, with the\
        \ exception of the D79A mutant, which was almost completely resistant to 100\
        \ nM-NKA-induced desensitization (R2/R1 = 0.90\xB10.10 ; n=33 ; Table 1).\
        \ However, this mutant was fully desensitized upon the application of 1 \xB5\
        M NKA, despite a similar current amplitude.Whereas N303D displayed wild-type-like\
        \ activation and desensitization properties, the N303A and N303S mutants displayed\
        \ marked decreases in agonist-induced current amplitudes and the ability to\
        \ be desensitized by NKA.", ligand_long: '[3H]SR48968', ligand_short: '',
    pubmed: '10085227', seq: '303', to_res: D}
- {entry_name: nk2r_human, from_res: N, info: "The D79N and D79E mutants, as well\
        \ as the three Asn-303 mutants, also displayed wild-type-like binding affinities\
        \ for 125I-NKA (Figure 2). In contrast, the D79A mutant could not be easily\
        \ detected in 125I-NKA homologous binding assays, despite it wild-type-like\
        \ expression levels and antagonist-binding properties.In oocytes expressing\
        \ receptors from cells injected with 10 ng of cDNA, all of the Asp-79 and\
        \ Asn-303 mutant receptors displayed an agonist-induced current amplitude\
        \ similar to that of the wild-type receptor upon application of 100 nM NKA\
        \ (Table 1).The ability of all the mutant receptors to undergo agonist-induced\
        \ desensitization also resembled that of the wild-type receptor, with the\
        \ exception of the D79A mutant, which was almost completely resistant to 100\
        \ nM-NKA-induced desensitization (R2/R1 = 0.90\xB10.10 ; n=33 ; Table 1).\
        \ However, this mutant was fully desensitized upon the application of 1 \xB5\
        M NKA, despite a similar current amplitude.Whereas N303D displayed wild-type-like\
        \ activation and desensitization properties, the N303A and N303S mutants displayed\
        \ marked decreases in agonist-induced current amplitudes and the ability to\
        \ be desensitized by NKA.", ligand_long: '[3H]SR48968', ligand_short: '',
    pubmed: '10085227', seq: '303', to_res: A}
- {entry_name: nk2r_human, from_res: D, info: "In our experiments, all receptors resulting\
        \ from single mutations at either Asp-79 or Asn-303 displayed both expression\
        \ levels and [3H]SR48968 antagonist-binding affinities similar to those of\
        \ the wild-type receptor (Table 1).The D79N and D79E mutants, as well as the\
        \ three Asn-303 mutants, also displayed wild-type-like binding affinities\
        \ for 125I-NKA (Figure 2). In contrast, the D79A mutant could not be easily\
        \ detected in 125I-NKA homologous binding assays, despite it wild-type-like\
        \ expression levels and antagonist-binding properties.In oocytes expressing\
        \ receptors from cells injected with 10 ng of cDNA, all of the Asp-79 and\
        \ Asn-303 mutant receptors displayed an agonist-induced current amplitude\
        \ similar to that of the wild-type receptor upon application of 100 nM NKA\
        \ (Table 1).The ability of all the mutant receptors to undergo agonist-induced\
        \ desensitization also resembled that of the wild-type receptor, with the\
        \ exception of the D79A mutant, which was almost completely resistant to 100\
        \ nM-NKA-induced desensitization (R2/R1 = 0.90\xB10.10 ; n=33 ; Table 1).\
        \ However, this mutant was fully desensitized upon the application of 1 \xB5\
        M NKA, despite a similar current amplitude.", ligand_long: '[3H]SR48968',
    ligand_short: '', pubmed: '10085227', seq: '79', to_res: N}
- {entry_name: nk2r_human, from_res: D, info: "In our experiments, all receptors resulting\
        \ from single mutations at either Asp-79 or Asn-303 displayed both expression\
        \ levels and [3H]SR48968 antagonist-binding affinities similar to those of\
        \ the wild-type receptor (Table 1).The D79N and D79E mutants, as well as the\
        \ three Asn-303 mutants, also displayed wild-type-like binding affinities\
        \ for 125I-NKA (Figure 2). In contrast, the D79A mutant could not be easily\
        \ detected in 125I-NKA homologous binding assays, despite it wild-type-like\
        \ expression levels and antagonist-binding properties.In oocytes expressing\
        \ receptors from cells injected with 10 ng of cDNA, all of the Asp-79 and\
        \ Asn-303 mutant receptors displayed an agonist-induced current amplitude\
        \ similar to that of the wild-type receptor upon application of 100 nM NKA\
        \ (Table 1).The ability of all the mutant receptors to undergo agonist-induced\
        \ desensitization also resembled that of the wild-type receptor, with the\
        \ exception of the D79A mutant, which was almost completely resistant to 100\
        \ nM-NKA-induced desensitization (R2/R1 = 0.90\xB10.10 ; n=33 ; Table 1).\
        \ However, this mutant was fully desensitized upon the application of 1 \xB5\
        M NKA, despite a similar current amplitude.", ligand_long: '[3H]SR48968',
    ligand_short: '', pubmed: '10085227', seq: '79', to_res: E}
- {entry_name: nk2r_human, from_res: D, info: "In our experiments, all receptors resulting\
        \ from single mutations at either Asp-79 or Asn-303 displayed both expression\
        \ levels and [3H]SR48968 antagonist-binding affinities similar to those of\
        \ the wild-type receptor (Table 1).The D79N and D79E mutants, as well as the\
        \ three Asn-303 mutants, also displayed wild-type-like binding affinities\
        \ for 125I-NKA (Figure 2). In contrast, the D79A mutant could not be easily\
        \ detected in 125I-NKA homologous binding assays, despite it wild-type-like\
        \ expression levels and antagonist-binding properties.In oocytes expressing\
        \ receptors from cells injected with 10 ng of cDNA, all of the Asp-79 and\
        \ Asn-303 mutant receptors displayed an agonist-induced current amplitude\
        \ similar to that of the wild-type receptor upon application of 100 nM NKA\
        \ (Table 1).The ability of all the mutant receptors to undergo agonist-induced\
        \ desensitization also resembled that of the wild-type receptor, with the\
        \ exception of the D79A mutant, which was almost completely resistant to 100\
        \ nM-NKA-induced desensitization (R2/R1 = 0.90\xB10.10 ; n=33 ; Table 1).\
        \ However, this mutant was fully desensitized upon the application of 1 \xB5\
        M NKA, despite a similar current amplitude.", ligand_long: '[3H]SR48968',
    ligand_short: '', pubmed: '10085227', seq: '79', to_res: A}
- {entry_name: nk2r_human, from_res: N, info: 'Using oocytes injected with cDNA, the
        Asn-51 mutants produced a similar degree of NKA-induced chloride-current activation
        as the wild-type receptor. Despite the inability of these mutants to detect
        [3H]SR48968 antagonist binding, the NKA-induced responses were, unexpectedly,
        almost completely abolished in the presence of 10 nM SR48968 (approx. 2 x
        Kd of the wild-type NK2R).In oocytes injected with 25 ng of cRNA, the N51D
        and N51H mutants displayed significantly lower NKA-induced current amplitudes
        compared with the wild-type receptor, while current activation was undetectable
        for the N51S mutant (Table 2).', ligand_long: '[3H]SR48968', ligand_short: '',
    pubmed: '10085227', seq: '51', to_res: S}
- {entry_name: nk2r_human, from_res: N, info: 'Using oocytes injected with cDNA, the
        Asn-51 mutants produced a similar degree of NKA-induced chloride-current activation
        as the wild-type receptor. Despite the inability of these mutants to detect
        [3H]SR48968 antagonist binding, the NKA-induced responses were, unexpectedly,
        almost completely abolished in the presence of 10 nM SR48968 (approx. 2 x
        Kd of the wild-type NK2R).In oocytes injected with 25 ng of cRNA, the N51D
        and N51H mutants displayed significantly lower NKA-induced current amplitudes
        compared with the wild-type receptor, while current activation was undetectable
        for the N51S mutant (Table 2).', ligand_long: '[3H]SR48968', ligand_short: '',
    pubmed: '10085227', seq: '51', to_res: H}
- {entry_name: nk2r_human, from_res: N, info: 'The receptors resulting from point
        mutations at the Asn-51 locus could not be detected using either the 125I-NKA
        or the [3H]SR48968 homologous competition binding assays after transfection
        of COS-1 cells. However, these mutant receptors surprisingly produced responses
        with wild-type-like amplitudes and desensitization properties when expressed
        in oocytes injected with cDNA, showing that they are correctly folded and
        translocated to the plasma membrane (Table 1).Using oocytes injected with
        cDNA, the Asn-51 mutants produced a similar degree of NKA-induced chloride-current
        activation as the wild-type receptor. Despite the inability of these mutants
        to detect [3H]SR48968 antagonist binding, the NKA-induced responses were,
        unexpectedly, almost completely abolished in the presence of 10 nM SR48968
        (approx. 2 x Kd of the wild-type NK2R).In oocytes injected with 25 ng of cRNA,
        the N51D and N51H mutants displayed significantly lower NKA-induced current
        amplitudes compared with the wild-type receptor, while current activation
        was undetectable for the N51S mutant (Table 2).', ligand_long: '[3H]SR48968',
    ligand_short: '', pubmed: '10085227', seq: '51', to_res: D}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '', ligand_short: Carbachol, pubmed: '1657592', seq: '537',
    to_res: A}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '', ligand_short: Acetylcholine, pubmed: '1657592',
    seq: '537', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '', ligand_short: Trihexyphenidyl, pubmed: '1657592',
    seq: '537', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '[3H]NMS', ligand_short: '', pubmed: '1657592', seq: '537',
    to_res: A}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Carbachol,
    pubmed: '1657592', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '1657592', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Trihexyphenidyl,
    pubmed: '1657592', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '1657592', seq: '533', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Carbachol,
    pubmed: '1657592', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '1657592', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Trihexyphenidyl,
    pubmed: '1657592', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '1657592', seq: '529', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Carbachol,
    pubmed: '1657592', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '1657592', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Trihexyphenidyl,
    pubmed: '1657592', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '1657592', seq: '506', to_res: F}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '', ligand_short: Carbachol, pubmed: '1657592', seq: '502',
    to_res: A}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '', ligand_short: Acetylcholine, pubmed: '1657592',
    seq: '502', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '', ligand_short: Trihexyphenidyl, pubmed: '1657592',
    seq: '502', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: Amino acid replacements of residues buried
        deeper in the membrane such as Thr502 and Thr537 had little effect on agonist
        binding., ligand_long: '[3H]NMS', ligand_short: '', pubmed: '1657592', seq: '502',
    to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Carbachol,
    pubmed: '1657592', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '1657592', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Trihexyphenidyl,
    pubmed: '1657592', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '1657592', seq: '234', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Carbachol,
    pubmed: '1657592', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '1657592', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Trihexyphenidyl,
    pubmed: '1657592', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: T, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '1657592', seq: '231', to_res: A}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Carbachol,
    pubmed: '1657592', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '1657592', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '', ligand_short: Trihexyphenidyl,
    pubmed: '1657592', seq: '148', to_res: F}
- {entry_name: acm3_rat, from_res: Y, info: 'Six out of the nine mutant receptors
        studied (Tyr148 -> Phe, Thr231 ->Ala, Thr234->Ala, Tyr506->Phe, Tyr529->Phe
        and 533->Phe) showed >10-fold lower agonist binding affinities than the wild-type
        receptor (Table II, Figure 2B). This decrease was most pronounced (~30- to
        40-fold) for Thr234->Ala and Tyr506->Phe. Interestingly, these mutant receptors
        displayed antagonist binding affinities which were similar to the values obtained
        with the wild-type receptor (Table I).The six mutant receptors which showed
        strongly reduced agonist binding affinities (see above), also displayed considerably
        reduced potencies in carbachol-induced stimulation of PI hydrolysis (Table
        II, Figure 3B). The increases in EC50 values (compared with wild-type m3)
        were against most pronounced (13- to 17-fold) for Thr234->Ala and Tyr506->Phe.
        While the majority of mutant receptors induced similar maximum responses as
        the wild-type m3 receptor, the maximum IP1 accumulation  mediated by Thr234->Ala
        was reduced to ~50% (Table II, Figure 3B).', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '1657592', seq: '148', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.In the N111Y mutant, the IP stimulation by\
        \ [Sar1,Asn4]Ang II did not reach the wild-type level. Activation of function\
        \ was impaired in this mutant in response to several other Ang II analogues\
        \ as well.The affinity of N111F, N111Y and N111K mutants towards [Sar1,Asp4]Ang\
        \ II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang II was 290, 198 and 2980\
        \ nM, respectively.", ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.In the N111Y mutant, the IP stimulation by\
        \ [Sar1,Asn4]Ang II did not reach the wild-type level. Activation of function\
        \ was impaired in this mutant in response to several other Ang II analogues\
        \ as well.The affinity of N111F, N111Y and N111K mutants towards [Sar1,Asp4]Ang\
        \ II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang II was 290, 198 and 2980\
        \ nM, respectively.", ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.In the N111Y mutant, the IP stimulation by\
        \ [Sar1,Asn4]Ang II did not reach the wild-type level. Activation of function\
        \ was impaired in this mutant in response to several other Ang II analogues\
        \ as well.The affinity of N111F, N111Y and N111K mutants towards [Sar1,Asp4]Ang\
        \ II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang II was 290, 198 and 2980\
        \ nM, respectively.", ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.In the N111Y mutant, the IP stimulation by\
        \ [Sar1,Asn4]Ang II did not reach the wild-type level. Activation of function\
        \ was impaired in this mutant in response to several other Ang II analogues\
        \ as well.The affinity of N111F, N111Y and N111K mutants towards [Sar1,Asp4]Ang\
        \ II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang II was 290, 198 and 2980\
        \ nM, respectively.", ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '',
    ligand_short: '', pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '',
    ligand_short: '', pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '',
    ligand_short: '', pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "High affinity for [Sar1, Asn4]Ang II\
        \ was regained in the N111F (Kd = 0.49 \xB1 0.05 nM) and N111Y (Kd = 1.8 \xB1\
        \ 0.2 nM) mutant AT1 receptors.The most impressive effect of the reversal\
        \ of the bonding was gain of function: the IP production stimulated [Sar1,Ang4]Ang\
        \ II in the N111F receptor was identical (maximum = 79 \xB1 6% and EC50 =\
        \ 3.8 \xB1 0.7 nM) to that elicted by [Sar1,Phe4]Ang II in the wild-type receptor.\
        \ Although the maximum IP production stimulated by [Sar1,Phe4]Ang II in N111F\
        \ mutant receptor was nearly the same, the EC50 was distinct.Binding of [Sar1,Gln4]Ang\
        \ II to N111F (Kd = 24 nM) mutant was not a high affinity interaction and\
        \ was not associated with a gain of function.The affinity of N111F, N111Y\
        \ and N111K mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward\
        \ [Sar1,Glu4]Ang II was 290, 198 and 2980 nM, respectively.", ligand_long: '',
    ligand_short: '', pubmed: '10066768', seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: 'Most importantly, magnitude of increased
        affinity of the N111I mutant was consistent with an interaction dependent
        of the size and hydrophobicity.', ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'Most importantly, magnitude of increased
        affinity of the N111I mutant was consistent with an interaction dependent
        of the size and hydrophobicity.', ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'Most importantly, magnitude of increased
        affinity of the N111I mutant was consistent with an interaction dependent
        of the size and hydrophobicity.', ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'Most importantly, magnitude of increased
        affinity of the N111I mutant was consistent with an interaction dependent
        of the size and hydrophobicity.', ligand_long: '', ligand_short: '', pubmed: '10066768',
    seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'The affinity of N111F, N111Y and N111K
        mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang
        II was 290, 198 and 2980 nM, respectively.', ligand_long: '', ligand_short: '',
    pubmed: '10066768', seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, info: 'The affinity of N111F, N111Y and N111K
        mutants towards [Sar1,Asp4]Ang II was 91, 20 and 468 nM and toward [Sar1,Glu4]Ang
        II was 290, 198 and 2980 nM, respectively.', ligand_long: '', ligand_short: '',
    pubmed: '10066768', seq: '111', to_res: K}
- {entry_name: grpr_mouse, from_res: N, info: 'two affinities (KD2/KD1) was significantly
        increased for thismutant compared with wild-type GRP-R, whereas the fractionof
        mutant receptors in the high-affinity state (R1) was decreased.GDP/guanosine-59-O-(3-thio)triphosphate
        exchangecatalyzed by the N281A mutant was lower than that observedfor the
        wild-type GRP-R. However, bombesinwas still able to stimulate 1,4,5-inositol
        triphosphate in transfectedcells albeit with reduced activity.', ligand_long: '',
    ligand_short: '', pubmed: '10945859', seq: '281', to_res: A}
- {entry_name: grpr_mouse, from_res: N, info: 'two affinities (KD2/KD1) was significantly
        increased for thismutant compared with wild-type GRP-R, whereas the fractionof
        mutant receptors in the high-affinity state (R1) was decreased.GDP/guanosine-59-O-(3-thio)triphosphate
        exchangecatalyzed by the N281A mutant was lower than that observedfor the
        wild-type GRP-R. However, bombesinwas still able to stimulate 1,4,5-inositol
        triphosphate in transfectedcells albeit with reduced activity.', ligand_long: 125I-BN,
    ligand_short: '', pubmed: '10945859', seq: '281', to_res: A}
- {entry_name: mshr_human, from_res: H, info: Other examples of how mutations differentially
        affect the agonists include E94A and H260A. Both of these mutations have a
        much more marked effect on alpha-MSH and comparatively little effect on NDP-MSH
        or MT-II., ligand_long: 125-NDP-MSH, ligand_short: gamma-MSH, pubmed: '9287296',
    seq: '260', to_res: A}
- {entry_name: mshr_human, from_res: H, info: Other examples of how mutations differentially
        affect the agonists include E94A and H260A. Both of these mutations have a
        much more marked effect on alpha-MSH and comparatively little effect on NDP-MSH
        or MT-II., ligand_long: 125I-NDP-MSH, ligand_short: MT-II, pubmed: '9287296',
    seq: '260', to_res: A}
- {entry_name: mshr_human, from_res: H, info: Other examples of how mutations differentially
        affect the agonists include E94A and H260A. Both of these mutations have a
        much more marked effect on alpha-MSH and comparatively little effect on NDP-MSH
        or MT-II., ligand_long: 125I-NDP-MSH, ligand_short: NDP-MSH, pubmed: '9287296',
    seq: '260', to_res: A}
- {entry_name: mshr_human, from_res: H, info: Other examples of how mutations differentially
        affect the agonists include E94A and H260A. Both of these mutations have a
        much more marked effect on alpha-MSH and comparatively little effect on NDP-MSH
        or MT-II., ligand_long: 125I-NDP-MSH, ligand_short: alpha-MSH, pubmed: '9287296',
    seq: '260', to_res: A}
- {entry_name: mshr_human, from_res: F, info: '[...], substitution of individual receptor
        residues Phe157 in TM4 and Phe257 in TM6 caused a statistically significant
        loss, albeit only a very small loss, of NDP-MSH binding affinity and potency.The
        observations that Phe175, Phe196, Phe257, and more complex aromatic mutations
        have effects on agonist affinity and potency also indicates that hydrophobic
        interactions play a role in the ligand-receptor interaction between melanocortins
        and hMC1R.', ligand_long: 125I-NDP-MSH, ligand_short: gamma-MSH, pubmed: '9287296',
    seq: '257', to_res: A}
- {entry_name: mshr_human, from_res: F, info: '[...], substitution of individual receptor
        residues Phe157 in TM4 and Phe257 in TM6 caused a statistically significant
        loss, albeit only a very small loss, of NDP-MSH binding affinity and potency.The
        observations that Phe175, Phe196, Phe257, and more complex aromatic mutations
        have effects on agonist affinity and potency also indicates that hydrophobic
        interactions play a role in the ligand-receptor interaction between melanocortins
        and hMC1R.', ligand_long: 125I-NDP-MSH, ligand_short: MT-II, pubmed: '9287296',
    seq: '257', to_res: A}
- {entry_name: mshr_human, from_res: F, info: '[...], substitution of individual receptor
        residues Phe157 in TM4 and Phe257 in TM6 caused a statistically significant
        loss, albeit only a very small loss, of NDP-MSH binding affinity and potency.The
        observations that Phe175, Phe196, Phe257, and more complex aromatic mutations
        have effects on agonist affinity and potency also indicates that hydrophobic
        interactions play a role in the ligand-receptor interaction between melanocortins
        and hMC1R.', ligand_long: 125I-NDP-MSH, ligand_short: NDP-MSH, pubmed: '9287296',
    seq: '257', to_res: A}
- {entry_name: mshr_human, from_res: F, info: '[...], substitution of individual receptor
        residues Phe157 in TM4 and Phe257 in TM6 caused a statistically significant
        loss, albeit only a very small loss, of NDP-MSH binding affinity and potency.The
        observations that Phe175, Phe196, Phe257, and more complex aromatic mutations
        have effects on agonist affinity and potency also indicates that hydrophobic
        interactions play a role in the ligand-receptor interaction between melanocortins
        and hMC1R.', ligand_long: 125I-NDP-MSH, ligand_short: alpha-MSH, pubmed: '9287296',
    seq: '257', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: gamma-MSH, pubmed: '9287296', seq: '196', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: MT-II, pubmed: '9287296', seq: '196', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: NDP-MSH, pubmed: '9287296', seq: '196', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: alpha-MSH, pubmed: '9287296', seq: '196', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: gamma-MSH, pubmed: '9287296', seq: '175', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: MT-II, pubmed: '9287296', seq: '175', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: NDP-MSH, pubmed: '9287296', seq: '175', to_res: A}
- {entry_name: mshr_human, from_res: F, info: 'The observations that Phe175, Phe196,
        Phe257, and more complex aromatic mutations have effects on agonist affinity
        and potency also indicates that hydrophobic interactions play a role in the
        ligand-receptor interaction between melanocortins and hMC1R.', ligand_long: 125I-NDP-MSH,
    ligand_short: alpha-MSH, pubmed: '9287296', seq: '175', to_res: A}
- {entry_name: mshr_human, from_res: N, info: 'experimentally, however, we could not
        detect any change in the binding affinity or potency of NDP-MSH at the mutation
        of N281A.Suprisingly, replacement of Asn281 in TM7 by Ala completely abolished
        gamma-MSH binding and activation while having no affect on the other agonists.',
    ligand_long: 125I-NDP-MSH, ligand_short: gamma-MSH, pubmed: '9287296', seq: '281',
    to_res: A}
- {entry_name: mshr_human, from_res: N, info: 'experimentally, however, we could not
        detect any change in the binding affinity or potency of NDP-MSH at the mutation
        of N281A.Suprisingly, replacement of Asn281 in TM7 by Ala completely abolished
        gamma-MSH binding and activation while having no affect on the other agonists.',
    ligand_long: 125I-NDP-MSH, ligand_short: MT-II, pubmed: '9287296', seq: '281',
    to_res: A}
- {entry_name: mshr_human, from_res: N, info: 'experimentally, however, we could not
        detect any change in the binding affinity or potency of NDP-MSH at the mutation
        of N281A.Suprisingly, replacement of Asn281 in TM7 by Ala completely abolished
        gamma-MSH binding and activation while having no affect on the other agonists.',
    ligand_long: 125I-NDP-MSH, ligand_short: NDP-MSH, pubmed: '9287296', seq: '281',
    to_res: A}
- {entry_name: mshr_human, from_res: N, info: 'experimentally, however, we could not
        detect any change in the binding affinity or potency of NDP-MSH at the mutation
        of N281A.Suprisingly, replacement of Asn281 in TM7 by Ala completely abolished
        gamma-MSH binding and activation while having no affect on the other agonists.',
    ligand_long: 125I-NDP-MSH, ligand_short: alpha-MSH, pubmed: '9287296', seq: '281',
    to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: gamma-MSH, pubmed: '9287296',
    seq: '121', to_res: K}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: MT-II, pubmed: '9287296',
    seq: '121', to_res: K}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: NDP-MSH, pubmed: '9287296',
    seq: '121', to_res: K}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: NDP-MSH, ligand_short: alpha-MSH, pubmed: '9287296',
    seq: '121', to_res: K}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: gamma-MSH, pubmed: '9287296',
    seq: '121', to_res: N}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: MT-II, pubmed: '9287296',
    seq: '121', to_res: N}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: NDP-MSH, pubmed: '9287296',
    seq: '121', to_res: N}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: alpha-MSH, pubmed: '9287296',
    seq: '121', to_res: N}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: gamma-MSH, pubmed: '9287296',
    seq: '121', to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: MT-II, pubmed: '9287296',
    seq: '121', to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: NDP-MSH, pubmed: '9287296',
    seq: '121', to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'Both mutations caused changes in agonist
        affinity and potency that were more marked than those observed for D121A (D121K
        > D121N).No increased basal cAMP production was observed with mutant D121K
        compared with wild-type hMC1R.The logarithmic magnitude of the changes observed
        in these experiments in both binding affinity and potency with alanine substitution
        of Glu94, Asp117, or Asp121 strongly implicates these amino acids as critical
        receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction
        and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: alpha-MSh, pubmed: '9287296',
    seq: '121', to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Frandberg et al. have previously reported that Asp117 alters the
        binding affinity of alpha-MSH and gamma-MSH but not NDP-MSH in competitive
        binding studies using 125I-labeled NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: gamma-MSH,
    pubmed: '9287296', seq: '117', to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Frandberg et al. have previously reported that Asp117 alters the
        binding affinity of alpha-MSH and gamma-MSH but not NDP-MSH in competitive
        binding studies using 125I-labeled NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: MT-II,
    pubmed: '9287296', seq: '117', to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Frandberg et al. have previously reported that Asp117 alters the
        binding affinity of alpha-MSH and gamma-MSH but not NDP-MSH in competitive
        binding studies using 125I-labeled NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: NDP-MSH,
    pubmed: '9287296', seq: '117', to_res: A}
- {entry_name: mshr_human, from_res: D, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Frandberg et al. have previously reported that Asp117 alters the
        binding affinity of alpha-MSH and gamma-MSH but not NDP-MSH in competitive
        binding studies using 125I-labeled NDP-MSH.', ligand_long: 125I-NDP-MSH, ligand_short: alpha-MSh,
    pubmed: '9287296', seq: '117', to_res: A}
- {entry_name: mshr_human, from_res: E, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Other examples of how mutations differentially affect the agonists
        include E94A and H260A. Both of these mutations have a much more marked effect
        on alpha-MSH and comparatively little effect on NDP-MSH or MT-II.', ligand_long: 125I-NDP-MSH,
    ligand_short: gamma-MSH, pubmed: '9287296', seq: '94', to_res: A}
- {entry_name: mshr_human, from_res: E, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Other examples of how mutations differentially affect the agonists
        include E94A and H260A. Both of these mutations have a much more marked effect
        on alpha-MSH and comparatively little effect on NDP-MSH or MT-II.', ligand_long: 125I-NDP-MSH,
    ligand_short: MT-II, pubmed: '9287296', seq: '94', to_res: A}
- {entry_name: mshr_human, from_res: E, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Other examples of how mutations differentially affect the agonists
        include E94A and H260A. Both of these mutations have a much more marked effect
        on alpha-MSH and comparatively little effect on NDP-MSH or MT-II.', ligand_long: 125I-NDP-MSH,
    ligand_short: NDP-MSH, pubmed: '9287296', seq: '94', to_res: A}
- {entry_name: mshr_human, from_res: E, info: 'The logarithmic magnitude of the changes
        observed in these experiments in both binding affinity and potency with alanine
        substitution of Glu94, Asp117, or Asp121 strongly implicates these amino acids
        as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor
        interaction and the interaction of the other melanocortin agonists tested.Nonetheless,
        these results are consistent with the hypothesis that Glu94, Asp117, and Asp121
        act collectively as counteranions for the single cationic ligand residue Arg8
        of NDP-MSH.Other examples of how mutations differentially affect the agonists
        include E94A and H260A. Both of these mutations have a much more marked effect
        on alpha-MSH and comparatively little effect on NDP-MSH or MT-II.', ligand_long: 125I-NDP-MSH,
    ligand_short: alpha-MSH, pubmed: '9287296', seq: '94', to_res: A}
- {entry_name: acm3_rat, from_res: N, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).Comments: The rat M3 muscarinic receptor used
        in this study is a modified version of the wild-type receptor and is referred
        to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope tag
        and lacks all five potential N-terminal N-glycosylation sites and most endogenous
        Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover, the central
        portion of the i3 loop (the third intracellular loop of GPCR''s; Ala-274-Lys-469)
        is replaced with two factor Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: carbachol,
    pubmed: '16093246', seq: '152', to_res: C}
- {entry_name: acm3_rat, from_res: N, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).Comments: The rat M3 muscarinic receptor used
        in this study is a modified version of the wild-type receptor and is referred
        to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope tag
        and lacks all five potential N-terminal N-glycosylation sites and most endogenous
        Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover, the central
        portion of the i3 loop (the third intracellular loop of GPCR''s; Ala-274-Lys-469)
        is replaced with two factor Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '16093246', seq: '152', to_res: C}
- {entry_name: acm3_rat, from_res: S, info: 'In contrast, carbachol stimulation led
        to a pronounced increase in the intensity of the cross-linking signal in the
        case of the S151C mutant receptor.We therefore wanted to exclude the possibility
        that agonist-promoted disulfide cross-linking between Cys-151 and Cys-532
        occured intermolecularly (between two or more receptor molecules) rather than
        intramolecularly.In any case, our data indicate that the formation of a disulfide
        bond between Cys-151 and Cys-532 in the S151C construct does not involve interactions
        between different receptors monomers.Radioligand binding studies showed that
        N-(Et3)-ACh retained the ability to bind to the S151C and M3''-(3C)-Xa receptors,
        although with ~2-5-fold lower affinity than carbachol.These data indicate
        that N-(Et3)-ACh can bind to the S151C and M3''-(3C)-Xa receptors, but is
        unable to activate these receptors, characteristics of the behaviour of a
        muscarinic antagonist.N-(Et3)-ACh failed to promote disulfide bond formation
        in the S151C mutant construct.Moreover, similar to the muscarinic antagonist
        atropine and in contrast to the agonist ACh and carbachol, N-(Et3)-ACh failed
        to promote the formation of a disulfide bridge between S151C and Cys-532.Comments:
        The rat M3 muscarinic receptor used in this study is a modified version of
        the wild-type receptor and is referred to as: M3''-(3C)-Xa and contains: an
        N-terminal Hemagglutinin epitope tag and lacks all five potential N-terminal
        N-glycosylation sites and most endogenous Cys residues, except for Cys-140,
        Cys-220, and Cys-532. Moreover, the central portion of the i3 loop (the third
        intracellular loop of GPCR''s; Ala-274-Lys-469) is replaced with two factor
        Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: carbachol, pubmed: '16093246',
    seq: '151', to_res: C}
- {entry_name: acm3_rat, from_res: S, info: 'In contrast, carbachol stimulation led
        to a pronounced increase in the intensity of the cross-linking signal in the
        case of the S151C mutant receptor.We therefore wanted to exclude the possibility
        that agonist-promoted disulfide cross-linking between Cys-151 and Cys-532
        occured intermolecularly (between two or more receptor molecules) rather than
        intramolecularly.In any case, our data indicate that the formation of a disulfide
        bond between Cys-151 and Cys-532 in the S151C construct does not involve interactions
        between different receptors monomers.Radioligand binding studies showed that
        N-(Et3)-ACh retained the ability to bind to the S151C and M3''-(3C)-Xa receptors,
        although with ~2-5-fold lower affinity than carbachol.These data indicate
        that N-(Et3)-ACh can bind to the S151C and M3''-(3C)-Xa receptors, but is
        unable to activate these receptors, characteristics of the behaviour of a
        muscarinic antagonist.N-(Et3)-ACh failed to promote disulfide bond formation
        in the S151C mutant construct.Moreover, similar to the muscarinic antagonist
        atropine and in contrast to the agonist ACh and carbachol, N-(Et3)-ACh failed
        to promote the formation of a disulfide bridge between S151C and Cys-532.Comments:
        The rat M3 muscarinic receptor used in this study is a modified version of
        the wild-type receptor and is referred to as: M3''-(3C)-Xa and contains: an
        N-terminal Hemagglutinin epitope tag and lacks all five potential N-terminal
        N-glycosylation sites and most endogenous Cys residues, except for Cys-140,
        Cys-220, and Cys-532. Moreover, the central portion of the i3 loop (the third
        intracellular loop of GPCR''s; Ala-274-Lys-469) is replaced with two factor
        Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '16093246',
    seq: '151', to_res: C}
- {entry_name: acm3_rat, from_res: A, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).However, two mutant receptors, (A150C and S151C)
        gave a distinct cross-linking signal in both the absence and presence of the
        muscarinic agonist.Carbachol treatment had no significant effect on the intensity
        of the 38-KDa band in the case of the A150C construct.[...], the A150C mutant
        receptor gave a weak cross-linking signal that remained essentially unchanged
        after the addition of the agonist carbachol.Comments: The rat M3 muscarinic
        receptor used in this study is a modified version of the wild-type receptor
        and is referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin
        epitope tag and lacks all five potential N-terminal N-glycosylation sites
        and most endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532.
        Moreover, the central portion of the i3 loop (the third intracellular loop
        of GPCR''s; Ala-274-Lys-469) is replaced with two factor Xa cleavage sites.',
    ligand_long: '[3H]NMS', ligand_short: carbachol, pubmed: '16093246', seq: '150',
    to_res: C}
- {entry_name: acm3_rat, from_res: A, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).However, two mutant receptors, (A150C and S151C)
        gave a distinct cross-linking signal in both the absence and presence of the
        muscarinic agonist.Carbachol treatment had no significant effect on the intensity
        of the 38-KDa band in the case of the A150C construct.[...], the A150C mutant
        receptor gave a weak cross-linking signal that remained essentially unchanged
        after the addition of the agonist carbachol.Comments: The rat M3 muscarinic
        receptor used in this study is a modified version of the wild-type receptor
        and is referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin
        epitope tag and lacks all five potential N-terminal N-glycosylation sites
        and most endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532.
        Moreover, the central portion of the i3 loop (the third intracellular loop
        of GPCR''s; Ala-274-Lys-469) is replaced with two factor Xa cleavage sites.',
    ligand_long: '[3H]NMS', ligand_short: '', pubmed: '16093246', seq: '150', to_res: C}
- {entry_name: acm3_rat, from_res: V, info: 'Comments: The rat M3 muscarinic receptor
        used in this study is a modified version of the wild-type receptor and is
        referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope
        tag and lacks all five potential N-terminal N-glycosylation sites and most
        endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover,
        the central portion of the i3 loop (the third intracellular loop of GPCR''s;
        Ala-274-Lys-469) is replaced with two factor Xa cleavage sites.', ligand_long: '[3H]NMS',
    ligand_short: carbachol, pubmed: '16093246', seq: '149', to_res: C}
- {entry_name: acm3_rat, from_res: V, info: 'Comments: The rat M3 muscarinic receptor
        used in this study is a modified version of the wild-type receptor and is
        referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope
        tag and lacks all five potential N-terminal N-glycosylation sites and most
        endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover,
        the central portion of the i3 loop (the third intracellular loop of GPCR''s;
        Ala-274-Lys-469) is replaced with two factor Xa cleavage sites.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '16093246', seq: '149', to_res: C}
- {entry_name: acm3_rat, from_res: Y, info: 'However, three mutant receptors (W143C,
        D147C, and Y148C) showed a significant reduction (~4-6-fold) in [3H]NMS binding
        affinities.However, four mutant receptors (D147C, Y148C, A150C, and N152C)
        showed an ~3-9-fold reduction in carbachol binding affinities.Strikingly,
        the S145C, D147C, and Y148C mutant receptors were completely devoid of functional
        activity.Moreover, PI assays showed that three of the examined mutant receptors
        (S145C, D147C, and Y148C) lost the ability to interact with G proteins, [...].Comments:
        The rat M3 muscarinic receptor used in this study is a modified version of
        the wild-type receptor and is referred to as: M3''-(3C)-Xa and contains: an
        N-terminal Hemagglutinin epitope tag and lacks all five potential N-terminal
        N-glycosylation sites and most endogenous Cys residues, except for Cys-140,
        Cys-220, and Cys-532. Moreover, the central portion of the i3 loop (the third
        intracellular loop of GPCR''s; Ala-274-Lys-469) is replaced with two factor
        Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: carbachol, pubmed: '16093246',
    seq: '148', to_res: C}
- {entry_name: acm3_rat, from_res: Y, info: 'However, three mutant receptors (W143C,
        D147C, and Y148C) showed a significant reduction (~4-6-fold) in [3H]NMS binding
        affinities.However, four mutant receptors (D147C, Y148C, A150C, and N152C)
        showed an ~3-9-fold reduction in carbachol binding affinities.Strikingly,
        the S145C, D147C, and Y148C mutant receptors were completely devoid of functional
        activity.Moreover, PI assays showed that three of the examined mutant receptors
        (S145C, D147C, and Y148C) lost the ability to interact with G proteins, [...].Comments:
        The rat M3 muscarinic receptor used in this study is a modified version of
        the wild-type receptor and is referred to as: M3''-(3C)-Xa and contains: an
        N-terminal Hemagglutinin epitope tag and lacks all five potential N-terminal
        N-glycosylation sites and most endogenous Cys residues, except for Cys-140,
        Cys-220, and Cys-532. Moreover, the central portion of the i3 loop (the third
        intracellular loop of GPCR''s; Ala-274-Lys-469) is replaced with to factor
        Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '16093246',
    seq: '148', to_res: C}
- {entry_name: acm3_rat, from_res: D, info: 'However, four mutant receptors (D147C,
        Y148C, A150C, and N152C) showed an ~3-9-fold reduction in carbachol binding
        affinities.Strikingly, the S145C, D147C, and Y148C mutant receptors were completely
        devoid of functional activity.Moreover, PI assays showed that three of the
        examined mutant receptors (S145C, D147C, and Y148C) lost the ability to interact
        with G proteins, [...].Comments: The rat M3 muscarinic receptor used in this
        study is a modified version of the wild-type receptor and is referred to as:
        M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope tag and lacks
        all five potential N-terminal N-glycosylation sites and most endogenous Cys
        residues, except for Cys-140, Cys-220, and Cys-532. Moreover, the central
        portion of the i3 loop (the third intracellular loop of GPCR''s; Ala-274-Lys-469)
        is replaced with to factor Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: carbachol,
    pubmed: '16093246', seq: '147', to_res: C}
- {entry_name: acm3_rat, from_res: D, info: 'However, four mutant receptors (D147C,
        Y148C, A150C, and N152C) showed an ~3-9-fold reduction in carbachol binding
        affinities.Strikingly, the S145C, D147C, and Y148C mutant receptors were completely
        devoid of functional activity.Moreover, PI assays showed that three of the
        examined mutant receptors (S145C, D147C, and Y148C) lost the ability to interact
        with G proteins, [...].Comments: The rat M3 muscarinic receptor used in this
        study is a modified version of the wild-type receptor and is referred to as:
        M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope tag and lacks
        all five potential N-terminal N-glycosylation sites and most endogenous Cys
        residues, except for Cys-140, Cys-220, and Cys-532. Moreover, the central
        portion of the i3 loop (the third intracellular loop of GPCR''s; Ala-274-Lys-469)
        is replaced with to factor Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '16093246', seq: '147', to_res: C}
- {entry_name: acm3_rat, from_res: I, info: 'Comments: The rat M3 muscarinic receptor
        used in this study is a modified version of the wild-type receptor and is
        referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope
        tag and lacks all five potential N-terminal N-glycosylation sites and most
        endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover,
        the central portion of the i3 loop (the third intracellular loop of GPCR''s;
        Ala-274-Lys-469) is replaced with to factor Xa cleavage sites.', ligand_long: '[3H]NMS',
    ligand_short: carbachol, pubmed: '16093246', seq: '146', to_res: C}
- {entry_name: acm3_rat, from_res: I, info: 'Comments: The rat M3 muscarinic receptor
        used in this study is a modified version of the wild-type receptor and is
        referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope
        tag and lacks all five potential N-terminal N-glycosylation sites and most
        endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover,
        the central portion of the i3 loop (the third intracellular loop of GPCR''s;
        Ala-274-Lys-469) is replaced with to factor Xa cleavage sites.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '16093246', seq: '146', to_res: C}
- {entry_name: acm3_rat, from_res: S, info: 'Strikingly, the S145C, D147C, and Y148C
        mutant receptors were completely devoid of functional activity.Moreover, PI
        assays showed that three of the examined mutant receptors (S145C, D147C, and
        Y148C) lost the ability to interact with G proteins, [...].Comments: The rat
        M3 muscarinic receptor used in this study is a modified version of the wild-type
        receptor and is referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin
        epitope tag and lacks all five potential N-terminal N-glycosylation sites
        and most endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532.
        Moreover, the central portion of the i3 loop (the third intracellular loop
        of GPCR''s; Ala-274-Lys-469) is replaced with to factor Xa cleavage sites.',
    ligand_long: '[3H]NMS', ligand_short: carbachol, pubmed: '16093246', seq: '145',
    to_res: C}
- {entry_name: acm3_rat, from_res: S, info: 'Strikingly, the S145C, D147C, and Y148C
        mutant receptors were completely devoid of functional activity.Moreover, PI
        assays showed that three of the examined mutant receptors (S145C, D147C, and
        Y148C) lost the ability to interact with G proteins, [...].Comments: The rat
        M3 muscarinic receptor used in this study is a modified version of the wild-type
        receptor and is referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin
        epitope tag and lacks all five potential N-terminal N-glycosylation sites
        and most endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532.
        Moreover, the central portion of the i3 loop (the third intracellular loop
        of GPCR''s; Ala-274-Lys-469) is replaced with to factor Xa cleavage sites.',
    ligand_long: '[3H]NMS', ligand_short: '', pubmed: '16093246', seq: '145', to_res: C}
- {entry_name: acm3_rat, from_res: L, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).The L144C construct showed by far the most pronounced
        decrease in carbachol potency, displaying an ~500-fold reduction in carbachol
        potency compared with the M3''(3C)-Xa receptor.Comments: The rat M3 muscarinic
        receptor used in this study is a modified version of the wild-type receptor
        and is referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin
        epitope tag and lacks all five potential N-terminal N-glycosylation sites
        and most endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532.
        Moreover, the central portion of the i3 loop (the third intracellular loop
        of GPCR''s; Ala-274-Lys-469) is replaced with to factor Xa cleavage sites.',
    ligand_long: '[3H]NMS', ligand_short: carbachol, pubmed: '16093246', seq: '144',
    to_res: C}
- {entry_name: acm3_rat, from_res: L, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).The L144C construct showed by far the most pronounced
        decrease in carbachol potency, displaying an ~500-fold reduction in carbachol
        potency compared with the M3''(3C)-Xa receptor.Comments: The rat M3 muscarinic
        receptor used in this study is a modified version of the wild-type receptor
        and is referred to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin
        epitope tag and lacks all five potential N-terminal N-glycosylation sites
        and most endogenous Cys residues, except for Cys-140, Cys-220, and Cys-532.
        Moreover, the central portion of the i3 loop (the third intracellular loop
        of GPCR''s; Ala-274-Lys-469) is replaced with to factor Xa cleavage sites.',
    ligand_long: '[3H]NMS', ligand_short: '', pubmed: '16093246', seq: '144', to_res: C}
- {entry_name: acm3_rat, from_res: W, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).Comments: The rat M3 muscarinic receptor used
        in this study is a modified version of the wild-type receptor and is referred
        to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope tag
        and lacks all five potential N-terminal N-glycosylation sites and most endogenous
        Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover, the central
        portion of the i3 loop (the third intracellular loop of GPCR''s; Ala-274-Lys-469)
        is replaced with to factor Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: carbachol,
    pubmed: '16093246', seq: '143', to_res: C}
- {entry_name: acm3_rat, from_res: W, info: 'In the PI assays, five of the analyzed
        mutant receptors (W143C, L144C, I146C, A150C, and N152C) showed clearly reduced
        (>9-fold) carbachol potencies (increased EC50 values) compared with the M3''(3C)-Xa
        construct (EC50 = 20+-11 nM).Comments: The rat M3 muscarinic receptor used
        in this study is a modified version of the wild-type receptor and is referred
        to as: M3''-(3C)-Xa and contains: an N-terminal Hemagglutinin epitope tag
        and lacks all five potential N-terminal N-glycosylation sites and most endogenous
        Cys residues, except for Cys-140, Cys-220, and Cys-532. Moreover, the central
        portion of the i3 loop (the third intracellular loop of GPCR''s; Ala-274-Lys-469)
        is replaced with to factor Xa cleavage sites.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '16093246', seq: '143', to_res: C}
- {entry_name: p2ry1_human, from_res: S, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].Furthermore,
        residue S317 is not involved in binding of either agonist or the antagonist
        MRS 2179.', ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '317',
    to_res: A}
- {entry_name: p2ry1_human, from_res: S, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].Furthermore,
        residue S317 is not involved in binding of either agonist or the antagonist
        MRS 2179.', ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '317',
    to_res: A}
- {entry_name: p2ry1_human, from_res: S, info: 'It was not feasible to measure the
        effect of MRS2179 at the R128A, R301A, and S314A mutant receptors, because
        the agonsit did not fully activate these receptors.Steric requirements are
        present at Ser314, since the Thr substitution reduced the affinity of the
        antagonist.', ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '314',
    to_res: T}
- {entry_name: p2ry1_human, from_res: S, info: 'It was not feasible to measure the
        effect of MRS2179 at the R128A, R301A, and S314A mutant receptors, because
        the agonsit did not fully activate these receptors.Steric requirements are
        present at Ser314, since the Thr substitution reduced the affinity of the
        antagonist.', ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '314',
    to_res: T}
- {entry_name: p2ry1_human, from_res: R, info: 'The differential effects on antagonist
        affinity and antagonist potency in F131A, H277A, and R310K mutant receptors
        do not appear to be due to reduced intrinsic activity in these receptors,
        since maximal efficacy noted for three different agonists in these mutants
        receptors reached levels similar to that of wild-type receptors.', ligand_long: '',
    ligand_short: '', pubmed: '9554879', seq: '310', to_res: K}
- {entry_name: p2ry1_human, from_res: R, info: 'The differential effects on antagonist
        affinity and antagonist potency in F131A, H277A, and R310K mutant receptors
        do not appear to be due to reduced intrinsic activity in these receptors,
        since maximal efficacy noted for three different agonists in these mutants
        receptors reached levels similar to that of wild-type receptors.', ligand_long: '',
    ligand_short: '', pubmed: '9554879', seq: '310', to_res: K}
- {entry_name: p2ry1_human, from_res: Q, info: 'For the K280, Q307A, and Y136A mutant
        receptors, additional concentration-response curves for 2-MeSADP were measured
        at a much higher concentration of MRS 2179 (50 microM).Approximate IC50 values
        (microM) for antagonism of PLC activation by MRS 2179 were 5 (S314T), 42 (Y136A),
        30 (K280A), and 42 (Q307A). In these experiments, the concentration of agonist
        was 3.3- (K280A), 7.7- (Q307A), 9.6- (S314T), and 81- (Y136A) fold greater
        than the EC50 value at each mutant receptor in the absence of MRS 2179.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '307', to_res: A}
- {entry_name: p2ry1_human, from_res: Q, info: 'For the K280, Q307A, and Y136A mutant
        receptors, additional concentration-response curves for 2-MeSADP were measured
        at a much higher concentration of MRS 2179 (50 microM).Approximate IC50 values
        (microM) for antagonism of PLC activation by MRS 2179 were 5 (S314T), 42 (Y136A),
        30 (K280A), and 42 (Q307A). In these experiments, the concentration of agonist
        was 3.3- (K280A), 7.7- (Q307A), 9.6- (S314T), and 81- (Y136A) fold greater
        than the EC50 value at each mutant receptor in the absence of MRS 2179.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '307', to_res: A}
- {entry_name: p2ry1_human, from_res: K, info: 'For the K280, Q307A, and Y136A mutant
        receptors, additional concentration-response curves for 2-MeSADP were measured
        at a much higher concentration of MRS 2179 (50 microM).Approximate IC50 values
        (microM) for antagonism of PLC activation by MRS 2179 were 5 (S314T), 42 (Y136A),
        30 (K280A), and 42 (Q307A). In these experiments, the concentration of agonist
        was 3.3- (K280A), 7.7- (Q307A), 9.6- (S314T), and 81- (Y136A) fold greater
        than the EC50 value at each mutant receptor in the absence of MRS 2179.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '280', to_res: A}
- {entry_name: p2ry1_human, from_res: K, info: 'For the K280, Q307A, and Y136A mutant
        receptors, additional concentration-response curves for 2-MeSADP were measured
        at a much higher concentration of MRS 2179 (50 microM).Approximate IC50 values
        (microM) for antagonism of PLC activation by MRS 2179 were 5 (S314T), 42 (Y136A),
        30 (K280A), and 42 (Q307A). In these experiments, the concentration of agonist
        was 3.3- (K280A), 7.7- (Q307A), 9.6- (S314T), and 81- (Y136A) fold greater
        than the EC50 value at each mutant receptor in the absence of MRS 2179.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '280', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].The
        differential effects on antagonist affinity and antagonist potency in F131A,
        H277A, and R310K mutant receptors do not appear to be due to reduced intrinsic
        activity in these receptors, since maximal efficacy noted for three different
        agonists in these mutants receptors reached levels similar to that of wild-type
        receptors.In particular, Phe226 in TM5 is more important for the antagonist
        MRS 2179 than for agonists, and residues Phe 131, Thr 221, and His277 are
        less important for the antagonist than for agonists.', ligand_long: '', ligand_short: '',
    pubmed: '9554879', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].The
        differential effects on antagonist affinity and antagonist potency in F131A,
        H277A, and R310K mutant receptors do not appear to be due to reduced intrinsic
        activity in these receptors, since maximal efficacy noted for three different
        agonists in these mutants receptors reached levels similar to that of wild-type
        receptors.In particular, Phe226 in TM5 is more important for the antagonist
        MRS 2179 than for agonists, and residues Phe 131, Thr 221, and His277 are
        less important for the antagonist than for agonists.', ligand_long: '', ligand_short: '',
    pubmed: '9554879', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'In particular, Phe226 in TM5 is more
        important for the antagonist MRS 2179 than for agonists, and residues Phe
        131, Thr 221, and His277 are less important for the antagonist than for agonists.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '226', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'In particular, Phe226 in TM5 is more
        important for the antagonist MRS 2179 than for agonists, and residues Phe
        131, Thr 221, and His277 are less important for the antagonist than for agonists.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '226', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'Thus, the His132, Tyr136, and Thr222
        residues located in TM3 and TM5 appear to have a modulatory role in recognition
        of this antagonist.', ligand_long: '', ligand_short: '', pubmed: '9554879',
    seq: '222', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'Thus, the His132, Tyr136, and Thr222
        residues located in TM3 and TM5 appear to have a modulatory role in recognition
        of this antagonist.', ligand_long: '', ligand_short: '', pubmed: '9554879',
    seq: '222', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].In
        particular, Phe226 in TM5 is more important for the antagonist MRS 2179 than
        for agonists, and residues Phe 131, Thr 221, and His277 are less important
        for the antagonist than for agonists.', ligand_long: '', ligand_short: '',
    pubmed: '9554879', seq: '221', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].In
        particular, Phe226 in TM5 is more important for the antagonist MRS 2179 than
        for agonists, and residues Phe 131, Thr 221, and His277 are less important
        for the antagonist than for agonists.', ligand_long: '', ligand_short: '',
    pubmed: '9554879', seq: '221', to_res: A}
- {entry_name: p2ry1_human, from_res: Y, info: 'Approximate IC50 values (microM) for
        antagonism of PLC activation by MRS 2179 were 5 (S314T), 42 (Y136A), 30 (K280A),
        and 42 (Q307A). In these experiments, the concentration of agonist was 3.3-
        (K280A), 7.7- (Q307A), 9.6- (S314T), and 81- (Y136A) fold greater than the
        EC50 value at each mutant receptor in the absence of MRS 2179.At the H132A,
        Y136A, T222A, and S134T mutant receptors, MRS2179 (1 microM) produced an intermediate
        shift, i.e a 2- to 3-fold reduction in agonist potency, of the concentration
        response curve of 2-MeSADP.Thus, the His132, Tyr136, and Thr222 residues located
        in TM3 and TM5 appear to have a modulatory role in recognition of this antagonist.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '136', to_res: A}
- {entry_name: p2ry1_human, from_res: Y, info: 'Approximate IC50 values (microM) for
        antagonism of PLC activation by MRS 2179 were 5 (S314T), 42 (Y136A), 30 (K280A),
        and 42 (Q307A). In these experiments, the concentration of agonist was 3.3-
        (K280A), 7.7- (Q307A), 9.6- (S314T), and 81- (Y136A) fold greater than the
        EC50 value at each mutant receptor in the absence of MRS 2179.At the H132A,
        Y136A, T222A, and S134T mutant receptors, MRS2179 (1 microM) produced an intermediate
        shift, i.e a 2- to 3-fold reduction in agonist potency, of the concentration
        response curve of 2-MeSADP.Thus, the His132, Tyr136, and Thr222 residues located
        in TM3 and TM5 appear to have a modulatory role in recognition of this antagonist.',
    ligand_long: '', ligand_short: '', pubmed: '9554879', seq: '136', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'Thus, the His132, Tyr136, and Thr222
        residues located in TM3 and TM5 appear to have a modulatory role in recognition
        of this antagonist.', ligand_long: '', ligand_short: '', pubmed: '9554879',
    seq: '132', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'Thus, the His132, Tyr136, and Thr222
        residues located in TM3 and TM5 appear to have a modulatory role in recognition
        of this antagonist.', ligand_long: '', ligand_short: '', pubmed: '9554879',
    seq: '132', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].The
        differential effects on antagonist affinity and antagonist potency in F131A,
        H277A, and R310K mutant receptors do not appear to be due to reduced intrinsic
        activity in these receptors, since maximal efficacy noted for three different
        agonists in these mutants receptors reached levels similar to that of wild-type
        receptors.In particular, Phe226 in TM5 is more important for the antagonist
        MRS 2179 than for agonists, and residues Phe 131, Thr 221, and His277 are
        less important for the antagonist than for agonists.', ligand_long: '', ligand_short: '',
    pubmed: '9554879', seq: '131', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'Thus, the residues Phe131, Thr221,
        His277, and Ser317 are not essential for recognition of MRS2179, [...].The
        differential effects on antagonist affinity and antagonist potency in F131A,
        H277A, and R310K mutant receptors do not appear to be due to reduced intrinsic
        activity in these receptors, since maximal efficacy noted for three different
        agonists in these mutants receptors reached levels similar to that of wild-type
        receptors.In particular, Phe226 in TM5 is more important for the antagonist
        MRS 2179 than for agonists, and residues Phe 131, Thr 221, and His277 are
        less important for the antagonist than for agonists.', ligand_long: '', ligand_short: '',
    pubmed: '9554879', seq: '131', to_res: A}
- {entry_name: drd2_human, from_res: Y, info: 'F189Y and Y408V had approximately 5-fold
        higher affinities for clozapine than did the D2 receptor.Our docking results
        suggested two major factors in the D4 selectivity of CPPMA: the gain of an
        interaction of the chlorophenyl substituent with Phe91 and the loss of steric
        clash of the ligand with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: clozapine, pubmed: '10570038', seq: '408', to_res: V}
- {entry_name: drd2_human, from_res: Y, info: 'F189Y and Y408V had approximately 5-fold
        higher affinities for clozapine than did the D2 receptor.Our docking results
        suggested two major factors in the D4 selectivity of CPPMA: the gain of an
        interaction of the chlorophenyl substituent with Phe91 and the loss of steric
        clash of the ligand with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: CPPMA, pubmed: '10570038', seq: '408', to_res: V}
- {entry_name: drd2_human, from_res: Y, info: 'F189Y and Y408V had approximately 5-fold
        higher affinities for clozapine than did the D2 receptor.Our docking results
        suggested two major factors in the D4 selectivity of CPPMA: the gain of an
        interaction of the chlorophenyl substituent with Phe91 and the loss of steric
        clash of the ligand with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10570038', seq: '408', to_res: V}
- {entry_name: drd2_human, from_res: F, info: F189Y and Y408V had approximately 5-fold
        higher affinities for clozapine than did the D2 receptor., ligand_long: '[3H]N-methylspiperone',
    ligand_short: clozapine, pubmed: '10570038', seq: '189', to_res: Y}
- {entry_name: drd2_human, from_res: F, info: F189Y and Y408V had approximately 5-fold
        higher affinities for clozapine than did the D2 receptor., ligand_long: '[3H]N-methylspiperone',
    ligand_short: CPPMA, pubmed: '10570038', seq: '189', to_res: Y}
- {entry_name: drd2_human, from_res: F, info: F189Y and Y408V had approximately 5-fold
        higher affinities for clozapine than did the D2 receptor., ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10570038', seq: '189', to_res: Y}
- {entry_name: ednra_human, from_res: D, info: 'In all cases, naphthalene sulfonamide
        binding was more severely affected by mutation of Asp133 than by mutation
        of Asp126.', ligand_long: '', ligand_short: BMS-182874, pubmed: '8611558',
    seq: '126', to_res: A}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: bosentan, pubmed: '8611558', seq: '129',
    to_res: A}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: SB 209670, pubmed: '8611558', seq: '129',
    to_res: A}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BMS-182874, pubmed: '8611558', seq: '129',
    to_res: A}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BQ-123, pubmed: '8611558', seq: '129',
    to_res: A}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-3, pubmed: '8611558', seq: '129',
    to_res: A}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-1, pubmed: '8611558', seq: '129',
    to_res: A}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: bosentan, pubmed: '8611558', seq: '129',
    to_res: S}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: SB 209670, pubmed: '8611558', seq: '129',
    to_res: S}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BMS-182874, pubmed: '8611558', seq: '129',
    to_res: S}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BQ-123, pubmed: '8611558', seq: '129',
    to_res: S}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-3, pubmed: '8611558', seq: '129',
    to_res: S}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-1, pubmed: '8611558', seq: '129',
    to_res: S}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: bosentan, pubmed: '8611558', seq: '129',
    to_res: T}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: SB 209670, pubmed: '8611558', seq: '129',
    to_res: T}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BMS-182874, pubmed: '8611558', seq: '129',
    to_res: T}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BQ-123, pubmed: '8611558', seq: '129',
    to_res: T}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-3, pubmed: '8611558', seq: '129',
    to_res: T}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-1, pubmed: '8611558', seq: '129',
    to_res: T}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: bosentan, pubmed: '8611558', seq: '129',
    to_res: I}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: SB 209670, pubmed: '8611558', seq: '129',
    to_res: I}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BMS-182874, pubmed: '8611558', seq: '129',
    to_res: I}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BQ-123, pubmed: '8611558', seq: '129',
    to_res: I}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-3, pubmed: '8611558', seq: '129',
    to_res: I}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-1, pubmed: '8611558', seq: '129',
    to_res: I}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: bosentan, pubmed: '8611558', seq: '129',
    to_res: K}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: SB 209670, pubmed: '8611558', seq: '129',
    to_res: K}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BMS-182874, pubmed: '8611558', seq: '129',
    to_res: K}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: BQ-123, pubmed: '8611558', seq: '129',
    to_res: K}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-3, pubmed: '8611558', seq: '129',
    to_res: K}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.', ligand_long: '', ligand_short: ET-1, pubmed: '8611558', seq: '129',
    to_res: K}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.High affinity BQ-123 binding was maintained by replacement of the native
        Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670 were not
        greatly altered from wild-type when Tyr129 was replaced with Phe or Trp.The
        data show that the Phe and Trp were the preferred substitutes for Tyr for
        the four peptide or nonpeptide antagonists examined.', ligand_long: '', ligand_short: bosentan,
    pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.High affinity BQ-123 binding was maintained by replacement of the native
        Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670 were not
        greatly altered from wild-type when Tyr129 was replaced with Phe or Trp.The
        data show that the Phe and Trp were the preferred substitutes for Tyr for
        the four peptide or nonpeptide antagonists examined.', ligand_long: '', ligand_short: SB
        209670, pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.High affinity BQ-123 binding was maintained by replacement of the native
        Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670 were not
        greatly altered from wild-type when Tyr129 was replaced with Phe or Trp.The
        data show that the Phe and Trp were the preferred substitutes for Tyr for
        the four peptide or nonpeptide antagonists examined.', ligand_long: '', ligand_short: BMS-182874,
    pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.High affinity BQ-123 binding was maintained by replacement of the native
        Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670 were not
        greatly altered from wild-type when Tyr129 was replaced with Phe or Trp.The
        data show that the Phe and Trp were the preferred substitutes for Tyr for
        the four peptide or nonpeptide antagonists examined.', ligand_long: '', ligand_short: BQ-123,
    pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.High affinity BQ-123 binding was maintained by replacement of the native
        Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670 were not
        greatly altered from wild-type when Tyr129 was replaced with Phe or Trp.The
        data show that the Phe and Trp were the preferred substitutes for Tyr for
        the four peptide or nonpeptide antagonists examined.', ligand_long: '', ligand_short: ET-3,
    pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased.Specific replacement
        of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in a panel of Eta
        mutants that differed in bulk, charge, and hydrophobicity from the wild type
        Eta.High affinity BQ-123 binding was maintained by replacement of the native
        Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670 were not
        greatly altered from wild-type when Tyr129 was replaced with Phe or Trp.The
        data show that the Phe and Trp were the preferred substitutes for Tyr for
        the four peptide or nonpeptide antagonists examined.', ligand_long: '', ligand_short: ET-1,
    pubmed: '8611558', seq: '129', to_res: W}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased. Specific
        replacement of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in
        a panel of Eta mutants that differed in bulk, charge, and hydrophobicity from
        the wild type Eta.High affinity BQ-123 binding was maintained by replacement
        of the native Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670
        were not greatly altered from wild-type when Tyr129 was replaced with Phe
        or Trp.The data show that the Phe and Trp were the preferred substitutes for
        Tyr for the four peptide or nonpeptide antagonists examined.', ligand_long: '',
    ligand_short: Bosentan, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased. Specific
        replacement of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in
        a panel of Eta mutants that differed in bulk, charge, and hydrophobicity from
        the wild type Eta.High affinity BQ-123 binding was maintained by replacement
        of the native Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670
        were not greatly altered from wild-type when Tyr129 was replaced with Phe
        or Trp.The data show that the Phe and Trp were the preferred substitutes for
        Tyr for the four peptide or nonpeptide antagonists examined.', ligand_long: '',
    ligand_short: SB 209670, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased. Specific
        replacement of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in
        a panel of Eta mutants that differed in bulk, charge, and hydrophobicity from
        the wild type Eta.High affinity BQ-123 binding was maintained by replacement
        of the native Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670
        were not greatly altered from wild-type when Tyr129 was replaced with Phe
        or Trp.The data show that the Phe and Trp were the preferred substitutes for
        Tyr for the four peptide or nonpeptide antagonists examined.', ligand_long: '',
    ligand_short: BMS-182874, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased. Specific
        replacement of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in
        a panel of Eta mutants that differed in bulk, charge, and hydrophobicity from
        the wild type Eta.High affinity BQ-123 binding was maintained by replacement
        of the native Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670
        were not greatly altered from wild-type when Tyr129 was replaced with Phe
        or Trp.The data show that the Phe and Trp were the preferred substitutes for
        Tyr for the four peptide or nonpeptide antagonists examined.', ligand_long: '',
    ligand_short: BQ-123, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased. Specific
        replacement of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in
        a panel of Eta mutants that differed in bulk, charge, and hydrophobicity from
        the wild type Eta.High affinity BQ-123 binding was maintained by replacement
        of the native Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670
        were not greatly altered from wild-type when Tyr129 was replaced with Phe
        or Trp.The data show that the Phe and Trp were the preferred substitutes for
        Tyr for the four peptide or nonpeptide antagonists examined.', ligand_long: '',
    ligand_short: ET-3, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: ednra_human, from_res: Y, info: 'Transfected COS-7 cells expressing
        each Tyr129 variant was 75-90%.Competitiion binding analysis demonstrated
        that the IC50 values for ET1 to Tyr129 Eta variants were similar to wild-type
        affinity with the exception of the Tyr129Ile and Tyr129Thr mutants. In these
        cases, the affinity for ET-1 was 8-10fold decreased. Binding affinity of ET-3
        for all of the Tyr129 ETa mutants was improved >10fold with the exception
        of ET-3 binding to Tyr129Trp which showed a 7-fold improvement.The affinity
        of BMS-182874 for all the Tyr129 receptor mutants was decreased. Specific
        replacement of Tyr129 by Trp, Phe, Lys, Ile, Thr, Ser, or Ala resulted in
        a panel of Eta mutants that differed in bulk, charge, and hydrophobicity from
        the wild type Eta.High affinity BQ-123 binding was maintained by replacement
        of the native Tyr with Phe or Trp.Binding affinities of bosentan and SB 209670
        were not greatly altered from wild-type when Tyr129 was replaced with Phe
        or Trp.The data show that the Phe and Trp were the preferred substitutes for
        Tyr for the four peptide or nonpeptide antagonists examined.', ligand_long: '',
    ligand_short: ET-1, pubmed: '8611558', seq: '129', to_res: F}
- {entry_name: npy1r_human, from_res: Y, info: 'Binding sites per cell could not be
        determined for mutants, which bound neither NPY nor BIBP 3226. However, to
        ensure correct expression, those cells were investigated with fluorescent
        labeled anti-FLAG antibodies. All mutants were correctly expressed at the
        cell surface according to FLAG epitope binding studies.Comment: positive FLAG
        test.Comment: Based on a recent L-alanine scan of the 36 amino acid peptide
        NPY and a site-directed mutagenesis experiment on the extracellular loops,
        a three-dimensional model was made, showing  a hydrophobic pocket by the residues
        Y100, F286, and H298. The carboxyl-terminal tyrosine amide moiety of NPS binds
        here.', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135', seq: '100',
    to_res: A}
- {entry_name: trfr_mouse, from_res: R, info: 'Mutation of Arg-306 to alanine increased
        the EC50 of the mutant TRH-R by a factor of 1500, compared with the WT TRH-R.compared
        with WT TRH-R, the EC50 values for TRH stimulation of IP formation in COS-1
        cells expressing R306L and R306E TRH-R''s were 1200- and 3000-fold higher,
        respectively, whereas that in cells expressing R306K TRH-Rs was only 10-fold
        higher.Arg-306 is not important for receptor activation.At position 306, substitution
        for arginine by all amino acids tested led to mutant TRH-Rs that were capable
        of stimulating IP formation to the same maximal level as WT TRH-Rs.Arg-283
        is involved in activation and binding, whereas Arg-306 is necessary for binding
        but not activation.', ligand_long: '', ligand_short: '', pubmed: '7700246',
    seq: '306', to_res: L}
- {entry_name: trfr_mouse, from_res: R, info: 'Mutation of Arg-306 to alanine increased
        the EC50 of the mutant TRH-R by a factor of 1500, compared with the WT TRH-R.compared
        with WT TRH-R, the EC50 values for TRH stimulation of IP formation in COS-1
        cells expressing R306L and R306E TRH-R''s were 1200- and 3000-fold higher,
        respectively, whereas that in cells expressing R306K TRH-Rs was only 10-fold
        higher.Arg-306 is not important for receptor activation.At position 306, substitution
        for arginine by all amino acids tested led to mutant TRH-Rs that were capable
        of stimulating IP formation to the same maximal level as WT TRH-Rs.Arg-283
        is involved in activation and binding, whereas Arg-306 is necessary for binding
        but not activation.', ligand_long: '', ligand_short: '', pubmed: '7700246',
    seq: '306', to_res: E}
- {entry_name: trfr_mouse, from_res: R, info: 'Mutation of Arg-306 to alanine increased
        the EC50 of the mutant TRH-R by a factor of 1500, compared with the WT TRH-R.compared
        with WT TRH-R, the EC50 values for TRH stimulation of IP formation in COS-1
        cells expressing R306L and R306E TRH-R''s were 1200- and 3000-fold higher,
        respectively, whereas that in cells expressing R306K TRH-Rs was only 10-fold
        higher.Arg-306 is not important for receptor activation.At position 306, substitution
        for arginine by all amino acids tested led to mutant TRH-Rs that were capable
        of stimulating IP formation to the same maximal level as WT TRH-Rs.Arg-283
        is involved in activation and binding, whereas Arg-306 is necessary for binding
        but not activation.', ligand_long: '', ligand_short: '', pubmed: '7700246',
    seq: '306', to_res: A}
- {entry_name: trfr_mouse, from_res: R, info: 'Mutation of Arg-306 to alanine increased
        the EC50 of the mutant TRH-R by a factor of 1500, compared with the WT TRH-R.compared
        with WT TRH-R, the EC50 values for TRH stimulation of IP formation in COS-1
        cells expressing R306L and R306E TRH-R''s were 1200- and 3000-fold higher,
        respectively, whereas that in cells expressing R306K TRH-Rs was only 10-fold
        higher.Arg-306 is not important for receptor activation.At position 306, substitution
        for arginine by all amino acids tested led to mutant TRH-Rs that were capable
        of stimulating IP formation to the same maximal level as WT TRH-Rs.Arg-283
        is involved in activation and binding, whereas Arg-306 is necessary for binding
        but not activation.', ligand_long: '[3H]MeTRH', ligand_short: '', pubmed: '7700246',
    seq: '306', to_res: K}
- {entry_name: ghsr_human, from_res: M, info: 'Finally, for some mutants a significant
        reduction in specific binding affinity is not paralleled by an equal decrease
        in functional activity (e.g. pFLAG-E124D; pFLAG-M213K).', ligand_long: '',
    ligand_short: '', pubmed: '9440817', seq: '213', to_res: K}
- {entry_name: ghsr_human, from_res: E, info: 'However, functional rescue of the E124Q
        mutant was achieved by L-168740, with an EC50 of 1.3 microM.Shown for comparison
        from the same experiment are dose-response curves for the activation of wild-type
        and E124Q mutant receptor by MK-0677, which produced a more than 200-fold
        decrease in potency against the E124Q mutant (EC50:wild-type, 13.6 nM; E124Q,
        3200 nM).The conservative change, E124>D, is not disruptive, [...].Finally,
        for some mutants a significant reduction in specific binding affinity is not
        paralleled by an equal decrease in functional activity (e.g. pFLAG-E124D;
        pFLAG-M213K).', ligand_long: '', ligand_short: '', pubmed: '9440817', seq: '124',
    to_res: Q}
- {entry_name: ghsr_human, from_res: E, info: 'However, functional rescue of the E124Q
        mutant was achieved by L-168740, with an EC50 of 1.3 microM.Shown for comparison
        from the same experiment are dose-response curves for the activation of wild-type
        and E124Q mutant receptor by MK-0677, which produced a more than 200-fold
        decrease in potency against the E124Q mutant (EC50:wild-type, 13.6 nM; E124Q,
        3200 nM).The conservative change, E124>D, is not disruptive, [...].Finally,
        for some mutants a significant reduction in specific binding affinity is not
        paralleled by an equal decrease in functional activity (e.g. pFLAG-E124D;
        pFLAG-M213K).', ligand_long: '', ligand_short: '', pubmed: '9440817', seq: '124',
    to_res: D}
- {entry_name: c5ar_human, from_res: G, info: '[...], three (Trp230 --> Phe, Gly306
        --> Ala, Ser314,317 --> Ala) have no effect on maximal binding of C5a relative
        to wild-type receptor, [...].', ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117',
    seq: '306', to_res: A}
- {entry_name: c5ar_human, from_res: W, info: '[...], three (Trp230 --> Phe, Gly306
        --> Ala, Ser314,317 --> Ala) have no effect on maximal binding of C5a relative
        to wild-type receptor, [...].', ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117',
    seq: '230', to_res: F}
- {entry_name: c5ar_human, from_res: L, info: Additional mutations (Leu277 --> Pro
        and Pro270 --> Leu) were made in the extracellular loop connecting TMS6-7.
        Both of these mutants are expressed on the cell surface., ligand_long: '',
    ligand_short: '', pubmed: '7629117', seq: '277', to_res: P}
- {entry_name: c5ar_human, from_res: P, info: Additional mutations (Leu277 --> Pro
        and Pro270 --> Leu) were made in the extracellular loop connecting TMS6-7.
        Both of these mutants are expressed on the cell surface., ligand_long: 125I-C5a,
    ligand_short: '', pubmed: '7629117', seq: '270', to_res: L}
- {entry_name: c5ar_human, from_res: P, info: 'Three fail to express well at the cell
        surface (Pro90 --> Ala, Pro257 --> Ala, and Pro297 --> Ala, [...].', ligand_long: 125I-C5a,
    ligand_short: '', pubmed: '7629117', seq: '297', to_res: A}
- {entry_name: c5ar_human, from_res: P, info: 'Three fail to express well at the cell
        surface (Pro90 --> Ala, Pro257 --> Ala, and Pro297 --> Ala, [...].', ligand_long: 125I-C5a,
    ligand_short: '', pubmed: '7629117', seq: '257', to_res: A}
- {entry_name: c5ar_human, from_res: P, info: 'With the exception of pro113 --> Ala,
        all other mutations were only partially effective (Pro37 --> Ala, Pro170 -->
        Ala, and Pro214 --> Ala) for generating intracellular signals.[...], But Pro214
        --> Ala provides 76% of the wild-type binding and is diminished in its activation
        of PLC.', ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117', seq: '214',
    to_res: A}
- {entry_name: c5ar_human, from_res: P, info: 'only one of the binding-impaired mutants
        expressed robustly (Pro170 --> Ala);With the exception of pro113 --> Ala,
        all other mutations were only partially effective (Pro37 --> Ala, Pro170 -->
        Ala, and Pro214 --> Ala) for generating intracellular signals.Pro170 --> Ala
        is expressed on the cell surface and binds ligand weakly, [...].', ligand_long: 125IC5a,
    ligand_short: '', pubmed: '7629117', seq: '170', to_res: A}
- {entry_name: c5ar_human, from_res: P, info: 'With the exception of pro113 --> Ala,
        all other mutations were only partially effective (Pro37 --> Ala, Pro170 -->
        Ala, and Pro214 --> Ala) for generating intracellular signals.', ligand_long: 125I-C5a,
    ligand_short: '', pubmed: '7629117', seq: '113', to_res: A}
- {entry_name: c5ar_human, from_res: P, info: 'Three fail to express well at the cell
        surface (Pro90 --> Ala, Pro257 --> Ala, and Pro297 --> Ala, [...].[...], and
        the expression of Pro90 --> Ala appears to cause dramatic changes in the morphology
        of COS cells.', ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117',
    seq: '90', to_res: A}
- {entry_name: c5ar_human, from_res: P, info: '[...], three mutants (Pro37 --> Ala,
        Pro113 --> Ala, and Pro214 --> Ala) bind ligand at 0.1 nM 125I-C5a comparable
        to wild-type receptor, despite the observation that the Bmax determinde from
        Scatchard analysis for each of these mutants is substantially less than wild-type.',
    ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117', seq: '36', to_res: N}
- {entry_name: c5ar_human, from_res: C, info: 'The Bmax, for each of these mutants
        is close to that of wild-type, except for Cys285 --> Ser, which shows 4-fold
        greater number of sites.Two (Cys86 --> Ser and Cys285 --> Ser) have diminished
        ability to stimulate PLC.', ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117',
    seq: '285', to_res: S}
- {entry_name: c5ar_human, from_res: C, info: 'Fig. 2 shows typical results with wild-type
        receptor and the Cys221 --> Ser where both are expressed at high levels on
        the cell membrane of unpermeabilized cells. These results indicate that Cys221
        is required only for the binding of C5a.Cys221 --> Ser mutant does not bind
        or signal and is expressed well at the surface of COS cells.[...], we have
        identified amino acids that are involved in the activity of the message site.
        These amino acids located in the transmembrane segments are Asp82, Asn119,
        Cys157, and Cys221.', ligand_long: '', ligand_short: '', pubmed: '7629117',
    seq: '221', to_res: S}
- {entry_name: c5ar_human, from_res: C, info: 'The Cys157 --> Ser mutant binds C5a
        almost as well as the wild-type receptor, but when co-transfected with G-alpha16,
        fails to activate PLC.[...], we have identified amino acids that are involved
        in the activity of the message site. These amino acids located in the transmembrane
        segments are Asp82, Asn119, Cys157, and Cys221.', ligand_long: 125I-C5a, ligand_short: '',
    pubmed: '7629117', seq: '157', to_res: S}
- {entry_name: c5ar_human, from_res: D, info: Conservative mutations at these sites
        demonstrate that Asp132 is essential for the proper expression and trafficking
        of the C5a receptor., ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117',
    seq: '133', to_res: N}
- {entry_name: c5ar_human, from_res: N, info: 'The Asp82 --> Asn mutant is completely
        defective at stimulating PLC activity, while the Asn119 --> Gln mutant is
        only 35% as efefctive as wild-type.Asp82 and Asn119 bind ligand nearly as
        well as wild-type, but both are defective at stimulation of PLC via G-alpha16.[...],
        we have identified amino acids that are involved in the activity of the message
        site. These amino acids located in the transmembrane segments are Asp82, Asn119,
        Cys157, and Cys221.', ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117',
    seq: '119', to_res: Q}
- {entry_name: c5ar_human, from_res: C, info: Two (Cys86 --> Ser and Cys285 --> Ser)
        have diminished ability to stimulate PLC., ligand_long: 125I-C5a, ligand_short: '',
    pubmed: '7629117', seq: '86', to_res: S}
- {entry_name: c5ar_human, from_res: D, info: 'The Asp82 --> Asn mutant is completely
        defective at stimulating PLC activity, while the Asn119 --> Gln mutant is
        only 35% as efefctive as wild-type.Asp82 and Asn119 bind ligand nearly as
        well as wild-type, but both are defective at stimulation of PLC via G-alpha16.[...],
        we have identified amino acids that are involved in the activity of the message
        site. These amino acids located in the transmembrane segments are Asp82, Asn119,
        Cys157, and Cys221.', ligand_long: 125I-C5a, ligand_short: '', pubmed: '7629117',
    seq: '82', to_res: N}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: natrindole, pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: deltrophin II, pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: deltrophin II, pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: DPDPE, pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: SNC-80, pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: '', pubmed: '8702536', seq: '297', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: Naltrindole, pubmed: '8702536', seq: '296', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: deltrophin II, pubmed: '8702536', seq: '296', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: DPDPE, pubmed: '8702536', seq: '296', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: SNC-80, pubmed: '8702536', seq: '296', to_res: A}
- {entry_name: oprd_human, from_res: R, info: 'In contrast, in our study, mutation
        of these two arginines did not affect the binding of delta-selective ligands
        with the exception of Arg-291 which seems important for the binding of deltorphin
        II.', ligand_long: '[3H]bremazocine', ligand_short: naltrindole, pubmed: '8702536',
    seq: '291', to_res: A}
- {entry_name: oprd_human, from_res: R, info: 'In contrast, in our study, mutation
        of these two arginines did not affect the binding of delta-selective ligands
        with the exception of Arg-291 which seems important for the binding of deltorphin
        II.', ligand_long: '[3H]bremazocine', ligand_short: deltrophin II, pubmed: '8702536',
    seq: '291', to_res: A}
- {entry_name: oprd_human, from_res: R, info: 'In contrast, in our study, mutation
        of these two arginines did not affect the binding of delta-selective ligands
        with the exception of Arg-291 which seems important for the binding of deltorphin
        II.', ligand_long: '[3H]bremazocine', ligand_short: DPDPE, pubmed: '8702536',
    seq: '291', to_res: A}
- {entry_name: oprd_human, from_res: R, info: 'In contrast, in our study, mutation
        of these two arginines did not affect the binding of delta-selective ligands
        with the exception of Arg-291 which seems important for the binding of deltorphin
        II.', ligand_long: '[3H]bremazocine', ligand_short: SNC-80, pubmed: '8702536',
    seq: '291', to_res: A}
- {entry_name: oprd_human, from_res: R, info: 'In contrast, in our study, mutation
        of these two arginines did not affect the binding of delta-selective ligands
        with the exception of Arg-291 which seems important for the binding of deltorphin
        II.', ligand_long: '[3H]bremazocine', ligand_short: '', pubmed: '8702536',
    seq: '291', to_res: A}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: naltriindole, pubmed: '8702536', seq: '284', to_res: K}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: deltrophin II, pubmed: '8702536', seq: '284', to_res: K}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: DPDPE, pubmed: '8702536', seq: '284', to_res: K}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: SNC-80, pubmed: '8702536', seq: '284', to_res: K}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: '', pubmed: '8702536', seq: '284', to_res: K}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: naltrindole, pubmed: '8702536', seq: '284', to_res: A}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: deltrophin II, pubmed: '8702536', seq: '284', to_res: A}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: DPDPE, pubmed: '8702536', seq: '284', to_res: A}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: SNC-80, pubmed: '8702536', seq: '284', to_res: A}
- {entry_name: oprd_human, from_res: W, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.However,
        the mutantion of Trp-284 for a lysine produced an effect of over 10-fold on
        the binding of DPDPE, deltorphin II, and naltrindole but led to a particularly
        pronounced effect on SNC-80 binding (373-fold).', ligand_long: '[3H]bremazocine',
    ligand_short: '', pubmed: '8702536', seq: '284', to_res: A}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-159588, pubmed: '7536886', seq: '287',
    to_res: H}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L161644, pubmed: '7536886', seq: '287',
    to_res: H}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-159588, pubmed: '7536886', seq: '287',
    to_res: F}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-161644, pubmed: '7536886', seq: '287',
    to_res: F}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-159588, pubmed: '7536886', seq: '287',
    to_res: W}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-161664, pubmed: '7536886', seq: '287',
    to_res: W}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-159588, pubmed: '7536886', seq: '287',
    to_res: S}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125]L-703606', ligand_short: l161664, pubmed: '7536886', seq: '287',
    to_res: S}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-159588, pubmed: '7536886', seq: '287',
    to_res: Q}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: L-703606, ligand_short: L-161664, pubmed: '7536886', seq: '287',
    to_res: Q}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-159588, pubmed: '7536886', seq: '287',
    to_res: A}
- {entry_name: nk1r_human, from_res: Y, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], and the Y287A mutant has low affinity
        for 125I-SP but normal affinity for the quinuclidine amine antagonist [125I]L-703606.Because
        the mutant in which Tyr-287 is substituted with alanine has poor affinity
        for 125I-SP, experiments using this mutant were conducted using the iodinated
        quinuclidine amine antagonist [125I]L-703606. This ligand has the same affinity
        for the Y287A mutant receptor as for the wild-type receptor. Histidine can
        substitute for Tyr-287 in the interaction of L-161664 with the receptor, but
        phenylalanine, glutamine, serine and tryptophan are poor substitutes.In contrast,
        L-159588 has 5-fold, 15-fold, and 29-fold lower affinity for the H197A, H265A,
        and Y287A mutants, respectively, than for the wild-type receptor [...].The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: '[125I]L-703606', ligand_short: L-161664, pubmed: '7536886', seq: '287',
    to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125I-SP, ligand_short: L-159588, pubmed: '7536886', seq: '265', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125I-SP, ligand_short: L-161664, pubmed: '7536886', seq: '265', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125I-SP, ligand_short: L-159588, pubmed: '7536886', seq: '265', to_res: Y}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125I-SP, ligand_short: L-161664, pubmed: '7536886', seq: '265', to_res: Y}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125ISP, ligand_short: L-159588, pubmed: '7536886', seq: '265', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125I-SP, ligand_short: L-161664, pubmed: '7536886', seq: '265', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125I-SP, ligand_short: L-161664, pubmed: '7536886', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].In contrast, substitution
        of His-265 with glutamine, tyrosine, or phenylalanine results in a 5-6-fold
        reduced affinity of L-161664, compared with its affinityfor the wild-type
        receptor, [...].In contrast, L-159588 has 5-fold, 15-fold, and 29-fold lower
        affinity for the H197A, H265A, and Y287A mutants, respectively, than for the
        wild-type receptor [...].In contrast to the interaction of L-161664 with His-265,
        tyrosine can also substitute for His-265 in maintaining affinity for L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy for L-159588.',
    ligand_long: 125I-SP, ligand_short: L-161664, pubmed: '7536886', seq: '265', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-159588, pubmed: '7536886', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-161664, pubmed: '7536886', seq: '197', to_res: Q}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-159588, pubmed: '7536886', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-161664, pubmed: '7536886', seq: '197', to_res: F}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-159588, pubmed: '7536886', seq: '197', to_res: S}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-161664, pubmed: '7536886', seq: '197', to_res: S}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-159588, pubmed: '7536886', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: H, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.As described previously, the H197A and H265A
        mutant receptors have normal affinity for 125I-SP, [..].Glutamine and phenylalanine,
        but not serine, can substitute for His-197 in maintaining the high affinity
        of the receptor for L-161664.In contrast, L-159588 has 5-fold, 15-fold, and
        29-fold lower affinity for the H197A, H265A, and Y287A mutants, respectively,
        than for the wild-type receptorAs is the case with L-161664, glutamine and
        phenylamine can substitute for His-197 in the interaction with L-159588.The
        acyclic aminoethyl ether L-732106 inhibits binding to the human NK-1 receptor
        with an IC50 of 5.5+-3.7 nM (five experiments). This compound has 20-fold,
        60-fold, and 80-fold reduced affinity for the Q165A, H197A, and H265A mutants,
        respectively, and has normal affinity for the Y287A mutant.In contrast, substitution
        of His-197, His-265, or Tyr-287 with alanine results in a further loss of
        0.9, 1.6 or 2.0 kcal/mol, respectively, of binding energy', ligand_long: 125I-SP,
    ligand_short: L-161664, pubmed: '7536886', seq: '197', to_res: A}
- {entry_name: nk1r_human, from_res: Q, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], the Q165A mutant has 7-fold reduced affinity
        for 125I-SP but normal affinity for the tryptophan benzyl ester antagonist
        L-732138, [...].L-159588 has similar affinity for the Q165A mutant and for
        the wild-type receptor.The acyclic aminoethyl ether L-732106 inhibits binding
        to the human NK-1 receptor with an IC50 of 5.5+-3.7 nM (five experiments).
        This compound has 20-fold, 60-fold, and 80-fold reduced affinity for the Q165A,
        H197A, and H265A mutants, respectively, and has normal affinity for the Y287A
        mutant.Replacement of Gln-165 with alanine, thereby removing the amide side
        chain from this position in the receptor, results in a 1.3 kcal/mol loss in
        binding energy for L-161-664.', ligand_long: 125I-SP, ligand_short: L-159588,
    pubmed: '7536886', seq: '165', to_res: A}
- {entry_name: nk1r_human, from_res: Q, info: 'L-161664 has 10-fold, 6-fold, 30-fold,
        and 78-fold reduced affinity for the Q165A, H197A, H265A, and Y287A mutant
        NK-1 receptors, respectively.[...], the Q165A mutant has 7-fold reduced affinity
        for 125I-SP but normal affinity for the tryptophan benzyl ester antagonist
        L-732138, [...].L-159588 has similar affinity for the Q165A mutant and for
        the wild-type receptor.The acyclic aminoethyl ether L-732106 inhibits binding
        to the human NK-1 receptor with an IC50 of 5.5+-3.7 nM (five experiments).
        This compound has 20-fold, 60-fold, and 80-fold reduced affinity for the Q165A,
        H197A, and H265A mutants, respectively, and has normal affinity for the Y287A
        mutant.Replacement of Gln-165 with alanine, thereby removing the amide side
        chain from this position in the receptor, results in a 1.3 kcal/mol loss in
        binding energy for L-161-664.', ligand_long: '[125I-SP', ligand_short: L-161664,
    pubmed: '7536886', seq: '165', to_res: A}
- {entry_name: tshr_human, from_res: V, info: 'The mutation at codon 656 (Val656Phe)
        showed a 4- to 5-fold increase in basal cAMP (10.6+-2.0 pmol/well) compared
        to the wild-type TSHR (2.3+-0.17 pmol/well) and a similar response to maximal
        TSH stimulation (31.9+-3.1 and 29.0+-5.8 pmol/well for the mutant receptor
        and the wild-type receptor, respectively).Binding experiments showed similar
        binding capacities (Bmax) for the wild-type and Val656Phe mutant receptors
        (0.43+-0.09 and 0.54+-0.07, respectively), [...].The Kd values (2.57+-0.5
        and 2.02+-0.25 for the wild-type and Val656Phe mutant receptors, respectively)
        showed similar affinity for bovine TSH.As the Val656Phe mutation displayed
        a 4- to 5-fold increase in basal cAMP levels, it is a mutation with a relative
        high constitutive activity.', ligand_long: '', ligand_short: '', pubmed: '9360556',
    seq: '656', to_res: F}
- {entry_name: drd2_human, from_res: F, info: 'Our docking results suggested two major
        factors in the D4 selectivity of CPPMA: the gain of an interaction of the
        chlorophenyl substituent with Phe91 and the loss of steric clash of the ligand
        with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone', ligand_short: clozapine,
    pubmed: '10570038', seq: '110', to_res: L}
- {entry_name: drd2_human, from_res: F, info: 'Our docking results suggested two major
        factors in the D4 selectivity of CPPMA: the gain of an interaction of the
        chlorophenyl substituent with Phe91 and the loss of steric clash of the ligand
        with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone', ligand_short: CPPMA,
    pubmed: '10570038', seq: '110', to_res: L}
- {entry_name: drd2_human, from_res: F, info: 'Our docking results suggested two major
        factors in the D4 selectivity of CPPMA: the gain of an interaction of the
        chlorophenyl substituent with Phe91 and the loss of steric clash of the ligand
        with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone', ligand_short: '',
    pubmed: '10570038', seq: '110', to_res: L}
- {entry_name: drd2_human, from_res: V, info: 'V91F had a nearly 100-fold increase
        in affinity for CPPMA compared with that of the wild-type D2 receptor.V91F
        had a 49-fold higher affinity for clozapine. Thus, this single mutation enabled
        the D2 receptor to bind clozapine in a D4-like manner.The 100-fold gain in
        affinity for CPPMA seen with mutation Val91 to Phe was substantially less
        than the approximately 1200-fold higher affinity of the D4 receptor.Our docking
        results suggested two major factors in the D4 selectivity of CPPMA: the gain
        of an interaction of the chlorophenyl substituent with Phe91 and the loss
        of steric clash of the ligand with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: clozapine, pubmed: '10570038', seq: '91', to_res: F}
- {entry_name: drd2_human, from_res: V, info: 'V91F had a nearly 100-fold increase
        in affinity for CPPMA compared with that of the wild-type D2 receptor.V91F
        had a 49-fold higher affinity for clozapine. Thus, this single mutation enabled
        the D2 receptor to bind clozapine in a D4-like manner.The 100-fold gain in
        affinity for CPPMA seen with mutation Val91 to Phe was substantially less
        than the approximately 1200-fold higher affinity of the D4 receptor.Our docking
        results suggested two major factors in the D4 selectivity of CPPMA: the gain
        of an interaction of the chlorophenyl substituent with Phe91 and the loss
        of steric clash of the ligand with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: CPPMA, pubmed: '10570038', seq: '91', to_res: F}
- {entry_name: drd2_human, from_res: V, info: 'V91F had a nearly 100-fold increase
        in affinity for CPPMA compared with that of the wild-type D2 receptor.V91F
        had a 49-fold higher affinity for clozapine. Thus, this single mutation enabled
        the D2 receptor to bind clozapine in a D4-like manner.The 100-fold gain in
        affinity for CPPMA seen with mutation Val91 to Phe was substantially less
        than the approximately 1200-fold higher affinity of the D4 receptor.Our docking
        results suggested two major factors in the D4 selectivity of CPPMA: the gain
        of an interaction of the chlorophenyl substituent with Phe91 and the loss
        of steric clash of the ligand with Phe110 and Tyr408.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10570038', seq: '91', to_res: F}
- {entry_name: oar_drome, from_res: Y, info: 'The binding affinity of the Y583A derivative
        for tyramine (0.15+-0.02 microM) is substantially greater compared with the
        binding affinity of the wild-type receptor for tyramine (clone 1, 4.04+-0.455
        microM; clone 2, 5.17+-0.72 microM). The binding affinity of the Y583A derivative
        for DL-p-octopamine (13.02+-0.51 microM) is also substantially greater compared
        with the binding affinity of the wild-type receptor for DL-p-octopamine (clone
        1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).Further, the Y583A mutant
        receptor showed an increased binding affinity for both octopamine and tyrmaine
        whilst showein little change in potency but a dramatic reduction in efficacy
        for the inhibition of adenylyl cyclase activity.Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: DL-p-octopamine,
    pubmed: '12535676', seq: '583', to_res: A}
- {entry_name: oar_drome, from_res: Y, info: 'The binding affinity of the Y583A derivative
        for tyramine (0.15+-0.02 microM) is substantially greater compared with the
        binding affinity of the wild-type receptor for tyramine (clone 1, 4.04+-0.455
        microM; clone 2, 5.17+-0.72 microM). The binding affinity of the Y583A derivative
        for DL-p-octopamine (13.02+-0.51 microM) is also substantially greater compared
        with the binding affinity of the wild-type receptor for DL-p-octopamine (clone
        1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).Further, the Y583A mutant
        receptor showed an increased binding affinity for both octopamine and tyrmaine
        whilst showein little change in potency but a dramatic reduction in efficacy
        for the inhibition of adenylyl cyclase activity.Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: tyramine,
    pubmed: '12535676', seq: '583', to_res: A}
- {entry_name: oar_drome, from_res: Y, info: 'The binding affinity of the Y583A derivative
        for tyramine (0.15+-0.02 microM) is substantially greater compared with the
        binding affinity of the wild-type receptor for tyramine (clone 1, 4.04+-0.455
        microM; clone 2, 5.17+-0.72 microM). The binding affinity of the Y583A derivative
        for DL-p-octopamine (13.02+-0.51 microM) is also substantially greater compared
        with the binding affinity of the wild-type receptor for DL-p-octopamine (clone
        1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).Further, the Y583A mutant
        receptor showed an increased binding affinity for both octopamine and tyrmaine
        whilst showein little change in potency but a dramatic reduction in efficacy
        for the inhibition of adenylyl cyclase activity.Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: '',
    pubmed: '12535676', seq: '583', to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'The binding affinity of the S576A derivative
        for tyramine (6.90+-0.41 microM) is slightly reduced compared with the binding
        affinity of the wild-type receptor for tyramine (clone 1, 4.04+-0.455 microM;
        clone 2, 5.17+-0.72 microM). The binding affinity of the S1576A derivative
        for DL-p-octopamine (201.27+-35.07 microM) is also slightly reduced compared
        with the binding affinity of the wild-type receptor for DL-p-octopamine (clone
        1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).In the present study mutants
        S196A and S576A produced dramatic reductions in both the potency and the efficacy
        of the coupling of the recpetors to the inhibition of adenylyl cyclase activity
        compared to the wild type receptor, [...].Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: DL-p-octopamine,
    pubmed: '12535676', seq: '576', to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'The binding affinity of the S576A derivative
        for tyramine (6.90+-0.41 microM) is slightly reduced compared with the binding
        affinity of the wild-type receptor for tyramine (clone 1, 4.04+-0.455 microM;
        clone 2, 5.17+-0.72 microM). The binding affinity of the S1576A derivative
        for DL-p-octopamine (201.27+-35.07 microM) is also slightly reduced compared
        with the binding affinity of the wild-type receptor for DL-p-octopamine (clone
        1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).In the present study mutants
        S196A and S576A produced dramatic reductions in both the potency and the efficacy
        of the coupling of the recpetors to the inhibition of adenylyl cyclase activity
        compared to the wild type receptor, [...].Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: tyramine,
    pubmed: '12535676', seq: '576', to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'The binding affinity of the S576A derivative
        for tyramine (6.90+-0.41 microM) is slightly reduced compared with the binding
        affinity of the wild-type receptor for tyramine (clone 1, 4.04+-0.455 microM;
        clone 2, 5.17+-0.72 microM). The binding affinity of the S1576A derivative
        for DL-p-octopamine (201.27+-35.07 microM) is also slightly reduced compared
        with the binding affinity of the wild-type receptor for DL-p-octopamine (clone
        1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).In the present study mutants
        S196A and S576A produced dramatic reductions in both the potency and the efficacy
        of the coupling of the recpetors to the inhibition of adenylyl cyclase activity
        compared to the wild type receptor, [...].Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: '',
    pubmed: '12535676', seq: '576', to_res: A}
- {entry_name: oar_drome, from_res: A, info: 'No significant differences between the
        basal levels of cyclic AMP in the absence of forskolin stimulation were observed
        between the wild-type receptor and the A528K derivative (data not shown) again
        suggesting that the A528K substitution does not result in a constitutively
        active mutant.Comments: Wild-type OcR receptor clone 1 data was used to perform
        the percentage calculations, except for the DL-p-octopamine EC50 percentage
        of mutation Y583A where wild-type OcR receptor clone 2 was used. Data presented
        in the article for wild-type OcR clone 2 are: Bmax (pmol/mg^-1) 9.91+-0.38;
        Kd (nM) 12.00+-1.78; pEC50 tyramine (M) 1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72;
        pEC50 octopamine (M) 1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine',
    ligand_short: '', pubmed: '12535676', seq: '528', to_res: K}
- {entry_name: oar_drome, from_res: S, info: 'Comments: Wild-type OcR receptor clone
        1 data was used to perform the percentage calculations, except for the DL-p-octopamine
        EC50 percentage of mutation Y583A where wild-type OcR receptor clone 2 was
        used. Data presented in the article for wild-type OcR clone 2 are: Bmax (pmol/mg^-1)
        9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M) 1.00+-0.33*10^-8; Ki (microM)
        5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.',
    ligand_long: '[3H]yohimbine', ligand_short: '', pubmed: '12535676', seq: '242',
    to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'Comments: Wild-type OcR receptor clone
        1 data was used to perform the percentage calculations, except for the DL-p-octopamine
        EC50 percentage of mutation Y583A where wild-type OcR receptor clone 2 was
        used. Data presented in the article for wild-type OcR clone 2 are: Bmax (pmol/mg^-1)
        9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M) 1.00+-0.33*10^-8; Ki (microM)
        5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.',
    ligand_long: '[3H]yohimbine', ligand_short: '', pubmed: '12535676', seq: '241',
    to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'Comments: Wild-type OcR receptor clone
        1 data was used to perform the percentage calculations, except for the DL-p-octopamine
        EC50 percentage of mutation Y583A where wild-type OcR receptor clone 2 was
        used. Data presented in the article for wild-type OcR clone 2 are: Bmax (pmol/mg^-1)
        9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M) 1.00+-0.33*10^-8; Ki (microM)
        5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.',
    ligand_long: '[3H]yohimbine', ligand_short: '', pubmed: '12535676', seq: '237',
    to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'Although there are no significant differences
        in binding affinity for DL-p-octopamine between the wild-type receptor the
        wild-type receptor and the S196A derivate, the binding affinity of the S196A
        derivative for tyramine (7.96+-0.91 microM) is slightly reduced compared with
        the binding affinity of the wild-type receptor for tyramine (clone 2, 5.17+-0.72
        microM; clone 1, 4.04+-0.455 microM).In the present study mutants S196A and
        S576A produced dramatic reductions in both the potency and the efficacy of
        the coupling of the recpetors to the inhibition of adenylyl cyclase activity
        compared to the wild type receptor, [...].Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: DL-p-octopamine,
    pubmed: '12535676', seq: '196', to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'Although there are no significant differences
        in binding affinity for DL-p-octopamine between the wild-type receptor the
        wild-type receptor and the S196A derivate, the binding affinity of the S196A
        derivative for tyramine (7.96+-0.91 microM) is slightly reduced compared with
        the binding affinity of the wild-type receptor for tyramine (clone 2, 5.17+-0.72
        microM; clone 1, 4.04+-0.455 microM).In the present study mutants S196A and
        S576A produced dramatic reductions in both the potency and the efficacy of
        the coupling of the recpetors to the inhibition of adenylyl cyclase activity
        compared to the wild type receptor, [...].Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: tyramine,
    pubmed: '12535676', seq: '196', to_res: A}
- {entry_name: oar_drome, from_res: S, info: 'Although there are no significant differences
        in binding affinity for DL-p-octopamine between the wild-type receptor the
        wild-type receptor and the S196A derivate, the binding affinity of the S196A
        derivative for tyramine (7.96+-0.91 microM) is slightly reduced compared with
        the binding affinity of the wild-type receptor for tyramine (clone 2, 5.17+-0.72
        microM; clone 1, 4.04+-0.455 microM).In the present study mutants S196A and
        S576A produced dramatic reductions in both the potency and the efficacy of
        the coupling of the recpetors to the inhibition of adenylyl cyclase activity
        compared to the wild type receptor, [...].Comments: Wild-type OcR receptor
        clone 1 data was used to perform the percentage calculations, except for the
        DL-p-octopamine EC50 percentage of mutation Y583A where wild-type OcR receptor
        clone 2 was used. Data presented in the article for wild-type OcR clone 2
        are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M)
        1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6;
        Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine', ligand_short: '',
    pubmed: '12535676', seq: '196', to_res: A}
- {entry_name: oar_drome, from_res: T, info: 'Comments: Wild-type OcR receptor clone
        1 data was used to perform the percentage calculations, except for the DL-p-octopamine
        EC50 percentage of mutation Y583A where wild-type OcR receptor clone 2 was
        used. Data presented in the article for wild-type OcR clone 2 are: Bmax (pmol/mg^-1)
        9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50 tyramine (M) 1.00+-0.33*10^-8; Ki (microM)
        5.17+-0.72; pEC50 octopamine (M) 1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.',
    ligand_long: '[3H]yohimbine', ligand_short: '', pubmed: '12535676', seq: '194',
    to_res: A}
- {entry_name: oar_drome, from_res: N, info: 'Although there are no significant differences
        in binding affinity for tyramine between the wild-type abd the N166A derivate,
        the binding affinity of the N166A derivate for DL-p-octopamine (31.37+-5.98
        microM) is greater than the binding affinity of the wild-type receptor for
        DL-P-octopamine (clone 1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).Comments:
        Wild-type OcR receptor clone 1 data was used to perform the percentage calculations,
        except for the DL-p-octopamine EC50 percentage of mutation Y583A where wild-type
        OcR receptor clone 2 was used. Data presented in the article for wild-type
        OcR clone 2 are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50
        tyramine (M) 1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M)
        1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine',
    ligand_short: DL-p-octopamine, pubmed: '12535676', seq: '166', to_res: A}
- {entry_name: oar_drome, from_res: N, info: 'Although there are no significant differences
        in binding affinity for tyramine between the wild-type abd the N166A derivate,
        the binding affinity of the N166A derivate for DL-p-octopamine (31.37+-5.98
        microM) is greater than the binding affinity of the wild-type receptor for
        DL-P-octopamine (clone 1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).Comments:
        Wild-type OcR receptor clone 1 data was used to perform the percentage calculations,
        except for the DL-p-octopamine EC50 percentage of mutation Y583A where wild-type
        OcR receptor clone 2 was used. Data presented in the article for wild-type
        OcR clone 2 are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50
        tyramine (M) 1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M)
        1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine',
    ligand_short: Tyramine, pubmed: '12535676', seq: '166', to_res: A}
- {entry_name: oar_drome, from_res: N, info: 'Although there are no significant differences
        in binding affinity for tyramine between the wild-type abd the N166A derivate,
        the binding affinity of the N166A derivate for DL-p-octopamine (31.37+-5.98
        microM) is greater than the binding affinity of the wild-type receptor for
        DL-P-octopamine (clone 1, 112.5+-11.52 microM; clone 2, 174+-4.56 microM).Comments:
        Wild-type OcR receptor clone 1 data was used to perform the percentage calculations,
        except for the DL-p-octopamine EC50 percentage of mutation Y583A where wild-type
        OcR receptor clone 2 was used. Data presented in the article for wild-type
        OcR clone 2 are: Bmax (pmol/mg^-1) 9.91+-0.38; Kd (nM) 12.00+-1.78; pEC50
        tyramine (M) 1.00+-0.33*10^-8; Ki (microM) 5.17+-0.72; pEC50 octopamine (M)
        1.40+-0.55*10^-6; Ki (microM) 174.40+-4.56.', ligand_long: '[3H]yohimbine',
    ligand_short: '', pubmed: '12535676', seq: '166', to_res: A}
- {entry_name: hrh4_human, from_res: S, info: 'Interestingly, both mutations of Ser320
        (6.52) also seemed to affect the signaling of the H4 receptor. Although mutation
        of this residue to Ala resulted in some reduction of histamine potency, mutation
        to Phe resulted in a 250-fold increase in the EC50 for histamine. In addition,
        both mutations consistently exhibited an increase in maximal Ca2+ flux of
        60 and 100% for both Ser320 (6.52) --> Ala and Ser320 (6.52) --> Phe, respectively.Because
        the affinity of the H4 receptor for [3H]Histamine was only slightly affected
        by mutations, as shown in our [3H]histamine-binding assay, we conclude that
        Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for histamine
        binding.thus, although the maximal responses for all compounds were reduced
        at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest effect
        on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On the other
        hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency and
        increased efficacy for all compounds, although the effects were greatest for
        histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '320', to_res: A}
- {entry_name: hrh4_human, from_res: S, info: 'Interestingly, both mutations of Ser320
        (6.52) also seemed to affect the signaling of the H4 receptor. Although mutation
        of this residue to Ala resulted in some reduction of histamine potency, mutation
        to Phe resulted in a 250-fold increase in the EC50 for histamine. In addition,
        both mutations consistently exhibited an increase in maximal Ca2+ flux of
        60 and 100% for both Ser320 (6.52) --> Ala and Ser320 (6.52) --> Phe, respectively.Because
        the affinity of the H4 receptor for [3H]Histamine was only slightly affected
        by mutations, as shown in our [3H]histamine-binding assay, we conclude that
        Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for histamine
        binding.thus, although the maximal responses for all compounds were reduced
        at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest effect
        on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On the other
        hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency and
        increased efficacy for all compounds, although the effects were greatest for
        histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '320', to_res: F}
- {entry_name: hrh4_human, from_res: S, info: 'Interestingly, both mutations of Ser320
        (6.52) also seemed to affect the signaling of the H4 receptor. Although mutation
        of this residue to Ala resulted in some reduction of histamine potency, mutation
        to Phe resulted in a 250-fold increase in the EC50 for histamine. In addition,
        both mutations consistently exhibited an increase in maximal Ca2+ flux of
        60 and 100% for both Ser320 (6.52) --> Ala and Ser320 (6.52) --> Phe, respectively.Because
        the affinity of the H4 receptor for [3H]Histamine was only slightly affected
        by mutations, as shown in our [3H]histamine-binding assay, we conclude that
        Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for histamine
        binding.thus, although the maximal responses for all compounds were reduced
        at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest effect
        on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On the other
        hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency and
        increased efficacy for all compounds, although the effects were greatest for
        histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '320', to_res: F}
- {entry_name: hrh4_human, from_res: S, info: 'Interestingly, both mutations of Ser320
        (6.52) also seemed to affect the signaling of the H4 receptor. Although mutation
        of this residue to Ala resulted in some reduction of histamine potency, mutation
        to Phe resulted in a 250-fold increase in the EC50 for histamine. In addition,
        both mutations consistently exhibited an increase in maximal Ca2+ flux of
        60 and 100% for both Ser320 (6.52) --> Ala and Ser320 (6.52) --> Phe, respectively.Because
        the affinity of the H4 receptor for [3H]Histamine was only slightly affected
        by mutations, as shown in our [3H]histamine-binding assay, we conclude that
        Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for histamine
        binding.thus, although the maximal responses for all compounds were reduced
        at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest effect
        on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On the other
        hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency and
        increased efficacy for all compounds, although the effects were greatest for
        histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '320', to_res: F}
- {entry_name: hrh4_human, from_res: S, info: 'Interestingly, both mutations of Ser320
        (6.52) also seemed to affect the signaling of the H4 receptor. Although mutation
        of this residue to Ala resulted in some reduction of histamine potency, mutation
        to Phe resulted in a 250-fold increase in the EC50 for histamine. In addition,
        both mutations consistently exhibited an increase in maximal Ca2+ flux of
        60 and 100% for both Ser320 (6.52) --> Ala and Ser320 (6.52) --> Phe, respectively.Because
        the affinity of the H4 receptor for [3H]Histamine was only slightly affected
        by mutations, as shown in our [3H]histamine-binding assay, we conclude that
        Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for histamine
        binding.thus, although the maximal responses for all compounds were reduced
        at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest effect
        on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On the other
        hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency and
        increased efficacy for all compounds, although the effects were greatest for
        histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '320', to_res: F}
- {entry_name: hrh4_human, from_res: S, info: 'Interestingly, both mutations of Ser320
        (6.52) also seemed to affect the signaling of the H4 receptor. Although mutation
        of this residue to Ala resulted in some reduction of histamine potency, mutation
        to Phe resulted in a 250-fold increase in the EC50 for histamine. In addition,
        both mutations consistently exhibited an increase in maximal Ca2+ flux of
        60 and 100% for both Ser320 (6.52) --> Ala and Ser320 (6.52) --> Phe, respectively.Because
        the affinity of the H4 receptor for [3H]Histamine was only slightly affected
        by mutations, as shown in our [3H]histamine-binding assay, we conclude that
        Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for histamine
        binding.thus, although the maximal responses for all compounds were reduced
        at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest effect
        on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On the other
        hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency and
        increased efficacy for all compounds, although the effects were greatest for
        histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '320', to_res: F}
- {entry_name: hrh4_human, from_res: E, info: 'In contrast, mutation of Glu182 (5.46)
        to Asp partially preserved [3H]histamine binding, with Bmax and Kd values
        being reduced by approximately 50% and 10-fold, respectively.As expected from
        the results of the [3H]histamine-binding assay, the mutant H4 receptors that
        did not demonstrate binding of [3H]histamine [Asp94 (3.32) --> Ala, Asp94
        (3.32) --> Glu, Asp94 (3.32) --> Asn, Glu182 (5.46) --> Ala, and Glu182 (5.46)
        --> Gln receptors] also did not stimulate histamine-induced Ca2+ mobilization.In
        contrast, mutation of Glu182 (5.46) --> Asp resulted in a 50% reduction in
        maximal Ca2+ mobilization by histamine and a 20-fold increase in the EC50
        for histamine, compared with the wild-type receptor.', ligand_long: '', ligand_short: '',
    pubmed: '12065753', seq: '182', to_res: Q}
- {entry_name: hrh4_human, from_res: E, info: 'In contrast, mutation of Glu182 (5.46)
        to Asp partially preserved [3H]histamine binding, with Bmax and Kd values
        being reduced by approximately 50% and 10-fold, respectively.As expected from
        the results of the [3H]histamine-binding assay, the mutant H4 receptors that
        did not demonstrate binding of [3H]histamine [Asp94 (3.32) --> Ala, Asp94
        (3.32) --> Glu, Asp94 (3.32) --> Asn, Glu182 (5.46) --> Ala, and Glu182 (5.46)
        --> Gln receptors] also did not stimulate histamine-induced Ca2+ mobilization.In
        contrast, mutation of Glu182 (5.46) --> Asp resulted in a 50% reduction in
        maximal Ca2+ mobilization by histamine and a 20-fold increase in the EC50
        for histamine, compared with the wild-type receptor.', ligand_long: '[3H]histamine',
    ligand_short: '', pubmed: '12065753', seq: '182', to_res: D}
- {entry_name: hrh4_human, from_res: E, info: 'In contrast, mutation of Glu182 (5.46)
        to Asp partially preserved [3H]histamine binding, with Bmax and Kd values
        being reduced by approximately 50% and 10-fold, respectively.As expected from
        the results of the [3H]histamine-binding assay, the mutant H4 receptors that
        did not demonstrate binding of [3H]histamine [Asp94 (3.32) --> Ala, Asp94
        (3.32) --> Glu, Asp94 (3.32) --> Asn, Glu182 (5.46) --> Ala, and Glu182 (5.46)
        --> Gln receptors] also did not stimulate histamine-induced Ca2+ mobilization.In
        contrast, mutation of Glu182 (5.46) --> Asp resulted in a 50% reduction in
        maximal Ca2+ mobilization by histamine and a 20-fold increase in the EC50
        for histamine, compared with the wild-type receptor.', ligand_long: '', ligand_short: '',
    pubmed: '12065753', seq: '182', to_res: A}
- {entry_name: hrh4_human, from_res: S, info: 'The Thr178 (5.42) --> Ala, Ser 179
        (5.43) --> Ala, [...] mutant H4 receptors all demonstrated EC50 values slightly
        higher (four times) than that of the wild-type receptor. These three mutations
        did not alter the maximal histamine-induced Ca2+ mobilization.', ligand_long: '[3H]histamine',
    ligand_short: '', pubmed: '12065753', seq: '179', to_res: A}
- {entry_name: hrh4_human, from_res: T, info: 'Introduction of the Thr178 (5.42) -->
        Ala mutation alone also did not alter cell-surface FLAG staining intensity
        bur reduced the level of [3H]histamine binding to the H4 receptor by 31%.The
        Thr178 (5.42) --> Ala, Ser 179 (5.43) --> Ala, [...] mutant H4 receptors all
        demonstrated EC50 values slightly higher (four times) than that of the wild-type
        receptor. These three mutations did not alter the maximal histamine-induced
        Ca2+ mobilization.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '178', to_res: A}
- {entry_name: hrh4_human, from_res: N, info: 'For the Asn147 --> Tyr mutant receptor,
        no change in EC50 was observed, although the maximal responses to histamine
        were reduced by about 60%. Changing the same residue to Ala, however, increased
        the EC50 for histamine by 7-fold and decreased the maximal stimulation by
        50%.Because the affinity of the H4 receptor for [3H]Histamine was only slightly
        affected by mutations, as shown in our [3H]histamine-binding assay, we conclude
        that Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for
        histamine binding.thus, although the maximal responses for all compounds were
        reduced at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest
        effect on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On
        the other hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency
        and increased efficacy for all compounds, although the effects were greatest
        for histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '147', to_res: A}
- {entry_name: hrh4_human, from_res: N, info: 'For the Asn147 --> Tyr mutant receptor,
        no change in EC50 was observed, although the maximal responses to histamine
        were reduced by about 60%. Changing the same residue to Ala, however, increased
        the EC50 for histamine by 7-fold and decreased the maximal stimulation by
        50%.Because the affinity of the H4 receptor for [3H]Histamine was only slightly
        affected by mutations, as shown in our [3H]histamine-binding assay, we conclude
        that Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for
        histamine binding.thus, although the maximal responses for all compounds were
        reduced at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest
        effect on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On
        the other hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency
        and increased efficacy for all compounds, although the effects were greatest
        for histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '147', to_res: Y}
- {entry_name: hrh4_human, from_res: N, info: 'For the Asn147 --> Tyr mutant receptor,
        no change in EC50 was observed, although the maximal responses to histamine
        were reduced by about 60%. Changing the same residue to Ala, however, increased
        the EC50 for histamine by 7-fold and decreased the maximal stimulation by
        50%.Because the affinity of the H4 receptor for [3H]Histamine was only slightly
        affected by mutations, as shown in our [3H]histamine-binding assay, we conclude
        that Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for
        histamine binding.thus, although the maximal responses for all compounds were
        reduced at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest
        effect on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On
        the other hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency
        and increased efficacy for all compounds, although the effects were greatest
        for histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '147', to_res: Y}
- {entry_name: hrh4_human, from_res: N, info: 'For the Asn147 --> Tyr mutant receptor,
        no change in EC50 was observed, although the maximal responses to histamine
        were reduced by about 60%. Changing the same residue to Ala, however, increased
        the EC50 for histamine by 7-fold and decreased the maximal stimulation by
        50%.Because the affinity of the H4 receptor for [3H]Histamine was only slightly
        affected by mutations, as shown in our [3H]histamine-binding assay, we conclude
        that Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for
        histamine binding.thus, although the maximal responses for all compounds were
        reduced at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest
        effect on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On
        the other hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency
        and increased efficacy for all compounds, although the effects were greatest
        for histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '147', to_res: Y}
- {entry_name: hrh4_human, from_res: N, info: 'For the Asn147 --> Tyr mutant receptor,
        no change in EC50 was observed, although the maximal responses to histamine
        were reduced by about 60%. Changing the same residue to Ala, however, increased
        the EC50 for histamine by 7-fold and decreased the maximal stimulation by
        50%.Because the affinity of the H4 receptor for [3H]Histamine was only slightly
        affected by mutations, as shown in our [3H]histamine-binding assay, we conclude
        that Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for
        histamine binding.thus, although the maximal responses for all compounds were
        reduced at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest
        effect on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On
        the other hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency
        and increased efficacy for all compounds, although the effects were greatest
        for histamine.', ligand_long: '[3H]histamine', ligand_short: '', pubmed: '12065753',
    seq: '147', to_res: Y}
- {entry_name: hrh4_human, from_res: N, info: 'For the Asn147 --> Tyr mutant receptor,
        no change in EC50 was observed, although the maximal responses to histamine
        were reduced by about 60%. Changing the same residue to Ala, however, increased
        the EC50 for histamine by 7-fold and decreased the maximal stimulation by
        50%.Because the affinity of the H4 receptor for [3H]Histamine was only slightly
        affected by mutations, as shown in our [3H]histamine-binding assay, we conclude
        that Asn147 (4.57) and Ser320 (5.62) of the H4 receptor are not critical for
        histamine binding.thus, although the maximal responses for all compounds were
        reduced at the Asn147 (4.57) --> Tyr mutant, this mutation had the smallest
        effect on R-(-)-alpha-methylhistamine and the greatest effect on imepip. On
        the other hand, mutation of Ser320 (6.52) --> Phe resulted in decreased potency
        and increased efficacy for all compounds, although the effects were greatest
        for histamine.', ligand_long: '[3H]Histamine', ligand_short: '', pubmed: '12065753',
    seq: '147', to_res: Y}
- {entry_name: hrh4_human, from_res: D, info: 'As expected from the results of the
        [3H]histamine-binding assay, the mutant H4 receptors that did not demonstrate
        binding of [3H]histamine [Asp94 (3.32) --> Ala, Asp94 (3.32) --> Glu, Asp94
        (3.32) --> Asn, Glu182 (5.46) --> Ala, and Glu182 (5.46) --> Gln receptors]
        also did not stimulate histamine-induced Ca2+ mobilization.', ligand_long: '',
    ligand_short: '', pubmed: '12065753', seq: '94', to_res: N}
- {entry_name: hrh4_human, from_res: D, info: 'As expected from the results of the
        [3H]histamine-binding assay, the mutant H4 receptors that did not demonstrate
        binding of [3H]histamine [Asp94 (3.32) --> Ala, Asp94 (3.32) --> Glu, Asp94
        (3.32) --> Asn, Glu182 (5.46) --> Ala, and Glu182 (5.46) --> Gln receptors]
        also did not stimulate histamine-induced Ca2+ mobilization.', ligand_long: '',
    ligand_short: '', pubmed: '12065753', seq: '94', to_res: E}
- {entry_name: hrh4_human, from_res: D, info: 'As expected from the results of the
        [3H]histamine-binding assay, the mutant H4 receptors that did not demonstrate
        binding of [3H]histamine [Asp94 (3.32) --> Ala, Asp94 (3.32) --> Glu, Asp94
        (3.32) --> Asn, Glu182 (5.46) --> Ala, and Glu182 (5.46) --> Gln receptors]
        also did not stimulate histamine-induced Ca2+ mobilization.', ligand_long: '',
    ligand_short: '', pubmed: '12065753', seq: '94', to_res: A}
- {entry_name: 5ht4r_human, from_res: N, info: 'On the other hand, competition curve
        analysis with the endogenous agonist 5-HT showed a remarkable reduced affinity
        for the D100(3.32)N and the N279(6.55)L mutant receptors (Ki = >10000 nM)
        compared with the wild-type receptor (Ki = 772 nM).,In contrast, no change
        in the ML10302 affinity was observed when residue N279(6.55) was mutated to
        leucine. D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction
        of the affinity for the antagonist ML10375, which was more pronounced than
        that observed for ML10302 (26 fold and 63 fold respectively).The same immunoreactive
        band of 60 KDa was detected in plasma membranes of COS-7 cells transfected
        with mutant receptors S197(5.43)A, P149(4.53)A, F275(6.51)A, F276(6.52)V/N279(6.55)L
        and Y302(7.43)A. Therefore, we can conclude that mutant receptors for which
        no [3H]-GR113808 binding was observed, are well expressed at the plasma membrane
        of COS-7 cells.On the contrary, COS-7 cells transfected with N279(6.55)L mutant
        showed appreciable response to 5-HT despite the decrease in the affinity of
        5-HT (Ki >10000 nM) and of [3H]-GR13808 (Kd = 1.2 nM).On the other hand, COS-7
        cells expressing S197(5.43)A, Y302(7.43)A and F276(6.52)V-N279(6.55)L mutant
        receptors were unable to induce cyclic AMP production in response to 5-HT
        (1 microM).Second, mutations in TMDVI of the highly conserved aromatic residues
        F275(6.51)A, and F276(6.52)V and the largely present N279(6.55)L have no effect
        on the ability of serotonin to activate adenylyl cyclase.', ligand_long: '[3H]-GR113808',
    ligand_short: ML10302, pubmed: '10821780', seq: '279', to_res: L}
- {entry_name: 5ht4r_human, from_res: N, info: 'On the other hand, competition curve
        analysis with the endogenous agonist 5-HT showed a remarkable reduced affinity
        for the D100(3.32)N and the N279(6.55)L mutant receptors (Ki = >10000 nM)
        compared with the wild-type receptor (Ki = 772 nM).,In contrast, no change
        in the ML10302 affinity was observed when residue N279(6.55) was mutated to
        leucine. D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction
        of the affinity for the antagonist ML10375, which was more pronounced than
        that observed for ML10302 (26 fold and 63 fold respectively).The same immunoreactive
        band of 60 KDa was detected in plasma membranes of COS-7 cells transfected
        with mutant receptors S197(5.43)A, P149(4.53)A, F275(6.51)A, F276(6.52)V/N279(6.55)L
        and Y302(7.43)A. Therefore, we can conclude that mutant receptors for which
        no [3H]-GR113808 binding was observed, are well expressed at the plasma membrane
        of COS-7 cells.On the contrary, COS-7 cells transfected with N279(6.55)L mutant
        showed appreciable response to 5-HT despite the decrease in the affinity of
        5-HT (Ki >10000 nM) and of [3H]-GR13808 (Kd = 1.2 nM).On the other hand, COS-7
        cells expressing S197(5.43)A, Y302(7.43)A and F276(6.52)V-N279(6.55)L mutant
        receptors were unable to induce cyclic AMP production in response to 5-HT
        (1 microM).Second, mutations in TMDVI of the highly conserved aromatic residues
        F275(6.51)A, and F276(6.52)V and the largely present N279(6.55)L have no effect
        on the ability of serotonin to activate adenylyl cyclase.', ligand_long: '[3H]-GR113808',
    ligand_short: 5-HT, pubmed: '10821780', seq: '279', to_res: L}
- {entry_name: 5ht4r_human, from_res: N, info: 'On the other hand, competition curve
        analysis with the endogenous agonist 5-HT showed a remarkable reduced affinity
        for the D100(3.32)N and the N279(6.55)L mutant receptors (Ki = >10000 nM)
        compared with the wild-type receptor (Ki = 772 nM).,In contrast, no change
        in the ML10302 affinity was observed when residue N279(6.55) was mutated to
        leucine. D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction
        of the affinity for the antagonist ML10375, which was more pronounced than
        that observed for ML10302 (26 fold and 63 fold respectively).The same immunoreactive
        band of 60 KDa was detected in plasma membranes of COS-7 cells transfected
        with mutant receptors S197(5.43)A, P149(4.53)A, F275(6.51)A, F276(6.52)V/N279(6.55)L
        and Y302(7.43)A. Therefore, we can conclude that mutant receptors for which
        no [3H]-GR113808 binding was observed, are well expressed at the plasma membrane
        of COS-7 cells.On the contrary, COS-7 cells transfected with N279(6.55)L mutant
        showed appreciable response to 5-HT despite the decrease in the affinity of
        5-HT (Ki >10000 nM) and of [3H]-GR13808 (Kd = 1.2 nM).On the other hand, COS-7
        cells expressing S197(5.43)A, Y302(7.43)A and F276(6.52)V-N279(6.55)L mutant
        receptors were unable to induce cyclic AMP production in response to 5-HT
        (1 microM).Second, mutations in TMDVI of the highly conserved aromatic residues
        F275(6.51)A, and F276(6.52)V and the largely present N279(6.55)L have no effect
        on the ability of serotonin to activate adenylyl cyclase.', ligand_long: '[3H]-GR113808',
    ligand_short: '', pubmed: '10821780', seq: '279', to_res: L}
- {entry_name: 5ht4r_human, from_res: F, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.The same immunoreactive band of 60 KDa was detected in
        plasma membranes of COS-7 cells transfected with mutant receptors S197(5.43)A,
        P149(4.53)A, F275(6.51)A, F276(6.52)V/N279(6.55)L and Y302(7.43)A. Therefore,
        we can conclude that mutant receptors for which no [3H]-GR113808 binding was
        observed, are well expressed at the plasma membrane of COS-7 cells.Mutant
        receptors D66(2.50)N, T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V
        stimulated cyclic AMP production with the same efficiency as the wild-type
        receptor (34.1+-6.0%).On the other hand, COS-7 cells expressing S197(5.43)A,
        Y302(7.43)A and F276(6.52)V-N279(6.55)L mutant receptors were unable to induce
        cyclic AMP production in response to 5-HT (1 microM).Second, mutations in
        TMDVI of the highly conserved aromatic residues F275(6.51)A, and F276(6.52)V
        and the largely present N279(6.55)L have no effect on the ability of serotonin
        to activate adenylyl cyclase.', ligand_long: '[3H]-GR113808', ligand_short: ML10375,
    pubmed: '10821780', seq: '276', to_res: V}
- {entry_name: 5ht4r_human, from_res: F, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.The same immunoreactive band of 60 KDa was detected in
        plasma membranes of COS-7 cells transfected with mutant receptors S197(5.43)A,
        P149(4.53)A, F275(6.51)A, F276(6.52)V/N279(6.55)L and Y302(7.43)A. Therefore,
        we can conclude that mutant receptors for which no [3H]-GR113808 binding was
        observed, are well expressed at the plasma membrane of COS-7 cells.Mutant
        receptors D66(2.50)N, T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V
        stimulated cyclic AMP production with the same efficiency as the wild-type
        receptor (34.1+-6.0%).On the other hand, COS-7 cells expressing S197(5.43)A,
        Y302(7.43)A and F276(6.52)V-N279(6.55)L mutant receptors were unable to induce
        cyclic AMP production in response to 5-HT (1 microM).Second, mutations in
        TMDVI of the highly conserved aromatic residues F275(6.51)A, and F276(6.52)V
        and the largely present N279(6.55)L have no effect on the ability of serotonin
        to activate adenylyl cyclase.', ligand_long: '[3H]-GR113808', ligand_short: ML10302,
    pubmed: '10821780', seq: '276', to_res: V}
- {entry_name: 5ht4r_human, from_res: F, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.The same immunoreactive band of 60 KDa was detected in
        plasma membranes of COS-7 cells transfected with mutant receptors S197(5.43)A,
        P149(4.53)A, F275(6.51)A, F276(6.52)V/N279(6.55)L and Y302(7.43)A. Therefore,
        we can conclude that mutant receptors for which no [3H]-GR113808 binding was
        observed, are well expressed at the plasma membrane of COS-7 cells.Mutant
        receptors D66(2.50)N, T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V
        stimulated cyclic AMP production with the same efficiency as the wild-type
        receptor (34.1+-6.0%).On the other hand, COS-7 cells expressing S197(5.43)A,
        Y302(7.43)A and F276(6.52)V-N279(6.55)L mutant receptors were unable to induce
        cyclic AMP production in response to 5-HT (1 microM).Second, mutations in
        TMDVI of the highly conserved aromatic residues F275(6.51)A, and F276(6.52)V
        and the largely present N279(6.55)L have no effect on the ability of serotonin
        to activate adenylyl cyclase.', ligand_long: '[3H]-GR113808', ligand_short: 5-HT,
    pubmed: '10821780', seq: '276', to_res: V}
- {entry_name: 5ht4r_human, from_res: F, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.The same immunoreactive band of 60 KDa was detected in
        plasma membranes of COS-7 cells transfected with mutant receptors S197(5.43)A,
        P149(4.53)A, F275(6.51)A, F276(6.52)V/N279(6.55)L and Y302(7.43)A. Therefore,
        we can conclude that mutant receptors for which no [3H]-GR113808 binding was
        observed, are well expressed at the plasma membrane of COS-7 cells.Mutant
        receptors D66(2.50)N, T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V
        stimulated cyclic AMP production with the same efficiency as the wild-type
        receptor (34.1+-6.0%).On the other hand, COS-7 cells expressing S197(5.43)A,
        Y302(7.43)A and F276(6.52)V-N279(6.55)L mutant receptors were unable to induce
        cyclic AMP production in response to 5-HT (1 microM).Second, mutations in
        TMDVI of the highly conserved aromatic residues F275(6.51)A, and F276(6.52)V
        and the largely present N279(6.55)L have no effect on the ability of serotonin
        to activate adenylyl cyclase.', ligand_long: '[3H]-GR113808', ligand_short: '',
    pubmed: '10821780', seq: '276', to_res: V}
- {entry_name: 5ht4r_human, from_res: C, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: ML10375, pubmed: '10821780', seq: '196', to_res: A}
- {entry_name: 5ht4r_human, from_res: C, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: 5-HT, pubmed: '10821780', seq: '196', to_res: A}
- {entry_name: 5ht4r_human, from_res: C, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: ML10302, pubmed: '10821780', seq: '196', to_res: A}
- {entry_name: 5ht4r_human, from_res: C, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: 5-HT, pubmed: '10821780', seq: '196', to_res: A}
- {entry_name: 5ht4r_human, from_res: C, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: '', pubmed: '10821780', seq: '196', to_res: A}
- {entry_name: 5ht4r_human, from_res: S, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: ML10375, pubmed: '10821780', seq: '153', to_res: A}
- {entry_name: 5ht4r_human, from_res: S, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: ML10302, pubmed: '10821780', seq: '153', to_res: A}
- {entry_name: 5ht4r_human, from_res: S, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: 5-HT, pubmed: '10821780', seq: '153', to_res: A}
- {entry_name: 5ht4r_human, from_res: S, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.Mutant receptors D66(2.50)N, T149(4.54)V, S153(4.57)A,
        C196(5.42)A and F276(6.52)V stimulated cyclic AMP production with the same
        efficiency as the wild-type receptor (34.1+-6.0%).', ligand_long: '[3H]-GR113808',
    ligand_short: '', pubmed: '10821780', seq: '153', to_res: A}
- {entry_name: 5ht4r_human, from_res: T, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.', ligand_long: '[3H]-GR113808', ligand_short: ML10375,
    pubmed: '10821780', seq: '150', to_res: V}
- {entry_name: 5ht4r_human, from_res: T, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.', ligand_long: '[3H]-GR113808', ligand_short: ML10302,
    pubmed: '10821780', seq: '150', to_res: V}
- {entry_name: 5ht4r_human, from_res: T, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.', ligand_long: '[3H]-GR113808', ligand_short: 5-HT, pubmed: '10821780',
    seq: '150', to_res: V}
- {entry_name: 5ht4r_human, from_res: T, info: 'We observed that mutations T150(4.54)V,
        S153(4.57)A and F276(6.52)V did not affect the binding affinities for 5-HT,
        ML10302 and ML10375.', ligand_long: '[3H]-GR113808', ligand_short: '', pubmed: '10821780',
    seq: '150', to_res: V}
- {entry_name: 5ht4r_human, from_res: D, info: 'On the other hand, competition curve
        analysis with the endogenous agonist 5-HT showed a remarkable reduced affinity
        for the D100(3.32)N and the N279(6.55)L mutant receptors (Ki = >10000 nM)
        compared with the wild-type receptor (Ki = 772 nM).,In addition, the selective
        partial agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively
        for the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).COS-7 cells transfected
        with D100(3.32)N mutant 5-HT4(a) receptor showed no response to 5-HT and this
        was correlated with a drastic decrease in the affinity of 5-HT (Ki >10000
        nM).On the contrary, COS-7 cells transfected with N279(6.55)L mutant showed
        appreciable response to 5-HT despite the decrease in the affinity of 5-HT
        (Ki >10000 nM) and of [3H]-GR13808 (Kd = 1.2 nM).The mutation D100(3.32)N
        totally impaired the ability of the h5-HT4(a) receptor to bind 5-HT and to
        stimulate cyclic AMP production.', ligand_long: '[3H]-GR113808', ligand_short: ML10375,
    pubmed: '10821780', seq: '100', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, info: 'On the other hand, competition curve
        analysis with the endogenous agonist 5-HT showed a remarkable reduced affinity
        for the D100(3.32)N and the N279(6.55)L mutant receptors (Ki = >10000 nM)
        compared with the wild-type receptor (Ki = 772 nM).,In addition, the selective
        partial agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively
        for the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).COS-7 cells transfected
        with D100(3.32)N mutant 5-HT4(a) receptor showed no response to 5-HT and this
        was correlated with a drastic decrease in the affinity of 5-HT (Ki >10000
        nM).On the contrary, COS-7 cells transfected with N279(6.55)L mutant showed
        appreciable response to 5-HT despite the decrease in the affinity of 5-HT
        (Ki >10000 nM) and of [3H]-GR13808 (Kd = 1.2 nM).The mutation D100(3.32)N
        totally impaired the ability of the h5-HT4(a) receptor to bind 5-HT and to
        stimulate cyclic AMP production.', ligand_long: '[3H]-GR113808', ligand_short: ML10302,
    pubmed: '10821780', seq: '100', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, info: 'On the other hand, competition curve
        analysis with the endogenous agonist 5-HT showed a remarkable reduced affinity
        for the D100(3.32)N and the N279(6.55)L mutant receptors (Ki = >10000 nM)
        compared with the wild-type receptor (Ki = 772 nM).,In addition, the selective
        partial agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively
        for the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).COS-7 cells transfected
        with D100(3.32)N mutant 5-HT4(a) receptor showed no response to 5-HT and this
        was correlated with a drastic decrease in the affinity of 5-HT (Ki >10000
        nM).On the contrary, COS-7 cells transfected with N279(6.55)L mutant showed
        appreciable response to 5-HT despite the decrease in the affinity of 5-HT
        (Ki >10000 nM) and of [3H]-GR13808 (Kd = 1.2 nM).The mutation D100(3.32)N
        totally impaired the ability of the h5-HT4(a) receptor to bind 5-HT and to
        stimulate cyclic AMP production.', ligand_long: '[3H]-GR113808', ligand_short: 5-HT,
    pubmed: '10821780', seq: '100', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, info: 'On the other hand, competition curve
        analysis with the endogenous agonist 5-HT showed a remarkable reduced affinity
        for the D100(3.32)N and the N279(6.55)L mutant receptors (Ki = >10000 nM)
        compared with the wild-type receptor (Ki = 772 nM).,In addition, the selective
        partial agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively
        for the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).COS-7 cells transfected
        with D100(3.32)N mutant 5-HT4(a) receptor showed no response to 5-HT and this
        was correlated with a drastic decrease in the affinity of 5-HT (Ki >10000
        nM).On the contrary, COS-7 cells transfected with N279(6.55)L mutant showed
        appreciable response to 5-HT despite the decrease in the affinity of 5-HT
        (Ki >10000 nM) and of [3H]-GR13808 (Kd = 1.2 nM).The mutation D100(3.32)N
        totally impaired the ability of the h5-HT4(a) receptor to bind 5-HT and to
        stimulate cyclic AMP production.', ligand_long: '[3H]-GR113808', ligand_short: '',
    pubmed: '10821780', seq: '100', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, info: 'In contrast, residues D66(2.50) and
        C196(5.42) did not affect 5-HT binding when mutated to asparagine (Ki = 6.72
        nM) and alanine (Ki = 378 nM) respectively.In addition, the selective partial
        agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively for
        the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).Mutant receptors D66(2.50)N,
        T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V stimulated cyclic AMP
        production with the same efficiency as the wild-type receptor (34.1+-6.0%).First,
        in TMDII, mutation D66(2.50)N does not affect the affinity of the antagonist
        [3H]-GR113808 and of 5-HT, and retains the same level of serotonin stimulated
        production of cyclic AMP as compared with the wild type receptor.', ligand_long: '[3H]-GR113808',
    ligand_short: ML10375, pubmed: '10821780', seq: '66', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, info: 'In contrast, residues D66(2.50) and
        C196(5.42) did not affect 5-HT binding when mutated to asparagine (Ki = 6.72
        nM) and alanine (Ki = 378 nM) respectively.In addition, the selective partial
        agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively for
        the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).Mutant receptors D66(2.50)N,
        T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V stimulated cyclic AMP
        production with the same efficiency as the wild-type receptor (34.1+-6.0%).First,
        in TMDII, mutation D66(2.50)N does not affect the affinity of the antagonist
        [3H]-GR113808 and of 5-HT, and retains the same level of serotonin stimulated
        production of cyclic AMP as compared with the wild type receptor.', ligand_long: '[3H]-GR113808',
    ligand_short: ML10302, pubmed: '10821780', seq: '66', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, info: 'In contrast, residues D66(2.50) and
        C196(5.42) did not affect 5-HT binding when mutated to asparagine (Ki = 6.72
        nM) and alanine (Ki = 378 nM) respectively.In addition, the selective partial
        agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively for
        the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).Mutant receptors D66(2.50)N,
        T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V stimulated cyclic AMP
        production with the same efficiency as the wild-type receptor (34.1+-6.0%).First,
        in TMDII, mutation D66(2.50)N does not affect the affinity of the antagonist
        [3H]-GR113808 and of 5-HT, and retains the same level of serotonin stimulated
        production of cyclic AMP as compared with the wild type receptor.', ligand_long: '[3H]-GR113808',
    ligand_short: 5-HT, pubmed: '10821780', seq: '66', to_res: N}
- {entry_name: 5ht4r_human, from_res: D, info: 'In contrast, residues D66(2.50) and
        C196(5.42) did not affect 5-HT binding when mutated to asparagine (Ki = 6.72
        nM) and alanine (Ki = 378 nM) respectively.In addition, the selective partial
        agonist ML10302 had a 6 fold and 3 fold reduced affinity respectively for
        the D66(2.50)N (Ki = 57.5 nM) and D100(3.32)N (Ki = 29.6 nM) mutant receptors
        and a 5 fold higher affinity for the C196(5.42)A (Ki = 1.8 nM) mutant receptor,
        as compared to the wild-type form (Ki = 8.5 nM).In contrast, no change in
        the ML10302 affinity was observed when residue N279(6.55) was mutated to leucine.
        D66(2.50)N and D100(3.32)N mutant receptors also displayed a reduction of
        the affinity for the antagonist ML10375, which was more pronounced than that
        observed for ML10302 (26 fold and 63 fold respectively).Mutant receptors D66(2.50)N,
        T149(4.54)V, S153(4.57)A, C196(5.42)A and F276(6.52)V stimulated cyclic AMP
        production with the same efficiency as the wild-type receptor (34.1+-6.0%).First,
        in TMDII, mutation D66(2.50)N does not affect the affinity of the antagonist
        [3H]-GR113808 and of 5-HT, and retains the same level of serotonin stimulated
        production of cyclic AMP as compared with the wild type receptor.', ligand_long: '[3H]-GR113808',
    ligand_short: '', pubmed: '10821780', seq: '66', to_res: N}
- {entry_name: npy1r_human, from_res: H, info: 'A loss of affinity for NPY but nor
        for BIBP 3226 was found for Y100A, D104A, W288A, and H298A.All mutants showed
        ~10-6 binding sites/cell, with exception of S206A (2.82 x 10-5 binding sites
        for NYP/cell)For wild-type and all other mutants, Bmax values range from 7
        x 10-(-)11 to 3 x 10-(-)10 for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for
        BIBP 3226.', ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135',
    seq: '298', to_res: A}
- {entry_name: npy1r_human, from_res: Q, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '291', to_res: A}
- {entry_name: npy1r_human, from_res: H, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '290', to_res: A}
- {entry_name: npy1r_human, from_res: N, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '289', to_res: A}
- {entry_name: npy1r_human, from_res: W, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '288', to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135',
    seq: '287', to_res: A}
- {entry_name: npy1r_human, from_res: F, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Comment: Based
        on a recent L-alanine scan of the 36 amino acid peptide NPY and a site-directed
        mutagenesis experiment on the extracellular loops, a three-dimensional model
        was made, showing  a hydrophobic pocket by the residues Y100, F286, and H298.
        The carboxyl-terminal tyrosine amide moiety of NPS binds here.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '286', to_res: A}
- {entry_name: npy1r_human, from_res: T, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '284', to_res: A}
- {entry_name: npy1r_human, from_res: N, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135',
    seq: '283', to_res: A}
- {entry_name: npy1r_human, from_res: T, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '280', to_res: A}
- {entry_name: npy1r_human, from_res: Q, info: 'Comment: suggesting that these residues
        are involved in ligand binding.All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135',
    seq: '219', to_res: A}
- {entry_name: npy1r_human, from_res: T, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '212', to_res: A}
- {entry_name: npy1r_human, from_res: Y, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135',
    seq: '211', to_res: A}
- {entry_name: npy1r_human, from_res: S, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '210', to_res: A}
- {entry_name: npy1r_human, from_res: H, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '207', to_res: A}
- {entry_name: npy1r_human, from_res: S, info: 'Mutants that show Ki values similar
        to those of wild-type for both NPY or BIBP 3226 (H105A, S170A, L174A, V178A,
        D200A, D205A, S206A, H207A, S210A, T212A, T280A, T284A, N289A, H290A, and
        Q291A)All mutants showed ~10-6 binding sites/cell, with exception of S206A
        (2.82 x 10-5 binding sites for NYP/cell)', ligand_long: '[3H]BIBP 3226', ligand_short: '',
    pubmed: '8700135', seq: '206', to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'For wild-type and all other mutants,
        Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10 for NYP and from 2 x 10-(-)10
        to 1 x 10-(-)9 for BIBP 3226.Mutants that show Ki values similar to those
        of wild-type for both NPY or BIBP 3226 (H105A, S170A, L174A, V178A, D200A,
        D205A, S206A, H207A, S210A, T212A, T280A, T284A, N289A, H290A, and Q291A)',
    ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135', seq: '205',
    to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '200', to_res: A}
- {entry_name: npy1r_human, from_res: V, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '178', to_res: A}
- {entry_name: npy1r_human, from_res: L, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '174', to_res: A}
- {entry_name: npy1r_human, from_res: F, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135',
    seq: '173', to_res: A}
- {entry_name: npy1r_human, from_res: S, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '170', to_res: A}
- {entry_name: npy1r_human, from_res: W, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[3H]BIBP 3226', ligand_short: '', pubmed: '8700135',
    seq: '163', to_res: A}
- {entry_name: npy1r_human, from_res: H, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '105', to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '104', to_res: A}
- {entry_name: npy1r_human, from_res: Y, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Comment: Based
        on a recent L-alanine scan of the 36 amino acid peptide NPY and a site-directed
        mutagenesis experiment on the extracellular loops, a three-dimensional model
        was made, showing  a hydrophobic pocket by the residues Y100, F286, and H298.
        The carboxyl-terminal tyrosine amide moiety of NPS binds here.', ligand_long: '[3H]BIBP
        3226', ligand_short: '', pubmed: '8700135', seq: '100', to_res: A}
- {entry_name: npy1r_human, from_res: H, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positiveComment: Based on a recent L-alanine scan of the 36 amino
        acid peptide NPY and a site-directed mutagenesis experiment on the extracellular
        loops, a three-dimensional model was made, showing  a hydrophobic pocket by
        the residues Y100, F286, and H298. The carboxyl-terminal tyrosine amide moiety
        of NPS binds here.', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135',
    seq: '298', to_res: A}
- {entry_name: npy1r_human, from_res: Q, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '291', to_res: A}
- {entry_name: npy1r_human, from_res: H, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '290', to_res: A}
- {entry_name: npy1r_human, from_res: N, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '289', to_res: A}
- {entry_name: npy1r_human, from_res: W, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135',
    seq: '288', to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135',
    seq: '287', to_res: A}
- {entry_name: npy1r_human, from_res: F, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Comment: Based
        on a recent L-alanine scan of the 36 amino acid peptide NPY and a site-directed
        mutagenesis experiment on the extracellular loops, a three-dimensional model
        was made, showing  a hydrophobic pocket by the residues Y100, F286, and H298.
        The carboxyl-terminal tyrosine amide moiety of NPS binds here.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '286', to_res: A}
- {entry_name: npy1r_human, from_res: T, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '284', to_res: A}
- {entry_name: npy1r_human, from_res: N, info: 'Comment: suggesting that these residues
        are involved in ligand binding.All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135',
    seq: '283', to_res: A}
- {entry_name: npy1r_human, from_res: T, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '280', to_res: A}
- {entry_name: npy1r_human, from_res: Q, info: 'Comment: suggesting that these residues
        are involved in ligand binding.All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.Binding sites per
        cell could not be determined for mutants, which bound neither NPY nor BIBP
        3226. However, to ensure correct expression, those cells were investigated
        with fluorescent labeled anti-FLAG antibodies. All mutants were correctly
        expressed at the cell surface according to FLAG epitope binding studies.Comment:
        FLAG test positive', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135',
    seq: '219', to_res: A}
- {entry_name: npy1r_human, from_res: T, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '212', to_res: A}
- {entry_name: npy1r_human, from_res: Y, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '211', to_res: A}
- {entry_name: npy1r_human, from_res: S, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '210', to_res: A}
- {entry_name: npy1r_human, from_res: H, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '207', to_res: A}
- {entry_name: npy1r_human, from_res: S, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '206', to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '205', to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '200', to_res: A}
- {entry_name: npy1r_human, from_res: V, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-(-)11 to 3 x 10-(-)10
        for NYP and from 2 x 10-(-)10 to 1 x 10-(-)9 for BIBP 3226.', ligand_long: '[125]NPY',
    ligand_short: '', pubmed: '8700135', seq: '178', to_res: A}
- {entry_name: npy1r_human, from_res: L, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-11 to 3 x 10-10 for NYP
        and from 2 x 10-10 to 1 x 10-9 for BIBP 3226.', ligand_long: '[125]NPY', ligand_short: '',
    pubmed: '8700135', seq: '174', to_res: A}
- {entry_name: npy1r_human, from_res: F, info: 'Comment: suggesting that these residues
        are involved in ligand binding.All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 10-5 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-11 to 3 x 10-10 for NYP
        and from 2 x 10-10 to 1 x 10-9 for BIBP 3226.Binding sites per cell could
        not be determined for mutants, which bound neither NPY nor BIBP 3226. However,
        to ensure correct expression, those cells were investigated with fluorescent
        labeled anti-FLAG antibodies. All mutants were correctly expressed at the
        cell surface according to FLAG epitope binding studies.Comment: FLAG test
        positive', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135', seq: '173',
    to_res: A}
- {entry_name: npy1r_human, from_res: S, info: 'All mutants showed ~106 binding sites/cell,
        with exception of S206A (2.82 x 105 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-11 to 3 x 10-10 for NYP
        and from 2 x 10-10 to 1 x 10-9 for BIBP 3226.', ligand_long: '[125]NPY', ligand_short: '',
    pubmed: '8700135', seq: '170', to_res: A}
- {entry_name: npy1r_human, from_res: W, info: 'Comment: suggesting that these residues
        are involved in ligand binding.All mutants showed ~106 binding sites/cell,
        with exception of S206A (2.82 x 105 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-11 to 3 x 10-10 for NYP
        and from 2 x 10-10 to 1 x 10-9 for BIBP 3226.Binding sites per cell could
        not be determined for mutants, which bound neither NPY nor BIBP 3226. However,
        to ensure correct expression, those cells were investigated with fluorescent
        labeled anti-FLAG antibodies. All mutants were correctly expressed at the
        cell surface according to FLAG epitope binding studies.Comment: FLAG test
        positive', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135', seq: '163',
    to_res: A}
- {entry_name: npy1r_human, from_res: H, info: 'All mutants showed ~10-6 binding sites/cell,
        with exception of S206A (2.82 x 105 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-11 to 3 x 10-10 for NYP
        and from 2 x 10-10 to 1 x 10-9 for BIBP 3226.', ligand_long: '[125]NPY', ligand_short: '',
    pubmed: '8700135', seq: '105', to_res: A}
- {entry_name: npy1r_human, from_res: D, info: 'All mutants showed ~106 binding sites/cell,
        with exception of S206A (2.82 x 105 binding sites for NYP/cell)For wild-type
        and all other mutants, Bmax values range from 7 x 10-11 to 3 x 10-10 for NYP
        and from 2 x 10-10 to 1 x 10-9 for BIBP 3226.Binding sites per cell could
        not be determined for mutants, which bound neither NPY nor BIBP 3226. However,
        to ensure correct expression, those cells were investigated with fluorescent
        labeled anti-FLAG antibodies. All mutants were correctly expressed at the
        cell surface according to FLAG epitope binding studies.Comment: FLAG test
        positive', ligand_long: '[125]NPY', ligand_short: '', pubmed: '8700135', seq: '104',
    to_res: A}
- {entry_name: glp1r_rat, from_res: V, info: 'For each mutation examined, it was apparent
        that the EC50 value for cAMP stimulation was approximately 10-fold greater
        than the WT GLP-1R (V327 = 26 nM, I328 = 16 nM, V331 = 23 nM vs. WT = 1.7
        nM), despite the observation that the affinity of each receptor for tGLP-1
        binding was not significantly different.', ligand_long: '[125I]tGLP-1', ligand_short: '',
    pubmed: '9092794', seq: '331', to_res: A}
- {entry_name: glp1r_rat, from_res: I, info: 'For each mutation examined, it was apparent
        that the EC50 value for cAMP stimulation was approximately 10-fold greater
        than the WT GLP-1R (V327 = 26 nM, I328 = 16 nM, V331 = 23 nM vs. WT = 1.7
        nM), despite the observation that the affinity of each receptor for tGLP-1
        binding was not significantly different.', ligand_long: '[125I]tGLP-1', ligand_short: '',
    pubmed: '9092794', seq: '328', to_res: A}
- {entry_name: glp1r_rat, from_res: V, info: 'For each mutation examined, it was apparent
        that the EC50 value for cAMP stimulation was approximately 10-fold greater
        than the WT GLP-1R (V327 = 26 nM, I328 = 16 nM, V331 = 23 nM vs. WT = 1.7
        nM), despite the observation that the affinity of each receptor for tGLP-1
        binding was not significantly different.', ligand_long: '[125I]tGLP-1', ligand_short: '',
    pubmed: '9092794', seq: '327', to_res: A}
- {entry_name: glp1r_rat, from_res: N, info: 'With mutants C174A and N177A, Bmax values
        were found to correlate weel with reduced receptor activation because significantly
        lower values compared with WT (45+-5 and 22+-2% of WT, P<0.01) were observed.',
    ligand_long: '[125I]tGLP-1', ligand_short: '', pubmed: '9092794', seq: '177',
    to_res: A}
- {entry_name: glp1r_rat, from_res: R, info: 'Further, dose-dependent analysis of
        the cAMP response to tGLP-1 (10^-12 through 10^-6 M) with the R176A mutant
        indicated that the EC50 was approximately 10-fold higher (R176A = 22 nM vs.
        WT GLP-1R = 1.7 nM), [...].', ligand_long: '[125I]tGLP-1', ligand_short: '',
    pubmed: '9092794', seq: '176', to_res: A}
- {entry_name: glp1r_rat, from_res: T, info: 'In contrast, with L172A, H173A and T175A,
        receptor expression (Bmax) was reduced, with little effect on cAMP accumulation,
        [...].', ligand_long: '[125I]tGLP-1', ligand_short: '', pubmed: '9092794',
    seq: '175', to_res: A}
- {entry_name: glp1r_rat, from_res: C, info: 'With mutants C174A and N177A, Bmax values
        were found to correlate weel with reduced receptor activation because significantly
        lower values compared with WT (45+-5 and 22+-2% of WT, P<0.01) were observed.',
    ligand_long: '[125I]tGLP-1', ligand_short: '', pubmed: '9092794', seq: '174',
    to_res: A}
- {entry_name: glp1r_rat, from_res: H, info: 'In contrast, with L172A, H173A and T175A,
        receptor expression (Bmax) was reduced, with little effect on cAMP accumulation,
        [...].', ligand_long: '[125I]tGLP-1', ligand_short: '', pubmed: '9092794',
    seq: '173', to_res: A}
- {entry_name: aa2br_human, from_res: S, info: 'Three point-mutated receptors were
        obtained twice independently: V54L (a and b), F84L (a and b), and S91G (a
        and b).After constitutive activity in absence of NECA, we determined the growth
        concentration-response curves of these mutants for NECA. Again the two copies
        of V54L, F84L, and S91G mutants behaved similarly. The EC50 values of V54La
        and V54Lb were 14 and 17 nM, respectively; and of S91Ga and S91Gb, 56 and
        66 nM, respectively.Comments: values respresented under activation data do
        not respresent percentages based on second messenger production but on the
        induction of growth.', ligand_long: '', ligand_short: '', pubmed: '14978249',
    seq: '91', to_res: G}
- {entry_name: aa2br_human, from_res: S, info: 'Three point-mutated receptors were
        obtained twice independently: V54L (a and b), F84L (a and b), and S91G (a
        and b).After constitutive activity in absence of NECA, we determined the growth
        concentration-response curves of these mutants for NECA. Again the two copies
        of V54L, F84L, and S91G mutants behaved similarly. The EC50 values of V54La
        and V54Lb were 14 and 17 nM, respectively; and of S91Ga and S91Gb, 56 and
        66 nM, respectively.Comments: values respresented under activation data do
        not respresent percentages based on second messenger production but on the
        induction of growth.', ligand_long: '', ligand_short: '', pubmed: '14978249',
    seq: '91', to_res: G}
- {entry_name: aa2br_human, from_res: F, info: 'After constitutive activity in absence
        of NECA, we determined the growth concentration-response curves of these mutants
        for NECA. Again the two copies of V54L, F84L, and S91G mutants behaved similarly.
        The EC50 values of V54La and V54Lb were 14 and 17 nM, respectively; and of
        S91Ga and S91Gb, 56 and 66 nM, respectively.As stated, the F84La and F84Lb
        mutants were slightly constitutively active (3.3- and 2.1-fold, respectively)
        and the EC50 value of NECA was decreased moderately (2.2- and 4.0-fold, respectively).
        Mutation of the same residue to serine (F84S) resulted in more constitutive
        activity (7.1-fold) and a stronger decrease of the EC50 value of NECA (6.5-fold).Comments:
        values respresented under activation data do not respresent percentages based
        on second messenger production but on the induction of growth.', ligand_long: '',
    ligand_short: '', pubmed: '14978249', seq: '84', to_res: S}
- {entry_name: aa2br_human, from_res: F, info: 'Three point-mutated receptors were
        obtained twice independently: V54L (a and b), F84L (a and b), and S91G (a
        and b).After constitutive activity in absence of NECA, we determined the growth
        concentration-response curves of these mutants for NECA. Again the two copies
        of V54L, F84L, and S91G mutants behaved similarly. The EC50 values of V54La
        and V54Lb were 14 and 17 nM, respectively; and of S91Ga and S91Gb, 56 and
        66 nM, respectively.As stated, the F84La and F84Lb mutants were slightly constitutively
        active (3.3- and 2.1-fold, respectively) and the EC50 value of NECA was decreased
        moderately (2.2- and 4.0-fold, respectively). Mutation of the same residue
        to serine (F84S) resulted in more constitutive activity (7.1-fold) and a stronger
        decrease of the EC50 value of NECA (6.5-fold).Comments: values respresented
        under activation data do not respresent percentages based on second messenger
        production but on the induction of growth.', ligand_long: '', ligand_short: '',
    pubmed: '14978249', seq: '84', to_res: L}
- {entry_name: aa2br_human, from_res: F, info: 'Three point-mutated receptors were
        obtained twice independently: V54L (a and b), F84L (a and b), and S91G (a
        and b).After constitutive activity in absence of NECA, we determined the growth
        concentration-response curves of these mutants for NECA. Again the two copies
        of V54L, F84L, and S91G mutants behaved similarly. The EC50 values of V54La
        and V54Lb were 14 and 17 nM, respectively; and of S91Ga and S91Gb, 56 and
        66 nM, respectively.As stated, the F84La and F84Lb mutants were slightly constitutively
        active (3.3- and 2.1-fold, respectively) and the EC50 value of NECA was decreased
        moderately (2.2- and 4.0-fold, respectively). Mutation of the same residue
        to serine (F84S) resulted in more constitutive activity (7.1-fold) and a stronger
        decrease of the EC50 value of NECA (6.5-fold).Comments: values respresented
        under activation data do not respresent percentages based on second messenger
        production but on the induction of growth.', ligand_long: '', ligand_short: '',
    pubmed: '14978249', seq: '84', to_res: L}
- {entry_name: aa2br_human, from_res: V, info: 'Three point-mutated receptors were
        obtained twice independently: V54L (a and b), F84L (a and b), and S91G (a
        and b).After constitutive activity in absence of NECA, we determined the growth
        concentration-response curves of these mutants for NECA. Again the two copies
        of V54L, F84L, and S91G mutants behaved similarly. The EC50 values of V54La
        and V54Lb were 14 and 17 nM, respectively; and of S91Ga and S91Gb, 56 and
        66 nM, respectively.Comments: values respresented under activation data do
        not respresent percentages based on second messenger production but on the
        induction of growth.', ligand_long: '', ligand_short: '', pubmed: '14978249',
    seq: '54', to_res: L}
- {entry_name: aa2br_human, from_res: V, info: 'Three point-mutated receptors were
        obtained twice independently: V54L (a and b), F84L (a and b), and S91G (a
        and b).After constitutive activity in absence of NECA, we determined the growth
        concentration-response curves of these mutants for NECA. Again the two copies
        of V54L, F84L, and S91G mutants behaved similarly. The EC50 values of V54La
        and V54Lb were 14 and 17 nM, respectively; and of S91Ga and S91Gb, 56 and
        66 nM, respectively.Comments: values respresented under activation data do
        not respresent percentages based on second messenger production but on the
        induction of growth.', ligand_long: '', ligand_short: '', pubmed: '14978249',
    seq: '54', to_res: L}
- {entry_name: aa2br_human, from_res: T, info: 'The EC50 values of NECA for cAMP stimulation
        were 1.3+-0.4 microM and 0.15+-0.04 microM for the wt and the T42A mutant
        receptor, respectively. Thus, the responsiveness of the T42A rceptor for NECA
        was increased 8.7-fold. Basal cAMP production was slightly higher (2.3-fold)
        for the T42A receptor compared with the wt receptor.In the yeast assay, NECA
        had a 4.9-fold lower EC50 for the T42A receptor than for the wt receptor,
        which was mimicked in the CHO cells, in which the EC50 for cAMP production
        was decreased 8.7-fold compared with the wt receptor. Basal cAMP production
        in the CHO cells was slightly higher (2.3-fold) for the T42A receptor compared
        with the wt receptor.Comments: values respresented under activation data do
        not respresent percentages based on second messenger production but on the
        induction of growth.', ligand_long: '', ligand_short: '', pubmed: '14978249',
    seq: '42', to_res: A}
- {entry_name: aa2br_human, from_res: N, info: 'Comments: values respresented under
        activation data do not respresent percentages based on second messenger production
        but on the induction of growth.', ligand_long: '', ligand_short: '', pubmed: '14978249',
    seq: '36', to_res: D}
- {entry_name: hrh3_human, from_res: E, info: '[...], and interestingly, R-alpha-methylhistamine
        is the most sensitive agonist to the E206A mutation.For instance, int this
        assay the E206A mutation results in a 65-fold increase in the half-maximally
        effective concentration of histamine compared with the 22-fold difference
        seen in the cyclase assay.However, impentamine was able to stimulate the E206A
        receptor but with a lower efficacy than the other ligands.Comments: Percentages
        for the ligand binding data are based on the WT low-affinity receptor which
        are 12.74+-7.10, and 9.34+-4.08 nM for R-alpha-methylhistamine, and Imetit,
        respectively. The WT high affinity receptor data are: R-alpha-methylhistamine:
        0.77+-0.163; Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: imetit,
    pubmed: '11961043', seq: '206', to_res: A}
- {entry_name: hrh3_human, from_res: E, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.For instance, the increases
        in potency seen with W196A, T201A, and T204A were consistent, and in all cases
        the largest decreases in potency was noted with the E206A mutation.Glutamate
        206 showed a large, 2052-fold decrease in (low) affinity binding, where the
        Ki was determined to be 32.5 microM. [...], E206A had the greatest effect
        on the affinity of the agonist, with histamine and R-alpha-methylhistamine
        being affected the most.The effects of the mutations were also exaggerated
        in this assay (e.g. E206A led to a 45-fold decrease in histamine potency compared
        with the 22-fold change seen in the cAMP assay).The mutation of glutamate
        206 had the greatest effect on the agonists studied, particularly on R-alpha-methylhistamine,
        for which EC50 was increased 2499-fold.[...] impentamine, a potent full agonist
        in the wild-type H3 cAMP assay, failed to stimulate the wild-type and mutant
        receptors in the FLIPR assay with the exception of E206A.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).[...], and interestingly,
        R-alpha-methylhistamine is the most sensitive agonist to the E206A mutation.For
        instance, int this assay the E206A mutation results in a 65-fold increase
        in the half-maximally effective concentration of histamine compared with the
        22-fold difference seen in the cyclase assay.However, impentamine was able
        to stimulate the E206A receptor but with a lower efficacy than the other ligands.Comments:
        Percentages for the ligand binding data are based on the WT low-affinity receptor
        which are 12.74+-7.10, and 9.34+-4.08 nM for R-alpha-methylhistamine, and
        Imetit, respectively. The WT high affinity receptor data are: R-alpha-methylhistamine:
        0.77+-0.163; Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: R-alpha-methylhistamine,
    pubmed: '11961043', seq: '206', to_res: A}
- {entry_name: hrh3_human, from_res: T, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.Comments: Percentages for the ligand
        binding data are based on the WT low-affinity receptor which are 12.74+-7.10,
        and 9.34+-4.08 nM for R-alpha-methylhistamine, and Imetit, respectively. The
        WT high affinity receptor data are: R-alpha-methylhistamine: 0.77+-0.163;
        Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: imetit,
    pubmed: '11961043', seq: '204', to_res: A}
- {entry_name: hrh3_human, from_res: T, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.Comments: Percentages for the ligand
        binding data are based on the WT low-affinity receptor which are 12.74+-7.10,
        and 9.34+-4.08 nM for R-alpha-methylhistamine, and Imetit, respectively. The
        WT high affinity receptor data are: R-alpha-methylhistamine: 0.77+-0.163;
        Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: R-alpha-methylhistamine,
    pubmed: '11961043', seq: '204', to_res: A}
- {entry_name: hrh3_human, from_res: A, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).', ligand_long: '[125I]iodoproxyfan',
    ligand_short: imetit, pubmed: '11961043', seq: '202', to_res: Q}
- {entry_name: hrh3_human, from_res: A, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).', ligand_long: '[125I]iodoproxyfan',
    ligand_short: R-alpha-methylhistamine, pubmed: '11961043', seq: '202', to_res: Q}
- {entry_name: hrh3_human, from_res: L, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.L199A had little or
        only small effects on the binding affinity.Comments: Percentages for the ligand
        binding data are based on the WT low-affinity receptor which are 12.74+-7.10,
        and 9.34+-4.08 nM for R-alpha-methylhistamine, and Imetit, respectively. The
        WT high affinity receptor data are: R-alpha-methylhistamine: 0.77+-0.163;
        Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: imetit,
    pubmed: '11961043', seq: '199', to_res: A}
- {entry_name: hrh3_human, from_res: L, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.L199A had little or
        only small effects on the binding affinity.Comments: Percentages for the ligand
        binding data are based on the WT low-affinity receptor which are 12.74+-7.10,
        and 9.34+-4.08 nM for R-alpha-methylhistamine, and Imetit, respectively. The
        WT high affinity receptor data are: R-alpha-methylhistamine: 0.77+-0.163;
        Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: R-alpha-methylhistamine,
    pubmed: '11961043', seq: '199', to_res: A}
- {entry_name: hrh3_human, from_res: W, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.Comments: Percentages for the ligand
        binding data are based on the WT low-affinity receptor which are 12.74+-7.10,
        and 9.34+-4.08 nM for R-alpha-methylhistamine, and Imetit, respectively. The
        WT high affinity receptor data are: R-alpha-methylhistamine: 0.77+-0.163;
        Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: imetit,
    pubmed: '11961043', seq: '196', to_res: A}
- {entry_name: hrh3_human, from_res: W, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.Comments: Percentages for the ligand
        binding data are based on the WT low-affinity receptor which are 12.74+-7.10,
        and 9.34+-4.08 nM for R-alpha-methylhistamine, and Imetit, respectively. The
        WT high affinity receptor data are: R-alpha-methylhistamine: 0.77+-0.163;
        Imetit: 0.45+-0.15 nM.', ligand_long: '[125I]iodoproxyfan', ligand_short: R-alpha-methylhistamine,
    pubmed: '11961043', seq: '196', to_res: A}
- {entry_name: hrh3_human, from_res: E, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.For instance, the increases
        in potency seen with W196A, T201A, and T204A were consistent, and in all cases
        the largest decreases in potency was noted with the E206A mutation.Glutamate
        206 showed a large, 2052-fold decrease in (low) affinity binding, where the
        Ki was determined to be 32.5 microM. [...], E206A had the greatest effect
        on the affinity of the agonist, with histamine and R-alpha-methylhistamine
        being affected the most.The effects of the mutations were also exaggerated
        in this assay (e.g. E206A led to a 45-fold decrease in histamine potency compared
        with the 22-fold change seen in the cAMP assay).The mutation of glutamate
        206 had the greatest effect on the agonists studied, particularly on R-alpha-methylhistamine,
        for which EC50 was increased 2499-fold.[...] impentamine, a potent full agonist
        in the wild-type H3 cAMP assay, failed to stimulate the wild-type and mutant
        receptors in the FLIPR assay with the exception of E206A.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).[...], and interestingly,
        R-alpha-methylhistamine is the most sensitive agonist to the E206A mutation.For
        instance, int this assay the E206A mutation results in a 65-fold increase
        in the half-maximally effective concentration of histamine compared with the
        22-fold difference seen in the cyclase assay.However, impentamine was able
        to stimulate the E206A receptor but with a lower efficacy than the other ligands.',
    ligand_long: forskolin, ligand_short: impentamine, pubmed: '11961043', seq: '206',
    to_res: A}
- {entry_name: hrh3_human, from_res: E, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.For instance, the increases
        in potency seen with W196A, T201A, and T204A were consistent, and in all cases
        the largest decreases in potency was noted with the E206A mutation.Glutamate
        206 showed a large, 2052-fold decrease in (low) affinity binding, where the
        Ki was determined to be 32.5 microM. [...], E206A had the greatest effect
        on the affinity of the agonist, with histamine and R-alpha-methylhistamine
        being affected the most.The effects of the mutations were also exaggerated
        in this assay (e.g. E206A led to a 45-fold decrease in histamine potency compared
        with the 22-fold change seen in the cAMP assay).The mutation of glutamate
        206 had the greatest effect on the agonists studied, particularly on R-alpha-methylhistamine,
        for which EC50 was increased 2499-fold.[...] impentamine, a potent full agonist
        in the wild-type H3 cAMP assay, failed to stimulate the wild-type and mutant
        receptors in the FLIPR assay with the exception of E206A.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).[...], and interestingly,
        R-alpha-methylhistamine is the most sensitive agonist to the E206A mutation.For
        instance, int this assay the E206A mutation results in a 65-fold increase
        in the half-maximally effective concentration of histamine compared with the
        22-fold difference seen in the cyclase assay.However, impentamine was able
        to stimulate the E206A receptor but with a lower efficacy than the other ligands.',
    ligand_long: forskolin, ligand_short: imetit, pubmed: '11961043', seq: '206',
    to_res: A}
- {entry_name: hrh3_human, from_res: E, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.For instance, the increases
        in potency seen with W196A, T201A, and T204A were consistent, and in all cases
        the largest decreases in potency was noted with the E206A mutation.Glutamate
        206 showed a large, 2052-fold decrease in (low) affinity binding, where the
        Ki was determined to be 32.5 microM. [...], E206A had the greatest effect
        on the affinity of the agonist, with histamine and R-alpha-methylhistamine
        being affected the most.The effects of the mutations were also exaggerated
        in this assay (e.g. E206A led to a 45-fold decrease in histamine potency compared
        with the 22-fold change seen in the cAMP assay).The mutation of glutamate
        206 had the greatest effect on the agonists studied, particularly on R-alpha-methylhistamine,
        for which EC50 was increased 2499-fold.[...] impentamine, a potent full agonist
        in the wild-type H3 cAMP assay, failed to stimulate the wild-type and mutant
        receptors in the FLIPR assay with the exception of E206A.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).[...], and interestingly,
        R-alpha-methylhistamine is the most sensitive agonist to the E206A mutation.For
        instance, int this assay the E206A mutation results in a 65-fold increase
        in the half-maximally effective concentration of histamine compared with the
        22-fold difference seen in the cyclase assay.However, impentamine was able
        to stimulate the E206A receptor but with a lower efficacy than the other ligands.',
    ligand_long: forskolin, ligand_short: R-alpha-methylhistamine, pubmed: '11961043',
    seq: '206', to_res: A}
- {entry_name: hrh3_human, from_res: E, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.For instance, the increases
        in potency seen with W196A, T201A, and T204A were consistent, and in all cases
        the largest decreases in potency was noted with the E206A mutation.Glutamate
        206 showed a large, 2052-fold decrease in (low) affinity binding, where the
        Ki was determined to be 32.5 microM. [...], E206A had the greatest effect
        on the affinity of the agonist, with histamine and R-alpha-methylhistamine
        being affected the most.The effects of the mutations were also exaggerated
        in this assay (e.g. E206A led to a 45-fold decrease in histamine potency compared
        with the 22-fold change seen in the cAMP assay).The mutation of glutamate
        206 had the greatest effect on the agonists studied, particularly on R-alpha-methylhistamine,
        for which EC50 was increased 2499-fold.[...] impentamine, a potent full agonist
        in the wild-type H3 cAMP assay, failed to stimulate the wild-type and mutant
        receptors in the FLIPR assay with the exception of E206A.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).[...], and interestingly,
        R-alpha-methylhistamine is the most sensitive agonist to the E206A mutation.For
        instance, int this assay the E206A mutation results in a 65-fold increase
        in the half-maximally effective concentration of histamine compared with the
        22-fold difference seen in the cyclase assay.However, impentamine was able
        to stimulate the E206A receptor but with a lower efficacy than the other ligands.',
    ligand_long: forskolin, ligand_short: histamine, pubmed: '11961043', seq: '206',
    to_res: A}
- {entry_name: hrh3_human, from_res: T, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: impentamine,
    pubmed: '11961043', seq: '204', to_res: A}
- {entry_name: hrh3_human, from_res: T, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: imetit,
    pubmed: '11961043', seq: '204', to_res: A}
- {entry_name: hrh3_human, from_res: T, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: R-alpha-methylhistamine,
    pubmed: '11961043', seq: '204', to_res: A}
- {entry_name: hrh3_human, from_res: T, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: histamine,
    pubmed: '11961043', seq: '204', to_res: A}
- {entry_name: hrh3_human, from_res: A, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).', ligand_long: forskolin,
    ligand_short: impentamine, pubmed: '11961043', seq: '202', to_res: Q}
- {entry_name: hrh3_human, from_res: A, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).', ligand_long: forskolin,
    ligand_short: imetit, pubmed: '11961043', seq: '202', to_res: Q}
- {entry_name: hrh3_human, from_res: A, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).', ligand_long: forskolin,
    ligand_short: R-alpha-methylhistamine, pubmed: '11961043', seq: '202', to_res: Q}
- {entry_name: hrh3_human, from_res: A, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.In this study, the
        potency of histamine at both the A202Q and E206A mutants was decreased approximately
        20-fold, whereas the effects of mutating the glutamate 206 were much greater
        in the binding studies (2000-fold decrease in affinity).', ligand_long: forskolin,
    ligand_short: histamine, pubmed: '11961043', seq: '202', to_res: Q}
- {entry_name: hrh3_human, from_res: L, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.L199A had little or
        only small effects on the binding affinity.', ligand_long: forskolin, ligand_short: imetit,
    pubmed: '11961043', seq: '199', to_res: A}
- {entry_name: hrh3_human, from_res: L, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.L199A had little or
        only small effects on the binding affinity.', ligand_long: forskolin, ligand_short: R-alpha-methylhistamine,
    pubmed: '11961043', seq: '199', to_res: A}
- {entry_name: hrh3_human, from_res: L, info: 'Furthermore, the L199A, I200A, A202Q,
        and E206A mutations led to small decreases in efficacy.L199A had little or
        only small effects on the binding affinity.', ligand_long: forskolin, ligand_short: histamine,
    pubmed: '11961043', seq: '199', to_res: A}
- {entry_name: hrh3_human, from_res: W, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: impentamine,
    pubmed: '11961043', seq: '196', to_res: A}
- {entry_name: hrh3_human, from_res: W, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: imetit,
    pubmed: '11961043', seq: '196', to_res: A}
- {entry_name: hrh3_human, from_res: W, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: R-alpha-methylhistamine,
    pubmed: '11961043', seq: '196', to_res: A}
- {entry_name: hrh3_human, from_res: W, info: 'For instance, the increases in potency
        seen with W196A, T201A, and T204A were consistent, and in all cases the largest
        decreases in potency was noted with the E206A mutation.The increases seen
        with W196A and T204A in the functional data were not refelected in the binding
        to the low-affinity, uncoupled receptor.', ligand_long: forskolin, ligand_short: histamine,
    pubmed: '11961043', seq: '196', to_res: A}
- {entry_name: hrh3_human, from_res: F, info: 'Phenylalanine 207 is a residue that
        is conserved across the GPCR''s, and the observed 17-fold decrease in the
        potency of histamine may reflect a role in receptor structure and/or function
        that is common to the whole GPCR family.', ligand_long: forskolin, ligand_short: histamine,
    pubmed: '11961043', seq: '207', to_res: A}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '[3H]QNB', ligand_short: '', pubmed: '17848601',
    seq: '178', to_res: N}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '17848601',
    seq: '178', to_res: N}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '', ligand_short: Acetylcholine, pubmed: '17848601',
    seq: '178', to_res: N}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '[3H]QNB', ligand_short: '', pubmed: '17848601',
    seq: '178', to_res: A}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '17848601',
    seq: '178', to_res: A}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '', ligand_short: Acetylcholine, pubmed: '17848601',
    seq: '178', to_res: A}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '[3H]QNB', ligand_short: '', pubmed: '17848601',
    seq: '98', to_res: A}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '17848601',
    seq: '98', to_res: A}
- {entry_name: acm1_rat, from_res: C, info: 'It was difficult or impossible to measure
        specific binding of the radioligands to mutants of Cys178, Cys98 and Phe197.
        The expression levels of C98A, C178A and F197A were raised from less than
        10% of wild-type to 15-50% by treatment of the transfected cells with atropine
        (10^-6M).Single and double substitution of Cys98 and Cys178 reduced the affinities
        of both NMS and QNB by 10- to 20-fold, as did the nonconservative substitution
        C178N.The single and double mutations of Cys98 and Cys178 all diminished the
        potency of the ACh-induced PhI response by 3000-fold. In contrast to the other
        ECL2 point mutants, mutations of the cysteine residues significantly reduced
        the maximum ACh-induced signal and the agonist-independent basal signal. The
        cysteine mutations all caused large, 30- to 60-fold reductions in the calculated
        ACh signaling efficacy.', ligand_long: '', ligand_short: Acetylcholine, pubmed: '17848601',
    seq: '98', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: ZM-241385, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: BTH4, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: XAC, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: CGS-15943, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: SCH-58261, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: ADAC, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: IB-MECA, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: R-PIA, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: NECA, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: DPMA, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: CADO, pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'The agonist order (decreasing) for
        enhancement of affinity produced by the S281N mutation was R-PIA (17.0-fold)
        > CADO (13.5-fold) = DPMA (13.1-fold) > ADAC (8.5-fold) = IB-MECA (8.1-fold)
        > NECA (6.1-fold) > CGS-21680 (2.5-fold). Antagonist affinity at the S281N
        mutant receptor was generally diminished (3-10-fold) compared with wild-type
        receptors, except for BTH4 (3.5-fold enhancement).', ligand_long: '[3H]CGS-21680',
    ligand_short: '', pubmed: '8794889', seq: '281', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: ZM-241385, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: BTH4, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: XAC, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: CGS-15943, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: SCH-58261, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: ADAC, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: IB-MECA, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: R-PIA, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: NECA, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: DPMA, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: CADO, pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The 2''-
        and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A mutant
        receptor elicited a dose-dependent stimulation of cAMP production with an
        EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at wild-type
        receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was observed
        for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the wild-type
        and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase, P<0.05).
        This effect was even more pronounced for the 5''-substituted compound NECA
        (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: '', pubmed: '8794889',
    seq: '91', to_res: A}
- {entry_name: oprd_human, from_res: V, info: '[...], three mutants appeared to have
        their affinities altered (from 3- to 25-fold) for all or three of the four
        delta-selective ligands. These mutants are W284A, V296A, and V297A.', ligand_long: '[3H]bremazocine',
    ligand_short: '', pubmed: '8702536', seq: '296', to_res: A}
- {entry_name: aa2ar_human, from_res: N, info: 'Substitution of Asn-253 with Ser or
        Gln almost completely abolished [3H]CGS 21680 (<2% specific binding compared
        to wt) or [3H]XAC (<10% specific binding compared to wt) binding.', ligand_long: '',
    ligand_short: '', pubmed: '7775460', seq: '253', to_res: Q}
- {entry_name: aa2ar_human, from_res: N, info: 'Substitution of Asn-253 with Ser or
        Gln almost completely abolished [3H]CGS 21680 (<2% specific binding compared
        to wt) or [3H]XAC (<10% specific binding compared to wt) binding.', ligand_long: '',
    ligand_short: '', pubmed: '7775460', seq: '253', to_res: S}
- {entry_name: aa2ar_human, from_res: N, info: 'Assuming that the Ala mutant receptors
        are properly expressed on the cell surface (see ELISA results below) these
        results indicate that the above five residues are important, either directly
        or indirectly, for the high affinity binding of both agonist and antagonist
        ligands.', ligand_long: '', ligand_short: '', pubmed: '7775460', seq: '253',
    to_res: A}
- {entry_name: aa2ar_human, from_res: H, info: 'Assuming that the Ala mutant receptors
        are properly expressed on the cell surface (see ELISA results below) these
        results indicate that the above five residues are important, either directly
        or indirectly, for the high affinity binding of both agonist and antagonist
        ligands.', ligand_long: '', ligand_short: '', pubmed: '7775460', seq: '250',
    to_res: A}
- {entry_name: aa2ar_human, from_res: F, info: 'Assuming that the Ala mutant receptors
        are properly expressed on the cell surface (see ELISA results below) these
        results indicate that the above five residues are important, either directly
        or indirectly, for the high affinity binding of both agonist and antagonist
        ligands.', ligand_long: '[3H]XAC', ligand_short: '', pubmed: '7775460', seq: '182',
    to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: 'Substitution of Ser-281 with Thr (present
        in A1 receptors) led to an about 10-fold increase in affinity for the agonists
        CADO and R-PIA, both of which are more potent at A1 versus A2a receptors.',
    ligand_long: '[3H]CGS 21680', ligand_short: XAC, pubmed: '7775460', seq: '281',
    to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Substitution of Ser-281 with Thr (present
        in A1 receptors) led to an about 10-fold increase in affinity for the agonists
        CADO and R-PIA, both of which are more potent at A1 versus A2a receptors.',
    ligand_long: '[3H]CGS 21680', ligand_short: CGS 15943, pubmed: '7775460', seq: '281',
    to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Substitution of Ser-281 with Thr (present
        in A1 receptors) led to an about 10-fold increase in affinity for the agonists
        CADO and R-PIA, both of which are more potent at A1 versus A2a receptors.',
    ligand_long: '[3H]CGS 21680', ligand_short: R-PIA, pubmed: '7775460', seq: '281',
    to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Substitution of Ser-281 with Thr (present
        in A1 receptors) led to an about 10-fold increase in affinity for the agonists
        CADO and R-PIA, both of which are more potent at A1 versus A2a receptors.',
    ligand_long: '[3H]CGS 21680', ligand_short: NECA, pubmed: '7775460', seq: '281',
    to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Substitution of Ser-281 with Thr (present
        in A1 receptors) led to an about 10-fold increase in affinity for the agonists
        CADO and R-PIA, both of which are more potent at A1 versus A2a receptors.',
    ligand_long: '[3H]CGS 21680', ligand_short: DPMA, pubmed: '7775460', seq: '281',
    to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Substitution of Ser-281 with Thr (present
        in A1 receptors) led to an about 10-fold increase in affinity for the agonists
        CADO and R-PIA, both of which are more potent at A1 versus A2a receptors.',
    ligand_long: '[3H]CGS 21680', ligand_short: CADO, pubmed: '7775460', seq: '281',
    to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Substitution of Ser-281 with Thr (present
        in A1 receptors) led to an about 10-fold increase in affinity for the agonists
        CADO and R-PIA, both of which are more potent at A1 versus A2a receptors.',
    ligand_long: '[3H]CGS 21680', ligand_short: '', pubmed: '7775460', seq: '281',
    to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: XAC, pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: CGS 15943, pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: R-PIA, pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: NECA, pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: DPMA, pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: CADO, pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: '', pubmed: '7775460', seq: '277', to_res: T}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: XAC, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: CGS 15943, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: R-PIA, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: NECA, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: DPMA, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: CADO, pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: aa2ar_human, from_res: S, info: 'Curiously, the S277A mutant receptor
        was unable to bind significant amounts of [3H]CGS 21680 present at 15 nM but
        showed normal affinity for [3H]XAC. Thus, the hydroxy group present in the
        side chain of Ser-277 is required for high-affinity binding of agonists, but
        not antagonists.Substitution of Ser-277 with Asn or Thr resulted in only minor
        changes in binding affinities of all ligand examined.', ligand_long: '[3H]CGS
        21680', ligand_short: '', pubmed: '7775460', seq: '277', to_res: N}
- {entry_name: drd2_human_nwt, from_res: C, info: 'The binding of N-methylspiperone
        to Cys-182A was significantly inhibited by 2.5 mM MTSEA, [...].C182A was significantly
        potentiated by MTSES, an effect similar to that seen with D108C, [...].',
    ligand_long: '[3H]N-methylspiperone', ligand_short: YM-09151-2, pubmed: '14704269',
    seq: '182', to_res: A}
- {entry_name: drd2_human_nwt, from_res: C, info: 'The binding of N-methylspiperone
        to Cys-182A was significantly inhibited by 2.5 mM MTSEA, [...].C182A was significantly
        potentiated by MTSES, an effect similar to that seen with D108C, [...].',
    ligand_long: '[3H]N-methylspiperone', ligand_short: '', pubmed: '14704269', seq: '182',
    to_res: A}
- {entry_name: drd2_human_nwt, from_res: N, info: 'The antagonist YM-09151-2 at 20
        nM significantly protected against the reaction with MTSEA by 62+-3% (n=4,
        P<0.01) and 79+-10% (n=4, P<0.01) for I184C and N186C, respectively.In addition
        to I184C and N186C, I183C was significantly inhibited by treatment with 1
        mM MTSET.Ligand binding to 5 of the 10 cysteine-substitution mutants in E2
        was inhibited by one or more of the sulfhydryl reagents tested. These include
        A177C, E181C, I183C, I184C, and N186C.The reaction of I184C and N186C with
        MTsea strongly inhibited [3H]N-methylspiperone binding.Thus, the residues
        after Cys-E2, Ile-184, and Asn-186, are likely close to the core of the ligand-binding
        pocket, consistent with the strong impact on ligand binding of the attachment
        of -SCH2CH2NH3+.The residues Gly-173 and Asn-175, at the extracellular end
        of TM4, are also likely located close to the core of the ligand-binding pocket,
        as the corresponding cysteine mutants have similar reaction profiles with
        the MTS reagents as do those for Ile-184 and Asn-186.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: YM-09151-2, pubmed: '14704269', seq: '186', to_res: C}
- {entry_name: drd2_human_nwt, from_res: N, info: 'The antagonist YM-09151-2 at 20
        nM significantly protected against the reaction with MTSEA by 62+-3% (n=4,
        P<0.01) and 79+-10% (n=4, P<0.01) for I184C and N186C, respectively.In addition
        to I184C and N186C, I183C was significantly inhibited by treatment with 1
        mM MTSET.Ligand binding to 5 of the 10 cysteine-substitution mutants in E2
        was inhibited by one or more of the sulfhydryl reagents tested. These include
        A177C, E181C, I183C, I184C, and N186C.The reaction of I184C and N186C with
        MTsea strongly inhibited [3H]N-methylspiperone binding.Thus, the residues
        after Cys-E2, Ile-184, and Asn-186, are likely close to the core of the ligand-binding
        pocket, consistent with the strong impact on ligand binding of the attachment
        of -SCH2CH2NH3+.The residues Gly-173 and Asn-175, at the extracellular end
        of TM4, are also likely located close to the core of the ligand-binding pocket,
        as the corresponding cysteine mutants have similar reaction profiles with
        the MTS reagents as do those for Ile-184 and Asn-186.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '14704269', seq: '186', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The Ki of the antagonist YM-09151-2
        in competition with [3H]N-methylspiperone was also determined. For A177C,
        the Ki was 4.5 fold (P<0.05) that of C118S; for I183C and I184C, the Ki values
        were 11- and 12-fold (P<0.01) that of C118S.[...], I184C and N186C, a 2-min
        application of 2.5 mM MTSEA significantly inhibited [3H]N-methylspiperone
        binding.The antagonist YM-09151-2 at 20 nM significantly protected against
        the reaction with MTSEA by 62+-3% (n=4, P<0.01) and 79+-10% (n=4, P<0.01)
        for I184C and N186C, respectively.In addition to I184C and N186C, I183C was
        significantly inhibited by treatment with 1 mM MTSET.In contrast, in the I184C
        construct, MTSES had a strong inhibitory effect on N-methylspiperone binding,
        [...].Ligand binding to 5 of the 10 cysteine-substitution mutants in E2 was
        inhibited by one or more of the sulfhydryl reagents tested. These include
        A177C, E181C, I183C, I184C, and N186C.The reaction of I184C and N186C with
        MTsea strongly inhibited [3H]N-methylspiperone binding.Thus, the residues
        after Cys-E2, Ile-184, and Asn-186, are likely close to the core of the ligand-binding
        pocket, consistent with the strong impact on ligand binding of the attachment
        of -SCH2CH2NH3+.The residues Gly-173 and Asn-175, at the extracellular end
        of TM4, are also likely located close to the core of the ligand-binding pocket,
        as the corresponding cysteine mutants have similar reaction profiles with
        the MTS reagents as do those for Ile-184 and Asn-186.However, for three of
        the mutants A177C, I183C, and I184C, the binding affinity for the antagonist
        YM-09151-2 was significantly lower than that of the background receptor, consistent
        with a possible role of these WT side chains in the direct binding of this
        antagonist.', ligand_long: '[3H]N-methylspiperone', ligand_short: Ym-09151-2,
    pubmed: '14704269', seq: '184', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The Ki of the antagonist YM-09151-2
        in competition with [3H]N-methylspiperone was also determined. For A177C,
        the Ki was 4.5 fold (P<0.05) that of C118S; for I183C and I184C, the Ki values
        were 11- and 12-fold (P<0.01) that of C118S.[...], I184C and N186C, a 2-min
        application of 2.5 mM MTSEA significantly inhibited [3H]N-methylspiperone
        binding.The antagonist YM-09151-2 at 20 nM significantly protected against
        the reaction with MTSEA by 62+-3% (n=4, P<0.01) and 79+-10% (n=4, P<0.01)
        for I184C and N186C, respectively.In addition to I184C and N186C, I183C was
        significantly inhibited by treatment with 1 mM MTSET.In contrast, in the I184C
        construct, MTSES had a strong inhibitory effect on N-methylspiperone binding,
        [...].Ligand binding to 5 of the 10 cysteine-substitution mutants in E2 was
        inhibited by one or more of the sulfhydryl reagents tested. These include
        A177C, E181C, I183C, I184C, and N186C.The reaction of I184C and N186C with
        MTsea strongly inhibited [3H]N-methylspiperone binding.Thus, the residues
        after Cys-E2, Ile-184, and Asn-186, are likely close to the core of the ligand-binding
        pocket, consistent with the strong impact on ligand binding of the attachment
        of -SCH2CH2NH3+.The residues Gly-173 and Asn-175, at the extracellular end
        of TM4, are also likely located close to the core of the ligand-binding pocket,
        as the corresponding cysteine mutants have similar reaction profiles with
        the MTS reagents as do those for Ile-184 and Asn-186.However, for three of
        the mutants A177C, I183C, and I184C, the binding affinity for the antagonist
        YM-09151-2 was significantly lower than that of the background receptor, consistent
        with a possible role of these WT side chains in the direct binding of this
        antagonist.', ligand_long: '[3H]N-methylspiperone', ligand_short: '', pubmed: '14704269',
    seq: '184', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The Ki of the antagonist YM-09151-2
        in competition with [3H]N-methylspiperone was also determined. For A177C,
        the Ki was 4.5 fold (P<0.05) that of C118S; for I183C and I184C, the Ki values
        were 11- and 12-fold (P<0.01) that of C118S.In addition to I184C and N186C,
        I183C was significantly inhibited by treatment with 1 mM MTSET.Ligand binding
        to 5 of the 10 cysteine-substitution mutants in E2 was inhibited by one or
        more of the sulfhydryl reagents tested. These include A177C, E181C, I183C,
        I184C, and N186C.MTSET, which is bulkier than MTSEA, identified an additional
        residue, I183C, the reaction of which inhibited binding.However, for three
        of the mutants A177C, I183C, and I184C, the binding affinity for the antagonist
        YM-09151-2 was significantly lower than that of the background receptor, consistent
        with a possible role of these WT side chains in the direct binding of this
        antagonist.', ligand_long: '[3H]N-methylspiperone', ligand_short: YM-09151-2,
    pubmed: '14704269', seq: '183', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The Ki of the antagonist YM-09151-2
        in competition with [3H]N-methylspiperone was also determined. For A177C,
        the Ki was 4.5 fold (P<0.05) that of C118S; for I183C and I184C, the Ki values
        were 11- and 12-fold (P<0.01) that of C118S.In addition to I184C and N186C,
        I183C was significantly inhibited by treatment with 1 mM MTSET.Ligand binding
        to 5 of the 10 cysteine-substitution mutants in E2 was inhibited by one or
        more of the sulfhydryl reagents tested. These include A177C, E181C, I183C,
        I184C, and N186C.MTSET, which is bulkier than MTSEA, identified an additional
        residue, I183C, the reaction of which inhibited binding.However, for three
        of the mutants A177C, I183C, and I184C, the binding affinity for the antagonist
        YM-09151-2 was significantly lower than that of the background receptor, consistent
        with a possible role of these WT side chains in the direct binding of this
        antagonist.', ligand_long: '[3H]N-methylspiperone', ligand_short: '', pubmed: '14704269',
    seq: '183', to_res: C}
- {entry_name: drd2_human_nwt, from_res: E, info: 'In contrast, Ala-177 and Glu-181
        are likely more distant from the binding site, consistent with the need for
        attachment of the bulkier bioin moieties to perturb ligand binding.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: YM-09151-2, pubmed: '14704269', seq: '181', to_res: C}
- {entry_name: drd2_human_nwt, from_res: E, info: 'In contrast, Ala-177 and Glu-181
        are likely more distant from the binding site, consistent with the need for
        attachment of the bulkier bioin moieties to perturb ligand binding.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '14704269', seq: '181', to_res: C}
- {entry_name: drd2_human_nwt, from_res: A, info: 'Ligand binding to 5 of the 10 cysteine-substitution
        mutants in E2 was inhibited by one or more of the sulfhydryl reagents tested.
        These include A177C, E181C, I183C, I184C, and N186C.In contrast, Ala-177 and
        Glu-181 are likely more distant from the binding site, consistent with the
        need for attachment of the bulkier bioin moieties to perturb ligand binding.However,
        for three of the mutants A177C, I183C, and I184C, the binding affinity for
        the antagonist YM-09151-2 was significantly lower than that of the background
        receptor, consistent with a possible role of these WT side chains in the direct
        binding of this antagonist.', ligand_long: '[3H]N-methylspiperone', ligand_short: YM-09151-2,
    pubmed: '14704269', seq: '177', to_res: C}
- {entry_name: drd2_human_nwt, from_res: A, info: 'Ligand binding to 5 of the 10 cysteine-substitution
        mutants in E2 was inhibited by one or more of the sulfhydryl reagents tested.
        These include A177C, E181C, I183C, I184C, and N186C.In contrast, Ala-177 and
        Glu-181 are likely more distant from the binding site, consistent with the
        need for attachment of the bulkier bioin moieties to perturb ligand binding.However,
        for three of the mutants A177C, I183C, and I184C, the binding affinity for
        the antagonist YM-09151-2 was significantly lower than that of the background
        receptor, consistent with a possible role of these WT side chains in the direct
        binding of this antagonist.', ligand_long: '[3H]N-methylspiperone', ligand_short: '',
    pubmed: '14704269', seq: '177', to_res: C}
- {entry_name: acm1_rat, from_res: A, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '196', to_res: G}
- {entry_name: acm1_rat, from_res: A, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: formylcholine,
    pubmed: '10860940', seq: '196', to_res: G}
- {entry_name: acm1_rat, from_res: A, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '10860940', seq: '196', to_res: G}
- {entry_name: agtr1_human, from_res: T, info: 'One mutation, A104V, at the top of
        TM III impaired the binding of both compounds regardless of their biological
        properties. At the top of TM VII, an overlap in mutational susceptibility
        was found at residue Thr287 between angiotensin II and the new nonpeptide
        antagonist L-162,389.', ligand_long: '125I-[Sar,Leu]Angiotensin II', ligand_short: 'L-162,389',
    pubmed: '9203636', seq: '287', to_res: A}
- {entry_name: agtr1_human, from_res: T, info: 'At the top of TM VII, an overlap in
        mutational susceptibility was found at residue Thr287 between angiotensin
        II and the new nonpeptide antagonist L-162,389.', ligand_long: '125I-[Sar,Leu]Angiotensin
        II', ligand_short: Angiotensin II, pubmed: '9203636', seq: '287', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: prazosin, pubmed: '8980109', seq: '338', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)-norepinephrine, pubmed: '8980109', seq: '338', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (+)-epinephrine, pubmed: '8980109', seq: '338', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)-epinephrine, pubmed: '8980109', seq: '338', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: Prazosin, pubmed: '8980109', seq: '203', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)-norepinephrine, pubmed: '8980109', seq: '203', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (+)-epinephrine, pubmed: '8980109', seq: '203', to_res: A}
- {entry_name: ada1b_mesau, from_res: Y, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)-epinephrine, pubmed: '8980109', seq: '203', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '',
    ligand_short: '', pubmed: '8980109', seq: '135', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: prazosin, pubmed: '8980109', seq: '132', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)-norepinephrine, pubmed: '8980109', seq: '132', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (+)-epinephrine, pubmed: '8980109', seq: '132', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Comments: activation data were calcuted
        as followed:  IP accumulation MUTATION (expressed as % over OWN basal level)
        / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)-epinephrine, pubmed: '8980109', seq: '132', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: '', pubmed: '8794889',
    seq: '89', to_res: R}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: '', pubmed: '8794889',
    seq: '89', to_res: H}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: '', pubmed: '8794889',
    seq: '89', to_res: L}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: '', pubmed: '8794889',
    seq: '89', to_res: S}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: '', pubmed: '8794889',
    seq: '89', to_res: N}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: ZM-241385, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: BTH4, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: XAC, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: CGS-15943, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: SCH-58261, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: ADAC, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: IB-MECA, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: R-PIA, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: NECA, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: DPMA, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: CADO, pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'From saturation binding, it was determined
        that the Q89A mutant receptor had a 4.6-fold greater affinity for [3H]CGS-21680
        (6.70+-0.86 nM) than the wild-type receptor (31.0+-1.0 nM). The affinities
        of the competing ligands at the Q89A mutant receptor were dramatically higher
        than in the wild-type receptor. IB-MECA had the greatest ratio of affinities
        (136-fold versus the wild-type receptor), whereas the the potencies of ADAC
        and NECA were enhanced 32- and 15-fold respectively. Other N6-modified analogues,
        such as R-PIA and DPMA, and the C2-modified analogue CADO were 5-12-fold more
        potent in binding at the Q89A mutant receptor. The antagonist generally displayed
        a 4-5-fold enhancement of affinity at the Q89A mutant receptor versus the
        wild-type receptor.Substitution of Q89 by residues, charged or uncharged,
        larger than alanine (Q89S, Q89N, Q89L, Q89H, and Q89R) did not preclude the
        high affinity binding of [3H]CGS-21680.The mutant receptors Q89S and Q89N
        had a lower affinity (3-fold) for the radioligand than wild-type receptors.
        The mutant receptor Q89A was unique in having increased affinity for [3H]CGS-21680.The
        2''- and 5''-disubstituted adenosine agonist CGS-21680 acting at the Q89A
        mutant receptor elicited a dose-dependent stimulation of cAMP production with
        an EC50 value of 0.223+-0.054 nM [i.e., 4-fold more potent (P<0.05) than at
        wild-type receptors (EC50 = 0.915+-0.213 nM)]. A similar gain of potency was
        observed for the N6-substituted compound DPMA (EC50 = 10.8+-1.4 nM at the
        wild-type and 2.73+-0.59 nM at the Q89A mutant receptor; a 4-fold increase,
        P<0.05). This effect was even more pronounced for the 5''-substituted compound
        NECA (EC50 = 44.5+-6.2 nM at the wild-type and 2.91+-0.54 nM at the Q89A mutant
        receptor), whereas the Q89A mutation induced a 15.3-fold increase in potency
        (P<0.01).', ligand_long: '[3H]CGS-21680', ligand_short: '', pubmed: '8794889',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: ZM-241385, pubmed: '8794889',
    seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CGS-15943, pubmed: '8794889',
    seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CGS-21680, pubmed: '8794889',
    seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: NECA, pubmed: '8794889',
    seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: DPMA, pubmed: '8794889',
    seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CADO, pubmed: '8794889',
    seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: '', pubmed: '8794889',
    seq: '88', to_res: R}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: ZM-241385, pubmed: '8794889',
    seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CGS-15943, pubmed: '8794889',
    seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CGS-21680, pubmed: '8794889',
    seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: NECA, pubmed: '8794889',
    seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: DPMA, pubmed: '8794889',
    seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CADO, pubmed: '8794889',
    seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: '', pubmed: '8794889',
    seq: '88', to_res: S}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: ZM-241385, pubmed: '8794889',
    seq: '88', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CGS-15943, pubmed: '8794889',
    seq: '88', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CGS-21680, pubmed: '8794889',
    seq: '88', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: NECA, pubmed: '8794889',
    seq: '88', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: DPMA, pubmed: '8794889',
    seq: '88', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: CADO, pubmed: '8794889',
    seq: '88', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'Ki values for competition of binding
        of [3H]XAC by agonists in T88A and T88R mutant receptors indicated a 60-830-fold
        lower affinity than in wild-type receptors.Even the T88S mutant receptor,
        which differs only in the absence of a methyl group, bound agonist with 6.6-fold
        (for CADO) to 41-fold (for NECA) lower affinity. Affinities of the antagonist
        XAC and ZM-241385 were unchanged in the T88S mutant-receptor, whereas CGS-15943
        was 5.2-fold weaker than in wild-type receptors.The removal of the serine
        hydroxyl group of the T88S mutant, already impaired in its ability to bind
        agonist, diminished by 52-fold the affinity of this adenosine derivative.expression
        levels for the various mutants (HA-tagged wild-type receptor = 100%) determined
        according to this method were as follows (six experiments): T88A, 77.3+-12.5%;
        T88S, 89.8+-43.0%; and T88R, 134+-38.3%.Thus, functional potency of CGS-21680
        was far less at the T88A and T88S mutant receptors than at wild-type receptors
        (EC50 = 0.915+-0.213 nM) by factors of 15,700 and 353, respectively.The T88R
        mutant however, showed minimal stimulation of adenyl cyclase even at 1 mM
        CGS-21680.', ligand_long: '[3H]XAC', ligand_short: '', pubmed: '8794889',
    seq: '88', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: Prazosin, pubmed: '8980109',
    seq: '211', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: synephrine, pubmed: '8980109',
    seq: '211', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: phenylephrine, pubmed: '8980109',
    seq: '211', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: (-)-Norepinephrine, pubmed: '8980109',
    seq: '211', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: (+)-epinephrine, pubmed: '8980109',
    seq: '211', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: (-)-epinephrine, pubmed: '8980109',
    seq: '211', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: Prazosin, pubmed: '8980109',
    seq: '208', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: Synephrine, pubmed: '8980109',
    seq: '208', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: phenylepiphrine, pubmed: '8980109',
    seq: '208', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: (-)-Norepinephrine, pubmed: '8980109',
    seq: '208', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: (+)-epinephrine, pubmed: '8980109',
    seq: '208', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Mutations of either S208 or S211 did
        not impair the receptor''s ability to mediate epinephrine-induced IP accumulation.[..],
        the integrity of at least one of S208 and S211 is a crucial requirement for
        receptor activation despite having a marginal role on ligand binding.Comments:
        activation data were calcuted as followed:  IP accumulation MUTATION (expressed
        as % over OWN basal level) / IP accumulation WT (expressed as % over OWN basal
        level).', ligand_long: '[125I]HEAT', ligand_short: (-)-epinephrine, pubmed: '8980109',
    seq: '208', to_res: A}
- {entry_name: acm1_rat, from_res: W, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.', ligand_long: '[3H]QNB',
    ligand_short: '', pubmed: '17848601', seq: '378', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Dose-response of (-)epinephrine in
        rat cells expressing the S207A receptor indicated that the maximal levels
        of IP accumulation (Rmax) were comparable to that of cells expressing the
        wild-type alpha1b-AR, whereas its potency (EC50) was about 100-fold lower
        in agreement with its reduced binding affinity.Comments: activation data were
        calcuted as followed:  IP accumulation MUTATION (expressed as % over OWN basal
        level) / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: prazosin, pubmed: '8980109', seq: '207', to_res: A}
- {entry_name: acm1_rat, from_res: W, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '17848601', seq: '378', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Dose-response of (-)epinephrine in
        rat cells expressing the S207A receptor indicated that the maximal levels
        of IP accumulation (Rmax) were comparable to that of cells expressing the
        wild-type alpha1b-AR, whereas its potency (EC50) was about 100-fold lower
        in agreement with its reduced binding affinity.Comments: activation data were
        calcuted as followed:  IP accumulation MUTATION (expressed as % over OWN basal
        level) / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: synephrine, pubmed: '8980109', seq: '207', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Dose-response of (-)epinephrine in
        rat cells expressing the S207A receptor indicated that the maximal levels
        of IP accumulation (Rmax) were comparable to that of cells expressing the
        wild-type alpha1b-AR, whereas its potency (EC50) was about 100-fold lower
        in agreement with its reduced binding affinity.Comments: activation data were
        calcuted as followed:  IP accumulation MUTATION (expressed as % over OWN basal
        level) / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: phenylephrine, pubmed: '8980109', seq: '207', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Dose-response of (-)epinephrine in
        rat cells expressing the S207A receptor indicated that the maximal levels
        of IP accumulation (Rmax) were comparable to that of cells expressing the
        wild-type alpha1b-AR, whereas its potency (EC50) was about 100-fold lower
        in agreement with its reduced binding affinity.Comments: activation data were
        calcuted as followed:  IP accumulation MUTATION (expressed as % over OWN basal
        level) / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)-Norepinephrine, pubmed: '8980109', seq: '207', to_res: A}
- {entry_name: acm1_rat, from_res: W, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '17848601', seq: '378', to_res: A}
- {entry_name: ada1b_mesau, from_res: S, info: 'Dose-response of (-)epinephrine in
        rat cells expressing the S207A receptor indicated that the maximal levels
        of IP accumulation (Rmax) were comparable to that of cells expressing the
        wild-type alpha1b-AR, whereas its potency (EC50) was about 100-fold lower
        in agreement with its reduced binding affinity.Comments: activation data were
        calcuted as followed:  IP accumulation MUTATION (expressed as % over OWN basal
        level) / IP accumulation WT (expressed as % over OWN basal level).', ligand_long: '[125I]HEAT',
    ligand_short: (-)epinephrine, pubmed: '8980109', seq: '207', to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.Expression in F197A was rescued
        by atropine treatment of the cells after transfection. The ability of atropine
        to act as a "pharmacological chaperone" for poorly expressed mutants has been
        described previously (Lu and Hulme, 1999).', ligand_long: '[3H]QNB', ligand_short: '',
    pubmed: '17848601', seq: '197', to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.Expression in F197A was rescued
        by atropine treatment of the cells after transfection. The ability of atropine
        to act as a "pharmacological chaperone" for poorly expressed mutants has been
        described previously (Lu and Hulme, 1999).', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '17848601', seq: '197', to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '17848601', seq: '197', to_res: A}
- {entry_name: acm1_rat, from_res: D, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.', ligand_long: '[3H]QNB',
    ligand_short: '', pubmed: '17848601', seq: '99', to_res: A}
- {entry_name: acm1_rat, from_res: D, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '17848601', seq: '99', to_res: A}
- {entry_name: acm1_rat, from_res: D, info: 'Mutation of Asp99 and Trp378 (the latter
        measured by inhibition of [3H]QNB binding) reduced ACh affinity by 10-fold,
        but mutation of Phe197 had no significant effect.', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '17848601', seq: '99', to_res: A}
- {entry_name: acm1_rat, from_res: Y, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '[3H]QNB', ligand_short: '',
    pubmed: '17848601', seq: '179', to_res: A}
- {entry_name: acm1_rat, from_res: Y, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '17848601', seq: '179', to_res: A}
- {entry_name: acm1_rat, from_res: Y, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '17848601', seq: '179', to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.', ligand_long: '[3H]QNB', ligand_short: '', pubmed: '17848601', seq: '182',
    to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '17848601', seq: '182',
    to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.', ligand_long: '', ligand_short: Acetylcholine, pubmed: '17848601',
    seq: '182', to_res: A}
- {entry_name: acm1_rat, from_res: I, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '[3H]QNB', ligand_short: '',
    pubmed: '17848601', seq: '180', to_res: A}
- {entry_name: acm1_rat, from_res: I, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '17848601', seq: '180', to_res: A}
- {entry_name: acm1_rat, from_res: I, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '17848601', seq: '180', to_res: A}
- {entry_name: acm1_rat, from_res: R, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '[3H]QNB', ligand_short: '',
    pubmed: '17848601', seq: '171', to_res: A}
- {entry_name: acm1_rat, from_res: R, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '17848601', seq: '171', to_res: A}
- {entry_name: acm1_rat, from_res: R, info: 'Alanine substitution of the ECL2 loop
        residues Arg171, Tyr179, Ile180 and Phe182 marginally reduced the affinity
        of NMS from the wild type value of 6.6+-0.5*10^9/M. The maximum effect was
        5-fold (R171A). These mutations did not significantly affect  the affinity
        of QNB.Among the ECL2 residues, only mutations of Arg171 and Ile180 decreased
        the affinity of Ach, by 3- to 4-fold.', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '17848601', seq: '171', to_res: A}
- {entry_name: acm1_rat, from_res: E, info: 'Among the ECL2 residues, only mutations
        of Arg171 and Ile180 decreased the affinity of ACh.', ligand_long: '', ligand_short: Acetylcholine,
    pubmed: '17848601', seq: '170', to_res: A}
- {entry_name: p2ry1_human, from_res: S, info: 'In the case of the S317A mutant receptor,
        the potency ratio 2-MeSADP versus HT-AMP was ~400.Comments: Mutation is located
        in TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613', seq: '317',
    to_res: A}
- {entry_name: agtr1_human, from_res: A, info: 'One mutation, A104V, at the top of
        TM III impaired the binding of both compounds (L-162,389 and L-162,782 red.)
        regardless of their biological properties.', ligand_long: '125I-[Sar,Leu]Angiotensin
        II', ligand_short: 'L-162,782', pubmed: '9203636', seq: '104', to_res: V}
- {entry_name: p2ry1_human, from_res: S, info: 'In the case of the S317A mutant receptor,
        the potency ratio 2-MeSADP versus HT-AMP was ~400.Comments: Mutation is located
        in TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613', seq: '317',
    to_res: A}
- {entry_name: p2ry1_human, from_res: S, info: 'In the case of the S317A mutant receptor,
        the potency ratio 2-MeSADP versus HT-AMP was ~400.Comments: Mutation is located
        in TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613', seq: '317',
    to_res: A}
- {entry_name: p2ry1_human, from_res: S, info: 'The ligand recognition properties
        of the S314A mutant could be rescued substantially by substitution with T
        instead of A. Thus, the potency of 2-MeSATP at S314T mutant receptors was
        only 8.9-fold reduced compared with wild-typer receptors.The residues that
        were found most critical for activation by 2-MeSATP (R128, R310, and S314)
        were also absolutely critical for activation of the receptor by monophosphates
        and diphosphates.Alanine scanning mutagenesis showed that residues R128, K280,
        Q307, R310, and S314 are critical for high potency agonist-induced activation
        of phosholipase C.Comments: Mutation is located in TM7.', ligand_long: '',
    ligand_short: '', pubmed: '9281613', seq: '314', to_res: T}
- {entry_name: p2ry1_human, from_res: S, info: 'The ligand recognition properties
        of the S314A mutant could be rescued substantially by substitution with T
        instead of A. Thus, the potency of 2-MeSATP at S314T mutant receptors was
        only 8.9-fold reduced compared with wild-typer receptors.The residues that
        were found most critical for activation by 2-MeSATP (R128, R310, and S314)
        were also absolutely critical for activation of the receptor by monophosphates
        and diphosphates.Alanine scanning mutagenesis showed that residues R128, K280,
        Q307, R310, and S314 are critical for high potency agonist-induced activation
        of phosholipase C.Comments: Mutation is located in TM7.', ligand_long: '',
    ligand_short: '', pubmed: '9281613', seq: '314', to_res: T}
- {entry_name: agtr1_human, from_res: A, info: 'Thus, except for the A104V substituion,
        none of the tested mutations in the TM of the AT1 receptor had any major effect
        on the affinity of the nonpeptide partial agonist compounds as determined
        in competition binding assays, albeit slight effects were observed for the
        most antagonistic one, L-162,389.One mutation, A104V, at the top of TM III
        impaired the binding of both compounds regardless of their biological properties
        (L-162,389 and L-162,782 red.).', ligand_long: '125I-[Sar,Leu]Angiotensin
        II', ligand_short: 'L-162,389', pubmed: '9203636', seq: '104', to_res: V}
- {entry_name: p2ry1_human, from_res: S, info: 'The ligand recognition properties
        of the S314A mutant could be rescued substantially by substitution with T
        instead of A. Thus, the potency of 2-MeSATP at S314T mutant receptors was
        only 8.9-fold reduced compared with wild-typer receptors.The residues that
        were found most critical for activation by 2-MeSATP (R128, R310, and S314)
        were also absolutely critical for activation of the receptor by monophosphates
        and diphosphates.Alanine scanning mutagenesis showed that residues R128, K280,
        Q307, R310, and S314 are critical for high potency agonist-induced activation
        of phosholipase C.Comments: Mutation is located in TM7.', ligand_long: '',
    ligand_short: '', pubmed: '9281613', seq: '314', to_res: T}
- {entry_name: p2ry1_human, from_res: S, info: 'The ligand recognition properties
        of the S314A mutant could be rescued substantially by substitution with T
        instead of A. Thus, the potency of 2-MeSATP at S314T mutant receptors was
        only 8.9-fold reduced compared with wild-typer receptors.The residues that
        were found most critical for activation by 2-MeSATP (R128, R310, and S314)
        were also absolutely critical for activation of the receptor by monophosphates
        and diphosphates.Alanine scanning mutagenesis showed that residues R128, K280,
        Q307, R310, and S314 are critical for high potency agonist-induced activation
        of phosholipase C.Comments: Mutation is located in TM7.', ligand_long: '',
    ligand_short: '', pubmed: '9281613', seq: '314', to_res: A}
- {entry_name: p2ry1_human, from_res: R, info: 'The residues that were found most
        critical for activation by 2-MeSATP (R128, R310, and S314) were also absolutely
        critical for activation of the receptor by monophosphates and diphosphates.Alanine
        scanning mutagenesis showed that residues R128, K280, Q307, R310, and S314
        are critical for high potency agonist-induced activation of phosholipase C.Comments:
        Mutation is located in TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '310', to_res: K}
- {entry_name: p2ry1_human, from_res: R, info: 'The residues that were found most
        critical for activation by 2-MeSATP (R128, R310, and S314) were also absolutely
        critical for activation of the receptor by monophosphates and diphosphates.Alanine
        scanning mutagenesis showed that residues R128, K280, Q307, R310, and S314
        are critical for high potency agonist-induced activation of phosholipase C.Comments:
        Mutation is located in TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '310', to_res: K}
- {entry_name: p2ry1_human, from_res: R, info: 'The residues that were found most
        critical for activation by 2-MeSATP (R128, R310, and S314) were also absolutely
        critical for activation of the receptor by monophosphates and diphosphates.Alanine
        scanning mutagenesis showed that residues R128, K280, Q307, R310, and S314
        are critical for high potency agonist-induced activation of phosholipase C.Comments:
        Mutation is located in TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '310', to_res: K}
- {entry_name: p2ry1_human, from_res: R, info: 'The residues that were found most
        critical for activation by 2-MeSATP (R128, R310, and S314) were also absolutely
        critical for activation of the receptor by monophosphates and diphosphates.Alanine
        scanning mutagenesis showed that residues R128, K280, Q307, R310, and S314
        are critical for high potency agonist-induced activation of phosholipase C.Comments:
        Mutation is located in TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '310', to_res: A}
- {entry_name: p2ry1_human, from_res: Q, info: 'Alanine scanning mutagenesis showed
        that residues R128, K280, Q307, R310, and S314 are critical for high potency
        agonist-induced activation of phosholipase C.For K280A and Q307A mutant receptors,
        [...], and 2-MeSATP was shown to be a full agonist, although at markedly reduced
        potency compared with wild-type receptors.Comments: Mutation is located in
        TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613', seq: '307', to_res: A}
- {entry_name: p2ry1_human, from_res: Q, info: 'Alanine scanning mutagenesis showed
        that residues R128, K280, Q307, R310, and S314 are critical for high potency
        agonist-induced activation of phosholipase C.For K280A and Q307A mutant receptors,
        [...], and 2-MeSATP was shown to be a full agonist, although at markedly reduced
        potency compared with wild-type receptors.Comments: Mutation is located in
        TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613', seq: '307', to_res: A}
- {entry_name: p2ry1_human, from_res: Q, info: 'Alanine scanning mutagenesis showed
        that residues R128, K280, Q307, R310, and S314 are critical for high potency
        agonist-induced activation of phosholipase C.For K280A and Q307A mutant receptors,
        [...], and 2-MeSATP was shown to be a full agonist, although at markedly reduced
        potency compared with wild-type receptors.Comments: Mutation is located in
        TM7.', ligand_long: '', ligand_short: '', pubmed: '9281613', seq: '307', to_res: A}
- {entry_name: agtr1_human, from_res: A, info: 'The binding of L-162,389 was most
        seriously affected (26 fold) by the A104V substitution at the top of TM III,
        which also impaired L-158,809 binding by 8-fold.Thus, except for the A104V
        substituion, none of the tested mutations in the TM of the AT1 receptor had
        any major effect on the affinity of the nonpeptide partial agonist compounds
        as determined in competition binding assays, albeit slight effects were observed
        for the most antagonistic one, L-162,389.', ligand_long: '125I-[Sar,Leu]Angiotensin
        II', ligand_short: 'L-158,809', pubmed: '9203636', seq: '104', to_res: V}
- {entry_name: p2ry1_human, from_res: K, info: 'In addition, the K280A mutant receptor
        had greatly diminished potency of monophosphates and diphosophates as well
        as the triphosphates.Alanine scanning mutagenesis showed that residues R128,
        K280, Q307, R310, and S314 are critical for high potency agonist-induced activation
        of phosholipase C.For K280A and Q307A mutant receptors, [...], and 2-MeSATP
        was shown to be a full agonist, although at markedly reduced potency compared
        with wild-type receptors.Comments: Mutation is located in TM6.', ligand_long: '',
    ligand_short: '', pubmed: '9281613', seq: '280', to_res: A}
- {entry_name: p2ry1_human, from_res: K, info: 'In addition, the K280A mutant receptor
        had greatly diminished potency of monophosphates and diphosophates as well
        as the triphosphates.Alanine scanning mutagenesis showed that residues R128,
        K280, Q307, R310, and S314 are critical for high potency agonist-induced activation
        of phosholipase C.For K280A and Q307A mutant receptors, [...], and 2-MeSATP
        was shown to be a full agonist, although at markedly reduced potency compared
        with wild-type receptors.Comments: Mutation is located in TM6.', ligand_long: '',
    ligand_short: '', pubmed: '9281613', seq: '280', to_res: A}
- {entry_name: p2ry1_human, from_res: K, info: 'In addition, the K280A mutant receptor
        had greatly diminished potency of monophosphates and diphosophates as well
        as the triphosphates.Alanine scanning mutagenesis showed that residues R128,
        K280, Q307, R310, and S314 are critical for high potency agonist-induced activation
        of phosholipase C.For K280A and Q307A mutant receptors, [...], and 2-MeSATP
        was shown to be a full agonist, although at markedly reduced potency compared
        with wild-type receptors.Comments: Mutation is located in TM6.', ligand_long: '',
    ligand_short: '', pubmed: '9281613', seq: '280', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        ratio for potency of diphosphate versus triphosphate was generally 5-10-fold.
        An exception wasa the H277A mutant receptor, where diphosphates and triphosphates
        were equipotent.Comments: Mutation is located in TM6.', ligand_long: '', ligand_short: '',
    pubmed: '9281613', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        ratio for potency of diphosphate versus triphosphate was generally 5-10-fold.
        An exception wasa the H277A mutant receptor, where diphosphates and triphosphates
        were equipotent.Comments: Mutation is located in TM6.', ligand_long: '', ligand_short: '',
    pubmed: '9281613', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        ratio for potency of diphosphate versus triphosphate was generally 5-10-fold.
        An exception wasa the H277A mutant receptor, where diphosphates and triphosphates
        were equipotent.Comments: Mutation is located in TM6.', ligand_long: '', ligand_short: '',
    pubmed: '9281613', seq: '277', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '226', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '226', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        potency shifts for agonist at other mutant receptors versus wild-type receptors
        were less pronounced for HT-AMP versus 2-MeSATP: H132A (6.7- versus 12-fold),
        Y135A (4.8- versus 18-fold), T221A (5.1- versus 89-fold), and T222A (3.4-
        versus 33-fold).The change in potencies of 2-MeSATP at T221A and T222A mutant
        receptors (13-and 8.8-fold, respectively) versus wild-type receptors were
        intermediate between those for monophospates and triphosphates.Comments: Mutation
        is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '222', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        potency shifts for agonist at other mutant receptors versus wild-type receptors
        were less pronounced for HT-AMP versus 2-MeSATP: H132A (6.7- versus 12-fold),
        Y135A (4.8- versus 18-fold), T221A (5.1- versus 89-fold), and T222A (3.4-
        versus 33-fold).The change in potencies of 2-MeSATP at T221A and T222A mutant
        receptors (13-and 8.8-fold, respectively) versus wild-type receptors were
        intermediate between those for monophospates and triphosphates.Comments: Mutation
        is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '222', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        potency shifts for agonist at other mutant receptors versus wild-type receptors
        were less pronounced for HT-AMP versus 2-MeSATP: H132A (6.7- versus 12-fold),
        Y135A (4.8- versus 18-fold), T221A (5.1- versus 89-fold), and T222A (3.4-
        versus 33-fold).The change in potencies of 2-MeSATP at T221A and T222A mutant
        receptors (13-and 8.8-fold, respectively) versus wild-type receptors were
        intermediate between those for monophospates and triphosphates.Comments: Mutation
        is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '222', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        potency shifts for agonist at other mutant receptors versus wild-type receptors
        were less pronounced for HT-AMP versus 2-MeSATP: H132A (6.7- versus 12-fold),
        Y135A (4.8- versus 18-fold), T221A (5.1- versus 89-fold), and T222A (3.4-
        versus 33-fold).The change in potencies of 2-MeSATP at T221A and T222A mutant
        receptors (13-and 8.8-fold, respectively) versus wild-type receptors were
        intermediate between those for monophospates and triphosphates.Comments: Mutation
        is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '221', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        potency shifts for agonist at other mutant receptors versus wild-type receptors
        were less pronounced for HT-AMP versus 2-MeSATP: H132A (6.7- versus 12-fold),
        Y135A (4.8- versus 18-fold), T221A (5.1- versus 89-fold), and T222A (3.4-
        versus 33-fold).The change in potencies of 2-MeSATP at T221A and T222A mutant
        receptors (13-and 8.8-fold, respectively) versus wild-type receptors were
        intermediate between those for monophospates and triphosphates.Comments: Mutation
        is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '221', to_res: A}
- {entry_name: p2ry1_human, from_res: T, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.The
        potency shifts for agonist at other mutant receptors versus wild-type receptors
        were less pronounced for HT-AMP versus 2-MeSATP: H132A (6.7- versus 12-fold),
        Y135A (4.8- versus 18-fold), T221A (5.1- versus 89-fold), and T222A (3.4-
        versus 33-fold).The change in potencies of 2-MeSATP at T221A and T222A mutant
        receptors (13-and 8.8-fold, respectively) versus wild-type receptors were
        intermediate between those for monophospates and triphosphates.Comments: Mutation
        is located in TM5.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '221', to_res: A}
- {entry_name: p2ry1_human, from_res: Y, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '136', to_res: A}
- {entry_name: p2ry1_human, from_res: Y, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '136', to_res: A}
- {entry_name: p2ry1_human, from_res: Y, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '136', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '132', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '132', to_res: A}
- {entry_name: p2ry1_human, from_res: H, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '132', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.For
        example, the F131A mutation was relatively more important in reducing the
        potency of HT-AMP (150-fold) than of 2-MeSATP (6.5-fold).Comments: Mutation
        is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '131', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.For
        example, the F131A mutation was relatively more important in reducing the
        potency of HT-AMP (150-fold) than of 2-MeSATP (6.5-fold).Comments: Mutation
        is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '131', to_res: A}
- {entry_name: p2ry1_human, from_res: F, info: 'The potency of 2-MeSATP was reduced
        compared with wild-type receptors by 15-100-fold in Y136, T221, T222, and
        H277 mutant receptors and by 3-15-fold in F131A, H132A, and F226A mutant receptors.For
        example, the F131A mutation was relatively more important in reducing the
        potency of HT-AMP (150-fold) than of 2-MeSATP (6.5-fold).Comments: Mutation
        is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '131', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: 'Thus, in the N295D construct, there
        was a relatively close relationship between the affinity of the compounds
        as determined in competition binding assays (IC50 = 21-37 nm) and the IC50
        values obtained for these compounds as antagonists for a submaximal stimulatory
        dose of angiotensin.This mutant (N295D red.) does not affect the binding affinity
        of any of the three compounds, yet they all act as an almost pure antagonist
        in this receptor construct and, importantly, have IC50 values for inhibition
        of a submaximal stimulation with angiotensin that are similar to that of the
        most potent antagonist, L-162,389, on the wild-type receptor.', ligand_long: '125I-[Sar,Leu]Angiotensin
        II', ligand_short: 'L-162,782', pubmed: '9203636', seq: '295', to_res: D}
- {entry_name: agtra_rat, from_res: N, info: 'In regard to antagonistic property,
        all three nonpeptide compounds surprisingly acted as equally potent inhibitors
        of the angiotensin-induced increase in phosphatidylionositol turnover in the
        N295D construct, with IC50 values of 90-180 nm.Thus, in the N295D construct,
        there was a relatively close relationship between the affinity of the compounds
        as determined in competition binding assays (IC50 = 21-37 nm) and the IC50
        values obtained for these compounds as antagonists for a submaximal stimulatory
        dose of angiotensin. In the N295D construct, the L-162,389 behaved as an insurmountable
        antagonist as it did in the wild-type AT1 receptor, which unfortunately complicates
        a more thorough analysis of antagonist potency.This mutant (N295D red.) does
        not affect the binding affinity of any of the three compounds, yet they all
        act as an almost pure antagonist in this receptor construct and, importantly,
        have IC50 values for inhibition of a submaximal stimulation with angiotensin
        that are similar to that of the most potent antagonist, L-162,389, on the
        wild-type receptor.', ligand_long: '125I-[Sar,Leu]Angiotensin II', ligand_short: 'L-162,389',
    pubmed: '9203636', seq: '295', to_res: D}
- {entry_name: agtra_rat, from_res: N, info: 'The effects of the nonpeptide compounds
        were studied in greater detail in the N295D rat At1 construct. In this mutant,
        the increase in phosphatidylinositol turnover in response to L-162,782 and
        L-162,313 amounted to only 19.4 +- 2.6% and 19.4 +- 3.4% of the angiotensin
        response, respectively. Interestingly, no clear bell-shaped dose-response
        curves were observed in the N295D rat AT1 construct for the nonpeptide compounds
        that here functioned as merely relatively poor, classic partial agonists.
        In regard to antagonistic property, all three nonpeptide compounds surprisingly
        acted as equally potent inhibitors of the angiotensin-induced increase in
        phosphatidylionositol turnover in the N295D construct, with IC50 values of
        90-180 nm.Thus, in the N295D construct, there was a relatively close relationship
        between the affinity of the compounds as determined in competition binding
        assays (IC50 = 21-37 nm) and the IC50 values obtained for these compounds
        as antagonists for a submaximal stimulatory dose of angiotensin.This mutant
        (N295D red.) does not affect the binding affinity of any of the three compounds,
        yet they all act as an almost pure antagonist in this receptor construct and,
        importantly, have IC50 values for inhibition of a submaximal stimulation with
        angiotensin that are similar to that of the most potent antagonist, L-162,389,
        on the wild-type receptor.Surprisingly, we have not yet identified any receptor
        mutation that seriously affects the binding affinity of the prototype nonopeptide
        agonist L-162,313, although some substitutions, such as N295D, certainly impair
        the ability of the compound to activate the receptor.', ligand_long: '125I-[Sar,Leu]Angiotensin
        II', ligand_short: 'L-162,313', pubmed: '9203636', seq: '295', to_res: D}
- {entry_name: agtra_rat, from_res: N, info: 'Interestingly, no clear bell-shaped
        dose-response curves were observed in the N295D rat AT1 construct for the
        nonpeptide compounds that here functioned as merely relatively poor, classic
        partial agonists. In regard to antagonistic property, all three nonpeptide
        compounds surprisingly acted as equally potent inhibitors of the angiotensin-induced
        increase in phosphatidylionositol turnover in the N295D construct, with IC50
        values of 90-180 nm.Thus, in the N295D construct, there was a relatively close
        relationship between the affinity of the compounds as determined in competition
        binding assays (IC50 = 21-37 nm) and the IC50 values obtained for these compounds
        as antagonists for a submaximal stimulatory dose of angiotensin.This mutant
        (N295D red.) does not affect the binding affinity of any of the three compounds,
        yet they all act as an almost pure antagonist in this receptor construct and,
        importantly, have IC50 values for inhibition of a submaximal stimulation with
        angiotensin that are similar to that of the most potent antagonist, L-162,389,
        on the wild-type receptor.', ligand_long: '125I-[Sar,Leu]Angiotensin II',
    ligand_short: '[Sar,Leu]Angiotensin II', pubmed: '9203636', seq: '295', to_res: D}
- {entry_name: p2ry1_human, from_res: R, info: 'The residues that were found most
        critical for activation by 2-MeSATP (R128, R310, and S314) were also absolutely
        critical for activation of the receptor by monophosphates and diphosphates.Alanine
        scanning mutagenesis showed that residues R128, K280, Q307, R310, and S314
        are critical for high potency agonist-induced activation of phosholipase C.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '128', to_res: A}
- {entry_name: p2ry1_human, from_res: R, info: 'The residues that were found most
        critical for activation by 2-MeSATP (R128, R310, and S314) were also absolutely
        critical for activation of the receptor by monophosphates and diphosphates.Alanine
        scanning mutagenesis showed that residues R128, K280, Q307, R310, and S314
        are critical for high potency agonist-induced activation of phosholipase C.Comments:
        Mutation is located in TM3.', ligand_long: '', ligand_short: '', pubmed: '9281613',
    seq: '128', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: 'CP96,345', pubmed: '9261122',
    seq: '268', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: 'Dns-CP96,345', pubmed: '9261122',
    seq: '268', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: Substance P, pubmed: '9261122',
    seq: '268', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: 'CP96,345', pubmed: '9261122',
    seq: '267', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: 'Dns-CP96,345', pubmed: '9261122',
    seq: '267', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: Substance P, pubmed: '9261122',
    seq: '267', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.In contrast, adding bulk in the cavity by introduction of an hydroxyl
        group in the F264Y mutation decreased Dns-CP39,345 affinity more than that
        of CP39,345, [...].', ligand_long: 125I-BH-SP, ligand_short: 'CP96,345', pubmed: '9261122',
    seq: '264', to_res: Y}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.In contrast, adding bulk in the cavity by introduction of an hydroxyl
        group in the F264Y mutation decreased Dns-CP39,345 affinity more than that
        of CP39,345, [...].', ligand_long: 125I-BH-SP, ligand_short: 'Dns-CP96,345',
    pubmed: '9261122', seq: '264', to_res: Y}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.In contrast, adding bulk in the cavity by introduction of an hydroxyl
        group in the F264Y mutation decreased Dns-CP39,345 affinity more than that
        of CP39,345, [...].', ligand_long: 125I-BH-SP, ligand_short: Substance P,
    pubmed: '9261122', seq: '264', to_res: Y}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: 'CP96,345', pubmed: '9261122',
    seq: '264', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: 'Dns-CP96,345', pubmed: '9261122',
    seq: '264', to_res: A}
- {entry_name: nk1r_human, from_res: F, info: 'Dns-CP39,345, [...], has a binding
        profile similar to that of its parent compound CP39,345, as determined by
        the ability to displace 125I-BH-SP binding to NK1. The only significant differences
        were found at positions 264, 267, and 268 which all have Phe in wild-type
        NK1.', ligand_long: 125I-BH-SP, ligand_short: Substance P, pubmed: '9261122',
    seq: '264', to_res: A}
- {entry_name: hrh1_cavpo, from_res: K, info: The Lys200Ala mutations results in a
        30- (acrivastine) tot 10-fold (d-cetirizine) loss of affinity of the zwitterionic
        antagonists.A huge reduction of the affinity of acrivastine was observed for
        the Lys200Met receptor mutant.Histamine was less responsive at Lys200Met and
        Lys200Arg H1 receptor., ligand_long: '[3H]mepyramine', ligand_short: '', pubmed: '10514483',
    seq: '200', to_res: R}
- {entry_name: hrh1_cavpo, from_res: K, info: The Lys200Ala mutations results in a
        30- (acrivastine) tot 10-fold (d-cetirizine) loss of affinity of the zwitterionic
        antagonists.A huge reduction of the affinity of acrivastine was observed for
        the Lys200Met receptor mutant.Histamine was less responsive at Lys200Met and
        Lys200Arg H1 receptor., ligand_long: '[3H]mepyramine', ligand_short: '', pubmed: '10514483',
    seq: '200', to_res: M}
- {entry_name: hrh1_cavpo, from_res: K, info: The Lys200Ala mutations results in a
        30- (acrivastine) tot 10-fold (d-cetirizine) loss of affinity of the zwitterionic
        antagonists., ligand_long: '[3H]mepyramine', ligand_short: '', pubmed: '10514483',
    seq: '200', to_res: A}
- {entry_name: hrh1_cavpo, from_res: F, info: 'Similar EC50 values for histamine were
        observed for the wild type receptor and the Trp161Met, Trp161Phe and Phe433Ala
        receptors, whereas the Phe433Met, Phe436Ala and Phe436Met mutant receptors
        were stimulated less effectively for histamine.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '436', to_res: M}
- {entry_name: hrh1_cavpo, from_res: F, info: 'Similar EC50 values for histamine were
        observed for the wild type receptor and the Trp161Met, Trp161Phe and Phe433Ala
        receptors, whereas the Phe433Met, Phe436Ala and Phe436Met mutant receptors
        were stimulated less effectively for histamine.Comment: the value for the
        Kd is given as a >15 value, so the real kd can''t be calculated.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '436', to_res: A}
- {entry_name: hrh1_cavpo, from_res: F, info: 'Similar EC50 values for histamine were
        observed for the wild type receptor and the Trp161Met, Trp161Phe and Phe433Ala
        receptors, whereas the Phe433Met, Phe436Ala and Phe436Met mutant receptors
        were stimulated less effectively for histamine.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '433', to_res: M}
- {entry_name: hrh1_cavpo, from_res: F, info: 'Similar EC50 values for histamine were
        observed for the wild type receptor and the Trp161Met, Trp161Phe and Phe433Ala
        receptors, whereas the Phe433Met, Phe436Ala and Phe436Met mutant receptors
        were stimulated less effectively for histamine.', ligand_long: '', ligand_short: '',
    pubmed: '10514483', seq: '433', to_res: A}
- {entry_name: hrh1_cavpo, from_res: W, info: 'The introduction of the Trp174Ala mutation
        did not reduce the affinity of [3H]mepyramine.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '174', to_res: A}
- {entry_name: hrh1_cavpo, from_res: W, info: 'Comment: the real Kd value was given
        as a >15 value, so the real Kd can''t be calculated.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '167', to_res: F}
- {entry_name: hrh1_cavpo, from_res: W, info: 'Comment: the Kd value was givens as
        a >15, so the real Kd can''t be calculated.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '167', to_res: M}
- {entry_name: hrh1_cavpo, from_res: W, info: 'For the Trp167Ala receptor the affinity
        for the H1 antagonist was reduced more than 10-fold.Comment: the Kd value
        was givens as a >15, so the real Kd can''t be calculated.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '167', to_res: A}
- {entry_name: hrh1_cavpo, from_res: W, info: 'In contrast to the Trp161Ala receptor
        mutant, the Trp161Met and Trp161Phe receptor mutants bound [3H]mepyramine
        with high affinity.The affinity of the Trp161Met and Trp161Phe mutant receptors
        for histamine was not changed, whereas a small to major reduction of the agonist
        affinity was observed for the Phe433Met and Phe436Met receptor mutants.Evaluation
        of the various receptor mutants showed that the Trp161Met, Phe433Ala, Phe433Met,
        Phe436Ala and Phe436Met mutant receptors stimulated the [3H]inositol phosphate
        accumulation as the wild type H1 receptor.Similar EC50 values for histamine
        were observed for the wild type receptor and the Trp161Met, Trp161Phe and
        Phe433Ala receptors, whereas the Phe433Met, Phe436Ala and Phe436Met mutant
        receptors were stimulated less effectively for histamine.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '161', to_res: F}
- {entry_name: hrh1_cavpo, from_res: W, info: 'In contrast to the Trp161Ala receptor
        mutant, the Trp161Met and Trp161Phe receptor mutants bound [3H]mepyramine
        with high affinity.The affinity of the Trp161Met and Trp161Phe mutant receptors
        for histamine was not changed, whereas a small to major reduction of the agonist
        affinity was observed for the Phe433Met and Phe436Met receptor mutants.Evaluation
        of the various receptor mutants showed that the Trp161Met, Phe433Ala, Phe433Met,
        Phe436Ala and Phe436Met mutant receptors stimulated the [3H]inositol phosphate
        accumulation as the wild type H1 receptor.Similar EC50 values for histamine
        were observed for the wild type receptor and the Trp161Met, Trp161Phe and
        Phe433Ala receptors, whereas the Phe433Met, Phe436Ala and Phe436Met mutant
        receptors were stimulated less effectively for histamine.', ligand_long: '[3H]mepyramine',
    ligand_short: '', pubmed: '10514483', seq: '161', to_res: M}
- {entry_name: hrh1_cavpo, from_res: W, info: 'Cells expressing the Trp161Ala receptor
        did not show binding of [3H]mepyramine significantly higher than binding to
        the wild type.In contrast to the Trp161Ala receptor mutant, the Trp161Met
        and Trp161Phe receptor mutants bound [3H]mepyramine with high affinity.',
    ligand_long: '', ligand_short: '', pubmed: '10514483', seq: '161', to_res: A}
- {entry_name: c5ar_human, from_res: F, info: 'A Point mutation in helix VI, F251A,
        did generate a constitutively active receptor.Thus mutations that decrease
        the hydrophobicity of closely adjacent surfaces of either III (I124N, L127Q)
        or VI (F251A) activate the receptor.', ligand_long: '', ligand_short: '',
    pubmed: '10336477', seq: '251', to_res: A}
- {entry_name: c5ar_human, from_res: L, info: 'Receptors containing individual substitutions
        of either I124N or L127Q show weak constitutive activity.Thus mutations that
        decrease the hydrophobicity of closely adjacent surfaces of either III (I124N,
        L127Q) or VI (F251A) activate the receptor.', ligand_long: '', ligand_short: '',
    pubmed: '10336477', seq: '127', to_res: Q}
- {entry_name: c5ar_human, from_res: I, info: 'Receptors containing individual substitutions
        of either I124N or L127Q show weak constitutive activity.Thus mutations that
        decrease the hydrophobicity of closely adjacent surfaces of either III (I124N,
        L127Q) or VI (F251A) activate the receptor.', ligand_long: '', ligand_short: '',
    pubmed: '10336477', seq: '124', to_res: N}
- {entry_name: agtrb_rat, from_res: F, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '301', to_res: L}
- {entry_name: agtrb_rat, from_res: F, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '301', to_res: L}
- {entry_name: agtrb_rat, from_res: L, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '300', to_res: F}
- {entry_name: agtrb_rat, from_res: L, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '300', to_res: F}
- {entry_name: agtrb_rat, from_res: A, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '277', to_res: Y}
- {entry_name: agtrb_rat, from_res: A, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '277', to_res: Y}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '258', to_res: V}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '258', to_res: V}
- {entry_name: agtrb_rat, from_res: S, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '252', to_res: C}
- {entry_name: agtrb_rat, from_res: S, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '252', to_res: C}
- {entry_name: acm1_rat, from_res: A, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '196', to_res: C}
- {entry_name: acm1_rat, from_res: A, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: formylcholine,
    pubmed: '10860940', seq: '196', to_res: C}
- {entry_name: acm1_rat, from_res: A, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '10860940', seq: '196', to_res: C}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.The affinity of the oxadiazole
        agonist L-698,583 (Ward et al., 1999) was reduced only 3-fold by the Thr-192
        --> Cys mutation, and this compound was not investigated further.Although
        the Bmax value of the wild-type membranes was not significantly affected,
        the Bmax value of the Thr-192 --> Cys membranes was reduced by 70+-14% (n=2).Mutations
        of four amino acids, Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38,
        5.39, 5.42, and 5.46) significantly reduced both the affinity of ACh and the
        potency of ACh in activating the receptor. The effects of mutating the residues
        to Cys, or to Ala or Gly, in the case of Ile-188, Thr-192, and Ala-196, were
        similar and the effects on binding and activity were also of similar magnitudes.Interestingly,
        in contrast to the situation found in COS-7 cells, a significant fraction
        of GTP-sensitive high-affinity binding sites was detected, and these showed
        greater sensitivity to the effects of the Thr-192 --> Ala mutation.The mutations
        of Ile-188, Thr-192, and Ala-196 had a similar but smaller effect on the binding
        of two other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS',
    ligand_short: BrACh, pubmed: '10860940', seq: '192', to_res: A}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.The affinity of the oxadiazole
        agonist L-698,583 (Ward et al., 1999) was reduced only 3-fold by the Thr-192
        --> Cys mutation, and this compound was not investigated further.Although
        the Bmax value of the wild-type membranes was not significantly affected,
        the Bmax value of the Thr-192 --> Cys membranes was reduced by 70+-14% (n=2).Mutations
        of four amino acids, Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38,
        5.39, 5.42, and 5.46) significantly reduced both the affinity of ACh and the
        potency of ACh in activating the receptor. The effects of mutating the residues
        to Cys, or to Ala or Gly, in the case of Ile-188, Thr-192, and Ala-196, were
        similar and the effects on binding and activity were also of similar magnitudes.Interestingly,
        in contrast to the situation found in COS-7 cells, a significant fraction
        of GTP-sensitive high-affinity binding sites was detected, and these showed
        greater sensitivity to the effects of the Thr-192 --> Ala mutation.The mutations
        of Ile-188, Thr-192, and Ala-196 had a similar but smaller effect on the binding
        of two other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS',
    ligand_short: formylcholine, pubmed: '10860940', seq: '192', to_res: A}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.The affinity of the oxadiazole
        agonist L-698,583 (Ward et al., 1999) was reduced only 3-fold by the Thr-192
        --> Cys mutation, and this compound was not investigated further.Although
        the Bmax value of the wild-type membranes was not significantly affected,
        the Bmax value of the Thr-192 --> Cys membranes was reduced by 70+-14% (n=2).Mutations
        of four amino acids, Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38,
        5.39, 5.42, and 5.46) significantly reduced both the affinity of ACh and the
        potency of ACh in activating the receptor. The effects of mutating the residues
        to Cys, or to Ala or Gly, in the case of Ile-188, Thr-192, and Ala-196, were
        similar and the effects on binding and activity were also of similar magnitudes.Interestingly,
        in contrast to the situation found in COS-7 cells, a significant fraction
        of GTP-sensitive high-affinity binding sites was detected, and these showed
        greater sensitivity to the effects of the Thr-192 --> Ala mutation.The mutations
        of Ile-188, Thr-192, and Ala-196 had a similar but smaller effect on the binding
        of two other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '10860940', seq: '192', to_res: A}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.The affinity of the oxadiazole
        agonist L-698,583 (Ward et al., 1999) was reduced only 3-fold by the Thr-192
        --> Cys mutation, and this compound was not investigated further.Although
        the Bmax value of the wild-type membranes was not significantly affected,
        the Bmax value of the Thr-192 --> Cys membranes was reduced by 70+-14% (n=2).Mutations
        of four amino acids, Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38,
        5.39, 5.42, and 5.46) significantly reduced both the affinity of ACh and the
        potency of ACh in activating the receptor. The effects of mutating the residues
        to Cys, or to Ala or Gly, in the case of Ile-188, Thr-192, and Ala-196, were
        similar and the effects on binding and activity were also of similar magnitudes.Interestingly,
        in contrast to the situation found in COS-7 cells, a significant fraction
        of GTP-sensitive high-affinity binding sites was detected, and these showed
        greater sensitivity to the effects of the Thr-192 --> Ala mutation.The mutations
        of Ile-188, Thr-192, and Ala-196 had a similar but smaller effect on the binding
        of two other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS',
    ligand_short: BrACh, pubmed: '10860940', seq: '192', to_res: C}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.The affinity of the oxadiazole
        agonist L-698,583 (Ward et al., 1999) was reduced only 3-fold by the Thr-192
        --> Cys mutation, and this compound was not investigated further.Although
        the Bmax value of the wild-type membranes was not significantly affected,
        the Bmax value of the Thr-192 --> Cys membranes was reduced by 70+-14% (n=2).Mutations
        of four amino acids, Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38,
        5.39, 5.42, and 5.46) significantly reduced both the affinity of ACh and the
        potency of ACh in activating the receptor. The effects of mutating the residues
        to Cys, or to Ala or Gly, in the case of Ile-188, Thr-192, and Ala-196, were
        similar and the effects on binding and activity were also of similar magnitudes.Interestingly,
        in contrast to the situation found in COS-7 cells, a significant fraction
        of GTP-sensitive high-affinity binding sites was detected, and these showed
        greater sensitivity to the effects of the Thr-192 --> Ala mutation.The mutations
        of Ile-188, Thr-192, and Ala-196 had a similar but smaller effect on the binding
        of two other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS',
    ligand_short: formylcholine, pubmed: '10860940', seq: '192', to_res: C}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.The affinity of the oxadiazole
        agonist L-698,583 (Ward et al., 1999) was reduced only 3-fold by the Thr-192
        --> Cys mutation, and this compound was not investigated further.Although
        the Bmax value of the wild-type membranes was not significantly affected,
        the Bmax value of the Thr-192 --> Cys membranes was reduced by 70+-14% (n=2).Mutations
        of four amino acids, Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38,
        5.39, 5.42, and 5.46) significantly reduced both the affinity of ACh and the
        potency of ACh in activating the receptor. The effects of mutating the residues
        to Cys, or to Ala or Gly, in the case of Ile-188, Thr-192, and Ala-196, were
        similar and the effects on binding and activity were also of similar magnitudes.Interestingly,
        in contrast to the situation found in COS-7 cells, a significant fraction
        of GTP-sensitive high-affinity binding sites was detected, and these showed
        greater sensitivity to the effects of the Thr-192 --> Ala mutation.The mutations
        of Ile-188, Thr-192, and Ala-196 had a similar but smaller effect on the binding
        of two other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS',
    ligand_short: '', pubmed: '10860940', seq: '192', to_res: C}
- {entry_name: acm1_rat, from_res: F, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The mutation Phe-190 --> Cys resulted in a 10-fold increase
        in ACh potency, again in parallel to the binding assay. [...]. This mutation
        also significantly increased the agonist-independent activity of the receptor,
        to 17% of the total signal.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '190', to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The mutation Phe-190 --> Cys resulted in a 10-fold increase
        in ACh potency, again in parallel to the binding assay. [...]. This mutation
        also significantly increased the agonist-independent activity of the receptor,
        to 17% of the total signal.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '10860940',
    seq: '190', to_res: A}
- {entry_name: acm1_rat, from_res: F, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The mutation Phe-190 --> Cys resulted in a 10-fold increase
        in ACh potency, again in parallel to the binding assay. [...]. This mutation
        also significantly increased the agonist-independent activity of the receptor,
        to 17% of the total signal.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '190', to_res: C}
- {entry_name: acm1_rat, from_res: F, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The mutation Phe-190 --> Cys resulted in a 10-fold increase
        in ACh potency, again in parallel to the binding assay. [...]. This mutation
        also significantly increased the agonist-independent activity of the receptor,
        to 17% of the total signal.', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '10860940',
    seq: '190', to_res: C}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).Mutations of four amino acids, Ile-188, Thr-189, Thr-192,
        and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46) significantly reduced both
        the affinity of ACh and the potency of ACh in activating the receptor. The
        effects of mutating the residues to Cys, or to Ala or Gly, in the case of
        Ile-188, Thr-192, and Ala-196, were similar and the effects on binding and
        activity were also of similar magnitudes.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '189', to_res: C}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).Mutations of four amino acids, Ile-188, Thr-189, Thr-192,
        and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46) significantly reduced both
        the affinity of ACh and the potency of ACh in activating the receptor. The
        effects of mutating the residues to Cys, or to Ala or Gly, in the case of
        Ile-188, Thr-192, and Ala-196, were similar and the effects on binding and
        activity were also of similar magnitudes.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '189', to_res: S}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).Mutations of four amino acids, Ile-188, Thr-189, Thr-192,
        and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46) significantly reduced both
        the affinity of ACh and the potency of ACh in activating the receptor. The
        effects of mutating the residues to Cys, or to Ala or Gly, in the case of
        Ile-188, Thr-192, and Ala-196, were similar and the effects on binding and
        activity were also of similar magnitudes.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '10860940', seq: '189', to_res: S}
- {entry_name: acm1_rat, from_res: T, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).Mutations of four amino acids, Ile-188, Thr-189, Thr-192,
        and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46) significantly reduced both
        the affinity of ACh and the potency of ACh in activating the receptor. The
        effects of mutating the residues to Cys, or to Ala or Gly, in the case of
        Ile-188, Thr-192, and Ala-196, were similar and the effects on binding and
        activity were also of similar magnitudes.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '10860940', seq: '189', to_res: C}
- {entry_name: acm1_rat, from_res: I, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '188', to_res: A}
- {entry_name: acm1_rat, from_res: I, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: formylcholine,
    pubmed: '10860940', seq: '188', to_res: A}
- {entry_name: acm1_rat, from_res: I, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '10860940', seq: '188', to_res: A}
- {entry_name: acm1_rat, from_res: I, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: BrACh,
    pubmed: '10860940', seq: '188', to_res: C}
- {entry_name: acm1_rat, from_res: I, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: Formylcholine,
    pubmed: '10860940', seq: '188', to_res: C}
- {entry_name: acm1_rat, from_res: I, info: 'The effects of the Cys mutations of Ile-188,
        Thr-189, Phe-190, Thr-192, and Ala-196 on the binding affinities of two other
        muscarine agonists of high efficacy, carbachol and oxotremorine-M were qualitatively
        similar to but quantitively smaller than their effects on the binding of ACh
        (carbachol: 3-fold increase at Phe-190 --> Cys, 7-fold reduction at Thr-192
        --> Cys, 3-fold reduction at Ala-196 --> Cys; oxotremorine-M: 2-fold increase
        at Phe-190 --> Cys, 4-fold reduction at Thr-192 --> Cys, 8-fold reduction
        at Ala-196 --> Cys).The affinity of formylcholine, which lacks the terminal
        methyl group of ACh, showed less than a 3-fold change in response to Cys mutations
        of Ile-188, Thr-192, and Ala-196, and less than a 2-fold reduction on making
        the corresponding Ala or Gly substitutions.Mutations of four amino acids,
        Ile-188, Thr-189, Thr-192, and Ala-196 (positions 5.38, 5.39, 5.42, and 5.46)
        significantly reduced both the affinity of ACh and the potency of ACh in activating
        the receptor. The effects of mutating the residues to Cys, or to Ala or Gly,
        in the case of Ile-188, Thr-192, and Ala-196, were similar and the effects
        on binding and activity were also of similar magnitudes.The mutations of Ile-188,
        Thr-192, and Ala-196 had a similar but smaller effect on the binding of two
        other agonists, carbachol and oxotremorine-M.', ligand_long: '[3H]NMS', ligand_short: '',
    pubmed: '10860940', seq: '188', to_res: C}
- {entry_name: agtrb_rat, from_res: F, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '248', to_res: L}
- {entry_name: ada2a_human, from_res: R, info: 'In the c-terminal binding region,
        mutation of Lys-358 almost completely attenuated binding, whereas mutation
        of additional basic residues (Arg-361, Arg-368,Lys-370, Arg-371) had minimal
        effect on GRK2 binding.It also worth noting that the putative BXBB G protein
        binding and activation motif in the alpha2a-AR (Arg-368, Lys-370, Arg-371)
        had minimal effect on GRK2 binding.Comments: Value added under activation
        data, is data from binding assays of G protein-coupled receptor kinase 2 (GRK2)
        to the mutated intracellular loop 3 of the alpha 2a adrenergic receptor.',
    ligand_long: '', ligand_short: '', pubmed: '15653687', seq: '371', to_res: A}
- {entry_name: agtrb_rat, from_res: M, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '243', to_res: V}
- {entry_name: ada2a_human, from_res: K, info: 'In the c-terminal binding region,
        mutation of Lys-358 almost completely attenuated binding, whereas mutation
        of additional basic residues (Arg-361, Arg-368,Lys-370, Arg-371) had minimal
        effect on GRK2 binding.It also worth noting that the putative BXBB G protein
        binding and activation motif in the alpha2a-AR (Arg-368, Lys-370, Arg-371)
        had minimal effect on GRK2 binding.Comments: Value added under activation
        data, is data from binding assays of G protein-coupled receptor kinase 2 (GRK2)
        to the mutated intracellular loop 3 of the alpha 2a adrenergic receptor.',
    ligand_long: '', ligand_short: '', pubmed: '15653687', seq: '370', to_res: A}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '241', to_res: M}
- {entry_name: agtrb_rat, from_res: F, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '206', to_res: I}
- {entry_name: ada2a_human, from_res: R, info: 'In the c-terminal binding region,
        mutation of Lys-358 almost completely attenuated binding, whereas mutation
        of additional basic residues (Arg-361, Arg-368,Lys-370, Arg-371) had minimal
        effect on GRK2 binding.It is also worth noting that the putative BXBB G protein
        binding and activation motif in the alpha2a-AR (Arg-368, Lys 370, Arg-371)
        does not appear to play a role in GRK2 bindingComments: Value added under
        activation data, is data from binding assays of G protein-coupled receptor
        kinase 2 (GRK2) to the mutated intracellular loop 3 of the alpha 2a adrenergic
        receptor.', ligand_long: '', ligand_short: '', pubmed: '15653687', seq: '368',
    to_res: A}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losertan,
    pubmed: '8206967', seq: '202', to_res: V}
- {entry_name: agtrb_rat, from_res: F, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '248', to_res: L}
- {entry_name: ada2a_human, from_res: R, info: 'In the c-terminal binding region,
        mutation of Lys-358 almost completely attenuated binding, whereas mutation
        of additional basic residues (Arg-361, Arg-368,Lys-370, Arg-371) had minimal
        effect on GRK2 binding.Comments: Value added under activation data, is data
        from binding assays of G protein-coupled receptor kinase 2 (GRK2) to the mutated
        intracellular loop 3 of the alpha 2a adrenergic receptor.', ligand_long: '',
    ligand_short: '', pubmed: '15653687', seq: '361', to_res: A}
- {entry_name: agtrb_rat, from_res: F, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '248', to_res: L}
- {entry_name: agtrb_rat, from_res: M, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '243', to_res: V}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '241', to_res: M}
- {entry_name: agtrb_rat, from_res: F, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '206', to_res: I}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '202', to_res: V}
- {entry_name: ada2a_human, from_res: K, info: 'In the c-terminal binding region,
        mutation of Lys-358 almost completely attenuated binding, whereas mutation
        of additional basic residues (Arg-361, Arg-368,Lys-370, Arg-371) had minimal
        effect on GRK2 binding.Comments: Value added under activation data, is data
        from binding assays of G protein-coupled receptor kinase 2 (GRK2) to the mutated
        intracellular loop 3 of the alpha 2a adrenergic receptor.', ligand_long: '',
    ligand_short: '', pubmed: '15653687', seq: '358', to_res: A}
- {entry_name: agtrb_rat, from_res: T, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '198', to_res: A}
- {entry_name: agtrb_rat, from_res: P, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '192', to_res: M}
- {entry_name: agtrb_rat, from_res: T, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '198', to_res: A}
- {entry_name: agtrb_rat, from_res: P, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '192', to_res: M}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '191', to_res: F}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '191', to_res: F}
- {entry_name: agtrb_rat, from_res: A, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '163', to_res: S}
- {entry_name: agtrb_rat, from_res: A, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '163', to_res: S}
- {entry_name: ada2a_human, from_res: R, info: '[...], whereas mutation of Lys-320
        or Arg-322 completely disrupted binding.Comments: Value added under activation
        data, is data from binding assays of G protein-coupled receptor kinase 2 (GRK2)
        to the mutated intracellular loop 3 of the alpha 2a adrenergic receptor.',
    ligand_long: '', ligand_short: '', pubmed: '15653687', seq: '322', to_res: A}
- {entry_name: agtrb_rat, from_res: G, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '157', to_res: L}
- {entry_name: ada2a_human, from_res: K, info: '[...], whereas mutation of Lys-320
        or Arg-322 completely disrupted binding.Comments: Value added under activation
        data, is data from binding assays of G protein-coupled receptor kinase 2 (GRK2)
        to the mutated intracellular loop 3 of the alpha 2a adrenergic receptor.',
    ligand_long: '', ligand_short: '', pubmed: '15653687', seq: '320', to_res: A}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '151', to_res: G}
- {entry_name: agtrb_rat, from_res: K, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '146', to_res: R}
- {entry_name: agtrb_rat, from_res: G, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '157', to_res: L}
- {entry_name: ada2a_human, from_res: K, info: 'Comments: Value added under activation
        data, is data from binding assays of G protein-coupled receptor kinase 2 (GRK2)
        to the mutated intracellular loop 3 of the alpha 2a adrenergic receptor.',
    ligand_long: '', ligand_short: '', pubmed: '15653687', seq: '318', to_res: A}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '151', to_res: G}
- {entry_name: agtrb_rat, from_res: K, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '146', to_res: R}
- {entry_name: ada2a_human, from_res: P, info: 'Several mutations within the GST-alpha2a-AR
        (218-245) fusion protein significantly reduced GRK2 binding including R218A,
        R225A, and R226A, whereas mutation of Lys-224, Pro-242, and Pro-243 had minimal
        effect.Comments: Value added under activation data, is data from binding assays
        of G protein-coupled receptor kinase 2 (GRK2) to the mutated intracellular
        loop 3 of the alpha 2a adrenergic receptor.', ligand_long: '', ligand_short: '',
    pubmed: '15653687', seq: '243', to_res: A}
- {entry_name: ada2a_human, from_res: P, info: 'Several mutations within the GST-alpha2a-AR
        (218-245) fusion protein significantly reduced GRK2 binding including R218A,
        R225A, and R226A, whereas mutation of Lys-224, Pro-242, and Pro-243 had minimal
        effect.Comments: Value added under activation data, is data from binding assays
        of G protein-coupled receptor kinase 2 (GRK2) to the mutated intracellular
        loop 3 of the alpha 2a adrenergic receptor.', ligand_long: '', ligand_short: '',
    pubmed: '15653687', seq: '242', to_res: A}
- {entry_name: ada2a_human, from_res: R, info: 'Several mutations within the GST-alpha2a-AR
        (218-245) fusion protein significantly reduced GRK2 binding including R218A,
        R225A, and R226A, whereas mutation of Lys-224, Pro-242, and Pro-243 had minimal
        effect.Comments: Value added under activation data, is data from binding assays
        of G protein-coupled receptor kinase 2 (GRK2) to the mutated intracellular
        loop 3 of the alpha 2a adrenergic receptor.', ligand_long: '', ligand_short: '',
    pubmed: '15653687', seq: '226', to_res: A}
- {entry_name: agtrb_rat, from_res: V, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '108', to_res: I}
- {entry_name: ada2a_human, from_res: R, info: 'Several mutations within the GST-alpha2a-AR
        (218-245) fusion protein significantly reduced GRK2 binding including R218A,
        R225A, and R226A, whereas mutation of Lys-224, Pro-242, and Pro-243 had minimal
        effect. The R225A mutant was particularly effective in attenuating GRK2 binding.Mutations
        of Arg-225, Lys-320, and Lys-358 in the I3 loop disrupted GRK2 binding and
        resulted in decreased activation of GRK2 and decreased receptor phosphorylation.Comments:
        Value added under activation data, is data from binding assays of G protein-coupled
        receptor kinase 2 (GRK2) to the mutated intracellular loop 3 of the alpha
        2a adrenergic receptor.', ligand_long: '', ligand_short: '', pubmed: '15653687',
    seq: '225', to_res: A}
- {entry_name: agtrb_rat, from_res: V, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '108', to_res: I}
- {entry_name: agtrb_rat, from_res: S, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: losartan, pubmed: '8206967',
    seq: '107', to_res: A}
- {entry_name: agtrb_rat, from_res: S, info: 'Selective point mutations in transmembrane
        (TM) domains III (S107A, V108I,), IV (A163S), V (P192M, T198A), VI (S252C),
        and VII (L300F, F301L) caused significant reduction in losartan binding affinities.
        The rank order of these effects was V108I > A163S > S252C > L300F = F301L
        > S107A = P192M = T198A.', ligand_long: '', ligand_short: saralasin, pubmed: '8206967',
    seq: '107', to_res: A}
- {entry_name: ada2a_human, from_res: K, info: 'Several mutations within the GST-alpha2a-AR
        (218-245) fusion protein significantly reduced GRK2 binding including R218A,
        R225A, and R226A, whereas mutation of Lys-224, Pro-242, and Pro-243 had minimal
        effect.Comments: Value added under activation data, is data from binding assays
        of G protein-coupled receptor kinase 2 (GRK2) to the mutated intracellular
        loop 3 of the alpha 2a adrenergic receptor.', ligand_long: '', ligand_short: '',
    pubmed: '15653687', seq: '224', to_res: A}
- {entry_name: ada2a_human, from_res: R, info: 'Several mutations within the GST-alpha2a-AR
        (218-245) fusion protein significantly reduced GRK2 binding including R218A,
        R225A, and R226A, whereas mutation of Lys-224, Pro-242, and Pro-243 had minimal
        effect.Comments: Value added under activation data, is data from binding assays
        of G protein-coupled receptor kinase 2 (GRK2) to the mutated intracellular
        loop 3 of the alpha 2a adrenergic receptor.', ligand_long: '', ligand_short: '',
    pubmed: '15653687', seq: '218', to_res: A}
- {entry_name: agtrb_rat, from_res: A, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '106', to_res: T}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '79', to_res: I}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '34', to_res: I}
- {entry_name: agtrb_rat, from_res: A, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '106', to_res: T}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '79', to_res: I}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '34', to_res: I}
- {entry_name: agtrb_rat, from_res: S, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '352', to_res: A}
- {entry_name: agtrb_rat, from_res: N, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '344', to_res: T}
- {entry_name: agtrb_rat, from_res: S, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '331', to_res: N}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '305', to_res: F}
- {entry_name: agtrb_rat, from_res: K, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '227', to_res: E}
- {entry_name: agtrb_rat, from_res: K, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '224', to_res: E}
- {entry_name: agtrb_rat, from_res: W, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '219', to_res: G}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '128', to_res: S}
- {entry_name: agtrb_rat, from_res: S, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '352', to_res: A}
- {entry_name: agtrb_rat, from_res: N, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '344', to_res: T}
- {entry_name: agtrb_rat, from_res: S, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '331', to_res: N}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '305', to_res: F}
- {entry_name: agtrb_rat, from_res: K, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '227', to_res: E}
- {entry_name: agtrb_rat, from_res: K, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '224', to_res: E}
- {entry_name: agtrb_rat, from_res: W, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '219', to_res: G}
- {entry_name: agtrb_rat, from_res: L, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '128', to_res: S}
- {entry_name: agtrb_rat, from_res: R, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '272', to_res: Q}
- {entry_name: agtrb_rat, from_res: G, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '269', to_res: D}
- {entry_name: agtrb_rat, from_res: S, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '189', to_res: I}
- {entry_name: agtrb_rat, from_res: Q, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '187', to_res: G}
- {entry_name: agtrb_rat, from_res: H, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '183', to_res: V}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '177', to_res: Q}
- {entry_name: agtrb_rat, from_res: A, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '21', to_res: S}
- {entry_name: agtrb_rat, from_res: D, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '16', to_res: V}
- {entry_name: agtrb_rat, from_res: Q, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '15', to_res: A}
- {entry_name: agtrb_rat, from_res: T, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: losartan,
    pubmed: '8206967', seq: '2', to_res: L}
- {entry_name: agtrb_rat, from_res: R, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '272', to_res: Q}
- {entry_name: agtrb_rat, from_res: G, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '269', to_res: D}
- {entry_name: agtrb_rat, from_res: S, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '189', to_res: I}
- {entry_name: agtrb_rat, from_res: Q, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '187', to_res: G}
- {entry_name: agtrb_rat, from_res: H, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '183', to_res: V}
- {entry_name: agtrb_rat, from_res: I, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '177', to_res: Q}
- {entry_name: agtrb_rat, from_res: A, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '21', to_res: S}
- {entry_name: agtrb_rat, from_res: D, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '16', to_res: V}
- {entry_name: agtrb_rat, from_res: Q, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '15', to_res: A}
- {entry_name: agtrb_rat, from_res: T, info: 'Comment: no significant change in losartan
        binding affinity was observed.', ligand_long: '', ligand_short: saralasin,
    pubmed: '8206967', seq: '2', to_res: L}
- {entry_name: gasr_human, from_res: H, info: 'While the substitution mutant H376L
        had a slight decrease in affinity for CCK-8 (to approximately 4-fold lower
        than observed for the CCK-A receptor), it also demonstrated a 63-fold increase
        in affinity for the CCK-A receptor specific antagonist, L364,718.Four amino
        acid substitutions, R57Q, S131T, S219H, and H376L, decreased affinity for
        gastrin, an agonist with high specificity for the CCK-B/gastrin receptor subtype.
        In each of these mutant receptors, the loss of affinity for gastrin was mirrored
        by an increase in affinity for the CCK-A receptor specific antagonist, L365,718,
        by 6.7-, 3.6-, 4.8-, and 62.5-fold respectively.Four amino acids substitutions,
        T111N, S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor
        specific antagonist, L356,260.', ligand_long: '', ligand_short: 'L364,718',
    pubmed: '7890609', seq: '376', to_res: L}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)T111N, S219H, and T354A, significantly
        decreased PD135,158 affinity toward the value expected for a CCK-A receptor,
        3.7 +-0.4, 60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: 'L364,718', pubmed: '7890609', seq: '354', to_res: A}
- {entry_name: gasr_human, from_res: Y, info: All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference), ligand_long: '', ligand_short: 'L364,718',
    pubmed: '7890609', seq: '350', to_res: F}
- {entry_name: gasr_human, from_res: V, info: All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference), ligand_long: '', ligand_short: 'L364,718',
    pubmed: '7890609', seq: '349', to_res: I}
- {entry_name: gasr_human, from_res: S, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.T111N, S219H, and T354A, significantly decreased
        PD135,158 affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4,
        60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: 'L364,718', pubmed: '7890609', seq: '219', to_res: H}
- {entry_name: gasr_human, from_res: S, info: All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference), ligand_long: '', ligand_short: 'L364,718',
    pubmed: '7890609', seq: '219', to_res: Q}
- {entry_name: gasr_human, from_res: S, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.', ligand_long: '', ligand_short: 'L364,718',
    pubmed: '7890609', seq: '131', to_res: T}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acids substitutions, T111N,
        S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor specific
        antagonist, L356,260.T111N, S219H, and T354A, significantly decreased PD135,158
        affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4, 60.9 +-
        20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '', ligand_short: 'L364,718',
    pubmed: '7890609', seq: '111', to_res: N}
- {entry_name: gasr_human, from_res: R, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.', ligand_long: '', ligand_short: 'L364,718',
    pubmed: '7890609', seq: '57', to_res: Q}
- {entry_name: gasr_human, from_res: H, info: 'While the substitution mutant H376L
        had a slight decrease in affinity for CCK-8 (to approximately 4-fold lower
        than observed for the CCK-A receptor), it also demonstrated a 63-fold increase
        in affinity for the CCK-A receptor specific antagonist, L364,718.Four amino
        acid substitutions, R57Q, S131T, S219H, and H376L, decreased affinity for
        gastrin, an agonist with high specificity for the CCK-B/gastrin receptor subtype.
        In each of these mutant receptors, the loss of affinity for gastrin was mirrored
        by an increase in affinity for the CCK-A receptor specific antagonist, L365,718,
        by 6.7-, 3.6-, 4.8-, and 62.5-fold respectively.Four amino acids substitutions,
        T111N, S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor
        specific antagonist, L356,260.', ligand_long: '', ligand_short: 'L365,260',
    pubmed: '7890609', seq: '376', to_res: L}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)T111N, S219H, and T354A, significantly
        decreased PD135,158 affinity toward the value expected for a CCK-A receptor,
        3.7 +-0.4, 60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: 'L365,260', pubmed: '7890609', seq: '354', to_res: A}
- {entry_name: gasr_human, from_res: S, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.T111N, S219H, and T354A, significantly decreased
        PD135,158 affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4,
        60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: 'L365,260', pubmed: '7890609', seq: '219', to_res: H}
- {entry_name: gasr_human, from_res: S, info: All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference), ligand_long: '', ligand_short: 'L365,260',
    pubmed: '7890609', seq: '219', to_res: Q}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acids substitutions, T111N,
        S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor specific
        antagonist, L356,260.T111N, S219H, and T354A, significantly decreased PD135,158
        affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4, 60.9 +-
        20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '', ligand_short: 'L365,260',
    pubmed: '7890609', seq: '111', to_res: N}
- {entry_name: gasr_human, from_res: R, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.', ligand_long: '', ligand_short: 'L365,260',
    pubmed: '7890609', seq: '57', to_res: Q}
- {entry_name: gasr_human, from_res: H, info: 'While the substitution mutant H376L
        had a slight decrease in affinity for CCK-8 (to approximately 4-fold lower
        than observed for the CCK-A receptor), it also demonstrated a 63-fold increase
        in affinity for the CCK-A receptor specific antagonist, L364,718.Four amino
        acid substitutions, R57Q, S131T, S219H, and H376L, decreased affinity for
        gastrin, an agonist with high specificity for the CCK-B/gastrin receptor subtype.
        In each of these mutant receptors, the loss of affinity for gastrin was mirrored
        by an increase in affinity for the CCK-A receptor specific antagonist, L365,718,
        by 6.7-, 3.6-, 4.8-, and 62.5-fold respectively.Four amino acids substitutions,
        T111N, S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor
        specific antagonist, L356,260.', ligand_long: '', ligand_short: gastrin, pubmed: '7890609',
    seq: '376', to_res: L}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)T111N, S219H, and T354A, significantly
        decreased PD135,158 affinity toward the value expected for a CCK-A receptor,
        3.7 +-0.4, 60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: gastrin, pubmed: '7890609', seq: '354', to_res: A}
- {entry_name: gasr_human, from_res: S, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.T111N, S219H, and T354A, significantly decreased
        PD135,158 affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4,
        60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: gastrin, pubmed: '7890609', seq: '219', to_res: H}
- {entry_name: gasr_human, from_res: S, info: All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference), ligand_long: '', ligand_short: gastrin,
    pubmed: '7890609', seq: '219', to_res: Q}
- {entry_name: gasr_human, from_res: S, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.', ligand_long: '', ligand_short: gastrin,
    pubmed: '7890609', seq: '131', to_res: T}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acids substitutions, T111N,
        S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor specific
        antagonist, L356,260.T111N, S219H, and T354A, significantly decreased PD135,158
        affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4, 60.9 +-
        20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '', ligand_short: gastrin,
    pubmed: '7890609', seq: '111', to_res: N}
- {entry_name: gasr_human, from_res: R, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.', ligand_long: '', ligand_short: Gastrin,
    pubmed: '7890609', seq: '57', to_res: Q}
- {entry_name: gasr_human, from_res: H, info: 'While the substitution mutant H376L
        had a slight decrease in affinity for CCK-8 (to approximately 4-fold lower
        than observed for the CCK-A receptor), it also demonstrated a 63-fold increase
        in affinity for the CCK-A receptor specific antagonist, L364,718.Four amino
        acid substitutions, R57Q, S131T, S219H, and H376L, decreased affinity for
        gastrin, an agonist with high specificity for the CCK-B/gastrin receptor subtype.
        In each of these mutant receptors, the loss of affinity for gastrin was mirrored
        by an increase in affinity for the CCK-A receptor specific antagonist, L365,718,
        by 6.7-, 3.6-, 4.8-, and 62.5-fold respectively.Four amino acids substitutions,
        T111N, S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor
        specific antagonist, L356,260.', ligand_long: '', ligand_short: CCK-8, pubmed: '7890609',
    seq: '376', to_res: L}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)T111N, S219H, and T354A, significantly
        decreased PD135,158 affinity toward the value expected for a CCK-A receptor,
        3.7 +-0.4, 60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: CCK-8, pubmed: '7890609', seq: '354', to_res: A}
- {entry_name: gasr_human, from_res: V, info: All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference), ligand_long: '', ligand_short: '',
    pubmed: '7890609', seq: '349', to_res: I}
- {entry_name: gasr_human, from_res: S, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.T111N, S219H, and T354A, significantly decreased
        PD135,158 affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4,
        60.9 +- 20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '',
    ligand_short: CCK-8, pubmed: '7890609', seq: '219', to_res: I}
- {entry_name: gasr_human, from_res: S, info: All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference), ligand_long: '', ligand_short: CCK-8,
    pubmed: '7890609', seq: '219', to_res: Q}
- {entry_name: gasr_human, from_res: S, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.', ligand_long: '', ligand_short: CCK-8,
    pubmed: '7890609', seq: '131', to_res: T}
- {entry_name: gasr_human, from_res: T, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acids substitutions, T111N,
        S219H or Q and H376L, reduced affinity for the CCK-B/gastrin receptor specific
        antagonist, L356,260.T111N, S219H, and T354A, significantly decreased PD135,158
        affinity toward the value expected for a CCK-A receptor, 3.7 +-0.4, 60.9 +-
        20.1 and 5.3 +- 0.7-fold, respectively (IC50).', ligand_long: '', ligand_short: CCK-8,
    pubmed: '7890609', seq: '111', to_res: N}
- {entry_name: gasr_human, from_res: R, info: 'All mutant receptors except for H376L
        had IC50 values for CCK-8 in the range between the wild type CCK-B/gastrin
        and CCK-A receptor (7.6-fold difference)Four amino acid substitutions, R57Q,
        S131T, S219H, and H376L, decreased affinity for gastrin, an agonist with high
        specificity for the CCK-B/gastrin receptor subtype. In each of these mutant
        receptors, the loss of affinity for gastrin was mirrored by an increase in
        affinity for the CCK-A receptor specific antagonist, L365,718, by 6.7-, 3.6-,
        4.8-, and 62.5-fold respectively.', ligand_long: '', ligand_short: CCK-8,
    pubmed: '7890609', seq: '57', to_res: Q}
- {entry_name: pth1r_didma, from_res: T, info: 'Comments: PTH/PTHr receptor mutations
        H223R and T410P are the most likely cause for Jansen''s metaphyseal chondrodysplasia.
        Mutation equivalents of H223R and T410P in related receptors was assesed.',
    ligand_long: '', ligand_short: '', pubmed: '9178745', seq: '404', to_res: P}
- {entry_name: pth1r_rat, from_res: T, info: 'These studies suggest that two residues
        in the human PTH/PTHrP receptor, 223 and 410, have critical roles in signal
        transduction.H223R or the T410P mutation showed constitutive, ligand-independent
        basal cAMP accumulation and increased binding affinity for agonists, but not
        for antagonists.At position 410; most recpetors with mutations at this site,
        with the exception of T410I, T410P, and T410V, had levels of surface expression
        that reached at least 50% those of the WT receptor. The average maximal specific
        radioligand binding of all mutant receptors at position 410 was 115+-8%.Most
        of the amino acid substitutions at this site resulted in mutant receptors
        with some degree of constitutive activity, which range from 2-fold (d410)
        to 7.5-fold (C410) above basal levels of WT receptors.The natural threonine
        at position 410 seems to constrain the receptor in an inactive conformation;
        this constrain can be relieved by either agonist binding or mutation to almost
        any other amino acidComments: PTH/PTHr receptor mutations H223R and T410P
        are the most likely cause for Jansen''s metaphyseal chondrodysplasia. Mutation
        equivalents of H223R and T410P in related receptors was assesed.', ligand_long: '',
    ligand_short: '', pubmed: '9178745', seq: '410', to_res: P}
- {entry_name: glp1r_rat, from_res: H, info: 'Comments: PTH/PTHr receptor mutations
        H223R and T410P are the most likely cause for Jansen''s metaphyseal chondrodysplasia.
        Mutation equivalents of H223R and T410P in related receptors was assesed.',
    ligand_long: '', ligand_short: '', pubmed: '9178745', seq: '180', to_res: R}
- {entry_name: pth1r_didma, from_res: H, info: 'Comments: PTH/PTHr receptor mutations
        H223R and T410P are the most likely cause for Jansen''s metaphyseal chondrodysplasia.
        Mutation equivalents of H223R and T410P in related receptors was assesed.',
    ligand_long: '', ligand_short: '', pubmed: '9178745', seq: '220', to_res: R}
- {entry_name: pth1r_rat, from_res: H, info: 'H223R or the T410P mutation showed constitutive,
        ligand-independent basal cAMP accumulation and increased binding affinity
        for agonists, but not for antagonists.At position 223, only arginine and lysine
        led to agonist-independent cAMP accumulation.All amino substitions at position
        223, with the exception of H223N, H223V, and H223T, resulted in mutant receptors
        with levels of surface expression less than 50% of those observed with the
        WT receptor....specific radioligand binding to the WT receptor, was 58+-9.7%.
        In contrast, H223N, H223V, and H223T showed higher radioligand binding of
        109+-8.4%, as predicted by their higher levels of expression.Residue 223 is
        important for efficient receptor expression, and a positive charge at this
        site appears to be required for agonist-independent receptor activation.Comments:
        PTH/PTHr receptor mutations H223R and T410P are the most likely cause for
        Jansen''s metaphyseal chondrodysplasia. Mutation equivalents of H223R and
        T410P in related receptors was assesed.', ligand_long: '', ligand_short: '',
    pubmed: '9178745', seq: '223', to_res: R}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: K}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: H}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: Q}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: I}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: C}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: A}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: S}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '111',
    to_res: G}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: C}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: G}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: H}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: Q}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: C}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile8]Ang II', pubmed: '9843384',
    seq: '111', to_res: G}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: H}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: Q}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: C}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1, Ile4]Ang II', pubmed: '9843384',
    seq: '111', to_res: G}
- {entry_name: lshr_rat, from_res: N, info: 'The two activating mutations, N593R and
        N597Q, lead to dramatic shifts in TMHs 6 and 7 respectively. The two loss-of-function
        mutants, N593Q and N597R, also lead to helix reorientation, but of a somewhat
        different nature.', ligand_long: '', ligand_short: '', pubmed: '10770485',
    seq: '623', to_res: R}
- {entry_name: lshr_rat, from_res: N, info: 'The N597Q mutant expressed at a level
        comparable to that of WT LHR and, like the N593R mutant, exhibited constitutive
        receptor activation as judged by the increase in basal cAMP; moreover, responsiveness
        to hCG was like that of WT LHR.The two activating mutations, N593R and N597Q,
        lead to dramatic shifts in TMHs 6 and 7 respectively. The two loss-of-function
        mutants, N593Q and N597R, also lead to helix reorientation, but of a somewhat
        different nature.', ligand_long: '', ligand_short: '', pubmed: '10770485',
    seq: '623', to_res: Q}
- {entry_name: lshr_rat, from_res: N, info: 'Two mutant forms represents a loss-of-function
        mutant, N593A, and a gain-of-function, N593R.The two activating mutations,
        N593R and N597Q, lead to dramatic shifts in TMHs 6 and 7 respectively.', ligand_long: '',
    ligand_short: '', pubmed: '10770485', seq: '619', to_res: R}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: Y}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: F}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: K}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: H}
- {entry_name: agtra_rat, from_res: N, info: "The Ile-, Gln-, His-, Lys-, Phe-, and\
        \ Tyr-substituted mutant receptors were not constitutively active. The [Sar1]Ang\
        \ II-dependent maximum IP formation in these mutants was reduced by 35-70%.\
        \ The basal IP production without agonist stimulation in cells transfected\
        \ with these mutant receptors was not significantly from that observed in\
        \ wild-type receptor transfected cells. The expression level of these mutants\
        \ varied, but the surface receptor expression was not significantly different.\
        \ However, in distinct contrast to the constitutively activated mutant AT1\
        \ receptors, Ile-, Gln-, His-, Lys-, Phe-, and Tyr-substituted mutant receptors\
        \ did not show a dramatic increase of affinity toward the  partial agonist\
        \ analogue [Sar1, Ile4]Ang II and the inactive analogue [Sar1, Ile4, Ile8]Ang\
        \ II.Residues larger than Asn at position 111 favor the basal inactive state,\
        \ and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: Q}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: I}
- {entry_name: lshr_rat, from_res: N, info: 'The two activating mutations, N593R and
        N597Q, lead to dramatic shifts in TMHs 6 and 7 respectively. The two loss-of-function
        mutants, N593Q and N597R, also lead to helix reorientation, but of a somewhat
        different nature.', ligand_long: '', ligand_short: '', pubmed: '10770485',
    seq: '619', to_res: Q}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: C}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: S}
- {entry_name: agtra_rat, from_res: N, info: "Gly-, Ala-, Ser-, and Cys-substituted\
        \ mutant receptors were constitutively active: The IP stimulation in the absence\
        \ of agonist by these mutants was significantly increased over the wild-type\
        \ receptor.All of these mutant receptors expressed well, bound [Sar1]Ang II,\
        \ [Sar1, Ile8]Ang II nearly with the same affinity as the wild-type. Affinity\
        \ of these mutants was increased >100-fold toward the partial agonist analogue\
        \ [Sar1, Ile4]Ang II and >200-fold toward the inactive analogue [Sar1, Ile4,\
        \ Ile8]Ang II.Residues larger than Asn at position 111 favor the basal inactive\
        \ state, and smaller residues favor the intermediate active state.The difference\
        \ in the basal activation from the smallest (Gly111) to the largest (Tyr111)\
        \ residue examined was 40% of the maximal achievable activation using [Sar1]Ang\
        \ II.The Asn side chain at position 111 is not uniquely important for either\
        \ the maintenance of the basal or the generation of the fully active state\
        \ of the receptor.Asn111 is considered as an \u201Cagonist-switch-binding\u201D\
        \ residue because it functionally interacts with the Tyr4 agonist group of\
        \ Ang II.", ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384',
    seq: '111', to_res: G}
- {entry_name: lshr_rat, from_res: T, info: 'For the N597A and T605A mutants, both
        expression levels and hCG responsiveness were reduced relative to WT LHR.',
    ligand_long: 125-I-hCG, ligand_short: hCG, pubmed: '10770485', seq: '631', to_res: A}
- {entry_name: lshr_rat, from_res: F, info: 'The receptor mutant L586A, V587A, and
        S594A, but not N593A, C595A, N597A, F604A, or T605A, also showed a slight
        depence of Rmax on receptor expression levels, and there was no significant
        change in basal cAMP values with recptor desity for WT and the mutant LHRs
        (data not shown).', ligand_long: 125-I-hCG, ligand_short: hCG, pubmed: '10770485',
    seq: '630', to_res: A}
- {entry_name: lshr_rat, from_res: N, info: 'For the N597A and T605A mutants, both
        expression levels and hCG responsiveness were reduced relative to WT LHR.Compared
        with WT LHR, the N597A, N597D, and N597K mutants expressed at lower levels
        and exhibited reduced responsiveness to hCG; basal cAMP values were similar
        to that of WT LHR. The N597R mutant exhibited a basal cAMP level like that
        of WT LHR, but responed poorly to hCG. Thus, the N597A replacement represents
        a loss-of-function mutant.', ligand_long: 125-I-hCG, ligand_short: hCG, pubmed: '10770485',
    seq: '623', to_res: A}
- {entry_name: lshr_rat, from_res: C, info: 'For the N593A and C595A mutants, receptor
        expression was comparable to or exceeded that of WT HLR, but responsiveness
        to hCG was diminished.', ligand_long: 125-I-hCG, ligand_short: hCG, pubmed: '10770485',
    seq: '621', to_res: A}
- {entry_name: lshr_rat, from_res: S, info: 'The receptor mutant L586A, V587A, and
        S594A, but not N593A, C595A, N597A, F604A, or T605A, also showed a slight
        depence of Rmax on receptor expression levels, and there was no significant
        change in basal cAMP values with recptor desity for WT and the mutant LHRs
        (data not shown).', ligand_long: 125-I-hCG, ligand_short: hCG, pubmed: '10770485',
    seq: '620', to_res: A}
- {entry_name: lshr_rat, from_res: N, info: 'For the N593A and C595A mutants, receptor
        expression was comparable to or exceeded that of WT HLR, but responsiveness
        to hCG was diminished.The Asn593 -> Ala, Gln and Ser replacements yielded
        LHR mutants that expressed at levels comparable to WT LHR, yet responsiveness
        to hCG was blunted.Two mutant forms represents a loss-of-function mutant,
        N593A, and a gain-of-function, N593R.', ligand_long: 125-I-hCG, ligand_short: hCG,
    pubmed: '10770485', seq: '619', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '295', to_res: F}
- {entry_name: lshr_rat, from_res: V, info: 'The receptor mutant L586A, V587A, and
        S594A, but not N593A, C595A, N597A, f604A, or T605A, also showed a slight
        depence of Rmax on receptor expression levels, and there was no significant
        change in basal cAMP values with recptor desity for WT and the mutant LHRs
        (data not shown).', ligand_long: 125-I-hCG, ligand_short: hCG, pubmed: '10770485',
    seq: '613', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '295', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '295', to_res: S}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '295', to_res: C}
- {entry_name: lshr_rat, from_res: L, info: 'The receptor mutant L586A, V587A, and
        S594A, but not N593A, C595A, N597A, f604A, or T605A, also showed a slight
        depence of Rmax on receptor expression levels, and there was no significant
        change in basal cAMP values with recptor desity for WT and the mutant LHRs
        (data not shown).', ligand_long: 125-I-hCG, ligand_short: hCG, pubmed: '10770485',
    seq: '612', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '295', to_res: A}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: Losartan, pubmed: '9843384', seq: '295', to_res: G}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '295',
    to_res: F}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '295',
    to_res: I}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '295',
    to_res: S}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '295',
    to_res: C}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '295',
    to_res: A}
- {entry_name: agtra_rat, from_res: N, info: 'The N295G, N295S, N295A, N295C, N295I
        and N295F mutants did not show any significant increase in basal activity,
        and most mutants were like the Wild-Type in being stimulated by [Sar1]Ang
        II.Comment: I interpreted the data from table 2 at the last row as Bmax values.',
    ligand_long: '', ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '295',
    to_res: G}
- {entry_name: agtra_rat, from_res: Y, info: 'The Y292Q, Y292A and Y292G mutants did
        not show significantly different properties from the wild-type AT1 receptor
        in basal activation.Furthermore, these mutants were able to fully activate
        IP production to within 74-83% of that of the wild-type AT1 receptor.Comment:
        I interpreted the data from table 2 at the last row as Bmax values.', ligand_long: '',
    ligand_short: Losartan, pubmed: '9843384', seq: '292', to_res: Q}
- {entry_name: agtra_rat, from_res: Y, info: 'The Y292Q, Y292A and Y292G mutants did
        not show significantly different properties from the wild-type AT1 receptor
        in basal activation.Furthermore, these mutants were able to fully activate
        IP production to within 74-83% of that of the wild-type AT1 receptor.Comment:
        I interpreted the data from table 2 at the last row as Bmax values.', ligand_long: '',
    ligand_short: Losartan, pubmed: '9843384', seq: '292', to_res: A}
- {entry_name: agtra_rat, from_res: Y, info: 'The Y292Q, Y292A and Y292G mutants did
        not show significantly different properties from the wild-type AT1 receptor
        in basal activation.Furthermore, these mutants were able to fully activate
        IP production to within 74-83% of that of the wild-type AT1 receptor.Comment:
        I interpreted the data from table 2 at the last row as Bmax values.', ligand_long: '',
    ligand_short: Losartan, pubmed: '9843384', seq: '292', to_res: G}
- {entry_name: agtra_rat, from_res: Y, info: 'The Y292Q, Y292A and Y292G mutants did
        not show significantly different properties from the wild-type AT1 receptor
        in basal activation.Furthermore, these mutants were able to fully activate
        IP production to within 74-83% of that of the wild-type AT1 receptor.Comment:
        I interpreted the data from table 2 at the last row as Bmax values.', ligand_long: '',
    ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '292', to_res: Q}
- {entry_name: agtra_rat, from_res: Y, info: 'The Y292Q, Y292A and Y292G mutants did
        not show significantly different properties from the wild-type AT1 receptor
        in basal activation.Furthermore, these mutants were able to fully activate
        IP production to within 74-83% of that of the wild-type AT1 receptor.Comment:
        I interpreted the data from table 2 at the last row as Bmax values.', ligand_long: '',
    ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '292', to_res: A}
- {entry_name: agtra_rat, from_res: Y, info: 'The Y292Q, Y292A and Y292G mutants did
        not show significantly different properties from the wild-type AT1 receptor
        in basal activation.Furthermore, these mutants were able to fully activate
        IP production to within 74-83% of that of the wild-type AT1 receptor.Comment:
        I interpreted the data from table 2 at the last row as Bmax values.', ligand_long: '',
    ligand_short: '[Sar1]Ang II', pubmed: '9843384', seq: '292', to_res: G}
- {entry_name: drd2_human_nwt, from_res: H, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '398', to_res: C}
- {entry_name: drd2_human_nwt, from_res: H, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '398', to_res: C}
- {entry_name: adrb2_human, from_res: S, info: 'In view of the experimental evidence
        on the key role played by helix 7 in binding, particularly to antagonists,
        it is very interesting to observe interactions between the antagonist and
        Leu311 and Asn312 and also between the agonist and Leu311 and Gly315 (and
        Ser319).Mutation effect: low agonist bindingComments: Mutation is located
        on helix 7.', ligand_long: '', ligand_short: '', pubmed: '9397168', seq: '319',
    to_res: A}
- {entry_name: drd2_human_nwt, from_res: I, info: 'We infer that 10 of 22 residues
        tested are on the water-accessible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        tested except H393C.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-) Sulpiride,
    pubmed: '9454590', seq: '397', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'We infer that 10 of 22 residues
        tested are on the water-accessible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        tested except H393C.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '9454590',
    seq: '397', to_res: C}
- {entry_name: drd2_human_nwt, from_res: N, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '396', to_res: C}
- {entry_name: drd2_human_nwt, from_res: N, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '396', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '395', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '395', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'We infer that 10 of 22 residues
        tested are on the water-accessible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        tested except H393C.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-) Sulpiride,
    pubmed: '9454590', seq: '394', to_res: C}
- {entry_name: adrb2_human, from_res: N, info: 'The first pocket, complemented by
        Asn312 and Tyr308 on helix 7, contributes to the antagonist-binding site;
        ...Association of the first hydrophobic pocket with the antagonist-binding
        site comes largely through the site-directed mutagenesis studies of Suryaranayana
        who showed that Asn312 played an important part in binding beta-selective
        antagonists which had an ether oxygen.Mutation effect: No binding of antagonist/agonistComments:
        Mutation is located on helix 7.', ligand_long: '', ligand_short: '', pubmed: '9397168',
    seq: '312', to_res: F}
- {entry_name: adrb2_human, from_res: N, info: 'The first pocket, complemented by
        Asn312 and Tyr308 on helix 7, contributes to the antagonist-binding site;
        ...Association of the first hydrophobic pocket with the antagonist-binding
        site comes largely through the site-directed mutagenesis studies of Suryaranayana
        who showed that Asn312 played an important part in binding beta-selective
        antagonists which had an ether oxygen.Mutation effect: no antagonist bindingComments:
        Mutation is located on helix 7.', ligand_long: '', ligand_short: '', pubmed: '9397168',
    seq: '312', to_res: T}
- {entry_name: drd2_human_nwt, from_res: I, info: 'We infer that 10 of 22 residues
        tested are on the water-accesible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        tested except H393C.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '9454590',
    seq: '394', to_res: C}
- {entry_name: adrb2_human, from_res: N, info: 'The first pocket, complemented by
        Asn312 and Tyr308 on helix 7, contributes to the antagonist-binding site;
        ...Association of the first hydrophobic pocket with the antagonist-binding
        site comes largely through the site-directed mutagenesis studies of Suryaranayana
        who showed that Asn312 played an important part in binding beta-selective
        antagonists which had an ether oxygen.Mutation effect: no antagonist bindingComments:
        Mutation is located on helix 7.', ligand_long: '', ligand_short: '', pubmed: '9397168',
    seq: '312', to_res: A}
- {entry_name: drd2_human_nwt, from_res: H, info: 'In F382C, P388C, F390C, and H393C,
        the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that 10 of 22
        residues tested are on the water-accesible surface of the D2 receptor. These
        residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393,
        Ile394, and Ile397.The competitive antagonist sulpiride protected all of the
        residues tested except H393C. The reason for the inability of sulpiride to
        protect H393C is not clear. Sulpiride''s affinity was reduced nearly 10-fold
        in this mutant. A similar 10-fold reduction in the affinity of sulpiride was
        previously seen after mutation of this histidine to leucine.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '393', to_res: C}
- {entry_name: drd2_human, from_res: I, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '130', to_res: C}
- {entry_name: drd2_human, from_res: S, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '129', to_res: C}
- {entry_name: drd2_human, from_res: I, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '128', to_res: C}
- {entry_name: drd2_human_nwt, from_res: H, info: 'In F382C, P388C, F390C, and H393C,
        the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that 10 of 22
        residues tested are on the water-accessible surface of the D2 receptor. These
        residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393C,
        Ile394, and Ile397.The competitive antagonist sulpiride protected all of the
        residues tested except H393C. The reason for the inability of sulpiride to
        protect H393C is not clear. Sulpiride''s affinity was reduced nearly 10-fold
        in this mutant. A similar 10-fold reduction in the affinity of sulpiride was
        previously seen after mutation of this histidine to leucine.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '393', to_res: C}
- {entry_name: drd2_human, from_res: A, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '127', to_res: C}
- {entry_name: drd2_human, from_res: L, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '125', to_res: C}
- {entry_name: drd2_human, from_res: N, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '124', to_res: C}
- {entry_name: drd2_human, from_res: L, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '123', to_res: C}
- {entry_name: drd2_human, from_res: I, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '122', to_res: C}
- {entry_name: drd2_human, from_res: S, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '121', to_res: C}
- {entry_name: drd2_human, from_res: A, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '120', to_res: C}
- {entry_name: drd2_human, from_res: T, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '119', to_res: C}
- {entry_name: drd2_human, from_res: M, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '117', to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: 'We infer that 10 of 22 residues
        tested are on the water-accesible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His2929, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        tested except H393C.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-) Sulpiride,
    pubmed: '9454590', seq: '392', to_res: C}
- {entry_name: drd2_human, from_res: M, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '116', to_res: C}
- {entry_name: drd2_human, from_res: V, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '115', to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: 'We infer that 10 of 22 residues
        tested are on the water-accesible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His2929, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        tested except H393C.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '9454590',
    seq: '392', to_res: C}
- {entry_name: drd2_human, from_res: L, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '113', to_res: C}
- {entry_name: drd2_human, from_res: T, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '112', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '391', to_res: C}
- {entry_name: drd2_human, from_res: V, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '111', to_res: C}
- {entry_name: drd2_human, from_res: F, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '110', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '391', to_res: C}
- {entry_name: drd2_human, from_res: I, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '109', to_res: C}
- {entry_name: drd2_human, from_res: D, info: 'The most reactive cysteines are Cys-118
        and those substituted for Val-111 and Val-115.Cysteines substituted for Ser-121
        and Ile-122, located closer to the cytoplasmic side than the highly reactive
        Cys-118, were of intermediate reactivity with MTSEA.Cysteines substituted
        for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic,
        susceptible residues were the least reactive.Of the residues that reacted
        with MTSEA, MTSET reacted with cysteines substituted only for Asp-108, Ile-109,
        Phe-110, Val-111, Val-115, Cys-118, Ser-121 and no other.MTSES reacted only
        with residues substituted for Asp-108, Ile-109, Phe-110, Val-111, at the extracellular
        end of M3.At D108C, MTSES increased binding increased.MTSES did not react
        with cysteines substituted for residues more cytoplasmic than Val-111.', ligand_long: '',
    ligand_short: '', pubmed: '7718244', seq: '108', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: 'In P388C and F390C, the Kd''s were
        3.7 and 3.1 times the Kd of C118S, respectivily. In F382C, P388C, F390C, and
        H393C, the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that
        10 of 22 residues tested are on the water-accesible surface of the D2 receptor.
        These residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392,
        His2929, Ile394, and Ile397.The competitive antagonist sulpiride protected
        all of the residues tested except H393C.F390C had only an about 4-fold decreased
        affinity for N-methylspiperone, while F390A was previously reported to have
        undetectable binding. Thus, Cys is a much better tolerated substitution for
        Phe390 than is Ala.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-) Sulpiride,
    pubmed: '9454590', seq: '390', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: 'In P388C and F390C, the Kd''s were
        3.7 and 3.1 times the Kd of C118S, respectivily. In F382C, P388C, F390C, and
        H393C, the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that
        10 of 22 residues tested are on the water-accesible surface of the D2 receptor.
        These residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392,
        His2929, Ile394, and Ile397.The competitive antagonist sulpiride protected
        all of the residues tested except H393C.F390C had only an about 4-fold decreased
        affinity for N-methylspiperone, while F390A was previously reported to have
        undetectable binding. Thus, Cys is a much better tolerated substitution for
        Phe390 than is Ala.Comment: the expression data was determined as (Bmax_mut
        / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '9454590',
    seq: '390', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: 'We found F389C to bind both N-methylspiperone
        and sulpiride with greatly reduced affinity.For W386C and F389C, the affinity
        of [3H]-N-Methylspiperone was too low for accurate determination of the Kd
        and Bmax from saturation experiments, for these mutants, the IC50''s for unlabeled
        N-methylspiperone in competition with [3H]-N-Methylspiperone were 2-3 orders
        of magnitude greater than that for C118S.In W386C and F389C the IC50 > 10
        mM, more than 1500 fold higher than the Ki of C118S.We infer that 10 of 22
        residues tested are on the water-accesible surface of the D2 receptor. These
        residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His2929,
        Ile394, and Ile397.We were unable to test for sulpiride protection with the
        mutants W386C and F389C because the binding affinity was too low.Comment:
        the presented value for F389C was > 1500 (Ki_mut/Ki_NWT).Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: N-methylspiperone, pubmed: '9454590', seq: '389', to_res: C}
- {entry_name: adrb2_human, from_res: C, info: 'Comments: Mutation is located on helix
        6', ligand_long: '', ligand_short: '', pubmed: '9397168', seq: '285', to_res: S}
- {entry_name: adrb2_human, from_res: E, info: 'Comments: Mutation is located on intracellular
        loop 3', ligand_long: '', ligand_short: '', pubmed: '9397168', seq: '268',
    to_res: G}
- {entry_name: drd2_human_nwt, from_res: P, info: 'In P388C and F390C, the Kd''s were
        3.7 and 3.1 times the Kd of C118S, respectivily. In F382C, P388C, F390C, and
        H393C, the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that
        10 of 22 residues tested are on the water-accesible surface of the D2 receptor.
        These residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392,
        His2929, Ile394, and Ile397.The competitive antagonist sulpiride protected
        all of the residues tested except H393C.Comment: the expression data was determined
        as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)
        Sulpiride, pubmed: '9454590', seq: '388', to_res: C}
- {entry_name: drd2_human_nwt, from_res: P, info: 'In P388C and F390C, the Kd''s were
        3.7 and 3.1 times the Kd of C118S, respectivily. In F382C, P388C, F390C, and
        H393C, the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that
        10 of 22 residues tested are on the water-accesible surface of the D2 receptor.
        These residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392,
        His2929, Ile394, and Ile397.The competitive antagonist sulpiride protected
        all of the residues tested except H393C.Comment: the expression data was determined
        as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: '',
    pubmed: '9454590', seq: '388', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '9454590', seq: '387', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The competitive antagonist sulpiride
        protected all of the residues tested except H393C.Comment: the expression
        data was determined as (Bmax_mut / Bmax_NWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '387', to_res: C}
- {entry_name: adrb2_human, from_res: S, info: 'For the catecholamines, this is almost
        equivalent to starting with the catechol hydroxyl groups pointing toward Ser204
        and Ser207 on helix 5.The only relevant sites where water had a clear preference
        were the aspartates, including Asp113 on helix 3, and the backbone carbonyl
        on Ser207. In our model there was a tendency in very long simulations for
        helix 5 to rotate so that the catechol could bind to the hydroxyl and carbonyl
        groups of Ser207 (rather than to the hydroxyl groups of Ser204 and Ser207).Mutation
        effect: reduced agonist binding.Comments: Mutation is located on helix 5',
    ligand_long: '', ligand_short: '', pubmed: '9397168', seq: '207', to_res: A}
- {entry_name: drd2_human_nwt, from_res: W, info: 'For W386C and F389C, the affinity
        of [3H]-N-Methylspiperone was too low for accurate determination of the Kd
        and Bmax from saturation experiments, for these mutants, the IC50''s for unlabeled
        N-methylspiperone in competition with [3H]-N-Methylspiperone were 2-3 orders
        of magnitude greater than that for C118S.In W386C and F389C the IC50 > 10
        mM, more than 1500 fold higher than the Ki of C118S.We infer that 10 of 22
        residues tested are on the water-accesible surface of the D2 receptor. These
        residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His2929,
        Ile394, and Ile397.We were unable to test for sulpiride protection with the
        mutants W386C and F389C because the binding affinity was too low.Comment:
        the presented value for W386C was > 1500 (Ki_mut/Ki_NWT).', ligand_long: '',
    ligand_short: '', pubmed: '9454590', seq: '386', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '384', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)Sulpiride, pubmed: '9454590', seq: '383', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'In F382C, P388C, F390C, and H393C,
        the Ki was between 3.5 and 9.6 times the Ki of C118S.The competitive antagonist
        sulpiride protected all of the residues except H393C.Comment: the expression
        data is determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '383', to_res: C}
- {entry_name: adrb2_human, from_res: P, info: 'comments: Comments: mutation is located
        in intracellular loop 2.', ligand_long: '', ligand_short: '', pubmed: '9397168',
    seq: '138', to_res: T}
- {entry_name: drd2_human, from_res: D, info: 'It is clear for D108C that there is
        an electrostatic component to the alteration of binding due to the addition
        of -SCH2CH2X.Replacement of the aspartate by cysteine in D108C decreased affinity
        4-fold, modifications by MTSES, which restores negative charge to the side
        chain, increased the affinity 2-fold, increased binding.', ligand_long: '[3H]YM-09151-2',
    ligand_short: '', pubmed: '7718244', seq: '108', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: 'In F382C, P388C, F390C, and H393C,
        the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that 10 of the
        22 residues tested are on the water-accessible surface of the D2 receptor.
        These residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392,
        His393, Ile394, and Ile397.The competitive antagonist sulpiride protected
        all of the residues except H393C.Comment: the expression data is determined
        as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)Sulspiride,
    pubmed: '9454590', seq: '382', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: 'In F382C, P388C, F390C, and H393C,
        the Ki was between 3.5 and 9.6 times the Ki of C118S.We infer that 10 of the
        22 residues tested are on the water-accessible surface of the D2 receptor.
        These residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392,
        His393, Ile394, and Ile397.The competitive antagonist sulpiride protected
        all of the residues except H393C.Comment: the expression data is determined
        as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: '',
    pubmed: '9454590', seq: '382', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '381', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '381', to_res: C}
- {entry_name: drd2_human_nwt, from_res: G, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '380', to_res: C}
- {entry_name: adrb2_human, from_res: D, info: 'Comments: Mutation is located in helix
        3.', ligand_long: '', ligand_short: '', pubmed: '9397168', seq: '130', to_res: N}
- {entry_name: drd2_human_nwt, from_res: G, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '380', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '379', to_res: C}
- {entry_name: adrb2_human, from_res: D, info: 'The only relevant sites where the
        water had a clear preference were the aspartates, including Asp113 on helix
        3, and the backbone carbonyl group on Ser207.Mutation effect: reduced agonist/antagonist
        binding.comments: mutation is located on helix 3.', ligand_long: '', ligand_short: '',
    pubmed: '9397168', seq: '113', to_res: Q}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '379', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'We infer that 10 of the 22 residues
        tested are on the water-accessible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        except H393C.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)Sulpiride, pubmed: '9454590',
    seq: '378', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '9454590', seq: '377', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'We infer that 10 of the 22 residues
        tested are on the water-accessible surface of the D2 receptor. These residues
        are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His393, Ile394,
        and Ile397.The competitive antagonist sulpiride protected all of the residues
        except H393C.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '9454590', seq: '378',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '9454590', seq: '377', to_res: C}
- {entry_name: adrb2_human, from_res: D, info: 'mutation effect: reduced agonist binding.Comments:
        mutation is located in helix 2.', ligand_long: '', ligand_short: '', pubmed: '9397168',
    seq: '79', to_res: N}
- {entry_name: adrb2_human, from_res: D, info: 'mutation effect: increased agonist
        binding.Comments: mutation is located in helix 2.', ligand_long: '', ligand_short: '',
    pubmed: '9397168', seq: '79', to_res: A}
- {entry_name: adrb2_human, from_res: L, info: 'Comments: mutation is located in the
        intracellular loop', ligand_long: '', ligand_short: '', pubmed: '9397168',
    seq: '64', to_res: K}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: F}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: V}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: G}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: A}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: D}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: C}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: Q}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: T}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: K}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: Y}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: H}
- {entry_name: acm5_human, from_res: N, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '459', to_res: S}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: Atropine,
    pubmed: '9705286', seq: '451', to_res: W}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: Atropine,
    pubmed: '9705286', seq: '451', to_res: G}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: Atropine,
    pubmed: '9705286', seq: '451', to_res: A}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: Atropine,
    pubmed: '9705286', seq: '451', to_res: C}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: Atropine,
    pubmed: '9705286', seq: '451', to_res: L}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: Atropine,
    pubmed: '9705286', seq: '451', to_res: V}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: P}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: W}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: G}
- {entry_name: adrb1_human, from_res: F, info: 'Comment: To examine the role of the
        amino acids (Leu110, Thr117 andPhe 359) in an active state of the receptor
        these amino acids are mutated into a constitutively active beta1-adrenergic
        receptor.', ligand_long: '', ligand_short: (-)-RO636, pubmed: '11907156',
    seq: '359', to_res: A}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: N}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: Q}
- {entry_name: adrb1_human, from_res: T, info: 'Comment: To examine the role of the
        amino acids (Leu110, Thr117 andPhe 359) in an active state of the receptor
        these amino acids are mutated into a constitutively active beta1-adrenergic
        receptor.', ligand_long: '', ligand_short: (-)-RO636, pubmed: '11907156',
    seq: '117', to_res: A}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: A}
- {entry_name: adrb1_human, from_res: L, info: 'Comment: To examine the role of the
        amino acids (Leu110, Thr117 andPhe 359) in an active state of the receptor
        these amino acids are mutated into a constitutively active beta1-adrenergic
        receptor.', ligand_long: '', ligand_short: (-)-RO636, pubmed: '11907156',
    seq: '110', to_res: A}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: C}
- {entry_name: adrb1_human, from_res: T, info: 'Comment: To examine the role of the
        amino acids (Leu110, Thr117 andPhe 359) in an active state of the receptor
        these amino acids are mutated into a constitutively active beta1-adrenergic
        receptor.', ligand_long: 125I-Cyanopindolol, ligand_short: '', pubmed: '11907156',
    seq: '117', to_res: A}
- {entry_name: adrb1_human, from_res: L, info: 'Comment: To examine the role of the
        amino acids (Leu110, Thr117 andPhe 359) in an active state of the receptor
        these amino acids are mutated into a constitutively active beta1-adrenergic
        receptor.', ligand_long: 125I-Cyanopindolol, ligand_short: '', pubmed: '11907156',
    seq: '110', to_res: A}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: T}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: L}
- {entry_name: acm5_human, from_res: F, info: 'Asn-459 differed from Phe-451 in that,
        of the wide range of substitutions tolerated at this residue, only histidine,
        and serine caused significant increases in constitutive activity. With the
        exception of the very conservative mutation N459Q, all mutations to Asn-459
        caused decreases of over 100-fold in atropine potency. Carbachol potency was
        also decreased by mutation of Asn-459.', ligand_long: '', ligand_short: '',
    pubmed: '9705286', seq: '451', to_res: V}
- {entry_name: adrb1_human, from_res: F, info: Phe359 in an active state locates in
        a closer position than in the resting state.Phe359 in transmembrane domain
        7 is a major determinant of beta1-selectivity of (-)-RO636., ligand_long: 125I-Cyanopindolol,
    ligand_short: '', pubmed: '11907156', seq: '359', to_res: A}
- {entry_name: adrb1_human, from_res: T, info: 'Yhr117 in transmembrane domain 2 play
        a major role in the subtyp-selective binding of beta1-selective agonists containing
        dimethoxyphenyl group such as T-0509, denopamine and (-)-RO363.', ligand_long: '',
    ligand_short: (-)-RO636, pubmed: '11907156', seq: '117', to_res: A}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Cysteines substituted for Asp80,
        Leu81, Val87, Trp90, Val92, and Val96 were least reactive.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '10387039', seq: '96', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Cysteines substituted for Asp80,
        Leu81, Val87, Trp90, Val92, and Val96 were least reactive.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10387039', seq: '96', to_res: C}
- {entry_name: drd2_human_nwt, from_res: E, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone', ligand_short: (-)sulpiride,
    pubmed: '10387039', seq: '95', to_res: C}
- {entry_name: drd2_human_nwt, from_res: E, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone', ligand_short: '',
    pubmed: '10387039', seq: '95', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone', ligand_short: (-)sulpiride,
    pubmed: '10387039', seq: '94', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone', ligand_short: '',
    pubmed: '10387039', seq: '94', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Cysteines substituted for Asp80,
        Leu81, Val87, Trp90, Val92, and Val96 were least reactive.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '10387039', seq: '92', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Cysteines substituted for Asp80,
        Leu81, Val87, Trp90, Val92, and Val96 were least reactive.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10387039', seq: '92', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone', ligand_short: (-)sulpiride,
    pubmed: '10387039', seq: '91', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone', ligand_short: '',
    pubmed: '10387039', seq: '91', to_res: C}
- {entry_name: drd2_human_nwt, from_res: W, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Cysteines substituted for Asp80, Leu81, Val87,
        Trp90, Val92, and Val96 were least reactive.Comments: drd2_human_nwt = mutant
        C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '10387039', seq: '90', to_res: C}
- {entry_name: drd2_human_nwt, from_res: W, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Cysteines substituted for Asp80, Leu81, Val87,
        Trp90, Val92, and Val96 were least reactive.Comments: drd2_human_nwt = mutant
        C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10387039', seq: '90', to_res: C}
- {entry_name: drd2_human_nwt, from_res: P, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone', ligand_short: (-)sulpiride,
    pubmed: '10387039', seq: '89', to_res: C}
- {entry_name: drd2_human_nwt, from_res: P, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Comments: drd2_human_nwt = mutant C118S.
        All mutants are located in TM2.', ligand_long: '[3H]N-Methylspiperone', ligand_short: '',
    pubmed: '10387039', seq: '89', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.Cysteines substituted
        for Asp80, Leu81, Val87, Trp90, Val92, and Val96 were least reactive.Comments:
        drd2_human_nwt = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '10387039', seq: '87', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.Cysteines substituted
        for Asp80, Leu81, Val87, Trp90, Val92, and Val96 were least reactive.Comments:
        drd2_human_nwt = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10387039', seq: '87', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.The most reactive
        cysteines were those substituted for Val83, Val91, Leu94, and Glu95.Comments:
        drd2_human_nwt = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10387039', seq: '83', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.The most reactive
        cysteines were those substituted for Val83, Val91, Leu94, and Glu95.Comments:
        drd2_human_nwt = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '10387039', seq: '83', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10387039', seq: '81', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '10387039', seq: '81', to_res: C}
- {entry_name: drd2_human_nwt, from_res: D, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: '', pubmed: '10387039', seq: '80', to_res: C}
- {entry_name: drd2_human_nwt, from_res: D, info: 'The reversible antagonist sulpiride
        significantly retarded the reaction of MTSEA with D80C, L81C, V83C, V87C,
        P89C, W90C, V91C, L94C, and E95C.Thus, it is likely that Asp80 is necessary
        for the receptor to adopt its active conformation. While we observed a 7-fold
        decrease in the affinity of D80C for sulpiride, its affinity for N-methylspiperone,
        which is not sodium dependent, was increased nearly 3-fold.Comments: drd2_human_nwt
        = mutant C118S. All mutants are located in TM2.', ligand_long: '[3H]N-methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '10387039', seq: '80', to_res: C}
- {entry_name: ada1b_mesau, from_res: F, info: 'Previous studies have shown that mutation
        of this residue into Asn or Gly totally impairs the IP response but markedly
        increases the affinity of epinephrine (Chen et al., 1999, 2000)....the F303G
        receptor displayed a 50-fold increase in affinity for epinephrine and an almost
        complete loss of receptor mediated signaling. The F303A mutant was functionally
        similar to the F303G.The mutation of F303 to Tyr impaired the receptor mediated
        maximal response to epinephrine by about 50%. Whereas the affinity of epinephrine
        was not significantly changed at the F303Y mutant, its potency was decreased
        by almost 20-fold.In contrast, the mutation of F303 to Leu [...] increased
        the constitutive as well as the agonist-induced activity of the receptor.
        this mutation resulted also in a 30-fold increase in affinity and a 20-fold
        increase in potency of epinephrine.In addition, F303 interacts with S132 and
        I133 as well as with N344 of the NPXXY motif.This is consistent with experimental
        findings showing that the F303Y is not constitutively active.In fact, mutations
        of F303 to Gly, Ala and Leu markedly increased the affinity of epinephrine.
        However, this increase in agonist affinity was correlated with increased constitutive
        activity only for the F303L mutant, in which which the interaction pattern
        of R143 was perturbed by the mutation.Comments: data from WT low was used
        to calculate percentages. data for WT low: expression 128+-9 fmol/well; IP
        accumulation: basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50
        4.7 microM and EC50 29+-6 nM. Data for WT high was also present but not used
        in calculations: expression 347+-58 fmol/well; IP accumulation: basal 17+-2%
        and epinephrine-induced 432+-44%; no epinephrine IC50 and EC50 data was present.',
    ligand_long: 125I-HEAT, ligand_short: epinephrine, pubmed: '11961120', seq: '303',
    to_res: Y}
- {entry_name: ada1b_mesau, from_res: F, info: 'Previous studies have shown that mutation
        of this residue into Asn or Gly totally impairs the IP response but markedly
        increases the affinity of epinephrine (Chen et al., 1999, 2000)....the F303G
        receptor displayed a 50-fold increase in affinity for epinephrine and an almost
        complete loss of receptor mediated signaling. The F303A mutant was functionally
        similar to the F303G.The mutation of F303 to Tyr impaired the receptor mediated
        maximal response to epinephrine by about 50%. Whereas the affinity of epinephrine
        was not significantly changed at the F303Y mutant, its potency was decreased
        by almost 20-fold.In contrast, the mutation of F303 to Leu [...] increased
        the constitutive as well as the agonist-induced activity of the receptor.
        this mutation resulted also in a 30-fold increase in affinity and a 20-fold
        increase in potency of epinephrine.In addition, F303 interacts with S132 and
        I133 as well as with N344 of the NPXXY motif.This is consistent with experimental
        findings showing that the F303Y is not constitutively active.In fact, mutations
        of F303 to Gly, Ala and Leu markedly increased the affinity of epinephrine.
        However, this increase in agonist affinity was correlated with increased constitutive
        activity only for the F303L mutant, in which which the interaction pattern
        of R143 was perturbed by the mutation.Comments: data from WT low was used
        to calculate percentages. data for WT low: expression 128+-9 fmol/well; IP
        accumulation: basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50
        4.7 microM and EC50 29+-6 nM. Data for WT high was also present but not used
        in calculations: expression 347+-58 fmol/well; IP accumulation: basal 17+-2%
        and epinephrine-induced 432+-44%; no epinephrine IC50 and EC50 data was present.',
    ligand_long: 125I-HEAT, ligand_short: epinephrine, pubmed: '11961120', seq: '303',
    to_res: L}
- {entry_name: ada1b_mesau, from_res: F, info: 'Previous studies have shown that mutation
        of this residue into Asn or Gly totally impairs the IP response but markedly
        increases the affinity of epinephrine (Chen et al., 1999, 2000)....the F303G
        receptor displayed a 50-fold increase in affinity for epinephrine and an almost
        complete loss of receptor mediated signaling. The F303A mutant was functionally
        similar to the F303G.The mutation of F303 to Tyr impaired the receptor mediated
        maximal response to epinephrine by about 50%. Whereas the affinity of epinephrine
        was not significantly changed at the F303Y mutant, its potency was decreased
        by almost 20-fold.In contrast, the mutation of F303 to Leu [...] increased
        the constitutive as well as the agonist-induced activity of the receptor.
        this mutation resulted also in a 30-fold increase in affinity and a 20-fold
        increase in potency of epinephrine.In addition, F303 interacts with S132 and
        I133 as well as with N344 of the NPXXY motif.This is consistent with experimental
        findings showing that the F303Y is not constitutively active.In fact, mutations
        of F303 to Gly, Ala and Leu markedly increased the affinity of epinephrine.
        However, this increase in agonist affinity was correlated with increased constitutive
        activity only for the F303L mutant, in which which the interaction pattern
        of R143 was perturbed by the mutation.Comments: data from WT low was used
        to calculate percentages. data for WT low: expression 128+-9 fmol/well; IP
        accumulation: basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50
        4.7 microM and EC50 29+-6 nM. Data for WT high was also present but not used
        in calculations: expression 347+-58 fmol/well; IP accumulation: basal 17+-2%
        and epinephrine-induced 432+-44%; no epinephrine IC50 and EC50 data was present.',
    ligand_long: 125I-HEAT, ligand_short: epinephrine, pubmed: '11961120', seq: '303',
    to_res: A}
- {entry_name: ada1b_mesau, from_res: F, info: 'Previous studies have shown that mutation
        of this residue into Asn or Gly totally impairs the IP response but markedly
        increases the affinity of epinephrine (Chen et al., 1999, 2000)....the F303G
        receptor displayed a 50-fold increase in affinity for epinephrine and an almost
        complete loss of receptor mediated signaling. The F303A mutant was functionally
        similar to the F303G.The mutation of F303 to Tyr impaired the receptor mediated
        maximal response to epinephrine by about 50%. Whereas the affinity of epinephrine
        was not significantly changed at the F303Y mutant, its potency was decreased
        by almost 20-fold.In contrast, the mutation of F303 to Leu [...] increased
        the constitutive as well as the agonist-induced activity of the receptor.
        this mutation resulted also in a 30-fold increase in affinity and a 20-fold
        increase in potency of epinephrine.In addition, F303 interacts with S132 and
        I133 as well as with N344 of the NPXXY motif.This is consistent with experimental
        findings showing that the F303Y is not constitutively active.In fact, mutations
        of F303 to Gly, Ala and Leu markedly increased the affinity of epinephrine.
        However, this increase in agonist affinity was correlated with increased constitutive
        activity only for the F303L mutant, in which which the interaction pattern
        of R143 was perturbed by the mutation.Comments: data from WT low was used
        to calculate percentages. data for WT low: expression 128+-9 fmol/well; IP
        accumulation: basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50
        4.7 microM and EC50 29+-6 nM. Data for WT high was also present but not used
        in calculations: expression 347+-58 fmol/well; IP accumulation: basal 17+-2%
        and epinephrine-induced 432+-44%; no epinephrine IC50 and EC50 data was present.',
    ligand_long: 125I-HEAT, ligand_short: epinephrine, pubmed: '11961120', seq: '303',
    to_res: G}
- {entry_name: ada1b_mesau, from_res: V, info: 'In agreement with this, experimental
        mutagenesis indicated that the mutations of V299 and V300 into either Ala
        or Phe did not impair receptor activation.In this study, we have found that
        mutating V299 and V300 to Ala or Phe did not markedly change the receptor-mediated
        IP response.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '300', to_res: F}
- {entry_name: ada1b_mesau, from_res: V, info: 'In agreement with this, experimental
        mutagenesis indicated that the mutations of V299 and V300 into either Ala
        or Phe did not impair receptor activation.In this study, we have found that
        mutating V299 and V300 to Ala or Phe did not markedly change the receptor-mediated
        IP response.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '300', to_res: A}
- {entry_name: ada1b_mesau, from_res: V, info: 'In fact, V299 lies between I347 and
        Y348 of the NPXXY highly conserverd motif in helix 7.In agreement with this,
        experimental mutagenesis indicated that the mutations of V299 and V300 into
        either Ala or Phe did not impair receptor activation. However, the mutation
        of of V299 into Phe increased the affinity for epinephrine by 100-fold. The
        potency of epinephrine was also significantly increased at the V299F mutant,
        bur only by 5-fold.However, the structural change induced by the mutation
        of V299 to Phe has a marked effect on agonist binding resulting in a large
        increase in its affinity.Comments: data from WT low was used to calculate
        percentages. data for WT low: expression 128+-9 fmol/well; IP accumulation:
        basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM
        and EC50 29+-6 nM. Data for WT high was also present but not used in calculations:
        expression 347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced
        432+-44%; no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT,
    ligand_short: epinephrine, pubmed: '11961120', seq: '299', to_res: F}
- {entry_name: ada1b_mesau, from_res: V, info: 'In fact, V299 lies between I347 and
        Y348 of the NPXXY highly conserverd motif in helix 7.In agreement with this,
        experimental mutagenesis indicated that the mutations of V299 and V300 into
        either Ala or Phe did not impair receptor activation. However, the mutation
        of of V299 into Phe increased the affinity for epinephrine by 100-fold. The
        potency of epinephrine was also significantly increased at the V299F mutant,
        bur only by 5-fold.However, the structural change induced by the mutation
        of V299 to Phe has a marked effect on agonist binding resulting in a large
        increase in its affinity.Comments: data from WT low was used to calculate
        percentages. data for WT low: expression 128+-9 fmol/well; IP accumulation:
        basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM
        and EC50 29+-6 nM. Data for WT high was also present but not used in calculations:
        expression 347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced
        432+-44%; no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT,
    ligand_short: epinephrine, pubmed: '11961120', seq: '299', to_res: A}
- {entry_name: ada1b_mesau, from_res: L, info: 'Both mutations of L296 to Ala and
        Phe resulted in a decrease in IP response of greater than 70%. At the same
        time, the epinephrine affinity of these mutants was unchanged.The mutation
        of L296 to Phe introduces additional interactions between the mutated amino
        acid and residues on helices 2 and 7 but leaves the interactions of R143 unaltered.
        Thus, L296 seems to have an important structural role in controlling the helix
        3-helix 6 packing that is perturbed by mutations of this residue to either
        Ala or Phe.In fact, the substitution of L296 with Ala or Phe profoundly impaired
        the receptor-mediated IP response.Comments: data from WT low was used to calculate
        percentages. data for WT low: expression 128+-9 fmol/well; IP accumulation:
        basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM
        and EC50 29+-6 nM. Data for WT high was also present but not used in calculations:
        expression 347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced
        432+-44%; no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT,
    ligand_short: epinephrine, pubmed: '11961120', seq: '296', to_res: F}
- {entry_name: ada1b_mesau, from_res: L, info: 'Both mutations of L296 to Ala and
        Phe resulted in a decrease in IP response of greater than 70%. At the same
        time, the epinephrine affinity of these mutants was unchanged.The mutation
        of L296 to Phe introduces additional interactions between the mutated amino
        acid and residues on helices 2 and 7 but leaves the interactions of R143 unaltered.
        Thus, L296 seems to have an important structural role in controlling the helix
        3-helix 6 packing that is perturbed by mutations of this residue to either
        Ala or Phe.In fact, the substitution of L296 with Ala or Phe profoundly impaired
        the receptor-mediated IP response.Comments: data from WT low was used to calculate
        percentages. data for WT low: expression 128+-9 fmol/well; IP accumulation:
        basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM
        and EC50 29+-6 nM. Data for WT high was also present but not used in calculations:
        expression 347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced
        432+-44%; no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT,
    ligand_short: epinephrine, pubmed: '11961120', seq: '296', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated high
        affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.Comment: For mutations S23A, N33A, N58A, T60A,
        D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A,
        H249A, Q252A, Q276A, T278A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '289', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, info: 'Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '285', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T278A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '284', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, info: 'PAF scarcely bound to other mutants
        such as H188A, H248A, H249A, Q252A, T278A, and S283A (with ratios under 0.30)
        among TM V, VI, and VII domain mutants.Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T278A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '283', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'PAF scarcely bound to other mutants
        such as H188A, H248A, H249A, Q252A, T278A, and S283A (with ratios under 0.30)
        among TM V, VI, and VII domain mutants.Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T278A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '278', to_res: A}
- {entry_name: ptafr_cavpo, from_res: Q, info: 'In all signals tested, dose-dependent
        curves in high affinity mutants (N100A, T101A and S104A), whereas those in
        low affinity mutants (H188A, H248A, and Q276A) were all shifted right by 1
        or 2 log units.Comment: For mutations N100A, T101A, S104A, H188A, H248A, and
        Q276A, competition binding data and signal transduction data with different
        ligands are determined but not quantified.Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.Comment:
        For mutations H188A, H248A, and Q276A, the effects of different divalent cations
        are determined but not quantified.', ligand_long: '[3H]WEB 2086', ligand_short: '',
    pubmed: '9065450', seq: '276', to_res: A}
- {entry_name: ada1b_mesau, from_res: A, info: 'In agreement with this prediction,
        the A292E mutant displays a profoundly impaired IP response without any significant
        change in the affinity of epinephrine.Comments: data from WT low was used
        to calculate percentages. data for WT low: expression 128+-9 fmol/well; IP
        accumulation: basal 14+-2% and epinephrine-induced 313+-69%; epinephrine IC50
        4.7 microM and EC50 29+-6 nM. Data for WT high was also present but not used
        in calculations: expression 347+-58 fmol/well; IP accumulation: basal 17+-2%
        and epinephrine-induced 432+-44%; no epinephrine IC50 and EC50 data was present.',
    ligand_long: 125I-HEAT, ligand_short: epinephrine, pubmed: '11961120', seq: '292',
    to_res: E}
- {entry_name: ptafr_cavpo, from_res: Q, info: 'PAF scarcely bound to other mutants
        such as H188A, H248A, H249A, Q252A, T278A, and S283A (with ratios under 0.30)
        among TM V, VI, and VII domain mutants.Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '252', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, info: 'PAF scarcely bound to other mutants
        such as H188A, H248A, H249A, Q252A, T278A, and S283A (with ratios under 0.30)
        among TM V, VI, and VII domain mutants.Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '249', to_res: A}
- {entry_name: ptafr_cavpo, from_res: H, info: 'PAF scarcely bound to other mutants
        such as H188A, H248A, H249A, Q252A, T278A, and S283A (with ratios under 0.30)
        among TM V, VI, and VII domain mutants.Even thought the Kd values of [3H]WEB
        2086 binding in H188A and H248A mutants were higher than that of the wild
        type, higher concentrations of zinc were needed to inhibit specific WEB 2086
        binding in these mutants.In all signals tested, dose-dependent curves in high
        affinity mutants (N100A, T101A and S104A), whereas those in low affinity mutants
        (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.Comment:
        For mutations H188A, H248A, and Q276A, the effects of different divalent cations
        are determined but not quantified.', ligand_long: '[3H]WEB 2086', ligand_short: '',
    pubmed: '9065450', seq: '248', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '236', to_res: A}
- {entry_name: ada1b_mesau, from_res: E, info: '...those residues directed towards
        helix 3. There are only four amino acids belonging to this interface, F286,
        E289, L296, and F303.The receptor mutants in which E289 was mutated into Ala,
        Phe, Lys, and Arg displayed the typical features described for the active
        state (R*) of a GPCR (Samama et al., 1993), including a marked increase in
        the constitutive and agonist dependent activity of the receptor as well as
        increased affinity and potency of the agonist. IN agreement with the experimental
        findings, the model predicts that mutating E289 to the neutral amino acids
        Ala and Phe or to the positively charged residues Lys and Arg breaks the salt
        bridge interactions of R143 and should therefore constitutively activate the
        alpha1b-AR.In the E289D mutant, the charge-reinforced H-bonding interaction
        between positions 143 and 289 occurs less frequently than in the wild-type
        receptor,...However, the E289Q displayed a significant 50% increase in the
        maximal agonist-induced response, which is one of the features of the active
        state (R*) of the receptor (Samama et al., 1993).In fact, it was frequently
        observed that either the reversible or irreversible neutralization of E289
        resulting from its protonation or mutation to Gln, respectively, can break
        both the salt bridge interactions involving R143 and the residues at positions
        142 and 289.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '289', to_res: K}
- {entry_name: ptafr_cavpo, from_res: H, info: 'PAF scarcely bound to other mutants
        such as H188A, H248A, H249A, Q252A, T278A, and S283A (with ratios under 0.30)
        among TM V, VI, and VII domain mutants.Even thought the Kd values of [3H]WEB
        2086 binding in H188A and H248A mutants were higher than that of the wild
        type, higher concentrations of zinc were needed to inhibit specific WEB 2086
        binding in these mutants.In all signals tested, dose-dependent curves in high
        affinity mutants (N100A, T101A and S104A), whereas those in low affinity mutants
        (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.Comment:
        For mutations H188A, H248A, and Q276A, the effects of different divalent cations
        are determined but not quantified.', ligand_long: '[3H]WEB 2086', ligand_short: '',
    pubmed: '9065450', seq: '188', to_res: A}
- {entry_name: ada1b_mesau, from_res: E, info: '...those residues directed towards
        helix 3. There are only four amino acids belonging to this interface, F286,
        E289, L296, and F303.The receptor mutants in which E289 was mutated into Ala,
        Phe, Lys, and Arg displayed the typical features described for the active
        state (R*) of a GPCR (Samama et al., 1993), including a marked increase in
        the constitutive and agonist dependent activity of the receptor as well as
        increased affinity and potency of the agonist. IN agreement with the experimental
        findings, the model predicts that mutating E289 to the neutral amino acids
        Ala and Phe or to the positively charged residues Lys and Arg breaks the salt
        bridge interactions of R143 and should therefore constitutively activate the
        alpha1b-AR.In the E289D mutant, the charge-reinforced H-bonding interaction
        between positions 143 and 289 occurs less frequently than in the wild-type
        receptor,...However, the E289Q displayed a significant 50% increase in the
        maximal agonist-induced response, which is one of the features of the active
        state (R*) of the receptor (Samama et al., 1993).In fact, it was frequently
        observed that either the reversible or irreversible neutralization of E289
        resulting from its protonation or mutation to Gln, respectively, can break
        both the salt bridge interactions involving R143 and the residues at positions
        142 and 289.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '289', to_res: R}
- {entry_name: ptafr_cavpo, from_res: S, info: 'Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '150', to_res: A}
- {entry_name: ada1b_mesau, from_res: E, info: '...those residues directed towards
        helix 3. There are only four amino acids belonging to this interface, F286,
        E289, L296, and F303.The receptor mutants in which E289 was mutated into Ala,
        Phe, Lys, and Arg displayed the typical features described for the active
        state (R*) of a GPCR (Samama et al., 1993), including a marked increase in
        the constitutive and agonist dependent activity of the receptor as well as
        increased affinity and potency of the agonist. IN agreement with the experimental
        findings, the model predicts that mutating E289 to the neutral amino acids
        Ala and Phe or to the positively charged residues Lys and Arg breaks the salt
        bridge interactions of R143 and should therefore constitutively activate the
        alpha1b-AR.In the E289D mutant, the charge-reinforced H-bonding interaction
        between positions 143 and 289 occurs less frequently than in the wild-type
        receptor,...However, the E289Q displayed a significant 50% increase in the
        maximal agonist-induced response, which is one of the features of the active
        state (R*) of the receptor (Samama et al., 1993).In fact, it was frequently
        observed that either the reversible or irreversible neutralization of E289
        resulting from its protonation or mutation to Gln, respectively, can break
        both the salt bridge interactions involving R143 and the residues at positions
        142 and 289.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '289', to_res: D}
- {entry_name: ada1b_mesau, from_res: E, info: '...those residues directed towards
        helix 3. There are only four amino acids belonging to this interface, F286,
        E289, L296, and F303.The receptor mutants in which E289 was mutated into Ala,
        Phe, Lys, and Arg displayed the typical features described for the active
        state (R*) of a GPCR (Samama et al., 1993), including a marked increase in
        the constitutive and agonist dependent activity of the receptor as well as
        increased affinity and potency of the agonist. IN agreement with the experimental
        findings, the model predicts that mutating E289 to the neutral amino acids
        Ala and Phe or to the positively charged residues Lys and Arg breaks the salt
        bridge interactions of R143 and should therefore constitutively activate the
        alpha1b-AR.In the E289D mutant, the charge-reinforced H-bonding interaction
        between positions 143 and 289 occurs less frequently than in the wild-type
        receptor,...However, the E289Q displayed a significant 50% increase in the
        maximal agonist-induced response, which is one of the features of the active
        state (R*) of the receptor (Samama et al., 1993).In fact, it was frequently
        observed that either the reversible or irreversible neutralization of E289
        resulting from its protonation or mutation to Gln, respectively, can break
        both the salt bridge interactions involving R143 and the residues at positions
        142 and 289.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '289', to_res: F}
- {entry_name: ada1b_mesau, from_res: E, info: '...those residues directed towards
        helix 3. There are only four amino acids belonging to this interface, F286,
        E289, L296, and F303.The receptor mutants in which E289 was mutated into Ala,
        Phe, Lys, and Arg displayed the typical features described for the active
        state (R*) of a GPCR (Samama et al., 1993), including a marked increase in
        the constitutive and agonist dependent activity of the receptor as well as
        increased affinity and potency of the agonist. IN agreement with the experimental
        findings, the model predicts that mutating E289 to the neutral amino acids
        Ala and Phe or to the positively charged residues Lys and Arg breaks the salt
        bridge interactions of R143 and should therefore constitutively activate the
        alpha1b-AR.In the E289D mutant, the charge-reinforced H-bonding interaction
        between positions 143 and 289 occurs less frequently than in the wild-type
        receptor,...However, the E289Q displayed a significant 50% increase in the
        maximal agonist-induced response, which is one of the features of the active
        state (R*) of the receptor (Samama et al., 1993).In fact, it was frequently
        observed that either the reversible or irreversible neutralization of E289
        resulting from its protonation or mutation to Gln, respectively, can break
        both the salt bridge interactions involving R143 and the residues at positions
        142 and 289.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '289', to_res: Q}
- {entry_name: ada1b_mesau, from_res: E, info: '...those residues directed towards
        helix 3. There are only four amino acids belonging to this interface, F286,
        E289, L296, and F303.The receptor mutants in which E289 was mutated into Ala,
        Phe, Lys, and Arg displayed the typical features described for the active
        state (R*) of a GPCR (Samama et al., 1993), including a marked increase in
        the constitutive and agonist dependent activity of the receptor as well as
        increased affinity and potency of the agonist. IN agreement with the experimental
        findings, the model predicts that mutating E289 to the neutral amino acids
        Ala and Phe or to the positively charged residues Lys and Arg breaks the salt
        bridge interactions of R143 and should therefore constitutively activate the
        alpha1b-AR.In the E289D mutant, the charge-reinforced H-bonding interaction
        between positions 143 and 289 occurs less frequently than in the wild-type
        receptor,...However, the E289Q displayed a significant 50% increase in the
        maximal agonist-induced response, which is one of the features of the active
        state (R*) of the receptor (Samama et al., 1993).In fact, it was frequently
        observed that either the reversible or irreversible neutralization of E289
        resulting from its protonation or mutation to Gln, respectively, can break
        both the salt bridge interactions involving R143 and the residues at positions
        142 and 289.Comments: data from WT low was used to calculate percentages.
        data for WT low: expression 128+-9 fmol/well; IP accumulation: basal 14+-2%
        and epinephrine-induced 313+-69%; epinephrine IC50 4.7 microM and EC50 29+-6
        nM. Data for WT high was also present but not used in calculations: expression
        347+-58 fmol/well; IP accumulation: basal 17+-2% and epinephrine-induced 432+-44%;
        no epinephrine IC50 and EC50 data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine,
    pubmed: '11961120', seq: '289', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, info: 'Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '138', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '112', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated high
        affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.In all signals tested, dose-dependent curves
        in high affinity mutants (N100A, T101A and S104A), whereas those in low affinity
        mutants (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.', ligand_long: '[3H]WEB
        2086', ligand_short: '', pubmed: '9065450', seq: '104', to_res: A}
- {entry_name: ptafr_cavpo, from_res: S, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated high
        affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.In all signals tested, dose-dependent curves
        in high affinity mutants (N100A, T101A and S104A), whereas those in low affinity
        mutants (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.', ligand_long: '[3H]
        PAF C16', ligand_short: '', pubmed: '9065450', seq: '104', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated high
        affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.In all signals tested, dose-dependent curves
        in high affinity mutants (N100A, T101A and S104A), whereas those in low affinity
        mutants (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.', ligand_long: '[3H]WEB
        2086', ligand_short: '', pubmed: '9065450', seq: '101', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated high
        affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.In all signals tested, dose-dependent curves
        in high affinity mutants (N100A, T101A and S104A), whereas those in low affinity
        mutants (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.', ligand_long: '[3H]
        PAF', ligand_short: '', pubmed: '9065450', seq: '101', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).The basal arachidonate release in the N100A transformant was twice as
        large as those of other transformants. Micromolar concentrations of WEB 2086
        greatly reduced the basal arachidonate release in the N100A transformant,
        but not in the wild type. Thus, the N100A mutant proved to be a constitutively
        active receptor.Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated
        high affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.In all signals tested, dose-dependent curves
        in high affinity mutants (N100A, T101A and S104A), whereas those in low affinity
        mutants (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.', ligand_long: '[3H]WEB
        2086', ligand_short: '', pubmed: '9065450', seq: '100', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).The basal arachidonate release in the N100A transformant was twice as
        large as those of other transformants. Micromolar concentrations of WEB 2086
        greatly reduced the basal arachidonate release in the N100A transformant,
        but not in the wild type. Thus, the N100A mutant proved to be a constitutively
        active receptor.Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated
        high affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.In all signals tested, dose-dependent curves
        in high affinity mutants (N100A, T101A and S104A), whereas those in low affinity
        mutants (H188A, H248A, and Q276A) were all shifted right by 1 or 2 log units.Comment:
        For mutations N100A, T101A, S104A, H188A, H248A, and Q276A, competition binding
        data and signal transduction data with different ligands are determined but
        not quantified.Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A,
        N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A,
        Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding properties are
        determined, but not with the parameters described in this database.', ligand_long: '[3H]PAF
        C16', ligand_short: '', pubmed: '9065450', seq: '100', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Comment: For mutations S23A, N33A, N58A, T60A, D63A, T69A, N100A, T101A,
        S104A, T112A, S138A, S150A, H188A, T236A, H248A, H249A, Q252A, Q276A, T287A,
        S283A, T284A, N285A, and D289A, ligand-binding properties are determined,
        but not with the parameters described in this database.', ligand_long: '',
    ligand_short: '', pubmed: '9065450', seq: '69', to_res: A}
- {entry_name: ptafr_cavpo, from_res: D, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated high
        affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.Comment: For mutations S23A, N33A, N58A, T60A,
        D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A,
        H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '63', to_res: A}
- {entry_name: ptafr_cavpo, from_res: T, info: 'Comment: For mutations S23A, N33A,
        N58A, T60A, D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A,
        H248A, H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '60', to_res: A}
- {entry_name: ptafr_cavpo, from_res: N, info: 'PAF preferentially bound to some mutants
        such as N58A, D63A, T69A, N100A, T101A, S104A, and D289A (with ratios over
        1.40).Mutations of N58A, D63A, N100A, T101A, S104A, and D289A generated high
        affinity mutants, as determined both by the binding ratio and the specific
        PAF binding per FLAG expression.Comment: For mutations S23A, N33A, N58A, T60A,
        D63A, T69A, N100A, T101A, S104A, T112A, S138A, S150A, H188A, T236A, H248A,
        H249A, Q252A, Q276A, T287A, S283A, T284A, N285A, and D289A, ligand-binding
        properties are determined, but not with the parameters described in this database.',
    ligand_long: '', ligand_short: '', pubmed: '9065450', seq: '58', to_res: A}
- {entry_name: ada1b_mesau, from_res: F, info: 'In the structure of the WT receptor,
        F286 makes van der Waals'' contacts with V147 and R148, the first amino acid
        in the i2 loop. Mutating F286 to Ala increased the maximal epinephrine-induced
        IP response by 50% and, to a lesser extent, the constitutive activity. In
        contrast the E mutation impaired the maximal epinephirine-induced IP response
        by 30%. For both mutants of F286, the affinity of epinephrine was dramatically
        increased by more than 100-fold. However, whereas the potency of epinephrine
        at the F286A mutant was also markedly increased by 30-fold, it was only increased
        by 4-fold at the F286E.The F286A mutant displayed the breakage of the D142-R143
        interaction, whereas the R143-E289 interaction was conserved. In contrast,
        the mutation of F286 to Glu favored the formation of a salt bridge between
        the replacing glutamate and R148 in the second intracellular.Comments: data
        from WT low was used to calculate percentages. data for WT low: expression
        128+-9 fmol/well; IP accumulation: basal 14+-2% and epinephrine-induced 313+-69%;
        epinephrine IC50 4.7 microM and EC50 29+-6 nM. Data for WT high was also present
        but not used in calculations: expression 347+-58 fmol/well; IP accumulation:
        basal 17+-2% and epinephrine-induced 432+-44%; no epinephrine IC50 and EC50
        data was present.', ligand_long: 125I-HEAT, ligand_short: epinephrine, pubmed: '11961120',
    seq: '286', to_res: E}
- {entry_name: ada1b_mesau, from_res: F, info: 'In the structure of the WT receptor,
        F286 makes van der Waals'' contacts with V147 and R148, the first amino acid
        in the i2 loop. Mutating F286 to Ala increased the maximal epinephrine-induced
        IP response by 50% and, to a lesser extent, the constitutive activity. In
        contrast the E mutation impaired the maximal epinephirine-induced IP response
        by 30%. For both mutants of F286, the affinity of epinephrine was dramatically
        increased by more than 100-fold. However, whereas the potency of epinephrine
        at the F286A mutant was also markedly increased by 30-fold, it was only increased
        by 4-fold at the F286E.The F286A mutant displayed the breakage of the D142-R143
        interaction, whereas the R143-E289 interaction was conserved. In contrast,
        the mutation of F286 to Glu favored the formation of a salt bridge between
        the replacing glutamate and R148 in the second intracellular.Comments: data
        from WT low was used to calculate percentages. data for WT low: expression
        128+-9 fmol/well; IP accumulation: basal 14+-2% and epinephrine-induced 313+-69%;
        epinephrine IC50 4.7 microM and EC50 29+-6 nM. Data for WT high was also present
        but not used in calculations: expression 347+-58 fmol/well; IP accumulation:
        basal 17+-2% and epinephrine-induced 432+-44%; no epinephrine IC50 and EC50
        data was present.', ligand_long: 125I-HEAT, ligand_short: Epinephrine, pubmed: '11961120',
    seq: '286', to_res: A}
- {entry_name: adrb1_human, from_res: L, info: 'Leu110 in transmembrane domain 2 play
        a major role in the subtyp-selective binding of beta1-selective agonists containing
        dimethoxyphenyl group such as T-0509, denopamine and (-)-RO363.', ligand_long: '',
    ligand_short: (-)-RO636, pubmed: '11907156', seq: '110', to_res: A}
- {entry_name: agtrb_rat, from_res: N, info: 'Only N295S and N295A caused significant
        reductions in both nonpeptide and peptide ligand binding affinities. these
        mutations also caused significant reductions in [sar1-ile8]AngII binding affinities
        (rAT1b, Ki = 1.2+-0.1 nM; N295S, Ki = 17+-2.0; N295A, Ki = 20+-2.5 nM.Our
        findings that Saralasin affinities are reduced 10-fold in the N295S and N295A
        mutants raise the possibility that local pertubations in receptor conformation
        may contribute to the loss of Losartan binding observed in these mutants.Comments:
        Saralasin = Sarcosine1-Ala8-AngII. Mutation is located in TM VII', ligand_long: '125I-[Sar1-Ile8]AngII',
    ligand_short: Losartan, pubmed: '7568109', seq: '295', to_res: A}
- {entry_name: agtrb_rat, from_res: N, info: 'Only N295S and N295A caused significant
        reductions in both nonpeptide and peptide ligand binding affinities. these
        mutations also caused significant reductions in [sar1-ile8]AngII binding affinities
        (rAT1b, Ki = 1.2+-0.1 nM; N295S, Ki = 17+-2.0; N295A, Ki = 20+-2.5 nM.Our
        findings that Saralasin affinities are reduced 10-fold in the N295S and N295A
        mutants raise the possibility that local pertubations in receptor conformation
        may contribute to the loss of Losartan binding observed in these mutants.Comments:
        Saralasin = Sarcosine1-Ala8-AngII. Mutation is located in TM VII', ligand_long: '125I-[sar1-ile8]AngII',
    ligand_short: Saralasin, pubmed: '7568109', seq: '295', to_res: A}
- {entry_name: agtrb_rat, from_res: N, info: 'In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Only N295S and N295A caused significant reductions in both
        nonpeptide and peptide ligand binding affinities. these mutations also caused
        significant reductions in [sar1-ile8]AngII binding affinities (rAT1b, Ki =
        1.2+-0.1 nM; N295S, Ki = 17+-2.0; N295A, Ki = 20+-2.5 nM.Our findings that
        Saralasin affinities are reduced 10-fold in the N295S and N295A mutants raise
        the possibility that local pertubations in receptor conformation may contribute
        to the loss of Losartan binding observed in these mutants.Comments: Saralasin
        = Sarcosine1-Ala8-AngII. Mutation is located in TM VII', ligand_long: '125I-[Sar1-Ile8]AngII',
    ligand_short: Losartan, pubmed: '7568109', seq: '295', to_res: S}
- {entry_name: agtrb_rat, from_res: N, info: 'In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Only N295S and N295A caused significant reductions in both
        nonpeptide and peptide ligand binding affinities. these mutations also caused
        significant reductions in [sar1-ile8]AngII binding affinities (rAT1b, Ki =
        1.2+-0.1 nM; N295S, Ki = 17+-2.0; N295A, Ki = 20+-2.5 nM.Our findings that
        Saralasin affinities are reduced 10-fold in the N295S and N295A mutants raise
        the possibility that local pertubations in receptor conformation may contribute
        to the loss of Losartan binding observed in these mutants.Comments: Saralasin
        = Sarcosine1-Ala8-AngII. Mutation is located in TM VII', ligand_long: '125I-[Sar1-Ile8]AngII',
    ligand_short: Saralasin, pubmed: '7568109', seq: '295', to_res: S}
- {entry_name: agtrb_rat, from_res: S, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TM VI', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '252', to_res: A}
- {entry_name: agtrb_rat, from_res: S, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TM VI', ligand_long: '125I-[sar1-Ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '252', to_res: A}
- {entry_name: agtrb_rat, from_res: S, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TM VI', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: losartan,
    pubmed: '7568109', seq: '252', to_res: C}
- {entry_name: agtrb_rat, from_res: S, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TM VI', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '252', to_res: C}
- {entry_name: agtrb_rat, from_res: K, info: 'alternate strategies indicate that the
        conserved residue Lys-199 is critical to losartan biding in the mammalian
        AT1 receptor.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is located
        in TM V', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Losartan, pubmed: '7568109',
    seq: '199', to_res: A}
- {entry_name: agtrb_rat, from_res: K, info: 'alternate strategies indicate that the
        conserved residue Lys-199 is critical to losartan biding in the mammalian
        AT1 receptor.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is located
        in TM V', ligand_long: '125i-[sar1-ile8]AngII', ligand_short: Saralasin, pubmed: '7568109',
    seq: '199', to_res: A}
- {entry_name: agtrb_rat, from_res: T, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TM V', ligand_long: '125I-[Sar1-Ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '198', to_res: A}
- {entry_name: agtrb_rat, from_res: T, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TM V', ligand_long: '125I-[Sar1-Ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '198', to_res: A}
- {entry_name: agtrb_rat, from_res: P, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TM V', ligand_long: '125I-[Sar1-Ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '192', to_res: M}
- {entry_name: agtrb_rat, from_res: P, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TM V', ligand_long: '125I-[Sar1-Ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '192', to_res: M}
- {entry_name: agtrb_rat, from_res: A, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIV', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '163', to_res: S}
- {entry_name: agtrb_rat, from_res: A, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: saralasin,
    pubmed: '7568109', seq: '163', to_res: S}
- {entry_name: ada1b_mesau, from_res: D, info: 'There was a significantly lowered
        epinephrine affinity for these Asp125 mutant receptors when compared to the
        WT alfa 1b_ARThe Asp125 is the counter ion necessary for receptor docking
        with the protonated amine of epinephrine.No significant differences in the
        Ki of selective alfa1-AR antagonist were demonstrated.Comment: with values
        of respectively 0.24 and 0.33', ligand_long: '', ligand_short: Prazosin, pubmed: '8910453',
    seq: '125', to_res: K}
- {entry_name: ada1b_mesau, from_res: D, info: 'There was a significantly lowered
        epinephrine affinity for these Asp125 mutant receptors when compared to the
        WT alfa 1b_ARThe Asp125 is the counter ion necessary for receptor docking
        with the protonated amine of epinephrine.No significant differences in the
        Ki of selective alfa1-AR antagonist were demonstrated.Comment: with values
        of respectively 25.5+- 14.7 and 52.8+-9.3', ligand_long: '', ligand_short: Phentolamine,
    pubmed: '8910453', seq: '125', to_res: K}
- {entry_name: ada1b_mesau, from_res: D, info: There was a significantly lowered epinephrine
        affinity for these Asp125 mutant receptors when compared to the WT alfa 1b_ARThe
        Asp125 is the counter ion necessary for receptor docking with the protonated
        amine of epinephrine.No significant differences in the Ki of selective alfa1-AR
        antagonist were demonstrated., ligand_long: 125I-HEAT, ligand_short: '', pubmed: '8910453',
    seq: '125', to_res: K}
- {entry_name: ada1b_mesau, from_res: D, info: There was a significantly lowered epinephrine
        affinity for these Asp125 mutant receptors when compared to the WT alfa 1b_ARThe
        Asp125 is the counter ion necessary for receptor docking with the protonated
        amine of epinephrine.The increased repulsion caused by the Lys125-Lys331 interface
        has the greatest effect on agonist-independent properties of constitutive
        activity., ligand_long: '', ligand_short: epinephrine, pubmed: '8910453',
    seq: '125', to_res: K}
- {entry_name: ada1b_mesau, from_res: D, info: There was a significantly lowered epinephrine
        affinity for these Asp125 mutant receptors when compared to the WT alfa 1b_ARThe
        Asp125 is the counter ion necessary for receptor docking with the protonated
        amine of epinephrine., ligand_long: '', ligand_short: Prazosin, pubmed: '8910453',
    seq: '125', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, info: There was a significantly lowered epinephrine
        affinity for these Asp125 mutant receptors when compared to the WT alfa 1b_ARThe
        Asp125 is the counter ion necessary for receptor docking with the protonated
        amine of epinephrine., ligand_long: '', ligand_short: Phentolamine, pubmed: '8910453',
    seq: '125', to_res: A}
- {entry_name: ada1b_mesau, from_res: D, info: 'There was a significantly lowered
        epinephrine affinity for these Asp125 mutant receptors when compared to the
        WT alfa 1b_ARThe Asp125 is the counter ion necessary for receptor docking
        with the protonated amine of epinephrine.Comment: with values of 0.12 and
        0.08 respectively.', ligand_long: 125I-HEAT, ligand_short: '', pubmed: '8910453',
    seq: '125', to_res: A}
- {entry_name: agtrb_rat, from_res: S, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: losartan,
    pubmed: '7568109', seq: '115', to_res: T}
- {entry_name: agtrb_rat, from_res: S, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '115', to_res: T}
- {entry_name: ada1b_mesau, from_res: D, info: There was a significantly lowered epinephrine
        affinity for these Asp125 mutant receptors when compared to the WT alfa 1b_ARThe
        Asp125 is the counter ion necessary for receptor docking with the protonated
        amine of epinephrine., ligand_long: '', ligand_short: Epinephrine, pubmed: '8910453',
    seq: '125', to_res: A}
- {entry_name: agtrb_rat, from_res: A, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8)AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '114', to_res: T}
- {entry_name: agtrb_rat, from_res: A, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '114', to_res: T}
- {entry_name: drd2_human_nwt, from_res: W, info: 'For W386C and F389C, the affinity
        of [3H]-N-Methylspiperone was too low for accurate determination of the Kd
        and Bmax from saturation experiments, for these mutants, the IC50''s for unlabeled
        N-methylspiperone in competition with [3H]-N-Methylspiperone were 2-3 orders
        of magnitude greater than that for C118S.In W386C and F389C the IC50 > 10
        mM, more than 1500 fold higher than the Ki of C118S.We infer that 10 of 22
        residues tested are on the water-accesible surface of the D2 receptor. These
        residues are Val378, Phe382, Trp386, Pro388, Phe389, Phe390, Thr392, His2929,
        Ile394, and Ile397.We were unable to test for sulpiride protection with the
        mutants W386C and F389C because the binding affinity was too low.', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: N-methylspiperone, pubmed: '9454590', seq: '386', to_res: C}
- {entry_name: adrb2_human, from_res: S, info: 'Association of the second hydrophobic
        pocket with the agonist-binding site comes through the work of strader in
        identifying the key role in binding played by Ser204 and Ser207. These studies
        are complemented by the work of Hwa who showed a key role for Ser204 on helix
        5 and Met314 on helix 6 in agonist binding but not antagonist binding, providing
        further evidence that the antagonist binds at the other end of the receptor,
        i.e., towards helix 2 and 7 rather than 5 and 6.for the catecholamines, this
        is almost equivalent to starting with the catechol hydroxyl groups pointing
        toward Ser204 and Ser207 on helix 5.In our model there was a tendency in very
        long simulations for helix 5 to rotate so that the catechol could bind to
        the hydroxyl and carbonyl groups of Ser207 (rather than to the hydroxyl groups
        of Ser204 and Ser207).Mutation effect: reduced agonist binding.Comments: Mutation
        is located on helix 5', ligand_long: '', ligand_short: '', pubmed: '9397168',
    seq: '204', to_res: A}
- {entry_name: drd2_human_nwt, from_res: I, info: 'The competitive antagonist sulpiride
        protected all of the residues except H393C.Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-) Sulpiride, pubmed: '9454590', seq: '384', to_res: C}
- {entry_name: ada1b_mesau, from_res: K, info: 'There is no significantly difference
        with different alfa1-AR antagonist and the Wt-alfa1 AR.Comment: with values
        0.23 and 0.33 respectively.', ligand_long: '', ligand_short: prazosin, pubmed: '8910453',
    seq: '331', to_res: E}
- {entry_name: agtrb_rat, from_res: S, info: 'Ser109 does not interact directly with
        Losartan since a Ser109 --> Ala substitution had negligible effects on Losartan
        affinity in contrast to the S109T mutant.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[Sar1-Ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '109', to_res: A}
- {entry_name: agtrb_rat, from_res: S, info: 'Ser109 does not interact directly with
        Losartan since a Ser109 --> Ala substitution had negligible effects on Losartan
        affinity in contrast to the S109T mutant.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '109', to_res: A}
- {entry_name: ada1b_mesau, from_res: K, info: 'There is no significant difference
        for the Ki of selective alfa1-AR antagonists and Wt alfa1-ARcomment: with
        values 0.23 and 0.08 respectively.', ligand_long: 125I-HEAT, ligand_short: '',
    pubmed: '8910453', seq: '331', to_res: E}
- {entry_name: agtrb_rat, from_res: S, info: 'Ser109 does not interact directly with
        Losartan since a Ser109 --> Ala substitution had negligible effects on Losartan
        affinity in contrast to the S109T mutant.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '109', to_res: T}
- {entry_name: agtrb_rat, from_res: S, info: 'Ser109 does not interact directly with
        Losartan since a Ser109 --> Ala substitution had negligible effects on Losartan
        affinity in contrast to the S109T mutant.Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '109', to_res: T}
- {entry_name: agtrb_rat, from_res: V, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '108', to_res: A}
- {entry_name: agtrb_rat, from_res: V, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '108', to_res: A}
- {entry_name: agtrb_rat, from_res: V, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '108', to_res: I}
- {entry_name: ada1b_mesau, from_res: K, info: 'No binding affinity differences for
        selective alfa1, AR antagonists were noted when compared to the WT alfa 1b-AR.Comment:
        With values of 0.23 and 0.33 respectively', ligand_long: '', ligand_short: Prazosin,
    pubmed: '8910453', seq: '331', to_res: A}
- {entry_name: ada1b_mesau, from_res: K, info: 'No binding affinity differences for
        selective alfa1, AR antagonists were noted when compared to the WT alfa 1b-AR.',
    ligand_long: 125I-HEAT, ligand_short: '', pubmed: '8910453', seq: '331', to_res: A}
- {entry_name: agtrb_rat, from_res: V, info: '...specific residues in TMs III (Val108),
        IV (Ala163), V (Thr198), VI (Ser252), and VII (Leu300/Phe301) are involved
        in binding Losartan based on significant reductions of nonpeptide ligand binding
        affinity in these mutant receptors.In comparison, Ala substitution of Val108,
        Ser252, Asn295, Leu300, and Phe301 still caused significant reductions in
        Losartan affinity. These results indicate that val108 (TMIII), Ser252 (TMVI),
        Leu300, Phe301, and/or Asn295 (TMVIII potentially interact directly with the
        Losartan molecule.Comments: Saralasin = Sarcosine1-Ala8-AngII. Mutation is
        located in TMIII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '108', to_res: I}
- {entry_name: agtrb_rat, from_res: A, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMII.', ligand_long: '125I-[Sar1-Ile8]AngII', ligand_short: Losartan,
    pubmed: '7568109', seq: '73', to_res: S}
- {entry_name: agtrb_rat, from_res: A, info: 'Comments: Saralasin = Sarcosine1-Ala8-AngII.
        Mutation is located in TMII.', ligand_long: '125I-[sar1-ile8]AngII', ligand_short: Saralasin,
    pubmed: '7568109', seq: '73', to_res: S}
- {entry_name: agtra_rat, from_res: L, info: '-The Ki for CGP42112A was much lower
        for the L305Q mutant than for the WT receptor. The Ki for the nonpeptide AT1
        agonist L162,313 was also significantly lower but the difference was smaller.
        the Ki for AngII, the peptide antagonist Sar1-Ile8-AngII, and the nonpeptide
        Losartan were not affected.-losartan efficiently abolished the agonist-independent
        IP production of the L305Q mutant.-The L305Q mutant is also very interesting
        in that the mutated amino acid lies at the extreme cytoplasmatic end of the
        seventh TM and cannot interact directly with ligands. The high CGP42112A sensitivity
        of this mutant is thus not attributable to a direct modification of the binding
        site but, rather, to indirect allosteric effects of constitutive activity.Comments:
        mutation is located in the TM7. CGP42112A is a classical AT2 agonist and a
        weak partial agonist of the WT AT1a receptor and becomes a full agonist for
        constitutively active AT1a mutants.', ligand_long: '', ligand_short: Losartan,
    pubmed: '10852946', seq: '305', to_res: Q}
- {entry_name: agtra_rat, from_res: L, info: '-The Ki for CGP42112A was much lower
        for the L305Q mutant than for the WT receptor. The Ki for the nonpeptide AT1
        agonist L162,313 was also significantly lower but the difference was smaller.
        the Ki for AngII, the peptide antagonist Sar1-Ile8-AngII, and the nonpeptide
        Losartan were not affected.-losartan efficiently abolished the agonist-independent
        IP production of the L305Q mutant.-The L305Q mutant is also very interesting
        in that the mutated amino acid lies at the extreme cytoplasmatic end of the
        seventh TM and cannot interact directly with ligands. The high CGP42112A sensitivity
        of this mutant is thus not attributable to a direct modification of the binding
        site but, rather, to indirect allosteric effects of constitutive activity.Comments:
        mutation is located in the TM7. CGP42112A is a classical AT2 agonist and a
        weak partial agonist of the WT AT1a receptor and becomes a full agonist for
        constitutively active AT1a mutants.', ligand_long: '', ligand_short: 'L162,313',
    pubmed: '10852946', seq: '305', to_res: Q}
- {entry_name: agtra_rat, from_res: L, info: '-The Ki for CGP42112A was much lower
        for the L305Q mutant than for the WT receptor. The Ki for the nonpeptide AT1
        agonist L162,313 was also significantly lower but the difference was smaller.
        the Ki for AngII, the peptide antagonist Sar1-Ile8-AngII, and the nonpeptide
        Losartan were not affected.-losartan efficiently abolished the agonist-independent
        IP production of the L305Q mutant.-The L305Q mutant is also very interesting
        in that the mutated amino acid lies at the extreme cytoplasmatic end of the
        seventh TM and cannot interact directly with ligands. The high CGP42112A sensitivity
        of this mutant is thus not attributable to a direct modification of the binding
        site but, rather, to indirect allosteric effects of constitutive activity.Comments:
        mutation is located in the TM7. CGP42112A is a classical AT2 agonist and a
        weak partial agonist of the WT AT1a receptor and becomes a full agonist for
        constitutively active AT1a mutants.', ligand_long: '', ligand_short: CGP42112A,
    pubmed: '10852946', seq: '305', to_res: Q}
- {entry_name: agtra_rat, from_res: L, info: '-The Ki for CGP42112A was much lower
        for the L305Q mutant than for the WT receptor. The Ki for the nonpeptide AT1
        agonist L162,313 was also significantly lower but the difference was smaller.
        the Ki for AngII, the peptide antagonist Sar1-Ile8-AngII, and the nonpeptide
        Losartan were not affected.-losartan efficiently abolished the agonist-independent
        IP production of the L305Q mutant.-The L305Q mutant is also very interesting
        in that the mutated amino acid lies at the extreme cytoplasmatic end of the
        seventh TM and cannot interact directly with ligands. The high CGP42112A sensitivity
        of this mutant is thus not attributable to a direct modification of the binding
        site but, rather, to indirect allosteric effects of constitutive activity.Comments:
        mutation is located in the TM7. CGP42112A is a classical AT2 agonist and a
        weak partial agonist of the WT AT1a receptor and becomes a full agonist for
        constitutively active AT1a mutants.', ligand_long: '', ligand_short: Sar1-Ile8-AngII,
    pubmed: '10852946', seq: '305', to_res: Q}
- {entry_name: agtra_rat, from_res: F, info: 'comment: mutation located in the TM2.
        CGP42112A is a AT2 agonist and a weak partial agonist of the WT AT1a.', ligand_long: '',
    ligand_short: '', pubmed: '10852946', seq: '77', to_res: S}
- {entry_name: ednrb_rat, from_res: N, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.Comments:
        basal activity and ERK kinase activity of the mutants were determined (Western
        blot) but not quantified.', ligand_long: '', ligand_short: '', pubmed: '10187821',
    seq: '373', to_res: A}
- {entry_name: ednrb_rat, from_res: D, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.Comments:
        basal activity and ERK kinase activity of the mutants were determined (Western
        blot) but not quantified.', ligand_long: 125I-Endothelin, ligand_short: '',
    pubmed: '10187821', seq: '368', to_res: A}
- {entry_name: ednrb_rat, from_res: F, info: '-Several of the mutations in TM7 of
        the ETB significantly decreased endothelin-stimulated AP-1 transcriptional
        activation. For example, N377P, S378K, P382K, A384K, L385A, K3909A, and F392A
        were compromised in their abilty to stimulate AP-1 reporter activity when
        exposed to ligand.Comments: basal activity and ERK kinase activity of the
        loop 3 mutants were determined (Western blot) but not quantified.', ligand_long: 125I-endothelin,
    ligand_short: '', pubmed: '10187821', seq: '393', to_res: A}
- {entry_name: ednrb_rat, from_res: K, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.-Several
        of the mutations in TM7 of the ETB significantly decreased endothelin-stimulated
        AP-1 transcriptional activation. For example, N377P, S378K, P382K, A384K,
        L385A, K390A, and F392A were compromised in their abilty to stimulate AP-1
        reporter activity when exposed to ligand.Comments: basal activity and ERK
        kinase activity of the loop 3 mutants were determined (Western blot) but not
        quantified.', ligand_long: 125I-Endothelin, ligand_short: '', pubmed: '10187821',
    seq: '391', to_res: A}
- {entry_name: ednrb_rat, from_res: V, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.Comments:
        basal activity and ERK kinase activity of the loop 3 mutants were determined
        (Western blot) but not quantified.', ligand_long: 125I-Endothelin, ligand_short: '',
    pubmed: '10187821', seq: '389', to_res: K}
- {entry_name: ednrb_rat, from_res: L, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.-Several
        of the mutations in TM7 of the ETB significantly decreased endothelin-stimulated
        AP-1 transcriptional activation. For example, N377P, S378K, P382K, A384K,
        L385A, K3909A, and F392A were compromised in their abilty to stimulate AP-1
        reporter activity when exposed to ligand.Comments: basal activity and ERK
        kinase activity of the loop 3 mutants were determined (Western blot) but not
        quantified.', ligand_long: 125I-Endothelin, ligand_short: '', pubmed: '10187821',
    seq: '386', to_res: A}
- {entry_name: ednrb_rat, from_res: P, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.-Several
        of the mutations in TM7 of the ETB significantly decreased endothelin-stimulated
        AP-1 transcriptional activation. For example, N377P, S378K, P382K, A384K,
        L385A, K3909A, and F392A were compromised in their abilty to stimulate AP-1
        reporter activity when exposed to ligand.Comments: basal activity and ERK
        kinase activity of the loop 3 mutants were determined (Western blot) but not
        quantified.', ligand_long: 125I-Endothelin, ligand_short: '', pubmed: '10187821',
    seq: '383', to_res: K}
- {entry_name: ednrb_rat, from_res: I, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.Comments:
        basal activity and ERK kinase activity of the loop 3 mutants were determined
        (Western blot) but not quantified.', ligand_long: 125I-Endothelin, ligand_short: '',
    pubmed: '10187821', seq: '381', to_res: A}
- {entry_name: ednrb_rat, from_res: S, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.-Several
        of the mutations in TM7 of the ETB significantly decreased endothelin-stimulated
        AP-1 transcriptional activation. For example, N377P, S378K, P382K, A384K,
        L385A, K3909A, and F392A were compromised in their abilty to stimulate AP-1
        reporter activity when exposed to ligand.Comments: basal activity and ERK
        kinase activity of the loop 3 mutants were determined (Western blot) but not
        quantified.', ligand_long: 125I-Endothelin, ligand_short: '', pubmed: '10187821',
    seq: '379', to_res: K}
- {entry_name: ednrb_rat, from_res: N, info: '-The mutant receptors were expressed
        and localized in essentially the same manner as the wild type receptor.-Several
        of the mutations in TM7 of the ETB significantly decreased endothelin-stimulated
        AP-1 transcriptional activation. For example, N377P, S378K, P382K, A384K,
        L385A, K3909A, and F392A were compromised in their abilty to stimulate AP-1
        reporter activity when exposed to ligand.Comments: basal activity and ERK
        kinase activity of the loop 3 mutants were determined (Western blot) but not
        quantified.', ligand_long: 125I-Endothelin, ligand_short: '', pubmed: '10187821',
    seq: '378', to_res: P}
- {entry_name: ednrb_rat, from_res: M, info: 'Comments: basal activity and ERK kinase
        activity of the loop 3 mutants were determined (Western blot) but not quantified.',
    ligand_long: '', ligand_short: endothelin, pubmed: '10187821', seq: '374', to_res: K}
- {entry_name: ednrb_rat, from_res: K, info: 'Comments: basal activity and ERK kinase
        activity of the loop 3 mutants were determined (Western blot) but not quantified.',
    ligand_long: '', ligand_short: endothelin, pubmed: '10187821', seq: '323', to_res: A}
- {entry_name: ednrb_rat, from_res: Q, info: 'Comments: basal activity and ERK kinase
        activity of the loop 3 mutants were determined (Western blot) but not quantified.',
    ligand_long: '', ligand_short: endothelin, pubmed: '10187821', seq: '317', to_res: A}
- {entry_name: ednrb_rat, from_res: D, info: 'Comments: basal activity and ERK kinase
        activity of the loop 3 mutants were determined (Western blot) but not quantified.',
    ligand_long: '', ligand_short: endothelin, pubmed: '10187821', seq: '313', to_res: A}
- {entry_name: ednrb_rat, from_res: M, info: 'Comment: basal activity and ERK kinase
        activity of loop 3 mutants were determined but not quantified.', ligand_long: '',
    ligand_short: endothelin, pubmed: '10187821', seq: '307', to_res: A}
- {entry_name: acm3_rat, from_res: P, info: 'Activation data is calculated as follow:
        bmax (mutant) / bmax (Wt)', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '9880506',
    seq: '540', to_res: A}
- {entry_name: drd2_human_nwt, from_res: I, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '431', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '431', to_res: C}
- {entry_name: acm3_rat, from_res: P, info: 'Activation data is calculated as follow:
        bmax (mutant) / bmax (Wt)', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '9880506',
    seq: '505', to_res: A}
- {entry_name: drd2_human_nwt, from_res: N, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '430', to_res: C}
- {entry_name: acm3_rat, from_res: P, info: 'Activation data is calculated as follow:
        bmax (mutant) / bmax (Wt)', ligand_long: '[3H]NMS', ligand_short: '', pubmed: '9880506',
    seq: '242', to_res: A}
- {entry_name: drd2_human_nwt, from_res: N, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '430', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '429', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '429', to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '428', to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '428', to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '427', to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '427', to_res: C}
- {entry_name: drd2_human_nwt, from_res: Y, info: 'In the mutants N422C, P423C and
        Y426C, the Ki was 2.3-3.3 times the Ki of nWT. Tyr426 is on the water-accessible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '426', to_res: C}
- {entry_name: drd2_human_nwt, from_res: Y, info: 'In the mutants N422C, P423C and
        Y426C, the Ki was 2.3-3.3 times the Ki of nWT. Tyr426 is on the water-accessible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '426',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '425', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '425', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)Sulpiride, pubmed: '8784181', seq: '424', to_res: C}
- {entry_name: drd2_human_nwt, from_res: I, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '424', to_res: C}
- {entry_name: drd2_human_nwt, from_res: P, info: 'Pro423 is on the water-accessible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '423', to_res: C}
- {entry_name: drd2_human_nwt, from_res: P, info: 'Pro423 is on the water-accessible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '423',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: N, info: 'Asn422 is on the water-accessible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '422', to_res: C}
- {entry_name: drd2_human_nwt, from_res: N, info: 'Asn422 is on the water-accessible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Comment: the expression data is determined as (Bmax_mut / Bmax_nWT).',
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '422',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '421', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '421', to_res: C}
- {entry_name: drd2_human_nwt, from_res: A, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '420', to_res: C}
- {entry_name: drd2_human_nwt, from_res: A, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '420', to_res: C}
- {entry_name: drd2_human_nwt, from_res: S, info: 'In Y416C, N418C, and S419C, the
        Ki was 185, 5, and 8 times the Ki of C118S, respectively.Comment: the expression
        data is determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '419', to_res: C}
- {entry_name: drd2_human_nwt, from_res: S, info: 'In Y416C, N418C, and S419C, the
        Ki was 185, 5, and 8 times the Ki of C118S, respectively.Comment: the expression
        data is determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '419', to_res: C}
- {entry_name: drd2_human_nwt, from_res: N, info: 'In Y416C, N418C, and S419C, the
        Ki was 185, 5, and 8 times the Ki of C118S, respectively. Asn418 is on the
        water-accessible surface of the D2 receptor. The competitive antagonist sulpiride
        protect this residue.Comment: the expression data is determined as (Bmax_mut
        / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride,
    pubmed: '8784181', seq: '418', to_res: C}
- {entry_name: drd2_human_nwt, from_res: N, info: 'In Y416C, N418C, and S419C, the
        Ki was 185, 5, and 8 times the Ki of C118S, respectively. Asn418 is on the
        water-accessible surface of the D2 receptor. The competitive antagonist sulpiride
        protect this residue.Comment: the expression data is determined as (Bmax_mut
        / Bmax_nWT).', ligand_long: '[3H]-N-methylspiperone', ligand_short: '', pubmed: '8784181',
    seq: '418', to_res: C}
- {entry_name: adrb2_human, from_res: S, info: The EC50 values of TA-2005 slightly
        decreased in 7.6 fold., ligand_long: 125I-CYP, ligand_short: '', pubmed: '9443940',
    seq: '207', to_res: A}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Comment: the expression data is
        determined as (Bmax_mut / Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '417', to_res: C}
- {entry_name: bkrb2_rat, from_res: N, info: The pair of mutations N230A and N234A
        did not affect the binding of F5-HOE-140 to the receptor., ligand_long: '[3H]Phe5-HOE-140',
    ligand_short: '', pubmed: '8910447', seq: '234', to_res: A}
- {entry_name: bkrb2_rat, from_res: N, info: The pair of mutations N230A and N234A
        did not affect the binding of F5-HOE-140 to the receptor., ligand_long: '[3H]Bradykinin',
    ligand_short: '', pubmed: '8910447', seq: '234', to_res: A}
- {entry_name: bkrb2_rat, from_res: N, info: The pair of mutations N230A and N234A
        did not affect the binding of F5-HOE-140 to the receptor., ligand_long: '[3H]Phe5-HOE-140',
    ligand_short: '', pubmed: '8910447', seq: '230', to_res: A}
- {entry_name: drd2_human_nwt, from_res: V, info: 'Comment: the expression data is
        determined as (Bmax_mut/Bmax_nWT).', ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '417', to_res: C}
- {entry_name: drd2_human_nwt, from_res: Y, info: In Y416C the Ki was 185 times the
        Ki of nWT. Tyr416 is on the water-accessible surface of the D2 receptor. The
        competitive antagonist sulpiride protect this residue.Expression data is determined
        by saturation assay (Bmax_mut / Bmax_nwt)., ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '416', to_res: C}
- {entry_name: drd2_human_nwt, from_res: Y, info: In Y416C the Ki was 185 times the
        Ki of nWT. Tyr416 is on the water-accessible surface of the D2 receptor. The
        competitive antagonist sulpiride protect this residue.Expression data is determined
        by saturation assay (Bmax_mut / Bmax_nwt)., ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '416', to_res: C}
- {entry_name: drd2_human_nwt, from_res: G, info: 'The mutant G415C failed to bind
        [3H]-N-Methylspiperone.Expression data is determined by saturation assay (Bmax_mut
        / Bmax_nwt).', ligand_long: '', ligand_short: '', pubmed: '8784181', seq: '415',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: Expression data is determined by
        saturation assay (Bmax_mut / Bmax_nwt)., ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: (-)sulpiride, pubmed: '8784181', seq: '414', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: Expression data is determined by
        saturation assay (Bmax_mut / Bmax_nwt)., ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '414', to_res: C}
- {entry_name: drd2_human_nwt, from_res: W, info: Trp413 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '413', to_res: C}
- {entry_name: drd2_human_nwt, from_res: W, info: Trp413 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '413',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: Thr412 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '412', to_res: C}
- {entry_name: drd2_human_nwt, from_res: T, info: Thr412 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '412',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: Phe411 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '411', to_res: C}
- {entry_name: drd2_human_nwt, from_res: F, info: Phe411 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '411',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: A, info: Ala410 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '410', to_res: C}
- {entry_name: drd2_human_nwt, from_res: A, info: Ala410 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '410',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: S, info: Ser409 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride does not
        protect this residue.Expression data is determined by saturation assay (Bmax_mut
        / Bmax_nwt)., ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride,
    pubmed: '8784181', seq: '409', to_res: C}
- {entry_name: drd2_human_nwt, from_res: S, info: Ser409 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride does not
        protect this residue.Expression data is determined by saturation assay (Bmax_mut
        / Bmax_nwt)., ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181',
    seq: '409', to_res: C}
- {entry_name: drd2_human_nwt, from_res: Y, info: Tyr408 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '408', to_res: C}
- {entry_name: drd2_human_nwt, from_res: Y, info: Tyr408 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-methylspiperone', ligand_short: '', pubmed: '8784181', seq: '408',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: Leu407 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: (-)sulpiride, pubmed: '8784181',
    seq: '407', to_res: C}
- {entry_name: drd2_human_nwt, from_res: L, info: Leu407 is on the water-accesible
        surface of the D2 receptor. The competitive antagonist sulpiride protect this
        residue.Expression data is determined by saturation assay (Bmax_mut / Bmax_nwt).,
    ligand_long: '[3H]-N-Methylspiperone', ligand_short: '', pubmed: '8784181', seq: '407',
    to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: Expression data is determined by
        saturation assay (Bmax_mut / Bmax_nwt)., ligand_long: '[3H] -N - methylspiperone',
    ligand_short: (-)Sulpiride, pubmed: '8784181', seq: '406', to_res: C}
- {entry_name: drd2_human_nwt, from_res: V, info: Expression data is determined by
        saturation assay (Bmax_mut / Bmax_nwt)., ligand_long: '[3H]-N-Methylspiperone',
    ligand_short: '', pubmed: '8784181', seq: '406', to_res: C}
- {entry_name: ednrb_rat, from_res: K, info: 'Although this residue is highly conserved,
        this area of the ETB does not appear to be sensitive to structural changes.',
    ligand_long: '', ligand_short: endothelin-1, pubmed: '10187821', seq: '346', to_res: A}
- {entry_name: ednrb_rat, from_res: S, info: 'Although this residue is highly conserved,
        this area of the ETB does not appear to be sensitive to structural changes.',
    ligand_long: '', ligand_short: endothelin-1, pubmed: '10187821', seq: '342', to_res: K}
- {entry_name: ednrb_rat, from_res: P, info: 'Although this residue is highly conserved,
        this area of the ETB does not appear to be sensitive to structural changes.',
    ligand_long: '', ligand_short: endothelin-1, pubmed: '10187821', seq: '338', to_res: A}
- {entry_name: ednrb_rat, from_res: W, info: 'Although this residue is highly conserved,
        this area of the ETB does not appear to be sensitive to structural changes.',
    ligand_long: '', ligand_short: endothelin-1, pubmed: '10187821', seq: '336', to_res: A}
- {entry_name: ednrb_rat, from_res: C, info: 'Although this residue is highly conserved,
        this area of the ETB does not appear to be sensitive to structural changes.',
    ligand_long: '', ligand_short: endothelin-1, pubmed: '10187821', seq: '335', to_res: A}
- {entry_name: ednrb_rat, from_res: F, info: 'Although this residue is highly conserved,
        this area of the ETB does not appear to be sensitive to structural changes.',
    ligand_long: '', ligand_short: endothelin-1, pubmed: '10187821', seq: '332', to_res: A}
- {entry_name: adrb2_human, from_res: E, info: leads to effects similar to those observed
        upon Asp130Asn and Glu168Gln mutations at an intermediate intensity, ligand_long: '[3H]CGP-12177',
    ligand_short: isoproterenol, pubmed: '11375997', seq: '268', to_res: A}
- {entry_name: adrb2_human, from_res: E, info: mutation leads to  effects similar
        to those observed  upon Asp130Asn mutation  but with at lower intensity, ligand_long: '3H]CGP-12177,
        4-[3-[(1,1-dimethylethyl)amino]2-hydroxypropoxyl]-1,3-dihydro-2H-benzimidazol-2-one',
    ligand_short: isoproterenol, pubmed: '11375997', seq: '268', to_res: Q}
- {entry_name: adrb2_human, from_res: D, info: 'mutation leads to constitutive activation
        and increase in the affinityof isoproterenol, an agonist of beta1- and beta2-adrenergic
        receptors.These effects are related to a stabilization of activated forms
        ofreceptors by withdrawal of the residue charge in the helix III position130
        and consequent breakage of ionic interactions between the cytosolicends of
        helices III and VI. The mutation also leads to reduction ofreceptor expression.',
    ligand_long: '[3H]CGP-12177', ligand_short: isoproterenol, pubmed: '11375997',
    seq: '130', to_res: N}
- {entry_name: acthr_human, from_res: G, info: 'Previous functional studies performed
        for a variety of mutations such as G116V (26), R137W (27), R146H (6;10), T159K
        (10), C251F (19) and Y254C (27) all found that there was impaired receptor
        signaling when stimulated with ACTH and low affinity for ACTH binding.', pubmed: '18840636',
    seq: '116', to_res: V}
- {entry_name: adrb2_human, from_res: F, info: "All rights reserved LETTER RESEARCH\
        \ a 18 R131\u2013L272 distance (\xC5) 14 10 6 0 3 I121/F282 r.m.s.d (\xC5\
        ) 2 1 0 0 5 10 15 Time (\u03BCs) 20 25 30 \u03B22AR\u2013Nb80 BI-167107-bound\
        \ simulation Carazolol-bound simulation \u03B22AR\u2013FAUC50 \u03B22AR\u2013\
        Cz 5 10 15 20 25 30 BI-167107-bound simulation Carazolol-bound simulation\
        \ \u03B22AR\u2013Nb80 \u03B22AR\u2013Cz \u03B22AR\u2013FAUC50 b R131\u2013\
        L272 distance E268 Y219 TM6 Y219 TM5 Y326 R131 TM3 D130 ICL2 \u03B22AR\u2013\
        Nb80 \u03B22AR\u2013BI simulation ICL2 TM3 D130 \u03B22AR\u2013FAUC50 \u03B2\
        2AR\u2013BI simulation E268 Y326 TM6 c Receptor Receptor + agonist Receptor\
        \ + agonist + Gs (or nanobody) TM5 Energy R (Inactive) Conformation R131 R\u2032\
        \ R\u2032\u2032 R* (Active) Figure 3", pubmed: '21228876', seq: '282', to_res: R}
- {entry_name: adrb2_human, from_res: H, info: "Incubation of compound FAUC50 with\
        \ mutant H93C receptor led to efficient and irreversible blocking of radioligand\
        \ binding (Supplementary Fig. 2, Supplementary Information).///All rights\
        \ reserved LETTER RESEARCH OH H N a b HN Carazolol O TM2 OH HN H N N H O BABC\
        \ TM5 TM4 TM3 H93 9.1 \xC5 O Br I O HN OH H N FAUC50 O O S S NH2 TM1 HO O\
        \ HN HO OH H N O O FAUC72 c \u03B22AR in HDL particles Wild-type \u03B22AR\
        \ 4 \u2013ICI 5 +ICI H93C Mutant Activity over basal 3 2 1 0 Is op ro te re\
        \ no l FA U C 72 Ba sa l FA U C 50 Activity over basal 4 3 2 1 0 Is op ro\
        \ te re no l Ba sa l FA U C 50 FA U C 72 Ligand-free + agonist + excess receptor\
        \ (basal) + agonist inverse agonist (ICI-118,551) Gs Figure 1", pubmed: '21228876',
    seq: '93', to_res: C}
- {entry_name: aa2ar_human, from_res: A, info: "The construct used for crystallography\
        \ consisted of the b2AR\u2013T4L fusion protein17 with the following modifications:\
        \ a TEV (tobacco etch virus) protease site was inserted after residue 23 of\
        \ the human b2AR sequence; Histidine 93 was mutated to cysteine; the construct\
        \ was terminated by a 63His tag after residue 348 of human b2AR.", pubmed: '21228876',
    seq: '63', to_res: H}
- {entry_name: adrb2_human, from_res: N, info: 'Both simulations included a glutamate
        at position 187, reflecting an Asn 187 Glu mutation made in both crystallization
        constructs to eliminate a glycosylation site.///Both simulations included
        a glutamate at position 187, reflecting an Asn 187 Glu mutation made in both
        crystallization constructs to eliminate a glycosylation site.///Both simulations
        included a glutamate at position 187, reflecting an Asn 187 Glu mutation made
        in both crystallization constructs to eliminate a glycosylation site.', pubmed: '21228876',
    seq: '187', to_res: E}
- {entry_name: nk1r_human, from_res: H, info: 'This result was also consonant with
        the results of mutation of the corresponding residue (H265A) in the human
        NK1 receptor, which decreased antagonist binding but did not affect the agonist
        binding (48).', pubmed: '11891221', seq: '265', to_res: A}
- {entry_name: aa3r_human, from_res: L, info: 'In contrast to L244A Ligand Recognition
        and Activation of A3 Adenosine Receptor 19059 Downloaded from www.jbc.org
        at Radboud Universiteit Nijmegen, on May 21, 2010 FIG. 3.///In the case of
        the L244A mutant receptor, Cl-IB-MECA could still stimulate PLC activity but
        with 36-fold decreased potency (EC50 9430 2470 nM; n 3).///Ki (nM) WT H95A
        (3.37) K152A (EL2) W243A (6.48) W243F (6.48) L244A (6.49) S247A (6.52) N250A
        (6.55) H272Ea (7.43) Agonists [125I]I-AB-MECA (Kd) 1.7 CADO 523 NECA 249 Cl-IB-MECA
        2.3 MRS1898 1.4 DBXRM 2830 Antagonists CGS15943 182 MRS1220 1.6 VUF8504 68
        XAC 142 0.4 116 72 0.6 0.4 570 71 0.3 19 35 5.7 58,200 3430 60 143 36,300
        5130 976 4000 9440 1.2 3.7 6500 323 900 278 15 1.7 36 2.3 11,500 6030 1140
        119 590 3260 571 5.4 575 726 1.4 107 44 0.6 0.6 2320 124 0.7 134 214 1.1 334
        166 2.9 2.1 4390 1160 45 2570 552 0.3 1.6 67 321 77 132 0.5 1.9 0.6 1.2 950
        2640 340 547 13 10.2 690 1340 79 263 0.2 0.85 0.11 14 ND 45 68 14 0.6 2.5
        0.7 0.3 0.73 0.31 530 7550 2340 87 3.3 370 46 209 0.63 42 61 48 0.14 15 18
        1.7 927 247 2.2 1.5 3040 333 3.1 81 165 0.3 353 60 0.2 0.5 570 144 1.4 26
        47 NA ND ND ND ND ND ND ND ND ND ND 11,600 4200 3200 770 20 4 9.9 2.6 ND 3260
        990 ND 1690 340 20,100 4500 Downloaded from www.jbc.org at Radboud Universiteit
        Nijmegen, on May 21, 2010 a Data are from Jacobson et al. (21).', pubmed: '11891221',
    seq: '244', to_res: A}
- {entry_name: aa2ar_human, from_res: N, info: 'Consistent with the present result,
        the mutation of the corresponding residue in the human A2A aden19062 Ligand
        Recognition and Activation of A3 Adenosine Receptor osine receptor (N253A)
        also caused a drastic decrease of the affinity for both agonists and antagonists
        (18).', pubmed: '11891221', seq: '253', to_res: A}
- {entry_name: aa2ar_human, from_res: H, info: 'In contrast to these results, the
        corresponding H250A mutation in the human A2A receptor diminished agonist
        and antagonist binding as well as receptor activation (18).', pubmed: '11891221',
    seq: '250', to_res: A}
- {entry_name: aa3r_human, from_res: W, info: "In contrast, the K152A (EL2), W243A\
        \ (6.48), and W243F (6.48) mutations did not significantly affect the agonist\
        \ binding but decreased antagonist affinity by 3\u201338-fold, suggesting\
        \ that these residues were critical for the high affinity of A3 adenosine\
        \ receptor antagonists.///The A3 agonist 2chloro-N 6 -(3-iodobenzyl)-5 -N-methylcarbamoyladenosine\
        \ stimulated phosphoinositide turnover in the WT but failed to evoke a response\
        \ in cells expressing W243A and W243F mutant receptors, in which agonist binding\
        \ was less sensitive to guanosine 5 - -thiotriphosphate than in WT.///In contrast,\
        \ no substantial stimulation of phosphoinositide turnover by Cl-IBMECA was\
        \ observed in COS-7 cells expressing W243A, W243F, and N250A mutant receptors.///Ki\
        \ (nM) WT H95A (3.37) K152A (EL2) W243A (6.48) W243F (6.48) L244A (6.49) S247A\
        \ (6.52) N250A (6.55) H272Ea (7.43) Agonists [125I]I-AB-MECA (Kd) 1.7 CADO\
        \ 523 NECA 249 Cl-IB-MECA 2.3 MRS1898 1.4 DBXRM 2830 Antagonists CGS15943\
        \ 182 MRS1220 1.6 VUF8504 68 XAC 142 0.4 116 72 0.6 0.4 570 71 0.3 19 35 5.7\
        \ 58,200 3430 60 143 36,300 5130 976 4000 9440 1.2 3.7 6500 323 900 278 15\
        \ 1.7 36 2.3 11,500 6030 1140 119 590 3260 571 5.4 575 726 1.4 107 44 0.6\
        \ 0.6 2320 124 0.7 134 214 1.1 334 166 2.9 2.1 4390 1160 45 2570 552 0.3 1.6\
        \ 67 321 77 132 0.5 1.9 0.6 1.2 950 2640 340 547 13 10.2 690 1340 79 263 0.2\
        \ 0.85 0.11 14 ND 45 68 14 0.6 2.5 0.7 0.3 0.73 0.31 530 7550 2340 87 3.3\
        \ 370 46 209 0.63 42 61 48 0.14 15 18 1.7 927 247 2.2 1.5 3040 333 3.1 81\
        \ 165 0.3 353 60 0.2 0.5 570 144 1.4 26 47 NA ND ND ND ND ND ND ND ND ND ND\
        \ 11,600 4200 3200 770 20 4 9.9 2.6 ND 3260 990 ND 1690 340 20,100 4500 Downloaded\
        \ from www.jbc.org at Radboud Universiteit Nijmegen, on May 21, 2010 a Data\
        \ are from Jacobson et al. (21).///Hence, the ability of WT and W243A and\
        \ W243F mutant receptors to interact with G proteins was further evaluated\
        \ by measuring the effects of GTP S on binding of the agonist [125I]I-AB-MECA\
        \ and on agonist Cl-IB-MECA competition for [3H]PSB-11 binding in membranes\
        \ of COS-7 cells expressing WT and mutant receptors.///The inhibitory effect\
        \ of this GTP analogue on agonist binding to W243A and W243F mutant receptors\
        \ was less pronounced compared with that of WT receptors, consistent with\
        \ the impaired ability of these mutant receptors to mediate inositol phosphate\
        \ production in response to an A3 agonist.///In W243F mutant receptors, the\
        \ respective Ki values were 2.3 0.2 and 3.2 0.4 nM.///Hence, the GTP analogue\
        \ induced a 3-fold affinity decrease of Cl-IBMECA in WT receptors, whereas\
        \ in the W243F mutant receptor only a 1.4-fold decrease of affinity was observed,\
        \ consistent with the impaired ability of agonist to activate PLC through\
        \ this mutant receptor.///The major consequence of the W243A and W243F mutations\
        \ was functional inactivation of the A3 receptor, indicating that Trp243 may\
        \ play a pivotal role in receptor transduction of the signal.///This conclusion\
        \ was based upon the differential effect on affinity toward antagonists upon\
        \ replacement of Trp243 with Phe and Ala (Table I).///This conclusion was\
        \ based upon the differential effect on affinity toward antagonists upon replacement\
        \ of Trp243 with Phe and Ala (Table I).", pubmed: '11891221', seq: '243',
    to_res: F}
- {entry_name: aa3r_human, from_res: H, info: "The H95A mutation significantly reduced\
        \ affinity of both agonists and antagonists.///As shown in Fig. 4, following\
        \ the mutation of His95 to Ala, the affinity of the high affinity selective\
        \ A3 agonist, Cl-IB-MECA, decreased 26-fold.///As shown in Fig. 4, following\
        \ the mutation of His95 to Ala, the affinity of the high affinity selective\
        \ A3 agonist, Cl-IB-MECA, decreased 26-fold.///Similar to Cl-IB-MECA, the\
        \ affinity of other agonists and antagonists with different structures was\
        \ decreased by the H95A mutation (Table I).///The affinity of most test ligands\
        \ for the H95A mutant receptor was 10 \u2013100-fold lower than that for the\
        \ WT receptor, suggesting that this residue is important for ligand recognition\
        \ in the A3 adenosine receptor.///The H95A mutation did not influence the\
        \ production of inositol phosphates significantly (EC50 224 57 nM; n 3) (p\
        \ 0.05 compared with WT).///Ki (nM) WT H95A (3.37) K152A (EL2) W243A (6.48)\
        \ W243F (6.48) L244A (6.49) S247A (6.52) N250A (6.55) H272Ea (7.43) Agonists\
        \ [125I]I-AB-MECA (Kd) 1.7 CADO 523 NECA 249 Cl-IB-MECA 2.3 MRS1898 1.4 DBXRM\
        \ 2830 Antagonists CGS15943 182 MRS1220 1.6 VUF8504 68 XAC 142 0.4 116 72\
        \ 0.6 0.4 570 71 0.3 19 35 5.7 58,200 3430 60 143 36,300 5130 976 4000 9440\
        \ 1.2 3.7 6500 323 900 278 15 1.7 36 2.3 11,500 6030 1140 119 590 3260 571\
        \ 5.4 575 726 1.4 107 44 0.6 0.6 2320 124 0.7 134 214 1.1 334 166 2.9 2.1\
        \ 4390 1160 45 2570 552 0.3 1.6 67 321 77 132 0.5 1.9 0.6 1.2 950 2640 340\
        \ 547 13 10.2 690 1340 79 263 0.2 0.85 0.11 14 ND 45 68 14 0.6 2.5 0.7 0.3\
        \ 0.73 0.31 530 7550 2340 87 3.3 370 46 209 0.63 42 61 48 0.14 15 18 1.7 927\
        \ 247 2.2 1.5 3040 333 3.1 81 165 0.3 353 60 0.2 0.5 570 144 1.4 26 47 NA\
        \ ND ND ND ND ND ND ND ND ND ND 11,600 4200 3200 770 20 4 9.9 2.6 ND 3260\
        \ 990 ND 1690 340 20,100 4500 Downloaded from www.jbc.org at Radboud Universiteit\
        \ Nijmegen, on May 21, 2010 a Data are from Jacobson et al. (21).///Yet, the\
        \ interaction seemed to depend upon the precise juxtaposition of the ligand,\
        \ because affinity of the H95A receptor toward I-AB-MECA was only 3-fold lower\
        \ compared with that of the WT receptor, whereas for NECA the ratio was 14-fold.///Whereas\
        \ the 100-fold affinity decrease of the H95A receptor toward CADO could be\
        \ attributed to interaction with the 2-chloro substituent, comparison of the\
        \ relative affinities of MRS1898 and MRS1939 did not support such a conclusion\
        \ (Table II).///TABLE II Examination of the influence of 2-chloro substitution\
        \ on the effects of mutangenesis on agonist affinity Agonista WT Ki, n M H95A\
        \ KI mutant/KI WT for 2-H 2-Cl analogue Adenosine IB-MECA 4.5 MRS1939 1.6\
        \ 1.6 44 0.3 147 12 45 9.8 92 111 26 100 a The 2-H analogue is listed in this\
        \ column.///It is interesting that the H95A mutation impaired agonist binding\
        \ but not agonist-induced receptor activation, whereas the W243A mutation\
        \ impaired functional coupling but did not diminish agonist affinity.", pubmed: '11891221',
    seq: '95', to_res: A}
- {entry_name: aa3r_human, from_res: K, info: "In contrast, the K152A (EL2), W243A\
        \ (6.48), and W243F (6.48) mutations did not significantly affect the agonist\
        \ binding but decreased antagonist affinity by 3\u201338-fold, suggesting\
        \ that these residues were critical for the high affinity of A3 adenosine\
        \ receptor antagonists.///Following the K152A mutation, the affinity of all\
        \ the agonists tested was essentially unchanged; however, the antagonist affinity\
        \ decreased 3\u20139-fold, suggestive of the possible involvement of this\
        \ residue in antagonist recognition.///Ki (nM) WT H95A (3.37) K152A (EL2)\
        \ W243A (6.48) W243F (6.48) L244A (6.49) S247A (6.52) N250A (6.55) H272Ea\
        \ (7.43) Agonists [125I]I-AB-MECA (Kd) 1.7 CADO 523 NECA 249 Cl-IB-MECA 2.3\
        \ MRS1898 1.4 DBXRM 2830 Antagonists CGS15943 182 MRS1220 1.6 VUF8504 68 XAC\
        \ 142 0.4 116 72 0.6 0.4 570 71 0.3 19 35 5.7 58,200 3430 60 143 36,300 5130\
        \ 976 4000 9440 1.2 3.7 6500 323 900 278 15 1.7 36 2.3 11,500 6030 1140 119\
        \ 590 3260 571 5.4 575 726 1.4 107 44 0.6 0.6 2320 124 0.7 134 214 1.1 334\
        \ 166 2.9 2.1 4390 1160 45 2570 552 0.3 1.6 67 321 77 132 0.5 1.9 0.6 1.2\
        \ 950 2640 340 547 13 10.2 690 1340 79 263 0.2 0.85 0.11 14 ND 45 68 14 0.6\
        \ 2.5 0.7 0.3 0.73 0.31 530 7550 2340 87 3.3 370 46 209 0.63 42 61 48 0.14\
        \ 15 18 1.7 927 247 2.2 1.5 3040 333 3.1 81 165 0.3 353 60 0.2 0.5 570 144\
        \ 1.4 26 47 NA ND ND ND ND ND ND ND ND ND ND 11,600 4200 3200 770 20 4 9.9\
        \ 2.6 ND 3260 990 ND 1690 340 20,100 4500 Downloaded from www.jbc.org at Radboud\
        \ Universiteit Nijmegen, on May 21, 2010 a Data are from Jacobson et al. (21).",
    pubmed: '11891221', seq: '152', to_res: A}
- {entry_name: cxcr3_human, from_res: K, info: "Dose-dependent stimulation of PI turnover\
        \ with either ITAC (A) or IP10 (C) in COS-7 cells transiently transfected\
        \ with either the wildtype CXCR3 ( ), the S304E ( ), the K300A (\u201A), or\
        \ the K300A,S304E (E) mutant form of CXCR3.///Dose-dependent stimulation of\
        \ PI turnover with either ITAC (A) or IP10 (C) in COS-7 cells transiently\
        \ transfected with either the wildtype CXCR3 ( ), the S304E ( ), the K300A\
        \ (\u201A), or the K300A,S304E (E) mutant form of CXCR3.///Dose-dependent\
        \ stimulation of PI turnover with either ITAC (A) or IP10 (C) in COS-7 cells\
        \ transiently transfected with either the wildtype CXCR3 ( ), the S304E (\
        \ ), the K300A (\u201A), or the K300A,S304E (E) mutant form of CXCR3.///Dose-dependent\
        \ stimulation of PI turnover with either ITAC (A) or IP10 (C) in COS-7 cells\
        \ transiently transfected with either the wildtype CXCR3 ( ), the S304E (\
        \ ), the K300A (\u201A), or the K300A,S304E (E) mutant form of CXCR3.///B\
        \ and D, dose-dependent inhibition of 10 nM ITAC (B) or 10 nM IP10 (D) induced\
        \ IP turnover by AMD3100 in the wild-type CXCR3 (f), the K300A (\u0152), the\
        \ S304E ( ), or the K300A,S304E (q) mutant form of CXCR3.///B and D, dose-dependent\
        \ inhibition of 10 nM ITAC (B) or 10 nM IP10 (D) induced IP turnover by AMD3100\
        \ in the wild-type CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E\
        \ (q) mutant form of CXCR3.///B and D, dose-dependent inhibition of 10 nM\
        \ ITAC (B) or 10 nM IP10 (D) induced IP turnover by AMD3100 in the wild-type\
        \ CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E (q) mutant\
        \ form of CXCR3.///B and D, dose-dependent inhibition of 10 nM ITAC (B) or\
        \ 10 nM IP10 (D) induced IP turnover by AMD3100 in the wild-type CXCR3 (f),\
        \ the K300A (\u0152), the S304E ( ), or the K300A,S304E (q) mutant form of\
        \ CXCR3.///Improvement of the inhibitory potency and efficacy of AMD3100 in\
        \ inhibiting agonist-induced IP turnover in the K300A,S304E-CXCR3 receptor.///Improvement\
        \ of the inhibitory potency and efficacy of AMD3100 in inhibiting agonist-induced\
        \ IP turnover in the K300A,S304E-CXCR3 receptor.///Thus, just the Ala substitution\
        \ of LysVII:02 (K300A), which is proposed to \u201Cneutralize\u201D AspVI:23\
        \ (Fig. 5), shifted the dose-response curve for AMD3100 43-fold to the left\
        \ in inhibition of IP10-induced signaling (Fig. 8B).///Thus, just the Ala\
        \ substitution of LysVII:02 (K300A), which is proposed to \u201Cneutralize\u201D\
        \ AspVI:23 (Fig. 5), shifted the dose-response curve for AMD3100 43-fold to\
        \ the left in inhibition of IP10-induced signaling (Fig. 8B).///Introduction\
        \ of Glu in position VII:06 (S304E) had an even larger effect, 113-fold, and\
        \ the combination of the two substitutions (K300A,S304E) gave a potency for\
        \ AMD3100 of 136 nM, which is an 820-fold improvement from the wild-type CXCR3\
        \ receptor and within 10-fold of that observed on the CXCR4 receptor.///Introduction\
        \ of Glu in position VII:06 (S304E) had an even larger effect, 113-fold, and\
        \ the combination of the two substitutions (K300A,S304E) gave a potency for\
        \ AMD3100 of 136 nM, which is an 820-fold improvement from the wild-type CXCR3\
        \ receptor and within 10-fold of that observed on the CXCR4 receptor.///For\
        \ the inhibition of ITAC-induced signaling, an even larger effect was observed\
        \ for the combined CXCR4mutated CXCR3 receptor, K300A,S304E-CXCR3, because\
        \ a total of 1420-fold improvement was observed for this construct.///For\
        \ the inhibition of ITAC-induced signaling, an even larger effect was observed\
        \ for the combined CXCR4mutated CXCR3 receptor, K300A,S304E-CXCR3, because\
        \ a total of 1420-fold improvement was observed for this construct.///Also,\
        \ in respect of the two single mutations K300A-CXCR3 and S304E-CXCR3, a gradual\
        \ build-up of the binding pocket was observed when looking at the ITAC-induced\
        \ signaling (Fig. 8A).///Also, in respect of the two single mutations K300A-CXCR3\
        \ and S304E-CXCR3, a gradual build-up of the binding pocket was observed when\
        \ looking at the ITAC-induced signaling (Fig. 8A).///Dose-dependent inhibition\
        \ of 10 nM ITAC (A) or 10 nM IP10 (B) induced IP turnover by AMD3100(Zn2)\
        \ in the wildtype CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E\
        \ (q) mutant form of CXCR3.///Dose-dependent inhibition of 10 nM ITAC (A)\
        \ or 10 nM IP10 (B) induced IP turnover by AMD3100(Zn2) in the wildtype CXCR3\
        \ (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E (q) mutant form\
        \ of CXCR3.///Dose-dependent inhibition of 10 nM ITAC (A) or 10 nM IP10 (B)\
        \ induced IP turnover by AMD3100(Zn2) in the wildtype CXCR3 (f), the K300A\
        \ (\u0152), the S304E ( ), or the K300A,S304E (q) mutant form of CXCR3.///Dose-dependent\
        \ inhibition of 10 nM ITAC (A) or 10 nM IP10 (B) induced IP turnover by AMD3100(Zn2)\
        \ in the wildtype CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E\
        \ (q) mutant form of CXCR3.///Data are shown as means S.E. (n 3\u2013 4).\
        \ inhibition of ITAC was shifted respectively 51-fold and 38-fold to the right\
        \ when either AspIV:20 (D186N) or AspVI:23 (D278N) were mutated to Asn in\
        \ the K300A,S304E-CXCR3 receptor background (Fig. 9).///Data are shown as\
        \ means S.E. (n 3\u2013 4). inhibition of ITAC was shifted respectively 51-fold\
        \ and 38-fold to the right when either AspIV:20 (D186N) or AspVI:23 (D278N)\
        \ were mutated to Asn in the K300A,S304E-CXCR3 receptor background (Fig. 9).///Probing\
        \ for the importance of AspIV:20 and AspVI:23 for the binding of AMD3100(Zn2)\
        \ in the CXCR4-like K300A,S304E-CXCR3 receptor.///Probing for the importance\
        \ of AspIV:20 and AspVI:23 for the binding of AMD3100(Zn2) in the CXCR4-like\
        \ K300A,S304E-CXCR3 receptor.///Dose-dependent inhibition of 10 nM ITAC induced\
        \ IP turnover by AMD3100(Zn2) in COS-7 cells transiently transfected with\
        \ the wild-type CXCR3 receptor (f) and the CXCR4-like (K300A,S304E) mutant\
        \ of CXCR3 (q).///Dose-dependent inhibition of 10 nM ITAC induced IP turnover\
        \ by AMD3100(Zn2) in COS-7 cells transiently transfected with the wild-type\
        \ CXCR3 receptor (f) and the CXCR4-like (K300A,S304E) mutant of CXCR3 (q).///A,\
        \ inhibition curve in D186N,K300A,S304E-CXCR3 (\u0152) where the carboxylic\
        \ group in position IV:20 has been eliminated in the CXCR4-like CXCR3 receptor.///A,\
        \ inhibition curve in D186N,K300A,S304E-CXCR3 (\u0152) where the carboxylic\
        \ group in position IV:20 has been eliminated in the CXCR4-like CXCR3 receptor.///B,\
        \ inhibition curve D278N,K300A,S304E-CXCR3 ( ) where the carboxylic group\
        \ in position VI:23 has been eliminated.///B, inhibition curve D278N,K300A,S304E-CXCR3\
        \ ( ) where the carboxylic group in position VI:23 has been eliminated.",
    pubmed: '14585837', seq: '300', to_res: A}
- {entry_name: acthr_human, from_res: Y, info: 'Interestingly, substitution of the
        next amino acid in the DRY motif - the Y129C mutant caused significant intracellular
        retention.', pubmed: '18840636', seq: '129', to_res: C}
- {entry_name: aa3r_human, from_res: N, info: 'The N250A mutant receptor lost the
        ability to bind both radiolabeled agonist and antagonist.///The data shown
        are from a representative example out of at least three independent experiments
        performed in duplicate. and S247A mutant receptors, the specific binding of
        [125I]I-ABMECA (1.0 nM) to the N250A mutant receptor was not detectable.///In
        contrast, no substantial stimulation of phosphoinositide turnover by Cl-IBMECA
        was observed in COS-7 cells expressing W243A, W243F, and N250A mutant receptors.///A
        Ki value could not be determined (ND) for the N250A (6.55) mutant receptor,
        as this mutant receptor did bind to the agonist radioligand [125I]I-AB-MECA
        or the antagonist radioligand [3H]PSB-11.///Ki (nM) WT H95A (3.37) K152A (EL2)
        W243A (6.48) W243F (6.48) L244A (6.49) S247A (6.52) N250A (6.55) H272Ea (7.43)
        Agonists [125I]I-AB-MECA (Kd) 1.7 CADO 523 NECA 249 Cl-IB-MECA 2.3 MRS1898
        1.4 DBXRM 2830 Antagonists CGS15943 182 MRS1220 1.6 VUF8504 68 XAC 142 0.4
        116 72 0.6 0.4 570 71 0.3 19 35 5.7 58,200 3430 60 143 36,300 5130 976 4000
        9440 1.2 3.7 6500 323 900 278 15 1.7 36 2.3 11,500 6030 1140 119 590 3260
        571 5.4 575 726 1.4 107 44 0.6 0.6 2320 124 0.7 134 214 1.1 334 166 2.9 2.1
        4390 1160 45 2570 552 0.3 1.6 67 321 77 132 0.5 1.9 0.6 1.2 950 2640 340 547
        13 10.2 690 1340 79 263 0.2 0.85 0.11 14 ND 45 68 14 0.6 2.5 0.7 0.3 0.73
        0.31 530 7550 2340 87 3.3 370 46 209 0.63 42 61 48 0.14 15 18 1.7 927 247
        2.2 1.5 3040 333 3.1 81 165 0.3 353 60 0.2 0.5 570 144 1.4 26 47 NA ND ND
        ND ND ND ND ND ND ND ND 11,600 4200 3200 770 20 4 9.9 2.6 ND 3260 990 ND 1690
        340 20,100 4500 Downloaded from www.jbc.org at Radboud Universiteit Nijmegen,
        on May 21, 2010 a Data are from Jacobson et al. (21).///The most deleterious
        of the mutations with respect to binding affinity and functional potency was
        N250A (6.55), indicating that Asn250 is crucially involved in either human
        A3 adenosine receptor-ligand recognition or in maintaining receptor structure.',
    pubmed: '11891221', seq: '250', to_res: A}
- {entry_name: aa1r_bovin, from_res: H, info: 'The mutation of the corresponding residue
        (H251L) diminished antagonist binding 4-fold, but agonist binding was essentially
        not affected (47).', pubmed: '11891221', seq: '251', to_res: L}
- {entry_name: acm3_rat, from_res: W, info: 'In rat m3 muscarinic receptor, the corresponding
        W503F mutation decreased both agonist and antagonist binding; however, receptor
        activation was not affected.', pubmed: '11891221', seq: '503', to_res: F}
- {entry_name: agtra_rat, from_res: W, info: 'In the rat AT1A receptor, the mutation
        of the homologous residue (W253A) decreased agonist but not antagonist binding
        (41).', pubmed: '11891221', seq: '253', to_res: A}
- {entry_name: acm3_rat, from_res: N, info: 'In rat m3 muscarinic receptors, the binding
        of agonist and antagonist was also impaired by the homologous N507A mutation
        (49).', pubmed: '11891221', seq: '507', to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: 'However, in the human A2A adenosine
        receptor, the mutation of the corresponding residue into Ala (Q89A) increased
        both agonist and antagonist affinity (33).', pubmed: '11891221', seq: '89',
    to_res: A}
- {entry_name: trfr_mouse, from_res: N, info: 'Similar to the results obtained here,
        Perlman et al. (37) have demonstrated in a site-directed mutagenesis study
        that the mutation of the corresponding residue in murine thyrotropin-releasing
        hormone receptor (N110A) also decreased agonist binding.', pubmed: '11891221',
    seq: '110', to_res: A}
- {entry_name: trfr_mouse, from_res: R, info: 'Similarly, in the m3 receptor, the
        agonist binding was decreased after the homologous R283A mutation in the murine
        thyrotropin-releasing hormone receptor (42).', pubmed: '11891221', seq: '283',
    to_res: A}
- {entry_name: trfr_mouse, from_res: W, info: 'Consistent with the present study,
        the mutation of the corresponding residue in the murine thyrotropin-releasing
        hormone receptor (W279A) did not affect agonist binding (42).', pubmed: '11891221',
    seq: '279', to_res: A}
- {entry_name: aa3r_human, from_res: S, info: 'Following the substitution of Leu244
        or Ser247 with Ala, saturation experiments were carried out using [125I]I-AB-MECA
        as a radioligand.///Following the substitution of Leu244 or Ser247 with Ala,
        saturation experiments were carried out using [125I]I-AB-MECA as a radioligand.///The
        data shown are from a representative example out of at least three independent
        experiments performed in duplicate. and S247A mutant receptors, the specific
        binding of [125I]I-ABMECA (1.0 nM) to the N250A mutant receptor was not detectable.///Ki
        (nM) WT H95A (3.37) K152A (EL2) W243A (6.48) W243F (6.48) L244A (6.49) S247A
        (6.52) N250A (6.55) H272Ea (7.43) Agonists [125I]I-AB-MECA (Kd) 1.7 CADO 523
        NECA 249 Cl-IB-MECA 2.3 MRS1898 1.4 DBXRM 2830 Antagonists CGS15943 182 MRS1220
        1.6 VUF8504 68 XAC 142 0.4 116 72 0.6 0.4 570 71 0.3 19 35 5.7 58,200 3430
        60 143 36,300 5130 976 4000 9440 1.2 3.7 6500 323 900 278 15 1.7 36 2.3 11,500
        6030 1140 119 590 3260 571 5.4 575 726 1.4 107 44 0.6 0.6 2320 124 0.7 134
        214 1.1 334 166 2.9 2.1 4390 1160 45 2570 552 0.3 1.6 67 321 77 132 0.5 1.9
        0.6 1.2 950 2640 340 547 13 10.2 690 1340 79 263 0.2 0.85 0.11 14 ND 45 68
        14 0.6 2.5 0.7 0.3 0.73 0.31 530 7550 2340 87 3.3 370 46 209 0.63 42 61 48
        0.14 15 18 1.7 927 247 2.2 1.5 3040 333 3.1 81 165 0.3 353 60 0.2 0.5 570
        144 1.4 26 47 NA ND ND ND ND ND ND ND ND ND ND 11,600 4200 3200 770 20 4 9.9
        2.6 ND 3260 990 ND 1690 340 20,100 4500 Downloaded from www.jbc.org at Radboud
        Universiteit Nijmegen, on May 21, 2010 a Data are from Jacobson et al. (21).///In
        the present study, the mutation of the serine residue (S247A) in the TM6 of
        the human A3 adenosine receptor did not influence agonist binding and only
        slightly affected antagonist binding, which is consistent with the results
        from the mutagenesis study of the bovine A1 adenosine receptor.', pubmed: '11891221',
    seq: '247', to_res: A}
- {entry_name: drd2_human, from_res: T, info: 'Similar results have also been reported
        in a study of human D2 dopamine receptors, in which the antagonist binding
        affinity was significantly diminished after the mutation of the corresponding
        residue (T119C) (38).', pubmed: '11891221', seq: '119', to_res: C}
- {entry_name: aa3r_human, from_res: W, info: "In contrast, the K152A (EL2), W243A\
        \ (6.48), and W243F (6.48) mutations did not significantly affect the agonist\
        \ binding but decreased antagonist affinity by 3\u201338-fold, suggesting\
        \ that these residues were critical for the high affinity of A3 adenosine\
        \ receptor antagonists.///The A3 agonist 2chloro-N 6 -(3-iodobenzyl)-5 -N-methylcarbamoyladenosine\
        \ stimulated phosphoinositide turnover in the WT but failed to evoke a response\
        \ in cells expressing W243A and W243F mutant receptors, in which agonist binding\
        \ was less sensitive to guanosine 5 - -thiotriphosphate than in WT.///In contrast\
        \ to the agonist binding, the binding affinity of the A3 antagonist MRS1220\
        \ was diminished 30-fold for the W243A mutant receptor (Fig. 5).///In contrast,\
        \ no substantial stimulation of phosphoinositide turnover by Cl-IBMECA was\
        \ observed in COS-7 cells expressing W243A, W243F, and N250A mutant receptors.///Ki\
        \ (nM) WT H95A (3.37) K152A (EL2) W243A (6.48) W243F (6.48) L244A (6.49) S247A\
        \ (6.52) N250A (6.55) H272Ea (7.43) Agonists [125I]I-AB-MECA (Kd) 1.7 CADO\
        \ 523 NECA 249 Cl-IB-MECA 2.3 MRS1898 1.4 DBXRM 2830 Antagonists CGS15943\
        \ 182 MRS1220 1.6 VUF8504 68 XAC 142 0.4 116 72 0.6 0.4 570 71 0.3 19 35 5.7\
        \ 58,200 3430 60 143 36,300 5130 976 4000 9440 1.2 3.7 6500 323 900 278 15\
        \ 1.7 36 2.3 11,500 6030 1140 119 590 3260 571 5.4 575 726 1.4 107 44 0.6\
        \ 0.6 2320 124 0.7 134 214 1.1 334 166 2.9 2.1 4390 1160 45 2570 552 0.3 1.6\
        \ 67 321 77 132 0.5 1.9 0.6 1.2 950 2640 340 547 13 10.2 690 1340 79 263 0.2\
        \ 0.85 0.11 14 ND 45 68 14 0.6 2.5 0.7 0.3 0.73 0.31 530 7550 2340 87 3.3\
        \ 370 46 209 0.63 42 61 48 0.14 15 18 1.7 927 247 2.2 1.5 3040 333 3.1 81\
        \ 165 0.3 353 60 0.2 0.5 570 144 1.4 26 47 NA ND ND ND ND ND ND ND ND ND ND\
        \ 11,600 4200 3200 770 20 4 9.9 2.6 ND 3260 990 ND 1690 340 20,100 4500 Downloaded\
        \ from www.jbc.org at Radboud Universiteit Nijmegen, on May 21, 2010 a Data\
        \ are from Jacobson et al. (21).///Hence, the ability of WT and W243A and\
        \ W243F mutant receptors to interact with G proteins was further evaluated\
        \ by measuring the effects of GTP S on binding of the agonist [125I]I-AB-MECA\
        \ and on agonist Cl-IB-MECA competition for [3H]PSB-11 binding in membranes\
        \ of COS-7 cells expressing WT and mutant receptors.///The inhibitory effect\
        \ of this GTP analogue on agonist binding to W243A and W243F mutant receptors\
        \ was less pronounced compared with that of WT receptors, consistent with\
        \ the impaired ability of these mutant receptors to mediate inositol phosphate\
        \ production in response to an A3 agonist.///In the case of the W243A mutant\
        \ receptor, the agonist affinity shift could not be observed due to the extremely\
        \ low affinity of this mutant receptor for the antagonist radioligand [3H]PSB-11.///Interestingly,\
        \ we have identified a mutant receptor W243A (6.48) that bound agonist strongly\
        \ but was functionally inactive.///The major consequence of the W243A and\
        \ W243F mutations was functional inactivation of the A3 receptor, indicating\
        \ that Trp243 may play a pivotal role in receptor transduction of the signal.///By\
        \ comparison, mutation of residue Leu244 (at a neighboring position to Trp243)\
        \ to Ala did not influence the antagonist binding.///It is interesting that\
        \ the H95A mutation impaired agonist binding but not agonist-induced receptor\
        \ activation, whereas the W243A mutation impaired functional coupling but\
        \ did not diminish agonist affinity.///The mutation of residue Leu244 (adjacent\
        \ to Trp243) to Ala resulted in nearly the same agonist binding affinity as\
        \ that of the WT receptor, but the activation was only partly impaired, also\
        \ suggesting the involvement in the receptor activation process.///This conclusion\
        \ was based upon the differential effect on affinity toward antagonists upon\
        \ replacement of Trp243 with Phe and Ala (Table I).", pubmed: '11891221',
    seq: '243', to_res: A}
- {entry_name: aa1r_human, from_res: Q, info: 'In A1 adenosine receptors (the residue
        at the homologous position is Gln), the mutation (Q92A) also demonstrated
        its critical role in ligand recognition (34).', pubmed: '11891221', seq: '92',
    to_res: A}
- {entry_name: adrb2_human, from_res: E, info: "Interestingly, the lysozyme protein\
        \ has different tilting angles in the adenosine A2A\u2013T4L(DC), b2\u2013\
        T4L(DC):carazolol and b2AR (Glu122Trp)\u2013T4L(DC):timolol structures.///Interestingly,\
        \ the lysozyme protein has different tilting angles in the adenosine A2A\u2013\
        T4L(DC), b2\u2013T4L(DC):carazolol and b2AR (Glu122Trp)\u2013T4L(DC):timolol\
        \ structures.///Interestingly, the lysozyme protein has different tilting\
        \ angles in the adenosine A2A\u2013T4L(DC), b2\u2013T4L(DC):carazolol and\
        \ b2AR (Glu122Trp)\u2013T4L(DC):timolol structures.///Interestingly, the lysozyme\
        \ protein has different tilting angles in the adenosine A2A\u2013T4L(DC),\
        \ b2\u2013T4L(DC):carazolol and b2AR (Glu122Trp)\u2013T4L(DC):timolol structures.",
    pubmed: '20538452', seq: '122', to_res: W}
- {entry_name: adrb2_human, from_res: F, info: "Trp 6.48 is highly conserved in Family\
        \ A GPCRs, and it has been proposed that its rotameric state has a role in\
        \ GPCR activation (rotamer a b \u03B22AR\u2013Cz \u03B22AR\u2013Nb80 TM5 1\
        \ Ser 203 Pro 211 Ser 207 2.1 \xC5 Ile 121 Pro 211 Phe 282 Asn 318 Trp 286\
        \ 3 2 Figure 4", pubmed: '21228869', seq: '282', to_res: N}
- {entry_name: agtra_mouse, from_res: R, info: 'Mutation R240Q only abolishes function
        when the protein is coexpressed with collectrin or ACE2, but does not affect
        transport activity when B0 AT1 is expressed alone [43].', pubmed: '21568940',
    seq: '240', to_res: Q}
- {entry_name: cxcr4_human, from_res: I, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '284', to_res: A}
- {entry_name: cxcr4_human, from_res: F, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '174', to_res: A}
- {entry_name: cxcr4_human, from_res: G, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '207', to_res: W}
- {entry_name: cxcr4_human, from_res: S, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '263', to_res: A}
- {entry_name: cxcr4_human, from_res: E, info: "Residue Number Position Bmax SEM log\
        \ Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479\
        \ SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07\
        \ TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A\
        \ V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N\
        \ VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61\
        \ 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11\
        \ 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81\
        \ 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15\
        \ 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14\
        \ 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03\
        \ 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4)\
        \ (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9\
        \ 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33\
        \ 6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8\
        \ 0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02\
        \ 0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1\
        \ 0.17 63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3)\
        \ (11) (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1\
        \ 0.2 1.2 71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56\
        \ 6.08 4.89 7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4)\
        \ 0.26 0.01 (4) 0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07\
        \ 0.02 (3) 0.05 0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84\
        \ (2) 0.58 13 (3) 0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0\
        \ 4.1 0.6 0.6 12 28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue\
        \ Number Position Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM\
        \ Ki uM (N) fmut log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4\
        \ TM-III H113A III:03 T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23\
        \ A175F IV:24 TM-V V196A V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A\
        \ V:17 I259A VI:20 I259W VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01\
        \ I284A VII:02 E288A VII:06 137 49 61 85 70 44 42 27 139 117 235 172 40 71\
        \ 162 101 116 116 140 37 14 28 49 11 15 21 6 15 76 101 73 8 6 59 44 35 16\
        \ 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99\
        \ 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32\
        \ 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51\
        \ 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15 0.36 0.83 1.47 0.96 (19) (4)\
        \ (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3) (3) (13) (3) (8) (5) (16) 1.0\
        \ 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6\
        \ 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52 5.01 5.40 5.81 5.34 4.34\
        \ 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46 0.12 0.74 0.13 13 0.16\
        \ 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7 0.33 4.0 0.05 1.5 0.33\
        \ 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17) (7) (5) (6) (13) (5)\
        \ (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15) 1.0 2.0 0.5 0.8 15\
        \ 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61 7.00 7.86 7.84 6.55\
        \ 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10 7.54 6.64 5.64 0.10\
        \ 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23 0.28 (11) 0.31 0.68\
        \ (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25 (2) 0.09 0.53 (3)\
        \ 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17 0.08 (3) 0.14\
        \ 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350 68 0.7 10\
        \ 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///The competition curves for the\
        \ unlabeled 12G5 are indicated with squares (A and B): , wild-type receptor,\
        \ and f, E288A-CXCR4.///The competition curves for the unlabeled 12G5 are\
        \ indicated with squares (A and B): , wild-type receptor, and f, E288A-CXCR4.///B,\
        \ displacement with AMD3100(Zn2) in wild-type receptor (\u201A) and E288A-CXCR4\
        \ (\u0152).///B, displacement with AMD3100(Zn2) in wild-type receptor (\u201A\
        ) and E288A-CXCR4 (\u0152).///Dose-response curves for SDF-1 are shown in\
        \ A: wild-type receptor (\u201A) and E288A-CXCR4 (\u0152).///Dose-response\
        \ curves for SDF-1 are shown in A: wild-type receptor (\u201A) and E288A-CXCR4\
        \ (\u0152).///Inhibition of SDF1-induced PLC activity by AMD3100 are shown\
        \ in B: wild-type receptor (E), E288A-CXCR4 (q), AMD3100(Zn2), wild-type receptor\
        \ ( ), and E288A-CXCR4 (f).///Inhibition of SDF1-induced PLC activity by AMD3100\
        \ are shown in B: wild-type receptor (E), E288A-CXCR4 (q), AMD3100(Zn2), wild-type\
        \ receptor ( ), and E288A-CXCR4 (f).///Inhibition of SDF1-induced PLC activity\
        \ by AMD3100 are shown in B: wild-type receptor (E), E288A-CXCR4 (q), AMD3100(Zn2),\
        \ wild-type receptor ( ), and E288A-CXCR4 (f).///Inhibition of SDF1-induced\
        \ PLC activity by AMD3100 are shown in B: wild-type receptor (E), E288A-CXCR4\
        \ (q), AMD3100(Zn2), wild-type receptor ( ), and E288A-CXCR4 (f).///In contrast,\
        \ substitution of GluVII:06 (Glu288) to Ala affected AMD3100 around 70-fold.///As\
        \ shown in Fig. 3, by using [125I]12G5 as a radioligand, the Glu288 to Ala\
        \ substitution shifted the competition binding curve for AMD3100 with or without\
        \ Zn(II) 70- to 90-fold to the right.///As shown in Fig. 3, by using [125I]12G5\
        \ as a radioligand, the Glu288 to Ala substitution shifted the competition\
        \ binding curve for AMD3100 with or without Zn(II) 70- to 90-fold to the right.///This\
        \ is very likely a reflection of a decreased affinity of SDF-1 on the Glu288\
        \ to Ala mutant receptor, as the potency of SDF-1 in signaling was impaired\
        \ 87-fold in this construct (Fig. 4A).///This is very likely a reflection\
        \ of a decreased affinity of SDF-1 on the Glu288 to Ala mutant receptor, as\
        \ the potency of SDF-1 in signaling was impaired 87-fold in this construct\
        \ (Fig. 4A).///By using appropriate sub-maximal doses of SDF-1 on the wild-type\
        \ and on the Glu288 to Ala mutant form of CXCR4, respectively, it was possible\
        \ to demonstrate that, not only the affinity (Table I and Fig. 3), but also\
        \ the potency of AMD3100 (with or without Zn(II)) were highly dependent on\
        \ the presence of a Glu in position VII:06.///By using appropriate sub-maximal\
        \ doses of SDF-1 on the wild-type and on the Glu288 to Ala mutant form of\
        \ CXCR4, respectively, it was possible to demonstrate that, not only the affinity\
        \ (Table I and Fig. 3), but also the potency of AMD3100 (with or without Zn(II))\
        \ were highly dependent on the presence of a Glu in position VII:06.///Thus,\
        \ in the wild-type CXCR4, receptor potencies of 79 nM and 17 nM were observed\
        \ for AMD3100 and the Zn(II)-loaded version, respectively, whereas right shifts\
        \ of 23- to 116-fold of the bicyclam inhibition curves were observed in the\
        \ Glu288 to Ala mutant form of CXCR4 (Fig. 4B).///Thus, in the wild-type CXCR4,\
        \ receptor potencies of 79 nM and 17 nM were observed for AMD3100 and the\
        \ Zn(II)-loaded version, respectively, whereas right shifts of 23- to 116-fold\
        \ of the bicyclam inhibition curves were observed in the Glu288 to Ala mutant\
        \ form of CXCR4 (Fig. 4B).", pubmed: '14585837', seq: '288', to_res: A}
- {entry_name: cxcr4_human, from_res: Y, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '255', to_res: A}
- {entry_name: cxcr3_human, from_res: D, info: "Data are shown as means S.E. (n 3\u2013\
        \ 4). inhibition of ITAC was shifted respectively 51-fold and 38-fold to the\
        \ right when either AspIV:20 (D186N) or AspVI:23 (D278N) were mutated to Asn\
        \ in the K300A,S304E-CXCR3 receptor background (Fig. 9).///Data are shown\
        \ as means S.E. (n 3\u2013 4). inhibition of ITAC was shifted respectively\
        \ 51-fold and 38-fold to the right when either AspIV:20 (D186N) or AspVI:23\
        \ (D278N) were mutated to Asn in the K300A,S304E-CXCR3 receptor background\
        \ (Fig. 9).///A, inhibition curve in D186N,K300A,S304E-CXCR3 (\u0152) where\
        \ the carboxylic group in position IV:20 has been eliminated in the CXCR4-like\
        \ CXCR3 receptor.///A, inhibition curve in D186N,K300A,S304E-CXCR3 (\u0152\
        ) where the carboxylic group in position IV:20 has been eliminated in the\
        \ CXCR4-like CXCR3 receptor.", pubmed: '14585837', seq: '186', to_res: N}
- {entry_name: adrb2_human, from_res: S, info: "Indeed, experimental results in ref.(Ambrosio\
        \ and others 2000) provide some initial evidence in support of this effect\
        \ by demonstrating decrease in \u03B22AR basal activity by as much as 50%-60%\
        \ upon the S204A/S207A double mutation.///Indeed, experimental results in\
        \ ref.(Ambrosio and others 2000) provide some initial evidence in support\
        \ of this effect by demonstrating decrease in \u03B22AR basal activity by\
        \ as much as 50%-60% upon the S204A/S207A double mutation.", pubmed: '19353579',
    seq: '207', to_res: A}
- {entry_name: cxcr4_human, from_res: H, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '113', to_res: A}
- {entry_name: cxcr4_human, from_res: D, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '262', to_res: N}
- {entry_name: cxcr4_human, from_res: D, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///pIV:20 (Asp171)
        to Asn has previously been shown to affect AMD3100 38-fold in competition
        against the natural chemokine ligand SDF-1 (9).', pubmed: '14585837', seq: '171',
    to_res: N}
- {entry_name: cxcr4_human, from_res: A, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///The relatively
        large effect of the steric-hindrance substitution of Ala175 with Phe is in
        good agreement with the assumption that one of the cyclam rings of AMD3100
        should be located in the pocket between TM-III, -IV, and -V, i.e. in front
        of Asp171, which is where the large aromatic side chain of the introduced
        Phe residue would be expected to be located in the (A175F) mutant.///The relatively
        large effect of the steric-hindrance substitution of Ala175 with Phe is in
        good agreement with the assumption that one of the cyclam rings of AMD3100
        should be located in the pocket between TM-III, -IV, and -V, i.e. in front
        of Asp171, which is where the large aromatic side chain of the introduced
        Phe residue would be expected to be located in the (A175F) mutant.///The relatively
        large effect of the steric-hindrance substitution of Ala175 with Phe is in
        good agreement with the assumption that one of the cyclam rings of AMD3100
        should be located in the pocket between TM-III, -IV, and -V, i.e. in front
        of Asp171, which is where the large aromatic side chain of the introduced
        Phe residue would be expected to be located in the (A175F) mutant.///The relatively
        large effect of the steric-hindrance substitution of Ala175 with Phe is in
        good agreement with the assumption that one of the cyclam rings of AMD3100
        should be located in the pocket between TM-III, -IV, and -V, i.e. in front
        of Asp171, which is where the large aromatic side chain of the introduced
        Phe residue would be expected to be located in the (A175F) mutant.///Important
        Acidic Residue in TM-VII for the Binding of AMD3100 -GluVII:06 (Glu288) is
        clearly the most interesting among the novel potential interaction sites for
        AMD3100, because the only other mutation which has a relatively large effect
        on the binding of the antagonist (Ala175 to Phe) is conDissection and Transfer
        of AMD3100 Site from CXCR4 to CXCR3 3037 FIG. 5.///Important Acidic Residue
        in TM-VII for the Binding of AMD3100 -GluVII:06 (Glu288) is clearly the most
        interesting among the novel potential interaction sites for AMD3100, because
        the only other mutation which has a relatively large effect on the binding
        of the antagonist (Ala175 to Phe) is conDissection and Transfer of AMD3100
        Site from CXCR4 to CXCR3 3037 FIG. 5.', pubmed: '14585837', seq: '175', to_res: F}
- {entry_name: cxcr4_human, from_res: V, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '196', to_res: A}
- {entry_name: cxcr3_human, from_res: D, info: "Data are shown as means S.E. (n 3\u2013\
        \ 4). inhibition of ITAC was shifted respectively 51-fold and 38-fold to the\
        \ right when either AspIV:20 (D186N) or AspVI:23 (D278N) were mutated to Asn\
        \ in the K300A,S304E-CXCR3 receptor background (Fig. 9).///Data are shown\
        \ as means S.E. (n 3\u2013 4). inhibition of ITAC was shifted respectively\
        \ 51-fold and 38-fold to the right when either AspIV:20 (D186N) or AspVI:23\
        \ (D278N) were mutated to Asn in the K300A,S304E-CXCR3 receptor background\
        \ (Fig. 9).///B, inhibition curve D278N,K300A,S304E-CXCR3 ( ) where the carboxylic\
        \ group in position VI:23 has been eliminated.///B, inhibition curve D278N,K300A,S304E-CXCR3\
        \ ( ) where the carboxylic group in position VI:23 has been eliminated.",
    pubmed: '14585837', seq: '278', to_res: N}
- {entry_name: cxcr4_human, from_res: Y, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '256', to_res: A}
- {entry_name: cxcr4_human, from_res: T, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '168', to_res: A}
- {entry_name: cxcr4_human, from_res: I, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '259', to_res: A}
- {entry_name: cxcr4_human, from_res: H, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '281', to_res: A}
- {entry_name: cxcr4_human, from_res: Q, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '200', to_res: A}
- {entry_name: cxcr3_human, from_res: S, info: "Red background indicates the conserved\
        \ Asp186 (position IV:20) and Asp278 (position VI:23), which are both present\
        \ in the CXCR3 wild-type and the introduced Glu for Ser304 at position VII:06.///Dose-dependent\
        \ stimulation of PI turnover with either ITAC (A) or IP10 (C) in COS-7 cells\
        \ transiently transfected with either the wildtype CXCR3 ( ), the S304E (\
        \ ), the K300A (\u201A), or the K300A,S304E (E) mutant form of CXCR3.///Dose-dependent\
        \ stimulation of PI turnover with either ITAC (A) or IP10 (C) in COS-7 cells\
        \ transiently transfected with either the wildtype CXCR3 ( ), the S304E (\
        \ ), the K300A (\u201A), or the K300A,S304E (E) mutant form of CXCR3.///Dose-dependent\
        \ stimulation of PI turnover with either ITAC (A) or IP10 (C) in COS-7 cells\
        \ transiently transfected with either the wildtype CXCR3 ( ), the S304E (\
        \ ), the K300A (\u201A), or the K300A,S304E (E) mutant form of CXCR3.///Dose-dependent\
        \ stimulation of PI turnover with either ITAC (A) or IP10 (C) in COS-7 cells\
        \ transiently transfected with either the wildtype CXCR3 ( ), the S304E (\
        \ ), the K300A (\u201A), or the K300A,S304E (E) mutant form of CXCR3.///B\
        \ and D, dose-dependent inhibition of 10 nM ITAC (B) or 10 nM IP10 (D) induced\
        \ IP turnover by AMD3100 in the wild-type CXCR3 (f), the K300A (\u0152), the\
        \ S304E ( ), or the K300A,S304E (q) mutant form of CXCR3.///B and D, dose-dependent\
        \ inhibition of 10 nM ITAC (B) or 10 nM IP10 (D) induced IP turnover by AMD3100\
        \ in the wild-type CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E\
        \ (q) mutant form of CXCR3.///B and D, dose-dependent inhibition of 10 nM\
        \ ITAC (B) or 10 nM IP10 (D) induced IP turnover by AMD3100 in the wild-type\
        \ CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E (q) mutant\
        \ form of CXCR3.///B and D, dose-dependent inhibition of 10 nM ITAC (B) or\
        \ 10 nM IP10 (D) induced IP turnover by AMD3100 in the wild-type CXCR3 (f),\
        \ the K300A (\u0152), the S304E ( ), or the K300A,S304E (q) mutant form of\
        \ CXCR3.///Improvement of the inhibitory potency and efficacy of AMD3100 in\
        \ inhibiting agonist-induced IP turnover in the K300A,S304E-CXCR3 receptor.///Improvement\
        \ of the inhibitory potency and efficacy of AMD3100 in inhibiting agonist-induced\
        \ IP turnover in the K300A,S304E-CXCR3 receptor.///Introduction of Glu in\
        \ position VII:06 (S304E) had an even larger effect, 113-fold, and the combination\
        \ of the two substitutions (K300A,S304E) gave a potency for AMD3100 of 136\
        \ nM, which is an 820-fold improvement from the wild-type CXCR3 receptor and\
        \ within 10-fold of that observed on the CXCR4 receptor.///Introduction of\
        \ Glu in position VII:06 (S304E) had an even larger effect, 113-fold, and\
        \ the combination of the two substitutions (K300A,S304E) gave a potency for\
        \ AMD3100 of 136 nM, which is an 820-fold improvement from the wild-type CXCR3\
        \ receptor and within 10-fold of that observed on the CXCR4 receptor.///Introduction\
        \ of Glu in position VII:06 (S304E) had an even larger effect, 113-fold, and\
        \ the combination of the two substitutions (K300A,S304E) gave a potency for\
        \ AMD3100 of 136 nM, which is an 820-fold improvement from the wild-type CXCR3\
        \ receptor and within 10-fold of that observed on the CXCR4 receptor.///Introduction\
        \ of Glu in position VII:06 (S304E) had an even larger effect, 113-fold, and\
        \ the combination of the two substitutions (K300A,S304E) gave a potency for\
        \ AMD3100 of 136 nM, which is an 820-fold improvement from the wild-type CXCR3\
        \ receptor and within 10-fold of that observed on the CXCR4 receptor.///For\
        \ the inhibition of ITAC-induced signaling, an even larger effect was observed\
        \ for the combined CXCR4mutated CXCR3 receptor, K300A,S304E-CXCR3, because\
        \ a total of 1420-fold improvement was observed for this construct.///For\
        \ the inhibition of ITAC-induced signaling, an even larger effect was observed\
        \ for the combined CXCR4mutated CXCR3 receptor, K300A,S304E-CXCR3, because\
        \ a total of 1420-fold improvement was observed for this construct.///Also,\
        \ in respect of the two single mutations K300A-CXCR3 and S304E-CXCR3, a gradual\
        \ build-up of the binding pocket was observed when looking at the ITAC-induced\
        \ signaling (Fig. 8A).///Also, in respect of the two single mutations K300A-CXCR3\
        \ and S304E-CXCR3, a gradual build-up of the binding pocket was observed when\
        \ looking at the ITAC-induced signaling (Fig. 8A).///Dose-dependent inhibition\
        \ of 10 nM ITAC (A) or 10 nM IP10 (B) induced IP turnover by AMD3100(Zn2)\
        \ in the wildtype CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E\
        \ (q) mutant form of CXCR3.///Dose-dependent inhibition of 10 nM ITAC (A)\
        \ or 10 nM IP10 (B) induced IP turnover by AMD3100(Zn2) in the wildtype CXCR3\
        \ (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E (q) mutant form\
        \ of CXCR3.///Dose-dependent inhibition of 10 nM ITAC (A) or 10 nM IP10 (B)\
        \ induced IP turnover by AMD3100(Zn2) in the wildtype CXCR3 (f), the K300A\
        \ (\u0152), the S304E ( ), or the K300A,S304E (q) mutant form of CXCR3.///Dose-dependent\
        \ inhibition of 10 nM ITAC (A) or 10 nM IP10 (B) induced IP turnover by AMD3100(Zn2)\
        \ in the wildtype CXCR3 (f), the K300A (\u0152), the S304E ( ), or the K300A,S304E\
        \ (q) mutant form of CXCR3.///Data are shown as means S.E. (n 3\u2013 4).\
        \ inhibition of ITAC was shifted respectively 51-fold and 38-fold to the right\
        \ when either AspIV:20 (D186N) or AspVI:23 (D278N) were mutated to Asn in\
        \ the K300A,S304E-CXCR3 receptor background (Fig. 9).///Data are shown as\
        \ means S.E. (n 3\u2013 4). inhibition of ITAC was shifted respectively 51-fold\
        \ and 38-fold to the right when either AspIV:20 (D186N) or AspVI:23 (D278N)\
        \ were mutated to Asn in the K300A,S304E-CXCR3 receptor background (Fig. 9).///Probing\
        \ for the importance of AspIV:20 and AspVI:23 for the binding of AMD3100(Zn2)\
        \ in the CXCR4-like K300A,S304E-CXCR3 receptor.///Probing for the importance\
        \ of AspIV:20 and AspVI:23 for the binding of AMD3100(Zn2) in the CXCR4-like\
        \ K300A,S304E-CXCR3 receptor.///Dose-dependent inhibition of 10 nM ITAC induced\
        \ IP turnover by AMD3100(Zn2) in COS-7 cells transiently transfected with\
        \ the wild-type CXCR3 receptor (f) and the CXCR4-like (K300A,S304E) mutant\
        \ of CXCR3 (q).///Dose-dependent inhibition of 10 nM ITAC induced IP turnover\
        \ by AMD3100(Zn2) in COS-7 cells transiently transfected with the wild-type\
        \ CXCR3 receptor (f) and the CXCR4-like (K300A,S304E) mutant of CXCR3 (q).///A,\
        \ inhibition curve in D186N,K300A,S304E-CXCR3 (\u0152) where the carboxylic\
        \ group in position IV:20 has been eliminated in the CXCR4-like CXCR3 receptor.///A,\
        \ inhibition curve in D186N,K300A,S304E-CXCR3 (\u0152) where the carboxylic\
        \ group in position IV:20 has been eliminated in the CXCR4-like CXCR3 receptor.///B,\
        \ inhibition curve D278N,K300A,S304E-CXCR3 ( ) where the carboxylic group\
        \ in position VI:23 has been eliminated.///B, inhibition curve D278N,K300A,S304E-CXCR3\
        \ ( ) where the carboxylic group in position VI:23 has been eliminated.",
    pubmed: '14585837', seq: '304', to_res: E}
- {entry_name: cxcr4_human, from_res: I, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '259', to_res: W}
- {entry_name: cxcr4_human, from_res: T, info: 'Residue Number Position Bmax SEM log
        Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut log Ki AMD3479
        SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03 T117A III:07
        TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A V:01 Q200A
        V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W VI:20 D262N
        VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06 137 49 61
        85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28 49 11 15
        21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29 8.81 9.05
        9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23 0.15 0.19
        0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16 0.14 0.06
        1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30 1.03 1.15
        0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4) (4) (3)
        (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6 0.9 0.9
        0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33 6.25 5.52
        5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8 0.09 0.46
        0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02 0.27 9.7
        0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17 63 (17)
        (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11) (4) (15)
        1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2 71 7.61
        7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89 7.10
        7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4) 0.23
        0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05 0.25
        (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3) 0.17
        0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12 28 350
        68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.///Residue Number Position
        Bmax SEM log Kd SEM 12G5 Kd nM (N) fmut log Ki AMD3100 SEM Ki uM (N) fmut
        log Ki AMD3479 SEM Ki uM (N) fmut fmol/10 cell 5 wt CXCR4 TM-III H113A III:03
        T117A III:07 TM-IV T168A V:17 D171N IV:20 F174A IV:23 A175F IV:24 TM-V V196A
        V:01 Q200A V:05 G207W V:12 TM-VI Y255A VI:16 Y256A V:17 I259A VI:20 I259W
        VI:20 D262N VI:23 S263A V:24 TM-VII H281A VII:-01 I284A VII:02 E288A VII:06
        137 49 61 85 70 44 42 27 139 117 235 172 40 71 162 101 116 116 140 37 14 28
        49 11 15 21 6 15 76 101 73 8 6 59 44 35 16 46 8.80 8.79 9.21 9.20 9.06 9.29
        8.81 9.05 9.31 9.03 8.87 8.87 9.52 8.99 8.94 9.44 9.08 8.83 9.02 0.09 0.23
        0.15 0.19 0.09 0.24 0.12 0.10 0.14 0.32 0.13 0.16 0.12 0.16 0.13 0.20 0.16
        0.14 0.06 1.57 1.63 0.62 0.63 0.87 0.51 1.55 0.89 0.49 0.93 1.36 1.36 0.30
        1.03 1.15 0.36 0.83 1.47 0.96 (19) (4) (5) (6) (14) (5) (4) (4) (3) (4) (4)
        (4) (3) (3) (13) (3) (8) (5) (16) 1.0 1.0 0.4 0.4 0.6 0.3 1.0 0.6 0.3 0.6
        0.9 0.9 0.2 0.7 0.7 0.2 0.5 0.9 0.6 6.05 5.75 6.34 6.13 4.87 5.50 4.45 5.33
        6.25 5.52 5.01 5.40 5.81 5.34 4.34 5.27 6.80 5.96 4.20 0.11 0.89 0.19 1.8
        0.09 0.46 0.12 0.74 0.13 13 0.16 3.16 0.24 36 0.13 4.6 0.10 0.56 0.33 3.02
        0.27 9.7 0.33 4.0 0.05 1.5 0.33 4.6 0.15 46 0.14 5.4 0.21 0.16 0.36 1.1 0.17
        63 (17) (7) (5) (6) (13) (5) (4) (4) (3) (4) (4) (3) (3) (3) (13) (3) (11)
        (4) (15) 1.0 2.0 0.5 0.8 15 3.5 40 5.2 0.6 3.4 11 5 1.7 5.2 52 6.1 0.2 1.2
        71 7.61 7.00 7.86 7.84 6.55 6.17 5.07 5.78 7.75 6.60 6.28 6.73 7.56 6.08 4.89
        7.10 7.54 6.64 5.64 0.10 0.02 (9) 0.22 0.10 (4) 0.09 0.01 (4) 0.26 0.01 (4)
        0.23 0.28 (11) 0.31 0.68 (4) 0.34 8.6 (3) 0.17 1.7 (3) 0.07 0.02 (3) 0.05
        0.25 (2) 0.09 0.53 (3) 0.23 0.19 (4) 0.06 0.03 (3) 0.36 0.84 (2) 0.58 13 (3)
        0.17 0.08 (3) 0.14 0.03 (5) 0.07 0.23 (3) 0.32 2.3 (3) 1.0 4.1 0.6 0.6 12
        28 350 68 0.7 10 22 7.6 1.1 34 522 3.2 1.2 9.3 93 FIG. 2.', pubmed: '14585837',
    seq: '117', to_res: A}
- {entry_name: adrb2_human, from_res: S, info: "The distortion in the helix caused\
        \ by Thr49 (B) or Ser204 (C) in the g\xC0 conformation is monitored by the\
        \ local bend (left plot) and twist (right plot) angles as calculated with\
        \ the HelAnal program (Bansal et al., 2000) (see Section 2).///The distortion\
        \ in the helix caused by Thr49 (B) or Ser204 (C) in the g\xC0 conformation\
        \ is monitored by the local bend (left plot) and twist (right plot) angles\
        \ as calculated with the HelAnal program (Bansal et al., 2000) (see Section\
        \ 2).", pubmed: '19766191', seq: '204', to_res: C}
- {entry_name: mc4r_human, from_res: D, info: "All these mutations reduce the ability\
        \ of the receptor to respond to a-MSH (data not shown and [26,32\u201334].\
        \ In addition, structure-functions studies of MC4R have delineated the role\
        \ of three key acidic residues (E100A, D122A and D126A) in transmembrane regions\
        \ 2 and 3 (TM2 and 3) that are critical for a-MSH binding and activation [28,29]\
        \ (Fig. 1).///All these mutations reduce the ability of the receptor to respond\
        \ to a-MSH (data not shown and [26,32\u201334]. In addition, structure-functions\
        \ studies of MC4R have delineated the role of three key acidic residues (E100A,\
        \ D122A and D126A) in transmembrane regions 2 and 3 (TM2 and 3) that are critical\
        \ for a-MSH binding and activation [28,29] (Fig. 1).///To identify a receptor\
        \ that was not activated by a-MSH, but still activated by a synthetic ligand,\
        \ with minimal loss of membrane expression, we focused on five mutations (N97D,\
        \ G98R, I102S, L106P and S127L) in extracellular loop 1 (EL1) and three in\
        \ its flanking TM regions (E100A, D122A and D126A).///To identify a receptor\
        \ that was not activated by a-MSH, but still activated by a synthetic ligand,\
        \ with minimal loss of membrane expression, we focused on five mutations (N97D,\
        \ G98R, I102S, L106P and S127L) in extracellular loop 1 (EL1) and three in\
        \ its flanking TM regions (E100A, D122A and D126A).///All point mutants examined,\
        \ that is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///The EC50s for D122A, D126A, and S127L\
        \ were in the mM range, well above the physiological range of a-MSH in vivo\
        \ (Table 1).///The EC50s for D122A, D126A, and S127L were in the mM range,\
        \ well above the physiological range of a-MSH in vivo (Table 1).///The D122A\
        \ mutant, identified from structure-function studies of MC4R to be important\
        \ for a-MSH binding [28], also responded robustly to THIQ (EC50 = 29.5 nM).///The\
        \ D122A mutant, identified from structure-function studies of MC4R to be important\
        \ for a-MSH binding [28], also responded robustly to THIQ (EC50 = 29.5 nM).///These\
        \ experiments identified two RASSLs, L106P-MC4R and D122A-MC4R, which we designated\
        \ RASSL MC4R 1 (Rm1) and RASSL MC4R 2 (Rm2), respectively.///These experiments\
        \ identified two RASSLs, L106P-MC4R and D122A-MC4R, which we designated RASSL\
        \ MC4R 1 (Rm1) and RASSL MC4R 2 (Rm2), respectively.///PLoS ONE", pubmed: '17668051',
    seq: '122', to_res: A}
- {entry_name: mc4r_human, from_res: D, info: "All these mutations reduce the ability\
        \ of the receptor to respond to a-MSH (data not shown and [26,32\u201334].\
        \ In addition, structure-functions studies of MC4R have delineated the role\
        \ of three key acidic residues (E100A, D122A and D126A) in transmembrane regions\
        \ 2 and 3 (TM2 and 3) that are critical for a-MSH binding and activation [28,29]\
        \ (Fig. 1).///All these mutations reduce the ability of the receptor to respond\
        \ to a-MSH (data not shown and [26,32\u201334]. In addition, structure-functions\
        \ studies of MC4R have delineated the role of three key acidic residues (E100A,\
        \ D122A and D126A) in transmembrane regions 2 and 3 (TM2 and 3) that are critical\
        \ for a-MSH binding and activation [28,29] (Fig. 1).///To identify a receptor\
        \ that was not activated by a-MSH, but still activated by a synthetic ligand,\
        \ with minimal loss of membrane expression, we focused on five mutations (N97D,\
        \ G98R, I102S, L106P and S127L) in extracellular loop 1 (EL1) and three in\
        \ its flanking TM regions (E100A, D122A and D126A).///To identify a receptor\
        \ that was not activated by a-MSH, but still activated by a synthetic ligand,\
        \ with minimal loss of membrane expression, we focused on five mutations (N97D,\
        \ G98R, I102S, L106P and S127L) in extracellular loop 1 (EL1) and three in\
        \ its flanking TM regions (E100A, D122A and D126A).///All point mutants examined,\
        \ that is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///The EC50s for D122A, D126A, and S127L\
        \ were in the mM range, well above the physiological range of a-MSH in vivo\
        \ (Table 1).///The EC50s for D122A, D126A, and S127L were in the mM range,\
        \ well above the physiological range of a-MSH in vivo (Table 1).///PLoS ONE",
    pubmed: '17668051', seq: '126', to_res: A}
- {entry_name: mc4r_human, from_res: I, info: "To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///All point mutants examined, that\
        \ is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///PLoS ONE", pubmed: '17668051', seq: '102',
    to_res: S}
- {entry_name: adrb2_human, from_res: S, info: "Trp 6.48 is highly conserved in Family\
        \ A GPCRs, and it has been proposed that its rotameric state has a role in\
        \ GPCR activation (rotamer a b \u03B22AR\u2013Cz \u03B22AR\u2013Nb80 TM5 1\
        \ Ser 203 Pro 211 Ser 207 2.1 \xC5 Ile 121 Pro 211 Phe 282 Asn 318 Trp 286\
        \ 3 2 Figure 4", pubmed: '21228869', seq: '203', to_res: P}
- {entry_name: acthr_human, from_res: S, info: 'The S74I, I130N (Figure 2G and H)
        and T152K demonstrated partial trafficking impairment, which did not reach
        a statistically significant difference on cell surface assay.///There is partial
        cell surface expression in S74I, I130N and T152K, as there is no significance
        difference when compared with wild type.///G: S74I and H: I130N have partial
        expression at the cell surface.', pubmed: '18840636', seq: '74', to_res: I}
- {entry_name: mc4r_human, from_res: N, info: "To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///All point mutants examined, that\
        \ is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///PLoS ONE", pubmed: '17668051', seq: '97',
    to_res: D}
- {entry_name: mc4r_human, from_res: G, info: "To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///All point mutants examined, that\
        \ is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///PLoS ONE", pubmed: '17668051', seq: '98',
    to_res: R}
- {entry_name: mc4r_human, from_res: L, info: "To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///All point mutants examined, that\
        \ is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///Notably, the human MC4R mutation L106P\
        \ generated a robust cAMP response to THIQ, with an EC50 of 24.2 nM, similar\
        \ to that of a-MSH at wild-type MC4R (EC50 = 30.3 nM).///Notably, the human\
        \ MC4R mutation L106P generated a robust cAMP response to THIQ, with an EC50\
        \ of 24.2 nM, similar to that of a-MSH at wild-type MC4R (EC50 = 30.3 nM).///These\
        \ experiments identified two RASSLs, L106P-MC4R and D122A-MC4R, which we designated\
        \ RASSL MC4R 1 (Rm1) and RASSL MC4R 2 (Rm2), respectively.///These experiments\
        \ identified two RASSLs, L106P-MC4R and D122A-MC4R, which we designated RASSL\
        \ MC4R 1 (Rm1) and RASSL MC4R 2 (Rm2), respectively.///PLoS ONE", pubmed: '17668051',
    seq: '106', to_res: P}
- {entry_name: mc4r_human, from_res: C, info: PLoS ONE, pubmed: '17668051', seq: '271',
    to_res: Y}
- {entry_name: mc4r_human, from_res: E, info: "All these mutations reduce the ability\
        \ of the receptor to respond to a-MSH (data not shown and [26,32\u201334].\
        \ In addition, structure-functions studies of MC4R have delineated the role\
        \ of three key acidic residues (E100A, D122A and D126A) in transmembrane regions\
        \ 2 and 3 (TM2 and 3) that are critical for a-MSH binding and activation [28,29]\
        \ (Fig. 1).///All these mutations reduce the ability of the receptor to respond\
        \ to a-MSH (data not shown and [26,32\u201334]. In addition, structure-functions\
        \ studies of MC4R have delineated the role of three key acidic residues (E100A,\
        \ D122A and D126A) in transmembrane regions 2 and 3 (TM2 and 3) that are critical\
        \ for a-MSH binding and activation [28,29] (Fig. 1).///To identify a receptor\
        \ that was not activated by a-MSH, but still activated by a synthetic ligand,\
        \ with minimal loss of membrane expression, we focused on five mutations (N97D,\
        \ G98R, I102S, L106P and S127L) in extracellular loop 1 (EL1) and three in\
        \ its flanking TM regions (E100A, D122A and D126A).///To identify a receptor\
        \ that was not activated by a-MSH, but still activated by a synthetic ligand,\
        \ with minimal loss of membrane expression, we focused on five mutations (N97D,\
        \ G98R, I102S, L106P and S127L) in extracellular loop 1 (EL1) and three in\
        \ its flanking TM regions (E100A, D122A and D126A).///All point mutants examined,\
        \ that is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///The Emax of all mutated receptors was\
        \ ,5% to 40% of wild-type (Table 1); the EC50s of N97D, G98R, E100A, I102S,\
        \ and L106P could not be determined.///PLoS ONE", pubmed: '17668051', seq: '100',
    to_res: A}
- {entry_name: mc4r_human, from_res: S, info: "To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///To identify a receptor that was not\
        \ activated by a-MSH, but still activated by a synthetic ligand, with minimal\
        \ loss of membrane expression, we focused on five mutations (N97D, G98R, I102S,\
        \ L106P and S127L) in extracellular loop 1 (EL1) and three in its flanking\
        \ TM regions (E100A, D122A and D126A).///All point mutants examined, that\
        \ is, N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///All point mutants examined, that is,\
        \ N97D, G98R, E100A, I102S, L106P, D122A, D126A and S127L were relatively\
        \ well-expressed at the cell surface (i.e., 70\u2013120% of that seen with\
        \ the wild-type receptor) (Fig. 2).///With the exception of the S127L mutant,\
        \ a-MSH was unable to internalize the mutant receptors, suggesting that the\
        \ ligand fails to fully activate receptor signaling and initiate desensitization\
        \ and internalization.///With the exception of the S127L mutant, a-MSH was\
        \ unable to internalize the mutant receptors, suggesting that the ligand fails\
        \ to fully activate receptor signaling and initiate desensitization and internalization.///The\
        \ EC50s for D122A, D126A, and S127L were in the mM range, well above the physiological\
        \ range of a-MSH in vivo (Table 1).///The EC50s for D122A, D126A, and S127L\
        \ were in the mM range, well above the physiological range of a-MSH in vivo\
        \ (Table 1).///PLoS ONE", pubmed: '17668051', seq: '127', to_res: L}
- {entry_name: adrb2_human, from_res: I, info: "Trp 6.48 is highly conserved in Family\
        \ A GPCRs, and it has been proposed that its rotameric state has a role in\
        \ GPCR activation (rotamer a b \u03B22AR\u2013Cz \u03B22AR\u2013Nb80 TM5 1\
        \ Ser 203 Pro 211 Ser 207 2.1 \xC5 Ile 121 Pro 211 Phe 282 Asn 318 Trp 286\
        \ 3 2 Figure 4", pubmed: '21228869', seq: '121', to_res: P}
- {entry_name: adrb2_human, from_res: I, info: 'Thus, the energetics of activation
        and conformational c TM3 Carazolol TM5 TM7 TM3 BI-167107 TM7 Ile 121 5 4 Ile
        121 Asn 318 Pro 211 Phe 282 Asn 318 Phe 282 TM6 TM6 between Pro 211 in TM5,
        Ile 121 in TM3, Phe 282 in TM6 and Asn 318 in TM7.', pubmed: '21228869', seq: '121',
    to_res: N}
- {entry_name: adrb2_human, from_res: N, info: 'Thus, the energetics of activation
        and conformational c TM3 Carazolol TM5 TM7 TM3 BI-167107 TM7 Ile 121 5 4 Ile
        121 Asn 318 Pro 211 Phe 282 Asn 318 Phe 282 TM6 TM6 between Pro 211 in TM5,
        Ile 121 in TM3, Phe 282 in TM6 and Asn 318 in TM7.', pubmed: '21228869', seq: '318',
    to_res: F}
- {entry_name: adrb2_human, from_res: P, info: 'Thus, the energetics of activation
        and conformational c TM3 Carazolol TM5 TM7 TM3 BI-167107 TM7 Ile 121 5 4 Ile
        121 Asn 318 Pro 211 Phe 282 Asn 318 Phe 282 TM6 TM6 between Pro 211 in TM5,
        Ile 121 in TM3, Phe 282 in TM6 and Asn 318 in TM7.', pubmed: '21228869', seq: '211',
    to_res: F}
- {entry_name: 5ht2a_bovin, from_res: Y, info: '3 H NMS binding Bmax pmol/mg Carbachol
        binding (Ki) Relative basal activity PI assays Emax % EC50 nM Receptor KD
        pM M WT D113N D113N/R165M D113N/R165W D113N/Y250D R165M R165W Y250D D113N/R165A
        D113N/R165Q D113N/R165L D113N/R165E R165A R165Q R165L R165E Y250A D113N/Y250A
        I253Y/Y254I (EX)c EX/R165W EX/R165M R165E/Y250D 59.8 64.3 49.7 50.9 36.9 74.8
        75.9 50.3 57.6 61.5 58.2 52.3 62.8 64.7 44.1 75.8 49.4 48.2 59.9 14.6 77.9
        77.5 6.0 4.8 3.1 3.1 3.5 8.1 2.4 1.5 6.4 4.6 1.5 8.7 4.8 4.6 3.4 7.2 4.7 3.7
        6.3 6.8 9.2 8.5 5.74 3.57 4.65 2.17 2.55 6.85 1.70 2.86 3.54 4.44 4.50 2.66
        3.36 5.36 8.39 7.87 3.67 3.38 1.84 0.085 0.54 1.63 0.22 0.20 0.50 0.20 0.17
        0.18 0.08 0.17 0.34 0.24 0.36 0.17 0.17 0.24 0.10 0.13 0.24 0.22 0.11 0.003
        0.05 0.09 8.83 0.11 1.07 0.10 0.20 0.01 0.037 0.006 0.35 0.03 2.63 0.06 0.87
        0.09 4.43 0.30 0.65 0.04 1.73 0.14 0.73 0.15 0.37 0.04 13.99 2.87 12.39 2.79
        12.19 3.65 32.83 5.10 12.66 1.20 0.82 0.08 8.38 0.10 NSd 9.35 0.18 5.43 0.56
        1.0 0.7 0.1 6.2 0.4 1.2 0.2 1.0 0.1 0.7 0.1 0.7 0.1 0.9 0.2 1.2 0.1 0.8 0.1
        0.7 0.1 0.7 0.1 0.8 0.1 0.8 0.1 1.0 0.2 1.0 0.2 0.7 0.1 0.6 0.1 0.7 0.1 0.8
        0.1 0.6 0.1 0.9 0.1 100 11.9 1.6 118 20 88.2 5.1 50.9 10.1 72.6 8.1 27.2 6.4
        63.6 14.2 65.4 4.2 42.1 1.1 20.2 2.8 13.7 2.1 66.6 3.2 41.5 2.1 14.1 3.5 27.0
        10.4 93.5 1.2 _b _ _ _ 9.2 0.7 93.1 2.8 NDa 72.6 6.1 227 24 133 52 2,629 573
        1,739 182 175 7 485 36 658 33 627 16.1 ND 5,769 76 19,651 3,422 ND ND 184
        8 Downloaded from www.jbc.org at Radboud Universiteit Nijmegen on June 29,
        2009 ND a b c ND, not determinable with sufficient accuracy.///3 H NMS binding
        Bmax pmol/mg Carbachol binding (Ki) Relative basal activity PI assays Emax
        % EC50 nM Receptor KD pM M WT D113N D113N/R165M D113N/R165W D113N/Y250D R165M
        R165W Y250D D113N/R165A D113N/R165Q D113N/R165L D113N/R165E R165A R165Q R165L
        R165E Y250A D113N/Y250A I253Y/Y254I (EX)c EX/R165W EX/R165M R165E/Y250D 59.8
        64.3 49.7 50.9 36.9 74.8 75.9 50.3 57.6 61.5 58.2 52.3 62.8 64.7 44.1 75.8
        49.4 48.2 59.9 14.6 77.9 77.5 6.0 4.8 3.1 3.1 3.5 8.1 2.4 1.5 6.4 4.6 1.5
        8.7 4.8 4.6 3.4 7.2 4.7 3.7 6.3 6.8 9.2 8.5 5.74 3.57 4.65 2.17 2.55 6.85
        1.70 2.86 3.54 4.44 4.50 2.66 3.36 5.36 8.39 7.87 3.67 3.38 1.84 0.085 0.54
        1.63 0.22 0.20 0.50 0.20 0.17 0.18 0.08 0.17 0.34 0.24 0.36 0.17 0.17 0.24
        0.10 0.13 0.24 0.22 0.11 0.003 0.05 0.09 8.83 0.11 1.07 0.10 0.20 0.01 0.037
        0.006 0.35 0.03 2.63 0.06 0.87 0.09 4.43 0.30 0.65 0.04 1.73 0.14 0.73 0.15
        0.37 0.04 13.99 2.87 12.39 2.79 12.19 3.65 32.83 5.10 12.66 1.20 0.82 0.08
        8.38 0.10 NSd 9.35 0.18 5.43 0.56 1.0 0.7 0.1 6.2 0.4 1.2 0.2 1.0 0.1 0.7
        0.1 0.7 0.1 0.9 0.2 1.2 0.1 0.8 0.1 0.7 0.1 0.7 0.1 0.8 0.1 0.8 0.1 1.0 0.2
        1.0 0.2 0.7 0.1 0.6 0.1 0.7 0.1 0.8 0.1 0.6 0.1 0.9 0.1 100 11.9 1.6 118 20
        88.2 5.1 50.9 10.1 72.6 8.1 27.2 6.4 63.6 14.2 65.4 4.2 42.1 1.1 20.2 2.8
        13.7 2.1 66.6 3.2 41.5 2.1 14.1 3.5 27.0 10.4 93.5 1.2 _b _ _ _ 9.2 0.7 93.1
        2.8 NDa 72.6 6.1 227 24 133 52 2,629 573 1,739 182 175 7 485 36 658 33 627
        16.1 ND 5,769 76 19,651 3,422 ND ND 184 8 Downloaded from www.jbc.org at Radboud
        Universiteit Nijmegen on June 29, 2009 ND a b c ND, not determinable with
        sufficient accuracy.///Allele Specificity of the Y250D, R165M, and R165W Secondsite
        Suppressor Mutations-We reported previously (55) that a mutant M3 receptor
        in which the positions of Ile-253 and Tyr254 had been exchanged (referred
        to as I253Y/Y254I or simply as EX) was unable to activate G proteins, similar
        to the D113N receptor.///Allele Specificity of the Y250D, R165M, and R165W
        Secondsite Suppressor Mutations-We reported previously (55) that a mutant
        M3 receptor in which the positions of Ile-253 and Tyr254 had been exchanged
        (referred to as I253Y/Y254I or simply as EX) was unable to activate G proteins,
        similar to the D113N receptor.///In the I253Y/Y254I mutant M3 receptor (abbreviated
        as EX), the positions of Ile-253 and Tyr-254 were exchanged (55).///In the
        I253Y/Y254I mutant M3 receptor (abbreviated as EX), the positions of Ile-253
        and Tyr-254 were exchanged (55).///For example, we demonstrated that the R165M
        substitution was unable to restore function to a mutant receptor containing
        an inactivating mutation at the cytoplasmic end of TM V (I253Y/Y254I EX; Fig.
        9).///For example, we demonstrated that the R165M substitution was unable
        to restore function to a mutant receptor containing an inactivating mutation
        at the cytoplasmic end of TM V (I253Y/Y254I EX; Fig. 9).', pubmed: '15572356',
    seq: '254', to_res: I}
- {entry_name: opsd_bovin, from_res: T, info: "We then selected 5668 Mutational Analysis\
        \ of the M3 Muscarinic Receptor in Yeast TABLE II Summary of second-site mutations\
        \ recovered in a yeast genetic screen which restore function to the D113N\
        \ mutant M3 muscarinic receptor Amino acid substitution in M3 receptora No.\
        \ of clones isolated Positionb Y250D Y250D/T229S R165M R165M/T261A R165W R165W/I483F\
        \ R165W/T181A R165W/V197F 1 1 1 1 12 1 1 1 5.58 3.50 3.50 a All mutations\
        \ were introduced into a modified version of the rat M3 muscarinic receptor\
        \ (\u2018WT\u2019-M3) lacking the central portion of the i3 loop (Ala-274\
        \ to Lys-469) (14).///We then selected 5668 Mutational Analysis of the M3\
        \ Muscarinic Receptor in Yeast TABLE II Summary of second-site mutations recovered\
        \ in a yeast genetic screen which restore function to the D113N mutant M3\
        \ muscarinic receptor Amino acid substitution in M3 receptora No. of clones\
        \ isolated Positionb Y250D Y250D/T229S R165M R165M/T261A R165W R165W/I483F\
        \ R165W/T181A R165W/V197F 1 1 1 1 12 1 1 1 5.58 3.50 3.50 a All mutations\
        \ were introduced into a modified version of the rat M3 muscarinic receptor\
        \ (\u2018WT\u2019-M3) lacking the central portion of the i3 loop (Ala-274\
        \ to Lys-469) (14).", pubmed: '15572356', seq: '229', to_res: S}
- {entry_name: acthr_human, from_res: G, info: "Figure 4b demonstrates interaction\
        \ with MRAP\u03B1 for L55P, I130N, R137W and G226R.///CHO cells were transfected\
        \ with Wt-MC2R, L55P, I130N, R137W and G226R mutants and MRAP\u03B1-Flag (4B).",
    pubmed: '18840636', seq: '226', to_res: R}
- {entry_name: acthr_human, from_res: R, info: "Figure 4b demonstrates interaction\
        \ with MRAP\u03B1 for L55P, I130N, R137W and G226R.///Previous functional\
        \ studies performed for a variety of mutations such as G116V (26), R137W (27),\
        \ R146H (6;10), T159K (10), C251F (19) and Y254C (27) all found that there\
        \ was impaired receptor signaling when stimulated with ACTH and low affinity\
        \ for ACTH binding.///CHO cells were transfected with Wt-MC2R, L55P, I130N,\
        \ R137W and G226R mutants and MRAP\u03B1-Flag (4B).", pubmed: '18840636',
    seq: '137', to_res: W}
- {entry_name: acthr_human, from_res: T, info: 'The trafficking-defective mutants
        such as R146H, T159K and Y254C (Figure 2D, E and F) exhibit marked intracellular
        retention consistent with the results from the cell surface assay.///These
        mutants demonstrate ER retention, an example shown with T159K which co-localises
        with calnexin (Figure 2J, K and L).///Previous functional studies performed
        for a variety of mutations such as G116V (26), R137W (27), R146H (6;10), T159K
        (10), C251F (19) and Y254C (27) all found that there was impaired receptor
        signaling when stimulated with ACTH and low affinity for ACTH binding.///D:
        R146H; E: T159K and F: Y254C fail to reach the plasma membrane and are retained
        intracellularly.///J, K and L: MC2R harbouring mutation T159K (red) co-localise
        with ER marker, calnexin (green).', pubmed: '18840636', seq: '159', to_res: K}
- {entry_name: acthr_human, from_res: I, info: "Similarly D103N and R128C showed substantial\
        \ plasma membrane expression, as did the other mutants which reached the cell\
        \ surface, (D20N, I44M, D107N and H170L-data not shown).///Furthermore, both\
        \ D20N and I44M demonstrated similar function when compared with Wt-HA-MC2R\
        \ (Figure 5).///Both D20N and I44M were found to have efficient cell surface\
        \ expression and cell signaling.///I44M was described in a Finnish girl by\
        \ Weber et al (6), as a compound heterozygous mutation in combination with\
        \ L192fs.///It is not clear how the I44M mutation alters receptor function,\
        \ if at all, as this isoleucine in the first transmembrane domain is not a\
        \ conserved residue and is substituted by the relatively hydrophobic methionine\
        \ in the bovine ACTH receptor.///A further possibility is that both D20N and\
        \ I44M are in linkage disequilibrium with a more functionally significant\
        \ mutation elsewhere in the gene and outside the coding region such as the\
        \ previously reported \u22122 substitution in the MC2R promoter initiator\
        \ element (24;25).", pubmed: '18840636', seq: '44', to_res: M}
- {entry_name: acthr_human, from_res: Y, info: 'The trafficking-defective mutants
        such as R146H, T159K and Y254C (Figure 2D, E and F) exhibit marked intracellular
        retention consistent with the results from the cell surface assay.///Previous
        functional studies performed for a variety of mutations such as G116V (26),
        R137W (27), R146H (6;10), T159K (10), C251F (19) and Y254C (27) all found
        that there was impaired receptor signaling when stimulated with ACTH and low
        affinity for ACTH binding.///D: R146H; E: T159K and F: Y254C fail to reach
        the plasma membrane and are retained intracellularly.', pubmed: '18840636',
    seq: '254', to_res: C}
- {entry_name: tshr_human, from_res: L, info: "Out of 13 double mutants constructed\
        \ and tested for their thermostability, the L48A-Q89A mutant had the highest\
        \ thermostability, which was only slightly lower than the Tm predicted by\
        \ adding the \u0394Tm for Q89A to the Tm for L89A.", pubmed: '21501622', seq: '89',
    to_res: A}
- {entry_name: aa2ar_human, from_res: Q, info: "The second category contained mutants\
        \ S47A, F83A and Q89A, which stabilised the NECA-bound conformation and destabilised\
        \ the ZM241385-bound conformation.///Five of the double mutants did not increase\
        \ 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265\
        \ 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283\
        \ 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301\
        \ 302 303 304 Apparent Tm (\xB0C) t1:4 t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10\
        \ t1:11 t1:12 t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20 t1:21 t1:22\
        \ A2AR mutation WT V12A S47A L48A A50L A54L V57A F62A T65A F79A F83A Q89A\
        \ S90A A236L I238A F242A V282A Ballesteros\u2013 Weinstein - 1.38 2.45 2.46\
        \ 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38 6.38 6.40 6.44 7.47 Agonist\
        \ [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31 33 31 30 34.5 32 31 31 31 30.5\
        \ \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5 + 4.5 + 2.5 + 1.5 +6 + 3.5 +\
        \ 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385 32 n.d.a 25.5 0b 38.5 38 38\
        \ 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d. \u2212 6.5 n.d.///One mutant\
        \ showed an additive effect for the third mutation, L48A-Q89A-T65A (A2AR-GL23),\
        \ which had an apparent Tm of 49.9 \xB1 0.1 \xB0C (Fig. 2).///All of the remaining\
        \ double mutants showed higher thermostabilities compared to GL0, with the\
        \ best combination being L48A-Q89A (A2ARGL10) with an apparent Tm of 46.7\
        \ \xB1 0.4 \xB0C (Fig. 2).///The stabilities of the best thermostable mutants\
        \ containing one, two or three point mutations are labelled, respectively,\
        \ as follows: L48A (GL0), green diamond; L48A-Q89A (GL10), dark-blue diamond;\
        \ and L48A-Q89AT65A (GL23), red diamond.///Combinations of mutants tested\
        \ for thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5\
        \ t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18\
        \ t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30\
        \ t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double\
        \ mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15\
        \ GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations\
        \ - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A\
        \ L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A\
        \ L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted -\
        \ 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5\
        \ Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5\
        \ 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa\
        \ 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5\
        \ \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n =\
        \ 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26\
        \ GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Therefore,\
        \ the predicted Nglycosylation site Asn154 was mutated to Ala to make A2AR-GL31\
        \ (L48A-Q89A-T65A-A54L-N154A).///Out of 13 double mutants constructed and\
        \ tested for their thermostability, the L48A-Q89A mutant had the highest thermostability,\
        \ which was only slightly lower than the Tm predicted by adding the \u0394\
        Tm for Q89A to the Tm for L89A.///Out of 13 double mutants constructed and\
        \ tested for their thermostability, the L48A-Q89A mutant had the highest thermostability,\
        \ which was only slightly lower than the Tm predicted by adding the \u0394\
        Tm for Q89A to the Tm for L89A.///In a similar fashion, T65A was found to\
        \ further thermostabilise the receptor to make the triple mutant GL23 (L48A-Q89A-T65A)\
        \ with an apparent Tm of 50 \xB0C in DDM.///It is therefore likely that the\
        \ introduction of the four thermostabilising mutations L48A, T65A, Q89A and\
        \ A54L has induced a conformational change in the receptor, and the binding\
        \ data support the view that the mutant is in an agonist-binding conformation\
        \ between R and R\u204E.///34 The Q89A mutation was previously reported to\
        \ increase the affinity of agonists and decrease the affinity for antagonists,\
        \ perhaps through an indirect effect on (a) 140 120 [3H] NECA bound (%) 100\
        \ 80 60 40 20 0 -12 -11 -10 -9 -8 -7 -6 -5 -4 Log[ZM241385] (M) Fig. 5.///The\
        \ four amino acid residues mutated in A2AR to generate the thermostable mutant\
        \ GL26 (L48A, Q89A, T65A and A54L) are depicted as space-filling models (dark\
        \ grey).", pubmed: '21501622', seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///As previously mentioned, mutating residues close to each\
        \ other often does not have an additive effect; thus, the S90A mutation was\
        \ not tested, and in addition, GL10 containing the mutation F83A could not\
        \ be made.///Combinations of mutants tested for thermostabilising the NECA-bound\
        \ conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12\
        \ t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24\
        \ t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple\
        \ mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1 GL4 GL5\
        \ GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent\
        \ Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A\
        \ L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A\
        \ L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A\
        \ L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45\
        \ 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45\
        \ 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0\
        C) Predicted Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3\
        \ (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2\
        \ (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1\
        \ 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L\
        \ L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values\
        \ were determined initially from a single thermostability curve, with measurements\
        \ performed in triplicate, to find the most thermostable mutants; replicate\
        \ experiments were performed only for key mutants.", pubmed: '21501622', seq: '90',
    to_res: A}
- {entry_name: aa2ar_human, from_res: V, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///Combinations of mutants tested for thermostabilising the\
        \ NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '57', to_res: A}
- {entry_name: aa2ar_human, from_res: N, info: 'Therefore, the predicted Nglycosylation
        site Asn154 was mutated to Ala to make A2AR-GL31 (L48A-Q89A-T65A-A54L-N154A).///Therefore,
        the predicted Nglycosylation site Asn154 was mutated to Ala to make A2AR-GL31
        (L48A-Q89A-T65A-A54L-N154A).///Initial purification of A2ARGL26 showed that
        the receptor was present as both an unglycosylated and an N-glycosylated product
        (results not shown); thus, the additional mutation N154A was introduced into
        A2AR-GL26 to make the non-glycosylated mutant A2AR-GL31.', pubmed: '21501622',
    seq: '154', to_res: A}
- {entry_name: aa2ar_human, from_res: F, info: "The second category contained mutants\
        \ S47A, F83A and Q89A, which stabilised the NECA-bound conformation and destabilised\
        \ the ZM241385-bound conformation.///Five of the double mutants did not increase\
        \ 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265\
        \ 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283\
        \ 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301\
        \ 302 303 304 Apparent Tm (\xB0C) t1:4 t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10\
        \ t1:11 t1:12 t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20 t1:21 t1:22\
        \ A2AR mutation WT V12A S47A L48A A50L A54L V57A F62A T65A F79A F83A Q89A\
        \ S90A A236L I238A F242A V282A Ballesteros\u2013 Weinstein - 1.38 2.45 2.46\
        \ 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38 6.38 6.40 6.44 7.47 Agonist\
        \ [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31 33 31 30 34.5 32 31 31 31 30.5\
        \ \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5 + 4.5 + 2.5 + 1.5 +6 + 3.5 +\
        \ 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385 32 n.d.a 25.5 0b 38.5 38 38\
        \ 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d. \u2212 6.5 n.d.///As previously\
        \ mentioned, mutating residues close to each other often does not have an\
        \ additive effect; thus, the S90A mutation was not tested, and in addition,\
        \ GL10 containing the mutation F83A could not be made.///Combinations of mutants\
        \ tested for thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4\
        \ t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17\
        \ t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29\
        \ t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double\
        \ mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15\
        \ GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations\
        \ - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A\
        \ L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A\
        \ L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted -\
        \ 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5\
        \ Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5\
        \ 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa\
        \ 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5\
        \ \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n =\
        \ 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26\
        \ GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '83', to_res: A}
- {entry_name: aa2ar_human, from_res: L, info: "The L48A mutant provided the greatest\
        \ thermostabilisation of the [3H]NECA-bound A2AR, conferring a 13.6 \xB0C\
        \ improvement in stability (apparent Tm of 42.2 \xB1 0.75 \xB0C; Fig. 2);\
        \ the Ballesteros\u2013Weinstein numbers for all the amino acid residues discussed\
        \ are presented in Table 1.///The first category contained mutants L48A, F62A,\
        \ F79A and F242A, which did not bind [3H]ZM241385 at 4 \xB0C in this experiment,\
        \ suggesting a dramatic loss of affinity (see below for ligand binding experiments),\
        \ and their thermostability with [ 3 H]ZM241385 bound was not determined.///Combining\
        \ mutants to make the optimally thermostable agonist-bound receptor A2AR-GL26\
        \ Given the unusually large increase in thermostability observed for A2AR-L48A,\
        \ it was used as the starting point for the construction of an optimally stable\
        \ agonist-binding receptor for structural studies, and it was renamed GL0.///Therefore,\
        \ 13 of the remaining thermostabilising point mutations were individually\
        \ combined with the L48A mutation (Table 2).///Previous experience of combining\
        \ thermostabilising mutations has shown that mutants close to each other in\
        \ the primary amino acid sequence were often not additive;21,23,24 thus, the\
        \ double mutants of L48A with either S47A or A50L were not made.///Five of\
        \ the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///For final values for WT A2AR and L48A (GL0), please refer\
        \ to Table 2. a Not determined. b No binding detected at antagonist concentration\
        \ used.///One mutant showed an additive effect for the third mutation, L48A-Q89A-T65A\
        \ (A2AR-GL23), which had an apparent Tm of 49.9 \xB1 0.1 \xB0C (Fig. 2).///It\
        \ is interesting to note that all the mutations used to construct GL23 are\
        \ in TM2 and TM3 and that none of the mutations in TM6 were additive with\
        \ L48A (Fig. 1 and Table 2).///Provided that all the assays are performed\
        \ under identical conditions, this can be used 305 306 307 308 309 310 311\
        \ 312 thermostability compared to the L48A single mutant (Fig. 2).///All of\
        \ the remaining double mutants showed higher thermostabilities compared to\
        \ GL0, with the best combination being L48A-Q89A (A2ARGL10) with an apparent\
        \ Tm of 46.7 \xB1 0.4 \xB0C (Fig. 2).///The stabilities of the best thermostable\
        \ mutants containing one, two or three point mutations are labelled, respectively,\
        \ as follows: L48A (GL0), green diamond; L48A-Q89A (GL10), dark-blue diamond;\
        \ and L48A-Q89AT65A (GL23), red diamond.///The stabilities of the best thermostable\
        \ mutants containing one, two or three point mutations are labelled, respectively,\
        \ as follows: L48A (GL0), green diamond; L48A-Q89A (GL10), dark-blue diamond;\
        \ and L48A-Q89AT65A (GL23), red diamond.///The stabilities of the best thermostable\
        \ mutants containing one, two or three point mutations are labelled, respectively,\
        \ as follows: L48A (GL0), green diamond; L48A-Q89A (GL10), dark-blue diamond;\
        \ and L48A-Q89AT65A (GL23), red diamond.///Combinations of mutants tested\
        \ for thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5\
        \ t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18\
        \ t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30\
        \ t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double\
        \ mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15\
        \ GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations\
        \ - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A\
        \ L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A\
        \ L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted -\
        \ 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5\
        \ Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5\
        \ 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa\
        \ 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5\
        \ \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n =\
        \ 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26\
        \ GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///The data show that the major influence\
        \ on the conformation of the ultimate mutant A2AR-GL26 is from the L48A mutation\
        \ in GL0.///Therefore, the predicted Nglycosylation site Asn154 was mutated\
        \ to Ala to make A2AR-GL31 (L48A-Q89A-T65A-A54L-N154A).///The single mutation\
        \ with the greatest thermostabilising effect was L48A, which increased the\
        \ stability of NECA-bound A2AR by 14.5 \xB0C.///The L48A mutant was therefore\
        \ an obvious candidate to start the thermostabilisation of the A2A NECA-bound\
        \ conformation.///The strategy was to make a series of double mutants by adding\
        \ the best thermostabilising mutants to L48A, testing their thermostability,\
        \ Please cite this article as: Lebon, G., et al., Thermostabilisation of an\
        \ Agonist-Bound Conformation of the Human Adenosine A2A Receptor, J.///Out\
        \ of 13 double mutants constructed and tested for their thermostability, the\
        \ L48A-Q89A mutant had the highest thermostability, which was only slightly\
        \ lower than the Tm predicted by adding the \u0394Tm for Q89A to the Tm for\
        \ L89A.///In a similar fashion, T65A was found to further thermostabilise\
        \ the receptor to make the triple mutant GL23 (L48A-Q89A-T65A) with an apparent\
        \ Tm of 50 \xB0C in DDM.///It is therefore likely that the introduction of\
        \ the four thermostabilising mutations L48A, T65A, Q89A and A54L has induced\
        \ a conformational change in the receptor, and the binding data support the\
        \ view that the mutant is in an agonist-binding conformation between R and\
        \ R\u204E.///The single biggest effect on ligand binding was seen for the\
        \ mutation L48A2.46 (superscript refers to the Ballesteros\u2013Weinstein\
        \ numbering system 33 ) with a 2-fold increase in the affinity for the agonist\
        \ NECA and a 50-fold decrease in affinity for the inverse agonist ZM241385.///The\
        \ four amino acid residues mutated in A2AR to generate the thermostable mutant\
        \ GL26 (L48A, Q89A, T65A and A54L) are depicted as space-filling models (dark\
        \ grey).", pubmed: '21501622', seq: '48', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///One mutant showed an additive effect for the third mutation,\
        \ L48A-Q89A-T65A (A2AR-GL23), which had an apparent Tm of 49.9 \xB1 0.1 \xB0\
        C (Fig. 2).///Combinations of mutants tested for thermostabilising the NECA-bound\
        \ conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12\
        \ t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24\
        \ t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple\
        \ mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1 GL4 GL5\
        \ GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent\
        \ Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A\
        \ L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A\
        \ L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A\
        \ L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45\
        \ 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45\
        \ 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0\
        C) Predicted Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3\
        \ (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2\
        \ (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1\
        \ 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L\
        \ L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values\
        \ were determined initially from a single thermostability curve, with measurements\
        \ performed in triplicate, to find the most thermostable mutants; replicate\
        \ experiments were performed only for key mutants.///Combinations of mutants\
        \ tested for thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4\
        \ t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17\
        \ t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29\
        \ t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double\
        \ mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15\
        \ GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations\
        \ - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A\
        \ L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A\
        \ L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted -\
        \ 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5\
        \ Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5\
        \ 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa\
        \ 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5\
        \ \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n =\
        \ 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26\
        \ GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Therefore, the predicted Nglycosylation\
        \ site Asn154 was mutated to Ala to make A2AR-GL31 (L48A-Q89A-T65A-A54L-N154A).///In\
        \ a similar fashion, T65A was found to further thermostabilise the receptor\
        \ to make the triple mutant GL23 (L48A-Q89A-T65A) with an apparent Tm of 50\
        \ \xB0C in DDM.///In a similar fashion, T65A was found to further thermostabilise\
        \ the receptor to make the triple mutant GL23 (L48A-Q89A-T65A) with an apparent\
        \ Tm of 50 \xB0C in DDM.///It is therefore likely that the introduction of\
        \ the four thermostabilising mutations L48A, T65A, Q89A and A54L has induced\
        \ a conformational change in the receptor, and the binding data support the\
        \ view that the mutant is in an agonist-binding conformation between R and\
        \ R\u204E.///In the crystal structure of A2AR bound to ZM241385, both T65A\
        \ and A54L are located in TM2 facing the lipid bilayer; thus, it is unclear\
        \ why these mutations are thermostabilising.///The four amino acid residues\
        \ mutated in A2AR to generate the thermostable mutant GL26 (L48A, Q89A, T65A\
        \ and A54L) are depicted as space-filling models (dark grey).", pubmed: '21501622',
    seq: '65', to_res: A}
- {entry_name: acthr_human, from_res: D, info: "Similarly D103N and R128C showed substantial\
        \ plasma membrane expression, as did the other mutants which reached the cell\
        \ surface, (D20N, I44M, D107N and H170L-data not shown).///However, all other\
        \ mutants (D103N, D107N, R128C and H170L) had significant impairment of cAMP\
        \ generation, as seen by the decreased luciferase activity.///Four out of\
        \ six trafficking-competent mutations, D103N, D107N, R128C and H170L, failed\
        \ to signal despite receptor cell surface expression.///Previous studies found\
        \ that both D103N and D107N fail to bind ACTH (10;19).///CHO\u03B11 cells\
        \ were transiently transfected with A: Wt-HA-MC2R (positive control); B: D103N;\
        \ C: R128C all of which show good cell surface expression.", pubmed: '18840636',
    seq: '103', to_res: N}
- {entry_name: aa2ar_human, from_res: N, info: "The thermostabilized A2AR-GL31 construct\
        \ contains amino acid residues 1\u2013316 of the human A2AR, four thermostabilizing\
        \ point mutations (L48A2.46, A54L2.52, T65A2.63 and Q89A3.37) and the mutation\
        \ N154A to remove a potential N-glycosylation site.///The human A2A construct,\
        \ GL31, contains four thermostabilizing point mutations (L48A2.46, A54L2.52,\
        \ T65A2.63 and Q89A3.37), the mutation N154A to remove the potential N-glycosylation\
        \ site and a truncation at the C terminus after Ala 316 (ref. 32).", pubmed: '21593763',
    seq: '154', to_res: A}
- {entry_name: adrb2_human, from_res: S, info: "This stabilizing effect of Ser2045.43\
        \ - Asn2936.55 H-bond suggests a significant indirect contribution of Ser2045.43\
        \ side chain into agonist binding affinity, and also predicts significant\
        \ impact of the S204A mutation on the basal activity of \u03B22AR.///This\
        \ stabilizing effect of Ser2045.43 - Asn2936.55 H-bond suggests a significant\
        \ indirect contribution of Ser2045.43 side chain into agonist binding affinity,\
        \ and also predicts significant impact of the S204A mutation on the basal\
        \ activity of \u03B22AR.///Indeed, experimental results in ref.(Ambrosio and\
        \ others 2000) provide some initial evidence in support of this effect by\
        \ demonstrating decrease in \u03B22AR basal activity by as much as 50%-60%\
        \ upon the S204A/S207A double mutation.///Indeed, experimental results in\
        \ ref.(Ambrosio and others 2000) provide some initial evidence in support\
        \ of this effect by demonstrating decrease in \u03B22AR basal activity by\
        \ as much as 50%-60% upon the S204A/S207A double mutation.", pubmed: '19353579',
    seq: '204', to_res: A}
- {entry_name: adrb2_human, from_res: Y, info: "The described model also provides\
        \ a reasonable explanation of TA-2005 selectivity to \u03B22AR, predicting\
        \ approximately 1 pKd affinity drop for Y308F and Y308A mutations, as shown\
        \ in Table 2 (Kikkawa and others 1998).///The described model also provides\
        \ a reasonable explanation of TA-2005 selectivity to \u03B22AR, predicting\
        \ approximately 1 pKd affinity drop for Y308F and Y308A mutations, as shown\
        \ in Table 2 (Kikkawa and others 1998).", pubmed: '19353579', seq: '308',
    to_res: A}
- {entry_name: adrb2_human, from_res: N, info: "At the same time, biochemical data\
        \ from ref (Suryanarayana and Kobilka 1993), support involvement of Asn3127.39\
        \ side chain in \u03B22AR H-bonding to both agonists and antagonists, because\
        \ N312A mutation was found to be responsible for a \u223C100-fold (\u223C\
        2pKd) reduction of the binding affinity for both types of ligands.///At the\
        \ same time, biochemical data from ref (Suryanarayana and Kobilka 1993), support\
        \ involvement of Asn3127.39 side chain in \u03B22AR H-bonding to both agonists\
        \ and antagonists, because N312A mutation was found to be responsible for\
        \ a \u223C100-fold (\u223C2pKd) reduction of the binding affinity for both\
        \ types of ligands.", pubmed: '19353579', seq: '312', to_res: A}
- {entry_name: adrb2_human, from_res: Y, info: "The described model also provides\
        \ a reasonable explanation of TA-2005 selectivity to \u03B22AR, predicting\
        \ approximately 1 pKd affinity drop for Y308F and Y308A mutations, as shown\
        \ in Table 2 (Kikkawa and others 1998).///The described model also provides\
        \ a reasonable explanation of TA-2005 selectivity to \u03B22AR, predicting\
        \ approximately 1 pKd affinity drop for Y308F and Y308A mutations, as shown\
        \ in Table 2 (Kikkawa and others 1998).", pubmed: '19353579', seq: '308',
    to_res: F}
- {entry_name: adrb2_human, from_res: Y, info: 'TMs 6 and 7 and residues Phe 289,
        Asn 293 and Tyr 308 Ser 2035.42 and Ser 2075.46 on TM5 (Fig. 2a).', pubmed: '21228876',
    seq: '308', to_res: S}
- {entry_name: adrb2_human, from_res: I, info: 2 3 8, pubmed: '21228876', seq: '121',
    to_res: P}
- {entry_name: adrb2_human, from_res: P, info: 2 3 8, pubmed: '21228876', seq: '211',
    to_res: I}
- {entry_name: adrb2_human, from_res: I, info: 2 3 8, pubmed: '21228876', seq: '121',
    to_res: F}
- {entry_name: adrb2_human, from_res: P, info: 2 3 8, pubmed: '21228876', seq: '211',
    to_res: F}
- {entry_name: cnr1_human, from_res: F, info: Other amino acid substitutions at this
        position (F268N/Y/W) revealed that highly hydrophobic residues are required
        to accomplish both functions.///Other amino acid substitutions at this position
        (F268N/Y/W) revealed that highly hydrophobic residues are required to accomplish
        both functions., pubmed: '21365223', seq: '289', to_res: N}
- {entry_name: aa2br_human, from_res: T, info: "Mutants N36S/T42A, N36S/T42A/T66A,\
        \ and T42A/V54A showed intermediate levels of agonist-independent growth.///Mutants\
        \ N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate levels of agonist-independent\
        \ growth.///Mutants N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate\
        \ levels of agonist-independent growth.///Mutants N36S/T42A, N36S/T42A/T66A,\
        \ and T42A/V54A showed intermediate levels of agonist-independent growth.///Mutants\
        \ N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate levels of agonist-independent\
        \ growth.///Mutants N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate\
        \ levels of agonist-independent growth.///Finally, the three point mutants\
        \ T42A, F84L, and F84S and the double mutant F84L/S95G exhibited relatively\
        \ low levels of constitutive activity (Table 1).///Finally, the three point\
        \ mutants T42A, F84L, and F84S and the double mutant F84L/S95G exhibited relatively\
        \ low levels of constitutive activity (Table 1).///WT/Mutant Constitutive\
        \ Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A\
        \ A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The basal growth of yeast cells expressing T42A, F84L,\
        \ F84S, or F84L/S95G mutant receptors was dose dependently reduced by ZM241385,\
        \ DPCPX, and MRS1706 from 91 to 99%.///The basal growth of yeast cells expressing\
        \ T42A, F84L, F84S, or F84L/S95G mutant receptors was dose dependently reduced\
        \ by ZM241385, DPCPX, and MRS1706 from 91 to 99%.///The mutants with intermediate\
        \ levels of constitutive activity, N36S/T42A, N36S/T42A/T66A, and T42A/V54A\
        \ were inhibited by all three inverse agonists albeit with lower intrinsic\
        \ activities, ranging from 28 to 79%.///The mutants with intermediate levels\
        \ of constitutive activity, N36S/T42A, N36S/T42A/T66A, and T42A/V54A were\
        \ inhibited by all three inverse agonists albeit with lower intrinsic activities,\
        \ ranging from 28 to 79%.///The mutants with intermediate levels of constitutive\
        \ activity, N36S/T42A, N36S/T42A/T66A, and T42A/V54A were inhibited by all\
        \ three inverse agonists albeit with lower intrinsic activities, ranging from\
        \ 28 to 79%.///The mutants with intermediate levels of constitutive activity,\
        \ N36S/T42A, N36S/T42A/T66A, and T42A/V54A were inhibited by all three inverse\
        \ agonists albeit with lower intrinsic activities, ranging from 28 to 79%.///The\
        \ mutants with intermediate levels of constitutive activity, N36S/T42A, N36S/T42A/T66A,\
        \ and T42A/V54A were inhibited by all three inverse agonists albeit with lower\
        \ intrinsic activities, ranging from 28 to 79%.///The mutants with intermediate\
        \ levels of constitutive activity, N36S/T42A, N36S/T42A/T66A, and T42A/V54A\
        \ were inhibited by all three inverse agonists albeit with lower intrinsic\
        \ activities, ranging from 28 to 79%.///Like the point mutants F84L and F84S,\
        \ the T42A mutant exhibited relatively low constitutive activity that was\
        \ completely inhibited by all three inverse agonists.///Like the point mutants\
        \ F84L and F84S, the T42A mutant exhibited relatively low constitutive activity\
        \ that was completely inhibited by all three inverse agonists.///Comparison\
        \ of the T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants\
        \ showed that the IC50 values of the three inverse agonists were at most 3-fold\
        \ altered when an additional V54A or N36S mutation was present.///Comparison\
        \ of the T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants\
        \ showed that the IC50 values of the three inverse agonists were at most 3-fold\
        \ altered when an additional V54A or N36S mutation was present.///Comparison\
        \ of the T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants\
        \ showed that the IC50 values of the three inverse agonists were at most 3-fold\
        \ altered when an additional V54A or N36S mutation was present.///Comparison\
        \ of the T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants\
        \ showed that the IC50 values of the three inverse agonists were at most 3-fold\
        \ altered when an additional V54A or N36S mutation was present.///Comparison\
        \ of the T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants\
        \ showed that the IC50 values of the three inverse agonists were at most 3-fold\
        \ altered when an additional V54A or N36S mutation was present.///Comparison\
        \ of the T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants\
        \ showed that the IC50 values of the three inverse agonists were at most 3-fold\
        \ altered when an additional V54A or N36S mutation was present.///However,\
        \ whereas the constitutive activity of the T42A mutant could be completely\
        \ inhibited by all three inverse agonists, an additional V54A or N36S mutation\
        \ resulted in a higher level of constitutive activity and could be only partially\
        \ inhibited.///However, whereas the constitutive activity of the T42A mutant\
        \ could be completely inhibited by all three inverse agonists, an additional\
        \ V54A or N36S mutation resulted in a higher level of constitutive activity\
        \ and could be only partially inhibited.///Whereas the N36S mutation did not\
        \ cause significant changes with respect to the potency of the three compounds,\
        \ an additional T66A mutation along with the T42A/N36S double mutation increased\
        \ the IC50 values of ZM241385 and DPCPX from 187 to 522 nM and from 1.44 to\
        \ 6.25 M, respectively.///Whereas the N36S mutation did not cause significant\
        \ changes with respect to the potency of the three compounds, an additional\
        \ T66A mutation along with the T42A/N36S double mutation increased the IC50\
        \ values of ZM241385 and DPCPX from 187 to 522 nM and from 1.44 to 6.25 M,\
        \ respectively.///Due to the small window, the IC50 value of MRS1706 for the\
        \ T42A/N36S/T66A triple mutant could not be determined.///Due to the small\
        \ window, the IC50 value of MRS1706 for the T42A/N36S/T66A triple mutant could\
        \ not be determined.///In addition, the level of constitutive activity of\
        \ this N36S/T42A/T66A triple mutant is increased compared with the N36S/T42A\
        \ double mutant.///In addition, the level of constitutive activity of this\
        \ N36S/T42A/T66A triple mutant is increased compared with the N36S/T42A double\
        \ mutant.///In addition, the level of constitutive activity of this N36S/T42A/T66A\
        \ triple mutant is increased compared with the N36S/T42A double mutant.///In\
        \ addition, the level of constitutive activity of this N36S/T42A/T66A triple\
        \ mutant is increased compared with the N36S/T42A double mutant.///The most\
        \ interesting observation concerning the CAM receptors containing a T42A mutation\
        \ was that the additional mutations not only increased the constitutive activity\
        \ of the receptor but also made the receptor less sensitive toward the inverse\
        \ agonists.///The most interesting observation concerning the CAM receptors\
        \ containing a T42A mutation was that the additional mutations not only increased\
        \ the constitutive activity of the receptor but also made the receptor less\
        \ sensitive toward the inverse agonists.///For example, the IC50 values of\
        \ ZM241385 for the medium-level CAM N36S/T42A and T42A/V54A were approximately\
        \ 2-fold higher than the IC50 values for this compound on the low-level CAM\
        \ receptors.///For example, the IC50 values of ZM241385 for the medium-level\
        \ CAM N36S/T42A and T42A/V54A were approximately 2-fold higher than the IC50\
        \ values for this compound on the low-level CAM receptors.///For example,\
        \ the IC50 values of ZM241385 for the medium-level CAM N36S/T42A and T42A/V54A\
        \ were approximately 2-fold higher than the IC50 values for this compound\
        \ on the low-level CAM receptors.///For example, the IC50 values of ZM241385\
        \ for the medium-level CAM N36S/T42A and T42A/V54A were approximately 2-fold\
        \ higher than the IC50 values for this compound on the low-level CAM receptors.///In\
        \ addition, the IC50 value of ZM241385 increased another 2.5- to 3-fold for\
        \ N36S/ T42A/T66A, which had slightly higher constitutive activity than the\
        \ other two medium-level CAM receptors.///In addition, the IC50 value of ZM241385\
        \ increased another 2.5- to 3-fold for N36S/ T42A/T66A, which had slightly\
        \ higher constitutive activity than the other two medium-level CAM receptors.///ZM241385\
        \ Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102\
        \ 71 210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4\
        \ 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68\
        \ 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102\
        \ 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57\
        \ 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined\
        \ due to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE\
        \ IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A\
        \ T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34\
        \ 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100\
        \ 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92\
        \ 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40\
        \ 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97\
        \ 97 68 77 44 a IC50 value could not be determined due to small experimental\
        \ window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM\
        \ Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A\
        \ 135 107 102 71 210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7\
        \ 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25\
        \ 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11\
        \ 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94\
        \ 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not\
        \ be determined due to small experimental window.///ZM241385 Mutant CA IC50\
        \ nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S\
        \ F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187\
        \ 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100\
        \ 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31\
        \ 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62 43\
        \ 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11\
        \ 16 96 95 97 97 68 77 44 a IC50 value could not be determined due to small\
        \ experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50 M Imax\
        \ % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A\
        \ N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34 86 105 239\
        \ 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91\
        \ 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96\
        \ 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62\
        \ 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77\
        \ 44 a IC50 value could not be determined due to small experimental window.///ZM241385\
        \ Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102\
        \ 71 210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4\
        \ 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68\
        \ 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102\
        \ 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57\
        \ 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined\
        \ due to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE\
        \ IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A\
        \ T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34\
        \ 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100\
        \ 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92\
        \ 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40\
        \ 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97\
        \ 97 68 77 44 a IC50 value could not be determined due to small experimental\
        \ window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM\
        \ Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A\
        \ 135 107 102 71 210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7\
        \ 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25\
        \ 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11\
        \ 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94\
        \ 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not\
        \ be determined due to small experimental window.///However, the potency of\
        \ DPCPX for mutants with increased level of constitutive activity did not\
        \ increase except for N36S/T42A/T66A triple mutant.///However, the potency\
        \ of DPCPX for mutants with increased level of constitutive activity did not\
        \ increase except for N36S/T42A/T66A triple mutant.///The rank order of potencies\
        \ of the inverse agonists showed that with the exception of the T42A/V54A\
        \ double mutant, the IC50 values of DPCPX were 8- to 22-fold higher than the\
        \ values for ZM241385.///The rank order of potencies of the inverse agonists\
        \ showed that with the exception of the T42A/V54A double mutant, the IC50\
        \ values of DPCPX were 8- to 22-fold higher than the values for ZM241385.///The\
        \ fitted L values differentiated into two groups (Table 4): low-level CAM\
        \ receptors have L values around or slightly smaller than 0.2; intermediate-level\
        \ CAM receptors have L values ranging from 1.38 for the T42A/V54A mutant to\
        \ 1.90 for the N36S/T42A/T66A mutant.///The fitted L values differentiated\
        \ into two groups (Table 4): low-level CAM receptors have L values around\
        \ or slightly smaller than 0.2; intermediate-level CAM receptors have L values\
        \ ranging from 1.38 for the T42A/V54A mutant to 1.90 for the N36S/T42A/T66A\
        \ mutant.///The fitted L values differentiated into two groups (Table 4):\
        \ low-level CAM receptors have L values around or slightly smaller than 0.2;\
        \ intermediate-level CAM receptors have L values ranging from 1.38 for the\
        \ T42A/V54A mutant to 1.90 for the N36S/T42A/T66A mutant.///The fitted L values\
        \ differentiated into two groups (Table 4): low-level CAM receptors have L\
        \ values around or slightly smaller than 0.2; intermediate-level CAM receptors\
        \ have L values ranging from 1.38 for the T42A/V54A mutant to 1.90 for the\
        \ N36S/T42A/T66A mutant.///The parameters were L 0.2 (mixed line), 2 (continuous\
        \ line), 20 (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.///The\
        \ parameters were L 0.2 (mixed line), 2 (continuous line), 20 (dotted line),\
        \ and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally determined curves\
        \ from growth assays of mutants F84L (F), N36S/T42A (\u0152), and Q214L/I230N/\
        \ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates containing a range\
        \ of concentrations of the inverse agonist MRS1706.///TABLE 4 Fitted values\
        \ of the L parameter for mutants with low- or mediumlevel constitutive activity\
        \ Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A\
        \ N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10\
        \ 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69\
        \ 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11\
        \ A possibly low constitutive activity of the WT adenosine A2B receptor, however,\
        \ would render discrimination between antagonists and inverse agonists for\
        \ this receptor subtype difficult.///TABLE 4 Fitted values of the L parameter\
        \ for mutants with low- or mediumlevel constitutive activity Mutant ZM241385\
        \ DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A\
        \ 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12\
        \ 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22\
        \ 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low\
        \ constitutive activity of the WT adenosine A2B receptor, however, would render\
        \ discrimination between antagonists and inverse agonists for this receptor\
        \ subtype difficult.///TABLE 4 Fitted values of the L parameter for mutants\
        \ with low- or mediumlevel constitutive activity Mutant ZM241385 DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22\
        \ 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02\
        \ 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38\
        \ 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive\
        \ activity of the WT adenosine A2B receptor, however, would render discrimination\
        \ between antagonists and inverse agonists for this receptor subtype difficult.///TABLE\
        \ 4 Fitted values of the L parameter for mutants with low- or mediumlevel\
        \ constitutive activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G\
        \ T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20\
        \ 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02\
        \ 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02\
        \ 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive activity of the WT\
        \ adenosine A2B receptor, however, would render discrimination between antagonists\
        \ and inverse agonists for this receptor subtype difficult.///TABLE 4 Fitted\
        \ values of the L parameter for mutants with low- or mediumlevel constitutive\
        \ activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A\
        \ N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10\
        \ 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47\
        \ 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08\
        \ 0.08 0.11 A possibly low constitutive activity of the WT adenosine A2B receptor,\
        \ however, would render discrimination between antagonists and inverse agonists\
        \ for this receptor subtype difficult.///TABLE 4 Fitted values of the L parameter\
        \ for mutants with low- or mediumlevel constitutive activity Mutant ZM241385\
        \ DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A\
        \ 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12\
        \ 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22\
        \ 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low\
        \ constitutive activity of the WT adenosine A2B receptor, however, would render\
        \ discrimination between antagonists and inverse agonists for this receptor\
        \ subtype difficult.///TABLE 4 Fitted values of the L parameter for mutants\
        \ with low- or mediumlevel constitutive activity Mutant ZM241385 DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22\
        \ 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02\
        \ 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38\
        \ 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive\
        \ activity of the WT adenosine A2B receptor, however, would render discrimination\
        \ between antagonists and inverse agonists for this receptor subtype difficult.///TABLE\
        \ 4 Fitted values of the L parameter for mutants with low- or mediumlevel\
        \ constitutive activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G\
        \ T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20\
        \ 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02\
        \ 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02\
        \ 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive activity of the WT\
        \ adenosine A2B receptor, however, would render discrimination between antagonists\
        \ and inverse agonists for this receptor subtype difficult.", pubmed: '17077318',
    seq: '42', to_res: A}
- {entry_name: aa2br_human, from_res: V, info: 'Mutants N36S/T42A, N36S/T42A/T66A,
        and T42A/V54A showed intermediate levels of agonist-independent growth.///Mutants
        N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate levels of agonist-independent
        growth.///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S F84L/S95G
        N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///The mutants with intermediate levels of constitutive activity,
        N36S/T42A, N36S/T42A/T66A, and T42A/V54A were inhibited by all three inverse
        agonists albeit with lower intrinsic activities, ranging from 28 to 79%.///The
        mutants with intermediate levels of constitutive activity, N36S/T42A, N36S/T42A/T66A,
        and T42A/V54A were inhibited by all three inverse agonists albeit with lower
        intrinsic activities, ranging from 28 to 79%.///Comparison of the T42A point
        mutant with the T42A/V54A and the N36S/ T42A double mutants showed that the
        IC50 values of the three inverse agonists were at most 3-fold altered when
        an additional V54A or N36S mutation was present.///Comparison of the T42A
        point mutant with the T42A/V54A and the N36S/ T42A double mutants showed that
        the IC50 values of the three inverse agonists were at most 3-fold altered
        when an additional V54A or N36S mutation was present.///Comparison of the
        T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants showed
        that the IC50 values of the three inverse agonists were at most 3-fold altered
        when an additional V54A or N36S mutation was present.///Comparison of the
        T42A point mutant with the T42A/V54A and the N36S/ T42A double mutants showed
        that the IC50 values of the three inverse agonists were at most 3-fold altered
        when an additional V54A or N36S mutation was present.///However, whereas the
        constitutive activity of the T42A mutant could be completely inhibited by
        all three inverse agonists, an additional V54A or N36S mutation resulted in
        a higher level of constitutive activity and could be only partially inhibited.///However,
        whereas the constitutive activity of the T42A mutant could be completely inhibited
        by all three inverse agonists, an additional V54A or N36S mutation resulted
        in a higher level of constitutive activity and could be only partially inhibited.///For
        example, the IC50 values of ZM241385 for the medium-level CAM N36S/T42A and
        T42A/V54A were approximately 2-fold higher than the IC50 values for this compound
        on the low-level CAM receptors.///For example, the IC50 values of ZM241385
        for the medium-level CAM N36S/T42A and T42A/V54A were approximately 2-fold
        higher than the IC50 values for this compound on the low-level CAM receptors.///ZM241385
        Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706
        F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71
        210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100
        100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31
        0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51
        78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6
        8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined due
        to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50
        M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A
        N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34 86 105 239
        95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91 1.43
        1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39
        3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133
        66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value
        could not be determined due to small experimental window.///The rank order
        of potencies of the inverse agonists showed that with the exception of the
        T42A/V54A double mutant, the IC50 values of DPCPX were 8- to 22-fold higher
        than the values for ZM241385.///The rank order of potencies of the inverse
        agonists showed that with the exception of the T42A/V54A double mutant, the
        IC50 values of DPCPX were 8- to 22-fold higher than the values for ZM241385.///The
        fitted L values differentiated into two groups (Table 4): low-level CAM receptors
        have L values around or slightly smaller than 0.2; intermediate-level CAM
        receptors have L values ranging from 1.38 for the T42A/V54A mutant to 1.90
        for the N36S/T42A/T66A mutant.///The fitted L values differentiated into two
        groups (Table 4): low-level CAM receptors have L values around or slightly
        smaller than 0.2; intermediate-level CAM receptors have L values ranging from
        1.38 for the T42A/V54A mutant to 1.90 for the N36S/T42A/T66A mutant.///TABLE
        4 Fitted values of the L parameter for mutants with low- or mediumlevel constitutive
        activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A
        N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10
        1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10
        1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08
        0.11 A possibly low constitutive activity of the WT adenosine A2B receptor,
        however, would render discrimination between antagonists and inverse agonists
        for this receptor subtype difficult.///TABLE 4 Fitted values of the L parameter
        for mutants with low- or mediumlevel constitutive activity Mutant ZM241385
        DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A
        0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12
        0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22
        0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low
        constitutive activity of the WT adenosine A2B receptor, however, would render
        discrimination between antagonists and inverse agonists for this receptor
        subtype difficult.', pubmed: '17077318', seq: '54', to_res: A}
- {entry_name: acthr_human, from_res: C, info: 'Previous functional studies performed
        for a variety of mutations such as G116V (26), R137W (27), R146H (6;10), T159K
        (10), C251F (19) and Y254C (27) all found that there was impaired receptor
        signaling when stimulated with ACTH and low affinity for ACTH binding.', pubmed: '18840636',
    seq: '251', to_res: F}
- {entry_name: agtr1_human, from_res: H, info: 'The experimental supports can be summarized
        as follows: receptor inactivation upon Y292F (15), W253F (5), and H256A mutations
        (5, 16); strong constitutive activation upon Asn111 mutations (6, 17); detailed
        analysis of the induction of intermediary or activated conformations (17,
        18).', pubmed: '11495910', seq: '256', to_res: A}
- {entry_name: aa2br_human, from_res: A, info: 'The upper limit of 0 was set at 0.999
        (which means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///The upper limit of 0 was set at 0.999 (which
        means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///Because the two highly CAM receptors A18T/A23V/C83Y/A106V/
        R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop could not be inhibited
        by any of the compounds tested, the growth of these two mutants in the presence
        and absence of inverse agonist could not be used for curve fitting in Prism.///Because
        the two highly CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        could not be inhibited by any of the compounds tested, the growth of these
        two mutants in the presence and absence of inverse agonist could not be used
        for curve fitting in Prism.///Among them, the highest levels of constitutive
        activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S
        and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop, missing
        the C-terminal and transmembrane helix 7.///Among them, the highest levels
        of constitutive activity were obtained with two multiple mutant receptors,
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/
        N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant
        Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A
        T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated
        mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond to ZM241385,
        DPCPX or MRS1706 at any of the concentrations tested.///The multiple mutant
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/
        T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the
        concentrations tested.///Effect of ZM241385 on the constitutive activity of
        the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/
        I230N/V240M/V250M/N254Y/T257S/K269stop (\u008D) adenosine A2B receptors.///Effect
        of ZM241385 on the constitutive activity of the highly constitutively active
        A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop
        (\u008D) adenosine A2B receptors.', pubmed: '17077318', seq: '18', to_res: T}
- {entry_name: aa2br_human, from_res: R, info: 'The upper limit of 0 was set at 0.999
        (which means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///The upper limit of 0 was set at 0.999 (which
        means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///Because the two highly CAM receptors A18T/A23V/C83Y/A106V/
        R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop could not be inhibited
        by any of the compounds tested, the growth of these two mutants in the presence
        and absence of inverse agonist could not be used for curve fitting in Prism.///Because
        the two highly CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        could not be inhibited by any of the compounds tested, the growth of these
        two mutants in the presence and absence of inverse agonist could not be used
        for curve fitting in Prism.///Among them, the highest levels of constitutive
        activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S
        and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop, missing
        the C-terminal and transmembrane helix 7.///Among them, the highest levels
        of constitutive activity were obtained with two multiple mutant receptors,
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/
        N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant
        Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A
        T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated
        mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond to ZM241385,
        DPCPX or MRS1706 at any of the concentrations tested.///The multiple mutant
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/
        T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the
        concentrations tested.///Effect of ZM241385 on the constitutive activity of
        the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/
        I230N/V240M/V250M/N254Y/T257S/K269stop (\u008D) adenosine A2B receptors.///Effect
        of ZM241385 on the constitutive activity of the highly constitutively active
        A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop
        (\u008D) adenosine A2B receptors.', pubmed: '17077318', seq: '112', to_res: S}
- {entry_name: aa2br_human, from_res: V, info: "The upper limit of 0 was set at 0.999\
        \ (which means 99.9% of receptors are active) for the growth obtained upon\
        \ expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///The upper limit of 0\
        \ was set at 0.999 (which means 99.9% of receptors are active) for the growth\
        \ obtained upon expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///Because the two highly\
        \ CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Because the two highly CAM receptors\
        \ A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Among them, the highest levels of constitutive\
        \ activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop,\
        \ missing the C-terminal and transmembrane helix 7.///Among them, the highest\
        \ levels of constitutive activity were obtained with two multiple mutant receptors,\
        \ A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/\
        \ N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the\
        \ truncated mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond\
        \ to ZM241385, DPCPX or MRS1706 at any of the concentrations tested.///The\
        \ multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/\
        \ T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the\
        \ concentrations tested.///Effect of ZM241385 on the constitutive activity\
        \ of the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/\
        \ I230N/V240M/V250M/N254Y/T257S/K269stop (\\u008D) adenosine A2B receptors.///Effect\
        \ of ZM241385 on the constitutive activity of the highly constitutively active\
        \ A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) adenosine A2B receptors.///The parameters were L 0.2 (mixed line),\
        \ 2 (continuous line), 20 (dotted line), and 200 (dashed line); 0.2; and KA\
        \ 50 nM. b, experimentally determined curves from growth assays of mutants\
        \ F84L (F), N36S/T42A (\u0152), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) on agar plates containing a range of concentrations of the inverse\
        \ agonist MRS1706.///The parameters were L 0.2 (mixed line), 2 (continuous\
        \ line), 20 (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.", pubmed: '17077318',
    seq: '250', to_res: M}
- {entry_name: aa2br_human, from_res: Q, info: "The upper limit of 0 was set at 0.999\
        \ (which means 99.9% of receptors are active) for the growth obtained upon\
        \ expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///The upper limit of 0\
        \ was set at 0.999 (which means 99.9% of receptors are active) for the growth\
        \ obtained upon expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///Because the two highly\
        \ CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Because the two highly CAM receptors\
        \ A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Among them, the highest levels of constitutive\
        \ activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop,\
        \ missing the C-terminal and transmembrane helix 7.///Among them, the highest\
        \ levels of constitutive activity were obtained with two multiple mutant receptors,\
        \ A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/\
        \ N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the\
        \ truncated mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond\
        \ to ZM241385, DPCPX or MRS1706 at any of the concentrations tested.///The\
        \ multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/\
        \ T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the\
        \ concentrations tested.///Effect of ZM241385 on the constitutive activity\
        \ of the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/\
        \ I230N/V240M/V250M/N254Y/T257S/K269stop (\\u008D) adenosine A2B receptors.///Effect\
        \ of ZM241385 on the constitutive activity of the highly constitutively active\
        \ A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) adenosine A2B receptors.///The parameters were L 0.2 (mixed line),\
        \ 2 (continuous line), 20 (dotted line), and 200 (dashed line); 0.2; and KA\
        \ 50 nM. b, experimentally determined curves from growth assays of mutants\
        \ F84L (F), N36S/T42A (\u0152), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) on agar plates containing a range of concentrations of the inverse\
        \ agonist MRS1706.///The parameters were L 0.2 (mixed line), 2 (continuous\
        \ line), 20 (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.", pubmed: '17077318',
    seq: '214', to_res: L}
- {entry_name: aa2br_human, from_res: C, info: 'The upper limit of 0 was set at 0.999
        (which means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///The upper limit of 0 was set at 0.999 (which
        means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///Because the two highly CAM receptors A18T/A23V/C83Y/A106V/
        R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop could not be inhibited
        by any of the compounds tested, the growth of these two mutants in the presence
        and absence of inverse agonist could not be used for curve fitting in Prism.///Because
        the two highly CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        could not be inhibited by any of the compounds tested, the growth of these
        two mutants in the presence and absence of inverse agonist could not be used
        for curve fitting in Prism.///Among them, the highest levels of constitutive
        activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S
        and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop, missing
        the C-terminal and transmembrane helix 7.///Among them, the highest levels
        of constitutive activity were obtained with two multiple mutant receptors,
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/
        N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant
        Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A
        T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated
        mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond to ZM241385,
        DPCPX or MRS1706 at any of the concentrations tested.///The multiple mutant
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/
        T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the
        concentrations tested.///Effect of ZM241385 on the constitutive activity of
        the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/
        I230N/V240M/V250M/N254Y/T257S/K269stop (\u008D) adenosine A2B receptors.///Effect
        of ZM241385 on the constitutive activity of the highly constitutively active
        A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop
        (\u008D) adenosine A2B receptors.', pubmed: '17077318', seq: '83', to_res: Y}
- {entry_name: aa2br_human, from_res: F, info: "Moreover, varying L, the ratio of\
        \ active versus inactive receptors in this model, from 0.11 for mutant F84L\
        \ to 999 for two highly constitutively active mutants yielded simulated dose-response\
        \ curves that mimicked the experimental curves.///Moreover, varying L, the\
        \ ratio of active versus inactive receptors in this model, from 0.11 for mutant\
        \ F84L to 999 for two highly constitutively active mutants yielded simulated\
        \ dose-response curves that mimicked the experimental curves.///Finally, the\
        \ three point mutants T42A, F84L, and F84S and the double mutant F84L/S95G\
        \ exhibited relatively low levels of constitutive activity (Table 1).///Finally,\
        \ the three point mutants T42A, F84L, and F84S and the double mutant F84L/S95G\
        \ exhibited relatively low levels of constitutive activity (Table 1).///Finally,\
        \ the three point mutants T42A, F84L, and F84S and the double mutant F84L/S95G\
        \ exhibited relatively low levels of constitutive activity (Table 1).///Finally,\
        \ the three point mutants T42A, F84L, and F84S and the double mutant F84L/S95G\
        \ exhibited relatively low levels of constitutive activity (Table 1).///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The basal growth of yeast cells expressing T42A, F84L,\
        \ F84S, or F84L/S95G mutant receptors was dose dependently reduced by ZM241385,\
        \ DPCPX, and MRS1706 from 91 to 99%.///The basal growth of yeast cells expressing\
        \ T42A, F84L, F84S, or F84L/S95G mutant receptors was dose dependently reduced\
        \ by ZM241385, DPCPX, and MRS1706 from 91 to 99%.///The basal growth of yeast\
        \ cells expressing T42A, F84L, F84S, or F84L/S95G mutant receptors was dose\
        \ dependently reduced by ZM241385, DPCPX, and MRS1706 from 91 to 99%.///The\
        \ basal growth of yeast cells expressing T42A, F84L, F84S, or F84L/S95G mutant\
        \ receptors was dose dependently reduced by ZM241385, DPCPX, and MRS1706 from\
        \ 91 to 99%.///Point mutants F84L and F84S behaved similar to each other with\
        \ respect to both the potency and relative intrinsic efficacy of the inverse\
        \ agonists, indicating that a mutation from phenylalanine to leucine or serine\
        \ has the same effect.///Point mutants F84L and F84S behaved similar to each\
        \ other with respect to both the potency and relative intrinsic efficacy of\
        \ the inverse agonists, indicating that a mutation from phenylalanine to leucine\
        \ or serine has the same effect.///Like the point mutants F84L and F84S, the\
        \ T42A mutant exhibited relatively low constitutive activity that was completely\
        \ inhibited by all three inverse agonists.///Like the point mutants F84L and\
        \ F84S, the T42A mutant exhibited relatively low constitutive activity that\
        \ was completely inhibited by all three inverse agonists.///ZM241385 Mutant\
        \ CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L\
        \ F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71 210\
        \ 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100\
        \ 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98\
        \ 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78\
        \ 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8\
        \ 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined due\
        \ to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50\
        \ M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A\
        \ N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34 86 105 239\
        \ 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91\
        \ 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96\
        \ 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62\
        \ 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77\
        \ 44 a IC50 value could not be determined due to small experimental window.///ZM241385\
        \ Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102\
        \ 71 210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4\
        \ 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68\
        \ 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102\
        \ 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57\
        \ 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined\
        \ due to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE\
        \ IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A\
        \ T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34\
        \ 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100\
        \ 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92\
        \ 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40\
        \ 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97\
        \ 97 68 77 44 a IC50 value could not be determined due to small experimental\
        \ window.///The parameters were L 0.2 (mixed line), 2 (continuous line), 20\
        \ (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.///The\
        \ parameters were L 0.2 (mixed line), 2 (continuous line), 20 (dotted line),\
        \ and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally determined curves\
        \ from growth assays of mutants F84L (F), N36S/T42A (\u0152), and Q214L/I230N/\
        \ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates containing a range\
        \ of concentrations of the inverse agonist MRS1706.///TABLE 4 Fitted values\
        \ of the L parameter for mutants with low- or mediumlevel constitutive activity\
        \ Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A\
        \ N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10\
        \ 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69\
        \ 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11\
        \ A possibly low constitutive activity of the WT adenosine A2B receptor, however,\
        \ would render discrimination between antagonists and inverse agonists for\
        \ this receptor subtype difficult.///TABLE 4 Fitted values of the L parameter\
        \ for mutants with low- or mediumlevel constitutive activity Mutant ZM241385\
        \ DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A\
        \ 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12\
        \ 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22\
        \ 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low\
        \ constitutive activity of the WT adenosine A2B receptor, however, would render\
        \ discrimination between antagonists and inverse agonists for this receptor\
        \ subtype difficult.///TABLE 4 Fitted values of the L parameter for mutants\
        \ with low- or mediumlevel constitutive activity Mutant ZM241385 DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22\
        \ 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02\
        \ 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38\
        \ 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive\
        \ activity of the WT adenosine A2B receptor, however, would render discrimination\
        \ between antagonists and inverse agonists for this receptor subtype difficult.///TABLE\
        \ 4 Fitted values of the L parameter for mutants with low- or mediumlevel\
        \ constitutive activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G\
        \ T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20\
        \ 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02\
        \ 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02\
        \ 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive activity of the WT\
        \ adenosine A2B receptor, however, would render discrimination between antagonists\
        \ and inverse agonists for this receptor subtype difficult.", pubmed: '17077318',
    seq: '84', to_res: L}
- {entry_name: aa2br_human, from_res: A, info: 'The upper limit of 0 was set at 0.999
        (which means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///The upper limit of 0 was set at 0.999 (which
        means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///Because the two highly CAM receptors A18T/A23V/C83Y/A106V/
        R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop could not be inhibited
        by any of the compounds tested, the growth of these two mutants in the presence
        and absence of inverse agonist could not be used for curve fitting in Prism.///Because
        the two highly CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        could not be inhibited by any of the compounds tested, the growth of these
        two mutants in the presence and absence of inverse agonist could not be used
        for curve fitting in Prism.///Among them, the highest levels of constitutive
        activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S
        and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop, missing
        the C-terminal and transmembrane helix 7.///Among them, the highest levels
        of constitutive activity were obtained with two multiple mutant receptors,
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/
        N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant
        Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A
        T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated
        mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond to ZM241385,
        DPCPX or MRS1706 at any of the concentrations tested.///The multiple mutant
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/
        T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the
        concentrations tested.///Effect of ZM241385 on the constitutive activity of
        the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/
        I230N/V240M/V250M/N254Y/T257S/K269stop (\u008D) adenosine A2B receptors.///Effect
        of ZM241385 on the constitutive activity of the highly constitutively active
        A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop
        (\u008D) adenosine A2B receptors.', pubmed: '17077318', seq: '106', to_res: V}
- {entry_name: aa2br_human, from_res: I, info: "The upper limit of 0 was set at 0.999\
        \ (which means 99.9% of receptors are active) for the growth obtained upon\
        \ expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///The upper limit of 0\
        \ was set at 0.999 (which means 99.9% of receptors are active) for the growth\
        \ obtained upon expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///Because the two highly\
        \ CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Because the two highly CAM receptors\
        \ A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Among them, the highest levels of constitutive\
        \ activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop,\
        \ missing the C-terminal and transmembrane helix 7.///Among them, the highest\
        \ levels of constitutive activity were obtained with two multiple mutant receptors,\
        \ A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/\
        \ N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the\
        \ truncated mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond\
        \ to ZM241385, DPCPX or MRS1706 at any of the concentrations tested.///The\
        \ multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/\
        \ T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the\
        \ concentrations tested.///Effect of ZM241385 on the constitutive activity\
        \ of the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/\
        \ I230N/V240M/V250M/N254Y/T257S/K269stop (\\u008D) adenosine A2B receptors.///Effect\
        \ of ZM241385 on the constitutive activity of the highly constitutively active\
        \ A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) adenosine A2B receptors.///The parameters were L 0.2 (mixed line),\
        \ 2 (continuous line), 20 (dotted line), and 200 (dashed line); 0.2; and KA\
        \ 50 nM. b, experimentally determined curves from growth assays of mutants\
        \ F84L (F), N36S/T42A (\u0152), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) on agar plates containing a range of concentrations of the inverse\
        \ agonist MRS1706.///The parameters were L 0.2 (mixed line), 2 (continuous\
        \ line), 20 (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.", pubmed: '17077318',
    seq: '230', to_res: N}
- {entry_name: aa2br_human, from_res: T, info: "The upper limit of 0 was set at 0.999\
        \ (which means 99.9% of receptors are active) for the growth obtained upon\
        \ expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///The upper limit of 0\
        \ was set at 0.999 (which means 99.9% of receptors are active) for the growth\
        \ obtained upon expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///Because the two highly\
        \ CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Because the two highly CAM receptors\
        \ A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Among them, the highest levels of constitutive\
        \ activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop,\
        \ missing the C-terminal and transmembrane helix 7.///Among them, the highest\
        \ levels of constitutive activity were obtained with two multiple mutant receptors,\
        \ A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/\
        \ N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the\
        \ truncated mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond\
        \ to ZM241385, DPCPX or MRS1706 at any of the concentrations tested.///The\
        \ multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/\
        \ T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the\
        \ concentrations tested.///Effect of ZM241385 on the constitutive activity\
        \ of the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/\
        \ I230N/V240M/V250M/N254Y/T257S/K269stop (\\u008D) adenosine A2B receptors.///Effect\
        \ of ZM241385 on the constitutive activity of the highly constitutively active\
        \ A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) adenosine A2B receptors.///The parameters were L 0.2 (mixed line),\
        \ 2 (continuous line), 20 (dotted line), and 200 (dashed line); 0.2; and KA\
        \ 50 nM. b, experimentally determined curves from growth assays of mutants\
        \ F84L (F), N36S/T42A (\u0152), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) on agar plates containing a range of concentrations of the inverse\
        \ agonist MRS1706.///The parameters were L 0.2 (mixed line), 2 (continuous\
        \ line), 20 (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.", pubmed: '17077318',
    seq: '257', to_res: S}
- {entry_name: aa2br_human, from_res: N, info: "The upper limit of 0 was set at 0.999\
        \ (which means 99.9% of receptors are active) for the growth obtained upon\
        \ expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///The upper limit of 0\
        \ was set at 0.999 (which means 99.9% of receptors are active) for the growth\
        \ obtained upon expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///Because the two highly\
        \ CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Because the two highly CAM receptors\
        \ A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Among them, the highest levels of constitutive\
        \ activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop,\
        \ missing the C-terminal and transmembrane helix 7.///Among them, the highest\
        \ levels of constitutive activity were obtained with two multiple mutant receptors,\
        \ A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/\
        \ N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the\
        \ truncated mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond\
        \ to ZM241385, DPCPX or MRS1706 at any of the concentrations tested.///The\
        \ multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/\
        \ T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the\
        \ concentrations tested.///Effect of ZM241385 on the constitutive activity\
        \ of the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/\
        \ I230N/V240M/V250M/N254Y/T257S/K269stop (\\u008D) adenosine A2B receptors.///Effect\
        \ of ZM241385 on the constitutive activity of the highly constitutively active\
        \ A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) adenosine A2B receptors.///The parameters were L 0.2 (mixed line),\
        \ 2 (continuous line), 20 (dotted line), and 200 (dashed line); 0.2; and KA\
        \ 50 nM. b, experimentally determined curves from growth assays of mutants\
        \ F84L (F), N36S/T42A (\u0152), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) on agar plates containing a range of concentrations of the inverse\
        \ agonist MRS1706.///The parameters were L 0.2 (mixed line), 2 (continuous\
        \ line), 20 (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.", pubmed: '17077318',
    seq: '254', to_res: Y}
- {entry_name: aa2br_human, from_res: S, info: 'Finally, the three point mutants T42A,
        F84L, and F84S and the double mutant F84L/S95G exhibited relatively low levels
        of constitutive activity (Table 1).///Finally, the three point mutants T42A,
        F84L, and F84S and the double mutant F84L/S95G exhibited relatively low levels
        of constitutive activity (Table 1).///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S
        F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///The basal growth of yeast cells expressing
        T42A, F84L, F84S, or F84L/S95G mutant receptors was dose dependently reduced
        by ZM241385, DPCPX, and MRS1706 from 91 to 99%.///The basal growth of yeast
        cells expressing T42A, F84L, F84S, or F84L/S95G mutant receptors was dose
        dependently reduced by ZM241385, DPCPX, and MRS1706 from 91 to 99%.///An additional
        S95G mutation seemed to have no effect on either the constitutive activity
        or the inverse agonistic effect.///An additional S95G mutation seemed to have
        no effect on either the constitutive activity or the inverse agonistic effect.///ZM241385
        Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706
        F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71
        210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100
        100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31
        0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51
        78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6
        8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined due
        to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50
        M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A
        N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34 86 105 239
        95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91 1.43
        1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39
        3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133
        66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value
        could not be determined due to small experimental window.///TABLE 4 Fitted
        values of the L parameter for mutants with low- or mediumlevel constitutive
        activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A
        N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10
        1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10
        1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08
        0.11 A possibly low constitutive activity of the WT adenosine A2B receptor,
        however, would render discrimination between antagonists and inverse agonists
        for this receptor subtype difficult.///TABLE 4 Fitted values of the L parameter
        for mutants with low- or mediumlevel constitutive activity Mutant ZM241385
        DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A
        0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12
        0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22
        0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low
        constitutive activity of the WT adenosine A2B receptor, however, would render
        discrimination between antagonists and inverse agonists for this receptor
        subtype difficult.', pubmed: '17077318', seq: '95', to_res: G}
- {entry_name: aa2br_human, from_res: T, info: 'Mutants N36S/T42A, N36S/T42A/T66A,
        and T42A/V54A showed intermediate levels of agonist-independent growth.///Mutants
        N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate levels of agonist-independent
        growth.///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S F84L/S95G
        N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///The mutants with intermediate levels of constitutive activity,
        N36S/T42A, N36S/T42A/T66A, and T42A/V54A were inhibited by all three inverse
        agonists albeit with lower intrinsic activities, ranging from 28 to 79%.///The
        mutants with intermediate levels of constitutive activity, N36S/T42A, N36S/T42A/T66A,
        and T42A/V54A were inhibited by all three inverse agonists albeit with lower
        intrinsic activities, ranging from 28 to 79%.///Whereas the N36S mutation
        did not cause significant changes with respect to the potency of the three
        compounds, an additional T66A mutation along with the T42A/N36S double mutation
        increased the IC50 values of ZM241385 and DPCPX from 187 to 522 nM and from
        1.44 to 6.25 M, respectively.///Whereas the N36S mutation did not cause significant
        changes with respect to the potency of the three compounds, an additional
        T66A mutation along with the T42A/N36S double mutation increased the IC50
        values of ZM241385 and DPCPX from 187 to 522 nM and from 1.44 to 6.25 M, respectively.///Due
        to the small window, the IC50 value of MRS1706 for the T42A/N36S/T66A triple
        mutant could not be determined.///Due to the small window, the IC50 value
        of MRS1706 for the T42A/N36S/T66A triple mutant could not be determined.///In
        addition, the level of constitutive activity of this N36S/T42A/T66A triple
        mutant is increased compared with the N36S/T42A double mutant.///In addition,
        the level of constitutive activity of this N36S/T42A/T66A triple mutant is
        increased compared with the N36S/T42A double mutant.///In addition, the IC50
        value of ZM241385 increased another 2.5- to 3-fold for N36S/ T42A/T66A, which
        had slightly higher constitutive activity than the other two medium-level
        CAM receptors.///In addition, the IC50 value of ZM241385 increased another
        2.5- to 3-fold for N36S/ T42A/T66A, which had slightly higher constitutive
        activity than the other two medium-level CAM receptors.///ZM241385 Mutant
        CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L
        F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71 210
        187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100
        100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98
        0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62
        43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5
        11 16 96 95 97 97 68 77 44 a IC50 value could not be determined due to small
        experimental window.///However, the potency of DPCPX for mutants with increased
        level of constitutive activity did not increase except for N36S/T42A/T66A
        triple mutant.///However, the potency of DPCPX for mutants with increased
        level of constitutive activity did not increase except for N36S/T42A/T66A
        triple mutant.///The fitted L values differentiated into two groups (Table
        4): low-level CAM receptors have L values around or slightly smaller than
        0.2; intermediate-level CAM receptors have L values ranging from 1.38 for
        the T42A/V54A mutant to 1.90 for the N36S/T42A/T66A mutant.///The fitted L
        values differentiated into two groups (Table 4): low-level CAM receptors have
        L values around or slightly smaller than 0.2; intermediate-level CAM receptors
        have L values ranging from 1.38 for the T42A/V54A mutant to 1.90 for the N36S/T42A/T66A
        mutant.///TABLE 4 Fitted values of the L parameter for mutants with low- or
        mediumlevel constitutive activity Mutant ZM241385 DPCPX MRS1706 F84L F84S
        F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22
        0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02
        0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90
        0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive activity of
        the WT adenosine A2B receptor, however, would render discrimination between
        antagonists and inverse agonists for this receptor subtype difficult.', pubmed: '17077318',
    seq: '66', to_res: A}
- {entry_name: aa2br_human, from_res: A, info: 'The upper limit of 0 was set at 0.999
        (which means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///The upper limit of 0 was set at 0.999 (which
        means 99.9% of receptors are active) for the growth obtained upon expression
        of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/
        V250M/N254Y/T257S/K269stop.///Because the two highly CAM receptors A18T/A23V/C83Y/A106V/
        R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop could not be inhibited
        by any of the compounds tested, the growth of these two mutants in the presence
        and absence of inverse agonist could not be used for curve fitting in Prism.///Because
        the two highly CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        could not be inhibited by any of the compounds tested, the growth of these
        two mutants in the presence and absence of inverse agonist could not be used
        for curve fitting in Prism.///Among them, the highest levels of constitutive
        activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S
        and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop, missing
        the C-terminal and transmembrane helix 7.///Among them, the highest levels
        of constitutive activity were obtained with two multiple mutant receptors,
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/
        N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant
        Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A
        T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated
        mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond to ZM241385,
        DPCPX or MRS1706 at any of the concentrations tested.///The multiple mutant
        A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/
        T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the
        concentrations tested.///Effect of ZM241385 on the constitutive activity of
        the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/
        I230N/V240M/V250M/N254Y/T257S/K269stop (\u008D) adenosine A2B receptors.///Effect
        of ZM241385 on the constitutive activity of the highly constitutively active
        A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop
        (\u008D) adenosine A2B receptors.', pubmed: '17077318', seq: '23', to_res: V}
- {entry_name: aa1r_cavpo, from_res: G, info: 'For the adenosine A1 receptor, we identified
        a locked mutant receptor containing a G14T mutation.///For the adenosine A1
        receptor, we identified a locked mutant receptor containing a G14T mutation.',
    pubmed: '17077318', seq: '14', to_res: T}
- {entry_name: aa2br_human, from_res: N, info: "Mutants N36S/T42A, N36S/T42A/T66A,\
        \ and T42A/V54A showed intermediate levels of agonist-independent growth.///Mutants\
        \ N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate levels of agonist-independent\
        \ growth.///Mutants N36S/T42A, N36S/T42A/T66A, and T42A/V54A showed intermediate\
        \ levels of agonist-independent growth.///Mutants N36S/T42A, N36S/T42A/T66A,\
        \ and T42A/V54A showed intermediate levels of agonist-independent growth.///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S\
        \ F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The mutants with intermediate levels of constitutive activity,\
        \ N36S/T42A, N36S/T42A/T66A, and T42A/V54A were inhibited by all three inverse\
        \ agonists albeit with lower intrinsic activities, ranging from 28 to 79%.///The\
        \ mutants with intermediate levels of constitutive activity, N36S/T42A, N36S/T42A/T66A,\
        \ and T42A/V54A were inhibited by all three inverse agonists albeit with lower\
        \ intrinsic activities, ranging from 28 to 79%.///The mutants with intermediate\
        \ levels of constitutive activity, N36S/T42A, N36S/T42A/T66A, and T42A/V54A\
        \ were inhibited by all three inverse agonists albeit with lower intrinsic\
        \ activities, ranging from 28 to 79%.///The mutants with intermediate levels\
        \ of constitutive activity, N36S/T42A, N36S/T42A/T66A, and T42A/V54A were\
        \ inhibited by all three inverse agonists albeit with lower intrinsic activities,\
        \ ranging from 28 to 79%.///Comparison of the T42A point mutant with the T42A/V54A\
        \ and the N36S/ T42A double mutants showed that the IC50 values of the three\
        \ inverse agonists were at most 3-fold altered when an additional V54A or\
        \ N36S mutation was present.///Comparison of the T42A point mutant with the\
        \ T42A/V54A and the N36S/ T42A double mutants showed that the IC50 values\
        \ of the three inverse agonists were at most 3-fold altered when an additional\
        \ V54A or N36S mutation was present.///Comparison of the T42A point mutant\
        \ with the T42A/V54A and the N36S/ T42A double mutants showed that the IC50\
        \ values of the three inverse agonists were at most 3-fold altered when an\
        \ additional V54A or N36S mutation was present.///Comparison of the T42A point\
        \ mutant with the T42A/V54A and the N36S/ T42A double mutants showed that\
        \ the IC50 values of the three inverse agonists were at most 3-fold altered\
        \ when an additional V54A or N36S mutation was present.///However, whereas\
        \ the constitutive activity of the T42A mutant could be completely inhibited\
        \ by all three inverse agonists, an additional V54A or N36S mutation resulted\
        \ in a higher level of constitutive activity and could be only partially inhibited.///However,\
        \ whereas the constitutive activity of the T42A mutant could be completely\
        \ inhibited by all three inverse agonists, an additional V54A or N36S mutation\
        \ resulted in a higher level of constitutive activity and could be only partially\
        \ inhibited.///Whereas the N36S mutation did not cause significant changes\
        \ with respect to the potency of the three compounds, an additional T66A mutation\
        \ along with the T42A/N36S double mutation increased the IC50 values of ZM241385\
        \ and DPCPX from 187 to 522 nM and from 1.44 to 6.25 M, respectively.///Whereas\
        \ the N36S mutation did not cause significant changes with respect to the\
        \ potency of the three compounds, an additional T66A mutation along with the\
        \ T42A/N36S double mutation increased the IC50 values of ZM241385 and DPCPX\
        \ from 187 to 522 nM and from 1.44 to 6.25 M, respectively.///Whereas the\
        \ N36S mutation did not cause significant changes with respect to the potency\
        \ of the three compounds, an additional T66A mutation along with the T42A/N36S\
        \ double mutation increased the IC50 values of ZM241385 and DPCPX from 187\
        \ to 522 nM and from 1.44 to 6.25 M, respectively.///Whereas the N36S mutation\
        \ did not cause significant changes with respect to the potency of the three\
        \ compounds, an additional T66A mutation along with the T42A/N36S double mutation\
        \ increased the IC50 values of ZM241385 and DPCPX from 187 to 522 nM and from\
        \ 1.44 to 6.25 M, respectively.///Due to the small window, the IC50 value\
        \ of MRS1706 for the T42A/N36S/T66A triple mutant could not be determined.///Due\
        \ to the small window, the IC50 value of MRS1706 for the T42A/N36S/T66A triple\
        \ mutant could not be determined.///In addition, the level of constitutive\
        \ activity of this N36S/T42A/T66A triple mutant is increased compared with\
        \ the N36S/T42A double mutant.///In addition, the level of constitutive activity\
        \ of this N36S/T42A/T66A triple mutant is increased compared with the N36S/T42A\
        \ double mutant.///In addition, the level of constitutive activity of this\
        \ N36S/T42A/T66A triple mutant is increased compared with the N36S/T42A double\
        \ mutant.///In addition, the level of constitutive activity of this N36S/T42A/T66A\
        \ triple mutant is increased compared with the N36S/T42A double mutant.///For\
        \ example, the IC50 values of ZM241385 for the medium-level CAM N36S/T42A\
        \ and T42A/V54A were approximately 2-fold higher than the IC50 values for\
        \ this compound on the low-level CAM receptors.///For example, the IC50 values\
        \ of ZM241385 for the medium-level CAM N36S/T42A and T42A/V54A were approximately\
        \ 2-fold higher than the IC50 values for this compound on the low-level CAM\
        \ receptors.///In addition, the IC50 value of ZM241385 increased another 2.5-\
        \ to 3-fold for N36S/ T42A/T66A, which had slightly higher constitutive activity\
        \ than the other two medium-level CAM receptors.///In addition, the IC50 value\
        \ of ZM241385 increased another 2.5- to 3-fold for N36S/ T42A/T66A, which\
        \ had slightly higher constitutive activity than the other two medium-level\
        \ CAM receptors.///ZM241385 Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50\
        \ nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A\
        \ N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34 86 105 239 95 99 97\
        \ 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55\
        \ 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3\
        \ 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133\
        \ 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50\
        \ value could not be determined due to small experimental window.///ZM241385\
        \ Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102\
        \ 71 210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4\
        \ 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68\
        \ 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102\
        \ 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57\
        \ 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined\
        \ due to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE\
        \ IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A\
        \ T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34\
        \ 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100\
        \ 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92\
        \ 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40\
        \ 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97\
        \ 97 68 77 44 a IC50 value could not be determined due to small experimental\
        \ window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM\
        \ Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A\
        \ 135 107 102 71 210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7\
        \ 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25\
        \ 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11\
        \ 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94\
        \ 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not\
        \ be determined due to small experimental window.///However, the potency of\
        \ DPCPX for mutants with increased level of constitutive activity did not\
        \ increase except for N36S/T42A/T66A triple mutant.///However, the potency\
        \ of DPCPX for mutants with increased level of constitutive activity did not\
        \ increase except for N36S/T42A/T66A triple mutant.///The fitted L values\
        \ differentiated into two groups (Table 4): low-level CAM receptors have L\
        \ values around or slightly smaller than 0.2; intermediate-level CAM receptors\
        \ have L values ranging from 1.38 for the T42A/V54A mutant to 1.90 for the\
        \ N36S/T42A/T66A mutant.///The fitted L values differentiated into two groups\
        \ (Table 4): low-level CAM receptors have L values around or slightly smaller\
        \ than 0.2; intermediate-level CAM receptors have L values ranging from 1.38\
        \ for the T42A/V54A mutant to 1.90 for the N36S/T42A/T66A mutant.///The parameters\
        \ were L 0.2 (mixed line), 2 (continuous line), 20 (dotted line), and 200\
        \ (dashed line); 0.2; and KA 50 nM. b, experimentally determined curves from\
        \ growth assays of mutants F84L (F), N36S/T42A (\u0152), and Q214L/I230N/\
        \ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates containing a range\
        \ of concentrations of the inverse agonist MRS1706.///The parameters were\
        \ L 0.2 (mixed line), 2 (continuous line), 20 (dotted line), and 200 (dashed\
        \ line); 0.2; and KA 50 nM. b, experimentally determined curves from growth\
        \ assays of mutants F84L (F), N36S/T42A (\u0152), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) on agar plates containing a range of concentrations of the inverse\
        \ agonist MRS1706.///TABLE 4 Fitted values of the L parameter for mutants\
        \ with low- or mediumlevel constitutive activity Mutant ZM241385 DPCPX MRS1706\
        \ F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22\
        \ 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02\
        \ 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38\
        \ 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive\
        \ activity of the WT adenosine A2B receptor, however, would render discrimination\
        \ between antagonists and inverse agonists for this receptor subtype difficult.///TABLE\
        \ 4 Fitted values of the L parameter for mutants with low- or mediumlevel\
        \ constitutive activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G\
        \ T42A T42A/V54A N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20\
        \ 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02\
        \ 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02\
        \ 0.02 0.02 0.08 0.08 0.11 A possibly low constitutive activity of the WT\
        \ adenosine A2B receptor, however, would render discrimination between antagonists\
        \ and inverse agonists for this receptor subtype difficult.///TABLE 4 Fitted\
        \ values of the L parameter for mutants with low- or mediumlevel constitutive\
        \ activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A\
        \ N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10\
        \ 1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47\
        \ 0.10 1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08\
        \ 0.08 0.11 A possibly low constitutive activity of the WT adenosine A2B receptor,\
        \ however, would render discrimination between antagonists and inverse agonists\
        \ for this receptor subtype difficult.///TABLE 4 Fitted values of the L parameter\
        \ for mutants with low- or mediumlevel constitutive activity Mutant ZM241385\
        \ DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A\
        \ 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12\
        \ 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22\
        \ 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low\
        \ constitutive activity of the WT adenosine A2B receptor, however, would render\
        \ discrimination between antagonists and inverse agonists for this receptor\
        \ subtype difficult.", pubmed: '17077318', seq: '36', to_res: S}
- {entry_name: acthr_human, from_res: R, info: 'The trafficking-defective mutants
        such as R146H, T159K and Y254C (Figure 2D, E and F) exhibit marked intracellular
        retention consistent with the results from the cell surface assay.///Previous
        functional studies performed for a variety of mutations such as G116V (26),
        R137W (27), R146H (6;10), T159K (10), C251F (19) and Y254C (27) all found
        that there was impaired receptor signaling when stimulated with ACTH and low
        affinity for ACTH binding.///D: R146H; E: T159K and F: Y254C fail to reach
        the plasma membrane and are retained intracellularly.', pubmed: '18840636',
    seq: '146', to_res: H}
- {entry_name: agtr1_human, from_res: Y, info: 'The experimental supports can be summarized
        as follows: receptor inactivation upon Y292F (15), W253F (5), and H256A mutations
        (5, 16); strong constitutive activation upon Asn111 mutations (6, 17); detailed
        analysis of the induction of intermediary or activated conformations (17,
        18).', pubmed: '11495910', seq: '292', to_res: F}
- {entry_name: aa2br_human, from_res: F, info: 'Finally, the three point mutants T42A,
        F84L, and F84S and the double mutant F84L/S95G exhibited relatively low levels
        of constitutive activity (Table 1).///Finally, the three point mutants T42A,
        F84L, and F84S and the double mutant F84L/S95G exhibited relatively low levels
        of constitutive activity (Table 1).///WT/Mutant Constitutive Activitya Wild
        type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S
        Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow
        on the selection plate due to the lack of constitutive receptor activity;
        , yeast cells did grow on the selection plates, but only a weak constitutive
        activity was detectable; , mutants exhibited constitutive activity 2to 4-fold
        higher than ; and , constitutive activity of the mutants was at least 5-fold
        greater than .///WT/Mutant Constitutive Activitya Wild type T42A F84L F84S
        F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop
        a , yeast cells did not grow on the selection plate due to the lack of constitutive
        receptor activity; , yeast cells did grow on the selection plates, but only
        a weak constitutive activity was detectable; , mutants exhibited constitutive
        activity 2to 4-fold higher than ; and , constitutive activity of the mutants
        was at least 5-fold greater than .///The basal growth of yeast cells expressing
        T42A, F84L, F84S, or F84L/S95G mutant receptors was dose dependently reduced
        by ZM241385, DPCPX, and MRS1706 from 91 to 99%.///The basal growth of yeast
        cells expressing T42A, F84L, F84S, or F84L/S95G mutant receptors was dose
        dependently reduced by ZM241385, DPCPX, and MRS1706 from 91 to 99%.///Point
        mutants F84L and F84S behaved similar to each other with respect to both the
        potency and relative intrinsic efficacy of the inverse agonists, indicating
        that a mutation from phenylalanine to leucine or serine has the same effect.///Point
        mutants F84L and F84S behaved similar to each other with respect to both the
        potency and relative intrinsic efficacy of the inverse agonists, indicating
        that a mutation from phenylalanine to leucine or serine has the same effect.///Like
        the point mutants F84L and F84S, the T42A mutant exhibited relatively low
        constitutive activity that was completely inhibited by all three inverse agonists.///Like
        the point mutants F84L and F84S, the T42A mutant exhibited relatively low
        constitutive activity that was completely inhibited by all three inverse agonists.///ZM241385
        Mutant CA IC50 nM Imax % RE IC50 M Imax % RE IC50 nM Imax % RE DPCPX MRS1706
        F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A 135 107 102 71
        210 187 522 88 37 60 34 86 105 239 95 99 97 96 79 74 63 7 2 4 5 7 7 4 100
        100 100 100 100 100 100 1.44 1.91 1.43 1.55 0.86 1.44 6.25 1.39 0.68 0.31
        0.98 0.31 1.02 2.46 92 97 99 96 40 58 39 3 3 2 2 12 3 11 97 98 102 100 51
        78 62 43 21 54 12 40 32 98 62 166 138 133 66 -a 91 94 94 93 54 57 28 12 6
        8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value could not be determined due
        to small experimental window.///ZM241385 Mutant CA IC50 nM Imax % RE IC50
        M Imax % RE IC50 nM Imax % RE DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A
        N36S/T42A N36S/T42A/T66A 135 107 102 71 210 187 522 88 37 60 34 86 105 239
        95 99 97 96 79 74 63 7 2 4 5 7 7 4 100 100 100 100 100 100 100 1.44 1.91 1.43
        1.55 0.86 1.44 6.25 1.39 0.68 0.31 0.98 0.31 1.02 2.46 92 97 99 96 40 58 39
        3 3 2 2 12 3 11 97 98 102 100 51 78 62 43 21 54 12 40 32 98 62 166 138 133
        66 -a 91 94 94 93 54 57 28 12 6 8 5 5 11 16 96 95 97 97 68 77 44 a IC50 value
        could not be determined due to small experimental window.///TABLE 4 Fitted
        values of the L parameter for mutants with low- or mediumlevel constitutive
        activity Mutant ZM241385 DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A
        N36S/T42A N36S/T42A/T66A 0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10
        1.49 0.10 1.9 0.17 0.12 0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10
        1.69 0.10 0.14 0.22 0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08
        0.11 A possibly low constitutive activity of the WT adenosine A2B receptor,
        however, would render discrimination between antagonists and inverse agonists
        for this receptor subtype difficult.///TABLE 4 Fitted values of the L parameter
        for mutants with low- or mediumlevel constitutive activity Mutant ZM241385
        DPCPX MRS1706 F84L F84S F84L/S95G T42A T42A/V54A N36S/T42A N36S/T42A/T66A
        0.11 0.02 0.22 0.03 0.22 0.02 0.20 0.02 1.38 0.10 1.49 0.10 1.9 0.17 0.12
        0.02 0.16 0.02 0.17 0.02 0.16 0.02 1.6 0.10 1.47 0.10 1.69 0.10 0.14 0.22
        0.20 0.18 1.38 1.52 1.90 0.02 0.02 0.02 0.02 0.08 0.08 0.11 A possibly low
        constitutive activity of the WT adenosine A2B receptor, however, would render
        discrimination between antagonists and inverse agonists for this receptor
        subtype difficult.', pubmed: '17077318', seq: '84', to_res: S}
- {entry_name: aa2br_human, from_res: V, info: "The upper limit of 0 was set at 0.999\
        \ (which means 99.9% of receptors are active) for the growth obtained upon\
        \ expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///The upper limit of 0\
        \ was set at 0.999 (which means 99.9% of receptors are active) for the growth\
        \ obtained upon expression of either one of the two mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ or Q214L/I230N/V240M/ V250M/N254Y/T257S/K269stop.///Because the two highly\
        \ CAM receptors A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Because the two highly CAM receptors\
        \ A18T/A23V/C83Y/A106V/ R112S and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ could not be inhibited by any of the compounds tested, the growth of these\
        \ two mutants in the presence and absence of inverse agonist could not be\
        \ used for curve fitting in Prism.///Among them, the highest levels of constitutive\
        \ activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S\
        \ and the truncated mutant Q214L/I230N/V240M/V250M/ N254Y/T257S/K269stop,\
        \ missing the C-terminal and transmembrane helix 7.///Among them, the highest\
        \ levels of constitutive activity were obtained with two multiple mutant receptors,\
        \ A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/\
        \ N254Y/T257S/K269stop, missing the C-terminal and transmembrane helix 7.///WT/Mutant\
        \ Constitutive Activitya Wild type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A\
        \ T42A/V54A A18T/A23V/C83Y/A106V/R112S Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ a , yeast cells did not grow on the selection plate due to the lack of constitutive\
        \ receptor activity; , yeast cells did grow on the selection plates, but only\
        \ a weak constitutive activity was detectable; , mutants exhibited constitutive\
        \ activity 2to 4-fold higher than ; and , constitutive activity of the mutants\
        \ was at least 5-fold greater than .///WT/Mutant Constitutive Activitya Wild\
        \ type T42A F84L F84S F84L/S95G N36S/T42A N36S/T42A/T66A T42A/V54A A18T/A23V/C83Y/A106V/R112S\
        \ Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop a , yeast cells did not grow\
        \ on the selection plate due to the lack of constitutive receptor activity;\
        \ , yeast cells did grow on the selection plates, but only a weak constitutive\
        \ activity was detectable; , mutants exhibited constitutive activity 2to 4-fold\
        \ higher than ; and , constitutive activity of the mutants was at least 5-fold\
        \ greater than .///The multiple mutant A18T/A23V/C83Y/A106V/R112S and the\
        \ truncated mutant Q214L/I230N/V240M/V250M/N254Y/ T257S/K269stop did not respond\
        \ to ZM241385, DPCPX or MRS1706 at any of the concentrations tested.///The\
        \ multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/\
        \ T257S/K269stop did not respond to ZM241385, DPCPX or MRS1706 at any of the\
        \ concentrations tested.///Effect of ZM241385 on the constitutive activity\
        \ of the highly constitutively active A18T/A23V/C83Y/A106V/R112S (f) and Q214L/\
        \ I230N/V240M/V250M/N254Y/T257S/K269stop (\\u008D) adenosine A2B receptors.///Effect\
        \ of ZM241385 on the constitutive activity of the highly constitutively active\
        \ A18T/A23V/C83Y/A106V/R112S (f) and Q214L/ I230N/V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) adenosine A2B receptors.///The parameters were L 0.2 (mixed line),\
        \ 2 (continuous line), 20 (dotted line), and 200 (dashed line); 0.2; and KA\
        \ 50 nM. b, experimentally determined curves from growth assays of mutants\
        \ F84L (F), N36S/T42A (\u0152), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop\
        \ (\\u008D) on agar plates containing a range of concentrations of the inverse\
        \ agonist MRS1706.///The parameters were L 0.2 (mixed line), 2 (continuous\
        \ line), 20 (dotted line), and 200 (dashed line); 0.2; and KA 50 nM. b, experimentally\
        \ determined curves from growth assays of mutants F84L (F), N36S/T42A (\u0152\
        ), and Q214L/I230N/ V240M/V250M/N254Y/T257S/K269stop (\\u008D) on agar plates\
        \ containing a range of concentrations of the inverse agonist MRS1706.", pubmed: '17077318',
    seq: '240', to_res: M}
- {entry_name: adrb2_human, from_res: D, info: 'It is noteworthy that the signaling
        efficacy of the allosteric agonist, LY2033298, was also completely insensitive
        to the D3.49N mutation.', pubmed: '21300722', seq: '130', to_res: N}
- {entry_name: acm1_human, from_res: W, info: 'Specifically, allosteric ligand affinity
        was reduced at both the W1083.28A and L1093.29A mutant M4 mAChRs (Table 2,
        Figures 3 and 4), suggesting that these two residues represent an interface
        between the prototypical orthosteric binding site and a more extracellular
        allosteric site; a previous study of the M1 mAChR had identified a similar
        inhibitory effect of the W3.28A on the binding of the allosteric modulator,
        gallamine (Matsui et al., 1995).', pubmed: '21300722', seq: '101', to_res: A}
- {entry_name: acm4_human, from_res: D, info: 'However, prior studies at the M1 and
        M5 mAChRs have found minimal effects of the D3.49N mutation on the efficacy
        of ACh itself (Burstein et al., 1998; Lu et al., 1997), which is also in agreement
        with our current study at the M4 mAChR, suggesting that this mechanism need
        not be universal.', pubmed: '21300722', seq: '129', to_res: N}
- {entry_name: cnr1_human, from_res: D, info: 'Using D6.30N mutant of CB1 and CB2
        receptors Nebane et al. [65] found that D6.30 is essential for full activation
        of both cannabinoid receptors.', pubmed: '21365223', seq: '338', to_res: N}
- {entry_name: cnr2_human, from_res: D, info: 'Both CB1 and CB2 D6.30N mutants demonstrated
        a level of constitutive activity not greater than that of their wild type
        counterparts, indicating that either D6.30 does not participate in a salt
        bridge with R3.50 (DRY motif), or the salt bridge is not critical for keeping
        cannabinoid receptors in the inactive conformation.', pubmed: '21365223',
    seq: '240', to_res: N}
- {entry_name: aa2ar_human, from_res: F, info: "The first category contained mutants\
        \ L48A, F62A, F79A and F242A, which did not bind [3H]ZM241385 at 4 \xB0C in\
        \ this experiment, suggesting a dramatic loss of affinity (see below for ligand\
        \ binding experiments), and their thermostability with [ 3 H]ZM241385 bound\
        \ was not determined.///Five of the double mutants did not increase 248 249\
        \ 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267\
        \ 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285\
        \ 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303\
        \ 304 Apparent Tm (\xB0C) t1:4 t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12\
        \ t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation\
        \ WT V12A S47A L48A A50L A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A\
        \ F242A V282A Ballesteros\u2013 Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55\
        \ 2.60 2.63 3.27 3.31 3.37 3.38 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5\
        \ 30.5 31 42.5 31 33.5 34.5 31 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2\
        \ + 2.5 + 14 + 2.5 +5 +6 + 2.5 + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5\
        \ +2 Antagonist [3H] ZM241385 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32\
        \ 38 36 0 33 \u0394Tm - n.d. \u2212 6.5 n.d.///Combinations of mutants tested\
        \ for thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5\
        \ t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18\
        \ t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30\
        \ t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double\
        \ mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15\
        \ GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations\
        \ - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A\
        \ L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A\
        \ L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted -\
        \ 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5\
        \ Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5\
        \ 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa\
        \ 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5\
        \ \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n =\
        \ 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26\
        \ GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.", pubmed: '21501622', seq: '242', to_res: A}
- {entry_name: aa2ar_human, from_res: V, info: "Five of the double mutants did not\
        \ increase 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263\
        \ 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281\
        \ 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299\
        \ 300 301 302 303 304 Apparent Tm (\xB0C) t1:4 t1:5 t1:3 t1:6 t1:7 t1:8 t1:9\
        \ t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20 t1:21\
        \ t1:22 A2AR mutation WT V12A S47A L48A A50L A54L V57A F62A T65A F79A F83A\
        \ Q89A S90A A236L I238A F242A V282A Ballesteros\u2013 Weinstein - 1.38 2.45\
        \ 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38 6.38 6.40 6.44 7.47 Agonist\
        \ [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31 33 31 30 34.5 32 31 31 31 30.5\
        \ \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5 + 4.5 + 2.5 + 1.5 +6 + 3.5 +\
        \ 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385 32 n.d.a 25.5 0b 38.5 38 38\
        \ 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d. \u2212 6.5 n.d.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.", pubmed: '21501622', seq: '12', to_res: A}
- {entry_name: aa2ar_human, from_res: A, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Previous\
        \ experience of combining thermostabilising mutations has shown that mutants\
        \ close to each other in the primary amino acid sequence were often not additive;21,23,24\
        \ thus, the double mutants of L48A with either S47A or A50L were not made.///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///Combinations of mutants tested for thermostabilising the\
        \ NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '50', to_res: L}
- {entry_name: aa2ar_human, from_res: F, info: "The first category contained mutants\
        \ L48A, F62A, F79A and F242A, which did not bind [3H]ZM241385 at 4 \xB0C in\
        \ this experiment, suggesting a dramatic loss of affinity (see below for ligand\
        \ binding experiments), and their thermostability with [ 3 H]ZM241385 bound\
        \ was not determined.///Five of the double mutants did not increase 248 249\
        \ 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267\
        \ 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285\
        \ 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303\
        \ 304 Apparent Tm (\xB0C) t1:4 t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12\
        \ t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation\
        \ WT V12A S47A L48A A50L A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A\
        \ F242A V282A Ballesteros\u2013 Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55\
        \ 2.60 2.63 3.27 3.31 3.37 3.38 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5\
        \ 30.5 31 42.5 31 33.5 34.5 31 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2\
        \ + 2.5 + 14 + 2.5 +5 +6 + 2.5 + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5\
        \ +2 Antagonist [3H] ZM241385 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32\
        \ 38 36 0 33 \u0394Tm - n.d. \u2212 6.5 n.d.///Combinations of mutants tested\
        \ for thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5\
        \ t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18\
        \ t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30\
        \ t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double\
        \ mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15\
        \ GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations\
        \ - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A\
        \ L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A\
        \ L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted -\
        \ 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5\
        \ Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5\
        \ 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa\
        \ 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5\
        \ \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n =\
        \ 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26\
        \ GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '62', to_res: A}
- {entry_name: aa2ar_human, from_res: I, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///Combinations of mutants tested for thermostabilising the\
        \ NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '238', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: "Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.", pubmed: '21501622', seq: '263', to_res: A}
- {entry_name: acthr_human, from_res: I, info: "The S74I, I130N (Figure 2G and H)\
        \ and T152K demonstrated partial trafficking impairment, which did not reach\
        \ a statistically significant difference on cell surface assay.///Figure 4b\
        \ demonstrates interaction with MRAP\u03B1 for L55P, I130N, R137W and G226R.///There\
        \ is partial cell surface expression in S74I, I130N and T152K, as there is\
        \ no significance difference when compared with wild type.///G: S74I and H:\
        \ I130N have partial expression at the cell surface.///CHO cells were transfected\
        \ with Wt-MC2R, L55P, I130N, R137W and G226R mutants and MRAP\u03B1-Flag (4B).",
    pubmed: '18840636', seq: '130', to_res: N}
- {entry_name: acthr_human, from_res: T, info: 'The S74I, I130N (Figure 2G and H)
        and T152K demonstrated partial trafficking impairment, which did not reach
        a statistically significant difference on cell surface assay.///There is partial
        cell surface expression in S74I, I130N and T152K, as there is no significance
        difference when compared with wild type.', pubmed: '18840636', seq: '152',
    to_res: K}
- {entry_name: aa2ar_human, from_res: A, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///Combinations of mutants tested for thermostabilising the\
        \ NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '236', to_res: L}
- {entry_name: aa2ar_human, from_res: F, info: "The first category contained mutants\
        \ L48A, F62A, F79A and F242A, which did not bind [3H]ZM241385 at 4 \xB0C in\
        \ this experiment, suggesting a dramatic loss of affinity (see below for ligand\
        \ binding experiments), and their thermostability with [ 3 H]ZM241385 bound\
        \ was not determined.///Five of the double mutants did not increase 248 249\
        \ 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267\
        \ 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285\
        \ 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303\
        \ 304 Apparent Tm (\xB0C) t1:4 t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12\
        \ t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation\
        \ WT V12A S47A L48A A50L A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A\
        \ F242A V282A Ballesteros\u2013 Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55\
        \ 2.60 2.63 3.27 3.31 3.37 3.38 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5\
        \ 30.5 31 42.5 31 33.5 34.5 31 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2\
        \ + 2.5 + 14 + 2.5 +5 +6 + 2.5 + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5\
        \ +2 Antagonist [3H] ZM241385 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32\
        \ 38 36 0 33 \u0394Tm - n.d. \u2212 6.5 n.d.///Combinations of mutants tested\
        \ for thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5\
        \ t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18\
        \ t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30\
        \ t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double\
        \ mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15\
        \ GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations\
        \ - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A\
        \ L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A\
        \ L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted -\
        \ 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5\
        \ Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5\
        \ 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa\
        \ 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5\
        \ \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n =\
        \ 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26\
        \ GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '79', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: "The second category contained mutants\
        \ S47A, F83A and Q89A, which stabilised the NECA-bound conformation and destabilised\
        \ the ZM241385-bound conformation.///Previous experience of combining thermostabilising\
        \ mutations has shown that mutants close to each other in the primary amino\
        \ acid sequence were often not additive;21,23,24 thus, the double mutants\
        \ of L48A with either S47A or A50L were not made.///Five of the double mutants\
        \ did not increase 248 249 250 251 252 253 254 255 256 257 258 259 260 261\
        \ 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279\
        \ 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297\
        \ 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4 t1:5 t1:3 t1:6 t1:7\
        \ t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20\
        \ t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L A54L V57A F62A T65A F79A\
        \ F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013 Weinstein - 1.38\
        \ 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38 6.38 6.40 6.44 7.47\
        \ Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31 33 31 30 34.5 32 31\
        \ 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5 + 4.5 + 2.5 + 1.5\
        \ +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385 32 n.d.a 25.5 0b\
        \ 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d. \u2212 6.5 n.d.",
    pubmed: '21501622', seq: '47', to_res: A}
- {entry_name: aa2ar_human, from_res: V, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///Combinations of mutants tested for thermostabilising the\
        \ NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.", pubmed: '21501622',
    seq: '282', to_res: A}
- {entry_name: aa2ar_human, from_res: A, info: "The third group is composed of the\
        \ remaining mutations that stabilised both agonist- and inverseagonist-bound\
        \ conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).///Five\
        \ of the double mutants did not increase 248 249 250 251 252 253 254 255 256\
        \ 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274\
        \ 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292\
        \ 293 294 295 296 297 298 299 300 301 302 303 304 Apparent Tm (\xB0C) t1:4\
        \ t1:5 t1:3 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16\
        \ t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 A2AR mutation WT V12A S47A L48A A50L\
        \ A54L V57A F62A T65A F79A F83A Q89A S90A A236L I238A F242A V282A Ballesteros\u2013\
        \ Weinstein - 1.38 2.45 2.46 2.48 2.52 2.55 2.60 2.63 3.27 3.31 3.37 3.38\
        \ 6.38 6.40 6.44 7.47 Agonist [3H] NECA 28.5 30.5 31 42.5 31 33.5 34.5 31\
        \ 33 31 30 34.5 32 31 31 31 30.5 \u0394Tm - +2 + 2.5 + 14 + 2.5 +5 +6 + 2.5\
        \ + 4.5 + 2.5 + 1.5 +6 + 3.5 + 2.5 + 2.5 + 2.5 +2 Antagonist [3H] ZM241385\
        \ 32 n.d.a 25.5 0b 38.5 38 38 0 38 0 16.5 26 32 38 36 0 33 \u0394Tm - n.d.\
        \ \u2212 6.5 n.d.///After a last round of mutagenesis combining the additive\
        \ mutants to GL23, it was found that the addition of A54L to make mutant GL26\
        \ yield the highest thermostability.///Combinations of mutants tested for\
        \ thermostabilising the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6\
        \ t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19\
        \ t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31\
        \ t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant Double mutant\
        \ Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19\
        \ GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A\
        \ L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A\
        \ L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L\
        \ L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5\
        \ 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa\
        \ - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5\
        \ 46 50 Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44\
        \ 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n\
        \ = 3) Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1\
        \ 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29\
        \ L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A\
        \ L48A-Q89A-T65A- S263A t2:33 a Values were determined initially from a single\
        \ thermostability curve, with measurements performed in triplicate, to find\
        \ the most thermostable mutants; replicate experiments were performed only\
        \ for key mutants.///Combinations of mutants tested for thermostabilising\
        \ the NECA-bound conformation of A2AR t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10\
        \ t2:11 t2:12 t2:13 t2:14 t2:15 t2:16 t2:17 t2:18 t2:19 t2:20 t2:21 t2:22\
        \ t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 Triple mutant\
        \ Quadruple mutant WT A2AR Single mutant Double mutant Mutant name - GL0 GL1\
        \ GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14 GL15 GL17 GL19 GL20 GL21 GL22 GL24\
        \ GL23 Apparent Tm in DDM (\xB0C) A2AR mutations - L48A L48A-V12A L48A-A54L\
        \ L48A-V57A L48A-F62A L48A-T65A L48A-F79A L48A-F83A L48A-Q89A L48A-S90A L48A-A236L\
        \ L48A-I238A L48A-F242A L48A-V282A L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A\
        \ L48A-Q89A-F79A L48A-Q89A-T65A Predicted - 42.5 45 47.5 48.5 45 47 45 44\
        \ 48.5 46 45 45 45 44.5 49.5 52 49.5 49.5 51.5 Single measurementa - 42.5\
        \ 45.5 46 41.5 45 45 45.5 43.5 47.5 46 40.5 42.5 39.5 40 46 46 45.5 46 50\
        \ Apparent Tm in DM (\xB0C) Predicted Single measurementa 44.5 46 44 44.5\
        \ Final valuesa 42.2 \xB1 0.3 (n = 2) 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3)\
        \ Final valuesa 28.6 \xB1 0.2 (n = 8) 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4\
        \ (n = 3) Triple mutant 49.9 \xB1 0.1 (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A\
        \ L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L L48A-Q89A-T65A-F83A L48A-Q89A-T65A-\
        \ S263A t2:33 a Values were determined initially from a single thermostability\
        \ curve, with measurements performed in triplicate, to find the most thermostable\
        \ mutants; replicate experiments were performed only for key mutants.///Combinations\
        \ of mutants tested for thermostabilising the NECA-bound conformation of A2AR\
        \ t2:3 t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12 t2:13 t2:14 t2:15 t2:16\
        \ t2:17 t2:18 t2:19 t2:20 t2:21 t2:22 t2:23 t2:24 t2:25 t2:26 t2:27 t2:28\
        \ t2:29 t2:30 t2:31 t2:32 Triple mutant Quadruple mutant WT A2AR Single mutant\
        \ Double mutant Mutant name - GL0 GL1 GL4 GL5 GL6 GL7 GL8 GL9 GL10 GL11 GL14\
        \ GL15 GL17 GL19 GL20 GL21 GL22 GL24 GL23 Apparent Tm in DDM (\xB0C) A2AR\
        \ mutations - L48A L48A-V12A L48A-A54L L48A-V57A L48A-F62A L48A-T65A L48A-F79A\
        \ L48A-F83A L48A-Q89A L48A-S90A L48A-A236L L48A-I238A L48A-F242A L48A-V282A\
        \ L48A-Q89A-V12A L48A-Q89A-A54L L48A-Q89A-F62A L48A-Q89A-F79A L48A-Q89A-T65A\
        \ Predicted - 42.5 45 47.5 48.5 45 47 45 44 48.5 46 45 45 45 44.5 49.5 52\
        \ 49.5 49.5 51.5 Single measurementa - 42.5 45.5 46 41.5 45 45 45.5 43.5 47.5\
        \ 46 40.5 42.5 39.5 40 46 46 45.5 46 50 Apparent Tm in DM (\xB0C) Predicted\
        \ Single measurementa 44.5 46 44 44.5 Final valuesa 42.2 \xB1 0.3 (n = 2)\
        \ 46 49 44.5 44.5 44.5 \xB1 0.8 (n = 3) Final valuesa 28.6 \xB1 0.2 (n = 8)\
        \ 42.2 \xB1 1.0 (n = 5) 46.7 \xB1 0.4 (n = 3) Triple mutant 49.9 \xB1 0.1\
        \ (n = 2) GL23 GL25 GL26 GL27 GL29 L48A-Q89A-T65A L48A-Q89A-T65A-A50L L48A-Q89A-T65A-A54L\
        \ L48A-Q89A-T65A-F83A L48A-Q89A-T65A- S263A t2:33 a Values were determined\
        \ initially from a single thermostability curve, with measurements performed\
        \ in triplicate, to find the most thermostable mutants; replicate experiments\
        \ were performed only for key mutants.///Therefore, the predicted Nglycosylation\
        \ site Asn154 was mutated to Ala to make A2AR-GL31 (L48A-Q89A-T65A-A54L-N154A).///Among\
        \ the five mutations tested, the best additive effect was observed for the\
        \ A54L mutant.///It is therefore likely that the introduction of the four\
        \ thermostabilising mutations L48A, T65A, Q89A and A54L has induced a conformational\
        \ change in the receptor, and the binding data support the view that the mutant\
        \ is in an agonist-binding conformation between R and R\u204E.///In the crystal\
        \ structure of A2AR bound to ZM241385, both T65A and A54L are located in TM2\
        \ facing the lipid bilayer; thus, it is unclear why these mutations are thermostabilising.///The\
        \ four amino acid residues mutated in A2AR to generate the thermostable mutant\
        \ GL26 (L48A, Q89A, T65A and A54L) are depicted as space-filling models (dark\
        \ grey).///Note that the amino acid sequence shown is that of A2AR-StaR2,\
        \ which also contains the A54L thermostabilising mutation,25 whereas Leu48,\
        \ Gln89 and Thr65 are identical with WT A2AR.", pubmed: '21501622', seq: '54',
    to_res: L}
- {entry_name: acthr_human, from_res: D, info: "Similarly D103N and R128C showed substantial\
        \ plasma membrane expression, as did the other mutants which reached the cell\
        \ surface, (D20N, I44M, D107N and H170L-data not shown).///Furthermore, both\
        \ D20N and I44M demonstrated similar function when compared with Wt-HA-MC2R\
        \ (Figure 5).///Both D20N and I44M were found to have efficient cell surface\
        \ expression and cell signaling.///A further possibility is that both D20N\
        \ and I44M are in linkage disequilibrium with a more functionally significant\
        \ mutation elsewhere in the gene and outside the coding region such as the\
        \ previously reported \u22122 substitution in the MC2R promoter initiator\
        \ element (24;25).", pubmed: '18840636', seq: '20', to_res: N}
- {entry_name: acthr_human, from_res: H, info: 'Similarly D103N and R128C showed substantial
        plasma membrane expression, as did the other mutants which reached the cell
        surface, (D20N, I44M, D107N and H170L-data not shown).///However, all other
        mutants (D103N, D107N, R128C and H170L) had significant impairment of cAMP
        generation, as seen by the decreased luciferase activity.///Four out of six
        trafficking-competent mutations, D103N, D107N, R128C and H170L, failed to
        signal despite receptor cell surface expression.', pubmed: '18840636', seq: '170',
    to_res: L}
- {entry_name: acthr_human, from_res: R, info: "Similarly D103N and R128C showed substantial\
        \ plasma membrane expression, as did the other mutants which reached the cell\
        \ surface, (D20N, I44M, D107N and H170L-data not shown).///Interestingly,\
        \ one of the trafficking-competent mutation located within the 2nd intracellular\
        \ loop of the MC2R is the R128 substitution (R128C), which lies within the\
        \ highly conserved DRY (Asparagine-Arginine-Tyrosine) motif, which is required\
        \ for G protein coupling and activation (17;18).///However, all other mutants\
        \ (D103N, D107N, R128C and H170L) had significant impairment of cAMP generation,\
        \ as seen by the decreased luciferase activity.///Four out of six trafficking-competent\
        \ mutations, D103N, D107N, R128C and H170L, failed to signal despite receptor\
        \ cell surface expression.///The only receptor mutation which traffics successfully\
        \ to the cell surface and is located intracelluarly is R128C.///CHO\u03B1\
        1 cells were transiently transfected with A: Wt-HA-MC2R (positive control);\
        \ B: D103N; C: R128C all of which show good cell surface expression.", pubmed: '18840636',
    seq: '128', to_res: C}
- {entry_name: acthr_human, from_res: D, info: 'Similarly D103N and R128C showed substantial
        plasma membrane expression, as did the other mutants which reached the cell
        surface, (D20N, I44M, D107N and H170L-data not shown).///However, all other
        mutants (D103N, D107N, R128C and H170L) had significant impairment of cAMP
        generation, as seen by the decreased luciferase activity.///Four out of six
        trafficking-competent mutations, D103N, D107N, R128C and H170L, failed to
        signal despite receptor cell surface expression.///Previous studies found
        that both D103N and D107N fail to bind ACTH (10;19).', pubmed: '18840636',
    seq: '107', to_res: N}
- {entry_name: acthr_human, from_res: L, info: "Figure 4b demonstrates interaction\
        \ with MRAP\u03B1 for L55P, I130N, R137W and G226R.///CHO cells were transfected\
        \ with Wt-MC2R, L55P, I130N, R137W and G226R mutants and MRAP\u03B1-Flag (4B).",
    pubmed: '18840636', seq: '55', to_res: P}
- {entry_name: acthr_human, from_res: S, info: "Using a stable Y6 cell expression\
        \ system, we demonstrate that either the C21R or S247G mutations alone produce\
        \ an inactive receptor with loss of ligand binding and responsiveness.///This\
        \ patient was found to have two mutations on the same allele of the MC2R-the\
        \ substitution of Cys 21 by Arg (C21R) and substitution of Ser 247 by Gly\
        \ (S247G).///This patient was found to have two mutations on the same allele\
        \ of the MC2R-the substitution of Cys 21 by Arg (C21R) and substitution of\
        \ Ser 247 by Gly (S247G).///The site directed mutagenesis protocol was then\
        \ repeated using the C21R plasmid as template and introducing the S247G as\
        \ a second mutation within this plasmid.///Clones expressing empty vector\
        \ showed no specific binding with 0.13 \xB1 0.05 pmol ACTH/mg protein, while\
        \ all four independent clones expressing either C21R, S247G or the double\
        \ mutant showed no specific binding: 0.29 \xB1 0.11 pmol ACTH/mg protein for\
        \ C21R, 0.04 \xB1 0.02 pmol ACTH/mg protein for S247G, 0.17 \xB1 0.06 pmol\
        \ ACTH/mg protein for the double mutant.///Clones expressing empty vector\
        \ showed no specific binding with 0.13 \xB1 0.05 pmol ACTH/mg protein, while\
        \ all four independent clones expressing either C21R, S247G or the double\
        \ mutant showed no specific binding: 0.29 \xB1 0.11 pmol ACTH/mg protein for\
        \ C21R, 0.04 \xB1 0.02 pmol ACTH/mg protein for S247G, 0.17 \xB1 0.06 pmol\
        \ ACTH/mg protein for the double mutant.///Clones expressing either the C21R\
        \ or S247G mutant MC2R also showed no significant cAMP accumulation above\
        \ Y6 cells expressing the empty vector alone: C21R: 208 \xB1 8, S247G: 184\
        \ \xB1 22 pmol F.M.///Clones expressing either the C21R or S247G mutant MC2R\
        \ also showed no significant cAMP accumulation above Y6 cells expressing the\
        \ empty vector alone: C21R: 208 \xB1 8, S247G: 184 \xB1 22 pmol F.M.///Swords\
        \ et al. / Molecular and Cellular Endocrinology 213 (2004) 149\u2013154 151\
        \ 20 pmol ACTH bound/ mg protein 500 10 cAMP (pmol/mg protein) 400 300 200\
        \ 100 0 pcDNA3.1 WT p<0.005 0 -10 pcDNA3.1 WT C21R S247G Double C21R S247G\
        \ Double cAMP pmol/mg protein Fig. 1.///Swords et al. / Molecular and Cellular\
        \ Endocrinology 213 (2004) 149\u2013154 151 20 pmol ACTH bound/ mg protein\
        \ 500 10 cAMP (pmol/mg protein) 400 300 200 100 0 pcDNA3.1 WT p<0.005 0 -10\
        \ pcDNA3.1 WT C21R S247G Double C21R S247G Double cAMP pmol/mg protein Fig.\
        \ 1.///Specific binding following a single exposure to 125 I ACTH for each\
        \ individual clone (1\u20134) expressing each different vector: empty vector\
        \ (pcDNA3.1), pcDNA3 containing human wild type MC2R (WT), pcDNA3 containing\
        \ the C21R mutant (C21R), pcDNA3 containing the S247G mutant (S247G), or pcDNA\
        \ containing the C21/S247G double mutant (Double).///Specific binding following\
        \ a single exposure to 125 I ACTH for each individual clone (1\u20134) expressing\
        \ each different vector: empty vector (pcDNA3.1), pcDNA3 containing human\
        \ wild type MC2R (WT), pcDNA3 containing the C21R mutant (C21R), pcDNA3 containing\
        \ the S247G mutant (S247G), or pcDNA containing the C21/S247G double mutant\
        \ (Double).///Specific binding following a single exposure to 125 I ACTH for\
        \ each individual clone (1\u20134) expressing each different vector: empty\
        \ vector (pcDNA3.1), pcDNA3 containing human wild type MC2R (WT), pcDNA3 containing\
        \ the C21R mutant (C21R), pcDNA3 containing the S247G mutant (S247G), or pcDNA\
        \ containing the C21/S247G double mutant (Double).///Mean percentage response\
        \ to ACTH over basal was 39.7 \xB1 19.3% for C21R, 33.8 \xB1 37.5% for S247G,\
        \ 26.7 \xB1 33.7% for the double mutant and \u221214% for cells expressing\
        \ empty vector.///For empty vector ( ), C21R ( ), S247G ( ) and double mutant\
        \ ( ) expressing cells the response to 10\u22126 M ACTH is shown.///Specific\
        \ binding following a single exposure to 125 I ACTH for each individual clone\
        \ expressing: empty vector pcDNA3 and the C21/S247G double mutant, pcDNA3\
        \ and the human wild type MC2R (WT MC2R), or WT MC2R and the double mutant.///Substitution\
        \ of S247 by glycine would then permit the interaction of the arginine at\
        \ position 21 with the acidic active site of the receptor.", pubmed: '15062562',
    seq: '247', to_res: G}
- {entry_name: acthr_human, from_res: G, info: Rhodopsin mutation G90D and a molecular
        mechanism for congenital night blindness., pubmed: '15062562', seq: '90',
    to_res: D}
- {entry_name: acthr_human, from_res: C, info: "Using a stable Y6 cell expression\
        \ system, we demonstrate that either the C21R or S247G mutations alone produce\
        \ an inactive receptor with loss of ligand binding and responsiveness.///This\
        \ patient was found to have two mutations on the same allele of the MC2R-the\
        \ substitution of Cys 21 by Arg (C21R) and substitution of Ser 247 by Gly\
        \ (S247G).///This patient was found to have two mutations on the same allele\
        \ of the MC2R-the substitution of Cys 21 by Arg (C21R) and substitution of\
        \ Ser 247 by Gly (S247G).///The site directed mutagenesis protocol was then\
        \ repeated using the C21R plasmid as template and introducing the S247G as\
        \ a second mutation within this plasmid.///Clones expressing empty vector\
        \ showed no specific binding with 0.13 \xB1 0.05 pmol ACTH/mg protein, while\
        \ all four independent clones expressing either C21R, S247G or the double\
        \ mutant showed no specific binding: 0.29 \xB1 0.11 pmol ACTH/mg protein for\
        \ C21R, 0.04 \xB1 0.02 pmol ACTH/mg protein for S247G, 0.17 \xB1 0.06 pmol\
        \ ACTH/mg protein for the double mutant.///Clones expressing empty vector\
        \ showed no specific binding with 0.13 \xB1 0.05 pmol ACTH/mg protein, while\
        \ all four independent clones expressing either C21R, S247G or the double\
        \ mutant showed no specific binding: 0.29 \xB1 0.11 pmol ACTH/mg protein for\
        \ C21R, 0.04 \xB1 0.02 pmol ACTH/mg protein for S247G, 0.17 \xB1 0.06 pmol\
        \ ACTH/mg protein for the double mutant.///Clones expressing either the C21R\
        \ or S247G mutant MC2R also showed no significant cAMP accumulation above\
        \ Y6 cells expressing the empty vector alone: C21R: 208 \xB1 8, S247G: 184\
        \ \xB1 22 pmol F.M.///Clones expressing either the C21R or S247G mutant MC2R\
        \ also showed no significant cAMP accumulation above Y6 cells expressing the\
        \ empty vector alone: C21R: 208 \xB1 8, S247G: 184 \xB1 22 pmol F.M.///Swords\
        \ et al. / Molecular and Cellular Endocrinology 213 (2004) 149\u2013154 151\
        \ 20 pmol ACTH bound/ mg protein 500 10 cAMP (pmol/mg protein) 400 300 200\
        \ 100 0 pcDNA3.1 WT p<0.005 0 -10 pcDNA3.1 WT C21R S247G Double C21R S247G\
        \ Double cAMP pmol/mg protein Fig. 1.///Swords et al. / Molecular and Cellular\
        \ Endocrinology 213 (2004) 149\u2013154 151 20 pmol ACTH bound/ mg protein\
        \ 500 10 cAMP (pmol/mg protein) 400 300 200 100 0 pcDNA3.1 WT p<0.005 0 -10\
        \ pcDNA3.1 WT C21R S247G Double C21R S247G Double cAMP pmol/mg protein Fig.\
        \ 1.///Specific binding following a single exposure to 125 I ACTH for each\
        \ individual clone (1\u20134) expressing each different vector: empty vector\
        \ (pcDNA3.1), pcDNA3 containing human wild type MC2R (WT), pcDNA3 containing\
        \ the C21R mutant (C21R), pcDNA3 containing the S247G mutant (S247G), or pcDNA\
        \ containing the C21/S247G double mutant (Double).///Specific binding following\
        \ a single exposure to 125 I ACTH for each individual clone (1\u20134) expressing\
        \ each different vector: empty vector (pcDNA3.1), pcDNA3 containing human\
        \ wild type MC2R (WT), pcDNA3 containing the C21R mutant (C21R), pcDNA3 containing\
        \ the S247G mutant (S247G), or pcDNA containing the C21/S247G double mutant\
        \ (Double).///Mean percentage response to ACTH over basal was 39.7 \xB1 19.3%\
        \ for C21R, 33.8 \xB1 37.5% for S247G, 26.7 \xB1 33.7% for the double mutant\
        \ and \u221214% for cells expressing empty vector.///For empty vector ( ),\
        \ C21R ( ), S247G ( ) and double mutant ( ) expressing cells the response\
        \ to 10\u22126 M ACTH is shown.", pubmed: '15062562', seq: '21', to_res: R}
- {entry_name: acthr_human, from_res: R, info: "Results MC2R mutations were found\
        \ in three individuals or kindred (I: homozygous S74I; II: novel compound\
        \ heterozygous R146H/560delT; III: novel homozygous 579-581delTGT).///Clinical\
        \ and biochemical data in patients with severe loss-of-function mutations\
        \ in MC2R I S74I 1 Female II R146H/560delT 1 Male 2 Female III 579\u2013581delTGT\
        \ 1 Male 2 Female 3 Female 4 Female Kindred Mutation Patient Sex Age at presentation\
        \ 3 months 19 months 12 months Clinical presentation Pigmentation Pigmentation\
        \ Pigmentation Hypoglycaemia Hypoglycaemia Hypoglycaemia Jaundice Convulsion\
        \ Viral illness ACTH (pmol/l) 302 \u2013 > 275 (normal range) (< 10) (< 10)\
        \ Cortisol (nmol/l) (basal/peak) < 55/281 < 14/< 14 < 28/< 28a PRA (pmol/ml/h)\
        \ 24\u201330\xB73 3\xB72 1\xB74 (normal range for assay/age) (5\xB70\u2013\
        12) (0\xB71\u20132\xB70) (0\xB78\u20134\xB76) Aldosterone (pmol/l) 1052 \u2013\
        \ 86 (normal range for age) (1000\u20134000) (500\u20131500) Sodium (mmol/l)\
        \ 137 136 129 Potassium (mmol/l) 4\xB73 3\xB79 4\xB70 Treatment HC, FC HC,\
        \ FC* HC, FC* 2 months 4 days 1 day 1 day Pigmentation Pigmentation Pigmentation\
        \ Pigmentation Hypoglycaemia Hypoglycaemia Hypoglycaemia Hypoglycaemia Convulsion\
        \ Convulsion Family history Family history \u2013 \u2013 440 210 (< 10) (<\
        \ 10) 33/10 < 14/< 14 56/45 < 14/19 13\xB75 \u2013 \u2013 \u2013 (5\xB70\u2013\
        12) 1189 \u2013 \u2013 \u2013 (1000\u20134000) 127 147 130 138 6\xB75 5\xB7\
        7 4\xB73 4\xB76 HC, FC HC HC HC, FC Patient II.2 had a normal cortisol response\
        \ to stimulation (peak, 769 nmol/l) at one month of age.///This change likely\
        \ reduces ligand-binding affinity and signal transduction, and has been shown\
        \ to be associated with marked loss of MC2R function in previous in vitro\
        \ studies using Y6 and OS3 cells.10,11 Kindred II (R146H/560delT) The second\
        \ family are from Iran, with an affected boy and girl.///Mutational analysis\
        \ revealed compound heterozygous mutations (R146H/560delT) in MC2R in both\
        \ children (Fig. 2).///The R146H change affects a highly conserved arginine\
        \ in the second intracellular loop of the receptor.///Mutations found in the\
        \ three individuals/kindred reported here (S74I; R146H/560delT; 579\u2013\
        581delTGT) are indicated in boxes. \xA9 2006 The Authors Journal compilation\
        \ \xA9 2006 Blackwell Publishing Ltd, Clinical Endocrinology, 66, 205\u2013\
        210 208 L.///In kindred II (R146H/560delT), the proband presented with a hypoglycaemic\
        \ convulsion at 19 months of age, after an insidious period of failure to\
        \ thrive.", pubmed: '17223989', seq: '146', to_res: H}
- {entry_name: acthr_human, from_res: C, info: 'Our results indicate that four mutations,
        C21S in NH2 terminus, C245S, C251S, and C253S in EL3, resulted in significant
        decrease both in receptor expression and receptor function.///Downloaded from
        ajpregu.physiology.org on May 5, 2011 stituted the extracellular cysteine
        residues, C21, C245, C251, and C253, with serine.///Total ACTH binding was
        significantly reduced at the mutations of C21S, C245S, C251S, and C253S.///Specific
        ACTH binding at C21S, C245S, C251S, and C253S was only 48%, 56%, 46%, and
        38% of that of the hMC2R-WT, respectively (Table 1).///ACTH induced cAMP production
        at C21S, C245S, C251S, and C253S was only 26, 34, 25, 23% of that of the hMC2R-WT,
        respectively (Table 1).///To determine whether the extracellular loop cysteines
        are involved in disulfide bond, the mutant receptors C21S, C231S, C245S, C251S,
        and C253S were treated with DTT.///Our results indicate that DTT treatment
        did not significantly affect ACTH binding affinity and potency at mutant receptor
        C21S, C231S, and C253S, which were already depressed (Table 2).///To determine
        whether this residue is important for receptor function, ACTH binding hMC2RWT
        C21S C64S C158S C191S C231S C245S C251S C253S C267S C293S 100 48 3.8 87 3.2
        78 6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9 0.4 43.4 4.4* 4.6
        0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9* 4.8 0.9 3.7 0.9
        2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8 6.9* 36 8.4*
        3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1 25 5.9 23 6.4
        83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor WT.///Effect
        of double mutations of cysteine residues of hMC2R on ACTH-induced cAMP production
        Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S
        C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S C253S C245S C251S
        C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5
        31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations of cysteine residues
        of hMC2R on ACTH-induced cAMP production Receptor Expression, %WT cAMP Production
        Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S
        C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25
        3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///Effect of
        double mutations of cysteine residues of hMC2R on ACTH-induced cAMP production
        Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S
        C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S C253S C245S C251S
        C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5
        31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations of cysteine residues
        of hMC2R on ACTH-induced cAMP production Receptor Expression, %WT cAMP Production
        Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S
        C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25
        3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///DTT (0 mM)
        Emax, %WT DTT (10 mM) Emax, %WT hMC2RWT C21S C231S C245S C251S C253S 100 24
        3.4 31 6.1 36 7.5 22 6.3 31 2.5 SE.', pubmed: '17596328', seq: '253', to_res: S}
- {entry_name: ccr4_canfa, from_res: K, info: "This compound\u2019s binding is affected\
        \ by mutations K320A, Y314A in the C-terminal tail and D84N (2.40) in TM2.71\
        \ A similar binding site has been identified for other CXCR2 antagonists34\
        \ and is also thought to exist in CCR4 and CCR5 receptors.72 The CXCR4 structure\
        \ gives insight into how non-peptide antagonist ligands can block the activity\
        \ of the much larger peptide agonist CXCL12.", pubmed: '21593763', seq: '320',
    to_res: A}
- {entry_name: acthr_human, from_res: S, info: "Results MC2R mutations were found\
        \ in three individuals or kindred (I: homozygous S74I; II: novel compound\
        \ heterozygous R146H/560delT; III: novel homozygous 579-581delTGT).///Mutational\
        \ analysis of MC2R Following Institutional Board Approval and with informed\
        \ consent, genomic DNA was extracted from peripheral blood lymphocytes and\
        \ the entire coding region of MC2R (exon 2) was amplified using variations\
        \ on conditions reported previously.3 Polymerase chain reaction (PCR) products\
        \ were purified using 1 unit/ml Exonuclease I (New England Biolabs, Hitchin,\
        \ UK) and 0\xB71 unit/ml Shrimp Alkaline Results Kindred I (S74I) Patient\
        \ 1 is a female (46,XX) Causcasian child who presented with a history of prolonged\
        \ jaundice, poor weight gain and progressive hyperpigmentation in the first\
        \ three months of life.///Clinical and biochemical data in patients with severe\
        \ loss-of-function mutations in MC2R I S74I 1 Female II R146H/560delT 1 Male\
        \ 2 Female III 579\u2013581delTGT 1 Male 2 Female 3 Female 4 Female Kindred\
        \ Mutation Patient Sex Age at presentation 3 months 19 months 12 months Clinical\
        \ presentation Pigmentation Pigmentation Pigmentation Hypoglycaemia Hypoglycaemia\
        \ Hypoglycaemia Jaundice Convulsion Viral illness ACTH (pmol/l) 302 \u2013\
        \ > 275 (normal range) (< 10) (< 10) Cortisol (nmol/l) (basal/peak) < 55/281\
        \ < 14/< 14 < 28/< 28a PRA (pmol/ml/h) 24\u201330\xB73 3\xB72 1\xB74 (normal\
        \ range for assay/age) (5\xB70\u201312) (0\xB71\u20132\xB70) (0\xB78\u2013\
        4\xB76) Aldosterone (pmol/l) 1052 \u2013 86 (normal range for age) (1000\u2013\
        4000) (500\u20131500) Sodium (mmol/l) 137 136 129 Potassium (mmol/l) 4\xB7\
        3 3\xB79 4\xB70 Treatment HC, FC HC, FC* HC, FC* 2 months 4 days 1 day 1 day\
        \ Pigmentation Pigmentation Pigmentation Pigmentation Hypoglycaemia Hypoglycaemia\
        \ Hypoglycaemia Hypoglycaemia Convulsion Convulsion Family history Family\
        \ history \u2013 \u2013 440 210 (< 10) (< 10) 33/10 < 14/< 14 56/45 < 14/19\
        \ 13\xB75 \u2013 \u2013 \u2013 (5\xB70\u201312) 1189 \u2013 \u2013 \u2013\
        \ (1000\u20134000) 127 147 130 138 6\xB75 5\xB77 4\xB73 4\xB76 HC, FC HC HC\
        \ HC, FC Patient II.2 had a normal cortisol response to stimulation (peak,\
        \ 769 nmol/l) at one month of age.///Mutational analysis revealed a homozygous\
        \ S74I missense mutation in MC2R (Fig. 2).///Mutations found in the three\
        \ individuals/kindred reported here (S74I; R146H/560delT; 579\u2013581delTGT)\
        \ are indicated in boxes. \xA9 2006 The Authors Journal compilation \xA9 2006\
        \ Blackwell Publishing Ltd, Clinical Endocrinology, 66, 205\u2013210 208 L.///Finally,\
        \ Patient 1 \u2013 who harbours a severe loss-of-function missense mutation\
        \ (S74I) \u2013 had long-standing evidence of subtle disturbances in renin-aldosterone\
        \ and was eventually commenced on fludrocortisone replacement at 4 years of\
        \ age (Fig. 1) as it was felt she had a subtle form of adrenal hypoplasia.///This\
        \ S74I mutation is one of the more frequent mutations reported in MC2R and\
        \ has been reported in approximately 10 patients previously.2 To our knowledge,\
        \ none of these other patients have received mineralocorticoid replacement.",
    pubmed: '17223989', seq: '74', to_res: I}
- {entry_name: acthr_human, from_res: C, info: 'Our results indicate that four mutations,
        C21S in NH2 terminus, C245S, C251S, and C253S in EL3, resulted in significant
        decrease both in receptor expression and receptor function.///Total ACTH binding
        was significantly reduced at the mutations of C21S, C245S, C251S, and C253S.///Specific
        ACTH binding at C21S, C245S, C251S, and C253S was only 48%, 56%, 46%, and
        38% of that of the hMC2R-WT, respectively (Table 1).///ACTH induced cAMP production
        at C21S, C245S, C251S, and C253S was only 26, 34, 25, 23% of that of the hMC2R-WT,
        respectively (Table 1).///To determine whether the extracellular loop cysteines
        are involved in disulfide bond, the mutant receptors C21S, C231S, C245S, C251S,
        and C253S were treated with DTT.///However, incubation of the mutant receptor
        C245S and C251S with 10 mM DTT significantly and partially restored C245S
        and C251S functions by increasing ACTH-induced cAMP production (Fig. 6B).///However,
        incubation of the mutant receptor C245S and C251S with 10 mM DTT significantly
        and partially restored C245S and C251S functions by increasing ACTH-induced
        cAMP production (Fig. 6B).///These findings support the theory in which the
        malfunction of C245S and C251S is caused by the formation of an improper disulfide
        bond rather than by the loss of a disulfide bridge in the absence of Cys-245
        or C251.///To determine whether this residue is important for receptor function,
        ACTH binding hMC2RWT C21S C64S C158S C191S C231S C245S C251S C253S C267S C293S
        100 48 3.8 87 3.2 78 6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9
        0.4 43.4 4.4* 4.6 0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9*
        4.8 0.9 3.7 0.9 2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8
        6.9* 36 8.4* 3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1
        25 5.9 23 6.4 83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor
        WT.///Effect of double mutations of cysteine residues of hMC2R on ACTH-induced
        cAMP production Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT
        C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S
        C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2
        19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations
        of cysteine residues of hMC2R on ACTH-induced cAMP production Receptor Expression,
        %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S
        C253S C231S C245S C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S
        100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5
        SE.///Effect of double mutations of cysteine residues of hMC2R on ACTH-induced
        cAMP production Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT
        C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S
        C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2
        19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations
        of cysteine residues of hMC2R on ACTH-induced cAMP production Receptor Expression,
        %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S
        C253S C231S C245S C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S
        100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5
        SE.///DTT (0 mM) Emax, %WT DTT (10 mM) Emax, %WT hMC2RWT C21S C231S C245S
        C251S C253S 100 24 3.4 31 6.1 36 7.5 22 6.3 31 2.5 SE.///Further studies indicate
        that DTT treatment had minimal impairment of the receptor function at the
        mutant receptor C21 and C253 but partially restored ACTH binding and signaling
        at C245S and C251S, implying that disulfide bonds are broken between these
        conserved Cys residues, in a similar fashion to that observed in the hMC2R
        WT.', pubmed: '17596328', seq: '245', to_res: S}
- {entry_name: acthr_human, from_res: C, info: 'Our results indicate that four mutations,
        C21S in NH2 terminus, C245S, C251S, and C253S in EL3, resulted in significant
        decrease both in receptor expression and receptor function.///Total ACTH binding
        was significantly reduced at the mutations of C21S, C245S, C251S, and C253S.///Specific
        ACTH binding at C21S, C245S, C251S, and C253S was only 48%, 56%, 46%, and
        38% of that of the hMC2R-WT, respectively (Table 1).///ACTH induced cAMP production
        at C21S, C245S, C251S, and C253S was only 26, 34, 25, 23% of that of the hMC2R-WT,
        respectively (Table 1).///To determine whether the extracellular loop cysteines
        are involved in disulfide bond, the mutant receptors C21S, C231S, C245S, C251S,
        and C253S were treated with DTT.///However, incubation of the mutant receptor
        C245S and C251S with 10 mM DTT significantly and partially restored C245S
        and C251S functions by increasing ACTH-induced cAMP production (Fig. 6B).///However,
        incubation of the mutant receptor C245S and C251S with 10 mM DTT significantly
        and partially restored C245S and C251S functions by increasing ACTH-induced
        cAMP production (Fig. 6B).///These findings support the theory in which the
        malfunction of C245S and C251S is caused by the formation of an improper disulfide
        bond rather than by the loss of a disulfide bridge in the absence of Cys-245
        or C251.///To determine whether this residue is important for receptor function,
        ACTH binding hMC2RWT C21S C64S C158S C191S C231S C245S C251S C253S C267S C293S
        100 48 3.8 87 3.2 78 6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9
        0.4 43.4 4.4* 4.6 0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9*
        4.8 0.9 3.7 0.9 2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8
        6.9* 36 8.4* 3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1
        25 5.9 23 6.4 83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor
        WT.///Effect of double mutations of cysteine residues of hMC2R on ACTH-induced
        cAMP production Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT
        C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S
        C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2
        19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations
        of cysteine residues of hMC2R on ACTH-induced cAMP production Receptor Expression,
        %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S
        C253S C231S C245S C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S
        100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5
        SE.///Effect of double mutations of cysteine residues of hMC2R on ACTH-induced
        cAMP production Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT
        C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S
        C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2
        19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations
        of cysteine residues of hMC2R on ACTH-induced cAMP production Receptor Expression,
        %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S
        C253S C231S C245S C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S
        100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5
        SE.///DTT (0 mM) Emax, %WT DTT (10 mM) Emax, %WT hMC2RWT C21S C231S C245S
        C251S C253S 100 24 3.4 31 6.1 36 7.5 22 6.3 31 2.5 SE.///Further studies indicate
        that DTT treatment had minimal impairment of the receptor function at the
        mutant receptor C21 and C253 but partially restored ACTH binding and signaling
        at C245S and C251S, implying that disulfide bonds are broken between these
        conserved Cys residues, in a similar fashion to that observed in the hMC2R
        WT.', pubmed: '17596328', seq: '251', to_res: S}
- {entry_name: acthr_human, from_res: C, info: 'In contrast, the five other mutated
        receptors (C64S, C158S, C191S, C267S, and C293S) did not significantly alter
        ACTH binding affinity and potency.///Mutations of cysteine (C64S, C158S, and
        C191S) did not significantly alter receptor function, and their binding affinities
        Fig. 3.///To determine whether this residue is important for receptor function,
        ACTH binding hMC2RWT C21S C64S C158S C191S C231S C245S C251S C253S C267S C293S
        100 48 3.8 87 3.2 78 6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9
        0.4 43.4 4.4* 4.6 0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9*
        4.8 0.9 3.7 0.9 2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8
        6.9* 36 8.4* 3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1
        25 5.9 23 6.4 83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor
        WT.', pubmed: '17596328', seq: '191', to_res: S}
- {entry_name: acthr_human, from_res: C, info: 'Our results indicate that four mutations,
        C21S in NH2 terminus, C245S, C251S, and C253S in EL3, resulted in significant
        decrease both in receptor expression and receptor function.///Total ACTH binding
        was significantly reduced at the mutations of C21S, C245S, C251S, and C253S.///Specific
        ACTH binding at C21S, C245S, C251S, and C253S was only 48%, 56%, 46%, and
        38% of that of the hMC2R-WT, respectively (Table 1).///ACTH induced cAMP production
        at C21S, C245S, C251S, and C253S was only 26, 34, 25, 23% of that of the hMC2R-WT,
        respectively (Table 1).///To determine whether the extracellular loop cysteines
        are involved in disulfide bond, the mutant receptors C21S, C231S, C245S, C251S,
        and C253S were treated with DTT.///Our results indicate that DTT treatment
        did not significantly affect ACTH binding affinity and potency at mutant receptor
        C21S, C231S, and C253S, which were already depressed (Table 2).///To determine
        whether this residue is important for receptor function, ACTH binding hMC2RWT
        C21S C64S C158S C191S C231S C245S C251S C253S C267S C293S 100 48 3.8 87 3.2
        78 6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9 0.4 43.4 4.4* 4.6
        0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9* 4.8 0.9 3.7 0.9
        2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8 6.9* 36 8.4*
        3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1 25 5.9 23 6.4
        83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor WT.///Effect
        of double mutations of cysteine residues of hMC2R on ACTH-induced cAMP production
        Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S
        C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S C253S C245S C251S
        C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5
        31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations of cysteine residues
        of hMC2R on ACTH-induced cAMP production Receptor Expression, %WT cAMP Production
        Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S
        C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25
        3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///Effect of
        double mutations of cysteine residues of hMC2R on ACTH-induced cAMP production
        Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S
        C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S C253S C245S C251S
        C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5
        31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations of cysteine residues
        of hMC2R on ACTH-induced cAMP production Receptor Expression, %WT cAMP Production
        Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S
        C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25
        3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///DTT (0 mM)
        Emax, %WT DTT (10 mM) Emax, %WT hMC2RWT C21S C231S C245S C251S C253S 100 24
        3.4 31 6.1 36 7.5 22 6.3 31 2.5 SE.', pubmed: '17596328', seq: '21', to_res: S}
- {entry_name: acthr_human, from_res: R, info: 'Interestingly, functional analysis
        of the neighbouring amino acid R128C showed that this mutant traffics to the
        cell surface but fails to signal through loss of high-affinity binding (20,
        21).', pubmed: '19151134', seq: '128', to_res: C}
- {entry_name: acthr_human, from_res: C, info: 'A second cause of increased receptor
        basal activity was described in a patient with two mutations (C21R and S247G)
        on the same allele of the MC2R that had synergistic activity resulting in
        a syndrome of ACTH hypersensitivity (16, 17).', pubmed: '19151134', seq: '21',
    to_res: R}
- {entry_name: acthr_human, from_res: S, info: 'A second cause of increased receptor
        basal activity was described in a patient with two mutations (C21R and S247G)
        on the same allele of the MC2R that had synergistic activity resulting in
        a syndrome of ACTH hypersensitivity (16, 17).', pubmed: '19151134', seq: '247',
    to_res: G}
- {entry_name: acthr_human, from_res: C, info: 'To determine whether the extracellular
        loop cysteines are involved in disulfide bond, the mutant receptors C21S,
        C231S, C245S, C251S, and C253S were treated with DTT.///Our results indicate
        that DTT treatment did not significantly affect ACTH binding affinity and
        potency at mutant receptor C21S, C231S, and C253S, which were already depressed
        (Table 2).///However, mutation C231S dramatically decreased ACTH binding affinity
        and ACTHinduced cAMP accumulation (Fig. 5B).///To determine whether this residue
        is important for receptor function, ACTH binding hMC2RWT C21S C64S C158S C191S
        C231S C245S C251S C253S C267S C293S 100 48 3.8 87 3.2 78 6.8 91 12 65 9.8
        56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9 0.4 43.4 4.4* 4.6 0.1 4.1 0.6 4.8 0.6
        75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9* 4.8 0.9 3.7 0.9 2.8 0.2 83 8.4* 3.8
        0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8 6.9* 36 8.4* 3.2 0.3 2.6 0.8 100
        26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1 25 5.9 23 6.4 83 7.6 94 2.4 Values
        are expressed as means melanocortin-2 receptor WT.///Effect of double mutations
        of cysteine residues of hMC2R on ACTH-induced cAMP production Receptor Expression,
        %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S
        C253S C231S C245S C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S
        100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5
        SE.///Effect of double mutations of cysteine residues of hMC2R on ACTH-induced
        cAMP production Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT
        C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S
        C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2
        19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///Effect of double mutations
        of cysteine residues of hMC2R on ACTH-induced cAMP production Receptor Expression,
        %WT cAMP Production Emax, %WT hMC2RWT C21S C231S C21S C245S C21S C251S C21S
        C253S C231S C245S C231S C251S C231S C253S C245S C251S C245S C253S C251S C253S
        100 27 3.4 25 3.2 21 1.6 17 1.2 19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5
        SE.///Effect of double mutations of cysteine residues of hMC2R on ACTH-induced
        cAMP production Receptor Expression, %WT cAMP Production Emax, %WT hMC2RWT
        C21S C231S C21S C245S C21S C251S C21S C253S C231S C245S C231S C251S C231S
        C253S C245S C251S C245S C253S C251S C253S 100 27 3.4 25 3.2 21 1.6 17 1.2
        19 2.1 29 6.1 22 2.5 31 7.5 32 4.7 18 4.5 SE.///DTT (0 mM) Emax, %WT DTT (10
        mM) Emax, %WT hMC2RWT C21S C231S C245S C251S C253S 100 24 3.4 31 6.1 36 7.5
        22 6.3 31 2.5 SE.', pubmed: '17596328', seq: '231', to_res: S}
- {entry_name: acthr_human, from_res: C, info: 'In contrast, the five other mutated
        receptors (C64S, C158S, C191S, C267S, and C293S) did not significantly alter
        ACTH binding affinity and potency.///Mutations of cysteine (C64S, C158S, and
        C191S) did not significantly alter receptor function, and their binding affinities
        Fig. 3.///To determine whether this residue is important for receptor function,
        ACTH binding hMC2RWT C21S C64S C158S C191S C231S C245S C251S C253S C267S C293S
        100 48 3.8 87 3.2 78 6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9
        0.4 43.4 4.4* 4.6 0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9*
        4.8 0.9 3.7 0.9 2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8
        6.9* 36 8.4* 3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1
        25 5.9 23 6.4 83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor
        WT.', pubmed: '17596328', seq: '158', to_res: S}
- {entry_name: acthr_human, from_res: C, info: 'In contrast, the five other mutated
        receptors (C64S, C158S, C191S, C267S, and C293S) did not significantly alter
        ACTH binding affinity and potency.///Mutations of cysteine (C64S, C158S, and
        C191S) did not significantly alter receptor function, and their binding affinities
        Fig. 3.///To determine whether this residue is important for receptor function,
        ACTH binding hMC2RWT C21S C64S C158S C191S C231S C245S C251S C253S C267S C293S
        100 48 3.8 87 3.2 78 6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9
        0.4 43.4 4.4* 4.6 0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9*
        4.8 0.9 3.7 0.9 2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8
        6.9* 36 8.4* 3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1
        25 5.9 23 6.4 83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor
        WT.', pubmed: '17596328', seq: '64', to_res: S}
- {entry_name: acthr_human, from_res: C, info: 'In contrast, the five other mutated
        receptors (C64S, C158S, C191S, C267S, and C293S) did not significantly alter
        ACTH binding affinity and potency.///Our results indicate that mutation of
        C293S did not significantly alter ACTH binding affinity and potency, preserving
        the wild-type ACTH binding and activation ability.///To determine whether
        this residue is important for receptor function, ACTH binding hMC2RWT C21S
        C64S C158S C191S C231S C245S C251S C253S C267S C293S 100 48 3.8 87 3.2 78
        6.8 91 12 65 9.8 56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9 0.4 43.4 4.4* 4.6
        0.1 4.1 0.6 4.8 0.6 75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9* 4.8 0.9 3.7 0.9
        2.8 0.2 83 8.4* 3.8 0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8 6.9* 36 8.4*
        3.2 0.3 2.6 0.8 100 26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1 25 5.9 23 6.4
        83 7.6 94 2.4 Values are expressed as means melanocortin-2 receptor WT.',
    pubmed: '17596328', seq: '293', to_res: S}
- {entry_name: acthr_human, from_res: C, info: 'In contrast, the five other mutated
        receptors (C64S, C158S, C191S, C267S, and C293S) did not significantly alter
        ACTH binding affinity and potency.///To determine whether this residue is
        important for receptor function, ACTH binding hMC2RWT C21S C64S C158S C191S
        C231S C245S C251S C253S C267S C293S 100 48 3.8 87 3.2 78 6.8 91 12 65 9.8
        56 7.5 46 8.5 38 6.7 89 6.5 91 9.5 3.9 0.4 43.4 4.4* 4.6 0.1 4.1 0.6 4.8 0.6
        75.1 10.6* 53.5 1.2* 27.4 5.9* 78 6.9* 4.8 0.9 3.7 0.9 2.8 0.2 83 8.4* 3.8
        0.51 4.8 0.9 4.3 0.5 103* 81.5 7.9* 64.8 6.9* 36 8.4* 3.2 0.3 2.6 0.8 100
        26 3.9 89 4.5 92 5.2 93 3.3 16 6.1 34 4.1 25 5.9 23 6.4 83 7.6 94 2.4 Values
        are expressed as means melanocortin-2 receptor WT.', pubmed: '17596328', seq: '267',
    to_res: S}
- {entry_name: acthr_human, from_res: S, info: This phenomenon has also been seen
        with MC2R mutations in particular S74I (7)., pubmed: '20427498', seq: '97',
    to_res: I}
- {entry_name: acthr_human, from_res: A, info: "Main Outcome Measures: The mutant\
        \ MC2R-Ala126Ser showed significantly lower activity when it was stimulated\
        \ with ACTH-(1\u201324) than did cells transfected with wild-type MC2R.///We\
        \ also found a novel heterozygous mutation alanine 126 by serine.///Conclusions:\
        \ We propose a molecular explanation for the reduced activity exhibited by\
        \ the MC2R alanine 126 by serine mutant.///Abbreviations: Ala126Ser, Alanine\
        \ 126 by serine; DPPC, 1,2-dipalmitoylphosphatidylcholine; FGD, familial glucocorticoid\
        \ deficiency; GPCR, G protein-coupled receptor; Luc, luciferase; MCR, melanocortin\
        \ receptor; MC2R, ACTH receptor; MD, molecular dynamic, NR, normal range;\
        \ PRA, plasma renin activity; qPCR, real-time PCR; RMSD, root mean square\
        \ deviation; TMH, transmembrane helix.///Abbreviations: Ala126Ser, Alanine\
        \ 126 by serine; DPPC, 1,2-dipalmitoylphosphatidylcholine; FGD, familial glucocorticoid\
        \ deficiency; GPCR, G protein-coupled receptor; Luc, luciferase; MCR, melanocortin\
        \ receptor; MC2R, ACTH receptor; MD, molecular dynamic, NR, normal range;\
        \ PRA, plasma renin activity; qPCR, real-time PCR; RMSD, root mean square\
        \ deviation; TMH, transmembrane helix.///Molecular dynamic (MD) simulations\
        \ performed in explicit membrane conditions, using comparative models of the\
        \ wild-type MC2R and the alanine 126 by serine (Ala126Ser) mutant, permitted\
        \ us to compose a structural hypothesis that could be used to explain this\
        \ reduced activity.///Molecular dynamic (MD) simulations performed in explicit\
        \ membrane conditions, using comparative models of the wild-type MC2R and\
        \ the alanine 126 by serine (Ala126Ser) mutant, permitted us to compose a\
        \ structural hypothesis that could be used to explain this reduced activity.///J\
        \ Clin Endocrinol Metab, August 2008, 93(8):3097\u20133105 jcem.endojournals.org\
        \ 3099 Site-directed mutagenesis and transient transfection pcDNA3.1-MC2R\
        \ plasmid (generously donated by Professor Walter L. Miller, University of\
        \ California, San Francisco, San Francisco, CA) was used to perform the expression\
        \ studies and generate the mutant MC2R cDNA (Ala126Ser) vector (8) by means\
        \ of a site-directed mutagenesis system (Stratagene, La Jolla, CA) and oligonucleotides\
        \ designed following the manufacturer\u2019s instructions.///An Ala126Ser\
        \ mutant model was produced using the BuildMutant module available within\
        \ MODELLER version 8, being subsequently energy optimized using the loop optimization\
        \ procedure available in this program.///For qPCR, 2 l of total cDNA were\
        \ amplified with QuantiSyg (Quantimix Easy SYG kit, BioTools; B&M Labs, S.A.,\
        \ Madrid, Spain) and gene-specific primers (Q-MC2R-S and The MC2R wild-type\
        \ and Ala126Ser mutant models (see supplemental Fig. II) were independently\
        \ embedded in a preequilibrated lipid bilayer consisting of 288 molecules\
        \ of 1,2-dipalmitoylphosphatidylcholine (DPPC) (28).///B, Sequence analysis\
        \ and identification of the MC2R mutation Ala126Ser.///This is a novel mutation\
        \ that results an amino acid change: Ala126Ser, Het(GCG/TCG).///Either father\
        \ or mother carries one of the heterozygous mutations, Ala126Ser and InsA1347Het\
        \ (G217fs), respectively, without symptoms of glucocorticoid deficiency.///Expression\
        \ studies To determine the functional consequences of the Ala126Ser substitution,\
        \ we constructed expression vectors to produce the normal and mutant MC2R\
        \ proteins in suitable mammalian cells.///We then evaluated the surface expression\
        \ of both wild-type and Ala126Ser MC2R through flow cytometry.///To test the\
        \ activity of the Ala126Ser mutation, CHO cells were transfected with MC2R\
        \ wild-type, MC2R-Ala126Ser, and cotransfected with pCREluc and incubated\
        \ with synthetic ACTH-(1\u201324).///To test the activity of the Ala126Ser\
        \ mutation, CHO cells were transfected with MC2R wild-type, MC2R-Ala126Ser,\
        \ and cotransfected with pCREluc and incubated with synthetic ACTH-(1\u2013\
        24).///A mutant model was derived from the MC2R wild-type structure to find\
        \ a putative structural-based explanation to the reduced activity shown by\
        \ the Ala126Ser substitution (supplemental Fig. II).///The surface expression\
        \ of both wild-type (WT) and Ala126Ser MC2R was assessed through flow cytometry.///CHO\
        \ cells were transfected with the vector pcDNA3.1 expressing the wild-type\
        \ MC2R cDNA and mutant MC2R(Ala126Ser) cDNA and cotransfected with the reporter\
        \ plasmid pCREluc cDNA or with an equal mass of empty pcDNA3.1.///To gain\
        \ insights into the dynamic effects of this single substitution, both the\
        \ MC2R wild-type and MC2R-Ala126Ser mutant models were independently embedded\
        \ in a DPPC preequilibrated lipid bilayer and subjected to MD simulations.///With\
        \ the aim to reveal the effects of the 1 angle transient shift, we proceeded\
        \ to compute the 3102 Artigas, Gonzalez et al. Novel Mutation of the ACTH\
        \ Receptor Gene (MC2R) J Clin Endocrinol Metab, August 2008, 93(8):3097\u2013\
        3105 the same simulation time (Fig. 5D), showed significant variations in\
        \ the number and volume of the available binding cavities, in comparison with\
        \ the average ensemble of the Ala126Ser mutant (Fig. 5B).///As can be noted,\
        \ the average ensemble of the Ala126Ser mutant presents a compartmentalized\
        \ and diminished binding site on both sides of the receptor that is not compensated,\
        \ even by summing the available volume cavities.///Discussion In this study\
        \ we described a novel MC2R gene mutation and predicted the resulting MC2R\
        \ 3D structure, in a compound heterozygous patient with FGD phenotype due\
        \ to InsA1347 (maternal) and Ala126Ser (paternal).///Either father or mother\
        \ carries one of the heterozygous mutations, Ala126Ser and insA1347 (G217fs),\
        \ respectively, without symptoms of glucocorticoid deficiency confirming an\
        \ autosomal recessive mode of inheritance and indicating that mutations of\
        \ the ACTH receptor are the cause of the disorder within this family.///A,\
        \ RMSD of the MC2R wild-type (WT) and Ala126Ser protein backbones during simulation.///The\
        \ figure also shows a longitudinal view of the TMH3 C-terminal region at 1,\
        \ 3, and 5 ns of simulation. these pups leads to neonatal lethality in 75%\
        \ of the cases, and those surviving to adultvolume of the receptor cavities\
        \ using the average structures of hood resemble many features observed in\
        \ FGD patients such as the MC2R wild-type and Ala126Ser mutant, extracted\
        \ from undetectable levels of corticosterone (cortisol) despite high levels\
        \ the MD simulation trajectory (Fig. 5, A and B).///However, tall MC2R wild-type\
        \ and the Ala126Ser models resulted in sig- stature is also found in patients\
        \ with MC4R mutations typinificant volumetric variations to the extent that\
        \ the three cav- cally presented with severe obesity (body mass index 40 ities\
        \ available in the wild-type model were transformed into kg/m2) and normal\
        \ adrenal function (42). five cavities: two at the extracellular side and\
        \ three at the The first mutation reported in this study, already described,\
        \ intracellular side of Ala126Ser receptor (see Fig. 5, A and B). corresponding\
        \ to InsA 1347 (G217fs), producing a frameIt is interesting to note that the\
        \ wild-type model obtained at 3 shift loss, generating a premature stop codon\
        \ and an aberrant ns of simulation time (Fig. 5C), mostly conserves the binding\u2019\
        s receptor (43).///However, tall MC2R wild-type and the Ala126Ser models resulted\
        \ in sig- stature is also found in patients with MC4R mutations typinificant\
        \ volumetric variations to the extent that the three cav- cally presented\
        \ with severe obesity (body mass index 40 ities available in the wild-type\
        \ model were transformed into kg/m2) and normal adrenal function (42). five\
        \ cavities: two at the extracellular side and three at the The first mutation\
        \ reported in this study, already described, intracellular side of Ala126Ser\
        \ receptor (see Fig. 5, A and B). corresponding to InsA 1347 (G217fs), producing\
        \ a frameIt is interesting to note that the wild-type model obtained at 3\
        \ shift loss, generating a premature stop codon and an aberrant ns of simulation\
        \ time (Fig. 5C), mostly conserves the binding\u2019s receptor (43).///In\
        \ contrast, the Ala126Ser mutant model, obtained at eliminate the entire TMH7\
        \ of the receptor, including the J Clin Endocrinol Metab, August 2008, 93(8):3097\u2013\
        3105 jcem.endojournals.org 3103 is a novel mutation, corresponding to a guanine\
        \ to thymidine change, converting Ala126 to Ser causing the substitution of\
        \ an apolar (alanine) for a polar (serine) amino acid.///In contrast, the\
        \ Ala126Ser mutant model, obtained at eliminate the entire TMH7 of the receptor,\
        \ including the J Clin Endocrinol Metab, August 2008, 93(8):3097\u20133105\
        \ jcem.endojournals.org 3103 is a novel mutation, corresponding to a guanine\
        \ to thymidine change, converting Ala126 to Ser causing the substitution of\
        \ an apolar (alanine) for a polar (serine) amino acid.///In our study, the\
        \ functional consequences of the novel mutation Ala126Ser were evaluated in\
        \ an assay activity of MC2R in vitro, suggesting that the novel mutation of\
        \ Ala126Ser is impairing the functionality of the receptor by approximately\
        \ 40%.///In our study, the functional consequences of the novel mutation Ala126Ser\
        \ were evaluated in an assay activity of MC2R in vitro, suggesting that the\
        \ novel mutation of Ala126Ser is impairing the functionality of the receptor\
        \ by approximately 40%.///Comparative analyses of cavities between the MC2R\
        \ wild-type and Ala126Ser molecular models.///Volumes (cubic amstrongs) of\
        \ the major cavities identified in the MC2R wild-type and Ala126Ser MD consider\
        \ the available evidence that supports the important role representative structures\
        \ of TMHs 3 and 6, in the activation of various class A GPCRs (49 \u201352).///Thus,\
        \ it is expected that perturbations in the structure WT A126S WT A126S Site\
        \ average (A) average (B) (3ns) (C) (3ns) (D) of TMHs, close to a functionally\
        \ conserved region as DRY, conforms a scenario in which some conformational\
        \ changes could 1 848,125 262 778,5 694,25 2 275,375 51,25 370,375 230,625\
        \ compromise the activation process (53).///Thus, it is expected that perturbations\
        \ in the structure WT A126S WT A126S Site average (A) average (B) (3ns) (C)\
        \ (3ns) (D) of TMHs, close to a functionally conserved region as DRY, conforms\
        \ a scenario in which some conformational changes could 1 848,125 262 778,5\
        \ 694,25 2 275,375 51,25 370,375 230,625 compromise the activation process\
        \ (53).///In searching for these 3 103 198,875 121,25 132,25 changes, a binding\
        \ site analysis was performed using MD rep4 117,5 resentative structures of\
        \ both wild-type and Ala126Ser mutant 5 94,625 MC2R models, results that can\
        \ be reviewed in Fig. 5, A\u2013D and also in Table 1.///Moreover, due to\
        \ the transient nature of the 1 angle shift (Fig. 4B), it is expected that\
        \ the MC2R Ala126Ser mutant could fluctuate within a set of intermediate states\
        \ in which some functionality is retained.///In summary, we report a case\
        \ of FGD associated with a novel Ala126Ser mutation that impairs the functionality\
        \ of the ACTH receptor.///The MC2R structure modeling suggests that the Ala126Ser\
        \ mutation induces a perturbation in TMH 3 that could be related to the observed\
        \ changes in the number and disposition of the receptor internal\u2019s cavities.///These\
        \ observations, as a whole, propose a suitable molecular explanation for the\
        \ reduced activity exhibited by the MC2R Ala126Ser mutant.", pubmed: '18492762',
    seq: '126', to_res: S}
- {entry_name: mshr_mouse, from_res: L, info: "Our results indicate that unlike L156M\
        \ and L133M in hMC3R and hMC4R, M128L did significantly decrease NDNal (2\u2019\
        )7-ACTH1-17 agonist potency, suggesting that this residue is crucial for NDNal\
        \ (2\u2019)7-ACTH1-17 activity (Table 5).", pubmed: '19743876', seq: '156',
    to_res: M}
- {entry_name: mshr_human, from_res: M, info: "Potency of NDNal (2\u2019)7-ACTH1-17\
        \ at the mutations, M128L in hMC1R, L165M in hMC3R and L133M in hMC4R.", pubmed: '19743876',
    seq: '128', to_res: L}
- {entry_name: mc3r_human, from_res: L, info: "We tested L165M of hMC3R and L133M\
        \ of hMC4R and examined the effects of the mutations on NDNal (2\u2019)7-ACTH1-17\
        \ agonist activity.///As shown in Figure 7, our results indicate that L165M\
        \ and L133M did not dramatically increase NDNal (2\u2019)7-ACTH1-17 agonist\
        \ potency, suggesting that these residues are not crucial NDNal (2\u2019)7-ACTH1-17\
        \ agonist activity.///The substitutions of theses residue with methionine\
        \ made SHU9119 from antagonist to agonist (L165M in hMC3R and L133M in hMC4R)\
        \ (42).///Potency of NDNal (2\u2019)7-ACTH1-17 at the mutations, M128L in\
        \ hMC1R, L165M in hMC3R and L133M in hMC4R.///Panel B shows that the effects\
        \ of DPhe7-ACTH1-17 and NDNal (2\u2019)7-ACTH1-17 to stimulate cAMP production\
        \ at L165M of the hMC3R.///NIH-PA Author Manuscript NIH-PA Author Manuscript\
        \ NIH-PA Author Manuscript hMC1R-M128L NDP-\u03B1-MSH DPhe7-ACTH1-17 NDNal(2')7-ACTH1-17\
        \ 0.63 \xB1 0.1 0.71 \xB1 0.3 >103 EC50 (nM) hMC3R-L165M 3.2 \xB1 0.2 3.7\
        \ \xB1 0.1 78 \xB1 14 MC4R-L133M 1.9 \xB1 0.2 2.3 \xB1 0.3 121 \xB1 11 Biochemistry.",
    pubmed: '19743876', seq: '165', to_res: M}
- {entry_name: mshr_human, from_res: S, info: '', pubmed: '19743876', seq: '130',
    to_res: L}
- {entry_name: mc4r_human, from_res: L, info: "We tested L165M of hMC3R and L133M\
        \ of hMC4R and examined the effects of the mutations on NDNal (2\u2019)7-ACTH1-17\
        \ agonist activity.///As shown in Figure 7, our results indicate that L165M\
        \ and L133M did not dramatically increase NDNal (2\u2019)7-ACTH1-17 agonist\
        \ potency, suggesting that these residues are not crucial NDNal (2\u2019)7-ACTH1-17\
        \ agonist activity.///Our results indicate that unlike L156M and L133M in\
        \ hMC3R and hMC4R, M128L did significantly decrease NDNal (2\u2019)7-ACTH1-17\
        \ agonist potency, suggesting that this residue is crucial for NDNal (2\u2019\
        )7-ACTH1-17 activity (Table 5).///The substitutions of theses residue with\
        \ methionine made SHU9119 from antagonist to agonist (L165M in hMC3R and L133M\
        \ in hMC4R) (42).///Potency of NDNal (2\u2019)7-ACTH1-17 at the mutations,\
        \ M128L in hMC1R, L165M in hMC3R and L133M in hMC4R.///Panel C shows that\
        \ the effects of NDPhe7-ACTH1-17 and NDNal (2\u2019)7-ACTH1-17 to stimulate\
        \ cAMP production at L133M of the hMC4R.///NIH-PA Author Manuscript NIH-PA\
        \ Author Manuscript NIH-PA Author Manuscript hMC1R-M128L NDP-\u03B1-MSH DPhe7-ACTH1-17\
        \ NDNal(2')7-ACTH1-17 0.63 \xB1 0.1 0.71 \xB1 0.3 >103 EC50 (nM) hMC3R-L165M\
        \ 3.2 \xB1 0.2 3.7 \xB1 0.1 78 \xB1 14 MC4R-L133M 1.9 \xB1 0.2 2.3 \xB1 0.3\
        \ 121 \xB1 11 Biochemistry.", pubmed: '19743876', seq: '155', to_res: M}
- {entry_name: acthr_human, from_res: F, info: "Methods and results: MC2R gene analysis\
        \ revealed an unusual combination of two homozygous missense mutations, consisting\
        \ of the novel mutation Y129C and the previously described F278C activating\
        \ mutation.///The double mutant Y129C-F278C also failed to traffic to the\
        \ cell surface.///Furthermore, the absence of cell surface expression of MC2R\
        \ would account for the lack of activation of the receptor due to the F278C\
        \ mutation located at the C-terminal tail.///The missense mutation, resulting\
        \ in the substitution of a phenylalanine residue by a cysteine at position\
        \ 278 (F278C) in the C-terminal tail, was functionally characterised by Swords\
        \ et al. (15).///A combination of cAMP accumulation, ACTH competitive binding\
        \ and receptor internalisation assays were used to show that the F278C mutant\
        \ receptor was at the cell surface and exhibited increased basal activity\
        \ behaving as a receptor with constitutive activity.///3xHA-Y129C and 3xHA-F278C\
        \ single MC2R mutants, in addition to 3xHA-Y129C-F278C double mutant MC2R\
        \ were generated using the Quick Change site-directed mutagenesis protocol\
        \ (Stratagene, Amsterdam, The Netherlands).///3xHA-Y129C and 3xHA-F278C single\
        \ MC2R mutants, in addition to 3xHA-Y129C-F278C double mutant MC2R were generated\
        \ using the Quick Change site-directed mutagenesis protocol (Stratagene, Amsterdam,\
        \ The Netherlands).///Fluorescent cell surface assay and confocal microscopy\
        \ MRAPa stable cells were grown in 24-well plates and transfected with WT\
        \ 3xHA-MC2R, 3xHA-Y129C, 3xHA-F278C or 3xHA-Y129C-F278C construct.///Fluorescent\
        \ cell surface assay and confocal microscopy MRAPa stable cells were grown\
        \ in 24-well plates and transfected with WT 3xHA-MC2R, 3xHA-Y129C, 3xHA-F278C\
        \ or 3xHA-Y129C-F278C construct.///Statistical analysis Experiments were performed\
        \ in duplicate, and the results represent the mean of three independent experiments\
        \ (with the exception of 3xHA-F278C; nZ2).///The second mutation, also A to\
        \ G, is the previously described F278C activating mutation (substituting the\
        \ phenylalanine at position 278 with a cysteine residue).///Partial sequence\
        \ of the MC2R showing the Y129C mutation and F278C mutation in heterozygosity\
        \ in the parents and homozygosity in index case (filled box).///Y129C single\
        \ mutant fails to traffic to the cell surface and is intracellularly retained,\
        \ despite interacting with MRAP: Y129C-F278C double mutant also fails to traffic\
        \ to the cell surface The transient transfection of WT 3xHA-MC2R into MRAPa\
        \ stably transfected CHO cells enable efficient surface expression of the\
        \ receptor in this heterologous cell line.///The 3xHA-F278C mutant receptor\
        \ traffics efficiently to the cell surface.///By contrast, the 3xHAY129C and\
        \ 3xHA-Y129C-F278C mutants fail to traffic to the plasma membrane in the presence\
        \ of MRAP (Fig. 2).///Confocal imaging shows surface localisation of the F278C\
        \ mutant receptor but intracellular retention of the Y129C and Y129C-F278C\
        \ double mutant protein.///Confocal imaging shows surface localisation of\
        \ the F278C mutant receptor but intracellular retention of the Y129C and Y129C-F278C\
        \ double mutant protein.///Using CHO cells transiently co-transfected with\
        \ 3xHA-Y129C and MRAP-FLAG, immunoprecipitation of mutant Y129C using anti-HA,\
        \ www.eje-online.org 708 L F Chan, T-T Chung and others EUROPEAN JOURNAL OF\
        \ ENDOCRINOLOGY (2009) 160 Figure 2 (A) Failed surface localisation of the\
        \ Y129C single mutant receptor and Y129C-F278C double mutant receptor in MRAP\
        \ expressing cell lines.///In comparison, WT MC2R and F278C mutation traffics\
        \ efficiently to the plasma membrane in the presence of MRAP.///Fluorescent\
        \ cell surface assay performed in duplicate in three independent experiments\
        \ (with the exception of F278C experiments, nZ2).///Surface expression of\
        \ Y129C was included as part of a larger study (21) (B) Confocal images to\
        \ show the intracellular retention of the 3xHA-Y129C and Y129C-F278C mutant\
        \ in MRAP stable cell lines.///By contrast, the WT 3xHA-MC2R and 3xHA-F278C\
        \ in the presence of MRAP localises to the cell surface efficiently.///One\
        \ of these mutations (F278C mutation) was previously studied in www.eje-online.org\
        \ EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009) 160 great detail and shown to cause\
        \ constitutive MC2R activity.///Specifically, surface expression of F278C\
        \ mutant receptor was demonstrated by [125] ACTH binding assays (15).///We\
        \ therefore assessed the second mutation, a novel inactivating missense mutation,\
        \ Y129C, located in the second intracellular loop in isolation and with the\
        \ F278C mutation.///We hypothesised that the Y129C mutation may affect cell\
        \ surface expression of MC2R, which would provide an explanation for the apparent\
        \ lack of activation secondary to the F278C mutation.///The inability of the\
        \ Y129C mutant receptor to localise to the cell surface in this child essentially\
        \ inactivates the ability of the F278C mutation to cause constitutive activity\
        \ and a Cushing\u2019s syndrome phenotype, thus providing a unique molecular\
        \ explanation for the existence of two opposing MC2R mutations resulting in\
        \ FGD.", pubmed: '19151134', seq: '278', to_res: C}
- {entry_name: acthr_human, from_res: Y, info: "European Journal of Endocrinology\
        \ (2009) 160 705\u2013710 ISSN 0804-4643 CASE REPORT Functional consequence\
        \ of a novel Y129C mutation in a patient with two contradictory melanocortin-2-receptor\
        \ mutations Li F Chan*, Teng-Teng Chung*, Ahmed F Massoud1, Louise A Metherell\
        \ and Adrian J L Clark Queen Mary University of London, Centre for Endocrinology,\
        \ Barts & the London School of Medicine & Dentistry, London EC1M 6BQ, UK and\
        \ 1 Department of Paediatrics, Northwick Park Hospital, Harrow, Middlesex,\
        \ London, UK (Correspondence should be addressed to A J L Clark; Email: a.j.clark@qmul.ac.uk)\
        \ *(L F Chan and T-T Chung contributed equally to this work) Abstract Context:\
        \ Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disease,\
        \ characterised by isolated glucocorticoid deficiency in the absence of mineralocorticoid\
        \ deficiency.///Methods and results: MC2R gene analysis revealed an unusual\
        \ combination of two homozygous missense mutations, consisting of the novel\
        \ mutation Y129C and the previously described F278C activating mutation.///In\
        \ vitro analysis of the Y129C mutation using a fluorescent cell surface assay\
        \ showed that this mutant was unable to reach the cell surface in CHO cells\
        \ stably transfected with MC2R accessory protein (MRAP), despite the demonstration\
        \ of an interaction with MRAP by co-immunoprecipitation.///The double mutant\
        \ Y129C-F278C also failed to traffic to the cell surface.///3xHA-Y129C and\
        \ 3xHA-F278C single MC2R mutants, in addition to 3xHA-Y129C-F278C double mutant\
        \ MC2R were generated using the Quick Change site-directed mutagenesis protocol\
        \ (Stratagene, Amsterdam, The Netherlands).///3xHA-Y129C and 3xHA-F278C single\
        \ MC2R mutants, in addition to 3xHA-Y129C-F278C double mutant MC2R were generated\
        \ using the Quick Change site-directed mutagenesis protocol (Stratagene, Amsterdam,\
        \ The Netherlands).///Western blot and co-immunoprecipitation (Co-IP) The\
        \ interaction between MRAP and mutant MC2R was assessed by Co-IP using a FLAG-tagged\
        \ MRAP construct and 3xHA-Y129C mutant receptor.///Fluorescent cell surface\
        \ assay and confocal microscopy MRAPa stable cells were grown in 24-well plates\
        \ and transfected with WT 3xHA-MC2R, 3xHA-Y129C, 3xHA-F278C or 3xHA-Y129C-F278C\
        \ construct.///Fluorescent cell surface assay and confocal microscopy MRAPa\
        \ stable cells were grown in 24-well plates and transfected with WT 3xHA-MC2R,\
        \ 3xHA-Y129C, 3xHA-F278C or 3xHA-Y129C-F278C construct.///The first of these\
        \ is a novel homozygous mutation of an A to G nucleotide substitution resulting\
        \ in the Y129C change (substitution of the tyrosine residue with a cysteine\
        \ at position 129).///Partial sequence of the MC2R showing the Y129C mutation\
        \ and F278C mutation in heterozygosity in the parents and homozygosity in\
        \ index case (filled box).///(B) Pseudostructural plot of the MC2R showing\
        \ the location of Y129C in the second intracellular loop and F278C* in the\
        \ C-terminal tail.///Y129C single mutant fails to traffic to the cell surface\
        \ and is intracellularly retained, despite interacting with MRAP: Y129C-F278C\
        \ double mutant also fails to traffic to the cell surface The transient transfection\
        \ of WT 3xHA-MC2R into MRAPa stably transfected CHO cells enable efficient\
        \ surface expression of the receptor in this heterologous cell line.///Y129C\
        \ single mutant fails to traffic to the cell surface and is intracellularly\
        \ retained, despite interacting with MRAP: Y129C-F278C double mutant also\
        \ fails to traffic to the cell surface The transient transfection of WT 3xHA-MC2R\
        \ into MRAPa stably transfected CHO cells enable efficient surface expression\
        \ of the receptor in this heterologous cell line.///By contrast, the 3xHAY129C\
        \ and 3xHA-Y129C-F278C mutants fail to traffic to the plasma membrane in the\
        \ presence of MRAP (Fig. 2).///Confocal imaging shows surface localisation\
        \ of the F278C mutant receptor but intracellular retention of the Y129C and\
        \ Y129C-F278C double mutant protein.///Confocal imaging shows surface localisation\
        \ of the F278C mutant receptor but intracellular retention of the Y129C and\
        \ Y129C-F278C double mutant protein.///Using CHO cells transiently co-transfected\
        \ with 3xHA-Y129C and MRAP-FLAG, immunoprecipitation of mutant Y129C using\
        \ anti-HA, www.eje-online.org 708 L F Chan, T-T Chung and others EUROPEAN\
        \ JOURNAL OF ENDOCRINOLOGY (2009) 160 Figure 2 (A) Failed surface localisation\
        \ of the Y129C single mutant receptor and Y129C-F278C double mutant receptor\
        \ in MRAP expressing cell lines.///Using CHO cells transiently co-transfected\
        \ with 3xHA-Y129C and MRAP-FLAG, immunoprecipitation of mutant Y129C using\
        \ anti-HA, www.eje-online.org 708 L F Chan, T-T Chung and others EUROPEAN\
        \ JOURNAL OF ENDOCRINOLOGY (2009) 160 Figure 2 (A) Failed surface localisation\
        \ of the Y129C single mutant receptor and Y129C-F278C double mutant receptor\
        \ in MRAP expressing cell lines.///Using CHO cells transiently co-transfected\
        \ with 3xHA-Y129C and MRAP-FLAG, immunoprecipitation of mutant Y129C using\
        \ anti-HA, www.eje-online.org 708 L F Chan, T-T Chung and others EUROPEAN\
        \ JOURNAL OF ENDOCRINOLOGY (2009) 160 Figure 2 (A) Failed surface localisation\
        \ of the Y129C single mutant receptor and Y129C-F278C double mutant receptor\
        \ in MRAP expressing cell lines.///Using CHO cells transiently co-transfected\
        \ with 3xHA-Y129C and MRAP-FLAG, immunoprecipitation of mutant Y129C using\
        \ anti-HA, www.eje-online.org 708 L F Chan, T-T Chung and others EUROPEAN\
        \ JOURNAL OF ENDOCRINOLOGY (2009) 160 Figure 2 (A) Failed surface localisation\
        \ of the Y129C single mutant receptor and Y129C-F278C double mutant receptor\
        \ in MRAP expressing cell lines.///Surface expression of Y129C was included\
        \ as part of a larger study (21) (B) Confocal images to show the intracellular\
        \ retention of the 3xHA-Y129C and Y129C-F278C mutant in MRAP stable cell lines.///Surface\
        \ expression of Y129C was included as part of a larger study (21) (B) Confocal\
        \ images to show the intracellular retention of the 3xHA-Y129C and Y129C-F278C\
        \ mutant in MRAP stable cell lines.///Surface expression of Y129C was included\
        \ as part of a larger study (21) (B) Confocal images to show the intracellular\
        \ retention of the 3xHA-Y129C and Y129C-F278C mutant in MRAP stable cell lines.///(C)\
        \ Co-immunoprecipitation of MRAP-FLAG and HA tagged receptor show direct interaction\
        \ between MRAP and Y129C receptor as well as WT MC2R.///The Y129C trafficking\
        \ was one of the mutations studied as part of a larger study (21).///We therefore\
        \ assessed the second mutation, a novel inactivating missense mutation, Y129C,\
        \ located in the second intracellular loop in isolation and with the F278C\
        \ mutation.///We hypothesised that the Y129C mutation may affect cell surface\
        \ expression of MC2R, which would provide an explanation for the apparent\
        \ lack of activation secondary to the F278C mutation.///We tested this hypothesis\
        \ by studying the ability of the Y129C receptor to traffic to the cell surface,\
        \ using a fluorescent cell surface assay.///Transfection of the Y129C single\
        \ and double mutant MC2R into CHO cells stably transfected with MRAP revealed\
        \ that the Y129C mutant fails to reach the cell surface, despite its interaction\
        \ with MRAP.///Transfection of the Y129C single and double mutant MC2R into\
        \ CHO cells stably transfected with MRAP revealed that the Y129C mutant fails\
        \ to reach the cell surface, despite its interaction with MRAP.///The inability\
        \ of the Y129C mutant receptor to localise to the cell surface in this child\
        \ essentially inactivates the ability of the F278C mutation to cause constitutive\
        \ activity and a Cushing\u2019s syndrome phenotype, thus providing a unique\
        \ molecular explanation for the existence of two opposing MC2R mutations resulting\
        \ in FGD.", pubmed: '19151134', seq: '129', to_res: C}
- {entry_name: hrh1_human, from_res: R, info: "CRTH2 negatively regulates adenylyl\
        \ cyABBREVIATIONS: PDG2, prostaglandin D2; DP, prostaglandin D receptor; CRTH2,\
        \ chemoattractant receptor-homologous molecule expressed on T helper 2 cells;\
        \ Th2, T helper 2; TM27868, 1-(4-ethoxyphenyl)-5-methoxy-2-methylindole-3-carboxylic\
        \ acid; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent\
        \ assay; -arr2, -arrestin2; arr2-GFP2, green fluorescent protein- -arrestin2-(R393E,\
        \ R395E) fusion protein; CRTH2-Rluc, Renilla reniformis luciferase-CRTH2 fusion\
        \ protein; HEK, human embryonic kidney; BRET, bioluminescence resonance energy\
        \ transfer; HBSS, Hanks\u2019 balanced salt solution; DMSO, dimethyl sulfoxide;\
        \ BSA, bovine serum albumin; PBS, phosphate-buffered saline; GTP S, guanosine\
        \ 5 -O-(3-thio)triphosphate; PTX, pertussis toxin; EXP3174, 2-butyl-4-chloro-1-((2\
        \ -(1H-tetrazol-5-yl)(1,1 -biphenyl)-4-yl)methyl)1H-imidazole-5-carboxylic\
        \ acid; SC-54629, 1-(2,6-dimethylphenyl)-4-butyl-1,3-dihydro-3-((6-(2-(1H-tetrazol-5-yl)phenyl)-3-pyridinyl)methyl)2H-imidazol-2-one;\
        \ SC-54628, 1-(2-methylphenyl)-4-butyl-1,3-dihydro-3-((6-(2-(1H-tetrazol-5-yl)phenyl)-3-pyridinyl)methyl)-2H-imidazol-2-one;\
        \ TM30642, 3-{3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic\
        \ acid; TM30643, [3-(4-fluoro-benzenesulfonylamino)-1,2,3,4-tetrahydro-carbazol-9-yl]-acetic\
        \ acid; TM30089, {3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}acetic\
        \ acid.///Human -arrestin2 ( -arr2) N-terminally tagged with GFP2 (GFP2/ -arr2)\
        \ and R. reniformis luciferase were purchased from Packard BioSignal Inc.\
        \ The -arr2 mutant incapable of interacting with the endocytic machinery (\
        \ - arr2, R393E, R395E) was a generous gift from R.///To perform the functional\
        \ bioluminescence resonance energy transfer (BRET) assays, a HEK293 cell clone\
        \ stably expressing arr2-R393E, R395E-GFP2, and CRTH2-Rluc was generated.///Functional\
        \ BRET2 (hereafter referred to as BRET) assays were performed on HEK293 cells\
        \ stably expressing human CRTH2-Rluc and GFP2- -arr2, R393E, R395E essentially\
        \ as described previously (Vrecl et al., 2004).///Use of the BRET2 assay and\
        \ the GFP2- -arr2, R393E, R395E mutant for BRET2 requires a license from 7TM\
        \ Pharma A/S.///Andresen for excellent technical assistance, to Kate Hansen\
        \ for excellent cloning support, and to Anders Heding (7TM Pharma A/S) for\
        \ development of the improved BRET2 assay using the GFP2- -arr2, R393E, R395E\
        \ mutant. References", pubmed: '16418339', seq: '395', to_res: E}
- {entry_name: hrh1_human, from_res: R, info: "CRTH2 negatively regulates adenylyl\
        \ cyABBREVIATIONS: PDG2, prostaglandin D2; DP, prostaglandin D receptor; CRTH2,\
        \ chemoattractant receptor-homologous molecule expressed on T helper 2 cells;\
        \ Th2, T helper 2; TM27868, 1-(4-ethoxyphenyl)-5-methoxy-2-methylindole-3-carboxylic\
        \ acid; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent\
        \ assay; -arr2, -arrestin2; arr2-GFP2, green fluorescent protein- -arrestin2-(R393E,\
        \ R395E) fusion protein; CRTH2-Rluc, Renilla reniformis luciferase-CRTH2 fusion\
        \ protein; HEK, human embryonic kidney; BRET, bioluminescence resonance energy\
        \ transfer; HBSS, Hanks\u2019 balanced salt solution; DMSO, dimethyl sulfoxide;\
        \ BSA, bovine serum albumin; PBS, phosphate-buffered saline; GTP S, guanosine\
        \ 5 -O-(3-thio)triphosphate; PTX, pertussis toxin; EXP3174, 2-butyl-4-chloro-1-((2\
        \ -(1H-tetrazol-5-yl)(1,1 -biphenyl)-4-yl)methyl)1H-imidazole-5-carboxylic\
        \ acid; SC-54629, 1-(2,6-dimethylphenyl)-4-butyl-1,3-dihydro-3-((6-(2-(1H-tetrazol-5-yl)phenyl)-3-pyridinyl)methyl)2H-imidazol-2-one;\
        \ SC-54628, 1-(2-methylphenyl)-4-butyl-1,3-dihydro-3-((6-(2-(1H-tetrazol-5-yl)phenyl)-3-pyridinyl)methyl)-2H-imidazol-2-one;\
        \ TM30642, 3-{3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic\
        \ acid; TM30643, [3-(4-fluoro-benzenesulfonylamino)-1,2,3,4-tetrahydro-carbazol-9-yl]-acetic\
        \ acid; TM30089, {3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}acetic\
        \ acid.///Human -arrestin2 ( -arr2) N-terminally tagged with GFP2 (GFP2/ -arr2)\
        \ and R. reniformis luciferase were purchased from Packard BioSignal Inc.\
        \ The -arr2 mutant incapable of interacting with the endocytic machinery (\
        \ - arr2, R393E, R395E) was a generous gift from R.///To perform the functional\
        \ bioluminescence resonance energy transfer (BRET) assays, a HEK293 cell clone\
        \ stably expressing arr2-R393E, R395E-GFP2, and CRTH2-Rluc was generated.///Functional\
        \ BRET2 (hereafter referred to as BRET) assays were performed on HEK293 cells\
        \ stably expressing human CRTH2-Rluc and GFP2- -arr2, R393E, R395E essentially\
        \ as described previously (Vrecl et al., 2004).///Use of the BRET2 assay and\
        \ the GFP2- -arr2, R393E, R395E mutant for BRET2 requires a license from 7TM\
        \ Pharma A/S.///Andresen for excellent technical assistance, to Kate Hansen\
        \ for excellent cloning support, and to Anders Heding (7TM Pharma A/S) for\
        \ development of the improved BRET2 assay using the GFP2- -arr2, R393E, R395E\
        \ mutant. References", pubmed: '16418339', seq: '393', to_res: E}
- {entry_name: tshr_human, from_res: P, info: "For most of the mutants TSH-mediated\
        \ cAMP accumulation was comparable to wild type or slightly decreased (not\
        \ under 50% compared to maximum of Table 1. Alanine mutagenesis and functional\
        \ characterization of amino acids in the ICL1 and transitions to the helices\
        \ 1 and 2. Construct Cell surface expression cAMP accumulation IP accumulation\
        \ [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100 mU/ml TSH constitutive\
        \ activity (slope) basal 100 mU/ml TSH wt TSHR pcDNA I438A L439A L440A T441A\
        \ S442A H443A Y444A K445A L446A N447A V448A P449A R450A F451A 100 361 10866\
        \ 9565 8365b 8267a 8964 9465 10467 9266 5263 5764 1 0.260.1 0.860.3 2.960.5\
        \ 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b\
        \ 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4 2.560.9 25.161.0\
        \ 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c 17.560.7c\
        \ 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c a 16.960.7\
        \ 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2 13.761.1\
        \ 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7 3.260.6\
        \ 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4 3.160.3\
        \ a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267 a 8167b\
        \ 4966a COS-7 cells were transfected with wt TSHR or various mutant TSHRs.",
    pubmed: '20305779', seq: '449', to_res: A}
- {entry_name: tshr_human, from_res: H, info: 'Construct Cell surface expression cAMP
        accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal
        100mU/ml TSH basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E
        R450K R450M R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4
        14.360.8 9.161.2c 4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3
        1.960.3 2.060.2 2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c
        12.861.9c 22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1
        0.560.1 0.960.1 0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666
        8065 6165 c 6965c COS-7 cells were transfected with wt TSHR or various mutant
        TSHRs.', pubmed: '20305779', seq: '443', to_res: R}
- {entry_name: tshr_human, from_res: R, info: 'Furthermore, at position 450 a naturally
        occurring loss-of-function mutation R450H has been reported [42].', pubmed: '20305779',
    seq: '450', to_res: H}
- {entry_name: tshr_human, from_res: S, info: 'Several mutations identified by mutagenesis
        studies (L417V, TMH1 [64]; S562A, ECL2 [64]; Y605A, TMH5 [41]; N658A, ECL3
        [65]) of the TSHR are characterized by the same functional finding.', pubmed: '20305779',
    seq: '562', to_res: A}
- {entry_name: tshr_human, from_res: T, info: "In contrast to this newly identified\
        \ constitutively activating mutation (CAM) the mutants L440A, T441A, S442A,\
        \ Y444A, V448A and R450A displayed decreased basal cAMP accumulation.///For\
        \ most of the mutants TSH-mediated cAMP accumulation was comparable to wild\
        \ type or slightly decreased (not under 50% compared to maximum of Table 1.\
        \ Alanine mutagenesis and functional characterization of amino acids in the\
        \ ICL1 and transitions to the helices 1 and 2. Construct Cell surface expression\
        \ cAMP accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR\
        \ basal 100 mU/ml TSH constitutive activity (slope) basal 100 mU/ml TSH wt\
        \ TSHR pcDNA I438A L439A L440A T441A S442A H443A Y444A K445A L446A N447A V448A\
        \ P449A R450A F451A 100 361 10866 9565 8365b 8267a 8964 9465 10467 9266 5263\
        \ 5764 1 0.260.1 0.860.3 2.960.5 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2\
        \ 16.660.8 0.360.1 9.361.3b 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013 \u2013 \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4\
        \ 2.560.9 25.161.0 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c\
        \ 17.560.7c 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c\
        \ a 16.960.7 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2\
        \ 13.761.1 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7\
        \ 3.260.6 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4\
        \ 3.160.3 a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267\
        \ a 8167b 4966a COS-7 cells were transfected with wt TSHR or various mutant\
        \ TSHRs.///Alanine mutations of I438 and S442 in ICL1 and R450 at the junction\
        \ with TMH2 decrease both cAMP and IP-mediated cascades, while L440A, T441A\
        \ and H443A in ICL1 impair IP activation selectively.", pubmed: '20305779',
    seq: '441', to_res: A}
- {entry_name: lt4r1_human, from_res: C, info: 'All rights reserved ARTICLE RESEARCH
        cleavable signal sequence followed by the M1 Flag epitope (DYKDDDDA), the
        Tobacco etch virus (TEV) protease recognition sequence (ENLYFQG), bacteriophage
        T4 lysozyme from N2 through Y161 including C54T and C97A mutations, and a
        two residue alanine linker fused to the human b2AR sequence D29 through G365.',
    pubmed: '21772288', seq: '97', to_res: A}
- {entry_name: tshr_human, from_res: R, info: 'Construct Cell surface expression cAMP
        accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal
        100mU/ml TSH basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E
        R450K R450M R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4
        14.360.8 9.161.2c 4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3
        1.960.3 2.060.2 2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c
        12.861.9c 22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1
        0.560.1 0.960.1 0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666
        8065 6165 c 6965c COS-7 cells were transfected with wt TSHR or various mutant
        TSHRs.', pubmed: '20305779', seq: '450', to_res: E}
- {entry_name: tshr_human, from_res: H, info: "For most of the mutants TSH-mediated\
        \ cAMP accumulation was comparable to wild type or slightly decreased (not\
        \ under 50% compared to maximum of Table 1. Alanine mutagenesis and functional\
        \ characterization of amino acids in the ICL1 and transitions to the helices\
        \ 1 and 2. Construct Cell surface expression cAMP accumulation IP accumulation\
        \ [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100 mU/ml TSH constitutive\
        \ activity (slope) basal 100 mU/ml TSH wt TSHR pcDNA I438A L439A L440A T441A\
        \ S442A H443A Y444A K445A L446A N447A V448A P449A R450A F451A 100 361 10866\
        \ 9565 8365b 8267a 8964 9465 10467 9266 5263 5764 1 0.260.1 0.860.3 2.960.5\
        \ 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b\
        \ 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4 2.560.9 25.161.0\
        \ 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c 17.560.7c\
        \ 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c a 16.960.7\
        \ 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2 13.761.1\
        \ 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7 3.260.6\
        \ 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4 3.160.3\
        \ a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267 a 8167b\
        \ 4966a COS-7 cells were transfected with wt TSHR or various mutant TSHRs.///Alanine\
        \ mutations of I438 and S442 in ICL1 and R450 at the junction with TMH2 decrease\
        \ both cAMP and IP-mediated cascades, while L440A, T441A and H443A in ICL1\
        \ impair IP activation selectively.", pubmed: '20305779', seq: '443', to_res: A}
- {entry_name: tshr_human, from_res: K, info: 'In detail, mutation K618A located in
        the transition between ICL3 and TMH6 was reported to decrease Gq-mediated
        IP only and not Gs-related cAMP accumulation [41].', pubmed: '20305779', seq: '618',
    to_res: A}
- {entry_name: tshr_human, from_res: L, info: "The expression rate of mutants L446A,\
        \ N447A and F451A was less than 60% of the wild type.///For most of the mutants\
        \ TSH-mediated cAMP accumulation was comparable to wild type or slightly decreased\
        \ (not under 50% compared to maximum of Table 1. Alanine mutagenesis and functional\
        \ characterization of amino acids in the ICL1 and transitions to the helices\
        \ 1 and 2. Construct Cell surface expression cAMP accumulation IP accumulation\
        \ [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100 mU/ml TSH constitutive\
        \ activity (slope) basal 100 mU/ml TSH wt TSHR pcDNA I438A L439A L440A T441A\
        \ S442A H443A Y444A K445A L446A N447A V448A P449A R450A F451A 100 361 10866\
        \ 9565 8365b 8267a 8964 9465 10467 9266 5263 5764 1 0.260.1 0.860.3 2.960.5\
        \ 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b\
        \ 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4 2.560.9 25.161.0\
        \ 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c 17.560.7c\
        \ 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c a 16.960.7\
        \ 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2 13.761.1\
        \ 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7 3.260.6\
        \ 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4 3.160.3\
        \ a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267 a 8167b\
        \ 4966a COS-7 cells were transfected with wt TSHR or various mutant TSHRs.",
    pubmed: '20305779', seq: '446', to_res: A}
- {entry_name: tshr_human, from_res: I, info: "For most of the mutants TSH-mediated\
        \ cAMP accumulation was comparable to wild type or slightly decreased (not\
        \ under 50% compared to maximum of Table 1. Alanine mutagenesis and functional\
        \ characterization of amino acids in the ICL1 and transitions to the helices\
        \ 1 and 2. Construct Cell surface expression cAMP accumulation IP accumulation\
        \ [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100 mU/ml TSH constitutive\
        \ activity (slope) basal 100 mU/ml TSH wt TSHR pcDNA I438A L439A L440A T441A\
        \ S442A H443A Y444A K445A L446A N447A V448A P449A R450A F451A 100 361 10866\
        \ 9565 8365b 8267a 8964 9465 10467 9266 5263 5764 1 0.260.1 0.860.3 2.960.5\
        \ 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b\
        \ 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4 2.560.9 25.161.0\
        \ 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c 17.560.7c\
        \ 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c a 16.960.7\
        \ 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2 13.761.1\
        \ 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7 3.260.6\
        \ 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4 3.160.3\
        \ a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267 a 8167b\
        \ 4966a COS-7 cells were transfected with wt TSHR or various mutant TSHRs.///doi:10.1371/journal.pone.0009745.g002\
        \ wild type), except for mutants I438A, S442A and R450A,Q,E which have significantly\
        \ impaired signaling activity.", pubmed: '20305779', seq: '438', to_res: A}
- {entry_name: tshr_human, from_res: Y, info: 'Several mutations identified by mutagenesis
        studies (L417V, TMH1 [64]; S562A, ECL2 [64]; Y605A, TMH5 [41]; N658A, ECL3
        [65]) of the TSHR are characterized by the same functional finding.', pubmed: '20305779',
    seq: '605', to_res: A}
- {entry_name: tshr_human, from_res: S, info: "In contrast to this newly identified\
        \ constitutively activating mutation (CAM) the mutants L440A, T441A, S442A,\
        \ Y444A, V448A and R450A displayed decreased basal cAMP accumulation.///For\
        \ most of the mutants TSH-mediated cAMP accumulation was comparable to wild\
        \ type or slightly decreased (not under 50% compared to maximum of Table 1.\
        \ Alanine mutagenesis and functional characterization of amino acids in the\
        \ ICL1 and transitions to the helices 1 and 2. Construct Cell surface expression\
        \ cAMP accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR\
        \ basal 100 mU/ml TSH constitutive activity (slope) basal 100 mU/ml TSH wt\
        \ TSHR pcDNA I438A L439A L440A T441A S442A H443A Y444A K445A L446A N447A V448A\
        \ P449A R450A F451A 100 361 10866 9565 8365b 8267a 8964 9465 10467 9266 5263\
        \ 5764 1 0.260.1 0.860.3 2.960.5 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2\
        \ 16.660.8 0.360.1 9.361.3b 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013 \u2013 \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4\
        \ 2.560.9 25.161.0 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c\
        \ 17.560.7c 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c\
        \ a 16.960.7 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2\
        \ 13.761.1 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7\
        \ 3.260.6 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4\
        \ 3.160.3 a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267\
        \ a 8167b 4966a COS-7 cells were transfected with wt TSHR or various mutant\
        \ TSHRs.///doi:10.1371/journal.pone.0009745.g002 wild type), except for mutants\
        \ I438A, S442A and R450A,Q,E which have significantly impaired signaling activity.",
    pubmed: '20305779', seq: '442', to_res: A}
- {entry_name: opsd_bovin, from_res: E, info: "Notably, the ionic lock, a salt bridge\
        \ between Arg135 (3.50) and Glu247 (6.30), is also broken in these structures;\
        \ this is another element that is thought to contribute to the activation\
        \ process.79 Changes in other so-called \u201Cmicroswitches\u201D are also\
        \ observed.45 More recent insights into the stages of receptor activation\
        \ have come from an agonist-bound structure of rhodopsin containing a constitutively\
        \ active mutation E113Q (3.28)46 (Figure 5B).", pubmed: '21593763', seq: '113',
    to_res: Q}
- {entry_name: tshr_human, from_res: K, info: "For most of the mutants TSH-mediated\
        \ cAMP accumulation was comparable to wild type or slightly decreased (not\
        \ under 50% compared to maximum of Table 1. Alanine mutagenesis and functional\
        \ characterization of amino acids in the ICL1 and transitions to the helices\
        \ 1 and 2. Construct Cell surface expression cAMP accumulation IP accumulation\
        \ [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100 mU/ml TSH constitutive\
        \ activity (slope) basal 100 mU/ml TSH wt TSHR pcDNA I438A L439A L440A T441A\
        \ S442A H443A Y444A K445A L446A N447A V448A P449A R450A F451A 100 361 10866\
        \ 9565 8365b 8267a 8964 9465 10467 9266 5263 5764 1 0.260.1 0.860.3 2.960.5\
        \ 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b\
        \ 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4 2.560.9 25.161.0\
        \ 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c 17.560.7c\
        \ 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c a 16.960.7\
        \ 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2 13.761.1\
        \ 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7 3.260.6\
        \ 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4 3.160.3\
        \ a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267 a 8167b\
        \ 4966a COS-7 cells were transfected with wt TSHR or various mutant TSHRs.",
    pubmed: '20305779', seq: '445', to_res: A}
- {entry_name: tshr_human, from_res: R, info: 'Construct Cell surface expression cAMP
        accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal
        100mU/ml TSH basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E
        R450K R450M R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4
        14.360.8 9.161.2c 4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3
        1.960.3 2.060.2 2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c
        12.861.9c 22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1
        0.560.1 0.960.1 0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666
        8065 6165 c 6965c COS-7 cells were transfected with wt TSHR or various mutant
        TSHRs.///Interestingly, the R450M substitution showed cAMP accumulation of
        around 80% of the wild type.///However, since mutation R450M selectively impairs
        IP but not cAMP accumulation (Table 2), we conclude that R450 of TSHR does
        not interact with a hydrophilic residue such as Q349 in the Cterminal region
        of Gas.', pubmed: '20305779', seq: '450', to_res: M}
- {entry_name: tshr_human, from_res: L, info: 'For the TSHR it is reported that the
        naturally occurring loss-of-function mutation, L653V [29], in extracellular
        loop 3 leads to a selective impairment of IP but not of cAMP accumulation
        after TSH treatment.', pubmed: '20305779', seq: '653', to_res: V}
- {entry_name: tshr_human, from_res: R, info: 'Construct Cell surface expression cAMP
        accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal
        100mU/ml TSH basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E
        R450K R450M R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4
        14.360.8 9.161.2c 4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3
        1.960.3 2.060.2 2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c
        12.861.9c 22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1
        0.560.1 0.960.1 0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666
        8065 6165 c 6965c COS-7 cells were transfected with wt TSHR or various mutant
        TSHRs.', pubmed: '20305779', seq: '450', to_res: Q}
- {entry_name: tshr_human, from_res: L, info: 'Several mutations identified by mutagenesis
        studies (L417V, TMH1 [64]; S562A, ECL2 [64]; Y605A, TMH5 [41]; N658A, ECL3
        [65]) of the TSHR are characterized by the same functional finding.', pubmed: '20305779',
    seq: '417', to_res: V}
- {entry_name: tshr_human, from_res: L, info: "Mutation L439A in TMH1 was characterized\
        \ by an increased basal Gas mediated cAMP signaling compared to wt (Table\
        \ 1).///For most of the mutants TSH-mediated cAMP accumulation was comparable\
        \ to wild type or slightly decreased (not under 50% compared to maximum of\
        \ Table 1. Alanine mutagenesis and functional characterization of amino acids\
        \ in the ICL1 and transitions to the helices 1 and 2. Construct Cell surface\
        \ expression cAMP accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS %\
        \ of wt TSHR basal 100 mU/ml TSH constitutive activity (slope) basal 100 mU/ml\
        \ TSH wt TSHR pcDNA I438A L439A L440A T441A S442A H443A Y444A K445A L446A\
        \ N447A V448A P449A R450A F451A 100 361 10866 9565 8365b 8267a 8964 9465 10467\
        \ 9266 5263 5764 1 0.260.1 0.860.3 2.960.5 0.660.1 0.560.1 0.560.1 0.760.1\
        \ 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b 1 \u2013 \u2013 3.760.6 \u2013\
        \ \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\u2013 \u2013 \u2013\
        \ \u2013 3.060.3 3.760.4 2.560.9 25.161.0 3.760.4 4.161.1c 22.360.5 14.160.9c\
        \ 8.660.2c 9.760.5c 11.760.3c 17.560.7c 19.960.9c 12.361.2c 9.960.7c 16.762.3c\
        \ 26.863.1 4.160.5c 10.860.9c a 16.960.7 15.661.3 14.161.3 10.261.2b 13.561.4\
        \ 16.161.6 14.861.6 15.161.2 13.761.1 14.960.8 18.661.8 11.761.5b 11.961.6c\
        \ c 2.660.5 2.860.7 3.560.7 3.260.6 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6\
        \ 2.560.1 3.360.3 3.460.4 3.160.3 a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1\
        \ 0.560.1 71610 9267 a 8167b 4966a COS-7 cells were transfected with wt TSHR\
        \ or various mutant TSHRs.///Constitutive activity by linear regression analyses\
        \ was determined for mutant L439A.///Distinct amino acid side-chains of the\
        \ ICL1 and its spatial conformation are important for (selective) G-protein\
        \ activation Discussion Despite fast progress in the investigation of molecular\
        \ mechanisms concerning contacts between receptor and G-protein [18,19,22]\
        \ or mechanisms of G-protein activation, fundamental questions regarding these\
        \ processes are still open such as: How and We identified L439A in TMH1 as\
        \ a new CAM with elevated basal CAMP activation.", pubmed: '20305779', seq: '439',
    to_res: A}
- {entry_name: tshr_human, from_res: Y, info: "In contrast to this newly identified\
        \ constitutively activating mutation (CAM) the mutants L440A, T441A, S442A,\
        \ Y444A, V448A and R450A displayed decreased basal cAMP accumulation.///For\
        \ most of the mutants TSH-mediated cAMP accumulation was comparable to wild\
        \ type or slightly decreased (not under 50% compared to maximum of Table 1.\
        \ Alanine mutagenesis and functional characterization of amino acids in the\
        \ ICL1 and transitions to the helices 1 and 2. Construct Cell surface expression\
        \ cAMP accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR\
        \ basal 100 mU/ml TSH constitutive activity (slope) basal 100 mU/ml TSH wt\
        \ TSHR pcDNA I438A L439A L440A T441A S442A H443A Y444A K445A L446A N447A V448A\
        \ P449A R450A F451A 100 361 10866 9565 8365b 8267a 8964 9465 10467 9266 5263\
        \ 5764 1 0.260.1 0.860.3 2.960.5 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2\
        \ 16.660.8 0.360.1 9.361.3b 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013 \u2013 \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4\
        \ 2.560.9 25.161.0 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c\
        \ 17.560.7c 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c\
        \ a 16.960.7 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2\
        \ 13.761.1 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7\
        \ 3.260.6 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4\
        \ 3.160.3 a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267\
        \ a 8167b 4966a COS-7 cells were transfected with wt TSHR or various mutant\
        \ TSHRs.", pubmed: '20305779', seq: '444', to_res: A}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '234',
    to_res: A}
- {entry_name: taar1_mouse, from_res: A, info: 'To determine if tyramine and 1 have
        similar or distinct binding modes, we mutated alanine 5.42 in rTAAR1 to a
        threonine, leucine, or isoleucine [rTAAR1(A5.42T), rTAAR1(A5.42L), and rTAAR1(A5.42I),
        respectively] and examined the effects of the mutations on the potency of
        tyramine and 1.', pubmed: '19256523', seq: '193', to_res: I}
- {entry_name: tshr_human, from_res: F, info: "The expression rate of mutants L446A,\
        \ N447A and F451A was less than 60% of the wild type.///For most of the mutants\
        \ TSH-mediated cAMP accumulation was comparable to wild type or slightly decreased\
        \ (not under 50% compared to maximum of Table 1. Alanine mutagenesis and functional\
        \ characterization of amino acids in the ICL1 and transitions to the helices\
        \ 1 and 2. Construct Cell surface expression cAMP accumulation IP accumulation\
        \ [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100 mU/ml TSH constitutive\
        \ activity (slope) basal 100 mU/ml TSH wt TSHR pcDNA I438A L439A L440A T441A\
        \ S442A H443A Y444A K445A L446A N447A V448A P449A R450A F451A 100 361 10866\
        \ 9565 8365b 8267a 8964 9465 10467 9266 5263 5764 1 0.260.1 0.860.3 2.960.5\
        \ 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b\
        \ 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4 2.560.9 25.161.0\
        \ 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c 17.560.7c\
        \ 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c a 16.960.7\
        \ 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2 13.761.1\
        \ 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7 3.260.6\
        \ 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4 3.160.3\
        \ a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267 a 8167b\
        \ 4966a COS-7 cells were transfected with wt TSHR or various mutant TSHRs.",
    pubmed: '20305779', seq: '451', to_res: A}
- {entry_name: tshr_human, from_res: R, info: 'Construct Cell surface expression cAMP
        accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal
        100mU/ml TSH basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E
        R450K R450M R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4
        14.360.8 9.161.2c 4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3
        1.960.3 2.060.2 2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c
        12.861.9c 22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1
        0.560.1 0.960.1 0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666
        8065 6165 c 6965c COS-7 cells were transfected with wt TSHR or various mutant
        TSHRs.///Moreover, since the R450K mutant also impairs IP (Gq) mediated signaling
        selectively, it is assumed that it is not the positive charge but rather the
        full H-donator function and/or size of the arginine in position 450 which
        is necessary for establishing the Gaq specific interaction.', pubmed: '20305779',
    seq: '450', to_res: K}
- {entry_name: tshr_human, from_res: V, info: "In contrast to this newly identified\
        \ constitutively activating mutation (CAM) the mutants L440A, T441A, S442A,\
        \ Y444A, V448A and R450A displayed decreased basal cAMP accumulation.///For\
        \ most of the mutants TSH-mediated cAMP accumulation was comparable to wild\
        \ type or slightly decreased (not under 50% compared to maximum of Table 1.\
        \ Alanine mutagenesis and functional characterization of amino acids in the\
        \ ICL1 and transitions to the helices 1 and 2. Construct Cell surface expression\
        \ cAMP accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR\
        \ basal 100 mU/ml TSH constitutive activity (slope) basal 100 mU/ml TSH wt\
        \ TSHR pcDNA I438A L439A L440A T441A S442A H443A Y444A K445A L446A N447A V448A\
        \ P449A R450A F451A 100 361 10866 9565 8365b 8267a 8964 9465 10467 9266 5263\
        \ 5764 1 0.260.1 0.860.3 2.960.5 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2\
        \ 16.660.8 0.360.1 9.361.3b 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013 \u2013 \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4\
        \ 2.560.9 25.161.0 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c\
        \ 17.560.7c 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c\
        \ a 16.960.7 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2\
        \ 13.761.1 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7\
        \ 3.260.6 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4\
        \ 3.160.3 a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267\
        \ a 8167b 4966a COS-7 cells were transfected with wt TSHR or various mutant\
        \ TSHRs.", pubmed: '20305779', seq: '448', to_res: A}
- {entry_name: tshr_human, from_res: H, info: 'Construct Cell surface expression cAMP
        accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal
        100mU/ml TSH basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E
        R450K R450M R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4
        14.360.8 9.161.2c 4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3
        1.960.3 2.060.2 2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c
        12.861.9c 22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1
        0.560.1 0.960.1 0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666
        8065 6165 c 6965c COS-7 cells were transfected with wt TSHR or various mutant
        TSHRs.', pubmed: '20305779', seq: '443', to_res: F}
- {entry_name: tshr_human, from_res: N, info: 'Several mutations identified by mutagenesis
        studies (L417V, TMH1 [64]; S562A, ECL2 [64]; Y605A, TMH5 [41]; N658A, ECL3
        [65]) of the TSHR are characterized by the same functional finding.', pubmed: '20305779',
    seq: '658', to_res: A}
- {entry_name: tshr_human, from_res: H, info: 'Construct Cell surface expression cAMP
        accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal
        100mU/ml TSH basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E
        R450K R450M R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4
        14.360.8 9.161.2c 4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3
        1.960.3 2.060.2 2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c
        12.861.9c 22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1
        0.560.1 0.960.1 0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666
        8065 6165 c 6965c COS-7 cells were transfected with wt TSHR or various mutant
        TSHRs.', pubmed: '20305779', seq: '443', to_res: E}
- {entry_name: tshr_human, from_res: L, info: "In contrast to this newly identified\
        \ constitutively activating mutation (CAM) the mutants L440A, T441A, S442A,\
        \ Y444A, V448A and R450A displayed decreased basal cAMP accumulation.///For\
        \ most of the mutants TSH-mediated cAMP accumulation was comparable to wild\
        \ type or slightly decreased (not under 50% compared to maximum of Table 1.\
        \ Alanine mutagenesis and functional characterization of amino acids in the\
        \ ICL1 and transitions to the helices 1 and 2. Construct Cell surface expression\
        \ cAMP accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR\
        \ basal 100 mU/ml TSH constitutive activity (slope) basal 100 mU/ml TSH wt\
        \ TSHR pcDNA I438A L439A L440A T441A S442A H443A Y444A K445A L446A N447A V448A\
        \ P449A R450A F451A 100 361 10866 9565 8365b 8267a 8964 9465 10467 9266 5263\
        \ 5764 1 0.260.1 0.860.3 2.960.5 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2\
        \ 16.660.8 0.360.1 9.361.3b 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013 \u2013 \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4\
        \ 2.560.9 25.161.0 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c\
        \ 17.560.7c 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c\
        \ a 16.960.7 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2\
        \ 13.761.1 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7\
        \ 3.260.6 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4\
        \ 3.160.3 a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267\
        \ a 8167b 4966a COS-7 cells were transfected with wt TSHR or various mutant\
        \ TSHRs.///Alanine mutations of I438 and S442 in ICL1 and R450 at the junction\
        \ with TMH2 decrease both cAMP and IP-mediated cascades, while L440A, T441A\
        \ and H443A in ICL1 impair IP activation selectively.", pubmed: '20305779',
    seq: '440', to_res: A}
- {entry_name: opsd_bovin, from_res: D, info: "List of Published GPCR Crystal Structures\
        \ PERSPECTIVE receptor Rhodopsin: bovine rod outer segment Rhodopsin: bovine\
        \ rod outer segment Rhodopsin: bovine rod outer segment Rhodopsin: bovine\
        \ rod outer segment Rhodopsin, photoactivated: bovine rod outer segment Rhodopsin:\
        \ recombinant bovine rhodopsin mutant, N2C/D282C Rhodopsin: squid Rhodopsin:\
        \ squid Human \u03B22 adrenergic receptor Fab5 complex.", pubmed: '21593763',
    seq: '282', to_res: C}
- {entry_name: tshr_human, from_res: N, info: "The expression rate of mutants L446A,\
        \ N447A and F451A was less than 60% of the wild type.///For most of the mutants\
        \ TSH-mediated cAMP accumulation was comparable to wild type or slightly decreased\
        \ (not under 50% compared to maximum of Table 1. Alanine mutagenesis and functional\
        \ characterization of amino acids in the ICL1 and transitions to the helices\
        \ 1 and 2. Construct Cell surface expression cAMP accumulation IP accumulation\
        \ [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100 mU/ml TSH constitutive\
        \ activity (slope) basal 100 mU/ml TSH wt TSHR pcDNA I438A L439A L440A T441A\
        \ S442A H443A Y444A K445A L446A N447A V448A P449A R450A F451A 100 361 10866\
        \ 9565 8365b 8267a 8964 9465 10467 9266 5263 5764 1 0.260.1 0.860.3 2.960.5\
        \ 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2 16.660.8 0.360.1 9.361.3b\
        \ 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4 2.560.9 25.161.0\
        \ 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c 17.560.7c\
        \ 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c a 16.960.7\
        \ 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2 13.761.1\
        \ 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7 3.260.6\
        \ 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4 3.160.3\
        \ a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267 a 8167b\
        \ 4966a COS-7 cells were transfected with wt TSHR or various mutant TSHRs.",
    pubmed: '20305779', seq: '447', to_res: A}
- {entry_name: tshr_human, from_res: R, info: 'We constructed the R687A mutation and
        tested it functionally.///Construct Cell surface expression cAMP accumulation
        IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR basal 100mU/ml TSH
        basal 100mU/ml TSH wt TSHR pcDNA H443F H443E H443R R450Q R450E R450K R450M
        R687A 100 460 7764 1 0.260.1 13.761.1 0.260.1 10.561.1 10.960.4 14.360.8 9.161.2c
        4.860.6c 12.560.3 11.760.5 10.960.8 1.960.2 2.160.2 1.960.3 1.960.3 2.060.2
        2.460.1 2.460.2 2.260.2 2.060.3 2.361.0 23.862.6 2.260.2 3.160.3c 12.861.9c
        22.962.5 8.360.6c 2.560.2b 7.361.1c 3.160.5b 7.860.6b b 0.560.1 0.560.1 0.960.1
        0.460.1 0.360.1 0.560.1 0.560.2 1.060.2 9964 10362 9261 8666 8065 6165 c 6965c
        COS-7 cells were transfected with wt TSHR or various mutant TSHRs.///Indeed
        mutation R687A decreased the IP accumulation significantly to 25% of the wild
        type without affecting cAMP signaling (Table 2).', pubmed: '20305779', seq: '687',
    to_res: A}
- {entry_name: tshr_human, from_res: R, info: "In contrast to this newly identified\
        \ constitutively activating mutation (CAM) the mutants L440A, T441A, S442A,\
        \ Y444A, V448A and R450A displayed decreased basal cAMP accumulation.///For\
        \ most of the mutants TSH-mediated cAMP accumulation was comparable to wild\
        \ type or slightly decreased (not under 50% compared to maximum of Table 1.\
        \ Alanine mutagenesis and functional characterization of amino acids in the\
        \ ICL1 and transitions to the helices 1 and 2. Construct Cell surface expression\
        \ cAMP accumulation IP accumulation [IPs (%IP/IPs + PI)] FACS % of wt TSHR\
        \ basal 100 mU/ml TSH constitutive activity (slope) basal 100 mU/ml TSH wt\
        \ TSHR pcDNA I438A L439A L440A T441A S442A H443A Y444A K445A L446A N447A V448A\
        \ P449A R450A F451A 100 361 10866 9565 8365b 8267a 8964 9465 10467 9266 5263\
        \ 5764 1 0.260.1 0.860.3 2.960.5 0.660.1 0.560.1 0.560.1 0.760.1 0.660.1 0.760.2\
        \ 16.660.8 0.360.1 9.361.3b 1 \u2013 \u2013 3.760.6 \u2013 \u2013 \u2013 \u2013\
        \ \u2013 \u2013 \u2013 \u2013 \u2013\u2013 \u2013 \u2013 \u2013 3.060.3 3.760.4\
        \ 2.560.9 25.161.0 3.760.4 4.161.1c 22.360.5 14.160.9c 8.660.2c 9.760.5c 11.760.3c\
        \ 17.560.7c 19.960.9c 12.361.2c 9.960.7c 16.762.3c 26.863.1 4.160.5c 10.860.9c\
        \ a 16.960.7 15.661.3 14.161.3 10.261.2b 13.561.4 16.161.6 14.861.6 15.161.2\
        \ 13.761.1 14.960.8 18.661.8 11.761.5b 11.961.6c c 2.660.5 2.860.7 3.560.7\
        \ 3.260.6 3.060.8 2.960.6 3.360.3 2.960.5 2.960.6 2.560.1 3.360.3 3.460.4\
        \ 3.160.3 a a b 0.560.1 0.760.0 0.660.1 0.960.1 0.460.1 0.560.1 71610 9267\
        \ a 8167b 4966a COS-7 cells were transfected with wt TSHR or various mutant\
        \ TSHRs.///doi:10.1371/journal.pone.0009745.g002 wild type), except for mutants\
        \ I438A, S442A and R450A,Q,E which have significantly impaired signaling activity.///If\
        \ the interacting conformations of Gaq and Gas with TSHR were identical then\
        \ an interaction of R450 with the H-bond accepting residue Q349 of Gas would\
        \ be expected and indeed, the mutants R450A,Q,E significantly change the biophysical\
        \ properties and impair both Gs and Gq subtype mediated signaling cascades.",
    pubmed: '20305779', seq: '450', to_res: A}
- {entry_name: acthr_mouse, from_res: S, info: "A mutant MC2R in which the single\
        \ consensus PKA phosphorylation site has been mutated (S208A) when expressed\
        \ in MC2R-negative Y6 cells is also unable to desensitize.///Functional response\
        \ of the mutant MC2R, S208A, to ACTH stimulation and desensitization. a, dose\
        \ response curves to a single ACTH stimulation of Y6 cells stably expressing\
        \ either the wild type (E) or S208A mutant MC2R (q). b, desensitization of\
        \ wild type (E) and S208A mutant MC2R (q) in Y6 cells.///Functional response\
        \ of the mutant MC2R, S208A, to ACTH stimulation and desensitization. a, dose\
        \ response curves to a single ACTH stimulation of Y6 cells stably expressing\
        \ either the wild type (E) or S208A mutant MC2R (q). b, desensitization of\
        \ wild type (E) and S208A mutant MC2R (q) in Y6 cells.///Functional response\
        \ of the mutant MC2R, S208A, to ACTH stimulation and desensitization. a, dose\
        \ response curves to a single ACTH stimulation of Y6 cells stably expressing\
        \ either the wild type (E) or S208A mutant MC2R (q). b, desensitization of\
        \ wild type (E) and S208A mutant MC2R (q) in Y6 cells.///Cells were stimulated\
        \ with 10 6 M ACTH for varying times as shown, then restimulated with the\
        \ same dose of ACTH for 30 min. *, p 0.05. gene (S208A) was stably expressed\
        \ in Y6 cells.///Stable cell lines expressing the wild type and S208A receptors\
        \ were selected.///These receptors expressed in Y6 cells have highly comparable\
        \ function with very similar EC50 values (1.8 10 7 M (wild type); 2.1 10 7\
        \ M (S208A) although these values are about an order of magnitude greater\
        \ than that of the endogenous MC2R expressed by Y1 cells (Figs. 1a and 4a).///In\
        \ accordance with the result obtained using H89, desensitization is absent\
        \ for the first 30 \u2013 60 min in cells expressing S208A in comparison with\
        \ the wild type MC2R-expressing cells (Fig. 4b).///S208A and wild type MC2R-expressing\
        \ cell lines show highly comparable dose response curves, yet the mutant receptor\
        \ shows a similar effect on early desensitization (Fig. 4b) as is seen when\
        \ Y1 cells are treated with H89 (Fig. 3a).", pubmed: '11579104', seq: '208',
    to_res: A}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '318',
    to_res: A}
- {entry_name: mc3r_human, from_res: E, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).', pubmed: '16430209', seq: '131', to_res: A}
- {entry_name: mc3r_human, from_res: K, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).', pubmed: '16430209', seq: '197', to_res: A}
- {entry_name: mc3r_human, from_res: D, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).', pubmed: '16430209', seq: '158', to_res: A}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '290',
    to_res: A}
- {entry_name: mc3r_human, from_res: I, info: Functional analysis of this altered
        MC3R (I183N) has indicated that the mutation completely abolishes agonist-mediated
        receptor activation.///Functional analysis of this MC3R mutation (I183N) has
        indicated that the mutation completely abolishes agonist-mediated receptor
        activation (16)., pubmed: '16430209', seq: '183', to_res: N}
- {entry_name: mc3r_human, from_res: R, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).', pubmed: '16430209', seq: '196', to_res: A}
- {entry_name: mc3r_human, from_res: H, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).', pubmed: '16430209', seq: '317', to_res: A}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '233',
    to_res: A}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '288',
    to_res: A}
- {entry_name: mc3r_human, from_res: D, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).', pubmed: '16430209', seq: '154', to_res: A}
- {entry_name: adrb2_human, from_res: E, info: "Complex with cyanopindolol Human \u03B2\
        2 adrenergic receptor: T4 lysozyme replaces ICL3, E122W stability mutation.",
    pubmed: '21593763', seq: '122', to_res: W}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '295',
    to_res: A}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '216',
    to_res: A}
- {entry_name: mc3r_human, from_res: D, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).///No positive FLAG signals were observed in the mutant D121A and D332A,
        but positive FLAG signals were observed in the mutant D121N and D332N.///Our
        next step was to substitute these two residues, D131 and D332, with asparagines
        (D131N, D332N) instead of alanine, and again assess effects on receptor expression
        and function.///We were now able to observe dose-dependent displacement of
        125I-NDP-MSH bound to D131N and D332N and dose-dependent induction of cAMP
        production (Figure 6); however, mutant receptor binding affinity and activation
        were dramatically reduced compared to the WT receptor.///It has been proposed
        that there is NDP-MSH Binding FIGURE 6: Binding affinity and potency of NDP-MSH
        upon binding to mutant hMC3R D121N and D332N.', pubmed: '16430209', seq: '332',
    to_res: N}
- {entry_name: mc3r_human, from_res: D, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).///Table 3: Effect of NDP-MSH on 125I NDP-MSH Binding and cAMP Production
        in HEK Cells Transfected with the Mutated Forms of the of hMC3R Bmax (fmol/mg
        pro) hMC3RWT D121A D121N E131A D154A D158A R196A K197A H298A H317A D332A D332N
        325 ( 5.8 no 235 ( 3.2 233 ( 16 203 ( 13 210 ( 11 269 ( 7.5 238 ( 7.5 281
        ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2 * 33.4 ( 2.3* 285 ( 43* 1.5 (
        0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3* 5.6 ( 1.0 NB 11.2 ( 2.1* 27.9
        ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 ( 0.9 98 ( 6.9* 8.0 ( 1.7 NB 23
        ( 2.5* a *P < 0.05 compared with WT receptor. activation, we mutated residue
        D121in TM2 and D332 in TM7 by exchanging aspartic acid with alanine. Our results
        indicate that mutations D121A and D332A resulted in a complete loss of receptor-ligand
        binding and activation. Chen et al. FIGURE 5: Expression of mutant hMC3R in
        HEK-293 cells. FLAGtagged hMC3RWT or mutated hMC3Rs were transfected into
        HEK293 cells and detected by FACs (A).///No positive FLAG signals were observed
        in the mutant D121A and D332A, but positive FLAG signals were observed in
        the mutant D121N and D332N.///Because of the possibility that these mutations
        impaired receptor expression, we utilized FACS to determine FLAGtagged mutant
        D121A and D332A protein expression on the cell surface (Figure 5).///Our results
        show that strong signal was detected at FLAG tagged MC3R WT but not detected
        in FLAG-tagged mutants D121A and D332A, suggesting that these two mutants
        were not properly expressed on the cell surface.///Our current results indicates
        that mutations of the homologues residues of hMC3R (D121A and D332A) abolish
        both NDP-MSH binding and receptor signaling.', pubmed: '16430209', seq: '121',
    to_res: A}
- {entry_name: mc3r_human, from_res: F, info: 'Our results indicate that mutations
        of F295A and F296A in TM6 significantly reduced NDP-MSH binding affinity and
        receptor activity while mutations of F216A, F233A, F234A, F288A, F290A, and
        F318A did not significantly alter NDP-MSH binding affinity and receptor activity
        (Figure 7 and Table 4).///Table 4: Effect of NDP-MSH on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the Mutated Forms of the
        hMC3Ra Bmax (fmol/mg pro) hMC3RWT F216A F233A F234A F288A F290A F295A F296A
        F318A 325 ( 5.8 278 ( 22.4 287 ( 23.4 295 ( 12.6 283 ( 10.2 290 ( 9.2 276
        ( 12.2 311 ( 14.5 282 ( 12.3 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.1 1.6 ( 0.2 2.1 ( 0.3 1.3 ( 1.0 1.4 ( 0.1 1.9 ( 0.2 28 (
        6.5* 7.6 ( 0.3* 1.2 ( 0.2 5.6 ( 1.0 5.9 ( 0.6 6.3 ( 1.1 7.1 ( 1.7 6.1 ( 0.6
        5.6 ( 0.3 155 ( 11* 17.8 ( 13* 6.3 ( 1.1 a *P < 0.05 compared with WT receptor.
        and is an antagonist at hMC3R and hMC4R (27).', pubmed: '16430209', seq: '296',
    to_res: A}
- {entry_name: mc3r_human, from_res: L, info: "Data points represent the mean ( SE\
        \ of three independent experiments with duplicate wells. FIGURE 9: Binding\
        \ affinity and potency of MTII and SHU9119 upon binding to mutant hMC3R L165A.\
        \ Panel A shows the binding affinity of different ligands to displace 125I\
        \ NDP-MSH. Panel B shows the ability of the ligands to stimulate cAMP production.\
        \ HMC3R mutant L165A did not change ligand binding affinity but switched SHU9119\
        \ from antagonist to agonist. Data points represent the mean ( SE of three\
        \ independent experiments with duplicate wells. action, we replaced this residue\
        \ in hMC3R with methionine, which corresponds to the amino acid that resides\
        \ in the homologous residue in hMC1R (methionine 128 in TM3).///Data points\
        \ represent the mean ( SE of three independent experiments with duplicate\
        \ wells. FIGURE 9: Binding affinity and potency of MTII and SHU9119 upon binding\
        \ to mutant hMC3R L165A. Panel A shows the binding affinity of different ligands\
        \ to displace 125I NDP-MSH. Panel B shows the ability of the ligands to stimulate\
        \ cAMP production. HMC3R mutant L165A did not change ligand binding affinity\
        \ but switched SHU9119 from antagonist to agonist. Data points represent the\
        \ mean ( SE of three independent experiments with duplicate wells. action,\
        \ we replaced this residue in hMC3R with methionine, which corresponds to\
        \ the amino acid that resides in the homologous residue in hMC1R (methionine\
        \ 128 in TM3).///To further determine whether specific methionine is required\
        \ for this activity, we substituted residue leucine 165 with alanine (L165A).///To\
        \ further determine whether specific methionine is required for this activity,\
        \ we substituted residue leucine 165 with alanine (L165A).///Our results indicate\
        \ that L165A also converts SHU9119 from antagonist to agonist (Figure 9 and\
        \ Table 5).///Table 5: Effect of Melanocortin Ligands on 125I NDP-MSH Binding\
        \ and cAMP Production in HEK Cells Transfected with the WT hMC1R, hMC3R, and\
        \ Mutated Forms of the of hMC3Ra 125 I-NDP-MSH binding Ki (nM) MTII 6.1 (\
        \ 1.0 5.9 ( 0.6 5.7 ( 0.5 4.3 ( 0.7 SHU9119 5.9 ( 0.2 5.7 ( 0.5 6.1 ( 0.1\
        \ 4.3 ( 0.4 NDP cAMP production EC50 (nM) MTII 0.7( 0.1 1.6 ( 0.5 0.9 ( 0.1\
        \ 1.3 ( 1.0 SHU9119 NR 15.3 ( 1.7* 21 ( 0.3* 7.8 ( 0.6 0.8 ( 0.1 1.1 ( 0.1\
        \ 1.2 ( 0.2 0.7 ( 0.1 Bmax (fmol/mg pro) hMC3RWT L165M L165A hMC1RWT 325 (\
        \ 5.8 307 ( 12.2 311 ( 11.1 295 ( 12.6 NDP 5.6 ( 1.0 6.1 ( 0.5 5.9 ( 0.3 3.2\
        \ ( 0.3 a NR: no response. *P < 0.05 compared with WT hMC3R. NDP-MSH Binding\
        \ DISCUSSION The discovery that melanocortin-3 and -4 receptors are involved\
        \ in the hypothalamic control of feeding behavior has generated substantial\
        \ academic and pharmaceutical industry interest because of the possibility\
        \ of using melanocortin agonists as anti-obesity drugs. In this study, we\
        \ have confirmed that NDP-MSH residues His6, Arg8, D-Phe7, and Trp9 are important\
        \ for ligand binding and biological activities at hMC3R. TM3 and TM6 of hMC3R\
        \ are important for NDP-MSH binding, while Asp 121 in TM2 and Asp332 in TM7\
        \ are crucial for receptor activity and signaling. In addition, L165 in TM3\
        \ is critical for agonist or antagonist selectivity. Our structure activity\
        \ studies of NDP-MSH demonstrated that substitution of residue Arg8 with an\
        \ uncharged amino acid, Nle8, or substitution of residues D-Phe7 and Trp9,\
        \ with nonaromatic amino acids, DAla7 and Leu9, greatly decreased binding\
        \ affinity and potency of substituted NDP-MSH peptides at the hMC3R. Studies\
        \ with truncated NDP-MSH peptides further highlighted the importance of residues\
        \ 6-9 by demonstrating that the smallest NDP-MSH fragment that possesses full\
        \ agonist efficacy is the tetrapeptide His-D-Phe7Arg8-Trp9, which is consistent\
        \ with the previous data (26).///To further determine whether methionine is\
        \ specifically required for this activity, we further substituted residue\
        \ leucine 165 with alanine, L165A.///To further determine whether methionine\
        \ is specifically required for this activity, we further substituted residue\
        \ leucine 165 with alanine, L165A.///45, No. 4, 2006 (2\u2032)7 in SHU9119,\
        \ the mutation of L165A would alter this interaction and SHU9119 would not\
        \ activate the receptor to induce cAMP production.///However, our results\
        \ indicate that mutation L165A also switches SHU9119 from antagonist to agonist.///SHU9119\
        \ has the same binding affinity and potency at L165M and L165A, suggesting\
        \ that there is no direct interaction between DNal of SHU9119 and L165 of\
        \ hMC3R.", pubmed: '16430209', seq: '165', to_res: A}
- {entry_name: mc3r_human, from_res: D, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).///No positive FLAG signals were observed in the mutant D121A and D332A,
        but positive FLAG signals were observed in the mutant D121N and D332N.///It
        has been proposed that there is NDP-MSH Binding FIGURE 6: Binding affinity
        and potency of NDP-MSH upon binding to mutant hMC3R D121N and D332N.', pubmed: '16430209',
    seq: '121', to_res: N}
- {entry_name: cxcr4_human, from_res: D, info: "This compound\u2019s binding is affected\
        \ by mutations K320A, Y314A in the C-terminal tail and D84N (2.40) in TM2.71\
        \ A similar binding site has been identified for other CXCR2 antagonists34\
        \ and is also thought to exist in CCR4 and CCR5 receptors.72 The CXCR4 structure\
        \ gives insight into how non-peptide antagonist ligands can block the activity\
        \ of the much larger peptide agonist CXCL12.", pubmed: '21593763', seq: '84',
    to_res: N}
- {entry_name: mc3r_human, from_res: H, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).', pubmed: '16430209', seq: '298', to_res: A}
- {entry_name: mc3r_human, from_res: D, info: 'Table 3: Effect of NDP-MSH on 125I
        NDP-MSH Binding and cAMP Production in HEK Cells Transfected with the Mutated
        Forms of the of hMC3R Bmax (fmol/mg pro) hMC3RWT D121A D121N E131A D154A D158A
        R196A K197A H298A H317A D332A D332N 325 ( 5.8 no 235 ( 3.2 233 ( 16 203 (
        13 210 ( 11 269 ( 7.5 238 ( 7.5 281 ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH
        binding Ki (nM) cAMP production EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2
        * 33.4 ( 2.3* 285 ( 43* 1.5 ( 0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3*
        5.6 ( 1.0 NB 11.2 ( 2.1* 27.9 ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 (
        0.9 98 ( 6.9* 8.0 ( 1.7 NB 23 ( 2.5* a *P < 0.05 compared with WT receptor.
        activation, we mutated residue D121in TM2 and D332 in TM7 by exchanging aspartic
        acid with alanine. Our results indicate that mutations D121A and D332A resulted
        in a complete loss of receptor-ligand binding and activation. Chen et al.
        FIGURE 5: Expression of mutant hMC3R in HEK-293 cells. FLAGtagged hMC3RWT
        or mutated hMC3Rs were transfected into HEK293 cells and detected by FACs
        (A).///Table 3: Effect of NDP-MSH on 125I NDP-MSH Binding and cAMP Production
        in HEK Cells Transfected with the Mutated Forms of the of hMC3R Bmax (fmol/mg
        pro) hMC3RWT D121A D121N E131A D154A D158A R196A K197A H298A H317A D332A D332N
        325 ( 5.8 no 235 ( 3.2 233 ( 16 203 ( 13 210 ( 11 269 ( 7.5 238 ( 7.5 281
        ( 7.5 287 ( 11.2 no 218 ( 21 125 I-NDP-MSH binding Ki (nM) cAMP production
        EC50 (nM) 0.8 ( 0.2 NR 7.8 ( 1.1* 15.8 ( 3.2 * 33.4 ( 2.3* 285 ( 43* 1.5 (
        0.9 1.7 ( 0.2 216 ( 18* 3.2 ( 0.8* NR 87 ( 4.3* 5.6 ( 1.0 NB 11.2 ( 2.1* 27.9
        ( 7.6* 76.6 ( 12* 234 ( 23* 7.4 ( 1.2 6.0 ( 0.9 98 ( 6.9* 8.0 ( 1.7 NB 23
        ( 2.5* a *P < 0.05 compared with WT receptor. activation, we mutated residue
        D121in TM2 and D332 in TM7 by exchanging aspartic acid with alanine. Our results
        indicate that mutations D121A and D332A resulted in a complete loss of receptor-ligand
        binding and activation. Chen et al. FIGURE 5: Expression of mutant hMC3R in
        HEK-293 cells. FLAGtagged hMC3RWT or mutated hMC3Rs were transfected into
        HEK293 cells and detected by FACs (A).///No positive FLAG signals were observed
        in the mutant D121A and D332A, but positive FLAG signals were observed in
        the mutant D121N and D332N.///Because of the possibility that these mutations
        impaired receptor expression, we utilized FACS to determine FLAGtagged mutant
        D121A and D332A protein expression on the cell surface (Figure 5).///Our results
        show that strong signal was detected at FLAG tagged MC3R WT but not detected
        in FLAG-tagged mutants D121A and D332A, suggesting that these two mutants
        were not properly expressed on the cell surface.///Our current results indicates
        that mutations of the homologues residues of hMC3R (D121A and D332A) abolish
        both NDP-MSH binding and receptor signaling.', pubmed: '16430209', seq: '332',
    to_res: A}
- {entry_name: mc3r_human, from_res: L, info: '45, No. 4, 2006 Chen et al. FIGURE
        8: Binding affinity and potency of MTII and SHU9119 upon binding to mutant
        hMC3R L165M.///HMC3R mutant L165M did not exhibit altered ligand binding affinity
        but did switch SHU9119 from antagonist to agonist.///As shown in Figure 8,
        the mutant receptor L165M is functionally expressed on the cell surface, and
        the Bmax for cAMP stimulation and binding affinity for NDP-MSH, MTII (MSH
        analogue), and SHU9119 are all in the range of the wild-type receptor (Table
        5).///However, substituting the residue L165 with methionine in the hMC3R
        did lead to complete conversion of SHU9119 activity from antagonist to agonist
        (Figure 8).///Table 5: Effect of Melanocortin Ligands on 125I NDP-MSH Binding
        and cAMP Production in HEK Cells Transfected with the WT hMC1R, hMC3R, and
        Mutated Forms of the of hMC3Ra 125 I-NDP-MSH binding Ki (nM) MTII 6.1 ( 1.0
        5.9 ( 0.6 5.7 ( 0.5 4.3 ( 0.7 SHU9119 5.9 ( 0.2 5.7 ( 0.5 6.1 ( 0.1 4.3 (
        0.4 NDP cAMP production EC50 (nM) MTII 0.7( 0.1 1.6 ( 0.5 0.9 ( 0.1 1.3 (
        1.0 SHU9119 NR 15.3 ( 1.7* 21 ( 0.3* 7.8 ( 0.6 0.8 ( 0.1 1.1 ( 0.1 1.2 ( 0.2
        0.7 ( 0.1 Bmax (fmol/mg pro) hMC3RWT L165M L165A hMC1RWT 325 ( 5.8 307 ( 12.2
        311 ( 11.1 295 ( 12.6 NDP 5.6 ( 1.0 6.1 ( 0.5 5.9 ( 0.3 3.2 ( 0.3 a NR: no
        response. *P < 0.05 compared with WT hMC3R. NDP-MSH Binding DISCUSSION The
        discovery that melanocortin-3 and -4 receptors are involved in the hypothalamic
        control of feeding behavior has generated substantial academic and pharmaceutical
        industry interest because of the possibility of using melanocortin agonists
        as anti-obesity drugs. In this study, we have confirmed that NDP-MSH residues
        His6, Arg8, D-Phe7, and Trp9 are important for ligand binding and biological
        activities at hMC3R. TM3 and TM6 of hMC3R are important for NDP-MSH binding,
        while Asp 121 in TM2 and Asp332 in TM7 are crucial for receptor activity and
        signaling. In addition, L165 in TM3 is critical for agonist or antagonist
        selectivity. Our structure activity studies of NDP-MSH demonstrated that substitution
        of residue Arg8 with an uncharged amino acid, Nle8, or substitution of residues
        D-Phe7 and Trp9, with nonaromatic amino acids, DAla7 and Leu9, greatly decreased
        binding affinity and potency of substituted NDP-MSH peptides at the hMC3R.
        Studies with truncated NDP-MSH peptides further highlighted the importance
        of residues 6-9 by demonstrating that the smallest NDP-MSH fragment that possesses
        full agonist efficacy is the tetrapeptide His-D-Phe7Arg8-Trp9, which is consistent
        with the previous data (26).///We replaced this residue with methionine, which
        exists in this position of hMC1R, and found that the substitution of leucine
        165 to methionine did not alter receptor NDP-MSH binding affinity but led
        to complete conversion of SHU9119 activity from antagonist to agonist.///SHU9119
        has the same binding affinity and potency at L165M and L165A, suggesting that
        there is no direct interaction between DNal of SHU9119 and L165 of hMC3R.',
    pubmed: '16430209', seq: '165', to_res: M}
- {entry_name: mc4r_rat, from_res: T, info: 'We also substituted threonine 232 with
        valine (T232V), a nonpolar amino acid, or 31314 G-protein Coupling of MC3R
        and MC4R TABLE IV Summary of estimated EC50 values of the melanocortin agonist
        -MSH-NDP for MC3R, MC4R and chimeric receptors Kd and Bmax values were calculated
        at a 95% confidence interval using GraphPad Prism software for binding assay
        using 125I-labeled NDP-MSH upon MC3R and MC4R, and upon chimeric receptors
        expressed in HEX 293T cells.///We also substituted threonine 232 with valine
        (T232V), a nonpolar amino acid, or 31314 G-protein Coupling of MC3R and MC4R
        TABLE IV Summary of estimated EC50 values of the melanocortin agonist -MSH-NDP
        for MC3R, MC4R and chimeric receptors Kd and Bmax values were calculated at
        a 95% confidence interval using GraphPad Prism software for binding assay
        using 125I-labeled NDP-MSH upon MC3R and MC4R, and upon chimeric receptors
        expressed in HEX 293T cells.///Mutants R220A, T232V, and T232A showed enhanced
        reporter gene activity, which was very near that of MC3R, whereas the other
        mutant receptors had CRE-luciferase reporter gene activities similar to that
        of MC4R (Fig. 4, A and B).///The EC50 value of R220A was 12-fold lower than
        that of MC4R, and the EC50 value of T232V and T232A was 6.5- and 5.9-fold,
        respectively, lower than that of MC4R (Table VI).///Mutant receptor EC50 nM
        Bmax fmol/mg protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3
        282.0 397.5 339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75
        41.17 16.73 28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081
        4.529 3.839 4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330
        1.1980 1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V
        I235P R236A R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744
        3.61 1.24 1.26 2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a
        1.851 0.5365 0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from
        the EC50 values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg protein Kd
        nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C
        361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5
        20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56
        3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005
        0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505
        1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783
        4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205
        0.6933 1.478 a p 0.05, significantly different from the EC50 values of MC4R.',
    pubmed: '12045190', seq: '232', to_res: V}
- {entry_name: mc4r_rat, from_res: K, info: 'Charged amino acids, such as, arginine
        220, lysine 224, arginine 225, and arginine 236 were substituted with alanine
        (R220A, K224A, R225A, and R236A respectively), which lacks an amino acid chain
        beyond the carbon and also avoids the introduction of steric hindrance or
        unwanted ionic interactions.///The mutant receptors K224A (2.1-fold), R225A
        (3.5-fold), R236A (3.9-fold), FIG. 4.///Mutant receptor EC50 nM Bmax fmol/mg
        protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5
        339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73
        28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839
        4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980
        1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26
        2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365
        0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from the EC50
        values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R
        MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7
        375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47
        40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775
        4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906
        1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303
        0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S
        N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363
        1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.', pubmed: '12045190',
    seq: '224', to_res: A}
- {entry_name: nk2r_human, from_res: C, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///C281Y (fourth extracellular\
        \ loop) and I202F [TM4] were mutated as such because these mutations spontaneously\
        \ occur in the rat tachykinin NK2R, and ibodutant displays low affinity for\
        \ this species (Cialdai et al., 2006).", pubmed: '19218528', seq: '281', to_res: Y}
- {entry_name: mc4r_rat, from_res: R, info: 'In addition, isoleucine 235 and arginine
        236 in MC4R were substituted with proline and glutamine, respectively (I235P
        and R236Q), which are native amino acids located at these positions in MC3R
        (Fig. 3).///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R MC4R R220A
        K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7 375.9 325.9
        297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47 40.07 25.23
        18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775 4.269 3.893
        4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906 1.0090
        0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303 0.5872
        MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C
        4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363 1.18
        0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.///Mutant
        receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R MC4R R220A K224A R225A T232A
        T232V I235P R236A R236Q G238H A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8
        304.8 309.6 296.3 282.0 397.5 339 346.5 20.47 40.07 25.23 18.47 26.67 28.21
        34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559
        3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527
        0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A
        R225A T232A T232V I235P R236A R236Q G238H A239S N240C 4.86 3.945 0.405 2.36
        1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363 1.18 0.472 0.0939a 1.760
        0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933 1.478 a p 0.05, significantly
        different from the EC50 values of MC4R.///DISCUSSION R236Q (3.9-fold), and
        G238H (1.9-fold) showed slightly enhanced EC50 efficiencies, although their
        maximum CRE-luciferase reporter gene activities were unchanged (Table VI).',
    pubmed: '12045190', seq: '236', to_res: Q}
- {entry_name: mc4r_rat, from_res: N, info: 'Other MC4Rspecific amino acids in the
        i3 loop, such as glycine 238, alanine 239, and asparagine 240 were also substituted
        with the amino acids present at the same position in the i3 loop of MC3R,
        respectively (G238H, A239S, and N240C).///Mutant receptor EC50 nM Bmax fmol/mg
        protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5
        339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73
        28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839
        4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980
        1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26
        2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365
        0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from the EC50
        values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R
        MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7
        375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47
        40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775
        4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906
        1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303
        0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S
        N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363
        1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.///The
        mutants I235P, A239S, and N240C showed no significant changes in EC50 values
        or maximal reporter gene activity (Fig. 4, Table VI).///The mutants I235P,
        A239S, and N240C, where MC4R-specific amino acids were substituted by the
        amino acids present at the same position in MC3R, did not display significant
        changes in the CRE-luciferase activity by the mutation.', pubmed: '12045190',
    seq: '240', to_res: C}
- {entry_name: mc4r_rat, from_res: R, info: 'Charged amino acids, such as, arginine
        220, lysine 224, arginine 225, and arginine 236 were substituted with alanine
        (R220A, K224A, R225A, and R236A respectively), which lacks an amino acid chain
        beyond the carbon and also avoids the introduction of steric hindrance or
        unwanted ionic interactions.///The mutant receptors K224A (2.1-fold), R225A
        (3.5-fold), R236A (3.9-fold), FIG. 4.///Mutant receptor EC50 nM Bmax fmol/mg
        protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5
        339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73
        28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839
        4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980
        1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26
        2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365
        0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from the EC50
        values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R
        MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7
        375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47
        40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775
        4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906
        1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303
        0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S
        N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363
        1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.', pubmed: '12045190',
    seq: '236', to_res: A}
- {entry_name: mc4r_rat, from_res: R, info: 'Reporter gene analysis showed that single
        mutations of Arg220 to Ala and Thr232 to either Val or Ala increased the relative
        luciferase activities, which suggests that these specific amino acids, Arg220
        and Thr232, in the i3 loop of MC4R play crucial roles in G-protein coupling
        and the subtype-specific signaling pathways.///Charged amino acids, such as,
        arginine 220, lysine 224, arginine 225, and arginine 236 were substituted
        with alanine (R220A, K224A, R225A, and R236A respectively), which lacks an
        amino acid chain beyond the carbon and also avoids the introduction of steric
        hindrance or unwanted ionic interactions.///Mutants R220A, T232V, and T232A
        showed enhanced reporter gene activity, which was very near that of MC3R,
        whereas the other mutant receptors had CRE-luciferase reporter gene activities
        similar to that of MC4R (Fig. 4, A and B).///The EC50 value of R220A was 12-fold
        lower than that of MC4R, and the EC50 value of T232V and T232A was 6.5- and
        5.9-fold, respectively, lower than that of MC4R (Table VI).///Mutant receptor
        EC50 nM Bmax fmol/mg protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V
        I235P R236A R236Q G238H A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8
        309.6 296.3 282.0 397.5 339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29
        15.92 38.75 41.17 16.73 28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514
        3.621 4.081 4.529 3.839 4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007
        0.9270 0.4330 1.1980 1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A
        T232A T232V I235P R236A R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39
        0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258
        0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933 1.478 a p 0.05, significantly
        different from the EC50 values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg
        protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5
        339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73
        28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839
        4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980
        1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26
        2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365
        0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from the EC50
        values of MC4R.///A mutation introduced by replacing Arg220 with alanine enhanced
        the EC50 13.9-fold versus native MC4R.', pubmed: '12045190', seq: '220', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: "The other two mutations, A54L and\
        \ T65A, are at the receptor\u2013lipid interface and the reason for their\
        \ thermostabilizing effect is unclear.///The thermostabilized A2AR-GL31 construct\
        \ contains amino acid residues 1\u2013316 of the human A2AR, four thermostabilizing\
        \ point mutations (L48A2.46, A54L2.52, T65A2.63 and Q89A3.37) and the mutation\
        \ N154A to remove a potential N-glycosylation site.///The human A2A construct,\
        \ GL31, contains four thermostabilizing point mutations (L48A2.46, A54L2.52,\
        \ T65A2.63 and Q89A3.37), the mutation N154A to remove the potential N-glycosylation\
        \ site and a truncation at the C terminus after Ala 316 (ref. 32).", pubmed: '21593763',
    seq: '65', to_res: A}
- {entry_name: aa2ar_human, from_res: A, info: "The other two mutations, A54L and\
        \ T65A, are at the receptor\u2013lipid interface and the reason for their\
        \ thermostabilizing effect is unclear.///The thermostabilized A2AR-GL31 construct\
        \ contains amino acid residues 1\u2013316 of the human A2AR, four thermostabilizing\
        \ point mutations (L48A2.46, A54L2.52, T65A2.63 and Q89A3.37) and the mutation\
        \ N154A to remove a potential N-glycosylation site.///The human A2A construct,\
        \ GL31, contains four thermostabilizing point mutations (L48A2.46, A54L2.52,\
        \ T65A2.63 and Q89A3.37), the mutation N154A to remove the potential N-glycosylation\
        \ site and a truncation at the C terminus after Ala 316 (ref. 32).", pubmed: '21593763',
    seq: '54', to_res: L}
- {entry_name: adrb2_human, from_res: L, info: 'CAM and UCM mutants The CAMs (constitutively
        active mutants) described in the literature that are the basis for Figure
        6A and the associated discussion are: L124A (6), C116F (7), D130A (8), L272C
        (9), and C285T (10).', pubmed: '17962519', seq: '124', to_res: A}
- {entry_name: mc4r_rat, from_res: G, info: 'Other MC4Rspecific amino acids in the
        i3 loop, such as glycine 238, alanine 239, and asparagine 240 were also substituted
        with the amino acids present at the same position in the i3 loop of MC3R,
        respectively (G238H, A239S, and N240C).///Mutant receptor EC50 nM Bmax fmol/mg
        protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5
        339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73
        28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839
        4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980
        1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26
        2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365
        0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from the EC50
        values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R
        MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7
        375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47
        40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775
        4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906
        1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303
        0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S
        N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363
        1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.///DISCUSSION
        R236Q (3.9-fold), and G238H (1.9-fold) showed slightly enhanced EC50 efficiencies,
        although their maximum CRE-luciferase reporter gene activities were unchanged
        (Table VI).', pubmed: '12045190', seq: '238', to_res: H}
- {entry_name: mc4r_rat, from_res: T, info: 'Mutations generated by site-directed
        mutagenesis in the i3 loop domain of MC4R are indicated. with alanine (T232A).///Mutants
        R220A, T232V, and T232A showed enhanced reporter gene activity, which was
        very near that of MC3R, whereas the other mutant receptors had CRE-luciferase
        reporter gene activities similar to that of MC4R (Fig. 4, A and B).///The
        EC50 value of R220A was 12-fold lower than that of MC4R, and the EC50 value
        of T232V and T232A was 6.5- and 5.9-fold, respectively, lower than that of
        MC4R (Table VI).///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R
        MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7
        375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47
        40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775
        4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906
        1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303
        0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S
        N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363
        1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.///Mutant
        receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R MC4R R220A K224A R225A T232A
        T232V I235P R236A R236Q G238H A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8
        304.8 309.6 296.3 282.0 397.5 339 346.5 20.47 40.07 25.23 18.47 26.67 28.21
        34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559
        3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527
        0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A
        R225A T232A T232V I235P R236A R236Q G238H A239S N240C 4.86 3.945 0.405 2.36
        1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363 1.18 0.472 0.0939a 1.760
        0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933 1.478 a p 0.05, significantly
        different from the EC50 values of MC4R.', pubmed: '12045190', seq: '232',
    to_res: A}
- {entry_name: mc4r_rat, from_res: R, info: 'Charged amino acids, such as, arginine
        220, lysine 224, arginine 225, and arginine 236 were substituted with alanine
        (R220A, K224A, R225A, and R236A respectively), which lacks an amino acid chain
        beyond the carbon and also avoids the introduction of steric hindrance or
        unwanted ionic interactions.///The mutant receptors K224A (2.1-fold), R225A
        (3.5-fold), R236A (3.9-fold), FIG. 4.///Mutant receptor EC50 nM Bmax fmol/mg
        protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5
        339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73
        28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839
        4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980
        1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26
        2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365
        0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from the EC50
        values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R
        MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7
        375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47
        40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775
        4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906
        1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303
        0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S
        N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363
        1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.', pubmed: '12045190',
    seq: '225', to_res: A}
- {entry_name: mc4r_rat, from_res: A, info: 'Other MC4Rspecific amino acids in the
        i3 loop, such as glycine 238, alanine 239, and asparagine 240 were also substituted
        with the amino acids present at the same position in the i3 loop of MC3R,
        respectively (G238H, A239S, and N240C).///Mutant receptor EC50 nM Bmax fmol/mg
        protein Kd nM MC3R MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H
        A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5
        339 346.5 20.47 40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73
        28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839
        4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980
        1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A
        R236Q G238H A239S N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26
        2.442 4.783 4.363 1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365
        0.9031 1.205 0.6933 1.478 a p 0.05, significantly different from the EC50
        values of MC4R.///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R
        MC4R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7
        375.9 325.9 297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47
        40.07 25.23 18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775
        4.269 3.893 4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906
        1.0090 0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303
        0.5872 MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S
        N240C 4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363
        1.18 0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.///The
        mutants I235P, A239S, and N240C showed no significant changes in EC50 values
        or maximal reporter gene activity (Fig. 4, Table VI).///The mutants I235P,
        A239S, and N240C, where MC4R-specific amino acids were substituted by the
        amino acids present at the same position in MC3R, did not display significant
        changes in the CRE-luciferase activity by the mutation.', pubmed: '12045190',
    seq: '239', to_res: S}
- {entry_name: mc4r_rat, from_res: I, info: 'In addition, isoleucine 235 and arginine
        236 in MC4R were substituted with proline and glutamine, respectively (I235P
        and R236Q), which are native amino acids located at these positions in MC3R
        (Fig. 3).///Mutant receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R MC4R R220A
        K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C 361.7 375.9 325.9
        297.9 323.8 334.8 304.8 309.6 296.3 282.0 397.5 339 346.5 20.47 40.07 25.23
        18.47 26.67 28.21 34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775 4.269 3.893
        4.967 4.066 3.559 3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906 1.0090
        0.6862 0.6529 0.7527 0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303 0.5872
        MC4R MC3R R220A K224A R225A T232A T232V I235P R236A R236Q G238H A239S N240C
        4.86 3.945 0.405 2.36 1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363 1.18
        0.472 0.0939a 1.760 0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933
        1.478 a p 0.05, significantly different from the EC50 values of MC4R.///Mutant
        receptor EC50 nM Bmax fmol/mg protein Kd nM MC3R MC4R R220A K224A R225A T232A
        T232V I235P R236A R236Q G238H A239S N240C 361.7 375.9 325.9 297.9 323.8 334.8
        304.8 309.6 296.3 282.0 397.5 339 346.5 20.47 40.07 25.23 18.47 26.67 28.21
        34.29 15.92 38.75 41.17 16.73 28.43 32.56 3.775 4.269 3.893 4.967 4.066 3.559
        3.514 3.621 4.081 4.529 3.839 4.858 3.005 0.4906 1.0090 0.6862 0.6529 0.7527
        0.7007 0.9270 0.4330 1.1980 1.4400 0.3505 1.303 0.5872 MC4R MC3R R220A K224A
        R225A T232A T232V I235P R236A R236Q G238H A239S N240C 4.86 3.945 0.405 2.36
        1.39 0.870 0.744 3.61 1.24 1.26 2.442 4.783 4.363 1.18 0.472 0.0939a 1.760
        0.7258 0.201a 0.4138a 1.851 0.5365 0.9031 1.205 0.6933 1.478 a p 0.05, significantly
        different from the EC50 values of MC4R.///The mutants I235P, A239S, and N240C
        showed no significant changes in EC50 values or maximal reporter gene activity
        (Fig. 4, Table VI).///The mutants I235P, A239S, and N240C, where MC4R-specific
        amino acids were substituted by the amino acids present at the same position
        in MC3R, did not display significant changes in the CRE-luciferase activity
        by the mutation.', pubmed: '12045190', seq: '235', to_res: P}
- {entry_name: aa2ar_human, from_res: Q, info: "The two most thermostabilizing mutations,\
        \ L48A and Q89A, are in regions of the receptor that are involved in transitions\
        \ between R and R*, providing a possible explanation for their thermostabilizing\
        \ effect (Supplementary Fig. 4).///The thermostabilized A2AR-GL31 construct\
        \ contains amino acid residues 1\u2013316 of the human A2AR, four thermostabilizing\
        \ point mutations (L48A2.46, A54L2.52, T65A2.63 and Q89A3.37) and the mutation\
        \ N154A to remove a potential N-glycosylation site.///The human A2A construct,\
        \ GL31, contains four thermostabilizing point mutations (L48A2.46, A54L2.52,\
        \ T65A2.63 and Q89A3.37), the mutation N154A to remove the potential N-glycosylation\
        \ site and a truncation at the C terminus after Ala 316 (ref. 32).", pubmed: '21593763',
    seq: '89', to_res: A}
- {entry_name: aa2ar_human, from_res: L, info: "The two most thermostabilizing mutations,\
        \ L48A and Q89A, are in regions of the receptor that are involved in transitions\
        \ between R and R*, providing a possible explanation for their thermostabilizing\
        \ effect (Supplementary Fig. 4).///The thermostabilized A2AR-GL31 construct\
        \ contains amino acid residues 1\u2013316 of the human A2AR, four thermostabilizing\
        \ point mutations (L48A2.46, A54L2.52, T65A2.63 and Q89A3.37) and the mutation\
        \ N154A to remove a potential N-glycosylation site.///The human A2A construct,\
        \ GL31, contains four thermostabilizing point mutations (L48A2.46, A54L2.52,\
        \ T65A2.63 and Q89A3.37), the mutation N154A to remove the potential N-glycosylation\
        \ site and a truncation at the C terminus after Ala 316 (ref. 32).", pubmed: '21593763',
    seq: '48', to_res: A}
- {entry_name: p2y11_human, from_res: A, info: 'Carriers of the Ala-87-Thr polymorphism
        of P2Y11 receptors have an increased risk of acute myocardial infarction (Amisten
        et al., 2007).', pubmed: '19815812', seq: '87', to_res: T}
- {entry_name: p2y11_human, from_res: R, info: 'The mutation of Arg268Ala reduced
        the potency of ATP by three orders of magnitude (Zylberg et al., 2007).',
    pubmed: '19815812', seq: '268', to_res: A}
- {entry_name: acm5_human, from_res: Y, info: 'This assumption is supported by the
        observation that Y3.60A mutation in M5 muscarinic receptors increased the
        basal activity (Burstein et al., 1998).', pubmed: '20106995', seq: '138',
    to_res: A}
- {entry_name: hrh4_human, from_res: A, info: "To elucidate whether this mutation\
        \ causes the high constitutive activity of hH4R, we aimed at reconstituting\
        \ the ionic lock by constructing the A6.30E mutant.///In order to investigate\
        \ whether the missing ionic lock is responsible for the high constitutive\
        \ activity of hH4R, we aimed at reconstituting this interaction by generating\
        \ the hH4R-A6.30E mutant.///For the generation of the amino acid exchange\
        \ Ala2986.30 Glu2986.30 (A6.30E) and to introduce a new BseR I site (GAGGAG),\
        \ the antisense primer 5\u2019-GCC AGT GAC TTG GCT AAT CTC CTC TCT CTA AGC-3\u2019\
        \ was used.///For the generation of the A6.30E mutation and to introduce a\
        \ new BseR I site (GAGGAG), the sense primer encoded the sequence 5\u2019\
        -GCT TAG AGA GAG GAG ATT AGC CAA GTC ACT GGC-3\u2019.///pGEM-3Z-SF-hH4R-R3.50A-His6\
        \ and pGEM-3Z-SF-hH4R-A6.30E-His6 were digested again with Sac I and Xba I,\
        \ and cloned into the baculovirus transfer vector pVL1392-SF-hH4R-His6 digested\
        \ with the same enzymes.///The hH4R, the R3.50A- and the A6.30E mutant were\
        \ co-expressed with G\u03B1i2 and G\u03B21\u03B32 in Sf9 cells using genetically\
        \ modified baculoviruses.///The KD value of histamine (HA) was determined\
        \ in saturation binding experiments with [3H]HA, using membranes expressing\
        \ hH4R, hH4RR3.50A or hH4R-A6.30E without G-proteins (Fig. 3A) or in the presence\
        \ of mammalian G\u03B1i2 11 JPET #163220 and G\u03B21\u03B32 (Fig. 3C).///This\
        \ G-protein independency of HA affinity was also observed for the hH4R-A6.30E\
        \ and hH4R-R3.50A mutant (Fig. 3A and C, Table 2).///The KD value of [3H]HA\
        \ at hH4R R3.50A was significantly (p < 0.05) increased, compared to the hH4R\
        \ or the hH4R-A6.30E mutant.///Surprisingly, the Ki value of THIO at the hH4R\
        \ and hH4R-A6.30E was increased by a factor of ~2 in the presence of G-proteins,\
        \ compared to the G-protein free system (Table 2).///This difference reached\
        \ significance (p < 0.05) for the hH4R, but not for hH4R-A6.30E.///Despite\
        \ the G-protein-independent [3H]HA affinities of hH4R and hH4R A6.30E (KD\
        \ values in Table 2), the inverse agonist THIO can still differentiate between\
        \ R* and R states.///When both hH4R and hH4R-A6.30E were expressed under the\
        \ same conditions (with or without mammalian G\u03B1i2 and G\u03B21\u03B3\
        2), the Ki values of THIO were not significantly different (Table 2).///Interestingly,\
        \ the affinity of THIO to the R3.50A mutant was significantly increased (p<0.05)\
        \ by a factor of 3-4, compared to hH4R and hH4R-A6.30E (Fig. 3B and D, Table\
        \ 2).///hH4R, hH4R-R3.50A and hH4R-A6.30E were coexpressed with G\u03B1i2\
        \ and G\u03B21\u03B32 and functionally characterized in steady-state GTPase\
        \ assays.///When comparing the hH4R with hH4R-A6.30E, there was no significant\
        \ difference, either in absolute GTPase activities, or in the relative magnitudes\
        \ of the HA- or THIO-induced signals.///Complete concentration-response curves\
        \ were recorded for HA and THIO at hH4R and hH4R-A6.30E.///The hH4R and the\
        \ hH4R-A6.30E mutant (both co-expressed with G\u03B1i2 and G\u03B21\u03B3\
        2) were characterized in steady-state GTPase enzyme kinetics.///The apparent\
        \ Km values in the presence of HA and THIO did not significantly differ in\
        \ the systems expressing the hH4R or hH4R-A6.30E (Fig. 5C, Table 2).///Interestingly,\
        \ the percentage of THIO-inhibited constitutive activity was slightly decreased\
        \ in the membranes expressing hH4R- A6.30E (Fig. 5C, Table 2).///Similarly,\
        \ for A6.30E, compared to the hH4R, we observed a weak non-significant (p\
        \ = 0.18, unpaired two-tailed t-test) reduction of the turnover number (Table\
        \ 2).///To confirm the results from steady-state GTPase assays, we also investigated\
        \ hH4R-R3.50A and hH4R-A6.30E (co-expressed with G\u03B1i2 and G\u03B21\u03B3\
        2) in [35S]GTP\u03B3S saturation binding experiments.///Again, HA and THIO\
        \ did not induce a signal in the membranes expressing hH4RR3.50A (data not\
        \ shown), whereas hH4R-A6.30E behaved very similarly to the hH4R (Fig. 5D).///The\
        \ Kd values of [35S]GTP\u03B3S in the agonist-stimulated and the inverse agonist-inhibited\
        \ system did not significantly differ between hH4R and hH4R A6.30E (Table\
        \ 2).///Consistent with the results for the turnover number, also the coupling\
        \ factor of the A6.30E mutant, compared to the hH4R, was slightly and not\
        \ significantly (p = 0.14, unpaired two-tailed t-test) reduced (Table 2).///To\
        \ test this hypothesis, we aimed at reconstituting the ionic lock of hH4R\
        \ by preparing the A6.30E mutant and expressing it with and without mammalian\
        \ G-proteins.///Unexpectedly, hH4R-A6.30E and wild-type hH4R did not significantly\
        \ differ in [3H]HA high-affinity agonist binding, steady state GTPase assays\
        \ and [35S]GTP\u03B3S binding experiments.///We found only a non-significant\
        \ reduction of constitutive activity of the A6.30E mutant (co-expressed with\
        \ G\u03B1i2 and G\u03B21\u03B32) compared to wild-type hH4R in GTPase enzyme\
        \ kinetics and [35S]GTP\u03B3S saturation binding experiments.///Our data\
        \ suggest that the equilibrium of hH4R-A6.30E is slightly shifted towards\
        \ the R state, leading to less effective G-protein activation.///The largely\
        \ retained wild-type-like properties of the A6.30E mutant suggest that E6.30\
        \ and R3.50 do not interact or that there are additional interactions stabilizing\
        \ the active receptor conformation.///The A6.30E mutation is possible without\
        \ interrupting this interaction.///This may explain why hH4R-A6.30E remains\
        \ in the active state.///Consistently, the affinity of the inverse agonist\
        \ THIO at hH4R-R3.50A is increased, compared to hH4R and hH4R-A6.30E.///By\
        \ contrast, the Bmax values of [3H]HA binding to hH4R-R3.50A, wild-type hH4R\
        \ and hH4R-A6.30E are similar.", pubmed: '20106995', seq: '298', to_res: E}
- {entry_name: hrh4_human, from_res: R, info: "The role of R3.50 was investigated\
        \ by generating hH4R-R3.50A.///By contrast, hH4R-R3.50A did not stimulate\
        \ G-proteins.///Thioperamide affinity at hH4R-R3.50A was increased by 300-400%,\
        \ whereas histamine affinity was reduced by ~50%.///We conclude that (i) constitutive\
        \ activity of hH4R is rather facilitated by the salt bridge D5.69-R6.31 than\
        \ by the missing ionic lock, (ii) Y3.60 may form alternative locks in active\
        \ and inactive GPCR states, (iii) R3.50 is crucial for hH4R-G-protein coupling,\
        \ and (iv) hH4R-R3.50A represents an inactive state with increased inverse\
        \ agonist- and reduced agonist affinity.///Construction of the cDNA for hH4R-R3.50A\
        \ and hH4R-A6.30 E.///An antisense primer with the sequence 5\u2019-CAG GTA\
        \ TGC ATC ATA GCT GAT GAG GAC-3\u2019 was used to generate the Arg1123.50\
        \ Ala1123.50 (R3.50A) mutation and to remove a Cla I site (ATCGAT) in the\
        \ hH4R.///The sense primer encoded the sequence 5\u2019-GCT ATG ATG CAT ACC\
        \ TGT CAG TCT CAA ATG C-3\u2019 to generate the R3.50A mutation and to remove\
        \ a Cla I site (ATCGAT) in wild type hH4R.///pGEM-3Z-SF-hH4R-R3.50A-His6 and\
        \ pGEM-3Z-SF-hH4R-A6.30E-His6 were digested again with Sac I and Xba I, and\
        \ cloned into the baculovirus transfer vector pVL1392-SF-hH4R-His6 digested\
        \ with the same enzymes.///The hH4R, the R3.50A- and the A6.30E mutant were\
        \ co-expressed with G\u03B1i2 and G\u03B21\u03B32 in Sf9 cells using genetically\
        \ modified baculoviruses.///From the immunoblot shown in Fig. 2, we obtained\
        \ a Bmax of 1.8 pmol/mg for the wild-type hH4R, 2.6 pmol/mg for hH4R-R3.50A\
        \ and 2.2 pmol/mg for hH4R-A 6.30 E (always co-expressed with G\u03B1i2 and\
        \ G\u03B21\u03B32).///This G-protein independency of HA affinity was also\
        \ observed for the hH4R-A6.30E and hH4R-R3.50A mutant (Fig. 3A and C, Table\
        \ 2).///Interestingly, in case of the hH4R-R3.50A mutant, the saturation curve\
        \ was slightly shifted to the right (Fig 3A and C).///The KD value of [3H]HA\
        \ at hH4R R3.50A was significantly (p < 0.05) increased, compared to the hH4R\
        \ or the hH4R-A6.30E mutant.///As shown in Table 2, the Bmax values of all\
        \ investigated receptor proteins were in a range between 1.2 \xB1 0.1 (hH4R\
        \ without G-proteins) and 2.1 \xB1 0.6 pmol/mg (hH4R-R3.50A without G-proteins)\
        \ and did not differ significantly.///Interestingly, the affinity of THIO\
        \ to the R3.50A mutant was significantly increased (p<0.05) by a factor of\
        \ 3-4, compared to hH4R and hH4R-A6.30E (Fig. 3B and D, Table 2).///The Ki\
        \ of THIO at hH4R-R3.50A did not significantly differ in the presence and\
        \ absence of Gproteins.///hH4R, hH4R-R3.50A and hH4R-A6.30E were coexpressed\
        \ with G\u03B1i2 and G\u03B21\u03B32 and functionally characterized in steady-state\
        \ GTPase assays.///Interestingly, compared to wild-type hH4R, in case of hH4R-R3.50A\
        \ absolute GTPase activity was significantly reduced under all conditions\
        \ (p < 0.01, ANOVA, followed by Bonferroni\u2019s test).///To confirm the\
        \ results from steady-state GTPase assays, we also investigated hH4R-R3.50A\
        \ and hH4R-A6.30E (co-expressed with G\u03B1i2 and G\u03B21\u03B32) in [35S]GTP\u03B3\
        S saturation binding experiments.///The R3.50A mutation caused a complete\
        \ loss of G-protein activation.///The Ki value of THIO at hH4R-R3.50A is independent\
        \ of the presence of G-proteins, indicating disrupted coupling or loss of\
        \ G-proteinmediated stabilization of the active R* state.///Since G proteins\
        \ stabilize the active R* state, the R state should predominate in the population\
        \ of hH4R-R3.50A.///Consistently, the affinity of the inverse agonist THIO\
        \ at hH4R-R3.50A is increased, compared to hH4R and hH4R-A6.30E.///By contrast,\
        \ the Bmax values of [3H]HA binding to hH4R-R3.50A, wild-type hH4R and hH4R-A6.30E\
        \ are similar.///The active state model of hH4R in complex with G\u03B1i2-CT\
        \ indicates improper coupling of hH4R-R3.50A to the G-protein because of the\
        \ lacking interactions of R3.50 with the G\u03B1i2 residues C352 and G353\
        \ (backbone oxygens).///This may be the reason why hH4R-R3.50A remains in\
        \ a conformation that still shows relatively high agonist affinity.", pubmed: '20106995',
    seq: '112', to_res: A}
- {entry_name: adrb2_human, from_res: E, info: "However, previous results suggest\
        \ that any lock of E6.30 favours the inactive state of the \u03B22AR, since\
        \ the \u03B22AR-E6.30A mutant showed a substantially higher constitutive activity\
        \ than the wild-type \u03B22AR (Ballesteros et al., 2001).", pubmed: '20106995',
    seq: '268', to_res: A}
- {entry_name: trfr_rat, from_res: R, info: 'Similarly, in the m3 receptor, the agonist
        binding was decreased after the homologous R283A mutation in the murine thyrotropin-releasing
        hormone receptor (42).', pubmed: '11891221', seq: '283', to_res: A}
- {entry_name: trfr_human, from_res: N, info: 'Similar to the results obtained here,
        Perlman et al. (37) have demonstrated in a site-directed mutagenesis study
        that the mutation of the corresponding residue in murine thyrotropin-releasing
        hormone receptor (N110A) also decreased agonist binding.', pubmed: '11891221',
    seq: '110', to_res: A}
- {entry_name: trfr_rat, from_res: W, info: 'Consistent with the present study, the
        mutation of the corresponding residue in the murine thyrotropin-releasing
        hormone receptor (W279A) did not affect agonist binding (42).', pubmed: '11891221',
    seq: '279', to_res: A}
- {entry_name: gnrhr_human, from_res: L, info: 'Furthermore, this model shows that
        4 residues from a non-contiguous motif interact with the EL2: F112 is located
        near the C114-C196 disulfide bridge that links EL2 to TM3, E208 and E302 may
        form H-bonds with EL2 residues (H199 and Q195, respectively), and L300V substitution
        facilitates the reorientation of Y290 interacting with EL2.///When the human
        motif in hGnRHR[E90K] was replaced with the orthologous rat residues (i.e.;
        L112F, Q208E, L300V, D302E), this decreased the measured CA. but modestly
        increased the IP production following rescue.///With the deletion of K191
        and L112F, Q208E, L300V, D302E substitutions, CA of the E90K mutant substantially
        increases.', pubmed: '21527534', seq: '300', to_res: V}
- {entry_name: gnrhr_human, from_res: R, info: 'Unlike mutants of the E90-K121 salt
        bridge, the R38 and D98 mutants do not show measurable CA following more than
        75% of their IP response to Buserelin stimulation and R38D and R38E are totally
        inactive mutants.///Restoration of responsiveness of R38A and R38K by In3
        suggests that they are misrouted (likely ER-retained mutants) and rescuable,
        while R38D and R38E may be permanently retained or unable to bind agonist
        or to achieve the active configuration needed to interact with G proteins.',
    pubmed: '21527534', seq: '38', to_res: E}
- {entry_name: gnrhr_human, from_res: D, info: 'When the human motif in hGnRHR[E90K]
        was replaced with the orthologous rat residues (i.e.; L112F, Q208E, L300V,
        D302E), this decreased the measured CA. but modestly increased the IP production
        following rescue.///With the deletion of K191 and L112F, Q208E, L300V, D302E
        substitutions, CA of the E90K mutant substantially increases.', pubmed: '21527534',
    seq: '302', to_res: E}
- {entry_name: gnrhr_human, from_res: Y, info: 'To further explore this possibility
        and the role of the S217-Y284 H-bond, we prepared Y284F, Y284C mutants that
        cannot form this H-bond.///The Y284C mutant also lacks the aromatic moiety
        of the native residue.///This effect is more pronounced for the Y284C mutant.///Both
        Y284F (Fig. 10B) and Y284C mutants as well as the S217G mutant can be rescued
        by the pharmacoperone In3 and/or deletion of K191 [Figure 10A,B and (Knollman
        et al., 2005)].///After pretreatment with In3 the S217G mutant demonstrates
        Buserelin-stimulated activation similar to the WT receptor, while Y284F and
        Y284C show 70% and 23% activity, respectively.///The larger impairment of
        the Y284C suggests the importance of both the OH-group and the aromatic ring
        of Y284 for proper receptor trafficking and activation.', pubmed: '21527534',
    seq: '284', to_res: C}
- {entry_name: gnrhr_human, from_res: Q, info: 'When the human motif in hGnRHR[E90K]
        was replaced with the orthologous rat residues (i.e.; L112F, Q208E, L300V,
        D302E), this decreased the measured CA. but modestly increased the IP production
        following rescue.///With the deletion of K191 and L112F, Q208E, L300V, D302E
        substitutions, CA of the E90K mutant substantially increases.', pubmed: '21527534',
    seq: '208', to_res: E}
- {entry_name: gnrhr_human, from_res: K, info: 'There was a slight responsiveness
        of K121A and K121Q and a more modest response of K121G and K121N to Buserelin,
        when these mutants where first rescued by pharmacoperone In3.///Further deletion
        of K191 in these mutants resulted in responsiveness from K121R, a more modest
        response from K121Q > A > N > G, and no response from the negatively charged
        D or E.', pubmed: '21527534', seq: '121', to_res: Q}
- {entry_name: gnrhr_human, from_res: K, info: 'There was a slight responsiveness
        of K121A and K121Q and a more modest response of K121G and K121N to Buserelin,
        when these mutants where first rescued by pharmacoperone In3.', pubmed: '21527534',
    seq: '121', to_res: N}
- {entry_name: gnrhr_human, from_res: K, info: 'There was a slight responsiveness
        of K121A and K121Q and a more modest response of K121G and K121N to Buserelin,
        when these mutants where first rescued by pharmacoperone In3.', pubmed: '21527534',
    seq: '121', to_res: G}
- {entry_name: gnrhr_human, from_res: S, info: 'In Fig. 8 we observe that the S217G
        mutation reduces CA in the human E90K mutant suggesting a role for this residue
        in the active state of the receptor.///The absence of this H-bond may explain
        the reduced CA of the S217G mutant.///Both Y284F (Fig. 10B) and Y284C mutants
        as well as the S217G mutant can be rescued by the pharmacoperone In3 and/or
        deletion of K191 [Figure 10A,B and (Knollman et al., 2005)].///After pretreatment
        with In3 the S217G mutant demonstrates Buserelin-stimulated activation similar
        to the WT receptor, while Y284F and Y284C show 70% and 23% activity, respectively.///Considering
        these results together with the reduced CA of the E90K/S217G double mutant,
        we conclude that; (a) the aromatic ring and OH-group of the Y284 are essential
        for receptor activation; and (b) the formation of the H-bond between S217
        and Y284 or other polar groups is likely involved in the activation process.',
    pubmed: '21527534', seq: '217', to_res: G}
- {entry_name: gnrhr_human, from_res: R, info: 'R38S retains about half its responsiveness
        (Fig. 3C).///In order to better understand the functional role of charged
        residues R38 and D98, we assessed the dose-response curves in the R38S, A,
        K and D98E, G, N mutants (Fig. 4) with 16 9 T Buserelin.', pubmed: '21527534',
    seq: '38', to_res: S}
- {entry_name: adrb2_human, from_res: N, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '322', to_res: A}
- {entry_name: gnrhr_human, from_res: K, info: 'Mutants K121R or K121R-desK191 did
        not show CA with or without rescue with either pharmacoperone (not shown).///Mutants
        K121R or K121R-desK191 did not show CA with or without rescue with either
        pharmacoperone (not shown).///Among those single mutants at residue 121 (A,
        D, E, G, N, Q, or R), only the conservative substitution, K121R, led to a
        response to Buserelin that was comparable to that of the WT hGnRHR (without
        pharmacoperone rescue).///Further deletion of K191 in these mutants resulted
        in responsiveness from K121R, a more modest response from K121Q > A > N >
        G, and no response from the negatively charged D or E.///These data are consistent
        with our modeling of K121A and K121R mutants, which suggests that modest CA
        observed in the K121A, but not in the K121R mutant, may be related to breaking
        of the ionic bridge in the K121A mutant.///These data are consistent with
        our modeling of K121A and K121R mutants, which suggests that modest CA observed
        in the K121A, but not in the K121R mutant, may be related to breaking of the
        ionic bridge in the K121A mutant.///This may explain the better response to
        Buserelin of the K121R mutant relative to the K121A mutant.', pubmed: '21527534',
    seq: '121', to_res: R}
- {entry_name: gnrhr_human, from_res: Y, info: 'To further explore this possibility
        and the role of the S217-Y284 H-bond, we prepared Y284F, Y284C mutants that
        cannot form this H-bond.///Both Y284F (Fig. 10B) and Y284C mutants as well
        as the S217G mutant can be rescued by the pharmacoperone In3 and/or deletion
        of K191 [Figure 10A,B and (Knollman et al., 2005)].///After pretreatment with
        In3 the S217G mutant demonstrates Buserelin-stimulated activation similar
        to the WT receptor, while Y284F and Y284C show 70% and 23% activity, respectively.',
    pubmed: '21527534', seq: '284', to_res: F}
- {entry_name: gnrhr_human, from_res: C, info: 'When the pharmacoperone is removed,
        cells expressing hGnRHR[C14A or C200A] regain the ability to bind and respond
        to agonists, suggesting that while this structure is important for trafficking,
        it is not absolutely required for receptor activation by agonist.///Deletion
        of the K191 residue also rescues the hGnRHR[C14A or C200A] mutants.///This
        was compared with mutants also containing C14A and C200A modifications that
        preclude formation of the C14-C200 bridge.///CA is substantially inhibited
        by the introduction of mutations C14A or C200A, even though the disulfide
        bridge is not requisite for trafficking to the plasma membrane in the rat
        sequence ((Janovick et al., 2006) and (Fig. 5)).', pubmed: '21527534', seq: '14',
    to_res: A}
- {entry_name: gnrhr_human, from_res: E, info: "Disruption of this ion pair in the\
        \ E90K mutant is the underlying cause in some cases of human hypogonadotropic\
        \ hypogonadism (Janovick et al., 2009).///In the present study, we provide\
        \ evidence from computer modeling and site-directed mutagenesis for the existence\
        \ of a second salt 5 9 T bridge, R38-D98, and suggest structural features\
        \ of the inactive and active receptor conformations that explain the observation\
        \ that Asp2-GnRH, which is inactive with the WT receptor (neither agonist\
        \ nor antagonist), becomes an agonist with rescued E90K.///Comparison of models\
        \ of human GnRH receptor and its E90K mutant in inactive and active conformations\
        \ with different peptide ligands (Fig. 1D-F) suggests that this hydrogen bond\
        \ 13 \u01FA hand, deletion of the K191 residue from the human receptor allows\
        \ the ~7 inward shift of the 9 T network may rearrange upon ligand binding\
        \ and receptor structural transitions.///The model of the E90K mutant in complex\
        \ with Asp2-GnRH (Fig. 1 F) represents an active receptor conformation with\
        \ broken interactions between positively charged K121 and K90 and an alternative\
        \ bridge formed between K121 and D98.///In this conformation K121 effectively\
        \ interacts with Asp2 of the ligand, which behaves as an agonist in the E90K\
        \ mutant.///Breaking the E90-K121 bridge in the E90K mutant results in a misrouted\
        \ protein retained in the ER.///However, the lower CA of K121A in comparison\
        \ with the E90K mutant can be explained by the lack of additional stabilization\
        \ of the TM2-TM7 proximity, which in the E90K mutant may be reinforced by\
        \ K90-D319 ionic interactions.///However, the lower CA of K121A in comparison\
        \ with the E90K mutant can be explained by the lack of additional stabilization\
        \ of the TM2-TM7 proximity, which in the E90K mutant may be reinforced by\
        \ K90-D319 ionic interactions.///This contrasts with the unchanged affinity\
        \ of the E90K mutant to Buserelin.///Comparisons Among Species: Pharmacoperone\
        \ In3 Rescues Constitutive Activity in Mutant E90K.///In contrast, the E90K\
        \ mutants of human and mouse GnRHRs, but not rat GnRHR, show measurable CA\
        \ following In3 rescue (Fig. 5).///To investigate the connection between the\
        \ receptor ability to undergo conformational transitions and structural constraints\
        \ in EL2, we measured responsiveness to agonist of WT and E90K mutants of\
        \ human (Fig. 6A, rat (Fig. 6B) and mouse (Fig. 6C) sequences following rescue\
        \ by pharmacoperone In3 and/or deletion of residue K191.///The human, mouse\
        \ and rat E90K sequences show measurable CA following rescue by In3.///These\
        \ observations suggest that the Cys bridge is required for CA in all species\
        \ of E90K mutants examined.///K191 deletion provides measurable improvement\
        \ in CA of In3-rescued E90K human receptor mutants.///This improvement is\
        \ highly pronounced for the E90K-\u0394K191 mutant having both disulfide bridges\
        \ (up to 10 fold increase in IP production, Fig, 5A), and it is noticeable\
        \ even for receptors with a broken C14-C200 bridge.///The elimination of the\
        \ C14-C200 disulfide bridge similarly affects agonist-induced activation of\
        \ E90K mutants of human and rodent receptors (Fig. 6).///In other experiments\
        \ we assessed the impact of breaking the disulfide bridge in the human WT\
        \ and E90K mutants on the receptor trafficking monitored by the specific binding\
        \ of radioligand (Fig. 7).///These data show that mutant E90K is not present\
        \ at the plasma membrane, consistent with the previous observation that this\
        \ mutant is retained in the ER by the cellular quality control system (Brothers\
        \ et al., 2004).///E90K mutants that cannot form the C14-C200 bridge were\
        \ further impaired in trafficking.///Thus, the small effect of K191 deletion\
        \ on the constitutive and agonist-induced activity of the E90K mutant may\
        \ be fully attributed to the improved trafficking of this receptor.///Impact\
        \ of EL2 Interactions on Ligand Binding and Constitutive Activation of E90K\
        \ Mutant.///When the human motif in hGnRHR[E90K] was replaced with the orthologous\
        \ rat residues (i.e.; L112F, Q208E, L300V, D302E), this decreased the measured\
        \ CA. but modestly increased the IP production following rescue.///Interestingly,\
        \ the human E90K mutant with 19 9 T rat-like substitutions including deletion\
        \ of K191, which demonstrates the biggest CA, has decreased CA after pretreatment\
        \ by In3.///In Fig. 8 we observe that the S217G mutation reduces CA in the\
        \ human E90K mutant suggesting a role for this residue in the active state\
        \ of the receptor.///Considering these results together with the reduced CA\
        \ of the E90K/S217G double mutant, we conclude that; (a) the aromatic ring\
        \ and OH-group of the Y284 are essential for receptor activation; and (b)\
        \ the formation of the H-bond between S217 and Y284 or other polar groups\
        \ is likely involved in the activation process.///This is consistent with\
        \ the observation that mutants which totally break the E90-K121 bridge (i.e.\
        \ E90K) show CA (Janovick and Conn, 2010).///The level of CA for the E90K\
        \ mutant is modest: the receptor does not produce the same robust response\
        \ that is observed with agonist occupancy, suggesting that the structure of\
        \ the receptor is non-identical with the physical change in the receptor which\
        \ occurs when an agonist binds.///Our modeling suggests that CA is likely\
        \ associated with relative movement of helices accompanied by the rearrangement\
        \ of the hydrogen bonding network between TMs 1, 2, 3, 6, 7, and formation\
        \ of a tight connection between TM2 and TM7 that may be stabilized by ionic\
        \ interactions between E90K and D319.///With the deletion of K191 and L112F,\
        \ Q208E, L300V, D302E substitutions, CA of the E90K mutant substantially increases.///The\
        \ importance of the region of the GnRHR molecule with these two salt bridges\
        \ is emphasized by the observation that a ligand (Asp2-GnRH) that was not\
        \ recognized by WT hGnRHR become an agonist for E90K once this molecule is\
        \ rescued and trafficked to the plasma membrane (Janovick and Conn, 2010).///The\
        \ computational models suggest that, in the active conformation of the E90K\
        \ mutant the side chain of K90 is rotated toward D98 forming a new K90D98\
        \ ionic bridge.///E90K mutants of human receptor with a broken bridge cannot\
        \ be fully rescued by deletion of K191 or by pharmacoperone In3, methods by\
        \ which trafficking to the membrane of human WT or mutant E90K is enhanced.///E90K\
        \ mutants of human receptor with a broken bridge cannot be fully rescued by\
        \ deletion of K191 or by pharmacoperone In3, methods by which trafficking\
        \ to the membrane of human WT or mutant E90K is enhanced.///Further, the CA\
        \ and agonist-induced activation is also reduced in rat E90K mutants with\
        \ a broken C14-C200 bridge even though this bridge is not a requirement for\
        \ trafficking of the rat receptor (Janovick et al., 2006).", pubmed: '21527534',
    seq: '90', to_res: K}
- {entry_name: gnrhr_human, from_res: R, info: 'Restoration of responsiveness of R38A
        and R38K by In3 suggests that they are misrouted (likely ER-retained mutants)
        and rescuable, while R38D and R38E may be permanently retained or unable to
        bind agonist or to achieve the active configuration needed to interact with
        G proteins.', pubmed: '21527534', seq: '38', to_res: K}
- {entry_name: gnrhr_human, from_res: L, info: 'When the human motif in hGnRHR[E90K]
        was replaced with the orthologous rat residues (i.e.; L112F, Q208E, L300V,
        D302E), this decreased the measured CA. but modestly increased the IP production
        following rescue.///With the deletion of K191 and L112F, Q208E, L300V, D302E
        substitutions, CA of the E90K mutant substantially increases.', pubmed: '21527534',
    seq: '112', to_res: F}
- {entry_name: gnrhr_mouse, from_res: D, info: 'In order to better understand the
        functional role of charged residues R38 and D98, we assessed the dose-response
        curves in the R38S, A, K and D98E, G, N mutants (Fig. 4) with 16 9 T Buserelin.',
    pubmed: '21527534', seq: '98', to_res: E}
- {entry_name: gnrhr_human, from_res: K, info: 'There was a slight responsiveness
        of K121A and K121Q and a more modest response of K121G and K121N to Buserelin,
        when these mutants where first rescued by pharmacoperone In3.///These data
        are consistent with our modeling of K121A and K121R mutants, which suggests
        that modest CA observed in the K121A, but not in the K121R mutant, may be
        related to breaking of the ionic bridge in the K121A mutant.///These data
        are consistent with our modeling of K121A and K121R mutants, which suggests
        that modest CA observed in the K121A, but not in the K121R mutant, may be
        related to breaking of the ionic bridge in the K121A mutant.///These data
        are consistent with our modeling of K121A and K121R mutants, which suggests
        that modest CA observed in the K121A, but not in the K121R mutant, may be
        related to breaking of the ionic bridge in the K121A mutant.///However, the
        lower CA of K121A in comparison with the E90K mutant can be explained by the
        lack of additional stabilization of the TM2-TM7 proximity, which in the E90K
        mutant may be reinforced by K90-D319 ionic interactions.///This may explain
        the better response to Buserelin of the K121R mutant relative to the K121A
        mutant.', pubmed: '21527534', seq: '121', to_res: A}
- {entry_name: gnrhr_human, from_res: R, info: 'Unlike mutants of the E90-K121 salt
        bridge, the R38 and D98 mutants do not show measurable CA following more than
        75% of their IP response to Buserelin stimulation and R38D and R38E are totally
        inactive mutants.///Restoration of responsiveness of R38A and R38K by In3
        suggests that they are misrouted (likely ER-retained mutants) and rescuable,
        while R38D and R38E may be permanently retained or unable to bind agonist
        or to achieve the active configuration needed to interact with G proteins.',
    pubmed: '21527534', seq: '38', to_res: D}
- {entry_name: gnrhr_human, from_res: C, info: 'When the pharmacoperone is removed,
        cells expressing hGnRHR[C14A or C200A] regain the ability to bind and respond
        to agonists, suggesting that while this structure is important for trafficking,
        it is not absolutely required for receptor activation by agonist.///Deletion
        of the K191 residue also rescues the hGnRHR[C14A or C200A] mutants.///This
        was compared with mutants also containing C14A and C200A modifications that
        preclude formation of the C14-C200 bridge.///CA is substantially inhibited
        by the introduction of mutations C14A or C200A, even though the disulfide
        bridge is not requisite for trafficking to the plasma membrane in the rat
        sequence ((Janovick et al., 2006) and (Fig. 5)).', pubmed: '21527534', seq: '200',
    to_res: A}
- {entry_name: gnrhr_human, from_res: R, info: 'We prepared mutants at both ends (i.e.
        R38A, D, E, K, S and D98 A, E, G, K, N, R) of the presumptive R38-D98 bridge.///Restoration
        of responsiveness of R38A and R38K by In3 suggests that they are misrouted
        (likely ER-retained mutants) and rescuable, while R38D and R38E may be permanently
        retained or unable to bind agonist or to achieve the active configuration
        needed to interact with G proteins.///The ability of pharmacoperones to rescue
        a substantial amount of the responsiveness of R38A, K and S, but not the mutants
        with charge changes, is reminiscent of the pattern seen with mutants that
        do not pass the cellular QCS (Conn et al., 2006b).', pubmed: '21527534', seq: '38',
    to_res: A}
- {entry_name: adrb2_human, from_res: T, info: "Basal activity of b2AR is important\
        \ physiologically, as shown by the T164I4.56 human polymorphism that reduces\
        \ the basal activity of b2AR to levels similar to b1AR21 and whose expression\
        \ has been associated with heart disease22.///In this regard, it is noteworthy\
        \ that the naturally occurring polymorphism in b2AR at the H4\u2013H5 interface,\
        \ T164I4.56, converts a polar residue to a hydrophobic residue as seen in\
        \ b1AR (Val 1724.56), which results in both reduced basal activity and reduced\
        \ agonist stimulation21.///The naturally occurring polymorphism Thr164Ile\
        \ in the 2AR, which results in reduced basal activity and agonist stimulation\
        \ (Green et al. (2001) Eur J Pharmacol.///This interaction would be altered\
        \ in the Thr164Ile 2AR polymorphism.", pubmed: '21228877', seq: '164', to_res: I}
- {entry_name: adrb1_melga, from_res: C, info: 'All constructs contain the C116L mutation
        that improves the expression of the turkey 1AR. trunc: wild-type turkey 1AR
        with part of the C-terminus deleted as found in the 6 construct.', pubmed: '21228877',
    seq: '116', to_res: L}
- {entry_name: acm3_human, from_res: F, info: "The two resulting mutant receptors\
        \ showed [3H]-NMS binding properties similar to M3-Luc and M3-LucTM7A1 (Bmax\
        \ in pmol/mg: M3-Luc-T524A, 25.7 \xB1 3.4; M3-Luc-F525A, 34.7 \xB1 7.7; [3H]NMS\
        \ KD in nM: M3-Luc-T524A, 0.51 \xB1 0.04; M3-Luc-F525A, 0.68 \xB1 0.09; n\
        \ = 2 or 3).///The two resulting mutant receptors showed [3H]-NMS binding\
        \ properties similar to M3-Luc and M3-LucTM7A1 (Bmax in pmol/mg: M3-Luc-T524A,\
        \ 25.7 \xB1 3.4; M3-Luc-F525A, 34.7 \xB1 7.7; [3H]NMS KD in nM: M3-Luc-T524A,\
        \ 0.51 \xB1 0.04; M3-Luc-F525A, 0.68 \xB1 0.09; n = 2 or 3).///In IP assays,\
        \ both mutant receptors showed a moderate reduction (by ~20%) in carbachol\
        \ Emax values (Table 4; Fig. 8B). inhibition [3H]-NMS/carbachol binding studies\
        \ demonstrated that the M3-LucTM7A1, M3-Luc-T524A, and M3-Luc-F525A constructs\
        \ were able to bind carbachol with similar affinity as M3-Luc (Fig. 8C; Table\
        \ 4), suggesting that T5247.33 and F5257.34 are required for efficient M3R\
        \ activation.", pubmed: '21685385', seq: '525', to_res: A}
- {entry_name: acm3_human, from_res: Y, info: 'All resulting mutant receptors were
        able to bind [3H]-NMS with high affinity and, with the exception of the Y255A
        construct, showed functional properties similar to the M3-Luc receptor from
        which they were derived (Supplementary Table 1).///The Y255A receptor showed
        a pronounced reduction in receptor expression levels (Bmax) and carbachol
        potency and efficacy (Supplementary Table 1).///Interestingly, the M3-Luc-Y255A
        receptor displayed a ~3fold increase in BRET50, as compared to M3Luc (Fig.
        7), suggesting that Y255 may contribute to the formation of M3R dimers.///It
        should be noted that the amounts of transfected DNAs were adjusted in the
        BRET assays, so that the M3-Luc-Y255A and M3Luc constructs were expressed
        at similar levels.///Interestingly, the M3-Luc-Y255A receptor displayed a
        ~3-fold increase in BRET50, as compared to M3-Luc (Fig. 7), suggesting that
        Y255 may contribute to the formation of M3R dimers, consistent with molecular
        modeling studies (Supplementary Fig. 3).///However, since the Y255A mutant
        receptor also showed clear functional deficits (Supplementary Table 1), it
        remains unclear to which extent the BRET data that we obtained with this mutant
        receptor were affected by indirect conformational changes induced by the Y255A
        point mutation.///However, since the Y255A mutant receptor also showed clear
        functional deficits (Supplementary Table 1), it remains unclear to which extent
        the BRET data that we obtained with this mutant receptor were affected by
        indirect conformational changes induced by the Y255A point mutation.///Consistent
        with the potential importance of this TM subsegment in M3R dimerization, we
        found that introduction of a single point mutation (Y255A) into this region
        led to a significantly impaired BRET signal (see discussion above).', pubmed: '21685385',
    seq: '255', to_res: A}
- {entry_name: acm3_human, from_res: T, info: "We therefore generated two additional\
        \ M3-Luc-based mutant receptors containing either the T5247.33A or the F5257.34A\
        \ point mutation (M3-Luc-T524A and M3-LucF525A, respectively).///The two resulting\
        \ mutant receptors showed [3H]-NMS binding properties similar to M3-Luc and\
        \ M3-LucTM7A1 (Bmax in pmol/mg: M3-Luc-T524A, 25.7 \xB1 3.4; M3-Luc-F525A,\
        \ 34.7 \xB1 7.7; [3H]NMS KD in nM: M3-Luc-T524A, 0.51 \xB1 0.04; M3-Luc-F525A,\
        \ 0.68 \xB1 0.09; n = 2 or 3).///The two resulting mutant receptors showed\
        \ [3H]-NMS binding properties similar to M3-Luc and M3-LucTM7A1 (Bmax in pmol/mg:\
        \ M3-Luc-T524A, 25.7 \xB1 3.4; M3-Luc-F525A, 34.7 \xB1 7.7; [3H]NMS KD in\
        \ nM: M3-Luc-T524A, 0.51 \xB1 0.04; M3-Luc-F525A, 0.68 \xB1 0.09; n = 2 or\
        \ 3).///In IP assays, both mutant receptors showed a moderate reduction (by\
        \ ~20%) in carbachol Emax values (Table 4; Fig. 8B). inhibition [3H]-NMS/carbachol\
        \ binding studies demonstrated that the M3-LucTM7A1, M3-Luc-T524A, and M3-Luc-F525A\
        \ constructs were able to bind carbachol with similar affinity as M3-Luc (Fig.\
        \ 8C; Table 4), suggesting that T5247.33 and F5257.34 are required for efficient\
        \ M3R activation.", pubmed: '21685385', seq: '524', to_res: A}
- {entry_name: 5ht2a_human, from_res: F, info: "The present article describes our\
        \ examination of a series of 5-HT2A receptor agonists, including a new series\
        \ of N-benzyl analogs, and the effects of the mutations F339L and F340L on\
        \ binding affinity to and functional activity at 5-HT2A receptors.///All DMEM\
        \ media for stably expressing cell lines contained 300 g/ml G-418 (Sigma-Aldrich)\
        \ for Nr2A and Nr2C cells, 22.5 units/ml Hygromycin B (Invitrogen) for CHO-1A\
        \ cells, and 30 g/ml Zeocin (Invitrogen) for Hh2A, Hh2A/F339L, and Hh2A/F340L\
        \ cells (described below).///The following sense primers were used, along\
        \ with their corresponding antisense primers (Integrated DNA Technologies,\
        \ Coralville, IA): GGTGATGTGGTGCCCTTTGTTCATCACAAACATCATGGCCG for F339L and\
        \ GGTGATGTGGTGCCCTTTCTTGATCACAAACATCATGGCCG for F340L.///The Hh2A/F339L and\
        \ Hh2A/F340L cell lines were chosen for moderate expression (2200 and 2500\
        \ fmol/mg, respectively).///Ligands were tested in competition binding assays\
        \ for their ability to displace 0.25 nM [125I]DOI at Nr2A, Nr2C, Hh2Ahi, and\
        \ Hh2A/F339L memDownloaded from molpharm.aspetjournals.org by guest on July\
        \ 5, 2011 1958 Braden et al. intrinsic activity values of human wild type\
        \ and mutant receptors, with a Bonferroni post test to compare replicate mean\
        \ values of mutant receptors to the wild type.///Compounds were tested for\
        \ their ability to stimulate hydrolysis of radiolabeled phosphatidylinositides\
        \ (PI) by measurement of radiolabeled inositol phosphate accumulation in Nr2A,\
        \ Hh2Ahet3, Hh2A/F339L, and Hh2A/ F340L cells, as described previously in\
        \ detail (Marona-Lewicka et al., 2002; Kurrasch-Orbaugh et al., 2003).///Primary\
        \ comparison of EC50 and intrinsic activity was performed between cell lines\
        \ with approximately equivalent expression of h5-HT2A wild type (1600 fmol/mg),\
        \ F339L mutant (2000 fmol/mg), and F340L mutant (2500 fmol/mg) receptors.///KD\
        \ values for [125I]DOI at Hh2A and Hh2A/F339L membrane preparations were 0.78\
        \ 0.01 and 0.86 0.14 nM, respectively.///1960 Braden et al. Hh2A/F339L, and\
        \ Hh2A/F340L membrane preparations were 1.10 0.12, 11.1 3.6, and 0.40 0.02\
        \ nM, respectively.///Furthermore, because of the high KD (11 nM) for [3H]ketanserin\
        \ at h5-HT2A/F339L, it was not practical to use this radioligand for competition\
        \ binding at this receptor.///Therefore, competition binding assays were performed\
        \ with [125I]DOI at h5-HT2A/F339L receptors, [3H]ketanserin at h5-HT2A/F340L\
        \ receptors, and both radioligands at wild-type receptors.///The newly constructed\
        \ Hh2Alo cell population had a Bmax of 1600 fmol/mg, compared with expression\
        \ levels of 2200 and 2500 fmol/mg, respectively, for the mutant Hh2A/F339L\
        \ and Hh2A/F340L cell lines.///P 0.01 for all values of pKi from unpaired\
        \ two-tailed student t tests between mutant and wild-type receptors tested\
        \ with the same radioligand. ( )Drug h5-HT2A Ki nM h5-HT2A/F339L Ki nM G\xB0\
        \ kcal/mol h5-HT2A Ki nM h5-HT2A/F340L Ki nM G\xB0 kcal/mol 125 I DOI 3 H\
        \ Ketanserin 5-HT LSD Psilocin 5-MeO-DMT Mescaline 25H 25H-NMe 25H-NPr 25H-NB\
        \ 25H-NBOMe 25H-NBOH 24 24-NB 24-NBOMe 24-NBOH 25I 25I-NB 25I-NNap 25I-NBOMe\
        \ 25I-NBOH 25I-NBF 25I-NBMD 4.84 (0.2) 0.40 (0.02) 11.8 (1.2) 7.54 (1.06)\
        \ 1499 (245) 377 (67) 1907 (254) 1295 (151) 68.1 (10.6) 2.83 (0.31) 3.73 (0.45)\
        \ 298 (29) 26.6 (2.7) 1.71 (0.34) 1.51 (0.20) 0.73 (0.06) 0.25 (0.05) 4.83\
        \ (0.55) 0.044 (0.006) 0.061 (0.012) 0.26 (0.05) 0.049 (0.008) 59.6 (10.0)\
        \ 0.60 (0.12)\u2021 28.6 (4.3) 129 (15) 4488 (608) 5786 (734) 8719 (671) 7863\
        \ (769) 2722 (470) 1435 (192) 2642 (455) 1013 (190) 1768 (339) 252 (49) 306\
        \ (57) 2.63 (0.32) 3.1 (0.1) 157 (31) 2.08 (0.35) 1.84 (0.16) 15.2 (1.7) 0.29\
        \ (0.03) 1.5 0.2 0.5 1.7 0.6 1.6 0.9 1.1 2.2 3.5 3.9 0.7 2.5 3.0 3.1 0.8 1.3\
        \ 2.1 2.3 2.0 2.4 1.1 77.6 (13.8) 0.81 (0.16) 22.8 (4.0) 49.2 (3.2) 14,640\
        \ (2447) 1999 (311) 5934 (92) 3597 (642) 184 (33) 11.0 (0.5) 11.6 (1.7) 999\
        \ (182) 71.9 (3.0) 5.24 (1.01) 2.83 (0.36) 4.52 (0.30) 0.28 (0.02) 6.68 (1.02)\
        \ 0.15 (0.03) 0.068 (0.012) 0.19 (0.03) 0.21 (0.03) 192,725 (36,305) 13.01\
        \ (1.09) 3659 (243) 23,726 (4726) 62,425 (10,485) 16,001 (3163) 43,918 (2271)\
        \ 9815 (943) 6698 (1031) 689 (107) 277 (40) 8391 (1200) 3316 (356) 703 (14)\
        \ 292 (14) 28.9 (4.8) 27.0 (1.8) 268 (268) 4.3 (0.76) 1.58 (0.17) 37.9 (1.3)\
        \ 0.94 (0.17) 4.6 1.6 3.0 3.7 0.9 1.2 1.2 0.6 2.1 2.5 1.9 1.3 2.3 2.9 2.7\
        \ 1.1 2.7 2.1 2.1 1.9 3.1 0.9 \u2021 P 0.01.///h5-HT2A Drug EC50 PI Hydrolysis\
        \ nM Intrinsic Activity (5-HT) % h5-HT2A/F339L EC50 PI Hydrolysis nM Intrinsic\
        \ Activity (5-HT) % h5-HT2A/F340L EC50 PI Hydrolysis nM Intrinsic Activity\
        \ (5-HT) % 5-HT LSD Psilocin 5-MeO-DMT Mescaline 25H 25H-NBOMe 25H-NBOH 24\
        \ 24-NBOMe 24-NBOH 25I 25I-NB 25I-NBOMe 25I-NBOH 25I-NBF 25I-NBMD 5.17 (0.97)\
        \ 0.22 (0.04) 7.29 (0.72) 4.33 (0.78) 1117 (223) 1021 (14) 15.3 (3.7) 23.5\
        \ (1.8) 832 (200) 4.00 (0.80) 5.42 (0.66) 2.54 (0.18) 1.96 (0.12) 0.44 (0.07)\
        \ 0.19 (0.03) 1.55 (0.21) 1.07 (0.20) 100 84 (3) 105 (9) 98 (4) 83 (5) 96\
        \ (10) 88 (6) 100 (6) 83 (5) 89 (6) 84 (4) 82 (3) 66 (2) 81 (4) 86 (5) 87\
        \ (11) 72 (3) 92.4 (10.5) 1.36 (0.23) 129 (18) 416 (71) 11,333 (991) 10,353\
        \ (1652) 3407 (390) 11,267 (758) 4077 (579) 1436 (281) 5623 (29) 22.8 (2.7)\
        \ 1093 (353) 28.0 (5.2) 42.3 (6.5) 150 (25) 91.0 (30.9) 100 55 (5) 44 (8)\
        \ 74 (5) 82 (7)\u2021 78 (1)\u2021 27 (4) 32 (6) 66 (4)\u2021 55 (5) 49 (8)\
        \ 72 (5)\u2021 14 (2) 51 (4) 45 (6) 8 (1) 11 (1) 9840 (458) 15.7 (2.9) 4529\
        \ (813) 5255 (969) 78,795 (3869) 141,033 (39,537) 1341 (53) 2156 (503) 109,311\
        \ (37,671) 2029 (199) 696 (139) 99.5 (5.3) 263 (40) 26.8 (4.2) 14.6 (2.9)\
        \ 410 (33) 145 (25) 100\u2021 20 (5) 9 (1) 15 (4) 30 (1) 12 (4) 43 (5) 28\
        \ (3) 17 (1) 66 (8)\u2021 31 (3) 38 (2) 82 (1)\u2021 84 (7)\u2021 82 (7)\u2021\
        \ 81 (6)\u2021 70 (5)\u2021 \u2021 P 0.01.", pubmed: '17000863', seq: '339',
    to_res: L}
- {entry_name: 5ht2a_human, from_res: F, info: "The present article describes our\
        \ examination of a series of 5-HT2A receptor agonists, including a new series\
        \ of N-benzyl analogs, and the effects of the mutations F339L and F340L on\
        \ binding affinity to and functional activity at 5-HT2A receptors.///All DMEM\
        \ media for stably expressing cell lines contained 300 g/ml G-418 (Sigma-Aldrich)\
        \ for Nr2A and Nr2C cells, 22.5 units/ml Hygromycin B (Invitrogen) for CHO-1A\
        \ cells, and 30 g/ml Zeocin (Invitrogen) for Hh2A, Hh2A/F339L, and Hh2A/F340L\
        \ cells (described below).///The following sense primers were used, along\
        \ with their corresponding antisense primers (Integrated DNA Technologies,\
        \ Coralville, IA): GGTGATGTGGTGCCCTTTGTTCATCACAAACATCATGGCCG for F339L and\
        \ GGTGATGTGGTGCCCTTTCTTGATCACAAACATCATGGCCG for F340L.///The Hh2A/F339L and\
        \ Hh2A/F340L cell lines were chosen for moderate expression (2200 and 2500\
        \ fmol/mg, respectively).///Amino acid residues are numbered with their position\
        \ in the h5-HT2A receptor and their position relative to the most highly conserved\
        \ residue of that transmembrane region, per Ballesteros and Weinstein (1995).\
        \ branes, 0.5 nM [3H]ketanserin at Hh2Ahi and Hh2A/F340L membranes, and 0.5\
        \ nM [3H]8-hydroxy-2-(dipropylamino)tetralin at Ch1A membranes.///Compounds\
        \ were tested for their ability to stimulate hydrolysis of radiolabeled phosphatidylinositides\
        \ (PI) by measurement of radiolabeled inositol phosphate accumulation in Nr2A,\
        \ Hh2Ahet3, Hh2A/F339L, and Hh2A/ F340L cells, as described previously in\
        \ detail (Marona-Lewicka et al., 2002; Kurrasch-Orbaugh et al., 2003).///Primary\
        \ comparison of EC50 and intrinsic activity was performed between cell lines\
        \ with approximately equivalent expression of h5-HT2A wild type (1600 fmol/mg),\
        \ F339L mutant (2000 fmol/mg), and F340L mutant (2500 fmol/mg) receptors.///1960\
        \ Braden et al. Hh2A/F339L, and Hh2A/F340L membrane preparations were 1.10\
        \ 0.12, 11.1 3.6, and 0.40 0.02 nM, respectively.///As anticipated from the\
        \ work of Roth et al. (1997), it was not possible to determine a KD value\
        \ for [125I]DOI at h5-HT2A/F340L receptors.///Therefore, competition binding\
        \ assays were performed with [125I]DOI at h5-HT2A/F339L receptors, [3H]ketanserin\
        \ at h5-HT2A/F340L receptors, and both radioligands at wild-type receptors.///The\
        \ newly constructed Hh2Alo cell population had a Bmax of 1600 fmol/mg, compared\
        \ with expression levels of 2200 and 2500 fmol/mg, respectively, for the mutant\
        \ Hh2A/F339L and Hh2A/F340L cell lines.///P 0.01 for all values of pKi from\
        \ unpaired two-tailed student t tests between mutant and wild-type receptors\
        \ tested with the same radioligand. ( )Drug h5-HT2A Ki nM h5-HT2A/F339L Ki\
        \ nM G\xB0 kcal/mol h5-HT2A Ki nM h5-HT2A/F340L Ki nM G\xB0 kcal/mol 125 I\
        \ DOI 3 H Ketanserin 5-HT LSD Psilocin 5-MeO-DMT Mescaline 25H 25H-NMe 25H-NPr\
        \ 25H-NB 25H-NBOMe 25H-NBOH 24 24-NB 24-NBOMe 24-NBOH 25I 25I-NB 25I-NNap\
        \ 25I-NBOMe 25I-NBOH 25I-NBF 25I-NBMD 4.84 (0.2) 0.40 (0.02) 11.8 (1.2) 7.54\
        \ (1.06) 1499 (245) 377 (67) 1907 (254) 1295 (151) 68.1 (10.6) 2.83 (0.31)\
        \ 3.73 (0.45) 298 (29) 26.6 (2.7) 1.71 (0.34) 1.51 (0.20) 0.73 (0.06) 0.25\
        \ (0.05) 4.83 (0.55) 0.044 (0.006) 0.061 (0.012) 0.26 (0.05) 0.049 (0.008)\
        \ 59.6 (10.0) 0.60 (0.12)\u2021 28.6 (4.3) 129 (15) 4488 (608) 5786 (734)\
        \ 8719 (671) 7863 (769) 2722 (470) 1435 (192) 2642 (455) 1013 (190) 1768 (339)\
        \ 252 (49) 306 (57) 2.63 (0.32) 3.1 (0.1) 157 (31) 2.08 (0.35) 1.84 (0.16)\
        \ 15.2 (1.7) 0.29 (0.03) 1.5 0.2 0.5 1.7 0.6 1.6 0.9 1.1 2.2 3.5 3.9 0.7 2.5\
        \ 3.0 3.1 0.8 1.3 2.1 2.3 2.0 2.4 1.1 77.6 (13.8) 0.81 (0.16) 22.8 (4.0) 49.2\
        \ (3.2) 14,640 (2447) 1999 (311) 5934 (92) 3597 (642) 184 (33) 11.0 (0.5)\
        \ 11.6 (1.7) 999 (182) 71.9 (3.0) 5.24 (1.01) 2.83 (0.36) 4.52 (0.30) 0.28\
        \ (0.02) 6.68 (1.02) 0.15 (0.03) 0.068 (0.012) 0.19 (0.03) 0.21 (0.03) 192,725\
        \ (36,305) 13.01 (1.09) 3659 (243) 23,726 (4726) 62,425 (10,485) 16,001 (3163)\
        \ 43,918 (2271) 9815 (943) 6698 (1031) 689 (107) 277 (40) 8391 (1200) 3316\
        \ (356) 703 (14) 292 (14) 28.9 (4.8) 27.0 (1.8) 268 (268) 4.3 (0.76) 1.58\
        \ (0.17) 37.9 (1.3) 0.94 (0.17) 4.6 1.6 3.0 3.7 0.9 1.2 1.2 0.6 2.1 2.5 1.9\
        \ 1.3 2.3 2.9 2.7 1.1 2.7 2.1 2.1 1.9 3.1 0.9 \u2021 P 0.01.///h5-HT2A Drug\
        \ EC50 PI Hydrolysis nM Intrinsic Activity (5-HT) % h5-HT2A/F339L EC50 PI\
        \ Hydrolysis nM Intrinsic Activity (5-HT) % h5-HT2A/F340L EC50 PI Hydrolysis\
        \ nM Intrinsic Activity (5-HT) % 5-HT LSD Psilocin 5-MeO-DMT Mescaline 25H\
        \ 25H-NBOMe 25H-NBOH 24 24-NBOMe 24-NBOH 25I 25I-NB 25I-NBOMe 25I-NBOH 25I-NBF\
        \ 25I-NBMD 5.17 (0.97) 0.22 (0.04) 7.29 (0.72) 4.33 (0.78) 1117 (223) 1021\
        \ (14) 15.3 (3.7) 23.5 (1.8) 832 (200) 4.00 (0.80) 5.42 (0.66) 2.54 (0.18)\
        \ 1.96 (0.12) 0.44 (0.07) 0.19 (0.03) 1.55 (0.21) 1.07 (0.20) 100 84 (3) 105\
        \ (9) 98 (4) 83 (5) 96 (10) 88 (6) 100 (6) 83 (5) 89 (6) 84 (4) 82 (3) 66\
        \ (2) 81 (4) 86 (5) 87 (11) 72 (3) 92.4 (10.5) 1.36 (0.23) 129 (18) 416 (71)\
        \ 11,333 (991) 10,353 (1652) 3407 (390) 11,267 (758) 4077 (579) 1436 (281)\
        \ 5623 (29) 22.8 (2.7) 1093 (353) 28.0 (5.2) 42.3 (6.5) 150 (25) 91.0 (30.9)\
        \ 100 55 (5) 44 (8) 74 (5) 82 (7)\u2021 78 (1)\u2021 27 (4) 32 (6) 66 (4)\u2021\
        \ 55 (5) 49 (8) 72 (5)\u2021 14 (2) 51 (4) 45 (6) 8 (1) 11 (1) 9840 (458)\
        \ 15.7 (2.9) 4529 (813) 5255 (969) 78,795 (3869) 141,033 (39,537) 1341 (53)\
        \ 2156 (503) 109,311 (37,671) 2029 (199) 696 (139) 99.5 (5.3) 263 (40) 26.8\
        \ (4.2) 14.6 (2.9) 410 (33) 145 (25) 100\u2021 20 (5) 9 (1) 15 (4) 30 (1)\
        \ 12 (4) 43 (5) 28 (3) 17 (1) 66 (8)\u2021 31 (3) 38 (2) 82 (1)\u2021 84 (7)\u2021\
        \ 82 (7)\u2021 81 (6)\u2021 70 (5)\u2021 \u2021 P 0.01.///Positive Int.Act.\
        \ values for 25I-NB and 25I-NBOMe at h5-HT2A/F340L receptors were not significantly\
        \ different from WT and are not shown for formatting reasons.", pubmed: '17000863',
    seq: '340', to_res: L}
- {entry_name: aa1r_human, from_res: H, info: "The 3\u2032-ureido analogue 13 was\
        \ reported as a neoligand for the H278E and H278D mutant A3 ARs (14) and was\
        \ therefore applied to Tailored Ligands for Reengineered A1 Adenosine Receptor\
        \ analogous A1 AR mutations.///46, No. 25, 2007 Table 1: Saturation Analysis\
        \ of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently Expressed\
        \ in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A H278D H278E\
        \ H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 ( 0.34\
        \ 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2 3.0\
        \ ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2. Values\
        \ are expressed as the mean ( sem from four to eight experiments, each performed\
        \ in duplicate. coordinate the ribose moiety of the nucleoside ligands, modification\
        \ of the selected amino acid residues would be expected to be more detrimental\
        \ to binding of agonist than antagonist. Attempted saturation analysis of\
        \ the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce\
        \ measurable specific binding (data not shown), making it impractical to use\
        \ this radioligand.///While compounds 13 and 14 exhibited modest 27- and 30fold\
        \ enhancements for the H278E mutant receptor, respectively, compounds 10 and\
        \ 16 exhibited 263- and 133-fold enhancements, respectively.///These reported\
        \ enhancements for compounds 10, 13, 14, and 16 at the H278E mutant can be\
        \ extended to the other His278 mutant receptors as well, e.g., H278D, H278L,\
        \ and H278A.///Table 3: Ki Values for the Inhibition by Nucleoside Derivatives\
        \ of Binding of Antagonist [3H]DPCPX at Wild-Type and Mutant Human A1 ARs\
        \ Transiently Expressed in HEK-293 Cellsa binding affinity, Ki (nM ( sem),\
        \ or % inhibition compound DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA 10 13 14 16\
        \ 18 19 20 21 22, NECA 23 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480\
        \ <10% <10% <10% 30% 17% 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13% 13% 38%\
        \ <10% <10% 1600 ( 100 <10% 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14% 24%\
        \ 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30 980\
        \ ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40\
        \ 15% <10% 20% 16% <10% <10% 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20\
        \ 48% 410 ( 120 810 ( 250 500 ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40\
        \ ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 (\
        \ 30 1000 ( 60 50% 834 940 670 8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90\
        \ ( 3 <10% 12% 17% 25% 17% 15% 820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100\
        \ 39% NDc NDc NDc 8800 ( 900 32% 58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10%\
        \ <10% <10% <10% <10% 7000 ( 800 41% 48% 50% 39% 22% <10% <10% 11% 25% 12%\
        \ 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5 <10% <10% <10% <10% <10% <10% 11% <10%\
        \ <10% 17% <10% <10% <10% NDc NDc <10% <10% <10% NDc a Structures are given\
        \ in Figure 2. Experiments were performed using HEK-293 cells transiently\
        \ expressing (using Lipofectamine 2000) a mutant hA1 AR.", pubmed: '17542617',
    seq: '278', to_res: E}
- {entry_name: aa1r_human, from_res: H, info: "These reengineered human A1 ARs revealed\
        \ orthogonality similar to that of the A3 but not the A2A AR, in which mutation\
        \ of the corresponding residue, His278, to Asp did not enhance nucleoside\
        \ affinity.///Functionally, the H278D A1 AR was detectable only in a measure\
        \ of membrane potential and not in calcium mobilization.///(B) Binding mode\
        \ of compound 10 at the H278D mutant A1 adenosine receptor obtained after\
        \ MCMM calculations.///(C) Superimposition of the models obtained for compound\
        \ 10 at the wild-type (green) and H278D mutant (residues colored by atom type,\
        \ with the carbon atoms of the ligand colored yellow) A1 adenosine receptor.///To\
        \ study the binding mode of compound 10 in the wildtype and H278D mutant A1\
        \ receptor, the same initial atomic coordinates of the ligand and receptor\
        \ residues were used, but in the model of the mutated receptor, the side chain\
        \ of His278 was replaced with the side chain of Asp using the Mutate Residue\
        \ option of MacroModel.///The 3\u2032-ureido analogue 13 was reported as a\
        \ neoligand for the H278E and H278D mutant A3 ARs (14) and was therefore applied\
        \ to Tailored Ligands for Reengineered A1 Adenosine Receptor analogous A1\
        \ AR mutations.///46, No. 25, 2007 Table 1: Saturation Analysis of [3H]DPCPX\
        \ at the Wild-Type and Mutant Human A1 ARs Transiently Expressed in HEK-293\
        \ Cellsa A1 AR construct wild-type T277A T277E H278A H278D H278E H278L Kd\
        \ (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 ( 0.34 4.96 (\
        \ 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2 3.0 ( 0.8\
        \ 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2. Values\
        \ are expressed as the mean ( sem from four to eight experiments, each performed\
        \ in duplicate. coordinate the ribose moiety of the nucleoside ligands, modification\
        \ of the selected amino acid residues would be expected to be more detrimental\
        \ to binding of agonist than antagonist. Attempted saturation analysis of\
        \ the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce\
        \ measurable specific binding (data not shown), making it impractical to use\
        \ this radioligand.///These reported enhancements for compounds 10, 13, 14,\
        \ and 16 at the H278E mutant can be extended to the other His278 mutant receptors\
        \ as well, e.g., H278D, H278L, and H278A.///Table 3: Ki Values for the Inhibition\
        \ by Nucleoside Derivatives of Binding of Antagonist [3H]DPCPX at Wild-Type\
        \ and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa binding\
        \ affinity, Ki (nM ( sem), or % inhibition compound DPCPXb CGS15943b 1 2 3\
        \ 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22, NECA 23 26 27 wild-type hA1 4.5\
        \ ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10% 30% 17% 610 ( 50 12% 15000 ( 3100\
        \ 6200 ( 1900 13% 13% 38% <10% <10% 1600 ( 100 <10% 14% <10% H278E 36 ( 2\
        \ 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210 ( 60\
        \ 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400 220\
        \ ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10% <10% 1000 ( 170 340 ( 20\
        \ 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250 500 ( 120 8500 ( 1400\
        \ 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400 (\
        \ 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670 8800 ( 700 14%\
        \ 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15% 820 ( 90 400\
        \ ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900 32% 58% NDc\
        \ T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000 ( 800 41% 48%\
        \ 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5 <10%\
        \ <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10% NDc NDc <10% <10%\
        \ <10% NDc a Structures are given in Figure 2. Experiments were performed\
        \ using HEK-293 cells transiently expressing (using Lipofectamine 2000) a\
        \ mutant hA1 AR.///Derivatization of the 5\u2032 position, as in 3\u2032ureido\
        \ derivatives 26 and 27, resulted in an enhanced affinity (Ki ) 1.6 \u03BC\
        M) at the H278D mutant receptor.///The H278D mutation of the human A1 AR and\
        \ the corresponding mutations of conserved His in TM7 of the A2A AR (H278D)\
        \ and A3 AR (H272D) were studied.///The H278D mutation of the human A1 AR\
        \ and the corresponding mutations of conserved His in TM7 of the A2A AR (H278D)\
        \ and A3 AR (H272D) were studied.///A preliminary functional study of the\
        \ effect of adding GTP during the binding of CCPA 9 and its 3\u2032-ureido\
        \ analogue 10 at the H278A and H278D mutant receptors indicated that in both\
        \ cases there was no pronounced GTP-induced shift (data not shown).///The\
        \ H278D mutation of the human A1 AR and the corresponding mutations of the\
        \ conserved His in TM7 of the A2A AR (H278D) and A3 AR (H272D) were studied.///The\
        \ H278D mutation of the human A1 AR and the corresponding mutations of the\
        \ conserved His in TM7 of the A2A AR (H278D) and A3 AR (H272D) were studied.///Antagonist\
        \ radioligands were used at the A1 ARs ([3H]DPCPX) and the A2A ARs ([3H]ZM241385),\
        \ and an agonist radioligand was used at the A3 ARs ([125I]I-AB-MECA). cells\
        \ transiently expressing the H278D mutant receptor (Figure 4).///The 5\u2032\
        -CH2OH derivative 13, at a concentration as high as 10 \u03BCM, did not have\
        \ any effect on the H278D mutant.///However, the 5\u2032-N-methylamide derivative\
        \ 26 was shown to be more potent in activating the H278D mutant receptor (3.5\
        \ ( 1.6 \u03BCM) than at the wild-type A1 AR (>10 \u03BCM) or the control\
        \ (nontransfected cells), although it was only partially efficacious compared\
        \ with the efficacy of CPA at the wild-type A1 AR.///An initial complex of\
        \ the A1 AR with NECA was further refined by energy optimization and MCMM\
        \ calculations implemented Tailored Ligands for Reengineered A1 Adenosine\
        \ Receptor FIGURE 5: Membrane hyperpolarization at the wild-type and H278D\
        \ mutant hA1 AR using known agonist CPA 8 and urea derivative 26.///46, No.\
        \ 25, 2007 7445 FIGURE 4: Stimulation of intracellular calcium levels at the\
        \ wild-type and H278D mutant hA1 ARs using known agonists CPA 8 and NECA 22\
        \ and urea derivatives 10 and 13 (n ) 3-4).///In contrast, in the model obtained\
        \ after MCMM calculations for compound 10 docked in the H278D mutant A1 AR,\
        \ we did not observe any significant changes in the ligand position or residue\
        \ side chain orientations (Figure 1B).///The obtained binding mode of compound\
        \ 10 at the H278D mutated A1 AR, demonstrating the absence of a direct interaction\
        \ between the ligand and Asp278, is in a good agreement with the experimental\
        \ data obtained for other mutations, in particular, for H278A and H278L.///The\
        \ present reengineered human A1 ARs revealed orthogonality similar to that\
        \ of the A3 but not the A2A AR, in which mutation of the corresponding residue,\
        \ His278, to Asp did not enhance the affinity of nucleosides derivatized with\
        \ amine functionality on the ribose moiety (8).///The H278D A1 AR was functionally\
        \ responsive only as a measure of membrane potential and not calcium mobilization.///SUPPORTING\
        \ INFORMATION AVAILABLE Compound 10 inside the putative binding site of the\
        \ H278D mutant A1 adenosine receptor and details of chemical synthesis.",
    pubmed: '17542617', seq: '278', to_res: D}
- {entry_name: nk2r_human, from_res: Y, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Results indicate that\
        \ the binding site of ibodutant is in part overlapping to that of the agonist\
        \ NKA and the antagonist nepadutant, comprised among TM4 (C167G), TM5 (Y206A),\
        \ and TM6 (W263A, Y266F, F270A) but shares a determinant in TM7 (Y289F, Y289T)\
        \ crucial for the binding of saredutant.", pubmed: '19218528', seq: '266',
    to_res: F}
- {entry_name: adrb2_human, from_res: L, info: 'CAM and UCM mutants The CAMs (constitutively
        active mutants) described in the literature that are the basis for Figure
        6A and the associated discussion are: L124A (6), C116F (7), D130A (8), L272C
        (9), and C285T (10).', pubmed: '17962519', seq: '272', to_res: C}
- {entry_name: aa1r_human, from_res: T, info: '46, No. 25, 2007 Table 1: Saturation
        Analysis of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently
        Expressed in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A H278D
        H278E H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 (
        0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2
        3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2.
        Values are expressed as the mean ( sem from four to eight experiments, each
        performed in duplicate. coordinate the ribose moiety of the nucleoside ligands,
        modification of the selected amino acid residues would be expected to be more
        detrimental to binding of agonist than antagonist. Attempted saturation analysis
        of the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce
        measurable specific binding (data not shown), making it impractical to use
        this radioligand.///Table 3: Ki Values for the Inhibition by Nucleoside Derivatives
        of Binding of Antagonist [3H]DPCPX at Wild-Type and Mutant Human A1 ARs Transiently
        Expressed in HEK-293 Cellsa binding affinity, Ki (nM ( sem), or % inhibition
        compound DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22,
        NECA 23 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10%
        30% 17% 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13% 13% 38% <10% <10% 1600 (
        100 <10% 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150
        380 ( 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700
        ( 900 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10%
        <10% 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250
        500 ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20%
        15% 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670
        8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15%
        820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900 32%
        58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000 ( 800
        41% 48% 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5
        <10% <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10% NDc NDc <10%
        <10% <10% NDc a Structures are given in Figure 2. Experiments were performed
        using HEK-293 cells transiently expressing (using Lipofectamine 2000) a mutant
        hA1 AR.', pubmed: '17542617', seq: '277', to_res: E}
- {entry_name: aa3r_human, from_res: H, info: The H278D mutation of the human A1 AR
        and the corresponding mutations of conserved His in TM7 of the A2A AR (H278D)
        and A3 AR (H272D) were studied.///The H278D mutation of the human A1 AR and
        the corresponding mutations of the conserved His in TM7 of the A2A AR (H278D)
        and A3 AR (H272D) were studied., pubmed: '17542617', seq: '272', to_res: D}
- {entry_name: aa1r_human, from_res: T, info: "For competitive binding studies, cell\
        \ membranes containing 15 \u03BCg (HEK-293hA1wt), 10 \u03BCg (HEK-293hA1-T277A),\
        \ or 35-40 \u03BCg (HEK293hA1-H278 mutant receptors) of protein were incubated\
        \ for 1 h at 25 \xB0C in 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl2,\
        \ with 0.4-0.6 nM [3H]DPCPX, and increasing concentrations of ligand, in a\
        \ total volume of 200 \u03BCL.///For saturation experiments, 10 \u03BCg (HEK-293hA1wt\
        \ and HEK-293hA1-T277A) or 15-20 \u03BCg (HEK-293hA1mutant receptors) of membrane\
        \ were incubated for 1 h at 25 \xB0C in 50 mM Tris-HCl with 10 mM MgCl2 buffer\
        \ (pH 7.4) with six different concentrations of [3H]DPCPX (0-9 nM).///46,\
        \ No. 25, 2007 Table 1: Saturation Analysis of [3H]DPCPX at the Wild-Type\
        \ and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa A1 AR construct\
        \ wild-type T277A T277E H278A H278D H278E H278L Kd (nM) 2.37 ( 0.20 1.12 (\
        \ 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 ( 0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg)\
        \ 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2 3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a\
        \ Structures are given in Figure 2. Values are expressed as the mean ( sem\
        \ from four to eight experiments, each performed in duplicate. coordinate\
        \ the ribose moiety of the nucleoside ligands, modification of the selected\
        \ amino acid residues would be expected to be more detrimental to binding\
        \ of agonist than antagonist. Attempted saturation analysis of the mutant\
        \ receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce measurable\
        \ specific binding (data not shown), making it impractical to use this radioligand.///However,\
        \ unlike the relative uniformity in the Kd values, the Bmax for the mutant\
        \ receptors was on average \u223C3-fold lower than that of the wild-type A1\
        \ AR, with the exception of the T277A mutant receptor.///Table 3: Ki Values\
        \ for the Inhibition by Nucleoside Derivatives of Binding of Antagonist [3H]DPCPX\
        \ at Wild-Type and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa\
        \ binding affinity, Ki (nM ( sem), or % inhibition compound DPCPXb CGS15943b\
        \ 1 2 3 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22, NECA 23 26 27 wild-type\
        \ hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10% 30% 17% 610 ( 50 12% 15000\
        \ ( 3100 6200 ( 1900 13% 13% 38% <10% <10% 1600 ( 100 <10% 14% <10% H278E\
        \ 36 ( 2 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210\
        \ ( 60 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400\
        \ 220 ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10% <10% 1000 ( 170 340\
        \ ( 20 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250 500 ( 120 8500 (\
        \ 1400 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400\
        \ ( 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670 8800 ( 700 14%\
        \ 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15% 820 ( 90 400\
        \ ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900 32% 58% NDc\
        \ T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000 ( 800 41% 48%\
        \ 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5 <10%\
        \ <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10% NDc NDc <10% <10%\
        \ <10% NDc a Structures are given in Figure 2. Experiments were performed\
        \ using HEK-293 cells transiently expressing (using Lipofectamine 2000) a\
        \ mutant hA1 AR.", pubmed: '17542617', seq: '277', to_res: A}
- {entry_name: aa1r_human, from_res: H, info: '46, No. 25, 2007 Table 1: Saturation
        Analysis of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently
        Expressed in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A H278D
        H278E H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 (
        0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2
        3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2.
        Values are expressed as the mean ( sem from four to eight experiments, each
        performed in duplicate. coordinate the ribose moiety of the nucleoside ligands,
        modification of the selected amino acid residues would be expected to be more
        detrimental to binding of agonist than antagonist. Attempted saturation analysis
        of the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce
        measurable specific binding (data not shown), making it impractical to use
        this radioligand.///These reported enhancements for compounds 10, 13, 14,
        and 16 at the H278E mutant can be extended to the other His278 mutant receptors
        as well, e.g., H278D, H278L, and H278A.///Table 3: Ki Values for the Inhibition
        by Nucleoside Derivatives of Binding of Antagonist [3H]DPCPX at Wild-Type
        and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa binding affinity,
        Ki (nM ( sem), or % inhibition compound DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA
        10 13 14 16 18 19 20 21 22, NECA 23 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1
        4600 ( 480 <10% <10% <10% 30% 17% 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13%
        13% 38% <10% <10% 1600 ( 100 <10% 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14%
        24% 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30
        980 ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40
        15% <10% 20% 16% <10% <10% 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20
        48% 410 ( 120 810 ( 250 500 ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40
        ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 ( 30
        1000 ( 60 50% 834 940 670 8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90 ( 3
        <10% 12% 17% 25% 17% 15% 820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100 39%
        NDc NDc NDc 8800 ( 900 32% 58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10%
        <10% <10% <10% 7000 ( 800 41% 48% 50% 39% 22% <10% <10% 11% 25% 12% 10% 16%
        T277A 3.5 ( 0.9 4.6 ( 1.5 <10% <10% <10% <10% <10% <10% 11% <10% <10% 17%
        <10% <10% <10% NDc NDc <10% <10% <10% NDc a Structures are given in Figure
        2. Experiments were performed using HEK-293 cells transiently expressing (using
        Lipofectamine 2000) a mutant hA1 AR.///The obtained binding mode of compound
        10 at the H278D mutated A1 AR, demonstrating the absence of a direct interaction
        between the ligand and Asp278, is in a good agreement with the experimental
        data obtained for other mutations, in particular, for H278A and H278L.', pubmed: '17542617',
    seq: '278', to_res: L}
- {entry_name: aa3r_human, from_res: H, info: "Jacobson*,\u2021 Molecular Recognition\
        \ Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes\
        \ and DigestiVe and Kidney Diseases, National Institutes of Health, Bethesda,\
        \ Maryland 20892, and Laboratory of Medicinal Chemistry, College of Pharmacy,\
        \ Ewha Womans UniVersity, Seoul 120-750, Korea ReceiVed January 29, 2007;\
        \ ReVised Manuscript ReceiVed April 23, 2007 ABSTRACT: His272 (7.43) in the\
        \ seventh transmembrane domain (TM7) of the human A3 adenosine receptor (AR)\
        \ interacts with the 3\u2032 position of nucleosides, based on selective affinity\
        \ enhancement at a H272E mutant A3 AR (neoceptor) of 3\u2032-ureido, but not\
        \ 3\u2032-OH, adenosine analogues.", pubmed: '17542617', seq: '272', to_res: E}
- {entry_name: rxfp2_mouse, from_res: T, info: 'Interestingly, mutation T123M causes
        a very rare type of cystinuria characterized by urinary hyperexcretion of
        cystine alone (i.e. isolated cystinuria) [88,94].', pubmed: '21568940', seq: '123',
    to_res: M}
- {entry_name: mchr1_human, from_res: R, info: 'Docking of aspartate in the proposed
        AGC2-binding site, based on the crystal structure of the ADP/ATP carrier [60]
        (PDB code 1OKC), suggested that mutation R388Q altered the substrate location
        in such a way that it is not interacting with the salt-bridge network (characteristic
        of SLC25A members), and thus causing loss of substrate translocation [56].',
    pubmed: '21568940', seq: '388', to_res: Q}
- {entry_name: agtr2_human, from_res: L, info: Another intriguing case is the combination
        of two mutations (L306V and N509S) in one individual (compound heterozygote).///Mutation
        L306V by itself does not change the transport activity of GlyT2., pubmed: '21568940',
    seq: '306', to_res: V}
- {entry_name: agtr2_human, from_res: T, info: 'Three mutants, T32R (<20 %), M273K
        (<20 %) and G190D (<40 %), retained significant activity, but proper trafficking
        to the mitochondrial inner membrane has only been tested for T32R.///Three
        mutants, T32R (<20 %), M273K (<20 %) and G190D (<40 %), retained significant
        activity, but proper trafficking to the mitochondrial inner membrane has only
        been tested for T32R.', pubmed: '21568940', seq: '32', to_res: R}
- {entry_name: aa1r_human, from_res: H, info: "46, No. 25, 2007 Table 1: Saturation\
        \ Analysis of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently\
        \ Expressed in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A\
        \ H278D H278E H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60\
        \ 3.11 ( 0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8\
        \ 6.0 ( 0.2 3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given\
        \ in Figure 2. Values are expressed as the mean ( sem from four to eight experiments,\
        \ each performed in duplicate. coordinate the ribose moiety of the nucleoside\
        \ ligands, modification of the selected amino acid residues would be expected\
        \ to be more detrimental to binding of agonist than antagonist. Attempted\
        \ saturation analysis of the mutant receptors with the agonist [3H]CCPA (9,\
        \ 1-5 nM) did not produce measurable specific binding (data not shown), making\
        \ it impractical to use this radioligand.///These reported enhancements for\
        \ compounds 10, 13, 14, and 16 at the H278E mutant can be extended to the\
        \ other His278 mutant receptors as well, e.g., H278D, H278L, and H278A.///Table\
        \ 3: Ki Values for the Inhibition by Nucleoside Derivatives of Binding of\
        \ Antagonist [3H]DPCPX at Wild-Type and Mutant Human A1 ARs Transiently Expressed\
        \ in HEK-293 Cellsa binding affinity, Ki (nM ( sem), or % inhibition compound\
        \ DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22, NECA 23\
        \ 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10% 30% 17%\
        \ 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13% 13% 38% <10% <10% 1600 ( 100 <10%\
        \ 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150 380 (\
        \ 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700 ( 900\
        \ 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10% <10%\
        \ 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250 500\
        \ ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20% 15%\
        \ 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670\
        \ 8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15%\
        \ 820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900\
        \ 32% 58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000\
        \ ( 800 41% 48% 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9\
        \ 4.6 ( 1.5 <10% <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10%\
        \ NDc NDc <10% <10% <10% NDc a Structures are given in Figure 2. Experiments\
        \ were performed using HEK-293 cells transiently expressing (using Lipofectamine\
        \ 2000) a mutant hA1 AR.///A preliminary functional study of the effect of\
        \ adding GTP during the binding of CCPA 9 and its 3\u2032-ureido analogue\
        \ 10 at the H278A and H278D mutant receptors indicated that in both cases\
        \ there was no pronounced GTP-induced shift (data not shown).///The obtained\
        \ binding mode of compound 10 at the H278D mutated A1 AR, demonstrating the\
        \ absence of a direct interaction between the ligand and Asp278, is in a good\
        \ agreement with the experimental data obtained for other mutations, in particular,\
        \ for H278A and H278L.", pubmed: '17542617', seq: '278', to_res: A}
- {entry_name: agtr1_human, from_res: S, info: "Both WT Bad and the S136A Bad mutant\
        \ were used.///Although the phosphorylation status of Bad at Ser136 is a significant\
        \ regulator of 14-3-3\u03B6 binding, there was some phosphorylation-independent\
        \ binding to this ligand (i.e. to S136A Bad) by 15C 14-3-3\u03B6 , which was\
        \ not evident for WT 14-3-3\u03B6 .///Williams and others Figure 3 Yeast two-hybrid\
        \ assays, SEC coupled with MALLS, far-UV CD spectra and DLS of WT 14-3-3\u03B6\
        \ and 15C 14-3-3\u03B6 (A) The ability of WT and 15C 14-3-3\u03B6 to interact\
        \ with the bait proteins Raf-1, Bad and S136A Bad in a yeast two-hybrid assay.",
    pubmed: '21554249', seq: '107', to_res: A}
- {entry_name: adrb2_mouse, from_res: L, info: Mutation of L272 to alanine was the
        first reported constitutively active mutant of the b2AR41., pubmed: '17952055',
    seq: '272', to_res: A}
- {entry_name: nk2r_human, from_res: T, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.", pubmed: '19218528', seq: '171',
    to_res: A}
- {entry_name: nk2r_human, from_res: Q, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.", pubmed: '19218528', seq: '109',
    to_res: A}
- {entry_name: nk2r_human, from_res: F, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Mutations that abrogate\
        \ the NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Results indicate that\
        \ the binding site of ibodutant is in part overlapping to that of the agonist\
        \ NKA and the antagonist nepadutant, comprised among TM4 (C167G), TM5 (Y206A),\
        \ and TM6 (W263A, Y266F, F270A) but shares a determinant in TM7 (Y289F, Y289T)\
        \ crucial for the binding of saredutant.", pubmed: '19218528', seq: '270',
    to_res: A}
- {entry_name: nk2r_human, from_res: W, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Mutations that abrogate\
        \ the NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Results indicate that\
        \ the binding site of ibodutant is in part overlapping to that of the agonist\
        \ NKA and the antagonist nepadutant, comprised among TM4 (C167G), TM5 (Y206A),\
        \ and TM6 (W263A, Y266F, F270A) but shares a determinant in TM7 (Y289F, Y289T)\
        \ crucial for the binding of saredutant.", pubmed: '19218528', seq: '263',
    to_res: A}
- {entry_name: nk2r_human, from_res: Y, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Mutations that abrogate\
        \ the NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Results indicate that\
        \ the binding site of ibodutant is in part overlapping to that of the agonist\
        \ NKA and the antagonist nepadutant, comprised among TM4 (C167G), TM5 (Y206A),\
        \ and TM6 (W263A, Y266F, F270A) but shares a determinant in TM7 (Y289F, Y289T)\
        \ crucial for the binding of saredutant.", pubmed: '19218528', seq: '206',
    to_res: A}
- {entry_name: nk2r_human, from_res: C, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///C167G is a previously investigated\
        \ mutation responsible for tachykinin Fig. 4.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Mutations that abrogate\
        \ the NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Results indicate that\
        \ the binding site of ibodutant is in part overlapping to that of the agonist\
        \ NKA and the antagonist nepadutant, comprised among TM4 (C167G), TM5 (Y206A),\
        \ and TM6 (W263A, Y266F, F270A) but shares a determinant in TM7 (Y289F, Y289T)\
        \ crucial for the binding of saredutant.", pubmed: '19218528', seq: '167',
    to_res: G}
- {entry_name: nk2r_human, from_res: Y, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Results indicate that\
        \ the binding site of ibodutant is in part overlapping to that of the agonist\
        \ NKA and the antagonist nepadutant, comprised among TM4 (C167G), TM5 (Y206A),\
        \ and TM6 (W263A, Y266F, F270A) but shares a determinant in TM7 (Y289F, Y289T)\
        \ crucial for the binding of saredutant.///Furthermore data obtained at the\
        \ two mutants of Tyr289 in TM7 indicate a stronger dependence of ibodutant\
        \ on the aromatic moiety of Tyr289 (greater reduction of affinity at the Y289T\
        \ than at the Y289F mutant).", pubmed: '19218528', seq: '289', to_res: F}
- {entry_name: nk2r_human, from_res: Y, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///Mutations that abrogate the\
        \ NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Mutations that abrogate\
        \ the NKA binding, C167G, Y206A, W263A, F270A, and Y289T; mutations that abrogate\
        \ the nepadutant binding, C167G, T171A, Y206A, W263A, Y266F, and F270A; mutations\
        \ that abrogate the saredutant binding, Y289F and Y289T. receptor subtype\
        \ affinity and selectivity (Ciucci et al., 1997), whereas the other investigated\
        \ mutated residues were all located in the TM portion of the human tachykinin\
        \ NK2R sequence, The affinity of ibodutant was evaluated in inhibiting the\
        \ binding of [125I]NKA, [3H]nepadutant, and [3H]saredutant, according to their\
        \ capability to bind the single mutant receptors.///Results indicate that\
        \ the binding site of ibodutant is in part overlapping to that of the agonist\
        \ NKA and the antagonist nepadutant, comprised among TM4 (C167G), TM5 (Y206A),\
        \ and TM6 (W263A, Y266F, F270A) but shares a determinant in TM7 (Y289F, Y289T)\
        \ crucial for the binding of saredutant.///Furthermore data obtained at the\
        \ two mutants of Tyr289 in TM7 indicate a stronger dependence of ibodutant\
        \ on the aromatic moiety of Tyr289 (greater reduction of affinity at the Y289T\
        \ than at the Y289F mutant).", pubmed: '19218528', seq: '289', to_res: T}
- {entry_name: nk2r_human, from_res: I, info: "125 I Neurokinin A Ibodutant Ki Fmut\
        \ 3 H Nepadutant Ibodutant Ki nM (95% CL) Fmut 3 H Saredutant Ibodutant Ki\
        \ Fmut Neurokinin A Kd Nepadutant Kd Saredutant Kd nM (95% CL) nM (95% CL)\
        \ Wild type Q109A C167G T171A I202F Y206A W263A Y266F F270A C281Y Y289F Y289T\
        \ 1.3 (0.8\u20132.2) 2.3 (1.5\u20133.4) N.D.B.///C281Y (fourth extracellular\
        \ loop) and I202F [TM4] were mutated as such because these mutations spontaneously\
        \ occur in the rat tachykinin NK2R, and ibodutant displays low affinity for\
        \ this species (Cialdai et al., 2006).///The I202F mutation spontaneously\
        \ occurs in the sequence of the rat/mouse tachykinin NK2 receptor and is suggested\
        \ to hamper the proper interaction of ibodutant with residues located at a\
        \ deeper level in the TM portion.///Last, the drop in affinity measured with\
        \ ibodutant at the I202F mutant, which spontaneously occurs in the rat tachykinin\
        \ NK2R, suggests that this residue could be largely responsible for the low\
        \ affinity of ibodutant in the rat species (rat urinary bladder smooth muscle\
        \ contractility pKB, 6.3; Cialdai et al., 2006), in agreement with that previously\
        \ reported for this class of ligands (Meini et al., 2004).", pubmed: '19218528',
    seq: '202', to_res: F}
- {entry_name: par2_human, from_res: C, info: "The hPAR2 C361A mutant cell line displayed\
        \ greater cell-surface expression compared with the wt (wild-type)-hPAR2 -expressing\
        \ cell line.///hPAR2 C361A also showed a decreased sensitivity and efficacy\
        \ (intracellular calcium signalling) towards both trypsin and SLIGKV.///In\
        \ stark contrast, hPAR2 C361A triggered greater and more prolonged ERK (extracellular-signal-regulated\
        \ kinase) phosphorylation compared with that of wt-hPAR2 possibly through\
        \ Gi , since pertussis toxin inhibited the ability of this receptor to activate\
        \ ERK.///hPAR2 C361A displayed faster internalization kinetics following trypsin\
        \ activation compared with wt-hPAR2 , whereas SLIGKV had a negligible effect\
        \ on internalization for either receptor.///Human PAR2 C361A was generated\
        \ using the QuikChange\xAE site-directed mutagenesis kit (Stratagene), according\
        \ to the manufacturer\u2019s instructions.///Determination of cell-surface\
        \ expression of wt-hPAR2 and hPAR2 C361A It has been found previously that\
        \ in the cell lines used \u2018receptor expression (is) sensitive to confluence\u2019\
        \ [1].///Localization of receptors by confocal imaging Confocal microscopy\
        \ was used to determine the location of wtPAR2 and PAR2 C361A within the cells.///wt-hPAR2\
        \ - and hPAR2 C361A-expressing Pro5 cell lines were seeded in 100-mm dishes,\
        \ pre-incubated overnight in serum-free medium and labelled with 1 mCi of\
        \ [3 H]palmitate for 4 h at 37 \u25E6 C.///RESULTS Expression and palmitoylated\
        \ state of wt-PAR2 and PAR2 C361A In order to study the potential role of\
        \ palmitoylation in regulating PAR2 function, Pro5 cells were stably transfected\
        \ with HA11-tagged wt-hPAR2 or hPAR2 C361A, where the putative palmitoylation\
        \ site (Cys361 ) had been replaced with an alanine residue.///RESULTS Expression\
        \ and palmitoylated state of wt-PAR2 and PAR2 C361A In order to study the\
        \ potential role of palmitoylation in regulating PAR2 function, Pro5 cells\
        \ were stably transfected with HA11-tagged wt-hPAR2 or hPAR2 C361A, where\
        \ the putative palmitoylation site (Cys361 ) had been replaced with an alanine\
        \ residue.///The staining pattern observed for hPAR2 C361A (Figure 3F) was\
        \ strikingly different to that of wt-hPAR2 (Figure 3E).///The ring staining\
        \ for hPAR2 C361A was not uniform and distinct pockets of intense staining\
        \ were observed at the cell surface.///However, the staining for hPAR2 C361A\
        \ appeared brighter than that of wt-PAR2 .///The palmitoylation state of wt-hPAR2\
        \ and hPAR2 C361A was then determined by metabolic labelling of the cells\
        \ with [3 H]palmitate, followed by immunoprecipitation of the receptors.///In\
        \ contrast, PAR2 C361A displayed an undetectable level of 3 H incorporation.///Western\
        \ blot analysis of the same samples that were employed for the palmitoylation\
        \ gel demonstrated that approximately equal amounts of PAR2 protein were present\
        \ in the wt-PAR2 and PAR2 C361A samples (Figure 4B).///Role of palmitoylation\
        \ in regulating intracellular calcium signalling To assess the importance\
        \ of palmitoylation in regulating hPAR2 coupling to calcium, we compared the\
        \ ability of wt-hPAR2 and hPAR2 C361A to trigger increases in intracellular\
        \ calcium in response to the hPAR2 agonists trypsin and SLIGKV.///Trypsin\
        \ and SLIGKV concentration\u2013effect curves for hPAR2 and hPAR2 C361A cell\
        \ lines with matched expression (Figure 2) were constructed (Figure 5).///In\
        \ contrast with wt-hPAR2 , trypsin and SLIGKV displayed significantly reduced\
        \ efficacy towards hPAR2 C361A (P = 0.0003 and P = 0.0058 respectively).///Botham\
        \ and others Figure 3 Figure 4 [3 H]Palmitate incorporation into wt-hPAR2\
        \ and hPAR2 C361A maximal obtainable responses to both trypsin and SLIGKV\
        \ were only \u223C50 % and \u223C30 % respectively of that observed for wthPAR2\
        \ (Figure 5).///The hPAR2 C361A EC50 values for trypsin and SLIGKV were 40.76\
        \ nM and 103.45 \u03BCM respectively, displaying a 4- and 6-fold increase\
        \ compared with that obtained for wthPAR2 .///Inhibition of trypsin-mediated\
        \ calcium signalling by PTX (pertussis toxin) PTX was used to ascertain what\
        \ proportion of the total Ins(1,4,5)P3 -induced calcium flux is due to signalling\
        \ through Gi in wt-hPAR2 and the palmitoylation-deficient mutant hPAR2 C361A.///PTX\
        \ dose-dependently inhibited wt-hPAR2 - and hPAR2 C361A-mediated calcium signalling\
        \ to trypsin.///(A) pcDNA3.1 empty vector, (B) wt-hPAR2 and (C) hPAR2 C361A.///(D)\
        \ pcDNA3.1 empty vector, (E) wt-hPAR2 and (F) hPAR2 C361A.///Images shown\
        \ are representative of three experiments HA11-epitope-immunoprecipitated\
        \ protein preparations from empty vector, wt-hPAR2 and hPAR2 C361A cells each\
        \ labelled with 1 mCi of [3 H]palmitate for 4 h were separated by SDS/PAGE\
        \ on a 10 % gel.///In contrast, hPAR2 C361A produced a maximum calcium signal\
        \ of \u223C30 % of A23187, reducing to <10 % of A23187 at the maximum PTX\
        \ concentration of 316 ng/ml.///Role of palmitoylation in regulating ERK1/2\
        \ phosphorylation Having established that the palmitoylation-deficient hPAR2\
        \ C361A mutant coupled less efficiently to calcium, we investigated whether\
        \ receptor palmitoylation possibly regulated hPAR2 signalling to ERK1/2 (p44/42\
        \ MAPK).///Significant differences in the pattern of the ERK1/2 stimulation\
        \ were observed for hPAR2 C361A compared with wt-hPAR2 (P < 0.001; Figure\
        \ 7A).///SLIGKV stimulated a significantly Figure 5 Agonist hPAR2 C361A concentration\u2013\
        effect curves for wt-hPAR2 and Fluo-3 AM-loaded Pro5 cells stably expressing\
        \ wt-hPAR2 and hPAR2 C361A were stimulated with increasing concentrations\
        \ of trypsin or SLIGKV, and increases in intracellular calcium concentrations\
        \ were measured.///SLIGKV stimulated a significantly Figure 5 Agonist hPAR2\
        \ C361A concentration\u2013effect curves for wt-hPAR2 and Fluo-3 AM-loaded\
        \ Pro5 cells stably expressing wt-hPAR2 and hPAR2 C361A were stimulated with\
        \ increasing concentrations of trypsin or SLIGKV, and increases in intracellular\
        \ calcium concentrations were measured.///Figure 6 Inhibition of trypsin-mediated\
        \ calcium release in wt-hPAR2 and hPAR2 C361A Changes in intracellular calcium\
        \ levels were measured using a fluorospectrometer in fluo-3 AM-loaded wt-hPAR2\
        \ and hPAR2 C361A incubated with different concentrations of PTX (for 18 h)\
        \ prior to the addition of 100 nM trypsin.///Figure 6 Inhibition of trypsin-mediated\
        \ calcium release in wt-hPAR2 and hPAR2 C361A Changes in intracellular calcium\
        \ levels were measured using a fluorospectrometer in fluo-3 AM-loaded wt-hPAR2\
        \ and hPAR2 C361A incubated with different concentrations of PTX (for 18 h)\
        \ prior to the addition of 100 nM trypsin.///Values shown are a percentage\
        \ of the maximum attainable response (response to A23187) and are means +\
        \ S.E.M. \u2212 greater degree of ERK1/2 phosphorylation in hPAR2 C361A cells\
        \ at the 5 and 10 min time points, and the ERK1/2 activation levels remaining\
        \ significantly elevated up to the 60 min time point tested.///Similarly,\
        \ trypsin was also found to stimulate a significantly greater degree of ERK1/2\
        \ phosphorylation through hPAR2 C361A compared with wt-hPAR2 (P < 0.001; Figure\
        \ 7B).///Trypsin stimulated a significantly greater degree of ERK1/2 phosphorylation\
        \ in hPAR2 C361A cells at the 5, 10 and 20 min time points, and a more sustained\
        \ ERK1/2 activation level remaining significantly elevated up to the 60 min\
        \ time point tested.///Results are means + S.E.M. for three separate experiments.\
        \ \u2212 Inhibition of MAPK signalling by PTX To ascertain what proportion\
        \ of the ERK signalling is due to signalling through Gi and to determine whether\
        \ the lack of palmitoylation altered this signalling, wt-hPAR2 , hPAR2 C361A\
        \ and empty vector control cells were pre-incubated with PTX before treating\
        \ with PAR2 agonists (trypsin and SLIGKV).///SLIGKV and trypsin evoked a 2-\
        \ and 3-fold increase in ERK1/2 signalling over NT respectively in hPAR2 C361A-expressing\
        \ cells (Figure 8B).///When pre-treated with PTX, ERK1/2 signalling in hPAR2\
        \ C361A-expressing cells decreased a small amount following NT and trypsin\
        \ treatment in comparison with samples not pre-treated with PTX.///Botham\
        \ and others Figure 8 Inhibition of MAPK by PTX Pro5 cells stably expressing\
        \ wt-hPAR2 (A) and hPAR2 C361A (B) were incubated without and with 100 ng/ml\
        \ PTX (for 18 h) prior to the addition of 20 nM trypsin (Tryp), 100 \u03BC\
        M SLIGKV (KV) or NT for 10 min.///In contrast with wt-hPAR2 , trypsin stimulated\
        \ a significantly greater loss of hPAR2 C361A from the cell surface at all\
        \ of the time points tested, with over 81 + 1.3 % lost from the cell \u2212\
        \ surface by 10 min post-agonist challenge (P = 0.016).///As with wt-hPAR2\
        \ , we also observed only a minor degree of receptor internalization with\
        \ hPAR2 C361A following treatment with SLIGKV, with maximal internalization\
        \ observed at 60 min + (16 \u2212 2 %).///The hPAR2 C361A cell line displayed\
        \ greater receptor expression than the wt-hPAR2 cell line.///Confocal microscopy\
        \ was employed next to compare the cellular distribution of wt-hPAR2 and hPAR2\
        \ C361A.///Confocal imaging shows that PAR2 is located at the plasma membrane,\
        \ along with some internal localization (which is greater in hPAR2 C361A);\
        \ this is presumably, at least in part, PAR2 contained in Golgi stores, which\
        \ is confirmatory of previous confocal imaging of PAR2 [18\u201320].///The\
        \ banding pattern observed is in keeping with the previous immunoblotting\
        \ of hPAR2 [1] and the C361A appears to have no perceptible effect on the\
        \ receptor molecular mass compared with wt-hPAR2 .///Despite flow cytometry\
        \ results showing higher hPAR2 C361A expression than wt-hPAR2 , three times\
        \ more cells were required to achieve matching quantities of receptor.///However,\
        \ if hPAR2 is palmitoylated at Cys361 , the C361A mutation will result in\
        \ a reduced C-terminal association with the cell membrane and potentially\
        \ leave the C-terminus available to be more easily cleaved by endogenous proteases,\
        \ thus removing the HA11 tag.///However, since no [3 H]palmitate signal is\
        \ evident in hPAR2 C361A, it seems likely that this is the sole palmitoylation\
        \ site for hPAR2 .///The decreased signal and agonist sensitivity observed\
        \ for the hPAR2 C361A mutant may be due to the revealing of phosphorylation\
        \ sites within the Cterminus, which may normally be obscured by association\
        \ with the membrane when palmitoylation is present.///This combined PAR2 is\
        \ regulated by palmitoylation 365 with \u03B2-arrestin 1 and 2 association\
        \ with ERK1/2 activation in the early and intermediate phases [38] supports\
        \ the hypothesis that ERK1/2 signalling in hPAR2 C361A may be enhanced due\
        \ to an increase in \u03B2-arrestin association.///This increased \u03B2-arrestin\
        \ association may also explain the increased receptor expression seen in hPAR2\
        \ C361A compared with wt-hPAR2 , as studies have shown a role for \u03B2-arrestins\
        \ in trafficking of PAR2 from the Golgi [35,38].///Further studies to investigate\
        \ the role of \u03B2-arrestins in hPAR2 C361A signalling, expression and internalization\
        \ are required.///Interestingly, calcium signalling of wt-hPAR2 and hPAR2\
        \ C361A was reduced by a similar magnitude; however, in the mutant receptor,\
        \ this reduction almost completely ablated the trypsin-evoked calcium response,\
        \ suggesting that signalling via hPAR2 C361A is due to coupling with Gi .///Interestingly,\
        \ calcium signalling of wt-hPAR2 and hPAR2 C361A was reduced by a similar\
        \ magnitude; however, in the mutant receptor, this reduction almost completely\
        \ ablated the trypsin-evoked calcium response, suggesting that signalling\
        \ via hPAR2 C361A is due to coupling with Gi .///A recent study has suggested\
        \ that PAR2 , unlike PAR1 , does not signal through Gi [43]; however, in our\
        \ cell system, it appears that in order to provoke calcium signalling hPAR2\
        \ C361A couples to Gi.///In contrast, the non-palmitoylated hPAR2 C361A displayed\
        \ reduced ERK phosphorylation postSLIGKV activation, suggesting a Gi -mediated\
        \ response.///As stated earlier, calcium mobilization following hPAR2 C361A\
        \ activation takes longer to reach a signalling plateau, thus it maybe that\
        \ the Gi -dependent activation of ERK1/2 activation observed is PYK2-mediated.///As\
        \ such we have also demonstrated that hPAR2 internalizes by clathrin-coated\
        \ pits, and hPAR2 C361A internalizes by the same mechanism albeit more rapidly.///Despite\
        \ increased expression of hPAR2 C361A compared with wt-PAR2 in the resting\
        \ state, with the addition of agonists the endocytosis of the mutant receptor\
        \ appears to be increased over wt-PAR2 .///If, as discussed previously, hPAR2\
        \ C361A is constitutively phosphorylated then \u03B2-arrestin may associate\
        \ with the receptor C-terminus.///Since hPAR2 C361A has reduced/abolished\
        \ coupling to Gq , PLC activity would be significantly reduced/abolished,\
        \ thus allowing increased endocytosis via clathrin-coated pits in the absence\
        \ of inhibition from PLC.", pubmed: '21627585', seq: '361', to_res: A}
- {entry_name: agtr2_human, from_res: G, info: "Reconstituted mutants G27R, M37R,\
        \ E180K and R275Q showed no transport activity, whereas mutants L71Q, P126R,\
        \ T272I and L283F retained some activity (4\u201310 %).", pubmed: '21568940',
    seq: '27', to_res: R}
- {entry_name: mchr1_human, from_res: T, info: "Reconstituted mutants G27R, M37R,\
        \ E180K and R275Q showed no transport activity, whereas mutants L71Q, P126R,\
        \ T272I and L283F retained some activity (4\u201310 %).", pubmed: '21568940',
    seq: '272', to_res: I}
- {entry_name: agtr1_human, from_res: R, info: "Reconstituted mutants G27R, M37R,\
        \ E180K and R275Q showed no transport activity, whereas mutants L71Q, P126R,\
        \ T272I and L283F retained some activity (4\u201310 %).///Mutations R275Q\
        \ and E180K involve residues in the proposed ornithinec The Authors Journal\
        \ compilation c 2011 Biochemical Society binding site, suggesting defective\
        \ substrate interaction with the transporter [56].///Arg588 is a well-conserved\
        \ residue in SLC25 family members and, indeed, mutation of the homologous\
        \ residue in human ORC1 (R275Q) causes HHH syndrome [56].", pubmed: '21568940',
    seq: '275', to_res: Q}
- {entry_name: casr_human, from_res: A, info: "Four additional, potentially pathogenic,\
        \ missense CASR variants, Glu354Ala, Ile686Val, Ala988Val, and Ala988Gly,\
        \ were observed in five individuals affected with idiopathic generalized epilepsy.///These\
        \ four nucleotide variants, g.58158A C, g.80072A G, g.80979C T, and g.80979C\
        \ G (GenBank accession number AC068754.16), lead to Glu354Ala, Ile686Val,\
        \ Ala988Val, and Ala988Gly amino acid alterations, respectively, in the CASR\
        \ protein (see Fig 3).///Epilepsy Families/Individuals, Missense Mutations\
        \ at CASR, and Allele Frequencies Family/Individual Family 1 Family 80 Family\
        \ 93 Individual 17 Individual 50 Individual 45 Variation AC068754.16 g.80709G\
        \ A AC068754.16 g.58158A C AC068754.16 g.80072A G AC068754.16 g.80979C T AC068754.16\
        \ g.80979C T AC068754.16 g.80979C G Predicted Effect on Protein p.Arg898Gln\
        \ p.Glu354Ala p.Ile686Val p.Ala988Val p.Ala988Val p.Ala988Gly Allele Frequency\
        \ in Control Population 0/504 0/504 0/504 0/504 0/504 0/504 Families 80, 93,\
        \ and 17 reported positive histories of epilepsy with one first-degree relative\
        \ affected with epilepsy.///(A\u2013E) Electropherograms of the amplicons\
        \ from the genomic DNA showing homozygosity of the wild-type allele in unaffected\
        \ individuals (WT/WT) and heterozygosity of each of the five CASR mutations\
        \ (E354A, I686V, R898Q, A988V, and A988G) identified in juvenile myoclonic\
        \ epilepsy (JME) families/ individuals.", pubmed: '18756473', seq: '988',
    to_res: G}
- {entry_name: casr_human, from_res: I, info: "Four additional, potentially pathogenic,\
        \ missense CASR variants, Glu354Ala, Ile686Val, Ala988Val, and Ala988Gly,\
        \ were observed in five individuals affected with idiopathic generalized epilepsy.///These\
        \ four nucleotide variants, g.58158A C, g.80072A G, g.80979C T, and g.80979C\
        \ G (GenBank accession number AC068754.16), lead to Glu354Ala, Ile686Val,\
        \ Ala988Val, and Ala988Gly amino acid alterations, respectively, in the CASR\
        \ protein (see Fig 3).///Epilepsy Families/Individuals, Missense Mutations\
        \ at CASR, and Allele Frequencies Family/Individual Family 1 Family 80 Family\
        \ 93 Individual 17 Individual 50 Individual 45 Variation AC068754.16 g.80709G\
        \ A AC068754.16 g.58158A C AC068754.16 g.80072A G AC068754.16 g.80979C T AC068754.16\
        \ g.80979C T AC068754.16 g.80979C G Predicted Effect on Protein p.Arg898Gln\
        \ p.Glu354Ala p.Ile686Val p.Ala988Val p.Ala988Val p.Ala988Gly Allele Frequency\
        \ in Control Population 0/504 0/504 0/504 0/504 0/504 0/504 Families 80, 93,\
        \ and 17 reported positive histories of epilepsy with one first-degree relative\
        \ affected with epilepsy.///(A\u2013E) Electropherograms of the amplicons\
        \ from the genomic DNA showing homozygosity of the wild-type allele in unaffected\
        \ individuals (WT/WT) and heterozygosity of each of the five CASR mutations\
        \ (E354A, I686V, R898Q, A988V, and A988G) identified in juvenile myoclonic\
        \ epilepsy (JME) families/ individuals.", pubmed: '18756473', seq: '686',
    to_res: V}
- {entry_name: casr_human, from_res: A, info: "Four additional, potentially pathogenic,\
        \ missense CASR variants, Glu354Ala, Ile686Val, Ala988Val, and Ala988Gly,\
        \ were observed in five individuals affected with idiopathic generalized epilepsy.///These\
        \ four nucleotide variants, g.58158A C, g.80072A G, g.80979C T, and g.80979C\
        \ G (GenBank accession number AC068754.16), lead to Glu354Ala, Ile686Val,\
        \ Ala988Val, and Ala988Gly amino acid alterations, respectively, in the CASR\
        \ protein (see Fig 3).///Epilepsy Families/Individuals, Missense Mutations\
        \ at CASR, and Allele Frequencies Family/Individual Family 1 Family 80 Family\
        \ 93 Individual 17 Individual 50 Individual 45 Variation AC068754.16 g.80709G\
        \ A AC068754.16 g.58158A C AC068754.16 g.80072A G AC068754.16 g.80979C T AC068754.16\
        \ g.80979C T AC068754.16 g.80979C G Predicted Effect on Protein p.Arg898Gln\
        \ p.Glu354Ala p.Ile686Val p.Ala988Val p.Ala988Val p.Ala988Gly Allele Frequency\
        \ in Control Population 0/504 0/504 0/504 0/504 0/504 0/504 Families 80, 93,\
        \ and 17 reported positive histories of epilepsy with one first-degree relative\
        \ affected with epilepsy.///Epilepsy Families/Individuals, Missense Mutations\
        \ at CASR, and Allele Frequencies Family/Individual Family 1 Family 80 Family\
        \ 93 Individual 17 Individual 50 Individual 45 Variation AC068754.16 g.80709G\
        \ A AC068754.16 g.58158A C AC068754.16 g.80072A G AC068754.16 g.80979C T AC068754.16\
        \ g.80979C T AC068754.16 g.80979C G Predicted Effect on Protein p.Arg898Gln\
        \ p.Glu354Ala p.Ile686Val p.Ala988Val p.Ala988Val p.Ala988Gly Allele Frequency\
        \ in Control Population 0/504 0/504 0/504 0/504 0/504 0/504 Families 80, 93,\
        \ and 17 reported positive histories of epilepsy with one first-degree relative\
        \ affected with epilepsy.///(A\u2013E) Electropherograms of the amplicons\
        \ from the genomic DNA showing homozygosity of the wild-type allele in unaffected\
        \ individuals (WT/WT) and heterozygosity of each of the five CASR mutations\
        \ (E354A, I686V, R898Q, A988V, and A988G) identified in juvenile myoclonic\
        \ epilepsy (JME) families/ individuals.", pubmed: '18756473', seq: '988',
    to_res: V}
- {entry_name: casr_human, from_res: R, info: "In this interval, we found a novel,\
        \ patient-specific, missense variant, Arg898Gln, at the extracellular calcium\
        \ sensing receptor (CASR), a gene belonging to the G-protein\u2013coupled\
        \ receptor family.///Epilepsy Families/Individuals, Missense Mutations at\
        \ CASR, and Allele Frequencies Family/Individual Family 1 Family 80 Family\
        \ 93 Individual 17 Individual 50 Individual 45 Variation AC068754.16 g.80709G\
        \ A AC068754.16 g.58158A C AC068754.16 g.80072A G AC068754.16 g.80979C T AC068754.16\
        \ g.80979C T AC068754.16 g.80979C G Predicted Effect on Protein p.Arg898Gln\
        \ p.Glu354Ala p.Ile686Val p.Ala988Val p.Ala988Val p.Ala988Gly Allele Frequency\
        \ in Control Population 0/504 0/504 0/504 0/504 0/504 0/504 Families 80, 93,\
        \ and 17 reported positive histories of epilepsy with one first-degree relative\
        \ affected with epilepsy.///(A\u2013E) Electropherograms of the amplicons\
        \ from the genomic DNA showing homozygosity of the wild-type allele in unaffected\
        \ individuals (WT/WT) and heterozygosity of each of the five CASR mutations\
        \ (E354A, I686V, R898Q, A988V, and A988G) identified in juvenile myoclonic\
        \ epilepsy (JME) families/ individuals.", pubmed: '18756473', seq: '898',
    to_res: Q}
- {entry_name: casr_human, from_res: E, info: "Four additional, potentially pathogenic,\
        \ missense CASR variants, Glu354Ala, Ile686Val, Ala988Val, and Ala988Gly,\
        \ were observed in five individuals affected with idiopathic generalized epilepsy.///These\
        \ four nucleotide variants, g.58158A C, g.80072A G, g.80979C T, and g.80979C\
        \ G (GenBank accession number AC068754.16), lead to Glu354Ala, Ile686Val,\
        \ Ala988Val, and Ala988Gly amino acid alterations, respectively, in the CASR\
        \ protein (see Fig 3).///Epilepsy Families/Individuals, Missense Mutations\
        \ at CASR, and Allele Frequencies Family/Individual Family 1 Family 80 Family\
        \ 93 Individual 17 Individual 50 Individual 45 Variation AC068754.16 g.80709G\
        \ A AC068754.16 g.58158A C AC068754.16 g.80072A G AC068754.16 g.80979C T AC068754.16\
        \ g.80979C T AC068754.16 g.80979C G Predicted Effect on Protein p.Arg898Gln\
        \ p.Glu354Ala p.Ile686Val p.Ala988Val p.Ala988Val p.Ala988Gly Allele Frequency\
        \ in Control Population 0/504 0/504 0/504 0/504 0/504 0/504 Families 80, 93,\
        \ and 17 reported positive histories of epilepsy with one first-degree relative\
        \ affected with epilepsy.///(A\u2013E) Electropherograms of the amplicons\
        \ from the genomic DNA showing homozygosity of the wild-type allele in unaffected\
        \ individuals (WT/WT) and heterozygosity of each of the five CASR mutations\
        \ (E354A, I686V, R898Q, A988V, and A988G) identified in juvenile myoclonic\
        \ epilepsy (JME) families/ individuals.", pubmed: '18756473', seq: '354',
    to_res: A}
- {entry_name: casr_human, from_res: R, info: 'Eight coding polymorphisms were observed
        in the control group: Ser18Ser (minor allele frequency [maf]: 0.002), Gln179Gln
        (maf: 0.005), Glu191Glu (maf: 0.009), Ser388Ser (maf: 0.002), Ile967Ile (maf:
        0.005), Ala986Ser (maf: 0.19), Arg990Gly (maf: 0.23), and Glu1011Gln (maf:
        0.05).', pubmed: '18756473', seq: '990', to_res: G}
- {entry_name: casr_human, from_res: A, info: 'Eight coding polymorphisms were observed
        in the control group: Ser18Ser (minor allele frequency [maf]: 0.002), Gln179Gln
        (maf: 0.005), Glu191Glu (maf: 0.009), Ser388Ser (maf: 0.002), Ile967Ile (maf:
        0.005), Ala986Ser (maf: 0.19), Arg990Gly (maf: 0.23), and Glu1011Gln (maf:
        0.05).', pubmed: '18756473', seq: '986', to_res: S}
- {entry_name: adrb2_human, from_res: L, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '339', to_res: A}
- {entry_name: cxcr4_human, from_res: E, info: "92, 0.1 31.5, \xC00.4 0, \xC01.4 3.7,\
        \ 7.4 3.7, 7.4 \xC02.9, 13.8 58.8, 57.5 0, 4.4 0, 4.4 66, 65.1 73.1, 67.3\
        \ 60.6, 92.3 63% 50% 59% 74% 38% 46% 43% 52% 35% 41% 47% 57% 52% 61% 47% 47%\
        \ 43% 36% 40% 38% 30% 29% 30% 26% 37% 34% 35% 41% 43% 0.96 2.13 1.22 1.23\
        \ 1.77 2.27 2.38 2.34 2.13 2.44 3.42 2.96 1.94 2.24 4.88 2.47 2.88 6.86 6.14\
        \ 5.17 7.49 6.41 9.46 8.88 15.61 13.90 17.06 10.53 11.85c 36 (9)/65 (15) 36\
        \ (12)/65 (15) 31 (10)/65 (15) 29 (10)/65 (15) 23 (11)/65 (15) 26 (11)/65\
        \ (15) 30 (11)/65 (15) 27 (9)/65 (15) 19 (8)/65 (15) 21 (8)/65 (15) 21 (7)/65\
        \ (15) 25 (7)/65 (15) 17 (6)/65 (15) 19 (10)/65 (15) 19 (5)/64 (13) 9 (2)/64\
        \ (13) 8 (4)/64 (13) 10 (2)/64 (13) 7 (4)/64 (13) 7 (4)/64 (13) 6 (2)/64 (13)\
        \ 5 (2)/64 (13) 9 (2)/64 (13) 7 (4)/181 (26) 11 (1)/181 (26) 6 (5)/181 (26)\
        \ 8 (5)/181 (26) 6 (1)/181 (26) 4 (1)/181 (26) 39.95 (58%) 38.75 (57%) 34.78\
        \ (51%) 32.46 (47%) 30.94 (45%) 30.5 (44%) 30.1 (44%) 26.47 (39%) 24.84 (36%)\
        \ 25.57 (37%) 28.95 (42%) 26.75 (39%) 22.51 (33%) 22.81 (33%) 21.16 (36%)\
        \ 10.56 (18%) 9.93 (17%) 10.28 (17%) 9.22 (15%) 7.7 (13%) 8.58 (14%) 7.41\
        \ (12%) 9.91 (17%) 11.64 (6%) 12.96 (7%) 9.51 (5%) 10.43 (6%) 5.49 (3%) 6.14\
        \ (3%) E288 n/a n/a n/a n/a n/a n/a D110 D110a D110a D110 D110 D110 D110 D110\
        \ D110 D110 Group D3/Eticlopride PompeuFabra CDD-CMBI COH-Vaidehi UCSF-Shoichet-1\
        \  \u0308 Schrodinger CDD-CMBI CDD-CMBI Warsaw CDD-CMBI CDD-CMBI Z-Score 2.39\
        \ 2.05 2.00 1.85 1.63 1.49 1.44 1.22 1.16 1.14 1.13 1.10 1.05 1.01 a D110a\
        \ Structure 19, 1108\u20131126, August 10, 2011 a2011 Elsevier Ltd All rights\
        \ reserved 1119 Helsinki-Xhaard COH-Vaidehi  \u0308 Schrodinger CXCR4/IT1t\
        \ VU-MedChem COH-Vaidehi COH-Vaidehi COH-Vaidehi UCSF-Shoichet-2 COH-Vaidehi\
        \ GaTech GaTech Caltech CXCR4/CVX15 UMich-Zhang COH-Vaidehi COH-Vaidehi UMich-Zhang\
        \ UMich-Zhang MolLife Monash-Sexton-2 3 D97, E288 3.49 D97 D97 D97 E288 D97\
        \ E288a 2.19 2.02 1.47 1.41 1.32 1.10 1.08 1.01 2.40 1.92 1.52 1.34 1.21 1.18\
        \ The results of analysis of these and all other models can be found in Tables\
        \ S1 and S2. n/a, not applicable. a Contact geometry incompatible with hydrogen\
        \ bond formation. b ECL2 not modeled or incomplete.", pubmed: '21827947',
    seq: '288', to_res: A}
- {entry_name: drd3_human, from_res: D, info: "92, 0.1 31.5, \xC00.4 0, \xC01.4 3.7,\
        \ 7.4 3.7, 7.4 \xC02.9, 13.8 58.8, 57.5 0, 4.4 0, 4.4 66, 65.1 73.1, 67.3\
        \ 60.6, 92.3 63% 50% 59% 74% 38% 46% 43% 52% 35% 41% 47% 57% 52% 61% 47% 47%\
        \ 43% 36% 40% 38% 30% 29% 30% 26% 37% 34% 35% 41% 43% 0.96 2.13 1.22 1.23\
        \ 1.77 2.27 2.38 2.34 2.13 2.44 3.42 2.96 1.94 2.24 4.88 2.47 2.88 6.86 6.14\
        \ 5.17 7.49 6.41 9.46 8.88 15.61 13.90 17.06 10.53 11.85c 36 (9)/65 (15) 36\
        \ (12)/65 (15) 31 (10)/65 (15) 29 (10)/65 (15) 23 (11)/65 (15) 26 (11)/65\
        \ (15) 30 (11)/65 (15) 27 (9)/65 (15) 19 (8)/65 (15) 21 (8)/65 (15) 21 (7)/65\
        \ (15) 25 (7)/65 (15) 17 (6)/65 (15) 19 (10)/65 (15) 19 (5)/64 (13) 9 (2)/64\
        \ (13) 8 (4)/64 (13) 10 (2)/64 (13) 7 (4)/64 (13) 7 (4)/64 (13) 6 (2)/64 (13)\
        \ 5 (2)/64 (13) 9 (2)/64 (13) 7 (4)/181 (26) 11 (1)/181 (26) 6 (5)/181 (26)\
        \ 8 (5)/181 (26) 6 (1)/181 (26) 4 (1)/181 (26) 39.95 (58%) 38.75 (57%) 34.78\
        \ (51%) 32.46 (47%) 30.94 (45%) 30.5 (44%) 30.1 (44%) 26.47 (39%) 24.84 (36%)\
        \ 25.57 (37%) 28.95 (42%) 26.75 (39%) 22.51 (33%) 22.81 (33%) 21.16 (36%)\
        \ 10.56 (18%) 9.93 (17%) 10.28 (17%) 9.22 (15%) 7.7 (13%) 8.58 (14%) 7.41\
        \ (12%) 9.91 (17%) 11.64 (6%) 12.96 (7%) 9.51 (5%) 10.43 (6%) 5.49 (3%) 6.14\
        \ (3%) E288 n/a n/a n/a n/a n/a n/a D110 D110a D110a D110 D110 D110 D110 D110\
        \ D110 D110 Group D3/Eticlopride PompeuFabra CDD-CMBI COH-Vaidehi UCSF-Shoichet-1\
        \  \u0308 Schrodinger CDD-CMBI CDD-CMBI Warsaw CDD-CMBI CDD-CMBI Z-Score 2.39\
        \ 2.05 2.00 1.85 1.63 1.49 1.44 1.22 1.16 1.14 1.13 1.10 1.05 1.01 a D110a\
        \ Structure 19, 1108\u20131126, August 10, 2011 a2011 Elsevier Ltd All rights\
        \ reserved 1119 Helsinki-Xhaard COH-Vaidehi  \u0308 Schrodinger CXCR4/IT1t\
        \ VU-MedChem COH-Vaidehi COH-Vaidehi COH-Vaidehi UCSF-Shoichet-2 COH-Vaidehi\
        \ GaTech GaTech Caltech CXCR4/CVX15 UMich-Zhang COH-Vaidehi COH-Vaidehi UMich-Zhang\
        \ UMich-Zhang MolLife Monash-Sexton-2 3 D97, E288 3.49 D97 D97 D97 E288 D97\
        \ E288a 2.19 2.02 1.47 1.41 1.32 1.10 1.08 1.01 2.40 1.92 1.52 1.34 1.21 1.18\
        \ The results of analysis of these and all other models can be found in Tables\
        \ S1 and S2. n/a, not applicable. a Contact geometry incompatible with hydrogen\
        \ bond formation. b ECL2 not modeled or incomplete.///92, 0.1 31.5, \xC00.4\
        \ 0, \xC01.4 3.7, 7.4 3.7, 7.4 \xC02.9, 13.8 58.8, 57.5 0, 4.4 0, 4.4 66,\
        \ 65.1 73.1, 67.3 60.6, 92.3 63% 50% 59% 74% 38% 46% 43% 52% 35% 41% 47% 57%\
        \ 52% 61% 47% 47% 43% 36% 40% 38% 30% 29% 30% 26% 37% 34% 35% 41% 43% 0.96\
        \ 2.13 1.22 1.23 1.77 2.27 2.38 2.34 2.13 2.44 3.42 2.96 1.94 2.24 4.88 2.47\
        \ 2.88 6.86 6.14 5.17 7.49 6.41 9.46 8.88 15.61 13.90 17.06 10.53 11.85c 36\
        \ (9)/65 (15) 36 (12)/65 (15) 31 (10)/65 (15) 29 (10)/65 (15) 23 (11)/65 (15)\
        \ 26 (11)/65 (15) 30 (11)/65 (15) 27 (9)/65 (15) 19 (8)/65 (15) 21 (8)/65\
        \ (15) 21 (7)/65 (15) 25 (7)/65 (15) 17 (6)/65 (15) 19 (10)/65 (15) 19 (5)/64\
        \ (13) 9 (2)/64 (13) 8 (4)/64 (13) 10 (2)/64 (13) 7 (4)/64 (13) 7 (4)/64 (13)\
        \ 6 (2)/64 (13) 5 (2)/64 (13) 9 (2)/64 (13) 7 (4)/181 (26) 11 (1)/181 (26)\
        \ 6 (5)/181 (26) 8 (5)/181 (26) 6 (1)/181 (26) 4 (1)/181 (26) 39.95 (58%)\
        \ 38.75 (57%) 34.78 (51%) 32.46 (47%) 30.94 (45%) 30.5 (44%) 30.1 (44%) 26.47\
        \ (39%) 24.84 (36%) 25.57 (37%) 28.95 (42%) 26.75 (39%) 22.51 (33%) 22.81\
        \ (33%) 21.16 (36%) 10.56 (18%) 9.93 (17%) 10.28 (17%) 9.22 (15%) 7.7 (13%)\
        \ 8.58 (14%) 7.41 (12%) 9.91 (17%) 11.64 (6%) 12.96 (7%) 9.51 (5%) 10.43 (6%)\
        \ 5.49 (3%) 6.14 (3%) E288 n/a n/a n/a n/a n/a n/a D110 D110a D110a D110 D110\
        \ D110 D110 D110 D110 D110 Group D3/Eticlopride PompeuFabra CDD-CMBI COH-Vaidehi\
        \ UCSF-Shoichet-1  \u0308 Schrodinger CDD-CMBI CDD-CMBI Warsaw CDD-CMBI CDD-CMBI\
        \ Z-Score 2.39 2.05 2.00 1.85 1.63 1.49 1.44 1.22 1.16 1.14 1.13 1.10 1.05\
        \ 1.01 a D110a Structure 19, 1108\u20131126, August 10, 2011 a2011 Elsevier\
        \ Ltd All rights reserved 1119 Helsinki-Xhaard COH-Vaidehi  \u0308 Schrodinger\
        \ CXCR4/IT1t VU-MedChem COH-Vaidehi COH-Vaidehi COH-Vaidehi UCSF-Shoichet-2\
        \ COH-Vaidehi GaTech GaTech Caltech CXCR4/CVX15 UMich-Zhang COH-Vaidehi COH-Vaidehi\
        \ UMich-Zhang UMich-Zhang MolLife Monash-Sexton-2 3 D97, E288 3.49 D97 D97\
        \ D97 E288 D97 E288a 2.19 2.02 1.47 1.41 1.32 1.10 1.08 1.01 2.40 1.92 1.52\
        \ 1.34 1.21 1.18 The results of analysis of these and all other models can\
        \ be found in Tables S1 and S2. n/a, not applicable. a Contact geometry incompatible\
        \ with hydrogen bond formation. b ECL2 not modeled or incomplete.///92, 0.1\
        \ 31.5, \xC00.4 0, \xC01.4 3.7, 7.4 3.7, 7.4 \xC02.9, 13.8 58.8, 57.5 0, 4.4\
        \ 0, 4.4 66, 65.1 73.1, 67.3 60.6, 92.3 63% 50% 59% 74% 38% 46% 43% 52% 35%\
        \ 41% 47% 57% 52% 61% 47% 47% 43% 36% 40% 38% 30% 29% 30% 26% 37% 34% 35%\
        \ 41% 43% 0.96 2.13 1.22 1.23 1.77 2.27 2.38 2.34 2.13 2.44 3.42 2.96 1.94\
        \ 2.24 4.88 2.47 2.88 6.86 6.14 5.17 7.49 6.41 9.46 8.88 15.61 13.90 17.06\
        \ 10.53 11.85c 36 (9)/65 (15) 36 (12)/65 (15) 31 (10)/65 (15) 29 (10)/65 (15)\
        \ 23 (11)/65 (15) 26 (11)/65 (15) 30 (11)/65 (15) 27 (9)/65 (15) 19 (8)/65\
        \ (15) 21 (8)/65 (15) 21 (7)/65 (15) 25 (7)/65 (15) 17 (6)/65 (15) 19 (10)/65\
        \ (15) 19 (5)/64 (13) 9 (2)/64 (13) 8 (4)/64 (13) 10 (2)/64 (13) 7 (4)/64\
        \ (13) 7 (4)/64 (13) 6 (2)/64 (13) 5 (2)/64 (13) 9 (2)/64 (13) 7 (4)/181 (26)\
        \ 11 (1)/181 (26) 6 (5)/181 (26) 8 (5)/181 (26) 6 (1)/181 (26) 4 (1)/181 (26)\
        \ 39.95 (58%) 38.75 (57%) 34.78 (51%) 32.46 (47%) 30.94 (45%) 30.5 (44%) 30.1\
        \ (44%) 26.47 (39%) 24.84 (36%) 25.57 (37%) 28.95 (42%) 26.75 (39%) 22.51\
        \ (33%) 22.81 (33%) 21.16 (36%) 10.56 (18%) 9.93 (17%) 10.28 (17%) 9.22 (15%)\
        \ 7.7 (13%) 8.58 (14%) 7.41 (12%) 9.91 (17%) 11.64 (6%) 12.96 (7%) 9.51 (5%)\
        \ 10.43 (6%) 5.49 (3%) 6.14 (3%) E288 n/a n/a n/a n/a n/a n/a D110 D110a D110a\
        \ D110 D110 D110 D110 D110 D110 D110 Group D3/Eticlopride PompeuFabra CDD-CMBI\
        \ COH-Vaidehi UCSF-Shoichet-1  \u0308 Schrodinger CDD-CMBI CDD-CMBI Warsaw\
        \ CDD-CMBI CDD-CMBI Z-Score 2.39 2.05 2.00 1.85 1.63 1.49 1.44 1.22 1.16 1.14\
        \ 1.13 1.10 1.05 1.01 a D110a Structure 19, 1108\u20131126, August 10, 2011\
        \ a2011 Elsevier Ltd All rights reserved 1119 Helsinki-Xhaard COH-Vaidehi\
        \  \u0308 Schrodinger CXCR4/IT1t VU-MedChem COH-Vaidehi COH-Vaidehi COH-Vaidehi\
        \ UCSF-Shoichet-2 COH-Vaidehi GaTech GaTech Caltech CXCR4/CVX15 UMich-Zhang\
        \ COH-Vaidehi COH-Vaidehi UMich-Zhang UMich-Zhang MolLife Monash-Sexton-2\
        \ 3 D97, E288 3.49 D97 D97 D97 E288 D97 E288a 2.19 2.02 1.47 1.41 1.32 1.10\
        \ 1.08 1.01 2.40 1.92 1.52 1.34 1.21 1.18 The results of analysis of these\
        \ and all other models can be found in Tables S1 and S2. n/a, not applicable.\
        \ a Contact geometry incompatible with hydrogen bond formation. b ECL2 not\
        \ modeled or incomplete.", pubmed: '21827947', seq: '110', to_res: A}
- {entry_name: opsd_bovin, from_res: K, info: 'Naturally occurring mutations in and
        near this salt bridge, A292E (7.39) and K296E (7.43), produce constitutively
        active receptors and the disease retinitis pigmentosa (52, 53).', pubmed: '15952782',
    seq: '296', to_res: E}
- {entry_name: cnr1_human, from_res: C, info: 'This mutation (C386M) was constructed
        in the shCB1-C13 background, and the construct is hereafter called shCB1-C12-C386M.///This
        mutation (C386M) was constructed in the shCB1-C13 background, and the construct
        is hereafter called shCB1-C12-C386M.///However, as anticipated, antagonist
        binding for shCB1-C12-C386M was severely impaired (Figure 6B).///To further
        assess the effect of the C386M mutation on SR141716A binding, we carried out
        heterologous binding assays that assessed the ability of SR141716A to displace
        tritiated CP55940.///These results indicate the C386M mutation lowers the
        apparent affinity for SR141716A, as judged by the Ki, approximately 5-fold
        compared to that of wild-type shCB1-C13 (Figure 6C).///Further heterologous
        binding assays showed the agonist WIN55212-2 can also displace tritiated CP55940,
        and this behavior is unaffected by the C386M mutation (data not shown).///A
        possible reason why the C386M mutation perturbs antagonist SR141716A binding
        but not agonist CP55940 binding is discussed in the text and in the legend
        of Figure 7.///In agreement with this hypothesis, introducing steric bulk
        at this site via a C386M mutation also impedes antagonist binding, but NOT
        agonist binding (Figure 6).', pubmed: '15952782', seq: '386', to_res: M}
- {entry_name: tshr_human, from_res: N, info: 'Analogously, in the human thyrotropin
        receptor, the N670S mutation (7.45) is thought to be involved in hyperplasia
        associated with hyperthyroidism and adenoma (54).', pubmed: '15952782', seq: '670',
    to_res: S}
- {entry_name: cnr1_human, from_res: C, info: The shCB1-C5 mutant was created gradually
        by incorporating the N-terminal coding region of the QuikChange product (C98A
        and C107A) into the shCB1-C7 construct using EcoRI and ScaI restriction sites.,
    pubmed: '15952782', seq: '98', to_res: A}
- {entry_name: cnr1_human, from_res: C, info: 'The creation of shCB1-C2 was accomplished
        by inserting a fragment containing C355A, C382A, and C386A mutations into
        shCB1C5 using SpeI and NotI sites.', pubmed: '15952782', seq: '355', to_res: A}
- {entry_name: opsd_bovin, from_res: A, info: 'Naturally occurring mutations in and
        near this salt bridge, A292E (7.39) and K296E (7.43), produce constitutively
        active receptors and the disease retinitis pigmentosa (52, 53).', pubmed: '15952782',
    seq: '292', to_res: E}
- {entry_name: cnr1_human, from_res: C, info: 'The creation of shCB1-C2 was accomplished
        by inserting a fragment containing C355A, C382A, and C386A mutations into
        shCB1C5 using SpeI and NotI sites.///Interestingly, since the C386A mutation
        does not alter either agonist or antagonist ligand binding, 3 Note that other
        cysteine residues in CB1 may still be labeled by the MTS reagents; however,
        if they are, they do not alter antagonist binding.', pubmed: '15952782', seq: '386',
    to_res: A}
- {entry_name: cnr1_human, from_res: C, info: 'The creation of shCB1-C2 was accomplished
        by inserting a fragment containing C355A, C382A, and C386A mutations into
        shCB1C5 using SpeI and NotI sites.', pubmed: '15952782', seq: '382', to_res: A}
- {entry_name: cnr1_human, from_res: C, info: The shCB1-C5 mutant was created gradually
        by incorporating the N-terminal coding region of the QuikChange product (C98A
        and C107A) into the shCB1-C7 construct using EcoRI and ScaI restriction sites.,
    pubmed: '15952782', seq: '107', to_res: A}
- {entry_name: v2r_mouse, from_res: R, info: "Residues Pflugers Arch - Eur J Physiol\
        \ (2010) 460:321\u2013341 important for PIP2 binding that have also been found\
        \ to be mutated in LQT syndrome patients include R243H, R539W, and R555C [152].",
    pubmed: '20396900', seq: '243', to_res: H}
- {entry_name: acm5_human, from_res: S, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '117', to_res: A}
- {entry_name: acm5_human, from_res: D, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '76', to_res: N}
- {entry_name: agtr1_human, from_res: N, info: 'There exists no evidence for or against
        the possible interaction of Asn113 with BK in the B2 receptor; the expected
        increase of agonist affinity for CAM receptors, recently observed for the
        B1 receptor mutated at its conserved Asn residue (28), was found neither for
        the Ala113 B2 receptor (4) nor for the N111A AT1 receptor (6).', pubmed: '11495910',
    seq: '111', to_res: A}
- {entry_name: bkrb2_human, from_res: F, info: 'Receptors [3H]BK Kd nM 125 I-HPP-HOE
        140 Kd IP BK Ki nM EC50 nM Emax % of WT WT F259A T263A F259A, T263A N113A
        N113A, F259A N113A, T263A W256A W256F W256Q F259H W256A, F259H W256F, F259H
        W256Q, F259H 0.53 0.05 UDa UD UD 0.27 0.12 7.00 0.8 1.55 0.20 1.00 0.21 0.52
        0.18 0.41 0.15 UD 0.22 0.28 0.15 0.37 0.29 1.08 0.28 0.40 0.23 0.33 0.17 0.48
        0.52 0.32 0.15 0.11 0.08 0.18 0.09 0.25 0.12 0.10 0.15 0.15 0.08 0.05 0.17
        0.07 0.70 70 1.40 300 0.15 142 174 0.50 15 25 35 0.05 2 50 0.19 31 0.20 7.00
        0.39 0.21 0.22 300 60 3.10 3.10 0.04 7 0.12 1.50 0.13 0.06 0.04 100 10 1.20
        0.77 100 78 3 195 315 114 160 168 60 105 167 146 50 50 19 15 14 1 13 5 18
        215 100 40 34 50 10 5 12 a UD, undetectable binding.///Receptors [3H]BK Kd
        nM 125 I-HPP-HOE 140 Kd IP BK Ki nM EC50 nM Emax % of WT WT F259A T263A F259A,
        T263A N113A N113A, F259A N113A, T263A W256A W256F W256Q F259H W256A, F259H
        W256F, F259H W256Q, F259H 0.53 0.05 UDa UD UD 0.27 0.12 7.00 0.8 1.55 0.20
        1.00 0.21 0.52 0.18 0.41 0.15 UD 0.22 0.28 0.15 0.37 0.29 1.08 0.28 0.40 0.23
        0.33 0.17 0.48 0.52 0.32 0.15 0.11 0.08 0.18 0.09 0.25 0.12 0.10 0.15 0.15
        0.08 0.05 0.17 0.07 0.70 70 1.40 300 0.15 142 174 0.50 15 25 35 0.05 2 50
        0.19 31 0.20 7.00 0.39 0.21 0.22 300 60 3.10 3.10 0.04 7 0.12 1.50 0.13 0.06
        0.04 100 10 1.20 0.77 100 78 3 195 315 114 160 168 60 105 167 146 50 50 19
        15 14 1 13 5 18 215 100 40 34 50 10 5 12 a UD, undetectable binding.///Receptors
        [3H]BK Kd nM 125 I-HPP-HOE 140 Kd IP BK Ki nM EC50 nM Emax % of WT WT F259A
        T263A F259A, T263A N113A N113A, F259A N113A, T263A W256A W256F W256Q F259H
        W256A, F259H W256F, F259H W256Q, F259H 0.53 0.05 UDa UD UD 0.27 0.12 7.00
        0.8 1.55 0.20 1.00 0.21 0.52 0.18 0.41 0.15 UD 0.22 0.28 0.15 0.37 0.29 1.08
        0.28 0.40 0.23 0.33 0.17 0.48 0.52 0.32 0.15 0.11 0.08 0.18 0.09 0.25 0.12
        0.10 0.15 0.15 0.08 0.05 0.17 0.07 0.70 70 1.40 300 0.15 142 174 0.50 15 25
        35 0.05 2 50 0.19 31 0.20 7.00 0.39 0.21 0.22 300 60 3.10 3.10 0.04 7 0.12
        1.50 0.13 0.06 0.04 100 10 1.20 0.77 100 78 3 195 315 114 160 168 60 105 167
        146 50 50 19 15 14 1 13 5 18 215 100 40 34 50 10 5 12 a UD, undetectable binding.///Receptors
        [3H]BK Kd nM 125 I-HPP-HOE 140 Kd IP BK Ki nM EC50 nM Emax % of WT WT F259A
        T263A F259A, T263A N113A N113A, F259A N113A, T263A W256A W256F W256Q F259H
        W256A, F259H W256F, F259H W256Q, F259H 0.53 0.05 UDa UD UD 0.27 0.12 7.00
        0.8 1.55 0.20 1.00 0.21 0.52 0.18 0.41 0.15 UD 0.22 0.28 0.15 0.37 0.29 1.08
        0.28 0.40 0.23 0.33 0.17 0.48 0.52 0.32 0.15 0.11 0.08 0.18 0.09 0.25 0.12
        0.10 0.15 0.15 0.08 0.05 0.17 0.07 0.70 70 1.40 300 0.15 142 174 0.50 15 25
        35 0.05 2 50 0.19 31 0.20 7.00 0.39 0.21 0.22 300 60 3.10 3.10 0.04 7 0.12
        1.50 0.13 0.06 0.04 100 10 1.20 0.77 100 78 3 195 315 114 160 168 60 105 167
        146 50 50 19 15 14 1 13 5 18 215 100 40 34 50 10 5 12 a UD, undetectable binding.///While
        the F259H receptor displayed properties similar to those of the F259A mutant,
        i.e. strongly decreased affinity for BK (Table II) and no constitutive activation,
        the F259H, W256F and F259H, W256Q receptors were constitutively activated,
        similarly to the single Phe256 and Gln256 mutants (not shown) and the EC50
        for BK stimulation were dramatically decreased as compared with the W256H
        receptor (these effects were much less pronounced for the F259H, W256A receptor,
        which was not constitutively activated) (Table II).///While the F259H receptor
        displayed properties similar to those of the F259A mutant, i.e. strongly decreased
        affinity for BK (Table II) and no constitutive activation, the F259H, W256F
        and F259H, W256Q receptors were constitutively activated, similarly to the
        single Phe256 and Gln256 mutants (not shown) and the EC50 for BK stimulation
        were dramatically decreased as compared with the W256H receptor (these effects
        were much less pronounced for the F259H, W256A receptor, which was not constitutively
        activated) (Table II).///While the F259H receptor displayed properties similar
        to those of the F259A mutant, i.e. strongly decreased affinity for BK (Table
        II) and no constitutive activation, the F259H, W256F and F259H, W256Q receptors
        were constitutively activated, similarly to the single Phe256 and Gln256 mutants
        (not shown) and the EC50 for BK stimulation were dramatically decreased as
        compared with the W256H receptor (these effects were much less pronounced
        for the F259H, W256A receptor, which was not constitutively activated) (Table
        II).///While the F259H receptor displayed properties similar to those of the
        F259A mutant, i.e. strongly decreased affinity for BK (Table II) and no constitutive
        activation, the F259H, W256F and F259H, W256Q receptors were constitutively
        activated, similarly to the single Phe256 and Gln256 mutants (not shown) and
        the EC50 for BK stimulation were dramatically decreased as compared with the
        W256H receptor (these effects were much less pronounced for the F259H, W256A
        receptor, which was not constitutively activated) (Table II).', pubmed: '11495910',
    seq: '259', to_res: H}
- {entry_name: agtr1_human, from_res: T, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '287', to_res: L}
- {entry_name: acm5_human, from_res: S, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '291', to_res: A}
- {entry_name: acm5_human, from_res: D, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '76', to_res: A}
- {entry_name: 5ht1b_human, from_res: N, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '202', to_res: A}
- {entry_name: agtr1_human, from_res: T, info: "As the mutation of Thr287 to Ala or\
        \ Leu, its B1 counterpart, had no incidence on affinity, we favored the existence\
        \ of an hydrogen bond interaction between Gln288 and the carbonyl group of\
        \ the prolyl moiety and we slightly rotated helix VII, by 20\xB0, so as to\
        \ fulfil this interaction preference while preserving the \u201Csandwich\u201D\
        \ interaction of the quinoline with the Trp256 and Tyr295 residues.///Receptors\
        \ TM [3H]BK Kd nM 125 LF 16\u20130335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki\
        \ wt LF 16\u20130687 Ki nM WT N48A D76A D76N N92A S111A S111K N113A Y115A\
        \ Y115F S116A S117A F120A M165A M165T N198A N202A F206A F252A C255A C255S\
        \ W256A W256F W256Q P258A F259A Q260A Q260H S262A S262F T263A F264A D284A\
        \ T287A T287L Q288A S291A F292A F292Y Y295A Y295F S296A N297A S298A N301A\
        \ N301D I II II II III III III III III III III III IV IV V V V VI VI VI VI\
        \ VI VI VI VI VI VI VI VI VI VI VII VII VII VII VII VII VII VII VII VII VII\
        \ VII VII VII 0.51 0.39 0.40 1.00 0.86 1.51 2.58 0.27 1.25 1.15 0.30 0.70\
        \ 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09 0.12 0.52 0.15 0.4 1.40 0.12 0.21\
        \ 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12 0.08 0.28 0.31 0.12 0.18 0.57 0.36\
        \ 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45 0.33 2.20 0.50 1.00 0.56 0.50 0.32\
        \ 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35 1.4 0.62 0.27 1.90 0.66 0.37 2.7\
        \ 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07 0.09 0.04 0.06 0.01 0.01 0.03 0.12\
        \ 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07 0.05 0.08 0.11 0.10 0.05 0.06 0.13\
        \ 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15 1.08 1.60 0.84 1.05 2.11 1.4 2.8\
        \ 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72 1.00 1.91 2.60 7.34 3.24 4.32 1.15\
        \ 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2 1.40 25.0 7.80 2.31 1.83 1.71 0.97\
        \ 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12 0.52 0.34 0.08 0.92 0.62 1.10 0.95\
        \ 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95 0.82 0.65 0.77 0.12 1.25 0.86 0.9\
        \ 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47 0.77 0.97 1.94 1.29 2.59 0.57 1.47\
        \ 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67\
        \ 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded\
        \ from www.jbc.org by guest, on September 5, 2011 0.35 2.60 0.75 0.04 0.52\
        \ 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52 0.18 0.41 0.15 1.21 0.12 80 14a\
        \ 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25 170 42a 0.41 0.13 4.40 0.88 0.62\
        \ 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53 0.54 2.94 0.70 1.09 0.05 0.04 0.40\
        \ 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80 0.62 0.22 4.70 1.10 0.35 0.07 0.38\
        \ 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08 0.52 0.27 0.07 42.9 11.5 3.78 0.45\
        \ UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined using [3H]BK as tracer ligand.",
    pubmed: '11495910', seq: '287', to_res: A}
- {entry_name: agtr2_human, from_res: F, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '120', to_res: A}
- {entry_name: bkrb2_human, from_res: F, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.///Receptors [3H]BK Kd nM 125 I-HPP-HOE 140\
        \ Kd IP BK Ki nM EC50 nM Emax % of WT WT F259A T263A F259A, T263A N113A N113A,\
        \ F259A N113A, T263A W256A W256F W256Q F259H W256A, F259H W256F, F259H W256Q,\
        \ F259H 0.53 0.05 UDa UD UD 0.27 0.12 7.00 0.8 1.55 0.20 1.00 0.21 0.52 0.18\
        \ 0.41 0.15 UD 0.22 0.28 0.15 0.37 0.29 1.08 0.28 0.40 0.23 0.33 0.17 0.48\
        \ 0.52 0.32 0.15 0.11 0.08 0.18 0.09 0.25 0.12 0.10 0.15 0.15 0.08 0.05 0.17\
        \ 0.07 0.70 70 1.40 300 0.15 142 174 0.50 15 25 35 0.05 2 50 0.19 31 0.20\
        \ 7.00 0.39 0.21 0.22 300 60 3.10 3.10 0.04 7 0.12 1.50 0.13 0.06 0.04 100\
        \ 10 1.20 0.77 100 78 3 195 315 114 160 168 60 105 167 146 50 50 19 15 14\
        \ 1 13 5 18 215 100 40 34 50 10 5 12 a UD, undetectable binding.///Receptors\
        \ [3H]BK Kd nM 125 I-HPP-HOE 140 Kd IP BK Ki nM EC50 nM Emax % of WT WT F259A\
        \ T263A F259A, T263A N113A N113A, F259A N113A, T263A W256A W256F W256Q F259H\
        \ W256A, F259H W256F, F259H W256Q, F259H 0.53 0.05 UDa UD UD 0.27 0.12 7.00\
        \ 0.8 1.55 0.20 1.00 0.21 0.52 0.18 0.41 0.15 UD 0.22 0.28 0.15 0.37 0.29\
        \ 1.08 0.28 0.40 0.23 0.33 0.17 0.48 0.52 0.32 0.15 0.11 0.08 0.18 0.09 0.25\
        \ 0.12 0.10 0.15 0.15 0.08 0.05 0.17 0.07 0.70 70 1.40 300 0.15 142 174 0.50\
        \ 15 25 35 0.05 2 50 0.19 31 0.20 7.00 0.39 0.21 0.22 300 60 3.10 3.10 0.04\
        \ 7 0.12 1.50 0.13 0.06 0.04 100 10 1.20 0.77 100 78 3 195 315 114 160 168\
        \ 60 105 167 146 50 50 19 15 14 1 13 5 18 215 100 40 34 50 10 5 12 a UD, undetectable\
        \ binding.///Receptors [3H]BK Kd nM 125 I-HPP-HOE 140 Kd IP BK Ki nM EC50\
        \ nM Emax % of WT WT F259A T263A F259A, T263A N113A N113A, F259A N113A, T263A\
        \ W256A W256F W256Q F259H W256A, F259H W256F, F259H W256Q, F259H 0.53 0.05\
        \ UDa UD UD 0.27 0.12 7.00 0.8 1.55 0.20 1.00 0.21 0.52 0.18 0.41 0.15 UD\
        \ 0.22 0.28 0.15 0.37 0.29 1.08 0.28 0.40 0.23 0.33 0.17 0.48 0.52 0.32 0.15\
        \ 0.11 0.08 0.18 0.09 0.25 0.12 0.10 0.15 0.15 0.08 0.05 0.17 0.07 0.70 70\
        \ 1.40 300 0.15 142 174 0.50 15 25 35 0.05 2 50 0.19 31 0.20 7.00 0.39 0.21\
        \ 0.22 300 60 3.10 3.10 0.04 7 0.12 1.50 0.13 0.06 0.04 100 10 1.20 0.77 100\
        \ 78 3 195 315 114 160 168 60 105 167 146 50 50 19 15 14 1 13 5 18 215 100\
        \ 40 34 50 10 5 12 a UD, undetectable binding.///Moreover the simultaneous\
        \ Ala mutation of Tyr295, Trp256, and Phe259 drastically affected the maximal\
        \ BK stimulated IP production, which was not observed for the W256A,F259A\
        \ double mutant despite decreased BK potency (not shown).///It was corroborated\
        \ by the fact that the N113A,F259A (and also N113A,T263A) double mutant displayed\
        \ striking increases in BK affinity or potency for IP production as compared\
        \ with the F259A single mutant (Table II), indicating that the Asn113 mutation\
        \ is also able to favor some other molecular events which are mediated by\
        \ the Phe259-BK (and Thr263-BK) interaction.///It was corroborated by the\
        \ fact that the N113A,F259A (and also N113A,T263A) double mutant displayed\
        \ striking increases in BK affinity or potency for IP production as compared\
        \ with the F259A single mutant (Table II), indicating that the Asn113 mutation\
        \ is also able to favor some other molecular events which are mediated by\
        \ the Phe259-BK (and Thr263-BK) interaction.///Other experimental findings\
        \ are in favor of a concerted role of Asn113 and Phe259: the behavior of B2\
        \ receptors possessing either N113A and F259A mutations or N113A and T263A\
        \ mutations deserves a comment: the properties of these double mutants revealed\
        \ a discrepancy between the BK Kd values determined by direct [3H]BK binding\
        \ (not possible in the single F259A and T263A mutants) and the Ki values evaluated\
        \ in competition binding assays using 125I-HPP-HOE 140 as tracer ligand (Table\
        \ II).///Other experimental findings are in favor of a concerted role of Asn113\
        \ and Phe259: the behavior of B2 receptors possessing either N113A and F259A\
        \ mutations or N113A and T263A mutations deserves a comment: the properties\
        \ of these double mutants revealed a discrepancy between the BK Kd values\
        \ determined by direct [3H]BK binding (not possible in the single F259A and\
        \ T263A mutants) and the Ki values evaluated in competition binding assays\
        \ using 125I-HPP-HOE 140 as tracer ligand (Table II).///While the F259H receptor\
        \ displayed properties similar to those of the F259A mutant, i.e. strongly\
        \ decreased affinity for BK (Table II) and no constitutive activation, the\
        \ F259H, W256F and F259H, W256Q receptors were constitutively activated, similarly\
        \ to the single Phe256 and Gln256 mutants (not shown) and the EC50 for BK\
        \ stimulation were dramatically decreased as compared with the W256H receptor\
        \ (these effects were much less pronounced for the F259H, W256A receptor,\
        \ which was not constitutively activated) (Table II).///The lack of constitutive\
        \ activation of the W256A,F259A double mutant might result from the preservation\
        \ or reinforcement of the Asn113-Tyr295 interaction.", pubmed: '11495910',
    seq: '259', to_res: A}
- {entry_name: agtr1_human, from_res: W, info: 'The experimental supports can be summarized
        as follows: receptor inactivation upon Y292F (15), W253F (5), and H256A mutations
        (5, 16); strong constitutive activation upon Asn111 mutations (6, 17); detailed
        analysis of the induction of intermediary or activated conformations (17,
        18).', pubmed: '11495910', seq: '253', to_res: F}
- {entry_name: acm5_human, from_res: N, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '48', to_res: A}
- {entry_name: bkrb2_human, from_res: M, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '165', to_res: A}
- {entry_name: agtr1_human, from_res: F, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '206', to_res: A}
- {entry_name: ccr4_canfa, from_res: Y, info: "This compound\u2019s binding is affected\
        \ by mutations K320A, Y314A in the C-terminal tail and D84N (2.40) in TM2.71\
        \ A similar binding site has been identified for other CXCR2 antagonists34\
        \ and is also thought to exist in CCR4 and CCR5 receptors.72 The CXCR4 structure\
        \ gives insight into how non-peptide antagonist ligands can block the activity\
        \ of the much larger peptide agonist CXCL12.", pubmed: '21593763', seq: '314',
    to_res: A}
- {entry_name: opsd_bovin, from_res: S, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '298', to_res: A}
- {entry_name: bkrb2_human, from_res: M, info: "Receptors TM [3H]BK Kd nM 125 LF 16\u2013\
        0335 I-HPP-HOE 140 Kd nM Ki nM Ki mut/Ki wt LF 16\u20130687 Ki nM WT N48A\
        \ D76A D76N N92A S111A S111K N113A Y115A Y115F S116A S117A F120A M165A M165T\
        \ N198A N202A F206A F252A C255A C255S W256A W256F W256Q P258A F259A Q260A\
        \ Q260H S262A S262F T263A F264A D284A T287A T287L Q288A S291A F292A F292Y\
        \ Y295A Y295F S296A N297A S298A N301A N301D I II II II III III III III III\
        \ III III III IV IV V V V VI VI VI VI VI VI VI VI VI VI VI VI VI VI VII VII\
        \ VII VII VII VII VII VII VII VII VII VII VII VII 0.51 0.39 0.40 1.00 0.86\
        \ 1.51 2.58 0.27 1.25 1.15 0.30 0.70 0.42 0.52 0.44 0.30 0.24 0.53 0.20 0.09\
        \ 0.12 0.52 0.15 0.4 1.40 0.12 0.21 0.35 0.05 0.12 0.11 0.04 0.11 0.04 0.12\
        \ 0.08 0.28 0.31 0.12 0.18 0.57 0.36 0.67 0.20 0.38 0.31 0.20 0.06 0.27 0.45\
        \ 0.33 2.20 0.50 1.00 0.56 0.50 0.32 0.32 0.28 0.38 0.31 0.32 0.17 0.15 0.35\
        \ 1.4 0.62 0.27 1.90 0.66 0.37 2.7 0.48 0.16 0.01 0.08 0.07 0.06 0.04 0.07\
        \ 0.09 0.04 0.06 0.01 0.01 0.03 0.12 0.05 0.80 0.12 0.25 0.12 0.16 0.13 0.07\
        \ 0.05 0.08 0.11 0.10 0.05 0.06 0.13 0.70 0.32 0.06 0.40 0.20 0.12 0.70 0.15\
        \ 1.08 1.60 0.84 1.05 2.11 1.4 2.8 0.62 1.60 0.62 1.17 1.90 0.47 3.99 1.72\
        \ 1.00 1.91 2.60 7.34 3.24 4.32 1.15 2.56 2.70 1.81 2.34 1.00 2.47 1.86 16.2\
        \ 1.40 25.0 7.80 2.31 1.83 1.71 0.97 0.53 0.25 0.28 0.07 0.85 0.50 1.22 0.12\
        \ 0.52 0.34 0.08 0.92 0.62 1.10 0.95 0.15 0.55 0.85 1.33 1.88 0.55 0.06 0.95\
        \ 0.82 0.65 0.77 0.12 1.25 0.86 0.9 0.52 5.5 4.90 3.10 0.72 0.75 0.11 1 1.47\
        \ 0.77 0.97 1.94 1.29 2.59 0.57 1.47 0.57 1.08 1.75 0.43 3.7 1.60 0.92 1.75\
        \ 2.30 6.8 3.00 4 1.06 2.30 2.50 1.67 2.16 0.92 2.30 1.71 15 1.29 23.5 7.2\
        \ 2.1 1.7 1.6 0.9 0.45 0.29 Downloaded from www.jbc.org by guest, on September\
        \ 5, 2011 0.35 2.60 0.75 0.04 0.52 0.15 0.21 0.07 1.09 1.40 1.00 0.21 0.52\
        \ 0.18 0.41 0.15 1.21 0.12 80 14a 0.55 0.11 0.45 0.01 1.92 0.94 1.44 0.25\
        \ 170 42a 0.41 0.13 4.40 0.88 0.62 3.45 0.30 0.61 0.15 0.12 0.50 0.15 0.53\
        \ 0.54 2.94 0.70 1.09 0.05 0.04 0.40 0.08 0.64 1.17 0.18 4.20 0.35 0.02 1.80\
        \ 0.62 0.22 4.70 1.10 0.35 0.07 0.38 0.17 UDb 0.18 0.05 0.78 0.15 0.25 0.08\
        \ 0.52 0.27 0.07 42.9 11.5 3.78 0.45 UD 0.51 0.25 0.50 .28 0.24 0.05 a b Determined\
        \ using [3H]BK as tracer ligand.", pubmed: '11495910', seq: '165', to_res: T}
- {entry_name: aa3r_human, from_res: H, info: 'However, a polar interaction between
        side chains at these positions may be a minimum condition for the integrity
        of the binding site, as a His7.43Ala mutant yields no detectable agonist or
        antagonist binding.88 Finally, it should be noted that a Glu1.39Gln mutant
        has little effect on agonist binding, which is more affected by a His7.43Tyr
        mutation,78 which led to the idea of position 7.43 interacting with the ribose
        moiety,79 recently confirmed by the crystal structure of the agonist-bound
        A2AAR.86 Altogether, these data support a polar interaction between the aforementioned
        positions in TM1 and TM7, which is presented as a weak, intermittent interaction
        according to our MD simulations (Figure 3C, simulations R1, R2, R10 , and
        R20 ), allowing a gradual separation of TM1 and TM7 that could be related
        to the conformational equilibrium of the receptor.', pubmed: '21480628', seq: '272',
    to_res: A}
- {entry_name: aa3r_human, from_res: H, info: 'However, a polar interaction between
        side chains at these positions may be a minimum condition for the integrity
        of the binding site, as a His7.43Ala mutant yields no detectable agonist or
        antagonist binding.88 Finally, it should be noted that a Glu1.39Gln mutant
        has little effect on agonist binding, which is more affected by a His7.43Tyr
        mutation,78 which led to the idea of position 7.43 interacting with the ribose
        moiety,79 recently confirmed by the crystal structure of the agonist-bound
        A2AAR.86 Altogether, these data support a polar interaction between the aforementioned
        positions in TM1 and TM7, which is presented as a weak, intermittent interaction
        according to our MD simulations (Figure 3C, simulations R1, R2, R10 , and
        R20 ), allowing a gradual separation of TM1 and TM7 that could be related
        to the conformational equilibrium of the receptor.', pubmed: '21480628', seq: '272',
    to_res: Y}
- {entry_name: aa3r_human, from_res: E, info: 'However, a polar interaction between
        side chains at these positions may be a minimum condition for the integrity
        of the binding site, as a His7.43Ala mutant yields no detectable agonist or
        antagonist binding.88 Finally, it should be noted that a Glu1.39Gln mutant
        has little effect on agonist binding, which is more affected by a His7.43Tyr
        mutation,78 which led to the idea of position 7.43 interacting with the ribose
        moiety,79 recently confirmed by the crystal structure of the agonist-bound
        A2AAR.86 Altogether, these data support a polar interaction between the aforementioned
        positions in TM1 and TM7, which is presented as a weak, intermittent interaction
        according to our MD simulations (Figure 3C, simulations R1, R2, R10 , and
        R20 ), allowing a gradual separation of TM1 and TM7 that could be related
        to the conformational equilibrium of the receptor.', pubmed: '21480628', seq: '19',
    to_res: Q}
- {entry_name: ada2a_human, from_res: R, info: "Hydrogen Bond Frequencies in the Structural\
        \ Motifs Depicted in Figures 2, 5, and 6 A2A hydrogen bond A2B RW1 R1 R2 a\
        \ R1 R2 TM1\xC0TM2\xC0TM6\xC0TM7b (Figure 2) N1.50\xC0S7.46 N1.50\xC0D2.50\
        \ D2.50\xC0S7.46 D2.50\xC0N7.49 N7.45\xC0N7.49 N7.45\xC0W6.48 N1.50\xC0N7.49\
        \ average pairsc 81.91% 0.64% 72.96% 20.66% 3.15% 0.00% 0.29% 1.80 70.88%\
        \ 0.84% 99.53% 95.06% 4.33% 0.00% 0.30% 2.71 67.93% 3.17% 99.04% 66.18% 0.16%\
        \ 0.03% 0.00% 2.37 70.67% 6.79% 59.05% 68.22% 6.68% 0.00% 0.85% 2.12 42.95%\
        \ 2.86% 48.40% 90.26% 0.00% 0.00% 4.58% 1.89 Ionic Lockd (Figure 5) D3.49\xC0\
        R3.50 e 100% 70.71% 99.10% 93.06% 3.63 100% 99.38% 81.50% 99.36% 3.80 99.99%\
        \ 81.51% 99.81% 99.66% 3.81 97.31% 99.38% 99.88% 61.25% 3.58 99.80% 98.86%\
        \ 99.92% 99.88% 3.98 E6.30\xC0R3.50e D3.49\xC0Y3.60 D3.49\xC0T2.39 average\
        \ pairsc Toggle Switchf (Figure 6) H6.52\xC0N5.42 H6.52\xC0N6.55 Q3.37\xC0\
        C5.46 Q3.37\xC0N5.42 average pairsc 8.78% 4.11% 94.22% 4.36% 1.11 1.25% 0.01%\
        \ 83.56% 0.01% 0.85 38.80% 0.19% 24.52% 3.11% 0.67 12.11% 1.43% 79.96% 62.01%\
        \ 1.56 40.61% 2.20% 95.46% 12.59% 1.51 Hydrogen bonding frequency computed\
        \ with the g_hbond utility in GROMACS, using the default parameters (cutoff\
        \ acceptor\xC0donor\xC0hydrogen angle of 30\xB0, cutoff acceptor\xC0donor\
        \ radius of 0.35 nm). b See Figure 2 for a representation of the polar interactions\
        \ depicted here.", pubmed: '21480628', seq: '131', to_res: E}
- {entry_name: opsd_bovin, from_res: R, info: Residues of the highly conserved E(D)R135Y
        and S., pubmed: '19447219', seq: '135', to_res: Y}
- {entry_name: t2r60_pantr, from_res: R, info: "Somatic mutations identified in the\
        \ Discovery, Prevalence and Validation Screens No. of mutations (% of tumors\
        \ Hete/Homo Sample Panel affected) Tumor Name Nucleotide Change Amino Acid\
        \ Change Type of Mutation CCDS number AKR1B10 CCDS5832.1 4 (7.7%) 91T G400A\
        \ G134R Nonsynonymous Homozygous Exome Capture 01T G691A D231N Nonsynonymous\
        \ Heterozygous Exome Capture 24T A730C T244P Nonsynonymous Heterozygous Exome\
        \ Capture 7T Exon 2 (-8) C/T N/A splice site Heterozygous Prevalence screen\
        \ TAS2R60 CCDS5885.1 5 (9.6%) 92T C272T P91L Nonsynonymous Homozygous Prevalence\
        \ screen 60T G429A W143* Stop Heterozygous Exome Capture 9T G449A G150E Nonsynonymous\
        \ Heterozygous Exome Capture 17T G639A M213I Nonsynonymous Heterozygous Prevalence\
        \ screen 43T G639A M213I Nonsynonymous Heterozygous Exome Capture KHDRBS2\
        \ CCDS4963.1 5 (9.6%) 119T T82A L28M Nonsynonymous Heterozygous Prevalence\
        \ screen 60T C178T L60F Nonsynonymous Heterozygous Exome Capture 91T C556T\
        \ R186C Nonsynonymous Heterozygous Exome Capture 05T C299T R224W Nonsynonymous\
        \ Homozygous Exome Capture 109T C733T P245S Nonsynonymous Heterozygous Prevalence\
        \ screen CCDS8675.1 4 (7.7%) 95T C838A S280Y Nonsynonymous Heterozygous Prevalence\
        \ screen PTPRO 60T C847T R283* Stop Heterozygous Exome Capture 12T G2560A\
        \ E854K Nonsynonymous Heterozygous Exome Capture 24T T2814G F938L Nonsynonymous\
        \ Heterozygous Exome Capture SYT4 CCDS11922.1 4 (7.7%) 43T G37A E13K Nonsynonymous\
        \ Heterozygous Exome Capture 22T G119A R40K Nonsynonymous Heterozygous Exome\
        \ Capture 12T G388A E130K Nonsynonymous Homozygous Exome Capture R384Q Nonsynonymous\
        \ Heterozygous Prevalence screen 119T G1151A UGT2B10 N/A 4 (7.7%) 12T C1177T\
        \ P393S Nonsynonymous Heterozygous Exome Capture 96T G1412A G471E Nonsynonymous\
        \ Heterozygous Exome Capture 60T A1586G *529W Nonsynonymous Heterozygous Exome\
        \ Capture 116T Exon 4 (-1) N/A Splice site Heterozygous Prevalence screen\
        \ SLC6A11 CCDS2602.1 3 (5.8%) 05T C660A H220Q Nonsynonymous Heterozygous Exome\
        \ Capture 12T G1084A E362K Nonsynonymous Heterozygous Exome Capture 51T G1435A\
        \ V479M Nonsynonymous Homozygous Exome Capture SLC17A5 CCDS4981.1 4 (5.8%)\
        \ 24T G776A S259F Nonsynonymous Heterozygous Exome Capture 24T G862A S288P\
        \ Nonsynonymous Heterozygous Exome Capture 12T C1090T R364C Nonsynonymous\
        \ Heterozygous Exome Capture 18T C1090T R364C Nonsynonymous Heterozygous Exome\
        \ Capture C12orf63 CCDS9062.1 6 (9.6%) 32T C62T S21F Nonsynonymous Heterozygous\
        \ Prevalence screen Exome Capture 91T C700T P234S Nonsynonymous Heterozygous\
        \ 12T G848A R283Q Nonsynonymous Heterozygous Exome Capture 125T G2857K E953K\
        \ Nonsynonymous Homozygous Prevalence screen 93T T3104C L1035P Nonsynonymous\
        \ Heterozygous Exome Capture 93T A3110G Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 CCDS4250.1 4 (7.7%) 12T G385A D129N Nonsynonymous Heterozygous\
        \ Exome Capture 18T A713G D238G Nonsynonymous Heterozygous Exome Capture 56T\
        \ G931A E311K Nonsynonymous Heterozygous Prevalence screen 22T G931A E311K\
        \ Nonsynonymous Homozygous Exome Capture ^Number of nonsynonymous, stop and\
        \ splice site mutations observed and percent of tumors affected for each of\
        \ the 15 genes in the panel of 52 untreated melanoma samples. ~\u2020 Number\
        \ of nonsynonymous, stop and splice site mutations observed and percent of\
        \ tumors affected for GRIN2A in validation set 1 and validation set 2 respectively.\
        \ * refers to stop codon.///SIFT analysis of somatic mutations identified\
        \ in highly mutated genes Amino Tumor Acid Hete/Homo Sample Panel Gene Name\
        \ Name Change Syn/NonSyn ZNF831 91T H453Y Nonsynonymous Heterozygous Exome\
        \ Capture ZNF831 96T T475M Nonsynonymous Heterozygous Exome Capture ZNF831\
        \ 86T T713R Nonsynonymous Heterozygous Prevalence screen ZNF831 64T R1077C\
        \ Nonsynonymous Heterozygous Prevalence screen ZNF831 90T S1319N Nonsynonymous\
        \ Heterozygous Prevalence screen ZNF831 81T S1357L Nonsynonymous Heterozygous\
        \ Prevalence screen ZNF831 43T S1474F Nonsynonymous Heterozygous Exome Capture\
        \ ZNF831 91T S1474F Nonsynonymous Heterozygous Exome Capture ZNF831 119T A1505V\
        \ Nonsynonymous Heterozygous Prevalence screen Exome Capture ZNF831 05T E1563K\
        \ Nonsynonymous Heterozygous PLCB4 12T L83P Nonsynonymous Heterozygous Exome\
        \ Capture PLCB4 91T P165L Nonsynonymous Heterozygous Exome Capture PLCB4 83T\
        \ R251Q Nonsynonymous Heterozygous Prevalence screen PLCB4 119T S342L Nonsynonymous\
        \ Heterozygous Prevalence screen PLCB4 84T D496N Nonsynonymous Heterozygous\
        \ Prevalence screen PLCB4 8T E737K Nonsynonymous Heterozygous Prevalence screen\
        \ PLCB4 01T R772W Nonsynonymous Heterozygous Exome Capture PLCB4 9T E1098K\
        \ Nonsynonymous Heterozygous Exome Capture AKR1B10 91T G134R Nonsynonymous\
        \ Homozygous Exome Capture AKR1B10 01T D231N Nonsynonymous Heterozygous Exome\
        \ Capture AKR1B10 24T T244P Nonsynonymous Heterozygous Exome Capture AKR1B10\
        \ 7T splice site Heterozygous Prevalence screen TAS2R60 92T P91L Nonsynonymous\
        \ Homozygous Prevalence screen TAS2R60 60T Stop Heterozygous Exome Capture\
        \ TAS2R60 9T G150E Nonsynonymous Heterozygous Exome Capture TAS2R60 17T M213I\
        \ Nonsynonymous Heterozygous Prevalence screen TAS2R60 43T M213I Nonsynonymous\
        \ Heterozygous Exome Capture KHDRBS2 119T L28M Nonsynonymous Heterozygous\
        \ Prevalence screen KHDRBS2 60T L60F Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture KHDRBS2 91T R186C Nonsynonymous Heterozygous KHDRBS2 05T R224W\
        \ Nonsynonymous Homozygous Exome Capture KHDRBS2 109T P245S Nonsynonymous\
        \ Heterozygous Prevalence screen PTPRO 12T E854K Nonsynonymous Heterozygous\
        \ Exome Capture PTPRO 24T F938L Nonsynonymous Heterozygous Exome Capture PTPRO\
        \ 95T S280Y Nonsynonymous Heterozygous Prevalence screen PTPRO 60T Stop Heterozygous\
        \ Exome Capture SYT4 43T E13K Nonsynonymous Heterozygous Exome Capture SYT4\
        \ 22T R40K Nonsynonymous Heterozygous Exome Capture SYT4 12T E130K Nonsynonymous\
        \ Homozygous Exome Capture SYT4 119T R384Q Nonsynonymous Heterozygous Prevalence\
        \ screen UGT2B10 12T P393S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture UGT2B10 96T G471E Nonsynonymous Heterozygous UGT2B10 60T *529W Nonsynonymous\
        \ Heterozygous Exome Capture UGT2B10 116T Splice site Heterozygous Prevalence\
        \ screen SLC6A11 05T H220Q Nonsynonymous Heterozygous Exome Capture SLC6A11\
        \ 12T E362K Nonsynonymous Heterozygous Exome Capture SLC6A11 51T V479M Nonsynonymous\
        \ Homozygous Exome Capture C12orf63 32T S21F Nonsynonymous Heterozygous Prevalence\
        \ screen C12orf63 91T P234S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture C12orf63 12T R283Q Nonsynonymous Heterozygous C12orf63 125T E953K\
        \ Nonsynonymous Homozygous Prevalence screen C12orf63 93T L1035P Nonsynonymous\
        \ Heterozygous Exome Capture C12orf63 93T Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 12T D129N Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture PCDHB8 18T D238G Nonsynonymous Heterozygous PCDHB8 56T E311K\
        \ Nonsynonymous Heterozygous Prevalence screen PCDHB8 22T E311K Nonsynonymous\
        \ Homozygous Exome Capture SLC17A5 24T S259F Nonsynonymous Heterozygous Exome\
        \ Capture SLC17A5 24T S288P Nonsynonymous Heterozygous Exome Capture SLC17A5\
        \ 12T R364C Nonsynonymous Heterozygous Exome Capture SLC17A5 18T R364C Nonsynonymous\
        \ Heterozygous Exome Capture Alterations with a SIFT score highlighted in\
        \ red are predicted to affect protein function.///N/A, not applicable Functional\
        \ Domain No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered PI-PLC-X No domain altered C2 No domain altered No domain\
        \ altered Aldo_ket_red Aldo_ket_red Aldo_ket_red No domain altered 7tm_1 No\
        \ domain altered 7tm_1 7tm_1 7tm_1 No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered C2 UDPGT UDPGT No domain altered No domain\
        \ altered SNF SNF SNF No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered Cadherin Cadherin MFS_1 Sugar_tr MFS_1 MFS_1 change H453Y\
        \ T475M T713R R1077C S1319N S1357L S1474F S1474F A1505V E1563K L83P P165L\
        \ R251Q S342L D496N E737K R772W E1098K G134R D231N T244P splice site P91L\
        \ Stop G150E M213I M213I L28M L60F R186C R224W P245S E854K F938L S280Y Stop\
        \ E13K R40K E130K R384Q P393S G471E Splice site H220Q E362K V479M S21F P234S\
        \ R283Q E953K L1035P Q1037R D129N D238G E311K E311K S259F S288P R364C R364C\
        \ SIFT score 0.04 0 0.61 0.22 0.36 0.17 0.74 0.74 0.2 0.87 0.02 0 0 0 0.28\
        \ 0.85 0.09 0.33 0.01 0.08 0 N/A 1 N/A 0.02 1 1 0.01 0.01 0.12 0.01 0.03 0.57\
        \ 0.1 0 N/A 0.05 0.04 0.3 0.02 0 0 N/A N/A 0.16 0.35 0.16 0.07 0.8 0.29 0.13\
        \ 0 0.33 0 0 0 0 0 0 0 0 SIFT median 2.3 2.19 2.04 2.12 2.35 2.53 2.48 2.48\
        \ 2.33 2.42 2.79 2.79 2.79 2.79 2.77 2.77 2.12 2.4 2.84 2.84 2.84 N /A 2.89\
        \ N /A 2.86 2.86 2.86 2.8 2.78 2.85 2.91 2.91 2.27 1.96 3.32 N /A 3.37 3.11\
        \ 2.84 2.78 2.73 2.73 N /A N /A 2.74 2.74 2.74 3.09 3.36 3.12 2.72 4.32 3.12\
        \ 2.83 2.83 2.83 2.83 2.76 2.77 2.76 2.76 Nature Genetics: doi:10.1038/ng.810\
        \ 12 Supplementary Table 6.", pubmed: '21499247', seq: '186', to_res: C}
- {entry_name: t2r60_pantr, from_res: G, info: "Somatic mutations identified in the\
        \ Discovery, Prevalence and Validation Screens No. of mutations (% of tumors\
        \ Hete/Homo Sample Panel affected) Tumor Name Nucleotide Change Amino Acid\
        \ Change Type of Mutation CCDS number AKR1B10 CCDS5832.1 4 (7.7%) 91T G400A\
        \ G134R Nonsynonymous Homozygous Exome Capture 01T G691A D231N Nonsynonymous\
        \ Heterozygous Exome Capture 24T A730C T244P Nonsynonymous Heterozygous Exome\
        \ Capture 7T Exon 2 (-8) C/T N/A splice site Heterozygous Prevalence screen\
        \ TAS2R60 CCDS5885.1 5 (9.6%) 92T C272T P91L Nonsynonymous Homozygous Prevalence\
        \ screen 60T G429A W143* Stop Heterozygous Exome Capture 9T G449A G150E Nonsynonymous\
        \ Heterozygous Exome Capture 17T G639A M213I Nonsynonymous Heterozygous Prevalence\
        \ screen 43T G639A M213I Nonsynonymous Heterozygous Exome Capture KHDRBS2\
        \ CCDS4963.1 5 (9.6%) 119T T82A L28M Nonsynonymous Heterozygous Prevalence\
        \ screen 60T C178T L60F Nonsynonymous Heterozygous Exome Capture 91T C556T\
        \ R186C Nonsynonymous Heterozygous Exome Capture 05T C299T R224W Nonsynonymous\
        \ Homozygous Exome Capture 109T C733T P245S Nonsynonymous Heterozygous Prevalence\
        \ screen CCDS8675.1 4 (7.7%) 95T C838A S280Y Nonsynonymous Heterozygous Prevalence\
        \ screen PTPRO 60T C847T R283* Stop Heterozygous Exome Capture 12T G2560A\
        \ E854K Nonsynonymous Heterozygous Exome Capture 24T T2814G F938L Nonsynonymous\
        \ Heterozygous Exome Capture SYT4 CCDS11922.1 4 (7.7%) 43T G37A E13K Nonsynonymous\
        \ Heterozygous Exome Capture 22T G119A R40K Nonsynonymous Heterozygous Exome\
        \ Capture 12T G388A E130K Nonsynonymous Homozygous Exome Capture R384Q Nonsynonymous\
        \ Heterozygous Prevalence screen 119T G1151A UGT2B10 N/A 4 (7.7%) 12T C1177T\
        \ P393S Nonsynonymous Heterozygous Exome Capture 96T G1412A G471E Nonsynonymous\
        \ Heterozygous Exome Capture 60T A1586G *529W Nonsynonymous Heterozygous Exome\
        \ Capture 116T Exon 4 (-1) N/A Splice site Heterozygous Prevalence screen\
        \ SLC6A11 CCDS2602.1 3 (5.8%) 05T C660A H220Q Nonsynonymous Heterozygous Exome\
        \ Capture 12T G1084A E362K Nonsynonymous Heterozygous Exome Capture 51T G1435A\
        \ V479M Nonsynonymous Homozygous Exome Capture SLC17A5 CCDS4981.1 4 (5.8%)\
        \ 24T G776A S259F Nonsynonymous Heterozygous Exome Capture 24T G862A S288P\
        \ Nonsynonymous Heterozygous Exome Capture 12T C1090T R364C Nonsynonymous\
        \ Heterozygous Exome Capture 18T C1090T R364C Nonsynonymous Heterozygous Exome\
        \ Capture C12orf63 CCDS9062.1 6 (9.6%) 32T C62T S21F Nonsynonymous Heterozygous\
        \ Prevalence screen Exome Capture 91T C700T P234S Nonsynonymous Heterozygous\
        \ 12T G848A R283Q Nonsynonymous Heterozygous Exome Capture 125T G2857K E953K\
        \ Nonsynonymous Homozygous Prevalence screen 93T T3104C L1035P Nonsynonymous\
        \ Heterozygous Exome Capture 93T A3110G Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 CCDS4250.1 4 (7.7%) 12T G385A D129N Nonsynonymous Heterozygous\
        \ Exome Capture 18T A713G D238G Nonsynonymous Heterozygous Exome Capture 56T\
        \ G931A E311K Nonsynonymous Heterozygous Prevalence screen 22T G931A E311K\
        \ Nonsynonymous Homozygous Exome Capture ^Number of nonsynonymous, stop and\
        \ splice site mutations observed and percent of tumors affected for each of\
        \ the 15 genes in the panel of 52 untreated melanoma samples. ~\u2020 Number\
        \ of nonsynonymous, stop and splice site mutations observed and percent of\
        \ tumors affected for GRIN2A in validation set 1 and validation set 2 respectively.\
        \ * refers to stop codon.///SIFT analysis of somatic mutations identified\
        \ in highly mutated genes Amino Tumor Acid Hete/Homo Sample Panel Gene Name\
        \ Name Change Syn/NonSyn ZNF831 91T H453Y Nonsynonymous Heterozygous Exome\
        \ Capture ZNF831 96T T475M Nonsynonymous Heterozygous Exome Capture ZNF831\
        \ 86T T713R Nonsynonymous Heterozygous Prevalence screen ZNF831 64T R1077C\
        \ Nonsynonymous Heterozygous Prevalence screen ZNF831 90T S1319N Nonsynonymous\
        \ Heterozygous Prevalence screen ZNF831 81T S1357L Nonsynonymous Heterozygous\
        \ Prevalence screen ZNF831 43T S1474F Nonsynonymous Heterozygous Exome Capture\
        \ ZNF831 91T S1474F Nonsynonymous Heterozygous Exome Capture ZNF831 119T A1505V\
        \ Nonsynonymous Heterozygous Prevalence screen Exome Capture ZNF831 05T E1563K\
        \ Nonsynonymous Heterozygous PLCB4 12T L83P Nonsynonymous Heterozygous Exome\
        \ Capture PLCB4 91T P165L Nonsynonymous Heterozygous Exome Capture PLCB4 83T\
        \ R251Q Nonsynonymous Heterozygous Prevalence screen PLCB4 119T S342L Nonsynonymous\
        \ Heterozygous Prevalence screen PLCB4 84T D496N Nonsynonymous Heterozygous\
        \ Prevalence screen PLCB4 8T E737K Nonsynonymous Heterozygous Prevalence screen\
        \ PLCB4 01T R772W Nonsynonymous Heterozygous Exome Capture PLCB4 9T E1098K\
        \ Nonsynonymous Heterozygous Exome Capture AKR1B10 91T G134R Nonsynonymous\
        \ Homozygous Exome Capture AKR1B10 01T D231N Nonsynonymous Heterozygous Exome\
        \ Capture AKR1B10 24T T244P Nonsynonymous Heterozygous Exome Capture AKR1B10\
        \ 7T splice site Heterozygous Prevalence screen TAS2R60 92T P91L Nonsynonymous\
        \ Homozygous Prevalence screen TAS2R60 60T Stop Heterozygous Exome Capture\
        \ TAS2R60 9T G150E Nonsynonymous Heterozygous Exome Capture TAS2R60 17T M213I\
        \ Nonsynonymous Heterozygous Prevalence screen TAS2R60 43T M213I Nonsynonymous\
        \ Heterozygous Exome Capture KHDRBS2 119T L28M Nonsynonymous Heterozygous\
        \ Prevalence screen KHDRBS2 60T L60F Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture KHDRBS2 91T R186C Nonsynonymous Heterozygous KHDRBS2 05T R224W\
        \ Nonsynonymous Homozygous Exome Capture KHDRBS2 109T P245S Nonsynonymous\
        \ Heterozygous Prevalence screen PTPRO 12T E854K Nonsynonymous Heterozygous\
        \ Exome Capture PTPRO 24T F938L Nonsynonymous Heterozygous Exome Capture PTPRO\
        \ 95T S280Y Nonsynonymous Heterozygous Prevalence screen PTPRO 60T Stop Heterozygous\
        \ Exome Capture SYT4 43T E13K Nonsynonymous Heterozygous Exome Capture SYT4\
        \ 22T R40K Nonsynonymous Heterozygous Exome Capture SYT4 12T E130K Nonsynonymous\
        \ Homozygous Exome Capture SYT4 119T R384Q Nonsynonymous Heterozygous Prevalence\
        \ screen UGT2B10 12T P393S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture UGT2B10 96T G471E Nonsynonymous Heterozygous UGT2B10 60T *529W Nonsynonymous\
        \ Heterozygous Exome Capture UGT2B10 116T Splice site Heterozygous Prevalence\
        \ screen SLC6A11 05T H220Q Nonsynonymous Heterozygous Exome Capture SLC6A11\
        \ 12T E362K Nonsynonymous Heterozygous Exome Capture SLC6A11 51T V479M Nonsynonymous\
        \ Homozygous Exome Capture C12orf63 32T S21F Nonsynonymous Heterozygous Prevalence\
        \ screen C12orf63 91T P234S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture C12orf63 12T R283Q Nonsynonymous Heterozygous C12orf63 125T E953K\
        \ Nonsynonymous Homozygous Prevalence screen C12orf63 93T L1035P Nonsynonymous\
        \ Heterozygous Exome Capture C12orf63 93T Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 12T D129N Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture PCDHB8 18T D238G Nonsynonymous Heterozygous PCDHB8 56T E311K\
        \ Nonsynonymous Heterozygous Prevalence screen PCDHB8 22T E311K Nonsynonymous\
        \ Homozygous Exome Capture SLC17A5 24T S259F Nonsynonymous Heterozygous Exome\
        \ Capture SLC17A5 24T S288P Nonsynonymous Heterozygous Exome Capture SLC17A5\
        \ 12T R364C Nonsynonymous Heterozygous Exome Capture SLC17A5 18T R364C Nonsynonymous\
        \ Heterozygous Exome Capture Alterations with a SIFT score highlighted in\
        \ red are predicted to affect protein function.///N/A, not applicable Functional\
        \ Domain No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered PI-PLC-X No domain altered C2 No domain altered No domain\
        \ altered Aldo_ket_red Aldo_ket_red Aldo_ket_red No domain altered 7tm_1 No\
        \ domain altered 7tm_1 7tm_1 7tm_1 No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered C2 UDPGT UDPGT No domain altered No domain\
        \ altered SNF SNF SNF No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered Cadherin Cadherin MFS_1 Sugar_tr MFS_1 MFS_1 change H453Y\
        \ T475M T713R R1077C S1319N S1357L S1474F S1474F A1505V E1563K L83P P165L\
        \ R251Q S342L D496N E737K R772W E1098K G134R D231N T244P splice site P91L\
        \ Stop G150E M213I M213I L28M L60F R186C R224W P245S E854K F938L S280Y Stop\
        \ E13K R40K E130K R384Q P393S G471E Splice site H220Q E362K V479M S21F P234S\
        \ R283Q E953K L1035P Q1037R D129N D238G E311K E311K S259F S288P R364C R364C\
        \ SIFT score 0.04 0 0.61 0.22 0.36 0.17 0.74 0.74 0.2 0.87 0.02 0 0 0 0.28\
        \ 0.85 0.09 0.33 0.01 0.08 0 N/A 1 N/A 0.02 1 1 0.01 0.01 0.12 0.01 0.03 0.57\
        \ 0.1 0 N/A 0.05 0.04 0.3 0.02 0 0 N/A N/A 0.16 0.35 0.16 0.07 0.8 0.29 0.13\
        \ 0 0.33 0 0 0 0 0 0 0 0 SIFT median 2.3 2.19 2.04 2.12 2.35 2.53 2.48 2.48\
        \ 2.33 2.42 2.79 2.79 2.79 2.79 2.77 2.77 2.12 2.4 2.84 2.84 2.84 N /A 2.89\
        \ N /A 2.86 2.86 2.86 2.8 2.78 2.85 2.91 2.91 2.27 1.96 3.32 N /A 3.37 3.11\
        \ 2.84 2.78 2.73 2.73 N /A N /A 2.74 2.74 2.74 3.09 3.36 3.12 2.72 4.32 3.12\
        \ 2.83 2.83 2.83 2.83 2.76 2.77 2.76 2.76 Nature Genetics: doi:10.1038/ng.810\
        \ 12 Supplementary Table 6.", pubmed: '21499247', seq: '150', to_res: E}
- {entry_name: t2r60_pantr, from_res: P, info: "Somatic mutations identified in the\
        \ Discovery, Prevalence and Validation Screens No. of mutations (% of tumors\
        \ Hete/Homo Sample Panel affected) Tumor Name Nucleotide Change Amino Acid\
        \ Change Type of Mutation CCDS number AKR1B10 CCDS5832.1 4 (7.7%) 91T G400A\
        \ G134R Nonsynonymous Homozygous Exome Capture 01T G691A D231N Nonsynonymous\
        \ Heterozygous Exome Capture 24T A730C T244P Nonsynonymous Heterozygous Exome\
        \ Capture 7T Exon 2 (-8) C/T N/A splice site Heterozygous Prevalence screen\
        \ TAS2R60 CCDS5885.1 5 (9.6%) 92T C272T P91L Nonsynonymous Homozygous Prevalence\
        \ screen 60T G429A W143* Stop Heterozygous Exome Capture 9T G449A G150E Nonsynonymous\
        \ Heterozygous Exome Capture 17T G639A M213I Nonsynonymous Heterozygous Prevalence\
        \ screen 43T G639A M213I Nonsynonymous Heterozygous Exome Capture KHDRBS2\
        \ CCDS4963.1 5 (9.6%) 119T T82A L28M Nonsynonymous Heterozygous Prevalence\
        \ screen 60T C178T L60F Nonsynonymous Heterozygous Exome Capture 91T C556T\
        \ R186C Nonsynonymous Heterozygous Exome Capture 05T C299T R224W Nonsynonymous\
        \ Homozygous Exome Capture 109T C733T P245S Nonsynonymous Heterozygous Prevalence\
        \ screen CCDS8675.1 4 (7.7%) 95T C838A S280Y Nonsynonymous Heterozygous Prevalence\
        \ screen PTPRO 60T C847T R283* Stop Heterozygous Exome Capture 12T G2560A\
        \ E854K Nonsynonymous Heterozygous Exome Capture 24T T2814G F938L Nonsynonymous\
        \ Heterozygous Exome Capture SYT4 CCDS11922.1 4 (7.7%) 43T G37A E13K Nonsynonymous\
        \ Heterozygous Exome Capture 22T G119A R40K Nonsynonymous Heterozygous Exome\
        \ Capture 12T G388A E130K Nonsynonymous Homozygous Exome Capture R384Q Nonsynonymous\
        \ Heterozygous Prevalence screen 119T G1151A UGT2B10 N/A 4 (7.7%) 12T C1177T\
        \ P393S Nonsynonymous Heterozygous Exome Capture 96T G1412A G471E Nonsynonymous\
        \ Heterozygous Exome Capture 60T A1586G *529W Nonsynonymous Heterozygous Exome\
        \ Capture 116T Exon 4 (-1) N/A Splice site Heterozygous Prevalence screen\
        \ SLC6A11 CCDS2602.1 3 (5.8%) 05T C660A H220Q Nonsynonymous Heterozygous Exome\
        \ Capture 12T G1084A E362K Nonsynonymous Heterozygous Exome Capture 51T G1435A\
        \ V479M Nonsynonymous Homozygous Exome Capture SLC17A5 CCDS4981.1 4 (5.8%)\
        \ 24T G776A S259F Nonsynonymous Heterozygous Exome Capture 24T G862A S288P\
        \ Nonsynonymous Heterozygous Exome Capture 12T C1090T R364C Nonsynonymous\
        \ Heterozygous Exome Capture 18T C1090T R364C Nonsynonymous Heterozygous Exome\
        \ Capture C12orf63 CCDS9062.1 6 (9.6%) 32T C62T S21F Nonsynonymous Heterozygous\
        \ Prevalence screen Exome Capture 91T C700T P234S Nonsynonymous Heterozygous\
        \ 12T G848A R283Q Nonsynonymous Heterozygous Exome Capture 125T G2857K E953K\
        \ Nonsynonymous Homozygous Prevalence screen 93T T3104C L1035P Nonsynonymous\
        \ Heterozygous Exome Capture 93T A3110G Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 CCDS4250.1 4 (7.7%) 12T G385A D129N Nonsynonymous Heterozygous\
        \ Exome Capture 18T A713G D238G Nonsynonymous Heterozygous Exome Capture 56T\
        \ G931A E311K Nonsynonymous Heterozygous Prevalence screen 22T G931A E311K\
        \ Nonsynonymous Homozygous Exome Capture ^Number of nonsynonymous, stop and\
        \ splice site mutations observed and percent of tumors affected for each of\
        \ the 15 genes in the panel of 52 untreated melanoma samples. ~\u2020 Number\
        \ of nonsynonymous, stop and splice site mutations observed and percent of\
        \ tumors affected for GRIN2A in validation set 1 and validation set 2 respectively.\
        \ * refers to stop codon.///SIFT analysis of somatic mutations identified\
        \ in highly mutated genes Amino Tumor Acid Hete/Homo Sample Panel Gene Name\
        \ Name Change Syn/NonSyn ZNF831 91T H453Y Nonsynonymous Heterozygous Exome\
        \ Capture ZNF831 96T T475M Nonsynonymous Heterozygous Exome Capture ZNF831\
        \ 86T T713R Nonsynonymous Heterozygous Prevalence screen ZNF831 64T R1077C\
        \ Nonsynonymous Heterozygous Prevalence screen ZNF831 90T S1319N Nonsynonymous\
        \ Heterozygous Prevalence screen ZNF831 81T S1357L Nonsynonymous Heterozygous\
        \ Prevalence screen ZNF831 43T S1474F Nonsynonymous Heterozygous Exome Capture\
        \ ZNF831 91T S1474F Nonsynonymous Heterozygous Exome Capture ZNF831 119T A1505V\
        \ Nonsynonymous Heterozygous Prevalence screen Exome Capture ZNF831 05T E1563K\
        \ Nonsynonymous Heterozygous PLCB4 12T L83P Nonsynonymous Heterozygous Exome\
        \ Capture PLCB4 91T P165L Nonsynonymous Heterozygous Exome Capture PLCB4 83T\
        \ R251Q Nonsynonymous Heterozygous Prevalence screen PLCB4 119T S342L Nonsynonymous\
        \ Heterozygous Prevalence screen PLCB4 84T D496N Nonsynonymous Heterozygous\
        \ Prevalence screen PLCB4 8T E737K Nonsynonymous Heterozygous Prevalence screen\
        \ PLCB4 01T R772W Nonsynonymous Heterozygous Exome Capture PLCB4 9T E1098K\
        \ Nonsynonymous Heterozygous Exome Capture AKR1B10 91T G134R Nonsynonymous\
        \ Homozygous Exome Capture AKR1B10 01T D231N Nonsynonymous Heterozygous Exome\
        \ Capture AKR1B10 24T T244P Nonsynonymous Heterozygous Exome Capture AKR1B10\
        \ 7T splice site Heterozygous Prevalence screen TAS2R60 92T P91L Nonsynonymous\
        \ Homozygous Prevalence screen TAS2R60 60T Stop Heterozygous Exome Capture\
        \ TAS2R60 9T G150E Nonsynonymous Heterozygous Exome Capture TAS2R60 17T M213I\
        \ Nonsynonymous Heterozygous Prevalence screen TAS2R60 43T M213I Nonsynonymous\
        \ Heterozygous Exome Capture KHDRBS2 119T L28M Nonsynonymous Heterozygous\
        \ Prevalence screen KHDRBS2 60T L60F Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture KHDRBS2 91T R186C Nonsynonymous Heterozygous KHDRBS2 05T R224W\
        \ Nonsynonymous Homozygous Exome Capture KHDRBS2 109T P245S Nonsynonymous\
        \ Heterozygous Prevalence screen PTPRO 12T E854K Nonsynonymous Heterozygous\
        \ Exome Capture PTPRO 24T F938L Nonsynonymous Heterozygous Exome Capture PTPRO\
        \ 95T S280Y Nonsynonymous Heterozygous Prevalence screen PTPRO 60T Stop Heterozygous\
        \ Exome Capture SYT4 43T E13K Nonsynonymous Heterozygous Exome Capture SYT4\
        \ 22T R40K Nonsynonymous Heterozygous Exome Capture SYT4 12T E130K Nonsynonymous\
        \ Homozygous Exome Capture SYT4 119T R384Q Nonsynonymous Heterozygous Prevalence\
        \ screen UGT2B10 12T P393S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture UGT2B10 96T G471E Nonsynonymous Heterozygous UGT2B10 60T *529W Nonsynonymous\
        \ Heterozygous Exome Capture UGT2B10 116T Splice site Heterozygous Prevalence\
        \ screen SLC6A11 05T H220Q Nonsynonymous Heterozygous Exome Capture SLC6A11\
        \ 12T E362K Nonsynonymous Heterozygous Exome Capture SLC6A11 51T V479M Nonsynonymous\
        \ Homozygous Exome Capture C12orf63 32T S21F Nonsynonymous Heterozygous Prevalence\
        \ screen C12orf63 91T P234S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture C12orf63 12T R283Q Nonsynonymous Heterozygous C12orf63 125T E953K\
        \ Nonsynonymous Homozygous Prevalence screen C12orf63 93T L1035P Nonsynonymous\
        \ Heterozygous Exome Capture C12orf63 93T Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 12T D129N Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture PCDHB8 18T D238G Nonsynonymous Heterozygous PCDHB8 56T E311K\
        \ Nonsynonymous Heterozygous Prevalence screen PCDHB8 22T E311K Nonsynonymous\
        \ Homozygous Exome Capture SLC17A5 24T S259F Nonsynonymous Heterozygous Exome\
        \ Capture SLC17A5 24T S288P Nonsynonymous Heterozygous Exome Capture SLC17A5\
        \ 12T R364C Nonsynonymous Heterozygous Exome Capture SLC17A5 18T R364C Nonsynonymous\
        \ Heterozygous Exome Capture Alterations with a SIFT score highlighted in\
        \ red are predicted to affect protein function.///N/A, not applicable Functional\
        \ Domain No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered PI-PLC-X No domain altered C2 No domain altered No domain\
        \ altered Aldo_ket_red Aldo_ket_red Aldo_ket_red No domain altered 7tm_1 No\
        \ domain altered 7tm_1 7tm_1 7tm_1 No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered C2 UDPGT UDPGT No domain altered No domain\
        \ altered SNF SNF SNF No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered Cadherin Cadherin MFS_1 Sugar_tr MFS_1 MFS_1 change H453Y\
        \ T475M T713R R1077C S1319N S1357L S1474F S1474F A1505V E1563K L83P P165L\
        \ R251Q S342L D496N E737K R772W E1098K G134R D231N T244P splice site P91L\
        \ Stop G150E M213I M213I L28M L60F R186C R224W P245S E854K F938L S280Y Stop\
        \ E13K R40K E130K R384Q P393S G471E Splice site H220Q E362K V479M S21F P234S\
        \ R283Q E953K L1035P Q1037R D129N D238G E311K E311K S259F S288P R364C R364C\
        \ SIFT score 0.04 0 0.61 0.22 0.36 0.17 0.74 0.74 0.2 0.87 0.02 0 0 0 0.28\
        \ 0.85 0.09 0.33 0.01 0.08 0 N/A 1 N/A 0.02 1 1 0.01 0.01 0.12 0.01 0.03 0.57\
        \ 0.1 0 N/A 0.05 0.04 0.3 0.02 0 0 N/A N/A 0.16 0.35 0.16 0.07 0.8 0.29 0.13\
        \ 0 0.33 0 0 0 0 0 0 0 0 SIFT median 2.3 2.19 2.04 2.12 2.35 2.53 2.48 2.48\
        \ 2.33 2.42 2.79 2.79 2.79 2.79 2.77 2.77 2.12 2.4 2.84 2.84 2.84 N /A 2.89\
        \ N /A 2.86 2.86 2.86 2.8 2.78 2.85 2.91 2.91 2.27 1.96 3.32 N /A 3.37 3.11\
        \ 2.84 2.78 2.73 2.73 N /A N /A 2.74 2.74 2.74 3.09 3.36 3.12 2.72 4.32 3.12\
        \ 2.83 2.83 2.83 2.83 2.76 2.77 2.76 2.76 Nature Genetics: doi:10.1038/ng.810\
        \ 12 Supplementary Table 6.", pubmed: '21499247', seq: '91', to_res: L}
- {entry_name: t2r60_pantr, from_res: M, info: "Somatic mutations identified in the\
        \ Discovery, Prevalence and Validation Screens No. of mutations (% of tumors\
        \ Hete/Homo Sample Panel affected) Tumor Name Nucleotide Change Amino Acid\
        \ Change Type of Mutation CCDS number AKR1B10 CCDS5832.1 4 (7.7%) 91T G400A\
        \ G134R Nonsynonymous Homozygous Exome Capture 01T G691A D231N Nonsynonymous\
        \ Heterozygous Exome Capture 24T A730C T244P Nonsynonymous Heterozygous Exome\
        \ Capture 7T Exon 2 (-8) C/T N/A splice site Heterozygous Prevalence screen\
        \ TAS2R60 CCDS5885.1 5 (9.6%) 92T C272T P91L Nonsynonymous Homozygous Prevalence\
        \ screen 60T G429A W143* Stop Heterozygous Exome Capture 9T G449A G150E Nonsynonymous\
        \ Heterozygous Exome Capture 17T G639A M213I Nonsynonymous Heterozygous Prevalence\
        \ screen 43T G639A M213I Nonsynonymous Heterozygous Exome Capture KHDRBS2\
        \ CCDS4963.1 5 (9.6%) 119T T82A L28M Nonsynonymous Heterozygous Prevalence\
        \ screen 60T C178T L60F Nonsynonymous Heterozygous Exome Capture 91T C556T\
        \ R186C Nonsynonymous Heterozygous Exome Capture 05T C299T R224W Nonsynonymous\
        \ Homozygous Exome Capture 109T C733T P245S Nonsynonymous Heterozygous Prevalence\
        \ screen CCDS8675.1 4 (7.7%) 95T C838A S280Y Nonsynonymous Heterozygous Prevalence\
        \ screen PTPRO 60T C847T R283* Stop Heterozygous Exome Capture 12T G2560A\
        \ E854K Nonsynonymous Heterozygous Exome Capture 24T T2814G F938L Nonsynonymous\
        \ Heterozygous Exome Capture SYT4 CCDS11922.1 4 (7.7%) 43T G37A E13K Nonsynonymous\
        \ Heterozygous Exome Capture 22T G119A R40K Nonsynonymous Heterozygous Exome\
        \ Capture 12T G388A E130K Nonsynonymous Homozygous Exome Capture R384Q Nonsynonymous\
        \ Heterozygous Prevalence screen 119T G1151A UGT2B10 N/A 4 (7.7%) 12T C1177T\
        \ P393S Nonsynonymous Heterozygous Exome Capture 96T G1412A G471E Nonsynonymous\
        \ Heterozygous Exome Capture 60T A1586G *529W Nonsynonymous Heterozygous Exome\
        \ Capture 116T Exon 4 (-1) N/A Splice site Heterozygous Prevalence screen\
        \ SLC6A11 CCDS2602.1 3 (5.8%) 05T C660A H220Q Nonsynonymous Heterozygous Exome\
        \ Capture 12T G1084A E362K Nonsynonymous Heterozygous Exome Capture 51T G1435A\
        \ V479M Nonsynonymous Homozygous Exome Capture SLC17A5 CCDS4981.1 4 (5.8%)\
        \ 24T G776A S259F Nonsynonymous Heterozygous Exome Capture 24T G862A S288P\
        \ Nonsynonymous Heterozygous Exome Capture 12T C1090T R364C Nonsynonymous\
        \ Heterozygous Exome Capture 18T C1090T R364C Nonsynonymous Heterozygous Exome\
        \ Capture C12orf63 CCDS9062.1 6 (9.6%) 32T C62T S21F Nonsynonymous Heterozygous\
        \ Prevalence screen Exome Capture 91T C700T P234S Nonsynonymous Heterozygous\
        \ 12T G848A R283Q Nonsynonymous Heterozygous Exome Capture 125T G2857K E953K\
        \ Nonsynonymous Homozygous Prevalence screen 93T T3104C L1035P Nonsynonymous\
        \ Heterozygous Exome Capture 93T A3110G Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 CCDS4250.1 4 (7.7%) 12T G385A D129N Nonsynonymous Heterozygous\
        \ Exome Capture 18T A713G D238G Nonsynonymous Heterozygous Exome Capture 56T\
        \ G931A E311K Nonsynonymous Heterozygous Prevalence screen 22T G931A E311K\
        \ Nonsynonymous Homozygous Exome Capture ^Number of nonsynonymous, stop and\
        \ splice site mutations observed and percent of tumors affected for each of\
        \ the 15 genes in the panel of 52 untreated melanoma samples. ~\u2020 Number\
        \ of nonsynonymous, stop and splice site mutations observed and percent of\
        \ tumors affected for GRIN2A in validation set 1 and validation set 2 respectively.\
        \ * refers to stop codon.///Somatic mutations identified in the Discovery,\
        \ Prevalence and Validation Screens No. of mutations (% of tumors Hete/Homo\
        \ Sample Panel affected) Tumor Name Nucleotide Change Amino Acid Change Type\
        \ of Mutation CCDS number AKR1B10 CCDS5832.1 4 (7.7%) 91T G400A G134R Nonsynonymous\
        \ Homozygous Exome Capture 01T G691A D231N Nonsynonymous Heterozygous Exome\
        \ Capture 24T A730C T244P Nonsynonymous Heterozygous Exome Capture 7T Exon\
        \ 2 (-8) C/T N/A splice site Heterozygous Prevalence screen TAS2R60 CCDS5885.1\
        \ 5 (9.6%) 92T C272T P91L Nonsynonymous Homozygous Prevalence screen 60T G429A\
        \ W143* Stop Heterozygous Exome Capture 9T G449A G150E Nonsynonymous Heterozygous\
        \ Exome Capture 17T G639A M213I Nonsynonymous Heterozygous Prevalence screen\
        \ 43T G639A M213I Nonsynonymous Heterozygous Exome Capture KHDRBS2 CCDS4963.1\
        \ 5 (9.6%) 119T T82A L28M Nonsynonymous Heterozygous Prevalence screen 60T\
        \ C178T L60F Nonsynonymous Heterozygous Exome Capture 91T C556T R186C Nonsynonymous\
        \ Heterozygous Exome Capture 05T C299T R224W Nonsynonymous Homozygous Exome\
        \ Capture 109T C733T P245S Nonsynonymous Heterozygous Prevalence screen CCDS8675.1\
        \ 4 (7.7%) 95T C838A S280Y Nonsynonymous Heterozygous Prevalence screen PTPRO\
        \ 60T C847T R283* Stop Heterozygous Exome Capture 12T G2560A E854K Nonsynonymous\
        \ Heterozygous Exome Capture 24T T2814G F938L Nonsynonymous Heterozygous Exome\
        \ Capture SYT4 CCDS11922.1 4 (7.7%) 43T G37A E13K Nonsynonymous Heterozygous\
        \ Exome Capture 22T G119A R40K Nonsynonymous Heterozygous Exome Capture 12T\
        \ G388A E130K Nonsynonymous Homozygous Exome Capture R384Q Nonsynonymous Heterozygous\
        \ Prevalence screen 119T G1151A UGT2B10 N/A 4 (7.7%) 12T C1177T P393S Nonsynonymous\
        \ Heterozygous Exome Capture 96T G1412A G471E Nonsynonymous Heterozygous Exome\
        \ Capture 60T A1586G *529W Nonsynonymous Heterozygous Exome Capture 116T Exon\
        \ 4 (-1) N/A Splice site Heterozygous Prevalence screen SLC6A11 CCDS2602.1\
        \ 3 (5.8%) 05T C660A H220Q Nonsynonymous Heterozygous Exome Capture 12T G1084A\
        \ E362K Nonsynonymous Heterozygous Exome Capture 51T G1435A V479M Nonsynonymous\
        \ Homozygous Exome Capture SLC17A5 CCDS4981.1 4 (5.8%) 24T G776A S259F Nonsynonymous\
        \ Heterozygous Exome Capture 24T G862A S288P Nonsynonymous Heterozygous Exome\
        \ Capture 12T C1090T R364C Nonsynonymous Heterozygous Exome Capture 18T C1090T\
        \ R364C Nonsynonymous Heterozygous Exome Capture C12orf63 CCDS9062.1 6 (9.6%)\
        \ 32T C62T S21F Nonsynonymous Heterozygous Prevalence screen Exome Capture\
        \ 91T C700T P234S Nonsynonymous Heterozygous 12T G848A R283Q Nonsynonymous\
        \ Heterozygous Exome Capture 125T G2857K E953K Nonsynonymous Homozygous Prevalence\
        \ screen 93T T3104C L1035P Nonsynonymous Heterozygous Exome Capture 93T A3110G\
        \ Q1037R Nonsynonymous Heterozygous Exome Capture PCDHB8 CCDS4250.1 4 (7.7%)\
        \ 12T G385A D129N Nonsynonymous Heterozygous Exome Capture 18T A713G D238G\
        \ Nonsynonymous Heterozygous Exome Capture 56T G931A E311K Nonsynonymous Heterozygous\
        \ Prevalence screen 22T G931A E311K Nonsynonymous Homozygous Exome Capture\
        \ ^Number of nonsynonymous, stop and splice site mutations observed and percent\
        \ of tumors affected for each of the 15 genes in the panel of 52 untreated\
        \ melanoma samples. ~\u2020 Number of nonsynonymous, stop and splice site\
        \ mutations observed and percent of tumors affected for GRIN2A in validation\
        \ set 1 and validation set 2 respectively. * refers to stop codon.///SIFT\
        \ analysis of somatic mutations identified in highly mutated genes Amino Tumor\
        \ Acid Hete/Homo Sample Panel Gene Name Name Change Syn/NonSyn ZNF831 91T\
        \ H453Y Nonsynonymous Heterozygous Exome Capture ZNF831 96T T475M Nonsynonymous\
        \ Heterozygous Exome Capture ZNF831 86T T713R Nonsynonymous Heterozygous Prevalence\
        \ screen ZNF831 64T R1077C Nonsynonymous Heterozygous Prevalence screen ZNF831\
        \ 90T S1319N Nonsynonymous Heterozygous Prevalence screen ZNF831 81T S1357L\
        \ Nonsynonymous Heterozygous Prevalence screen ZNF831 43T S1474F Nonsynonymous\
        \ Heterozygous Exome Capture ZNF831 91T S1474F Nonsynonymous Heterozygous\
        \ Exome Capture ZNF831 119T A1505V Nonsynonymous Heterozygous Prevalence screen\
        \ Exome Capture ZNF831 05T E1563K Nonsynonymous Heterozygous PLCB4 12T L83P\
        \ Nonsynonymous Heterozygous Exome Capture PLCB4 91T P165L Nonsynonymous Heterozygous\
        \ Exome Capture PLCB4 83T R251Q Nonsynonymous Heterozygous Prevalence screen\
        \ PLCB4 119T S342L Nonsynonymous Heterozygous Prevalence screen PLCB4 84T\
        \ D496N Nonsynonymous Heterozygous Prevalence screen PLCB4 8T E737K Nonsynonymous\
        \ Heterozygous Prevalence screen PLCB4 01T R772W Nonsynonymous Heterozygous\
        \ Exome Capture PLCB4 9T E1098K Nonsynonymous Heterozygous Exome Capture AKR1B10\
        \ 91T G134R Nonsynonymous Homozygous Exome Capture AKR1B10 01T D231N Nonsynonymous\
        \ Heterozygous Exome Capture AKR1B10 24T T244P Nonsynonymous Heterozygous\
        \ Exome Capture AKR1B10 7T splice site Heterozygous Prevalence screen TAS2R60\
        \ 92T P91L Nonsynonymous Homozygous Prevalence screen TAS2R60 60T Stop Heterozygous\
        \ Exome Capture TAS2R60 9T G150E Nonsynonymous Heterozygous Exome Capture\
        \ TAS2R60 17T M213I Nonsynonymous Heterozygous Prevalence screen TAS2R60 43T\
        \ M213I Nonsynonymous Heterozygous Exome Capture KHDRBS2 119T L28M Nonsynonymous\
        \ Heterozygous Prevalence screen KHDRBS2 60T L60F Nonsynonymous Heterozygous\
        \ Exome Capture Exome Capture KHDRBS2 91T R186C Nonsynonymous Heterozygous\
        \ KHDRBS2 05T R224W Nonsynonymous Homozygous Exome Capture KHDRBS2 109T P245S\
        \ Nonsynonymous Heterozygous Prevalence screen PTPRO 12T E854K Nonsynonymous\
        \ Heterozygous Exome Capture PTPRO 24T F938L Nonsynonymous Heterozygous Exome\
        \ Capture PTPRO 95T S280Y Nonsynonymous Heterozygous Prevalence screen PTPRO\
        \ 60T Stop Heterozygous Exome Capture SYT4 43T E13K Nonsynonymous Heterozygous\
        \ Exome Capture SYT4 22T R40K Nonsynonymous Heterozygous Exome Capture SYT4\
        \ 12T E130K Nonsynonymous Homozygous Exome Capture SYT4 119T R384Q Nonsynonymous\
        \ Heterozygous Prevalence screen UGT2B10 12T P393S Nonsynonymous Heterozygous\
        \ Exome Capture Exome Capture UGT2B10 96T G471E Nonsynonymous Heterozygous\
        \ UGT2B10 60T *529W Nonsynonymous Heterozygous Exome Capture UGT2B10 116T\
        \ Splice site Heterozygous Prevalence screen SLC6A11 05T H220Q Nonsynonymous\
        \ Heterozygous Exome Capture SLC6A11 12T E362K Nonsynonymous Heterozygous\
        \ Exome Capture SLC6A11 51T V479M Nonsynonymous Homozygous Exome Capture C12orf63\
        \ 32T S21F Nonsynonymous Heterozygous Prevalence screen C12orf63 91T P234S\
        \ Nonsynonymous Heterozygous Exome Capture Exome Capture C12orf63 12T R283Q\
        \ Nonsynonymous Heterozygous C12orf63 125T E953K Nonsynonymous Homozygous\
        \ Prevalence screen C12orf63 93T L1035P Nonsynonymous Heterozygous Exome Capture\
        \ C12orf63 93T Q1037R Nonsynonymous Heterozygous Exome Capture PCDHB8 12T\
        \ D129N Nonsynonymous Heterozygous Exome Capture Exome Capture PCDHB8 18T\
        \ D238G Nonsynonymous Heterozygous PCDHB8 56T E311K Nonsynonymous Heterozygous\
        \ Prevalence screen PCDHB8 22T E311K Nonsynonymous Homozygous Exome Capture\
        \ SLC17A5 24T S259F Nonsynonymous Heterozygous Exome Capture SLC17A5 24T S288P\
        \ Nonsynonymous Heterozygous Exome Capture SLC17A5 12T R364C Nonsynonymous\
        \ Heterozygous Exome Capture SLC17A5 18T R364C Nonsynonymous Heterozygous\
        \ Exome Capture Alterations with a SIFT score highlighted in red are predicted\
        \ to affect protein function.///SIFT analysis of somatic mutations identified\
        \ in highly mutated genes Amino Tumor Acid Hete/Homo Sample Panel Gene Name\
        \ Name Change Syn/NonSyn ZNF831 91T H453Y Nonsynonymous Heterozygous Exome\
        \ Capture ZNF831 96T T475M Nonsynonymous Heterozygous Exome Capture ZNF831\
        \ 86T T713R Nonsynonymous Heterozygous Prevalence screen ZNF831 64T R1077C\
        \ Nonsynonymous Heterozygous Prevalence screen ZNF831 90T S1319N Nonsynonymous\
        \ Heterozygous Prevalence screen ZNF831 81T S1357L Nonsynonymous Heterozygous\
        \ Prevalence screen ZNF831 43T S1474F Nonsynonymous Heterozygous Exome Capture\
        \ ZNF831 91T S1474F Nonsynonymous Heterozygous Exome Capture ZNF831 119T A1505V\
        \ Nonsynonymous Heterozygous Prevalence screen Exome Capture ZNF831 05T E1563K\
        \ Nonsynonymous Heterozygous PLCB4 12T L83P Nonsynonymous Heterozygous Exome\
        \ Capture PLCB4 91T P165L Nonsynonymous Heterozygous Exome Capture PLCB4 83T\
        \ R251Q Nonsynonymous Heterozygous Prevalence screen PLCB4 119T S342L Nonsynonymous\
        \ Heterozygous Prevalence screen PLCB4 84T D496N Nonsynonymous Heterozygous\
        \ Prevalence screen PLCB4 8T E737K Nonsynonymous Heterozygous Prevalence screen\
        \ PLCB4 01T R772W Nonsynonymous Heterozygous Exome Capture PLCB4 9T E1098K\
        \ Nonsynonymous Heterozygous Exome Capture AKR1B10 91T G134R Nonsynonymous\
        \ Homozygous Exome Capture AKR1B10 01T D231N Nonsynonymous Heterozygous Exome\
        \ Capture AKR1B10 24T T244P Nonsynonymous Heterozygous Exome Capture AKR1B10\
        \ 7T splice site Heterozygous Prevalence screen TAS2R60 92T P91L Nonsynonymous\
        \ Homozygous Prevalence screen TAS2R60 60T Stop Heterozygous Exome Capture\
        \ TAS2R60 9T G150E Nonsynonymous Heterozygous Exome Capture TAS2R60 17T M213I\
        \ Nonsynonymous Heterozygous Prevalence screen TAS2R60 43T M213I Nonsynonymous\
        \ Heterozygous Exome Capture KHDRBS2 119T L28M Nonsynonymous Heterozygous\
        \ Prevalence screen KHDRBS2 60T L60F Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture KHDRBS2 91T R186C Nonsynonymous Heterozygous KHDRBS2 05T R224W\
        \ Nonsynonymous Homozygous Exome Capture KHDRBS2 109T P245S Nonsynonymous\
        \ Heterozygous Prevalence screen PTPRO 12T E854K Nonsynonymous Heterozygous\
        \ Exome Capture PTPRO 24T F938L Nonsynonymous Heterozygous Exome Capture PTPRO\
        \ 95T S280Y Nonsynonymous Heterozygous Prevalence screen PTPRO 60T Stop Heterozygous\
        \ Exome Capture SYT4 43T E13K Nonsynonymous Heterozygous Exome Capture SYT4\
        \ 22T R40K Nonsynonymous Heterozygous Exome Capture SYT4 12T E130K Nonsynonymous\
        \ Homozygous Exome Capture SYT4 119T R384Q Nonsynonymous Heterozygous Prevalence\
        \ screen UGT2B10 12T P393S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture UGT2B10 96T G471E Nonsynonymous Heterozygous UGT2B10 60T *529W Nonsynonymous\
        \ Heterozygous Exome Capture UGT2B10 116T Splice site Heterozygous Prevalence\
        \ screen SLC6A11 05T H220Q Nonsynonymous Heterozygous Exome Capture SLC6A11\
        \ 12T E362K Nonsynonymous Heterozygous Exome Capture SLC6A11 51T V479M Nonsynonymous\
        \ Homozygous Exome Capture C12orf63 32T S21F Nonsynonymous Heterozygous Prevalence\
        \ screen C12orf63 91T P234S Nonsynonymous Heterozygous Exome Capture Exome\
        \ Capture C12orf63 12T R283Q Nonsynonymous Heterozygous C12orf63 125T E953K\
        \ Nonsynonymous Homozygous Prevalence screen C12orf63 93T L1035P Nonsynonymous\
        \ Heterozygous Exome Capture C12orf63 93T Q1037R Nonsynonymous Heterozygous\
        \ Exome Capture PCDHB8 12T D129N Nonsynonymous Heterozygous Exome Capture\
        \ Exome Capture PCDHB8 18T D238G Nonsynonymous Heterozygous PCDHB8 56T E311K\
        \ Nonsynonymous Heterozygous Prevalence screen PCDHB8 22T E311K Nonsynonymous\
        \ Homozygous Exome Capture SLC17A5 24T S259F Nonsynonymous Heterozygous Exome\
        \ Capture SLC17A5 24T S288P Nonsynonymous Heterozygous Exome Capture SLC17A5\
        \ 12T R364C Nonsynonymous Heterozygous Exome Capture SLC17A5 18T R364C Nonsynonymous\
        \ Heterozygous Exome Capture Alterations with a SIFT score highlighted in\
        \ red are predicted to affect protein function.///N/A, not applicable Functional\
        \ Domain No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered PI-PLC-X No domain altered C2 No domain altered No domain\
        \ altered Aldo_ket_red Aldo_ket_red Aldo_ket_red No domain altered 7tm_1 No\
        \ domain altered 7tm_1 7tm_1 7tm_1 No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered No domain altered No domain altered No\
        \ domain altered No domain altered C2 UDPGT UDPGT No domain altered No domain\
        \ altered SNF SNF SNF No domain altered No domain altered No domain altered\
        \ No domain altered No domain altered No domain altered No domain altered\
        \ No domain altered Cadherin Cadherin MFS_1 Sugar_tr MFS_1 MFS_1 change H453Y\
        \ T475M T713R R1077C S1319N S1357L S1474F S1474F A1505V E1563K L83P P165L\
        \ R251Q S342L D496N E737K R772W E1098K G134R D231N T244P splice site P91L\
        \ Stop G150E M213I M213I L28M L60F R186C R224W P245S E854K F938L S280Y Stop\
        \ E13K R40K E130K R384Q P393S G471E Splice site H220Q E362K V479M S21F P234S\
        \ R283Q E953K L1035P Q1037R D129N D238G E311K E311K S259F S288P R364C R364C\
        \ SIFT score 0.04 0 0.61 0.22 0.36 0.17 0.74 0.74 0.2 0.87 0.02 0 0 0 0.28\
        \ 0.85 0.09 0.33 0.01 0.08 0 N/A 1 N/A 0.02 1 1 0.01 0.01 0.12 0.01 0.03 0.57\
        \ 0.1 0 N/A 0.05 0.04 0.3 0.02 0 0 N/A N/A 0.16 0.35 0.16 0.07 0.8 0.29 0.13\
        \ 0 0.33 0 0 0 0 0 0 0 0 SIFT median 2.3 2.19 2.04 2.12 2.35 2.53 2.48 2.48\
        \ 2.33 2.42 2.79 2.79 2.79 2.79 2.77 2.77 2.12 2.4 2.84 2.84 2.84 N /A 2.89\
        \ N /A 2.86 2.86 2.86 2.8 2.78 2.85 2.91 2.91 2.27 1.96 3.32 N /A 3.37 3.11\
        \ 2.84 2.78 2.73 2.73 N /A N /A 2.74 2.74 2.74 3.09 3.36 3.12 2.72 4.32 3.12\
        \ 2.83 2.83 2.83 2.83 2.76 2.77 2.76 2.76 Nature Genetics: doi:10.1038/ng.810\
        \ 12 Supplementary Table 6.///N/A, not applicable Functional Domain No domain\
        \ altered No domain altered No domain altered No domain altered No domain\
        \ altered No domain altered No domain altered No domain altered No domain\
        \ altered No domain altered No domain altered No domain altered No domain\
        \ altered PI-PLC-X No domain altered C2 No domain altered No domain altered\
        \ Aldo_ket_red Aldo_ket_red Aldo_ket_red No domain altered 7tm_1 No domain\
        \ altered 7tm_1 7tm_1 7tm_1 No domain altered No domain altered No domain\
        \ altered No domain altered No domain altered No domain altered No domain\
        \ altered No domain altered No domain altered No domain altered No domain\
        \ altered No domain altered C2 UDPGT UDPGT No domain altered No domain altered\
        \ SNF SNF SNF No domain altered No domain altered No domain altered No domain\
        \ altered No domain altered No domain altered No domain altered No domain\
        \ altered Cadherin Cadherin MFS_1 Sugar_tr MFS_1 MFS_1 change H453Y T475M\
        \ T713R R1077C S1319N S1357L S1474F S1474F A1505V E1563K L83P P165L R251Q\
        \ S342L D496N E737K R772W E1098K G134R D231N T244P splice site P91L Stop G150E\
        \ M213I M213I L28M L60F R186C R224W P245S E854K F938L S280Y Stop E13K R40K\
        \ E130K R384Q P393S G471E Splice site H220Q E362K V479M S21F P234S R283Q E953K\
        \ L1035P Q1037R D129N D238G E311K E311K S259F S288P R364C R364C SIFT score\
        \ 0.04 0 0.61 0.22 0.36 0.17 0.74 0.74 0.2 0.87 0.02 0 0 0 0.28 0.85 0.09\
        \ 0.33 0.01 0.08 0 N/A 1 N/A 0.02 1 1 0.01 0.01 0.12 0.01 0.03 0.57 0.1 0\
        \ N/A 0.05 0.04 0.3 0.02 0 0 N/A N/A 0.16 0.35 0.16 0.07 0.8 0.29 0.13 0 0.33\
        \ 0 0 0 0 0 0 0 0 SIFT median 2.3 2.19 2.04 2.12 2.35 2.53 2.48 2.48 2.33\
        \ 2.42 2.79 2.79 2.79 2.79 2.77 2.77 2.12 2.4 2.84 2.84 2.84 N /A 2.89 N /A\
        \ 2.86 2.86 2.86 2.8 2.78 2.85 2.91 2.91 2.27 1.96 3.32 N /A 3.37 3.11 2.84\
        \ 2.78 2.73 2.73 N /A N /A 2.74 2.74 2.74 3.09 3.36 3.12 2.72 4.32 3.12 2.83\
        \ 2.83 2.83 2.83 2.76 2.77 2.76 2.76 Nature Genetics: doi:10.1038/ng.810 12\
        \ Supplementary Table 6.", pubmed: '21499247', seq: '213', to_res: I}
- {entry_name: opsd_felca, from_res: G, info: "This RGS-i mutation prevents RGS-box\
        \ binding to, and GAP activity at, Gi\u03B11 (G183S), Go\u03B1 (G184S), and\
        \ Gq\u03B1 (G188S), while preserving the kinetics of GDP release and intrinsic\
        \ GTP hydrolysis by these mutant G\u03B1 subunits22,23.///S. et al. Transgenic\
        \ expression of an RGSresistant Gqa mutant (G188S) in rat brain.///Rosenzweig-Lipson,\
        \ S. et al. Potentiation of 5-HT2C and 5-HT2A mediated effects in transgenic\
        \ RGS-insensitive Gq (G188S) mutant rats.///M. et al. Behavioral parallels\
        \ between transgenic RGS-insensitive Gq\u03B1 mutant (G188S) rats and those\
        \ treated with lithium chloride.", pubmed: '12120503', seq: '188', to_res: S}
- {entry_name: cxcr4_human, from_res: T, info: 'The receptor structure was obtained
        using a construct that included the T4L fusion but also contained two thermostabilizing
        mutations (L125W (3.41) and T240P (6.36)).///In all, five structures have
        been deposited in the Protein Data Bank (PDB) that differ in the truncation
        of the C-terminus, the presence or absence of the T240P (6.36) mutation, and
        the ligand (IT1t or CVX15).', pubmed: '21593763', seq: '240', to_res: P}
- {entry_name: cxcr4_human, from_res: L, info: 'The receptor structure was obtained
        using a construct that included the T4L fusion but also contained two thermostabilizing
        mutations (L125W (3.41) and T240P (6.36)).///However, each structure included
        the L125W (3.41) mutation and the T4L fusion.', pubmed: '21593763', seq: '125',
    to_res: W}
- {entry_name: adrb2_human, from_res: G, info: "The ADRB1 gene has a common non-synonymous\
        \ polymorphism leading to a substitution at codon 389 (G389A) that has been\
        \ well studied.///As the G389A polymorphism is common and clearly functionally\
        \ significant, it has formed the basis for a large number of clinical studies,\
        \ particularly on the relationship between genotype and response to \u03B2\
        -receptor antagonist treatment.", pubmed: '20626352', seq: '389', to_res: A}
- {entry_name: cnr1_human, from_res: F, info: 'The data (Table 1) demonstrate that
        the F174A2.61, F177A2.64, L193A3.29, and M363A6.55 mutant receptors exhibited
        the same rank order loss in HU210 potency for G protein activation, relative
        to the wild-type receptor (WT HU210 EC50 0.66 nM), as was observed for HU210
        binding affinity (Table 1).///Phe-1742.61 and Phe-1772.64 Stabilize the Minor
        Binding Pocket through Aromatic Stacking-Significant decreases in ligand binding
        by the F174A2.61 and F177A2.64 mutations were observed for all the tested
        ligands (Table 1), suggesting important roles for Phe-1742.61 and Phe-1772.64
        in classical and nonclassical cannabinoid binding.', pubmed: '21795705', seq: '174',
    to_res: A}
- {entry_name: cnr1_human, from_res: F, info: 'The data (Table 1) demonstrate that
        the F174A2.61, F177A2.64, L193A3.29, and M363A6.55 mutant receptors exhibited
        the same rank order loss in HU210 potency for G protein activation, relative
        to the wild-type receptor (WT HU210 EC50 0.66 nM), as was observed for HU210
        binding affinity (Table 1).///Phe-1742.61 and Phe-1772.64 Stabilize the Minor
        Binding Pocket through Aromatic Stacking-Significant decreases in ligand binding
        by the F174A2.61 and F177A2.64 mutations were observed for all the tested
        ligands (Table 1), suggesting important roles for Phe-1742.61 and Phe-1772.64
        in classical and nonclassical cannabinoid binding.', pubmed: '21795705', seq: '177',
    to_res: A}
- {entry_name: cnr1_human, from_res: L, info: 'The data (Table 1) demonstrate that
        the F174A2.61, F177A2.64, L193A3.29, and M363A6.55 mutant receptors exhibited
        the same rank order loss in HU210 potency for G protein activation, relative
        to the wild-type receptor (WT HU210 EC50 0.66 nM), as was observed for HU210
        binding affinity (Table 1).', pubmed: '21795705', seq: '193', to_res: A}
- {entry_name: cnr1_human, from_res: M, info: 'The data (Table 1) demonstrate that
        the F174A2.61, F177A2.64, L193A3.29, and M363A6.55 mutant receptors exhibited
        the same rank order loss in HU210 potency for G protein activation, relative
        to the wild-type receptor (WT HU210 EC50 0.66 nM), as was observed for HU210
        binding affinity (Table 1).', pubmed: '21795705', seq: '363', to_res: A}
- {entry_name: aa2ar_human, from_res: S, info: "Further mutagenesis in the presence\
        \ of the inverse agonist ligand ZM241385 (Poucher et al., 1995) resulted in\
        \ the identification of an additional four stabilizing mutations (R107A3.55,\
        \ L202A5.63, L235A6.37, S277A7.42) giving an apparent thermostability of 47\uFFFD\
        \ C in 0.1% decylmaltoside (Figure 1A) resulting in A2A-StaR2.///In order\
        \ to determine whether the loss of agonist affinity was directly related to\
        \ mutation of these residues both T88A3.36 and S277A7.42 in A2A-StaR2 were\
        \ mutated back to their wild-type amino acids, both individually and together.///The\
        \ stabilized receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41,\
        \ R107A3.55, L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42\
        \ still had identical pharmacology with respect to loss of agonist binding\
        \ (Table S2).///Although T88A3.36 and S277A7.42 have little effect on inverse\
        \ agonist/antagonist pharmacology we cannot rule out the possibility that\
        \ the presence of these mutations has an effect on the binding of the ligands\
        \ presented here, however, the consistency of the binding interactions described\
        \ here with previous extensive mutagenesis data (Dal Ben et al., 2010) and\
        \ the structures of A2A-T4L in complex with ZM241385 (Jaakola et al., 2008),\
        \ UK-432097 (Xu et al., 2011) and adenosine, and NECA (Lebon et al., 2011b)\
        \ suggest that this is not the case.///The hydrogen bonding interactions from\
        \ Ser2777.42 and Thr883.36 to the agonists may explain the effect of the S277A\
        \ and T88A mutants in the A2A-StaR2 conformational ground-state thermostabilization.",
    pubmed: '21885291', seq: '277', to_res: A}
- {entry_name: aa2ar_human, from_res: R, info: "Further mutagenesis in the presence\
        \ of the inverse agonist ligand ZM241385 (Poucher et al., 1995) resulted in\
        \ the identification of an additional four stabilizing mutations (R107A3.55,\
        \ L202A5.63, L235A6.37, S277A7.42) giving an apparent thermostability of 47\uFFFD\
        \ C in 0.1% decylmaltoside (Figure 1A) resulting in A2A-StaR2.///The stabilized\
        \ receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41, R107A3.55,\
        \ L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42 still\
        \ had identical pharmacology with respect to loss of agonist binding (Table\
        \ S2).", pubmed: '21885291', seq: '107', to_res: A}
- {entry_name: aa2ar_human, from_res: A, info: 'The Effect of StaR Mutations on Receptor
        Thermostability and Their Location on the Receptor (A) Thermostability plots
        of the wild-type adenosine A2A receptor (purple circles), A2A-T4L (orange
        squares), A2A-StaR1 (previously Rant21, yellow triangles), A2A-T4L engineered
        to include the A2A-StaR1 mutations in combination with the T4L fusion (A54L2.52/T88A3.36/K122A4.43/V239A6.41)
        (green triangles), and versus A2A-StaR2 (blue diamonds).///RESULTS AND DISCUSSION
        Thermostabilization of the Human Adenosine A2A Receptor The adenosine A2A
        receptor was previously stabilized in both agonist and inverse agonist conformations
        (Magnani et al., 2008), however, the stabilized inverse agonist receptor known
        as Rant21 or A2A-StaR1 (containing the stabilizing mutations A54L2.52, T88A3.36,
        K122A4.43, V239A6.41; superscripts refer to Ballesteros-Weinstein numbering17)
        was not considered of sufficient stability for structural studies.///The stabilized
        receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41, R107A3.55,
        L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42 still had
        identical pharmacology with respect to loss of agonist binding (Table S2).',
    pubmed: '21885291', seq: '54', to_res: L}
- {entry_name: aa2ar_human, from_res: N, info: Thermostabilizing residues are shown
        in red circles and the glycosylation site mutation N154A in blue.///An N154A
        mutation was introduced to remove the glycosylation site (Figure 1B)., pubmed: '21885291',
    seq: '154', to_res: A}
- {entry_name: agtr2_human, from_res: C, info: "Journal of Physiology METHODS Molecular\
        \ biology and preparation of Xenopus oocytes Site-directed mutations were\
        \ generated in a methanethiosulphonateinsensitive channel, IRK1J (C54V, C76V,\
        \ C89I, C101L, C149F and C169V; Lu et al. 1999) using \u2018Altered Sites\
        \ II: in vitro Mutagenesis Systems\u2019 (Promega, Madison, WI, USA).", pubmed: '12963788',
    seq: '169', to_res: V}
- {entry_name: taar1_mouse, from_res: Y, info: "When Y4.56 of mTAAR1 was converted\
        \ to phenylalanine [mTAAR1(Y4.56F)], the potency of 1 increased 5-fold from\
        \ 314 \xB1 43 nM to 67 \xB1 17 nM (Table 1 and 3b).///The same trend was also\
        \ observed for tyramine; where its potency increased 7-fold in mTAAR1(Y4.56F)\
        \ (EC50 = 40 \xB1 13 nM) but remained unaffected in rTAAR1(F4.56Y) (EC50 =\
        \ 54 \xB1 11 nM).///Interestingly, the potency of tyramine for mTAAR1(Y4.56F)\
        \ was equivalent to that of wild type rTAAR1.", pubmed: '19256523', seq: '153',
    to_res: F}
- {entry_name: aa2ar_human, from_res: V, info: 'The Effect of StaR Mutations on Receptor
        Thermostability and Their Location on the Receptor (A) Thermostability plots
        of the wild-type adenosine A2A receptor (purple circles), A2A-T4L (orange
        squares), A2A-StaR1 (previously Rant21, yellow triangles), A2A-T4L engineered
        to include the A2A-StaR1 mutations in combination with the T4L fusion (A54L2.52/T88A3.36/K122A4.43/V239A6.41)
        (green triangles), and versus A2A-StaR2 (blue diamonds).///RESULTS AND DISCUSSION
        Thermostabilization of the Human Adenosine A2A Receptor The adenosine A2A
        receptor was previously stabilized in both agonist and inverse agonist conformations
        (Magnani et al., 2008), however, the stabilized inverse agonist receptor known
        as Rant21 or A2A-StaR1 (containing the stabilizing mutations A54L2.52, T88A3.36,
        K122A4.43, V239A6.41; superscripts refer to Ballesteros-Weinstein numbering17)
        was not considered of sufficient stability for structural studies.///The stabilized
        receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41, R107A3.55,
        L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42 still had
        identical pharmacology with respect to loss of agonist binding (Table S2).',
    pubmed: '21885291', seq: '239', to_res: A}
- {entry_name: aa2ar_human, from_res: L, info: "Further mutagenesis in the presence\
        \ of the inverse agonist ligand ZM241385 (Poucher et al., 1995) resulted in\
        \ the identification of an additional four stabilizing mutations (R107A3.55,\
        \ L202A5.63, L235A6.37, S277A7.42) giving an apparent thermostability of 47\uFFFD\
        \ C in 0.1% decylmaltoside (Figure 1A) resulting in A2A-StaR2.///The stabilized\
        \ receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41, R107A3.55,\
        \ L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42 still\
        \ had identical pharmacology with respect to loss of agonist binding (Table\
        \ S2).", pubmed: '21885291', seq: '235', to_res: A}
- {entry_name: aa2ar_human, from_res: K, info: 'The Effect of StaR Mutations on Receptor
        Thermostability and Their Location on the Receptor (A) Thermostability plots
        of the wild-type adenosine A2A receptor (purple circles), A2A-T4L (orange
        squares), A2A-StaR1 (previously Rant21, yellow triangles), A2A-T4L engineered
        to include the A2A-StaR1 mutations in combination with the T4L fusion (A54L2.52/T88A3.36/K122A4.43/V239A6.41)
        (green triangles), and versus A2A-StaR2 (blue diamonds).///RESULTS AND DISCUSSION
        Thermostabilization of the Human Adenosine A2A Receptor The adenosine A2A
        receptor was previously stabilized in both agonist and inverse agonist conformations
        (Magnani et al., 2008), however, the stabilized inverse agonist receptor known
        as Rant21 or A2A-StaR1 (containing the stabilizing mutations A54L2.52, T88A3.36,
        K122A4.43, V239A6.41; superscripts refer to Ballesteros-Weinstein numbering17)
        was not considered of sufficient stability for structural studies.///The stabilized
        receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41, R107A3.55,
        L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42 still had
        identical pharmacology with respect to loss of agonist binding (Table S2).',
    pubmed: '21885291', seq: '122', to_res: A}
- {entry_name: aa2ar_human, from_res: L, info: "Further mutagenesis in the presence\
        \ of the inverse agonist ligand ZM241385 (Poucher et al., 1995) resulted in\
        \ the identification of an additional four stabilizing mutations (R107A3.55,\
        \ L202A5.63, L235A6.37, S277A7.42) giving an apparent thermostability of 47\uFFFD\
        \ C in 0.1% decylmaltoside (Figure 1A) resulting in A2A-StaR2.///The stabilized\
        \ receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41, R107A3.55,\
        \ L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42 still\
        \ had identical pharmacology with respect to loss of agonist binding (Table\
        \ S2).", pubmed: '21885291', seq: '202', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: 'The Effect of StaR Mutations on Receptor
        Thermostability and Their Location on the Receptor (A) Thermostability plots
        of the wild-type adenosine A2A receptor (purple circles), A2A-T4L (orange
        squares), A2A-StaR1 (previously Rant21, yellow triangles), A2A-T4L engineered
        to include the A2A-StaR1 mutations in combination with the T4L fusion (A54L2.52/T88A3.36/K122A4.43/V239A6.41)
        (green triangles), and versus A2A-StaR2 (blue diamonds).///RESULTS AND DISCUSSION
        Thermostabilization of the Human Adenosine A2A Receptor The adenosine A2A
        receptor was previously stabilized in both agonist and inverse agonist conformations
        (Magnani et al., 2008), however, the stabilized inverse agonist receptor known
        as Rant21 or A2A-StaR1 (containing the stabilizing mutations A54L2.52, T88A3.36,
        K122A4.43, V239A6.41; superscripts refer to Ballesteros-Weinstein numbering17)
        was not considered of sufficient stability for structural studies.///In order
        to determine whether the loss of agonist affinity was directly related to
        mutation of these residues both T88A3.36 and S277A7.42 in A2A-StaR2 were mutated
        back to their wild-type amino acids, both individually and together.///The
        stabilized receptor containing the six mutations A54L2.52, K122A4.43, V239A6.41,
        R107A3.55, L202A5.63, L235A6.37 in the absence of T88A3.36, and/or S277A7.42
        still had identical pharmacology with respect to loss of agonist binding (Table
        S2).///Although T88A3.36 and S277A7.42 have little effect on inverse agonist/antagonist
        pharmacology we cannot rule out the possibility that the presence of these
        mutations has an effect on the binding of the ligands presented here, however,
        the consistency of the binding interactions described here with previous extensive
        mutagenesis data (Dal Ben et al., 2010) and the structures of A2A-T4L in complex
        with ZM241385 (Jaakola et al., 2008), UK-432097 (Xu et al., 2011) and adenosine,
        and NECA (Lebon et al., 2011b) suggest that this is not the case.///The hydrogen
        bonding interactions from Ser2777.42 and Thr883.36 to the agonists may explain
        the effect of the S277A and T88A mutants in the A2A-StaR2 conformational ground-state
        thermostabilization.', pubmed: '21885291', seq: '88', to_res: A}
- {entry_name: acm1_human, from_res: W, info: 'Furthermore, muta2 idues likely to
        contribute to ERK1/2-specific functional selec- tion of W3.28A had a significant
        inhibitory effect on the affintivity: Y1043.33A in the orthosteric site, which
        selectively abol- ity of NDMC for the M1 mAChR (44) but no effect at the M2
        ished signaling to the ERK1/2 pathway while retaining the mAChR in our study.',
    pubmed: '20051519', seq: '101', to_res: A}
- {entry_name: acm2_human, from_res: Y, info: "Two point mutations (Y1043.33A (Ballesteros\
        \ and Weinstein numbers in superscript) in the orthosteric and Y177A in the\
        \ allosteric site) unmasked ligand-selective and signaling pathway-selective\
        \ effects, providing evidence for the existence of pathway-specific receptor\
        \ conformations.///The primers for the E172Q/D173N/E175Q, Y177A, T4237.36A,5\
        \ and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs have been reported\
        \ previously (19, 35).///The primers for the E172Q/D173N/E175Q, Y177A, T4237.36A,5\
        \ and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs have been reported\
        \ previously (19, 35).///The spacing divides mutations into predominantly\
        \ orthosteric (top) versus allosteric site M2 receptor Bmaxa pKDb 3H QNB pKIc\
        \ ACh Arecoline CCh Pilocarpine AC-42 77-LH-28-1 McN-A-343 0.24 0.08d 0.18\
        \ 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07 0.08d 0.06d 4.30 4.73 4.26 4.25 4.38\
        \ 4.45 4.44 4.44 4.42 4.61 4.50 4.61 0.03 0.10 0.06 0.07 0.19 0.07 0.08 0.10\
        \ 0.22 0.22 0.23 0.13 NDMC 6.15 6.32 5.03 5.76 5.74 5.85 5.91 6.17 6.16 5.99\
        \ 6.31 6.15 0.13 0.14 0.11d 0.22 0.07 0.15 0.02 0.02 0.09 0.07 0.14 0.06 pmol/mg\
        \ Wild type 2.11 0.36 10.01 0.04 5.11 0.15 4.99 0.27 4.85 0.19 5.00 4.16 0.68\
        \ 9.60 0.08d 4.45 0.06d 5.18 0.13 4.29 0.46 4.63 W993.28A 3.29 L100 A 4.87\
        \ 0.89 8.69 0.11d 3.34 0.16d 3.62 0.03d 3.34 0.36d 4.04 Y1043.33A 1.72 0.38\
        \ 8.41 0.03d 2.54 0.11d 3.04 0.31d 2.48 0.11d 2.95 S1073.36A 4.94 0.39 9.69\
        \ 0.07d 3.82 0.19d 4.27 0.06d 3.55 0.39d 4.76 Y4036.51A 4.61 0.92 9.49 0.04d\
        \ 3.06 0.12d 3.67 0.16d 3.04 0.18d 3.42 Y802.61A 3.22 1.27 9.62 0.11d 4.91\
        \ 0.25 4.66 0.12 4.21 0.23 4.77 Y177A 4.55 1.41 10.00 0.29 5.02 0.24 4.75\
        \ 0.17 4.43 0.22 4.82 N4197.32A 3.51 0.29 10.20 0.02 5.62 0.28 5.15 0.12 4.89\
        \ 0.22 5.24 T4237.36A 5.56 1.20 9.61 0.15d 5.54 0.32 5.16 0.23 4.85 0.15 5.10\
        \ E172Q/D173N/E175Q 2.84 0.88 10.30 0.14d 5.54 0.09 5.13 0.09 5.07 0.15 5.11\
        \ E172Q/D173N/E175Q/ 1.50 0.11 9.93 0.06 5.08 0.23 4.49 0.04 4.44 0.08 4.88\
        \ Y177A/T4237.36A a Maximum density of binding sites. b Negative logarithm\
        \ of the radioligand equilibrium dissociation constant.///The spacing divides\
        \ mutations into predominantly orthosteric (top) versus allosteric site M2\
        \ receptor Bmaxa pKDb 3H QNB pKIc ACh Arecoline CCh Pilocarpine AC-42 77-LH-28-1\
        \ McN-A-343 0.24 0.08d 0.18 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07 0.08d 0.06d\
        \ 4.30 4.73 4.26 4.25 4.38 4.45 4.44 4.44 4.42 4.61 4.50 4.61 0.03 0.10 0.06\
        \ 0.07 0.19 0.07 0.08 0.10 0.22 0.22 0.23 0.13 NDMC 6.15 6.32 5.03 5.76 5.74\
        \ 5.85 5.91 6.17 6.16 5.99 6.31 6.15 0.13 0.14 0.11d 0.22 0.07 0.15 0.02 0.02\
        \ 0.09 0.07 0.14 0.06 pmol/mg Wild type 2.11 0.36 10.01 0.04 5.11 0.15 4.99\
        \ 0.27 4.85 0.19 5.00 4.16 0.68 9.60 0.08d 4.45 0.06d 5.18 0.13 4.29 0.46\
        \ 4.63 W993.28A 3.29 L100 A 4.87 0.89 8.69 0.11d 3.34 0.16d 3.62 0.03d 3.34\
        \ 0.36d 4.04 Y1043.33A 1.72 0.38 8.41 0.03d 2.54 0.11d 3.04 0.31d 2.48 0.11d\
        \ 2.95 S1073.36A 4.94 0.39 9.69 0.07d 3.82 0.19d 4.27 0.06d 3.55 0.39d 4.76\
        \ Y4036.51A 4.61 0.92 9.49 0.04d 3.06 0.12d 3.67 0.16d 3.04 0.18d 3.42 Y802.61A\
        \ 3.22 1.27 9.62 0.11d 4.91 0.25 4.66 0.12 4.21 0.23 4.77 Y177A 4.55 1.41\
        \ 10.00 0.29 5.02 0.24 4.75 0.17 4.43 0.22 4.82 N4197.32A 3.51 0.29 10.20\
        \ 0.02 5.62 0.28 5.15 0.12 4.89 0.22 5.24 T4237.36A 5.56 1.20 9.61 0.15d 5.54\
        \ 0.32 5.16 0.23 4.85 0.15 5.10 E172Q/D173N/E175Q 2.84 0.88 10.30 0.14d 5.54\
        \ 0.09 5.13 0.09 5.07 0.15 5.11 E172Q/D173N/E175Q/ 1.50 0.11 9.93 0.06 5.08\
        \ 0.23 4.49 0.04 4.44 0.08 4.88 Y177A/T4237.36A a Maximum density of binding\
        \ sites. b Negative logarithm of the radioligand equilibrium dissociation\
        \ constant.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A\
        \ Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/\
        \ Y177A/T4237.36A pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94\
        \ 0.08 6.53 0.07c NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c\
        \ AC-42 NR 7.42b NR NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b\
        \ 5.18b 4.80 0.19 NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b\
        \ NR 3.55b 3.91 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47\
        \ 0.12 4.81 0.16 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53\
        \ NDMC 6.40 0.46 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17\
        \ 6.32 0.08 6.00 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR\
        \ 5.49 0.09 4.38 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b\
        \ 5.14 5.07 5.05 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A\
        \ Y802.61A Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13\
        \ AC-42 NR 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25\
        \ 5.21 0.12 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43\
        \ 2.90 0.12c ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37\
        \ 0.27 0.38 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42\
        \ 0.20 Pilocarpine 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07\
        \ 0.31c Downloaded from www.jbc.org at Monash University (CAUL), on March\
        \ 7, 2010 a Negative logarithm of the equilibrium dissociation constant for\
        \ each ligand, determined utilizing an operational model of agonism.///M2\
        \ receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A\
        \ Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A\
        \ pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94 0.08 6.53 0.07c\
        \ NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c AC-42 NR 7.42b NR\
        \ NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b 5.18b 4.80 0.19\
        \ NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b NR 3.55b 3.91\
        \ 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47 0.12 4.81 0.16\
        \ 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53 NDMC 6.40 0.46\
        \ 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17 6.32 0.08 6.00\
        \ 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR 5.49 0.09 4.38\
        \ 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b 5.14 5.07 5.05\
        \ 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A Y802.61A\
        \ Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13 AC-42 NR\
        \ 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25 5.21 0.12\
        \ 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43 2.90 0.12c\
        \ ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37 0.27 0.38\
        \ 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42 0.20 Pilocarpine\
        \ 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07 0.31c Downloaded\
        \ from www.jbc.org at Monash University (CAUL), on March 7, 2010 a Negative\
        \ logarithm of the equilibrium dissociation constant for each ligand, determined\
        \ utilizing an operational model of agonism.///M2 receptor Wild type W993.28A\
        \ L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A\
        \ E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 pKAa 77-LH-28-1\
        \ 5.56 0.37 8.84b 5.73 0.30 NR 5.94 0.08 6.53 0.07c NR 6.31 0.18c 5.97 0.15\
        \ 6.44 0.26c 6.07 0.15 6.78 0.16c AC-42 NR 7.42b NR NR NR 6.10 0.19 NR NR\
        \ NR NR NR 5.27 0.32 Arecoline 4.99b 5.18b 4.80 0.19 NR 4.27b 3.67b 4.66b\
        \ ND ND ND ND ND CCh 4.85b 4.29b 3.34b NR 3.55b 3.91 0.11 4.21b ND ND ND ND\
        \ ND McN-A-343 0.06 0.06 NR NR NR 5.47 0.12 4.81 0.16 4.77 0.20c 5.23 0.09\
        \ 5.25 0.12 4.96 0.11 4.61b 5.19 5.53 NDMC 6.40 0.46 6.66 0.11 6.07 0.11 NR\
        \ 6.12 0.11 5.85b 6.58 0.11 6.43 0.17 6.32 0.08 6.00 0.21c 5.80 0.24c 6.13\
        \ 0.06 Pilocarpine 0.23 0.21 0.11 NR 5.49 0.09 4.38 0.32c 4.77b 5.35 0.18\
        \ 5.59 0.09 5.25 0.07 5.23 0.10 4.88b 5.14 5.07 5.05 35 S GTP S pKA 77-LH-28-1\
        \ Wild type W993.28A Y1043.33A Y4036.51A Y802.61A Y177A 6.27 0.09 8.69 0.27c\
        \ 5.17b 6.92 0.05 6.90 0.40 6.75 0.13 AC-42 NR 7.61 0.10 5.71 0.28 6.08 0.25\
        \ 6.47 0.18 NR Arecoline 5.24 0.25 5.21 0.12 3.03 0.27c 4.06 0.22 ND 4.71\
        \ 0.58 CCh 4.85b 4.10 0.10 2.57 0.43 2.90 0.12c ND 4.75 0.39 McN-A-343 5.27\
        \ 4.94 5.05 5.13 4.50 5.01 0.13 0.37 0.27 0.38 0.14 0.22 NDMC 6.78 0.26 6.68\
        \ 0.10 5.76b 5.85b 6.23 0.14 6.42 0.20 Pilocarpine 5.55 4.49 3.18 3.71 4.82\
        \ 4.47 0.30 0.15c 0.20c 0.29c 0.07 0.31c Downloaded from www.jbc.org at Monash\
        \ University (CAUL), on March 7, 2010 a Negative logarithm of the equilibrium\
        \ dissociation constant for each ligand, determined utilizing an operational\
        \ model of agonism.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A\
        \ Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/\
        \ Y177A/T4237.36A pERK1/2 log ACh 0.07 0.04b 0.08b NR 2.20 0.10b 1.37 0.09b\
        \ 2.95 0.08 2.67 0.12 2.40 0.09b 1.82 0.12b 2.16 0.18b 2.53 0.10b 2.90 2.59\
        \ 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b 0.73 0.07b NR 0.29 0.09 0.18 0.08 NR\
        \ 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84 0.13b 0.28 0.11 AC-42 NR 0.69 0.09\
        \ NR NR NR 0.52 0.10 NR NR NR NR NR 0.42 0.09 Arecoline 2.18 0.09 1.65 0.08b\
        \ 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53 0.08 ND ND ND ND ND a C CCh 2.34\
        \ 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b 0.10 0.10b 2.66 0.07 ND ND ND ND\
        \ ND McN-A-343 0.38 0.07 0.39 0.20 NR NR NR 0.51 0.09 0.20 0.11 0.48 0.25b\
        \ 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b NDMC 0.08 0.08 0.12 0.14 0.48 0.06b\
        \ NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05 0.21 0.08 0.08 0.53 0.06b 0.36 0.10\
        \ 0.16 0.06 Pilocarpine 0.34 0.11 0.54 0.25 0.37 0.09b NR 0.37 0.08b 0.96\
        \ 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05 0.05 0.06b 0.07 0.07 0.80 0.09 35 S\
        \ GTP S log C ACh Wild type W993.28A Y1043.33A Y4036.51A Y802.61A Y177A 1.83\
        \ 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b 0.17 0.11b 77-LH-28-1 0.01\
        \ 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09 0.25b 0.11b AC-42 NR 0.44\
        \ 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline 1.02 0.31 0.07 0.04b 0.08\
        \ 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39 0.29 0.68 0.25 0.27 0.22\
        \ ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30 0.44 0.16 0.12 0.19 0.31\
        \ 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23 0.12b 0.09b 0.10b 0.13\
        \ 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18 0.14b 0.18 0.27b 0.09b\
        \ 0.14b a b Relative coupling efficiency parameter, , was determined via nonlinear\
        \ regression of the data to an operational model of agonism and corrected\
        \ for receptor expression levels to yield a corrected C parameter.///M2 receptor\
        \ Wild type W993.28A L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A Y177A\
        \ N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A\
        \ pERK1/2 log ACh 0.07 0.04b 0.08b NR 2.20 0.10b 1.37 0.09b 2.95 0.08 2.67\
        \ 0.12 2.40 0.09b 1.82 0.12b 2.16 0.18b 2.53 0.10b 2.90 2.59 2.20 77-LH-28-1\
        \ 0.25 0.14 0.14 0.07b 0.73 0.07b NR 0.29 0.09 0.18 0.08 NR 0.47 0.10 0.71\
        \ 0.09b 0.85 0.16b 0.84 0.13b 0.28 0.11 AC-42 NR 0.69 0.09 NR NR NR 0.52 0.10\
        \ NR NR NR NR NR 0.42 0.09 Arecoline 2.18 0.09 1.65 0.08b 0.17 0.09b NR 1.85\
        \ 0.05 0.97 0.27b 2.53 0.08 ND ND ND ND ND a C CCh 2.34 0.03 2.02 0.10 1.32\
        \ 0.13b NR 1.70 0.05b 0.10 0.10b 2.66 0.07 ND ND ND ND ND McN-A-343 0.38 0.07\
        \ 0.39 0.20 NR NR NR 0.51 0.09 0.20 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40\
        \ 0.12 0.86 0.09b NDMC 0.08 0.08 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b\
        \ 0.03 0.09 0.05 0.21 0.08 0.08 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine\
        \ 0.34 0.11 0.54 0.25 0.37 0.09b NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10\
        \ 0.28 0.15 0.05 0.05 0.06b 0.07 0.07 0.80 0.09 35 S GTP S log C ACh Wild\
        \ type W993.28A Y1043.33A Y4036.51A Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54\
        \ 0.53 0.22 0.22 0.18b 0.22b 0.17 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93\
        \ 0.68 0.08 0.37 0.16b 0.09 0.25b 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35\
        \ 0.12 0.81 0.20 NR Arecoline 1.02 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND\
        \ 0.02 0.13b CCh 1.03 0.18 0.39 0.29 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343\
        \ 0.09 0.57 0.50 0.68 0.30 0.44 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54\
        \ 0.81 0.78 0.20 0.54 0.23 0.12b 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37\
        \ 0.09 0.59 0.93 0.77 0.18 0.14b 0.18 0.27b 0.09b 0.14b a b Relative coupling\
        \ efficiency parameter, , was determined via nonlinear regression of the data\
        \ to an operational model of agonism and corrected for receptor expression\
        \ levels to yield a corrected C parameter.///M2 receptor Wild type W993.28A\
        \ L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A\
        \ E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 log ACh 0.07\
        \ 0.04b 0.08b NR 2.20 0.10b 1.37 0.09b 2.95 0.08 2.67 0.12 2.40 0.09b 1.82\
        \ 0.12b 2.16 0.18b 2.53 0.10b 2.90 2.59 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b\
        \ 0.73 0.07b NR 0.29 0.09 0.18 0.08 NR 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84\
        \ 0.13b 0.28 0.11 AC-42 NR 0.69 0.09 NR NR NR 0.52 0.10 NR NR NR NR NR 0.42\
        \ 0.09 Arecoline 2.18 0.09 1.65 0.08b 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53\
        \ 0.08 ND ND ND ND ND a C CCh 2.34 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b\
        \ 0.10 0.10b 2.66 0.07 ND ND ND ND ND McN-A-343 0.38 0.07 0.39 0.20 NR NR\
        \ NR 0.51 0.09 0.20 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b\
        \ NDMC 0.08 0.08 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05\
        \ 0.21 0.08 0.08 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine 0.34 0.11 0.54\
        \ 0.25 0.37 0.09b NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05\
        \ 0.05 0.06b 0.07 0.07 0.80 0.09 35 S GTP S log C ACh Wild type W993.28A Y1043.33A\
        \ Y4036.51A Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b\
        \ 0.17 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09\
        \ 0.25b 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline\
        \ 1.02 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39\
        \ 0.29 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30\
        \ 0.44 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23\
        \ 0.12b 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18\
        \ 0.14b 0.18 0.27b 0.09b 0.14b a b Relative coupling efficiency parameter,\
        \ , was determined via nonlinear regression of the data to an operational\
        \ model of agonism and corrected for receptor expression levels to yield a\
        \ corrected C parameter.///In addition, 77-LH-28-1 showed affinity increases\
        \ (3\u201330 fold) at Y4036.51A, Y802.61A, E172Q/ D173N/E175Q and the combined\
        \ E172Q/D173N/E175Q/Y177A/ T4237.36A mutant.///The combined mutations, E172Q/D173N/\
        \ E175Q and E172Q/D173N/E175Q/Y177A/T4237.36A, are indicated by EDGE and EDGE\
        \ Y T, respectively. on the Agonist-None of the mutaData represent the mean\
        \ S.E. of 5\u201316 experiments performed in duplicate. no resp., there was\
        \ no tions introduced into the M2 detectable agonism; *, significantly different\
        \ from wild type, p 0.05, one-way ANOVA, Dunnett\u2019s post- mAChR had any\
        \ discernible effect test. #, the agonist was capable of eliciting the maximal\
        \ system response, such that its pKA was constrained to equal that determined\
        \ by radioligand binding.///Interestingly, however, for [35S]GTP S binding\
        \ at the Y177A mutant (Fig. 6), the efficacy of McN-A-343 was not increased\
        \ (Fig. 8), which is in contrast to what was seen in the FIGURE 5.///The functional\
        \ affinity of activation was provided by the significant decreases in efficacy\
        \ 77-LH-28-1 was increased (7\u201325-fold) at Y177A, T4237.36A, that were\
        \ evident for ACh, arecoline, CCh, pilocarpine, 77-LHand the combined E172Q/D173N/E175Q/Y177A/T4237.36A\
        \ 28-1, and NDMC at this mutation (Fig. 8 and Table 4). mutant (Fig. 3 and\
        \ Table 3).///The functional affinity of activation was provided by the significant\
        \ decreases in efficacy 77-LH-28-1 was increased (7\u201325-fold) at Y177A,\
        \ T4237.36A, that were evident for ACh, arecoline, CCh, pilocarpine, 77-LHand\
        \ the combined E172Q/D173N/E175Q/Y177A/T4237.36A 28-1, and NDMC at this mutation\
        \ (Fig. 8 and Table 4). mutant (Fig. 3 and Table 3).///The efficacy of McN-A-343\
        \ was significantly increased at found that alanine substitution of this residue\
        \ resulted in Y177A and E172Q/D173N/E175Q/Y177A/T4237.36A (7- and almost complete\
        \ abrogation of agonist signaling to the ERK1/2 17-fold, respectively; Table\
        \ 4), such that McN-A-343 elicited a pathway; ACh could only maximally elicit\
        \ 10% of the wild similar maximal response to ACh.///The efficacy of McN-A-343\
        \ was significantly increased at found that alanine substitution of this residue\
        \ resulted in Y177A and E172Q/D173N/E175Q/Y177A/T4237.36A (7- and almost complete\
        \ abrogation of agonist signaling to the ERK1/2 17-fold, respectively; Table\
        \ 4), such that McN-A-343 elicited a pathway; ACh could only maximally elicit\
        \ 10% of the wild similar maximal response to ACh.///Although the efficacy\
        \ and/or affinities Effects of Selected Mutations on M2 mAChR-mediated for\
        \ the orthosteric ligands, ACh, arecoline, CCh, and pilo[35S]GTP S Binding\
        \ Provide Evidence for Pathway-specific carpine, at the Y1043.33A mutant were\
        \ decreased relative to the Changes in Coupling Efficiency-From the preceding\
        \ studies, M2 wild type mAChR (Fig. 8), NDMC and 77-LH-28-1 elicited the most\
        \ striking effects on the signaling properties of the novel similar maximal\
        \ responses to ACh, indicating significantly selective/bitopic agonists were\
        \ noted at the W993.28A, Y177A, increased efficacy (4 and 17-fold, respectively)\
        \ at this mutant and Y4036.51A mutations.///These differences are likely to\
        \ reflect ability to activate G proteins and mediate intracellular Ca2 the\
        \ different interactions the compounds make with the mobilization, and Y177A\
        \ in the allosteric site, which selectively receptors and may contribute in\
        \ part to the functional selecenhanced signaling of the bitopic ligand, McN-A-343\
        \ to the tivity that has been reported for the agonists for the M1 relERK1/2\
        \ pathway. ative to the M2 mAChR (39, 65).///The peak Ca2 response, found\
        \ that the single point mutadetermined as described under \u201CExperimental\
        \ Procedures,\u201D was corrected for the background level of tion of Y177A\
        \ in the E2 loop fluorescence and normalized to the response elicited by 2\
        \ M ionomycin.", pubmed: '20051519', seq: '177', to_res: A}
- {entry_name: acm2_human, from_res: E, info: "The primers for the E172Q/D173N/E175Q,\
        \ Y177A, T4237.36A,5 and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs\
        \ have been reported previously (19, 35).///The primers for the E172Q/D173N/E175Q,\
        \ Y177A, T4237.36A,5 and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs\
        \ have been reported previously (19, 35).///The spacing divides mutations\
        \ into predominantly orthosteric (top) versus allosteric site M2 receptor\
        \ Bmaxa pKDb 3H QNB pKIc ACh Arecoline CCh Pilocarpine AC-42 77-LH-28-1 McN-A-343\
        \ 0.24 0.08d 0.18 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07 0.08d 0.06d 4.30 4.73\
        \ 4.26 4.25 4.38 4.45 4.44 4.44 4.42 4.61 4.50 4.61 0.03 0.10 0.06 0.07 0.19\
        \ 0.07 0.08 0.10 0.22 0.22 0.23 0.13 NDMC 6.15 6.32 5.03 5.76 5.74 5.85 5.91\
        \ 6.17 6.16 5.99 6.31 6.15 0.13 0.14 0.11d 0.22 0.07 0.15 0.02 0.02 0.09 0.07\
        \ 0.14 0.06 pmol/mg Wild type 2.11 0.36 10.01 0.04 5.11 0.15 4.99 0.27 4.85\
        \ 0.19 5.00 4.16 0.68 9.60 0.08d 4.45 0.06d 5.18 0.13 4.29 0.46 4.63 W993.28A\
        \ 3.29 L100 A 4.87 0.89 8.69 0.11d 3.34 0.16d 3.62 0.03d 3.34 0.36d 4.04 Y1043.33A\
        \ 1.72 0.38 8.41 0.03d 2.54 0.11d 3.04 0.31d 2.48 0.11d 2.95 S1073.36A 4.94\
        \ 0.39 9.69 0.07d 3.82 0.19d 4.27 0.06d 3.55 0.39d 4.76 Y4036.51A 4.61 0.92\
        \ 9.49 0.04d 3.06 0.12d 3.67 0.16d 3.04 0.18d 3.42 Y802.61A 3.22 1.27 9.62\
        \ 0.11d 4.91 0.25 4.66 0.12 4.21 0.23 4.77 Y177A 4.55 1.41 10.00 0.29 5.02\
        \ 0.24 4.75 0.17 4.43 0.22 4.82 N4197.32A 3.51 0.29 10.20 0.02 5.62 0.28 5.15\
        \ 0.12 4.89 0.22 5.24 T4237.36A 5.56 1.20 9.61 0.15d 5.54 0.32 5.16 0.23 4.85\
        \ 0.15 5.10 E172Q/D173N/E175Q 2.84 0.88 10.30 0.14d 5.54 0.09 5.13 0.09 5.07\
        \ 0.15 5.11 E172Q/D173N/E175Q/ 1.50 0.11 9.93 0.06 5.08 0.23 4.49 0.04 4.44\
        \ 0.08 4.88 Y177A/T4237.36A a Maximum density of binding sites. b Negative\
        \ logarithm of the radioligand equilibrium dissociation constant.///The spacing\
        \ divides mutations into predominantly orthosteric (top) versus allosteric\
        \ site M2 receptor Bmaxa pKDb 3H QNB pKIc ACh Arecoline CCh Pilocarpine AC-42\
        \ 77-LH-28-1 McN-A-343 0.24 0.08d 0.18 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07\
        \ 0.08d 0.06d 4.30 4.73 4.26 4.25 4.38 4.45 4.44 4.44 4.42 4.61 4.50 4.61\
        \ 0.03 0.10 0.06 0.07 0.19 0.07 0.08 0.10 0.22 0.22 0.23 0.13 NDMC 6.15 6.32\
        \ 5.03 5.76 5.74 5.85 5.91 6.17 6.16 5.99 6.31 6.15 0.13 0.14 0.11d 0.22 0.07\
        \ 0.15 0.02 0.02 0.09 0.07 0.14 0.06 pmol/mg Wild type 2.11 0.36 10.01 0.04\
        \ 5.11 0.15 4.99 0.27 4.85 0.19 5.00 4.16 0.68 9.60 0.08d 4.45 0.06d 5.18\
        \ 0.13 4.29 0.46 4.63 W993.28A 3.29 L100 A 4.87 0.89 8.69 0.11d 3.34 0.16d\
        \ 3.62 0.03d 3.34 0.36d 4.04 Y1043.33A 1.72 0.38 8.41 0.03d 2.54 0.11d 3.04\
        \ 0.31d 2.48 0.11d 2.95 S1073.36A 4.94 0.39 9.69 0.07d 3.82 0.19d 4.27 0.06d\
        \ 3.55 0.39d 4.76 Y4036.51A 4.61 0.92 9.49 0.04d 3.06 0.12d 3.67 0.16d 3.04\
        \ 0.18d 3.42 Y802.61A 3.22 1.27 9.62 0.11d 4.91 0.25 4.66 0.12 4.21 0.23 4.77\
        \ Y177A 4.55 1.41 10.00 0.29 5.02 0.24 4.75 0.17 4.43 0.22 4.82 N4197.32A\
        \ 3.51 0.29 10.20 0.02 5.62 0.28 5.15 0.12 4.89 0.22 5.24 T4237.36A 5.56 1.20\
        \ 9.61 0.15d 5.54 0.32 5.16 0.23 4.85 0.15 5.10 E172Q/D173N/E175Q 2.84 0.88\
        \ 10.30 0.14d 5.54 0.09 5.13 0.09 5.07 0.15 5.11 E172Q/D173N/E175Q/ 1.50 0.11\
        \ 9.93 0.06 5.08 0.23 4.49 0.04 4.44 0.08 4.88 Y177A/T4237.36A a Maximum density\
        \ of binding sites. b Negative logarithm of the radioligand equilibrium dissociation\
        \ constant.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A\
        \ Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/\
        \ Y177A/T4237.36A pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94\
        \ 0.08 6.53 0.07c NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c\
        \ AC-42 NR 7.42b NR NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b\
        \ 5.18b 4.80 0.19 NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b\
        \ NR 3.55b 3.91 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47\
        \ 0.12 4.81 0.16 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53\
        \ NDMC 6.40 0.46 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17\
        \ 6.32 0.08 6.00 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR\
        \ 5.49 0.09 4.38 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b\
        \ 5.14 5.07 5.05 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A\
        \ Y802.61A Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13\
        \ AC-42 NR 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25\
        \ 5.21 0.12 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43\
        \ 2.90 0.12c ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37\
        \ 0.27 0.38 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42\
        \ 0.20 Pilocarpine 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07\
        \ 0.31c Downloaded from www.jbc.org at Monash University (CAUL), on March\
        \ 7, 2010 a Negative logarithm of the equilibrium dissociation constant for\
        \ each ligand, determined utilizing an operational model of agonism.///M2\
        \ receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A\
        \ Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A\
        \ pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94 0.08 6.53 0.07c\
        \ NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c AC-42 NR 7.42b NR\
        \ NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b 5.18b 4.80 0.19\
        \ NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b NR 3.55b 3.91\
        \ 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47 0.12 4.81 0.16\
        \ 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53 NDMC 6.40 0.46\
        \ 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17 6.32 0.08 6.00\
        \ 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR 5.49 0.09 4.38\
        \ 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b 5.14 5.07 5.05\
        \ 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A Y802.61A\
        \ Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13 AC-42 NR\
        \ 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25 5.21 0.12\
        \ 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43 2.90 0.12c\
        \ ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37 0.27 0.38\
        \ 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42 0.20 Pilocarpine\
        \ 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07 0.31c Downloaded\
        \ from www.jbc.org at Monash University (CAUL), on March 7, 2010 a Negative\
        \ logarithm of the equilibrium dissociation constant for each ligand, determined\
        \ utilizing an operational model of agonism.///M2 receptor Wild type W993.28A\
        \ L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A\
        \ E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 log ACh 0.07\
        \ 0.04b 0.08b NR 2.20 0.10b 1.37 0.09b 2.95 0.08 2.67 0.12 2.40 0.09b 1.82\
        \ 0.12b 2.16 0.18b 2.53 0.10b 2.90 2.59 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b\
        \ 0.73 0.07b NR 0.29 0.09 0.18 0.08 NR 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84\
        \ 0.13b 0.28 0.11 AC-42 NR 0.69 0.09 NR NR NR 0.52 0.10 NR NR NR NR NR 0.42\
        \ 0.09 Arecoline 2.18 0.09 1.65 0.08b 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53\
        \ 0.08 ND ND ND ND ND a C CCh 2.34 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b\
        \ 0.10 0.10b 2.66 0.07 ND ND ND ND ND McN-A-343 0.38 0.07 0.39 0.20 NR NR\
        \ NR 0.51 0.09 0.20 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b\
        \ NDMC 0.08 0.08 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05\
        \ 0.21 0.08 0.08 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine 0.34 0.11 0.54\
        \ 0.25 0.37 0.09b NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05\
        \ 0.05 0.06b 0.07 0.07 0.80 0.09 35 S GTP S log C ACh Wild type W993.28A Y1043.33A\
        \ Y4036.51A Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b\
        \ 0.17 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09\
        \ 0.25b 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline\
        \ 1.02 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39\
        \ 0.29 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30\
        \ 0.44 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23\
        \ 0.12b 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18\
        \ 0.14b 0.18 0.27b 0.09b 0.14b a b Relative coupling efficiency parameter,\
        \ , was determined via nonlinear regression of the data to an operational\
        \ model of agonism and corrected for receptor expression levels to yield a\
        \ corrected C parameter.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A\
        \ S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q\
        \ E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 log ACh 0.07 0.04b 0.08b NR 2.20\
        \ 0.10b 1.37 0.09b 2.95 0.08 2.67 0.12 2.40 0.09b 1.82 0.12b 2.16 0.18b 2.53\
        \ 0.10b 2.90 2.59 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b 0.73 0.07b NR 0.29\
        \ 0.09 0.18 0.08 NR 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84 0.13b 0.28 0.11 AC-42\
        \ NR 0.69 0.09 NR NR NR 0.52 0.10 NR NR NR NR NR 0.42 0.09 Arecoline 2.18\
        \ 0.09 1.65 0.08b 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53 0.08 ND ND ND ND\
        \ ND a C CCh 2.34 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b 0.10 0.10b 2.66\
        \ 0.07 ND ND ND ND ND McN-A-343 0.38 0.07 0.39 0.20 NR NR NR 0.51 0.09 0.20\
        \ 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b NDMC 0.08 0.08\
        \ 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05 0.21 0.08 0.08\
        \ 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine 0.34 0.11 0.54 0.25 0.37 0.09b\
        \ NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05 0.05 0.06b 0.07\
        \ 0.07 0.80 0.09 35 S GTP S log C ACh Wild type W993.28A Y1043.33A Y4036.51A\
        \ Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b 0.17\
        \ 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09 0.25b\
        \ 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline 1.02\
        \ 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39 0.29\
        \ 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30 0.44\
        \ 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23 0.12b\
        \ 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18 0.14b\
        \ 0.18 0.27b 0.09b 0.14b a b Relative coupling efficiency parameter, , was\
        \ determined via nonlinear regression of the data to an operational model\
        \ of agonism and corrected for receptor expression levels to yield a corrected\
        \ C parameter.///In addition, 77-LH-28-1 showed affinity increases (3\u2013\
        30 fold) at Y4036.51A, Y802.61A, E172Q/ D173N/E175Q and the combined E172Q/D173N/E175Q/Y177A/\
        \ T4237.36A mutant.///In addition, 77-LH-28-1 showed affinity increases (3\u2013\
        30 fold) at Y4036.51A, Y802.61A, E172Q/ D173N/E175Q and the combined E172Q/D173N/E175Q/Y177A/\
        \ T4237.36A mutant.///The combined mutations, E172Q/D173N/ E175Q and E172Q/D173N/E175Q/Y177A/T4237.36A,\
        \ are indicated by EDGE and EDGE Y T, respectively. on the Agonist-None of\
        \ the mutaData represent the mean S.E. of 5\u201316 experiments performed\
        \ in duplicate. no resp., there was no tions introduced into the M2 detectable\
        \ agonism; *, significantly different from wild type, p 0.05, one-way ANOVA,\
        \ Dunnett\u2019s post- mAChR had any discernible effect test. #, the agonist\
        \ was capable of eliciting the maximal system response, such that its pKA\
        \ was constrained to equal that determined by radioligand binding.///The combined\
        \ mutations, E172Q/D173N/ E175Q and E172Q/D173N/E175Q/Y177A/T4237.36A, are\
        \ indicated by EDGE and EDGE Y T, respectively. on the Agonist-None of the\
        \ mutaData represent the mean S.E. of 5\u201316 experiments performed in duplicate.\
        \ no resp., there was no tions introduced into the M2 detectable agonism;\
        \ *, significantly different from wild type, p 0.05, one-way ANOVA, Dunnett\u2019\
        s post- mAChR had any discernible effect test. #, the agonist was capable\
        \ of eliciting the maximal system response, such that its pKA was constrained\
        \ to equal that determined by radioligand binding.///The functional affinity\
        \ of activation was provided by the significant decreases in efficacy 77-LH-28-1\
        \ was increased (7\u201325-fold) at Y177A, T4237.36A, that were evident for\
        \ ACh, arecoline, CCh, pilocarpine, 77-LHand the combined E172Q/D173N/E175Q/Y177A/T4237.36A\
        \ 28-1, and NDMC at this mutation (Fig. 8 and Table 4). mutant (Fig. 3 and\
        \ Table 3).///The efficacy of McN-A-343 was significantly increased at found\
        \ that alanine substitution of this residue resulted in Y177A and E172Q/D173N/E175Q/Y177A/T4237.36A\
        \ (7- and almost complete abrogation of agonist signaling to the ERK1/2 17-fold,\
        \ respectively; Table 4), such that McN-A-343 elicited a pathway; ACh could\
        \ only maximally elicit 10% of the wild similar maximal response to ACh.",
    pubmed: '20051519', seq: '175', to_res: Q}
- {entry_name: acm2_human, from_res: E, info: "The primers for the E172Q/D173N/E175Q,\
        \ Y177A, T4237.36A,5 and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs\
        \ have been reported previously (19, 35).///The primers for the E172Q/D173N/E175Q,\
        \ Y177A, T4237.36A,5 and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs\
        \ have been reported previously (19, 35).///The spacing divides mutations\
        \ into predominantly orthosteric (top) versus allosteric site M2 receptor\
        \ Bmaxa pKDb 3H QNB pKIc ACh Arecoline CCh Pilocarpine AC-42 77-LH-28-1 McN-A-343\
        \ 0.24 0.08d 0.18 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07 0.08d 0.06d 4.30 4.73\
        \ 4.26 4.25 4.38 4.45 4.44 4.44 4.42 4.61 4.50 4.61 0.03 0.10 0.06 0.07 0.19\
        \ 0.07 0.08 0.10 0.22 0.22 0.23 0.13 NDMC 6.15 6.32 5.03 5.76 5.74 5.85 5.91\
        \ 6.17 6.16 5.99 6.31 6.15 0.13 0.14 0.11d 0.22 0.07 0.15 0.02 0.02 0.09 0.07\
        \ 0.14 0.06 pmol/mg Wild type 2.11 0.36 10.01 0.04 5.11 0.15 4.99 0.27 4.85\
        \ 0.19 5.00 4.16 0.68 9.60 0.08d 4.45 0.06d 5.18 0.13 4.29 0.46 4.63 W993.28A\
        \ 3.29 L100 A 4.87 0.89 8.69 0.11d 3.34 0.16d 3.62 0.03d 3.34 0.36d 4.04 Y1043.33A\
        \ 1.72 0.38 8.41 0.03d 2.54 0.11d 3.04 0.31d 2.48 0.11d 2.95 S1073.36A 4.94\
        \ 0.39 9.69 0.07d 3.82 0.19d 4.27 0.06d 3.55 0.39d 4.76 Y4036.51A 4.61 0.92\
        \ 9.49 0.04d 3.06 0.12d 3.67 0.16d 3.04 0.18d 3.42 Y802.61A 3.22 1.27 9.62\
        \ 0.11d 4.91 0.25 4.66 0.12 4.21 0.23 4.77 Y177A 4.55 1.41 10.00 0.29 5.02\
        \ 0.24 4.75 0.17 4.43 0.22 4.82 N4197.32A 3.51 0.29 10.20 0.02 5.62 0.28 5.15\
        \ 0.12 4.89 0.22 5.24 T4237.36A 5.56 1.20 9.61 0.15d 5.54 0.32 5.16 0.23 4.85\
        \ 0.15 5.10 E172Q/D173N/E175Q 2.84 0.88 10.30 0.14d 5.54 0.09 5.13 0.09 5.07\
        \ 0.15 5.11 E172Q/D173N/E175Q/ 1.50 0.11 9.93 0.06 5.08 0.23 4.49 0.04 4.44\
        \ 0.08 4.88 Y177A/T4237.36A a Maximum density of binding sites. b Negative\
        \ logarithm of the radioligand equilibrium dissociation constant.///The spacing\
        \ divides mutations into predominantly orthosteric (top) versus allosteric\
        \ site M2 receptor Bmaxa pKDb 3H QNB pKIc ACh Arecoline CCh Pilocarpine AC-42\
        \ 77-LH-28-1 McN-A-343 0.24 0.08d 0.18 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07\
        \ 0.08d 0.06d 4.30 4.73 4.26 4.25 4.38 4.45 4.44 4.44 4.42 4.61 4.50 4.61\
        \ 0.03 0.10 0.06 0.07 0.19 0.07 0.08 0.10 0.22 0.22 0.23 0.13 NDMC 6.15 6.32\
        \ 5.03 5.76 5.74 5.85 5.91 6.17 6.16 5.99 6.31 6.15 0.13 0.14 0.11d 0.22 0.07\
        \ 0.15 0.02 0.02 0.09 0.07 0.14 0.06 pmol/mg Wild type 2.11 0.36 10.01 0.04\
        \ 5.11 0.15 4.99 0.27 4.85 0.19 5.00 4.16 0.68 9.60 0.08d 4.45 0.06d 5.18\
        \ 0.13 4.29 0.46 4.63 W993.28A 3.29 L100 A 4.87 0.89 8.69 0.11d 3.34 0.16d\
        \ 3.62 0.03d 3.34 0.36d 4.04 Y1043.33A 1.72 0.38 8.41 0.03d 2.54 0.11d 3.04\
        \ 0.31d 2.48 0.11d 2.95 S1073.36A 4.94 0.39 9.69 0.07d 3.82 0.19d 4.27 0.06d\
        \ 3.55 0.39d 4.76 Y4036.51A 4.61 0.92 9.49 0.04d 3.06 0.12d 3.67 0.16d 3.04\
        \ 0.18d 3.42 Y802.61A 3.22 1.27 9.62 0.11d 4.91 0.25 4.66 0.12 4.21 0.23 4.77\
        \ Y177A 4.55 1.41 10.00 0.29 5.02 0.24 4.75 0.17 4.43 0.22 4.82 N4197.32A\
        \ 3.51 0.29 10.20 0.02 5.62 0.28 5.15 0.12 4.89 0.22 5.24 T4237.36A 5.56 1.20\
        \ 9.61 0.15d 5.54 0.32 5.16 0.23 4.85 0.15 5.10 E172Q/D173N/E175Q 2.84 0.88\
        \ 10.30 0.14d 5.54 0.09 5.13 0.09 5.07 0.15 5.11 E172Q/D173N/E175Q/ 1.50 0.11\
        \ 9.93 0.06 5.08 0.23 4.49 0.04 4.44 0.08 4.88 Y177A/T4237.36A a Maximum density\
        \ of binding sites. b Negative logarithm of the radioligand equilibrium dissociation\
        \ constant.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A\
        \ Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/\
        \ Y177A/T4237.36A pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94\
        \ 0.08 6.53 0.07c NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c\
        \ AC-42 NR 7.42b NR NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b\
        \ 5.18b 4.80 0.19 NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b\
        \ NR 3.55b 3.91 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47\
        \ 0.12 4.81 0.16 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53\
        \ NDMC 6.40 0.46 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17\
        \ 6.32 0.08 6.00 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR\
        \ 5.49 0.09 4.38 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b\
        \ 5.14 5.07 5.05 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A\
        \ Y802.61A Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13\
        \ AC-42 NR 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25\
        \ 5.21 0.12 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43\
        \ 2.90 0.12c ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37\
        \ 0.27 0.38 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42\
        \ 0.20 Pilocarpine 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07\
        \ 0.31c Downloaded from www.jbc.org at Monash University (CAUL), on March\
        \ 7, 2010 a Negative logarithm of the equilibrium dissociation constant for\
        \ each ligand, determined utilizing an operational model of agonism.///M2\
        \ receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A\
        \ Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A\
        \ pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94 0.08 6.53 0.07c\
        \ NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c AC-42 NR 7.42b NR\
        \ NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b 5.18b 4.80 0.19\
        \ NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b NR 3.55b 3.91\
        \ 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47 0.12 4.81 0.16\
        \ 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53 NDMC 6.40 0.46\
        \ 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17 6.32 0.08 6.00\
        \ 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR 5.49 0.09 4.38\
        \ 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b 5.14 5.07 5.05\
        \ 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A Y802.61A\
        \ Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13 AC-42 NR\
        \ 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25 5.21 0.12\
        \ 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43 2.90 0.12c\
        \ ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37 0.27 0.38\
        \ 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42 0.20 Pilocarpine\
        \ 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07 0.31c Downloaded\
        \ from www.jbc.org at Monash University (CAUL), on March 7, 2010 a Negative\
        \ logarithm of the equilibrium dissociation constant for each ligand, determined\
        \ utilizing an operational model of agonism.///M2 receptor Wild type W993.28A\
        \ L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A\
        \ E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 log ACh 0.07\
        \ 0.04b 0.08b NR 2.20 0.10b 1.37 0.09b 2.95 0.08 2.67 0.12 2.40 0.09b 1.82\
        \ 0.12b 2.16 0.18b 2.53 0.10b 2.90 2.59 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b\
        \ 0.73 0.07b NR 0.29 0.09 0.18 0.08 NR 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84\
        \ 0.13b 0.28 0.11 AC-42 NR 0.69 0.09 NR NR NR 0.52 0.10 NR NR NR NR NR 0.42\
        \ 0.09 Arecoline 2.18 0.09 1.65 0.08b 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53\
        \ 0.08 ND ND ND ND ND a C CCh 2.34 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b\
        \ 0.10 0.10b 2.66 0.07 ND ND ND ND ND McN-A-343 0.38 0.07 0.39 0.20 NR NR\
        \ NR 0.51 0.09 0.20 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b\
        \ NDMC 0.08 0.08 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05\
        \ 0.21 0.08 0.08 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine 0.34 0.11 0.54\
        \ 0.25 0.37 0.09b NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05\
        \ 0.05 0.06b 0.07 0.07 0.80 0.09 35 S GTP S log C ACh Wild type W993.28A Y1043.33A\
        \ Y4036.51A Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b\
        \ 0.17 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09\
        \ 0.25b 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline\
        \ 1.02 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39\
        \ 0.29 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30\
        \ 0.44 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23\
        \ 0.12b 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18\
        \ 0.14b 0.18 0.27b 0.09b 0.14b a b Relative coupling efficiency parameter,\
        \ , was determined via nonlinear regression of the data to an operational\
        \ model of agonism and corrected for receptor expression levels to yield a\
        \ corrected C parameter.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A\
        \ S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q\
        \ E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 log ACh 0.07 0.04b 0.08b NR 2.20\
        \ 0.10b 1.37 0.09b 2.95 0.08 2.67 0.12 2.40 0.09b 1.82 0.12b 2.16 0.18b 2.53\
        \ 0.10b 2.90 2.59 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b 0.73 0.07b NR 0.29\
        \ 0.09 0.18 0.08 NR 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84 0.13b 0.28 0.11 AC-42\
        \ NR 0.69 0.09 NR NR NR 0.52 0.10 NR NR NR NR NR 0.42 0.09 Arecoline 2.18\
        \ 0.09 1.65 0.08b 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53 0.08 ND ND ND ND\
        \ ND a C CCh 2.34 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b 0.10 0.10b 2.66\
        \ 0.07 ND ND ND ND ND McN-A-343 0.38 0.07 0.39 0.20 NR NR NR 0.51 0.09 0.20\
        \ 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b NDMC 0.08 0.08\
        \ 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05 0.21 0.08 0.08\
        \ 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine 0.34 0.11 0.54 0.25 0.37 0.09b\
        \ NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05 0.05 0.06b 0.07\
        \ 0.07 0.80 0.09 35 S GTP S log C ACh Wild type W993.28A Y1043.33A Y4036.51A\
        \ Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b 0.17\
        \ 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09 0.25b\
        \ 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline 1.02\
        \ 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39 0.29\
        \ 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30 0.44\
        \ 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23 0.12b\
        \ 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18 0.14b\
        \ 0.18 0.27b 0.09b 0.14b a b Relative coupling efficiency parameter, , was\
        \ determined via nonlinear regression of the data to an operational model\
        \ of agonism and corrected for receptor expression levels to yield a corrected\
        \ C parameter.///In addition, 77-LH-28-1 showed affinity increases (3\u2013\
        30 fold) at Y4036.51A, Y802.61A, E172Q/ D173N/E175Q and the combined E172Q/D173N/E175Q/Y177A/\
        \ T4237.36A mutant.///In addition, 77-LH-28-1 showed affinity increases (3\u2013\
        30 fold) at Y4036.51A, Y802.61A, E172Q/ D173N/E175Q and the combined E172Q/D173N/E175Q/Y177A/\
        \ T4237.36A mutant.///The combined mutations, E172Q/D173N/ E175Q and E172Q/D173N/E175Q/Y177A/T4237.36A,\
        \ are indicated by EDGE and EDGE Y T, respectively. on the Agonist-None of\
        \ the mutaData represent the mean S.E. of 5\u201316 experiments performed\
        \ in duplicate. no resp., there was no tions introduced into the M2 detectable\
        \ agonism; *, significantly different from wild type, p 0.05, one-way ANOVA,\
        \ Dunnett\u2019s post- mAChR had any discernible effect test. #, the agonist\
        \ was capable of eliciting the maximal system response, such that its pKA\
        \ was constrained to equal that determined by radioligand binding.///The combined\
        \ mutations, E172Q/D173N/ E175Q and E172Q/D173N/E175Q/Y177A/T4237.36A, are\
        \ indicated by EDGE and EDGE Y T, respectively. on the Agonist-None of the\
        \ mutaData represent the mean S.E. of 5\u201316 experiments performed in duplicate.\
        \ no resp., there was no tions introduced into the M2 detectable agonism;\
        \ *, significantly different from wild type, p 0.05, one-way ANOVA, Dunnett\u2019\
        s post- mAChR had any discernible effect test. #, the agonist was capable\
        \ of eliciting the maximal system response, such that its pKA was constrained\
        \ to equal that determined by radioligand binding.///The functional affinity\
        \ of activation was provided by the significant decreases in efficacy 77-LH-28-1\
        \ was increased (7\u201325-fold) at Y177A, T4237.36A, that were evident for\
        \ ACh, arecoline, CCh, pilocarpine, 77-LHand the combined E172Q/D173N/E175Q/Y177A/T4237.36A\
        \ 28-1, and NDMC at this mutation (Fig. 8 and Table 4). mutant (Fig. 3 and\
        \ Table 3).///Small reductions ( 3-fold) in Identification of Tyr-1043.33\
        \ as a Key Residue That Selectively 77-LH-28-1 efficacy were seen for the\
        \ N4197.32A, T4237.36A, Couples Receptor Activation to the ERK1/2 Pathway\
        \ Irrespecand E172Q/D173N/E1754Q mutants.///The efficacy of McN-A-343 was\
        \ significantly increased at found that alanine substitution of this residue\
        \ resulted in Y177A and E172Q/D173N/E175Q/Y177A/T4237.36A (7- and almost complete\
        \ abrogation of agonist signaling to the ERK1/2 17-fold, respectively; Table\
        \ 4), such that McN-A-343 elicited a pathway; ACh could only maximally elicit\
        \ 10% of the wild similar maximal response to ACh.", pubmed: '20051519', seq: '172',
    to_res: Q}
- {entry_name: acm2_human, from_res: D, info: "The primers for the E172Q/D173N/E175Q,\
        \ Y177A, T4237.36A,5 and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs\
        \ have been reported previously (19, 35).///The primers for the E172Q/D173N/E175Q,\
        \ Y177A, T4237.36A,5 and combined E172Q/D173N/E175Q/Y177A/T4237.36A constructs\
        \ have been reported previously (19, 35).///The spacing divides mutations\
        \ into predominantly orthosteric (top) versus allosteric site M2 receptor\
        \ Bmaxa pKDb 3H QNB pKIc ACh Arecoline CCh Pilocarpine AC-42 77-LH-28-1 McN-A-343\
        \ 0.24 0.08d 0.18 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07 0.08d 0.06d 4.30 4.73\
        \ 4.26 4.25 4.38 4.45 4.44 4.44 4.42 4.61 4.50 4.61 0.03 0.10 0.06 0.07 0.19\
        \ 0.07 0.08 0.10 0.22 0.22 0.23 0.13 NDMC 6.15 6.32 5.03 5.76 5.74 5.85 5.91\
        \ 6.17 6.16 5.99 6.31 6.15 0.13 0.14 0.11d 0.22 0.07 0.15 0.02 0.02 0.09 0.07\
        \ 0.14 0.06 pmol/mg Wild type 2.11 0.36 10.01 0.04 5.11 0.15 4.99 0.27 4.85\
        \ 0.19 5.00 4.16 0.68 9.60 0.08d 4.45 0.06d 5.18 0.13 4.29 0.46 4.63 W993.28A\
        \ 3.29 L100 A 4.87 0.89 8.69 0.11d 3.34 0.16d 3.62 0.03d 3.34 0.36d 4.04 Y1043.33A\
        \ 1.72 0.38 8.41 0.03d 2.54 0.11d 3.04 0.31d 2.48 0.11d 2.95 S1073.36A 4.94\
        \ 0.39 9.69 0.07d 3.82 0.19d 4.27 0.06d 3.55 0.39d 4.76 Y4036.51A 4.61 0.92\
        \ 9.49 0.04d 3.06 0.12d 3.67 0.16d 3.04 0.18d 3.42 Y802.61A 3.22 1.27 9.62\
        \ 0.11d 4.91 0.25 4.66 0.12 4.21 0.23 4.77 Y177A 4.55 1.41 10.00 0.29 5.02\
        \ 0.24 4.75 0.17 4.43 0.22 4.82 N4197.32A 3.51 0.29 10.20 0.02 5.62 0.28 5.15\
        \ 0.12 4.89 0.22 5.24 T4237.36A 5.56 1.20 9.61 0.15d 5.54 0.32 5.16 0.23 4.85\
        \ 0.15 5.10 E172Q/D173N/E175Q 2.84 0.88 10.30 0.14d 5.54 0.09 5.13 0.09 5.07\
        \ 0.15 5.11 E172Q/D173N/E175Q/ 1.50 0.11 9.93 0.06 5.08 0.23 4.49 0.04 4.44\
        \ 0.08 4.88 Y177A/T4237.36A a Maximum density of binding sites. b Negative\
        \ logarithm of the radioligand equilibrium dissociation constant.///The spacing\
        \ divides mutations into predominantly orthosteric (top) versus allosteric\
        \ site M2 receptor Bmaxa pKDb 3H QNB pKIc ACh Arecoline CCh Pilocarpine AC-42\
        \ 77-LH-28-1 McN-A-343 0.24 0.08d 0.18 0.25 0.19 0.15d 0.02d 0.10 0.08 0.07\
        \ 0.08d 0.06d 4.30 4.73 4.26 4.25 4.38 4.45 4.44 4.44 4.42 4.61 4.50 4.61\
        \ 0.03 0.10 0.06 0.07 0.19 0.07 0.08 0.10 0.22 0.22 0.23 0.13 NDMC 6.15 6.32\
        \ 5.03 5.76 5.74 5.85 5.91 6.17 6.16 5.99 6.31 6.15 0.13 0.14 0.11d 0.22 0.07\
        \ 0.15 0.02 0.02 0.09 0.07 0.14 0.06 pmol/mg Wild type 2.11 0.36 10.01 0.04\
        \ 5.11 0.15 4.99 0.27 4.85 0.19 5.00 4.16 0.68 9.60 0.08d 4.45 0.06d 5.18\
        \ 0.13 4.29 0.46 4.63 W993.28A 3.29 L100 A 4.87 0.89 8.69 0.11d 3.34 0.16d\
        \ 3.62 0.03d 3.34 0.36d 4.04 Y1043.33A 1.72 0.38 8.41 0.03d 2.54 0.11d 3.04\
        \ 0.31d 2.48 0.11d 2.95 S1073.36A 4.94 0.39 9.69 0.07d 3.82 0.19d 4.27 0.06d\
        \ 3.55 0.39d 4.76 Y4036.51A 4.61 0.92 9.49 0.04d 3.06 0.12d 3.67 0.16d 3.04\
        \ 0.18d 3.42 Y802.61A 3.22 1.27 9.62 0.11d 4.91 0.25 4.66 0.12 4.21 0.23 4.77\
        \ Y177A 4.55 1.41 10.00 0.29 5.02 0.24 4.75 0.17 4.43 0.22 4.82 N4197.32A\
        \ 3.51 0.29 10.20 0.02 5.62 0.28 5.15 0.12 4.89 0.22 5.24 T4237.36A 5.56 1.20\
        \ 9.61 0.15d 5.54 0.32 5.16 0.23 4.85 0.15 5.10 E172Q/D173N/E175Q 2.84 0.88\
        \ 10.30 0.14d 5.54 0.09 5.13 0.09 5.07 0.15 5.11 E172Q/D173N/E175Q/ 1.50 0.11\
        \ 9.93 0.06 5.08 0.23 4.49 0.04 4.44 0.08 4.88 Y177A/T4237.36A a Maximum density\
        \ of binding sites. b Negative logarithm of the radioligand equilibrium dissociation\
        \ constant.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A\
        \ Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/\
        \ Y177A/T4237.36A pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94\
        \ 0.08 6.53 0.07c NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c\
        \ AC-42 NR 7.42b NR NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b\
        \ 5.18b 4.80 0.19 NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b\
        \ NR 3.55b 3.91 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47\
        \ 0.12 4.81 0.16 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53\
        \ NDMC 6.40 0.46 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17\
        \ 6.32 0.08 6.00 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR\
        \ 5.49 0.09 4.38 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b\
        \ 5.14 5.07 5.05 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A\
        \ Y802.61A Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13\
        \ AC-42 NR 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25\
        \ 5.21 0.12 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43\
        \ 2.90 0.12c ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37\
        \ 0.27 0.38 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42\
        \ 0.20 Pilocarpine 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07\
        \ 0.31c Downloaded from www.jbc.org at Monash University (CAUL), on March\
        \ 7, 2010 a Negative logarithm of the equilibrium dissociation constant for\
        \ each ligand, determined utilizing an operational model of agonism.///M2\
        \ receptor Wild type W993.28A L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A\
        \ Y177A N4197.32A T4237.36A E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A\
        \ pERK1/2 pKAa 77-LH-28-1 5.56 0.37 8.84b 5.73 0.30 NR 5.94 0.08 6.53 0.07c\
        \ NR 6.31 0.18c 5.97 0.15 6.44 0.26c 6.07 0.15 6.78 0.16c AC-42 NR 7.42b NR\
        \ NR NR 6.10 0.19 NR NR NR NR NR 5.27 0.32 Arecoline 4.99b 5.18b 4.80 0.19\
        \ NR 4.27b 3.67b 4.66b ND ND ND ND ND CCh 4.85b 4.29b 3.34b NR 3.55b 3.91\
        \ 0.11 4.21b ND ND ND ND ND McN-A-343 0.06 0.06 NR NR NR 5.47 0.12 4.81 0.16\
        \ 4.77 0.20c 5.23 0.09 5.25 0.12 4.96 0.11 4.61b 5.19 5.53 NDMC 6.40 0.46\
        \ 6.66 0.11 6.07 0.11 NR 6.12 0.11 5.85b 6.58 0.11 6.43 0.17 6.32 0.08 6.00\
        \ 0.21c 5.80 0.24c 6.13 0.06 Pilocarpine 0.23 0.21 0.11 NR 5.49 0.09 4.38\
        \ 0.32c 4.77b 5.35 0.18 5.59 0.09 5.25 0.07 5.23 0.10 4.88b 5.14 5.07 5.05\
        \ 35 S GTP S pKA 77-LH-28-1 Wild type W993.28A Y1043.33A Y4036.51A Y802.61A\
        \ Y177A 6.27 0.09 8.69 0.27c 5.17b 6.92 0.05 6.90 0.40 6.75 0.13 AC-42 NR\
        \ 7.61 0.10 5.71 0.28 6.08 0.25 6.47 0.18 NR Arecoline 5.24 0.25 5.21 0.12\
        \ 3.03 0.27c 4.06 0.22 ND 4.71 0.58 CCh 4.85b 4.10 0.10 2.57 0.43 2.90 0.12c\
        \ ND 4.75 0.39 McN-A-343 5.27 4.94 5.05 5.13 4.50 5.01 0.13 0.37 0.27 0.38\
        \ 0.14 0.22 NDMC 6.78 0.26 6.68 0.10 5.76b 5.85b 6.23 0.14 6.42 0.20 Pilocarpine\
        \ 5.55 4.49 3.18 3.71 4.82 4.47 0.30 0.15c 0.20c 0.29c 0.07 0.31c Downloaded\
        \ from www.jbc.org at Monash University (CAUL), on March 7, 2010 a Negative\
        \ logarithm of the equilibrium dissociation constant for each ligand, determined\
        \ utilizing an operational model of agonism.///M2 receptor Wild type W993.28A\
        \ L1003.29A Y1043.33A S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A\
        \ E172Q/D173N/E175Q E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 log ACh 0.07\
        \ 0.04b 0.08b NR 2.20 0.10b 1.37 0.09b 2.95 0.08 2.67 0.12 2.40 0.09b 1.82\
        \ 0.12b 2.16 0.18b 2.53 0.10b 2.90 2.59 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b\
        \ 0.73 0.07b NR 0.29 0.09 0.18 0.08 NR 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84\
        \ 0.13b 0.28 0.11 AC-42 NR 0.69 0.09 NR NR NR 0.52 0.10 NR NR NR NR NR 0.42\
        \ 0.09 Arecoline 2.18 0.09 1.65 0.08b 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53\
        \ 0.08 ND ND ND ND ND a C CCh 2.34 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b\
        \ 0.10 0.10b 2.66 0.07 ND ND ND ND ND McN-A-343 0.38 0.07 0.39 0.20 NR NR\
        \ NR 0.51 0.09 0.20 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b\
        \ NDMC 0.08 0.08 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05\
        \ 0.21 0.08 0.08 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine 0.34 0.11 0.54\
        \ 0.25 0.37 0.09b NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05\
        \ 0.05 0.06b 0.07 0.07 0.80 0.09 35 S GTP S log C ACh Wild type W993.28A Y1043.33A\
        \ Y4036.51A Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b\
        \ 0.17 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09\
        \ 0.25b 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline\
        \ 1.02 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39\
        \ 0.29 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30\
        \ 0.44 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23\
        \ 0.12b 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18\
        \ 0.14b 0.18 0.27b 0.09b 0.14b a b Relative coupling efficiency parameter,\
        \ , was determined via nonlinear regression of the data to an operational\
        \ model of agonism and corrected for receptor expression levels to yield a\
        \ corrected C parameter.///M2 receptor Wild type W993.28A L1003.29A Y1043.33A\
        \ S1073.36A Y4036.51A Y802.61A Y177A N4197.32A T4237.36A E172Q/D173N/E175Q\
        \ E172Q/D173N/E175Q/ Y177A/T4237.36A pERK1/2 log ACh 0.07 0.04b 0.08b NR 2.20\
        \ 0.10b 1.37 0.09b 2.95 0.08 2.67 0.12 2.40 0.09b 1.82 0.12b 2.16 0.18b 2.53\
        \ 0.10b 2.90 2.59 2.20 77-LH-28-1 0.25 0.14 0.14 0.07b 0.73 0.07b NR 0.29\
        \ 0.09 0.18 0.08 NR 0.47 0.10 0.71 0.09b 0.85 0.16b 0.84 0.13b 0.28 0.11 AC-42\
        \ NR 0.69 0.09 NR NR NR 0.52 0.10 NR NR NR NR NR 0.42 0.09 Arecoline 2.18\
        \ 0.09 1.65 0.08b 0.17 0.09b NR 1.85 0.05 0.97 0.27b 2.53 0.08 ND ND ND ND\
        \ ND a C CCh 2.34 0.03 2.02 0.10 1.32 0.13b NR 1.70 0.05b 0.10 0.10b 2.66\
        \ 0.07 ND ND ND ND ND McN-A-343 0.38 0.07 0.39 0.20 NR NR NR 0.51 0.09 0.20\
        \ 0.11 0.48 0.25b 0.51 0.07 0.70 0.07 0.40 0.12 0.86 0.09b NDMC 0.08 0.08\
        \ 0.12 0.14 0.48 0.06b NR 0.33 0.05 0.72 0.14b 0.03 0.09 0.05 0.21 0.08 0.08\
        \ 0.53 0.06b 0.36 0.10 0.16 0.06 Pilocarpine 0.34 0.11 0.54 0.25 0.37 0.09b\
        \ NR 0.37 0.08b 0.96 0.13b 1.04 0.31b 0.10 0.28 0.15 0.05 0.05 0.06b 0.07\
        \ 0.07 0.80 0.09 35 S GTP S log C ACh Wild type W993.28A Y1043.33A Y4036.51A\
        \ Y802.61A Y177A 1.83 1.18 1.06 0.43 1.54 0.53 0.22 0.22 0.18b 0.22b 0.17\
        \ 0.11b 77-LH-28-1 0.01 0.13 1.24 0.26 0.93 0.68 0.08 0.37 0.16b 0.09 0.25b\
        \ 0.11b AC-42 NR 0.44 0.64 0.42 0.22 0.35 0.12 0.81 0.20 NR Arecoline 1.02\
        \ 0.31 0.07 0.04b 0.08 0.10b 0.08 0.08b ND 0.02 0.13b CCh 1.03 0.18 0.39 0.29\
        \ 0.68 0.25 0.27 0.22 ND 0.05 0.24b McN-A-343 0.09 0.57 0.50 0.68 0.30 0.44\
        \ 0.16 0.12 0.19 0.31 0.25 0.05 NDMC 0.12 0.54 0.81 0.78 0.20 0.54 0.23 0.12b\
        \ 0.09b 0.10b 0.13 0.11b Pilocarpine 0.30 0.37 0.09 0.59 0.93 0.77 0.18 0.14b\
        \ 0.18 0.27b 0.09b 0.14b a b Relative coupling efficiency parameter, , was\
        \ determined via nonlinear regression of the data to an operational model\
        \ of agonism and corrected for receptor expression levels to yield a corrected\
        \ C parameter.///In addition, 77-LH-28-1 showed affinity increases (3\u2013\
        30 fold) at Y4036.51A, Y802.61A, E172Q/ D173N/E175Q and the combined E172Q/D173N/E175Q/Y177A/\
        \ T4237.36A mutant.///In addition, 77-LH-28-1 showed affinity increases (3\u2013\
        30 fold) at Y4036.51A, Y802.61A, E172Q/ D173N/E175Q and the combined E172Q/D173N/E175Q/Y177A/\
        \ T4237.36A mutant.///The combined mutations, E172Q/D173N/ E175Q and E172Q/D173N/E175Q/Y177A/T4237.36A,\
        \ are indicated by EDGE and EDGE Y T, respectively. on the Agonist-None of\
        \ the mutaData represent the mean S.E. of 5\u201316 experiments performed\
        \ in duplicate. no resp., there was no tions introduced into the M2 detectable\
        \ agonism; *, significantly different from wild type, p 0.05, one-way ANOVA,\
        \ Dunnett\u2019s post- mAChR had any discernible effect test. #, the agonist\
        \ was capable of eliciting the maximal system response, such that its pKA\
        \ was constrained to equal that determined by radioligand binding.///The combined\
        \ mutations, E172Q/D173N/ E175Q and E172Q/D173N/E175Q/Y177A/T4237.36A, are\
        \ indicated by EDGE and EDGE Y T, respectively. on the Agonist-None of the\
        \ mutaData represent the mean S.E. of 5\u201316 experiments performed in duplicate.\
        \ no resp., there was no tions introduced into the M2 detectable agonism;\
        \ *, significantly different from wild type, p 0.05, one-way ANOVA, Dunnett\u2019\
        s post- mAChR had any discernible effect test. #, the agonist was capable\
        \ of eliciting the maximal system response, such that its pKA was constrained\
        \ to equal that determined by radioligand binding.///The functional affinity\
        \ of activation was provided by the significant decreases in efficacy 77-LH-28-1\
        \ was increased (7\u201325-fold) at Y177A, T4237.36A, that were evident for\
        \ ACh, arecoline, CCh, pilocarpine, 77-LHand the combined E172Q/D173N/E175Q/Y177A/T4237.36A\
        \ 28-1, and NDMC at this mutation (Fig. 8 and Table 4). mutant (Fig. 3 and\
        \ Table 3).///Small reductions ( 3-fold) in Identification of Tyr-1043.33\
        \ as a Key Residue That Selectively 77-LH-28-1 efficacy were seen for the\
        \ N4197.32A, T4237.36A, Couples Receptor Activation to the ERK1/2 Pathway\
        \ Irrespecand E172Q/D173N/E1754Q mutants.///The efficacy of McN-A-343 was\
        \ significantly increased at found that alanine substitution of this residue\
        \ resulted in Y177A and E172Q/D173N/E175Q/Y177A/T4237.36A (7- and almost complete\
        \ abrogation of agonist signaling to the ERK1/2 17-fold, respectively; Table\
        \ 4), such that McN-A-343 elicited a pathway; ACh could only maximally elicit\
        \ 10% of the wild similar maximal response to ACh.", pubmed: '20051519', seq: '173',
    to_res: N}
- {entry_name: acm2_human, from_res: Y, info: 'We have identified four broad classes
        of ago- Y2.61A at the M mAChR did not affect 77-LH-28-1 affinity 1 nist, which
        indicates multiple modes of agonist-receptor (44), whereas we noted a significant
        enhancement in affinity engagement.', pubmed: '20051519', seq: '80', to_res: A}
- {entry_name: aa2ar_human, from_res: L, info: 'Previous mutagenesis data on V84A
        or L249A suggested these non-polar interactions are essential for agonist
        binding (25, 29).', pubmed: '21393508', seq: '249', to_res: A}
- {entry_name: aa2ar_human, from_res: V, info: 'Previous mutagenesis data on V84A
        or L249A suggested these non-polar interactions are essential for agonist
        binding (25, 29).', pubmed: '21393508', seq: '84', to_res: A}
- {entry_name: aa2ar_human, from_res: T, info: "The N2 of this moiety makes a hydrogen\
        \ bond with Thr883.36 (3.0 \xC5), in accord with reduction in binding observed\
        \ for the T88A mutant of A2AAR (30).", pubmed: '21393508', seq: '88', to_res: A}
- {entry_name: agtr2_human, from_res: T, info: 'The following point mutants were made
        using overlap PCR: GIRK2 ATCLAN (G318A, C321T, A323C, I328L, T329A, S330N),
        GIRK2 ATC (G318A, C321T, A323C), IRK1 GCA (A306G, T309C, C311A) and GIRK2C321V.',
    pubmed: '15691717', seq: '309', to_res: C}
- {entry_name: acm2_rat, from_res: T, info: 'The following point mutants were made
        using overlap PCR: GIRK2 ATCLAN (G318A, C321T, A323C, I328L, T329A, S330N),
        GIRK2 ATC (G318A, C321T, A323C), IRK1 GCA (A306G, T309C, C311A) and GIRK2C321V.',
    pubmed: '15691717', seq: '342', to_res: A}
- {entry_name: gabr2_rat, from_res: S, info: 'The following point mutants were made
        using overlap PCR: GIRK2 ATCLAN (G318A, C321T, A323C, I328L, T329A, S330N),
        GIRK2 ATC (G318A, C321T, A323C), IRK1 GCA (A306G, T309C, C311A) and GIRK2C321V.',
    pubmed: '15691717', seq: '330', to_res: N}
- {entry_name: adrb2_human, from_res: F, info: b2AR mutant F139A has severely impaired
        coupling to Gs19., pubmed: '21772288', seq: '139', to_res: A}
- {entry_name: adrb2_human, from_res: N, info: The PNGaseF-inaccessible glycosylation
        site of the b2AR at N187 was mutated to Glu., pubmed: '21772288', seq: '187',
    to_res: E}
- {entry_name: taar1_rat, from_res: M, info: "In the rTAAR1 6.55 single mutant [rTAAR1(M6.55T)]\
        \ the potency and efficacy of 3 (EC50 = 55 \xB1 20 nM, Emax = 119 \xB1 6%)\
        \ and 5 (EC50 = 11 \xB1 1 nM, Emax = 117 \xB1 20%) decreased 2- to 3-fold\
        \ and \u2264 12%, respectively (Table 2).///The potency of 3 and 5 decreased\
        \ 333- to 526-fold for the rTAAR1 6.55 and 7.39 double mutant [rTAAR1(M6.55T/\
        \ N7.39Y)] but increased 70- to 320-fold for the mTAAR1 6.55 and 7.39 double\
        \ mutant equivalent [mTAAR1(T6.55M/Y7.39N)] (Table 2).///The same trend was\
        \ also observed with regards to efficacy; decreasing 44% to 85% for rTAAR1(M6.55T/N7.39Y)\
        \ and increasing 39% to 95% for mTAAR1(T6.55M/Y7.39N).", pubmed: '19256523',
    seq: '268', to_res: T}
- {entry_name: taar1_rat, from_res: N, info: "The potency of both compounds decreased\
        \ 167- to 526-fold in the rTAAR1 7.39 mutant [rTAAR1(N7.39Y)] (EC50 = ~10\
        \ \u03BCM and ~1 \u03BCM for 3 and 5, respectively) but increased 60to 100-fold\
        \ in its mTAAR1 7.39 mutant counterpart [mTAAR1(Y7.39N)] (EC50 = 102 \xB1\
        \ 21 NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript\
        \ ACS Chem Biol. Author manuscript; available in PMC 2010 March 20. Tan et\
        \ al. Page 4 nM and 176 \xB1 32 nM for 3 and 5, respectively) (Table 2).///For\
        \ rTAAR1(N7.39Y) the efficacy of 5 (Emax = 126%) increased 12% while that\
        \ of 3 (Emax = 85%) decreased 46% compared to wild type.///The potency of\
        \ 3 and 5 decreased 333- to 526-fold for the rTAAR1 6.55 and 7.39 double mutant\
        \ [rTAAR1(M6.55T/ N7.39Y)] but increased 70- to 320-fold for the mTAAR1 6.55\
        \ and 7.39 double mutant equivalent [mTAAR1(T6.55M/Y7.39N)] (Table 2).///The\
        \ same trend was also observed with regards to efficacy; decreasing 44% to\
        \ 85% for rTAAR1(M6.55T/N7.39Y) and increasing 39% to 95% for mTAAR1(T6.55M/Y7.39N).",
    pubmed: '19256523', seq: '287', to_res: Y}
- {entry_name: taar1_human, from_res: F, info: "Interestingly, the potency of 1 (EC50\
        \ = 38 \xB1 11 nM) for the tyrosine mutant of rTAAR1 [rTAAR1(F4.56Y)] was\
        \ comparable to wild type rTAAR1 (33 \xB1 3 nM).///The same trend was also\
        \ observed for tyramine; where its potency increased 7-fold in mTAAR1(Y4.56F)\
        \ (EC50 = 40 \xB1 13 nM) but remained unaffected in rTAAR1(F4.56Y) (EC50 =\
        \ 54 \xB1 11 nM).///Although mutating residue 4.56 improved the potency in\
        \ the mTAAR1 mutants, the reciprocal effect of 1 and tyramine becoming less\
        \ potent for rTAAR1(F4.56Y) was not observed.", pubmed: '19256523', seq: '154',
    to_res: Y}
- {entry_name: taar1_mouse, from_res: T, info: "When T6.55 was mutated to a methionine\
        \ in mTAAR1 [mTAAR1(T6.55M)], both compounds were still poor agonists activating\
        \ the receptor with potencies >10\u03BCM and efficacies ranging from 20% to\
        \ 45%.///The potency of 3 and 5 decreased 333- to 526-fold for the rTAAR1\
        \ 6.55 and 7.39 double mutant [rTAAR1(M6.55T/ N7.39Y)] but increased 70- to\
        \ 320-fold for the mTAAR1 6.55 and 7.39 double mutant equivalent [mTAAR1(T6.55M/Y7.39N)]\
        \ (Table 2).///The same trend was also observed with regards to efficacy;\
        \ decreasing 44% to 85% for rTAAR1(M6.55T/N7.39Y) and increasing 39% to 95%\
        \ for mTAAR1(T6.55M/Y7.39N).", pubmed: '19256523', seq: '268', to_res: M}
- {entry_name: taar1_mouse, from_res: Y, info: "The potency of both compounds decreased\
        \ 167- to 526-fold in the rTAAR1 7.39 mutant [rTAAR1(N7.39Y)] (EC50 = ~10\
        \ \u03BCM and ~1 \u03BCM for 3 and 5, respectively) but increased 60to 100-fold\
        \ in its mTAAR1 7.39 mutant counterpart [mTAAR1(Y7.39N)] (EC50 = 102 \xB1\
        \ 21 NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript\
        \ ACS Chem Biol. Author manuscript; available in PMC 2010 March 20. Tan et\
        \ al. Page 4 nM and 176 \xB1 32 nM for 3 and 5, respectively) (Table 2).///The\
        \ efficacy of 3 (Emax = 95 \xB1 6%) and 5 (Emax = 91 \xB1 11%) both increased\
        \ 29% to 89% in mTAAR1(Y7.39N).///The potency of 3 and 5 decreased 333- to\
        \ 526-fold for the rTAAR1 6.55 and 7.39 double mutant [rTAAR1(M6.55T/ N7.39Y)]\
        \ but increased 70- to 320-fold for the mTAAR1 6.55 and 7.39 double mutant\
        \ equivalent [mTAAR1(T6.55M/Y7.39N)] (Table 2).///The same trend was also\
        \ observed with regards to efficacy; decreasing 44% to 85% for rTAAR1(M6.55T/N7.39Y)\
        \ and increasing 39% to 95% for mTAAR1(T6.55M/Y7.39N).", pubmed: '19256523',
    seq: '287', to_res: N}
- {entry_name: taar1_mouse, from_res: A, info: "To determine if tyramine and 1 have\
        \ similar or distinct binding modes, we mutated alanine 5.42 in rTAAR1 to\
        \ a threonine, leucine, or isoleucine [rTAAR1(A5.42T), rTAAR1(A5.42L), and\
        \ rTAAR1(A5.42I), respectively] and examined the effects of the mutations\
        \ on the potency of tyramine and 1.///In the rTAAR1(A5.42L) mutant, the potency\
        \ of 1 (EC50 = 58 \xB1 16 nM) and tyramine (EC50 = ~2 \u03BCM) decreased 2-\
        \ and 31- fold, respectively (Table 3a).", pubmed: '19256523', seq: '193',
    to_res: L}
- {entry_name: taar1_mouse, from_res: A, info: "To determine if tyramine and 1 have\
        \ similar or distinct binding modes, we mutated alanine 5.42 in rTAAR1 to\
        \ a threonine, leucine, or isoleucine [rTAAR1(A5.42T), rTAAR1(A5.42L), and\
        \ rTAAR1(A5.42I), respectively] and examined the effects of the mutations\
        \ on the potency of tyramine and 1.///A similar trend was observed for the\
        \ rTAAR1(A5.42T) mutant where 1 (EC50 = 88 \xB1 13 nM) and tyramine (EC50\
        \ = >10 \u03BCM) were 3- and 154-fold less potent.", pubmed: '19256523', seq: '193',
    to_res: T}
- {entry_name: bkrb2_human, from_res: M, info: 'REV. which (M165I, A270S, R400C, and
        K432Q) occurred with frequencies higher than 1% and altered transporter function
        in Xenopus laevis oocytes for metformin, phenformin, procainamide, and quinidine
        (160).', pubmed: '17041143', seq: '165', to_res: I}
- {entry_name: bkrb2_human, from_res: K, info: 'Conformational changes in the 313-to-365
        region of albumin are thought to account for diminished binding, whereas an
        increase in affinity for binding of warfarin has been found for in vitro recombinant
        mutants of albumin, such as His242Glu and Lys199Ala, while for Try214Ala and
        Arg218His a small decrease in affinity was observed (272).', pubmed: '17041143',
    seq: '199', to_res: A}
- {entry_name: hrh2_human, from_res: R, info: "Constitutive Constitutive 1 8\u2013\
        15 5\u201312 1\u20135 10 15\u201320 16 (voriconazole, terbinafine) 8 (voriconazole,\
        \ terbinafine) 19 11 (terbinafine) 3 3 CYP2C19 10q24.1-q24.3 Constitutive\
        \ CYP2D6 22q13.1 Constitutive 2 5 CYP2E1 CYP3A4 10q24.3-qter 7q21.1 Constitutive/\
        \ inducible Constitutive 7\u201311 30\u201340 4 36 (itraconazole, ketoconazole,\
        \ voriconazole, terbinafine) CYP3A5 7q21.1 Constitutive 1 CYP1A1*2A&B 3801T\
        \ C I462V CYP1A2*1F 164C A CYP2A6*2 L160H CYP2A6*4 Gene deletion CYP2A6*9\
        \ TATA-mut CYP2B6*5 R487C CYP2B6*7 Q172H; K262R; R487C CYP2C8*2 1269F Decreased\
        \ activity CYP2C8*3 R139K, K399R Decreased activity CYP2C8*4 1264M Decreased\
        \ activity CYP2C9*2 R144C Reduced affinity for P450 reductase CYP2C9*3 I359L\
        \ Altered substrate specificity CYP2C19*2 Altered splice site Inactive enzyme\
        \ CYP2C19*3 Stop codon Inactive enzyme CYP2D6*2xn Gene duplication Increased\
        \ activity CYP2D6*4 Defective splicing Inactive enzyme CYP2D6*5 Gene deletion\
        \ No enzyme CYP2D6*6 1707T del P34S No enzyme CYP2D6*10 S486T T107I Unstable\
        \ enzyme CYP2D6*17 R296C S486T Reduced affinity for substrates CYP2E1*2 R76H\
        \ Less enzyme expressed CYP2E1*3 V389I No effects CYP2E1*4 V179I No effects\
        \ CYP3A4*2 S222P Higher Km for substrate CYP3A4*3 M445T Unknown CYP3A4*4 I118V\
        \ Decreased CYP3A4*5 P218R Decreased CYP3A4*6 831 insA Decreased CYP3A5*3\
        \ Splicing defect No enzyme CYP3A5*6 Splicing defect No enzyme Increased inducibility\
        \ Increased activity Higher inducibility Inactive enzyme No enzyme Less enzyme\
        \ Less enzyme Less enzyme a Modified from reference 68 with permission of\
        \ the publisher and from reference 215 with permission of Elsevier; includes\
        \ data from http://www.cypalleles.ki.se. from extensive metabolizers, who\
        \ have normal drug-metabolizing enzyme activity (the anticipated medication\
        \ response would be seen with standard doses).", pubmed: '17041143', seq: '296',
    to_res: C}
- {entry_name: adrb2_human, from_res: D, info: 'NAT1*14 (R187Q), -*15 (R187Stop),
        -*17 (R64W), -*19 (R33Stop), and -*22 (D251V) are associated with absent or
        low enzyme activity (115), although interindividual variation in NAT-1 levels
        has been reported with 4-aminobenzoic acid (48), and lowactivity alleles are
        probably rare (51).', pubmed: '17041143', seq: '251', to_res: V}
- {entry_name: adrb2_human, from_res: T, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '164', to_res: I}
- {entry_name: adrb2_human, from_res: N, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '318', to_res: K}
- {entry_name: adrb2_human, from_res: F, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '139', to_res: A}
- {entry_name: adrb2_human, from_res: C, info: 'CAM and UCM mutants The CAMs (constitutively
        active mutants) described in the literature that are the basis for Figure
        6A and the associated discussion are: L124A (6), C116F (7), D130A (8), L272C
        (9), and C285T (10).', pubmed: '17962519', seq: '116', to_res: F}
- {entry_name: adrb2_human, from_res: N, info: "The insect cell expression plasmid\
        \ that was used as a template for modification of the human \u03B22AR gene\
        \ has been described previously (1): the wild-type coding sequence of the\
        \ human \u03B22AR (starting at Gly2) was cloned into the pFastbac1 Sf-9 expression\
        \ vector (Invitrogen) with the HA signal sequence followed by the Flag epitope\
        \ tag at the amino terminus and the third glycosylation site mutated as N187E.",
    pubmed: '17962519', seq: '187', to_res: E}
- {entry_name: adrb2_human, from_res: L, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '340', to_res: A}
- {entry_name: adrb2_human, from_res: D, info: 'CAM and UCM mutants The CAMs (constitutively
        active mutants) described in the literature that are the basis for Figure
        6A and the associated discussion are: L124A (6), C116F (7), D130A (8), L272C
        (9), and C285T (10).', pubmed: '17962519', seq: '130', to_res: A}
- {entry_name: adrb2_human, from_res: P, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '323', to_res: A}
- {entry_name: adrb2_human, from_res: D, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '79', to_res: N}
- {entry_name: adrb2_human, from_res: C, info: 'CAM and UCM mutants The CAMs (constitutively
        active mutants) described in the literature that are the basis for Figure
        6A and the associated discussion are: L124A (6), C116F (7), D130A (8), L272C
        (9), and C285T (10).', pubmed: '17962519', seq: '285', to_res: T}
- {entry_name: adrb2_human, from_res: Y, info: 'The UCMs (uncoupling mutations) from
        the literature that were used for Figure 7 are: D79N (11), F139A (12), T164I
        (13), N318K (14), N322A (15), P323A (15), Y326A (15), L339A (16), and L340A
        (16).', pubmed: '17962519', seq: '326', to_res: A}
- {entry_name: opsd_bovin, from_res: Y, info: the bovine rhodopsin receptor residue
        Y60S, pubmed: adfads, seq: '60', to_res: S}
- {entry_name: grm1_human, from_res: L, info: 'On nsSNP, L575V, is of particular interest
        since it encodes on an important b-turn with positive w-torsion angle and
        is highly likely to form the nucleation site for protein folding [26,27],
        which precedes the formation of disulphide bonds [28,29].', pubmed: '21559497',
    seq: '575', to_res: V}
- {entry_name: grm1_human, from_res: K, info: All but one (K563N) of the nsSNPs found
        in the control cohort are excluded from the disease cluster (Figure 2A).,
    pubmed: '21559497', seq: '563', to_res: N}
- {entry_name: adrb1_melga, from_res: A, info: "Details of the constructs b6, b34,\
        \ b35 and b36 are shown in Fig. 1; m23 refers to the presence of the 6 thermostabilising\
        \ mutations R068S, M090V, Y227A, A282L, F327A and F338M in the relevant construct.///The\
        \ final construct, b1AR-m23, was based on b1AR6 and contained six (m23) mutations\
        \ (R068S, M090V, Y227A, A282L, F327A and F338M) that resulted in increased\
        \ thermal stability and stability in a wide range of shortchain detergents\
        \ [22].///Stabilized (\xC0m23) versions of b1AR6, 34 and 36 included in addition\
        \ the mutations R068S, M090V, Y227A, A282L, F327A and F338M, which enhanced\
        \ thermal stability [22].", pubmed: '19497262', seq: '282', to_res: L}
- {entry_name: adrb1_melga, from_res: M, info: "Details of the constructs b6, b34,\
        \ b35 and b36 are shown in Fig. 1; m23 refers to the presence of the 6 thermostabilising\
        \ mutations R068S, M090V, Y227A, A282L, F327A and F338M in the relevant construct.///The\
        \ final construct, b1AR-m23, was based on b1AR6 and contained six (m23) mutations\
        \ (R068S, M090V, Y227A, A282L, F327A and F338M) that resulted in increased\
        \ thermal stability and stability in a wide range of shortchain detergents\
        \ [22].///Stabilized (\xC0m23) versions of b1AR6, 34 and 36 included in addition\
        \ the mutations R068S, M090V, Y227A, A282L, F327A and F338M, which enhanced\
        \ thermal stability [22].", pubmed: '19497262', seq: '90', to_res: V}
- {entry_name: adrb1_melga, from_res: R, info: "Details of the constructs b6, b34,\
        \ b35 and b36 are shown in Fig. 1; m23 refers to the presence of the 6 thermostabilising\
        \ mutations R068S, M090V, Y227A, A282L, F327A and F338M in the relevant construct.///The\
        \ final construct, b1AR-m23, was based on b1AR6 and contained six (m23) mutations\
        \ (R068S, M090V, Y227A, A282L, F327A and F338M) that resulted in increased\
        \ thermal stability and stability in a wide range of shortchain detergents\
        \ [22].///Stabilized (\xC0m23) versions of b1AR6, 34 and 36 included in addition\
        \ the mutations R068S, M090V, Y227A, A282L, F327A and F338M, which enhanced\
        \ thermal stability [22].", pubmed: '19497262', seq: '68', to_res: S}
- {entry_name: adrb1_melga, from_res: C, info: "There is also a point mutation in\
        \ all constructs, C116L, which improves expression of b1AR.///b1AR34 and 36,\
        \ like b1AR6, had residues 3\u201332 deleted from the N-terminus and also\
        \ contained the mutation C116L to improve expression.", pubmed: '19497262',
    seq: '116', to_res: L}
- {entry_name: adrb1_melga, from_res: F, info: "Details of the constructs b6, b34,\
        \ b35 and b36 are shown in Fig. 1; m23 refers to the presence of the 6 thermostabilising\
        \ mutations R068S, M090V, Y227A, A282L, F327A and F338M in the relevant construct.///The\
        \ final construct, b1AR-m23, was based on b1AR6 and contained six (m23) mutations\
        \ (R068S, M090V, Y227A, A282L, F327A and F338M) that resulted in increased\
        \ thermal stability and stability in a wide range of shortchain detergents\
        \ [22].///Stabilized (\xC0m23) versions of b1AR6, 34 and 36 included in addition\
        \ the mutations R068S, M090V, Y227A, A282L, F327A and F338M, which enhanced\
        \ thermal stability [22].", pubmed: '19497262', seq: '327', to_res: A}
- {entry_name: adrb1_melga, from_res: F, info: "Details of the constructs b6, b34,\
        \ b35 and b36 are shown in Fig. 1; m23 refers to the presence of the 6 thermostabilising\
        \ mutations R068S, M090V, Y227A, A282L, F327A and F338M in the relevant construct.///The\
        \ final construct, b1AR-m23, was based on b1AR6 and contained six (m23) mutations\
        \ (R068S, M090V, Y227A, A282L, F327A and F338M) that resulted in increased\
        \ thermal stability and stability in a wide range of shortchain detergents\
        \ [22].///Stabilized (\xC0m23) versions of b1AR6, 34 and 36 included in addition\
        \ the mutations R068S, M090V, Y227A, A282L, F327A and F338M, which enhanced\
        \ thermal stability [22].", pubmed: '19497262', seq: '338', to_res: M}
- {entry_name: adrb1_melga, from_res: C, info: 'Thermostabilizing mutations are in
        red circles and two other mutations-C116L (increases functional expression)
        and C358A (eliminates palmitoylation site)-are in blue circles.///The construct
        included the following eight point mutations: C1163.27L increased expression;
        C358A at the C terminus of H8 removed palmitoylation and helped crystallization;
        and R681.59S, M902.53V, Y2275.58A, A2826.27L, F3277.37A and F3387.48M thermostabilized
        the receptor in the antagonist conformation15.', pubmed: '18594507', seq: '358',
    to_res: A}
- {entry_name: adrb1_melga, from_res: C, info: 'Deletion of the C-terminus and inclusion
        of the C358A mutation, both present in the resulting mutant b1AR34, did not
        greatly affect either the affinity of antagonist binding, expression or receptor
        stability (Fig. 2).///Crystallization of other constructs The b1AR36-m23 construct
        that crystallised contained the mutation C358A to prevent palmitoylation and
        was included to prevent the possibility of heterogeneity in the extent of
        palmitoylation.///b1AR34 and 36 were truncated at the C-terminus after Leu367,
        with the addition of a 6 His tag after the truncation and both constructs
        included the mutation C358A to eliminate the possibility of heterogeneous
        palmitoylation.///A second version of b1AR36-m23, b1AR36-m23/C358, lacked
        the mutation C358A.', pubmed: '19497262', seq: '358', to_res: A}
- {entry_name: adrb1_melga, from_res: Y, info: "Details of the constructs b6, b34,\
        \ b35 and b36 are shown in Fig. 1; m23 refers to the presence of the 6 thermostabilising\
        \ mutations R068S, M090V, Y227A, A282L, F327A and F338M in the relevant construct.///The\
        \ final construct, b1AR-m23, was based on b1AR6 and contained six (m23) mutations\
        \ (R068S, M090V, Y227A, A282L, F327A and F338M) that resulted in increased\
        \ thermal stability and stability in a wide range of shortchain detergents\
        \ [22].///Stabilized (\xC0m23) versions of b1AR6, 34 and 36 included in addition\
        \ the mutations R068S, M090V, Y227A, A282L, F327A and F338M, which enhanced\
        \ thermal stability [22].", pubmed: '19497262', seq: '227', to_res: A}
- {entry_name: adrb2_human, from_res: E, info: "The b2AR was modified both for enhanced\
        \ crystallizability by incorporation of T4-lysozyme between helices V and\
        \ VI (b2AR(E122W)-T4L), and for stability through the introduction of a point\
        \ mutation in the transmembrane domain (E1223.41W).///We also report the binding\
        \ mode for the partial inverse agonist timolol, which is bound at the orthosteric\
        \ binding site of the receptor (timb2AR(E122W)-T4L) and engages in many of\
        \ the same key interactions with the protein as carazolol, but with some important\
        \ differences.///RESULTS AND DISCUSSION Crystal Generation and Structure Solution\
        \ High-level expression of b2AR(E122W)-T4L was performed in Spodoptera frugiperda\
        \ (Sf9) insect cells using standard protocols (See Experimental Procedures).///A\
        \ simplified purification scheme was enabled by the presence of the E122W\
        \ mutation, which resulted in a higher yield of functionally active receptor\
        \ in the folded state than for the wild-type (85% for E122W versus 25% for\
        \ wild-type), as judged by size exclusion chromatography using a fluorescent-labeled\
        \ alprenolol probe and traditional binding assays (Roth et al., 2008).///A\
        \ simplified purification scheme was enabled by the presence of the E122W\
        \ mutation, which resulted in a higher yield of functionally active receptor\
        \ in the folded state than for the wild-type (85% for E122W versus 25% for\
        \ wild-type), as judged by size exclusion chromatography using a fluorescent-labeled\
        \ alprenolol probe and traditional binding assays (Roth et al., 2008).///We\
        \ purified, crystallized, and determined the three-dimensional structure of\
        \ b2AR(E122W)-T4L in the presence of a saturating concentration of S-(\xC0\
        )-1-(t-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxyl]-2-propanol\
        \ maleate (timolol) (Supplemental Data) Table 1.///Comparison between timolol-bound\
        \ b2AR(E122W)-T4L (timb2AR(E122W)-T4L) and carazolol-bound carb2AR-T4L (PDB\
        \ ID: 2RH1) (overall root  \u030A  \u030A mean squared deviation [rmsd]: 1.8\
        \ A, receptor rmsd: 0.34 A) reveals a change in the relative tilt angle between\
        \ T4L and the receptor, as well as a few minor shifts in intracellular loop\
        \ 2 and extracellular loop 3 that may be explained by the monomers packing\
        \ in a higher symmetry space group with different crystal packing interactions\
        \ (Figure 1A).///Comparison between timolol-bound b2AR(E122W)-T4L (timb2AR(E122W)-T4L)\
        \ and carazolol-bound carb2AR-T4L (PDB ID: 2RH1) (overall root  \u030A  \u030A\
        \ mean squared deviation [rmsd]: 1.8 A, receptor rmsd: 0.34 A) reveals a change\
        \ in the relative tilt angle between T4L and the receptor, as well as a few\
        \ minor shifts in intracellular loop 2 and extracellular loop 3 that may be\
        \ explained by the monomers packing in a higher symmetry space group with\
        \ different crystal packing interactions (Figure 1A).///Data Collection and\
        \ Refinement Statistics tim b2AR(E122W)-T4L Data collection (APS GM/CA CAT\
        \ ID-B/D, 10 mm beam) Space group  \u030A a, b, c (A) No. of reflections processed\
        \ No. unique reflections  \u030A Resolution (A)a Rsym Mean I/s(I) Completeness\
        \ (%) Redundancy Refinement  \u030A Resolution (A)a No. reflections (test\
        \ set) Rwork/Rfree No. atoms Protein Ions, lipids, ligand and other Water\
        \  \u030A Overall B values (A2) b2AR T4-Lysozyme Ligand Cholesterol #1 Cholesterol\
        \ #2 Lipid Rmsds  \u030A Bond lengths (A) Bond angles (\uFFFD ) Ramachandran\
        \ plot statistics (%): Most favored regions Additionally allowed regions Disallowed\
        \ regions 98.2 1.8 0 0.010 1.313 20-2.8 (3.0-2.8) 12,782 (640) 23.1(30.2)/27.3(38.3)\
        \ 3700 3528 152 20 69 63 80 49 71 84 71 P212121 40.0, 75.7, 172.7 54,405 12,782\
        \ 50-2.8 (3.0-2.8) 14.3 (56.9) 6.9 (1.9) 94.0 (91.0) 4.2 (2.9) Rsym = Shkl\
        \ jI(hkl) \xC0 < I(hkl) > j / Shkl(hkl), where < I(hkl) > is the mean of the\
        \ symmetry equivalent reflections of I(hkl). a Highest resolution shell is\
        \ shown in parentheses. current structure enables an altered crystal packing\
        \ environment despite the fact that the same number of residues are ordered\
        \ at the C terminus in both structures.///Timolol Binding Interactions Given\
        \ the established similarity between b2AR and b2AR(E122W) (Roth et al., 2008),\
        \ as well as between b2AR and b2AR-T4L (Rosenbaum et al., 2007), we feel confident\
        \ in drawing relevant conclusions from studies focusing on the molecular interactions\
        \ associated with b2AR and its small molecule effectors using the b2AR(E122W)-T4L\
        \ system, which we show here is structurally equivalent to carb2AR-T4L.///Timolol\
        \ Binding Interactions Given the established similarity between b2AR and b2AR(E122W)\
        \ (Roth et al., 2008), as well as between b2AR and b2AR-T4L (Rosenbaum et\
        \ al., 2007), we feel confident in drawing relevant conclusions from studies\
        \ focusing on the molecular interactions associated with b2AR and its small\
        \ molecule effectors using the b2AR(E122W)-T4L system, which we show here\
        \ is structurally equivalent to carb2AR-T4L.///Overview of the T4L Structure\
        \ tim b2AR(E122W)(A) The location of the tryptophan mutation is indicated,\
        \ as well as the position of the ligand timolol.///The tilt angle between\
        \ the receptor and T4L is markedly different between the tim b2AR(E122W)-T4L\
        \ structure (green ribbon trace) and carb2AR-T4L (blue ribbon trace).///With\
        \ the generation of crystals for timb2AR(E122W)-T4L in a higher symmetry space\
        \ group and the antiparallel orientation of the receptor molecules within\
        \ the asymmetric unit, the role of cholesterol in crystal packing is reduced\
        \ (Figure 2B).///The electron density for cholesterol 1 in the timb2AR(E122W)-T4L\
        \ does not support the position seen in the carb2AR-T4L structure-rather,\
        \ a 90\uFFFD rotation and slight translation along the long axis of the molecule\
        \ are necessary for optimal fitting of the experimental electron density (Figures\
        \ 2C and 2D).///(B) Crystal-packing environment of timb2AR(E122W)-T4L structure\
        \ where the receptor monomers pack in an antiparallel orientation.///(D) Comparison\
        \ of cholesterol binding between timb2AR(E122W)-T4L (yellow) and carb2AR-T4L\
        \ (cyan).///We have further characterized the thermal stability of b2AR(E122W)-T4L\
        \ solubilized in the detergent dodecylmaltoside (DDM) in the presence and\
        \ absence of CHS and timolol by monitoring the extent of covalent coupling\
        \ of receptor cysteines to the thiol-reactive dye, 7-diethylamino-3-(40 -maleimidylphenyl)4-methylcoumarin\
        \ (CPM), as a function of time in the presence of 1 M guanidinium hydrochloride\
        \ (GnHCl) (Figure 3D; Alexandrov et al., 2008).///The half-life of thermal\
        \ denaturation of b2AR(E122W)-T4L at 35\uFFFD C changes significantly upon\
        \ incorporation of both timolol and CHS (Figure 3D).///(B) Competition binding\
        \ curves for b2AR(E122W)-T4L in the presence and absence of cholesterol.///Expression\
        \ and Purification b2AR(E122W)-T4L was identical to b2AR-T4L in all but two\
        \ features: (1) residue 122 was mutated from a glutamate to a tryptophan using\
        \ standard site-directed mutagenesis protocols, and (2) the C terminus was\
        \ further truncated to residue 348 eliminating a total of 65 residues.", pubmed: '18547522',
    seq: '122', to_res: W}
- {entry_name: opsd_bovin, from_res: S, info: Loop E2 folds back into the protein
        to contribute residues Ser 186 to Ile 189 of strand b4 to the retinal-binding
        site., pubmed: '18563085', seq: '186', to_res: I}
- {entry_name: 5ht1b_human, from_res: A, info: 'FST 0.54 0.44 0.44 0.44 0.44 0.44
        0.44 0.44 0.44 0.44 0.44 0.44 0.44 0.44 0.44 0.42 0.40 Coding SNPs showing
        greatest differentiation between lines resistant and susceptible to SSG treatment
        Ca 34 2 4 7 12 16 19 21 24 25 31 31 32 35 36 33 34 Position 1046281e 36464
        337729g 383016 128965 690776 412141 412303 26882 702972g 553554g 555080 357021g
        1773762g 886126g 1316522e 493541e Sb 0.81 1.00 1.00 1.00 1.00 1.00 1.00 1.00
        1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.20 0.78 Rc 0.00 0.43 0.43 0.43 0.43 0.43
        0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.86 0.14 Typed N N N Syn N N
        Syn Syn N N Syn N N N Syn N Syn Gene product Conserved hypothetical protein
        Phosphatidylinositol 3-kinase Rhomboid-like serine protease Phosphoacetylglucosamine
        mutase Conserved hypothetical protein Conserved hypothetical protein 4-coumarate
        CoA ligase Hypothetical protein Ankyrin/TPR repeat protein Conserved hypothetical
        protein Conserved hypothetical proteinh Conserved hypothetical protein Conserved
        hypothetical protein Conserved hypothetical protein Conserved hypothetical
        protein Conserved hypothetical protein Amastin-like surface protein Site H523Rf
        R3452H A113V 161V Y1230C Y1214C 395V 251P A150V A61E 426T S268P V125L A54T
        347T A390V 209A Gene ID LdBPK_342390 LdBPK_020100 LdBPK_040850 LdBPK_070930
        LdBPK_120270 LdBPK_161760 LdBPK_190970 LdBPK_211240 LdBPK_240130 LdBPK_251890
        LdBPK_311340 LdBPK_311340 LdBPK_320990 LdBPK_354470 LdBPK_362330 LdBPK_333140
        LdBPK_341150 SNPs were ranked by FST: This set of 17 all had FST > 0.4 (bootstrapping
        P < 0.02) and were in coding sequence; noncoding SNPs with FST > 0.4 are in
        Supplemental Table S4. a Chromosome. b Frequency of ancestral allele in SSG-sensitive
        set.', pubmed: '22038251', seq: '150', to_res: V}
- {entry_name: agtr2_mouse, from_res: I, info: "Location, Name(s) References Krabbe\
        \ disease (1/100,000) Human GalCer, Galactosylsphingosine 3\u20136 months\
        \ or 10\u2013 40 years < 2 years or adult (111, 113, 335, 336, 337, 338) GALC\
        \ Chr 14: q31 Galactocereborside -galactosidase Galactosylceramide -galactosidase\
        \ Q14 Progressive CNS and PNS involvement, hypertonicity/ hyperactive reflexes,\
        \ progressive flaccidity, peripheral neuropathy, severe developmental delay,\
        \ blindness, spastic paraparesis, dementia and loss of vision in later onset\
        \ patients, infiltration of characteristic \u201Cgloboid cells\u201D Galc\
        \ Chr 12: 9944051099497547(-) twitcher Mouse >60 mutationsInfantile patients:502C\u2192\
        T polymorphism associated with a 30 kb deletion in intron 10Late onset patients:\
        \ missense mutations (R63H, G95S, M101L, G268S, G270D, Y298C, and I234T),\
        \ nonsense mutation (S7X), a one-base deletion (805delG), mutations interfere\
        \ with the splicing of intron 1and intron 6 Spontaneous mutation; G to A transition\
        \ at codon 339 GalCer, Galactosylsphingosine 6.5\u201312 weeks (116, 209,\
        \ 210, 339, 340) GalCer, Galactosylsphingosine Sulfatide 58 days 5\u201363+\
        \ years (120) (122, 123, 341, 342) MLD (1/40,000) Galc Chr 12: 99440510- Mouse\
        \ 99497547(-) Transgenic Krabbe ARSA Chr 22: q13.31- Human qter Arylsulphatase\
        \ A cerebroside-3-sulfate 3-sulfohydrolase, ASA Mouse Mouse Sulfatide Sulfatide\
        \ Insertion of human mutation (H168C) in exon 5 >40 mutations Deletions, insertions,\
        \ splice site mutation, and missense mutations Asa Chr 15: 8930295989306545(-)\
        \ Asa / Asa + Gal3st1 Normal lifespan < 2 years (129) (130) Fabry disease\
        \ (1/40,000 to 1/117,000) GLA Chr X: q22-q21 -Galactosidase A Human A neomycin\
        \ selection cassette inserted into exon 4 ASA / mice overexpressing sulfatide\
        \ synthesizing enzyme CST >400 mutations in the GLA gene, including missense\
        \ (76.4%), nonsense (16.4%), frameshift (3.6%), and splice site defects (3.6%)\
        \ Gb3, lyso-Gb3 A neomycin resistance cassette inserted into fragment containing\
        \ part of exon 3 and intron 3 Gb3 20\u201375.4 years (137, 295, 343\u2013\
        348) Downloaded from www.jlr.org by guest, on November 9, 2011 Genetic defects\
        \ in sphingolipid metabolism Gla Chr X: 131122688131135664(-) Gla / Mouse\
        \ Generalized tremors, 3 weeks progressive weakness, wasting, dys/demyelination,\
        \ abnormal multinucleated \u201Cgloboid\u201D cells infiltration, gray matter\
        \ unaffected Tremor, hindleg weakness, 25\u201330 days microphage infiltration\
        \ in PNS Difficulty walking after the 6 months \u201316+ first year of life,\
        \ progressive years peripheral neuropathies, muscle wasting/weakness, developmental\
        \ delay, seizures, dementia Mild phenotype compared 1 year with humans, normal\
        \ lifespan, no widespread demyelination More severe phenotype of 1 year ASA\
        \ deficiency alone, more aggressive CNS and PNS demyelination Males more severely\
        \ affected, Childhood painful acroparesthesias, to 30+ years angiokeratoma,\
        \ renal disease, cardiomyopathy, stroke, no clear neuronal involvement, 50%\
        \ of heterozygous females affected Normal lipid accumulation in kidneys, endothelium,\
        \ liver, and peripheral nerve Normal lifespan (137, 138, 349) 1649 Downloaded\
        \ from www.jlr.org by guest, on November 9, 2011 1650 TABLE 1.", pubmed: '20211931',
    seq: '234', to_res: T}
- {entry_name: agtr2_mouse, from_res: S, info: "Location, Name(s) References NPC (1/120,000\
        \ to 1/150,000) In utero to adult <6 months to adult NPC1 (95% cases) Chr18:q11-q12\
        \ NPC1 Human Cholesterol, Sphingomyelin, GlcCer, LacCer and GM2 Progressive\
        \ Purkinje cell loss, ataxia, dystonia, dementia, variable hepa tosplenomegaly,\
        \ sea blue histiocytes in bone marrow, liver, spleen, and lung (312, 326\u2013\
        \ 330) Journal of Lipid Research Volume 51, 2010 Npc1 Chr 18: 1234820212394909(-)spm\
        \ NPC1 / Mouse Cholesterol, GlcCer, LacCer and GM2 Infantile and \u201Cclassic\u201D\
        \ (severe) phenotype: Premature stop codon mutations,missense mutations in\
        \ the sterolsensing domain (SSD), A1054T in the cysteinerich luminal loop\
        \ \u201CVariant\u201D (mild) phenotype: Missense mutations (I943M, V950M,\
        \ G986S, G992R, P1007A) clustered within the cysteine-rich luminal loop between\
        \ transmembrane domains 8 and 9 Spontaneous mutation 7 weeks 12\u201314 weeks\
        \ (260, 326, 331) Npc1 Chr 18: 1234820212394909(-)npcnih NPC1 / Mouse Human\
        \ Cholesterol, Sphingomyelin, lyso(bis)phosphatidic acid, GlcCer, LacCer,\
        \ GA2, GM2 and GM3 Cholesterol, Sphingomyelin, GlcCer, LacCer and GM2 NPC2/HE1\
        \ (5% cases) Chr 14: q24.3 HE1, NP-C2, NPC2, HE1/NPC2 Progressive Purkinje\
        \ cell loss, demyelination, tremors, hind limb paralysis, poor fee ding, foamy\
        \ macrophages in viscera, hepatosplenomegaly, enlarge lymph nodes, infertile\
        \ Progressive Purkinje cell loss, demyelination, tremors, hind limb paralysis,\
        \ poor feeding, foamy macrophages in viscera Same as NPC1 5\u20137 weeks 11\u2013\
        14 weeks (218, 260, 326, 332\u2013 334) In utero to adult <6 mos to adult\
        \ (326\u2013330) Npc2 Chr 12: 8609744286113848(-) Mouse Spontaneous mutation,\
        \ transposon insertion deleting 11/13 transmembrane domains Severe disease:\
        \ 27delG leading to early termination of protein, a missense mutation (S67P),E20X,\
        \ E118X, S67P, and E20X/ 27delG mutations Milder disease: splice mutation\
        \ (VS2+5G\u2192A) in the consensus sequence of the 5\u2032 donor site of intron\
        \ 2 Insertion of neo cassette into intron 3 Cholesterol, Sphingomyelin, lyso(bis)phosphatidic\
        \ acid, GlcCer, LacCer, GA2, GM2 and GM3 Weight loss, tremors, ataxia, generalized\
        \ locomotor dysfunction 7.9 weeks 13\u201318.5 weeks (200) TABLE 1.///Location,\
        \ Name(s) References NPC (1/120,000 to 1/150,000) In utero to adult <6 months\
        \ to adult NPC1 (95% cases) Chr18:q11-q12 NPC1 Human Cholesterol, Sphingomyelin,\
        \ GlcCer, LacCer and GM2 Progressive Purkinje cell loss, ataxia, dystonia,\
        \ dementia, variable hepa tosplenomegaly, sea blue histiocytes in bone marrow,\
        \ liver, spleen, and lung (312, 326\u2013 330) Journal of Lipid Research Volume\
        \ 51, 2010 Npc1 Chr 18: 1234820212394909(-)spm NPC1 / Mouse Cholesterol, GlcCer,\
        \ LacCer and GM2 Infantile and \u201Cclassic\u201D (severe) phenotype: Premature\
        \ stop codon mutations,missense mutations in the sterolsensing domain (SSD),\
        \ A1054T in the cysteinerich luminal loop \u201CVariant\u201D (mild) phenotype:\
        \ Missense mutations (I943M, V950M, G986S, G992R, P1007A) clustered within\
        \ the cysteine-rich luminal loop between transmembrane domains 8 and 9 Spontaneous\
        \ mutation 7 weeks 12\u201314 weeks (260, 326, 331) Npc1 Chr 18: 1234820212394909(-)npcnih\
        \ NPC1 / Mouse Human Cholesterol, Sphingomyelin, lyso(bis)phosphatidic acid,\
        \ GlcCer, LacCer, GA2, GM2 and GM3 Cholesterol, Sphingomyelin, GlcCer, LacCer\
        \ and GM2 NPC2/HE1 (5% cases) Chr 14: q24.3 HE1, NP-C2, NPC2, HE1/NPC2 Progressive\
        \ Purkinje cell loss, demyelination, tremors, hind limb paralysis, poor fee\
        \ ding, foamy macrophages in viscera, hepatosplenomegaly, enlarge lymph nodes,\
        \ infertile Progressive Purkinje cell loss, demyelination, tremors, hind limb\
        \ paralysis, poor feeding, foamy macrophages in viscera Same as NPC1 5\u2013\
        7 weeks 11\u201314 weeks (218, 260, 326, 332\u2013 334) In utero to adult\
        \ <6 mos to adult (326\u2013330) Npc2 Chr 12: 8609744286113848(-) Mouse Spontaneous\
        \ mutation, transposon insertion deleting 11/13 transmembrane domains Severe\
        \ disease: 27delG leading to early termination of protein, a missense mutation\
        \ (S67P),E20X, E118X, S67P, and E20X/ 27delG mutations Milder disease: splice\
        \ mutation (VS2+5G\u2192A) in the consensus sequence of the 5\u2032 donor\
        \ site of intron 2 Insertion of neo cassette into intron 3 Cholesterol, Sphingomyelin,\
        \ lyso(bis)phosphatidic acid, GlcCer, LacCer, GA2, GM2 and GM3 Weight loss,\
        \ tremors, ataxia, generalized locomotor dysfunction 7.9 weeks 13\u201318.5\
        \ weeks (200) TABLE 1.", pubmed: '20211931', seq: '67', to_res: P}
- {entry_name: opsd_bovin, from_res: V, info: 'The mutations that showed the largest
        decrease in transducin activation rate were L226C5.61, T229C, V230C and T243C.',
    pubmed: '18638482', seq: '230', to_res: C}
- {entry_name: opsd_bovin, from_res: T, info: 'The mutations that showed the largest
        decrease in transducin activation rate were L226C5.61, T229C, V230C and T243C.',
    pubmed: '18638482', seq: '229', to_res: C}
- {entry_name: opsd_bovin, from_res: L, info: 'The mutations that showed the largest
        decrease in transducin activation rate were L226C5.61, T229C, V230C and T243C.',
    pubmed: '18638482', seq: '226', to_res: C}
- {entry_name: opsd_bovin, from_res: T, info: 'The mutations that showed the largest
        decrease in transducin activation rate were L226C5.61, T229C, V230C and T243C.',
    pubmed: '18638482', seq: '243', to_res: C}
- {entry_name: opsd_bovin, from_res: H, info: "In a different study,26 it was shown\
        \ by FTIR difference spectroscopy that the mutants H211F and H211N shifted\
        \ the absorption spectra more toward the blue region compared to wild-type\
        \ rhodopsin.///However, only H211F showed reduced transducin activation (measured\
        \ in terms of GTP\u03B3S binding), whereas H211N did not show any change.///Thus,\
        \ there is no change in transducin activation shown for the H211N mutant.",
    pubmed: '18638482', seq: '211', to_res: N}
- {entry_name: opsd_bovin, from_res: H, info: "The rotamer of W2656.48 on TM6 is shown\
        \ to change upon activation and this could modulate the bend angle around\
        \ the conserved proline on TM6 (rotamer toggle switch).22 Evidence of rotamer\
        \ toggle switching has been found in other GPCRs such as the \u03B22AR.23\
        \ H2115.46 on TM5 also plays an important role in the activation process,\
        \ since mutating H2115.46 to C, E, N and F shifts the mutant absorption spectra\
        \ more towards Meta I,24\u201326 whereas the H211F mutant shows reduced transducin\
        \ binding as well.///In a different study,26 it was shown by FTIR difference\
        \ spectroscopy that the mutants H211F and H211N shifted the absorption spectra\
        \ more toward the blue region compared to wild-type rhodopsin.///However,\
        \ only H211F showed reduced transducin activation (measured in terms of GTP\u03B3\
        S binding), whereas H211N did not show any change.", pubmed: '18638482', seq: '211',
    to_res: F}
- {entry_name: opsd_bovin, from_res: V, info: 'In a recent study by Janz and Farrens,27
        mutating three hydrophobic residues on ICL3, L2265.61, T229 and V230 to alanine
        reduced the transducin activa546 Active State Model of Rhodopsin Fig. 4.',
    pubmed: '18638482', seq: '230', to_res: A}
- {entry_name: adrb1_melga, from_res: C, info: Thermostabilizing mutations are in
        red circles and two other mutations-C116L (increases functional expression)
        and C358A (eliminates palmitoylation site)-are in blue circles., pubmed: '18594507',
    seq: '116', to_res: L}
- {entry_name: adrb1_melga, from_res: Y, info: Supporting evidence for this structural
        role of Tyr 149 comes from the observation that the Y149A mutation makes b1AR
        less thermally stable (Supplementary Table 2)., pubmed: '18594507', seq: '149',
    to_res: A}
- {entry_name: acm5_human, from_res: Y, info: 'Interestingly, a pattern of mutations
        consistent with an a-helical conformation for CL2 was found in the muscarinic
        M5 receptor, and the equivalent M5 mutation Y138A led to increased Figure
        2', pubmed: '18594507', seq: '138', to_res: A}
- {entry_name: agtr2_rat, from_res: R, info: 'The following mutations on the relaxin-3
        B-chain were made to assess their function in receptor interactions: Arg8
        to Ala (R8A) or Ser (R8S); Arg12 to Ala (R12A), Leu (R12L), Ser (R12S) or
        Lys (R12K); Arg16 to Ala (R16A) or Ser (R16S); Ile15 to Gly (I15G), Ala (I15A),
        or Val (I15V); Ile19 to Ala (I19A) or Glu (I19E); Arg12 to Lys and Arg16 to
        Lys (R12K&R16K); Phe20 to Ala (F20A), Arg (F20R), Ser (F20S), or Tyr (F20Y);
        For all mutants described above, the A-chain was kept unchanged.///Arg12 to
        Ala (R12A), Leu (R12L), or Ser (R12S) mutants had no detectable agonist activity
        or affinity for LGR7 Downloaded from www.jbc.org by Sophie Newton on November
        9, 2011 6 but retained weak agonist activity and low affinity for GPCR135
        while possessed high affinity and almost full agonist potency for GPCR142.',
    pubmed: '17606621', seq: '12', to_res: S}
- {entry_name: agtr2_rat, from_res: R, info: 'The following mutations on the relaxin-3
        B-chain were made to assess their function in receptor interactions: Arg8
        to Ala (R8A) or Ser (R8S); Arg12 to Ala (R12A), Leu (R12L), Ser (R12S) or
        Lys (R12K); Arg16 to Ala (R16A) or Ser (R16S); Ile15 to Gly (I15G), Ala (I15A),
        or Val (I15V); Ile19 to Ala (I19A) or Glu (I19E); Arg12 to Lys and Arg16 to
        Lys (R12K&R16K); Phe20 to Ala (F20A), Arg (F20R), Ser (F20S), or Tyr (F20Y);
        For all mutants described above, the A-chain was kept unchanged.///The following
        mutations on the relaxin-3 B-chain were made to assess their function in receptor
        interactions: Arg8 to Ala (R8A) or Ser (R8S); Arg12 to Ala (R12A), Leu (R12L),
        Ser (R12S) or Lys (R12K); Arg16 to Ala (R16A) or Ser (R16S); Ile15 to Gly
        (I15G), Ala (I15A), or Val (I15V); Ile19 to Ala (I19A) or Glu (I19E); Arg12
        to Lys and Arg16 to Lys (R12K&R16K); Phe20 to Ala (F20A), Arg (F20R), Ser
        (F20S), or Tyr (F20Y); For all mutants described above, the A-chain was kept
        unchanged.///Arg12 to Ala (R12A), Leu (R12L), or Ser (R12S) mutants had no
        detectable agonist activity or affinity for LGR7 Downloaded from www.jbc.org
        by Sophie Newton on November 9, 2011 6 but retained weak agonist activity
        and low affinity for GPCR135 while possessed high affinity and almost full
        agonist potency for GPCR142.///Arg12 to Ala (R12A), Leu (R12L), or Ser (R12S)
        mutants had no detectable agonist activity or affinity for LGR7 Downloaded
        from www.jbc.org by Sophie Newton on November 9, 2011 6 but retained weak
        agonist activity and low affinity for GPCR135 while possessed high affinity
        and almost full agonist potency for GPCR142.', pubmed: '17606621', seq: '12',
    to_res: A}
- {entry_name: agtr2_rat, from_res: R, info: 'The following mutations on the relaxin-3
        B-chain were made to assess their function in receptor interactions: Arg8
        to Ala (R8A) or Ser (R8S); Arg12 to Ala (R12A), Leu (R12L), Ser (R12S) or
        Lys (R12K); Arg16 to Ala (R16A) or Ser (R16S); Ile15 to Gly (I15G), Ala (I15A),
        or Val (I15V); Ile19 to Ala (I19A) or Glu (I19E); Arg12 to Lys and Arg16 to
        Lys (R12K&R16K); Phe20 to Ala (F20A), Arg (F20R), Ser (F20S), or Tyr (F20Y);
        For all mutants described above, the A-chain was kept unchanged.///Arg12 to
        Ala (R12A), Leu (R12L), or Ser (R12S) mutants had no detectable agonist activity
        or affinity for LGR7 Downloaded from www.jbc.org by Sophie Newton on November
        9, 2011 6 but retained weak agonist activity and low affinity for GPCR135
        while possessed high affinity and almost full agonist potency for GPCR142.',
    pubmed: '17606621', seq: '12', to_res: L}
- {entry_name: agtr2_rat, from_res: R, info: "Mutant peptides R12K, R12K&R16K, W27R\
        \ were made by solid phase peptide synthesis using methods described previously\
        \ (1, 26).///The following mutations on the relaxin-3 B-chain were made to\
        \ assess their function in receptor interactions: Arg8 to Ala (R8A) or Ser\
        \ (R8S); Arg12 to Ala (R12A), Leu (R12L), Ser (R12S) or Lys (R12K); Arg16\
        \ to Ala (R16A) or Ser (R16S); Ile15 to Gly (I15G), Ala (I15A), or Val (I15V);\
        \ Ile19 to Ala (I19A) or Glu (I19E); Arg12 to Lys and Arg16 to Lys (R12K&R16K);\
        \ Phe20 to Ala (F20A), Arg (F20R), Ser (F20S), or Tyr (F20Y); For all mutants\
        \ described above, the A-chain was kept unchanged.///The following mutations\
        \ on the relaxin-3 B-chain were made to assess their function in receptor\
        \ interactions: Arg8 to Ala (R8A) or Ser (R8S); Arg12 to Ala (R12A), Leu (R12L),\
        \ Ser (R12S) or Lys (R12K); Arg16 to Ala (R16A) or Ser (R16S); Ile15 to Gly\
        \ (I15G), Ala (I15A), or Val (I15V); Ile19 to Ala (I19A) or Glu (I19E); Arg12\
        \ to Lys and Arg16 to Lys (R12K&R16K); Phe20 to Ala (F20A), Arg (F20R), Ser\
        \ (F20S), or Tyr (F20Y); For all mutants described above, the A-chain was\
        \ kept unchanged.///R12K had high affinity and potency for both GPCR135 and\
        \ GPCR142 but no activity for LGR7 (Fig. 2).///Even a conserved change (Arg12\
        \ to Lys), which does not dramatically affect relaxin-3\u2019s activity for\
        \ GPCR135 and GPCR142, abolishes relaxin-3 activity for LGR7.", pubmed: '17606621',
    seq: '12', to_res: K}
- {entry_name: cxcr7_mouse, from_res: Y, info: 'In certain heterologous overexpression
        systems, WT-PKC overexpression slows proliferation, whereas a single Y155F-substitution
        is sufficient to link PKC to an enhanced growth response (1, 104, 219).///The
        mechanism(s) that control PKC -Y155 phosphorylation or the downstream signals
        linking the PKC -Y155F mutant to altered growth regulation have not been examined.',
    pubmed: '18923184', seq: '155', to_res: F}
- {entry_name: calcr_rat, from_res: M, info: 'While some studies have focused on ceramide
        as a lipid cofactor that localizes PKC and PKC (through their C1B domains)
        to the Golgi (91; see sect. IB), Larsson and colleagues (183) have used sequence
        alignment, structural modeling, and mutagenesis studies to implicate a conserved
        C1B domain methionine (Met267 in the C1B domain of PKC ) as a Golgi localization
        signal, showing that 1) this residue lies outside the C1 domain lipid binding
        surface; 2) a methionine or similar residue at this position is a highly conserved
        feature of C1 domains that localize to Golgi (including the C1B domains of
        PKCs, the C1A domain of PKD, and the C1 domain of -chimaerin), but not C1
        domains that accumulate at other cellular membranes; and 3) a single M267G
        substitution is sufficient to fully abrogate PKC localization to Golgi (and
        the resultant apoptosis) without interfering with PMA-dependent PKC translocation
        to the nucleus.', pubmed: '18923184', seq: '267', to_res: G}
- {entry_name: opsr_human, from_res: W, info: "Analysis of the array revealed a missense\
        \ mutation (c. 529T>C [p. W177R]) in exon 3 of both the long-wavelengthsensitive\
        \ (LW, red) and medium-wavelength-sensitive (MW, green) cone opsin genes that\
        \ segregated with disease.///We show that W177R in MW opsin and the equivalent\
        \ W161R mutation in rod opsin result in protein misfolding and retention in\
        \ the endoplasmic reticulum.///We also demonstrate that W177R misfolding,\
        \ unlike the P23H mutation in rod opsin that causes retinitis pigmentosa,\
        \ is not rescued by treatment with the pharmacological chaperone 9-cis-retinal.///We\
        \ subsequently identified the causative gene mutation as a missense mutation\
        \ (c. 529T>C [p.W177R]) in both the long-wavelengthsensitive (LW) and the\
        \ medium-wavelength-sensitive (MW) cone opsin genes, and we investigated the\
        \ functional consequence of this mutation.///Using site-directed mutagenesis\
        \ (Quickchange, Stratagene), we produced a wild-type (WT) green opsin construct\
        \ and subsequently created a construct with the W177R mutation (primers available\
        \ on request).///Importantly, a missense mutation, c.529T>C, was also detected\
        \ in MW exon 3, creating a Trp-to-Arg change in a highly conserved residue\
        \ at p.177 (p.W177R) (Figure 3B).///The lined box highlights the location\
        \ of a c.529T>C missense mutation in exon 3 resulting in p.W177R.///Both LW\
        \ and MW opsin genes contain identical copies of mutant MW exon 3 with the\
        \ c.529T>C missense mutation (p.W177R).///The cone opsin gene array in affected\
        \ members of the XLCOD family therefore consists of an LW gene containing\
        \ a W177R mutant MW exon 3, followed by an MW gene containing an identical\
        \ W177R mutant MW exon 3 (Figure 3C).///The cone opsin gene array in affected\
        \ members of the XLCOD family therefore consists of an LW gene containing\
        \ a W177R mutant MW exon 3, followed by an MW gene containing an identical\
        \ W177R mutant MW exon 3 (Figure 3C).///This indicates that W177R was transferred\
        \ in a block of exon 3 sequence from the MW gene into the LW gene by gene\
        \ conversion.///Cellular and Biochemical Consequence of the W177R Opsin Mutation\
        \ W177 is located in transmembrane helix IV of red and green opsins (Figure\
        \ 4A).///A 1D4 epitope-tagged MW opsin construct was used to study the fate\
        \ of the W177R mutation.///We compared the MW W177R mutation to the previously\
        \ characterized C203R mutation, known to cause blue cone monochromacy (BCM\
        \ [MIM 303700]) and shown to result in protein misfolding and endoplasmic\
        \ reticulum (ER) retention.24 We also studied the W161R rod opsin mutation\
        \ in comparison to the common RP-causing P23H misfolding mutation.25,34 Immunoblot\
        \ analysis of the WT MW opsin revealed a major band of approximately 40\u2013\
        50 kDa, with a 35 kDa species representing other glycosylated forms of the\
        \ opsin and higher molecular weight aggregates near the top of the resolving\
        \ gel (Figure 5A).///The C203R and W177R MW proteins were expressed at lower\
        \ levels in comparison to WT.///The C203R and W177R MW proteins also had a\
        \ different band pattern than that of WT protein (Figure 5A), with both resolving\
        \ to a major species of approximately 35 kDa.///WT MW opsin was resistant\
        \ to the glycosidase EndoH, whereas the C203R and W177R 35 kDa species were\
        \ sensitive to Endo H digestion.///Immunocytochemistry of the C203R and W177R\
        \ mutants confirmed that these proteins were retained within the ER, shown\
        \ by colocalization with calnexin.///9-cis-retinal treatment had no effect\
        \ on W177R or C203R, because no change in banding pattern The American Journal\
        \ of Human Genetics 87, 26\u201339, July 9, 2010 33 Figure 5.///55 55 Both\
        \ W177R and C203R show fewer glyco35 35 sylated species as compared to WT\
        \ and a shift in glycosylated species following Endo H treatment (arrowhead).///Expression\
        \ of WT MW opsin (top), C203R (middle), or W177R (bottom) in SK-N-SH cells\
        \ detected with 1D4 (green in merged panel) and counterstained for the ER\
        \ marker calnexin (Cnx, red in merged panel).///A B C2 03 R W 17 7R MW WT\
        \ C2 03 R W 17 7R MW C203R W177R W161R P23H WT was detected by immunoblot\
        \ analysis, indicating that the chromophore did not alleviate the mutant protein-folding\
        \ defect.///It is more likely that the W177R mutation originally occurred\
        \ in an ancestral MW gene and was then transferred to the LW gene by a gene-conversion\
        \ event.///This is supported by the fact that the W177R mutation in the LW\
        \ gene was embedded in a block of MW sequence.///The high sequence similarity\
        \ (96% amino acid identity) and close linkage of the LW and MW genes predisposes\
        \ the array to interlocus gene-conversion events in a manner similar to those\
        \ occurring in other gene families with high homology; for example, the human\
        \ fetal g-globin gene cluster, the DRB1 loci of the major histocompatibility\
        \ complex class II, and the Rh blood group antigen genes RHD and RHCE.36\u2013\
        39 Population genetic and statistical analyses of polymorphism at the opsin\
        \ array have shown how gene conversion has contributed to sequence diversity\
        \ within the array40 and, more recently, how polymorphism in the LW gene is\
        \ maintained through a combination of both gene conversion and natural selection.41\
        \ Gene conversion in the opsin array has also been implicated in the pathogenesis\
        \ of two cases of BCM caused by a C203R missense mutation in both LW and MW\
        \ genes.42,43 Interestingly, studies of haplotype diversity A RETINAL C2 03\
        \ R W 17 7R C2 03 R W 17 7R MW MW B 250 130 100 70 55 35 C203R 250 130 100\
        \ 70 55 35 MW CANX Merge RHO-GFP W177R W161R P23H have shown that sequence\
        \ exchange at the opsin array locus is particularly frequent in exon 3, possibly\
        \ mediated by the presence of a recombination hotspot (Chi (c) sequence element)\
        \ in the 50 part of the exon.40,41 This high frequency of gene conversion\
        \ and recombination is believed to be partly responsible for the high number\
        \ of shared exon 3 polymorphisms (Figure S1) in the LW and MW genes.43 Some\
        \ polymorphisms shift the lmax of the LW opsin into the \u2018\u2018red-orange\u2019\
        \u2019 portion of the visible spectrum, potentially enhancing color discrimination\
        \ in heterozygotes.44,45 It has thus been suggested that purifying selection\
        \ may be an additional factor for maintenance of exonic polymorphism between\
        \ the LW and MW genes, whereas historically their introns have become homogenized.41\
        \ In this XLCOD family, the exon 3 haplotype block in the LW gene carried\
        \ by affected individuals contains the mutation (W177R) in linkage disequilibrium\
        \ with several SNPs (M153, V171, V174, V178, A180) (Figure S1B).///The high\
        \ sequence similarity (96% amino acid identity) and close linkage of the LW\
        \ and MW genes predisposes the array to interlocus gene-conversion events\
        \ in a manner similar to those occurring in other gene families with high\
        \ homology; for example, the human fetal g-globin gene cluster, the DRB1 loci\
        \ of the major histocompatibility complex class II, and the Rh blood group\
        \ antigen genes RHD and RHCE.36\u201339 Population genetic and statistical\
        \ analyses of polymorphism at the opsin array have shown how gene conversion\
        \ has contributed to sequence diversity within the array40 and, more recently,\
        \ how polymorphism in the LW gene is maintained through a combination of both\
        \ gene conversion and natural selection.41 Gene conversion in the opsin array\
        \ has also been implicated in the pathogenesis of two cases of BCM caused\
        \ by a C203R missense mutation in both LW and MW genes.42,43 Interestingly,\
        \ studies of haplotype diversity A RETINAL C2 03 R W 17 7R C2 03 R W 17 7R\
        \ MW MW B 250 130 100 70 55 35 C203R 250 130 100 70 55 35 MW CANX Merge RHO-GFP\
        \ W177R W161R P23H have shown that sequence exchange at the opsin array locus\
        \ is particularly frequent in exon 3, possibly mediated by the presence of\
        \ a recombination hotspot (Chi (c) sequence element) in the 50 part of the\
        \ exon.40,41 This high frequency of gene conversion and recombination is believed\
        \ to be partly responsible for the high number of shared exon 3 polymorphisms\
        \ (Figure S1) in the LW and MW genes.43 Some polymorphisms shift the lmax\
        \ of the LW opsin into the \u2018\u2018red-orange\u2019\u2019 portion of the\
        \ visible spectrum, potentially enhancing color discrimination in heterozygotes.44,45\
        \ It has thus been suggested that purifying selection may be an additional\
        \ factor for maintenance of exonic polymorphism between the LW and MW genes,\
        \ whereas historically their introns have become homogenized.41 In this XLCOD\
        \ family, the exon 3 haplotype block in the LW gene carried by affected individuals\
        \ contains the mutation (W177R) in linkage disequilibrium with several SNPs\
        \ (M153, V171, V174, V178, A180) (Figure S1B).///The W177R MW Mutation Is\
        \ Not Rescued with 9-cis-Retinal (A) Immunoblot analysis of SK-N-SH cell lysates\
        \ transfected with WT MW opsin, W177R MW mutant and C203R MW mutant opsins,\
        \ with and without 9-cisretinal treatment, as indicated.///The W177R MW Mutation\
        \ Is Not Rescued with 9-cis-Retinal (A) Immunoblot analysis of SK-N-SH cell\
        \ lysates transfected with WT MW opsin, W177R MW mutant and C203R MW mutant\
        \ opsins, with and without 9-cisretinal treatment, as indicated.///We report\
        \ a misfolding mutation, W177R, in both the LW and MW opsin genes as a cause\
        \ of progressive cone dystrophy.///On the basis of the crystal structure of\
        \ rhodopsin and comparative modeling with cone opsins,56,57 mutation of this\
        \ conserved tryptophan residue would be predicted to cause a major conformational\
        \ change in the structure of the encoded protein, such that mutant W177R LW\
        \ and MW cone opsins would be nonfunctional in their respective photoreceptors.///The\
        \ W177R MW mutant and the equivalent mutation in rod opsin (W161R) were retained\
        \ in the ER, formed inclusions, and were targeted for degradation by the proteasome.///Although\
        \ P23H traffic was partially rescued after treatment, the mutants MW C203R,\
        \ W177R, and rod opsin W161R were not affected by 9-cis-retinal.///Although\
        \ the W177R mutation results in protein misfolding and retention in the ER\
        \ in a manner similar to that of the C203R mutation, the physiological difference\
        \ between the resulting severity in phenotype of the C203R in stationary disease\
        \ and W177R in XLCOD5 is currently not clear, and it may involve other genetic\
        \ or environmental modifying factors.///Although the W177R mutation results\
        \ in protein misfolding and retention in the ER in a manner similar to that\
        \ of the C203R mutation, the physiological difference between the resulting\
        \ severity in phenotype of the C203R in stationary disease and W177R in XLCOD5\
        \ is currently not clear, and it may involve other genetic or environmental\
        \ modifying factors.///We have demonstrated that the W177R mutation results\
        \ in misfolding of cone opsin, such that cone degeneration may result from\
        \ the loss of functional photopigment, ER stress, and the accumulation of\
        \ structurally defective opsin, similar to mutations in rod opsin that cause\
        \ autosomal-dominant RP.58,59 The equivalent amino acid in rhodopsin (W161)\
        \ is thought to be involved in packing interactions between transmembrane\
        \ helices III and IV.56,57 It has also been suggested that W161 may have a\
        \ role in signal transfer following light activation of the chromophore;60\u2013\
        62 therefore, it is possible that this mutation might affect other cone opsin\
        \ properties, such as activation of the phototransduction cascade, as a potential\
        \ mechanism affecting cone cell survival.///Interestingly, substitution in\
        \ rod opsin to W161L or W161F had no effect on rod opsin folding.60,63 In\
        \ a mutagenesis study of all the tryptophan residues in LW opsin, substitution\
        \ to W177F and W177Y caused misfolding of the LW opsin protein and accumulation\
        \ in the ER, similar to the W177R mutant described here.64 Mutations in the\
        \ LW/MW cone opsin array can cause a wider range of retinal conditions than\
        \ previously recognized, ranging from the stationary congenital disorders\
        \ of cone function, to BCM with progression in later life, to early-onset\
        \ retinal degeneration (XLCOD5).", pubmed: '20579627', seq: '177', to_res: R}
- {entry_name: opsg_human, from_res: A, info: 'The allele c.G538 encodes the MW gene
        spectral-tuning amino acid p.A180 (Figure 3B).32 Two additional known nonsynonymous
        SNPs, c.521C>T (p.A174V) and c.532A>G (p.I178V), were also identified in MW
        exon 3 (Figure 3B).///Sequencing of both amplicons in affected family members
        confirmed the presence of an MW exon 3 to LW exon 4 hybrid gene and revealed
        that both the hybrid 3MW/4LW gene and the MW gene had the p.W177R mutation
        together with p.A174V and p.I178V SNPs (Figure 3C).', pubmed: '20579627',
    seq: '174', to_res: V}
- {entry_name: opsr_human, from_res: W, info: 'Interestingly, substitution in rod
        opsin to W161L or W161F had no effect on rod opsin folding.60,63 In a mutagenesis
        study of all the tryptophan residues in LW opsin, substitution to W177F and
        W177Y caused misfolding of the LW opsin protein and accumulation in the ER,
        similar to the W177R mutant described here.64 Mutations in the LW/MW cone
        opsin array can cause a wider range of retinal conditions than previously
        recognized, ranging from the stationary congenital disorders of cone function,
        to BCM with progression in later life, to early-onset retinal degeneration
        (XLCOD5).', pubmed: '20579627', seq: '177', to_res: F}
- {entry_name: opsg_human, from_res: W, info: Sequencing of both amplicons in affected
        family members confirmed the presence of an MW exon 3 to LW exon 4 hybrid
        gene and revealed that both the hybrid 3MW/4LW gene and the MW gene had the
        p.W177R mutation together with p.A174V and p.I178V SNPs (Figure 3C)., pubmed: '20579627',
    seq: '177', to_res: R}
- {entry_name: opsr_human, from_res: S, info: 'Among males, variations in red-green
        color vision are common and estimated to be approximately 8% for individuals
        of European descent.20,46 Polymorphisms and structural rearrangements within
        the LW/ MW cone opsin genes are common, and these can alter the spectral characteristics
        of the encoded proteins, giving rise to a range of both normal and defective
        color-vision phenotypes within a population.48 Normal variants are believed
        to have been generated between the highly homologous LW and MW genes through
        ancestral gene conversions (as has been proposed for the S180A polymorphism
        in exon 3 that results in two spectrally different LW pigments) or by unequal
        recombination (as occurs in the visual pigment hybrids).', pubmed: '20579627',
    seq: '180', to_res: A}
- {entry_name: opsd_human, from_res: P, info: "We also demonstrate that W177R misfolding,\
        \ unlike the P23H mutation in rod opsin that causes retinitis pigmentosa,\
        \ is not rescued by treatment with the pharmacological chaperone 9-cis-retinal.///Untagged\
        \ and green fluorescent protein (GFP)-tagged WT rod opsin and untagged and\
        \ GFP-tagged P23H mutant rod opsin were generated as previously described.25\
        \ Site-directed mutagenesis was used to introduce the W161R mutation in untagged\
        \ and GFP-tagged rod opsin (primers available on request).///We compared the\
        \ MW W177R mutation to the previously characterized C203R mutation, known\
        \ to cause blue cone monochromacy (BCM [MIM 303700]) and shown to result in\
        \ protein misfolding and endoplasmic reticulum (ER) retention.24 We also studied\
        \ the W161R rod opsin mutation in comparison to the common RP-causing P23H\
        \ misfolding mutation.25,34 Immunoblot analysis of the WT MW opsin revealed\
        \ a major band of approximately 40\u201350 kDa, with a 35 kDa species representing\
        \ other glycosylated forms of the opsin and higher molecular weight aggregates\
        \ near the top of the resolving gel (Figure 5A).///The P23H and W161R rod\
        \ opsin mutants were expressed at lower levels than the WT protein and were\
        \ sensitive to EndoH.///GFP-tagged WT rod opsin localized to the plasma membrane,\
        \ with some staining in the ER, whereas both P23H and W161R localized exclusively\
        \ to the ER, confirming that W161R causes rod opsin misfolding (Figure 5B).///W161R\
        \ was also more prone to aggregation in comparison to P23H, as judged by increased\
        \ intracellular inclusion formation (Figure S3).///It has previously been\
        \ shown that the addition of 11-cis-retinal or 9-cis-retinal to cells expressing\
        \ P23H rod opsin can improve folding and traffic.25,35 Therefore, we investigated\
        \ the effect of 9-cis-retinal on cells expressing the tryptophan-to-arginine\
        \ substitution in MW opsin and rod opsin.///Expression of GFP-tagged RHO (top),\
        \ P23H (middle), and W161R (bottom) (green) counterstained for calnexin (red).///A\
        \ B C2 03 R W 17 7R MW WT C2 03 R W 17 7R MW C203R W177R W161R P23H WT was\
        \ detected by immunoblot analysis, indicating that the chromophore did not\
        \ alleviate the mutant protein-folding defect.///However, 9-cis-retinal treatment\
        \ of cells expressing P23H rhodopsin increased the amount of P23H, as detected\
        \ by immunoblotting, and restored traffic of P23H to the plasma membrane (Figure\
        \ 6B).///However, 9-cis-retinal treatment of cells expressing P23H rhodopsin\
        \ increased the amount of P23H, as detected by immunoblotting, and restored\
        \ traffic of P23H to the plasma membrane (Figure 6B).///However, 9-cis-retinal\
        \ treatment of cells expressing P23H rhodopsin increased the amount of P23H,\
        \ as detected by immunoblotting, and restored traffic of P23H to the plasma\
        \ membrane (Figure 6B).///The high sequence similarity (96% amino acid identity)\
        \ and close linkage of the LW and MW genes predisposes the array to interlocus\
        \ gene-conversion events in a manner similar to those occurring in other gene\
        \ families with high homology; for example, the human fetal g-globin gene\
        \ cluster, the DRB1 loci of the major histocompatibility complex class II,\
        \ and the Rh blood group antigen genes RHD and RHCE.36\u201339 Population\
        \ genetic and statistical analyses of polymorphism at the opsin array have\
        \ shown how gene conversion has contributed to sequence diversity within the\
        \ array40 and, more recently, how polymorphism in the LW gene is maintained\
        \ through a combination of both gene conversion and natural selection.41 Gene\
        \ conversion in the opsin array has also been implicated in the pathogenesis\
        \ of two cases of BCM caused by a C203R missense mutation in both LW and MW\
        \ genes.42,43 Interestingly, studies of haplotype diversity A RETINAL C2 03\
        \ R W 17 7R C2 03 R W 17 7R MW MW B 250 130 100 70 55 35 C203R 250 130 100\
        \ 70 55 35 MW CANX Merge RHO-GFP W177R W161R P23H have shown that sequence\
        \ exchange at the opsin array locus is particularly frequent in exon 3, possibly\
        \ mediated by the presence of a recombination hotspot (Chi (c) sequence element)\
        \ in the 50 part of the exon.40,41 This high frequency of gene conversion\
        \ and recombination is believed to be partly responsible for the high number\
        \ of shared exon 3 polymorphisms (Figure S1) in the LW and MW genes.43 Some\
        \ polymorphisms shift the lmax of the LW opsin into the \u2018\u2018red-orange\u2019\
        \u2019 portion of the visible spectrum, potentially enhancing color discrimination\
        \ in heterozygotes.44,45 It has thus been suggested that purifying selection\
        \ may be an additional factor for maintenance of exonic polymorphism between\
        \ the LW and MW genes, whereas historically their introns have become homogenized.41\
        \ In this XLCOD family, the exon 3 haplotype block in the LW gene carried\
        \ by affected individuals contains the mutation (W177R) in linkage disequilibrium\
        \ with several SNPs (M153, V171, V174, V178, A180) (Figure S1B).///(B) Immunoblot\
        \ analysis of SK-N-SH cell lysates transfected with RHO and the RHO mutants\
        \ P23H and W161R, with and without 9-cis-retinal treatment resulted in increased\
        \ expression of P23H, but not W161R.///(B) Immunoblot analysis of SK-N-SH\
        \ cell lysates transfected with RHO and the RHO mutants P23H and W161R, with\
        \ and without 9-cis-retinal treatment resulted in increased expression of\
        \ P23H, but not W161R.///9-cis-retinal treatment led to an increase in P23H\
        \ traffic to the plasma membrane (arrowhead), whereas W161R was retained in\
        \ the ER, where it colocalized with calnexin. and stationary cone dysfunction\
        \ syndromes, including BCM.46\u201348 In trichromats, normal color vision\
        \ requires a neural comparison between the light-absorption spectra of the\
        \ three (SW, LW, and MW) different cone visual pigments.///We explored the\
        \ biochemical and cellular consequence of this mutation in both cone opsin\
        \ (MW) and rod opsin, and we compared this mutant with the most common point\
        \ mutation associated with BCM, C203R, and the RP-associated rod opsin class\
        \ II misfolding mutant P23H.///Although P23H traffic was partially rescued\
        \ after treatment, the mutants MW C203R, W177R, and rod opsin W161R were not\
        \ affected by 9-cis-retinal.", pubmed: '20579627', seq: '23', to_res: H}
- {entry_name: opsd_human, from_res: W, info: 'Interestingly, substitution in rod
        opsin to W161L or W161F had no effect on rod opsin folding.60,63 In a mutagenesis
        study of all the tryptophan residues in LW opsin, substitution to W177F and
        W177Y caused misfolding of the LW opsin protein and accumulation in the ER,
        similar to the W177R mutant described here.64 Mutations in the LW/MW cone
        opsin array can cause a wider range of retinal conditions than previously
        recognized, ranging from the stationary congenital disorders of cone function,
        to BCM with progression in later life, to early-onset retinal degeneration
        (XLCOD5).', pubmed: '20579627', seq: '161', to_res: F}
- {entry_name: opsg_human, from_res: P, info: "Inactivating point mutations identified\
        \ to date are C203R, P307L, and R247X.42,43,47 The second pathway consists\
        \ of a one-step inactivation of both LW and MW genes by deletion of the LCR\
        \ sequence (40% of all cases).43,47,49\u201352 A third, more rare, mechanism\
        \ is deletion of an exon.23,53 Interestingly, the mechanism leading to the\
        \ XLCOD phenotype described here is a divergent two-step pathway; The American\
        \ Journal of Human Genetics 87, 26\u201339, July 9, 2010 35 inactivation mutation\
        \ followed by gene conversion, leading to two nonfunctional genes in the array,\
        \ which represents a fourth class of opsin array inactivation.", pubmed: '20579627',
    seq: '307', to_res: L}
- {entry_name: opsg_human, from_res: I, info: 'The allele c.G538 encodes the MW gene
        spectral-tuning amino acid p.A180 (Figure 3B).32 Two additional known nonsynonymous
        SNPs, c.521C>T (p.A174V) and c.532A>G (p.I178V), were also identified in MW
        exon 3 (Figure 3B).///Sequencing of both amplicons in affected family members
        confirmed the presence of an MW exon 3 to LW exon 4 hybrid gene and revealed
        that both the hybrid 3MW/4LW gene and the MW gene had the p.W177R mutation
        together with p.A174V and p.I178V SNPs (Figure 3C).', pubmed: '20579627',
    seq: '178', to_res: V}
- {entry_name: opsg_human, from_res: C, info: "Constructs, Antibodies, and Reagents\
        \ To create cone opsin constructs with a 1D4 epitope for transient transfection,\
        \ we subcloned 1D4-tagged green (MW) opsin with a C203R mutation from pGrnC203R24\
        \ into pBK-CMV.///We compared the MW W177R mutation to the previously characterized\
        \ C203R mutation, known to cause blue cone monochromacy (BCM [MIM 303700])\
        \ and shown to result in protein misfolding and endoplasmic reticulum (ER)\
        \ retention.24 We also studied the W161R rod opsin mutation in comparison\
        \ to the common RP-causing P23H misfolding mutation.25,34 Immunoblot analysis\
        \ of the WT MW opsin revealed a major band of approximately 40\u201350 kDa,\
        \ with a 35 kDa species representing other glycosylated forms of the opsin\
        \ and higher molecular weight aggregates near the top of the resolving gel\
        \ (Figure 5A).///The C203R and W177R MW proteins were expressed at lower levels\
        \ in comparison to WT.///The C203R and W177R MW proteins also had a different\
        \ band pattern than that of WT protein (Figure 5A), with both resolving to\
        \ a major species of approximately 35 kDa.///WT MW opsin was resistant to\
        \ the glycosidase EndoH, whereas the C203R and W177R 35 kDa species were sensitive\
        \ to Endo H digestion.///Immunocytochemistry of the C203R and W177R mutants\
        \ confirmed that these proteins were retained within the ER, shown by colocalization\
        \ with calnexin.///9-cis-retinal treatment had no effect on W177R or C203R,\
        \ because no change in banding pattern The American Journal of Human Genetics\
        \ 87, 26\u201339, July 9, 2010 33 Figure 5.///55 55 Both W177R and C203R show\
        \ fewer glyco35 35 sylated species as compared to WT and a shift in glycosylated\
        \ species following Endo H treatment (arrowhead).///Expression of WT MW opsin\
        \ (top), C203R (middle), or W177R (bottom) in SK-N-SH cells detected with\
        \ 1D4 (green in merged panel) and counterstained for the ER marker calnexin\
        \ (Cnx, red in merged panel).///A B C2 03 R W 17 7R MW WT C2 03 R W 17 7R\
        \ MW C203R W177R W161R P23H WT was detected by immunoblot analysis, indicating\
        \ that the chromophore did not alleviate the mutant protein-folding defect.///The\
        \ high sequence similarity (96% amino acid identity) and close linkage of\
        \ the LW and MW genes predisposes the array to interlocus gene-conversion\
        \ events in a manner similar to those occurring in other gene families with\
        \ high homology; for example, the human fetal g-globin gene cluster, the DRB1\
        \ loci of the major histocompatibility complex class II, and the Rh blood\
        \ group antigen genes RHD and RHCE.36\u201339 Population genetic and statistical\
        \ analyses of polymorphism at the opsin array have shown how gene conversion\
        \ has contributed to sequence diversity within the array40 and, more recently,\
        \ how polymorphism in the LW gene is maintained through a combination of both\
        \ gene conversion and natural selection.41 Gene conversion in the opsin array\
        \ has also been implicated in the pathogenesis of two cases of BCM caused\
        \ by a C203R missense mutation in both LW and MW genes.42,43 Interestingly,\
        \ studies of haplotype diversity A RETINAL C2 03 R W 17 7R C2 03 R W 17 7R\
        \ MW MW B 250 130 100 70 55 35 C203R 250 130 100 70 55 35 MW CANX Merge RHO-GFP\
        \ W177R W161R P23H have shown that sequence exchange at the opsin array locus\
        \ is particularly frequent in exon 3, possibly mediated by the presence of\
        \ a recombination hotspot (Chi (c) sequence element) in the 50 part of the\
        \ exon.40,41 This high frequency of gene conversion and recombination is believed\
        \ to be partly responsible for the high number of shared exon 3 polymorphisms\
        \ (Figure S1) in the LW and MW genes.43 Some polymorphisms shift the lmax\
        \ of the LW opsin into the \u2018\u2018red-orange\u2019\u2019 portion of the\
        \ visible spectrum, potentially enhancing color discrimination in heterozygotes.44,45\
        \ It has thus been suggested that purifying selection may be an additional\
        \ factor for maintenance of exonic polymorphism between the LW and MW genes,\
        \ whereas historically their introns have become homogenized.41 In this XLCOD\
        \ family, the exon 3 haplotype block in the LW gene carried by affected individuals\
        \ contains the mutation (W177R) in linkage disequilibrium with several SNPs\
        \ (M153, V171, V174, V178, A180) (Figure S1B).///The high sequence similarity\
        \ (96% amino acid identity) and close linkage of the LW and MW genes predisposes\
        \ the array to interlocus gene-conversion events in a manner similar to those\
        \ occurring in other gene families with high homology; for example, the human\
        \ fetal g-globin gene cluster, the DRB1 loci of the major histocompatibility\
        \ complex class II, and the Rh blood group antigen genes RHD and RHCE.36\u2013\
        39 Population genetic and statistical analyses of polymorphism at the opsin\
        \ array have shown how gene conversion has contributed to sequence diversity\
        \ within the array40 and, more recently, how polymorphism in the LW gene is\
        \ maintained through a combination of both gene conversion and natural selection.41\
        \ Gene conversion in the opsin array has also been implicated in the pathogenesis\
        \ of two cases of BCM caused by a C203R missense mutation in both LW and MW\
        \ genes.42,43 Interestingly, studies of haplotype diversity A RETINAL C2 03\
        \ R W 17 7R C2 03 R W 17 7R MW MW B 250 130 100 70 55 35 C203R 250 130 100\
        \ 70 55 35 MW CANX Merge RHO-GFP W177R W161R P23H have shown that sequence\
        \ exchange at the opsin array locus is particularly frequent in exon 3, possibly\
        \ mediated by the presence of a recombination hotspot (Chi (c) sequence element)\
        \ in the 50 part of the exon.40,41 This high frequency of gene conversion\
        \ and recombination is believed to be partly responsible for the high number\
        \ of shared exon 3 polymorphisms (Figure S1) in the LW and MW genes.43 Some\
        \ polymorphisms shift the lmax of the LW opsin into the \u2018\u2018red-orange\u2019\
        \u2019 portion of the visible spectrum, potentially enhancing color discrimination\
        \ in heterozygotes.44,45 It has thus been suggested that purifying selection\
        \ may be an additional factor for maintenance of exonic polymorphism between\
        \ the LW and MW genes, whereas historically their introns have become homogenized.41\
        \ In this XLCOD family, the exon 3 haplotype block in the LW gene carried\
        \ by affected individuals contains the mutation (W177R) in linkage disequilibrium\
        \ with several SNPs (M153, V171, V174, V178, A180) (Figure S1B).///The W177R\
        \ MW Mutation Is Not Rescued with 9-cis-Retinal (A) Immunoblot analysis of\
        \ SK-N-SH cell lysates transfected with WT MW opsin, W177R MW mutant and C203R\
        \ MW mutant opsins, with and without 9-cisretinal treatment, as indicated.///Inactivating\
        \ point mutations identified to date are C203R, P307L, and R247X.42,43,47\
        \ The second pathway consists of a one-step inactivation of both LW and MW\
        \ genes by deletion of the LCR sequence (40% of all cases).43,47,49\u2013\
        52 A third, more rare, mechanism is deletion of an exon.23,53 Interestingly,\
        \ the mechanism leading to the XLCOD phenotype described here is a divergent\
        \ two-step pathway; The American Journal of Human Genetics 87, 26\u201339,\
        \ July 9, 2010 35 inactivation mutation followed by gene conversion, leading\
        \ to two nonfunctional genes in the array, which represents a fourth class\
        \ of opsin array inactivation.///Molecular genetic analysis of the LW/MW opsin\
        \ array in these cases has shown deletion of the LCR in two families,47,50\
        \ as well as a single 50 -LW/MW-30 hybrid gene inactivated by a C203R mutation\
        \ and a 50 -LW/MW-30 gene with deletion of exon 2, each in a single family.23,54\
        \ No molecular diagnosis has been reported in the remaining family.55 Therefore,\
        \ there is currently no clear genotype-phenotype correlation.///We explored\
        \ the biochemical and cellular consequence of this mutation in both cone opsin\
        \ (MW) and rod opsin, and we compared this mutant with the most common point\
        \ mutation associated with BCM, C203R, and the RP-associated rod opsin class\
        \ II misfolding mutant P23H.///Similarly, the C203R MW mutant, which results\
        \ in misfolded protein due to disruption of a disulphide bond with C126, was\
        \ retained in the ER, as reported previously.24 We then tested the ability\
        \ of 9-cis-retinal treatment to rescue the protein-processing defect of all\
        \ four mutants.///Although P23H traffic was partially rescued after treatment,\
        \ the mutants MW C203R, W177R, and rod opsin W161R were not affected by 9-cis-retinal.///Although\
        \ the W177R mutation results in protein misfolding and retention in the ER\
        \ in a manner similar to that of the C203R mutation, the physiological difference\
        \ between the resulting severity in phenotype of the C203R in stationary disease\
        \ and W177R in XLCOD5 is currently not clear, and it may involve other genetic\
        \ or environmental modifying factors.///Although the W177R mutation results\
        \ in protein misfolding and retention in the ER in a manner similar to that\
        \ of the C203R mutation, the physiological difference between the resulting\
        \ severity in phenotype of the C203R in stationary disease and W177R in XLCOD5\
        \ is currently not clear, and it may involve other genetic or environmental\
        \ modifying factors.///Adaptive optics imaging in dichromatic individuals\
        \ with a C203R MW cone opsin mutation has shown that this mutation results\
        \ in disruption of the cone photoreceptor mosaic, a reduction in cone density,\
        \ and thinning of the outer nuclear layer.68 The application of this technique\
        \ to the study of individuals with cone dysfunction and cone dystrophy, and\
        \ correlation of genotypes to cone mosaic and cone density, is likely to lead\
        \ to improved understanding of the functional and visual consequence of cone\
        \ opsin mutations.", pubmed: '20579627', seq: '203', to_res: R}
- {entry_name: opsr_human, from_res: M, info: 'At nucleotide c.706 in exon 4, a single
        peak was observed (Figure S1), representing an A>G transition in the LW gene
        resulting in the known SNP p.M236V.', pubmed: '20579627', seq: '236', to_res: V}
- {entry_name: opsd_human, from_res: W, info: 'Interestingly, substitution in rod
        opsin to W161L or W161F had no effect on rod opsin folding.60,63 In a mutagenesis
        study of all the tryptophan residues in LW opsin, substitution to W177F and
        W177Y caused misfolding of the LW opsin protein and accumulation in the ER,
        similar to the W177R mutant described here.64 Mutations in the LW/MW cone
        opsin array can cause a wider range of retinal conditions than previously
        recognized, ranging from the stationary congenital disorders of cone function,
        to BCM with progression in later life, to early-onset retinal degeneration
        (XLCOD5).', pubmed: '20579627', seq: '161', to_res: L}
- {entry_name: opsr_human, from_res: W, info: 'Interestingly, substitution in rod
        opsin to W161L or W161F had no effect on rod opsin folding.60,63 In a mutagenesis
        study of all the tryptophan residues in LW opsin, substitution to W177F and
        W177Y caused misfolding of the LW opsin protein and accumulation in the ER,
        similar to the W177R mutant described here.64 Mutations in the LW/MW cone
        opsin array can cause a wider range of retinal conditions than previously
        recognized, ranging from the stationary congenital disorders of cone function,
        to BCM with progression in later life, to early-onset retinal degeneration
        (XLCOD5).', pubmed: '20579627', seq: '177', to_res: Y}
- {entry_name: opsd_human, from_res: W, info: "We show that W177R in MW opsin and\
        \ the equivalent W161R mutation in rod opsin result in protein misfolding\
        \ and retention in the endoplasmic reticulum.///Untagged and green fluorescent\
        \ protein (GFP)-tagged WT rod opsin and untagged and GFP-tagged P23H mutant\
        \ rod opsin were generated as previously described.25 Site-directed mutagenesis\
        \ was used to introduce the W161R mutation in untagged and GFP-tagged rod\
        \ opsin (primers available on request).///We compared the MW W177R mutation\
        \ to the previously characterized C203R mutation, known to cause blue cone\
        \ monochromacy (BCM [MIM 303700]) and shown to result in protein misfolding\
        \ and endoplasmic reticulum (ER) retention.24 We also studied the W161R rod\
        \ opsin mutation in comparison to the common RP-causing P23H misfolding mutation.25,34\
        \ Immunoblot analysis of the WT MW opsin revealed a major band of approximately\
        \ 40\u201350 kDa, with a 35 kDa species representing other glycosylated forms\
        \ of the opsin and higher molecular weight aggregates near the top of the\
        \ resolving gel (Figure 5A).///The P23H and W161R rod opsin mutants were expressed\
        \ at lower levels than the WT protein and were sensitive to EndoH.///GFP-tagged\
        \ WT rod opsin localized to the plasma membrane, with some staining in the\
        \ ER, whereas both P23H and W161R localized exclusively to the ER, confirming\
        \ that W161R causes rod opsin misfolding (Figure 5B).///GFP-tagged WT rod\
        \ opsin localized to the plasma membrane, with some staining in the ER, whereas\
        \ both P23H and W161R localized exclusively to the ER, confirming that W161R\
        \ causes rod opsin misfolding (Figure 5B).///W161R was also more prone to\
        \ aggregation in comparison to P23H, as judged by increased intracellular\
        \ inclusion formation (Figure S3).///Endo H treatment results in a shift in\
        \ glycosylated species of the W161R mutant (arrowhead).///Expression of GFP-tagged\
        \ RHO (top), P23H (middle), and W161R (bottom) (green) counterstained for\
        \ calnexin (red).///A B C2 03 R W 17 7R MW WT C2 03 R W 17 7R MW C203R W177R\
        \ W161R P23H WT was detected by immunoblot analysis, indicating that the chromophore\
        \ did not alleviate the mutant protein-folding defect.///Treatment with 9-cis-retinal\
        \ had no effect on W161R rhodopsin expression or localization.///The high\
        \ sequence similarity (96% amino acid identity) and close linkage of the LW\
        \ and MW genes predisposes the array to interlocus gene-conversion events\
        \ in a manner similar to those occurring in other gene families with high\
        \ homology; for example, the human fetal g-globin gene cluster, the DRB1 loci\
        \ of the major histocompatibility complex class II, and the Rh blood group\
        \ antigen genes RHD and RHCE.36\u201339 Population genetic and statistical\
        \ analyses of polymorphism at the opsin array have shown how gene conversion\
        \ has contributed to sequence diversity within the array40 and, more recently,\
        \ how polymorphism in the LW gene is maintained through a combination of both\
        \ gene conversion and natural selection.41 Gene conversion in the opsin array\
        \ has also been implicated in the pathogenesis of two cases of BCM caused\
        \ by a C203R missense mutation in both LW and MW genes.42,43 Interestingly,\
        \ studies of haplotype diversity A RETINAL C2 03 R W 17 7R C2 03 R W 17 7R\
        \ MW MW B 250 130 100 70 55 35 C203R 250 130 100 70 55 35 MW CANX Merge RHO-GFP\
        \ W177R W161R P23H have shown that sequence exchange at the opsin array locus\
        \ is particularly frequent in exon 3, possibly mediated by the presence of\
        \ a recombination hotspot (Chi (c) sequence element) in the 50 part of the\
        \ exon.40,41 This high frequency of gene conversion and recombination is believed\
        \ to be partly responsible for the high number of shared exon 3 polymorphisms\
        \ (Figure S1) in the LW and MW genes.43 Some polymorphisms shift the lmax\
        \ of the LW opsin into the \u2018\u2018red-orange\u2019\u2019 portion of the\
        \ visible spectrum, potentially enhancing color discrimination in heterozygotes.44,45\
        \ It has thus been suggested that purifying selection may be an additional\
        \ factor for maintenance of exonic polymorphism between the LW and MW genes,\
        \ whereas historically their introns have become homogenized.41 In this XLCOD\
        \ family, the exon 3 haplotype block in the LW gene carried by affected individuals\
        \ contains the mutation (W177R) in linkage disequilibrium with several SNPs\
        \ (M153, V171, V174, V178, A180) (Figure S1B).///(B) Immunoblot analysis of\
        \ SK-N-SH cell lysates transfected with RHO and the RHO mutants P23H and W161R,\
        \ with and without 9-cis-retinal treatment resulted in increased expression\
        \ of P23H, but not W161R.///(B) Immunoblot analysis of SK-N-SH cell lysates\
        \ transfected with RHO and the RHO mutants P23H and W161R, with and without\
        \ 9-cis-retinal treatment resulted in increased expression of P23H, but not\
        \ W161R.///9-cis-retinal treatment led to an increase in P23H traffic to the\
        \ plasma membrane (arrowhead), whereas W161R was retained in the ER, where\
        \ it colocalized with calnexin. and stationary cone dysfunction syndromes,\
        \ including BCM.46\u201348 In trichromats, normal color vision requires a\
        \ neural comparison between the light-absorption spectra of the three (SW,\
        \ LW, and MW) different cone visual pigments.///The W177R MW mutant and the\
        \ equivalent mutation in rod opsin (W161R) were retained in the ER, formed\
        \ inclusions, and were targeted for degradation by the proteasome.///Although\
        \ P23H traffic was partially rescued after treatment, the mutants MW C203R,\
        \ W177R, and rod opsin W161R were not affected by 9-cis-retinal.", pubmed: '20579627',
    seq: '161', to_res: R}
- {entry_name: acm3_rat, from_res: K, info: 'As a proof of concept, we expressed a
        rat M3 muscarinic acetylcholine receptor (mAChR) bearing a mutation (K7.32E)
        recently identified to confer positive cooperativity between acetylcholine
        and the allosteric modulator brucine in various strains of S. cerevisiae,
        each expressing a different human G /yeast Gpa1 protein chimera, and probed
        for G protein-biased allosteric modulation.///As a proof of concept, we focused
        on the brucine-carbachol (CCh) interaction at the K7.32E M3 mAChR mutant.///The
        K7.32E (K522E) mutation was introduced by site-directed mutagenesis using
        the QuikChange mutagenesis kit (Stratagene, La Jolla, CA) by annealing the
        following oligodeoxynucleotide pair into the open vector: 5 -GACAGCTGCATACCCGAAACCTATTGGAATC
        3 and 5 -GATTCCAATAGGTTTCGGGTATGCAGCTGTC-3 .///It is noteworthy, however,
        that the modulatory effect of brucine on orthosteric ligand binding was altered
        by the K7.32E mutation, because brucine displayed slight negative cooperativity
        for [3H]NMS and CCh binding at the M3 mAChR but modest positive cooperativity
        at the M3K7.32E mAChR.///Furthermore, using the yeast system and the unique
        properties of brucine at the K7.32E mutant as pharmacological tools allowed
        us to determine a putative G protein candidate for brucine biased modulation
        of M 3 K 7.32 E mAChR-mediated ERK1/2 phosphorylation pathway in mammalian
        (CHO) cells.///The data generated from the yeast signaling assays at the K7.32E
        mutant, however, suggested that brucine was an agonist with modest enhancement
        of CCh signaling when coupled to Gqmediated pathways.///Interaction binding
        assays between CCh and brucine in membranes expressing the M3 and M3K7.32E
        mAChR demonstrated that the K7.32E mutation did not greatly affect the binding
        of [3H]NMS, CCh, or brucine but rather weakly enhanced the cooperativity of
        brucine with the orthosteric ligands.///Therefore, perhaps, the K7.32E mutation
        in the M3 mAChR alters the interaction of TMVII with the plasma membrane and,
        in turn, increases the propensity of the receptor to be activated/modulated
        by brucine.///Irrespective of the mode of receptor activation induced by ligands
        acting at the K7.32E mutation, it is clear that the cooperativity between
        brucine and CCh is increased by the presence this mutation.', pubmed: '20466821',
    seq: '522', to_res: E}
- {entry_name: acm3_human, from_res: K, info: "The same processes were applied to\
        \ generate a vector containing the gene encoding the human M3K7.32E (K523E)\
        \ mAChR; however, before the BP Clonase reaction, a mutation was introduced\
        \ using the QuikChange mutagenesis kit (Stratagene) by applying the oligonucleotides\
        \ 5 -GTGACAGCTGCATACCCGAGACCTTTTGGAATCTGG-3 and 5 -CCAGATTCCAAAAGGTCTCGGGTATGCAGCTGTCAC-3\
        \ to the open vector, then following the manufacturer\u2019s instructions.",
    pubmed: '20466821', seq: '549', to_res: E}
- {entry_name: acm3_rat, from_res: K, info: 'The K7.32E (K522E) mutation was introduced
        by site-directed mutagenesis using the QuikChange mutagenesis kit (Stratagene,
        La Jolla, CA) by annealing the following oligodeoxynucleotide pair into the
        open vector: 5 -GACAGCTGCATACCCGAAACCTATTGGAATC 3 and 5 -GATTCCAATAGGTTTCGGGTATGCAGCTGTC-3
        .', pubmed: '20466821', seq: '548', to_res: E}
- {entry_name: agtr1_human, from_res: N, info: 'The resulting mutants, hTAS2R46E70V,
        -L71F, -N76Y, -I82T, -I91T, -N92G, -N150K, -Q151E, -W154R, -N176D, and -E253G
        were functionally characterized with absinthin, strychnine, denatonium, and
        aristolochic acid (Fig. 4A).///Four mutants, hTAS2R46E70V, -I82T, -N176D,
        and -E253G exhibited agonist-selective reductions of responses, the most pronounced
        seen for hTAS2R46E70V, which was not activated by absinthin.', pubmed: '20534469',
    seq: '176', to_res: D}
- {entry_name: opsd_human, from_res: E, info: "In one, the mutation E113Q3.28 (9)\
        \ was incorporated into rhodopsin to neutralize the counterion of the retinal\
        \ Schiff base (10) preventing dissociation of retinal.///The E113Q3.28 mutant\
        \ lacks the Schiff base covalent bond between retinal and the protein and\
        \ the back-soaked opsin shows an unexpected rotation of the ligand.///With\
        \ the crystal structure of the constitutively active E113Q3.28 counterion\
        \ mutant (9), we have recently presented an example for the first category.///The\
        \ crystal structure of M257Y/G\u03B1CT was solved at 3.3 \xC5 resolution using\
        \ the E113Q/ G\u03B1CTrhodopsin structure (9) as a molecular replacement model.///Beside\
        \ the posttranslationally modified polypeptide, the structure contains one\
        \ octyl-glycoside molecule, one acetate molecule bound close to a proposed\
        \ exit channel for retinal (21), density for nine of the 18 water molecules\
        \ identified previously in the structure of constitutively active E113Q3.28\
        \ rhodopsin (9), and the covalently bound all-trans-retinal agonist.///The\
        \ structures of constitutively active E113Q3.28 and M257Y6.40 rhodopsin are\
        \ very similar with an average RMSD(C\u03B1) of 0.316 \xC5.///Specific differences,\
        \ however, can be observed close to where the mutations have been introduced;\
        \ i.e., in the retinal binding site for the E113Q3.28 mutant and the G protein\
        \ binding sites for the M257Y6.40 mutant.///Only minimal modifications are\
        \ necessary to form these interactions, with the C\u03B1 atom of Y2576.40\
        \ differing by only 0.3 \xC5 from the E113Q3.28 active state structure, which\
        \ contains the native methionine at this position.///In the structure of the\
        \ constitutively active E113Q3.28 structure (D) the hydrophobic barrier has\
        \ opened and Y2235.58 in TM5 and Y3067.53 of the NPxxY motif in TM7 swing\
        \ into the created cavity, stabilized by a water-mediated H-bond network (9).///The\
        \ rearrangements involving the \u03B2-ionone are very similar to the ones\
        \ found in the structure of E113Q3.28 rhodopsin, where retinal is noncovalently\
        \ bound (SI Appendix, Fig. 3).///Our crystal structures of the constitutively\
        \ active E113Q3.28 and M257Y6.40 rhodopsin mutants provide two examples in\
        \ which the molecular basis for constitutive activity is more specific.///Standfuss\
        \ J, Zaitseva E, Mahalingam M, Vogel R (2008) Structural impact of the E113Q\
        \ counterion mutation on the activation and deactivation pathways of the G\
        \ proteincoupled receptor rhodopsin.///Phases were obtained by molecular replacement\
        \ using the polypeptide of the E113Q mutant (9) as search model.", pubmed: '22198838',
    seq: '113', to_res: Q}
- {entry_name: opsd_human, from_res: M, info: Several amino acid substitutions at
        M2576.40 lead to limited constitutive activity but only M257N6.40 and M257S6.40
        reach at least half the level of M257Y6.40 (17)., pubmed: '22198838', seq: '257',
    to_res: N}
- {entry_name: opsd_human, from_res: M, info: Several amino acid substitutions at
        M2576.40 lead to limited constitutive activity but only M257N6.40 and M257S6.40
        reach at least half the level of M257Y6.40 (17)., pubmed: '22198838', seq: '257',
    to_res: S}
- {entry_name: opsd_human, from_res: M, info: "The constitutively active mutation\
        \ M257Y6.40 was introduced in the context of another rhodopsin mutant, N2C/D282C,\
        \ containing an engineered disulfide bond known to enhance thermal stability\
        \ of the protein (SI Appendix, Fig. 1) without affecting activity (15, 16).///Here,\
        \ we have used the M257Y6.40 constitutively active mutant of the photoreceptor\
        \ rhodopsin in combination with the specific binding of a C-terminal fragment\
        \ from the G protein alpha subunit (G\u03B1CT) to trap a light activated state\
        \ for crystallization.///The structure of the M257Y/G\u03B1CT complex contains\
        \ the agonist all-trans-retinal covalently bound to the native binding pocket\
        \ and resembles the G protein binding metarhodopsin-II conformation obtained\
        \ by the natural activation mechanism; i.e., illumination of the prebound\
        \ chromophore 11-cis-retinal.///Here we present an example for the second\
        \ category, the constitutively active M257Y6.40 rhodopsin mutant.///Most importantly,\
        \ the M257Y6.40 mutation does not change the retinal binding site and shows\
        \ all-trans-retinal covalently bound in its native environment.///A comparison\
        \ with published biochemical, spectroscopic, and structural data shows that\
        \ the M257Y/G\u03B1CT structure presents all the features of metarhodopsin-II,\
        \ the G protein binding conformation obtained by the natural activation mechanism.\
        \ solved the structure of this stabilized mutant and showed it to be virtually\
        \ identical to the native protein (4).///To investigate the biochemistry of\
        \ the M257Y6.40 mutation in the context of the N2C/D282C background, we first\
        \ analyzed its ability to activate the G protein transducin (Fig. 1).///G\
        \ protein activation is fully suppressed by reconstitution with the inverse\
        \ agonist 11-cis-retinal, in both thermo-stabilized N2C/D282C and N2C/M257Y/\
        \ D282C (from hereon called M257Y6.40 ).///G protein activation is fully suppressed\
        \ by reconstitution with the inverse agonist 11-cis-retinal, in both thermo-stabilized\
        \ N2C/D282C and N2C/M257Y/ D282C (from hereon called M257Y6.40 ).///G protein\
        \ activation of M257Y6.40 and N2C/D282C rhodopsin is virtually indistinguishable\
        \ if triggered by light-induced isomerization of retinal (Fig. 1A).///By contrast,\
        \ clear differences in activity can be observed in the absence of retinal,\
        \ where N2C/D282C opsin is completely inactive, but inclusion of the M257Y6.40\
        \ mutation increases the basal activity to about 40% of the photoactivated\
        \ state.///Reconstitution of the M257Y6.40 opsin with all-trans-retinal further\
        \ increases the activity to the same level as after light activation of rhodopsin\
        \ reconstituted with 11-cis-retinal (Fig. 1B, Inset).///Spectral analysis\
        \ of the M257Y6.40 pigment reconstituted with all-trans-retinal under dim\
        \ red light shows a maximum absorbance at 380 nm that red-shifts to 415 nm\
        \ upon protonation of the Schiff base through acidification (Fig. 1B).///Even\
        \ though M257Y6.40 opsin expresses full activity when incubated with all-trans-retinal,\
        \ we first reconstituted it with 11-cis-retinal under dim red light during\
        \ purification.///Structure of the M257Y/G\u03B1CT Complex.///The crystal\
        \ structure of M257Y/G\u03B1CT was solved at 3.3 \xC5 resolution using the\
        \ E113Q/ G\u03B1CTrhodopsin structure (9) as a molecular replacement model.///A\
        \ single M257Y/G\u03B1CT complex was found per asymmetric unit and was refined\
        \ to a crystallographic R value of 0.22 and an Rfree of 0.26 (SI Appendix,\
        \ Table 1).///Our final structural model contains residues 1-326 of rhodopsin\
        \ with mutations N2C/D282C/M257Y and all eleven residues of the G\u03B1CT\
        \ peptide including the K341L mutation.///The structures of constitutively\
        \ active E113Q3.28 and M257Y6.40 rhodopsin are very similar with an average\
        \ RMSD(C\u03B1) of 0.316 \xC5.///Specific differences, however, can be observed\
        \ close to where the mutations have been introduced; i.e., in the retinal\
        \ binding site for the E113Q3.28 mutant and the G protein binding sites for\
        \ the M257Y6.40 mutant.///The M257Y6.40 mutant increases constitutive Fig.\
        \ 1.///Biochemical assessment of M257Y6.40 in the context of the N2C/D282C\
        \ background.///(A) Assessment of G protein activation (pmol) by bovine opsin\
        \ (open symbols and dashed regression lines) or 11-cis-retinal reconstituted\
        \ rhodopsin (solid symbols and regression lines) for the N2C/D282C (blue circles)\
        \ and N2C/M257Y/D282C (red triangles) mutants.///Absorbance spectra of purified\
        \ N2C/M257Y/D282C reconstituted with all-trans-retinal were recorded at pH\
        \ 7.4 (solid line) and pH 3.5 (dotted line).///The inset shows that reconstitution\
        \ of N2C/M257Y/D282C with all-trans-retinal (squares, dotted regression line,\
        \ slope 1\u20444 1.37 pmol\u2215 min) increases G protein activation levels\
        \ to those of fully light activated metarhodopsin-II that had been reconstituted\
        \ with 11-cis-retinal (red triangles, solid regression line, slope 1\u2044\
        4 1.35 pmol\u2215 min).///The M257Y6.40 mutation modifies the hydrophobic\
        \ barrier between the NPxxY motif and the G protein binding site by introducing\
        \ a hydrophilic hydroxyl group that disturbs the tight helix packing in the\
        \ ground state.///The M257Y/G\u03B1CT active state shows the tilted rotation\
        \ of TM6 that opens the G protein binding site and a reorganization of H-bond\
        \ networks (9).///Several amino acid substitutions at M2576.40 lead to limited\
        \ constitutive activity but only M257N6.40 and M257S6.40 reach at least half\
        \ the level of M257Y6.40 (17).///During structure determination of the light\
        \ activated M257Y/G\u03B1CTcomplex, retinal could be readily localized in\
        \ its binding pocket (Fig. 3 and SI Appendix, Fig. 3).///Effect of the M257Y6.40\
        \ mutation on the ionic lock region.///The M257Y6.40 mutation (C) interferes\
        \ with this packing and lowers the energy barrier for reorganizations of TM6\
        \ that characterize the active conformation.///The constitutively active M257Y6.40\
        \ mutant (C) introduces only minor changes to the overall structure of the\
        \ ionic lock region, however the introduced tyrosine forms an edge-face interaction\
        \ with Y2235.58 , a parallel-displaced \u03C0-\u03C0 stacking interaction\
        \ to Y3067.53 , and hydrophilic interactions to R1353.50 , three interactions\
        \ that stabilize the open G protein binding site.///Conformation of all-trans-retinal\
        \ in the M257Y/G\u03B1CT structure.///Altogether, the position of retinal\
        \ in our structure of the light activated constitutively active rhodopsin\
        \ mutant M257Y6.40 agrees very well with the retinal position obtained from\
        \ opsin crystals soaked with all-transretinal (11).///This has been possible\
        \ by using the constitutively active M257Y6.40 mutant combined with two functionally\
        \ neutral but stabilizing cysteines (15, 16).///In agreement with previous\
        \ reports on the M257Y6.40 single mutation (17), we demonstrate that the stabilized\
        \ M257Y6.40 mutant binds all-trans-retinal in the correct orientation to form\
        \ a covalent bond to the receptor (Figs. 1B and 3A) like in metarhodopsin-II.///In\
        \ agreement with previous reports on the M257Y6.40 single mutation (17), we\
        \ demonstrate that the stabilized M257Y6.40 mutant binds all-trans-retinal\
        \ in the correct orientation to form a covalent bond to the receptor (Figs.\
        \ 1B and 3A) like in metarhodopsin-II.///The stabilized M257Y6.40 mutant furthermore\
        \ expresses the same levels of G protein activation as wild-type metarhodopsin-II,\
        \ both in presence of all-trans-retinal, as well as after light-activation\
        \ of the ground state reconstituted with 11-cisretinal.///We further verified\
        \ that the M257Y6.40 mutant could be activated under crystallization conditions\
        \ using light-induced FTIR difference spectroscopy (SI Appendix, Fig. 2).///As\
        \ intended, crystallization of light-activated constitutively active M257Y6.40\
        \ allowed us to determine a structure with major hallmarks of the fully active\
        \ metarhodopsin-II state.///122 \u2223 www.pnas.org/cgi/doi/10.1073/pnas.1114089108\
        \ Deupi et al. The M257Y6.40 Mutation Selectively Stabilizes the G Protein\
        \ Binding Site.///Indeed it has been suggested that constitutive activity\
        \ of the M257Y6.40 mutant originates from interference of the helix packing\
        \ in the ground state (3).///In summary, our structure shows that M257Y6.40\
        \ stabilizes the G protein binding site through interactions with three residues\
        \ that are critical for receptor activation (Fig. 2).///Conclusions Here we\
        \ present the crystal structure of the light activated constitutively active\
        \ rhodopsin mutant M257Y6.40 in complex with the C-terminal end of the G protein\
        \ \u03B1-subunit.///Our crystal structures of the constitutively active E113Q3.28\
        \ and M257Y6.40 rhodopsin mutants provide two examples in which the molecular\
        \ basis for constitutive activity is more specific.///124 \u2223 www.pnas.org/cgi/doi/10.1073/pnas.1114089108\
        \ Bovine rhodopsin containing the stabilizing N2C/D282C and M257Y6.40 mutations\
        \ was expressed in HEK293S-GnTI\u2212 cells with homogenous N-glycosylation.",
    pubmed: '22198838', seq: '257', to_res: Y}
- {entry_name: opsd_bovin, from_res: G, info: 'Rao VR, Cohen GB, Oprian DD (1994)
        Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness.',
    pubmed: '22198838', seq: '90', to_res: D}
- {entry_name: opsd_bovin, from_res: D, info: "The constitutively active mutation\
        \ M257Y6.40 was introduced in the context of another rhodopsin mutant, N2C/D282C,\
        \ containing an engineered disulfide bond known to enhance thermal stability\
        \ of the protein (SI Appendix, Fig. 1) without affecting activity (15, 16).///To\
        \ investigate the biochemistry of the M257Y6.40 mutation in the context of\
        \ the N2C/D282C background, we first analyzed its ability to activate the\
        \ G protein transducin (Fig. 1).///G protein activation is fully suppressed\
        \ by reconstitution with the inverse agonist 11-cis-retinal, in both thermo-stabilized\
        \ N2C/D282C and N2C/M257Y/ D282C (from hereon called M257Y6.40 ).///G protein\
        \ activation is fully suppressed by reconstitution with the inverse agonist\
        \ 11-cis-retinal, in both thermo-stabilized N2C/D282C and N2C/M257Y/ D282C\
        \ (from hereon called M257Y6.40 ).///G protein activation of M257Y6.40 and\
        \ N2C/D282C rhodopsin is virtually indistinguishable if triggered by light-induced\
        \ isomerization of retinal (Fig. 1A).///By contrast, clear differences in\
        \ activity can be observed in the absence of retinal, where N2C/D282C opsin\
        \ is completely inactive, but inclusion of the M257Y6.40 mutation increases\
        \ the basal activity to about 40% of the photoactivated state.///Side-by-side\
        \ analysis of the ability of N2C/D282C opsin to reconstitute with alltrans-retinal\
        \ produced only a minor peak at 380 nm that did not significantly shift upon\
        \ acidification.///Our final structural model contains residues 1-326 of rhodopsin\
        \ with mutations N2C/D282C/M257Y and all eleven residues of the G\u03B1CT\
        \ peptide including the K341L mutation.///Biochemical assessment of M257Y6.40\
        \ in the context of the N2C/D282C background.///(A) Assessment of G protein\
        \ activation (pmol) by bovine opsin (open symbols and dashed regression lines)\
        \ or 11-cis-retinal reconstituted rhodopsin (solid symbols and regression\
        \ lines) for the N2C/D282C (blue circles) and N2C/M257Y/D282C (red triangles)\
        \ mutants.///(A) Assessment of G protein activation (pmol) by bovine opsin\
        \ (open symbols and dashed regression lines) or 11-cis-retinal reconstituted\
        \ rhodopsin (solid symbols and regression lines) for the N2C/D282C (blue circles)\
        \ and N2C/M257Y/D282C (red triangles) mutants.///Absorbance spectra of purified\
        \ N2C/M257Y/D282C reconstituted with all-trans-retinal were recorded at pH\
        \ 7.4 (solid line) and pH 3.5 (dotted line).///The inset shows that reconstitution\
        \ of N2C/M257Y/D282C with all-trans-retinal (squares, dotted regression line,\
        \ slope 1\u20444 1.37 pmol\u2215 min) increases G protein activation levels\
        \ to those of fully light activated metarhodopsin-II that had been reconstituted\
        \ with 11-cis-retinal (red triangles, solid regression line, slope 1\u2044\
        4 1.35 pmol\u2215 min).///124 \u2223 www.pnas.org/cgi/doi/10.1073/pnas.1114089108\
        \ Bovine rhodopsin containing the stabilizing N2C/D282C and M257Y6.40 mutations\
        \ was expressed in HEK293S-GnTI\u2212 cells with homogenous N-glycosylation.",
    pubmed: '22198838', seq: '282', to_res: C}
- {entry_name: drd2_human, from_res: K, info: 'Mutagenesis of the fusion proteins
        identified a residue at the C terminus of IC2, Lys149, that was important
        for the preferential binding of arrestin3 to D2-IC2; arrestin binding to D2-IC2-K149C
        was greatly decreased compared with wild-type D2-IC2, whereas binding to the
        reciprocal mutant D3-IC2C147K was enhanced compared with wild-type D3-IC2.///HEK
        293 cells grown to 80% confluence were cotransfected with D2 wild type (1
        g), D2-K149C (3 g), D3 wild type(1 g), or D3-C147K receptor DNA (0.5 g; the
        amount of each plasmid was adjusted to achieve similar cell-surface expression
        levels) and 3 g of arrestin3-pCMV5 using Lipofectamine2000 (Invitrogen, Carlsbad,
        CA).///Substitution of cysteine for Lys149 in the fulllength mutant receptor
        D2-K149C reduced agonist-induced translocation of arrestin3 to the membrane
        and receptor internalization.///Replacing Lys149 with C and Thr153 with A
        (D2-IC2-K149C/T153A) decreased binding to the level observed for D3-IC2.///The
        binding of arrestin to D2-IC2 was unaffected by the mutation T153A but was
        greatly decreased by the mutation K149C (Fig. 2D).///In contrast, dopamine
        treatment caused no significant translocation of arrestin3 to the membrane
        in cells expressing D2-K149C (vehicle 0.7 0.1 ng; dopamine 0.9 0.2 ng).///Cells
        transiently transfected with arrestin3 and wild-type D2 receptor (WT) or D2-K149C
        (C149) were treated with 10 M dopamine (DA) or vehicle (CTL) for 20 min, membranes
        were prepared, and levels of arrestin3 were determined by quantitative immunoblotting.///The
        D2 receptor with the IC2 mutation K149C exhibited significantly decreased
        agonist-induced internalization (17 1%), consistent with the reduced translocation
        of arrestin3, whereas the internalization of D3-C147K was not significantly
        different from the wild-type D3 receptor (Fig. 5).///The D2 receptor mutant
        with a cysteine residue at position 149, D2-K149C, displayed reduced dopamine-induced
        arrestin3 translocation and receptor internalization compared with the wild-type
        D2 receptor.', pubmed: '18820126', seq: '149', to_res: C}
- {entry_name: drd2_human, from_res: T, info: Replacing Lys149 with C and Thr153 with
        A (D2-IC2-K149C/T153A) decreased binding to the level observed for D3-IC2.///The
        binding of arrestin to D2-IC2 was unaffected by the mutation T153A but was
        greatly decreased by the mutation K149C (Fig. 2D)., pubmed: '18820126', seq: '153',
    to_res: A}
- {entry_name: drd3_rat, from_res: A, info: 'Arrestin Binding to D2 and D3 Receptor
        IC2 23 A151T exhibited arrestin binding that was significantly greater than
        to wild type D3-IC2, albeit less than to D2-IC2.///Likewise, the binding of
        arrestin to D3-IC2 was unaffected by the mutation A151T but was significantly
        enhanced by the mutation C147K.///This is demonstrated by the observation
        that the C-terminal portions of D3-IC2-C147K/A151T and D2-IC2M6 are identical
        (Fig. 2A), yet more arrestin bound to D3-IC2-C147K/A151T than to D2-IC2M6
        (Fig. 2C).///This is demonstrated by the observation that the C-terminal portions
        of D3-IC2-C147K/A151T and D2-IC2M6 are identical (Fig. 2A), yet more arrestin
        bound to D3-IC2-C147K/A151T than to D2-IC2M6 (Fig. 2C).', pubmed: '18820126',
    seq: '151', to_res: T}
- {entry_name: drd3_rat, from_res: C, info: 'The GST-IC2 chimeras and the full-length
        receptor mutants D2K149C and D3-C147K were constructed through one or more
        mutagenesis steps using the QuikChange mutagenesis kit (Stratagene, La Jolla,
        CA), with GST-D2-IC2, GST-D3-IC2, a rat myc-D2L receptor cDNA (Lan et al.,
        2008), or a rat D3 receptor cDNA (Cox et al., 1995) as template.///HEK 293
        cells grown to 80% confluence were cotransfected with D2 wild type (1 g),
        D2-K149C (3 g), D3 wild type(1 g), or D3-C147K receptor DNA (0.5 g; the amount
        of each plasmid was adjusted to achieve similar cell-surface expression levels)
        and 3 g of arrestin3-pCMV5 using Lipofectamine2000 (Invitrogen, Carlsbad,
        CA).///The reciprocal mutant D3-C147K mediated significantly more agonist-induced
        translocation of arrestin3 than did the wild-type D3 receptor, although agonist-induced
        internalization of wild-type and mutant D3 receptors was similar.///Likewise,
        the binding of arrestin to D3-IC2 was unaffected by the mutation A151T but
        was significantly enhanced by the mutation C147K.///This is demonstrated by
        the observation that the C-terminal portions of D3-IC2-C147K/A151T and D2-IC2M6
        are identical (Fig. 2A), yet more arrestin bound to D3-IC2-C147K/A151T than
        to D2-IC2M6 (Fig. 2C).///This is demonstrated by the observation that the
        C-terminal portions of D3-IC2-C147K/A151T and D2-IC2M6 are identical (Fig.
        2A), yet more arrestin bound to D3-IC2-C147K/A151T than to D2-IC2M6 (Fig.
        2C).///To determine whether the presence of lysine or cysteine in IC2 at position
        149 (D2) or 147 (D3), respectively, contributes to the differential ability
        of the full-length receptors to mediate agonist-induced translocation of arrestin,
        we created the mutant receptors D2K149C and D3-C147K.///Dopamine treatment
        of cells expressing the IC2 mutant D3-C147K, on the other hand, caused a modest
        but significant increase from 1.0 0.1 to 1.4 0.1 ng of arrestin3 in the membrane
        fraction (Fig. 4).///Cells transiently transfected with arrestin3 and wild-type
        D3 receptor (WT) or D3-C147K (K147) were treated with 10 M dopamine (DA) or
        vehicle (CTL) for 20 min, membranes were prepared, and levels of arrestin3
        were determined by quantitative immunoblotting.///The D2 receptor with the
        IC2 mutation K149C exhibited significantly decreased agonist-induced internalization
        (17 1%), consistent with the reduced translocation of arrestin3, whereas the
        internalization of D3-C147K was not significantly different from the wild-type
        D3 receptor (Fig. 5).///The reciprocal D3 receptor mutant D3-C147K exhibited
        increased dopamineinduced translocation of arrestin3, indicating that Lys149
        contributes significantly to the higher affinity of the D2 receptor for arrestin3.',
    pubmed: '18820126', seq: '147', to_res: K}
- {entry_name: ada2a_human, from_res: I, info: 'However, potentiation of cAMP production
        was also observed in response to cannabinoid agonists under conditions of
        PTX pretreatment in cultured neurons and CB1-transfected CHO cells (Glass
        and Felder, 1997; Bonhaus et al., 1998; Felder et al., 1998), and upon co-expression
        of CB1 receptors with D2 dopamine receptors in striatal cells and in HEK293
        cells (Bonhaus et al., 1998; Felder et al., Coupling of cannabinoid CB1 receptors
        to Gs and Gi BJP Table 3 Functional characterization of leucine-222 mutations
        of cannabinoid receptor Receptors CB1WT L222F L222I L222V L222P I222A Surface
        expression FACS; % of WT 100 95 98 97 85 73 5.0 6.3 6.3 5.3 5.3 cAMP accumulation
        Basal Maximal stimulation % of WT basal % of WT maximal 100 177 19 22 16 16
        9.1 3.0 3.3 1.7 2.1 100 63 ND ND ND ND 1.3 Fold increase/ (inhibition rate
        %) 56 20 (33 6.2 (45 2.2 (75 (76 2.0 1.2 1.6)%a 0.4 2.5)%a 0.1 0.5)%a 0.9)%a
        EC50 (nM) 59 48 0.022 1530 0.34 365 48 28 3.8 3.2 0.009a 210 0.20a 150 3.1a
        7.9a The values are expressed as the mean SEM (n = 3 experiments).', pubmed: '20735408',
    seq: '222', to_res: A}
- {entry_name: opsd_human, from_res: R, info: "The \u2018ionic lock\u2019, a salt\
        \ bridge between Arg3.50 in the conserved D(E)R3.50Y motif and Asp/Glu6.30,\
        \ which is suggested to stabilize the inactive conformation, was observed\
        \ in rhodopsin structures17,21 and D3R23, but was broken in all the other\
        \ GPCRs18\u201320,22.", pubmed: '21697825', seq: '135', to_res: Y}
- {entry_name: hrh1_human, from_res: R, info: 'Three conserved motifs D(E)R3.50Y,
        CWxP6.50 and NP7.50xxY are highlighted in blue. b, Superimposition of the
        H1R (green) and b2-AR (cyan) structures.///In H1R, Arg 1253.50 of the D(E)R3.50Y
        motif does not form a salt bridge either with Glu 4106.30 or with Asp 1243.49.',
    pubmed: '21697825', seq: '125', to_res: Y}
- {entry_name: aa1r_human, from_res: H, info: "The 3\u2032-ureido analogue 13 was\
        \ reported as a neoligand for the H278E and H278D mutant A3 ARs (14) and was\
        \ therefore applied to Tailored Ligands for Reengineered A1 Adenosine Receptor\
        \ analogous A1 AR mutations.///46, No. 25, 2007 Table 1: Saturation Analysis\
        \ of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently Expressed\
        \ in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A H278D H278E\
        \ H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 ( 0.34\
        \ 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2 3.0\
        \ ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2. Values\
        \ are expressed as the mean ( sem from four to eight experiments, each performed\
        \ in duplicate. coordinate the ribose moiety of the nucleoside ligands, modification\
        \ of the selected amino acid residues would be expected to be more detrimental\
        \ to binding of agonist than antagonist. Attempted saturation analysis of\
        \ the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce\
        \ measurable specific binding (data not shown), making it impractical to use\
        \ this radioligand.///While compounds 13 and 14 exhibited modest 27- and 30fold\
        \ enhancements for the H278E mutant receptor, respectively, compounds 10 and\
        \ 16 exhibited 263- and 133-fold enhancements, respectively.///These reported\
        \ enhancements for compounds 10, 13, 14, and 16 at the H278E mutant can be\
        \ extended to the other His278 mutant receptors as well, e.g., H278D, H278L,\
        \ and H278A.///Table 3: Ki Values for the Inhibition by Nucleoside Derivatives\
        \ of Binding of Antagonist [3H]DPCPX at Wild-Type and Mutant Human A1 ARs\
        \ Transiently Expressed in HEK-293 Cellsa binding affinity, Ki (nM ( sem),\
        \ or % inhibition compound DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA 10 13 14 16\
        \ 18 19 20 21 22, NECA 23 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480\
        \ <10% <10% <10% 30% 17% 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13% 13% 38%\
        \ <10% <10% 1600 ( 100 <10% 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14% 24%\
        \ 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30 980\
        \ ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40\
        \ 15% <10% 20% 16% <10% <10% 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20\
        \ 48% 410 ( 120 810 ( 250 500 ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40\
        \ ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 (\
        \ 30 1000 ( 60 50% 834 940 670 8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90\
        \ ( 3 <10% 12% 17% 25% 17% 15% 820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100\
        \ 39% NDc NDc NDc 8800 ( 900 32% 58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10%\
        \ <10% <10% <10% <10% 7000 ( 800 41% 48% 50% 39% 22% <10% <10% 11% 25% 12%\
        \ 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5 <10% <10% <10% <10% <10% <10% 11% <10%\
        \ <10% 17% <10% <10% <10% NDc NDc <10% <10% <10% NDc a Structures are given\
        \ in Figure 2. Experiments were performed using HEK-293 cells transiently\
        \ expressing (using Lipofectamine 2000) a mutant hA1 AR.", pubmed: '3140710',
    seq: '278', to_res: E}
- {entry_name: aa1r_human, from_res: H, info: "These reengineered human A1 ARs revealed\
        \ orthogonality similar to that of the A3 but not the A2A AR, in which mutation\
        \ of the corresponding residue, His278, to Asp did not enhance nucleoside\
        \ affinity.///Functionally, the H278D A1 AR was detectable only in a measure\
        \ of membrane potential and not in calcium mobilization.///(B) Binding mode\
        \ of compound 10 at the H278D mutant A1 adenosine receptor obtained after\
        \ MCMM calculations.///(C) Superimposition of the models obtained for compound\
        \ 10 at the wild-type (green) and H278D mutant (residues colored by atom type,\
        \ with the carbon atoms of the ligand colored yellow) A1 adenosine receptor.///To\
        \ study the binding mode of compound 10 in the wildtype and H278D mutant A1\
        \ receptor, the same initial atomic coordinates of the ligand and receptor\
        \ residues were used, but in the model of the mutated receptor, the side chain\
        \ of His278 was replaced with the side chain of Asp using the Mutate Residue\
        \ option of MacroModel.///The 3\u2032-ureido analogue 13 was reported as a\
        \ neoligand for the H278E and H278D mutant A3 ARs (14) and was therefore applied\
        \ to Tailored Ligands for Reengineered A1 Adenosine Receptor analogous A1\
        \ AR mutations.///46, No. 25, 2007 Table 1: Saturation Analysis of [3H]DPCPX\
        \ at the Wild-Type and Mutant Human A1 ARs Transiently Expressed in HEK-293\
        \ Cellsa A1 AR construct wild-type T277A T277E H278A H278D H278E H278L Kd\
        \ (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 ( 0.34 4.96 (\
        \ 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2 3.0 ( 0.8\
        \ 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2. Values\
        \ are expressed as the mean ( sem from four to eight experiments, each performed\
        \ in duplicate. coordinate the ribose moiety of the nucleoside ligands, modification\
        \ of the selected amino acid residues would be expected to be more detrimental\
        \ to binding of agonist than antagonist. Attempted saturation analysis of\
        \ the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce\
        \ measurable specific binding (data not shown), making it impractical to use\
        \ this radioligand.///These reported enhancements for compounds 10, 13, 14,\
        \ and 16 at the H278E mutant can be extended to the other His278 mutant receptors\
        \ as well, e.g., H278D, H278L, and H278A.///Table 3: Ki Values for the Inhibition\
        \ by Nucleoside Derivatives of Binding of Antagonist [3H]DPCPX at Wild-Type\
        \ and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa binding\
        \ affinity, Ki (nM ( sem), or % inhibition compound DPCPXb CGS15943b 1 2 3\
        \ 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22, NECA 23 26 27 wild-type hA1 4.5\
        \ ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10% 30% 17% 610 ( 50 12% 15000 ( 3100\
        \ 6200 ( 1900 13% 13% 38% <10% <10% 1600 ( 100 <10% 14% <10% H278E 36 ( 2\
        \ 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210 ( 60\
        \ 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400 220\
        \ ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10% <10% 1000 ( 170 340 ( 20\
        \ 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250 500 ( 120 8500 ( 1400\
        \ 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400 (\
        \ 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670 8800 ( 700 14%\
        \ 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15% 820 ( 90 400\
        \ ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900 32% 58% NDc\
        \ T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000 ( 800 41% 48%\
        \ 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5 <10%\
        \ <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10% NDc NDc <10% <10%\
        \ <10% NDc a Structures are given in Figure 2. Experiments were performed\
        \ using HEK-293 cells transiently expressing (using Lipofectamine 2000) a\
        \ mutant hA1 AR.///Derivatization of the 5\u2032 position, as in 3\u2032ureido\
        \ derivatives 26 and 27, resulted in an enhanced affinity (Ki ) 1.6 \u03BC\
        M) at the H278D mutant receptor.///The H278D mutation of the human A1 AR and\
        \ the corresponding mutations of conserved His in TM7 of the A2A AR (H278D)\
        \ and A3 AR (H272D) were studied.///The H278D mutation of the human A1 AR\
        \ and the corresponding mutations of conserved His in TM7 of the A2A AR (H278D)\
        \ and A3 AR (H272D) were studied.///A preliminary functional study of the\
        \ effect of adding GTP during the binding of CCPA 9 and its 3\u2032-ureido\
        \ analogue 10 at the H278A and H278D mutant receptors indicated that in both\
        \ cases there was no pronounced GTP-induced shift (data not shown).///The\
        \ H278D mutation of the human A1 AR and the corresponding mutations of the\
        \ conserved His in TM7 of the A2A AR (H278D) and A3 AR (H272D) were studied.///The\
        \ H278D mutation of the human A1 AR and the corresponding mutations of the\
        \ conserved His in TM7 of the A2A AR (H278D) and A3 AR (H272D) were studied.///Antagonist\
        \ radioligands were used at the A1 ARs ([3H]DPCPX) and the A2A ARs ([3H]ZM241385),\
        \ and an agonist radioligand was used at the A3 ARs ([125I]I-AB-MECA). cells\
        \ transiently expressing the H278D mutant receptor (Figure 4).///The 5\u2032\
        -CH2OH derivative 13, at a concentration as high as 10 \u03BCM, did not have\
        \ any effect on the H278D mutant.///However, the 5\u2032-N-methylamide derivative\
        \ 26 was shown to be more potent in activating the H278D mutant receptor (3.5\
        \ ( 1.6 \u03BCM) than at the wild-type A1 AR (>10 \u03BCM) or the control\
        \ (nontransfected cells), although it was only partially efficacious compared\
        \ with the efficacy of CPA at the wild-type A1 AR.///An initial complex of\
        \ the A1 AR with NECA was further refined by energy optimization and MCMM\
        \ calculations implemented Tailored Ligands for Reengineered A1 Adenosine\
        \ Receptor FIGURE 5: Membrane hyperpolarization at the wild-type and H278D\
        \ mutant hA1 AR using known agonist CPA 8 and urea derivative 26.///46, No.\
        \ 25, 2007 7445 FIGURE 4: Stimulation of intracellular calcium levels at the\
        \ wild-type and H278D mutant hA1 ARs using known agonists CPA 8 and NECA 22\
        \ and urea derivatives 10 and 13 (n ) 3-4).///In contrast, in the model obtained\
        \ after MCMM calculations for compound 10 docked in the H278D mutant A1 AR,\
        \ we did not observe any significant changes in the ligand position or residue\
        \ side chain orientations (Figure 1B).///The obtained binding mode of compound\
        \ 10 at the H278D mutated A1 AR, demonstrating the absence of a direct interaction\
        \ between the ligand and Asp278, is in a good agreement with the experimental\
        \ data obtained for other mutations, in particular, for H278A and H278L.///The\
        \ present reengineered human A1 ARs revealed orthogonality similar to that\
        \ of the A3 but not the A2A AR, in which mutation of the corresponding residue,\
        \ His278, to Asp did not enhance the affinity of nucleosides derivatized with\
        \ amine functionality on the ribose moiety (8).///The H278D A1 AR was functionally\
        \ responsive only as a measure of membrane potential and not calcium mobilization.///SUPPORTING\
        \ INFORMATION AVAILABLE Compound 10 inside the putative binding site of the\
        \ H278D mutant A1 adenosine receptor and details of chemical synthesis.",
    pubmed: '3140710', seq: '278', to_res: D}
- {entry_name: aa1r_human, from_res: H, info: "46, No. 25, 2007 Table 1: Saturation\
        \ Analysis of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently\
        \ Expressed in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A\
        \ H278D H278E H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60\
        \ 3.11 ( 0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8\
        \ 6.0 ( 0.2 3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given\
        \ in Figure 2. Values are expressed as the mean ( sem from four to eight experiments,\
        \ each performed in duplicate. coordinate the ribose moiety of the nucleoside\
        \ ligands, modification of the selected amino acid residues would be expected\
        \ to be more detrimental to binding of agonist than antagonist. Attempted\
        \ saturation analysis of the mutant receptors with the agonist [3H]CCPA (9,\
        \ 1-5 nM) did not produce measurable specific binding (data not shown), making\
        \ it impractical to use this radioligand.///These reported enhancements for\
        \ compounds 10, 13, 14, and 16 at the H278E mutant can be extended to the\
        \ other His278 mutant receptors as well, e.g., H278D, H278L, and H278A.///Table\
        \ 3: Ki Values for the Inhibition by Nucleoside Derivatives of Binding of\
        \ Antagonist [3H]DPCPX at Wild-Type and Mutant Human A1 ARs Transiently Expressed\
        \ in HEK-293 Cellsa binding affinity, Ki (nM ( sem), or % inhibition compound\
        \ DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22, NECA 23\
        \ 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10% 30% 17%\
        \ 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13% 13% 38% <10% <10% 1600 ( 100 <10%\
        \ 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150 380 (\
        \ 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700 ( 900\
        \ 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10% <10%\
        \ 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250 500\
        \ ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20% 15%\
        \ 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670\
        \ 8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15%\
        \ 820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900\
        \ 32% 58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000\
        \ ( 800 41% 48% 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9\
        \ 4.6 ( 1.5 <10% <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10%\
        \ NDc NDc <10% <10% <10% NDc a Structures are given in Figure 2. Experiments\
        \ were performed using HEK-293 cells transiently expressing (using Lipofectamine\
        \ 2000) a mutant hA1 AR.///A preliminary functional study of the effect of\
        \ adding GTP during the binding of CCPA 9 and its 3\u2032-ureido analogue\
        \ 10 at the H278A and H278D mutant receptors indicated that in both cases\
        \ there was no pronounced GTP-induced shift (data not shown).///The obtained\
        \ binding mode of compound 10 at the H278D mutated A1 AR, demonstrating the\
        \ absence of a direct interaction between the ligand and Asp278, is in a good\
        \ agreement with the experimental data obtained for other mutations, in particular,\
        \ for H278A and H278L.", pubmed: '3140710', seq: '278', to_res: A}
- {entry_name: aa3r_human, from_res: H, info: "Jacobson*,\u2021 Molecular Recognition\
        \ Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes\
        \ and DigestiVe and Kidney Diseases, National Institutes of Health, Bethesda,\
        \ Maryland 20892, and Laboratory of Medicinal Chemistry, College of Pharmacy,\
        \ Ewha Womans UniVersity, Seoul 120-750, Korea ReceiVed January 29, 2007;\
        \ ReVised Manuscript ReceiVed April 23, 2007 ABSTRACT: His272 (7.43) in the\
        \ seventh transmembrane domain (TM7) of the human A3 adenosine receptor (AR)\
        \ interacts with the 3\u2032 position of nucleosides, based on selective affinity\
        \ enhancement at a H272E mutant A3 AR (neoceptor) of 3\u2032-ureido, but not\
        \ 3\u2032-OH, adenosine analogues.", pubmed: '3140710', seq: '272', to_res: E}
- {entry_name: gasr_human, from_res: G, info: '(C) Functionally relevant hTAS2R46
        residues identified in this study were collected in recipient receptors hTAS2R31
        and -R43 resulting in the constructs hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I
        G92N K150N D176N G253E K265E R268A) and hTAS2R43 PM46 (hTAS2R43 V70E T82I
        G253E K265E R268A), respectively.///(C) Functionally relevant hTAS2R46 residues
        identified in this study were collected in recipient receptors hTAS2R31 and
        -R43 resulting in the constructs hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I G92N
        K150N D176N G253E K265E R268A) and hTAS2R43 PM46 (hTAS2R43 V70E T82I G253E
        K265E R268A), respectively.///hTAS2R46, functionally relevant positions were
        assembled in the construct hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I G92N K150N
        D176N G253E K265E R268A), and calcium imaging analyses were performed (Fig.
        4C and Table S1).///This time, because of higher amino acid sequence identity
        among hTAS2R46 and -R43, fewer exchanges were necessary to result in the mutant
        receptor hTAS2R43 PM46 (hTAS2R43 V70E T82I G253E K265E R268A), resembling
        the pharmacological features of hTAS2R46 (Fig. 4C and Table S1).', pubmed: '20534469',
    seq: '253', to_res: E}
- {entry_name: 5ht2a_human, from_res: N, info: 'The resulting mutants, hTAS2R46E70V,
        -L71F, -N76Y, -I82T, -I91T, -N92G, -N150K, -Q151E, -W154R, -N176D, and -E253G
        were functionally characterized with absinthin, strychnine, denatonium, and
        aristolochic acid (Fig. 4A).///Another three mutations, hTAS2R46L71F, -N92G,
        and -N150K, showed decreased receptor activation by all agonists.', pubmed: '20534469',
    seq: '92', to_res: G}
- {entry_name: aa1r_human, from_res: H, info: '46, No. 25, 2007 Table 1: Saturation
        Analysis of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently
        Expressed in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A H278D
        H278E H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 (
        0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2
        3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2.
        Values are expressed as the mean ( sem from four to eight experiments, each
        performed in duplicate. coordinate the ribose moiety of the nucleoside ligands,
        modification of the selected amino acid residues would be expected to be more
        detrimental to binding of agonist than antagonist. Attempted saturation analysis
        of the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce
        measurable specific binding (data not shown), making it impractical to use
        this radioligand.///These reported enhancements for compounds 10, 13, 14,
        and 16 at the H278E mutant can be extended to the other His278 mutant receptors
        as well, e.g., H278D, H278L, and H278A.///Table 3: Ki Values for the Inhibition
        by Nucleoside Derivatives of Binding of Antagonist [3H]DPCPX at Wild-Type
        and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa binding affinity,
        Ki (nM ( sem), or % inhibition compound DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA
        10 13 14 16 18 19 20 21 22, NECA 23 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1
        4600 ( 480 <10% <10% <10% 30% 17% 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13%
        13% 38% <10% <10% 1600 ( 100 <10% 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14%
        24% 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30
        980 ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40
        15% <10% 20% 16% <10% <10% 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20
        48% 410 ( 120 810 ( 250 500 ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40
        ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 ( 30
        1000 ( 60 50% 834 940 670 8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90 ( 3
        <10% 12% 17% 25% 17% 15% 820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100 39%
        NDc NDc NDc 8800 ( 900 32% 58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10%
        <10% <10% <10% 7000 ( 800 41% 48% 50% 39% 22% <10% <10% 11% 25% 12% 10% 16%
        T277A 3.5 ( 0.9 4.6 ( 1.5 <10% <10% <10% <10% <10% <10% 11% <10% <10% 17%
        <10% <10% <10% NDc NDc <10% <10% <10% NDc a Structures are given in Figure
        2. Experiments were performed using HEK-293 cells transiently expressing (using
        Lipofectamine 2000) a mutant hA1 AR.///The obtained binding mode of compound
        10 at the H278D mutated A1 AR, demonstrating the absence of a direct interaction
        between the ligand and Asp278, is in a good agreement with the experimental
        data obtained for other mutations, in particular, for H278A and H278L.', pubmed: '3140710',
    seq: '278', to_res: L}
- {entry_name: aa1r_human, from_res: T, info: "For competitive binding studies, cell\
        \ membranes containing 15 \u03BCg (HEK-293hA1wt), 10 \u03BCg (HEK-293hA1-T277A),\
        \ or 35-40 \u03BCg (HEK293hA1-H278 mutant receptors) of protein were incubated\
        \ for 1 h at 25 \xB0C in 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl2,\
        \ with 0.4-0.6 nM [3H]DPCPX, and increasing concentrations of ligand, in a\
        \ total volume of 200 \u03BCL.///For saturation experiments, 10 \u03BCg (HEK-293hA1wt\
        \ and HEK-293hA1-T277A) or 15-20 \u03BCg (HEK-293hA1mutant receptors) of membrane\
        \ were incubated for 1 h at 25 \xB0C in 50 mM Tris-HCl with 10 mM MgCl2 buffer\
        \ (pH 7.4) with six different concentrations of [3H]DPCPX (0-9 nM).///46,\
        \ No. 25, 2007 Table 1: Saturation Analysis of [3H]DPCPX at the Wild-Type\
        \ and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa A1 AR construct\
        \ wild-type T277A T277E H278A H278D H278E H278L Kd (nM) 2.37 ( 0.20 1.12 (\
        \ 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 ( 0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg)\
        \ 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2 3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a\
        \ Structures are given in Figure 2. Values are expressed as the mean ( sem\
        \ from four to eight experiments, each performed in duplicate. coordinate\
        \ the ribose moiety of the nucleoside ligands, modification of the selected\
        \ amino acid residues would be expected to be more detrimental to binding\
        \ of agonist than antagonist. Attempted saturation analysis of the mutant\
        \ receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce measurable\
        \ specific binding (data not shown), making it impractical to use this radioligand.///However,\
        \ unlike the relative uniformity in the Kd values, the Bmax for the mutant\
        \ receptors was on average \u223C3-fold lower than that of the wild-type A1\
        \ AR, with the exception of the T277A mutant receptor.///Table 3: Ki Values\
        \ for the Inhibition by Nucleoside Derivatives of Binding of Antagonist [3H]DPCPX\
        \ at Wild-Type and Mutant Human A1 ARs Transiently Expressed in HEK-293 Cellsa\
        \ binding affinity, Ki (nM ( sem), or % inhibition compound DPCPXb CGS15943b\
        \ 1 2 3 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22, NECA 23 26 27 wild-type\
        \ hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10% 30% 17% 610 ( 50 12% 15000\
        \ ( 3100 6200 ( 1900 13% 13% 38% <10% <10% 1600 ( 100 <10% 14% <10% H278E\
        \ 36 ( 2 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150 380 ( 80 560 ( 170 210\
        \ ( 60 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700 ( 900 26% 1200 ( 400\
        \ 220 ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10% <10% 1000 ( 170 340\
        \ ( 20 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250 500 ( 120 8500 (\
        \ 1400 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20% 15% 14% <10% 1400\
        \ ( 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670 8800 ( 700 14%\
        \ 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15% 820 ( 90 400\
        \ ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900 32% 58% NDc\
        \ T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000 ( 800 41% 48%\
        \ 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5 <10%\
        \ <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10% NDc NDc <10% <10%\
        \ <10% NDc a Structures are given in Figure 2. Experiments were performed\
        \ using HEK-293 cells transiently expressing (using Lipofectamine 2000) a\
        \ mutant hA1 AR.", pubmed: '3140710', seq: '277', to_res: A}
- {entry_name: aa3r_human, from_res: H, info: The H278D mutation of the human A1 AR
        and the corresponding mutations of conserved His in TM7 of the A2A AR (H278D)
        and A3 AR (H272D) were studied.///The H278D mutation of the human A1 AR and
        the corresponding mutations of the conserved His in TM7 of the A2A AR (H278D)
        and A3 AR (H272D) were studied., pubmed: '3140710', seq: '272', to_res: D}
- {entry_name: aa1r_human, from_res: T, info: '46, No. 25, 2007 Table 1: Saturation
        Analysis of [3H]DPCPX at the Wild-Type and Mutant Human A1 ARs Transiently
        Expressed in HEK-293 Cellsa A1 AR construct wild-type T277A T277E H278A H278D
        H278E H278L Kd (nM) 2.37 ( 0.20 1.12 ( 0.09 5.14 ( 0.74 4.72 ( 0.60 3.11 (
        0.34 4.96 ( 0.93 3.94 ( 0.10 Bmax (pmol/mg) 10.5 ( 1.2 14.7 ( 3.8 6.0 ( 0.2
        3.0 ( 0.8 2.2 ( 0.4 2.7 ( 0.6 3.1 ( 0. a Structures are given in Figure 2.
        Values are expressed as the mean ( sem from four to eight experiments, each
        performed in duplicate. coordinate the ribose moiety of the nucleoside ligands,
        modification of the selected amino acid residues would be expected to be more
        detrimental to binding of agonist than antagonist. Attempted saturation analysis
        of the mutant receptors with the agonist [3H]CCPA (9, 1-5 nM) did not produce
        measurable specific binding (data not shown), making it impractical to use
        this radioligand.///Table 3: Ki Values for the Inhibition by Nucleoside Derivatives
        of Binding of Antagonist [3H]DPCPX at Wild-Type and Mutant Human A1 ARs Transiently
        Expressed in HEK-293 Cellsa binding affinity, Ki (nM ( sem), or % inhibition
        compound DPCPXb CGS15943b 1 2 3 5 6 7 9, CCPA 10 13 14 16 18 19 20 21 22,
        NECA 23 26 27 wild-type hA1 4.5 ( 1.2 3.4 ( 1.1 4600 ( 480 <10% <10% <10%
        30% 17% 610 ( 50 12% 15000 ( 3100 6200 ( 1900 13% 13% 38% <10% <10% 1600 (
        100 <10% 14% <10% H278E 36 ( 2 120 ( 20 22% 17% 14% 24% 14% 18% 1200 ( 150
        380 ( 80 560 ( 170 210 ( 60 750 ( 150 44% 530 ( 30 980 ( 280 560 ( 80 9700
        ( 900 26% 1200 ( 400 220 ( 20 H278D 50 ( 3 110 ( 40 15% <10% 20% 16% <10%
        <10% 1000 ( 170 340 ( 20 450 ( 40 240 ( 30 590 ( 20 48% 410 ( 120 810 ( 250
        500 ( 120 8500 ( 1400 13% 1200 ( 300 350 H278A 40 ( 8 160 ( 3 13% 11% 20%
        15% 14% <10% 1400 ( 120 570 ( 60 570 ( 30 220 ( 30 1000 ( 60 50% 834 940 670
        8800 ( 700 14% 980 ( 450 NDc H278L 35 ( 2 90 ( 3 <10% 12% 17% 25% 17% 15%
        820 ( 90 400 ( 60 550 ( 50 290 ( 50 700 ( 100 39% NDc NDc NDc 8800 ( 900 32%
        58% NDc T277E 18.3 ( 1.6 8.6 ( 0.3 13% <10% <10% <10% <10% <10% 7000 ( 800
        41% 48% 50% 39% 22% <10% <10% 11% 25% 12% 10% 16% T277A 3.5 ( 0.9 4.6 ( 1.5
        <10% <10% <10% <10% <10% <10% 11% <10% <10% 17% <10% <10% <10% NDc NDc <10%
        <10% <10% NDc a Structures are given in Figure 2. Experiments were performed
        using HEK-293 cells transiently expressing (using Lipofectamine 2000) a mutant
        hA1 AR.', pubmed: '3140710', seq: '277', to_res: E}
- {entry_name: gpr17_human, from_res: A, info: "Mutational Analysis of Candidate Breast\
        \ Cancer Genes (Continued) Study  \u0308 Sjoblom et al. BB27T fs FS chr10:435084_435083ins\
        \ AGCACAGCTTGCTTT GGGGTCAAACGTGG ATCAGCAGCCTCTTG GTCAGTAAA Sample IDc cDNA\
        \ Protein gDNAd Classe CHASM FDRf MutationTasterg Symbol Chra CDS lengthb\
        \ 0.9 FLJ13479 16p11.2 1876 0.9 0.9 0.9 0.9 0.9 GEN1 2p24.2 2831 GAB1 4q31.21\
        \ 2165 GLI1 12q13.3 3409 0.9 1 0.9 0.9 1 0.9 GRIN2D 19q13.32 4107  \u0308\
        \ Sjoblom et al.  \u0308 Sjoblom et al.  \u0308 Sjoblom et al.  \u0308 Sjoblom\
        \ et al.  \u0308 Sjoblom et al.  \u0308 Sjoblom et al.  \u0308 Sjoblom et\
        \ al.  \u0308 Sjoblom et al. Wood et al.  \u0308 Sjoblom et al.  \u0308 Sjoblom\
        \ et al. Present  \u0308 Sjoblom et al.  \u0308 Sjoblom et al. Present Present\
        \ Present B8C BB12T B6C BB5T B8C BB12T BB30T BB9T B10C BB22T B3C BS43T BB9T\
        \ B2C BS45T BB85T BP35A586E fs V1264M A66T G286S T331R R556Q fs fs Y83C T387N\
        \ P535S T514I E817Q P727P S797P fs NS FS NS NS NS NS NS FS FS NS NS NS NS\
        \ NS S NS FS Disease causing Disease causing Disease causing Disease causing\
        \ Disease causing Polymorphism Polymorphism Disease causing Disease causing\
        \ Disease causing Disease causing Polymorphism Polymorphism Polymorphism Polymorphism\
        \ Disease causing Disease causing 0.9 0.9 0.9 0.9 MUTATIONAL ANALYSIS OF CANDIDATE\
        \ BREAST CANCER GENES HDLBP 2q37.3 4015  \u0308 Sjoblom et al.  \u0308 Sjoblom\
        \ et al.  \u0308 Sjoblom et al. Present Present  \u0308 Sjoblom et al. B2C\
        \ B4C BB28T BB91T BB54T BB31T P140S G286R E527G P313P K466N fs NS NS NS S\
        \ NS FS Disease causing Polymorphism Disease causing Polymorphism Disease\
        \ causing Disease causing HOXA3 7p15.2 1348 Genes, Chromosomes & Cancer DOI\
        \ 10.1002/gcc IKBKB 8p11.21 2439  \u0308 Sjoblom et al.  \u0308 Sjoblom et\
        \ al.  \u0308 Sjoblom et al.  \u0308 Sjoblom et al. Present  \u0308 Sjoblom\
        \ et al. BB18T B2C B11C BB28T BB48T B4C chr10:420086C>A chr10:398592delT chr10:363080G>A\
        \ chr16:30983086G>A chr16:30980894G>A chr16:30980758C>G chr16:30980083G>A\
        \ chr2:17874166_17874165delC chr2:17875550_17875553delGTAA chr4:144694410A>G\
        \ chr4:144717323C>A chr12:56150393C>T chr12:56149713C>T chr12:56151239G>C\
        \ chr19:53616943C>T chr19:53636974T>C 53637319_53637328ins ACATGGCGGG chr19:53593879C>T\
        \ chr19:53600193G>A chr19:53610100A>G chr2:241914920C>T chr2:241909360G>C\
        \ chr2:241916116_241916107del CAAAATCCAG chr2:241907435A>C chr2:241896108A>T\
        \ chr7:26923376G>A chr7:26923109G>A chr8:42266871G>C chr8:42293532G>T K568N\
        \ D939V D42N A131T E81Q A360S NS NS NS NS NS NS c.1225_1226ins AGCACAGC TTGCTTTG\
        \ GGGTCAA ACGTGGA TCAGCAG CCTCTTG GTCAGTAAA c.1757C>A c.2632delT c.3790G>A\
        \ c.196G>A c.856G>A c.992C>G c.1667G>A c.785_786delC c.824_827delGTAA c.248A>G\
        \ c.1160C>A c.1603C>T c.1541C>T c.2449G>C c.2181C>T c.2389T>C c.2541_2550ins\
        \ ACATGGCGGG c.418C>T c.856G>A c.1580A>G c.939C>T c.1398G>C c.546_555del CAAAATCCAG\
        \ c.1704A>C c.2816A>T c.124G>A c.391G>A c.241G>C c.1078G>T 0.9 0.9 1 0.9 0.3\
        \ 0.9 Disease causing Disease causing Polymorphism Polymorphism Disease causing\
        \ Disease causing (Continued) 5 6 TABLE 1.", pubmed: '22302350', seq: '131',
    to_res: T}
- {entry_name: opsd_human, from_res: W, info: 'We have used the hTAS2R variants hTAS2R46
        NM_176887.2, hTAS2R31 NM_176885.2 (variant position L162M, compare with dbSNP
        rs# cluster id rs10743938), and hTAS2R43 NM_176884.2 (variant position W35S,
        compare with dbSNP rs# cluster id rs68157013; variant position H212R, compare
        with dbSNP rs# cluster id rs71443637).', pubmed: '20534469', seq: '35', to_res: S}
- {entry_name: ada1b_human, from_res: V, info: '(C) Functionally relevant hTAS2R46
        residues identified in this study were collected in recipient receptors hTAS2R31
        and -R43 resulting in the constructs hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I
        G92N K150N D176N G253E K265E R268A) and hTAS2R43 PM46 (hTAS2R43 V70E T82I
        G253E K265E R268A), respectively.///(C) Functionally relevant hTAS2R46 residues
        identified in this study were collected in recipient receptors hTAS2R31 and
        -R43 resulting in the constructs hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I G92N
        K150N D176N G253E K265E R268A) and hTAS2R43 PM46 (hTAS2R43 V70E T82I G253E
        K265E R268A), respectively.///hTAS2R46, functionally relevant positions were
        assembled in the construct hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I G92N K150N
        D176N G253E K265E R268A), and calcium imaging analyses were performed (Fig.
        4C and Table S1).///This time, because of higher amino acid sequence identity
        among hTAS2R46 and -R43, fewer exchanges were necessary to result in the mutant
        receptor hTAS2R43 PM46 (hTAS2R43 V70E T82I G253E K265E R268A), resembling
        the pharmacological features of hTAS2R46 (Fig. 4C and Table S1).', pubmed: '20534469',
    seq: '70', to_res: E}
- {entry_name: p2ry2_human, from_res: L, info: 'We have used the hTAS2R variants hTAS2R46
        NM_176887.2, hTAS2R31 NM_176885.2 (variant position L162M, compare with dbSNP
        rs# cluster id rs10743938), and hTAS2R43 NM_176884.2 (variant position W35S,
        compare with dbSNP rs# cluster id rs68157013; variant position H212R, compare
        with dbSNP rs# cluster id rs71443637).', pubmed: '20534469', seq: '162', to_res: M}
- {entry_name: adrb2_human, from_res: F, info: '(C) Functionally relevant hTAS2R46
        residues identified in this study were collected in recipient receptors hTAS2R31
        and -R43 resulting in the constructs hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I
        G92N K150N D176N G253E K265E R268A) and hTAS2R43 PM46 (hTAS2R43 V70E T82I
        G253E K265E R268A), respectively.///hTAS2R46, functionally relevant positions
        were assembled in the construct hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I G92N
        K150N D176N G253E K265E R268A), and calcium imaging analyses were performed
        (Fig. 4C and Table S1).', pubmed: '20534469', seq: '71', to_res: L}
- {entry_name: t2r16_human, from_res: Q, info: 'The resulting mutants, hTAS2R46E70V,
        -L71F, -N76Y, -I82T, -I91T, -N92G, -N150K, -Q151E, -W154R, -N176D, and -E253G
        were functionally characterized with absinthin, strychnine, denatonium, and
        aristolochic acid (Fig. 4A).///Four of the mutants, hTAS2R46N76Y, -I91T, -Q151E,
        and -W154R, showed no obvious differences compared with hTAS2R46.', pubmed: '20534469',
    seq: '151', to_res: E}
- {entry_name: 5ht2a_human, from_res: L, info: 'The resulting mutants, hTAS2R46E70V,
        -L71F, -N76Y, -I82T, -I91T, -N92G, -N150K, -Q151E, -W154R, -N176D, and -E253G
        were functionally characterized with absinthin, strychnine, denatonium, and
        aristolochic acid (Fig. 4A).', pubmed: '20534469', seq: '71', to_res: F}
- {entry_name: 5ht1b_human, from_res: T, info: '(C) Functionally relevant hTAS2R46
        residues identified in this study were collected in recipient receptors hTAS2R31
        and -R43 resulting in the constructs hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I
        G92N K150N D176N G253E K265E R268A) and hTAS2R43 PM46 (hTAS2R43 V70E T82I
        G253E K265E R268A), respectively.///(C) Functionally relevant hTAS2R46 residues
        identified in this study were collected in recipient receptors hTAS2R31 and
        -R43 resulting in the constructs hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I G92N
        K150N D176N G253E K265E R268A) and hTAS2R43 PM46 (hTAS2R43 V70E T82I G253E
        K265E R268A), respectively.///hTAS2R46, functionally relevant positions were
        assembled in the construct hTAS2R31 PM46 (hTAS2R31 V70E F71L T82I G92N K150N
        D176N G253E K265E R268A), and calcium imaging analyses were performed (Fig.
        4C and Table S1).///This time, because of higher amino acid sequence identity
        among hTAS2R46 and -R43, fewer exchanges were necessary to result in the mutant
        receptor hTAS2R43 PM46 (hTAS2R43 V70E T82I G253E K265E R268A), resembling
        the pharmacological features of hTAS2R46 (Fig. 4C and Table S1).', pubmed: '20534469',
    seq: '82', to_res: I}
- {entry_name: agtra_rat, from_res: N, info: "The Asn111Gly mutant has even been reported\
        \ to favour G protein coupling over \u03B2-arrestin recruitment [111,112].",
    pubmed: '18848837', seq: '111', to_res: G}
- {entry_name: gasr_rat, from_res: R, info: 'NSF plays a major role in receptor internalization
        and recycling as exemplified by the R412A mutant of the b2AR, which does not
        bind anymore to NSF (Gage et al., 2005).', pubmed: '21907915', seq: '412',
    to_res: A}
- {entry_name: adrb2_bovin, from_res: L, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '311',
    to_res: F}
- {entry_name: acm1_human, from_res: N, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '414',
    to_res: H}
- {entry_name: adrb2_bovin, from_res: A, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '134',
    to_res: H}
- {entry_name: acm1_human, from_res: L, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '269',
    to_res: H}
- {entry_name: nk1r_human, from_res: Y, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '92', to_res: H}
- {entry_name: acm1_human, from_res: Y, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '272',
    to_res: H}
- {entry_name: opsd_bovin, from_res: F, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '276', to_res: C}
- {entry_name: adrb2_bovin, from_res: D, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '113',
    to_res: H}
- {entry_name: opsd_bovin, from_res: G, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '90', to_res: D}
- {entry_name: opsd_bovin, from_res: V, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '204', to_res: C}
- {entry_name: opsd_bovin, from_res: T, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '198', to_res: C}
- {entry_name: fshr_human, from_res: L, info: "Although the strucC D tural similarity\
        \ between threonine and serine led us to expect that IB: HA-G\u03B115/16 L148T\
        \ hGPR54 would be devoid of functional activity, surprisingly, L148T caused\
        \ only a small decrease in WT hGPR54 functional coupling.///Although the strucC\
        \ D tural similarity between threonine and serine led us to expect that IB:\
        \ HA-G\u03B115/16 L148T hGPR54 would be devoid of functional activity, surprisingly,\
        \ L148T caused only a small decrease in WT hGPR54 functional coupling.///Indeed,\
        \ the interaction affinity acid (L148E hGPR54), arginine (L148R hGPR54), alanine\
        \ between G q and IL2 was remarkably strong, since stringent (L148A hGPR54),\
        \ phenylalanine (L148F hGPR54), or threo- washes with up to 900 mM NaCl did\
        \ not disrupt binding (data nine (L148T hGPR54) in hGPR54-GFP.///Interestingly,\
        \ in contrast to the L148S mutant, L148T GPR54 (threonine hydropathy score\
        \ 0.75) displayed nearly a WT functional response, indicating that the methyl\
        \ group may sufficiently buffer the detrimental effect of the hydroxyl group\
        \ on the hydrophobic environment of IL2.", pubmed: '18772143', seq: '148',
    to_res: T}
- {entry_name: opsd_bovin, from_res: K, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '248', to_res: C}
- {entry_name: opsd_bovin, from_res: Q, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '225', to_res: C}
- {entry_name: nk1r_human, from_res: F, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '268',
    to_res: H}
- {entry_name: opsd_bovin, from_res: T, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '251', to_res: C}
- {entry_name: opsd_bovin, from_res: N, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '200', to_res: C}
- {entry_name: adrb2_bovin, from_res: I, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '169',
    to_res: C}
- {entry_name: opsd_bovin, from_res: F, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '261', to_res: A}
- {entry_name: opsd_bovin, from_res: H, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '65', to_res: C}
- {entry_name: opsd_bovin, from_res: V, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '139', to_res: C}
- {entry_name: nk2r_bovin, from_res: T, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '37', to_res: A}
- {entry_name: opsd_bovin, from_res: R, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '252', to_res: C}
- {entry_name: nk1r_human, from_res: N, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '109',
    to_res: H}
- {entry_name: acm3_bovin, from_res: K, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '487',
    to_res: C}
- {entry_name: opsd_bovin, from_res: Y, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.///Receptor names are abbreviated according to their SWISS-PROT\
        \ Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '136', to_res: C}
- {entry_name: gnrhr_human, from_res: N, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '87', to_res: D}
- {entry_name: adrb2_bovin, from_res: E, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '268',
    to_res: H}
- {entry_name: adrb2_bovin, from_res: N, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '312',
    to_res: C}
- {entry_name: opsd_bovin, from_res: E, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '249', to_res: C}
- {entry_name: ur2r_bovin, from_res: D, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '120',
    to_res: N}
- {entry_name: opsd_bovin, from_res: T, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '251', to_res: H}
- {entry_name: opsd_bovin, from_res: V, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '138', to_res: H}
- {entry_name: opsd_bovin, from_res: G, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '121', to_res: L}
- {entry_name: acm3_bovin, from_res: A, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '489',
    to_res: C}
- {entry_name: acm1_human, from_res: L, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '116',
    to_res: H}
- {entry_name: acm1_human, from_res: F, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '374',
    to_res: H}
- {entry_name: opsd_bovin, from_res: V, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '250', to_res: C}
- {entry_name: opsd_bovin, from_res: E, info: "Receptor names are abbreviated according\
        \ to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7trmrlist.txt\
        \ Residue Indices Experimental Methods Residues/Mutations C R Z E L F \xC5\
        \ C -C References 1.60 7.63 2.57 7.43 3.28 7.43 3.36 5.22 3.36 6.44 3.37 5.46\
        \ 3.51 5.57 3.51 5.60 3.53 6.34 3.54 5.60 3.54 6.30 3.54 6.31 3.54 6.32 3.54\
        \ 6.33 3.54 6.34 3.54 6.35 3.55 5.57 3.55 5.60 3.55 7.63 5.33 6.59 5.35 6.59\
        \ 5.39 6.59 H65C C316 G90D K296 E113 K296 C110 C187 G121L F261A E122 H211\
        \ Y136C C222 Y136C C225 V138H T251H V139C Q225C V139C E247C V139C K248C V139C\
        \ E249C V139C V250C V139C T251C V139C R252C C140 C222 C140 Q225C C140 C316\
        \ T198C F276C N200C F276C V204C F276C 5.3 8.3a 10.1 12.9 9.0 6.1 5.1 6.0 8.3\
        \ 8.6 6.3 8.2 11.8 8.9 5.7 10.8 8.3 4.9 28.5a 14.5 9.0 5.1 Yang et al., 1996;\
        \ Struthers et al., 2000 Oprian, 1992; Rao et al., 1994 Oprian, 1992; Rao\
        \ et al., 1994 Struthers et al., 2000 Han et al., 1996; Lin et al., 2000 Beck\
        \ et al., 1998 Yu and Oprian, 1999 Yu and Oprian, 1999 Sheikh et al., 1996\
        \ Yu and Oprian, 1999 Farrens et al., 1996 Farrens et al., 1996 Farrens et\
        \ al., 1996 Farrens et al., 1996 Farrens et al., 1996 Farrens et al., 1996\
        \ Farrens et al., 1996; Yu and Oprian, 1999 Yu and Oprian, 1999; Struthers\
        \ et al., 2000 Yu et al., 1999 Struthers et al., 1999 Struthers et al., 1999\
        \ Struthers et al., 1999, 2000 C, Cys-Cys crosslinking; R, double revertant\
        \ mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related; F,\
        \ Fourier-transform infrared difference spectroscopy. a Present only in the\
        \ active state.", pubmed: '11408595', seq: '247', to_res: C}
- {entry_name: adrb2_bovin, from_res: N, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '312',
    to_res: F}
- {entry_name: adrb2_bovin, from_res: L, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '272',
    to_res: H}
- {entry_name: nk1r_human, from_res: E, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.///Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '193',
    to_res: H}
- {entry_name: acm5_human, from_res: D, info: 'Receptor names are abbreviated according
        to their SWISS-PROT Annotated Protein Sequence Database entry names: http://www.expasy.ch/cgi-bin/lists?7tmrlist.txt
        Experimental Methods Residue Indices Receptors C R Z Residues/Mutations C
        -C References 1.39 7.36 2.50 7.49 2.50 7.49 2.64 3.28 3.29 5.35 3.32 7.39
        3.43 6.44 3.43 7.49 3.53 6.30 3.53 6.31 3.53 6.34 3.54 6.29 3.54 6.30 3.54
        6.31 3.54 6.32 3.54 6.33 3.54 6.34 3.54 6.35 3.54 6.36 5.35 6.59 5.39 6.55
        5.39 6.56 5.39 6.59 6.44 7.49 TM1/TM2 7.39 TM3/TM6 7.38 ACM2-ACM5 GRHR 5H2A
        NK1R NK1R B2AR ACM1 ACM1 B2AR B2AR B2AR ACM2 ACM3 ACM3 ACM3 ACM3 ACM3 ACM3
        ACM3 NK1R NK1R NK1R NK1R ACM1 B2AR-A2AA B2AR-A2AA T37A H423T N87D D318N D120N
        N376D Y92H H108 N109H E193H D113H N312C L116H F374H L116H N414H A134H E268H
        A134H H269 A134H L272H I169C K484C I169C E485C I169C K486C I169C K487C I169C
        A488C I169C A489C I169C Q490C I169C T491C E193H Y272H H197 F268H H197 L269H
        H197 Y272H F374H N414H N312F L311F 11.8 7.0 7.0 6.6 14.0 15.5a 6.3 10.1 6.1
        10.7 8.3 11.5 6.3 8.2 11.8 8.9 5.7 10.8 12.4 9.0 8.6 8.5 5.1 9.0 Liu et al.,
        1995 Zhou et al., 1994 Sealfon et al., 1995 Elling and Schwartz, 1996 Elling
        and Schwartz, 1996 Elling et al., 1999 Lu and Hulme, 2000 Lu and Hulme, 2000
        Sheikh et al., 1999 Sheikh et al., 1999 Sheikh et al., 1999 Zeng et al., 1999
        Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Zeng
        et al., 1999 Zeng et al., 1999 Zeng et al., 1999 Elling et al., 1995 Elling
        et al., 1995 Elling et al., 1995 Elling et al., 1995 Lu and Hulme, 2000 Mizobe
        et al., 1996 Mizobe et al., 1996 Downloaded from molpharm.aspetjournals.org
        at Radboud Univ Nijmegen on June 24, 2009 C, Cys-Cys crosslinking; R, double
        revertant mutations; Z, Zinc-His binding; E, spin-labeling; L, ligand related;
        F, Fourier-transform infrared difference spectroscopy. a Present only in the
        active state. ceptor are shown in Figs.', pubmed: '11408595', seq: '318',
    to_res: N}
- {entry_name: adrb2_mouse, from_res: D, info: "In an extension of this basic concept,\
        \ Sartania et al. (2007) demonstrated that, when each variant was expressed\
        \ individually, the agonist isoprenaline was able to cause internalization\
        \ of the wild-type b2-adrenoceptor but not of an Asp113Ser mutant that does\
        \ not bind catecholamine ligands with high affinity (Figure 1).///However,\
        \ following co-expression of the wild-type and Asp113Ser forms of the b2-adrenoceptor,\
        \ either isoprenaline or 1-(30 40 -dihydroxyphenyl)-3-methyl-1butanone caused\
        \ internalization of both forms of the receptor (Figure 1).///These data indicate\
        \ that wild-type and Asp113Ser b2-adrenoceptors dimerize and that agonist\
        \ occupancy of only one protomer within the dimer is sufficient to cause internalization.///III\
        \ D113 ISOPRENALINE V III S113 L-158,870 V IV VI IV D113 V ISOPRENALINE III\
        \ VI IV VI IV VI S113 L-158,870 III V wild type \u03B22-adrenoceptor Asp113Ser\
        \ \u03B22-adrenoceptor + L158,870 + Isoprenaline + Isoprenaline + L158,870\
        \ - DOX VSV-G-Asp113Ser\u03B22-AR HA-\u03B22-AR Merge + DOX Figure 1 The b2-adrenoceptor\
        \ is internalized as a dimer following the binding of a single molecule of\
        \ agonist ligand to either protomer. (a) Differentially epitope-tagged forms\
        \ of either the wild-type b2-adrenoceptor (green) or an Asp113Ser b2-adrenoceptor\
        \ mutant (red) were expressed in Flp-In, T-Rex HEK293 cells.///III D113 ISOPRENALINE\
        \ V III S113 L-158,870 V IV VI IV D113 V ISOPRENALINE III VI IV VI IV VI S113\
        \ L-158,870 III V wild type \u03B22-adrenoceptor Asp113Ser \u03B22-adrenoceptor\
        \ + L158,870 + Isoprenaline + Isoprenaline + L158,870 - DOX VSV-G-Asp113Ser\u03B2\
        2-AR HA-\u03B22-AR Merge + DOX Figure 1 The b2-adrenoceptor is internalized\
        \ as a dimer following the binding of a single molecule of agonist ligand\
        \ to either protomer. (a) Differentially epitope-tagged forms of either the\
        \ wild-type b2-adrenoceptor (green) or an Asp113Ser b2-adrenoceptor mutant\
        \ (red) were expressed in Flp-In, T-Rex HEK293 cells.///The wild-type receptor\
        \ was internalized in response to challenge with isoprenaline but not to L158,870\
        \ (1-(30 40 -dihydroxyphenyl)-3-methyl-1-butanone), while the reverse was\
        \ true for the Asp113Ser b2-adrenoceptor.///Docking of the ligands is based\
        \ on mutational analysis of how the b2-adrenoceptor binds ligands. (b) With\
        \ N-terminally HA-tagged wild-type b2-adrenoceptor (HA-b2-AR) (green) expressed\
        \ stably and constitutively and N-terminally VSV-G tagged Asp113Ser b2-adrenoceptor\
        \ (VSV-G-Asp113Ser-b2-AR) (red) cloned into the Flp-In locus, HA-b2-AR is\
        \ expressed in both the absence (\xC0) and presence ( \xFE ) of the antibiotic\
        \ DOX, while VSV-G-Asp113Ser-b2-AR is expressed only following exposure of\
        \ the cells to DOX.///Docking of the ligands is based on mutational analysis\
        \ of how the b2-adrenoceptor binds ligands. (b) With N-terminally HA-tagged\
        \ wild-type b2-adrenoceptor (HA-b2-AR) (green) expressed stably and constitutively\
        \ and N-terminally VSV-G tagged Asp113Ser b2-adrenoceptor (VSV-G-Asp113Ser-b2-AR)\
        \ (red) cloned into the Flp-In locus, HA-b2-AR is expressed in both the absence\
        \ (\xC0) and presence ( \xFE ) of the antibiotic DOX, while VSV-G-Asp113Ser-b2-AR\
        \ is expressed only following exposure of the cells to DOX.///Docking of the\
        \ ligands is based on mutational analysis of how the b2-adrenoceptor binds\
        \ ligands. (b) With N-terminally HA-tagged wild-type b2-adrenoceptor (HA-b2-AR)\
        \ (green) expressed stably and constitutively and N-terminally VSV-G tagged\
        \ Asp113Ser b2-adrenoceptor (VSV-G-Asp113Ser-b2-AR) (red) cloned into the\
        \ Flp-In locus, HA-b2-AR is expressed in both the absence (\xC0) and presence\
        \ ( \xFE ) of the antibiotic DOX, while VSV-G-Asp113Ser-b2-AR is expressed\
        \ only following exposure of the cells to DOX.///(c) Following co-expression\
        \ of HA-b2-AR (green) and VSV-G-Asp113Ser-b2-AR (red), isoprenaline causes\
        \ internalization of both forms of the b2-adrenoceptor and the co-internalized\
        \ receptors overlap in distribution (merge, yellow).///The cartoon illustrates\
        \ that a HA-b2-AR/VSV-G-Asp113Ser-b2-AR dimer can only bind a single molecule\
        \ of isoprenaline. (d) Following co-expression of HA-b2AR (green) and VSV-G-Asp113Ser-b2-AR\
        \ (red), L158,870 also causes internalization of both forms of the b2-adrenoceptor\
        \ and the co-internalized receptors overlap in distribution (merge, yellow).///The\
        \ cartoon illustrates that a HA-b2-AR/VSV-G-Asp113Ser-b2-AR dimer can only\
        \ bind a single molecule of isoprenaline. (d) Following co-expression of HA-b2AR\
        \ (green) and VSV-G-Asp113Ser-b2-AR (red), L158,870 also causes internalization\
        \ of both forms of the b2-adrenoceptor and the co-internalized receptors overlap\
        \ in distribution (merge, yellow).///The cartoon illustrates that a HA-b2-AR/VSV-G-Asp113Ser-b2-AR\
        \ dimer can only bind a single molecule of L158,870.///British Journal of\
        \ Pharmacology (2008) 153 S216\u2013S229 S222 GPCR dimerization G Milligan\
        \ III D113 ISOPRENALINE V IV VI IV VI 113 S113 III V Control + Isoprenaline\
        \ HA-\u03B22-AR VSV-G-Asp113Ser-\u03B22-AR Merge III D113 V IV VI IV VI S113\
        \ III V L-158,870 Control + L158,870 HA-\u03B22-AR Figure 1 Continued.///VSV-G-Asp113Ser-\u03B2\
        2-AR Merge Does the co-internalization of pairs of co-expressed GPCRs define\
        \ their hetero-dimerization?", pubmed: '17965750', seq: '113', to_res: S}
- {entry_name: gnrhr_human, from_res: Q, info: 'Binding Mutant WT WT NBI-42902a P173A
        Q174A L175A L175A NBI-42902a Y176A I177A F178A F178L F178L NBI-42902a F178W
        R179A R179A NBI-42902a M180A Rexp Teverelix 8.34 8.38 7.57 8.31 UD 7.82 7.90
        8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6) 0.18 (4.2) 0.12 (26.8) 0.18
        (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11 (5.9) 0.19 (6.0) 0.13 (7.0)
        0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71
        7.68 UD 7.96 7.48 GnRH I GnRH II 7.28 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58
        UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5) 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12
        (33.7) 0.32 (221) 0.04 (16.1) 0.10 (26600) 0.08 (4530) 0.05 (125) % WT pIC50
        (nM) 100 164 24 41 6 51 10 12 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8 6
        31 9 45 8 0.09 (3.4) 0.05 (2.7) 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03 (7.0)
        0.03 (9.1) 0.02 (9310) 0.39 (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded
        from www.jbc.org at Edinburgh University Library, on March 19, 2012 0.31 (80.3)
        0.01 (26.6) a Pretreated with NBI-42902.///GnRH I Mutant WT WT NBI-42902a
        P173A Q174A L175A NBI-42902a Y176A I177A F178A F178L NBI-42902a F178W R179A
        NBI-42902a M180A 8.77 8.74 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53 7.79
        pEC50 Emax pEC50 GnRH II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8) 0.17
        (41.2) 0.18 (27.7) 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11 (139)
        0.26 (5.1) 0.15 (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17 4 105 23
        82 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44 6.86 7.05
        7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1) 0.01 (153)
        0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14 (45.1) 100
        92 7 82 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21 a Pretreated
        with NBI-42902.', pubmed: '21832286', seq: '174', to_res: A}
- {entry_name: gnrhr_human, from_res: L, info: "The mutants P173A, L175A, Y176A, and\
        \ R179A gave 3\u2013 6-fold increases in OCTOBER 7, 2011 \u2022 VOLUME 286\
        \ \u2022 NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 34619 Role of GnRHR ECL2\
        \ in Ligand-induced Selective Conformations TABLE 1 Binding of GnRH ligands\
        \ to wild-type and mutant human GnRH receptors Ligand binding affinity (pIC50)\
        \ was measured on intact COS-7 cells at 48 h after transfection with wild-type\
        \ and mutant receptors by competition binding assays using 125 I-Teverelix\
        \ as a radioligand with increasing concentrations of unlabeled GnRH ligands.///Binding\
        \ Mutant WT WT NBI-42902a P173A Q174A L175A L175A NBI-42902a Y176A I177A F178A\
        \ F178L F178L NBI-42902a F178W R179A R179A NBI-42902a M180A Rexp Teverelix\
        \ 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11\
        \ (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2)\
        \ 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77\
        \ 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28\
        \ 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5)\
        \ 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10\
        \ (26600) 0.08 (4530) 0.05 (125) % WT pIC50 (nM) 100 164 24 41 6 51 10 12\
        \ 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7)\
        \ 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39\
        \ (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded from www.jbc.org at\
        \ Edinburgh University Library, on March 19, 2012 0.31 (80.3) 0.01 (26.6)\
        \ a Pretreated with NBI-42902.///Binding Mutant WT WT NBI-42902a P173A Q174A\
        \ L175A L175A NBI-42902a Y176A I177A F178A F178L F178L NBI-42902a F178W R179A\
        \ R179A NBI-42902a M180A Rexp Teverelix 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37\
        \ 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9)\
        \ 0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47\
        \ (16.3) 0.03 (10.1) 8.47 8.57 7.77 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68\
        \ UD 7.96 7.48 GnRH I GnRH II 7.28 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD\
        \ 5.34 6.90 UD 7.10 7.57 0.09 (52.5) 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12\
        \ (33.7) 0.32 (221) 0.04 (16.1) 0.10 (26600) 0.08 (4530) 0.05 (125) % WT pIC50\
        \ (nM) 100 164 24 41 6 51 10 12 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8\
        \ 6 31 9 45 8 0.09 (3.4) 0.05 (2.7) 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03\
        \ (7.0) 0.03 (9.1) 0.02 (9310) 0.39 (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1)\
        \ Downloaded from www.jbc.org at Edinburgh University Library, on March 19,\
        \ 2012 0.31 (80.3) 0.01 (26.6) a Pretreated with NBI-42902.///The cell surface\
        \ expression levels of the mutants with greatly reduced Rexp (less than one-fourth\
        \ of the wild type: L175A, F178L, and R179A mutant receptors) were rescued\
        \ by a non-peptide antagonist, NBI-42902 (26).///GnRH I Mutant WT WT NBI-42902a\
        \ P173A Q174A L175A NBI-42902a Y176A I177A F178A F178L NBI-42902a F178W R179A\
        \ NBI-42902a M180A 8.77 8.74 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53\
        \ 7.79 pEC50 Emax pEC50 GnRH II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8)\
        \ 0.17 (41.2) 0.18 (27.7) 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11\
        \ (139) 0.26 (5.1) 0.15 (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17\
        \ 4 105 23 82 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44\
        \ 6.86 7.05 7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1)\
        \ 0.01 (153) 0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14\
        \ (45.1) 100 92 7 82 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21\
        \ a Pretreated with NBI-42902.///A similar change in affinity and potency\
        \ of GnRH II was observed for most of the mutants, except for L175A, I177A,\
        \ and M180A, which displayed 2\u20133-fold increases in receptor binding affinity\
        \ for GnRH II, but gave little change (L175A), or a 2-fold (M180A) and 5-fold\
        \ (I177A) decrease in GnRH II potency (Table 3).///A similar change in affinity\
        \ and potency of GnRH II was observed for most of the mutants, except for\
        \ L175A, I177A, and M180A, which displayed 2\u20133-fold increases in receptor\
        \ binding affinity for GnRH II, but gave little change (L175A), or a 2-fold\
        \ (M180A) and 5-fold (I177A) decrease in GnRH II potency (Table 3).///Two\
        \ mutations, L175A and R179A, had a destabilized effect on the receptor structure,\
        \ reflected by the strongly decreased receptor cell surface expression level\
        \ to less than 80% of the wild-type level that could be rescued by NBI-42902.",
    pubmed: '21832286', seq: '175', to_res: A}
- {entry_name: cxcr4_human, from_res: F, info: "Details are given under \u201CExperimental\
        \ Procedures.\u201D Normalized competitive binding of GnRH I (A), GnRH II\
        \ (B), and [Phe3]GnRH I (C) at the wild-type f, F174A \u0152, F178L F, and\
        \ F178W receptors.", pubmed: '21832286', seq: '174', to_res: A}
- {entry_name: gnrhr_human, from_res: F, info: "Binding Mutant WT WT NBI-42902a P173A\
        \ Q174A L175A L175A NBI-42902a Y176A I177A F178A F178L F178L NBI-42902a F178W\
        \ R179A R179A NBI-42902a M180A Rexp Teverelix 8.34 8.38 7.57 8.31 UD 7.82\
        \ 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6) 0.18 (4.2) 0.12 (26.8)\
        \ 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11 (5.9) 0.19 (6.0) 0.13\
        \ (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77 7.52 UD 8.29 8.16 8.04 5.03\
        \ UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28 7.28 6.40 6.39 UD 7.47 6.66\
        \ 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5) 0.09 (52.1) 0.22 (401) 0.29\
        \ (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10 (26600) 0.08 (4530) 0.05 (125)\
        \ % WT pIC50 (nM) 100 164 24 41 6 51 10 12 1 45 6 26 5 77 24 324 40 23 3 78\
        \ 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7) 0.13 (17.1) 0.11 (30.3) 0.26\
        \ (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39 (195) 0.03 (21.0) 0.39 (11.1)\
        \ 0.06 (33.1) Downloaded from www.jbc.org at Edinburgh University Library,\
        \ on March 19, 2012 0.31 (80.3) 0.01 (26.6) a Pretreated with NBI-42902.///Binding\
        \ Mutant WT 6.30 WT NBI-42902a 6.45 F178A 4.52 F178L NBI-42902a 5.33 F178W\
        \ 6.17 pIC50 IP response pEC50 Emax (nM) (nM) % WT 0.08 (499) 7.12 0.31 (354)\
        \ 7.68 0.08 (30500) 4.94 0.08 (4680) 5.39 0.08 (672) 6.21 0.17 (76.6) 100\
        \ 0.23 (20.8) 98 9 0.15 (11400) 338 174 0.06 (4060) 178 61 0.17 (621) 209\
        \ 62 a Pretreated with NBI-42902.///COS-7 cells transfected with wild-type\
        \ or mutant receptors were preincubated with (F178L) or without (F178A and\
        \ F178W) 1 M NBI-42902 for 48 h and then washed prior to the binding assay.///Details\
        \ are given under \u201CExperimental Procedures.\u201D Normalized competitive\
        \ binding of GnRH I (A), GnRH II (B), and [Phe3]GnRH I (C) at the wild-type\
        \ f, F174A \u0152, F178L F, and F178W receptors.///GnRH I Mutant WT WT NBI-42902a\
        \ P173A Q174A L175A NBI-42902a Y176A I177A F178A F178L NBI-42902a F178W R179A\
        \ NBI-42902a M180A 8.77 8.74 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53\
        \ 7.79 pEC50 Emax pEC50 GnRH II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8)\
        \ 0.17 (41.2) 0.18 (27.7) 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11\
        \ (139) 0.26 (5.1) 0.15 (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17\
        \ 4 105 23 82 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44\
        \ 6.86 7.05 7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1)\
        \ 0.01 (153) 0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14\
        \ (45.1) 100 92 7 82 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21\
        \ a Pretreated with NBI-42902.///Mutation of Phe178 to Leu gave intermediate\
        \ decreases of potency with 82- and 181-fold increases in the EC50, whereas\
        \ mutation of Phe178 to Trp had only a small effect on potency with 3- and\
        \ 7-fold increases in the EC50 values.///However, although the affinity of\
        \ [Phe3]GnRH I was similar at both the wild-type and F178W mutant receptors,\
        \ the EC50 value of [Phe3]GnRH I at the F178W mutant was 8-fold higher than\
        \ the wild-type receptor.///However, although the affinity of [Phe3]GnRH I\
        \ was similar at both the wild-type and F178W mutant receptors, the EC50 value\
        \ of [Phe3]GnRH I at the F178W mutant was 8-fold higher than the wild-type\
        \ receptor.///Interestingly, [Phe3]GnRH I-stimulated IP responses at F178W\
        \ mutant receptors (reciprocal mutation between Trp3 of GnRH I and Phe178(4.66)\
        \ of the receptor) gave higher maximal IP responses than that of the wild-type\
        \ receptor (Fig. 6C), suggesting the reciprocal mutations between the ligand\
        \ and the receptor can rescue the maximum functional response.///The minor\
        \ reduction of F178W in affinity for GnRH suggests that substitution of Phe178(4.64)\
        \ with a bulkier Trp may have steric detrimental effect on agonist-induced\
        \ receptor conformational changes.///This is more obvious from the functional\
        \ assay results whereby F178W gave a reduced Emax for both GnRH I and GnRH\
        \ II to 39 \u2013 46% that of the wild type (Table 3 and Fig. 6, A and B).///More\
        \ interestingly, the functional response was partially rescued by the reciprocal\
        \ mutations between the receptor and ligand, as the maximum IP responses of\
        \ [Phe3]GnRH I in the F178W mutant exceeded that of [Phe3]GnRH I in the wildtype\
        \ receptor (Fig. 6C).", pubmed: '21832286', seq: '178', to_res: W}
- {entry_name: gnrhr_human, from_res: P, info: "The mutants P173A, L175A, Y176A, and\
        \ R179A gave 3\u2013 6-fold increases in OCTOBER 7, 2011 \u2022 VOLUME 286\
        \ \u2022 NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 34619 Role of GnRHR ECL2\
        \ in Ligand-induced Selective Conformations TABLE 1 Binding of GnRH ligands\
        \ to wild-type and mutant human GnRH receptors Ligand binding affinity (pIC50)\
        \ was measured on intact COS-7 cells at 48 h after transfection with wild-type\
        \ and mutant receptors by competition binding assays using 125 I-Teverelix\
        \ as a radioligand with increasing concentrations of unlabeled GnRH ligands.///Binding\
        \ Mutant WT WT NBI-42902a P173A Q174A L175A L175A NBI-42902a Y176A I177A F178A\
        \ F178L F178L NBI-42902a F178W R179A R179A NBI-42902a M180A Rexp Teverelix\
        \ 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11\
        \ (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2)\
        \ 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77\
        \ 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28\
        \ 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5)\
        \ 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10\
        \ (26600) 0.08 (4530) 0.05 (125) % WT pIC50 (nM) 100 164 24 41 6 51 10 12\
        \ 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7)\
        \ 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39\
        \ (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded from www.jbc.org at\
        \ Edinburgh University Library, on March 19, 2012 0.31 (80.3) 0.01 (26.6)\
        \ a Pretreated with NBI-42902.///GnRH I Mutant WT WT NBI-42902a P173A Q174A\
        \ L175A NBI-42902a Y176A I177A F178A F178L NBI-42902a F178W R179A NBI-42902a\
        \ M180A 8.77 8.74 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53 7.79 pEC50\
        \ Emax pEC50 GnRH II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8) 0.17 (41.2)\
        \ 0.18 (27.7) 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11 (139) 0.26\
        \ (5.1) 0.15 (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17 4 105 23 82\
        \ 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44 6.86 7.05\
        \ 7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1) 0.01 (153)\
        \ 0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14 (45.1)\
        \ 100 92 7 82 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21 a Pretreated\
        \ with NBI-42902.", pubmed: '21832286', seq: '173', to_res: A}
- {entry_name: gnrhr_human, from_res: M, info: "Binding Mutant WT WT NBI-42902a P173A\
        \ Q174A L175A L175A NBI-42902a Y176A I177A F178A F178L F178L NBI-42902a F178W\
        \ R179A R179A NBI-42902a M180A Rexp Teverelix 8.34 8.38 7.57 8.31 UD 7.82\
        \ 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6) 0.18 (4.2) 0.12 (26.8)\
        \ 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11 (5.9) 0.19 (6.0) 0.13\
        \ (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77 7.52 UD 8.29 8.16 8.04 5.03\
        \ UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28 7.28 6.40 6.39 UD 7.47 6.66\
        \ 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5) 0.09 (52.1) 0.22 (401) 0.29\
        \ (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10 (26600) 0.08 (4530) 0.05 (125)\
        \ % WT pIC50 (nM) 100 164 24 41 6 51 10 12 1 45 6 26 5 77 24 324 40 23 3 78\
        \ 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7) 0.13 (17.1) 0.11 (30.3) 0.26\
        \ (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39 (195) 0.03 (21.0) 0.39 (11.1)\
        \ 0.06 (33.1) Downloaded from www.jbc.org at Edinburgh University Library,\
        \ on March 19, 2012 0.31 (80.3) 0.01 (26.6) a Pretreated with NBI-42902.///GnRH\
        \ I Mutant WT WT NBI-42902a P173A Q174A L175A NBI-42902a Y176A I177A F178A\
        \ F178L NBI-42902a F178W R179A NBI-42902a M180A 8.77 8.74 7.39 7.56 8.41 7.82\
        \ 8.50 6.41 6.86 8.30 8.53 7.79 pEC50 Emax pEC50 GnRH II Emax (nM) % WT (nM)\
        \ % WT 0.11 (1.7) 0.08 (1.8) 0.17 (41.2) 0.18 (27.7) 0.06 (3.9) 0.11 (15.0)\
        \ 0.34 (3.1) 0.10 (386) 0.11 (139) 0.26 (5.1) 0.15 (3.0) 0.08 (16.4) 100 86\
        \ 10 79 8 81 4 60 8 37 3 17 4 105 23 82 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33\
        \ 7.66 6.81 7.02 4.71 5.44 6.86 7.05 7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787)\
        \ 0.12 (464) 0.04 (22.1) 0.01 (153) 0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25\
        \ (138) 0.17 (90.2) 0.14 (45.1) 100 92 7 82 10 90 1 59 7 31 7 17 8 103 79\
        \ 46 15 39 15 45 14 70 21 a Pretreated with NBI-42902.///A similar change\
        \ in affinity and potency of GnRH II was observed for most of the mutants,\
        \ except for L175A, I177A, and M180A, which displayed 2\u20133-fold increases\
        \ in receptor binding affinity for GnRH II, but gave little change (L175A),\
        \ or a 2-fold (M180A) and 5-fold (I177A) decrease in GnRH II potency (Table\
        \ 3).///A similar change in affinity and potency of GnRH II was observed for\
        \ most of the mutants, except for L175A, I177A, and M180A, which displayed\
        \ 2\u20133-fold increases in receptor binding affinity for GnRH II, but gave\
        \ little change (L175A), or a 2-fold (M180A) and 5-fold (I177A) decrease in\
        \ GnRH II potency (Table 3).", pubmed: '21832286', seq: '180', to_res: A}
- {entry_name: gnrhr_human, from_res: F, info: 'The marked decrease in signaling efficacy
        of I177A and F178A also indicates that IIe177(4.63) and Phe178(4.64) are important
        in stabilizing receptor-active conformations.///Surprisingly, the mutant F178A
        displayed a markedly increased receptor cell surface expression level as compared
        with the wild type (see below).///Binding Mutant WT WT NBI-42902a P173A Q174A
        L175A L175A NBI-42902a Y176A I177A F178A F178L F178L NBI-42902a F178W R179A
        R179A NBI-42902a M180A Rexp Teverelix 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37
        8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9)
        0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47 (16.3)
        0.03 (10.1) 8.47 8.57 7.77 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68 UD 7.96
        7.48 GnRH I GnRH II 7.28 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD 5.34 6.90
        UD 7.10 7.57 0.09 (52.5) 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12 (33.7) 0.32
        (221) 0.04 (16.1) 0.10 (26600) 0.08 (4530) 0.05 (125) % WT pIC50 (nM) 100
        164 24 41 6 51 10 12 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8 6 31 9 45 8
        0.09 (3.4) 0.05 (2.7) 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03 (7.0) 0.03 (9.1)
        0.02 (9310) 0.39 (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded from
        www.jbc.org at Edinburgh University Library, on March 19, 2012 0.31 (80.3)
        0.01 (26.6) a Pretreated with NBI-42902.///Overall there were reductions in
        cell surface expression of the mutant receptors except for the F178A mutant,
        which displayed approximately a 3-fold increase in cell surface expression
        (Table 1).///Binding Mutant WT 6.30 WT NBI-42902a 6.45 F178A 4.52 F178L NBI-42902a
        5.33 F178W 6.17 pIC50 IP response pEC50 Emax (nM) (nM) % WT 0.08 (499) 7.12
        0.31 (354) 7.68 0.08 (30500) 4.94 0.08 (4680) 5.39 0.08 (672) 6.21 0.17 (76.6)
        100 0.23 (20.8) 98 9 0.15 (11400) 338 174 0.06 (4060) 178 61 0.17 (621) 209
        62 a Pretreated with NBI-42902.///COS-7 cells transfected with wild-type or
        mutant receptors were preincubated with (F178L) or without (F178A and F178W)
        1 M NBI-42902 for 48 h and then washed prior to the binding assay.///GnRH
        I Mutant WT WT NBI-42902a P173A Q174A L175A NBI-42902a Y176A I177A F178A F178L
        NBI-42902a F178W R179A NBI-42902a M180A 8.77 8.74 7.39 7.56 8.41 7.82 8.50
        6.41 6.86 8.30 8.53 7.79 pEC50 Emax pEC50 GnRH II Emax (nM) % WT (nM) % WT
        0.11 (1.7) 0.08 (1.8) 0.17 (41.2) 0.18 (27.7) 0.06 (3.9) 0.11 (15.0) 0.34
        (3.1) 0.10 (386) 0.11 (139) 0.26 (5.1) 0.15 (3.0) 0.08 (16.4) 100 86 10 79
        8 81 4 60 8 37 3 17 4 105 23 82 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33 7.66
        6.81 7.02 4.71 5.44 6.86 7.05 7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787) 0.12
        (464) 0.04 (22.1) 0.01 (153) 0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25 (138)
        0.17 (90.2) 0.14 (45.1) 100 92 7 82 10 90 1 59 7 31 7 17 8 103 79 46 15 39
        15 45 14 70 21 a Pretreated with NBI-42902.///Most mutants, except for I177A
        and F178A, had little or only a marginal effect on the signaling efficacy
        of GnRH I (Fig. 5B) and GnRH II.///Similar to the outcome on affinity, mutation
        of Phe178 to Ala had the largest effect on potency, with 228- and 962-fold
        increases in EC50 in response to GnRH I (Fig. 6A) and GnRH II (Fig. 6B).///Despite
        the mutant F178A having an increased expression of 324% compared with the
        wild-type receptors, the maximum responses of GnRH I at this mutant were similar
        to the wild-type receptors with Emax values of 105%, implying a potential
        decrease in signaling efficacy (Fig. 5B).///A similar phenotype was also observed
        for GnRH II, derived from the calculated Emax, which could not be measured
        accurately because of the solubility limit of the maximum GnRH II concentration
        (10 5 M) to be used for F178A and F178L (Fig. 6B and Table 3).///This hydrophobic
        interaction is also important for GnRH-induced receptor activation, as F178A
        significantly reduced the maximum efficacy of GnRH I (Fig. 5B).', pubmed: '21832286',
    seq: '178', to_res: A}
- {entry_name: gnrhr_human, from_res: I, info: "The marked decrease in signaling efficacy\
        \ of I177A and F178A also indicates that IIe177(4.63) and Phe178(4.64) are\
        \ important in stabilizing receptor-active conformations.///Binding Mutant\
        \ WT WT NBI-42902a P173A Q174A L175A L175A NBI-42902a Y176A I177A F178A F178L\
        \ F178L NBI-42902a F178W R179A R179A NBI-42902a M180A Rexp Teverelix 8.34\
        \ 8.38 7.57 8.31 UD 7.82 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6)\
        \ 0.18 (4.2) 0.12 (26.8) 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11\
        \ (5.9) 0.19 (6.0) 0.13 (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77 7.52\
        \ UD 8.29 8.16 8.04 5.03 UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28 7.28\
        \ 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5) 0.09\
        \ (52.1) 0.22 (401) 0.29 (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10 (26600)\
        \ 0.08 (4530) 0.05 (125) % WT pIC50 (nM) 100 164 24 41 6 51 10 12 1 45 6 26\
        \ 5 77 24 324 40 23 3 78 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7) 0.13 (17.1)\
        \ 0.11 (30.3) 0.26 (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39 (195) 0.03\
        \ (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded from www.jbc.org at Edinburgh\
        \ University Library, on March 19, 2012 0.31 (80.3) 0.01 (26.6) a Pretreated\
        \ with NBI-42902.///GnRH I Mutant WT WT NBI-42902a P173A Q174A L175A NBI-42902a\
        \ Y176A I177A F178A F178L NBI-42902a F178W R179A NBI-42902a M180A 8.77 8.74\
        \ 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53 7.79 pEC50 Emax pEC50 GnRH\
        \ II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8) 0.17 (41.2) 0.18 (27.7)\
        \ 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11 (139) 0.26 (5.1) 0.15\
        \ (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17 4 105 23 82 18 46 8 59\
        \ 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44 6.86 7.05 7.35 0.07\
        \ (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1) 0.01 (153) 0.12 (94.6)\
        \ 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14 (45.1) 100 92 7 82\
        \ 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21 a Pretreated with\
        \ NBI-42902.///A similar change in affinity and potency of GnRH II was observed\
        \ for most of the mutants, except for L175A, I177A, and M180A, which displayed\
        \ 2\u20133-fold increases in receptor binding affinity for GnRH II, but gave\
        \ little change (L175A), or a 2-fold (M180A) and 5-fold (I177A) decrease in\
        \ GnRH II potency (Table 3).///A similar change in affinity and potency of\
        \ GnRH II was observed for most of the mutants, except for L175A, I177A, and\
        \ M180A, which displayed 2\u20133-fold increases in receptor binding affinity\
        \ for GnRH II, but gave little change (L175A), or a 2-fold (M180A) and 5-fold\
        \ (I177A) decrease in GnRH II potency (Table 3).///Most mutants, except for\
        \ I177A and F178A, had little or only a marginal effect on the signaling efficacy\
        \ of GnRH I (Fig. 5B) and GnRH II.///The mutant, I177A, was expressed at the\
        \ cell surface to 77% of wild-type level but gave reduced Emax to 17% that\
        \ of the wild-type for both GnRH I and GnRH II.///The GnRH II-induced IP responses\
        \ at the I177A mutant receptor also demonstrated a 5-fold decrease in potency\
        \ compared with wild-type receptors, yet there was a 3-fold increase in affinity\
        \ in addition to the decreased Emax (Table 3).", pubmed: '21832286', seq: '177',
    to_res: A}
- {entry_name: gnrhr_human, from_res: Y, info: "The mutants P173A, L175A, Y176A, and\
        \ R179A gave 3\u2013 6-fold increases in OCTOBER 7, 2011 \u2022 VOLUME 286\
        \ \u2022 NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 34619 Role of GnRHR ECL2\
        \ in Ligand-induced Selective Conformations TABLE 1 Binding of GnRH ligands\
        \ to wild-type and mutant human GnRH receptors Ligand binding affinity (pIC50)\
        \ was measured on intact COS-7 cells at 48 h after transfection with wild-type\
        \ and mutant receptors by competition binding assays using 125 I-Teverelix\
        \ as a radioligand with increasing concentrations of unlabeled GnRH ligands.///Binding\
        \ Mutant WT WT NBI-42902a P173A Q174A L175A L175A NBI-42902a Y176A I177A F178A\
        \ F178L F178L NBI-42902a F178W R179A R179A NBI-42902a M180A Rexp Teverelix\
        \ 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11\
        \ (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2)\
        \ 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77\
        \ 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28\
        \ 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5)\
        \ 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10\
        \ (26600) 0.08 (4530) 0.05 (125) % WT pIC50 (nM) 100 164 24 41 6 51 10 12\
        \ 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7)\
        \ 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39\
        \ (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded from www.jbc.org at\
        \ Edinburgh University Library, on March 19, 2012 0.31 (80.3) 0.01 (26.6)\
        \ a Pretreated with NBI-42902.///GnRH I Mutant WT WT NBI-42902a P173A Q174A\
        \ L175A NBI-42902a Y176A I177A F178A F178L NBI-42902a F178W R179A NBI-42902a\
        \ M180A 8.77 8.74 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53 7.79 pEC50\
        \ Emax pEC50 GnRH II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8) 0.17 (41.2)\
        \ 0.18 (27.7) 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11 (139) 0.26\
        \ (5.1) 0.15 (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17 4 105 23 82\
        \ 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44 6.86 7.05\
        \ 7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1) 0.01 (153)\
        \ 0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14 (45.1)\
        \ 100 92 7 82 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21 a Pretreated\
        \ with NBI-42902.", pubmed: '21832286', seq: '176', to_res: A}
- {entry_name: gnrhr_human, from_res: F, info: "Binding Mutant WT WT NBI-42902a P173A\
        \ Q174A L175A L175A NBI-42902a Y176A I177A F178A F178L F178L NBI-42902a F178W\
        \ R179A R179A NBI-42902a M180A Rexp Teverelix 8.34 8.38 7.57 8.31 UD 7.82\
        \ 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6) 0.18 (4.2) 0.12 (26.8)\
        \ 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11 (5.9) 0.19 (6.0) 0.13\
        \ (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77 7.52 UD 8.29 8.16 8.04 5.03\
        \ UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28 7.28 6.40 6.39 UD 7.47 6.66\
        \ 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5) 0.09 (52.1) 0.22 (401) 0.29\
        \ (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10 (26600) 0.08 (4530) 0.05 (125)\
        \ % WT pIC50 (nM) 100 164 24 41 6 51 10 12 1 45 6 26 5 77 24 324 40 23 3 78\
        \ 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7) 0.13 (17.1) 0.11 (30.3) 0.26\
        \ (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39 (195) 0.03 (21.0) 0.39 (11.1)\
        \ 0.06 (33.1) Downloaded from www.jbc.org at Edinburgh University Library,\
        \ on March 19, 2012 0.31 (80.3) 0.01 (26.6) a Pretreated with NBI-42902.///Binding\
        \ Mutant WT WT NBI-42902a P173A Q174A L175A L175A NBI-42902a Y176A I177A F178A\
        \ F178L F178L NBI-42902a F178W R179A R179A NBI-42902a M180A Rexp Teverelix\
        \ 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11\
        \ (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2)\
        \ 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77\
        \ 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28\
        \ 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5)\
        \ 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10\
        \ (26600) 0.08 (4530) 0.05 (125) % WT pIC50 (nM) 100 164 24 41 6 51 10 12\
        \ 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7)\
        \ 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39\
        \ (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded from www.jbc.org at\
        \ Edinburgh University Library, on March 19, 2012 0.31 (80.3) 0.01 (26.6)\
        \ a Pretreated with NBI-42902.///The cell surface expression levels of the\
        \ mutants with greatly reduced Rexp (less than one-fourth of the wild type:\
        \ L175A, F178L, and R179A mutant receptors) were rescued by a non-peptide\
        \ antagonist, NBI-42902 (26).///Binding Mutant WT 6.30 WT NBI-42902a 6.45\
        \ F178A 4.52 F178L NBI-42902a 5.33 F178W 6.17 pIC50 IP response pEC50 Emax\
        \ (nM) (nM) % WT 0.08 (499) 7.12 0.31 (354) 7.68 0.08 (30500) 4.94 0.08 (4680)\
        \ 5.39 0.08 (672) 6.21 0.17 (76.6) 100 0.23 (20.8) 98 9 0.15 (11400) 338 174\
        \ 0.06 (4060) 178 61 0.17 (621) 209 62 a Pretreated with NBI-42902.///COS-7\
        \ cells transfected with wild-type or mutant receptors were preincubated with\
        \ (F178L) or without (F178A and F178W) 1 M NBI-42902 for 48 h and then washed\
        \ prior to the binding assay.///Details are given under \u201CExperimental\
        \ Procedures.\u201D Normalized competitive binding of GnRH I (A), GnRH II\
        \ (B), and [Phe3]GnRH I (C) at the wild-type f, F174A \u0152, F178L F, and\
        \ F178W receptors.///GnRH I Mutant WT WT NBI-42902a P173A Q174A L175A NBI-42902a\
        \ Y176A I177A F178A F178L NBI-42902a F178W R179A NBI-42902a M180A 8.77 8.74\
        \ 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53 7.79 pEC50 Emax pEC50 GnRH\
        \ II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8) 0.17 (41.2) 0.18 (27.7)\
        \ 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11 (139) 0.26 (5.1) 0.15\
        \ (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17 4 105 23 82 18 46 8 59\
        \ 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44 6.86 7.05 7.35 0.07\
        \ (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1) 0.01 (153) 0.12 (94.6)\
        \ 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14 (45.1) 100 92 7 82\
        \ 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21 a Pretreated with\
        \ NBI-42902.///Mutation of Phe178 to Leu gave intermediate decreases of potency\
        \ with 82- and 181-fold increases in the EC50, whereas mutation of Phe178\
        \ to Trp had only a small effect on potency with 3- and 7-fold increases in\
        \ the EC50 values.///A similar phenotype was also observed for GnRH II, derived\
        \ from the calculated Emax, which could not be measured accurately because\
        \ of the solubility limit of the maximum GnRH II concentration (10 5 M) to\
        \ be used for F178A and F178L (Fig. 6B and Table 3).", pubmed: '21832286',
    seq: '178', to_res: L}
- {entry_name: gnrhr_human, from_res: R, info: "The mutants P173A, L175A, Y176A, and\
        \ R179A gave 3\u2013 6-fold increases in OCTOBER 7, 2011 \u2022 VOLUME 286\
        \ \u2022 NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 34619 Role of GnRHR ECL2\
        \ in Ligand-induced Selective Conformations TABLE 1 Binding of GnRH ligands\
        \ to wild-type and mutant human GnRH receptors Ligand binding affinity (pIC50)\
        \ was measured on intact COS-7 cells at 48 h after transfection with wild-type\
        \ and mutant receptors by competition binding assays using 125 I-Teverelix\
        \ as a radioligand with increasing concentrations of unlabeled GnRH ligands.///Binding\
        \ Mutant WT WT NBI-42902a P173A Q174A L175A L175A NBI-42902a Y176A I177A F178A\
        \ F178L F178L NBI-42902a F178W R179A R179A NBI-42902a M180A Rexp Teverelix\
        \ 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11\
        \ (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9) 0.20 (15.1) 0.20 (12.5) 0.09 (4.2)\
        \ 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47 (16.3) 0.03 (10.1) 8.47 8.57 7.77\
        \ 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68 UD 7.96 7.48 GnRH I GnRH II 7.28\
        \ 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD 5.34 6.90 UD 7.10 7.57 0.09 (52.5)\
        \ 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12 (33.7) 0.32 (221) 0.04 (16.1) 0.10\
        \ (26600) 0.08 (4530) 0.05 (125) % WT pIC50 (nM) 100 164 24 41 6 51 10 12\
        \ 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8 6 31 9 45 8 0.09 (3.4) 0.05 (2.7)\
        \ 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03 (7.0) 0.03 (9.1) 0.02 (9310) 0.39\
        \ (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1) Downloaded from www.jbc.org at\
        \ Edinburgh University Library, on March 19, 2012 0.31 (80.3) 0.01 (26.6)\
        \ a Pretreated with NBI-42902.///Binding Mutant WT WT NBI-42902a P173A Q174A\
        \ L175A L175A NBI-42902a Y176A I177A F178A F178L F178L NBI-42902a F178W R179A\
        \ R179A NBI-42902a M180A Rexp Teverelix 8.34 8.38 7.57 8.31 UD 7.82 7.90 8.37\
        \ 8.23 UD 8.22 8.16 UD 7.79 8.00 0.11 (4.6) 0.18 (4.2) 0.12 (26.8) 0.18 (4.9)\
        \ 0.20 (15.1) 0.20 (12.5) 0.09 (4.2) 0.11 (5.9) 0.19 (6.0) 0.13 (7.0) 0.47\
        \ (16.3) 0.03 (10.1) 8.47 8.57 7.77 7.52 UD 8.29 8.16 8.04 5.03 UD 6.71 7.68\
        \ UD 7.96 7.48 GnRH I GnRH II 7.28 7.28 6.40 6.39 UD 7.47 6.66 7.79 4.58 UD\
        \ 5.34 6.90 UD 7.10 7.57 0.09 (52.5) 0.09 (52.1) 0.22 (401) 0.29 (404) 0.12\
        \ (33.7) 0.32 (221) 0.04 (16.1) 0.10 (26600) 0.08 (4530) 0.05 (125) % WT pIC50\
        \ (nM) 100 164 24 41 6 51 10 12 1 45 6 26 5 77 24 324 40 23 3 78 1 55 8 8\
        \ 6 31 9 45 8 0.09 (3.4) 0.05 (2.7) 0.13 (17.1) 0.11 (30.3) 0.26 (5.1) 0.03\
        \ (7.0) 0.03 (9.1) 0.02 (9310) 0.39 (195) 0.03 (21.0) 0.39 (11.1) 0.06 (33.1)\
        \ Downloaded from www.jbc.org at Edinburgh University Library, on March 19,\
        \ 2012 0.31 (80.3) 0.01 (26.6) a Pretreated with NBI-42902.///The cell surface\
        \ expression levels of the mutants with greatly reduced Rexp (less than one-fourth\
        \ of the wild type: L175A, F178L, and R179A mutant receptors) were rescued\
        \ by a non-peptide antagonist, NBI-42902 (26).///GnRH I Mutant WT WT NBI-42902a\
        \ P173A Q174A L175A NBI-42902a Y176A I177A F178A F178L NBI-42902a F178W R179A\
        \ NBI-42902a M180A 8.77 8.74 7.39 7.56 8.41 7.82 8.50 6.41 6.86 8.30 8.53\
        \ 7.79 pEC50 Emax pEC50 GnRH II Emax (nM) % WT (nM) % WT 0.11 (1.7) 0.08 (1.8)\
        \ 0.17 (41.2) 0.18 (27.7) 0.06 (3.9) 0.11 (15.0) 0.34 (3.1) 0.10 (386) 0.11\
        \ (139) 0.26 (5.1) 0.15 (3.0) 0.08 (16.4) 100 86 10 79 8 81 4 60 8 37 3 17\
        \ 4 105 23 82 18 46 8 59 4 82 2 7.70 7.69 6.10 6.33 7.66 6.81 7.02 4.71 5.44\
        \ 6.86 7.05 7.35 0.07 (20.1) 0.04 (20.4) 0.12 (787) 0.12 (464) 0.04 (22.1)\
        \ 0.01 (153) 0.12 (94.6) 0.24 (19400) 0.16 (3640) 0.25 (138) 0.17 (90.2) 0.14\
        \ (45.1) 100 92 7 82 10 90 1 59 7 31 7 17 8 103 79 46 15 39 15 45 14 70 21\
        \ a Pretreated with NBI-42902.///Two mutations, L175A and R179A, had a destabilized\
        \ effect on the receptor structure, reflected by the strongly decreased receptor\
        \ cell surface expression level to less than 80% of the wild-type level that\
        \ could be rescued by NBI-42902.", pubmed: '21832286', seq: '179', to_res: A}
- {entry_name: fshr_human, from_res: L, info: "In contrast, substitution of leucine\
        \ 148 with basic (L148R) or 50 kDa acidic residues (L148E) impaired G\u03B1\
        q GPR54 function even more severely than that of the disease-causing L148S\
        \ mutant.///Indeed, the interaction affinity acid (L148E hGPR54), arginine\
        \ (L148R hGPR54), alanine between G q and IL2 was remarkably strong, since\
        \ stringent (L148A hGPR54), phenylalanine (L148F hGPR54), or threo- washes\
        \ with up to 900 mM NaCl did not disrupt binding (data nine (L148T hGPR54)\
        \ in hGPR54-GFP.", pubmed: '18772143', seq: '148', to_res: R}
- {entry_name: fshr_human, from_res: L, info: "Replacement of leucine 50 kDa 50 kDa\
        \ HA-G\u03B115/16 148 with small (L148A) or aromatic G\u03B1q (L148F) amino\
        \ acids caused a minor decrease in GPR54 functional reIL2 25 kDa sponses.///Indeed,\
        \ the interaction affinity acid (L148E hGPR54), arginine (L148R hGPR54), alanine\
        \ between G q and IL2 was remarkably strong, since stringent (L148A hGPR54),\
        \ phenylalanine (L148F hGPR54), or threo- washes with up to 900 mM NaCl did\
        \ not disrupt binding (data nine (L148T hGPR54) in hGPR54-GFP.///However,\
        \ in contrast to previous findings where mutation of IL2-10 to alanine abolished\
        \ GPCR functional coupling (14, 16, 19), we demonstrated that the L148A GPR54\
        \ mutant displayed only moderately decreased functional responses to kisspeptin.",
    pubmed: '18772143', seq: '148', to_res: A}
- {entry_name: fshr_human, from_res: L, info: "Replacement of leucine 50 kDa 50 kDa\
        \ HA-G\u03B115/16 148 with small (L148A) or aromatic G\u03B1q (L148F) amino\
        \ acids caused a minor decrease in GPR54 functional reIL2 25 kDa sponses.///Indeed,\
        \ the interaction affinity acid (L148E hGPR54), arginine (L148R hGPR54), alanine\
        \ between G q and IL2 was remarkably strong, since stringent (L148A hGPR54),\
        \ phenylalanine (L148F hGPR54), or threo- washes with up to 900 mM NaCl did\
        \ not disrupt binding (data nine (L148T hGPR54) in hGPR54-GFP.", pubmed: '18772143',
    seq: '148', to_res: F}
- {entry_name: fshr_human, from_res: L, info: "A point mutation (L148S) in the second\
        \ intracellular loop (IL2) of GPR54 causes idiopathic hypogonadotropic hypogonadism,\
        \ a disorder characterized by delayed puberty and infertility.///Here, we\
        \ characterize the molecular mechanism by which the L148S mutation causes\
        \ disease and address the role of IL2 in Class A GPCR function.///In contrast,\
        \ diverse GPR54 functional responses are markedly inhibited by the L148S mutation.///Indeed,\
        \ mutating the corresponding leucine of the 1A-AR recapitulates the effects\
        \ observed with L148S GPR54, suggesting the critical importance of this hydrophobic\
        \ IL2 residue for Class A GPCR functional coupling.///Interestingly, co-immunoprecipitation\
        \ studies indicate that L148S does not hinder the association of G subunits\
        \ with GPR54.///However, fluorescence resonance energy transfer analysis strongly\
        \ suggests that L148S impairs the ligand-induced catalytic activation of G\
        \ .///In an elegant study, Seminara et al. (7) demonstrated that a single\
        \ leucine to serine (L148S) mutation in the second intracellular loop (IL2)\
        \ of GPR54 causes autosomal recessive IHH in humans.///At the physiochemical\
        \ level, the L148S mutation results in the substitution of a hydrophobic with\
        \ a hydrophilic Downloaded from www.jbc.org at Edinburgh University Library,\
        \ on March 19, 2012 * This work was supported, in whole or in part, by National\
        \ Institutes of Health Grant T32 HD07453 (to J. L. W.); NIGMS National Research\
        \ Service Award T32 GM07270 (to J. S. L.); T32 GM07750 (to M. C. D.); and\
        \ T32 GM07108, RO1 NS08174 (BH), and U54HD12629 (to J. B. J.).///Although\
        \ the L148S GPR54 mutant displayed diminished functional responses in vitro,\
        \ whether these deficits were due to improper expression, trafficking to the\
        \ plasma membrane, or ligandbinding capacity was not examined (7) and remains\
        \ an important unexplored question.///Herein, we utilize biochemical and pharmacological\
        \ techniques to elucidate the molecular mechanism by which the clinically\
        \ relevant L148S mutation of GPR54 causes disease and assess the importance\
        \ of this IL2 residue for proper Class A GPCR-G-protein coupling.///Specifically,\
        \ we have developed an in vitro model to ascertain whether the L148S mutation\
        \ causes defects in the expression, trafficking, or signaling and/or alters\
        \ the protein interaction network of GPR54.///Importantly, characterization\
        \ of L148S hGPR54 revealed that conserved residues in the IL2 of Class A GPCRs\
        \ are essential for functional interactions between the GPCR and G-protein,\
        \ specifically G .///QuikChange site-directed mutagenesis (Stratagene, La\
        \ Jolla, CA) was used to introduce the L148S mutation into hGPR54 and L132S\
        \ mutation into the human 1A-AR and to create various Leu148 amino acid substitutions.///Stable\
        \ HEK293 cell lines expressing wild type (WT) or L148S hGPR54 were lysed overnight\
        \ in buffer containing 1% digitonin.///This cut-off provided a sensitivity\
        \ of 0.744 and 0.737 for WT hGPR54 and L148S hGPR54, respectively, and an\
        \ error rate of 0.074 and 0.064 for WT hGPR54 and L148S hGPR54, respectively.///This\
        \ cut-off provided a sensitivity of 0.744 and 0.737 for WT hGPR54 and L148S\
        \ hGPR54, respectively, and an error rate of 0.074 and 0.064 for WT hGPR54\
        \ and L148S hGPR54, respectively.///Co-immunoprecipitation of GPR54 and Gq\
        \ Family Members- 150-mm plates of HEK293 cells were transiently transfected\
        \ with TAP-WT or L148S hGPR54 and G q or G 15/16.///Co-purification of GPR54\
        \ IL2 and G q-An overlapping primer strategy was used to clone the WT and\
        \ L148S hGPR54 IL2 into a pGEX-2T-based, N-terminal GST expression vector.///Downloaded\
        \ from www.jbc.org at Edinburgh University Library, on March 19, 2012 RESULTS\
        \ L148S hGPR54 Expression, Localization, and Ligand Binding Are Equivalent\
        \ to Those of WT hGPR54-To address the mechanism by which a single L148S amino\
        \ acid conversion results in GPR54 loss of function, we compared the expression,\
        \ localization, and pharmacological characteristics of L148S and WT GPR54.///Downloaded\
        \ from www.jbc.org at Edinburgh University Library, on March 19, 2012 RESULTS\
        \ L148S hGPR54 Expression, Localization, and Ligand Binding Are Equivalent\
        \ to Those of WT hGPR54-To address the mechanism by which a single L148S amino\
        \ acid conversion results in GPR54 loss of function, we compared the expression,\
        \ localization, and pharmacological characteristics of L148S and WT GPR54.///Downloaded\
        \ from www.jbc.org at Edinburgh University Library, on March 19, 2012 RESULTS\
        \ L148S hGPR54 Expression, Localization, and Ligand Binding Are Equivalent\
        \ to Those of WT hGPR54-To address the mechanism by which a single L148S amino\
        \ acid conversion results in GPR54 loss of function, we compared the expression,\
        \ localization, and pharmacological characteristics of L148S and WT GPR54.///We\
        \ thus generated polyclonal HEK293 cell lines stably expressing WT or L148S\
        \ mutant human GPR54 (L148S hGPR54) with either N-terminal (HA or FLAG) or\
        \ C-terminal (GFP) epitope tags.///We thus generated polyclonal HEK293 cell\
        \ lines stably expressing WT or L148S mutant human GPR54 (L148S hGPR54) with\
        \ either N-terminal (HA or FLAG) or C-terminal (GFP) epitope tags.///Immunoprecipitation\
        \ of WT and L148S hGPR54-GFP showed that both WT and mutant receptors were\
        \ expressed at the expected molecular mass of 70 kDa, demonstrating that the\
        \ mutation does not interfere with protein expression (Fig. 1A).///Confocal\
        \ analysis revealed that WT and L148S hGPR54-GFP cellular localization patterns\
        \ were indistinguishable, suggesting that the L148S mutation does not cause\
        \ trafficking or expression deficits of GPR54 (Fig. 1B).///Confocal analysis\
        \ revealed that WT and L148S hGPR54-GFP cellular localization patterns were\
        \ indistinguishable, suggesting that the L148S mutation does not cause trafficking\
        \ or expression deficits of GPR54 (Fig. 1B).///To obtain a quantitative measurement\
        \ of plasma membrane expression, we employed fluorescence-activated cell sorting\
        \ analysis to detect the N-terminal HA tag of WT and L148S hGPR54.///As shown\
        \ in Fig. 1C, the cell surface expression of L148S HA-hGPR54 was statistically\
        \ equivalent to WT HA-hGPR54 (Fig. 1C), suggesting that this mutation does\
        \ not prevent GPR54 from reaching the plasma membrane in vitro.///To address\
        \ the potential effects of this mutation on ligand binding, we performed 125I-labeled\
        \ KP-10 saturation radioligand binding assays on HEK293 cells stably expressing\
        \ WT and L148S hGPR54.///Saturation analysis demonstrated that L148S hGPR54\
        \ bound 125I-labeled KP-10 in a manner indistinguishable from the WT receptor\
        \ (Fig. 1D).///A single, high affinity binding site with comparable equilibrium\
        \ dissociation constants was identified in cells expressing both WT (KD 1.6\
        \ nM) and L148S hGPR54 (KD 2.5 nM).///The L148S mutation does not alter the\
        \ expression, localization, or ligand-binding properties of hGPR54.///A, immunoprecipitation\
        \ of WT and L148S hGPR54-GFP.///B, confocal microscopy showing the localization\
        \ of WT and L148S hGPR54-GFP.///C, cell surface expression levels of WT and\
        \ L148S HA-hGPR54 measured using fluorescence-activated cell sorting analysis.///D,\
        \ saturation binding of 125I-labeled KP-10 to membranes from WT and L148S\
        \ hGPR54 expressing HEK293 cells.///IP, immunoprecipitation; IB, immunoblot.\
        \ tively, data obtained with multiple, independent techniques demonstrate\
        \ that L148S GPR54 loss-of-function cannot be accounted for by defects in\
        \ receptor expression, trafficking, or ligand-binding properties.///The L148S\
        \ Mutation Does Not Alter the Protein Interaction Network of GPR54-GPCRs are\
        \ now recognized to exist as multiprotein complexes composed of GPCR-interacting\
        \ proteins (GIPs) that impart precise spatial and temporal regulation of expression,\
        \ trafficking, ligand binding, and signaling (32).///We hypothesized that\
        \ alterations in the protein interaction network of GPR54 caused by the L148S\
        \ mutation might result in the clinical manifestation of IHH.///TAP/MS data\
        \ of isolated WT and L148S hGPR54 complexes identified both previously suspected\
        \ and novel interacting proteins involved in signal transduction, protein\
        \ quality control, trafficking, and transcriptional regulation (selected GIPs\
        \ presented in Table 1).///Importantly, direct comparison of WT and L148S\
        \ hits suggested that the mutation did not alter the protein interactome of\
        \ GPR54.///To perform a functional comparison, we created a study set of all\
        \ identified WT and L148S GPR54 GIPs using Gene Ontology annotations to proteins\
        \ in the UniProt Knowledgebase and performed an automated classification to\
        \ assign WT and L148S hGPR54 GIPs into categories for cellular localization,\
        \ involvement in a biologNOVEMBER 7, 2008 \u2022 VOLUME 283 \u2022 NUMBER\
        \ 45 JOURNAL OF BIOLOGICAL CHEMISTRY 31071 Leu148 of GPR54 Is a Critical G-protein\
        \ Interaction Site TABLE 1 Proteins associated with WT and L148S hGPR54 TAP-WT\
        \ hGPR54 and TAP-L148S hGPR54 were purified from HEK293 cells and analyzed\
        \ by mass spectrometry.///To perform a functional comparison, we created a\
        \ study set of all identified WT and L148S GPR54 GIPs using Gene Ontology\
        \ annotations to proteins in the UniProt Knowledgebase and performed an automated\
        \ classification to assign WT and L148S hGPR54 GIPs into categories for cellular\
        \ localization, involvement in a biologNOVEMBER 7, 2008 \u2022 VOLUME 283\
        \ \u2022 NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 31071 Leu148 of GPR54 Is\
        \ a Critical G-protein Interaction Site TABLE 1 Proteins associated with WT\
        \ and L148S hGPR54 TAP-WT hGPR54 and TAP-L148S hGPR54 were purified from HEK293\
        \ cells and analyzed by mass spectrometry.///To perform a functional comparison,\
        \ we created a study set of all identified WT and L148S GPR54 GIPs using Gene\
        \ Ontology annotations to proteins in the UniProt Knowledgebase and performed\
        \ an automated classification to assign WT and L148S hGPR54 GIPs into categories\
        \ for cellular localization, involvement in a biologNOVEMBER 7, 2008 \u2022\
        \ VOLUME 283 \u2022 NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 31071 Leu148\
        \ of GPR54 Is a Critical G-protein Interaction Site TABLE 1 Proteins associated\
        \ with WT and L148S hGPR54 TAP-WT hGPR54 and TAP-L148S hGPR54 were purified\
        \ from HEK293 cells and analyzed by mass spectrometry.///To perform a functional\
        \ comparison, we created a study set of all identified WT and L148S GPR54\
        \ GIPs using Gene Ontology annotations to proteins in the UniProt Knowledgebase\
        \ and performed an automated classification to assign WT and L148S hGPR54\
        \ GIPs into categories for cellular localization, involvement in a biologNOVEMBER\
        \ 7, 2008 \u2022 VOLUME 283 \u2022 NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY\
        \ 31071 Leu148 of GPR54 Is a Critical G-protein Interaction Site TABLE 1 Proteins\
        \ associated with WT and L148S hGPR54 TAP-WT hGPR54 and TAP-L148S hGPR54 were\
        \ purified from HEK293 cells and analyzed by mass spectrometry.///Hits shown\
        \ displayed a peptide prophet score of greater than 0.65 for both WT and L148S\
        \ hGPR54.///Swiss-Prot accession number Protein identity WT GPR54 Hits Coverage\
        \ L148S GPR54 Hits Coverage % % Bait protein Q969F8 Signal Transduction Q9NQ66\
        \ P68104 Protein quality control O75477 O95816 P07339 P11142 Q9Y385 Trafficking\
        \ Q9P0L0 Transcriptional Regulation Q6AW86 Q53AQ2 Q9NWT6 Other P29508 P31025\
        \ Q02413 Q6IB90 Unknown Q71RG4 Q9BVC6 G-protein-coupled receptor 54 (GPR54)\
        \ Phospholipase C 1 (PLC 1) Elongation factor 1 1 (EEF1A1) ER lipid raft-associated\
        \ protein 1 (ERLIN1, SPFH1) BAG family molecular chaperone regulator 2 (BAG2)\
        \ Cathepsin D precursor (CSTD) Heat shock cognate 71-kDa protein (HSPA8, HSC70)\
        \ Ubiquitin-conjugating enzyme 1 (UB2J1) Vesicle-associated membrane protein-associated\
        \ protein A (VAPA) Zinc finger protein 324B (ZNF324B) Hepatocyte odd protein\
        \ shuttling protein (HOPS) Hypoxia-inducible factor 1 inhibitor (HIF1AN) SERPINB3\
        \ Lipocalin-1 (LCN1) Desmoglein-1 precursor (DSG1) Cystatin A (CSTA) Transmembrane\
        \ and ubiquitin-like domain-containing protein 2 (TMUB2) Transmembrane protein\
        \ 109 (TMEM109) 2 1 7 2 2 1 5 1 9 2 1 6 2 1 2 4 1 1 1 1 1 1 1 27 5 4 11 5\
        \ 6 1 17 2 3 4 2 23 7 5 21 2 2 1 5 3 1 5 1 4 2 1 2 2 2 34 5 4 2 9 12 1 22\
        \ 2 8 4 2 28 7 10 Downloaded from www.jbc.org at Edinburgh University Library,\
        \ on March 19, 2012 ical process, and molecular function.///Functional comparison\
        \ of WT and L148S hGPR54 clearly demonstrated equivalent GIP profiles (Fig.\
        \ S1), suggesting that the L148S mutation does not significantly alter the\
        \ proteomic network of GPR54.///Functional comparison of WT and L148S hGPR54\
        \ clearly demonstrated equivalent GIP profiles (Fig. S1), suggesting that\
        \ the L148S mutation does not significantly alter the proteomic network of\
        \ GPR54.///Leucine 148 of GPR54 Is a Critical Regulator of G-protein Coupling-To\
        \ determine the impact of the L148S mutation on functional coupling of GPR54,\
        \ we next utilized the PI hydrolysis assay to generate concentration-response\
        \ curves for the full agonists, KP-54 and KP-10.///In contrast, L148S hGPR54\
        \ demonstrated 90% decreases in KP-10- and KP-54-stimulated maximal responses\
        \ (Fig. 2, A\u2013D).///Although the low coupling efficiency of L148S hGPR54\
        \ precluded determination of EC50 values, we observed that KP-10 displayed\
        \ a slightly higher intrinsic activity (IA 0.1) than KP-54 (IA 0.06) for the\
        \ mutant receptor (Fig. 2, A\u2013D).///To determine whether the L148S hGPR54\
        \ functional deficits could be reproduced with a different functional readout,\
        \ the ability of KP-10 to stimulate ERK1/2 activation was compared between\
        \ WT and L148S hGPR54 using a high throughput 96-well in-cell Western assay.///To\
        \ determine whether the L148S hGPR54 functional deficits could be reproduced\
        \ with a different functional readout, the ability of KP-10 to stimulate ERK1/2\
        \ activation was compared between WT and L148S hGPR54 using a high throughput\
        \ 96-well in-cell Western assay.///Similar to the PI hydrolysis experimental\
        \ results, L148S hGPR54 displayed 90% reductions in KP-10 intrinsic activity\
        \ for ERK1/2 activation (Fig. 2E).///Equivalent to the results of the L148S\
        \ hGPR54 functional analysis, the L132S 1A-AR mutation markedly decreased\
        \ the potency (WT EC50 76 nM; L132S 1.5 M) and intrinsic activity (L132S IA\
        \ 0.4) of phenylephrine (Fig. 3C).///A and B, the L148S mutation decreased\
        \ the intrinsic activity as measured by PI hydrolysis in response to KP-54\
        \ (A) or KP-10 (B) of FLAG-hGPR54 cells.///C and D, the L148S mutation also\
        \ decreased the intrinsic activity, measured by PI hydrolysis in response\
        \ to KP-54 (C) or KP-10 (D) of hGPR54-GFP cells.///E, KP-10-mediated ERK activation\
        \ was suppressed in L148S hGPR54-GFP cells.///A B GPR54/\u03B22-AR GPR54/\u03B2\
        2-AR Structural Modeling of Class A GPCR/G-protein Coupling- The observed\
        \ functional deficits of the L148S GPR54 and L132S 1A-AR mutants led us to\
        \ examine the potential structural role of the conserved hydrophobic IL2-10\
        \ residue in G-protein activation.///NOVEMBER 7, 2008 \u2022 VOLUME 283 \u2022\
        \ NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 31073 Leu148 of GPR54 Is a Critical\
        \ G-protein Interaction Site cells expressing individual hGPR54GFP variants\
        \ were stimulated with 1 L148S IL2 M KP-10 and assayed for PI hydrolysis (Fig.\
        \ 4D).///In contrast, substitution of leucine 148 with basic (L148R) or 50\
        \ kDa acidic residues (L148E) impaired G\u03B1q GPR54 function even more severely\
        \ than that of the disease-causing L148S mutant.///The L148S mutation does\
        \ not abolish G-protein binding, and overexpression of G-proteins partially\
        \ rescues the functional deficits of IL2-10 mutants.///A, in E. coli, both\
        \ WT and L148S mutant GST- major disruption of hydrophobicity hGPR54 IL2 fusion\
        \ proteins co-purify with G q.///B, co-immunoprecipi- at position 148 via\
        \ the introduction tation experiments reveal that both TAP-WT hGPR54 and TAP-L148S\
        \ hGPR54 proteins pull down G q and of a highly exposed hydroxyl (OH) G 15/16.///C,\
        \ overexpression of G 15/16 DNA in L148S hGPR54-GFP cells leads to a concentration-dependent\
        \ rescue of functional coupling, as measured by PI hydrolysis.///L148S hGPR54\
        \ results (C) are normalized to the WT group or a charged amino acid will\
        \ response to 1 M KP-10, which was set at 100%.///Inset, Western blot shows\
        \ that increasing the amount of G 15/16 significantly impair GPR54 funcDNA\
        \ transfected increases the relative levels of G 15/16 protein in L148S hGPR54-GFP\
        \ cells.///Affected by the L148S Mutation?-It has been proposed that upon\
        \ agothe orientation of IL2 that enables Phe139 to fit into a hydropho- nist\
        \ binding, GPCRs interact with G-proteins through a casbic groove that is\
        \ created by the 2/ 4 loop and the 3/ 5 loop cade of sequential protein-protein\
        \ interactions, yet the precise of G q (Fig. 4B).///Thus far, our experimental\
        \ evihydrophobic interactions with highly conserved G residues dence examining\
        \ the mechanism by which L148S uncouples Phe220 and Val223 that immediately\
        \ follow switch II, as well as GPR54 suggests that the IL2 is a critical determinant\
        \ in G-proPhe264 and Trp263.///However, we are unsure if L148S could interfere\
        \ the 2-AR IL3 lies in close proximity to the C-terminal 4 helix with either\
        \ the binding of G q to GPR54 or the catalytic actiand 6 loop of G q (Fig.\
        \ 4C).///To address the possibility that L148S is highlight the potential\
        \ importance of both IL2 and IL3 in estab- affecting G q/GPR54 binding, we\
        \ first determined whether lishing multisite structural interactions between\
        \ GPCRs and G q directly interacts with purified hGPR54-IL2.///Thus, GST G-proteins\
        \ to promote efficient functional coupling. fusions of WT and L148S hGPR54\
        \ IL2 were generated and coMutational Analysis of GPR54 Amino Acid 148-Cumula-\
        \ expressed in E. coli with His-G q.///Strikingly, the interaction between\
        \ GPR54 IL2 and imaging verified that the expression pattern of each GPR54\
        \ var- G q was completely unaffected by the L148S mutation (Fig. iant was\
        \ indistinguishable from WT hGPR54-GFP in HEK293 5A), suggesting that the\
        \ mechanism by which this mutation cells (data not shown).///Next, transiently\
        \ transfected HEK293 uncouples functional responses is not due to abrogating\
        \ GPCR/ A B GST alone WT IL2 WT L148S \u03BCg 5 25 2. \u03BCg Downloaded from\
        \ www.jbc.org at Edinburgh University Library, on March 19, 2012 31074 JOURNAL\
        \ OF BIOLOGICAL CHEMISTRY VOLUME 283 \u2022 NUMBER 45 \u2022 NOVEMBER 7, 2008\
        \ Leu148 of GPR54 Is a Critical G-protein Interaction Site G q interactions.///Similar\
        \ to our results using purified GST fusion constructs, we found that the ability\
        \ of GPR54 to bind G q or G 15/16 was unaltered by L148S (Fig. 5B), again\
        \ suggesting that mutation does not alter the G binding affinity to GPR54.///Overexpression\
        \ of G Subunits Can Partially Rescue the Functional Deficits of IL-10 Mutants-We\
        \ previously observed minimal activity of L148S GPR54 and L132S 1A-AR at saturating\
        \ concentrations of agonist.///Combined with our results demonstrating that\
        \ the L148S mutation did not disrupt G-protein docking, we speculated that\
        \ flooding the cells with high levels of G-proteins might compensate for the\
        \ apparent catalytic defect of the IL2-10 GPCR mutants.///Indeed, overexpression\
        \ of increasing concentrations of G 15/16 partially rescued the functional\
        \ deficits of L148S hGPR54, measured by KP-10-stimulated PI hydrolysis (Fig.\
        \ 5C).///Reminiscent of our results with L148S hGPR54, L132S 1A-AR coupling\
        \ to PI hydrolysis increased by 20% in the presence of overexpressed G q,\
        \ and again, no effect of G q overexpression was observed with WT 1A-AR.///The\
        \ L148S Mutation of GPR54 Inhibits the Catalytic Activation of G q-Next, we\
        \ utilized a novel FRET assay to investigate whether the L148S mutation inhibits\
        \ catalytic activation of the G q subunit by GPR54.///The L148S Mutation of\
        \ GPR54 Inhibits the Catalytic Activation of G q-Next, we utilized a novel\
        \ FRET assay to investigate whether the L148S mutation inhibits catalytic\
        \ activation of the G q subunit by GPR54.///This assay allows one to monitor\
        \ the kinetics of G-protein activation in real time for WT and L148S hGPR54,\
        \ as determined by the structural rearrangement of the G-protein heterotrimer,\
        \ specifically the liberation of G subunits from the activated G subunit,\
        \ that occurs in response to GPR54 activation by kisspeptin.///We transiently\
        \ transfected HEK293 cells with WT or L148S hGPR54, G q-CFP, G 1-YFP, G 2,\
        \ and GRK2 and examined the resting FRET ratio between G q-CFP and G 1-YFP\
        \ (Fig. 6A).///Next, we measured the average resting FRET ratios for WT (0.37\
        \ 0.03) and L148S (0.32 0.02) hGPR54 (Fig. 6, C and D).///In sharp contrast,\
        \ KP-10 treatment of L148S hGPR54 cells caused no change in the FRET ratio\
        \ (Fig. 6, C and D).///These results demonstrate that the L148S Downloaded\
        \ from www.jbc.org at Edinburgh University Library, on March 19, 2012 FIGURE\
        \ 6.///The L148S mutation abolishes the agonist-induced catalytic activation\
        \ of G q by GPR54.///B, representative confocal microscopy images showing\
        \ the membrane localization of G q-CFP and G 1-YFP in both WT hGPR54 (top)\
        \ and L148S hGPR54 (bottom) cells.///D, averaged FRET data from 11\u201313\
        \ cells from three distinct experiments expressing either WT or L148S hGPR54.///WT\
        \ hGPR54 shows a robust decrease in FRET in response to KP-10, whereas L148S\
        \ hGPR54 fails to respond.///Due to the overwhelming percentage of disease-causing\
        \ GPCR mutations that result in inefficient plasma membrane expression, we\
        \ suspected that the L148S mutation of GPR54 might cause intracellular retention\
        \ and thus explain the etiology of IHH.///However, in the present study, we\
        \ determined that the L148S GPR54 mutant retains normal expression, localization,\
        \ and kisspeptin binding properties.///Moreover, the protein interaction network\
        \ of GPR54 is unaltered by the L148S mutation, demonstrating that the mutant\
        \ protein is not directed toward the cellular protein degradation machinery.///Instead,\
        \ we find that L148S GPR54 is essentially uncoupled from all functional responses,\
        \ since the mutant receptor neither initiates G-protein dissociation nor activates\
        \ phospholipase C or ERK1/2.///Interestingly, in contrast to the L148S mutant,\
        \ L148T GPR54 (threonine hydropathy score 0.75) displayed nearly a WT functional\
        \ response, indicating that the methyl group may sufficiently buffer the detrimental\
        \ effect of the hydroxyl group on the hydrophobic environment of IL2.///Interestingly,\
        \ we observed that saturating agonist concentrations elicited minor increases\
        \ in functional activity for both the L148S GPR54 and L132S 1A-AR mutants\
        \ and that overexpressing G partially rescued L148S GPR54 and L132S 1A-AR\
        \ functional responses.///Interestingly, we observed that saturating agonist\
        \ concentrations elicited minor increases in functional activity for both\
        \ the L148S GPR54 and L132S 1A-AR mutants and that overexpressing G partially\
        \ rescued L148S GPR54 and L132S 1A-AR functional responses.///Although increasing\
        \ the relative concentration of G subunits caused minor increases in functional\
        \ coupling, we were unable to obtain even a modest rescue of L148S GPR54 or\
        \ L132S 1A-AR function, indicating that increasing the concentration of reactants\
        \ 25-fold is unable to compensate for the deficits in G-protein engagement.///Our\
        \ Downloaded from www.jbc.org at Edinburgh University Library, on March 19,\
        \ 2012 31076 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283 \u2022 NUMBER 45 \u2022\
        \ NOVEMBER 7, 2008 Leu148 of GPR54 Is a Critical G-protein Interaction Site\
        \ immunoprecipitation data show that the L148S mutation does not affect the\
        \ ability of GPR54 to bind G ; thus, it is more likely that the structural\
        \ disruption caused by the introduction of a hydrophilic residue into a hydrophobic\
        \ environment alters the catalytic activation of G .///Accordingly, our FRET\
        \ data demonstrate a clear defect of the L148S GPR54 in catalytically engaging\
        \ the G subunit to promote G-protein activation and functional coupling.///In\
        \ conclusion, our characterization of the IHH-causing L148S GPR54 mutant has\
        \ revealed fundamental concepts concerning GPCR/G-protein signaling.", pubmed: '18772143',
    seq: '148', to_res: S}
- {entry_name: fshr_human, from_res: L, info: "In contrast, substitution of leucine\
        \ 148 with basic (L148R) or 50 kDa acidic residues (L148E) impaired G\u03B1\
        q GPR54 function even more severely than that of the disease-causing L148S\
        \ mutant.///Indeed, the interaction affinity acid (L148E hGPR54), arginine\
        \ (L148R hGPR54), alanine between G q and IL2 was remarkably strong, since\
        \ stringent (L148A hGPR54), phenylalanine (L148F hGPR54), or threo- washes\
        \ with up to 900 mM NaCl did not disrupt binding (data nine (L148T hGPR54)\
        \ in hGPR54-GFP.", pubmed: '18772143', seq: '148', to_res: E}
- {entry_name: cxcr3_human, from_res: Y, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.', pubmed: '17170198', seq: '271', to_res: N}
- {entry_name: cxcr3_human, from_res: Y, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '271', to_res: A}
- {entry_name: cxcr3_human, from_res: Y, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.', pubmed: '17170198', seq: '271', to_res: L}
- {entry_name: cxcr3_human, from_res: D, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '278', to_res: N}
- {entry_name: cxcr3_human, from_res: R, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.', pubmed: '17170198', seq: '212', to_res: H}
- {entry_name: cxcr3_human, from_res: Y, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '308', to_res: A}
- {entry_name: cxcr3_human, from_res: G, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '128', to_res: H}
- {entry_name: cxcr3_human, from_res: K, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '300', to_res: A}
- {entry_name: cxcr3_human, from_res: W, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '268', to_res: A}
- {entry_name: cxcr3_human, from_res: Y, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.', pubmed: '17170198', seq: '271', to_res: F}
- {entry_name: cxcr3_human, from_res: R, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '212', to_res: A}
- {entry_name: cxcr3_human, from_res: F, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '131', to_res: A}
- {entry_name: cxcr3_human, from_res: H, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.', pubmed: '17170198', seq: '202', to_res: A}
- {entry_name: cxcr3_human, from_res: D, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.///Cu(II)-Bipyridine EC50 Kd M n Fdec. -fold EC50 Zn(II)-Bipyridine
        Kd M n Fdec. -fold Cu(II)-Phenanthroline EC50 Kd nM n Fdec. -fold III:05 Background
        III:08 IV:20 V:01; V:05 VI:13 VI:16 VI:23 VII:02 VII:10 G128H F131A D186N
        R208A;R212A W268A Y271A D278N K300A Y308A 4.7 2.8 3.1 4.9 4.3 3.1 4.3 4.7
        3.2 0.11 0.09 0.43 0.04 0.08 0.21 0.12 0.09 0.45 22 1415a 885a 12 50 812a
        55 20 651a 18 4 8 4 5 4 6 4 3 1.0 64 40 0.55 2.3 37 2.5 0.90 29 4.3 3.0 2.9
        4.5 3.7 2.9 3.7 4.3 3.2 0.08 0.15 0.31 0.08 0.24 0.27 0.16 0.07 0.70 53 971a
        1240a 29 190 1278a 212 45 568a 15 6 4 3 4 3 3 3 3 1.0 18 24 0.55 3.6 24 4.0
        0.86 11 4.7 3.0 3.6 5.1 4.5 3.4 4.5 5.1 3.4 0.05 0.13 0.14 0.15 0.08 0.02
        0.04 0.07 0.07 21 989a 241a 7.9 33 433a 35 7.8 400a 8 6 4 3 6 3 4 3 3 1.0
        47 12 0.38 1.6 21 1.7 0.37 19 Fdec, decrease in potency for each ligand on
        a given mutation compared with His III:05-CXCR3 (background). a The EC50 was
        estimated by a nonlinear regression using the sigmoidal dose-response algorithm
        in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to
        the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.',
    pubmed: '17170198', seq: '186', to_res: N}
- {entry_name: cxcr3_human, from_res: F, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.', pubmed: '17170198', seq: '135', to_res: L}
- {entry_name: cxcr3_human, from_res: Y, info: 'Cu(II)-Bipyridine Log EC50 EC50 M
        n Fdec -fold Emax fmol/105 cells Emax % Log EC50 EC50 nM ITAC Fdec -fold n
        Emax fmol/105 cells Emax % III:05 G128H Background III:08 F131A III:12 F135L
        IV:20 D186N EC2 H202A V:01; R208A; V:05 R212A V:05 R212H VI:13 W268A VI:16
        Y271A VI:16 Y271L VI:16 Y271N VI:16 Y271F VI:16 Y271H VI:23 D278N VII:02 K300A
        VII:10 Y308A 4.7 2.8 4.3 3.1 4.2 4.9 4.7 4.3 3.1 2.9 3.2 4.3 4.0 4.3 4.7 3.2
        0.11 0.09 0.23 0.43 0.27 0.05 0.05 0.08 0.21 0.36 0.06 0.05 0.03 0.12 0.09
        0.45 22 1415a 55 885a 58 12 19 50 794a 1278a 693a 51 108 55 20 631 18 4 3
        8 3 4 3 5 4 4 3 3 5 6 4 3 1.0 64 2.5 40 2.6 0.22 0.85 2.3 37 58 31 2.3 4.9
        2.5 0.90 29 347 32 162 NE 172 NE 180 259 227 460 NE NE NE 163 190 267 150
        NE 7.8 7.5 8.1 8.0 7.8 7.8 7.8 7.6 8.8 8.9 8.3 8.1 8.0 7.9 8.4 8.1 0.09 0.39
        0.14 0.20 0.13 0.36 0.03 0.18 0.20 0.18 0.38 0.15 0.28 0.02 0.05 0.22 15 35
        8.3 9 17 15 16 27 1.7 1.3 5.6 7.6 9.6 13 4.2 7.4 1.0 2.4 0.57 0.6 1.2 1.1
        1.1 1.9 0.12 0.09 0.39 0.52 0.66 0.88 0.29 0.21 16 3 3 8 3 4 2 6 3 4 3 3 5
        6 3 3 215 72 144 67 85 91 232 68 43 50 39 161 103 73 101 83 31 10 28 6.9 9.6
        14 33 11 1.8 3.0 2.9 37 22 14 12 40 36 8 22 7 11 12 39 7 2.5 3.9 1.8 25 14
        8 14 10 NE 247 29 NE 153 4.4 236 60 526 122 313 68 NE NE NE 263 34 196 29
        195 31 151 17 NE Fdec, decrease in potency for CuBip and ITAC on a given mutation
        compared with His III:05-CXCR3 (background); Emax, maximal stimulation of
        each ligand; Emax (%), for Cu(II)-bipyridine refers to the efficacy of Cu(II)-bipyridine
        compared with ITAC.', pubmed: '17170198', seq: '271', to_res: H}
